<SEC-DOCUMENT>0001679363-23-000011.txt : 20230223
<SEC-HEADER>0001679363-23-000011.hdr.sgml : 20230223
<ACCEPTANCE-DATETIME>20230223091424
ACCESSION NUMBER:		0001679363-23-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230223
DATE AS OF CHANGE:		20230223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Morphic Holding, Inc.
		CENTRAL INDEX KEY:			0001679363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473878772
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38940
		FILM NUMBER:		23656532

	BUSINESS ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE A2
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		9787296480

	MAIL ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE A2
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Morphic Holding, LLC
		DATE OF NAME CHANGE:	20160712
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>morf-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:3504fb1d-c703-4af8-962a-40bb538fa93a,g:d0f79058-117f-4d7c-9741-2cac766e63e2,d:6f157ddbee1a4723b8b2bfa75a59aa23--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:morf="http://morphictx.com/20221231" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>morf-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM180L2ZyYWc6OWEwMTkyZmQ4MjM0NDgyYThkNWJjZDVlMzFlNmFjZTYvdGFibGU6ZDNlMjQ3OTAxNzkyNDQzYzhjY2QzYzIxODE4ZDVmNjcvdGFibGVyYW5nZTpkM2UyNDc5MDE3OTI0NDNjOGNjZDNjMjE4MThkNWY2N18yLTEtMS0xLTY3NDc0_ce6a431c-60d3-45dd-87c9-b227c4a97b88">0001679363</ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM180L2ZyYWc6OWEwMTkyZmQ4MjM0NDgyYThkNWJjZDVlMzFlNmFjZTYvdGFibGU6ZDNlMjQ3OTAxNzkyNDQzYzhjY2QzYzIxODE4ZDVmNjcvdGFibGVyYW5nZTpkM2UyNDc5MDE3OTI0NDNjOGNjZDNjMjE4MThkNWY2N180LTEtMS0xLTY3NDc0_832ce996-a6ed-47c2-8740-9c639f0e13c1">2022</ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM180L2ZyYWc6OWEwMTkyZmQ4MjM0NDgyYThkNWJjZDVlMzFlNmFjZTYvdGFibGU6ZDNlMjQ3OTAxNzkyNDQzYzhjY2QzYzIxODE4ZDVmNjcvdGFibGVyYW5nZTpkM2UyNDc5MDE3OTI0NDNjOGNjZDNjMjE4MThkNWY2N181LTEtMS0xLTY3NDc0_85efe7b8-ca40-45ba-847d-3b9e1210dcf8">FY</ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM180L2ZyYWc6OWEwMTkyZmQ4MjM0NDgyYThkNWJjZDVlMzFlNmFjZTYvdGFibGU6ZDNlMjQ3OTAxNzkyNDQzYzhjY2QzYzIxODE4ZDVmNjcvdGFibGVyYW5nZTpkM2UyNDc5MDE3OTI0NDNjOGNjZDNjMjE4MThkNWY2N182LTEtMS0xLTY3NDc0_e6d14b42-d0bc-4bb0-b57b-c7ee723cc710">false</ix:nonNumeric><ix:nonNumeric contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODUwOQ_291e5ba1-214c-49bd-9743-84b648176853">http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_4277bab9-a4bc-4bb4-8619-266e108e3a33">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_450fd7b4-c958-4b0b-9afd-fcd530cac7f4">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="morf-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44dcf71d914947aeab1d6ca95df53425_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i4baab3edb5cc4574a112258bbd3606bb_I20230221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bfdc1a144904aff961163efe0b71fed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6348a4fce16d4a8495c328951bd63827_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c14a9ad52b943b0a9f70a1adc012b62_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0ec20e47be47eab177727935b230b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8445c41fd5491292904732bb0c4761_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76a6b759ffbb449e81cc565598a24220_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ceda5f5a33e4c9581ee108c783e1d6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f523ed243944c1952b9f439ae6591a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ca9447c43d4a3cb80fb8f78c3c39ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5918a2e0b4490086688e38b5dbd9e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875354d9000b443caa58d5fb686317b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e9ea2357bcd4e0b80ea5f90c117c183_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a2e7740aed41f39474ac66cdd34da5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc7a5cede0a3473c877c0673a0bcfa2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70cbfaa401bb4c92b9a9c2661d1df2b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5e9ea7d97544c62a5f4d876238911a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2d410f10fd43e0a3d21d4b9a945a0a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ee1b9fb78c472393ca0dd130c5b288_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib242abf1d8974e31acd46eb1e550e867_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04199a8b57a94afdb3894dd8f3611ef9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c83e86e5ecf4e049f03b221fd37ddc2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3021ee10eeff4228808670e25669c506_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89e4e41db194455b68dae07e4088634_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i229d09b827bb41a89b5f692014a5d842_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib148686698e04b2b916642950ccd1817_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c7558e92e8d4ff7ac77d9a2a034d000_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251a1f6f65c94d6ea46a8bf3f0bc6caf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i134fbbf1dfed4fa4814373cfe2ffcdb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica43711c0df64da7a4e706d076e6bdbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c50679b571740e19279ef7944cb3f16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e5bf0a1e4948d0971fff4b2f4bdb14_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac40f3b64c04bb6b11779403daca223_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c2e36cd1474c26b0d1a8bf3509e772_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f1c028c600f492ea22a0fc290237655_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f737a67eb34edebd4b964b94d03e20_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6217b53477e450c9212104a64166f49_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d715f0e90f4892a783060db407d98d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc0fc6fd3cc4a6085dbb3864bce300a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadaa15dc21b14e3db8588f66b4714a49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb7bba96f6fe49c1909da2aba38db320_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic313ab40bcfb4f66816203628eb7f0eb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6416f8f824ff4d4d8207b91e5c244618_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2edc7e86b640748d022ccc69c79483_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i5c75f7519ee24eed9649f1ec0217b28e_D20210811-20210811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-11</xbrli:startDate><xbrli:endDate>2021-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2d9d037833b403cbf8e599aeddd0edf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5715e43038646d4a427f7c14f57c05d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8aa7e1aba8a4110a761f965a1b311a5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37b2d1f438d44a009cda649034cdd00a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c29f3379b1841039eb81933bd0e600a_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e771d535ddd42f284b6e48b0a3ff9f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d3ccdb187fa404d929dd2ec91a44bcd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">morf:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a4ae752e5f34d0d89ac694b9812ea06_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">morf:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>morf:segment</xbrli:measure></xbrli:unit><xbrli:unit id="agreement"><xbrli:measure>morf:agreement</xbrli:measure></xbrli:unit><xbrli:context id="ib9cb810990e746309b39962a67440438_D20230213-20230213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-13</xbrli:startDate><xbrli:endDate>2023-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic242dad1f07949378faf34c59d7f5f88_I20230213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i604092d4d0e140bb95115f6f5f1a846d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d512dd5bdfe419cb8800b44352cd997_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2254b383dd1434c8eb41be8f1291d19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i702273bf69ee47298902b18d256ef436_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fcc2263734a44549091a97cc1630de9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d95317815642b1abbb1b41f9d0fcbe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51d81cccb60449a6a2bf1592ec8cf208_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06caa44988a1401d9cadf3a6919cc075_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84093c3db3c34ee9975edca937505f59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d8a3c8f6ba4c55be3e856fa074e12c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451016625f664d87b0f1149b4b460ca4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18e50ae5e2db43a2ba46810dc63df33e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if75f48a62b5e4f50be21277ae7a6a555_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6464b00ff1424290015908d925bcff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0afb206a6a142988b4b7c1c5c112488_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63cd7797863b4c878b6bd0037f63a034_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cef8c55113245b18d699b291da71849_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b5f1a419654cec9538eeec4eb6d001_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d5f8b0c8cf4bf1904278026e089ab9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291a0cdf99ae4372848ba10ce4515329_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc86524fc8604efaabb07582c77cd814_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162590f81a47412f95d12b41a46788fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i420d5fbd11644553ac2f20de753fb3be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie895696982894ca393ad2b4731ed0312_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d32d3ada9f945c991fb1e2c468a3056_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibee7cc6c73784af3a95d08dabf38f780_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f63d08cf43c445aab401c01568c17c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e9b237f63147898db008b76d81cc93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65bd95f6cce84501bc85ceb141f2ad69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b24e4bd1eca47dd863579e21bc04e0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f9f8031a004ca58585fa9bc615ac4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie618c17501df442fb50f6f5a9d0af3e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i461c0f15b1c64560b66aee8c7c5e1946_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i396cbab97ede453fa4531ea88932d4ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97846bbf5a2a45279b8fabd054295701_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2d05e295ffa4672bb1aa0fa78c22da2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb707bd819f4336b205ce25f8057e47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608c2d9be0664c69a0ac30c84a5bca4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05301005239d4ade9956b8262164a5aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d650c04838d45e090cfc3ae81926a54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55b4f455938e42d8a96daae58b3fa4c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ac46ba0e0664b0e977e59505ee5d97c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3d728458a5471e9ed4c1a92d4f66c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf582a62191e406a9ec5e7e9b0698e8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f2e7300f7184ac58092340abcc0b069_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5a3f4082fa1417b962818adcf991f1c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b30679359684bb791882ad58c6a044e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2813f455dff462a99153011829d659e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f1c205a6d14e4ba2e8721db48b2841_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb71b13217964931b29e2541f7607577_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8a7102b9d5346c292e630c2c88780d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i196fe36e4f60419799bbe38a05fd598e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">morf:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i765d898d413c42ecadfd22771b559151_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">morf:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e316a0be4b34afa97bceaaf82979c6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i773e6d896fab4cba847b5f4fa4a9f8b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic70e9fc24c404da2964ca9969e1b1582_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">morf:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>morf:vote</xbrli:measure></xbrli:unit><xbrli:context id="i0839d27335e24a70944c9e307b2f4ffd_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i836995cd69774ea6a3b54d9201496a27_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed3baf9425c4deb80dc4f747f071420_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77e987ed93cc4e8d9dfb645f146cde1f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174e9b0c5f7c46c78a563fe182cdb790_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd74a7f3cc934ea7bcea941a7ceb4135_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14cc5a3c0a534d1798020230d15314ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c1bfca603942ca815065d9e1dc6770_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31c5cf61778485d991ddab611e9d542_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a599d132d6483baa46f6bf673c0e6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88474183cda941d09a44d4d825426649_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8315abe4964879986d1a88cf096b3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76ce846988a44545a5367eba9a038043_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i318589b3af594468b4d7a4f435e6ebbe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib69dad785ae2431ebdb2f50942f10325_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f714ec6be446a99691b35600899a4c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9687b7a51c845ac993e26a0f4880580_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief146b6ab46a43909d51d8b1c46787e1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fe4eecb36748f5af8018f88fcb0c6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2140ecc30f7b44bab979e57fe3c6d43f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d4cafd342524466bff01db8b6fb6b1f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i101397ce8aac488895ed850a9c62f94a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i902baae07eda49b091ea19d753ae4bae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d6a05d3b283469d804ddf8e891690b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e4a0451e3944bb8b1e7d8a518951a90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic584c82f7fa941aaa1d9a7ca334e75f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c3053062ab47179828227426197a95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa9f54446643489fac9a8dbe66be6f9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8748f4e6ee9480c88e24d869168b315_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b5fdb614974175853f2513fb83dcec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f297cc869c04c60a6c213e1fb23bdf5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad5b858858b4142b730f313c6ba0354_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ff85e46b56d4930968dac9e3affabd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9a49673c39d457ca1650953807a3049_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4c949b67a814dcbae7f09a0249d0ed7_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id499edf539a74aff9a76526f02dd5aa9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e430e2b2d7d4b9bb5788a847d6c2d7e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ff867a6d934dccaf584133870acc01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i673a9cb8566f43ce9616ebf94921885b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd87bb47b7414650a95a2d45e1fd7c80_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34a0708e91b4ea5b31cedcf12f3227d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c53362d437417b8664cb0139c5b714_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2dfc56e30ef4261a5bd22e73cfeb905_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba08c24b4f646afab272849bef04fb2_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>morf:program</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>morf:option</xbrli:measure></xbrli:unit><xbrli:context id="i3e82d416fe9845cd845831adb23f5e51_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d620038457943e389fea375d17a3511_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i605039ce4c3546db8544ca5afe90071c_D20200825-20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-25</xbrli:startDate><xbrli:endDate>2020-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebbb4e4977534118b7062dc97e877188_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d9a0e35c7f042cf912b4e21edd47242_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76974348b5dd49dd867e3970e5e16d4c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08cc4df0448c42e6b1396ea92fa4ae8c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9645879e89545f6ae321d39d2ff49ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>morf:target</xbrli:measure></xbrli:unit><xbrli:context id="ia278688cc742407d889eeaac1398e425_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0af313c7bd8a4b4388148bb57bf130a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i995f63fe81fb4b9abb9716382e1dc8f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10cf228deb344a0bbe41e4dd68f6091d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c05f87e169c45feb95ae818058af3ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueFirstTwoProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e8a3b2b5f94dc1967ae1463aa4c8ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueFirstTwoProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d1093edead46de860e94adc1452272_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueThirdProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b07511e4f7642a9bfe31d2963ab5b4d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia95f81bdfee4430b81915be0cd95860b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6eb38babcc241e89553761903a11d61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5084eff2ed1d4f48a7da4984d71799cf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i035b3de5190f487586bd1ed38307c379_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af92416deea43878ba0ead3d0ecb13f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3511c82559894a9f98fb91e24620713a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5743f7e935fc434da814d8855536f21b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f5251e4aa084f7983207e980fdcdba4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia02854bc64fd499c8dbac9ce00351643_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd44d1dfb9c487f883da622bc30602d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a6c624908e845829a9ec116c04519ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce5d6357e054eb89f9f7070956ddd0f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53395b8e2227477fb7c23b0353062b98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a1b74d6b2bb4a4f98e936d596b79284_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436cc872d64b4d7b9aaa708f0706aa2a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia296bbbf833f49b2a6ab65ef01ab6bd8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadfe8416bc324e919e5e25cbad2d3372_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289b44ada87a4da1befaa2bbadc04a61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c3a69a38b5461d93693d703c6eda55_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a2adf60f5a46a4a34b1aa1bf2511b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia515039667cc4b22b0294f91e2b2a44a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjMw_8695308b-2501-4e81-a604-f0db07691787">10-K</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6MWUxNTQ4Zjg1OWJiNDc2NmEwN2VmNjZmOTdiNWFjODQvdGFibGVyYW5nZToxZTE1NDhmODU5YmI0NzY2YTA3ZWY2NmY5N2I1YWM4NF8xLTAtMS0xLTY3NDc0_fb717dd0-4d50-432e-9bb2-cf5d49cfddd9">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13, OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zODQ4MjkwNzAwNDg4_773d21fe-8963-4109-9192-4001aabb3683"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zODQ4MjkwNzAwNDg4_c272fba2-a22b-4989-ab89-4f97750ea16c">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6Yjk4NzYxMDA3ZGYwNGIwM2JlNzA4MmRmMTdiNjcyNDIvdGFibGVyYW5nZTpiOTg3NjEwMDdkZjA0YjAzYmU3MDgyZGYxN2I2NzI0Ml8wLTAtMS0xLTY3NDc0_ca40bd2c-cec1-4f16-b511-1eb1ec7583d7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="margin-bottom:6pt;text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM1_fc33e89f-f502-429f-bed6-9cc56361b459">001-38940</ix:nonNumeric></span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjMy_1f97b690-1b3f-4ac3-ba2e-0825693c93e9">MORPHIC HOLDING,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8wLTAtMS0xLTY3NDc0L3RleHRyZWdpb246MjBmMTdiNTQ5NjZiNDI2ZjhlNTM2NjgzOWE2OGQ2YjFfNQ_54dd6e1a-5b1e-4fcb-9663-1c47bda5884f">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8wLTEtMS0xLTY3NDc0L3RleHRyZWdpb246YmQwYWUzZTM0NmUyNDc5Nzg5ODdmNjk4Mzk2ZTE1NjdfNQ_5b863ced-4650-4d84-bf8e-842f22ad8f19">47-3878772</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTAtMS0xLTY3NDc0L3RleHRyZWdpb246ZTc4OWE0MzE0ZjYyNGNlNjkzYTNlZDdlYjM3OWE4ZDVfNw_47eb8979-f1a7-4e8c-9976-5b2ff1875ead">35 Gatehouse Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTAtMS0xLTY3NDc0L3RleHRyZWdpb246ZTc4OWE0MzE0ZjYyNGNlNjkzYTNlZDdlYjM3OWE4ZDVfMTE_271e64f9-7789-4711-bd08-187a81d59670">A2</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTAtMS0xLTY3NDc0L3RleHRyZWdpb246ZTc4OWE0MzE0ZjYyNGNlNjkzYTNlZDdlYjM3OWE4ZDVfMTQ_0872bd01-1590-4825-a117-07c0731e2d4a">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTAtMS0xLTY3NDc0L3RleHRyZWdpb246ZTc4OWE0MzE0ZjYyNGNlNjkzYTNlZDdlYjM3OWE4ZDVfMTg_5ea312b0-5c0e-4aac-8ea4-12aef09c9a08">MA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTEtMS0xLTY3NDc0L3RleHRyZWdpb246OTQ4ZTNmMWY3MTFhNDJjMWJmNzhlNjJiOWZkYTQwNWNfNw_8695be7a-e570-40b4-8ac5-f94f17563ec3">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM2_034aacd7-839b-4dff-a2a4-ffaecce2260b">781</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjQx_c3f0fed6-aaa4-4ac2-900c-678cd13dbd9a">996-0955</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6MzQ5NTE2NDM3ZjljNDgxNGEzY2MwMWU3ZGQ5Y2U5MzMvdGFibGVyYW5nZTozNDk1MTY0MzdmOWM0ODE0YTNjYzAxZTdkZDljZTkzM18xLTAtMS0xLTY3NDc0_724cee08-3544-4580-8759-37bd0c7ef59c">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6MzQ5NTE2NDM3ZjljNDgxNGEzY2MwMWU3ZGQ5Y2U5MzMvdGFibGVyYW5nZTozNDk1MTY0MzdmOWM0ODE0YTNjYzAxZTdkZDljZTkzM18xLTEtMS0xLTY3NDc0_8db3c336-98f7-413d-8c49-eb3c12b6a825">MORF</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6MzQ5NTE2NDM3ZjljNDgxNGEzY2MwMWU3ZGQ5Y2U5MzMvdGFibGVyYW5nZTozNDk1MTY0MzdmOWM0ODE0YTNjYzAxZTdkZDljZTkzM18xLTItMS0xLTY3NDc0_7531ecc1-4b1c-40f3-8eb4-f687748aac49">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM3_714d9f77-0313-4e2c-aeb1-75944eb56d37">Yes</ix:nonNumeric>&#160;&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;&#9744;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d) of the Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Yes&#160;&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM5_e1ed53ea-a1af-4c5c-b8da-71772e831f0e">No</ix:nonNumeric>&#160;&#9746;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjQy_32d96485-16c6-42c9-a5ea-8e65cd5c0fe6">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (Section&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjQw_b8d89020-9ff4-4182-8472-e56e4ee4a9b2">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer &#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer &#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6YmIwZDc3MTljOWU4NGFmY2ExYTU4ZDAzZjFlNzRlYmUvdGFibGVyYW5nZTpiYjBkNzcxOWM5ZTg0YWZjYTFhNThkMDNmMWU3NGViZV8xLTAtMS0xLTY3NTIxL3RleHRyZWdpb246MzNmNWQxZTM5NzI5NDg2ZmIyZjZkMmJmOTkyODVjZjVfMjE5OTAyMzI1NTYwNQ_765afb11-0408-4f23-8cff-8d70d3e0f858">Non-accelerated filer</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6YmIwZDc3MTljOWU4NGFmY2ExYTU4ZDAzZjFlNzRlYmUvdGFibGVyYW5nZTpiYjBkNzcxOWM5ZTg0YWZjYTFhNThkMDNmMWU3NGViZV8xLTEtMS0xLTY3NDc0L3RleHRyZWdpb246NjBmMDVmNmFmMzIxNGMzNmI2Zjc4OWJjZjQ5NjJhNzRfMzg0ODI5MDY5NzI0OQ_476b6239-b51d-4f27-b1c8-58883168f9ea">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6YmIwZDc3MTljOWU4NGFmY2ExYTU4ZDAzZjFlNzRlYmUvdGFibGVyYW5nZTpiYjBkNzcxOWM5ZTg0YWZjYTFhNThkMDNmMWU3NGViZV8yLTEtMS0xLTY3NDc0L3RleHRyZWdpb246NGZhZDA5NzVkNWM1NDI0OTk3YzIyMjA4MDJlNDYyNmNfMjg_383def54-ab5d-4970-b297-49321616bb2a">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF84MjQ2MzM3MjEyNzY5_11b0713a-1bc2-4d08-abe1-cebaf09a0986">&#9744;</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule&#160;12b-2).&#160;Yes&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM0_d2702fe4-637e-454b-b667-91d1dfe1ebaf">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;&#9746;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value (approximate)&#160;of the registrant&#8217;s common equity held by non-affiliates based on the closing price of a share of the registrant&#8217;s common stock for as reported on The Nasdaq Global Market on June 30, 2022 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was $<ix:nonFraction unitRef="usd" contextRef="i44dcf71d914947aeab1d6ca95df53425_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8yNzcw_39f651f9-d32f-4e2e-8298-b3dd4b808f67">559,358,817</ix:nonFraction>.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant&#8217;s Common Stock as of February&#160;21, 2023 was <ix:nonFraction unitRef="shares" contextRef="i4baab3edb5cc4574a112258bbd3606bb_I20230221" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8yODU0_9224666e-750d-4c6b-872a-30a0de7c9813">39,534,138</ix:nonFraction>.</span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjMx_dd49a2f5-0bc3-4aa4-85c8-d56d50479ff7" escape="true"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div style="text-indent:17.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Portions of the registrant&#8217;s definitive proxy statement to be filed for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div></ix:nonNumeric><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_10">Part&#160;I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_10">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_13">Forward Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_16">Item&#160;1. Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_19">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_19">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_1252">Item 1B. Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_22">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_22">Item 2. Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_22">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_25">Item&#160;3. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_25">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_28">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_28">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_34">Part&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_34">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_37">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_37">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_40">Item 6. Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_40">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_43">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_43">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_73">Item 8. Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_73">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_151">Item&#160;9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_151">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_154">Item&#160;9A. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_154">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_157">Item 9B. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_157">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_160">Item 9C. Disclosures Regarding Foreign Jurisdictions That Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_160">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_163">Part III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_163">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_166">Item 10. Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_166">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_169">Item 11. Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_169">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_172">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_172">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_175">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_175">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_178">Item 14. Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_178">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_181">Part IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_181">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_184">Item 15. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_184">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_187">Item 16. Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_187">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_190">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_190">98</a></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:120%"></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_13"></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD LOOKING STATEMENTS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and section 27A of the Securities Act of 1933, as amended, or the Securities Act. All statements contained in this Annual Report other than statements of historical fact, including statements regarding our future results of operations and financial position, business strategy, market size, potential growth opportunities, nonclinical and clinical development activities, efficacy and safety profile of our product candidates, our ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of nonclinical studies and clinical trials, collaboration with third parties, and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to many risks, uncertainties, and assumptions, including those described in &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These risks, uncertainties, and unrealized assumptions may mean the forward-looking events and circumstances discussed in or suggested by this Annual Report may not occur and actual results could differ materially and adversely from those forward-looking statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the forward-looking statements were reasonable when made, we cannot guarantee that the future results, levels of activity, performance or events, assumptions and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report to conform these statements to actual results or to changes in our expectations, except as required by law. You should read this Annual Report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from our forward-looking statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, as used in this Annual Report, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to Morphic Holding, Inc., a Delaware corporation, and its subsidiaries taken as a whole, unless otherwise noted. &#8220;Morphic,&#8221; &#8220;Morphic Therapeutic,&#8221; the Morphic logo, and all product names are our common law trademarks. This Annual Report contains additional trade names, trademarks and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_16"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ITEM 1. BUSINESS.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite this, we believe our unique platform can unlock the potential to reliably generate high-quality oral molecules against specific integrin targets. The Morphic integrin technology platform, or MInT Platform, was created leveraging our unique understanding of integrin structure and function to develop novel product candidates designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration. We are advancing our pipeline, including our lead product candidate, MORF-057, an &#945;4&#946;7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease, or IBD. We submitted an investigational new drug application, or IND, for MORF-057 in July 2020, and the FDA permitted the study submitted under the IND to proceed in August 2020. In September 2020, we initiated a Phase 1 clinical trial of MORF-057 in healthy volunteers to establish our clinical program and select doses for our Phase 2 program in IBD with an initial focus on ulcerative colitis, or UC. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#00101f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The MORF-057 Phase 1 study included single ascending dose, or SAD, multiple ascending dose, or MAD, and food effect, or FE, cohorts evaluating MORF-057 safety, pharmacokinetics, or PK, and pharmacodynamics, or PD. Healthy subjects were randomized 3:1 to receive a single dose of MORF-057 at 25, 50, 100, 150 and 400 mg or matching placebo in the SAD cohorts; or twice daily, or BID, doses of 25, 50 and 100 mg MORF-057 or matching placebo for a total of 14 days in the MAD cohorts. A total of 67 eligible healthy subjects were enrolled into the studies, with 36 in the SAD, nine in the FE and 22 in the MAD cohorts. 66 subjects completed study treatment and one from the 50 mg BID MAD cohort withdrew consent for personal reasons.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#00101f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MORF-057 was well tolerated in all cohorts and no safety signals were identified. MORF-057 demonstrated a favorable PK profile, where target engagement was confirmed, and a clear PK and PD relationship was established. MORF-057 was rapidly absorbed and systemic exposure was confirmed to increase approximately dose proportionally. A slight reduction in exposure without effect on trough concentrations was observed upon administration with a high fat meal in the food effect study. The results suggest food intake has no impact on trough MORF-057 levels and that MORF-057 can be administered without regard to food in planned studies in patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#00101f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#945;4&#946;7 receptor occupancy (RO) increased with dose and study day, achieving saturation (&gt;99% RO) in individual patients from all cohorts above 25 mg by day 14. In the 100 mg BID cohort, MORF-057 saturated the &#945;4&#946;7 receptor (mean RO &gt;99%). Dose-and time-dependent changes in biomarkers including specific &#945;4&#946;7 high expressing immune cell populations were observed, adding to evidence of proof of biology for MORF-057. These changes were consistent with those reported with other integrin inhibitors including the antibody drug vedolizumab which is approved for the treatment of IBD.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an additional MORF-057 Phase 1 study, subjects were dosed up to 200 mg twice daily (BID) and those receiving MORF-057 at 100 BID or 200 mg BID demonstrated &#945;4&#946;7 receptor saturation and statistically significant increases in circulating central memory, effector memory T lymphocyte and switched memory B lymphocyte populations compared with placebo. At the 25 mg and 50 mg BID exploratory doses, directionally increasing trends were also observed in key PD measures. All doses were well tolerated, no safety signals were identified, and a favorable PK profile was observed. In both single doses of 200 mg MORF-057 and 200 mg BID over the 14 days, MORF-057 demonstrated &#945;4&#946;7 receptor saturation at C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">trough</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Statistically significant changes in lymphocyte subset populations and CCR9 mRNA were observed, consistent with previous studies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the results from the Phase 1 studies, we initiated a Phase 2 clinical trial of MORF-057 in March 2022. EMERALD-1 (MORF-057-201), which is an open-label multi-center Phase 2a trial designed to evaluate the efficacy, safety and tolerability of MORF-057 in adults with moderate to severe UC, completed targeted enrollment in October 2022, with 30 patients enrolled in the study. Additionally, patients that were undergoing screening at the time the study completed targeted enrollment were enrolled in the study for a total of 35 patients enrolled in the main cohort. Enrollment of an exploratory cohort of up to ten patients who have previously failed treatment with vedolizumab is ongoing. Patients enrolled in the EMERALD-1 study are being treated with 100 mg BID at sites in the United States and Poland. The primary endpoint of the trial is the change in Robarts Histopathology Index (RHI), a validated instrument that measures histological disease activity in ulcerative colitis at 12 weeks compared to baseline. Patients will then continue for an additional 40 weeks of maintenance therapy followed by a 52-week assessment. Secondary and additional outcome measures in the EMERALD-1 study include change in the modified Mayo clinic score, safety, PK parameters and key PD measures including &#945;4&#946;7 receptor occupancy and lymphocyte subset trafficking. We expect that primary endpoint data from the main cohort of the EMERALD-1 Phase 2a trial of MORF-057 in patients with moderate to severe UC will report in the second quarter of 2023. EMERALD-2 (MORF-057-202) which is a global Phase 2b randomized controlled trial of MORF-057 began dosing patients in November 2022. Patients enrolled in the EMERALD-2 study are randomized to receive one of three active arms or a placebo arm: 100 mg BID, 200 mg BID, and a QD (once daily) arm, or a placebo arm which will cross over to MORF-057 after the 12-week induction phase. The primary endpoint of the trial is the clinical remission rate as measured by the modified Mayo score at 12 weeks. The secondary endpoints will include the change in RHI, PK and PD measures, as well as safety parameters. Following the 12-week induction phase, patients will move to a 40-week maintenance phase. We believe that we will achieve completion of the primary endpoint from the EMERALD-2 Phase 2b trial of MORF-057 in patients with moderate to severe UC in the first half of 2025. Given the progress achieved with MORF-057, we paused a second-generation development candidate at the pre-IND stage during 2022, focusing on the advancement of MORF-057 through Phase 2 clinical programs. We continue to expand our &#945;4&#946;7 portfolio and have positioned next-generation &#945;4&#946;7 small molecule development candidates for clinical studies in the future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 we reported that our collaboration with AbbVie Biotechnology, Ltd., or AbbVie, which was entered into in October 2018, or the AbbVie Agreement had been terminated for convenience. The subject of this collaboration was selective oral &#945;v&#946;6-specific integrin inhibitors we had developed for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis, or IPF, and additional indications under our collaboration with AbbVie. In August 2020, AbbVie exercised an option to license our &#945;v&#946;6-specific integrin inhibitor program and made a one-time $20.0 million payment to us. AbbVie informed us that it did not intend to advance any of our selective oral &#945;v&#946;6-specific integrin inhibitors due to a suspected on-target &#945;v&#946;6-mediated safety signal that has been observed in pre-clinical testing, the details of which were published in the Society for Toxicology journal in December 2022. The AbbVie Agreement terminated effective December 2022, and as a result we will not receive any additional payments thereunder. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, we entered into an agreement with Janssen Pharmaceuticals, Inc., or Janssen, to develop novel integrin therapeutics, or the Janssen Agreement. In February 2021 Janssen paid us $5.0 million to commence work on a third research program to discover antibody activators against a specific integrin target. In December 2021, Janssen informed us that they had decided not to exercise the options on the first two integrin targets and focused efforts on the third integrin research program which includes the potential development of integrin antibody activators. The first two integrin targets were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">eturned to us due to a lack of target validation in the specific disease of Janssen's interest. In January 2023, we received notice from Janssen that they had elected to terminate the agreement. The termination will be effective within 60 days of January 13, 2023, and as a result we do not expect to receive any additional payments under the Janssen Agreement except for potential nominal amounts related to research services completed in 2023 prior to termination.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beyond our lead target, MORF-057, we are using our MInT Platform to advance a broad pipeline of preclinical programs across a variety of therapeutic areas, all of which aim to harness the potential of inhibition or activation of an integrin receptor. Additional wholly-owned programs have advanced near to or into the lead optimization phase of discovery. We presented positive preclinical data from our &#945;v&#946;8 program at the American Association for Cancer Research Annual Meeting in April 2021, demonstrating anti-tumor activity in checkpoint refractory cancer models and we are continuing our focus on advancing our &#945;v&#946;8 program. We also have additional research stage programs ongoing against fibronectin integrin targets in pulmonary hypertensive diseases including pulmonary arterial hypertension (PAH) and other therapeutic areas. Integrins are known to promote cell proliferation, survival, hypertrophic growth and fibrosis, which are key elements in the progression of PAH.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were founded in 2014 by Dr. Timothy A. Springer of Harvard Medical School and Boston Children&#8217;s Hospital, a world-renowned immunologist and biophysicist who discovered integrins. He established the importance of integrin conformations in modulating disease activity. Today, pursuant to an exclusive license from the Children&#8217;s Medical Center Corporation, or the Springer Laboratory, our MInT platform is powered by these initial insights, together with our proprietary knowledge of integrin conformations, affinity regulation and dynamics. Together, this enables us to discover novel product candidates that bind and revert disease-specific integrin conformations to a non-disease physiologic state.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have assembled an experienced management team, board of directors and scientific advisory board with specialized expertise in integrin therapies. They collectively bring extensive experience in discovering, developing and commercializing therapeutics, having worked at companies such as ArQule, Inc., Biogen Inc., Cubist Pharmaceuticals, Inc., Johnson &amp; Johnson, Pfizer Inc., Pharmacia Corporation, Takeda Pharmaceutical Company Limited and Theravance Biopharma, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December 31, 2022, we have raised an aggregate of approximately $743.0 million in gross proceeds primarily through the issuance of equity, including our convertible preferred equity securities, our initial public offering, our underwritten public offering in March 2021, and sales of shares of our common stock pursuant to the ATM, along with payments received under our collaboration agreements.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to use our MInT Platform to discover and develop potentially first-in-class oral small-molecule integrin therapeutics. We believe our platform has the potential to transform the treatment paradigm for patients suffering from a broad range of serious chronic diseases. The key tenets of our business strategy to achieve this goal include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establishing orally available integrin modulators as a new treatment for serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. We are leveraging our MInT Platform to create a new class of oral integrin targeted therapeutics to treat diseases where integrins are dysregulated and a potential benefit for oral therapies exists. We have prioritized our initial development efforts on diseases with established clinical endpoints and biomarkers, which we believe will enable us to more rapidly achieve clinical proof of concept. We are advancing our lead wholly-owned product candidate, MORF-057, an &#945;4&#946;7 specific integrin inhibitor, through clinical development for the treatment of IBD.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging our proprietary MInT Platform and knowledge base to grow our pipeline of novel integrin therapeutics. Our comprehensive MInT Platform, coupled with our development capabilities, have enabled us to build a pipeline of novel product candidates targeting chronic diseases caused by integrin dysregulation. We intend to expand our pipeline by unlocking the therapeutic potential of the four integrin subgroups to treat diseases with high unmet medical need and to potentially expand our current product candidates into new indications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continuing to drive innovation across our MInT Platform. We intend to extend our leading position in the field of integrin medicine by continuing to develop and incorporate platform innovations that can further broaden the potential therapeutic reach of our oral integrin programs. Our key focus areas include iteratively expanding the breadth of our structural knowledge in crystallography through technological investments, broadening our library of conformationally-specific integrin chemotypes and deepening our fundamental understanding of integrin disease biology. We believe that as we further expand our knowledge base, we will be able to iteratively grow our platform and deepen our understanding of additional integrin targets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Independently commercializing our products, if approved, in indications and geographies where we believe we can realize maximum value. We plan to independently advance those product candidates that we believe have well-defined clinical and regulatory approval pathways, and that we believe we can commercialize successfully, if approved. We may also seek to form strategic collaborations around certain targets, product candidates or disease areas that we believe could benefit from the resources of either larger biopharmaceutical companies or those specialized in a particular area. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Focus &#8212; Integrin Receptors</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrins are the only receptors in the human body that use both intracellular and extracellular ligands to transmit signals both from the inside of the cell to the outside of the cell and from the outside of the cell to the inside of the cell. Reciprocally, these states are regulated by tensile forces transmitted through integrins when they bind to extracellular ligands and the intracellular cytoskeleton. This bi-directional signaling ability allows integrins to affect virtually every aspect of cell and organ homeostasis. Consequently, the dysregulation of integrin signaling is associated with many human diseases including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrin receptors are evolutionarily conserved. Integrins exist as paired combinations of 18 &#945; and eight &#946; subunits, and there are 24 known heterodimers. These pairings give integrins their unique abilities to recognize their ligands and modulate cellular function in specific ways. Integrins are subdivided into those on leukocytes, and those that recognize RGD-peptide, collagen and laminin ligands. They regulate numerous aspects of cell biology and physiology including leukocyte trafficking, activation of platelets and leukocytes, activation of growth factors such as TGF-&#946;, cell adhesion to the basement membrane and extracellular matrix, and retention or adhesion strengthening of cells within tissues. This diverse set of functions makes them actionable targets across a broad range of human diseases based on preclinical modeling or clinical establishment. The figure below summarizes the 24-member integrin family and areas of clinical relevance:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="morf-20221231_g1.jpg" alt="morf-20221231_g1.jpg" style="height:390px;margin-bottom:5pt;vertical-align:text-bottom;width:390px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="morf-20221231_g2.jpg" alt="morf-20221231_g2.jpg" style="height:235px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Integrins as a Therapeutic Target Family</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrins have long been recognized as drug targets. In the 1980s, the therapeutic interrogation of integrins focused on the RGD integrin, &#945;IIb&#946;3. When &#945;IIb&#946;3 on platelets is activated, it binds to fibrin, which bridges it to adjacent platelets and leads to clot formation. As the molecular details establishing the essential role of &#945;IIb&#946;3 in platelet aggregation emerged, it became clear that inhibition of its ligand binding function would be antithrombotic. In 1994, abciximab (marketed as ReoPro&#174;) became the first approved integrin therapy for patients undergoing percutaneous transluminal coronary angioplasty, followed by the approval of tirofiban (marketed as Aggrastat&#174;) and eptifibatide (marketed as Integrilin&#174;).</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The next stage of development of integrins as drug targets has focused on integrin receptors on leukocytes. These therapies modulate autoimmunity by inhibiting the ability of activated immune cells, including T-cells, to enter chronically inflamed tissues. Four approved integrin medicines belong to this category:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efalizumab (formerly marketed as Raptiva&#174; and subsequently withdrawn from the market), an injectable antibody inhibitor of &#945;L&#946;2, approved by the FDA in 2003 for the treatment of chronic moderate to severe psoriasis;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Natalizumab (marketed as Tysabri&#174;), an infusible antibody inhibitor of &#945;4&#946;1, approved by the FDA in 2004 for the treatment of relapsing forms of multiple sclerosis and in 2008 for the treatment of moderately to severely active Crohn&#8217;s disease;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vedolizumab (marketed as Entyvio&#174;), an infusible antibody inhibitor of &#945;4&#946;7, approved by the FDA in 2014 for the treatment of moderately to severely active ulcerative colitis or Crohn&#8217;s disease; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lifitegrast (marketed as Xiidra&#174;), a topical small-molecule inhibitor of &#945;L&#946;2, approved by the FDA in 2016 for the treatment of dry eye disease.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to Global Data, these autoimmune therapies were estimated to have achieved combined annual sales in their respective 2021 fiscal years of approximately $7.2 billion.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Challenges of Oral Integrin Modulators</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The infusible, injectable or topical nature of these therapies has limited their utility. To address these limitations, pharmaceutical companies have invested significant resources in discovering and developing oral systemic integrin therapies. For &#945;IIb&#946;3 alone, six different compounds (roxifiban, sibrafiban, orbofiban, xemilofiban, lefradafiban, lotrafiban) were advanced into registrational Phase 3 clinical trials. Disappointingly, the results of these trials showed these oral systemic inhibitors of &#945;IIb&#946;3 increased vascular death in patients with acute coronary syndrome. After a decade to understand these failures, we now know that all failed oral inhibitors stabilized the active integrin conformation and promoted ligand signaling if they were not potent enough to maintain full active site binding. These drawbacks resulted in greater platelet aggregation and an increased rate of adverse events.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the unexpected disease-activating activity of oral leukocyte integrin inhibitors was observed during a Phase 2 development of firategrast, an oral non-selective inhibitor of &#945;4&#946;1 and &#945;4&#946;7, where the symptoms in the patients with multiple sclerosis were exacerbated when firategrast was administered in non-saturating doses. This resulted in an increase in lesions and an increased rate of adverse events. The development of this compound was subsequently halted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Platform and Approach</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our MInT Platform allows us to address and overcome the challenges faced by developers of first-generation oral integrin-targeted therapeutics.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Integrin Model</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="morf-20221231_g3.jpg" alt="morf-20221231_g3.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our discovery platform enables us to be the only company working across the entire 24-member integrin target family. Our MInT Platform consists of these unique capabilities:</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Proprietary ability to determine integrin structures. Using our protein constructs, cell lines and know-how, we have elucidated over 500 proprietary structures for clinically important targets across the integrin class.</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">A computationally enabled product candidate design engine. We have built a library of over 16,500 optimized compounds using sophisticated medicinal and computational chemistry capabilities and biological assays for each integrin that allows us to tune highly potent and selective integrin inhibitors and activators into product candidates for preclinical and clinical development. Our ability to generate product candidates from our tunable product engine is significantly accelerated by our exclusive computational collaboration with Schr&#246;dinger, which uses advanced physics-based modeling and machine learning to create superior oral drug candidates. We have recently expanded our access as a special Schr&#246;dinger software customer enabling utilization of their software suite beyond the scope of integrins. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">An emerging ability to discover activating and inhibiting antibody candidates, by leveraging our unique ability to express and isolate specific integrin conformational constructs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biology and disease translation capability. Our sophisticated and comprehensive suite of biologic tools includes a gene and protein expression atlas, a single-cell resolution profiling of human tissues from diseases of interest and development of biomarkers, which allow us to assess target engagement and pharmacodynamic activity in the disease of interest.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initially focused on developing product candidates with a target class for areas of high unmet medical needs including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#945;4&#946;7 and &#945;4&#946;1, which are established targets for autoimmune diseases; their mechanism of action and the benefits and risks of their inhibition are well understood; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain &#945;v integrins that have a preclinically well-characterized mechanism of action through the activation of TGF-&#946;, a clinically important anti-inflammatory cytokine dysregulated in many human pathologies.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have only tested MORF-057, an &#945;4&#946;7-specific integrin inhibitor, in clinical studies, and we currently only have pre-clinical data regarding oral bioavailability of our other product candidates.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our understanding of the mechanism of integrin receptor activity, modulated by complex conformations and signaling, is unique and allows us to discover both inhibitors and activators across the integrin receptor target family. Our capability has been validated by our advancement of &#945;4&#946;7, &#945;v&#946;8 and other integrin programs. Our MInT Platform consists of three major components:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Proprietary ability to determine integrin structures;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tunable product candidate design engine; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biology and disease translation capability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leveraging our deep understanding of integrin conformation and molecular modes of action is a key element of our strategy to identify product candidates. These receptors undergo large conformational changes as shown in Figure 1, resulting in both inactive (bent-closed and extended-closed) and activated states of the receptor (extended-open). In the bent-closed form, the top portion of the integrin, formed by both &#945; and &#946; subunits, folds in half so that the top and lower half associate with each other (Figure 1 left) rendering the integrin inactive. For the integrin to be active, the extended-close state (Figure 1 middle) extends at the &#945; and &#946; mid-leg on the cell surface to render an extended open state (Figure 1 right). As shown with multiple integrins, the bent-closed and extended-closed conformations have low affinities for ligand, while depending on the integrin, the extended-open conformation is 700 to 5,000-fold higher in affinity for ligand. These changes in integrin conformation and affinity function to transmit bi-directional signals, enabling communication of the cell expressing the integrin on its surface and the extracellular matrix or ligands on other cells.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img src="morf-20221231_g4.jpg" alt="morf-20221231_g4.jpg" style="height:312px;margin-bottom:5pt;vertical-align:text-bottom;width:520px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 1: Integrin dynamic conformational states. Left &#8212; bent-closed inactive form of the integrin heterodimer pair, Middle &#8212; extended-closed inactive, and Right &#8212; extended-open active.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our novel MInT Platform is rooted in our structural biology capability based on deep insights into control of complex integrin conformational states. Dr. Springer characterized an initial set of small molecules to lock specific integrin conformations and we have used and advanced this knowledge to optimize the pharmacology of our oral integrins. We design our compounds to recognize integrin conformational states that are physiologic dysregulated in disease. Binding of our compounds to integrins promotes the integrin to adopt a structure that is characteristic of healthy tissue and stops disease-specific integrin signaling. We believe past attempts to develop small molecules targeting integrins have in part failed due to a lack of sufficient understanding </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these conformational changes and their impact on disease. We believe our MInT Platform has positioned us to apply our deep understanding of the biologic underpinnings of diseases linked to integrin dysfunction to develop a pipeline of novel integrin therapeutics.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Morphic Integrin Technology (MInT) Platform</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that the integrin target family consists of structurally and functionally related proteins, each cycle of the MInT Platform yields chemistry assets and biological data in our programs of interest while in parallel furthering our understanding of the structure and function of new integrin complexes. We believe this results in a rapid strategic compounding of knowledge and assets with each turn of the MInT design cycle. Our &#945;4&#946;7 program produced its first development candidate over three years after program initiation. Our &#945;v&#946;6 program took only two years to achieve the same goal, which we believe was due in part to insights we had gained on chemical features that optimized oral bioavailability, clearance and metabolic stability. Our &#945;v&#946;8 program has advanced even faster to development candidate profile compounds. The chemotypes and initial medicinal chemistry hits we discover become tools and compounds that can further our knowledge base around each individual integrin, which also extends to related integrins. For example, discovery efforts in &#945;v&#946;6 led to highly selective &#945;v&#946;8 advanced leads and starting points for additional targets, directly enabling new wholly-owned programs and supporting collaboration efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the graphic below, the iterative MInT design cycle consists of nine steps based on the three pillars of our MInT Platform: our proprietary ability to determine integrin structures, our tunable product candidate design engine, and our biology and disease translation capability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><img src="morf-20221231_g5.jpg" alt="morf-20221231_g5.jpg" style="height:624px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary ability to determine integrin structures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that an understanding of protein crystal structures enables more effective product candidate design. Integrins are difficult to characterize structurally because they are composed of many flexible domains and interdomain linkers (see Figure 1). Our unique position of integrin structural knowledge and cell lines, and access to crystal structures for half of the integrin targets, proprietary protein reagents and knowhow has allowed us to elucidate over 500 proprietary structures for clinically important targets. Our novel approach is based on combining our deep understanding of structural biology and how integrin protein conformation regulates function in disease. An example of this is in our &#945;4&#946;7 program where the crystal structure of the drug binding site enables the design of novel ligands that bind at the interface of the &#945; and &#946; subunits (Figure 2). This critical information at the molecular level directs our research to unlock the potential of this family of receptors and develop small molecules for targeting specific conformations of the integrin receptors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><img src="morf-20221231_g6.jpg" alt="morf-20221231_g6.jpg" style="height:410px;margin-bottom:5pt;vertical-align:text-bottom;width:620px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 2: Left &#8212; X-ray crystal structural of the top portion of the heterodimer or headpiece of the human &#945; 4&#946;7 integrin receptor with the &#945;-subunit on the left and &#946;-subunit on the right. The drug binding site for this receptor is at the interface of the &#945; and &#946; subunits. Right &#8212; Zoomed in view of the drug binding site showing the key interactions responsible for regulation of protein conformation in this integrin. Data for structural rendering from: Yu, Y., Zhu, J., Mi, L.Z., Walz, T., Sun, H., Chen, J.-F., Springer, T.A. (2012). Structural specializations of &#945;4&#946;7 an integrin that mediates rolling adhesion. J. Cell Biol. 196, 131-146.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tunable product candidate design engine</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Chemistry:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We have significant know-how in the development of molecules that stabilize specific integrin receptor conformations, which supports our novel approach to the identification of oral integrin inhibitors. Today, our small molecule chemical library, which continues to grow, contains over 16,500 uniquely designed integrin modulators (inhibitors and activators), and our drug design technology leverages our proprietary understanding of integrin target dynamics. When coupled with our deep understanding of the molecular mode of action of specific integrins, we believe we can design appropriate chemotypes for each integrin function. Further optimization of library compounds, combined with excellence in medicinal chemistry, enables the identification of potent, selective oral small molecule product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exclusive Schr&#246;dinger Computational Chemistry Collaboration:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  We have a collaboration with Schr&#246;dinger, a leader in chemical simulation and in silico drug discovery, that is exclusive as to integrins. We believe this collaboration enables us to undertake accelerated drug discovery through design, iteration and optimization of leads using a variety of next-generation physics-based computational technologies. Our collaboration with Schr&#246;dinger enables us to design molecules with atomic precision utilizing advanced structure-guided drug design technology. We have recently expanded our access as a special Schr&#246;dinger software customer enabling utilization of their software suite beyond the scope of integrins. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our In Vitro Integrin Assay Panels: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To identify novel inhibitors that stabilize disease-relevant receptor conformations, we have established a suite of robust in vitro assays that cover each of the integrin family members. These proprietary in-house screening assays enable biochemical and functional characterization of potency and selectivity within the integrin family, serving as powerful tools in different stages of the drug design process.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biology and disease translation capability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MInT Platform is built upon a deep understanding of integrin biology in human diseases, including integrin tissues and a cell expression atlas. We have built a sophisticated and comprehensive suite of in vitro, ex vivo, and disease-specific in vivo assays designed to evaluate the pharmacological effects of integrin modulation and to gain additional insights into their mechanism of action. The biological learnings from these assays have the potential to accelerate our work across multiple integrin discovery programs. We hope to strategically translate preclinical observations into our clinical development plans. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These, along with our growing capabilities in pharmacokinetic and pharmacodynamic modeling, have enabled our discovery of integrin inhibitors that have the potential to impact human diseases of autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted an analysis of opportunities for integrin inhibition in human disease based on validating biology, safety, technology readiness and development feasibility. We have identified several actionable integrin targets across all four integrin families, and our initial focus is in high unmet medical need areas of autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The following table summarizes key information about our current product candidates:</span></div><div><span><br/></span></div><div style="text-align:center"><img src="morf-20221231_g7.jpg" alt="morf-20221231_g7.jpg" style="height:223px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Lead Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MORF-057: Our &#945;4&#946;7-specific Integrin Inhibitor for Inflammatory Bowel Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing our lead &#945;4&#946;7 integrin inhibitor MORF-057 as a potential oral treatment for ulcerative colitis and Crohn&#8217;s disease, two of the most common types of inflammatory bowel disease, or IBD. Current IBD medical management strategies focus on inducing and maintaining disease remission with corticosteroids, immunomodulators and injectable monoclonal antibody therapies. We believe our oral integrins have the potential, if approved, to offer a targeted, safe, efficacious, and more convenient method of treatment for patients suffering from IBD.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on Inflammatory Bowel Diseases</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBD comprises several autoimmune and immune-mediated conditions characterized by chronic inflammation of the gastrointestinal tract. In ulcerative colitis, inflammation is limited to the lining of the colon, whereas in Crohn&#8217;s disease, inflammation can segmentally affect any part of the gastrointestinal tract and extend through the entire thickness of the bowel wall. Symptoms of these conditions include persistent diarrhea, abdominal pain, rectal bleeding, weight loss, and fatigue. Approved biologic medications for moderate-severe IBD have a primary induction non-response rate of up to 30 percent, and up to 45 percent of patients lose response over time; as such even newer agents may not adequately control tissue inflammation or symptoms for many of the sicker patients, and some will therefore develop complications that require surgical removal of the colon and rectum. According to the Crohn&#8217;s and Colitis Foundation, there were approximately 1.7 million people living with IBD in the United States. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mainstays of IBD therapy over many years have been oral and topical salicylates and glucocorticoids,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunosuppressive agents, and antibody therapies. Anti-integrin antibody therapy for IBD was first introduced with the approval of the &#945;4 integrin inhibitor natalizumab for Crohn&#8217;s disease, an indication approved following its initial approval for multiple sclerosis. Natalizumab therapy is associated with, and carries a black box warning for, progressive multifocal leukoencephalopathy, or PML, related to its &#945;4&#946;1 inhibitory activity, which has limited its use in Crohn&#8217;s disease. PML is a rare and often fatal viral disease characterized by progressive damage of the white matter of the brain at multiple locations. Vedolizumab, a monoclonal antibody inhibitor of the integrin &#945;4&#946;7, is approved for the treatment of moderately to severely active ulcerative colitis and Crohn&#8217;s disease, and does not carry a black box warning.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Pathway and Target Biology</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrin &#945;4&#946;7 binds to mucosal addressin cell adhesion molecule, or MAdCAM, which is expressed at a high level almost exclusively on the endothelial cells of the gut. Blockade of this interaction prevents immune cell entry into inflamed tissue in the gut and has been shown to be effective in treating IBD, as evidenced by the approval of vedolizumab.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Solution</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated oral small molecule integrin therapeutics targeting &#945;4&#946;7 intended to treat patients with ulcerative colitis and Crohn&#8217;s disease. Our strategy is driven by our ability to discover oral therapies and our knowledge of how to minimize off target risk of inhibiting &#945;4&#946;1, which is implicated in PML. We believe this program represents an example of a target class with opportunities to differentiate from established therapies, utilizing our MInT Platform. We believe that safe and effective oral therapies have the potential to transform the lives of IBD patients in two distinct ways: (i) as an earlier line of therapy, and (ii) in combination with other agents in the IBD landscape.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Data, Pharmacology and Biomarker Data</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our proprietary MInT Platform, we have designed &#945;4&#946;7 small molecule-inhibitors, including MORF-057, that are potent and have high selectivity for &#945;4&#946;7 relative to other integrins, including &#945;4&#946;1 and &#945;E&#946;7, as assessed by a suite of in vitro assays. Table 1 below shows measurements of the potency of MORF-057 as assessed in our cell adhesion assays, as compared to reference products vedolizumab, natalizumab and etrolizumab, as well as AJM300, a product candidate being developed by a third party. We determined all of these potencies in our laboratories. The cell adhesion assay evaluated the ability of &#945;4&#946;7 to bind to its ligand MAdCAM, &#945;4&#946;1 to its ligand VCAM, and &#945;E&#946;7 to its ligand E-cadherin in vitro. These assays have been shown to be useful in discovering drug candidates for IBD. IC50 values are commonly accepted measurements of drug potency.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MORF-057 has been observed to be a highly potent &#945;4&#946;7 inhibitor with &gt;3,000-fold selectivity in our cell adhesion assay- as compared to &#945;4&#946;1 and &#945;E&#946;7.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">a</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">a</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RPMI8866</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Jurkat</span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RPMI8866</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">a</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MAdCAM in 50%</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VCAM in 50%</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VCAM in 50%</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">/&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Fold</span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">K562- &#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">E-</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">/&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Fold</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">serum</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">serum</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">serum</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">selectivity</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cadherin</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">selectivity</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MORF-057</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 &#177; 0.8 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;50 &#181;M</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,290 &#177; 670 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;3,000</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 &#181;M</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;143,000</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vedolizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.035 &#177; 0.020 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;180 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;1,000 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;3,000</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ND</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">--</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Natalizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.166 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 - 12</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ND</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">--</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AJM300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">b</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 &#177; 66 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4200 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779 &#177; 261 nM</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 - 45</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ND</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">--</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Etrolizumab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0185 nM</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ND</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;1,000 nM</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">6</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 nM</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Table 1</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> *RPMI8866, Jurkat and K562- &#945;E&#946;7 transfected cell lines used for &#945;4&#946;7, &#945;4&#946;1 and &#945;E&#946;7, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ND = Not Determined</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">DDW 2020, Morphic Therapeutic, Jamie Wong, ePoster Tul1283</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The in vivo activity of our &#945;4&#946;7 inhibitor was also evaluated in a single dose acute pharmacodynamic model, where the impact of blocking the &#945;4&#946;7 integrin on the trafficking of T lymphocytes to the gut was assessed in mice. The procedure of the T lymphocyte homing uses fluorescently labelled TK1 cells, which expresses high level of &#945;4&#946;7 integrin on the surface and an n of 5 animals per group. Several of our compounds, including our development candidate MORF-057, have been evaluated in this assay to assess dose response (Figure 3). We observed a statistically significant response at all doses tested, and at the three highest doses tested, we observed our compound to be as potent as DATK32, a mouse surrogate of the &#945;4&#946;7 antibody vedolizumab. In Figure 3 below, the right panel shows dose-dependent inhibition of the carboxyflourescein succinimidyl ester, or CFSE, labeled T cells homing to mesenteric lymph nodes observed with our small molecule &#945;4&#946;7 inhibitor and DATK32, a mouse surrogate of vedolizumab in the assay. All treatment groups showed a statistically significant difference (***p&lt;0.0001) compared to vehicle, using a one-way analysis of variance (ANOVA), followed by Bonferroni&#8217;s multiple comparison test. MORF-057 exhibited good in vitro permeability, resulting in high oral exposure in multiple preclinical models. In addition, MORF-057 has a low to moderate clearance and moderate half-life in animal species, supporting twice daily use in human. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><img src="morf-20221231_g8.jpg" alt="morf-20221231_g8.jpg" style="height:298px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 3. The left panel on the left shows the mechanism of the &#945;4&#946;7expressing lymphocytes in IBD. The &#945;4&#946;7expressing lymphocytes traffic to the gut and adhere to MAdCAM, followed by extravasation and migration to the inflammation site. The panel on the right shows the results of the in vivo assay to detect activity of our product candidates as compared to a mouse surrogate of vedolizumab.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MORF-057 has also been shown to inhibit &#945;4&#946;7 CD4+ T cell trafficking to mucosal sites in a non-human primate model. In this model inhibition of the trafficking of cells to the intestine was monitored indirectly by observing their resulting increase in systemic circulation. Figure 4 below shows that MORF-057 dosed orally twice daily increases the level of T memory cells in circulation in a statistically significant manner.</span></div><div style="text-align:center"><img src="morf-20221231_g9.jpg" alt="morf-20221231_g9.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 4: Fold change in % &#945;4&#946;7 high T memory cells following oral dosing of MORF-057 in non-human primate. Means and SD of data normalized per individual at timepoint 0h (first dose administration). T test analysis was performed at each timepoint. Statistical significance determined using the Holm-Sidak method, with alpha = 0.05. ** p &lt; 0.01, *** p &lt; 0.001.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translational biomarkers such as receptor occupancy, or RO, have been validated as a PD marker in preclinical studies and early clinical trials of vedolizumab. When a product candidate binds to &#945;4&#946;7, it occupies the integrin ligand binding site and interferes with the ability of MAdCAM to bind and contribute to immune cell accumulation into the inflamed gut tissue. An assay that measures binding of the product candidate to &#945;4&#946;7 in lymphocytes in circulating blood is termed a blood based &#945;4&#946;7 RO assay. Free &#945;4&#946;7 and &#945;4&#946;1 signal intensities were inhibited by increasing concentrations of MORF-057. The results in Figure 5 also show that MORF-057 is highly potent and selective for &#945;4&#946;7. The RO assay exhibits almost identical performance between healthy subjects and UC patients. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img src="morf-20221231_g10.jpg" alt="morf-20221231_g10.jpg" style="height:255px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 5 left: Calculated percentage &#945;4&#946;7 and &#945;4&#946;1 occupancy at varying MORF-057 concentrations in blood isolated from healthy subjects and ulcerative colitis patients. Data are mean &#177; SD of 26 donors. Table 5 right: MORF-057 is a potent and selective inhibitor of &#945;4&#946;7 over &#945;4&#946;1 in human whole blood ex vivo in both normal healthy volunteers and UC patients. Values are the mean &#177; standard deviation.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development Overview</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we announced the initiation of a healthy volunteer Phase 1 clinical trial, with SAD, FE and MAD cohorts to evaluate the safety and PK profile of multiple doses of MORF-057. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we announced preliminary results from the Phase 1 SAD clinical trial of MORF-057 demonstrating that MORF-057 was well tolerated in all dose cohorts ranging from 25 mg to 400 mg, achieved greater than 95% mean receptor occupancy of &#945;4&#946;7 integrin at the three highest dose levels, and demonstrated the potential to saturate the &#945;4&#946;7 receptor with oral administration. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021, after completion of the MAD and food effect portions of the MORF-057 clinical program, we reported the full data set from the Phase 1 clinical trial at the European Crohn&#8217;s and Colitis Organisation (ECCO) 2021 Virtual Congress. The full MORF-057 Phase 1 study included SAD, MAD and FE cohorts evaluating MORF-057 safety, PK, and PD. Healthy subjects were randomized 3:1 to receive a single dose of MORF-057 at 25, 50, 100, 150 and 400 mg or matching placebo in the SAD cohorts; or twice daily (BID) doses of 25, 50 and 100 mg MORF-057 or matching placebo for a total of 14 days in the MAD cohorts. A total of 67 eligible healthy subjects were enrolled into the studies, with 36 in the SAD, nine in the FE and 22 in the MAD cohorts. 66 subjects completed study treatment and one from the 50 mg BID MAD cohort withdrew consent for personal reasons.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MORF-057 was well tolerated in all cohorts and no safety signals were identified. MORF-057 demonstrated a favorable PK profile, where target engagement was confirmed, and a clear PK and PD relationship was established. MORF-057 was rapidly absorbed and systemic exposure was confirmed to increase approximately dose proportionally. The FE results suggest food intake has no impact on trough MORF-057 levels and that MORF-057 can be administered without regard to food in planned studies in patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img src="morf-20221231_g11.jpg" alt="morf-20221231_g11.jpg" style="height:260px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 6: Receptor Occupancy with dose and study day, achieving saturation (&gt;99%) in individuals in each cohort above 25 mg.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;4&#946;7 receptor occupancy increased with dose and study day, achieving saturation (&gt;99% RO) (Figure 6) in individual patients from all cohorts above 25 mg by day 14. In the 100 mg BID cohort, MORF-057 saturated the &#945;4&#946;7 receptor (mean RO &gt;99%) at all measured timepoints. Dose-and time-dependent changes in biomarkers including specific &#945;4&#946;7 high expressing immune cell populations were observed, adding to evidence of proof of biology for MORF-057. These changes were consistent with those reported with other integrin inhibitors including the antibody drug vedolizumab which is approved for the treatment of IBD. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the MORF-057 Phase 1 study, subjects receiving MORF-057 at 200 mg BID twice daily demonstrated &#945;4&#946;7 receptor saturation and statistically significant increases in circulating central memory, effector memory T lymphocyte and switched memory B lymphocyte populations compared with placebo (Figure 7). At the 25 mg and 50 mg BID exploratory doses, directionally increasing trends were also observed in key pharmacodynamic measures. All doses were well tolerated, no safety signals were identified, and a favorable pharmacokinetic profile was observed. In both single doses of 200 mg MORF-057 and 200 mg BID over the 14 days, MORF-057 demonstrated &#945;4&#946;7 receptor saturation at C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">trough</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Statistically significant changes in lymphocyte subset populations and CCR9 mRNA were observed, consistent with previous studies. The full Phase 1 data set strongly supported the progression of MORF-057 into Phase 2 studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img src="morf-20221231_g12.jpg" alt="morf-20221231_g12.jpg" style="height:246px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Figure 7: Lymphocyte subset populations were measured using multi-color flow cytometry. Subjects receiving MORF-057 at 100 mg BID and 200 mg BID demonstrated statistically significant increases in circulating lymphocyte subsets, consistent with mechanistic expectations.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EMERALD Program in IBD</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results from the Phase 1 studies, we initiated a Phase 2 clinical trial of MORF-057 in March 2022. EMERALD-1 (MORF-057-201), which is an open-label multi-center Phase 2a trial designed to evaluate the efficacy, safety and tolerability of MORF-057 in adults with moderate to severe UC, completed targeted enrollment in October 2022, with 30 patients enrolled in the study. Additionally, patients that were undergoing screening at the time the study completed targeted enrollment were enrolled in the study for a total of 35 patients enrolled in the main cohort. Enrollment of an exploratory cohort of up to ten patients who have previously failed treatment with vedolizumab is ongoing. Patients enrolled in the EMERALD-1 study are being treated with 100 mg BID (twice daily) at sites in the United States and Poland. The primary endpoint of the trial is the change in Robarts Histopathology Index (RHI), a validated instrument that measures histological disease activity in ulcerative colitis at 12 weeks compared to baseline. Patients will then continue for an additional 40 weeks of maintenance therapy followed by a 52-week assessment. Secondary and additional outcome measures in the EMERALD-1 study include change in the modified Mayo clinic score, safety, PK parameters and key PD measures including &#945;4&#946;7 receptor occupancy and lymphocyte subset trafficking. We expect that primary endpoint data from the main cohort of the EMERALD-1 Phase 2a trial of MORF-057 in patients with moderate to severe UC will report in the second quarter of 2023. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img src="morf-20221231_g13.jpg" alt="morf-20221231_g13.jpg" style="height:292px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Figure 8. EMERALD-1 Phase 2 trial design</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EMERALD-2 (MORF-057-202) which is a global Phase 2b randomized controlled trial of MORF-057 began in November 2022. Patients enrolled in the EMERALD-2 study will be randomized to receive one of three active arms or a placebo arm: 100 mg BID (twice daily), 200 mg BID, and a QD (once daily) arm, or a placebo arm which will cross over to MORF-057 after the 12-week induction phase. The primary endpoint of the trial is the clinical remission rate as measured by the modified Mayo score at 12 weeks. The secondary endpoints will include the change in RHI, pharmacokinetic and pharmacodynamic measures, as well as safety parameters. Following the 12-week induction phase, patients will move to a 40-week maintenance phase. We believe that we will achieve completion of the primary endpoint from the EMERALD-2 Phase 2b trial of MORF-057 in patients with moderate to severe UC in the first half of 2025.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><img src="morf-20221231_g14.jpg" alt="morf-20221231_g14.jpg" style="height:307px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">FIGURE 9. EMREALD-2 Phase 2b trial design</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the progress achieved with MORF-057, we paused a second-generation &#945;4&#946;7 development candidate in the pre-IND stage during 2022, to focus on the advancement of MORF-057 through Phase 2 clinical programs. However, we continue to expand our &#945;4&#946;7 portfolio and have positioned next-generation &#945;4&#946;7 small molecule development candidates for clinical studies in the future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Preclinical and Discovery Efforts</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Next-generation &#945;4&#946;7 Integrin inhibitors for GI Diseases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the well-understood biology of &#945;4&#946;7 inhibition and our progress with the MORF-057 program, Morphic has discovered and is advancing a family of next-generation &#945;4&#946;7 inhibitors through pre-clinical development with an initial therapeutic focus on potential development in GI indications beyond IBD, including eosinophilic gastrointestinal disorders (EGIDs), pouchitis and other indications.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#945;v&#946;8 Integrin inhibitor program for myelofibrosis and immuno-oncology</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have advanced our &#945;v&#946;8 integrin inhibitor through preclinical development for the treatment of myelofibrosis and solid tumors. Based on the development path and commercial tractability of myelofibrosis, we have prioritized our &#945;v&#946;8 inhibitor program in myelofibrosis over our immune-oncology program in solid tumors as we await clinical and competitive landscape developments from external &#945;v&#946;8-targeted programs in immune-oncology.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrin &#945;v&#946;8 mediates cell type specific and tissue localized activation of TGF-&#946;1/3 which is a regulator in the myelofibrotic pathway. This program is in preclinical development. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Myelofibrosis (MF) is a subtype of myeloproliferative neoplasm (MPN), a group of hematologic malignancies manifested with the overproduction of blood cells (erythrocytes, leukocytes, or platelets). Three MPN subtypes have been identified: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PV or ET can progress into myelofibrosis (post-PV MF and post-ET MF, respectively). Constitutive activation of JAK-STAT signaling plays a central role in the pathogenesis of MF. Progression from the early stage MPN to MF is associated with the accumulative expansion of aberrant hematopoietic stem cells (HSCs), carrying somatic mutations acquired decades before disease manifestation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phenotypic mutations in the JAK2, CALR, and MPL genes are associated with most cases of MF. MF is characterized by cytopenias, burdensome symptoms, splenomegaly, progressive bone marrow (BM) fibrosis, and extramedullary hematopoiesis as a response to profibrotic changes and cytokine abnormalities in the BM niche. The overall survival (OS) is poor, typically between 5-7 years on average.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rationale for &#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> inhibition in MF is based on its role in TGF&#946; activation. Inhibition blocks &#945;v&#946;8 -mediated TGF-&#946;1 and TGF-&#946;3 activation, to enable tissue-specific and localized inhibition of TGF-&#946; signaling. TGF-&#946; likely plays a critical role in the pathogenesis of myeloproliferative neoplasms and myelofibrosis (MF) progression. It&#8217;s upregulated in MF patients, promoting collagen deposition and bone marrow fibrosis, hallmarks of MF. It is reported to have a direct effect on megakaryopoiesis, inhibiting megakaryocyte maturation and platelet production. Additionally, it promotes dormancy of normal but not MF hematopoietic stem cells. Inhibiting the TGF-&#946; signaling pathway in MF is expected to decrease the fibrogenic stimuli leading to MF and concomitantly restore megakaryocyte maturation and normal hematopoiesis by increasing the number of wild-type but not mutated progenitor cells. &#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> antagonism provides the benefit of isoform-selective TGF-&#946;1 and 3 inhibition to avoid global inhibition of TGF-&#946; signaling and prevent adverse toxicities, including cardiovascular, and pro-neoplastic. &#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is expressed on cell types related to MF pathogenesis, being a key mediator of TGF-&#946; activation in the bone marrow. Thus, the &#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> inhibitor allows for local and cell-type-specific suppression of TGF-&#946; signaling, within the pathogenic niche. The only approved therapies are JAK inhibitors that do not report any improvement in fibrosis, erythrocytes, and platelets.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TGF-&#946; is also a key regulator of inflammation and immunity that plays a crucial role in tumor formation, progression, and metastasis. In the tumor microenvironment (TME) TGF-&#946; is upregulated, allowing cancer cells to escape immune surveillance, impeding the immune system from mounting an anticancer response. TGF-&#946; overexpression is linked to poor clinical outcomes and checkpoint resistance. In agreement, TGF-&#946; inhibition was shown to enhance the efficacy of immune-checkpoint inhibitors by facilitating T cell anti-tumor immunity in animal models. Currently, multiple clinical trials by others that combine checkpoint inhibitor blockade and TGF-&#946; inhibition are ongoing against various solid tumors. However, TGF-&#946; plays important homeostatic roles across tissues and broad inhibitors of the pathway have encountered safety issues in the clinic.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;v&#946;8 has a well-described function in maintaining gut immune-homeostasis. &#945;v&#946;8 integrin on dendritic cells (DC) and other immune cells activates TGF-&#946;, induces tolerance and facilitates the generation of intestinal regulatory T cells (Treg). &#945;v&#946;8 on Tregs is crucial for Treg-mediated suppression of inflammatory T cells. Moreover, &#945;v&#946;8 regulates monocyte inflammatory responses and intestinal macrophage homeostasis. Overall, acting across different immune cell types, &#945;v&#946;8 is crucial for the negative regulation of adaptive immunity, and promotion of immune homeostasis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on described biology, &#945;v&#946;8 has the potential to systemically regulate tolerance, including tumor immune tolerance. The target is expressed in solid tumor and tumor stroma cells, including both immune and non-immune cells. The integrin modulator is expected to have several mechanisms of action, including inhibition of tumor intrinsic and extrinsic TGF-&#946; resulting in increased tumor infiltrating lymphocytes by effects including suppression of Treg, stimulation of antigen presentation by DC and reduced activity of cancer associated fibroblasts. For this program, chemical matter has advanced thanks to synergistic structure activity relationship, or SAR, screening with other integrin modulator programs. The crystal structure of the target integrin was elucidated for the first time in the field using our MInT Platform. Several of our compounds have been co-crystalized to fuel our understanding of the features driving compound selectivity and potency. Target validation and translational biology efforts are underway using small-molecule inhibitors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efficacy has been established in a number of syngeneic murine tumor models. For example, in an immune-excluded model of breast cancer (EMT6), a Morphic small molecule inhibitor reversed insensitivity to immune checkpoint blockade (ICB; Figure 10). Significant improvements in tumor burden and survival were accompanied by increased T cell infiltrates and evidence for reduced tumor tolerance. Inhibition of integrin &#945;v&#946;8 in combination with low dose radiation induces antitumor effects in an advanced immune checkpoint blockade refractory tumor model (Figure 11). These results suggest that an orally administered &#945;v&#946;8 targeted inhibitor has the potential to modulate anti-tumor immune response by acting across the immunologic synapse.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><img src="morf-20221231_g15.jpg" alt="morf-20221231_g15.jpg" style="height:228px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 10: Efficacy in the EMT6 syngeneic murine model of breast cancer following dosing days 6 through 27 following tumor implantations. The panel on the left shows that the combination causes a greater reduction in tumor volume than vehicle or single agents. The panel on the right shows that animals treated with the combination survive longer than vehicle or single agents.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><img src="morf-20221231_g16.jpg" alt="morf-20221231_g16.jpg" style="height:183px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%">Figure 11: (1A) Effect of combination therapy with low dose radiation (small animal radiation research platform (SARRP) at 5 Gray (Gy) on the day of staging (day 10)), PD-1 mAb (10 mg/kg twice weekly for 2 weeks) and &#945;v&#946;8mAb (7 mg/kg three times weekly for 3 weeks) measured by tumor burden. 5Gy+PD-1 and 5Gy+&#945;v&#946;8 has a minimal effect on tumor growth inhibition showing slight improvement relative to radiation alone (5Gy+IgG). Addition of &#945;v&#946;8 antagonism (5Gy+&#945;v&#946;8+PD-1) improves anti-tumor responses leading to CR in 8 of 10 mice. (1B) Kaplan-Meier Curve presenting time to progression. 5Gy+IgG improved survival over monotherapy with either &#945;v&#946;8 or PD-1 mAb. 5Gy+&#945;v&#946;8+PD-1 resulted in profound improvement of the survival over all other treatment conditions.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Integrin inhibitor program for pulmonary hypertensive diseases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inhibition of fibronectin integrins has been shown in preclinical studies to drive multiple key independent processes in hypertensive diseases including reversal of pulmonary vasculature remodeling, prevention of right ventricular fibrosis and improvement of cardiomyocyte metabolic efficiency. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by pulmonary vascular remodeling, resulting in high pulmonary artery pressure and progressive right ventricular (RV) dysfunction. Current treatments, which target the prostacyclin, endothelin-1, or nitric oxide pathways, slow disease progression. However, the 5-year survival rate of approximately 60% highlights the need for therapies targeting alternative pulmonary vascular remodeling pathways. It is now recognized that, like cancer cells, pulmonary artery (PA) smooth muscle cells (PASMCs) exhibit exaggerated proliferation and resistance to apoptosis in response to increased PA stiffness caused by extracellular matrix (ECM) remodeling. Integrins are known to promote cell proliferation, survival, hypertrophic growth and fibrosis, which are key elements in the progression of PAH, thus integrin expression and their effects on PA remodeling and RV failure was examined (Bonnet et. al. presented at AHA 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Circulation. 2021; 144:A10717).</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expression of fibronectin binding integrins is significantly increased in distal pulmonary arteries, pulmonary artery smooth muscle cells and the right ventricle from PAH patients. In addition, increased expression was found in monocrotaline (MCT) and pulmonary artery banding (PAB) rats. Pharmacological inhibition of fibronectin binding integrin in vitro decreased PAH pulmonary artery smooth muscle cells proliferation and resistance to apoptosis which were associated with a decreased activation of integrin downstream signaling pathways. In cardiomyocytes and human right ventricular fibroblasts, inhibition of these integrins decreased hypertrophy and right ventricular fibroblasts activation and proliferation. Inhibition of fibronectin binding integrins improved vascular remodeling and right ventricular function in vivo as assessed by echocardiography and right heart catheterization in MCT rats with established PAH. Broad-spectrum integrin inhibition resulted in improvements in vascular remodeling and RV failure, suggesting that integrins play an important role in the pathophysiology of PAH (Figure 12).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This understanding of fibronectin binding integrins is guiding Morphic in the identification of which integrins are important in PAH pathophysiology and translating those results into approaches for clinical development.</span></div><div style="text-align:center"><img src="morf-20221231_g17.jpg" alt="morf-20221231_g17.jpg" style="height:168px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Figure 12: Pharmacological inhibition of fibronectin binding integrins with a broad-spectrum integrin small molecule inhibitor (SMi) with and without standard of care (SOC) reverses PAH in MCT-rat model with established PAH. The use of combination SOC and SMi preserves RV function.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional new integrin programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy has enabled the identification of small molecules of multiple integrin targets that allow in-depth interrogations of these mechanisms. We are pursuing additional integrin modulator programs for fibrosis-related indications such as NASH, fibrostenosis, biliary fibrosis, and pulmonary arterial hypertension. Due to the role of integrins in TGF-&#946; activation, mechano-transduction, cell migration and cell proliferation, integrins may trigger different pathways to initiate or exacerbate fibrosis under various pathophysiologic states and their inhibitors may be distinctly well suited for treatment in the context of different organ systems. These programs are at different discovery stages, with at least one of them expected to transition to lead optimization over the next twelve to eighteen months.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, we entered into a research and development collaboration with AbbVie designed to advance a number of our oral integrin therapeutics, including our &#945;v&#946;6&#8211;specific integrin program, for fibrosis-related indications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie subsequently informed us that they did not intend to advance any of our selective oral &#945;v&#946;6-specific integrin inhibitors due to a suspected on-target/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &#945;v&#946;6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mediated safety signal that was observed in pre-clinical testing, the details of which were published in the Society for Toxicology journal in December 2022. In June 2022, AbbVie informed us that it had decided to exercise its right to terminate the AbbVie Agreement for convenience, which termination became effective in December 2022, and as a result we will not receive any additional payments under the AbbVie Agreement. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Agreement</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into an agreement with Janssen, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. The Janssen collaboration focused on three integrin targets, each target the subject of a research program, with the ability to substitute up to two integrin targets not explored by us. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, Janssen informed us that it had decided to exercise its right to terminate the Janssen Agreement for convenience, subject to a 60 day notification period. The Janssen Agreement will terminate effective March 2023 or earlier if agreed to by us and Janssen. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Schr&#246;dinger Agreement</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a collaboration agreement (as amended) with Schr&#246;dinger, or Schr&#246;dinger Agreement, to explore drug targets selected by us. Under the collaboration, Schr&#246;dinger will use its technology platform to perform virtual screens, and we and Schr&#246;dinger will collaborate to facilitate prioritization of targets, perform target validation and analysis, identify leads and perform lead optimization. Under the terms of the agreement, Schr&#246;dinger will exclusively work with us on integrin targets during the term of the agreement. In consideration for its performance of activities under the collaboration, Schr&#246;dinger received approximately 3.4 million units of Series Seed preferred units. In addition, with respect to compounds identified as part of the collaboration, Schr&#246;dinger may be eligible to receive certain payments from us related to development milestones, not to exceed in the aggregate $3.1 million, on a target-by-target basis, a low six-figure payment upon initiation of lead optimization and on a compound-by-compound basis, as well as royalties in the low single digits on sales of products containing such compounds. In addition, we have agreed to pay Schr&#246;dinger a percentage, in the mid-single digits, of certain payments we receive from third parties in connection with the licensing or transfer of the rights to exploit such compounds to such third parties, and a one-time fee of $1.0 million paid in 2019. Schr&#246;dinger may terminate the Schr&#246;dinger Agreement under certain circumstances, including if a certain number of developmental milestones have not been achieved by us within a certain timeframe.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we expanded our access as a special Schr&#246;dinger software customer enabling utilization of their software suite beyond the scope of integrins. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Children&#8217;s Medical Center Corporation Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, we entered into an exclusive license agreement (as amended) with CMCC, or CMCC Agreement, relating to technology on inhibiting integrins developed by Dr. Springer during his employment at Boston Children&#8217;s Hospital, an affiliate of CMCC. Under this agreement, we have an exclusive license under certain patent rights, and a non-exclusive license under certain know-how, owned by CMCC to develop and commercialize products worldwide for any therapeutic or diagnostic use in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">humans and veterinary applications. We also have the option to add new patent rights and know-how generated by the laboratory of Dr. Springer within a specified time after the effective date of the CMCC Agreement to that agreement for additional payments consistent with fair market value. In consideration of the license grants, upon execution of the CMCC Agreement we issued CMCC a number of shares of common stock representing 6% of the then issued and outstanding units on a fully diluted basis. We also paid CMCC an upfront license issue fee of $50,000, and reimbursed CMCC for certain patent prosecution costs. We have also agreed to pay CMCC a license maintenance fee for the first three years after the effective date of the CMCC Agreement, certain development milestones, a percentage of sublicensing income we may receive, and running royalties in the low single digits on net sales of licensed products.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CMCC Agreement, we have agreed to use commercially reasonably efforts to bring one or more licensed products to market, and to implement activities in a development plan within the timeframes set forth therein. In addition, if we fail to meet one or more specific developmental milestones, and do not take appropriate corrective action, then CMCC shall have the right to terminate the agreement.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, in part, on our ability to protect (i) our intellectual property related to our product candidates and related methods, and (ii) our MInT Platform for generating integrin structures and modulators of those structures. Our success also depends on having the freedom to operate to enable commercialization of our product candidates, if approved, and preventing others from infringing our patent rights. We protect our MInT Platform using trade secrets, proprietary know-how, and, on rare occasion, patents. We protect our small molecule products using patents, and our policy is to seek product patent protection in key jurisdictions, including the United States, major European countries, and other jurisdictions we deem appropriate or as required by our collaboration agreements.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file patent applications with respect to claims to compositions comprising our small-molecule inhibitors that modulate integrin activity, the compounds themselves, the use of such compounds to treat disease, as well as related manufacturing methods.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusively licensed issued U.S. patents and pending U.S. patent applications from CMCC with claims relating to modified integrin polypeptides and modified integrin polypeptide dimers. The licensed U.S. patents and any other U.S. patents that may issue from the pending U.S. patent applications are expected to expire in 2035, absent any adjustments or extensions. In addition, we rely extensively on trade secret protection for our MInT Platform, which extends beyond the initial integrin technology licensed from CMCC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we solely owned various issued patents and pending patent applications with respect to compositions of matter and methods of use for treating therapeutic indications related to the &#945;4&#946;7 integrins in the United States and many other major jurisdictions worldwide, including Europe, Japan and China. The expected expiration dates for the patents (or patent applications if granted) directed to our &#945;4&#946;7 program compounds are between 2039 and 2041 plus any extensions or adjustments of term available under national law. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property Protection</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether the patent applications we pursue will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide any proprietary protection from competitors. Further, any issued patents may expire before the expected expiration dates disclosed above due to actions taken during patent prosecution, such as submission of a disclaimer surrendering the term of a patent beyond a certain date. Even if our pending patent applications are granted as issued patents, those patents, as well as any patents we license from third parties, may be challenged, circumvented or invalidated by third parties. While there are currently no contested proceedings or third-party claims relating to any of the patent applications described above, we cannot provide any assurances that we will not have such proceedings or third-party claims at a later date or once any patent is granted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of a patent depends upon the legal term of patents in the particular country in which it is obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent that covers an FDA-approved drug may be eligible for patent term extension, which permits in some cases restoration of patent term as compensation for patent term lost during the FDA regulatory review process. In certain circumstances, the Hatch-Waxman Act permits a patent term extension of up to five years beyond the unextended expiration date of the U.S. patent. The length of the patent term extension is related to the length of time the approved drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended. Provisions are available in Europe </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other foreign jurisdictions to extend the term of a patent that covers an approved drug, or provide an additional period of protection for the approved pharmaceutical product following expiry of the patent. In the future, if our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the U.S. Patent and Trademark Office in the United States and the national patent offices in Europe, will agree with our assessment of whether such extensions should be granted, and, if granted, the length of such extensions.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our reliance on patent protection for our inventions, product candidates, and research programs, we also rely on trade secret protection for our confidential and proprietary information. For example, certain elements of our MInT Platform may be based on unpatented trade secrets that are not publicly disclosed. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential, and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides guidance on our expectations and practices to protect our trade secrets.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, all of our clinical manufacturing facilities for clinical drug manufacturing, storage, distribution or quality testing is outsourced to third-party manufacturers. As our development programs progress and we build new process efficiencies, we expect to continually evaluate this strategy with the objective of satisfying demand for registration trials and, if approved, the manufacture, sale and distribution of commercial products. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. While we believe that our MInT Platform and our knowledge, experience and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite significant biopharmaceutical industry investment, no oral integrin therapies have been approved in the United States or Europe. We are developing MORF-057, an oral small molecule &#945;4&#946;7-specific integrin inhibitor,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of IBD. Currently approved IBD therapies include Entyvio (vedolizumab), an injectable &#945;4&#946;7 monoclonal antibody marketed by Takeda Pharmaceutical Company Limited, as well as therapies with different mechanisms of action marketed by AbbVie, Johnson &amp; Johnson, UCB, Biogen Inc., Pfizer Inc., and Bristol-Myers Squibb, in addition to other pharmaceutical companies, against which our product candidate may compete, if approved. Further, we are aware of oral &#945;4&#946;7 therapies in clinical development for IBD by Protagonist Therapeutics, Inc., Gilead Sciences, Inc., and EA Pharma Co. LTD, as well as therapies with different mechanisms of action in clinical development by AbbVie, Johnson &amp; Johnson, Pfizer, Inc., Eli Lilly and Company, and Bristol-Myers Squibb, in addition to other pharmaceutical companies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our &#945;v&#946;8-specific small molecule integrin inhibitor program is under development for the treatment of myelofibrosis and solid tumors. Currently approved myelofibrosis therapies include the oral JAK inhibitors Jakafi (ruxolitinib), marketed by Incyte Corp and Novartis International AG, Inrebic (fedratinib), marketed by Bristol-Myers Squibb, and Vonjo (pacritinib), marketed by CTI Biopharma Corp. We are aware of myelofibrosis therapies in clinical development by GSK plc., MorphoSys AG, Incyte Corp, Geron Corporation, AbbVie, and Bristol-Myers Squibb. There are currently no approved &#945;v&#946;8 inhibitors for any indication. We are aware of an anti-&#945;v&#946;8 monoclonal antibody in clinical development for the treatment of solid tumors by Pfizer, Inc. In addition, we are aware of preclinical stage anti-&#945;v&#946;8 monoclonal antibody programs for solid tumors from Venn Therapeutics and Corbus Pharmaceuticals Holdings, Inc., and a small molecule program from Pliant Therapeutics. Furthermore, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">there are multiple antibody and small molecule therapeutics targeting the TGF-&#946; pathway for the treatment of solid tumors in development by Novartis International AG, AbbVie, Roche Holding AG, Merck &amp; Co., Inc., Bristol-Myers Squibb, and Scholar Rock, in addition to other pharmaceutical companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Additionally, our competitors may also include companies that are or will be developing therapies for the same therapeutic areas that we are targeting, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical product development for a new product or certain changes to an approved product in the U.S. typically involves preclinical laboratory and animal tests, the submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with good clinical practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board, or IRB, and ethics committee for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a drug demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial may be sufficient in rare instances, including (1) where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2) when in conjunction with other confirmatory evidence.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturer of an investigational drug in a Phase 2 or 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture and controls. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $3,200,000 for Fiscal Year 2023, and the manufacturer and/or sponsor under an approved NDA are also subject to annual program fees, currently exceeding $390,000 for each prescription product for Fiscal Year 2023. These fees are typically increased annually. Sponsors of applications for drugs granted Orphan Drug Designation are exempt from these user fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of an NDA to determine whether the application will be filed based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is filed, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs to encourage timeliness. Most applications for standard review drug products are reviewed within ten to twelve months of the date of submission of the NDA to the FDA; most applications for priority review drugs are reviewed in six to eight months of the date of submission of the NDA to the FDA. Priority review can be applied to drugs that the FDA determines offer major advances in treatment or provide a treatment where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an outside advisory committee &#8212; typically a panel that includes clinicians and other experts &#8212; for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practices, or cGMPs, is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, The FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track Designation and Accelerated Approval</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for Fast Track Designation within 60 days of receipt of the sponsor&#8217;s request. If a submission is granted Fast Track Designation, the sponsor may engage in more frequent interactions with the FDA, and the FDA may review sections of the NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, Fast Track Designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDA&#8217;s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.The accelerated approval pathway is contingent on a sponsor&#8217;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. These confirmatory trials must be completed with due diligence and, in most cases, the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Food and Drug Omnibus Reform Act, or FDORA, was recently enacted, which included provisions related to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions of any required post-approval study, which may include milestones such as a target date of study completion and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA not later than 180 days following approval and not less frequently than every 180 days thereafter until completion or termination of the study. FDORA enables the FDA to initiate enforcement action for the failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to priority review by the FDA.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough Therapy Designation</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is also required to expedite the development and review of the application for approval of drugs that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the Breakthrough Therapy program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for Breakthrough Therapy designation within 60 days of receipt of the sponsor&#8217;s request.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drugs</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition &#8212; generally a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan Drug designation must be requested before submitting an NDA. After the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug Designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and an exemption from the NDA application user fee.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure of Clinical Trial Information</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors of clinical trials of FDA regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. With certain exceptions, PREA does not apply to any drug for an indication for which orphan designation has been granted.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Best Pharmaceuticals for Children Act, or BPCA, provides NDA holders a six-month extension of any exclusivity &#8212; patent or nonpatent &#8212; for a drug if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event reporting and submission of periodic reports are required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as Phase 4 testing, risk evaluation and mitigation strategies, or REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the Agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Hatch-Waxman Act</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orange Book Listing</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#8217;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, pre-clinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book. Specifically, the applicant must certify that (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement certifying that its proposed ANDA label does not contain (or carve out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusivity</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon NDA approval of a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which the FDA cannot receive any ANDA seeking approval of a generic version of that drug. An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period. Certain changes to a drug, such as the addition of a new indication to the package insert, can be the subject of a three-year period of exclusivity if the application contains reports of new clinical investigations (other than bioavailability studies) conducted or sponsored by the sponsor that were essential to the approval of the application. The FDA cannot approve an ANDA for a generic drug that includes the change during the exclusivity period.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extension</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the drug&#8217;s testing phase (the time between IND application and NDA submission) and all of the review phase (the time between NDA submission and approval) up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years, and only one patent can be extended. For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the United States Patent and Trademark Office must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain general business and marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes, false claims statutes and other healthcare laws and regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, amended the intent element of the federal statute so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to commit a violation. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal civil and criminal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicare and Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Additionally, the ACA amended the federal Anti-Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal civil False Claims Act. Most states also have statutes or regulations similar to the federal Anti-Kickback Statute and civil False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payor knows or should know is likely to influence the beneficiary to order a receive a reimbursable item or service from a particular supplier, and the additional federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, including the Final Omnibus Rule published on January 25, 2013, impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, and often are not pre-empted by HIPAA.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, pursuant to the ACA, the Centers for Medicare &amp; Medicaid Services, or CMS, has issued a final rule that requires manufacturers of prescription drugs to collect and report information on certain payments or transfers of value to physicians, physician assistants, nurse practitioners or clinical nurse specialists, certified registered nurse anesthetists, certified nurse-midwives and teaching hospitals, as well as investment interests held by physicians and their immediate family members. The first reports were due in 2014 and must be submitted on an annual basis. The reported data is made available in searchable form on a public website on an annual basis. Failure to submit required information may result in civil monetary penalties. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual healthcare practitioners in these states. Other states prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals. Still other states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain drug pricing information, including information pertaining to and justifying price increases, or prohibit prescription drug price gouging. In addition, certain states require pharmaceutical companies to implement compliance programs and/or marketing codes. Certain states and local jurisdictions also require the registration of pharmaceutical sales and medical representatives. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. If a drug company&#8217;s operations are found to be in violation of any such requirements, it may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of its operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other federal or state government healthcare programs, including Medicare and Medicaid, integrity oversight and reporting obligations, imprisonment, and reputational harm. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action for an alleged or suspected violation can cause a drug company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business, even if such action is successfully defended.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Healthcare Reform</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of health care and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the ACA was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. These proposals recently culminated in the enactment of the Inflation Reduction Act, or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IRA, in August 2022, which will, among other things, allow HHS to negotiate the selling price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D, although only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price. Beginning in January 2023 for Medicare Part B and October 2022 for Medicare Part D, the IRA will also penalize drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA authorization under an FDA expanded access program; however, manufacturers are not obligated to provide investigational new drug products under the current federal right to try law.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 102 full-time employees. Of these employees, 43 have an M.D. or a Ph.D. From time to time, we also retain independent contractors to support our organization. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is good.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity &amp; Inclusion</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to creating and maintaining a workplace free from discrimination or harassment on the basis of color, race, sex, national origin, ethnicity, religion, age, disability, sexual orientation, gender identification or expression or any other status protected by applicable law. Our management team and employees are expected to exhibit and promote honest, ethical and respectful conduct in the workplace. All of our employees must adhere to a code of conduct that sets standards for appropriate behavior and are required to attend annual training to help prevent, identify, report and stop any type of discrimination and harassment. Our recruitment, hiring, development, training, compensation and advancement at our company is based on qualifications, performance, skills and experience without regard to gender, race and ethnicity.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competitive Pay &amp; Benefits</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to provide pay, comprehensive benefits and services that help meet the varying needs of our employees. Our total rewards package includes competitive pay, comprehensive healthcare benefits package for employees; family medical leave and flexible work schedules. In addition, we offer every full-time employee, both exempt and non-exempt, the benefit of equity ownership in the company through stock option grants and our employee stock purchase plan. We sponsor a 401(k) plan and we match employee contributions up to a certain limit.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Development &amp; Training</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus on attracting, retaining, and cultivating talented individuals. We emphasize employee development and training by providing access to a wide range of online and instructor led development and continual learning programs. Employees are encouraged to attend scientific, clinical and technological meetings and conferences and have access to broad resources they need to be successful.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The safety, health and wellness of our employees is a top priority. We continue to monitor developments regarding health pandemics or other concerns, including COVID-19, and will implement any safety protocols that may become necessary in the future.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were formed under the laws of the State of Delaware in August 2014 under the name Integrin Rock, LLC. We subsequently changed our name to Morphic Rock Holding, LLC in October 2014 and then to Morphic Holding, LLC in June 2016. On December 5, 2018, we completed a series of transactions, or the Reorganization, pursuant to which Morphic Holding, LLC was converted in a tax-free reorganization into Morphic Holding, Inc. and three wholly-owned subsidiaries, namely Lazuli, Inc., Tourmaline, Inc, and Phyllite, Inc, were merged with and into another wholly-owned subsidiary, Morphic Therapeutic, Inc. Our principal executive offices are located at 35 Gatehouse Drive, A2, Waltham, MA 02451, and our telephone number is (781) 996-0955. Our website address is www.morphictx.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into, this Annual Report.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission, or SEC, under the Securities Exchange Act of 1934, as amended, or Exchange Act. The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC. The public can obtain any documents that we file with the SEC at www.sec.gov. Copies of each of our filings with the SEC can also be viewed and downloaded free of charge at our website, www.morphictx.com, after the reports and amendments are electronically filed with or furnished to the SEC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_19"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks described below, together with the other information contained in this Annual Report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below summary risks provide an overview of many of the risks we are exposed to in the normal course of our business activities. As a result, the below summary risks do not contain all of the information that may be important to you, and you should read the summary risks together with the more detailed discussion of risks set forth following this section under the heading &#8220;Risk Factors,&#8221; as well as elsewhere in this Annual Report on Form 10-K under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Additional risks, beyond those summarized below or discussed in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; may apply to our activities or operations as currently conducted or as we may conduct them in the future or in the markets in which we operate or may in the future operate. Consistent with the foregoing, we are exposed to a variety of risks, including risks associated with: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are a clinical stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have a history of significant losses and expect to continue to incur significant losses for the foreseeable future.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We will need substantial additional funds to advance development of our product candidates, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development programs, commercialization efforts or other operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our product candidates are in early stages of development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may fail in development or suffer delays that materially adversely affect their commercial viability. If we or our collaborators are unable to complete development of, or commercialize, our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our current and future clinical trials or those of any collaborators may reveal significant adverse events not seen in our preclinical studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have historically entered into collaborations and may, in the future, seek to enter into collaborations with third parties for the discovery and development of our therapeutic candidates. If our future collaborators cease development efforts under collaboration agreements, or if those agreements are terminated, the collaborations may fail to lead to commercial products, and we may never receive milestone payments or future royalties under the agreements.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, U.S. or foreign regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, as a result, unable to commercialize our product candidates. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our principal stockholders and management own a significant percentage of our stock and will be able to control matters subject to stockholder approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We face competition from entities that have developed or may develop product candidates for autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Anti-takeover provisions in our charter documents and under Delaware law could prevent or delay an acquisition of us, which may be beneficial to our stockholders, and may prevent attempts by our stockholders.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The exclusive forum provision in our restated certificate of incorporation may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Business and Operations</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations, which could adversely affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ull time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial and other resources. In addition, we have limited experience in product development. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development and regulatory capabilities and contract with other organizations to provide manufacturing and other capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of Praveen P. Tipirneni, M.D., our chief executive officer, as well as other members of our management team, and other key employees and advisors. We currently do not maintain key person insurance on these individuals. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel, and personnel involved with crystallization of integrins in particular, because of the highly technical nature of our product candidates and technologies related to our MInT Platform, and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our operations at our facility in Waltham, Massachusetts. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. If we are unable to continue to attract and retain high-quality personnel, the rate at and success with which we can discover and develop product candidates will be limited, which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth may depend, in part, on our ability to develop and commercialize and/or promote our product candidates in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates in a foreign market before we receive regulatory approval from the applicable regulatory authority in that foreign market, and may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced, our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business, financial condition, results of operations and </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prospects could be materially and adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we conduct clinical trials of our product candidates, we may be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in increased difficulty enrolling participants in clinical trials, termination of clinical trial sites or entire trial programs, withdrawal of clinical trial participants, injury to our reputation and significant negative media attention, significant costs to defend the related litigation, a diversion of management&#8217;s time and our resources from our business operations, substantial monetary awards to trial participants or patients, loss of revenue, the inability to commercialize and products that we may develop, and a decline in our stock price. We currently maintain general liability insurance with coverage up to $10.0 million. We may, however, need to obtain higher levels of product liability insurance for later stages of clinical development or marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with FDA regulations, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we may establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our information technology systems, and any failure of these systems, or those of our CROs or other contractors or consultants we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal data. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from cyber incidents such as third parties getting access to employee accounts using stolen or inferred credentials, computer viruses, phishing attacks,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ransomware attacks, spamming, malware, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization, and attempts to gain unauthorized access to computer systems and networks. Our internal information technology systems and infrastructure is also vulnerable to damage from natural disasters, terrorism, war, telecommunication and electrical failures. System failures or outages could compromise our ability to perform these functions in a timely manner, which could harm our ability to conduct business or delay our financial reporting. Such failures could materially adversely affect our operating results and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of a security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. The occurrence of these and other more sophisticated or state-supported attack campaigns may increase as geopolitical tensions and intermittent warfare continue or escalate outside of the U.S., including, for example, due to the Russia-Ukraine conflict. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable, including the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. In addition, such cyber-attacks, data breaches or destruction or loss of data could result in violation of applicable international privacy, data protection and other laws, resulting in exposure to material civil and/or criminal liability. Further, our general liability insurance and corporate risk program may not cover all potential claims to which we are exposed and may not be adequate to indemnify us for all liability that may be imposed; and could materially adversely affect our business, results of operations, financial condition and prospects. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be affected adversely.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities include the use of hazardous chemicals and materials, including radioactive materials. We maintain quantities of various flammable and toxic chemicals in our facilities in Waltham, Massachusetts that are required for our research and development activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous chemicals and materials. Although we believe that our procedures for storing, handling and disposing such materials in our facilities comply with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the standards mandated by applicable regulations and guidelines, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance, this insurance may not provide adequate coverage against potential liabilities resulting from our employees&#8217; use of these materials, in connection with which we may incur significant </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs and expenses. We also may incur substantial costs to comply with, and substantial fines or penalties if we violate, applicable laws and regulations related to health and human safety and the use, manufacture, storage, handling, and disposal of hazardous chemicals and materials.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by extreme weather events or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operations are concentrated in Waltham, Massachusetts. Any unplanned event, such as a flood, fire, explosion, earthquake, extreme weather condition such as a hurricane or heavy snowstorm, medical epidemic or pandemic, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to our facilities or the manufacturing facilities of our third-party contract manufacturers may result in increased costs, delays in the development of our product candidates or interruption of our business operations. If a natural disaster, power outage or other event occurs that prevents us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical industry in particular are unclear and may heighten or intensify the existing risk of natural disasters. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, we cannot assure you that such insurance coverage will be sufficient to satisfy any damages and losses we may experience. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate for any reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to complex tax rules relating to our business, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income and non-income taxes in the United States. Income tax accounting often involves complex issues, and judgment is required in determining our provision for income taxes and other tax liabilities. We may operate in other non-United States jurisdictions in the future. We could become subject to income and non-income taxes in non-United States jurisdictions as well. In addition, many jurisdictions have detailed transfer pricing rules, which require that all transactions with non-resident related parties be priced using arm&#8217;s length pricing principles within the meaning of such rules. The application of withholding tax, goods and services tax, sales taxes and other non-income taxes is not always clear and we may be subject to tax audits relating to such withholding or non-income taxes. We believe that our tax positions are reasonable. We are currently not subject to any tax audits. However, the Internal Revenue Service or other taxing authorities may disagree with our positions. If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, we may be liable for additional tax and penalties and interest related thereto or other taxes, as applicable, in excess of any reserves established therefor, which may have a significant impact on our results and operations and future cash flow.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had net operating loss, or NOL, carryforwards for federal and state income tax purposes of $$180.3 million and $191.5 million, respectively, which begin to expire in 2037. As of December&#160;31, 2022, we also had available tax credit carryforwards for federal and state income tax purposes of $12.6 million and $5.7 million, respectively, which begin to expire in 2032. To the extent that our taxable income exceeds any current year operating losses, we plan to use our carryforwards to offset income that would otherwise be taxable. However, utilization of carryforwards generated in tax years beginning after December 31, 2017 is limited to a maximum of 80% of the taxable income for such year determined without regard to such carryforwards. In addition, under Section 382 of the Internal Revenue Code (the &#8220;Code&#8221;), changes in our ownership may limit the amount of our net operating loss carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a three-year period. We have not performed an analysis to determine whether there has been an ownership change pursuant to Section 382 of the Code. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carryforwards before they expire. Private placements, our IPO and other transactions that have occurred since our inception or that may occur in the future could result in such an ownership change pursuant to Section 382 of the Internal Revenue Code. Any such limitation, whether as the result of our IPO, prior private placements, sales of our common stock by our existing stockholders or additional sales of our common stock by us, could have a material adverse effect on our results of operations in future years. There is also a risk that due to regulatory changes at the state level, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities. </span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our stockholders or us. We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 (&#8220;Tax Act&#8221;) Tax Act eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five years. The U.S. Congress is considering legislation that would restore the current deductibility of research and development expenditures, however, we have no assurance that the provision will be repealed or otherwise modified</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Capital</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have a history of significant losses and expect to continue to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, MORF-057, has completed a Phase 1 clinical trial in healthy volunteers. We have initiated a Phase 2 program for MORF-057, initially in ulcerative colitis. We have no products approved for commercial sale and have not generated any revenue from commercial product sales to date, and we will continue to incur significant research and development and other expenses related to our clinical development and ongoing operations. For the fiscal year ended December&#160;31, 2022, we reported a net loss of $59.0 million. As of December&#160;31, 2022, we had an accumulated deficit of approximately $297.1 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct clinical trials for our current and any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discover and develop new product candidates, and conduct research and development activities, preclinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture, or have manufactured, preclinical, clinical and commercial supplies of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize our current product candidates or any future product candidates, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attempt to transition from a company with a research focus to a company capable of supporting commercial activities, including establishing sales, marketing and distribution infrastructure;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, scientific and management personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel, including international operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify additional compounds or product candidates and acquire rights from third parties to those compounds or product candidates through licenses; and </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays in our preclinical or clinical studies and regulatory approval for our product candidates due to the impacts of COVID-19 or supply chain disruptions (whether as a result of the impact of the COVID-19 pandemic, the ongoing conflict in the Ukraine, inflation, rising interest rates, the ongoing labor shortage or otherwise).</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we succeed in commercializing one or more product candidates, we may continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated revenue from product sales and may never be profitable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue, unless and until we, either alone or with a collaborator, are able to obtain regulatory approval for, and successfully commercialize, our lead product candidate for our &#945;4&#946;7 program, or any other product candidates we may develop. Successful commercialization will require achievement of many key milestones, including demonstrating safety and efficacy in clinical trials, obtaining regulatory, including marketing, approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our current or future collaborators, may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of any future revenue, the extent of any further losses or if or when we might achieve profitability. We and any current or future collaborators may never succeed in these activities and, even if we do, or any collaborators do, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to become and remain profitable may depress the market price of our common stock and could impair our ability to raise capital, expand our business or continue our operations. If we continue to suffer losses as we have in the past, investors may not receive any return on their investment and may lose their entire investment.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funds to advance development of our product candidates, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development programs, commercialization efforts or other operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of biopharmaceutical product candidates is capital-intensive. If our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand or create our development, regulatory, manufacturing, marketing and sales capabilities. We have used substantial funds to develop our technology and product candidates and will require significant funds to conduct further research and development and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any, which are approved for commercial sale. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities. As of December&#160;31, 2022, we had $348.2 million in cash, cash equivalents and marketable securities. Based on our current operating plan, we believe that our available cash, cash equivalents and marketable securities, along with the $100.0 million raised in our private issuance of common stock and pre-funded warrants in February 2023, will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of 2026. However, our future capital requirements and the period for which we expect our existing resources to support our operations and future capital requirements, may vary significantly from what we expect and we may need to seek additional funds sooner than planned. Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities for approved products. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, cost and progress of preclinical and clinical development activities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of preclinical and clinical programs we decide to pursue;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and/or research and development agreements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of milestone and other payments we may receive or make under our collaboration agreements;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in prosecuting and enforcing patent and other intellectual property claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of manufacturing our product candidates by third parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of regulatory submissions and timing of regulatory approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities if our product candidates or any future product candidates are approved for sale, including marketing, sales and distribution costs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems to satisfy our obligations as a public company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to raise additional funds may be adversely impacted by worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, including as a result of the COVID-19 pandemic, increase in inflation, rising interest rates, the ongoing labor shortage, disruptions to global supply chains, and the ongoing conflict in the Ukraine and the global sanctions imposed in response thereto. If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. To date, we have primarily financed our operations through payments received under our collaboration agreements, the sale of equity securities and debt financing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to seek additional funding in the future and currently intend to do so through public or private equity offerings or debt financings, additional collaborations and/or licensing agreements, credit or loan facilities, or a combination of one or more of these funding sources. If we raise additional funds by issuing equity securities, including pursuant to our currently effective registration statement on Form S-3, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Our future debt financings, if any, are likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. We also could be required to seek collaborators for product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Failure to obtain capital when needed on acceptable terms may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates, which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Discovery, Development and Commercialization</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is heavily dependent on the success of our current and future product candidates, including our lead product candidate for our &#945;4&#946;7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">program. Existing and future preclinical studies and clinical trials of these product candidates may not be successful, and if we are unable to commercialize these product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested a significant portion of our efforts and financial resources in the development of our &#945;4&#946;7- specific integrin inhibitors program. Our ability to generate commercial product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our lead product candidate for our &#945;4&#946;7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program. We have not previously submitted a new drug application, or NDA, to the FDA, or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. In addition, regulatory authorities may not complete their review processes in a timely manner, or additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. Regulatory authorities also may approve a product candidate for more limited indications than requested or with labeling that includes </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warnings, contraindications or precautions with respect to conditions of use. Regulatory authorities may also require Risk Evaluation and Mitigation Strategies, or REMS, or the performance of costly post-marketing clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. In order to obtain separate regulatory approvals in other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of our product candidates, and we may be required to expend significant resources to obtain regulatory approval, which may not be successful, and to comply with ongoing regulations in these jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our current and future product candidates will depend on many factors, including the following actions to be taken by us or our collaborators, as applicable:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of necessary preclinical studies to enable the initiation of clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment of patients in, and the completion of, our clinical trials with favorable results;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving required regulatory authorizations for the development and approvals for the commercialization of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining arrangements with third-party manufacturers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enforcing and defending our intellectual property rights and claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieving desirable therapeutic properties for our product candidates&#8217; intended indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are in early stages of development and may fail in development or suffer delays that materially adversely affect their commercial viability. If we or our collaborators are unable to complete development of, or commercialize, our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products on the market and all of our product candidates are in early stages of development. Additionally, we have a portfolio of targets and programs that are in earlier stages of discovery and preclinical development and may never advance to clinical-stage development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing our product candidates, either alone or with third parties, and we cannot guarantee you that we will ever obtain regulatory approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful or problematic side effects;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical studies conducted outside of the United States may be affected by tariffs or import/export restrictions imposed by the United States or other governments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product-related side effects experienced by patients in our clinical trials or by individuals using drugs or therapeutic biologics similar to our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party manufacturers&#8217; inability to successfully manufacture our products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability of any third-party contract manufacturer to scale up manufacturing of our product candidates and those of our collaborators to supply the needs of clinical trials or commercial sales;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in submitting INDs or comparable foreign applications or delays or failures in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">high drop-out rates of our clinical trial patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain alternative sources of supply for which we have a single source for product candidate components or materials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">harmful side effects or inability of our product candidates to meet efficacy endpoints during clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to demonstrate a benefit-risk profile acceptable to the FDA or other regulatory agencies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable FDA or other regulatory agency inspection and review of one or more clinical trial sites or manufacturing facilities used in the testing and manufacture of any of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">varying interpretations of our data by the FDA and similar foreign regulatory agencies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators&#8217; inability to complete development of, or commercialize our product candidates, or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a pipeline of product candidates using our MInT Platform. Historically, dozens of integrin-targeted oral small molecule candidates of other companies that entered late-stage clinical trials have failed to result in FDA or EMA </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved medicines. Development efforts and clinical results of other companies exploring oral approaches to integrins may be unsuccessful, resulting in a negative perception of oral integrins and negatively impacting the regulatory approval process of our product candidates, which would have a material and adverse effect on our business. We believe that product candidates identified with our MInT Platform may offer an optimized therapeutic approach by taking advantage of conformational targeting next-generation physics-based technologies augmented with machine learning and artificial intelligence, which allow us to design, iterate and optimize leads in our discovery process. However, the scientific research that forms the basis of our efforts to develop product candidates using our MInT Platform is ongoing and may not result in viable product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may ultimately discover that our MInT Platform and any product candidates resulting therefrom do not possess certain properties required for therapeutic effectiveness, including the ability to lock specific integrin conformations. Our product candidates may also be unable to remain stable in the human body for the period of time required for the drug to reach the target tissue or they may trigger immune responses that inhibit the ability of the product candidate to reach the target tissue or that cause adverse side effects in humans. In addition, product candidates based on our MInT Platform may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Our MInT Platform and any product candidates resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. For example, AbbVie informed us that it did not intend to advance any of its selective oral &#945;v&#946;6-specific integrin inhibitors due to a suspected on-target / &#945;v&#946;6-mediated safety signal that was observed in pre-clinical testing, and subsequently exercised its right to terminate the AbbVie Agreement for convenience, which termination became effective in December 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied product candidates. To our knowledge, no regulatory authority has granted approval for an oral small-molecule integrin inhibitor. We believe the FDA has limited experience with integrin-based therapeutics, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We and our existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or an existing or future collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If the products resulting from our MInT Platform and research programs prove to be ineffective, unsafe or commercially unviable, our MInT Platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical development involve a lengthy and expensive process, with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in preclinical or clinical development, and the risk of failure is high for all programs. It is impossible to predict accurately when or if any of our product candidates will receive regulatory approval. To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and lengthy, complex and expensive clinical trials that our product candidates are safe and effective in humans. Clinical testing can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or to unfavorable safety profiles, notwithstanding promising results in earlier trials. There is typically a high rate of failure of product candidates proceeding through clinical trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our future clinical trials will ultimately be successful or support clinical development of our current or any of our future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencement of clinical trials is subject to finalizing the trial design and submitting an IND or similar submission to the FDA or similar foreign regulatory authority. Even after we submit our IND or comparable submissions in other jurisdictions, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our clinical trials or disagree with our study design, which may require us to complete additional preclinical studies or amend our protocols or impose stricter conditions on the commencement of clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may experience delays in initiating or completing clinical trials. We or our collaborators also may experience numerous unforeseen events during, or as a result of, current or future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our integrin inhibitor programs or any future product candidates, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards, or IRBs, the FDA or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial sites may deviate from a trial&#8217;s protocol or drop out of a trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may elect to, or regulators, IRBs, or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of any of our product candidates may be greater than we anticipate;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be inadequate to initiate or complete a given clinical trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to manufacture sufficient quantities of our product candidates for use in clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate as well as data emerging from other molecules in the same class as our product candidate; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies or impose other requirements before permitting us to initiate a clinical trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the number and location of clinical sites we enroll, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the inability to obtain and maintain patient consents, the risk that enrolled participants will drop out before completion, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications being investigated by us. Furthermore, we expect to rely on our collaborators, CROs and clinical trial sites to ensure the proper and timely conduct of our current or future clinical trials, including the patient enrollment process, and we have limited influence over their performance. Additionally, we could encounter delays if treating physicians encounter unresolved ethical issues associated with enrolling patients in current or future clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA, EMA or other regulatory authorities, or if a clinical trial is recommended for suspension or termination by the Data Safety Monitoring Board, or the DSMB, for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA, EMA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of preclinical studies and early clinical trials may not be predictive of results of later clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we could face similar setbacks. As is common for early trials, we may examine a number of efficacy measures without accounting for multiplicity, and positive results in early clinical trials, including nominally statistically significant results, may not be replicated in future trials with a different design or in other future trials. The design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or future collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including differences in trial procedures set forth in protocols, including endpoints, differences in the size and characteristics of the patient populations, differences in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial patients. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim and preliminary or topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim and preliminary or topline data from our anticipated clinical trials. Data from prespecified interim analyses from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data we previously published. As a result, interim and preliminary or topline data should be viewed with caution until the final data are available. Adverse differences between interim, preliminary or topline data and final data could significantly harm our reputation and business prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future clinical trials or those of our current and future collaborators may reveal significant adverse events not seen in our preclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. For example, progressive multifocal leukoencephalopathy, or PML, has been observed by others as an adverse effect during late-stage clinical development of infusible antibody inhibitor of &#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> integrin, natalizumab. This adverse effect was not observed in the preclinical studies or </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during early clinical development of natalizumab. We, the FDA, EMA or other applicable regulatory authorities, or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use our MInT Platform to expand our pipeline of product candidates and develop marketable products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends in part upon our ability to discover, develop and commercialize products based on our MInT Platform. Our lead program for &#945;4&#946;7 and our research programs, or those of our collaborators, may fail to identify other potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or for multiple programs, which would materially harm our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus our research and development efforts on certain selected product candidates. For example, we are initially focused on our lead product candidate, MORF-057, in our &#945;4&#946;7-specific integrin inhibitor program. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from entities that have developed or may develop product candidates for autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of drugs is highly competitive. Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as with technologies and product candidates being developed at universities and other research institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments, including those based on novel technology platforms that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are trying, or may try, to develop product candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and integrin and immunoregulatory therapeutics fields. Competition from many sources exists or may arise in the future. Our competitors include larger and better funded biopharmaceutical, biotechnological and therapeutics companies, including companies focused on therapeutics for autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer, as well as numerous small companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. Some of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our existing or future collaborators. In addition, these companies compete with us in recruiting scientific and managerial talent.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend partially on our ability to develop and commercialize therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, or less expensive than the therapeutics we develop.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite significant biopharmaceutical industry investment, no oral integrin therapies have been approved in the United States or Europe. We are developing MORF-057, an oral small molecule &#945;4&#946;7-specific integrin inhibitor,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of IBD. Currently approved IBD therapies include Entyvio (vedolizumab), an injectable &#945;4&#946;7 monoclonal antibody marketed by Takeda Pharmaceutical Company Limited, as well as therapies with different mechanisms of action marketed by AbbVie, Johnson &amp; Johnson, UCB, Biogen Inc., Pfizer Inc., and Bristol-Myers Squibb, in addition to other pharmaceutical companies, against which our product candidate may compete, if approved. Further, we are aware of oral &#945;4&#946;7 therapies in clinical development for IBD by Protagonist Therapeutics, Inc., Gilead Sciences, Inc, and EA Pharma Co. LTD, as well as therapies with different mechanisms of action in clinical development by AbbVie, Johnson &amp; Johnson, Pfizer, Inc., Eli Lilly and Company, and Bristol-Myers Squibb, in addition to other pharmaceutical companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our &#945;v&#946;8-specific small molecule integrin inhibitor program is under development for the treatment of myelofibrosis and solid tumors. Currently approved myelofibrosis therapies include the oral JAK inhibitors Jakafi (ruxolitinib), marketed by Incyte Corp and Novartis International AG, Inrebic (fedratinib), marketed by Bristol-Myers Squibb, and Vonjo (pacritinib), marketed by CTI Biopharma Corp. We are aware of myelofibrosis therapies in clinical development by GSK plc., MorphoSys AG, Incyte Corp, Geron Corporation, AbbVie, and Bristol-Myers Squibb. There are currently no approved &#945;v&#946;8 inhibitors for any indication. We are aware of an anti-&#945;v&#946;8 monoclonal antibody in clinical development for the treatment of solid tumors by Pfizer, Inc. In addition, we are aware of preclinical stage anti-&#945;v&#946;8 monoclonal antibody programs for solid tumors from Venn Therapeutics and Corbus Pharmaceuticals Holdings, Inc., and a small molecule program from Pliant Therapeutics. Furthermore, there are multiple antibody and small molecule therapeutics targeting the TGF-&#946; pathway for the treatment of solid tumors in development by Novartis International AG, AbbVie, Roche Holding AG, Merck &amp; Co., Inc., Bristol-Myers Squibb, and Scholar Rock, in addition to other pharmaceutical companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these competitors have significantly greater financial, technical, manufacturing, marketing, sales, and supply resources or experience than we have. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current product candidates or any future product candidates may not achieve adequate market acceptance among physicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success, if approved, and we may not generate any future revenue from the sale or licensing of product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approval is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. Historically, several injectable integrin inhibitors have been approved by the FDA for treatment of inflammatory bowel disease, multiple sclerosis, psoriasis, acute coronary syndrome and dry eye disease. However, our product candidates are based on a novel approach to oral integrin therapies, and while integrins are a well-understood receptor family, to date, no oral small molecule integrin therapies have been approved by the FDA. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt an orally bioavailable product based on our novel technologies, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. Market acceptance of our product candidates will depend on, among other factors:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of our receipt of any marketing and commercialization approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any approvals and the countries in which approvals are obtained;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of our product candidates as demonstrated in clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse side effects associated with our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration of our product candidates;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to accept any new methods of administration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable publicity relating to our current product candidates or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our physician education programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of sales and marketing efforts;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement from government and third-party payors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products, particularly as compared to alternative treatments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our product candidates are based on new technology, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a product, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If in the future we are unable to establish U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market any of our product candidates that are approved, we may not be successful in commercializing such product candidates and may not be able to generate any revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able to obtain regulatory approval. To commercialize any product candidates after approval, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or arrange with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which would be expensive and time consuming and would require significant attention of our executive officers to manage. For example, some state and local jurisdictions have licensing and continuing education requirements for pharmaceutical sales representatives, which requires time and financial resources. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the commercialization of our product candidates that obtain regulatory approval, if any, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product candidate, our ability to market and derive revenue from the product candidates could be compromised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in more restrictive labeling or the delay or denial of regulatory approval by the FDA or other regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effects. In such an event, our future clinical trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to initiate or complete the clinical trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receive regulatory approval and we or others identify undesirable side effects caused by such product, any of the following adverse events could occur:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to recall the product or change the way the product is administered to patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a boxed warning or a contraindication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We anticipate that some of our product candidates may be studied in combination with third-party drugs, some of which may still be in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our product candidates may be studied in combination with third-party drugs. The development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. The FDA or other regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of these trials could show that any positive previous trial results are attributable to the combination therapy and not our product candidates. Moreover, following product approval, the FDA or other regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product&#8217;s safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we pursue such combination therapies, we cannot be certain that a steady supply of such drugs will be commercially available. Any failure to enter into such commercial relationships, or the expense of purchasing therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our product candidates as commercially viable combination therapies. The occurrence of any of these could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any future collaborator or supplier becomes unable or unwilling to supply their products on commercially reasonable terms or at all, we would need to identify alternatives for accessing such products. Additionally, should the supply of products of any collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source a supply of any alternative therapy, or are unable to do so on commercially reasonable terms, our business, results of operations and financial condition may be adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically entered into collaborations and may, in the future, seek to enter into collaborations with third parties for the discovery and development of our therapeutic candidates. If our future collaborators cease development efforts under collaboration agreements, or if those agreements are terminated, the collaborations may fail to lead to commercial products, and we may never receive milestone payments or future royalties under the agreements.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have in the past and may in the future seek to enter into collaboration agreements with third parties for the discovery or development of certain integrin-based therapeutics, and such collaborations could represent a significant portion of our product pipeline. We have derived substantially all of our revenue to date from collaboration agreements with third parties, and we may derive a portion of our future revenue from collaboration agreements or other similar agreements into which we may enter in the future. Revenue from research and development collaborations depends upon continuation of the collaborations, payments for research and development services and resulting options to acquire any licenses of successful product candidates, and the achievement of milestones, contingent payments and royalties, if any, derived from future products developed from our research. If we are unable to successfully advance the development of our product candidates or achieve milestones, or if our collaborations are otherwise not successful, revenue and cash resources from milestone payments under any collaboration agreements that we may enter into will be substantially less than expected. AbbVie informed us that it did not intend to advance any of its selective oral &#945;v&#946;6-specific integrin inhibitors due to a suspected on-target / &#945;v&#946;6-mediated safety signal that was observed in pre-clinical testing, and in June 2022, informed us that it had decided to exercise its right to terminate the AbbVie Agreement for convenience, which termination became effective in December 2022. In addition, in December 2021, Janssen informed us that it had decided not to exercise the options on the first two integrin targets under the Janssen Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">due to a lack of target validation in the specific disease of Janssen&#8217;s interest and, in January 2023, informed us that it had decided to exercise its right to terminate the Janssen Agreement for convenience and we have focused efforts on the third integrin research program which includes the potential development of integrin antibody activators. The Janssen Agreement will terminate effective March 2023 or earlier if agreed to by us and Janssen.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may in the future seek third-party collaborators for research, development and commercialization of other therapeutic technologies or product candidates. Biopharmaceutical companies are our prior and likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements. If we fail to enter into future collaborations on commercially reasonable terms, or at all, or such collaborations are not successful or are terminated, including the recent termination of the AbbVie Agreement and the Janssen Agreement, we may not be able to execute our strategy to develop certain targets, product candidates or disease areas that we believe could benefit from the resources of either larger biopharmaceutical companies or those specialized in a particular area of relevance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our existing collaboration agreements, and what we expect will be the case with any future collaboration agreements, we have and expect to continue to have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our product candidates currently pose, and will continue to pose, the following risks to us:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the foregoing, our current and any future collaboration agreements may not lead to development or commercialization of any or all of our product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, to the extent that any of our existing or future collaborators were to terminate a collaboration agreement, including the termination of the AbbVie Agreement and the Janssen Agreement, we may be forced to independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing discovery collaboration with Schr&#246;dinger is important to our business. If we are unable to maintain this collaboration, or if this collaboration is not successful, our business could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a Collaboration Agreement with Schr&#246;dinger, which was subsequently amended in March 2018 and in May 2019, or the Schr&#246;dinger Agreement. Under the collaboration, Schr&#246;dinger will use its technology platform to perform virtual screens of members of the target class of human integrins, and we and Schr&#246;dinger will collaborate to facilitate prioritization of targets, perform target validation and analysis, identify leads and perform lead optimization. Schr&#246;dinger has granted us an exclusive license for all intellectual property for our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we currently rely on Schr&#246;dinger for a substantial portion of our discovery capabilities, if Schr&#246;dinger experiences delays in performance of or fails to perform its obligations under the Schr&#246;dinger Agreement, disagrees with our interpretation of the terms of the collaboration or our discovery plan or terminates the Schr&#246;dinger Agreement, our pipeline of product candidates would be adversely affected. Schr&#246;dinger may also fail to properly maintain or defend the intellectual property we have licensed from them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or subjecting us to litigation or arbitration, any of which would be time-consuming and expensive. Additionally, either party has the right to terminate the collaboration pursuant to the terms of the Schr&#246;dinger Agreement. If our collaboration with Schr&#246;dinger is terminated, especially during our discovery phase, the development of our product candidates would be materially delayed or harmed.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have conflicts with our collaborators that could delay or prevent the development or commercialization of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have conflicts with our collaborators, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration. If any conflicts arise with any of our collaborators, such collaborator may act in a manner that is averse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a collaborator to pay us milestone payments or royalties we believe are due to us under a collaboration, which could require us to raise additional capital; uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the collaborator to cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the part of a collaborator to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating of litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the agreement.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions, including collaboration agreements, that could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may consider strategic transactions, such as collaboration agreements, acquisitions of companies, asset purchases and out or in licensing of product candidates or technologies that we believe will complement or augment our existing business. In particular, we will evaluate and, if strategically attractive, seek to enter into collaboration agreements with third parties, including with major biotechnology or biopharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator terminates the collaboration. In addition, a significant number of recent business combinations among large pharmaceutical companies has resulted in a reduced number of potential future strategic partners. Our collaborators may consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the strategic partner&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed strategic partner&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. Moreover, if we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are not able to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, testing, manufacturing and marketing any new products resulting from a strategic acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that following any such collaboration, or other strategic transaction, we will achieve the expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges, increase our near and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and would have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter any additional collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to conduct certain of our preclinical studies or clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or terminate the relationship, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely and intend to rely in the future on third-party clinical investigators, CROs, clinical data management organizations and consultants to assist or provide the design, conduct, supervision and monitoring of preclinical studies and clinical trials of our product candidates. Because we rely on these third parties and will not have the ability to conduct all preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial as well as applicable legal and regulatory requirements. The FDA generally requires preclinical studies to be conducted in accordance with good laboratory practices and clinical trials to be conducted in accordance with good clinical practices, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials as a result of our reliance on third parties could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers and suppliers to supply components of our product candidates. The loss of our third-party manufacturers or suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate facilities for drug manufacturing, storage, distribution or quality testing. We currently rely, and may continue to rely, on third-party contract manufacturers, including in the U.K. and China, to manufacture bulk drug substances, drug products, raw materials, samples, components, or other materials and reports. Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, terminated or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers or suppliers could require significant effort and expertise because there may be a limited number of qualified replacements. If our third-party manufacturers and suppliers, or any third-party in the supply chain, are adversely impacted, including as a result of the COVID-19 pandemic or global supply chain disruptions, we may be unable to secure the supply of product candidates required for our preclinical studies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. We, and our suppliers and manufacturers, must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices, or cGMPs. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA and foreign regulatory authorities. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our product candidates. Moreover, we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with current regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such to another third party. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines; and we may be required to repeat some of the development program. The delays associated with the validation of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. Any manufacturing facilities used to produce our products will be subject to periodic review and inspection by the FDA and foreign regulatory authorities, including for continued </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance with cGMP requirements, quality control, quality assurance and corresponding maintenance of records and documents. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements, comply with cGMPs or maintain a compliance status acceptable to the FDA or foreign regulatory authorities could adversely affect our business in a number of ways, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to initiate or continue clinical trials of product candidates under development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of the cooperation of existing or future collaborators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to cease distribution or to recall batches of our product candidates; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes, unstable political environments, epidemics or pandemics such as the COVID-19 pandemic, or global supply chain disruptions. If our contract manufacturers were to encounter any of these difficulties, our ability to provide our product candidates to patients in preclinical and clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the U.K. formally left the European Union, or EU, on January 31, 2020, often referred to as Brexit, and the transition period ended on December 31, 2020. However, the EU and the U.K. have concluded a trade and cooperation agreement, or TCA, which has been approved by the UK Parliament, European Council and European Parliament.. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of the U.K. and EU pharmaceutical regulations. As a result, companies now need to comply with a separate UK regulatory legal framework in order to commercialize medicinal products in Great Britain (England, Wales and Scotland). At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). While the regulatory regime in Great Britain therefore currently aligns in the most part with EU regulations, it is possible that these regimes will diverge in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of U.K. and EU pharmaceutical legislation. For example, the new Clinical Trials Regulation which became effective in the EU on January 31, 2022 and provides for a streamlined clinical trial application and assessment procedure covering multiple EU Member States has not been implemented into U.K. law, and a separate application will need to be submitted for clinical trial authorization in the U.K. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the trade and cooperation agreement or otherwise, could prevent us from commercializing any product candidates in the U.K. and/or the EU and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the U.K. and/or EU for any product candidates, which could significantly and materially harm our business. The current lack of detail and resolution with regard to the Brexit implementation may result in a disruption of the manufacturing and supply of components of our product candidates in the U.K. and we are unable to confidently predict the effects of such disruption to the regulatory framework in Europe. Any adjustments we make to our business and operations as a result of Brexit could result in significant delays and additional expense. Any of the foregoing factors could have a material adverse effect on our business, results of operations, or financial condition.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or our third-party contract research organizations, face risks related to health epidemics, pandemics and other outbreaks, including the COVID-19 pandemic, which could significantly disrupt our operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely impacted by the effects of the COVID-19 pandemic or other epidemics or pandemics. If there are closures or other restrictions in the places where we or our manufacturers and suppliers operate, we may experience disruptions to our operations. We have in the past and may in the future experience impacts to certain of our suppliers as a result of the COVID-19 pandemic or other health epidemics or outbreaks occurring in one or more of these locations, which may materially and adversely affect our business, financial condition and results of operations. Further, our operation has in the past and may in the future experience disruptions, including in connection with temporary office closures and suspension of services by our suppliers, which may result in us having to procure the components for our </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates from alternate suppliers, which may materially and adversely affect our development timelines, and our business, financial condition and results of operations. </span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacturing of our molecules is complex and our third-party manufacturers may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are biopharmaceuticals and the process of manufacturing biopharmaceuticals is complex, time-consuming, highly regulated and subject to multiple risks. Our contract manufacturers must comply with legal requirements, cGMPs and guidelines for the manufacturing of biopharmaceuticals used in clinical trials and, if approved, marketed products. Our contract manufacturers may have limited experience in the manufacturing of cGMP batches.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing biopharmaceuticals is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at our third-party manufacturers&#8217; facilities, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our third-party manufacturers&#8217; facilities are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny NDA approval until the deficiencies are corrected or we replace the manufacturer in our NDA with a manufacturer that is in compliance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of raw materials. Even if our collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scaling up a biopharmaceutical manufacturing process is a difficult and uncertain task, and our third-party manufacturers may not have the necessary capabilities to complete the implementation, manufacturing and development process. If we are unable to adequately validate or scale-up the manufacturing process at our current manufacturers&#8217; facilities, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and scale-up the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. If our third-party manufacturers were to encounter any of these difficulties, our ability to provide any product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products, if approved, and could have an adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our process development efforts, we also may make changes to the manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, maintain, and enforce patent protection for our technologies or product candidates, development and commercialization of our product candidates may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of December&#160;31, 2022, we solely owned various issued patents and pending patent applications protecting our integrin therapeutic compounds across multiple programs (including our product candidates) in the U.S. and many other major jurisdictions worldwide, including Europe, Japan and China. In addition, we hold an exclusive, worldwide license agreement with the Children&#8217;s Medical Center Corporation, or the CMCC Agreement, to certain U.S. patents and related pending U.S. patent application(s) relating to modified integrin polypeptides, crystallizable dimers comprising a modified integrin polypeptide, and related methods. We may not be able to apply for patents on certain aspects of our product candidates in a timely fashion or at all. Further, we may not be able to prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of all patent applications that we license from third parties, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our future issued or granted patents will not later be found to be invalid or unenforceable or that any future issued or granted patents will include claims that are sufficiently broad to cover our product candidates or to provide meaningful protection from our competitors. Moreover, the patent position of biotechnology and biopharmaceutical companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates are covered by valid and enforceable patents, or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our position in the market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first inventor to file a patent application is generally entitled to the patent. However, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we, our licensors or collaborators, or any future strategic partners were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we, our licensors or collaborators, or any future strategic partners were the first to file for patent protection of such inventions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a large number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and biopharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary products and technology. The process of obtaining patents is time consuming, expensive and sometimes unpredictable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once granted, for a given period after allowance or grant patents may remain open to opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification, or derivation action in court or before patent offices or similar proceedings, during which time third parties can raise objections against such initial grant. Such proceedings may continue for a protracted period of time and an adverse determination in any such proceedings could reduce the scope of the allowed or granted claims thus attacked, or could result in our patents being invalidated in whole or in part, or being held unenforceable, which could allow third parties to commercialize our product candidates and compete directly with us without payment to us. In addition, there can be no assurance that:</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or license;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors, or our existing or future collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors, or our existing or future collaborators are the first to file patent applications covering certain aspects of our inventions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third party may not challenge our patents and, if challenged, a court would hold that our patents are valid, enforceable and infringed;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any issued patents that we own or have licensed or that we may license in the future will provide us with any competitive advantages, or will not be challenged by third parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may develop additional proprietary technologies that are patentable;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for certain aspects of our product candidates, we also consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. We seek to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, we expect that, over time, our trade secrets, know-how and proprietary information may be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel to and from academic and industry scientific positions. Consequently, without costly efforts to protect our proprietary technology, we may be unable to prevent others from exploiting that technology, which could affect our ability to expand in domestic and international markets. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our products, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral integrin therapies in fibrosis and inflammatory bowel disease or other disease areas are a relatively new scientific field. We have applied for and have obtained a license from a third party on an exclusive basis to U.S. patent filings related to our MInT Platform. Other pending patent applications in the United States and in key markets around the world that we </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">own or license claim many different methods, compositions and processes relating to the discovery, development, and manufacture of small-molecule integrin inhibitor-based and other therapeutics.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the field of small-molecule integrin inhibitor-based therapeutics continues to mature, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material and adverse effect on our business, financial condition, results of operations and prospects or our ability to successfully compete. If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, defending and enforcing patents covering our technology in the United States and in other jurisdictions worldwide would be extremely costly, and our or our licensors&#8217; or collaborators&#8217; intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In jurisdictions where we or our licensors or collaborators have not obtained patent protection, competitors may seek to use our or our licensors&#8217; or collaborators&#8217; technology to develop competing products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the United States. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents or where our or our licensors&#8217; or collaborators&#8217; issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly relating to pharmaceuticals or biopharmaceuticals. This could make it difficult for us or our licensors or collaborators to prevent the infringement of our or their patents or marketing of competing products in violation of our or their proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our and our licensors&#8217; or collaborators&#8217; efforts and attention from other aspects of our business, could put our and our licensors&#8217; or collaborators&#8217; patents at risk of being invalidated or interpreted narrowly and our and our licensors&#8217; or collaborators&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors or collaborators. We or our licensors or collaborators may not prevail in any lawsuits that we or our licensors or collaborators initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we elect to pursue patent protection on an invention, we generally first file a U.S. provisional patent application (a priority filing) at the USPTO. An international patent application under the Patent Cooperation Treaty, or PCT, and/or a national application in a non-PCT country may then be filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in one or more PCT member countries. We have thus far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent office is an independent proceeding, which may lead to situations in which patent applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that, depending on the country, different scopes of patent protection may be granted on the same product candidate or technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors or collaborators encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such a patent. If we or any of our licensors or collaborators are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. Any termination of our licenses could result in the loss of significant rights and could harm our ability to develop our product candidates. Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell any future products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating a licensor&#8217;s rights. In addition, while we cannot determine currently the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, our licensors or collaborators, or any future strategic partners may need to resort to litigation to protect or enforce our patents, if and when granted, or other proprietary rights, all of which could be costly and time consuming, delay or prevent the development and commercialization of our product candidates, or put our patents, if and when granted, patent applications and other proprietary rights at risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our owned or licensed patents, if and when granted, patent applications or other intellectual property. If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, lack of adequate written description, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that an individual connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity or unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates or certain aspects of our platform technology. Such a loss of patent protection could have a material and adverse effect on our business, financial condition, results of operations and prospects. Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">necessary to determine the inventorship or priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Patents and other intellectual property rights will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights of third parties could adversely affect our ability to commercialize our product candidates, and we, our licensors or collaborators, or any future strategic partners may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights. We might be required to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our licensors or collaborators, or any future strategic partners, may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivations, oppositions and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings before the USPTO, and corresponding foreign patent offices. There may be issued patents and pending patent applications that claim aspects of our targets, our MInT Platform, or our product candidates and modifications that we may need to apply to our product candidates. There may be issued patents that claim integrin inhibitors which may be relevant to the products we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market products or perform research and development or other activities covered by these patents, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. If we, our licensors or collaborators, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages and attorneys&#8217; fees if we or they are found to have infringed willfully. In addition, we, our licensors or collaborators, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or our existing or future collaborators may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation could divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the integrin-based therapeutics landscape is still evolving, it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering integrins generally, covering integrins directed against the same targets as, or targets similar to, those we are pursuing, or covering compounds similar to our product candidates. Failure to receive a license could delay commercialization of our product candidates. Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our products, if approved, or product candidates or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products or product candidates until such patents expire or unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our MInT Platform and product candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our MInT Platform and product candidates. If such an </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringement claim should be brought and be successful, we may be required to pay substantial damages, including potentially treble damages and attorneys&#8217; fees for willful infringement, and we may be forced to abandon our product candidates or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before November 29, 2000, and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential unless and until corresponding patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or MInT Platform could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our MInT Platform, our product candidates or the use of our product candidates. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our products, if approved. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Moreover, such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, including our management, were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although no claims against us are currently pending, we may be subject to claims that these employees, employees of our licensors or collaborators or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we or our licensors or collaborators fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property rights or personnel. A loss of key research personnel or their work product could hamper our ability to develop and ultimately commercialize, or prevent us from developing and commercializing, our product candidates, which could severely harm our business. Even if we or our licensors or collaborators are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be insufficient to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various patent term adjustments or extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ consultants and an outside firm and/or rely on our outside counsel to pay these fees due to the USPTO and non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent and ex-U.S. patent laws could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In the United States, numerous recent changes to the patent laws and proposed changes to the rules of the USPTO may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. We cannot assure you that subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty regarding our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once granted. For example, although currently under review by the U.S. Supreme Court, in the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen v. Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Federal Circuit held that broad functional antibody claims are invalid for lack of enablement. In addition, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Juno v. Kite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Federal Circuit held broad antibody and chimeric antigen receptor claims supported by few examples invalid for lack of written description. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, and similar legislative and regulatory bodies in other countries in which may pursue patent protection, the laws and regulations governing patents could change in unpredictable ways, particularly with respect to pharmaceutical patent protection, that would weaken our ability to obtain new patents or to enforce our or our licensors&#8217; or collaborators&#8217; existing patents and patents that we might obtain in the future.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common law trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, post-approval monitoring, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be completed successfully in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the product candidates we may develop, either alone or with our collaborators, will obtain the regulatory approvals necessary for us or our existing or future collaborators to begin selling them.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no prior experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes it difficult to predict with certainty their application. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We or our collaborators may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. Further, infections and deaths related to COVID-19 are disrupting certain healthcare and healthcare regulatory systems globally. Such disruptions could divert healthcare resources away from, or materially delay review by, the FDA and comparable foreign regulatory agencies. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of preclinical studies or clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. It is impossible to predict whether additional legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or the impact of such changes, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that the product candidates we are developing, either alone or with our collaborators, represent a new therapeutic approach, the FDA and its foreign counterparts may not have established any definitive policies, practices or guidelines in relation to these product candidates. Moreover, the FDA may respond to any NDA that we may submit by defining requirements that we do not anticipate. Such responses could delay clinical development of our product candidates. In addition, because there may be approved treatments for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Furthermore, in recent years, there has been increased public and political pressure on the FDA with respect to the approval process for new drugs, and FDA standards, especially regarding product safety.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenues from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or on the labeling or other restrictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to or may in the future become subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with the FDA approval process described above, as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. FDA approval does not ensure approval by regulatory authorities outside the United States and vice versa. Any delay or failure to obtain U.S. or foreign regulatory approval for a product candidate could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal. We may also be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we or our existing or future collaborators obtain for our product candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing and surveillance to monitor the safety and efficacy of the product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, post-approval monitoring and adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. The manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. If we rely on third-party manufacturers, we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products. If we promote our product candidates in a manner inconsistent with FDA-approved labeling or otherwise not in compliance with FDA regulations, we may be subject to enforcement action. If we or our existing or future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA or similar foreign regulatory bodies to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning or untitled letters or holds on clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or revocation of product license approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December 2016, the 21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and to spur innovation. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Changes in FDA staffing could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. Similar consequences would also result in the event of another significant shutdown of the federal government such as the one that occurred from December 22, 2018 </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through January 25, 2019. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If any legislation, executive orders, or lapses in agency funding impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from healthcare legislative reform measures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act, or together, the ACA, was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been legislative and judicial efforts to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA, including measures taken during the Trump administration. The Tax Act, among other things, includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. It is possible that the ACA will be subject to judicial or congressional challenges in the future. It is unclear how any such efforts to repeal, replace, amend or invalidate the ACA or its implementing regulations, or portions thereof, and the healthcare reform measures of the Biden administration will impact the ACA or our business. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans and the medical device excise tax on non-exempt medical devices, and effective January 1, 2021, also eliminated the health insurer tax. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In addition, CMS published a final rule that would give states greater flexibility, effective January 1, 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. On August 2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA and the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, will remain in effect through 2031. Moreover, the American Taxpayer Relief Act of 2012 among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic class. While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare, and reform government program reimbursement methodologies for drug products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in November 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of this final rule was delayed by the Biden administration until January 1, 2023 and subsequently delayed by the Inflation Reduction Act, or IRA, until January 1, 2032.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than they receive on the sale of products. It is unclear to what extent these new requirements will be implemented and to what extent these regulations or any future legislation or regulations by the Biden administration will have on our business, including our ability to generate revenue and achieve profitability. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Recently, healthcare reform initiatives culminated in the enactment of the IRA in August 2022, which will, among other things, allow the HHS to negotiate the selling price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D, although only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price. Beginning in January 2023 for Medicare Part B and October 2022 for Medicare Part D, the IRA will also penalize drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. The full economic impact of the IRA is unknown at this time, but the law&#8217;s passage may affect the pricing of our products and product candidates. The adoption of restrictive price controls in new jurisdictions, more restrictive controls in existing jurisdictions or the failure to obtain or maintain timely or adequate pricing could also adversely impact revenue. We expect pricing pressures will continue globally.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or companion diagnostics or additional pricing pressures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA and IRA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations and relationships with healthcare providers, healthcare organizations, customers and third-party payors will be subject to applicable anti-bribery, anti-kickback, fraud and abuse, transparency and other healthcare and privacy laws and regulations, which could expose us to, among other things, enforcement actions, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future arrangements with healthcare providers, healthcare organizations, third-party payors and customers expose us to broadly applicable anti-bribery, fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our product </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. In addition, we may be subject to patient data privacy and security regulation by the U.S. federal government and the states and the foreign governments of countries in which we conduct our business. Restrictions under applicable federal and state anti-bribery and healthcare laws and regulations, include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal and state healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal criminal and civil false claims and civil monetary penalties laws, including the federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions against individuals or entities, prohibits, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Moreover, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which imposes criminal and civil liability, prohibits, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by HITECH, and their respective implementing regulations, including the Final Omnibus Rule published on January 25, 2013, which impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; the federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of covered drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members, with the information made publicly available on a searchable website;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state privacy laws and regulations, such as those of California Virginia, Colorado, Connecticut and Utah that impose restrictive requirements regulating the use and disclosure of health information and other sensitive personal information that is not subject to HIPAA. For example, in June 2018, California enacted the California Consumer Privacy Act, which became effective on January 1, 2020, and the California Privacy Rights Act, or CPRA, which modified the CCPA and created additional obligations beginning on January 1, 2022, gives California residents expanded rights to access and delete their personal information, restrict processing of sensitive personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used, and provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation; resulting in increased compliance costs and potential liability. Virginia&#8217;s Consumer Data Protection Act, which took effect on January 1, 2023, requires opt-in consent from consumers to acquire and process their sensitive personal information, which includes information revealing a consumer&#8217;s physical and mental health diagnosis and genetic and biometric information that can identify a consumer;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and drug pricing information, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclusion from participation in government-funded healthcare programs; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclusion from eligibility for the award of government contracts for our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy laws, rules and regulations evolve frequently, and their scope may continually change through new legislation, amendments to existing legislation, and changes in enforcement, and may be inconsistent from one jurisdiction to another. The interpretation and application of consumer, health-related and data protection laws, especially with respect to genetic samples and data, in the United States, the European Union and elsewhere, are often uncertain, contradictory and in flux. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot determine the impact such future laws, regulations and standards may have on our business. We cannot provide assurance that current or future legislation will not prevent us from generating or maintaining personal data or that patients will consent to the use of their personal data (as necessary); either of these circumstances may prevent us from undertaking or publishing essential research and development, manufacturing, and commercialization, which could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm, any of which could adversely affect our financial results. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern regulatory approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors including government authorities, such as Medicare and Medicaid, private health insurers and other organizations. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with their treatment. Coverage and adequate reimbursement from third-party payors are critical to new product acceptance. Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of coverage and reimbursement. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for biopharmaceutical products. If the price we are able to charge for any products we develop, or the coverage and reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be affected adversely.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug or therapeutic biologic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim reimbursement levels for new drugs, if applicable, may also be insufficient to cover our costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, obtaining coverage and reimbursement approval of a product from a third-party payor is a time consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for new drugs that we develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we decide to pursue a Fast Track Designation by the FDA, it may not lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek Fast Track Designation for one or more of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we decide to seek Orphan Drug Designation for some of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may seek Orphan Drug Designation for one or more of our product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain Orphan Drug Designation for our product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moiety can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for our product candidates, we may never receive such designations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax reform legislation, which was signed into law on December 22, 2017, reduced the amount of the qualified clinical research costs for a designated orphan product that a sponsor may claim as a credit from 50% to 25%. This may further limit the advantage and may impact our future business strategy of seeking the Orphan Drug Designation.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly member states of the EU the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. In addition, as a result of Brexit, there will be a transition period until a comprehensive trade agreement between the U.K. and EU is negotiated by year-end 2020. </span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal health data in the EU is governed by the General Data Protection Regulation, or GDPR. The GDPR imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU to the United States. The GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the European Economic Area to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws. For example, following a decision of the Court of Justice of the EU in October 2015, the transfer of personal data to U.S. companies that had certified as members of the U.S. Safe Harbor Scheme, was declared invalid. In July 2016, the European Commission adopted the EU-U.S. Privacy Shield Framework, or the Privacy Shield Framework, which replaced the U.S. Safe Harbor Scheme. On July 16, 2020, the Court of Justice of the European Union issued a decision that declared the Privacy Shield Framework invalid, and will also result in additional compliance obligations for companies that implement standard contractual clauses to ensure a valid basis for the transfer of personal data outside of Europe. On November 10, 2020, the European Data Protection Board issued recommendations on the additional safeguards required for standard contractual clauses to be valid. It is possible that the ability to transfer personal data from the European Union to the United States will be restricted. We and many other companies may be required to adopt additional measures to accomplish and maintain legitimate means for the transfer and receipt of personal data from the European Union to the United States and other third-party countries. Failure to comply with the requirements of the Data Protection Directive, the GDPR, and the related national data protection laws of the EU Member States may result in fines (for example, of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year (whichever is higher)) and other administrative penalties. The GDPR regulations may impose additional responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects. As a result of the implementation of the GDPR, we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR is not yet clear. For example, it is not clear if the authorities will conduct random audits of companies doing business in the EU, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance be onerous and adversely affect our business, financial condition, results of operations and prospects. Further, Brexit has created uncertainty with regard to data protection regulation in the U.K. The U.K. enacted the Data Protection Act 2018 to directly enforce the GDPR. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expense related to the ongoing development of our MInT Platform, product candidates or future development programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of preclinical and clinical trials, or the addition or termination of existing or future clinical trials or funding support by us, or existing or future collaborators or licensing partners;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions and departures of key personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic decisions by us, our collaborators or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our product candidates or those of our competitors; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in general market and economic conditions, including due to global pandemics such as COVID-19, the ongoing conflict in the Ukraine, inflation, rising interest rates, and the ongoing labor shortage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The trading prices for our common stock and the common stock of other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic among other factors. The market price for our common stock may be influenced by many factors, including the other risks described in this section and elsewhere in this report and the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of preclinical studies and clinical trials of our product candidates, or those of our competitors or our existing or future collaborators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to acquire or in-license additional technologies, products or product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any future collaborations, including but not limited to those with development and commercialization partners;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates and products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to raise additional capital and the terms on which we raise it;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement and expectation of additional financing efforts;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">speculation in the press or investment community;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and fluctuations of trading volume of our common stock, which may affect our trading liquidity and public float;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, insiders or our stockholders;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the concentrated ownership of our common stock;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions instituted by activist shareholders or others;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terrorist acts, acts of war or periods of widespread civil unrest, such as the ongoing conflict in the Ukraine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters and other calamities, including global pandemics, such as COVID-19; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions, including inflation, rising interest rates, and the ongoing labor shortage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations, including as a result of the COVID-19 pandemic, increase in inflation, rising interest rates, disruptions to global supply chains, and the ongoing conflict in the Ukraine and the global sanctions imposed in response thereto, that have been often unrelated or disproportionate to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock. In addition, it may be more difficult for stockholders to sell a substantial number of shares for the same price at which stockholders could sell a smaller number of shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility in recent years. Additionally, market volatility arising from the COVID-19 pandemic may lead to increased shareholder activism if we experience a market valuation that they believe are not reflective of our stock&#8217;s intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market the market price of our common stock could decline significantly. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of our outstanding warrant or options, or the perception that such sales may occur, could adversely affect the market price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner that we determine from time to time. To the extent that additional capital is raised through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to an &#8220;at-the-market&#8221; offering of our common stock pursuant to a sales agreement, as amended from time to time, between us and Jefferies. Subject to certain limitations in the sales agreement and compliance with applicable law, we may, in our sole discretion, deliver a placement notice to Jefferies at any time throughout the term of the sales agreement. The number of shares that are sold by Jefferies upon our delivery of a placement notice will fluctuate based on the market price of our common stock during the sales period and limits we set with Jefferies. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible to predict the number of shares that will be ultimately issued, if any, pursuant to the sales agreement. Issuances of any shares sold pursuant to the sales agreement will have a dilutive effect on our existing stockholders. Further, if we sell common stock, preferred stock, convertible securities and other equity securities in other transactions pursuant to our shelf registration statement on Form S-3, existing investors may be materially diluted by such subsequent sales and new investors could gain rights superior to our existing stockholders.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to control matters subject to stockholder approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the beneficial ownership of our common stock as of December&#160;31, 2022, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 50% of our outstanding voting stock. As a result, these stockholders, if acting together, will continue to have control over the outcome of corporate </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could prevent or delay an acquisition of us, which may be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it difficult for stockholders to elect directors who are not nominated by current members of our board of directors or take other corporate actions, including effecting changes in our management. These provisions:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors so that not all members of our board are elected at one time;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit only the board of directors to establish the number of directors and fill vacancies on the board;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require super-majority voting to amend some provisions in our restated certificate of incorporation and amended and restated bylaws;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The exclusive forum provision in our restated certificate of incorporation may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware is the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our restated certificate of incorporation, or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 203 of the DGCL may discourage, delay or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. In March 2020, we amended and restated our restated bylaws to provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. In addition, neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal court. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholders&#8217; ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over the industry or securities analysts, or the content and opinions included in their reports. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our preclinical studies and clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of such analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause a decline in our stock price or trading volume.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our business, results of operations, financial condition and cash flows and future prospects, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures and that we furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compliance with Section 404 will require that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group and we rely on limited accounting and finance staff to compile the system and process documentation necessary to perform the annual evaluation needed to comply with Section 404. We may not be able to complete our annual evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we fail to identify and to remediate any significant deficiencies or material weaknesses that may be identified, or encounter problems or delays in the evaluation of internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Stock Market, or NASDAQ, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_1252"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unresolved Staff Comments</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Properties</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive office is located in Waltham, Massachusetts. In August 2021, we exercised our one-time extension right through May 2025 for our existing lease for a total of approximately 32,405 square feet of office and laboratory space in three buildings that we use for our administrative, research and development and other activities. </span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II&#8212;OTHER INFORMATION</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Market under the symbol &#8220;MORF&#8221;. Trading of our common stock commenced on June 26, 2019, following the completion of our initial public offering. Prior to that time, there was no established public trading market for our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;21, 2023, there were 16 stockholders of record of our common stock. This number does not include beneficial owners whose shares are held in street name.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends to our stockholders since our inception and we do not plan to declare or pay cash dividends in the foreseeable future. We currently anticipate that we will retain all available funds and any future earnings for the operation and expansion of our business. Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend on, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from Registered Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2019, our Registration Statement on Form S-1 (File No. 333-231837) relating to our initial public offering, or IPO, of our common stock was declared effective by the SEC. Pursuant to such Registration Statement, we sold an aggregate of 6,900,000 shares of our common stock at a price of $15.00 per share for aggregate cash proceeds of approximately $93.3 million, net of underwriting discounts and commissions and offering costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the remaining net proceeds from our IPO to fund the further development of our oral small-molecule integrin therapeutics, the further development of our platform to broaden our pipeline of product candidates and for working capital and general corporate purposes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our equity compensation plans and the securities authorized for issuance thereunder is set forth in Part III, Item 12 of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide this information.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Reserved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as statements of our plans, objectives, expectations, intentions and belief. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part I, Item 1A.&#160;These forward-looking statements may include, but are not limited to, statements regarding our future results of operations and financial position, the impact of the COVID-19 pandemic, business strategy, market size, potential growth opportunities, preclinical and clinical development activities, efficacy and safety profile of our product candidates, use of net proceeds from our offerings, our ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical studies and clinical trials, commercial collaborations with third parties and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_46"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite this, we believe our unique platform can unlock the potential to reliably generate high-quality oral molecules against specific integrin targets. The Morphic integrin technology platform, or MInT Platform, was created leveraging our unique understanding of integrin structure and function to develop novel product candidates designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration. We are advancing our pipeline, including our lead product candidate, MORF-057, an &#945;4&#946;7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease, or IBD. We submitted an investigational new drug application, or IND, for MORF-057 in July 2020, and the FDA permitted the study submitted under the IND to proceed in August 2020. In September 2020, we initiated a Phase 1 clinical trial of MORF-057 in healthy volunteers to establish our clinical program and select doses for our Phase 2 program in IBD with an initial focus on ulcerative colitis, or UC. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#00101f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The MORF-057 Phase 1 study included SAD, MAD, and FE, cohorts evaluating MORF-057 safety, pharmacokinetics, or PK, and pharmacodynamics, or PD. Healthy subjects were randomized 3:1 to receive a single dose of MORF-057 at 25, 50, 100, 150 and 400 mg or matching placebo in the SAD cohorts; or twice daily, or BID, doses of 25, 50 and 100 mg MORF-057 or matching placebo for a total of 14 days in the MAD cohorts. A total of 67 eligible healthy subjects were enrolled into the studies, with 36 in the SAD, nine in the FE and 22 in the MAD cohorts. 66 subjects completed study treatment and one from the 50 mg BID MAD cohort withdrew consent for personal reasons</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#00101f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MORF-057 was well tolerated in all cohorts and no safety signals were identified. MORF-057 demonstrated a favorable PK profile, where target engagement was confirmed, and a clear PK and PD relationship was established. MORF-057 was rapidly absorbed and systemic exposure was confirmed to increase approximately dose proportionally. A slight reduction in exposure without effect on trough concentrations was observed upon administration with a high fat meal in the FE study. The results suggest food intake has no impact on trough MORF-057 levels and that MORF-057 can be administered without regard to food in planned studies in patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#00101f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#945;4&#946;7 RO increased with dose and study day, achieving saturation (&gt;99% RO) in individual patients from all cohorts above 25 mg by day 14. In the 100 mg BID cohort, MORF-057 saturated the &#945;4&#946;7 receptor (mean RO &gt;99%). Dose-and time-dependent changes in biomarkers including specific &#945;4&#946;7 high expressing immune cell populations were observed, adding to evidence of proof of biology for MORF-057. These changes were consistent with those reported with other integrin inhibitors including the antibody drug vedolizumab which is approved for the treatment of IBD.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an additional MORF-057 Phase 1 study, subjects were dosed up to 200 mg twice daily (BID) and those receiving MORF-057 at 100 BID or 200 mg BID demonstrated &#945;4&#946;7 receptor saturation and statistically significant increases in circulating central memory, effector memory T lymphocyte and switched memory B lymphocyte populations compared with placebo. At the 25 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mg and 50 mg BID exploratory doses, directionally increasing trends were also observed in key PD measures. All doses were well tolerated, no safety signals were identified, and a favorable PK profile was observed. In both single doses of 200 mg MORF-057 and 200 mg BID over the 14 days, MORF-057 demonstrated &#945;4&#946;7 receptor saturation at C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">trough</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Statistically significant changes in lymphocyte subset populations and CCR9 mRNA were observed, consistent with previous studies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the results from the Phase 1 studies, we initiated a Phase 2 clinical trial of MORF-057 in March 2022. EMERALD-1 (MORF-057-201), which is an open-label multi-center Phase 2a trial designed to evaluate the efficacy, safety and tolerability of MORF-057 in adults with moderate to severe UC, completed targeted enrollment in October 2022, with 30 patients enrolled in the study. Additionally, patients that were undergoing screening at the time the study completed targeted enrollment were enrolled in the study for a total of 35 patients enrolled in the main cohort. Enrollment of an exploratory cohort of up to ten patients who have previously failed treatment with vedolizumab is ongoing. Patients enrolled in the EMERALD-1 study are being treated with 100 mg BID at sites in the United States and Poland. The primary endpoint of the trial is the change in RHI, a validated instrument that measures histological disease activity in ulcerative colitis at 12 weeks compared to baseline. Patients will then continue for an additional 40 weeks of maintenance therapy followed by a 52-week assessment. Secondary and additional outcome measures in the EMERALD-1 study include change in the modified Mayo clinic score, safety, PK parameters and key PD measures including &#945;4&#946;7 receptor occupancy and lymphocyte subset trafficking. We expect that primary endpoint data from the main cohort of the EMERALD-1 Phase 2a trial of MORF-057 in patients with moderate to severe UC will report in the second quarter of 2023. EMERALD-2 (MORF-057-202) which is a global Phase 2b randomized controlled trial of MORF-057 began dosing patients in November 2022. Patients enrolled in the EMERALD-2 study are randomized to receive one of three active arms or a placebo arm: 100 mg BID, 200 mg BID, and a QD (once daily) arm, or a placebo arm which will cross over to MORF-057 after the 12-week induction phase. The primary endpoint of the trial is the clinical remission rate as measured by the modified Mayo score at 12 weeks. The secondary endpoints will include the change in RHI, PK and PD measures, as well as safety parameters. Following the 12-week induction phase, patients will move to a 40-week maintenance phase. We believe that we will achieve completion of the primary endpoint from the EMERALD-2 Phase 2b trial of MORF-057 in patients with moderate to severe UC in the first half of 2025. Given the progress achieved with MORF-057, we paused a second-generation development candidate at the pre-IND stage during 2022, focusing on the advancement of MORF-057 through Phase 2 clinical programs. We continue to expand our &#945;4&#946;7 portfolio and have positioned next-generation &#945;4&#946;7 small molecule development candidates for clinical studies in the future. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 we have reported that our collaboration with AbbVie Biotechnology, Ltd., or AbbVie, which was entered into in October 2018, or the AbbVie Agreement, had been terminated for convenience. The subject of this collaboration was selective oral &#945;v&#946;6-specific integrin inhibitors we had developed for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis, or IPF, and additional indications under our collaboration with AbbVie. In August 2020, AbbVie exercised an option to license our &#945;v&#946;6-specific integrin inhibitor program and made a one-time $20.0 million payment to us. AbbVie informed us that it did not intend to advance any of our selective oral &#945;v&#946;6-specific integrin inhibitors due to a suspected on-target &#945;v&#946;6-mediated safety signal that has been observed in pre-clinical testing, the details of which were published in the Society for Toxicology journal in December 2022. The AbbVie Agreement terminated effective December 2022, and as a result we will not receive any additional payments thereunder. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, we entered into an agreement with Janssen Pharmaceuticals, Inc., or Janssen, to develop novel integrin therapeutics, or the Janssen Agreement. In February 2021 Janssen paid us $5.0 million to commence work on a third research program to discover antibody activators against a specific integrin target. In December 2021, Janssen informed us that they had decided not to exercise the options on the first two integrin targets and focused efforts on the third integrin research program which includes the potential development of integrin antibody activators. The first two integrin targets were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">eturned to us due to a lack of target validation in the specific disease of Janssen's interest. In January 2023, we received notice from Janssen that they had elected to terminate the agreement. The termination will be effective within 60 days of January 13, 2023, and as a result we do not expect to receive any additional payments under the Janssen Agreement except for potential nominal amounts related to research services completed in 2023 prior to termination.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beyond our lead target, MORF-057, we are using our MInT Platform to advance a broad pipeline of preclinical programs across a variety of therapeutic areas, all of which aim to harness the potential of inhibition or activation of an integrin receptor. Additional wholly-owned programs have advanced near to or into the lead optimization phase of discovery. We presented positive preclinical data from our &#945;v&#946;8 program at the American Association for Cancer Research Annual Meeting in April 2021, demonstrating anti-tumor activity in checkpoint refractory cancer models and we are continuing our focus on advancing our &#945;v&#946;8 program. We also have additional research stage programs ongoing against fibronectin integrin targets in pulmonary hypertensive diseases including pulmonary arterial hypertension (PAH) and other therapeutic areas. Integrins are known to promote cell proliferation, survival, hypertrophic growth and fibrosis, which are key elements in the progression of PAH.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2021, we announced an upsized underwritten public offering of 3,500,000 shares of our common stock at a price to the public of $70.00 per share, resulting in net proceeds of approximately $230.0 million, after deducting underwriting discounts, commissions and other offering expenses paid by us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, we entered into an Open Market Sale Agreement, or the Original Agreement, with Jefferies LLC, or Jefferies, with respect to an at-the-market offering program, or the Previous ATM, under which we could offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering amount of up to $75,000,000, referred to as Placement Shares, through Jefferies as sales agent. In August 2021, we entered into Amendment No. 1 to the Original </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement with Jefferies, or the New ATM, to increase the total value of Placement Shares subject to offer and sale to up to an aggregate offering amount of up to $150,000,000. We refer to the Previous ATM and the New ATM, collectively, as the ATM. During the year ended December 31, 2022, 1,000,000 shares were issued under the New ATM for net proceeds of $39.2 million, after deducting offering commissions and expenses. As of December&#160;31, 2022, we had approximately $97.2 million of common stock remaining available for sale under the New ATM. We may not sell any Placement Shares under the Previous ATM. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, our operations have focused on organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio, and performing research to discover and develop oral small-molecule integrin therapeutics. Revenue generation activities to date have been limited to payments received from our collaboration agreements with AbbVie and Janssen, discussed further in Note 12 of the accompanying consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K. We do not have any products approved for sale and have not generated any revenue from product sales to date. From inception through December&#160;31, 2022, we raised an aggregate of approximately $743.0 million of gross proceeds primarily through the issuance of equity, including our convertible preferred equity securities, our initial public offering, our underwritten public offering in March 2021, and sales of shares of our common stock pursuant to the ATM, along with payments received under our collaboration agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. As of December&#160;31, 2022, we had an accumulated deficit of $297.1 million. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, seek regulatory approval for them, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing, and distribution activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as additional collaboration agreements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when, needed, could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash, cash equivalents, and marketable securities of $348.2 million. We believe that our existing cash, cash equivalents and marketable securities, along with the $100.0 million raised in our private issuance of common stock and pre-funded warrants in February 2023, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2026. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic continues to present public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The extent of the ongoing impact of COVID-19 including supply chain disruptions, as well as other economic conditions and trends including increases in consumer prices, inflation, the rise in interest rates and ongoing labor shortage, on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, the rise of variants that may be less responsive to existing vaccines, the impact on our clinical and preclinical studies, employee or industry events, and the effect on our suppliers and manufacturers, all of which are uncertain and cannot be predicted. Although we currently have not experienced much of an impact on our business, excluding minor changes to our development timelines, if there are closures or other restrictions in places where we or our vendors work or transport supply that may result in constrained supply of our product candidates or delays in our clinical and preclinical studies or planned clinical trials, our business, results of operations and overall financial performance in future periods could be materially adversely impacted. In addition, we have experienced impacts from changes in how we and companies worldwide conduct business due to the COVID-19 pandemic, including but not limited to restrictions on travel and in-person meetings, delays in future site activations and future enrollment of clinical trials, prioritization of hospital resources toward the COVID-19 pandemic effort, and delays in review by the FDA and comparable foreign regulatory agencies. As of the filing date of this Form 10-K, the extent to which COVID-19 and other economic conditions and trends or geo-political actions, including the current armed conflict in Ukraine, may impact our financial condition, results of operations or guidance is uncertain and the effects thereof may not be fully reflected in our results of operations and overall financial performance until future periods. See &#8220;Risk Factors&#8221; included elsewhere in this Annual Report on Form 10-K for further discussion of the possible impact of the COVID-19 pandemic, general economic conditions and geo-political actions on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any products approved for sale, and as a result, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, all of our collaboration revenue has been derived from collaboration agreements with AbbVie and Janssen. Our collaborations with AbbVie and Janssen are now concluded, and prospectively we remain open to opportunistically evaluating and entering into strategic partnerships around certain therapeutic candidates, geographic markets or disease areas. We expect that our revenue, until we have a marketed product, will be derived primarily from payments under collaboration and license agreements that we may enter into in the future, if any.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue &#8212; AbbVie</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a collaboration with AbbVie, an investor that held approximately 5% of our common stock at the time of the agreement, designed to advance a number of our oral integrin therapeutics for fibrosis-related indications. Under the terms of the AbbVie Agreement, AbbVie paid us an upfront payment of $100.0 million for research and development activities, and we provided to AbbVie exclusive license options on product candidates directed at multiple targets. In August 2020, AbbVie exercised its option to license the selective &#945;v&#946;6-specific integrin inhibitors program and paid us a one-time payment of $20.0 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, AbbVie informed us that it had decided to exercise its right to terminate the AbbVie Agreement for convenience, which termination became effective in December 2022.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue &#8212; Janssen</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into the Janssen Agreement to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. The Janssen Agreement focused on three integrin targets, each target the subject of a research program, with the ability to substitute up to two integrin targets not explored by us. In consideration for certain rights granted under the Janssen Agreement, during 2019 Janssen paid us an upfront commencement fee of $10.0 million for each of the first two research programs, and in February 2021 Janssen paid us an upfront commencement fee of $5.0 million for the third research program. In December 2021, Janssen informed us that it had decided not to exercise the options on the first two integrin targets which resulted in a reduction in scope of our responsibilities under the Janssen Agreement. In January 2023, Janssen informed us that it had decided to exercise its right to terminate the Janssen Agreement for convenience, subject to a 60 day notification period. The Janssen Agreement will terminate effective March 2023 or earlier if agreed to by us and Janssen. </span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research and development activities, including our product candidate discovery efforts and preclinical studies under our research programs, which include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, and equity-based compensation expense for our research and development personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of funding research performed by third parties that conduct research and development and preclinical activities on our behalf;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of manufacturing clinical supply related to any of our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations, or CROs and investigative sites that conduct our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of conducting preclinical studies of any of our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consulting and professional fees related to research and development activities, including equity-based compensation to non-employees;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of purchasing laboratory supplies and non-capital equipment used in our preclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with clinical regulatory requirements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility costs and other allocated expenses, which include expenses for rent and maintenance of facilities, insurance, depreciation and other supplies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees for maintaining licenses and other amounts due under our third-party licensing agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical studies or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period. Non-refundable advance payments for research and development goods or services to be received in the future from third parties are capitalized and expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing, and costs of the efforts that will be necessary to complete our future product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of our product candidates, if approved. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, rate of progress, and expenses of our ongoing research activities as well as any additional preclinical studies and clinical trials and other research and development activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing an appropriate safety profile;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in and completion of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our product candidates show safety and efficacy in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from applicable regulatory authorities, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued acceptable safety profile of the products following any regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of our current and future product candidates would significantly change the costs and timing associated with the development of those product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the foreseeable future as we continue the development of our product candidates. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of employee-related expenses, including salaries, benefits, and equity-based compensation expenses for personnel in executive, finance, accounting, business development, legal, and human resources functions. Other significant general and administrative expenses include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as our business expands to support expected growth in research and development activities, including our future clinical programs. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, among other expenses. We also incur expenses associated with being a public company, including costs for audit, legal, regulatory, and tax-related services related to compliance with the rules and regulations of the SEC, and listing standards applicable to companies listed on Nasdaq, director and officer compensation and insurance premiums, and investor relations costs. In addition, if we obtain regulatory approval for any of our product candidates and do not enter into a third-party commercialization collaboration, we expect to incur significant general and administrative expenses related to supporting product sales, marketing and distribution activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net consists primarily of interest income earned on our cash, cash equivalents and marketable securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Provision for) Benefit from Income Tax Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a provision or benefit for income taxes on pre-tax income or loss based on our effective tax rate for the year. For additional details about the current year tax provision, refer to the Notes to the Consolidated Financial Statements appearing elsewhere in this Annual Report on Form 10-K. </span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the years ended December 31, 2022 and 2021</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December 31, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,204&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,600&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,604&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,396)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,806)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,410&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,158&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,974)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,568&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,041)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in collaboration revenue of $51.0 million is attributable the conclusion of the AbbVie Agreement and reduction in the scope of the Janssen Agreement. In Q2 2022, we decreased our estimates to complete the remaining performance obligations under the AbbVie Agreement and recorded a cumulative catch-up to revenue based on AbbVie's notification of exercise of their option to terminate the AbbVie Agreement effective December 2022. In Q4 2022, we decreased our estimates to complete the remaining performance obligations under the Janssen Agreement based on changes in expected effort and the timing of the research services for the third integrin research program. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $14.3 million, or 16% from $87.8 million for the year ended December 31, 2021 to $102.1 million for the year ended December 31, 2022. A significant portion of our research and development costs have been external clinical and preclinical CRO costs, which we track on a program-by-program basis related to a clinical product candidate, once the candidate has been identified. Our internal research and development costs are primarily personnel-related costs, depreciation, and other indirect costs. The following table summarizes our research and development expense for years ended December 31, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External costs by program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MORF-057</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Agreement programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Agreement programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;v&#946;8 Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other early development candidates and unallocated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,292&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,417&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,875&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal costs:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total internal costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,770&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,372&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,398&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,789&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in research and development expense were primarily attributable to the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The $9.9 million increase in external costs from the year ended December 31, 2021 to the year ended December 31, 2022 primarily related to costs associated with the ongoing Phase 2 clinical studies and other development activities for MORF-057 and development milestone fees due to our collaborators as well as other external research costs to support our early development candidates, including &#945;v&#946;8. These increases were partially offset by decreases in activity under the AbbVie Agreement and the Janssen Agreement.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The $4.4 million increase in internal costs from the year ended December 31, 2021 to the year ended December 31, 2022 was primarily driven by an increase in non-cash equity-based compensation expense, subscriptions and executive searches to support the ongoing clinical activity for MORF-057 as well as our early-stage pipeline candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased by $4.3 million, or 16%, from $27.8 million for the year ended December 31, 2021 to $32.1 million for the year ended December 31, 2022. The increase in general and administrative expense was primarily attributable to a $4.2 million increase in non-cash equity-based compensation expense and a $0.8 million increase in legal and patent costs, partially offset by $0.5 million and $0.2 million decreases in consulting expenses and audit and tax fees, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by $4.3 million due to an increase in yields earned on cash equivalents and marketable securities and an increase in invested marketable securities during the year ended December 31, 2022 compared to the year ended December 31, 2021.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the years ended December 31, 2021 and 2020</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,600&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,125&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,475&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,806)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,180)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,626)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,347)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,569)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,973)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,999)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,543)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in collaboration revenue of $25.2 million is primarily attributable to a decrease in activity under the AbbVie Agreement. In the prior year period, AbbVie exercised its option for the selective &#945;v&#946;6 -specific integrin inhibitors program resulting in the payment of a $20.0 million option exercise payment from AbbVie, which was recognized during the year ended December 31, 2020. Further, upon the AbbVie option exercise, we revised our estimates to complete the remaining performance obligations under the &#945;v&#946;6 -specific integrin inhibitors program, which resulted in an increase in revenue during the prior year period. Offsetting the decrease in collaboration revenue from the prior year, based on recent scientific results, we decreased our estimates to complete the remaining performance obligations under the AbbVie Agreement based on changes in expected effort and the timing of the research services, which resulted in us recognizing $6.2&#160;million in revenue in Q4 2021. The revenue for our collaborations fluctuates based on the timing and magnitude of costs incurred under the collaboration programs, as well as changes to our estimates to complete the remaining performance obligations. The contract modification for the Janssen Agreement did not have a material effect on the collaboration revenue. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $14.2 million, or 19% from $73.6 million for the year ended December 31, 2020 to $87.8 million for the year ended December 31, 2021. A significant portion of our research and development costs have been external clinical and preclinical contract research organization (&#8220;CRO&#8221;) costs, which we track on a program-by-program basis related to a clinical product candidate, once the candidate has been identified. Our internal research and development costs are primarily personnel-related costs, depreciation, and other indirect costs. The following table summarizes our research and development expense for years ended December 31, 2021 and 2020:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External costs by program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MORF-057</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Agreement programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Agreement programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(929)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;v&#946;8 Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other early development candidates and unallocated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,417&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,536&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,881&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal costs:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total internal costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,372&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,094&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,789&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in research and development expense were primarily attributable to the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The $6.9 million increase in external costs from the year ended December 31, 2020 to the year ended December 31, 2021 primarily related to manufacturing costs and other development activities to support Phase 2 clinical studies for MORF-057, as well as other external research costs to support our early development candidates, including &#945;v&#946;8. These increases were partially offset by a decrease in expenditures associated with the &#945;v&#946;6 program as a result of the option exercise by AbbVie in August 2020 and decreases in activity regarding other programs with AbbVie and Janssen.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The $7.3 million increase in internal costs from the year ended December 31, 2020 to the year ended December 31, 2021 was primarily driven by an increase in headcount to support the ongoing clinical activity for MORF-057 as well as our early-stage pipeline candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased by $9.3 million, or 50%, from $18.5 million for the year ended December 31, 2020 to $27.8 million for the year ended December 31, 2021. The increase in general and administrative expense was primarily attributable to a $6.4 million increase in non-cash stock-based compensation expense, a $1.2 million increase in personnel costs, a $0.8 million increase in consulting fees, a $0.6 million increase in professional fees primarily due to increases in legal and accounting expenses related to public company administrative costs and a $0.4 million increase in D&amp;O insurance premiums.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased by $1.4 million due to a decrease in yields earned on marketable securities during the year ended December 31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefit from Income Tax</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into law. The CARES Act included several income tax changes, including allowing for the carryback of net operating losses, expanding interest deductibility, and allowing for accelerated expensing of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain capital improvements. Based on the anticipated recovery of the federal income tax paid for the December 31, 2019 tax period, we recognized an income tax benefit of $0.6 million for the year ended December 31, 2020. </span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2022, we raised an aggregate of approximately $743.0 million of gross proceeds primarily through the issuance of equity, including our convertible preferred equity securities, our IPO and follow-on equity offering, and sales of shares of our common stock under the ATM, as well as through payments received under collaboration agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our total cash, cash equivalents, and marketable securities, each of which are stated at their respective fair values as of December 31, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,451)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,162)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,672&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities was $101.0 million for the year ended December 31, 2022, compared to $83.5 million in cash used in operating activities for the year ended December 31, 2021. The increase in cash used in operating activities was primarily driven by a $61.8 million decrease in operating assets and liabilities, principally due a $52.8 million decrease in in deferred revenue, a $3.2 million increase in accounts receivable and a $2.5 million decrease in accounts payable, partially offset by a $36.5 million decrease in net loss and a $7.9 million increase in equity-based compensation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $46.0 million for the year ended December 31, 2020. The increase in cash used in operating activities between the year ended December 31, 2021 and the year ended December 31, 2020 was primarily driven by a $50.5 million increase in net loss in the year ended December 31, 2021, partially offset by changes in operating assets and liabilities, and a $10.1 million increase equity-based compensation. The increase in net loss was primarily attributable to the $20.0 million option exercise payment from AbbVie in 2020 as well as a $23.5 million increase in operating expenses in 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash (Used In) Provided by Investing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $56.5 million for the year ended December 31, 2022 compared to $113.2 million used in investing activities for the year ended December 31, 2021. The change in cash used in investing activities is primarily based on the timing of purchases or maturities in marketable securities in the period. During the year ended December 31, 2022, cash used in investing activities primarily resulted from purchases of marketable securities exceeding maturities and sales of marketable securities. During the year ended December 31, 2021, the increase in cash used in investing activities was due to an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in investments in marketable securities in the form of proceeds from the underwritten public offering completed in March 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities during the year ended December 31, 2020 primarily resulted from proceeds from maturities of marketable securities exceeding purchases of marketable securities by $8.7 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $45.3 million for the year ended December 31, 2022 resulted from $39.2 million in net proceeds received from sales of shares of common stock under the ATM and $6.1 million in proceeds received from issuance of common shares under 2019 Employee Stock Purchase Plan, or ESPP and stock option exercises. Net cash provided by financing activities of $266.3 million for the year ended December 31, 2021 primarily resulted from the $230.0 million in net proceeds received from the underwritten public offering completed in March 2021, $25.7 million in net proceeds received from sales of shares of common stock under the ATM, and $10.6 million in proceeds received from issuance of common shares under ESPP and stock option exercises. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $38.3 million for the year ended December 31, 2020 resulted from $33.7 million in net proceeds received from sales of shares of common stock under the ATM and $4.6 million from the issuance of common shares under ESPP and stock option exercises. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue research and development, conduct clinical trials, and seek marketing approval for our current and any of our future product candidates. In addition, if we obtain marketing approval for any of our current or our future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution, which costs we might offset through entry into collaboration agreements with third parties. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed on acceptable terms, or at all, including, but not limited to, as a result macroeconomic factors relating to COVID-19, the ongoing conflict in the Ukraine, inflation, or rising interest rates, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. We expect our existing cash, cash equivalents and marketable securities, along with the $100.0 million raised in our private issuance of common stock and pre-funded warrants in February 2023, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2023, we entered into a securities purchase agreement pursuant with existing investors for a private placement where we agreed to sell and issue 848,655 shares of our common stock at a price of $35.35 per share and pre-funded warrants to purchase 1,980,198 shares of common stock at a purchase price of $35.3499 where each pre-funded warrant has an exercise price of $0.0001 per share (the &#8220;Pre-Funded Warrants&#8221;). We received aggregate net proceeds of approximately $100.0&#160;million before deducting costs and offering expenses payable by us. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. Per their terms, the outstanding Pre-Funded Warrants to purchase shares of the Company&#8217;s common stock generally may not be exercised if the holder&#8217;s aggregate beneficial ownership would be more than 9.99% of the total issued and outstanding shares of our common stock following such exercise. The exercise price per share and number of shares of common stock issuable upon the exercise of the Pre-Funded Warrant shares are subject to adjustment in the event of any stock dividends and splits, recapitalization, reorganization or similar transaction, as described in the Pre-Funded Warrant agreement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of conducting additional clinical and preclinical studies and future clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of future manufacturing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of discovery, preclinical development, laboratory testing, and clinical trials for other potential product candidates we may develop, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to file and prosecute patent applications, obtain, maintain, and enforce our intellectual property rights, and defend intellectual property-related claims in certain countries that are subject to economic sanctions and/or hostile to U.S. and international companies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our headcount growth and associated costs as we expand our business operations and research and development activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the potential delays in our preclinical studies, our development programs and our current and planned clinical trials due to the effects of the COVID-19 pandemic (including supply chain interruptions) or geo-political actions, including war (such as the current armed conflict in Ukraine); </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic conditions and trends, including inflation, rising interest rates, and the ongoing labor shortage; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of operating as a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements.</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This management&#8217;s discussion and analysis is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included in this Annual Report on Form 10-K, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Contracts with Customers</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2022, all of our revenue to date has been generated from the AbbVie Agreement and Janssen Agreement. We account for revenue pursuant to ASC 606, Revenue from Contracts with Customers, or ASC 606, which is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. For additional details regarding our associated accounting policies of ASC 606, refer to Notes 2 and 12 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the process of preparing our consolidated financial statements, we are required to make estimates to determine amounts to be recognized in collaboration revenue. In particular, for our collaborations with AbbVie and Janssen, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date in proportion to total costs expected to satisfy those performance obligations. The estimated costs associated with the remaining effort requires judgment and impacts revenue recognition. The uncertainties in the estimated costs associated with the remaining effort is principally a result of those cost estimates being based on expected effort for novel research and is partially reliant on scientific results. The research and scientific results impact the timing and the magnitude of costs to complete the remaining performance obligations. Accordingly, revenue may fluctuate from period to period due to significant revisions to estimated costs, resulting in a change in the measure of progress for a performance obligation.</span><span style="font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The services provided by us under the AbbVie Agreement were completed in December 2022. We do not expect to recognize any further revenue related to the AbbVie Agreement. In January 2023, Janssen informed us that it had decided to exercise its right to terminate the Janssen Agreement for convenience, subject to a 60 day notification period. The Janssen Agreement will terminate effective March 2023 or earlier if agreed to by us and Janssen.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and adjust, if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced. In certain instances, we prepay for services to be provided in the future. These amounts are expensed as the services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect our estimates to be materially different from amounts incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure employee and nonemployee equity-based compensation based on the grant date fair value of the equity-based awards and recognize equity-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period of the respective award. We recognize forfeitures as they occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock option awards granted using the Black-Scholes option-pricing model, which uses as inputs, the fair value of our common stock and subjective assumptions we make, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. Due to insufficient company-specific historical data, we base the estimate of expected volatility on the historical volatility of a representative group of publicly traded companies for which historical information is available in addition to our own historical volatility. The historical volatility is generally calculated based on a period of time commensurate with the expected term assumption. We use the simplified method to calculate the expected term for options granted to employees and directors. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, we utilize the contractual term. The risk-free interest rate is based on a U.S. Treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero, as we have never paid dividends and do not have current plans to pay any dividends on our common stock.</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we exercised our one-time extension right for its existing lease for 32,405 square feet of office and laboratory space through May 2025, as provided for under the terms of the lease, and with future rent payments of $4.2 million as reflected in Note 6, "Leases", to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, with additional other rent payments of $0.3 million to be paid in 2023. As of&#160;December&#160;31, 2022, our contractual obligations for our primary office and laboratory space remain consistent with those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into contracts with a number of third parties, including external CROs, that require us to make upfront payments, some of which may be non-refundable. Under various licensing and related agreements with third parties, we have agreed to make milestone payments and pay royalties to third parties. Pursuant to an exclusive license agreement with Children&#8217;s Medical Center Corporation, as amended in 2018, we are required to pay $80,000 per year until the agreement is terminated. We will also be responsible for up to $1.3 million of development milestone payments through the first regulatory approval of a licensed product, tiered royalty payments of low single-digit percentages on net sales of licensed products in the event that we realize sales from products covered by the license agreement, and between 10% and 20% of non-royalty income attributable to a sublicense of the CMCC rights. Amounts paid to CMCC are recorded as research and development expense in the statements of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a collaboration agreement with Schr&#246;dinger, we may be required to pay Schr&#246;dinger certain development milestones, not to exceed in the aggregate, on a target-by-target basis, a low six-figure payment upon initiation of lead optimization and $3.1 million on a compound-by-compound basis, as well as royalties in the low single digits on sales of products containing such compounds. In addition, we have agreed to pay Schr&#246;dinger a percentage, in the mid-single digits, of certain payments we receive from third parties in connection with the licensing or transfer of the rights to exploit such compounds to such third parties, including a one-time fee of $1.0 million paid in 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with vendors for preclinical studies, preclinical and clinical supply and manufacturing services, professional consultants for expert advice, and other vendors for other services for operating purposes. We have not included these payments in the table of contractual obligations above since the contracts do not contain any minimum purchase commitments and are cancelable at any time by us, generally upon 30 days prior written notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our financial statements or do not otherwise apply to our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Item 8. Financial Statements And Supplementary Data.</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MORPHIC HOLDING, INC.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_76">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183My9mcmFnOjk2ZWJjZTZmMTc2MzRlNDVhZTA0YzllMGExOTVkZGVjL3RhYmxlOjE3OTUwMzBjMzc1YTRiMjQ4NmE1MGQzYWNjZjViNzRiL3RhYmxlcmFuZ2U6MTc5NTAzMGMzNzVhNGIyNDg2YTUwZDNhY2NmNWI3NGJfMi0wLTEtMS02NzQ3NC90ZXh0cmVnaW9uOjI1NDI4M2UwODA5ZTQ2YThhODlhYWIyOGM2NzhjNzVmXzcx_d766cbae-af1d-4110-b216-0b105ecbbde3">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_76">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_79">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_79">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_82">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_82">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_85">Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_85">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_88">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_88">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_91">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_91">6</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Shareholders and the Board of Directors of Morphic Holding, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Morphic Holding, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accordingly, we express no such opinion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Critical Audit Matter</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We determined that there are no critical audit matters.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183Ni9mcmFnOjBkNzBjZTdhYmIwOTRhOWFhZWQyOTc1NTkyMjczZDJiL3RleHRyZWdpb246MGQ3MGNlN2FiYjA5NGE5YWFlZDI5NzU1OTIyNzNkMmJfMzg2OQ_22646969-e870-4123-bb5b-c37776a2a9dd">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have served as the Company&#8217;s auditor since 2017.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183Ni9mcmFnOjBkNzBjZTdhYmIwOTRhOWFhZWQyOTc1NTkyMjczZDJiL3RleHRyZWdpb246MGQ3MGNlN2FiYjA5NGE5YWFlZDI5NzU1OTIyNzNkMmJfMzg3MA_fd8b8376-fe71-4ac4-be02-027b915340b1">Boston, Massachusetts</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 23, 2023</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MORPHIC HOLDING, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNC0xLTEtMS02NzQ3NA_8d226283-6294-4295-b8cc-883dc1aa5632">59,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNC0zLTEtMS02NzQ3NA_3c6825fc-d2a3-4939-b3a9-0102ed2dd383">171,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNS0xLTEtMS02NzQ3NA_486417b6-701d-41a9-8dec-a21ae6f5fab3">288,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNS0zLTEtMS02NzQ3NA_1b26fc9b-3a5d-41bf-b530-8bde840fddc8">236,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNi0xLTEtMS02NzQ3NA_2799196b-9300-4b9f-907a-f4749382cf21">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNi0zLTEtMS02NzQ3NA_4b215eb9-60cf-4acc-aa95-98f80f9d80e8">2,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNy0xLTEtMS02NzQ3NA_39a5e659-da44-4391-8ea8-549038afec38">13,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNy0zLTEtMS02NzQ3NA_f4b6659b-bd5e-487c-a804-2b26525c9618">7,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfOC0xLTEtMS02NzQ3NA_be92317b-8aea-4693-b9ac-0312524ae3be">362,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfOC0zLTEtMS02NzQ3NA_66255cf5-c188-4fa8-91e9-1c2339c94c02">418,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfOS0xLTEtMS02NzQ3NA_07c3bdef-2f94-4677-8150-d56c9b7ae2de">3,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfOS0zLTEtMS02NzQ3NA_4948de17-f33d-4312-95ed-1ea6f622ae5a">4,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTEtMS0xLTEtNjc0NzQ_8d393b48-d588-4c1e-bb81-f6da25fc7870">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTEtMy0xLTEtNjc0NzQ_b46b1b6c-aff7-4265-93cf-344a0317ffa8">2,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTItMS0xLTEtNjc0NzQ_3c87d602-47e9-4459-93d5-6dc4df9f0e37">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTItMy0xLTEtNjc0NzQ_055e322e-fa9e-4f9c-8950-95f4ab0ed127">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTMtMS0xLTEtNjc0NzQ_bb8cf4a9-f10d-4039-90b7-d4d427eebadc">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTMtMy0xLTEtNjc0NzQ_45a45b4e-4a86-43ae-a22b-f36f7510a2c4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTQtMS0xLTEtNjc0NzQ_b525b5df-6c85-469d-93fe-524203ff1c70">368,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTQtMy0xLTEtNjc0NzQ_2aeb6b26-3f08-4b16-8c3b-0f67236b993a">426,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTgtMS0xLTEtNjc0NzQ_43363c13-e278-4676-8e34-599dd9906efc">3,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTgtMy0xLTEtNjc0NzQ_9322e5c8-0e86-473c-b58a-cebc7b484ab2">4,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTktMS0xLTEtNjc0NzQ_0291cdd4-4f6b-4f36-9223-91c1da56341a">13,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTktMy0xLTEtNjc0NzQ_6e0d5863-8f2d-4353-a860-66943036d235">12,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjAtMS0xLTEtNjc0NzQ_7b774f4f-4c2b-413b-a0a4-1cce96ebeeb4">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjAtMy0xLTEtNjc0NzQ_44a49125-3676-4b43-b028-803cd5b50a33">20,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjItMS0xLTEtNjc0NzQ_86245366-d396-4f7e-89a9-362ff98bc2c9">17,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjItMy0xLTEtNjc0NzQ_d1aab1b7-e960-4989-ac45-7eee2ce5a2fe">38,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjQtMS0xLTEtNjc0NzQ_9a778d72-43f0-4556-84a7-04c2ee95e748">2,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjQtMy0xLTEtNjc0NzQ_d528441e-5b66-4ad8-a4a2-d8ff7ca88a1d">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjUtMS0xLTEtNjc0NzQ_db48c8e9-823f-470c-904e-584929650917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjUtMy0xLTEtNjc0NzQ_094af5e0-e072-4223-92ea-79552a1fec0b">47,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjctMS0xLTEtNjc0NzQ_e9b4800b-19c9-420a-84cd-f6399d88b24d">19,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjctMy0xLTEtNjc0NzQ_cc0d5339-f9bf-408b-9823-ff026000ca78">89,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjktMS0xLTEtNjc0NzQ_9301f7ff-b8fb-45f8-a3ba-8dbbac69fdaa"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjktMy0xLTEtNjc0NzQ_7f5e347b-c1f8-4c06-8238-f3640d30dc4b"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl8yMg_ac712806-4792-4744-b1cf-68abe45e4edb"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl8yMg_b3429064-13c1-4d3e-aa43-8577387838c3">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl8zNg_09d0571f-32aa-4c1e-bb0b-3c8c0cfe7b3f"><ix:nonFraction unitRef="shares" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl8zNg_2686ef59-8d1b-4c47-841e-897cc6254a00">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl81OA_200c4f37-8a81-4da9-89a6-199c381734cc"><ix:nonFraction unitRef="shares" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl81OA_393feeab-e3f1-4de2-8304-79ae9b1b7890"><ix:nonFraction unitRef="shares" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl81OA_aef066fe-5a44-43cb-a45a-187af5e2862e"><ix:nonFraction unitRef="shares" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl81OA_cb3ac5a8-963b-4a15-a49d-dd684bff9bed">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMS0xLTEtNjc0NzQ_33ed1b18-057e-48a9-8d0d-da645a6c8c65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMy0xLTEtNjc0NzQ_4132006e-f041-4f92-bee6-27b1c98a92e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8xOQ_1242b7c3-4d98-49c1-b06d-048d63bd7814"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8xOQ_851bbed0-3ecf-4187-8295-ad9899d28abd">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8zMw_7d24002a-513c-42ee-8715-3e661e004b2c"><ix:nonFraction unitRef="shares" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8zMw_c4ad2668-2029-418d-9107-9a90a837cd0c">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF81NQ_da49aa8a-1965-4eb5-b4ad-04e9fef61bbc"><ix:nonFraction unitRef="shares" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF81NQ_f2261ac9-0510-4e86-ad0d-fbb3acf3ace5">38,584,678</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8xMDE_4f681ece-5070-4bf1-99e7-50c2a32d8086"><ix:nonFraction unitRef="shares" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8xMDE_5f608d03-bfae-4539-b3b4-9b1cfbf25274">37,085,397</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMS0xLTEtNjc0NzQ_fdc9c284-ec2d-4dc7-bb97-9e510afce4d2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMy0xLTEtNjc0NzQ_243cdf31-e6de-42a2-8fc6-682002977d90">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid&#8209;in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzQtMS0xLTEtNjc0NzQ_dcd931f6-3bd8-4560-846f-a07b618e36ef">649,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzQtMy0xLTEtNjc0NzQ_d7483917-a0a1-48d2-8f75-5232c3a446b1">575,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzUtMS0xLTEtNjc0NzQ_dd6f306a-9719-4c1b-8b27-392bc5b074e2">297,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzUtMy0xLTEtNjc0NzQ_00c94aab-b8d3-4209-bb6e-ba75860e230e">238,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzYtMS0xLTEtNjc0NzQ_88663390-518a-4db6-85db-eec3fd7f12b6">3,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzYtMy0xLTEtNjc0NzQ_df55a1bc-47cc-4473-baaf-c11b8689ba62">482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzctMS0xLTEtNjc0NzQ_bd9a3647-cf2f-4ffa-a53b-074528e055c7">349,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzctMy0xLTEtNjc0NzQ_af313be0-1c41-499c-9595-637e9b966ced">336,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzgtMS0xLTEtNjc0NzQ_cc87060f-97d9-4a8f-b8be-34e24a8725f5">368,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzgtMy0xLTEtNjc0NzQ_4b0980eb-6895-4a8d-87a9-a006334ae774">426,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MORPHIC HOLDING, INC.<br/>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS<br/>(In thousands, except share and per share data)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMi01LTEtMS02NzQ3NA_9f56309d-f949-4192-89fe-9af7958d4b82">70,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMi03LTEtMS02NzQ3NA_8d351d2f-4c88-4b36-a93e-452b7d358384">19,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMi05LTEtMS02NzQ3NA_f9abe18f-f5be-4db4-a476-902c5d27be64">44,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNC01LTEtMS02NzQ3NA_78cc1b24-435f-499d-8985-324ef9c08463">102,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNC03LTEtMS02NzQ3NA_59ce9c08-a48e-4e69-86ed-780fef9d33ea">87,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNC05LTEtMS02NzQ3NA_e6987f22-b7b9-4601-9c67-39bfb016451d">73,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNS01LTEtMS02NzQ3NA_37a959ee-b456-4f5a-af43-060c4acd6d65">32,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNS03LTEtMS02NzQ3NA_296d4127-6315-46f7-818e-e8a1a72dae03">27,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNS05LTEtMS02NzQ3NA_5289e9a0-cfa1-47c6-bfec-b29a5abd5954">18,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNi01LTEtMS02NzQ3NA_eb12cec8-ca34-4f7a-ba12-c3b518cdae67">134,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNi03LTEtMS02NzQ3NA_e878d80f-a6b6-433f-869e-e28bb97ebe88">115,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNi05LTEtMS02NzQ3NA_19eca252-2099-409a-911d-92023016b2e0">92,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNy01LTEtMS02NzQ3NA_aaee53e3-1e44-4cf9-b2b9-6bd6e87abac0">63,396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNy03LTEtMS02NzQ3NA_dbf18caa-4a4d-4a37-a602-32f84ca70977">95,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNy05LTEtMS02NzQ3NA_40e0aba1-7e69-4c71-8201-a575c1560336">47,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfOS01LTEtMS02NzQ3NA_4a6a0000-c980-4a3c-a733-d0f531e35878">4,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfOS03LTEtMS02NzQ3NA_869b60f7-3369-487e-bf0d-c9a6bf625631">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfOS05LTEtMS02NzQ3NA_a28168d4-0324-42b1-9319-8a059ed8fb1e">1,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTAtNS0xLTEtNjc0NzQ_37b77f8a-632b-49ca-9553-df2efdd10cb2">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTAtNy0xLTEtNjc0NzQ_91cfdc6d-46d6-4e22-81db-0e7ccc5f1d6c">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTAtOS0xLTEtNjc0NzQ_8def3d87-7085-4214-8e40-745505c9acad">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTEtNS0xLTEtNjc0NzQ_8ef89b17-b507-4cc7-8be0-71981ae739d5">4,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTEtNy0xLTEtNjc0NzQ_7df90600-1da5-4ed5-945d-013a24c29713">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTEtOS0xLTEtNjc0NzQ_34b00d94-ecef-459a-b828-1354d0c38ac3">1,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before (provision for) benefit from income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTItNS0xLTEtNjc0NzQ_7d919a79-77fb-4be0-a7e9-12413bae7d67">58,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTItNy0xLTEtNjc0NzQ_9ceb770e-0faf-4484-8cfb-bab02c62ca72">95,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTItOS0xLTEtNjc0NzQ_130996d4-dde0-4294-9109-6ab10173451f">45,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Provision for) benefit from income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTMtNS0xLTEtNjc0NzQ_216af7b6-1528-48d8-b5ed-363606be8b11">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTMtNy0xLTEtNjc0NzQ_dc59de40-cbf2-4301-bb74-73806b5bc046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTMtOS0xLTEtNjc0NzQ_85da4a11-835d-458d-8b57-db57afea30ef">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTQtNS0xLTEtNjc0NzQ_24d5252a-cb23-455f-a737-795060391e32">59,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTQtNy0xLTEtNjc0NzQ_c0112ab3-dbc5-4802-a516-2bf18aaf74f9">95,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTQtOS0xLTEtNjc0NzQ_eda87952-8418-4060-af1c-70f89a9fe608">44,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtNS0xLTEtNjc0NzQ_8c120276-2bc6-4b34-872c-85daef93b6e2"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtNS0xLTEtNjc0NzQ_8e3c3f6a-4b36-4cfc-86d5-c3ccc5acf0fa">1.55</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtNy0xLTEtNjc0NzQ_4820e5a1-ef95-49a7-accc-25a78483c9b0"><ix:nonFraction unitRef="usdPerShare" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtNy0xLTEtNjc0NzQ_ebf8398d-ddd5-4420-855d-fa4e70772f67">2.67</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtOS0xLTEtNjc0NzQ_4d7f2820-df04-4b89-a27a-291b833519b6"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtOS0xLTEtNjc0NzQ_adc5ad40-3a70-454e-a2ff-0b90701d020f">1.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtNS0xLTEtNjc0NzQ_2e10b9a2-f35b-46a3-806c-7c070981994c"><ix:nonFraction unitRef="shares" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtNS0xLTEtNjc0NzQ_df112c88-b6b6-4937-8614-2f52efa78acb">38,112,498</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtNy0xLTEtNjc0NzQ_18bda248-9708-4384-a6ac-988bf55597de"><ix:nonFraction unitRef="shares" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtNy0xLTEtNjc0NzQ_21df57bb-4c26-4d15-8ce2-507b57e876a1">35,797,969</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtOS0xLTEtNjc0NzQ_3a8b38c3-ee84-4a67-810b-a33df352ac0c"><ix:nonFraction unitRef="shares" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtOS0xLTEtNjc0NzQ_e5a6d91a-86cc-4203-af57-9eba6082677c">30,594,897</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjItNS0xLTEtNjc0NzQ_fb67651a-858c-429a-a3f3-293f20b0873a">59,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjItNy0xLTEtNjc0NzQ_54c7bb68-07e0-470b-8a04-6bb5f8a07fb0">95,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjItOS0xLTEtNjc0NzQ_866b5f69-fcd9-46be-800b-80ec15a13292">44,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized holding losses on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjQtNS0xLTEtNjc0NzQ_37e1975a-69e5-4845-8543-e04a108737ae">2,857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjQtNy0xLTEtNjc0NzQ_5ac3d248-3d84-4f04-be71-b86518ef18c7">461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjQtOS0xLTEtNjc0NzQ_d206e762-f9b0-40d0-87df-fc80a9c69394">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjUtNS0xLTEtNjc0NzQ_7d439a6a-61a1-45af-abb3-98b32a009d74">2,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjUtNy0xLTEtNjc0NzQ_559f622d-cc87-4b26-8c59-3c67535369d0">461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjUtOS0xLTEtNjc0NzQ_cea2f643-6e34-4112-9764-2acf51843c0f">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjYtNS0xLTEtNjc0NzQ_7b5f8104-5d56-40d1-965a-95fa87c2f651">61,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjYtNy0xLTEtNjc0NzQ_e9ffc1e8-aefa-4975-982b-b9340b9277c2">96,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjYtOS0xLTEtNjc0NzQ_8c1bd1e3-e244-4a50-93fa-f2e825ae6bc5">45,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MORPHIC HOLDING, INC.<br/>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY<br/>(In thousands, except share data)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.731%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid&#8209;in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bfdc1a144904aff961163efe0b71fed_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0yLTEtMS02NzcyMw_c58a28c3-8443-42cc-9676-149cc26159cc">30,110,251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfdc1a144904aff961163efe0b71fed_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi00LTEtMS02NzcyNw_ed866a63-c71e-4452-b4c5-3b12dcbfc798">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6348a4fce16d4a8495c328951bd63827_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi02LTEtMS02NzcyNw_a945b2bb-1c62-4317-870d-8658c9ea3c54">238,384</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c14a9ad52b943b0a9f70a1adc012b62_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi04LTEtMS02NzczMQ_1c8a2fa7-40ff-4f13-b3ac-f4f2273a8303">97,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0ec20e47be47eab177727935b230b5_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0xMC0xLTEtNjc3MzE_089807ff-1fe5-4094-b6c6-110e64c53983">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8445c41fd5491292904732bb0c4761_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0xMi0xLTEtNjc3MzE_43a14105-3021-48d7-beef-c03fcc7fe4e0">140,918</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a6b759ffbb449e81cc565598a24220_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMy02LTEtMS02NzcyNw_17893d80-fe23-4eb1-8e19-7c830e87e227">11,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMy0xMi0xLTEtNjc3MzE_d71575e8-1cd5-4084-a968-b8f1d2230423">11,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ceda5f5a33e4c9581ee108c783e1d6f_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNC0yLTEtMS02NzcyMw_e9cc6d2e-ac62-4efc-9dff-13649ff19d5a">252,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares upon stock option exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ceda5f5a33e4c9581ee108c783e1d6f_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS0yLTEtMS02NzcyMw_6ef945d7-9a66-4ad9-8698-0e41ab9563b2">431,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a6b759ffbb449e81cc565598a24220_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS02LTEtMS02NzcyNw_54ed4db5-472e-4f81-9a65-9302d51a1e6f">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS0xMi0xLTEtNjc3MzE_94fdd8e9-0006-4c03-9dd0-2e793bd04174">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares under the Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ceda5f5a33e4c9581ee108c783e1d6f_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi0yLTEtMS02NzcyMw_0ec7a217-362f-4774-9fbe-df76b89b361c">85,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a6b759ffbb449e81cc565598a24220_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi02LTEtMS02NzcyNw_dc1a38cd-b103-47d1-b5df-9e2d13699b58">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi0xMi0xLTEtNjc3MzE_6401bf24-8571-4a08-bf99-d05219456b8f">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares through at-the-market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i03f523ed243944c1952b9f439ae6591a_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0wLTEtMS03MDMxMS90ZXh0cmVnaW9uOjhmYTJhODEwYjVlZTRiNzk4ZWU3YzZiY2IzZDI1YzU5XzM4NDgyOTA2OTczMTk_c09daf62-8df6-4c1e-894d-131b1c9b5586">1.5</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70ca9447c43d4a3cb80fb8f78c3c39ee_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0yLTEtMS02NzcyMw_29df9d51-b763-44a9-8db8-6c0fc8edd9fb">1,157,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5918a2e0b4490086688e38b5dbd9e3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy02LTEtMS02NzcyNw_ef98c11e-5fb5-4db2-aa9c-de7f668bdc23">33,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f523ed243944c1952b9f439ae6591a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0xMi0xLTEtNjc3MzE_ad695ac1-6226-4c38-9287-78103a6d0e63">33,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding losses on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i875354d9000b443caa58d5fb686317b6_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOC0xMC0xLTEtNjc3MzE_5a5905a0-d1ba-4bd1-8721-a5d828265a78">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOC0xMi0xLTEtNjc3MzE_aa608424-b665-41a3-8cbc-65aa103cbdef">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e9ea2357bcd4e0b80ea5f90c117c183_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOS04LTEtMS02NzczMQ_69fe9a00-a9fd-45b4-a237-26c40c603539">44,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOS0xMi0xLTEtNjc3MzE_af0618c9-c36a-42c2-a1c1-2adead0132f9">44,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9a2e7740aed41f39474ac66cdd34da5_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0yLTEtMS02NzQ3NA_84bc669e-7182-419a-901f-55f7c316cdbc">32,037,686</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a2e7740aed41f39474ac66cdd34da5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi00LTEtMS02NzQ3NA_d9a8fda4-a1ea-4659-bf4b-64dcc6d2c48f">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7a5cede0a3473c877c0673a0bcfa2a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi02LTEtMS02NzQ3NA_56aaf0df-21f1-4b4d-a8a8-99d1fcb1d6cb">287,727</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70cbfaa401bb4c92b9a9c2661d1df2b6_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi04LTEtMS02NzQ3NA_30ceb722-cf3f-4f9b-8589-554e2640716c">142,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e9ea7d97544c62a5f4d876238911a3_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0xMC0xLTEtNjc0NzQ_cfe16f3e-a739-482c-bb2e-eff7257f80ea">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0xMi0xLTEtNjc0NzQ_e0a7f4a2-d870-47ea-97eb-c4fd0ee84a97">145,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity&#8209;based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2d410f10fd43e0a3d21d4b9a945a0a_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMy02LTEtMS02NzQ3NA_3f6c6c8a-b5f2-479e-b5a4-1cb503c73643">21,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMy0xMi0xLTEtNjc0NzQ_5cde5cae-f01d-4335-baa9-7633b5266088">21,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5ee1b9fb78c472393ca0dd130c5b288_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNC0yLTEtMS02NzQ3NA_74ea9f40-2a60-41e5-a1bd-80cf2da479fa">127,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares upon stock option exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5ee1b9fb78c472393ca0dd130c5b288_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS0yLTEtMS02NzQ3NA_33fa3da5-9c8e-48d2-a6ed-58ba7f84da31">827,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2d410f10fd43e0a3d21d4b9a945a0a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS02LTEtMS02NzQ3NA_ebeee3fc-1746-4628-b64c-3c8e1e019612">9,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS0xMi0xLTEtNjc0NzQ_53dabf53-04ac-4cfb-87f7-3aec864cea6f">9,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares under the Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5ee1b9fb78c472393ca0dd130c5b288_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi0yLTEtMS02NzQ3NA_3787c6d4-45ac-4ce2-bbda-cd36afc49e5a">35,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2d410f10fd43e0a3d21d4b9a945a0a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi02LTEtMS02NzQ3NA_d4d64efc-dc08-4be3-967a-d6dd2ae50c3d">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi0xMi0xLTEtNjc0NzQ_c4c6c55e-a806-4348-a821-77920406deef">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares through at-the-market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ib242abf1d8974e31acd46eb1e550e867_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0wLTEtMS02NzQ3NC90ZXh0cmVnaW9uOjMyNDVkYzFhZTVjNjRlOWM5MzQzODIyZGMwYTExYWFkXzg3_17dad606-14d0-4697-8e99-e45946ac161e">1.2</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04199a8b57a94afdb3894dd8f3611ef9_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0yLTEtMS02NzQ3NA_d1f474bf-4059-4736-8eeb-0ee33bd236a8">556,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c83e86e5ecf4e049f03b221fd37ddc2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy02LTEtMS02NzQ3NA_0d434330-d55c-4a3e-a37b-1ae7ba43f1f4">25,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib242abf1d8974e31acd46eb1e550e867_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0xMi0xLTEtNjc0NzQ_4e61c495-e5ef-41d3-8bc2-38bbb751e900">25,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares in secondary offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i3021ee10eeff4228808670e25669c506_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtMC0xLTEtNzUxNjkvdGV4dHJlZ2lvbjozZWFjODdiMWU2ZTA0NzBkODFkYmRkMjI5ZWI1NTFlMV8yNzQ4Nzc5MDY5NTQ5_0d8e50a6-cbbe-4a7d-8eaf-e1d33012fc29">15.0</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib89e4e41db194455b68dae07e4088634_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtMi0xLTEtNzUxOTA_88fc00c4-09ae-40bd-bad2-c43b0e89d770">3,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib89e4e41db194455b68dae07e4088634_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtNC0xLTEtNzUxOTA_3a28c3d2-9452-4ff7-99f1-87db8e0972f0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229d09b827bb41a89b5f692014a5d842_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtNi0xLTEtNzUxOTA_fe053c29-b629-48ba-aca5-a29924ea0a2a">229,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3021ee10eeff4228808670e25669c506_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtMTItMS0xLTc1MTkw_4ab3b220-ebbc-435f-b884-866195c74d36">229,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding losses on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib148686698e04b2b916642950ccd1817_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOC0xMC0xLTEtNjc0NzQ_c5bf771c-800a-4ac0-be75-52989a79d540">461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOC0xMi0xLTEtNjc0NzQ_206f1273-438d-47d6-8e27-c90369890eb9">461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c7558e92e8d4ff7ac77d9a2a034d000_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOS04LTEtMS02NzQ3NA_0261aab1-6bd0-4d42-8d95-f7017767a95e">95,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOS0xMi0xLTEtNjc0NzQ_c437d198-a568-4b70-b231-b3eeb3cda6bc">95,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i251a1f6f65c94d6ea46a8bf3f0bc6caf_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtMi0xLTEtNjc0NzQ_1a6e5286-2bb6-4998-b040-ee21c6e1afe0">37,085,397</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i251a1f6f65c94d6ea46a8bf3f0bc6caf_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtNC0xLTEtNjc0NzQ_a34fb09a-0d31-41de-b1ab-8beb10999ade">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i134fbbf1dfed4fa4814373cfe2ffcdb2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtNi0xLTEtNjc0NzQ_0b0e6133-0516-4fd0-87f1-d8b2d92ec7a0">575,231</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica43711c0df64da7a4e706d076e6bdbc_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtOC0xLTEtNjc0NzQ_8e07d2be-3445-4393-9005-301437c3f821">238,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c50679b571740e19279ef7944cb3f16_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtMTAtMS0xLTY3NDc0_76bfd3dd-b79b-4b19-892d-296d559e6dca">482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtMTItMS0xLTY3NDc0_5126120d-66e1-47be-9562-5919a4f8d9ff">336,699</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity&#8209;based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e5bf0a1e4948d0971fff4b2f4bdb14_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTEtNi0xLTEtNjc0NzQ_abc46a98-2158-4e73-b94f-32cc519122c3">29,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTEtMTItMS0xLTY3NDc0_94a7ef94-f214-4359-90a2-287510764d54">29,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ac40f3b64c04bb6b11779403daca223_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTItMi0xLTEtNjc0NzQ_5c663391-87eb-4089-806e-33f118a1bf1a">9,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares upon stock option exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ac40f3b64c04bb6b11779403daca223_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTMtMi0xLTEtNjc0NzQ_ad57d752-84e5-45e4-bc50-8d76484c32b6">459,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e5bf0a1e4948d0971fff4b2f4bdb14_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTMtNi0xLTEtNjc0NzQ_51f9f668-fd26-42e7-8694-c39677d17d0c">5,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTMtMTItMS0xLTY3NDc0_b8838c54-edd2-44b4-b7d5-4a024dccfc8b">5,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares under the Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ac40f3b64c04bb6b11779403daca223_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTQtMi0xLTEtNjc0NzQ_d13919ad-8a7e-4c14-b806-cf57c9557d94">30,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e5bf0a1e4948d0971fff4b2f4bdb14_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTQtNi0xLTEtNjc0NzQ_67d9764a-ddfa-4a13-9dc2-aef3c7044458">885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTQtMTItMS0xLTY3NDc0_9e2b2114-97a9-49f7-b44a-e9f3a1409de5">885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares through at-the-market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTUtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpjNWY4YzYxMTUzNjE0OGQwOTFmZTM0Mjc1NjhhOTM4N184Nw_3c96caa5-2c4b-4e24-9bde-01ed3d91484a">1.3</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73c2e36cd1474c26b0d1a8bf3509e772_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTUtMi0xLTEtNjc0NzQ_79b3456f-992f-4357-991f-a3e9ddd53b5c">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1c028c600f492ea22a0fc290237655_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTUtNi0xLTEtNjc0NzQ_bb73ccae-1d1b-490f-8d07-3499279acf0f">39,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTUtMTItMS0xLTY3NDc0_1ebe206c-9fd2-4bda-a8ff-b091c17739de">39,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding losses on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64f737a67eb34edebd4b964b94d03e20_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTctMTAtMS0xLTY3NDc0_8b373330-8638-4bdf-a9e6-fa132cd55e6f">2,857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTctMTItMS0xLTY3NDc0_6a3e9446-d361-40cf-9116-de85b490791c">2,857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6217b53477e450c9212104a64166f49_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTgtOC0xLTEtNjc0NzQ_1742f430-05d1-4f8b-9f41-67124f810e0c">59,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTgtMTItMS0xLTY3NDc0_03b76e15-0446-466e-9aba-0ed580054bda">59,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1d715f0e90f4892a783060db407d98d_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktMi0xLTEtNjc0NzQ_d6a9de1b-17b4-4689-9916-dc83686b4317">38,584,678</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d715f0e90f4892a783060db407d98d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktNC0xLTEtNjc0NzQ_e65aefc2-b232-496c-afc5-4bfa6d86ce07">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc0fc6fd3cc4a6085dbb3864bce300a_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktNi0xLTEtNjc0NzQ_d9b1448e-4369-40f9-8af5-467604a35425">649,549</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadaa15dc21b14e3db8588f66b4714a49_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktOC0xLTEtNjc0NzQ_0be88f6f-2dff-438c-86f1-49f280462994">297,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb7bba96f6fe49c1909da2aba38db320_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktMTAtMS0xLTY3NDc0_3329f5e5-89d4-411b-a1a5-ef78c03e292b">3,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktMTItMS0xLTY3NDc0_c62cec13-b422-4785-9968-dbda6af1db55">349,119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MORPHIC HOLDING, INC.<br/>CONSOLIDATED STATEMENTS OF CASH FLOWS <br/>(In thousands)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMy0xLTEtMS02NzQ3NA_5b8576b1-3031-4464-9ed6-cfca771a5ddf">59,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMy0zLTEtMS02NzQ3NA_830f8740-3441-4805-87f1-eae092711042">95,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMy01LTEtMS02NzQ3NA_1e3e17c8-194c-4362-94fa-0858289d74df">44,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNS0xLTEtMS02NzQ3NA_0e208fe5-4765-48d2-8459-d16fed3502f9">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNS0zLTEtMS02NzQ3NA_6c90ba51-1dea-4195-9619-56c679b48502">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNS01LTEtMS02NzQ3NA_1d793fb0-9e3f-4559-a80c-46b369cbcaa9">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Premium amortization and discount accretion on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNi0xLTEtMS02NzQ3NA_82fab613-40f8-4ab9-9ee0-1eebd6823ba9">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNi0zLTEtMS02NzQ3NA_327b0e35-e97c-4a33-b740-c77ec80f3782">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNi01LTEtMS02NzQ3NA_be2364a4-d1d0-4a0a-b52c-571b3a66e5c7">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Equity&#8209;based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNy0xLTEtMS02NzQ3NA_7ca8b885-c980-4765-add8-2778a7588b91">29,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNy0zLTEtMS02NzQ3NA_dcc45184-67a5-4a27-90ca-fc5f6d252635">21,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNy01LTEtMS02NzQ3NA_57d3a19e-3ea4-4a32-9716-2bfd4332fa7b">11,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Loss on sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC0xLTEtMS03MDU4Nw_a1131f93-3f5b-4771-8670-68f6150c956d">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC0zLTEtMS03MDYwNA_bff8c9e0-0e00-46ab-a1bd-d2fab1e09f3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC01LTEtMS03MDYxMg_813a599e-88d4-45f2-a5f9-b80756ffbc42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Loss on disposal of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC0xLTEtMS02NzQ3NA_5e198048-57b9-49cc-8d85-367cb03f2ee7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC0zLTEtMS02NzQ3NA_032ca2cf-0624-4977-ba9f-c1b109879e23">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC01LTEtMS02NzQ3NA_c8ba3c52-b5f3-468d-92a4-4d30d56d5c13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTItMS0xLTEtNjc0NzQ_f2b06517-84e8-42b3-bb64-b2b3c84beb99">1,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTItMy0xLTEtNjc0NzQ_da0e665b-96b1-41fe-909f-ebca6c1eff49">5,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTItNS0xLTEtNjc0NzQ_1da5f8d9-82c6-4eb3-8be6-cd9bb5cb5ae5">3,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTMtMS0xLTEtNjc0NzQ_abbaf1eb-7e49-4760-b712-e2e2b9d24364">5,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTMtMy0xLTEtNjc0NzQ_eff1db6b-6404-424a-b4d7-1523ea2fa5b5">4,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTMtNS0xLTEtNjc0NzQ_3626803b-2a00-48ff-9371-ddd561befd1f">767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTQtMS0xLTEtNjc0NzQ_51e7bea8-5294-4358-a137-603e740aa995">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTQtMy0xLTEtNjc0NzQ_f0bfec8d-fd23-48d6-98c0-a0d2578eb514">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTQtNS0xLTEtNjc0NzQ_f6c6d308-236a-4212-8054-8a91eb155cd8">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="morf:IncreaseDecreaseOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTUtMS0xLTEtNjc0NzQ_74cd1f4d-3979-4f38-99f5-828edd0af494">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="morf:IncreaseDecreaseOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTUtMy0xLTEtNjc0NzQ_e43d9912-9a76-46b6-abd2-ffe59c2e8019">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="morf:IncreaseDecreaseOperatingLeaseRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTUtNS0xLTEtNjc0NzQ_86c9b29b-39a9-47db-8352-aa16e588fe37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTYtMS0xLTEtNjc0NzQ_a7f01116-5ec7-48ff-9a29-8b6adf5b10d5">1,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTYtMy0xLTEtNjc0NzQ_2f4daf7f-c8c4-433f-b1fa-44e98cc71498">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTYtNS0xLTEtNjc0NzQ_5d7a4b8b-ed33-4060-9f14-99f7f03acd7f">1,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTctMS0xLTEtNjc0NzQ_c53279af-abe3-4077-a4ea-72a2980a263f">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTctMy0xLTEtNjc0NzQ_c372fe8e-a400-4507-9d59-b4221329dc03">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTctNS0xLTEtNjc0NzQ_0a3734aa-f4b9-41b6-8e38-40bd921ee4c9">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTgtMS0xLTEtNjc0NzQ_a6c8aeaf-8669-4e03-bf7f-c0c2e1feb7a6">67,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTgtMy0xLTEtNjc0NzQ_a66ac5bf-05b8-4220-a443-c50e1dbad266">14,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTgtNS0xLTEtNjc0NzQ_a0b8fef1-6af3-4f95-bef1-2987a68637be">11,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="morf:IncreaseDecreaseInDeferredRent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTktMS0xLTEtNjc0NzQ_b0f4419d-c075-404d-94ef-ef1e7867a4ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="morf:IncreaseDecreaseInDeferredRent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTktMy0xLTEtNjc0NzQ_2f414be3-8815-4498-815c-6edf840ef742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="morf:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTktNS0xLTEtNjc0NzQ_d0f121de-c1e6-4727-a43a-4793cf0d98b1">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjAtMS0xLTEtNjc0NzQ_ee3f0cd9-35c2-4660-bd48-a46e58669171">1,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjAtMy0xLTEtNjc0NzQ_a2595d3e-4b46-46a9-95f4-8bdc80178861">1,097</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjAtNS0xLTEtNjc0NzQ_83d3b9b9-23f7-49a7-827d-86f228e00f19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjMtMS0xLTEtNjc0NzQ_782f66f7-20c8-44cf-b413-5ae0f738ca3a">100,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjMtMy0xLTEtNjc0NzQ_ac51a6d0-51ba-4e98-a1cc-d7bc91054062">83,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjMtNS0xLTEtNjc0NzQ_8822f9e2-8095-4cae-b243-cb2c12ce9e3e">45,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjUtMS0xLTEtNjc0NzQ_aa93e1fc-b17d-4bd9-a769-583347aa92dd">238,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjUtMy0xLTEtNjc0NzQ_9ec08918-21fe-458c-8b5b-94212703c090">244,160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjUtNS0xLTEtNjc0NzQ_29eec71d-75d1-4a39-b089-f2a95b1cd07e">145,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtMS0xLTEtNjc0NzQ_6a4795f4-d270-45ad-b388-0a504e120a53">175,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtMy0xLTEtNjc0NzQ_fdf8b720-35e7-4abf-9225-58bbfa2e5cf3">132,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtNS0xLTEtNjc0NzQ_cc60d60c-731c-41ca-8b66-8624a2b447a4">154,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtMS0xLTEtNzA2NjQ_909bd59c-82f3-47f7-a9e4-e29a8ae5be80">7,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtMy0xLTEtNzA2Nzg_ebc708a6-484a-4f84-8b11-9214de5a5469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtNS0xLTEtNzA2ODI_434590aa-38bf-4837-9910-fa9ed7f63afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjctMS0xLTEtNjc0NzQ_b0e7f3aa-3b70-4bce-8a44-702443e46250">365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjctMy0xLTEtNjc0NzQ_ebcf1ef9-012e-4a36-a8b5-1db56f08dbcc">1,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjctNS0xLTEtNjc0NzQ_f5c9cc2d-3678-4bd0-904f-5ae922e9ab01">544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjgtMS0xLTEtNjc0NzQ_139f4165-9028-4cbf-8392-b6363da0cd74">56,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjgtMy0xLTEtNjc0NzQ_e2e18f00-158b-43f2-95da-7b0a5dbcde7d">113,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjgtNS0xLTEtNjc0NzQ_aed1795a-473b-40c6-ac1c-e141eb14fa73">8,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Proceeds from issuance of common shares under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzItMS0xLTEtNjc0NzQ_d5c6bd67-a295-4661-bd22-a2079a2bf961">885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzItMy0xLTEtNjc0NzQ_8841dcc7-6955-4f72-ad38-71a6dd5a46ef">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzItNS0xLTEtNjc0NzQ_52429770-52bc-45eb-933a-ef855c64c90c">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Proceeds from at-the-market offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzMtMS0xLTEtNjc0NzQ_6b1c383f-3a22-4c09-b199-7c68eb974b73">39,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib242abf1d8974e31acd46eb1e550e867_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzMtMy0xLTEtNjc0NzQ_c6794c42-471e-4ae2-b880-ec078b41d46e">25,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f523ed243944c1952b9f439ae6591a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzMtNS0xLTEtNjc0NzQ_a02fb1c4-b24f-4b77-a9f6-34895994784c">33,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Proceeds from secondary offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic313ab40bcfb4f66816203628eb7f0eb_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzQtMS0xLTEtNjc0NzQ_3391e22b-cc7d-4d68-939c-bc164a37298f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3021ee10eeff4228808670e25669c506_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzQtMy0xLTEtNjc0NzQ_1485e62a-5e89-4d9f-8e0d-1e6ac468612a">229,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6416f8f824ff4d4d8207b91e5c244618_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzQtNS0xLTEtNjc0NzQ_f3ee1789-050f-4665-b247-1dc4adf9fa93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Proceeds from issuance of common shares upon stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzUtMS0xLTEtNjc0NzQ_9059854f-3ddf-4553-adb9-b0245aec9633">5,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzUtMy0xLTEtNjc0NzQ_3b1d033b-6519-4a00-ac0b-b6a6f68f4f3c">9,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzUtNS0xLTEtNjc0NzQ_dbaeb6d6-2083-4d8f-93c7-748936d95873">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzYtMS0xLTEtNjc0NzQ_67a41cae-e0c4-4552-adfa-bf8ad87cab48">45,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzYtMy0xLTEtNjc0NzQ_9f87f00b-d022-4488-ad44-2a8912177ae7">266,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzYtNS0xLTEtNjc0NzQ_f91bd88a-df7c-4b74-a1ed-38cb1e734006">38,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzctMS0xLTEtNjc0NzQ_a4c197bc-9d8d-4563-873c-63b9248779f2">112,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzctMy0xLTEtNjc0NzQ_ad9a0585-7fc9-44f5-acee-ec27303aa698">69,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzctNS0xLTEtNjc0NzQ_19c4642d-b7bf-45e1-ad07-087f9493da5d">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzgtMS0xLTEtNjc0NzQ_79a08e75-1fcc-42cc-b0f7-b79c2ec77ca1">171,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzgtMy0xLTEtNjc0NzQ_6572ea1e-9f22-4972-8c9d-20d05d74e68b">102,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8445c41fd5491292904732bb0c4761_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzgtNS0xLTEtNjc0NzQ_585054ca-5bc2-42b7-a8da-79faf255d28f">101,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzktMS0xLTEtNjc0NzQ_3c90530c-e43e-4e02-91a6-6b5205d8e1e0">59,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzktMy0xLTEtNjc0NzQ_fdd53fe6-0a4b-46a5-8305-438fce83433e">171,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzktNS0xLTEtNjc0NzQ_6158d58c-33ca-4e21-b130-25f24c0f2502">102,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchases of property and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDItMS0xLTEtNjc0NzQ_520bce4c-2581-4796-bf43-8e3da4fe77d1">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDItMy0xLTEtNjc0NzQ_27a8b4ce-2341-4592-b23a-f9f93fd771b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDItNS0xLTEtNjc0NzQ_a72096ab-109b-4d4c-af65-b4dedb17b24e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amounts from exercise of stock options included in prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDQtMS0xLTEtNjc0NzQ_008c092c-5e5a-4e66-a52c-ab83f3440c97">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDQtMy0xLTEtNjc0NzQ_af9f7e80-6c73-42f3-9dbb-820c407d0c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDMtNS0xLTEtNzA1Mzk_e8fc0c2e-d42e-4e4a-a858-7042808bda43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance costs included in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDYtMS0xLTEtNjc0NzQ_5b921b27-44f0-463c-a03f-3d2de811d5ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDYtMy0xLTEtNjc0NzQ_0284ee1e-09cc-4b8e-a3ff-d1fc9c29dc3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDYtNS0xLTEtNjc0NzQ_1bc4dfae-cd4f-43ba-b588-8a26c5bf17f5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDctMS0xLTEtNjc0NzQ_c5a963bb-2cea-42ba-994b-26896290bb87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDctMy0xLTEtNjc0NzQ_6ec9ec53-428b-4a96-8053-fc846057af9a">4,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDctNS0xLTEtNjc0NzQ_df0ad64f-7b07-44ae-8656-a46cfcd170ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNTEtMS0xLTEtNjc0NzQ_86839409-12fc-491c-861d-b2add84a013b">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNTEtMy0xLTEtNjc0NzQ_79627aac-5b68-4678-b61c-7d3f6bf754ba">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNTEtNS0xLTEtNjc0NzQ_b3949d5c-057d-42eb-b419-2c2b05709614">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_91"></div><div style="margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_94"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzk5Nw_b10cc8db-11e9-4897-a23b-47af69bce445" continuedAt="i50241d15d5814a8bb7074778f1e062a1" escape="true">Nature of the Business</ix:nonNumeric></span></div><ix:continuation id="i50241d15d5814a8bb7074778f1e062a1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morphic Holding, Inc. (the &#8220;Company&#8221;) was formed under the laws of the State of Delaware in August 2014. The Company is a biopharmaceutical company applying proprietary insights into integrin medicine to discover and develop first-in-class oral small molecule integrin therapeutics. Integrins are a validated target class with multiple approved drugs for the treatment of serious chronic diseases. Despite significant biopharmaceutical industry investment, no oral small molecule integrin therapies have been approved by the U.S. Food and Drug Administration. The Company has created the Morphic integrin technology platform, or MInT Platform, by leveraging its unique understanding of integrin structure and biology, to develop a pipeline of novel product candidates designed to achieve potency, high selectivity, and the pharmaceutical properties required for oral administration.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&#160;The Company expects to continue to incur losses from operations for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months from the date these financial statements were issued.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, the Company entered into an Open Market Sale Agreement (&#8220;the Original Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i0e2edc7e86b640748d022ccc69c79483_D20200701-20200731" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMjQ4Mw_1fad27ea-cae4-4a48-8a1b-556fc30eefcf">75.0</ix:nonFraction> million, referred to as Placement Shares, through Jefferies as its sales agent. The Company paid Jefferies a commission equal to <ix:nonFraction unitRef="number" contextRef="i0e2edc7e86b640748d022ccc69c79483_D20200701-20200731" decimals="2" name="morf:PercentageOfCommissionOnGrossSaleProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMjYwNw_726e772d-f288-43f9-a625-759987c37b5b">3.0</ix:nonFraction>% of the gross sales proceeds of any Placement Shares sold through Jefferies under the Original Agreement, and also has provided Jefferies with customary indemnification and contribution rights. On August 11, 2021, the Company entered into an Amendment No. 1 to the Original Agreement with Jefferies, establishing a new at-the-market offering (&#8220;New ATM&#8221;) with an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i5c75f7519ee24eed9649f1ec0217b28e_D20210811-20210811" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzAxMw_b1d896ee-28e2-4f1a-b2fc-de88ec06583c">150.0</ix:nonFraction> million, also subject to a commission equal to <ix:nonFraction unitRef="number" contextRef="i5c75f7519ee24eed9649f1ec0217b28e_D20210811-20210811" decimals="2" name="morf:PercentageOfCommissionOnGrossSaleProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzA1NQ_67ca1d74-1031-4b96-a0ee-f476f8cd6122">3.0</ix:nonFraction>% of gross sales proceeds from Placement Shares sold through Jefferies. Under the New ATM, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, referred to as Placement Shares, through Jefferies as its sales agent.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2022, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="if2d9d037833b403cbf8e599aeddd0edf_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzI5ODUzNDg4ODExMA_00291d13-ab6d-43dc-a910-94029cac6999"><ix:nonFraction unitRef="shares" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzI5ODUzNDg4ODExMA_ba9141c5-613f-4bc1-ac41-b9cc8e58b505">1,000,000</ix:nonFraction></ix:nonFraction> shares for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if2d9d037833b403cbf8e599aeddd0edf_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzI5ODUzNDg4ODEyNg_adc71cbb-6a99-4cec-a5de-a8cad15783e3">39.2</ix:nonFraction> million after deducting offering commissions and offering expenses paid by the Company under the New ATM. As of December&#160;31, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="id5715e43038646d4a427f7c14f57c05d_I20221231" decimals="-5" name="morf:CommonStockAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzU0NA_e0245143-bff9-426b-9047-54a16fe00903">97.2</ix:nonFraction> million of common stock remaining available for sale under the New ATM.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company completed an underwritten follow-on public offering of <ix:nonFraction unitRef="shares" contextRef="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzY4OQ_1e0d860b-cf0a-431d-a33d-f2fef11e57a8">3,500,000</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="if8aa7e1aba8a4110a761f965a1b311a5_I20220331" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzc0Nw_da01164a-f801-49fd-b302-fefa4c5b83b8">70.00</ix:nonFraction> per share. Gross proceeds from the secondary offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzgyMw_9f3c3c06-4d86-4cb1-b950-931e39d36d7d">245.0</ix:nonFraction> million, before deducting underwriting discounts, commissions and other offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzkyNQ_6f4650d8-c256-4d00-9e8e-f295805b653d">15.0</ix:nonFraction> million, paid by the Company, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzk5Mw_a05aae18-69b8-4597-9dc8-0b8b4d2549ef">230.0</ix:nonFraction> million.</span></div></ix:continuation><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_97"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjE_c461549b-3523-4f2c-abce-f507ef70263f" continuedAt="iee777848683547498844eebdc309a7da" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="iee777848683547498844eebdc309a7da" continuedAt="ic7a09e91be10477fb3122940b8b93494"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzI_3edfa120-3b27-400d-b539-18b40f2b3305" escape="true">The consolidated financial statements include the accounts of Morphic Holding, Inc. and its wholly-owned subsidiaries, Morphic Therapeutic, Inc., Morphic Therapeutic UK Ltd and Morphic Security Corporation. On March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, United Kingdom (the &#8220;U.K.&#8221;), to support Company functions outside of the United States. All intercompany balances have been eliminated in consolidation.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzM_6b4f76ee-e767-4632-af3c-dab7d2e23a5a" escape="true">These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="ic7a09e91be10477fb3122940b8b93494" continuedAt="i8a064e89243843a19d57036345ac8cff"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjU_6519ec43-878c-46c0-a242-8ee32669613c" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed above, on March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, U.K., to support Company functions outside of the United States. The geographic location of all long-lived assets of the Company continues to be the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional reporting currency of Morphic Therapeutic UK Ltd is the United States Dollar. Foreign currency remeasurement is included in other income (expense) in the Company&#8217;s consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjY_b7c76003-2c33-4106-81ed-0711730df6db" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, and accounts receivable. The Company&#8217;s cash and cash equivalents are held at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and maintenance of liquidity. The Company&#8217;s investment policy allows funds to be held outside bank accounts, but to be invested only in readily marketable fixed income instruments with readily ascertainable market values, denominated and payable in United States Dollars including obligations of the U.S. government, U.S. government-sponsored enterprises, U.S. government agencies and highly rated corporate debt obligations, including commercial paper and corporate bonds, and money market funds registered according to Rule 2a-7 of the Investment Company Act of 1940. Investments in the money market fund shall be consistent with approved instruments and assets under management must be at least $<ix:nonFraction unitRef="usd" contextRef="i37b2d1f438d44a009cda649034cdd00a_I20221231" decimals="-8" name="us-gaap:AssetsUnderManagementCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzI2MQ_9d083f51-d45f-4924-ae7e-d4ee14058213">1.0</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable generally represent amounts due from Janssen Pharmaceuticals, Inc. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign-hedging arrangements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjc_e35f84d5-6c0f-446a-9724-cbafa3d7f9e2" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. At December&#160;31, 2022, cash and cash equivalents include bank demand deposits, money market funds that invest primarily in U.S. government securities, and U.S. Treasury securities. At December&#160;31, 2021, cash and cash equivalents include bank demand deposits and money market funds that invest primarily in U.S. government securities. Cash equivalents are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash collateralizing a letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNDI0Mg_0b99d401-3537-4a8d-b9e7-53882577e375"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNDI0Mg_73445cde-9cc0-4528-bb33-68b901de3665">560,000</ix:nonFraction></ix:nonFraction> issued to the landlord of the Company&#8217;s facility lease as of December 31, 2022 and 2021. The letter of credit and cash collateralizing it increased to $<ix:nonFraction unitRef="usd" contextRef="i1c29f3379b1841039eb81933bd0e600a_I20210831" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNDM3NA_a3b56460-8a41-49ee-b2e6-dcdffce93091">560,000</ix:nonFraction> in August 2021 due to the operating lease extension discussed further in Note 6. The terms of the letter of credit extend beyond <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNDUwNg_79ce7cf0-1fdb-4ef1-a809-33a8572ac1ee">one year</ix:nonNumeric>. <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTc_6a0e1e7f-e7c2-4ade-96d8-9b1ac870a068" continuedAt="i934f6b177f924c809605dda34124eb0a" escape="true"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTc_b90d25ee-94ff-479c-9ec3-43ce5e932fcc" continuedAt="idbf771b1808549338684c353f2736742" escape="true">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div><ix:continuation id="i934f6b177f924c809605dda34124eb0a"><ix:continuation id="idbf771b1808549338684c353f2736742"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:51.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMi0xLTEtMS02NzQ3NA_c2486978-a86d-41e1-9b62-3b04f2e220d1">59,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMi0zLTEtMS02NzQ3NA_34db2127-0a7b-4444-809d-bdb2aecb88c6">171,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMi01LTEtMS03MTM4OQ_edd3ab12-3566-4641-a782-4117ae5eb28c">102,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMy0xLTEtMS02NzQ3NA_21a81e45-0e8a-4361-80d5-99f36e36cf6c">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMy0zLTEtMS02NzQ3NA_22d07640-46c6-4f46-927d-8789af8b6503">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMy01LTEtMS03MTM4OQ_0e53e2e5-30b9-4e8c-ae4b-1825e19f1b7b">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfNC0xLTEtMS02NzQ3NA_5765234a-0b17-48a1-81e9-bd6617fd2d9d">59,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfNC0zLTEtMS02NzQ3NA_c52c19f6-a567-4c7e-b2f5-e1d2ccb46166">171,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfNC01LTEtMS03MTM4OQ_ecff4cf2-b354-41d7-9ec2-49ee8a3d82a8">102,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i8a064e89243843a19d57036345ac8cff" continuedAt="i79b578e462744523b0366fc3c7b04e59"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTQ_236fb0b1-ae9f-4d19-b82f-400fe9880d79" continuedAt="i910b29e0d6ac4076afb900d0027bbf5a" escape="true">Marketable securities</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i910b29e0d6ac4076afb900d0027bbf5a">The Company invests funds in U.S. government debt securities, U.S. government-sponsored enterprise debt securities and corporate debt securities with original maturities at the date of purchase greater than three months as marketable securities. The marketable securities are classified as available-for-sale and carried at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all securities with maturity dates beyond three months at the date of purchase as current assets. Changes in the fair value of marketable securities are recorded in other comprehensive income (loss) as net unrealized gains (losses) on marketable securities.</ix:continuation> The Company recognized net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODU0NA_c7903147-53bb-454a-9b99-cd2c179c4d53">2.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODU1MA_a1e2d31c-ad7a-42e1-8134-a13613608cc1">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODU1NQ_2f9482a9-0411-480f-ad16-70e50c9ef280">0.1</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other expense, net, which is limited to the difference between the fair value and the amortized cost of the marketable security. To date, the Company has not recorded any credit losses on its available-for-sale debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable related to the Company&#8217;s available-for-sale debt securities is presented within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODUwOQ_291e5ba1-214c-49bd-9743-84b648176853">prepaid expenses and other current assets</span> on the Company&#8217;s consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="morf:InterestIncomeOnInvestmentsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTI_24a9d5fd-86f2-4990-937f-961aa1861352" continuedAt="i1ce8537e19234aa1a0718610d68a4a45" escape="true">Interest income on investments</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ce8537e19234aa1a0718610d68a4a45" continuedAt="i0f25a9b6033f4cd3b776add6974e1c9b">The Company recognizes interest income from investments in money market funds and available-for-sale debt securities, including amortization of premium or accretion of discount, on an accrual basis.</ix:continuation> For the years ended December 31, 2022, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNzY5OQ_1e9b5065-2f74-4d77-a763-b4a77b67906e">4.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNzcwMw_7029d3f9-48cb-46df-b1a6-4b4341e50a9f">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNzcxMA_f2384bcd-1994-4788-bca6-b5f247b3a71c">1.6</ix:nonFraction> million in interest income, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0f25a9b6033f4cd3b776add6974e1c9b">Interest income, net is included within other income, net on the consolidated statements of operations and comprehensive loss.</ix:continuation></span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzA_70ad240f-944e-4315-9df6-21adbb6a1be9" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Expenditures for major renewals or betterments that extend the useful lives of property and equipment are capitalized; expenditures for maintenance and repairs are charged to expense as incurred. <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTY_63f6d970-c122-4db1-99cc-f74dc00d3833" continuedAt="i0c7fb21ea0094b71a2195c08377987a5" escape="true">Depreciation is calculated on a straight-line basis over the estimated useful lives of the related asset. Property and equipment are depreciated as follows:</ix:nonNumeric></span></div><div><ix:continuation id="i0c7fb21ea0094b71a2195c08377987a5" continuedAt="i6a572f07667440a8b4836e5e4d0a5e39"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:34.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e771d535ddd42f284b6e48b0a3ff9f8_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOjBkNzYzMmM1NjBmNjQxN2M5ZTc0YjZkYzA5YjQ3MjU3L3RhYmxlcmFuZ2U6MGQ3NjMyYzU2MGY2NDE3YzllNzRiNmRjMDliNDcyNTdfMS0yLTEtMS02NzQ3NA_ac5acd44-1cb6-4675-b4a0-b8347f362d41">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0d3ccdb187fa404d929dd2ec91a44bcd_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOjBkNzYzMmM1NjBmNjQxN2M5ZTc0YjZkYzA5YjQ3MjU3L3RhYmxlcmFuZ2U6MGQ3NjMyYzU2MGY2NDE3YzllNzRiNmRjMDliNDcyNTdfMi0yLTEtMS02NzQ3NC90ZXh0cmVnaW9uOjg4NTg3NmM4M2I4YTRjY2NiY2U3NGEyMTBjMzczNjY1XzQ_4d5611c9-5eed-4694-9176-aaa896288664">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i4a4ae752e5f34d0d89ac694b9812ea06_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOjBkNzYzMmM1NjBmNjQxN2M5ZTc0YjZkYzA5YjQ3MjU3L3RhYmxlcmFuZ2U6MGQ3NjMyYzU2MGY2NDE3YzllNzRiNmRjMDliNDcyNTdfMi0yLTEtMS02NzQ3NC90ZXh0cmVnaW9uOjg4NTg3NmM4M2I4YTRjY2NiY2U3NGEyMTBjMzczNjY1Xzc_65fedfd0-073e-4b4b-afc5-4e2a1efb2e3a">5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the useful life or the remaining term of the lease</span></td></tr></table></ix:continuation></div></ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjM_5a842b36-0b09-46a2-88d8-8460b9bca08a" continuedAt="i27d1154d0572443384150f7156f481ac" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its lease obligations in accordance with ASC 842, Leases, (&#8220;ASC 842&#8221;), which requires lessees to recognize a right-of-use (&#8220;ROU&#8221;) asset and lease liability for most lease arrangements. Effective January 1, 2021, the Company adopted ASC 842 using the modified retrospective transition method and utilizing the effective date as its date of initial application. As a result, the year ended December 31, 2020 is presented in accordance with the previous guidance in ASC 840, Leases, and there have been no reclassifications of prior comparable periods due to this adoption.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. The Company considers its renewal </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i79b578e462744523b0366fc3c7b04e59" continuedAt="i0333dc8287ea4e7c92416298e8321c6f"><ix:continuation id="i27d1154d0572443384150f7156f481ac"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options and extensions within the arrangements and the Company includes these options when it is reasonably certain to extend the term of the lease.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. When a lease modification does not result in a separate contract, it is accounted for as a contract modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract modification requires the Company to reassess the classification of the lease to determine if it is an operating lease or a financing lease. The Company does not have any financing leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities may elect to not separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes an ROU asset and lease liability as of the transition date or contract modification date based on the present value of the future lease payments over the lease term. ASC 842 requires lessees to use the rate implicit in the lease unless it is not readily determinable and then it may use its incremental borrowing rate (&#8220;IBR&#8221;) to discount the future minimum lease payments. The Company's lease arrangement does not provide an implicit rate; therefore, the Company uses its IBR to discount the future minimum lease payments. The Company determines its IBR based on its credit rating, current economic information available as of the transition date or modification date, as well as the identified lease term. The Company&#8217;s ROU asset and related lease liability are not sensitive to changes in the Company&#8217;s IBR.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospectively, the Company will remeasure the lease liability at the present value using the same IBR that was in effect as of the transition date or contract modification date and adjust the ROU assets for straight-line rent expense.</span></div></ix:continuation><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTg_1873fdb5-3370-4335-9d21-41da47831740" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on long-lived assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTM_f00cfd4e-6628-4642-ace4-8e2c2d1d476e" continuedAt="i75a2017924264274bab9118031d05480" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December&#160;31, 2022, investments include U.S. Treasury securities, U.S. government-sponsored enterprise securities, and corporate debt securities, including corporate bonds and commercial paper, which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i0333dc8287ea4e7c92416298e8321c6f" continuedAt="i601038daa86a444f9967b805a1584d3f"><ix:continuation id="i75a2017924264274bab9118031d05480"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the carrying amounts of the Company&#8217;s consolidated financial instruments, including prepaid expenses and other current assets, accounts receivable, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.</span></div></ix:continuation><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzU_12eaad6f-a84c-4c5a-a233-033f42617471" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s Chief Executive Officer is its chief operating decision-maker and views operations and manages the Company&#8217;s business in <ix:nonFraction unitRef="segment" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMTU5MTU_f93b705f-b12e-4d69-b239-3544d4dd9d5d">one</ix:nonFraction> operating segment operating in the United States and the U.K.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjQ_decc2aef-1338-4434-83d6-1bccf3163c34" continuedAt="i29865836055c4293858439d9943f898e" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date all revenue has been generated from the Company&#8217;s agreements with AbbVie, executed in October 2018 and terminated as of December 2022, and Janssen, executed in February 2019 and amended in December 2020. Please refer to Note 12 below for details of ASC 606 application to the Company&#8217;s agreements with AbbVie and Janssen.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808, Collaborative Arrangements, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not a customer relationship, in accordance with ASC 808. Through December 31, 2022, the Company had <ix:nonFraction unitRef="agreement" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="morf:CollaborationAgreementNumberOfAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMTY4NjM_38459861-4a95-4724-8981-b089d5f60a44">two</ix:nonFraction> agreements &#8211; with AbbVie and Janssen &#8211; that have been accounted for pursuant to ASC 606.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the contract(s) with the customer, (ii) identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii) measurement of the transaction price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations, (ii) each party&#8217;s rights regarding the goods or services to be transferred can be identified, (iii) the payment terms for the goods or services to be transferred can be identified, (iv) the arrangement has commercial substance and (v) collection of substantially all of the consideration to which the Company will be entitled in exchange for the goods or services that will be transferred to the customer is probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. Options to purchase additional goods or services are considered to be marketing offers and are to be accounted for as separate contracts when the customer elects such options, unless the Company determines the option provides a material right which would not be provided without entering into the contract. If, however, an option is determined to provide a material right that would not be provided without entering into a contract, a portion of the transaction price is allocated to such option.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i601038daa86a444f9967b805a1584d3f" continuedAt="if4ddd7aa540845e6a9d49b429c03b1ea"><ix:continuation id="i29865836055c4293858439d9943f898e" continuedAt="i5455dc055845402c9b3026f6234f302c"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also evaluates whether instances in which the timing of payments by customers do not match the timing of performance obligation satisfaction contain an element of financing and adjusts the transaction price for the effect of the financing component, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s transactions with customers may include development and regulatory milestone payments. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the customer&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net income (loss) in the period of adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price of the identified performance obligations. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#8217;s collaborations with AbbVie, until its termination, and Janssen, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5455dc055845402c9b3026f6234f302c">The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional</ix:continuation>.</span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzQ_e657a4a8-4256-47f1-82ad-9af720863734" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred and consist of costs incurred in performing research and development activities, including compensation related expenses for research and development personnel, preclinical and clinical activities including cost of supply, overhead expenses including facilities expenses, materials and supplies, amounts paid to consultants and outside service providers, and depreciation of equipment. Upfront license payments related to acquired technologies which have not yet reached technological feasibility and have no alternative future use are also included in research and development expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="morf:ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzY_312a4d85-9c4e-4059-a61e-eb4f0af66f18" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Contract and Development Costs and Accruals</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research development service arrangements under which vendors perform various services on behalf of the Company. The Company records accrued expenses for estimated costs incurred under the arrangements. When evaluating the adequacy of the accrued expenses, the Company analyzes the progress of the studies, trials or other services performed, including invoices received and contracted costs. Judgments and estimates are made in determining the accrued expense balances at the end of each reporting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjg_7562c43f-ae3e-4dc0-a7ef-86579f55bfc0" continuedAt="i4a16cb2c9b5e469eaa293832f0abd486" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company issues stock options, restricted common stock, and restricted stock units to certain employees and non-employees, including directors. The Company accounts for restricted common stock and restricted stock unit expense based on the grant date fair value, which is generally the market price of the Company&#8217;s common stock on the date of grant, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company accounts for stock option compensation expense based on the grant date fair value of the respective award, determined using the Black-Scholes option-pricing model, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company classifies equity-based compensation expense in its </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="if4ddd7aa540845e6a9d49b429c03b1ea" continuedAt="i2a63d5fa72224505b390d172b0419403"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:continuation id="i4a16cb2c9b5e469eaa293832f0abd486">consolidated statements of operations and comprehensive loss in the same way the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified. The Company recognizes forfeitures as they occur.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 9 for additional information.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTk_bd9c4a24-4a24-49da-9bbe-7dc6ee73979f" continuedAt="i49673c162c7e4306b71fa869d318b81c" escape="true">Comprehensive Loss</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i49673c162c7e4306b71fa869d318b81c">Comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss and the change in accumulated other comprehensive loss for the period.</ix:continuation> For the years ended December 31, 2022, 2021 and 2020, comprehensive loss included $<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMjY1OTM_386f2f02-3bbf-45fa-be81-374912fc7171">2.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMjY2MDA_941cec29-4b1e-4ed3-a8ff-51a835c0f108">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMjc0ODc3OTExMDIzMA_fb19a50c-c31c-4077-a82d-bb18c517604c">0.1</ix:nonFraction> million, respectively, in unrealized holding losses, net on marketable securities.</span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzE_0c743abb-5a6e-4bf4-9838-c8af4f613e6b" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company recorded income taxes in accordance with FASB ASC Topic 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on temporary differences between the financial statement basis and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when it is more likely than not that some portion of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. At December 31, 2022 and 2021, the Company had not identified any significant uncertain tax positions.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjA_7dbb7092-a339-48e4-8907-cc8d7fb5e21b" continuedAt="i3e427b2b5b7643ecb54432c5713f6bad" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e427b2b5b7643ecb54432c5713f6bad">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements for potential recognition or disclosure in the consolidated financial statements. Subsequent events have been evaluated through the date these consolidated financial statements were issued for potential recognition or disclosure in the consolidated financial statements.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2a63d5fa72224505b390d172b0419403">On February 13, 2023, the Company entered into a securities purchase agreement with existing investors pursuant to which the Company agreed to sell and issue, in a private placement, <ix:nonFraction unitRef="shares" contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE1Mw_4db126ea-e534-4106-9185-b45e60af5e6f">848,655</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic242dad1f07949378faf34c59d7f5f88_I20230213" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE2Mg_a9e4736c-1231-4a5f-9611-bb0614adb379">35.35</ix:nonFraction> per share and pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213" decimals="INF" name="morf:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE3MA_a191a429-a3ed-472d-8178-49e0203e69e2">1,980,198</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213" decimals="4" name="morf:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE4MQ_50cdca5b-9abe-43be-a956-0d33ccef0e5d">35.3499</ix:nonFraction> per pre-funded warrant, where each pre-funded warrant has an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic242dad1f07949378faf34c59d7f5f88_I20230213" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE5MQ_b3ff756b-a1f9-4c58-9b6c-e6a03244472c">0.0001</ix:nonFraction> (the &#8220;Pre-Funded Warrants&#8221;). The Company received aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDIwMA_202187b3-ba3b-41d3-a307-78552fddacf7">100.0</ix:nonFraction>&#160;million before deducting costs and offering expenses payable by the Company. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. Per their terms, the outstanding Pre-Funded Warrants generally may not be exercised if the holder&#8217;s aggregate beneficial ownership would be more than <ix:nonFraction unitRef="number" contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213" decimals="4" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDIxNg_a2f82795-2cde-4360-b31b-ee6d48436679">9.99</ix:nonFraction>% of the total issued and outstanding shares of the Company&#8217;s common stock following such exercise. The exercise price per share and number of shares of common stock issuable upon the exercise of the Pre-Funded Warrant shares are subject to adjustment in the event of any stock dividends and splits, recapitalization, reorganization or similar transaction, as described in the Pre-Funded Warrants.</ix:continuation> </span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_103"></div><div style="margin-bottom:12pt;margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90ZXh0cmVnaW9uOmYyNjdkMGI4MzkyYjQ3NTQ4MTE0NjUzZWNhNWE3NTY2XzExNzI_8ca8b171-5bf7-4972-bbe3-4faf961a7b56" continuedAt="ic8221e318de34e0a9c224ffb3d4b6e3a" escape="true">Fair Value of Financial Assets and Liabilities</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8221e318de34e0a9c224ffb3d4b6e3a" continuedAt="i006343b6ba22443baf3cccfb509c587e"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90ZXh0cmVnaW9uOmYyNjdkMGI4MzkyYjQ3NTQ4MTE0NjUzZWNhNWE3NTY2XzExNzM_2941ca11-343a-4438-af13-1883ef6c4102" continuedAt="i22822bb8c6c942e690db352c7225948c" escape="true">The tables below present information about the Company&#8217;s financial assets that are measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i006343b6ba22443baf3cccfb509c587e"><ix:continuation id="i22822bb8c6c942e690db352c7225948c"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i604092d4d0e140bb95115f6f5f1a846d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzQtMS0xLTEtNjc0NzQ_dcf9eeaf-4ea7-4b85-b39e-f1fa8fee885e">58,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d512dd5bdfe419cb8800b44352cd997_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzQtMy0xLTEtNjc0NzQ_7411cd35-9c82-430f-b3a5-b72154c0dea6">38,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2254b383dd1434c8eb41be8f1291d19_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzQtNS0xLTEtNjc0NzQ_68a67950-af7c-4b5c-bac7-ba40f88e9560">19,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702273bf69ee47298902b18d256ef436_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzQtNy0xLTEtNjc0NzQ_d9dd43a5-e0c8-46df-9c5d-1a3be552cccc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fcc2263734a44549091a97cc1630de9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzYtMS0xLTEtNjc0NzQ_b004a39e-a0e1-4709-babd-617df228b09c">177,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d95317815642b1abbb1b41f9d0fcbe_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzYtMy0xLTEtNjc0NzQ_ad84c569-0f37-4ad5-b768-89a8f3849454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d81cccb60449a6a2bf1592ec8cf208_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzYtNS0xLTEtNjc0NzQ_cddc7af4-d5a1-48d8-8981-60ae5cf72b62">177,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06caa44988a1401d9cadf3a6919cc075_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzYtNy0xLTEtNjc0NzQ_a3686ad7-fad8-494e-9024-ab4880fe1095">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84093c3db3c34ee9975edca937505f59_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzctMS0xLTEtNjc0NzQ_4d47438f-9c8b-42b6-a094-c811a7c59603">12,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d8a3c8f6ba4c55be3e856fa074e12c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzctMy0xLTEtNjc0NzQ_de4053f2-d4d9-4743-bdda-1e4ccf492237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451016625f664d87b0f1149b4b460ca4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzctNS0xLTEtNjc0NzQ_3c6d7a37-16eb-4ef0-b1ea-2e9f9cfb0953">12,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e50ae5e2db43a2ba46810dc63df33e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzctNy0xLTEtNjc0NzQ_2348c55c-6ed0-45ea-a403-353939c1cc5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75f48a62b5e4f50be21277ae7a6a555_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzgtMS0xLTEtNjc0NzQ_c059c03c-3e83-48a1-a4b8-4be119b6856e">9,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6464b00ff1424290015908d925bcff_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzgtMy0xLTEtNjc0NzQ_396308ed-55ff-4dcd-bd0f-3732f1ee92be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0afb206a6a142988b4b7c1c5c112488_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzgtNS0xLTEtNjc0NzQ_2f733238-19a8-4962-8a6b-55e782280a7b">9,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63cd7797863b4c878b6bd0037f63a034_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzgtNy0xLTEtNjc0NzQ_91609bcb-9132-4d1e-b482-68689bbb2337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cef8c55113245b18d699b291da71849_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzktMS0xLTEtNjc0NzQ_904e6e22-456f-49e6-8d0f-08ff03acc181">88,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b5f1a419654cec9538eeec4eb6d001_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzktMy0xLTEtNjc0NzQ_affbfd9e-d2cd-446e-9154-b2f43bd769d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d5f8b0c8cf4bf1904278026e089ab9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzktNS0xLTEtNjc0NzQ_e1bf8781-e369-4246-933d-c2847f6c8ad8">88,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291a0cdf99ae4372848ba10ce4515329_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzktNy0xLTEtNjc0NzQ_2a3f3b6d-d237-4ae6-8b16-82ecf4cfd9da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc86524fc8604efaabb07582c77cd814_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzEyLTEtMS0xLTY3NDc0_5a345cd7-2bb5-4f26-ba2c-2349d991bd31">347,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162590f81a47412f95d12b41a46788fe_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzEyLTMtMS0xLTY3NDc0_52a4e083-9c0d-49ae-82f3-75cdc66c4d50">38,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i420d5fbd11644553ac2f20de753fb3be_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzEyLTUtMS0xLTY3NDc0_6cddbcb6-28aa-4610-9106-9d2048c0916f">308,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie895696982894ca393ad2b4731ed0312_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzEyLTctMS0xLTY3NDc0_d01570b2-6f37-405c-a2fa-e88ed429fb6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d32d3ada9f945c991fb1e2c468a3056_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzQtMS0xLTEtNjc0NzQ_9fd04a49-97a7-494a-b08e-7b12120f30f4">171,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee7cc6c73784af3a95d08dabf38f780_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzQtMy0xLTEtNjc0NzQ_f78321be-d154-4617-9ce3-c0e1ccc7e4a4">171,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f63d08cf43c445aab401c01568c17c1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzQtNS0xLTEtNjc0NzQ_1bdcc2e4-bd70-4cdb-b350-eae22989c311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e9b237f63147898db008b76d81cc93_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzQtNy0xLTEtNjc0NzQ_7d9bb5fd-3324-4cf2-9643-120ecac1485e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65bd95f6cce84501bc85ceb141f2ad69_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctMS0xLTEtNzAyMzQ_f4b75f36-12f4-4b80-af9d-8f7597c41463">16,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b24e4bd1eca47dd863579e21bc04e0a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctMy0xLTEtNzAyMzQ_601b9c31-5750-465a-9fcc-304cc9717d25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f9f8031a004ca58585fa9bc615ac4d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctNS0xLTEtNzAyMzQ_7fcd9095-5627-4cb1-8e4f-dba9e95a53ae">16,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie618c17501df442fb50f6f5a9d0af3e3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctNy0xLTEtNzAyMzQ_c249f1d2-ed46-419d-ae89-0330a85ec8b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461c0f15b1c64560b66aee8c7c5e1946_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtMS0xLTEtNzAyNDY_1bfce5d8-00c2-4aae-af80-959781bc85bd">99,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i396cbab97ede453fa4531ea88932d4ee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtMy0xLTEtNzAyNDY_7fd62d1d-9163-4e71-ac41-c84ab7b4b1af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97846bbf5a2a45279b8fabd054295701_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtNS0xLTEtNzAyNDY_c7e0dfd8-b089-4cc2-ab6c-21504bda8463">99,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d05e295ffa4672bb1aa0fa78c22da2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtNy0xLTEtNzAyNDY_d7a7b849-cdfc-4eb6-8407-831a258639f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb707bd819f4336b205ce25f8057e47_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctMS0xLTEtNjc0NzQ_f56ad89e-2e25-4ad2-962e-18e2afab30bd">120,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608c2d9be0664c69a0ac30c84a5bca4d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctMy0xLTEtNjc0NzQ_68f63eff-4785-4451-9f94-30069c95e5fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05301005239d4ade9956b8262164a5aa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctNS0xLTEtNjc0NzQ_4f96ba7f-c029-4b19-833c-239ab271f95b">120,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d650c04838d45e090cfc3ae81926a54_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctNy0xLTEtNjc0NzQ_769a822a-c117-4b24-9f2d-c11df18221a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b4f455938e42d8a96daae58b3fa4c0_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtMS0xLTEtNjc0NzQ_4a23379a-91e7-4abb-8fdc-62af670a3e23">407,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac46ba0e0664b0e977e59505ee5d97c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtMy0xLTEtNjc0NzQ_d67d2919-1b27-40ac-a7d2-d1d584f395e1">171,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3d728458a5471e9ed4c1a92d4f66c2_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtNS0xLTEtNjc0NzQ_c7699af3-69f8-4876-8246-ac6f7bcb5344">236,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf582a62191e406a9ec5e7e9b0698e8d_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtNy0xLTEtNjc0NzQ_9478462d-8611-4530-90db-5030a9ed99b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds and U.S. Treasury securities as of December&#160;31, 2022 and money market funds as of December&#160;31, 2021. The money market funds included in the tables above invest in U.S. government securities that are valued using quoted market prices. Accordingly, money market funds are categorized as Level 1 as of December&#160;31, 2022 and 2021. Marketable securities included in the tables above consist of U.S. Treasury securities, U.S. government- sponsored enterprise securities, commercial paper and corporate bonds, and these securities are categorized as Level 2 as of December&#160;31, 2022 and 2021. During the years ended December 31, 2022 and 2021, no assets were transferred between the fair value hierarchy categories. The Company had <ix:nonFraction unitRef="usd" contextRef="ifc86524fc8604efaabb07582c77cd814_I20221231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90ZXh0cmVnaW9uOmYyNjdkMGI4MzkyYjQ3NTQ4MTE0NjUzZWNhNWE3NTY2XzgxMw_4db3c805-c8f3-468d-a710-4a0e4bc70043"><ix:nonFraction unitRef="usd" contextRef="i55b4f455938e42d8a96daae58b3fa4c0_I20211231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90ZXh0cmVnaW9uOmYyNjdkMGI4MzkyYjQ3NTQ4MTE0NjUzZWNhNWE3NTY2XzgxMw_cbcc4f65-4b93-416c-9e3f-840f76c66b7e">no</ix:nonFraction></ix:nonFraction> liabilities measured at fair value on a recurring basis at December&#160;31, 2022 and 2021.</span></div></ix:continuation><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_106"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90ZXh0cmVnaW9uOmY5MjU2NTljZDgwNzRmMzFiY2IyZDNiZmQ2NzViNGE0XzExMzc_d9f03f07-5831-49f0-af3e-ffd2781d1d48" continuedAt="i90a3c888a2e048168796d3ef50f12e1c" escape="true">Marketable securities</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="i90a3c888a2e048168796d3ef50f12e1c" continuedAt="i40eb62589b034f26a70b5172ac7d979e"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90ZXh0cmVnaW9uOmY5MjU2NTljZDgwNzRmMzFiY2IyZDNiZmQ2NzViNGE0XzExMzg_10366ec8-9b74-4af0-b7fc-52c948582713" continuedAt="idfc0027db074469f8531947cea2c19a5" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s investments in marketable securities classified as available-for-sale (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzMtMy0xLTEtNjc0NzQ_654ba5e5-9ab0-435a-ad07-b7dc2f5ad187">179,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzMtNS0xLTEtNjc0NzQ_3192764b-cfce-48df-b6be-962192072996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzMtNy0xLTEtNjc0NzQ_f654555d-e556-4ea1-9949-d5649cc1446b">1,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzMtOS0xLTEtNjc0NzQ_4efdd6d0-d3cf-4f8b-ab32-2553fd61d6e5">177,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2e7300f7184ac58092340abcc0b069_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtMy0xLTEtNzAyNzY_c45a5d6a-c5f0-485b-ab24-cebfb5ca2700">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2e7300f7184ac58092340abcc0b069_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtNS0xLTEtNzAyNzY_ded97b41-11b4-4e41-a9e1-9a810fec5c9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2e7300f7184ac58092340abcc0b069_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtNy0xLTEtNzAyNzY_f723781f-6f9b-4392-a580-99e49c20e73b">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2e7300f7184ac58092340abcc0b069_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtOS0xLTEtNzAyNzY_bb71c166-ceeb-4eca-b2ed-59d5c8e4063a">12,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a3f4082fa1417b962818adcf991f1c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtMy0xLTEtNjc0NzQ_2019a766-2254-4175-913f-bf4ffe54437d">9,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a3f4082fa1417b962818adcf991f1c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtNS0xLTEtNjc0NzQ_54806ec8-dd00-4afe-8816-9f13a3aa0885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a3f4082fa1417b962818adcf991f1c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtNy0xLTEtNjc0NzQ_555a1f41-1ff0-40ac-b549-b77019f647c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a3f4082fa1417b962818adcf991f1c_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtOS0xLTEtNjc0NzQ_d70a4bcc-d572-46e7-959a-3979caa91e79">9,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b30679359684bb791882ad58c6a044e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzYtMy0xLTEtNjc0NzQ_7a7e0aaa-43fd-4860-88e3-52bcaa58fb2a">90,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b30679359684bb791882ad58c6a044e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzYtNS0xLTEtNjc0NzQ_bb00be5d-096a-45b0-8c98-61caa5744b03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b30679359684bb791882ad58c6a044e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzYtNy0xLTEtNjc0NzQ_eaa9743a-0f6d-4b7b-b3f9-e7695c8cf4bc">1,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b30679359684bb791882ad58c6a044e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzYtOS0xLTEtNjc0NzQ_537ad60e-317f-4214-91db-c205ed26768b">88,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzktMy0xLTEtNjc0NzQ_1aca9669-9e98-451d-be6e-e6020dae042a">292,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzktNS0xLTEtNjc0NzQ_33184684-cbf5-4017-b31d-8927f0bd1a03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzktNy0xLTEtNjc0NzQ_73add59f-c421-4a8e-be7c-e9bc313066e1">3,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzktOS0xLTEtNjc0NzQ_0902f10c-f1b7-49df-8a66-dbdd1796faf9">288,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i40eb62589b034f26a70b5172ac7d979e" continuedAt="i7445b3f8439d4118bd982f64a74cdfe9"><div><ix:continuation id="idfc0027db074469f8531947cea2c19a5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:30.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2813f455dff462a99153011829d659e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtMy0xLTEtNjc5MDc_2c246cf6-f5e1-4e5e-837d-397369f58a65">16,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2813f455dff462a99153011829d659e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtNS0xLTEtNjc5MDc_23e08f17-4b52-4114-a148-7a3f3481d0fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2813f455dff462a99153011829d659e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtNy0xLTEtNjc5MDc_c392901a-0717-4761-8175-b57932599b9c">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2813f455dff462a99153011829d659e_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtOS0xLTEtNjc5MDc_295e0524-faee-4375-ba2f-e4e250e78fad">16,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f1c205a6d14e4ba2e8721db48b2841_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtMy0xLTEtNjc0NzQ_fc2e2b1c-d818-41f5-a66f-0587f5252751">99,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f1c205a6d14e4ba2e8721db48b2841_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtNS0xLTEtNjc0NzQ_47eec613-0e0d-44f8-a33e-0cd2b1446a1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97f1c205a6d14e4ba2e8721db48b2841_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtNy0xLTEtNjc0NzQ_7558cfe3-002a-4c56-83a9-4ed143edc5fb">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f1c205a6d14e4ba2e8721db48b2841_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtOS0xLTEtNjc0NzQ_1b884d33-1ddc-4cc9-a1da-c2086156f6b8">99,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzQtMy0xLTEtNjc0NzQ_249dffaa-5285-476f-892a-1aca93f828bf">121,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzQtNS0xLTEtNjc0NzQ_4bc1c7e5-efbb-4cf3-9d68-6f947b6bfe6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzQtNy0xLTEtNjc0NzQ_10f6edd7-7bba-4e01-b5ce-f77ec9612535">443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzQtOS0xLTEtNjc0NzQ_9ea4dd1c-9918-41fd-a323-9f2c6092eebe">120,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzctMy0xLTEtNjc5MDc_2cf2c52b-a3d1-4049-8260-8579c2c34a3c">237,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzctNS0xLTEtNjc5MDc_cd0f9aff-4557-43f0-aac9-6c2fd2124df4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzctNy0xLTEtNjc5MDc_d625ba59-fc41-4444-a68e-d74660725221">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzctOS0xLTEtNjc5MDc_373e7de7-13f1-4e75-be5e-450e106bb340">236,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive loss. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all available-for-sale securities as current assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that there was no material change in the credit risk of the above investments during the years ended December 31, 2022 and 2021. As such, an allowance for credit losses was not recognized. As of December 31, 2022, the Company does not intend to sell such securities and it is not more likely than not that the Company will be required to sell the securities before recovery of its amortized cost basis.</span></div></ix:continuation><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7445b3f8439d4118bd982f64a74cdfe9">Accrued interest receivable on the Company&#8217;s available-for-sale debt securities totaled $<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90ZXh0cmVnaW9uOmY5MjU2NTljZDgwNzRmMzFiY2IyZDNiZmQ2NzViNGE0XzExMDU_e40a2e61-d61c-4033-8150-b9931de9f4d6">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90ZXh0cmVnaW9uOmY5MjU2NTljZDgwNzRmMzFiY2IyZDNiZmQ2NzViNGE0XzExMTI_8757e51d-5f78-43af-92dc-98bb5549f64b">1.2</ix:nonFraction> million as of December 31, 2022 and 2021, respectively.</ix:continuation> </span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_112"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90ZXh0cmVnaW9uOmM4YzhmYmRmNTYyNDQyMDk5NWMxN2JlMzFkZDQzYjNkXzIyMQ_bb4cf2cb-db54-43d4-9a47-11319ca58bf1" continuedAt="i5bcddff9a9434d3dae9707886225fef5" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><ix:continuation id="i5bcddff9a9434d3dae9707886225fef5"><ix:continuation id="i6a572f07667440a8b4836e5e4d0a5e39"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, property and equipment, net consists of the following (in thousands):</span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb71b13217964931b29e2541f7607577_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzItMS0xLTEtNjc0NzQ_f59e30dd-d94f-41d1-bb53-2a720973d3d2">6,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a7102b9d5346c292e630c2c88780d7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzItMy0xLTEtNjc0NzQ_7f370f9e-cc4b-4da1-b3c5-e0f198225ffb">5,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i196fe36e4f60419799bbe38a05fd598e_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzMtMS0xLTEtNjc0NzQ_175ce0e5-c1e0-463a-9734-96e83b9ef609">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765d898d413c42ecadfd22771b559151_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzMtMy0xLTEtNjc0NzQ_d7153d17-657f-4f13-a789-82ad6e1d4c76">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e316a0be4b34afa97bceaaf82979c6e_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzQtMS0xLTEtNjc0NzQ_609bcd68-29c3-449a-a5a7-94499f9b068d">611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i773e6d896fab4cba847b5f4fa4a9f8b1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzQtMy0xLTEtNjc0NzQ_2fd06390-8722-4a50-9744-70dc4786852a">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzYtMS0xLTEtNjc0NzQ_a06e0eb7-4a00-401f-b08b-ae350d694a0e">7,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzYtMy0xLTEtNjc0NzQ_ba07b9b7-089e-4808-98e7-1d31522e4428">6,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzctMS0xLTEtNjc0NzQ_e6c6312d-c45e-4a81-9825-d243bbdeb21d">5,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzctMy0xLTEtNjc0NzQ_f22afe3b-27a5-4df8-af69-68fad59ce59e">4,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzgtMS0xLTEtNjc0NzQ_389a21ee-d7ec-43f7-a8ca-160a248a659e">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzgtMy0xLTEtNjc0NzQ_69c369e1-314a-463e-a535-2b86186dd9ec">2,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90ZXh0cmVnaW9uOmM4YzhmYmRmNTYyNDQyMDk5NWMxN2JlMzFkZDQzYjNkXzE4Mw_84bd16a7-f151-49a2-b0b9-ff55e1495d73">1.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90ZXh0cmVnaW9uOmM4YzhmYmRmNTYyNDQyMDk5NWMxN2JlMzFkZDQzYjNkXzE4Nw_2e49e696-eb44-4d30-a444-305effdebb6c">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90ZXh0cmVnaW9uOmM4YzhmYmRmNTYyNDQyMDk5NWMxN2JlMzFkZDQzYjNkXzE5NA_5873bb0d-e044-4743-8ae8-e32897412270">1.1</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_115"></div><div style="margin-bottom:12pt;margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE5MDA_f8a5b498-1709-4aef-be25-e01a8d01ed17" continuedAt="i1403d96ae9224f9bb01db47efd270dec" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i1403d96ae9224f9bb01db47efd270dec" continuedAt="i4c1dea6ae0464555a8082e6c51e082de"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a lease arrangement for its corporate headquarters in Waltham, Massachusetts. In August 2021, the Company exercised its one-time extension right for its existing lease for <ix:nonFraction unitRef="sqft" contextRef="ic70e9fc24c404da2964ca9969e1b1582_I20210831" decimals="0" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzIxNA_b8aeef85-a918-4986-9907-7cdb94f487a9">32,405</ix:nonFraction> square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. Since the exercise of the one-time extension right for its existing lease did not qualify to be accounted for as a separate lease, the Company accounted for the exercise of the one-time extension right as a contract modification.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassessed the lease classification for the Company&#8217;s corporate headquarters as of the effective date of the modification using the modified terms and conditions and the facts and circumstances as of that date. This included using the remaining economic life of the underlying asset on that date, the discount rate for the lease on that date and a remeasurement and reallocation of the remaining consideration in the contract on that date. The Company concluded that the lease continues to be classified as an operating lease, reassessed the IBR as of the effective date of the modification, and remeasured the lease liability and ROU asset.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4c1dea6ae0464555a8082e6c51e082de"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Supplemental balance sheet information</span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="morf:LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE5MDE_27e197cd-2a94-4206-b927-8e549a58a81a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental operating lease balance sheet information is summarized as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzEtMi0xLTEtNjc0NzQ_62cf27bf-5787-4cf4-9af8-c97ef098bdc7">3,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_4277bab9-a4bc-4bb4-8619-266e108e3a33"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_450fd7b4-c958-4b0b-9afd-fcd530cac7f4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMi0xLTEtNjc0NzQ_2ec4b880-e796-443e-aaf7-77298e307eed">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzQtMi0xLTEtNjc0NzQ_8dc95eb5-38fe-41de-add7-6ad59b52520d">2,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzUtMi0xLTEtNjc0NzQ_c28e9d7f-d6ff-4ae7-b04c-458c5af3060f">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The short-term portion of operating lease liabilities is included within accrued expenses on the consolidated balance sheet.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other supplemental information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental operating lease information is summarized as follows (in thousands, except for years and discount rate):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTplZTIyYzgwY2JhNjA0MzY1ODc5MmZkZDI3M2NiYjBkMi90YWJsZXJhbmdlOmVlMjJjODBjYmE2MDQzNjU4NzkyZmRkMjczY2JiMGQyXzEtMi0xLTEtNjc0NzQ_9bff4786-eea0-4280-b96f-14171e66970d">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTplZTIyYzgwY2JhNjA0MzY1ODc5MmZkZDI3M2NiYjBkMi90YWJsZXJhbmdlOmVlMjJjODBjYmE2MDQzNjU4NzkyZmRkMjczY2JiMGQyXzMtMi0xLTEtNjc0NzQ_338dbf81-495f-4fef-8364-4d88d27b2d1a">2.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTplZTIyYzgwY2JhNjA0MzY1ODc5MmZkZDI3M2NiYjBkMi90YWJsZXJhbmdlOmVlMjJjODBjYmE2MDQzNjU4NzkyZmRkMjczY2JiMGQyXzQtMi0xLTEtNjc0NzQ_e74ba7ca-f1ed-44cb-bbc3-8c16545757ab">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturities of lease commitments</span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE5MDI_95c820ca-1da1-424e-beba-8a5c735eeea6" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maturities of operating lease commitments as of December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzItMi0xLTEtNjc0NzQ_4d7efcc8-1e18-440d-b307-bd7b433e7a25">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzMtMi0xLTEtNjc0NzQ_23ceca63-c74f-48f6-b38e-a96a997c725d">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzQtMi0xLTEtNjc0NzQ_ca5d6a0c-8e64-495b-97f3-e17be7c0f7cc">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzYtMi0xLTEtNjc0NzQ_ff606e9c-f38c-4338-9690-fe3785bd2a5b">4,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzctMi0xLTEtNjc0NzQ_ad9b4b77-8b46-40ff-9f99-c01ce30720cd">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzgtMi0xLTEtNjc0NzQ_da9e9b31-c1b6-4a5d-b653-a05c466f042c">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the years ended December 31, 2022, 2021 and 2020 the Company recognized operating lease expense of $<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE4NzM_9360133d-fd56-4b30-bd89-6af5eb3660a7">1.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE4Nzc_5be3c4ac-0a58-42ad-9e92-f79b8d90a0ea">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE4ODQ_27d7a0fa-36d0-4902-8dc9-be563486a546">1.1</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_118"></div><div style="margin-bottom:12pt;margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90ZXh0cmVnaW9uOjUwNDA2NmY1OTYzMjQ4NzY5MjUwMjkwMmUzNDBiNDJiXzk4_a9ba284e-1439-4a28-a3c8-e7802d503034" continuedAt="i2d7eebdc77cd463b9eeb2b68871eb834" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i2d7eebdc77cd463b9eeb2b68871eb834"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90ZXh0cmVnaW9uOjUwNDA2NmY1OTYzMjQ4NzY5MjUwMjkwMmUzNDBiNDJiXzk5_ead585d2-6ad0-431f-8531-c63fd96fc4ff" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021 accrued expenses consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzMtMS0xLTEtNjc0NzQ_84cea0f6-70e5-453a-884b-d27a27057fae">6,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzMtMy0xLTEtNjc0NzQ_c5ac51a5-ce0f-4d85-acef-342eb0a29b33">6,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="morf:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzQtMS0xLTEtNjc0NzQ_f05bf0da-0be0-4079-a1cd-838515fc20a9">4,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="morf:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzQtMy0xLTEtNjc0NzQ_314aa269-6a5a-4af1-821c-346b17277c1a">4,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzUtMS0xLTEtNjc0NzQ_6a399bb4-5f71-475b-b561-dd3e8cf0bd97">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzUtMy0xLTEtNjc0NzQ_cf432930-0c22-4aee-b254-6eef6bd94991">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzYtMS0xLTEtNjc0NzQ_51d5e3fb-c23f-4662-9b68-65497e2daec8">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzYtMy0xLTEtNjc0NzQ_de0cb0d4-6f9b-4fbd-ab12-350c9f48daa1">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzctMS0xLTEtNjc0NzQ_029d2607-0f82-4aaa-90d3-613ca40ae3d8">13,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzctMy0xLTEtNjc0NzQ_d3a21e53-41b3-4297-a4f0-d551bf6d078e">12,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzExNjk_bc473e6c-4d87-47fd-9ea8-8ba235a44f09" continuedAt="i824420997d8b49418b95e9c7f5aaa99e" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i824420997d8b49418b95e9c7f5aaa99e"><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The common stock has the following characteristics:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Voting</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="morf:VotingRights" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzE0NQ_0097286d-1906-45d3-bd93-67cd9231b324">one</ix:nonFraction> vote for each share of common stock held.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dividends</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of common stock are entitled to receive dividends, if and when declared by the Company&#8217;s board of directors. Cash dividends may not be declared or paid to holders of shares of common stock until all unpaid dividends on any preferred stock outstanding have been paid in accordance with their terms. As of December 31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzUzMA_50613f1d-bd62-4fd3-a6b9-14a8dc07da40"><ix:nonFraction unitRef="shares" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzUzMA_5328139c-8055-43a4-9431-318d9bad1efa">no</ix:nonFraction></ix:nonFraction> preferred stock was outstanding. <ix:nonFraction unitRef="usdPerShare" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzU2Ng_018a0a23-a42b-493a-9183-7a799f2ae55a"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzU2Ng_52b25a35-f0c0-4f70-aed4-5cbfee34c7b2"><ix:nonFraction unitRef="usdPerShare" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzU2Ng_e7769b23-51bd-4b4e-adf4-111eb55ce294"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzU2Ng_f8438998-57e2-48cd-af9c-3d6b270c4fde">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> dividends have been declared or paid by the Company to the holders of common stock since the issuance of the common stock.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Liquidation</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the common shares are entitled to receive distributions of cash, including in the event of a liquidation or dissolution of the Company, which preference is junior to the liquidation preference of any preferred stockholders. After any preferred stockholders have received their respective preferred distributions, any assets remaining for distribution shall be distributed to the holders of preferred or common shares determined on an as-converted basis.</span></div></ix:continuation><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_124"></div><div style="margin-bottom:12pt;margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2ODE_042e2e82-7626-441f-94ce-6ee377c46f38" continuedAt="ic23341beb9c141238fc8f19a1856136d" escape="true">Equity-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ic23341beb9c141238fc8f19a1856136d" continuedAt="ifb3c7422664d45dbb17d2383d2f1fb03"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the Company&#8217;s initial public offering in July 2019, the Company adopted the 2019 Equity Incentive Plan (the &#8220;Original 2019 Plan&#8221;) in June 2019, which replaced the 2018 Stock Incentive Plan. The board of directors adopted the Amended and Restated 2019 Equity Incentive Plan (the &#8220;A&amp;R 2019 Plan&#8221; and, together with the Original 2019 Plan, the &#8220;2019 Plan&#8221;) on April 27, 2022, which was subsequently approved by the Company&#8217;s stockholders on June 8, 2022, to revise the total annual compensation that may be awarded to the Company&#8217;s non-employee directors thereunder. The A&amp;R 2019 Plan provides for the grant of stock options, restricted stock awards, stock bonus awards, cash awards, stock appreciation right, restricted stock units, and performance awards to directors, officers and employees of the Company, as well as consultants and advisors of the Company. As a result of the automatic increase provision of the 2019 Plan, the number of shares of common stock available for issuance under the A&amp;R 2019 Plan increased by <ix:nonFraction unitRef="shares" contextRef="i0839d27335e24a70944c9e307b2f4ffd_I20220131" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzY2Nw_b112753e-b6e2-4771-b922-26724ccc308b">1.5</ix:nonFraction>&#160;million shares in January 2022. As of&#160;December&#160;31, 2022, there were a total of&#160;<ix:nonFraction unitRef="shares" contextRef="i836995cd69774ea6a3b54d9201496a27_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzcyNg_7f20873d-2e58-4b30-bf41-989808079064">1.8</ix:nonFraction> million shares available for future award grants under the 2019 Plan.</span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2Nzc_1e01b72a-e4d3-45f0-8aab-e8898540cb1e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzItNS0xLTEtNjc0NzQ_e0742164-d02f-4cb5-830b-8649c42e1d8c">25,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ed3baf9425c4deb80dc4f747f071420_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzItNy0xLTEtNjc0NzQ_810f5be9-eee0-4da5-923a-de786dc0e551">19,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e987ed93cc4e8d9dfb645f146cde1f_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzItOS0xLTEtNjc0NzQ_1c237725-1414-4937-bd00-1e795019b057">9,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i174e9b0c5f7c46c78a563fe182cdb790_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzMtNS0xLTEtNjc0NzQ_d956f2fd-835f-4f6e-a1e4-35b8c0e5e06d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd74a7f3cc934ea7bcea941a7ceb4135_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzMtNy0xLTEtNjc0NzQ_0e21c237-f8a8-4f39-9f38-eaed67a4ee60">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14cc5a3c0a534d1798020230d15314ca_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzMtOS0xLTEtNjc0NzQ_6d563a0b-352d-4a6c-8aa9-b13c3d796a94">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c1bfca603942ca815065d9e1dc6770_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzQtNS0xLTEtNjc0NzQ_e0e069b9-11a5-4353-bfe9-3db8c1a89620">2,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31c5cf61778485d991ddab611e9d542_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzQtNy0xLTEtNjc0NzQ_850e1051-b239-4402-b5f1-16b2327b1986">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a599d132d6483baa46f6bf673c0e6a_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzQtOS0xLTEtNjc0NzQ_fe83688f-369a-4454-b517-45db35fcc433">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88474183cda941d09a44d4d825426649_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzUtNS0xLTEtNjc0NzQ_80a9a1b7-be3c-4cd2-8c5f-7cc3e091a3cb">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c8315abe4964879986d1a88cf096b3b_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzUtNy0xLTEtNjc0NzQ_54941bef-957b-4da7-8d81-4439ab030174">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76ce846988a44545a5367eba9a038043_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzUtOS0xLTEtNjc0NzQ_6d5c7d8a-d26d-4221-914e-0f65c17d6cc3">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzYtNS0xLTEtNjc0NzQ_e1f0e8e8-1f93-424d-b275-eaa8ce54cbe1">29,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzYtNy0xLTEtNjc0NzQ_340e0113-0e93-4148-a76e-a27f36bf28ef">21,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzYtOS0xLTEtNjc0NzQ_a9f35fa6-fa4b-46b9-99d1-11bcf2090a77">11,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by expense category (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318589b3af594468b4d7a4f435e6ebbe_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzItNS0xLTEtNjc0NzQ_3d1a4538-8db5-4a06-8f38-73be335137c7">13,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69dad785ae2431ebdb2f50942f10325_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzItNy0xLTEtNjc0NzQ_aab8049b-b6f9-4856-8389-0bd4ca73ca48">9,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f714ec6be446a99691b35600899a4c_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzItOS0xLTEtNjc0NzQ_6cbddeb0-3f9d-4078-881f-2d599941918f">6,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9687b7a51c845ac993e26a0f4880580_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzMtNS0xLTEtNjc0NzQ_f6beb895-c9e7-446d-b292-cd98f43b5a3b">15,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief146b6ab46a43909d51d8b1c46787e1_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzMtNy0xLTEtNjc0NzQ_495e6084-a884-40cb-b253-e55d544d26da">11,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fe4eecb36748f5af8018f88fcb0c6f_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzMtOS0xLTEtNjc0NzQ_e3f7423a-bdaf-46d2-a8fe-04cb8aa5e57e">4,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzQtNS0xLTEtNjc0NzQ_28f15521-fbbf-4952-b858-3b0a82c78ab4">29,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzQtNy0xLTEtNjc0NzQ_e03d7e5e-c190-4130-ac04-d2164f1e8859">21,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzQtOS0xLTEtNjc0NzQ_b7452af0-6d97-4288-a87b-647dcac6d5d5">11,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="ifb3c7422664d45dbb17d2383d2f1fb03" continuedAt="i06743ab0cfb34e64851ff3d156045b6b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Common Stock</span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2Nzg_2a3f50e5-a8c9-4e19-87e5-4aad9ac1e5ab" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted common stock activity during the year ended December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2140ecc30f7b44bab979e57fe3c6d43f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzEtMS0xLTEtNjc0NzQ_8bf01171-986d-42c7-a69d-0ed1e559458b">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2140ecc30f7b44bab979e57fe3c6d43f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzEtMy0xLTEtNjc0NzQ_90389787-6c3b-499d-a036-5f2538ed4ae1">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzItMS0xLTEtNjc0NzQ_88c9bd04-a012-4f5d-81f0-73a30cc3189e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzItMy0xLTEtNjc0NzQ_e106550a-aa08-42b7-94aa-5855a05ce8b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzMtMS0xLTEtNjc0NzQ_90a4386d-40d9-442c-8e07-e3abc03d87b2">2,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzMtMy0xLTEtNjc0NzQ_0785d32f-5b17-4b35-888e-9d082c2ab9ee">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzQtMS0xLTEtNjc0NzQ_4f24f0d5-3314-4f51-b53b-ca36c906f95b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzQtMy0xLTEtNjc0NzQ_45cb7c04-d88f-449d-a082-dab7b0935f6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d4cafd342524466bff01db8b6fb6b1f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzUtMS0xLTEtNjc0NzQ_cfe793f1-e4cc-4a06-81a1-a4fae4ee6aed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d4cafd342524466bff01db8b6fb6b1f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzUtMy0xLTEtNjc0NzQ_c23a5196-46bb-4399-a2a4-d51521adecc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="i101397ce8aac488895ed850a9c62f94a_I20221231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzEwNDQ1MzYwNDcwNjA4_4f5f0a19-f3a3-4126-82f7-aadf7c6925a9">no</ix:nonFraction> unrecognized equity-based compensation expense related to the restricted common stock. The total fair value of restricted common stock awards vested during the years ended December 31, 2022, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i101397ce8aac488895ed850a9c62f94a_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzE1OTU_793c7c0f-a559-479a-8600-b9b2babe3669">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i902baae07eda49b091ea19d753ae4bae_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzE1OTk_8656d00a-af11-4e41-bcf5-40af806c47a0">5.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i6d6a05d3b283469d804ddf8e891690b7_I20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzE2MDc_962ee974-2513-42a8-a80e-5e0315992b00">5.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2NzQ_d0980cd6-00f9-41c9-af67-3ac081f2c000" continuedAt="i67424f39fe8f4843b2a4e9a9ee06f7a3" escape="true">The following table summarizes the restricted stock units activity during the year ended December 31, 2022:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i67424f39fe8f4843b2a4e9a9ee06f7a3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e4a0451e3944bb8b1e7d8a518951a90_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzEtMS0xLTEtNjc0NzQ_656f289e-9113-490d-b89a-1d8bd8c2edfc">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e4a0451e3944bb8b1e7d8a518951a90_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzEtMy0xLTEtNjc0NzQ_b7a82df0-aa6b-4e41-bd47-4e17a617ed00">57.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzItMS0xLTEtNjc0NzQ_7fbe7fcc-6da2-4105-b763-ef29665c6c51">291,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzItMy0xLTEtNjc0NzQ_e1da7873-724e-4de8-8f48-6d68ae21f98d">43.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzMtMS0xLTEtNjc0NzQ_15e13a8e-c679-4024-b84f-0a28aaa08ad4">7,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzMtMy0xLTEtNjc0NzQ_a73afb14-e0f9-4e1c-90b8-629926a95788">57.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzQtMS0xLTEtNjc0NzQ_0c19af7d-8488-48fe-a488-c5986f2bbec7">42,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzQtMy0xLTEtNjc0NzQ_f96b698d-f23c-4514-aad9-411ad6235c94">44.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic584c82f7fa941aaa1d9a7ca334e75f8_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzUtMS0xLTEtNjc0NzQ_e55d3f05-671d-43e2-9911-4c05e4540a0c">249,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic584c82f7fa941aaa1d9a7ca334e75f8_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzUtMy0xLTEtNjc0NzQ_e7675d99-138e-4b2d-ba6e-26bf6afe5995">43.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had unrecognized equity-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i44c3053062ab47179828227426197a95_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzI3NDg3NzkwNzU5NjY_660c4ee4-fb3c-4797-9ecc-bfcaebe80496">8.3</ix:nonFraction> million related to the restricted stock units, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i45c1bfca603942ca815065d9e1dc6770_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzI3NDg3NzkwNzYxMzA_34059424-6c15-4a65-8ac7-317e7b00ae52">3.1</ix:nonNumeric> years. The total fair value of restricted stock units vested during the years ended December 31, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i44c3053062ab47179828227426197a95_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzIwMzY_4dafbe39-def4-49fe-aae9-292af9de6ac7">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa9f54446643489fac9a8dbe66be6f9d_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzI3NDg3NzkwNzYxNjA_7f16a8db-60a2-493e-9907-b0d4473cff0b">2.1</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2NzU_cb83fdff-7740-4388-b3a5-c4aa70e49bad" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity during the year ended December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8748f4e6ee9480c88e24d869168b315_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzItMS0xLTEtNjc0NzQ_49d23301-cc47-4c2d-801d-3f6a66b546f6">4,781,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8748f4e6ee9480c88e24d869168b315_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzItMy0xLTEtNjc0NzQ_af278f4f-36fa-48a3-8a1f-fe98ca9a51f8">20.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzMtMS0xLTEtNjc0NzQ_07a8eda1-1bbb-4863-986d-c426dd186a62">1,498,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzMtMy0xLTEtNjc0NzQ_d4478333-81c1-479d-a24b-6bd107f6d507">39.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzQtMS0xLTEtNjc0NzQ_742a067e-48c7-4763-a86c-a58245ed0eb6">459,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzQtMy0xLTEtNjc0NzQ_9adadbeb-c3dc-4ec9-8a8e-dd8d11d108dd">11.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzUtMS0xLTEtNjc0NzQ_f21c2a96-53b6-4937-bb1e-118748df9fdc">557,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzUtMy0xLTEtNjc0NzQ_f1233ae0-74bc-4a8b-8f51-2c3c2d40b131">33.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzYtMS0xLTEtNjc0NzQ_9240e5ed-4c03-459e-adc4-2205f6d6f139">5,263,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzYtMy0xLTEtNjc0NzQ_df3d2572-e971-4742-951c-a454d7b44c48">24.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzYtNS0xLTEtNjc0NzQ_06b858ee-4646-4150-8bb9-324136ff3647">7.60</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzYtNy0xLTEtNjc0NzQ_d2e8e8a8-fbae-417e-b208-5e1379d43cc8">38,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzctMS0xLTEtNjc0NzQ_8e49b9be-0735-4cfe-b991-37b1a09dac56">2,990,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzctMy0xLTEtNjc0NzQ_873fd673-2d8b-40c5-b99c-9f59c3528f2a">19.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzctNS0xLTEtNjc0NzQ_fecc4b0a-8655-4227-9713-97f24d74811b">6.96</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzctNy0xLTEtNjc0NzQ_3b39e4a5-5056-4645-ae11-8d4bb6999ffa">32,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="morf:ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2Nzk_e0fe9038-407b-490f-8356-caec9a008e81" continuedAt="i4f11d345ce1446f4898ae5ad96764cf8" escape="true">The following table provides certain information related to the stock options granted, vested, and exercised during the years ended December 31, 2022, 2021 and 2020, in thousands, except for per option values:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i06743ab0cfb34e64851ff3d156045b6b"><div style="margin-bottom:12pt;margin-top:12pt"><ix:continuation id="i4f11d345ce1446f4898ae5ad96764cf8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted, per option</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzItMS0xLTEtNjc0NzQ_f7d4e942-ff71-41c8-8553-0b324c0fb1df">28.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzItMy0xLTEtNjc0NzQ_7ee04590-7351-41e6-8669-f20138ed6288">26.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzItNS0xLTEtNjc0NzQ_29e1676c-972e-4fc2-b935-9196bf552cb4">10.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash received from exercises of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzMtMS0xLTEtNjc0NzQ_02dd57d2-261a-4ad0-8198-6e26bc2f52f7">5,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzMtMy0xLTEtNjc0NzQ_114c853b-1b5f-43ed-b5c7-f8ed429c1c37">9,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzMtNS0xLTEtNjc0NzQ_cb5e53a6-a6d6-4b4e-9aeb-b41b8ab3ec82">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic market value of stock options exercised</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzQtMS0xLTEtNjc0NzQ_8a5f5288-147c-4edb-aa63-896b2e461d6f">8,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzQtMy0xLTEtNjc0NzQ_fae12beb-8008-486a-9da1-a8fad903d11f">39,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzQtNS0xLTEtNjc0NzQ_89e5908a-a1e7-4881-a75a-ebd88ace48e2">7,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2NzY_d2caeca3-4b6f-4097-8861-5c57b7f1a848" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average assumptions used in determining the fair value of the options granted during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk&#8209;free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f297cc869c04c60a6c213e1fb23bdf5_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzItMS0xLTEtNjc0NzQ_3a83606f-224a-43c9-ac48-6c9babad392b">2.02</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ad5b858858b4142b730f313c6ba0354_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzItMy0xLTEtNjc0NzQ_fc15b31c-5e1f-49fd-89a7-c1acf05009af">1.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ff85e46b56d4930968dac9e3affabd5_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzItNS0xLTEtNjc0NzQ_9a7b15c8-8780-4da7-b68c-644c9ac7c351">0.46</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f297cc869c04c60a6c213e1fb23bdf5_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzQtMS0xLTEtNjc0NzQ_5aa613f0-0f7a-45a2-9c7c-c11d059ae979">6.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ad5b858858b4142b730f313c6ba0354_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzQtMy0xLTEtNjc0NzQ_8cb5134d-090c-4bca-986f-87cd6ca08e11">6.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ff85e46b56d4930968dac9e3affabd5_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzQtNS0xLTEtNjc0NzQ_aea0aca1-0127-4b3a-a9a7-929e4f36409d">6.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f297cc869c04c60a6c213e1fb23bdf5_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzUtMS0xLTEtNjc0NzQ_1a4b9138-9bb5-4fd2-b1f9-eefb3883b774">86.81</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ad5b858858b4142b730f313c6ba0354_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzUtMy0xLTEtNjc0NzQ_720a6d7f-3718-48c1-b0ef-14c46161cc80">87.09</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ff85e46b56d4930968dac9e3affabd5_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzUtNS0xLTEtNjc0NzQ_bcfb828d-8b53-4cfc-a17d-c52015e22109">80.85</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term for employee and director stock options is the mid-point between the weighted average of vesting period and the contractual term. The Company determines the volatility for options granted based on the historical volatility of a representative group of publicly traded companies for which historical information is available in addition to the Company&#8217;s own historical volatility. The historical volatility is generally calculated based on a period of time commensurate with the expected term assumption. The risk-free interest rate is based on a zero-coupon U.S. Treasury instrument with terms consistent with the term of the stock options. The Company has not paid and does not anticipate paying cash dividends on shares of common stock; therefore, the expected dividend yield is assumed to be zero.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had unrecognized equity-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzM1ODQ_7bb88c06-dc5c-4e25-9a2b-f2d4ab837a9c">50.0</ix:nonFraction> million related to stock options issued to employees and non-employees, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzM3MjA_a17939fb-4686-4845-8dcf-59e9610f32ae">2.2</ix:nonNumeric> years.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective on June 26, 2019. The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="ib9a49673c39d457ca1650953807a3049_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzM4Nzg_f3991708-e42e-4920-8f34-b39e9c1199bf">300,000</ix:nonFraction> shares of common stock for sale under the ESPP. As a result of the automatic increase provision of the ESPP, the number of shares of common stock available for issuance under the ESPP increased by <ix:nonFraction unitRef="shares" contextRef="ia4c949b67a814dcbae7f09a0249d0ed7_I20210101" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQwNzg_88e7b948-0704-481b-bc2b-9cbf23f4052d">0.4</ix:nonFraction>&#160;million shares on January 1, 2022. The ESPP is a qualified, compensatory plan under Section 423 of the Internal Revenue Code and offers substantially all employees opportunity to purchase up to $<ix:nonFraction unitRef="usd" contextRef="id499edf539a74aff9a76526f02dd5aa9_D20220101-20221231" decimals="INF" name="morf:EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQyNjc_89016654-3315-453e-afd9-3badc61d4ae1">25,000</ix:nonFraction> of common stock per year at <ix:nonFraction unitRef="number" contextRef="i6e430e2b2d7d4b9bb5788a847d6c2d7e_D20220101-20221231" decimals="INF" name="morf:ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQyOTg_5896e6d5-e855-4836-86a3-d3474abcca96">15</ix:nonFraction>% discount to the lower of the beginning of the offering period price or the end of the offering period price.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the course of the offering period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzUwNTQ_64f2cdfb-c0f8-40d2-9e0a-63cad88cb929" continuedAt="i49dae2b803d94283bd85f908a443f564" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i49dae2b803d94283bd85f908a443f564" continuedAt="i5d7094dc9c9143b193bc2a227a666f60"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzYwNDczMTM5Njg3NzQ_5be0bf16-93a0-49a8-bdb4-57dced253174" escape="true"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income taxes for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzItMS0xLTEtNzYwOTQ_1423fe86-e478-434e-b2e4-79a0423a6371">59,036</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzItMy0xLTEtNzYwOTc_376d8ca0-b2a0-41b1-a1b6-de5c4bb2750e">95,542</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzItNS0xLTEtNzYwOTk_fb5185a4-bd63-4b6b-840b-d3daa2fd23d2">45,569</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzMtMS0xLTEtNzYwOTQ_2be19248-746c-4f4e-a949-9862fac7ecad">62</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzMtMy0xLTEtNzYwOTc_5ff68582-8d30-4d7b-b2be-f7a3824b2615">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzMtNS0xLTEtNzYwOTk_aaca796c-f1a9-4620-9045-64b19405e2db">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzQtMS0xLTEtNzYwOTQ_d80aa237-cce1-46dd-88a8-d55e8da2a91d">58,974</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzQtMy0xLTEtNzYwOTc_310b7773-e753-4657-9447-6a97c0d552db">95,542</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzQtNS0xLTEtNzYwOTk_b7bd1d3c-8b83-46da-b306-16ed555d07c2">45,569</ix:nonFraction>)</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzUwNTU_26549a8f-3abc-4c69-b682-37131fa6fcb2" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax (benefit) expense for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzMtMS0xLTEtNjc0NzQ_5cf50b3a-b165-4e30-9848-129ce44cd741">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzMtMy0xLTEtNjc0NzQ_1eca8ea6-6708-4df6-9172-e9ca60073dc4">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzMtNS0xLTEtNjc0NzQ_ef8a79aa-f84d-40b2-8b45-d4c2cc48c737">511</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtMS0xLTEtNzQyMTE_aa12ebe2-bc67-45a9-8c41-735d97bc82cf">55</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtMy0xLTEtNzQyMTE_bec6f15f-22af-44bf-a615-614293934cc5">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtNS0xLTEtNzQyMTE_dcb16f58-2ac4-4b82-899d-65c77de9abd1">59</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtMS0xLTEtNjc0NzQ_94b2f15c-ed03-4e49-af67-64eb3d6e7399">12</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtMy0xLTEtNjc0NzQ_e7e08f28-eb82-4d48-996e-2000707a4b96">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtNS0xLTEtNjc0NzQ_46251ec8-54f4-4f6d-b220-24773b3ea8ba">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzUtMS0xLTEtNjc0NzQ_db1cc014-5a0d-46f8-8dd5-fe7309bc90ed">67</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzUtMy0xLTEtNjc0NzQ_d905f150-ccf2-4a5a-a7a2-304457f83929">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzUtNS0xLTEtNjc0NzQ_9653b116-e3b5-41de-a063-414a491b4036">570</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzctMS0xLTEtNjc0NzQ_9ecee8a1-bdf8-4b3a-a1fd-7db648af6c14">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzctMy0xLTEtNjc0NzQ_fd835f1c-d903-42a4-b28f-1a42717c7c41">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzctNS0xLTEtNjc0NzQ_cd9827fa-743e-4146-82a4-7266144779a4">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktMS0xLTEtNzQyMTg_3eec168a-8c5b-42d0-afd2-4027a1fcaf97">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktMy0xLTEtNzQyMTg_50d95f18-4997-4736-a296-1998300c4cbe">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktNS0xLTEtNzQyMTg_27f37c9a-197c-4ad3-8809-d435d032103f">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzgtMS0xLTEtNjc0NzQ_79bb802a-90e1-42f4-aad0-465c58dfd7c5">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzgtMy0xLTEtNjc0NzQ_189f26ff-2882-47dd-9330-d40a5726df8e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzgtNS0xLTEtNjc0NzQ_43ef0903-fe00-4520-8dc2-d5d3b621cf7f">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktMS0xLTEtNjc0NzQ_7a03051e-d8cd-4f25-b3df-f946aa340527">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktMy0xLTEtNjc0NzQ_9a28c106-fd16-4820-a156-5d9e809890bf">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktNS0xLTEtNjc0NzQ_5950a6d7-9616-472f-bb12-bd7ea85d0cf3">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax (benefit) provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzEwLTEtMS0xLTY3NDc0_73777845-cf54-4f1a-87c6-598c4506a28e">67</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzEwLTMtMS0xLTY3NDc0_9e345a5f-1051-4847-9475-f1d8c9f5ea6d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzEwLTUtMS0xLTY3NDc0_d17cd875-9af3-4c20-89d6-c4c2dd43779b">570</ix:nonFraction>)</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzUwNTY_6af83491-a212-4ce0-a5ad-984a28c12ba3" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#8217;s loss before income taxes as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effected at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzItMS0xLTEtNjc0NzQ_bbed6925-f51a-4a26-9347-a0d35773cfc5">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzItMy0xLTEtNjc0NzQ_eed37909-8017-44ea-95b4-9b2800632b30">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzItNS0xLTEtNjc0NzQ_3e30df3b-ea72-4896-9deb-621de90a9250">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzMtMS0xLTEtNjc0NzQ_c3489d28-8e0e-48fc-9b25-f68fddf90dc3">7.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzMtMy0xLTEtNjc0NzQ_5f7ad433-fd55-4939-81b6-f7f949941db6">9.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzMtNS0xLTEtNjc0NzQ_ce2524c9-b9f7-479d-b2ba-16db611ad92d">8.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzQtMS0xLTEtNjc0NzQ_a53cb37d-b7e5-41d3-863e-148c9fb9a6b9">1.02</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzQtMy0xLTEtNjc0NzQ_19acd531-5825-4958-ba87-d0f6756c99be">5.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzQtNS0xLTEtNjc0NzQ_29634af5-d68f-4a76-be63-1a4afa53252d">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzUtMS0xLTEtNjc0NzQ_015c6a14-5882-4acd-a839-037eaf732e6d">3.87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzUtMy0xLTEtNjc0NzQ_1497ea27-2b8f-4ee1-bbd7-8b4e3696a0f9">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzUtNS0xLTEtNjc0NzQ_fdb62068-3ebc-45de-9c3c-5f7ae267f59b">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzYtMS0xLTEtNjc0NzQ_6ed0388f-1871-4f1c-85c9-a697adc30e1b">6.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzYtMy0xLTEtNjc0NzQ_9952c3d2-acc5-449b-8567-4d5da852a260">3.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzYtNS0xLTEtNjc0NzQ_402796fd-6d80-40e8-925f-ef0699ca4206">6.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzctMS0xLTEtNjc0NzQ_50899f35-92ef-4d3a-b6e0-bc4dec3ec411">30.89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzctMy0xLTEtNjc0NzQ_9b3eea6e-fc6c-41b2-a7a1-8d9b9fabddd5">38.97</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzctNS0xLTEtNjc0NzQ_5876021d-a72b-427a-97b1-68c4d1c2a3c3">35.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzgtMS0xLTEtNjc0NzQ_216f72d0-3cd1-4f90-9f8a-07119cd3fb9e">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzgtMy0xLTEtNjc0NzQ_a96b4a97-c814-4eaf-bd74-ea4a486b3633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzgtNS0xLTEtNjc0NzQ_a5d76cf9-38bc-48d6-9b88-5b6c944353a8">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i5d7094dc9c9143b193bc2a227a666f60" continuedAt="i9a3e840daee141c3800a036e5ab046ac"><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzUwNTc_68d23801-806e-4836-b0cd-afe490cc3c03" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities consist of the following at December 31, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzMtMS0xLTEtNjc0NzQ_cd1203ea-fba3-491c-ada9-25218bc91dbc">49,969</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzMtMy0xLTEtNjc0NzQ_df710122-eb70-4d92-9b1c-51af8ba68fdb">44,269</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and experimental expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzQtMS0xLTEtNzQ4MzQ_e430e602-07f8-4a42-a4e3-1c4a79f2bff9">22,147</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzQtMy0xLTEtNzQ4MzQ_4f031394-50eb-4f79-8fed-959971ad60ed">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzUtMS0xLTEtNzQ4NDk_0892586f-78b8-4fa9-a9f2-d83fef282c51">17,101</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzUtMy0xLTEtNzQ4NDk_674b308e-cf20-4b87-89e1-fb1c660bc614">10,843</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzQtMS0xLTEtNjc0NzQ_cd244029-2dfc-4901-a072-681d00632f3e">5,649</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzQtMy0xLTEtNjc0NzQ_ca8a50e0-b1e2-4c74-a362-d1165384a9a3">4,958</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="morf:DeferredTaxAssetsFixedAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzUtMS0xLTEtNjc0NzQ_82312c31-49f3-4dc7-82b5-c2ecff8e06d4">3,332</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="morf:DeferredTaxAssetsFixedAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzUtMy0xLTEtNjc0NzQ_a0041ece-951a-4d15-a449-07955d4e58b9">3,077</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzYtMS0xLTEtNjc0NzQ_322cb65c-5b90-4421-adbe-af2915bcd7a2">1,764</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzYtMy0xLTEtNjc0NzQ_5ad324fb-40c4-4109-b469-c8aa380357bd">1,790</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="morf:DeferredTaxAssetLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzctMS0xLTEtNjc0NzQ_b71d6204-c926-4464-96bf-c03afcaecd34">1,049</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="morf:DeferredTaxAssetLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzctMy0xLTEtNjc0NzQ_fd60171a-0834-438e-a923-f1f9dd1a0151">1,380</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzktMS0xLTEtNjc0NzQ_4d7bad39-14e1-44da-b059-50011a8bd536">128</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzktMy0xLTEtNjc0NzQ_afbcee56-8f0d-45ac-8a3e-5d381813f69a">18,610</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEwLTEtMS0xLTY3NDc0_af002c8d-84c9-4f5f-b51d-3138b1f50fcd">101,139</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEwLTMtMS0xLTY3NDc0_e6b698ff-6ca2-4a8e-9388-4485af498dc0">84,927</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzExLTEtMS0xLTY3NDc0_6e547c4e-c294-49dd-b3cc-6da5ded7af52">99,417</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzExLTMtMS0xLTY3NDc0_88fe1b55-ed15-42a6-bc12-328a4beb9a49">82,703</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEyLTEtMS0xLTY3NDc0_0e74a217-52c9-4241-b073-9d85d32ea098">1,722</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEyLTMtMS0xLTY3NDc0_ad2db470-59fd-4e0c-9bde-41d46e3d86ed">2,224</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE0LTEtMS0xLTc0OTA3_53065da0-64f8-4b8e-abaa-3796f1ec2c59">960</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE0LTMtMS0xLTc0OTA3_3afe4317-0361-4f62-92e3-0fe41351118f">1,313</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEzLTEtMS0xLTY3NDc0_0a557a45-5fe0-4580-8e3d-c90d72510f81">472</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEzLTMtMS0xLTY3NDc0_8374bdb2-77e4-4134-bfb4-317095c1caa5">572</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE1LTEtMS0xLTY3NDc0_55cea0cb-9faa-4ba0-9dcd-62e20d021de7">290</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE1LTMtMS0xLTY3NDc0_75cc11ad-eb10-48d7-9b0a-a35226c7c510">339</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE2LTEtMS0xLTY3NDc0_f85c5638-2efb-4f7e-ba4a-488ecea556ea">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE2LTMtMS0xLTY3NDc0_48977828-17ee-40f0-9ab9-13e406aa9e3a">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As required by ASC 740, the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of collaboration revenue that has been recognized as taxable but remains deferred for book reporting as of year end and net operating loss carryfowards. The Company has determined that it is more likely than not that the Company will not realize the benefits of its federal and state deferred tax assets, and, as a result, a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i98ff867a6d934dccaf584133870acc01_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzg0Ng_613d6adb-4693-493f-aa2e-383bd75fe37b">99.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i673a9cb8566f43ce9616ebf94921885b_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzg1Mw_1089a070-b09a-41ac-884d-c4d475cfdeeb">82.7</ix:nonFraction> million has been established at 2022 and 2021, respectively. The change in the valuation allowance was $<ix:nonFraction unitRef="usd" contextRef="idd87bb47b7414650a95a2d45e1fd7c80_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzk1MQ_aac47385-5f3a-4e4f-a021-bd7c83b7f963">16.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia34a0708e91b4ea5b31cedcf12f3227d_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzk1OA_b3c0cac7-1df1-413c-b3e4-6692de32a65e">37.1</ix:nonFraction> million for the years ended December 31, 2022 and 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in 2022, Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) amended Section 174 and now requires U.S.-based and non-U.S.-based research and experimental (&#8220;R&amp;E&#8221;) expenditures to be capitalized and amortized over a period of five or 15 years, respectively, for amounts paid in tax years starting after December 31, 2021. Prior to the TCJA amendment, Section 174 allowed taxpayers to immediately deduct R&amp;E expenditures in the year paid or incurred.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has applied this required change in accounting method beginning in 2022 and the computation may be adjusted pending future IRS guidance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred net operating losses (&#8220;NOLs&#8221;) from inception. At December 31, 2022, the Company has federal and state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i98ff867a6d934dccaf584133870acc01_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzExNzE_5c9577ff-4620-49fe-b22f-313023aced67">180.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia1c53362d437417b8664cb0139c5b714_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzIxOTkwMjMyNzEzMTc_c4d3249e-f89b-4423-8559-a328e6e129d7">191.5</ix:nonFraction> million, respectively, available to reduce future taxable income, that expire beginning in 2037, with $<ix:nonFraction unitRef="usd" contextRef="i98ff867a6d934dccaf584133870acc01_I20221231" decimals="-5" name="morf:OperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzEyNzU_99812e8c-380d-469b-a4eb-9cd033bfe3fc">176.4</ix:nonFraction> million of the federal NOLs having an unlimited carryover life. As of December 31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i98ff867a6d934dccaf584133870acc01_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzE0NjU_bec92a04-04f1-4d2f-adc2-ac2b7d832374">12.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia1c53362d437417b8664cb0139c5b714_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzE0NzI_c6a22634-81af-4c02-acfa-bae49a4cb2ef">5.7</ix:nonFraction> million, respectively,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to offset future income taxes, which will begin to expire beginning in December 2032. The Company&#8217;s NOL carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The company continues to review its historic ownership changes to determine if there are any IRC 382 limitations which may limit the annual utilization of the NOLs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes,&#8221; which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions. As of December 31, 2022 and 2021, the Company had no unrecognized tax benefits. The Company has not identified any uncertain positions with respect to the credit computations. The Company&#8217;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended December 31, 2022 and 2021, <ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzMzOTY_300fcf09-4a61-41ed-be71-6e6c4b132975"><ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzMzOTY_470d3c44-8a68-43c3-9c9e-1b30c49f1184">no</ix:nonFraction></ix:nonFraction> estimated interest or penalties were recognized on uncertain tax positions. The Company does not expect any significant change in its uncertain tax positions in the next 12 months.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i9a3e840daee141c3800a036e5ab046ac"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company files U.S. federal and state income tax returns and is generally subject to income tax examinations by these authorities for all tax years after December 31, 2018. Currently, no federal or state income tax returns are under examination by the respective income tax authorities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzM5NDA_7537337d-9ec9-45a4-b595-841b741803b3">0.1</ix:nonFraction> million for the year ended December 31, 2022, income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzQwMTI_14d1310e-4bf0-4422-9390-778da3a38a6a">0.0</ix:nonFraction> million for the year ended December 31, 2021 and a benefit from income taxes of $<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzQwNzg_1758c22a-40a3-4d10-82b3-aed0b98c2049">0.6</ix:nonFraction> million for the year ended December 31, 2020. The benefit recorded in 2020 was attributed to a federal net operating loss carryback claim allowed under the CARES Act. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the collaboration revenue, the Company continues to maintain a valuation allowance against all deferred tax assets. The Company believes that it is more likely than not that the Company will not realize a future tax benefit of these attributes, as the Company&#8217;s research programs continue to require significant investment and future revenue is subject to uncertainties. Ultimate realization of any deferred tax asset is dependent on the Company&#8217;s ability to generate sufficient future taxable income in the appropriate tax jurisdiction before the expiration of carryforward periods, if any.</span></div></ix:continuation><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_133"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzMvZnJhZzphYjU0NmM1MGI4N2M0NTViODViOGE2MGIwMDI4NjY5YS90ZXh0cmVnaW9uOmFiNTQ2YzUwYjg3YzQ1NWI4NWI4YTYwYjAwMjg2NjlhXzE4Mjg_01d196aa-134c-43be-881d-fc07adb98822" continuedAt="ib0a18f14a4bb427298189f3e36a015af" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ib0a18f14a4bb427298189f3e36a015af"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered, and intends to continue to enter, into separate indemnification agreements with directors, officers, and certain of key employees, in addition to the indemnification provided for in the restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, require the Company to indemnify directors, officers, and key employees for certain expenses, including attorneys&#8217; fees, judgments, penalties, fines, and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to the Company or any of its subsidiaries or any other company or enterprise to which these individuals provide services at the Company&#8217;s request. Subject to certain limitations, the indemnification agreements also require the Company to advance expenses incurred by directors, officers, and key employees for the defense of any action for which indemnification is required or permitted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has standard indemnification arrangements in its leases for laboratory and office space that require it to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under the Company&#8217;s lease.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2022, the Company had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any material legal proceedings.</span></div></ix:continuation><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_136"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE5MzEw_bd855219-410c-4e34-b244-e401573961b2" continuedAt="i7f78b446e16143f3933c5bd58d07c504" escape="true">Option and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i7f78b446e16143f3933c5bd58d07c504" continuedAt="ic503cb35e8a64027864fbb1dbf4dbf06"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Agreement Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, the Company entered into a <ix:nonNumeric contextRef="ia2dfc56e30ef4261a5bd22e73cfeb905_D20181001-20181031" name="morf:CollaborativeArrangementTermOfArrangement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE5MzEx_8cafce82-12fb-4288-8d46-68021cff56a2">5-year</ix:nonNumeric> collaboration and option agreement with AbbVie Biotechnology Ltd (the &#8220;AbbVie Agreement&#8221;), a research-based global biopharmaceutical company that held Series A and Series B Convertible Preferred Shares of the Company at the time the AbbVie Agreement was executed (&#8220;AbbVie&#8221;). Pursuant to this agreement, AbbVie paid the Company an upfront, non-refundable amount of $<ix:nonFraction unitRef="usd" contextRef="ia2dfc56e30ef4261a5bd22e73cfeb905_D20181001-20181031" decimals="-5" name="morf:CollaborativeArrangementUpfrontFeesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzQ1Mg_e5abd893-5750-47cf-b6c7-17cb39a50560">100.0</ix:nonFraction>&#160;million. In exchange, the Company: (i) assumed the obligation to perform research and development activities to identify and develop compounds directed at multiple fibrosis indications (grouped into <ix:nonFraction unitRef="program" contextRef="i2ba08c24b4f646afab272849bef04fb2_I20181031" decimals="INF" name="morf:CollaborativeArrangementNumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzY0Ng_68e38c09-b564-41d6-be2f-972b84096bdd">four</ix:nonFraction> research programs) through completion of Investigational New Drug (IND)-enabling studies, and (ii) granted AbbVie options to license the results of research and development in exchange for separate upfront option-exercise fees. In June 2022, AbbVie informed the Company that it had decided to exercise its right to terminate the AbbVie Agreement for convenience and the AbbVie Agreement terminated in December 2022. As a result, the Company does not expect to receive additional payments under the AbbVie Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the AbbVie Agreement termination, AbbVie held the right to exercise its license options for molecules with the selected pharmacological profiles by providing written notice to the Company and paying an option exercise fee of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="ic503cb35e8a64027864fbb1dbf4dbf06" continuedAt="i1f4e649c46564bc7b03f843d2057b8a2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2ba08c24b4f646afab272849bef04fb2_I20181031" decimals="-5" name="morf:CollaborativeArrangementOptionExerciseFeesReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzExMDg_9c06c734-aca1-4fe7-82d2-8929ab69a89f">20.0</ix:nonFraction>&#160;million per option exercised (up to <ix:nonFraction unitRef="option" contextRef="i2ba08c24b4f646afab272849bef04fb2_I20181031" decimals="INF" name="morf:CollaborativeArrangementNumberOfOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzM4NDgyOTA3MzEyNjU_758f06ba-e5fa-423c-b9f0-02633ccf9c52">three</ix:nonFraction> in total). Effective upon the termination of the AbbVie Agreement, all rights and licenses granted thereunder immediately terminated and were returned to the Company.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Agreement Accounting Analysis</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the performance obligations in the agreement had included the research services for the <ix:nonFraction unitRef="program" contextRef="i2ba08c24b4f646afab272849bef04fb2_I20181031" decimals="INF" name="morf:CollaborativeArrangementNumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzMxNDA_1573b020-4d56-4a2d-8f3b-f6515b7ef547">four</ix:nonFraction> research programs. The Company has concluded that the unexercised license options were marketing offers as the options did not provide any discounts or other rights that would be considered a material right in the arrangement. All other performance obligations were determined to be immaterial in the context of the contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the standalone selling price of each research program based on internal and external costs to perform the research plus a reasonable profit margin of <ix:nonFraction unitRef="number" contextRef="i3e82d416fe9845cd845831adb23f5e51_I20221231" decimals="2" name="morf:CollaborativeArrangementProfitMarginPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzM2NDE_6dd73b0c-261e-4664-a453-d4550383ea1a">10</ix:nonFraction>%. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services. The Company recognized revenue as research and development services were provided based on the costs incurred to date, as such costs have a direct relationship between the Company&#8217;s effort and the progress made towards satisfying its performance obligations to AbbVie. Changes to the estimated cost of internal and external development services were recognized in the period of change as a cumulative catch-up adjustment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the transaction price included only the non-refundable up-front payment of $<ix:nonFraction unitRef="usd" contextRef="i0d620038457943e389fea375d17a3511_I20181231" decimals="-5" name="morf:UpFrontPaymentIncludedInTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzQ1Njg_e11287d1-5dd7-4571-8aed-8559e3507fe5">100.0</ix:nonFraction>&#160;million and recorded this amount as deferred revenue as of December 31, 2018. The option exercise payments were not included in the transaction price, as the Company determined that the agreed upon fees represent fair value of such options. The milestone payments were fully constrained, as a result of the uncertainty regarding whether AbbVie would exercise any of the options and whether any of the associated milestones would be achieved. There were no changes to the transaction price prior to the AbbVie Agreement termination.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considered the existence of any significant financing component within the AbbVie Agreement given its upfront payment structure. Based upon this assessment, the Company concluded that the up-front payment was provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the AbbVie Agreement did not result in the existence of a significant financing component.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, AbbVie exercised its option to license and control further development and commercialization of Morphic&#8217;s &#945;v&#946;6&#8211;specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. In connection with the exercise of the option, AbbVie paid the Company $<ix:nonFraction unitRef="usd" contextRef="i605039ce4c3546db8544ca5afe90071c_D20200825-20200825" decimals="-5" name="morf:CollaborativeArrangementOptionExerciseFeesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzU5Mjc_082cdbec-8b8a-4643-9ede-5bad31fdb0cb">20.0</ix:nonFraction>&#160;million. Upon option exercise, the Company evaluated whether the change to the contract should be treated as the continuation of the current arrangement or as a separate agreement. As the additional performance obligations were deemed to be distinct and priced consistent with the standalone selling price of such obligations, the Company concluded that the license and any additional performance obligations should be accounted for as a separate contract. The potential performance obligations included in the arrangement were (1) the license to research, develop and commercialize &#945;v&#946;6&#8211;specific integrin inhibitors, and (2) options to purchase materials that were manufactured prior to option exercise (the &#8220;Material Options&#8221;). The Company concluded that the Material Options were not material rights as the price to purchase the materials approximated the standalone selling price. Based on this conclusion, the full transaction price of $<ix:nonFraction unitRef="usd" contextRef="iebbb4e4977534118b7062dc97e877188_D20200701-20200930" decimals="-5" name="morf:CollaborationAgreementOptionExerciseRevenueReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzY4NjM_968c6ee5-cc8e-4cf5-8e08-1ee03aa8d6d4">20.0</ix:nonFraction>&#160;million was allocated to the license and recognized upon delivery in the third quarter of 2020. The Company does not expect to receive any additional payments for this program from AbbVie as the license terminated upon termination of the AbbVie Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon receipt of notification of the exercise of the right to terminate the AbbVie Agreement, the Company concluded that there was a contract modification to an existing contract under ASC 606 because the notification of termination of the AbbVie Agreement resulted in a reduction in scope of the Company&#8217;s responsibilities for the <ix:nonFraction unitRef="program" contextRef="i3e82d416fe9845cd845831adb23f5e51_I20221231" decimals="INF" name="morf:CollaborativeArrangementNumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzM4NDgyOTA3MzEyNzU_5a4fca68-dcb2-49f1-aa88-3e5c26fa2497">three</ix:nonFraction> remaining research programs thereunder. The terms of the AbbVie Agreement termination notification did not include any additional promised goods or services. As a result of the notification from AbbVie, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i7d9a0e35c7f042cf912b4e21edd47242_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzgyNDYzMzcyMzgxMDQ_dd244783-8224-431a-9452-96cf2c206154">57.7</ix:nonFraction>&#160;million on a cumulative catch-up basis using an updated measure of progress towards satisfying the research and development services performance obligations thereunder. </span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i1f4e649c46564bc7b03f843d2057b8a2" continuedAt="ib609441007134f8ba4e26e57c6d54159"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company completed its performance obligations under the AbbVie Agreement. <ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE5MzEz_7c86c2bb-600d-41f9-b60b-3ead77051363" continuedAt="iaaef0feb1cde43f68a4898ae573ac976" escape="true">The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="iaaef0feb1cde43f68a4898ae573ac976" continuedAt="ic8fea59117c64d2784bae28d2caa1b41"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9a0e35c7f042cf912b4e21edd47242_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzItNS0xLTEtNjc0NzQ_ae977fef-184f-4b11-8671-cc77a661118c">60,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76974348b5dd49dd867e3970e5e16d4c_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzItNy0xLTEtNjc0NzQ_2ddb77b5-a127-4524-a027-3e39b0f0331d">11,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08cc4df0448c42e6b1396ea92fa4ae8c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzItOS0xLTEtNjc0NzQ_115a04e8-bef4-4c14-96fa-ab473f29a785">36,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9a0e35c7f042cf912b4e21edd47242_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzMtNS0xLTEtNjc0NzQ_d6babbe7-3039-4298-81e7-0d7a48410cef">631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76974348b5dd49dd867e3970e5e16d4c_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzMtNy0xLTEtNjc0NzQ_638478e4-41ff-4230-af92-8a403710214d">5,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08cc4df0448c42e6b1396ea92fa4ae8c_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzMtOS0xLTEtNjc0NzQ_5f084308-c7e8-4e9b-9526-3d075ab1da67">13,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ic9645879e89545f6ae321d39d2ff49ff_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzIxOTkwMjMyOTIwMTU_09c3f913-f178-4cd4-9cdc-ee56abf9d4a1">60.5</ix:nonFraction> million of deferred revenue, which was classified as either current or net of current portion in the accompanying consolidated balance sheets based on the period over which the revenue was expected to be recognized prior to the contract modification. This deferred revenue balance represented the aggregate amount of the transaction price allocated to the performance obligations that were partially unsatisfied as of December&#160;31, 2021. The Company has no further unsatisfied performance obligations for the AbbVie Agreement as of December&#160;31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Janssen Agreement Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company entered into a research collaboration and option agreement with Janssen Pharmaceuticals, Inc. (&#8220;Janssen Agreement&#8221;), a subsidiary of Johnson &amp; Johnson (&#8220;Janssen&#8221;), to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. The Janssen agreement focuses on <ix:nonFraction unitRef="target" contextRef="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228" decimals="INF" name="morf:CollaborativeArrangementNumberOfIntegrinTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEwNTcx_e7d3f15b-c427-42fc-8683-4ef357f3a867">three</ix:nonFraction> integrin targets, each target the subject of a research program, with a limited ability to substitute integrin targets for others, not explored by the Company, if research results are not favorable. Under the terms of the agreement, Janssen paid the Company an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228" decimals="-5" name="morf:CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEwODUw_1e2b07e3-21f9-4fec-8e50-9ceac09715f1">10.0</ix:nonFraction>&#160;million for the first <ix:nonFraction unitRef="program" contextRef="ia278688cc742407d889eeaac1398e425_I20190228" decimals="INF" name="morf:CollaborativeArrangementNumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEwODY3_9a568229-a7f7-4631-9db8-d31b44594450">two</ix:nonFraction> research programs in 2019 and in December 2020 the Company reached an agreement with Janssen to commence work on the third research program and Janssen agreed to pay $<ix:nonFraction unitRef="usd" contextRef="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228" decimals="-5" name="morf:CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzExMDM2_7bad93f9-f554-4193-aceb-bac6c239b55b">5.0</ix:nonFraction>&#160;million for the third research program commencement fee. In addition, Janssen reimburses the Company for all internal and external costs and expenses incurred during the term of the agreement at agreed-upon contractual rates. The Company invoices Janssen on a quarterly basis and payments are due within <ix:nonNumeric contextRef="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228" name="morf:CollaborativeArrangementPaymentDuePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzExMzMx_b077c860-795d-449b-9612-543e11f8504b">60</ix:nonNumeric> days. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, Janssen informed the Company that they had decided not to exercise its options on the first two integrin targets, thus also discontinuing those <ix:nonFraction unitRef="program" contextRef="i0af313c7bd8a4b4388148bb57bf130a0_I20211231" decimals="INF" name="morf:CollaborativeArrangementNumberOfResearchProgramsDiscontinued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEyNjA4_7cd17903-3b35-4e5e-a5be-555435643caa">two</ix:nonFraction> research programs. The Company has focused efforts on the third integrin research program which includes the potential development of integrin antibody activators. In January 2023, Janssen informed the Company that it had decided to exercise its right to terminate the Janssen Agreement for convenience, subject to a <ix:nonNumeric contextRef="i995f63fe81fb4b9abb9716382e1dc8f7_D20210101-20211231" name="morf:CollaborativeArrangementNotificationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzgyNDYzMzcyNDQ3ODA_ae9b85d2-5a44-4e54-9e2a-e2787c1152ee">60</ix:nonNumeric> day notification period. The Janssen Agreement will terminate effective March 2023 or earlier if agreed to by the Company and Janssen. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Agreement Accounting Analysis</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that the performance obligations in the agreement include the research services for the <ix:nonFraction unitRef="program" contextRef="i10cf228deb344a0bbe41e4dd68f6091d_I20221231" decimals="INF" name="morf:CollaborativeArrangementNumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEyOTI4_5e3c32bf-5fcd-4636-96a1-c6432313b5b2">three</ix:nonFraction> research programs and <ix:nonFraction unitRef="option" contextRef="i10cf228deb344a0bbe41e4dd68f6091d_I20221231" decimals="INF" name="morf:CollaborativeArrangementNumberOfOptionsToLicense" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEyOTUz_aaa76a42-46db-408a-8ac9-b942790183cf">three</ix:nonFraction> options to license the outcomes of those research programs, which were determined to provide Janssen with material rights. All other performance obligations were determined to be immaterial in the context of the contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the standalone selling price of each research program based on internal and external costs to perform the research plus a reasonable profit margin. The total estimated cost of the research and development services reflect the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services. The Company estimated the standalone selling price of each material right by determining the discount provided to the estimated standalone selling price of comparable options and applying appropriate likelihood of exercise, which includes the appropriate probability of successfully completing the research efforts. Based on the standalone selling prices determined, the Company allocates the total transaction price among the programs and material rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue as research services are provided based on the costs incurred to date, as such costs have a direct relationship between the Company&#8217;s effort and the progress made towards satisfying its performance obligations to Janssen. Transaction price allocated to the material rights was deferred and will be recognized as revenue when Janssen exercises the options or the option period expires. Changes in estimates of total internal and external costs expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the transaction price included: the non-refundable up-front payment of $<ix:nonFraction unitRef="usd" contextRef="i2c05f87e169c45feb95ae818058af3ef_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE0NzUz_d8bf68b6-3f1f-47de-9720-5f64bc5cfbc1">10.0</ix:nonFraction>&#160;million for the first <ix:nonFraction unitRef="program" contextRef="ie9e8a3b2b5f94dc1967ae1463aa4c8ed_I20221231" decimals="INF" name="morf:CollaborativeArrangementNumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzM4NDgyOTA3MzEyOTI_5c44e22d-017a-4f15-805a-a8d78a0015e7">two</ix:nonFraction> programs, $<ix:nonFraction unitRef="usd" contextRef="if5d1093edead46de860e94adc1452272_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE0Nzg0_ec4f00d2-3033-4b69-a190-28aa5cfabf10">5.0</ix:nonFraction>&#160;million non-refundable up-front payment for the third program, and the estimated reimbursement payments at agreed upon contractual rates to be received from Janssen for the Company&#8217;s on-going research services. The option exercise payments were not included in the transaction price. Exercise of any of the options will be accounted for as a continuation of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="ib609441007134f8ba4e26e57c6d54159" continuedAt="i89f4182479ad49509578d5b7b04392a5"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the current contract if and when Janssen delivers the written exercise notice. The milestone payments were fully constrained, as a result of the uncertainty regarding whether Janssen would exercise any of the options and whether any of the associated milestones would be achieved.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considered the existence of any significant financing component within the Janssen Agreement given its upfront payment structure. Based upon this assessment, the Company concluded that the up-front payment was provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the Janssen Agreement does not result in the existence of a significant financing component.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contract Modification</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon notification of discontinuation of the <ix:nonFraction unitRef="program" contextRef="i10cf228deb344a0bbe41e4dd68f6091d_I20221231" decimals="INF" name="morf:CollaborativeArrangementNumberOfResearchProgramsDiscontinued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE1OTgw_8daa9e6f-a105-4831-bfb6-73b742472c1f">two</ix:nonFraction> research programs and related options, the Company concluded that there was a contract modification to an existing contract under ASC 606 because the December 2021 notification resulted in a reduction in scope of the Company&#8217;s responsibilities under the Janssen Agreement. The December 2021 notification did not include any additional promised goods and services. Subsequent to the modification, there are two remaining performance obligations pursuant to the Janssen Agreement, research services for the remaining research program and a material right for Janssen&#8217;s remaining license option. The Company concluded that the remaining research services to be provided to satisfy the third research program were not distinct from its existing research services, and as a result treated the modification as part of the original contract (as opposed to a separate contract). Therefore, the Company updated the transaction price, which included the remaining deferred revenue and estimated variable consideration for research services and allocated the updated transaction price to the remaining performance obligations based on the estimated standalone selling prices at the date of the contract modification. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the research services, the effect that the contract modification had on the transaction price and the measure of progress towards satisfying the performance obligation of $<ix:nonFraction unitRef="usd" contextRef="i2b07511e4f7642a9bfe31d2963ab5b4d_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE3MzY0_664ea947-40ef-4774-b591-475392cb111e">1.9</ix:nonFraction>&#160;million has been recognized on a cumulative catch-up basis. The transaction price allocated to the remaining material right of $<ix:nonFraction unitRef="usd" contextRef="i10cf228deb344a0bbe41e4dd68f6091d_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE3NDg2_6758bf6a-0fc7-484b-b0dd-e03ad671c705">0.5</ix:nonFraction>&#160;million was deferred and will remain deferred until exercise or expiration. The accounting for any previously satisfied performance obligations as of the contract modification date are not affected by the modification. </span></div><ix:continuation id="ic8fea59117c64d2784bae28d2caa1b41"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes research and development costs incurred and revenue recognized in connection with the Company's performance under the Janssen Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f81bdfee4430b81915be0cd95860b_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzItNS0xLTEtNjc0NzQ_a1ea2a62-9e51-4bc7-a383-e645e27313d0">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6eb38babcc241e89553761903a11d61_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzItNy0xLTEtNjc0NzQ_8a3fbde2-b567-4cdf-8a01-09023170daab">4,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5084eff2ed1d4f48a7da4984d71799cf_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzItOS0xLTEtNjc0NzQ_cfa419cd-ec64-487b-a610-a32f4b434f02">6,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b07511e4f7642a9bfe31d2963ab5b4d_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzMtNS0xLTEtNjc0NzQ_1b324df5-22ad-445a-b9b8-5bb7d5f577c3">7,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035b3de5190f487586bd1ed38307c379_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzMtNy0xLTEtNjc0NzQ_52a95617-3df2-4bd1-9a39-a71926f06a3c">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af92416deea43878ba0ead3d0ecb13f_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzMtOS0xLTEtNjc0NzQ_4c2d495e-39b1-4353-8e9b-b2260f0a7526">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue recognized</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3511c82559894a9f98fb91e24620713a_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzQtNS0xLTEtNjc0NzQ_31748199-1609-455c-9a05-5340fc07987a">10,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5743f7e935fc434da814d8855536f21b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzQtNy0xLTEtNjc0NzQ_42b7f052-6859-4689-ba5f-1e519238e25d">8,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5251e4aa084f7983207e980fdcdba4_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzQtOS0xLTEtNjc0NzQ_c77f6688-6da5-495a-a07b-2b2985d53dfb">8,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3511c82559894a9f98fb91e24620713a_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzUtNS0xLTEtNjc0NzQ_bc1620bd-62be-4d7d-9539-ee87c1728c2b">2,637</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5743f7e935fc434da814d8855536f21b_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzUtNy0xLTEtNjc0NzQ_9ad7f66e-dd9f-48dc-832b-cc321d6e1721">4,426</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5251e4aa084f7983207e980fdcdba4_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzUtOS0xLTEtNjc0NzQ_049e8297-aa9f-4996-8903-4c41d314a07b">5,865</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Q4 2022, the Company recognized additional revenue of $<ix:nonFraction unitRef="usd" contextRef="ia02854bc64fd499c8dbac9ce00351643_D20221001-20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzgyNDYzMzcyNDgzMDU_a7e61a4f-e997-425c-a0bd-f3d387f3dda3">3.0</ix:nonFraction>&#160;million on a cumulative catch-up basis as a result of changes to the estimated costs associated with the remaining effort required to complete the research services for the third research program. The amount of future expected cost estimates has decreased based on a change in expected effort and based on the timing of the research services.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="iccd44d1dfb9c487f883da622bc30602d_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE3OTI0_ef08e55c-109b-499c-9ea4-23a6ed539390">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0a6c624908e845829a9ec116c04519ef_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE3OTMx_275a8d32-074f-4f04-859e-981fde75c118">2.3</ix:nonFraction> million, respectively, due from Janssen recorded in accounts receivable. As of December 31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="iccd44d1dfb9c487f883da622bc30602d_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE4MTU5_01b53adb-5016-45b0-84a6-91d658cbece2">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0a6c624908e845829a9ec116c04519ef_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE4MTY2_e7bff0a1-f944-4003-addf-87505c35ebd6">7.6</ix:nonFraction> million, respectively, of deferred revenue was classified as either current or net of current portion in the accompanying consolidated balance sheets based on the period over which the revenue is expected to be recognized. At December 31, 2022 and 2021 the deferred revenue balance represents the portion of the upfront payments received allocated to the performance obligations that are partially or wholly unsatisfied as of December 31, 2022 and 2021. The Company expects to recognize revenue related to the remaining performance obligations through Q1 2023.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i89f4182479ad49509578d5b7b04392a5">The Company's continuing obligation associated with the material right will terminate effective March 2023 or earlier if agreed to by the Company and Janssen.</ix:continuation> </span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_142"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90ZXh0cmVnaW9uOjgwNDM3NTUwODlhNjQ2MGQ5MDdmNTdkODYwNDZjZjYwXzE1ODg_a787569b-b6ab-4c7f-b131-54eaef880a6f" continuedAt="i97b8939b28ac43ec998697fcba83f241" escape="true">Net Loss per Share</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i97b8939b28ac43ec998697fcba83f241" continuedAt="i70fd5bf7903e473780e91d190fb7199d">Basic net loss per share is calculated by dividing net loss allocable to common stockholders by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i70fd5bf7903e473780e91d190fb7199d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net income per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents, including stock options and restricted common stock and stock units outstanding for the period as determined using the treasury stock method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are the same for periods with a net loss.</span></div><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90ZXh0cmVnaW9uOjgwNDM3NTUwODlhNjQ2MGQ5MDdmNTdkODYwNDZjZjYwXzE1ODk_315585a9-471f-41a9-a531-d4cd9cd9c3b9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzMtNS0xLTEtNjc0NzQ_0a5b64a9-885f-41e5-b258-a862e472151a">59,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzMtNy0xLTEtNjc0NzQ_f0010e89-74d7-405f-97b4-b322d58c11f9">95,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzMtOS0xLTEtNjc0NzQ_ddb92cc5-9262-4b20-b6c1-2669237c1a3a">44,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtNS0xLTEtNjc0NzQ_498d2895-ecf6-4f52-be83-0846fa66d26c"><ix:nonFraction unitRef="shares" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtNS0xLTEtNjc0NzQ_e3668934-a4f9-4e69-b183-45cf367ba9ef">38,112,498</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtNy0xLTEtNjc0NzQ_1232b63c-b918-4d23-af44-6e06a69b9529"><ix:nonFraction unitRef="shares" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtNy0xLTEtNjc0NzQ_8cfc87f4-86c2-4e38-8900-bddf9868548c">35,797,969</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtOS0xLTEtNjc0NzQ_2be1a754-c211-42a5-9fea-412be202b0eb"><ix:nonFraction unitRef="shares" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtOS0xLTEtNjc0NzQ_557c2e6f-e754-479c-bc0c-8ebc29f1348e">30,594,897</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtNS0xLTEtNjc0NzQ_3ccf7788-681f-46a7-bf77-cad7c4f2a9a4"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtNS0xLTEtNjc0NzQ_47616873-dd98-46a8-8be7-3c305a3747b9">1.55</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtNy0xLTEtNjc0NzQ_2b861220-70ba-4f16-885c-933334cc0a41"><ix:nonFraction unitRef="usdPerShare" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtNy0xLTEtNjc0NzQ_98a28844-ab61-4b56-bc57-f100b21c5a80">2.67</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtOS0xLTEtNjc0NzQ_09566b39-e1e8-41d4-a54d-cb113d42afcf"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtOS0xLTEtNjc0NzQ_0d1edf40-d2aa-4333-a92b-77fef7f150f3">1.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90ZXh0cmVnaW9uOjgwNDM3NTUwODlhNjQ2MGQ5MDdmNTdkODYwNDZjZjYwXzE1OTA_1c96e2d3-b99f-4bae-9129-63cb6e45170a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):</span></div><div style="margin-top:12pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ce5d6357e054eb89f9f7070956ddd0f_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzItNS0xLTEtNjc0NzQ_c4fefd7f-b015-451f-84df-448f77e8b119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53395b8e2227477fb7c23b0353062b98_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzItNy0xLTEtNjc0NzQ_ebd0bbf9-468d-47b4-942d-c1952f6b70af">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a1b74d6b2bb4a4f98e936d596b79284_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzItOS0xLTEtNjc0NzQ_e79fa5a9-ccdb-4cf7-b1e6-6fd30be38f5b">100,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i436cc872d64b4d7b9aaa708f0706aa2a_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzMtNS0xLTEtNjc0NzQ_fcef77f7-1dde-4746-8444-ee0fdc1c8b51">249,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia296bbbf833f49b2a6ab65ef01ab6bd8_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzMtNy0xLTEtNjc0NzQ_781b8d36-28b0-43f5-8971-70feff067edc">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadfe8416bc324e919e5e25cbad2d3372_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzMtOS0xLTEtNjc0NzQ_6c0a9e3d-e823-4238-acd6-d0da14644ebb">66,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i289b44ada87a4da1befaa2bbadc04a61_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzQtNS0xLTEtNjc0NzQ_26dfec0c-d090-4baa-830c-e7ce0d266cf6">5,263,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01c3a69a38b5461d93693d703c6eda55_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzQtNy0xLTEtNjc0NzQ_ecafc3c8-d6df-4aa3-ab41-444d1efe4d56">4,781,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22a2adf60f5a46a4a34b1aa1bf2511b1_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzQtOS0xLTEtNjc0NzQ_559f305a-aa7c-4b83-9388-dfbdfae0322c">4,352,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzUtNS0xLTEtNjc0NzQ_e631c65d-9179-45e3-adeb-4b3d3be95216">5,512,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzUtNy0xLTEtNjc0NzQ_695cd8a6-e691-4eef-8cbd-2d31429f1fe3">4,790,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzUtOS0xLTEtNjc0NzQ_8cea717d-032e-47e3-a468-e9238c0e4ec6">4,519,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the securities listed in the table above, as of December&#160;31, 2022 the Company had reserved <ix:nonFraction unitRef="shares" contextRef="ia515039667cc4b22b0294f91e2b2a44a_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90ZXh0cmVnaW9uOjgwNDM3NTUwODlhNjQ2MGQ5MDdmNTdkODYwNDZjZjYwXzE0Mjc_7a784a52-62fb-4ceb-b60a-af720ca18b71">1,142,204</ix:nonFraction> shares of common stock for sale under the ESPP, which, if issued, would be anti-dilutive if included in calculation of diluted net loss per share for the year ended December 31, 2022.</span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div></ix:continuation><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_148"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDgvZnJhZzpmYTZhNjViZTM4ZmE0NDc5ODUzN2YwMTAyN2ZiNWY5NC90ZXh0cmVnaW9uOmZhNmE2NWJlMzhmYTQ0Nzk4NTM3ZjAxMDI3ZmI1Zjk0XzM5Ng_6e47ee4a-ac19-471d-a9c3-144fd268c43d" continuedAt="i5cbdc73b777a4b9fa1bc3ed59017a168" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5cbdc73b777a4b9fa1bc3ed59017a168">In 2016, the Company adopted a qualified retirement plan, the Morphic Therapeutic, Inc. 401(k) Plan to provide retirement income for eligible employees through employee contributions and employer matching contributions. Matching contributions totaled $<ix:nonFraction unitRef="usd" contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDgvZnJhZzpmYTZhNjViZTM4ZmE0NDc5ODUzN2YwMTAyN2ZiNWY5NC90ZXh0cmVnaW9uOmZhNmE2NWJlMzhmYTQ0Nzk4NTM3ZjAxMDI3ZmI1Zjk0XzM1OA_8ba63d99-1d57-4d7d-a044-6d4337046b3e">0.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDgvZnJhZzpmYTZhNjViZTM4ZmE0NDc5ODUzN2YwMTAyN2ZiNWY5NC90ZXh0cmVnaW9uOmZhNmE2NWJlMzhmYTQ0Nzk4NTM3ZjAxMDI3ZmI1Zjk0XzM2Mg_2f40da6e-9f49-4b9d-8968-9adb9e4d8b0b">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDgvZnJhZzpmYTZhNjViZTM4ZmE0NDc5ODUzN2YwMTAyN2ZiNWY5NC90ZXh0cmVnaW9uOmZhNmE2NWJlMzhmYTQ0Nzk4NTM3ZjAxMDI3ZmI1Zjk0XzM2OQ_5caf56d9-d9ac-4767-bd20-62c774cf411a">0.5</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes In And Disagreements With Accountants on Accounting and Financial Disclosure</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_154"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Effectiveness of Disclosure Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted an evaluation as of December 31, 2022 under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), and concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended, the &#8220;Exchange Act&#8221;) were effective as of December&#160;31, 2022 and designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that it is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Inherent Limitations on Effectiveness of Controls</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the principal executive officer and principal financial officer, does not expect that our internal control over financial reporting or our internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Management's Annual Report on Internal Control Over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision of the principal executive officer and principal financial officer, management conducted an assessment of the effectiveness of our internal control over financial reporting as of December&#160;31, 2022 based on the framework in Internal Control - Integrated Framework (2013) published by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Changes in Internal Control Over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_157"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosures Regarding Foreign Jurisdictions That Prevent Inspections</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_166"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 10 will be included in our definitive proxy statement relating to our 2023 Annual Meeting of Stockholders, to be filed no later than 120 days after December&#160;31, 2022, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.  EXECUTIVE COMPENSATION.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 11 will be included in our definitive proxy statement relating to our 2023 Annual Meeting of Stockholders, to be filed no later than 120 days after December&#160;31, 2022, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_172"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 12 will be included in our definitive proxy statement relating to our 2023 Annual Meeting of Stockholders, to be filed no later than 120 days after December&#160;31, 2022, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_175"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 13 will be included in our definitive proxy statement relating to our 2023 Annual Meeting of Stockholders, to be filed no later than 120 days after December&#160;31, 2022, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_178"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  PRINCIPAL ACCOUNTING FEES AND SERVICES.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 14 will be included in our definitive proxy statement relating to our 2023 Annual Meeting of Stockholders, to be filed no later than 120 days after December&#160;31, 2022, and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_184"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits and Financial Statement Schedules</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Financial Statements:</span></div><div><span><br/></span></div><div style="padding-left:144pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are set forth in Part II, Item 8 of this Annual Report on Form 10-K and are incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statement Schedules:</span></div><div><span><br/></span></div><div style="padding-left:144pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules have been omitted since they are either not required or not applicable or the information is otherwise included herein.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report on Form 10-K are listed below.</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnish the exhibits required by Item 601 of Regulation S-K (&#167; 229.601 of this chapter).</span></div><div style="margin-top:12pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing <br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000155837019008082/morf-20190630ex3180232b9.htm">Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 13, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000110465923019132/tm236505d1_ex3-1.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 13, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-4_1.htm">Form of Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-4_2.htm">Investors</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-4_2.htm">'</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-4_2.htm"> Rights Agreement, dated December 5, 2018, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000155837021002073/morf-20201231ex43413498b.htm">Description of Registrant&#8217;s Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000037/exhibit43.htm">Form of Debt Security</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-258435</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000037/exhibit44.htm">Form of Indenture</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-258435</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000110465923019132/tm236505d1_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 13, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_1.htm">Form of Indemnity Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_2.htm">2018 Stock Incentive Plan and forms of award agreements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936322000047/morphicequityincentiveplan.htm">Amended and Restated 2019 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_3.htm">Form of Stock Option Award Agreement (Included in the 2019 Equity Incentive Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_3.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_3.htm">Restricted Stock </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_3.htm">Award Agreement (Included in the 2019 Equity Incentive Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_4.htm">2019 Employee Stock Purchase Plan and forms of award agreements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_5.htm">Offer Letter, dated June 10, 2019, by and between the Registrant and Praveen P. Tipirneni, MD</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_6.htm">Offer Letter, dated June 10, 2019, by and between the Registrant and Bruce N. Rogers, Ph.D</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000155837020001653/morf-20191231ex107c9fae2.htm">Offer Letter, dated June 10, 2019, by and between the Registrant and William DeVaul</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_9.htm">Lease, dated August 5, 2015, by and between the Registrant and AstraZeneca Pharmaceuticals Limited Partnership, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_10.htm">Research Collaboration and Option Agreement, dated February 15, 2019, by and among Janssen Pharmaceuticals, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_12.htm">Collaboration Agreement, dated June 10, 2015, by and between Morphic Rock Therapeutic, Inc. and Schr&#246;dinger, LLC, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_13.htm">Exclusive License Agreement, dated October 7, 2015, by and between Children's Medical Center Corporation and the Registrant, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000104746919003634/a2239019zex-10_17.htm">Form of Stock Registration Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231837</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000155837020010050/morf-20200630ex101adfa5a.htm">Offer Letter, dated February 3, 2020, by and between Marc Schegerin, and Morphic Holding, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000155837021002073/morf-20201231ex10198f03c.htm">Amendment No. 1 to the Research Collaboration and Option Agreement, dated December 30, 2020, by and among Janssen Pharmaceuticals, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000035/exhibit101-janssenamendment.htm">Amendment No. 2 to Research Collaboration and Option Agreement, dated as of June 18, 2021, by and between the Registrant and Janssen Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000067/exhibit101-rentamendment.htm">Fifth amendment of lease</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936322000010/morf-20211231x10kex1019.htm">Form of Change in Control and Severance Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000110465923019132/tm236505d1_ex10-1.htm">Securities Purchase Agreement, dated February 13, 2023, by and among Morphic Holding, Inc. and the investors listed on the signature pages thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 13, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000110465923019132/tm236505d1_ex10-2.htm">Registration Rights Agreement, dated February 13, 2023, by and among Morphic Holding, Inc. and the investors listed on the signature pages thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38940</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 13, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-20221231x10kex211.htm">Subsidiaries of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-20221231x10kex231.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_193">Powers of Attorney. Reference is made to the signature page hereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-20221231x10kex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-20221231x10kex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-20221231x10kex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-20221231x10kex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Executive compensation plan or agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and are not deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation S-K. </span></div><div><span><br/></span></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MORPHIC HOLDING, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Praveen P. Tipirneni</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praveen P. Tipirneni, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Marc Schegerin</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Schegerin, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer<br/>(Principal Financial Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert E. Farrell Jr.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Farrell Jr. CPA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer and Assistant Treasurer<br/>(Principal Accounting Officer)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i6f157ddbee1a4723b8b2bfa75a59aa23_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f157ddbee1a4723b8b2bfa75a59aa23_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Praveen P. Tipirneni and William D. DeVaul, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Praveen P. Tipirneni</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praveen P. Tipirneni, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Marc Schegerin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Schegerin, M.D. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert E. Farrell, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer and Assistant Treasurer (Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Farrell, Jr., CPA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Norbert Bischofberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norbert Bischofberger, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gustav Christensen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gustav Christensen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Martin Edwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Edwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Susannah Gray</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susannah Gray</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Nisha Nanda</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nisha Nanda, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Amir Nashat</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amir Nashat</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Joseph P. Slattery</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph P. Slattery, CPA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy A. Springer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy A. Springer, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>morf-20221231x10kex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie046f5c2ef68431083d745acb6ae734e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of Morphic Holding, Inc.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morphic Therapeutic, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morphic Security Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morphic Therapeutic UK Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>morf-20221231x10kex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i95897e5465984f2cbac94e9f247669e3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Registration Statement (Form S-3 Nos. 333-258703 and 333-239607) of Morphic Holding, Inc.,</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)&#160;&#160;&#160;&#160;Registration Statements (Form S-8 Nos. 333-236727, 333-253678 and 333-262950) pertaining to the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of Morphic Holding, Inc., and </font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)&#160;&#160;&#160;&#160;Registration Statement (Form S-8 No. 333-232372) pertaining to the 2019 Equity Incentive Plan, 2019 Employee Stock Purchase Plan and the 2018 Stock Incentive Plan of Morphic Holding, Inc.&#59; </font></div><div><font><br></font></div><div style="padding-left:18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our report dated February 23, 2023, with respect to the consolidated financial statements of Morphic Holding, Inc. included in this Annual Report (Form 10-K) of Morphic Holding, Inc. for the year ended December 31, 2022.</font></div><div style="padding-left:18pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Boston, Massachusetts</font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 23, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>morf-20221231x10kex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic03d0567cb0243e494d5599c23b2c614_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Praveen P. Tipirneni, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Morphic Holding, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 23, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Praveen P. Tipirneni</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praveen P. Tipirneni, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>morf-20221231x10kex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic24bb9d46ccd4059a146b81bf9d7f11a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Marc Schegerin, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Morphic Holding, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 23, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Marc Schegerin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Schegerin, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:32.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>morf-20221231x10kex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic41647d1805d42d6bf643d215d99dd28_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Praveen P. Tipirneni, Chief Executive Officer of Morphic Holding, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">the Annual Report on Form 10-K of the Company for the fiscal year ended December&#160;31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; February 23, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Praveen P. Tipirneni</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praveen P. Tipirneni, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>morf-20221231x10kex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia0806776ba4147f089189956810ab039_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Marc Schegerin, Chief Financial Officer and Chief Operating Officer of Morphic Holding, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">the Annual Report on Form 10-K of the Company for the fiscal year ended December&#160;31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; February 23, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Marc Schegerin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Schegerin, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>morf-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3504fb1d-c703-4af8-962a-40bb538fa93a,g:d0f79058-117f-4d7c-9741-2cac766e63e2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:morf="http://morphictx.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://morphictx.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="morf-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="morf-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="morf-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="morf-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://morphictx.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://morphictx.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusiness" roleURI="http://morphictx.com/role/NatureoftheBusiness">
        <link:definition>0000009 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilities" roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities">
        <link:definition>0000011 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Marketablesecurities" roleURI="http://morphictx.com/role/Marketablesecurities">
        <link:definition>0000012 - Disclosure - Marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://morphictx.com/role/PropertyandEquipmentNet">
        <link:definition>0000013 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://morphictx.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://morphictx.com/role/AccruedExpenses">
        <link:definition>0000015 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://morphictx.com/role/StockholdersEquity">
        <link:definition>0000016 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation" roleURI="http://morphictx.com/role/EquityBasedCompensation">
        <link:definition>0000017 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://morphictx.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://morphictx.com/role/CommitmentsandContingencies">
        <link:definition>0000019 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OptionandLicenseAgreements" roleURI="http://morphictx.com/role/OptionandLicenseAgreements">
        <link:definition>0000020 - Disclosure - Option and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://morphictx.com/role/NetLossperShare">
        <link:definition>0000021 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://morphictx.com/role/EmployeeBenefitPlan">
        <link:definition>0000022 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>0000023 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesTables" roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesTables">
        <link:definition>0000024 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesTables" roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables">
        <link:definition>0000025 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketablesecuritiesTables" roleURI="http://morphictx.com/role/MarketablesecuritiesTables">
        <link:definition>0000026 - Disclosure - Marketable securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://morphictx.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000027 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://morphictx.com/role/LeasesTables">
        <link:definition>0000028 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://morphictx.com/role/AccruedExpensesTables">
        <link:definition>0000029 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationTables" roleURI="http://morphictx.com/role/EquityBasedCompensationTables">
        <link:definition>0000030 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://morphictx.com/role/IncomeTaxesTables">
        <link:definition>0000031 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OptionandLicenseAgreementsTables" roleURI="http://morphictx.com/role/OptionandLicenseAgreementsTables">
        <link:definition>0000032 - Disclosure - Option and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://morphictx.com/role/NetLossperShareTables">
        <link:definition>0000033 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessDetails" roleURI="http://morphictx.com/role/NatureoftheBusinessDetails">
        <link:definition>0000034 - Disclosure - Nature of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails" roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000035 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000036 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails" roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails">
        <link:definition>0000037 - Disclosure - Basis of Presentation and Significant Accounting Policies - Property and Equipment Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesDetails" roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails">
        <link:definition>0000038 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketablesecuritiesDetails" roleURI="http://morphictx.com/role/MarketablesecuritiesDetails">
        <link:definition>0000039 - Disclosure - Marketable securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://morphictx.com/role/PropertyandEquipmentNetDetails">
        <link:definition>0000040 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://morphictx.com/role/LeasesNarrativeDetails">
        <link:definition>0000041 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofsupplementalinformationDetails" roleURI="http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails">
        <link:definition>0000042 - Disclosure - Leases - Summary of supplemental information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofleasecommitmentsDetails" roleURI="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails">
        <link:definition>0000043 - Disclosure - Leases - Maturities of lease commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofleasecommitmentsDetails_1" roleURI="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails_1">
        <link:definition>0000043 - Disclosure - Leases - Maturities of lease commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://morphictx.com/role/AccruedExpensesDetails">
        <link:definition>0000044 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://morphictx.com/role/StockholdersEquityDetails">
        <link:definition>0000045 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation2019equityincentiveplanDetails" roleURI="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails">
        <link:definition>0000046 - Disclosure - Equity-Based Compensation - 2019 equity incentive plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationEquitybasedcompensationexpenseDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails">
        <link:definition>0000047 - Disclosure - Equity-Based Compensation - Equity based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationRestrictedcommonstockactivityDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails">
        <link:definition>0000048 - Disclosure - Equity-Based Compensation - Restricted common stock activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationRestrictedstockunitsactivityDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails">
        <link:definition>0000049 - Disclosure - Equity-Based Compensation - Restricted stock units activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationStockoptionawardsDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails">
        <link:definition>0000050 - Disclosure - Equity-Based Compensation - Stock option awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails">
        <link:definition>0000051 - Disclosure - Equity-Based Compensation - Information related to options granted, vested and exercised (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>0000052 - Disclosure - Equity-Based Compensation- Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoflossbeforeincometaxesDetails" roleURI="http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails">
        <link:definition>0000053 - Disclosure - Income Taxes - Components of loss before income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofincometaxDetails" roleURI="http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails">
        <link:definition>0000054 - Disclosure - Income Taxes - Components of income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveincometaxrateDetails" roleURI="http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails">
        <link:definition>0000055 - Disclosure - Income Taxes - Effective income tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredtaxassetsandliabilitiesDetails" roleURI="http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails">
        <link:definition>0000056 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://morphictx.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000057 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OptionandLicenseAgreementsNarrativeDetails" roleURI="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails">
        <link:definition>0000058 - Disclosure - Option and License Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" roleURI="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails">
        <link:definition>0000059 - Disclosure - Option and License Agreements - Costs incurred and revenue recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareBasicnetincomelosspershareDetails" roleURI="http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails">
        <link:definition>0000060 - Disclosure - Net Loss per Share - Basic net income (loss) per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareCommonstockequivalentsharesDetails" roleURI="http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails">
        <link:definition>0000061 - Disclosure - Net Loss per Share- Common stock equivalent shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://morphictx.com/role/EmployeeBenefitPlanDetails">
        <link:definition>0000062 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="morf_CollaborativeArrangementNumberOfOptions" abstract="false" name="CollaborativeArrangementNumberOfOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="morf_CollaborativeArrangementDisclosureAbstract" abstract="true" name="CollaborativeArrangementDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="morf_PercentageOfCommissionOnGrossSaleProceeds" abstract="false" name="PercentageOfCommissionOnGrossSaleProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="morf_TwoThousandNineteenStockIncentivePlanMember" abstract="true" name="TwoThousandNineteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_CollaborationAgreementNumberOfAgreements" abstract="false" name="CollaborationAgreementNumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock" abstract="false" name="ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="morf_CollaborativeArrangementNotificationPeriod" abstract="false" name="CollaborativeArrangementNotificationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="morf_CollaborativeArrangementOptionExerciseFeesReceivable" abstract="false" name="CollaborativeArrangementOptionExerciseFeesReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_UpfrontPaymentRevenueFirstTwoProgramsMember" abstract="true" name="UpfrontPaymentRevenueFirstTwoProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" abstract="false" name="ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="morf_CollaborativeArrangementUpfrontFeesReceived" abstract="false" name="CollaborativeArrangementUpfrontFeesReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock" abstract="false" name="LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_OpenMarketSaleAgreementMember" abstract="true" name="OpenMarketSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_CollaborativeArrangementTermOfArrangement" abstract="false" name="CollaborativeArrangementTermOfArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction" abstract="false" name="ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="morf_CommonStockAvailableForIssuance" abstract="false" name="CommonStockAvailableForIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_CollaborativeArrangementNumberOfOptionsToLicense" abstract="false" name="CollaborativeArrangementNumberOfOptionsToLicense" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="morf_VotingRights" abstract="false" name="VotingRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="morf_DeferredTaxAssetLeaseLiabilities" abstract="false" name="DeferredTaxAssetLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_AccruedResearchAndDevelopment" abstract="false" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="morf_UpfrontPaymentRevenueMember" abstract="true" name="UpfrontPaymentRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram" abstract="false" name="CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_CollaborativeArrangementProfitMarginPercentage" abstract="false" name="CollaborativeArrangementProfitMarginPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued" abstract="false" name="CollaborativeArrangementNumberOfResearchProgramsDiscontinued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="morf_UpfrontPaymentRevenueThirdProgramMember" abstract="true" name="UpfrontPaymentRevenueThirdProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_SecondaryOfferingMember" abstract="true" name="SecondaryOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_CollaborativeArrangementNumberOfResearchPrograms" abstract="false" name="CollaborativeArrangementNumberOfResearchPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="morf_AbbVieMember" abstract="true" name="AbbVieMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_UpFrontPaymentIncludedInTransactionPrice" abstract="false" name="UpFrontPaymentIncludedInTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_CollaborativeArrangementOptionExerciseFeesPaid" abstract="false" name="CollaborativeArrangementOptionExerciseFeesPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_CollaborativeArrangementPaymentDuePeriod" abstract="false" name="CollaborativeArrangementPaymentDuePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="morf_AtMarketOfferingProgramMember" abstract="true" name="AtMarketOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_FollowOnPublicOfferingMember" abstract="true" name="FollowOnPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="morf_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_ReimbursementRevenueMember" abstract="true" name="ReimbursementRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_OfficeAndLaboratorySpaceMember" abstract="true" name="OfficeAndLaboratorySpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock" abstract="false" name="InterestIncomeOnInvestmentsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="morf_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" abstract="false" name="EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_JanssenPharmaceuticalsIncMember" abstract="true" name="JanssenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_CollaborativeArrangementNumberOfIntegrinTargets" abstract="false" name="CollaborativeArrangementNumberOfIntegrinTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="morf_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram" abstract="false" name="CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember" abstract="true" name="USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_DeferredTaxAssetsFixedAndIntangibleAssets" abstract="false" name="DeferredTaxAssetsFixedAndIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_CollaborationAgreementOptionExerciseRevenueReceived" abstract="false" name="CollaborationAgreementOptionExerciseRevenueReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>morf-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3504fb1d-c703-4af8-962a-40bb538fa93a,g:d0f79058-117f-4d7c-9741-2cac766e63e2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_27f356d0-9b3f-4660-8269-dbf60cb2e285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_010b3ae0-bb9c-4e8c-8540-62ad1832c053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_27f356d0-9b3f-4660-8269-dbf60cb2e285" xlink:to="loc_us-gaap_AssetsCurrent_010b3ae0-bb9c-4e8c-8540-62ad1832c053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b30f32a3-ab48-4675-90d1-53f07971aa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_27f356d0-9b3f-4660-8269-dbf60cb2e285" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b30f32a3-ab48-4675-90d1-53f07971aa4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f06d6fe7-d96a-4555-a8b4-39096874e96e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_27f356d0-9b3f-4660-8269-dbf60cb2e285" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f06d6fe7-d96a-4555-a8b4-39096874e96e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_ef994511-fabf-4733-933b-15d9fb594785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_27f356d0-9b3f-4660-8269-dbf60cb2e285" xlink:to="loc_us-gaap_RestrictedCash_ef994511-fabf-4733-933b-15d9fb594785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b770c4fe-6380-4e66-babf-5c29c257e74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_27f356d0-9b3f-4660-8269-dbf60cb2e285" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b770c4fe-6380-4e66-babf-5c29c257e74e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f3893fb-ca98-4db7-b11f-eeb8cc598ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b2b4a47c-10e4-4be8-a2ea-89e744ced119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f3893fb-ca98-4db7-b11f-eeb8cc598ef1" xlink:to="loc_us-gaap_Liabilities_b2b4a47c-10e4-4be8-a2ea-89e744ced119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e1439488-d252-45ff-903d-da0d5be6f419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f3893fb-ca98-4db7-b11f-eeb8cc598ef1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e1439488-d252-45ff-903d-da0d5be6f419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b9c46884-29c5-4129-9334-f41f8b312d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f3893fb-ca98-4db7-b11f-eeb8cc598ef1" xlink:to="loc_us-gaap_StockholdersEquity_b9c46884-29c5-4129-9334-f41f8b312d7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_51bdfd55-2196-4ea6-b6fc-c2f08ba6a8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ff8dd373-0bc5-439c-a5e5-42f446d3b932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_51bdfd55-2196-4ea6-b6fc-c2f08ba6a8e7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ff8dd373-0bc5-439c-a5e5-42f446d3b932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8865492f-b42e-48f6-9d06-10fded20b7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_51bdfd55-2196-4ea6-b6fc-c2f08ba6a8e7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8865492f-b42e-48f6-9d06-10fded20b7ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a095baec-0dd7-44c2-aa42-edcb3c77455f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_51bdfd55-2196-4ea6-b6fc-c2f08ba6a8e7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a095baec-0dd7-44c2-aa42-edcb3c77455f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e50b5678-0f17-4728-8703-8aeb138b4f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_51bdfd55-2196-4ea6-b6fc-c2f08ba6a8e7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e50b5678-0f17-4728-8703-8aeb138b4f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f1f5870-9554-4c54-b4bf-e2b727cdaebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_44af943b-9d2a-4e25-832f-60c1c6140474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2f1f5870-9554-4c54-b4bf-e2b727cdaebe" xlink:to="loc_us-gaap_PreferredStockValue_44af943b-9d2a-4e25-832f-60c1c6140474" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5be05be1-9796-4ed0-ba98-944c280bd54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2f1f5870-9554-4c54-b4bf-e2b727cdaebe" xlink:to="loc_us-gaap_CommonStockValue_5be05be1-9796-4ed0-ba98-944c280bd54d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2e38c5c5-3384-4296-8e67-9d0c1cbcf547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2f1f5870-9554-4c54-b4bf-e2b727cdaebe" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2e38c5c5-3384-4296-8e67-9d0c1cbcf547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a90df627-4e34-4ec6-b7f7-711af9a13ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2f1f5870-9554-4c54-b4bf-e2b727cdaebe" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a90df627-4e34-4ec6-b7f7-711af9a13ce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04393fb3-fdb7-4321-8d21-b6e66f76fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2f1f5870-9554-4c54-b4bf-e2b727cdaebe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04393fb3-fdb7-4321-8d21-b6e66f76fa26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0583e92f-a1fb-42b8-9684-b4be0215e576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d6b8840d-d0e7-4f53-91c3-288828f0522b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0583e92f-a1fb-42b8-9684-b4be0215e576" xlink:to="loc_us-gaap_LiabilitiesCurrent_d6b8840d-d0e7-4f53-91c3-288828f0522b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6b82d59-9b57-4f78-9d3b-4cc28e3bb0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0583e92f-a1fb-42b8-9684-b4be0215e576" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6b82d59-9b57-4f78-9d3b-4cc28e3bb0cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_80d78810-ae91-4854-8dde-ecccecc4e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0583e92f-a1fb-42b8-9684-b4be0215e576" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_80d78810-ae91-4854-8dde-ecccecc4e9a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b0871936-2de3-4b79-af86-f4d74e49e0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5330cbb5-6802-4e66-b190-2ff3bc20891a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0871936-2de3-4b79-af86-f4d74e49e0e7" xlink:to="loc_us-gaap_AccountsPayableCurrent_5330cbb5-6802-4e66-b190-2ff3bc20891a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_6f551b75-0e0b-4e26-9688-209d0eeb95d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0871936-2de3-4b79-af86-f4d74e49e0e7" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_6f551b75-0e0b-4e26-9688-209d0eeb95d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17b693ee-199c-4c19-9743-3c967fdcdffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0871936-2de3-4b79-af86-f4d74e49e0e7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17b693ee-199c-4c19-9743-3c967fdcdffd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09929097-6210-484d-bb0b-77426101ac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5f3b4f73-b299-4683-99fb-e6f2eddd7279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09929097-6210-484d-bb0b-77426101ac3c" xlink:to="loc_us-gaap_OperatingIncomeLoss_5f3b4f73-b299-4683-99fb-e6f2eddd7279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_12334bce-41e3-49ee-83b9-852037c2a2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09929097-6210-484d-bb0b-77426101ac3c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_12334bce-41e3-49ee-83b9-852037c2a2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0b0af26f-a967-41c5-abd0-0aac5a66d303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_23b1476b-2eb2-48fb-8bec-9d14898d4f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0b0af26f-a967-41c5-abd0-0aac5a66d303" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_23b1476b-2eb2-48fb-8bec-9d14898d4f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_862198fc-1a52-408b-8088-c16d5ce1c9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0b0af26f-a967-41c5-abd0-0aac5a66d303" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_862198fc-1a52-408b-8088-c16d5ce1c9dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_63fb2b18-cb35-4d66-96f8-3904735f059c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_5b2434fd-66dd-4f4a-a730-512c34b962dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_63fb2b18-cb35-4d66-96f8-3904735f059c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_5b2434fd-66dd-4f4a-a730-512c34b962dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_12ac8bcd-33c0-4ef4-b309-aae097f0652c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4a3ec0a3-c28d-4f3c-a66e-22e9fcda9f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_12ac8bcd-33c0-4ef4-b309-aae097f0652c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4a3ec0a3-c28d-4f3c-a66e-22e9fcda9f4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5c133697-c71d-46d3-afdc-8fead1a253c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_12ac8bcd-33c0-4ef4-b309-aae097f0652c" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5c133697-c71d-46d3-afdc-8fead1a253c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e263ddb8-19a4-4d55-b1b4-a1abd7a402d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_89d9ec3d-d079-492f-b6ff-e1199dc6de80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e263ddb8-19a4-4d55-b1b4-a1abd7a402d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_89d9ec3d-d079-492f-b6ff-e1199dc6de80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_63a0441d-b150-474b-b1eb-9bbc361e1528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e263ddb8-19a4-4d55-b1b4-a1abd7a402d5" xlink:to="loc_us-gaap_CostsAndExpenses_63a0441d-b150-474b-b1eb-9bbc361e1528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8360d2d8-a5a7-4361-b10f-140cdf0bd60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89652576-e45c-49db-a008-e19d288917a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8360d2d8-a5a7-4361-b10f-140cdf0bd60d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_89652576-e45c-49db-a008-e19d288917a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_73fbf062-960b-4aa2-b985-47e88399ab47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8360d2d8-a5a7-4361-b10f-140cdf0bd60d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_73fbf062-960b-4aa2-b985-47e88399ab47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d5007d8-2578-4d50-82d4-210cbdc47a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2bd02506-32df-4126-849a-4f1f7950fccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d5007d8-2578-4d50-82d4-210cbdc47a0e" xlink:to="loc_us-gaap_NetIncomeLoss_2bd02506-32df-4126-849a-4f1f7950fccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f512e1da-e34e-4a2e-a842-ad9de9b61fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d5007d8-2578-4d50-82d4-210cbdc47a0e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f512e1da-e34e-4a2e-a842-ad9de9b61fe6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2996e7d6-ccde-45e9-b939-f82d3e1888e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fd425448-6c2c-4a85-b95d-2ac6995974f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2996e7d6-ccde-45e9-b939-f82d3e1888e5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fd425448-6c2c-4a85-b95d-2ac6995974f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_911eb85a-87fe-43e8-9aa5-159f3236e731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2996e7d6-ccde-45e9-b939-f82d3e1888e5" xlink:to="loc_us-gaap_ProceedsFromStockPlans_911eb85a-87fe-43e8-9aa5-159f3236e731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d420cf13-d6fd-42ac-8bdd-8fe6cda88e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2996e7d6-ccde-45e9-b939-f82d3e1888e5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d420cf13-d6fd-42ac-8bdd-8fe6cda88e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_beb338e1-9bbb-43bf-b349-3c99cbf3b481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_beb338e1-9bbb-43bf-b349-3c99cbf3b481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_728fd219-8a35-41f3-9f59-84f39b1f97aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_728fd219-8a35-41f3-9f59-84f39b1f97aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f7e85e59-6d26-4cd2-8902-e2cbfc13cdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f7e85e59-6d26-4cd2-8902-e2cbfc13cdc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6c1c4084-2957-480e-92bf-709e81a3bf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6c1c4084-2957-480e-92bf-709e81a3bf8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_f0b69bf9-714f-452f-b22d-c38b1d0b9a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_DepreciationAndAmortization_f0b69bf9-714f-452f-b22d-c38b1d0b9a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseInDeferredRent_1fea5c91-c209-4608-bab8-39ee1b71f544" xlink:href="morf-20221231.xsd#morf_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_morf_IncreaseDecreaseInDeferredRent_1fea5c91-c209-4608-bab8-39ee1b71f544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f7cb395d-17b8-4826-9cbb-6ae7333d80c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f7cb395d-17b8-4826-9cbb-6ae7333d80c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_38b4c7c2-daf5-4ca8-9ca6-29447fb57bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_ShareBasedCompensation_38b4c7c2-daf5-4ca8-9ca6-29447fb57bb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets_2ba61ba5-7de8-4181-afce-8548e1138025" xlink:href="morf-20221231.xsd#morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets_2ba61ba5-7de8-4181-afce-8548e1138025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a688e9b3-bdca-4247-ae9c-524e3101533f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a688e9b3-bdca-4247-ae9c-524e3101533f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_383689ff-6d69-4caf-8184-156b8041a4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_383689ff-6d69-4caf-8184-156b8041a4f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_38ed3be5-dc9d-4a6a-863b-da3419e3ae3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_38ed3be5-dc9d-4a6a-863b-da3419e3ae3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_36142dd1-3c3c-4a4a-8688-ffd5540bdf14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_36142dd1-3c3c-4a4a-8688-ffd5540bdf14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c71f8310-03ba-48f5-be4a-966bc609be9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c71f8310-03ba-48f5-be4a-966bc609be9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_75764f9d-06ab-49b5-976a-4fb62c370c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af2338db-2ff6-4a02-8644-e9e30d32cb26" xlink:to="loc_us-gaap_ProfitLoss_75764f9d-06ab-49b5-976a-4fb62c370c5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2fdc20f5-54fa-4a03-9fa1-9f88f142b560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc72d7e1-d50a-4e0c-8ad1-481bc57e7ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2fdc20f5-54fa-4a03-9fa1-9f88f142b560" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc72d7e1-d50a-4e0c-8ad1-481bc57e7ba8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3228a43e-49ee-42d8-9263-3765f5f5c843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2fdc20f5-54fa-4a03-9fa1-9f88f142b560" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3228a43e-49ee-42d8-9263-3765f5f5c843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_17cb173f-e2f3-4680-bfdf-4657b24abe55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2fdc20f5-54fa-4a03-9fa1-9f88f142b560" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_17cb173f-e2f3-4680-bfdf-4657b24abe55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_70041541-79b6-4e58-983a-aa0e296d070d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2fdc20f5-54fa-4a03-9fa1-9f88f142b560" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_70041541-79b6-4e58-983a-aa0e296d070d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6865437f-c03c-4a83-ac7d-e7a617f69ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae4f7d9e-ea75-4ce2-aca8-60f9a44f102a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6865437f-c03c-4a83-ac7d-e7a617f69ba8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae4f7d9e-ea75-4ce2-aca8-60f9a44f102a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78ef6d23-2b55-485d-82ad-5e26bd077390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6865437f-c03c-4a83-ac7d-e7a617f69ba8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78ef6d23-2b55-485d-82ad-5e26bd077390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f24fc3d-d898-4145-b9b2-d26f2ce4a63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6865437f-c03c-4a83-ac7d-e7a617f69ba8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f24fc3d-d898-4145-b9b2-d26f2ce4a63d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f214ede0-59af-405e-a71f-3f8a5a42d87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_e1e02dd8-ead8-49e9-800e-edaa4798e756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f214ede0-59af-405e-a71f-3f8a5a42d87c" xlink:to="loc_us-gaap_RestrictedCash_e1e02dd8-ead8-49e9-800e-edaa4798e756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_705d3b2e-7cde-4022-97d1-3c1c74ab3213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f214ede0-59af-405e-a71f-3f8a5a42d87c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_705d3b2e-7cde-4022-97d1-3c1c74ab3213" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#FairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6678c938-6261-4290-85d9-d2230a116d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1068ded9-f6c8-4397-9d82-b60ced88ab9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6678c938-6261-4290-85d9-d2230a116d98" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1068ded9-f6c8-4397-9d82-b60ced88ab9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a4d3236-9da3-46ef-a77e-8a1a5a0a9239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6678c938-6261-4290-85d9-d2230a116d98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a4d3236-9da3-46ef-a77e-8a1a5a0a9239" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#MarketablesecuritiesDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8adb7034-a531-468c-8f30-43db5effb2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_19e11180-1ec7-4bdf-bd01-fb7980690b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8adb7034-a531-468c-8f30-43db5effb2e8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_19e11180-1ec7-4bdf-bd01-fb7980690b4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_96949231-ef42-4b38-a55e-bbdc1d3d9767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8adb7034-a531-468c-8f30-43db5effb2e8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_96949231-ef42-4b38-a55e-bbdc1d3d9767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_0079bffc-00db-4c86-8b64-c44f112d68c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8adb7034-a531-468c-8f30-43db5effb2e8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_0079bffc-00db-4c86-8b64-c44f112d68c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7c30d55c-71e3-47a5-a218-345c5687fc65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1dfd20b2-595a-4587-9ede-8c154b98ea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7c30d55c-71e3-47a5-a218-345c5687fc65" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1dfd20b2-595a-4587-9ede-8c154b98ea8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b0026fc4-2449-4f0a-a84e-aed7c01f0991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7c30d55c-71e3-47a5-a218-345c5687fc65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b0026fc4-2449-4f0a-a84e-aed7c01f0991" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#LeasesSummaryofsupplementalinformationDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8fe958d7-7df2-417f-82d3-201420a1fa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bb0e5187-d07e-47d9-ac8b-8e38a9a605d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8fe958d7-7df2-417f-82d3-201420a1fa1c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bb0e5187-d07e-47d9-ac8b-8e38a9a605d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_66aecff6-bbdd-47cb-b48b-6dc045a67e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8fe958d7-7df2-417f-82d3-201420a1fa1c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_66aecff6-bbdd-47cb-b48b-6dc045a67e71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#LeasesMaturitiesofleasecommitmentsDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_240fa129-086a-4be6-a6ba-b29dae24ff19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b182490b-ccc1-47e1-849b-c3afc80d3605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_240fa129-086a-4be6-a6ba-b29dae24ff19" xlink:to="loc_us-gaap_OperatingLeaseLiability_b182490b-ccc1-47e1-849b-c3afc80d3605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3fb090c3-ff5f-489d-8dec-ec9bbb784b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_240fa129-086a-4be6-a6ba-b29dae24ff19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3fb090c3-ff5f-489d-8dec-ec9bbb784b3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails_1" xlink:type="simple" xlink:href="morf-20221231.xsd#LeasesMaturitiesofleasecommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89e222de-ed92-4d64-95e6-7677bdf85c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1f60f19a-f5eb-4160-a844-aff299a65815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89e222de-ed92-4d64-95e6-7677bdf85c90" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1f60f19a-f5eb-4160-a844-aff299a65815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e0eb85aa-96c7-42b6-8371-51615a594b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89e222de-ed92-4d64-95e6-7677bdf85c90" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e0eb85aa-96c7-42b6-8371-51615a594b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0c4dc0a6-fad5-4206-a31a-da5f5e355b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89e222de-ed92-4d64-95e6-7677bdf85c90" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0c4dc0a6-fad5-4206-a31a-da5f5e355b4f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3eae0ca6-e24d-4a24-84b8-01a0ed9f2a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_591058ec-9338-4995-865d-317a300e8386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3eae0ca6-e24d-4a24-84b8-01a0ed9f2a43" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_591058ec-9338-4995-865d-317a300e8386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_eb4220f4-3726-4e07-93af-d1d502de7270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3eae0ca6-e24d-4a24-84b8-01a0ed9f2a43" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_eb4220f4-3726-4e07-93af-d1d502de7270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AccruedResearchAndDevelopment_cc1eb6de-6183-401a-a65e-5b5178e1df27" xlink:href="morf-20221231.xsd#morf_AccruedResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3eae0ca6-e24d-4a24-84b8-01a0ed9f2a43" xlink:to="loc_morf_AccruedResearchAndDevelopment_cc1eb6de-6183-401a-a65e-5b5178e1df27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_de053265-a1e0-4e0b-b953-5e9e02289de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3eae0ca6-e24d-4a24-84b8-01a0ed9f2a43" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_de053265-a1e0-4e0b-b953-5e9e02289de5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesComponentsoflossbeforeincometaxesDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_a3ee8f92-f686-4f39-a81f-ff1a2953ae46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_dbb2801a-168a-4545-9de5-110bb640b050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_a3ee8f92-f686-4f39-a81f-ff1a2953ae46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_dbb2801a-168a-4545-9de5-110bb640b050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d91187ec-15e7-4bf3-a5c4-84a01c7064ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_a3ee8f92-f686-4f39-a81f-ff1a2953ae46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d91187ec-15e7-4bf3-a5c4-84a01c7064ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesComponentsofincometaxDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2ade0121-a362-4fe8-a96c-dd4994d446a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2a04fa28-2d16-4159-ac78-21a8361eca3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2ade0121-a362-4fe8-a96c-dd4994d446a4" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2a04fa28-2d16-4159-ac78-21a8361eca3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_627415e1-79b8-441f-87ca-718b477ebd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2ade0121-a362-4fe8-a96c-dd4994d446a4" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_627415e1-79b8-441f-87ca-718b477ebd49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_bbe4f9f0-c89a-40c3-b4de-72eeddfd7849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2ade0121-a362-4fe8-a96c-dd4994d446a4" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_bbe4f9f0-c89a-40c3-b4de-72eeddfd7849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_066f7735-bbe7-47cc-bcf8-0a4c3953aeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_030c105a-9b98-4696-ac26-0c1ff91a5ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_066f7735-bbe7-47cc-bcf8-0a4c3953aeb9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_030c105a-9b98-4696-ac26-0c1ff91a5ba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af3ab82b-f937-43b9-9646-e97370f04fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_066f7735-bbe7-47cc-bcf8-0a4c3953aeb9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af3ab82b-f937-43b9-9646-e97370f04fa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6a297ee9-7a30-42e8-8e38-397456e9aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3911685a-4f7e-456d-bf6d-44a239c15b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6a297ee9-7a30-42e8-8e38-397456e9aa1f" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3911685a-4f7e-456d-bf6d-44a239c15b81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_049ff497-a486-4e6d-8a90-a446dbd91457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6a297ee9-7a30-42e8-8e38-397456e9aa1f" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_049ff497-a486-4e6d-8a90-a446dbd91457" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9fb6a3bc-4ace-4e91-8ff1-b26ca4e0a223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6a297ee9-7a30-42e8-8e38-397456e9aa1f" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9fb6a3bc-4ace-4e91-8ff1-b26ca4e0a223" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesEffectiveincometaxrateDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63ade9b4-086a-4caf-b0ae-e3cd23e870d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_a6136751-8331-4ce4-b58d-38733525da16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63ade9b4-086a-4caf-b0ae-e3cd23e870d9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_a6136751-8331-4ce4-b58d-38733525da16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_74548025-5e3a-4fba-ba0e-ecb5eb60b510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63ade9b4-086a-4caf-b0ae-e3cd23e870d9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_74548025-5e3a-4fba-ba0e-ecb5eb60b510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_37a7b3f0-fe78-4056-adef-4759a2f9e847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63ade9b4-086a-4caf-b0ae-e3cd23e870d9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_37a7b3f0-fe78-4056-adef-4759a2f9e847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_55b45301-1ce3-4d4c-94aa-5d0cff6acba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63ade9b4-086a-4caf-b0ae-e3cd23e870d9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_55b45301-1ce3-4d4c-94aa-5d0cff6acba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_14dee654-0d06-4097-9f45-2a3ea8154551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63ade9b4-086a-4caf-b0ae-e3cd23e870d9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_14dee654-0d06-4097-9f45-2a3ea8154551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a6e182e9-b419-4e6b-b667-09f3baef9348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63ade9b4-086a-4caf-b0ae-e3cd23e870d9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a6e182e9-b419-4e6b-b667-09f3baef9348" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesDeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_27006c14-b3da-468c-bf39-d3a1ec3dbe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_15645ea1-5401-4839-8282-6092e59f3525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_27006c14-b3da-468c-bf39-d3a1ec3dbe7c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_15645ea1-5401-4839-8282-6092e59f3525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fa182482-d8ac-4461-b49e-d8b27e3bb4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_27006c14-b3da-468c-bf39-d3a1ec3dbe7c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fa182482-d8ac-4461-b49e-d8b27e3bb4be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_160b2d31-f48e-47c3-8412-effa7aee9fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d1e85730-1a86-4c32-b776-1740f740e08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_160b2d31-f48e-47c3-8412-effa7aee9fe1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d1e85730-1a86-4c32-b776-1740f740e08f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_18e198c4-1113-47a2-8dce-5f9b5f4c9d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_160b2d31-f48e-47c3-8412-effa7aee9fe1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_18e198c4-1113-47a2-8dce-5f9b5f4c9d74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_DeferredTaxAssetLeaseLiabilities_042f10e2-45e2-4a5e-96b6-2c8b6a427377" xlink:href="morf-20221231.xsd#morf_DeferredTaxAssetLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_160b2d31-f48e-47c3-8412-effa7aee9fe1" xlink:to="loc_morf_DeferredTaxAssetLeaseLiabilities_042f10e2-45e2-4a5e-96b6-2c8b6a427377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_73c2f48f-2f0c-49b0-9b59-dd9eb90156ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_160b2d31-f48e-47c3-8412-effa7aee9fe1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_73c2f48f-2f0c-49b0-9b59-dd9eb90156ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_61095dee-c63b-422a-b73c-6016c4f2ade7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_160b2d31-f48e-47c3-8412-effa7aee9fe1" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_61095dee-c63b-422a-b73c-6016c4f2ade7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_12c764ad-e9b7-4c74-bdc7-86269f3f1bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_160b2d31-f48e-47c3-8412-effa7aee9fe1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_12c764ad-e9b7-4c74-bdc7-86269f3f1bbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_DeferredTaxAssetsFixedAndIntangibleAssets_fe24ffab-4f0c-4d55-8fa9-da0cb10917f7" xlink:href="morf-20221231.xsd#morf_DeferredTaxAssetsFixedAndIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_160b2d31-f48e-47c3-8412-effa7aee9fe1" xlink:to="loc_morf_DeferredTaxAssetsFixedAndIntangibleAssets_fe24ffab-4f0c-4d55-8fa9-da0cb10917f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_b58f01cc-f7ee-4e3a-b180-7449c42f72a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_160b2d31-f48e-47c3-8412-effa7aee9fe1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_b58f01cc-f7ee-4e3a-b180-7449c42f72a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_570f88bd-1c28-466e-9620-6335ec5c201a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ca836a64-ecee-40cb-bb15-3124fac81b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_570f88bd-1c28-466e-9620-6335ec5c201a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ca836a64-ecee-40cb-bb15-3124fac81b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_65872502-7d87-48fa-9b00-b0c34e3982d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_570f88bd-1c28-466e-9620-6335ec5c201a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_65872502-7d87-48fa-9b00-b0c34e3982d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_ee17f701-333e-4c11-8e0c-899fd2a9f18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_570f88bd-1c28-466e-9620-6335ec5c201a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_ee17f701-333e-4c11-8e0c-899fd2a9f18d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_cb055978-33c5-4ed2-92bc-ff99c088fe80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_570f88bd-1c28-466e-9620-6335ec5c201a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_cb055978-33c5-4ed2-92bc-ff99c088fe80" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>morf-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3504fb1d-c703-4af8-962a-40bb538fa93a,g:d0f79058-117f-4d7c-9741-2cac766e63e2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i29a3fe5928a24714ab857138fe5f7004_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_664b10bb-3c9d-4ca3-935c-7b15ebd77a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_664b10bb-3c9d-4ca3-935c-7b15ebd77a8d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_06be76a8-842b-42ae-95c0-33de8ddcc3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_SharesOutstanding_06be76a8-842b-42ae-95c0-33de8ddcc3b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_479f3f48-950e-40e7-b265-5e036a8f35e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockholdersEquity_479f3f48-950e-40e7-b265-5e036a8f35e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_4e97f53f-7fdc-41cf-bb60-33b78f1f60f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_4e97f53f-7fdc-41cf-bb60-33b78f1f60f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_824f0bec-33ce-4565-92ea-947fedfab883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_824f0bec-33ce-4565-92ea-947fedfab883" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b60f7bd5-ae14-450f-95ea-f6b0e371e849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b60f7bd5-ae14-450f-95ea-f6b0e371e849" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1a21209e-3c76-4337-afac-a6638229b669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1a21209e-3c76-4337-afac-a6638229b669" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_7ce8d45b-f14e-4443-990b-830fc1f73d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_7ce8d45b-f14e-4443-990b-830fc1f73d28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_8aeaf679-e91d-4252-b658-644dcfc7a564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_8aeaf679-e91d-4252-b658-644dcfc7a564" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5e66aa3-1cc2-4e40-8c96-00b18e947a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5e66aa3-1cc2-4e40-8c96-00b18e947a04" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d6886a20-b0a3-4ff2-b562-66cc60894cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d6886a20-b0a3-4ff2-b562-66cc60894cf9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f7ad7b95-c912-4024-91f4-1c5024dcf39d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f7ad7b95-c912-4024-91f4-1c5024dcf39d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_379b670a-a503-4ef4-8012-cc726c17aac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_NetIncomeLoss_379b670a-a503-4ef4-8012-cc726c17aac9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a207efd2-1fb7-4b09-b75a-606675e13888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0f394d5b-4158-4276-bfe2-f8a29e45bfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3a523b36-e880-4521-a879-90b33e9e2eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_664b10bb-3c9d-4ca3-935c-7b15ebd77a8d" xlink:to="loc_us-gaap_StatementTable_3a523b36-e880-4521-a879-90b33e9e2eb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8dec71f3-9163-499b-abd1-27b66cc36dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3a523b36-e880-4521-a879-90b33e9e2eb9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8dec71f3-9163-499b-abd1-27b66cc36dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8dec71f3-9163-499b-abd1-27b66cc36dbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8dec71f3-9163-499b-abd1-27b66cc36dbf" xlink:to="loc_us-gaap_EquityComponentDomain_8dec71f3-9163-499b-abd1-27b66cc36dbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8dec71f3-9163-499b-abd1-27b66cc36dbf" xlink:to="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_65749216-c6bf-4cad-bda4-04bdffe5c68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:to="loc_us-gaap_CommonStockMember_65749216-c6bf-4cad-bda4-04bdffe5c68f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ae3f28ad-9e62-45fb-a052-84e43ea42d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ae3f28ad-9e62-45fb-a052-84e43ea42d02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a7b8609a-2ae2-45cd-b980-84fb0e6fe166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:to="loc_us-gaap_RetainedEarningsMember_a7b8609a-2ae2-45cd-b980-84fb0e6fe166" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f81799d5-fb1a-4c4e-901b-c262f560c1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f81799d5-fb1a-4c4e-901b-c262f560c1af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7f8e7c72-e805-4c1e-82d4-47235cf95819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3a523b36-e880-4521-a879-90b33e9e2eb9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7f8e7c72-e805-4c1e-82d4-47235cf95819" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f8e7c72-e805-4c1e-82d4-47235cf95819_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7f8e7c72-e805-4c1e-82d4-47235cf95819" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f8e7c72-e805-4c1e-82d4-47235cf95819_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6483bc42-8f89-493d-ba54-44056efc6629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7f8e7c72-e805-4c1e-82d4-47235cf95819" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6483bc42-8f89-493d-ba54-44056efc6629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_8416f2ec-fa60-4da5-9b38-c63c10a42aa8" xlink:href="morf-20221231.xsd#morf_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6483bc42-8f89-493d-ba54-44056efc6629" xlink:to="loc_morf_AtTheMarketOfferingMember_8416f2ec-fa60-4da5-9b38-c63c10a42aa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_1663e9a2-14cf-488f-a676-9437da26a2d5" xlink:href="morf-20221231.xsd#morf_SecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6483bc42-8f89-493d-ba54-44056efc6629" xlink:to="loc_morf_SecondaryOfferingMember_1663e9a2-14cf-488f-a676-9437da26a2d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="idf84f9d8ea8245e1a12adeeb8224646e_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_21e7ff56-b3c1-446e-ad33-42ae85c4f073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_efe249f0-ef5f-43c1-822c-ee87446567d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21e7ff56-b3c1-446e-ad33-42ae85c4f073" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_efe249f0-ef5f-43c1-822c-ee87446567d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ca2efb81-2b59-43f8-b7b2-45ed5ef7b588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_21e7ff56-b3c1-446e-ad33-42ae85c4f073" xlink:to="loc_us-gaap_StatementTable_ca2efb81-2b59-43f8-b7b2-45ed5ef7b588" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d7cd93d5-2eac-42d8-9516-e1567a66197d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ca2efb81-2b59-43f8-b7b2-45ed5ef7b588" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d7cd93d5-2eac-42d8-9516-e1567a66197d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d7cd93d5-2eac-42d8-9516-e1567a66197d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d7cd93d5-2eac-42d8-9516-e1567a66197d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d7cd93d5-2eac-42d8-9516-e1567a66197d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6252776b-f3b0-474a-a080-d5e20c454033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d7cd93d5-2eac-42d8-9516-e1567a66197d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6252776b-f3b0-474a-a080-d5e20c454033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_54770528-1938-416d-a34e-9808573ed107" xlink:href="morf-20221231.xsd#morf_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6252776b-f3b0-474a-a080-d5e20c454033" xlink:to="loc_morf_AtTheMarketOfferingMember_54770528-1938-416d-a34e-9808573ed107" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_4f42a152-5ac5-4809-82f6-f6a511c1e266" xlink:href="morf-20221231.xsd#morf_SecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6252776b-f3b0-474a-a080-d5e20c454033" xlink:to="loc_morf_SecondaryOfferingMember_4f42a152-5ac5-4809-82f6-f6a511c1e266" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ic15dc82eeea3457b9f2d55150b715565_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fef9137b-062c-49b8-8a56-c1c29b8377a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:to="loc_us-gaap_ProfitLoss_fef9137b-062c-49b8-8a56-c1c29b8377a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_fc1820b3-d6d9-422c-9121-64ca967d04e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_DepreciationAndAmortization_fc1820b3-d6d9-422c-9121-64ca967d04e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4625f81a-4644-4926-8f18-03a638198504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4625f81a-4644-4926-8f18-03a638198504" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_78876594-4f07-47fa-9e0b-2ccfe670aef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_ShareBasedCompensation_78876594-4f07-47fa-9e0b-2ccfe670aef6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_0eb60e2d-f7b9-4568-97bd-aa7b9a45e4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_0eb60e2d-f7b9-4568-97bd-aa7b9a45e4b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_28b50e79-4584-461d-b568-228d70660153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_28b50e79-4584-461d-b568-228d70660153" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5b01d085-6f9e-4419-a6e5-a12b73a78986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5b01d085-6f9e-4419-a6e5-a12b73a78986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c00fc2cc-0dd2-439a-bea2-5c28e57f512e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c00fc2cc-0dd2-439a-bea2-5c28e57f512e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_afdc9250-82e9-450c-9222-de297263b80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_afdc9250-82e9-450c-9222-de297263b80d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets_e3bc8e13-e6c6-442d-a7a3-77b54e944d26" xlink:href="morf-20221231.xsd#morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets_e3bc8e13-e6c6-442d-a7a3-77b54e944d26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5fc36561-be1a-4685-81bc-23410c82384e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5fc36561-be1a-4685-81bc-23410c82384e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c793b955-914b-46a8-b6ac-65f0ff123a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c793b955-914b-46a8-b6ac-65f0ff123a91" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_4dddbde3-f6e8-41ca-92c5-9a2c956a25b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_4dddbde3-f6e8-41ca-92c5-9a2c956a25b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseInDeferredRent_42c7875d-9744-41c4-8280-f7df64ac1eae" xlink:href="morf-20221231.xsd#morf_IncreaseDecreaseInDeferredRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_morf_IncreaseDecreaseInDeferredRent_42c7875d-9744-41c4-8280-f7df64ac1eae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c43181dc-0be2-44ed-8227-9e0e5a6a2191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c43181dc-0be2-44ed-8227-9e0e5a6a2191" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58b06a29-df35-413d-8f94-9ae9aec1ab65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58b06a29-df35-413d-8f94-9ae9aec1ab65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dedee062-a8c5-46cd-8b7e-7928f446fbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dedee062-a8c5-46cd-8b7e-7928f446fbf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_41612a4f-f675-48c5-b1cd-95a2daa431c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_41612a4f-f675-48c5-b1cd-95a2daa431c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6059646d-256d-4fd9-a3ff-eb4fd2f4c1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6059646d-256d-4fd9-a3ff-eb4fd2f4c1c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a3dfacf-3027-453c-892c-35c8fa292e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a3dfacf-3027-453c-892c-35c8fa292e19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1b70faa-2653-4c4b-bd77-7606c19618f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1b70faa-2653-4c4b-bd77-7606c19618f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_5afc3379-a257-4840-990f-322ba801bc55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:to="loc_us-gaap_ProceedsFromStockPlans_5afc3379-a257-4840-990f-322ba801bc55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b25e332e-da88-49c6-9983-7a01222bab76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b25e332e-da88-49c6-9983-7a01222bab76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_96291ef2-7a51-499c-b06e-1c01b1c0e04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_96291ef2-7a51-499c-b06e-1c01b1c0e04f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d13db87-0e8c-4c84-ba35-dc16664534d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d13db87-0e8c-4c84-ba35-dc16664534d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a9f25d0-4477-4b4c-883c-fc7d0013f7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a9f25d0-4477-4b4c-883c-fc7d0013f7d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce0607b4-f289-4fcd-a13e-e3e5f1570e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce0607b4-f289-4fcd-a13e-e3e5f1570e15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcc1f3ad-e291-4f22-8c43-36952b26158a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_54cc0dc0-0a5e-43f1-a27d-b8e84b2cb25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_54cc0dc0-0a5e-43f1-a27d-b8e84b2cb25e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9e79c6ba-b792-4761-8c8c-91e733afeadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9e79c6ba-b792-4761-8c8c-91e733afeadc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2a6ed651-62ac-476e-aaa9-0409e04eacdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2a6ed651-62ac-476e-aaa9-0409e04eacdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c1127085-170a-49f3-a99c-7ab090014eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c1127085-170a-49f3-a99c-7ab090014eda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_03693470-8cc9-494a-b9a0-515226d5b6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_03693470-8cc9-494a-b9a0-515226d5b6b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_ecd9a12b-21b8-47e7-98a3-e8901200bcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_03693470-8cc9-494a-b9a0-515226d5b6b9" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_ecd9a12b-21b8-47e7-98a3-e8901200bcb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f685c59a-7c1d-4dba-93f6-c435651ec745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_StatementTable_f685c59a-7c1d-4dba-93f6-c435651ec745" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86c9b4cc-43a8-4a49-bae6-8c9ac173d0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f685c59a-7c1d-4dba-93f6-c435651ec745" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86c9b4cc-43a8-4a49-bae6-8c9ac173d0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86c9b4cc-43a8-4a49-bae6-8c9ac173d0a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86c9b4cc-43a8-4a49-bae6-8c9ac173d0a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86c9b4cc-43a8-4a49-bae6-8c9ac173d0a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff369b45-0ce0-485b-b765-a0eedade4537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86c9b4cc-43a8-4a49-bae6-8c9ac173d0a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff369b45-0ce0-485b-b765-a0eedade4537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_d02adf08-47b9-4de3-a9bf-f90bfa57e747" xlink:href="morf-20221231.xsd#morf_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff369b45-0ce0-485b-b765-a0eedade4537" xlink:to="loc_morf_AtTheMarketOfferingMember_d02adf08-47b9-4de3-a9bf-f90bfa57e747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_af9eae88-1d83-4ec3-9d5a-89ddf74972ed" xlink:href="morf-20221231.xsd#morf_SecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff369b45-0ce0-485b-b765-a0eedade4537" xlink:to="loc_morf_SecondaryOfferingMember_af9eae88-1d83-4ec3-9d5a-89ddf74972ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/NatureoftheBusinessDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#NatureoftheBusinessDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/NatureoftheBusinessDetails" xlink:type="extended" id="i912d61977f40486a8595ff26f299a332_NatureoftheBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_854b5640-8e28-4538-a082-f5000a10a62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_854b5640-8e28-4538-a082-f5000a10a62e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_PercentageOfCommissionOnGrossSaleProceeds_11462649-0a8c-4c8d-910d-fe58dcf0d79f" xlink:href="morf-20221231.xsd#morf_PercentageOfCommissionOnGrossSaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_morf_PercentageOfCommissionOnGrossSaleProceeds_11462649-0a8c-4c8d-910d-fe58dcf0d79f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aaa1784e-d906-4c81-89a5-89c0aa16a5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aaa1784e-d906-4c81-89a5-89c0aa16a5ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6c9fb952-1a23-4ff8-bea6-cfbdd0dc60ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6c9fb952-1a23-4ff8-bea6-cfbdd0dc60ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a4a70cfc-15fa-439b-b1ed-2acee792bbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a4a70cfc-15fa-439b-b1ed-2acee792bbdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CommonStockAvailableForIssuance_c3e0cf7e-1a3b-4e46-9eb2-be3c366fbfe5" xlink:href="morf-20221231.xsd#morf_CommonStockAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_morf_CommonStockAvailableForIssuance_c3e0cf7e-1a3b-4e46-9eb2-be3c366fbfe5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_809ddd73-fad4-4b8d-b779-fdaa26e3a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_809ddd73-fad4-4b8d-b779-fdaa26e3a1fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_252a69bd-8807-4f3d-a49e-3cce2549a66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_252a69bd-8807-4f3d-a49e-3cce2549a66f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4fbaf040-a99e-4776-8a5a-6c236884acd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4fbaf040-a99e-4776-8a5a-6c236884acd9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d2efd33b-6cbb-48ad-a464-d5a39b0da630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d2efd33b-6cbb-48ad-a464-d5a39b0da630" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_dfa6a9b7-a911-4f4a-92ce-0f3104003094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_dfa6a9b7-a911-4f4a-92ce-0f3104003094" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98725791-5f50-4e43-9468-6dc753cfa5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_dfa6a9b7-a911-4f4a-92ce-0f3104003094" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98725791-5f50-4e43-9468-6dc753cfa5b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98725791-5f50-4e43-9468-6dc753cfa5b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98725791-5f50-4e43-9468-6dc753cfa5b7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98725791-5f50-4e43-9468-6dc753cfa5b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397e52a4-0b27-4185-964c-95b0e2eebe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98725791-5f50-4e43-9468-6dc753cfa5b7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397e52a4-0b27-4185-964c-95b0e2eebe6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtMarketOfferingProgramMember_8b6be125-137d-4e02-ab84-7b334d2ff55a" xlink:href="morf-20221231.xsd#morf_AtMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397e52a4-0b27-4185-964c-95b0e2eebe6e" xlink:to="loc_morf_AtMarketOfferingProgramMember_8b6be125-137d-4e02-ab84-7b334d2ff55a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_FollowOnPublicOfferingMember_99bc8619-9652-4694-8e1a-5ed32f6cf09c" xlink:href="morf-20221231.xsd#morf_FollowOnPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397e52a4-0b27-4185-964c-95b0e2eebe6e" xlink:to="loc_morf_FollowOnPublicOfferingMember_99bc8619-9652-4694-8e1a-5ed32f6cf09c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_117ef25f-83da-439c-9e43-b83b691cb984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_dfa6a9b7-a911-4f4a-92ce-0f3104003094" xlink:to="loc_us-gaap_TypeOfArrangementAxis_117ef25f-83da-439c-9e43-b83b691cb984" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_117ef25f-83da-439c-9e43-b83b691cb984_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_117ef25f-83da-439c-9e43-b83b691cb984" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_117ef25f-83da-439c-9e43-b83b691cb984_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6f45b05c-99d2-40be-91eb-34a7f8899e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_117ef25f-83da-439c-9e43-b83b691cb984" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6f45b05c-99d2-40be-91eb-34a7f8899e39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OpenMarketSaleAgreementMember_7a425dfb-d2ca-4aa2-acce-17a208abd248" xlink:href="morf-20221231.xsd#morf_OpenMarketSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6f45b05c-99d2-40be-91eb-34a7f8899e39" xlink:to="loc_morf_OpenMarketSaleAgreementMember_7a425dfb-d2ca-4aa2-acce-17a208abd248" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i2b4f0256af3949038c159bc4e26ab255_BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsUnderManagementCarryingAmount_94e488a7-7607-4397-99bb-d8318b930d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsUnderManagementCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_AssetsUnderManagementCarryingAmount_94e488a7-7607-4397-99bb-d8318b930d64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_dfa88ff7-4ac6-45c0-b15c-3f291ea038f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_dfa88ff7-4ac6-45c0-b15c-3f291ea038f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_209cdfe0-115a-417b-9b99-01abcbfab27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_209cdfe0-115a-417b-9b99-01abcbfab27b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e47c8723-9c2e-4028-8737-fc3d7e513a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e47c8723-9c2e-4028-8737-fc3d7e513a30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6c9f1264-8cb6-4ea2-9a46-567c192d681b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6c9f1264-8cb6-4ea2-9a46-567c192d681b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborationAgreementNumberOfAgreements_fca20fa8-8d01-45a7-8c5a-ba1036e57899" xlink:href="morf-20221231.xsd#morf_CollaborationAgreementNumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_morf_CollaborationAgreementNumberOfAgreements_fca20fa8-8d01-45a7-8c5a-ba1036e57899" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_da08d98c-8c48-4d34-8f1e-da1cd7660094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_da08d98c-8c48-4d34-8f1e-da1cd7660094" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7dba6a4e-35f1-49f3-9002-9421239769ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7dba6a4e-35f1-49f3-9002-9421239769ed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction_0212a06c-338b-4576-ac40-cf9862114448" xlink:href="morf-20221231.xsd#morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction_0212a06c-338b-4576-ac40-cf9862114448" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction_6d3de7b2-45b0-4fd8-8a10-5f772ce92b18" xlink:href="morf-20221231.xsd#morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction_6d3de7b2-45b0-4fd8-8a10-5f772ce92b18" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3d071c37-b96e-4617-bc9e-00eb856373ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3d071c37-b96e-4617-bc9e-00eb856373ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_00a4ddef-a02c-4ac0-ad92-a30d4d21d82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_00a4ddef-a02c-4ac0-ad92-a30d4d21d82f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_f4ec2b7c-e1a2-4629-a592-73219661b6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_f4ec2b7c-e1a2-4629-a592-73219661b6bb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1411bb7-c873-4003-a54a-8a11289d3d08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:to="loc_srt_RangeAxis_b1411bb7-c873-4003-a54a-8a11289d3d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1411bb7-c873-4003-a54a-8a11289d3d08_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1411bb7-c873-4003-a54a-8a11289d3d08" xlink:to="loc_srt_RangeMember_b1411bb7-c873-4003-a54a-8a11289d3d08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26d3ee14-f907-40b9-aa5f-a8c07164cbdc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1411bb7-c873-4003-a54a-8a11289d3d08" xlink:to="loc_srt_RangeMember_26d3ee14-f907-40b9-aa5f-a8c07164cbdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bace3ba2-766d-44aa-82a7-6dc800bb7419" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_26d3ee14-f907-40b9-aa5f-a8c07164cbdc" xlink:to="loc_srt_MinimumMember_bace3ba2-766d-44aa-82a7-6dc800bb7419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d1d4b82c-d12b-4031-9670-c3870bf26655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d1d4b82c-d12b-4031-9670-c3870bf26655" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d1d4b82c-d12b-4031-9670-c3870bf26655_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d1d4b82c-d12b-4031-9670-c3870bf26655" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d1d4b82c-d12b-4031-9670-c3870bf26655_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_93391815-7e38-4c35-9a10-279fce528366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d1d4b82c-d12b-4031-9670-c3870bf26655" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_93391815-7e38-4c35-9a10-279fce528366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bceb5e0a-1d7d-4656-a5a4-158de3971df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_93391815-7e38-4c35-9a10-279fce528366" xlink:to="loc_us-gaap_SubsequentEventMember_bceb5e0a-1d7d-4656-a5a4-158de3971df8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bb106247-cdd7-4d49-aba4-23089adc4b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bb106247-cdd7-4d49-aba4-23089adc4b98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb106247-cdd7-4d49-aba4-23089adc4b98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bb106247-cdd7-4d49-aba4-23089adc4b98" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb106247-cdd7-4d49-aba4-23089adc4b98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef5cf639-c6b8-45c8-a749-cc449d9d67d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bb106247-cdd7-4d49-aba4-23089adc4b98" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef5cf639-c6b8-45c8-a749-cc449d9d67d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_91bcdaa6-2145-4181-8d00-a9888c19b750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef5cf639-c6b8-45c8-a749-cc449d9d67d7" xlink:to="loc_us-gaap_PrivatePlacementMember_91bcdaa6-2145-4181-8d00-a9888c19b750" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails" xlink:type="extended" id="i63412334e15f42aa84bd7f10f2fe85b8_BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f631e996-eca5-4459-967b-45a0b1fb5959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_af97123a-e57d-4e1e-a930-cf1abedc5e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f631e996-eca5-4459-967b-45a0b1fb5959" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_af97123a-e57d-4e1e-a930-cf1abedc5e4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb3634a-786c-45ca-8b6f-1a39e2ba9e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f631e996-eca5-4459-967b-45a0b1fb5959" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb3634a-786c-45ca-8b6f-1a39e2ba9e5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc0e30ca-229b-4d8d-ba41-5c71f08a70e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb3634a-786c-45ca-8b6f-1a39e2ba9e5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc0e30ca-229b-4d8d-ba41-5c71f08a70e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cc0e30ca-229b-4d8d-ba41-5c71f08a70e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc0e30ca-229b-4d8d-ba41-5c71f08a70e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cc0e30ca-229b-4d8d-ba41-5c71f08a70e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d36928b5-8b40-488b-812d-091bfad561ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc0e30ca-229b-4d8d-ba41-5c71f08a70e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d36928b5-8b40-488b-812d-091bfad561ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_3d502879-7e60-4a18-82d2-3cdce4232358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d36928b5-8b40-488b-812d-091bfad561ca" xlink:to="loc_us-gaap_EquipmentMember_3d502879-7e60-4a18-82d2-3cdce4232358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ComputerEquipmentAndSoftwareMember_8585eed1-2745-462a-ab48-900ad91c27bc" xlink:href="morf-20221231.xsd#morf_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d36928b5-8b40-488b-812d-091bfad561ca" xlink:to="loc_morf_ComputerEquipmentAndSoftwareMember_8585eed1-2745-462a-ab48-900ad91c27bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_25de5dbd-9477-4db3-b647-94330f8c61c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb3634a-786c-45ca-8b6f-1a39e2ba9e5f" xlink:to="loc_srt_RangeAxis_25de5dbd-9477-4db3-b647-94330f8c61c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_25de5dbd-9477-4db3-b647-94330f8c61c0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_25de5dbd-9477-4db3-b647-94330f8c61c0" xlink:to="loc_srt_RangeMember_25de5dbd-9477-4db3-b647-94330f8c61c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4db221e2-3824-47cb-928f-849af51a8a9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_25de5dbd-9477-4db3-b647-94330f8c61c0" xlink:to="loc_srt_RangeMember_4db221e2-3824-47cb-928f-849af51a8a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_33c71743-e648-4a72-b856-e66fc3218e58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4db221e2-3824-47cb-928f-849af51a8a9f" xlink:to="loc_srt_MinimumMember_33c71743-e648-4a72-b856-e66fc3218e58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b14cbd0-14c6-453f-a9b9-39b660aced32" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4db221e2-3824-47cb-928f-849af51a8a9f" xlink:to="loc_srt_MaximumMember_2b14cbd0-14c6-453f-a9b9-39b660aced32" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#FairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="i0ee0ff79a19b40d9b14c0f0abd30c9a8_FairValueofFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c9f6e3ed-dae3-4c4c-bc29-da797cc00af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c9f6e3ed-dae3-4c4c-bc29-da797cc00af0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f9da26b0-808f-4154-ba47-9ba6ae8652c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f9da26b0-808f-4154-ba47-9ba6ae8652c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bf23758-4813-477c-9d02-1616c2342958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bf23758-4813-477c-9d02-1616c2342958" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2d308c14-115b-49de-ac09-b86424115221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2d308c14-115b-49de-ac09-b86424115221" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_d9e13b76-ac94-4f75-b005-4693c248eaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c9f6e3ed-dae3-4c4c-bc29-da797cc00af0" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_d9e13b76-ac94-4f75-b005-4693c248eaca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c9f6e3ed-dae3-4c4c-bc29-da797cc00af0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_852ab8db-bf25-4f32-9a98-ff8ea1fac7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_852ab8db-bf25-4f32-9a98-ff8ea1fac7c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_852ab8db-bf25-4f32-9a98-ff8ea1fac7c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_852ab8db-bf25-4f32-9a98-ff8ea1fac7c5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_852ab8db-bf25-4f32-9a98-ff8ea1fac7c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_95007fd2-9da9-4a92-b792-e715d523db43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_852ab8db-bf25-4f32-9a98-ff8ea1fac7c5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_95007fd2-9da9-4a92-b792-e715d523db43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cb80109d-9809-4092-b0cb-28e3feef9b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_95007fd2-9da9-4a92-b792-e715d523db43" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cb80109d-9809-4092-b0cb-28e3feef9b05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_611cdc64-3d87-4c5f-b29b-8ee4ad96200b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_611cdc64-3d87-4c5f-b29b-8ee4ad96200b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_611cdc64-3d87-4c5f-b29b-8ee4ad96200b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_611cdc64-3d87-4c5f-b29b-8ee4ad96200b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_611cdc64-3d87-4c5f-b29b-8ee4ad96200b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_611cdc64-3d87-4c5f-b29b-8ee4ad96200b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_316f4bb2-b04a-4554-90b9-8cfd3c219c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_316f4bb2-b04a-4554-90b9-8cfd3c219c96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_69144a2c-9969-471f-80fa-9daeed00cbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_69144a2c-9969-471f-80fa-9daeed00cbb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7212aaba-a7e4-455f-8881-3618e181e25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7212aaba-a7e4-455f-8881-3618e181e25a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2c637c09-45af-46aa-9cf9-dee362582c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2c637c09-45af-46aa-9cf9-dee362582c7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2c637c09-45af-46aa-9cf9-dee362582c7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2c637c09-45af-46aa-9cf9-dee362582c7f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2c637c09-45af-46aa-9cf9-dee362582c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0c336543-22a9-4641-862f-5089664b8e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2c637c09-45af-46aa-9cf9-dee362582c7f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0c336543-22a9-4641-862f-5089664b8e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_afa1198d-acc4-41cf-a04d-6bdec034b27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0c336543-22a9-4641-862f-5089664b8e5d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_afa1198d-acc4-41cf-a04d-6bdec034b27c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d6f3e621-c5aa-45c5-9d2f-3ead7ad7f783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d6f3e621-c5aa-45c5-9d2f-3ead7ad7f783" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6f3e621-c5aa-45c5-9d2f-3ead7ad7f783_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d6f3e621-c5aa-45c5-9d2f-3ead7ad7f783" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6f3e621-c5aa-45c5-9d2f-3ead7ad7f783_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d6f3e621-c5aa-45c5-9d2f-3ead7ad7f783" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bf821f31-d056-4987-89d8-4611d3880a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bf821f31-d056-4987-89d8-4611d3880a6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_b4da7dff-901f-468f-9066-3843e351a4a0" xlink:href="morf-20221231.xsd#morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:to="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_b4da7dff-901f-468f-9066-3843e351a4a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bc5920f1-01a1-47eb-b6a8-3e551ffe2648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:to="loc_us-gaap_CommercialPaperMember_bc5920f1-01a1-47eb-b6a8-3e551ffe2648" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7f6e873e-2513-45a3-8722-d97218dab4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7f6e873e-2513-45a3-8722-d97218dab4c0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#MarketablesecuritiesDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="extended" id="i37bf51bdae9d434cb1b60f7f8686f3b3_MarketablesecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6ee833ef-9ba4-4072-a66f-69cb4c8d4daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6ee833ef-9ba4-4072-a66f-69cb4c8d4daa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_386ebd4d-3469-4fe4-be75-91d81e2cf643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_386ebd4d-3469-4fe4-be75-91d81e2cf643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c5eacd50-a56f-4d79-a701-1222bf96be1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c5eacd50-a56f-4d79-a701-1222bf96be1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_030eee29-3153-4cae-a047-180dfb308f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_030eee29-3153-4cae-a047-180dfb308f0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_79afadf3-f168-4486-aa4a-2aaa71d9ab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_79afadf3-f168-4486-aa4a-2aaa71d9ab6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_2b62166a-a9e0-48ae-9a04-ac7c69094956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6ee833ef-9ba4-4072-a66f-69cb4c8d4daa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_2b62166a-a9e0-48ae-9a04-ac7c69094956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ec645aca-fc7e-4f81-aa72-045e37515574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6ee833ef-9ba4-4072-a66f-69cb4c8d4daa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ec645aca-fc7e-4f81-aa72-045e37515574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_57c2ba73-19c0-4e22-8206-7cf08ee139b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ec645aca-fc7e-4f81-aa72-045e37515574" xlink:to="loc_us-gaap_FinancialInstrumentAxis_57c2ba73-19c0-4e22-8206-7cf08ee139b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57c2ba73-19c0-4e22-8206-7cf08ee139b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_57c2ba73-19c0-4e22-8206-7cf08ee139b7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57c2ba73-19c0-4e22-8206-7cf08ee139b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_57c2ba73-19c0-4e22-8206-7cf08ee139b7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_77085c53-3660-4755-a6d1-fb170bb88b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_77085c53-3660-4755-a6d1-fb170bb88b7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_d779a5af-4a54-4f94-96f0-500b691320a4" xlink:href="morf-20221231.xsd#morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:to="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_d779a5af-4a54-4f94-96f0-500b691320a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_989709bf-22b6-4f4a-aa55-39a864c5277d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:to="loc_us-gaap_CommercialPaperMember_989709bf-22b6-4f4a-aa55-39a864c5277d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5a21aced-5419-421c-adde-2c71b77b286a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5a21aced-5419-421c-adde-2c71b77b286a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="i7381e6aedf5541d39a933961bcb9e0e6_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2e3fddf9-f237-4dd0-957b-5ca7b4d11f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2e3fddf9-f237-4dd0-957b-5ca7b4d11f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f518fc9b-6705-452a-ad85-fbd328bd6b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f518fc9b-6705-452a-ad85-fbd328bd6b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4dacb52d-16c1-43b3-ac3d-561bef7d1074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4dacb52d-16c1-43b3-ac3d-561bef7d1074" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7eb19c59-ddbb-470f-907b-02924e2f2de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7eb19c59-ddbb-470f-907b-02924e2f2de8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_70f7d22a-014a-432b-90b6-b8b284d7b934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_70f7d22a-014a-432b-90b6-b8b284d7b934" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9eb96446-8b4d-4569-8212-83709f4a611d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_70f7d22a-014a-432b-90b6-b8b284d7b934" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9eb96446-8b4d-4569-8212-83709f4a611d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9eb96446-8b4d-4569-8212-83709f4a611d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9eb96446-8b4d-4569-8212-83709f4a611d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9eb96446-8b4d-4569-8212-83709f4a611d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9eb96446-8b4d-4569-8212-83709f4a611d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_06d77263-f117-4f34-88f5-be3bfa7fdf68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:to="loc_us-gaap_EquipmentMember_06d77263-f117-4f34-88f5-be3bfa7fdf68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ComputerEquipmentAndSoftwareMember_a764c3c3-44ee-4092-9426-21796d90cdcf" xlink:href="morf-20221231.xsd#morf_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:to="loc_morf_ComputerEquipmentAndSoftwareMember_a764c3c3-44ee-4092-9426-21796d90cdcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d2074e70-bdee-4058-9e28-db554d9a4d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d2074e70-bdee-4058-9e28-db554d9a4d06" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i37a08a8f803142afbd6dbc0c07d54a41_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a666d11-3653-4946-b9eb-84be7588d655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_e9cb51cb-554b-4b19-a221-1d29e2e2da29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a666d11-3653-4946-b9eb-84be7588d655" xlink:to="loc_us-gaap_AreaOfLand_e9cb51cb-554b-4b19-a221-1d29e2e2da29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_62f3457f-e966-4429-b08d-b6038cd34ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a666d11-3653-4946-b9eb-84be7588d655" xlink:to="loc_us-gaap_OperatingLeaseExpense_62f3457f-e966-4429-b08d-b6038cd34ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_86082cb0-e018-421e-9281-216c736ce776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a666d11-3653-4946-b9eb-84be7588d655" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_86082cb0-e018-421e-9281-216c736ce776" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_f2dd5941-114b-4116-acaa-4e8e5fbe7682" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_86082cb0-e018-421e-9281-216c736ce776" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_f2dd5941-114b-4116-acaa-4e8e5fbe7682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_f2dd5941-114b-4116-acaa-4e8e5fbe7682_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_f2dd5941-114b-4116-acaa-4e8e5fbe7682" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_f2dd5941-114b-4116-acaa-4e8e5fbe7682_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4778a429-42d6-452a-9a61-79318d9399d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_f2dd5941-114b-4116-acaa-4e8e5fbe7682" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4778a429-42d6-452a-9a61-79318d9399d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OfficeAndLaboratorySpaceMember_44327145-2ad6-4b0d-a478-20de66446d49" xlink:href="morf-20221231.xsd#morf_OfficeAndLaboratorySpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4778a429-42d6-452a-9a61-79318d9399d2" xlink:to="loc_morf_OfficeAndLaboratorySpaceMember_44327145-2ad6-4b0d-a478-20de66446d49" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensation2019equityincentiveplanDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails" xlink:type="extended" id="i54723182be5545608dff94b368cf956d_EquityBasedCompensation2019equityincentiveplanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b5f1cf-6940-4e1b-a63b-1967d1f220e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_036444d1-b298-4663-ad23-f99b41ec4fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b5f1cf-6940-4e1b-a63b-1967d1f220e8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_036444d1-b298-4663-ad23-f99b41ec4fcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af97f693-4a78-4c2f-beb6-4c1e27e0dfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b5f1cf-6940-4e1b-a63b-1967d1f220e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af97f693-4a78-4c2f-beb6-4c1e27e0dfb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4d7fe7e-e70c-421d-a2c0-5ea20da7ddde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b5f1cf-6940-4e1b-a63b-1967d1f220e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4d7fe7e-e70c-421d-a2c0-5ea20da7ddde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_20597835-7d57-4372-a25b-10440a65ac20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4d7fe7e-e70c-421d-a2c0-5ea20da7ddde" xlink:to="loc_us-gaap_PlanNameAxis_20597835-7d57-4372-a25b-10440a65ac20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_20597835-7d57-4372-a25b-10440a65ac20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_20597835-7d57-4372-a25b-10440a65ac20" xlink:to="loc_us-gaap_PlanNameDomain_20597835-7d57-4372-a25b-10440a65ac20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74b9a621-bf88-4b05-9cf5-bac1b50b48c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_20597835-7d57-4372-a25b-10440a65ac20" xlink:to="loc_us-gaap_PlanNameDomain_74b9a621-bf88-4b05-9cf5-bac1b50b48c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_1eef4d35-fe49-44c6-a8da-9419b880d2e6" xlink:href="morf-20221231.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_74b9a621-bf88-4b05-9cf5-bac1b50b48c2" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_1eef4d35-fe49-44c6-a8da-9419b880d2e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationEquitybasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails" xlink:type="extended" id="idf02e44d9edb4ec7a2ee8010b8baade6_EquityBasedCompensationEquitybasedcompensationexpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00079faf-52f5-4cac-9bb3-6bc3a8327229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_49771fd2-b013-47b7-8d44-e17363a6c86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00079faf-52f5-4cac-9bb3-6bc3a8327229" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_49771fd2-b013-47b7-8d44-e17363a6c86f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9faf57f4-675e-4fb8-8add-105cd0cd2f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00079faf-52f5-4cac-9bb3-6bc3a8327229" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9faf57f4-675e-4fb8-8add-105cd0cd2f98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c99ba72-e273-428f-9cab-8d7d74747626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9faf57f4-675e-4fb8-8add-105cd0cd2f98" xlink:to="loc_us-gaap_AwardTypeAxis_7c99ba72-e273-428f-9cab-8d7d74747626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c99ba72-e273-428f-9cab-8d7d74747626_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7c99ba72-e273-428f-9cab-8d7d74747626" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c99ba72-e273-428f-9cab-8d7d74747626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7c99ba72-e273-428f-9cab-8d7d74747626" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_19fad6ea-7780-49e9-aea8-99b752e2baf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_19fad6ea-7780-49e9-aea8-99b752e2baf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_855351b7-adca-4078-867e-f0b7f70db4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:to="loc_us-gaap_RestrictedStockMember_855351b7-adca-4078-867e-f0b7f70db4e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_accdac8c-4faf-44a5-bd87-d625c79e5b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_accdac8c-4faf-44a5-bd87-d625c79e5b02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d8122caa-afe4-4f5c-b3d6-7eb0b4ec9071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:to="loc_us-gaap_EmployeeStockMember_d8122caa-afe4-4f5c-b3d6-7eb0b4ec9071" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3eeb8ed3-b8a8-4435-930f-dce52b3dd115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9faf57f4-675e-4fb8-8add-105cd0cd2f98" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3eeb8ed3-b8a8-4435-930f-dce52b3dd115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3eeb8ed3-b8a8-4435-930f-dce52b3dd115_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3eeb8ed3-b8a8-4435-930f-dce52b3dd115" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3eeb8ed3-b8a8-4435-930f-dce52b3dd115_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_992b0e6f-5643-49d4-a25f-b025fe731fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3eeb8ed3-b8a8-4435-930f-dce52b3dd115" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_992b0e6f-5643-49d4-a25f-b025fe731fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_db36dce1-2999-40c6-882f-cca103bf470d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_992b0e6f-5643-49d4-a25f-b025fe731fa1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_db36dce1-2999-40c6-882f-cca103bf470d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d3697290-48be-4387-b347-5c417ada4a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_992b0e6f-5643-49d4-a25f-b025fe731fa1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d3697290-48be-4387-b347-5c417ada4a0b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationRestrictedcommonstockactivityDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails" xlink:type="extended" id="i44419104b4c949e8af938f964b7340bc_EquityBasedCompensationRestrictedcommonstockactivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b1f8d73e-43f7-4bc9-a540-a5f8546bead3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b1f8d73e-43f7-4bc9-a540-a5f8546bead3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_71aa36b1-fbbf-423d-bda6-45e4449ef949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_71aa36b1-fbbf-423d-bda6-45e4449ef949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e18f149e-6484-4f13-bc6e-2fdef5676e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e18f149e-6484-4f13-bc6e-2fdef5676e8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37ec0655-e141-4ff6-acfb-b2fcd406d7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37ec0655-e141-4ff6-acfb-b2fcd406d7c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2294b9ec-9799-410d-aa2e-b6033614f371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_491a9e4d-b874-4196-959c-d3add0a87743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_491a9e4d-b874-4196-959c-d3add0a87743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4141241c-1f1e-46a7-802f-bee31d1ee262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4141241c-1f1e-46a7-802f-bee31d1ee262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d4031fdd-03ef-4f0c-b3c5-f02b0e68ea73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d4031fdd-03ef-4f0c-b3c5-f02b0e68ea73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_623b65e1-4f62-406b-92e7-1bc91baccfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_623b65e1-4f62-406b-92e7-1bc91baccfcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9e26fb4-c3eb-44c8-b3f2-6bbbe0a37269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ddd628a3-f08a-4dc3-86d5-6ca173d32167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ddd628a3-f08a-4dc3-86d5-6ca173d32167" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_73102d9c-d46e-49c3-a07c-4dd795aced8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_73102d9c-d46e-49c3-a07c-4dd795aced8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_382916f4-b456-49be-b11e-098e3eed5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_382916f4-b456-49be-b11e-098e3eed5fe2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2696e5f3-57a6-4332-a9d3-9bbfa4b22371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_382916f4-b456-49be-b11e-098e3eed5fe2" xlink:to="loc_us-gaap_PlanNameAxis_2696e5f3-57a6-4332-a9d3-9bbfa4b22371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2696e5f3-57a6-4332-a9d3-9bbfa4b22371_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2696e5f3-57a6-4332-a9d3-9bbfa4b22371" xlink:to="loc_us-gaap_PlanNameDomain_2696e5f3-57a6-4332-a9d3-9bbfa4b22371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8b931d46-b02e-4afe-8263-fcfb4a1954a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2696e5f3-57a6-4332-a9d3-9bbfa4b22371" xlink:to="loc_us-gaap_PlanNameDomain_8b931d46-b02e-4afe-8263-fcfb4a1954a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_9f2f8fdd-e300-464a-94d2-42e1fce62386" xlink:href="morf-20221231.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8b931d46-b02e-4afe-8263-fcfb4a1954a0" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_9f2f8fdd-e300-464a-94d2-42e1fce62386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1493eae2-0951-4dfd-b188-c0d5375faade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_382916f4-b456-49be-b11e-098e3eed5fe2" xlink:to="loc_us-gaap_AwardTypeAxis_1493eae2-0951-4dfd-b188-c0d5375faade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1493eae2-0951-4dfd-b188-c0d5375faade_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1493eae2-0951-4dfd-b188-c0d5375faade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1493eae2-0951-4dfd-b188-c0d5375faade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb5af905-e27f-40c8-8337-998f8bac4015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1493eae2-0951-4dfd-b188-c0d5375faade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb5af905-e27f-40c8-8337-998f8bac4015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_09ceb54c-32b0-4fb2-af30-794a7db695a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb5af905-e27f-40c8-8337-998f8bac4015" xlink:to="loc_us-gaap_RestrictedStockMember_09ceb54c-32b0-4fb2-af30-794a7db695a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationRestrictedstockunitsactivityDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails" xlink:type="extended" id="i1b596a17f5fc48b48407690fa6837f0d_EquityBasedCompensationRestrictedstockunitsactivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b0a4c4ad-0047-460d-a236-fa38ed7b2a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b0a4c4ad-0047-460d-a236-fa38ed7b2a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_38669dda-8a0c-4f35-b1a2-964233ee6296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_38669dda-8a0c-4f35-b1a2-964233ee6296" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f7c279fa-fbb0-4061-ace2-68f5dcb9e11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f7c279fa-fbb0-4061-ace2-68f5dcb9e11e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3cd42cc-483e-4cd0-8bce-26a9c454147d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3cd42cc-483e-4cd0-8bce-26a9c454147d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fbfdefd8-664b-420f-833a-ac6d3830418b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e5fd58ec-4257-4c15-9e62-2df14f297643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e5fd58ec-4257-4c15-9e62-2df14f297643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_28f0c9f3-8a42-49a3-8af8-660c8d96024d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_28f0c9f3-8a42-49a3-8af8-660c8d96024d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9219b3a6-3ebb-49a3-96fb-eb74fe9e637d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9219b3a6-3ebb-49a3-96fb-eb74fe9e637d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6c8c587b-87f1-49fa-bf9d-12aa09190904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6c8c587b-87f1-49fa-bf9d-12aa09190904" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9843715-0fd7-448b-aadd-b9e7daedd77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_84d23833-c3fc-4d1b-b5eb-b2e894fe5e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_84d23833-c3fc-4d1b-b5eb-b2e894fe5e6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be42de8a-0277-4ab6-b2bd-dacd91a4af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be42de8a-0277-4ab6-b2bd-dacd91a4af6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_44557a70-2f38-4456-ab6c-a59a6d349321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_44557a70-2f38-4456-ab6c-a59a6d349321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993559b4-162d-49d3-953f-50c55afaca32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993559b4-162d-49d3-953f-50c55afaca32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_76053d25-adcd-4cf7-91eb-45fda93b462f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993559b4-162d-49d3-953f-50c55afaca32" xlink:to="loc_us-gaap_PlanNameAxis_76053d25-adcd-4cf7-91eb-45fda93b462f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_76053d25-adcd-4cf7-91eb-45fda93b462f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_76053d25-adcd-4cf7-91eb-45fda93b462f" xlink:to="loc_us-gaap_PlanNameDomain_76053d25-adcd-4cf7-91eb-45fda93b462f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_380aa657-29f6-42bd-926c-517b37a92c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_76053d25-adcd-4cf7-91eb-45fda93b462f" xlink:to="loc_us-gaap_PlanNameDomain_380aa657-29f6-42bd-926c-517b37a92c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_3c28f673-bf7b-40bd-9d69-455280ec2fde" xlink:href="morf-20221231.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_380aa657-29f6-42bd-926c-517b37a92c4b" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_3c28f673-bf7b-40bd-9d69-455280ec2fde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_59cbdeb8-9dbc-4ab0-be29-4aedee8149b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993559b4-162d-49d3-953f-50c55afaca32" xlink:to="loc_us-gaap_AwardTypeAxis_59cbdeb8-9dbc-4ab0-be29-4aedee8149b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59cbdeb8-9dbc-4ab0-be29-4aedee8149b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_59cbdeb8-9dbc-4ab0-be29-4aedee8149b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59cbdeb8-9dbc-4ab0-be29-4aedee8149b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a05c8d3-2e9c-4f3f-bfff-1fab7fb729d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_59cbdeb8-9dbc-4ab0-be29-4aedee8149b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a05c8d3-2e9c-4f3f-bfff-1fab7fb729d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e36c9993-82bb-4480-8837-fa4a63dc628c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a05c8d3-2e9c-4f3f-bfff-1fab7fb729d6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e36c9993-82bb-4480-8837-fa4a63dc628c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationStockoptionawardsDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails" xlink:type="extended" id="i5baf52fadccd46b8a4e2ed6546f2c218_EquityBasedCompensationStockoptionawardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e3838b74-5163-44b4-81f4-d5a6d4db65d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e3838b74-5163-44b4-81f4-d5a6d4db65d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60f6c7ef-d949-4048-88f8-fd1ec1f38217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60f6c7ef-d949-4048-88f8-fd1ec1f38217" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_59cc14fb-7976-4c34-bed2-dd337851bacd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_59cc14fb-7976-4c34-bed2-dd337851bacd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9309914d-d92f-4f22-8c2f-a085ae15f4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9309914d-d92f-4f22-8c2f-a085ae15f4d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b670a2d7-a24e-4226-8c18-d816982ed450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_680bf40b-0661-4185-9f9e-b2fae77031ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_680bf40b-0661-4185-9f9e-b2fae77031ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_350df418-58d7-4657-aa8f-0226544887fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_350df418-58d7-4657-aa8f-0226544887fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_98a7203f-8494-4892-b137-465dbe4097a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_98a7203f-8494-4892-b137-465dbe4097a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d45c55f3-3794-4848-bdfb-62c88938121b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d45c55f3-3794-4848-bdfb-62c88938121b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c05ab4ee-e555-4f96-ba00-5aa93483141a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c05ab4ee-e555-4f96-ba00-5aa93483141a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e1340d76-a259-4d99-a293-e3bf395e307a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cae8d1ab-76e1-4bed-bf2d-e867183809f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cae8d1ab-76e1-4bed-bf2d-e867183809f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8809c2d9-8c99-4fe8-b733-8171cf30050c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8809c2d9-8c99-4fe8-b733-8171cf30050c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0043ea7b-30ac-4106-9f30-53b1eda01ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0043ea7b-30ac-4106-9f30-53b1eda01ad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6d6f0508-8c4e-490a-830d-8b40386005c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6d6f0508-8c4e-490a-830d-8b40386005c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_62868635-b893-4255-a45a-063f74b44608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_62868635-b893-4255-a45a-063f74b44608" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f8767495-dd0f-4d9b-bbea-7c475f94bae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f8767495-dd0f-4d9b-bbea-7c475f94bae9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27afa4ef-703b-49e6-9c33-dca9294dda85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27afa4ef-703b-49e6-9c33-dca9294dda85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1894f85-defb-4c91-aebd-26b4318495af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1894f85-defb-4c91-aebd-26b4318495af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a243e8bc-9206-41ea-a08d-7871d4f6de52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1894f85-defb-4c91-aebd-26b4318495af" xlink:to="loc_us-gaap_AwardTypeAxis_a243e8bc-9206-41ea-a08d-7871d4f6de52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a243e8bc-9206-41ea-a08d-7871d4f6de52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a243e8bc-9206-41ea-a08d-7871d4f6de52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a243e8bc-9206-41ea-a08d-7871d4f6de52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f92a7686-3e7b-428f-b78e-c158a137830c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a243e8bc-9206-41ea-a08d-7871d4f6de52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f92a7686-3e7b-428f-b78e-c158a137830c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bd5c8048-7a41-4911-95e2-1a17a76ac6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f92a7686-3e7b-428f-b78e-c158a137830c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bd5c8048-7a41-4911-95e2-1a17a76ac6a6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails" xlink:type="extended" id="i153d0118ba7c4719a0eca16db653eb81_EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d34f2c-6153-4127-8d61-9690ab9a8c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d34f2c-6153-4127-8d61-9690ab9a8c05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4ed7d091-5423-4e64-9534-81757d7b05f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4ed7d091-5423-4e64-9534-81757d7b05f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b873b4e-93a4-4145-9b55-2b9ae686be7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b873b4e-93a4-4145-9b55-2b9ae686be7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3938a5cc-650c-438d-b717-cd69d6e3484a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3938a5cc-650c-438d-b717-cd69d6e3484a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1975a6af-677f-484b-ad7a-e8c4ec4d74d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d34f2c-6153-4127-8d61-9690ab9a8c05" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1975a6af-677f-484b-ad7a-e8c4ec4d74d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5911a360-630c-4cac-b005-adbaa28d9ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1975a6af-677f-484b-ad7a-e8c4ec4d74d1" xlink:to="loc_us-gaap_AwardTypeAxis_5911a360-630c-4cac-b005-adbaa28d9ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5911a360-630c-4cac-b005-adbaa28d9ed6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5911a360-630c-4cac-b005-adbaa28d9ed6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5911a360-630c-4cac-b005-adbaa28d9ed6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_457f62a6-721b-4345-a180-c45c29aecf48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5911a360-630c-4cac-b005-adbaa28d9ed6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_457f62a6-721b-4345-a180-c45c29aecf48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f22d4f18-cb31-4ba8-a0e2-bdd6312b24d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_457f62a6-721b-4345-a180-c45c29aecf48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f22d4f18-cb31-4ba8-a0e2-bdd6312b24d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_dd719a5b-d6dd-42dc-a935-646f07131711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1975a6af-677f-484b-ad7a-e8c4ec4d74d1" xlink:to="loc_us-gaap_PlanNameAxis_dd719a5b-d6dd-42dc-a935-646f07131711" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dd719a5b-d6dd-42dc-a935-646f07131711_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_dd719a5b-d6dd-42dc-a935-646f07131711" xlink:to="loc_us-gaap_PlanNameDomain_dd719a5b-d6dd-42dc-a935-646f07131711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9aa2418f-1e20-4639-b2f6-11f2f73e4230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_dd719a5b-d6dd-42dc-a935-646f07131711" xlink:to="loc_us-gaap_PlanNameDomain_9aa2418f-1e20-4639-b2f6-11f2f73e4230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_50e490d8-5f35-4ded-9df9-66a1fea63d4d" xlink:href="morf-20221231.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9aa2418f-1e20-4639-b2f6-11f2f73e4230" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_50e490d8-5f35-4ded-9df9-66a1fea63d4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i2f593e410c9d4128bdaa79c87ecd4ad9_EquityBasedCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f88512b0-174d-4007-93f6-c82cd9be2825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f88512b0-174d-4007-93f6-c82cd9be2825" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94096fe1-bee3-492d-b42a-34170757bc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94096fe1-bee3-492d-b42a-34170757bc3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_fd565d38-49f3-4b0b-8122-488fd8b3411d" xlink:href="morf-20221231.xsd#morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:to="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_fd565d38-49f3-4b0b-8122-488fd8b3411d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_7dd5cb03-3a7f-4e91-80dd-830b537d2628" xlink:href="morf-20221231.xsd#morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:to="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_7dd5cb03-3a7f-4e91-80dd-830b537d2628" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b1c2f5-ba09-4aef-9564-69d48a3b351a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b1c2f5-ba09-4aef-9564-69d48a3b351a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1ff5bc4c-21a5-499c-b0f6-09713efc4319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b1c2f5-ba09-4aef-9564-69d48a3b351a" xlink:to="loc_us-gaap_PlanNameAxis_1ff5bc4c-21a5-499c-b0f6-09713efc4319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1ff5bc4c-21a5-499c-b0f6-09713efc4319_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1ff5bc4c-21a5-499c-b0f6-09713efc4319" xlink:to="loc_us-gaap_PlanNameDomain_1ff5bc4c-21a5-499c-b0f6-09713efc4319_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_65ca5168-ccdc-44d6-91ff-d6bfaee76bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1ff5bc4c-21a5-499c-b0f6-09713efc4319" xlink:to="loc_us-gaap_PlanNameDomain_65ca5168-ccdc-44d6-91ff-d6bfaee76bcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember_eff2a2d6-c8b2-4a4e-bc07-a7eea444c1c2" xlink:href="morf-20221231.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_65ca5168-ccdc-44d6-91ff-d6bfaee76bcc" xlink:to="loc_morf_EmployeeStockPurchasePlanMember_eff2a2d6-c8b2-4a4e-bc07-a7eea444c1c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d9c58db-ce74-4496-b625-aab43f09be37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b1c2f5-ba09-4aef-9564-69d48a3b351a" xlink:to="loc_srt_RangeAxis_1d9c58db-ce74-4496-b625-aab43f09be37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d9c58db-ce74-4496-b625-aab43f09be37_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1d9c58db-ce74-4496-b625-aab43f09be37" xlink:to="loc_srt_RangeMember_1d9c58db-ce74-4496-b625-aab43f09be37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1cd2bbc-91b3-4be3-bd62-bf89ce7ba0ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1d9c58db-ce74-4496-b625-aab43f09be37" xlink:to="loc_srt_RangeMember_e1cd2bbc-91b3-4be3-bd62-bf89ce7ba0ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ed93e22-65de-492b-8d7f-83ec5675a432" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1cd2bbc-91b3-4be3-bd62-bf89ce7ba0ed" xlink:to="loc_srt_MaximumMember_1ed93e22-65de-492b-8d7f-83ec5675a432" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="id8f60a04776a499fa782519ccd6a4fff_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dc67387b-a3cf-4d82-8d2c-f17d3bdbf649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dc67387b-a3cf-4d82-8d2c-f17d3bdbf649" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_33fb2a6d-2d70-45c0-b5f9-0ad65d27646f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_33fb2a6d-2d70-45c0-b5f9-0ad65d27646f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0ab38498-3d7c-487c-8ba4-24291aa97c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0ab38498-3d7c-487c-8ba4-24291aa97c4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OperatingLossCarryforwardsNotSubjectToExpiration_1ebf5291-1db9-482a-a2c9-44ff9ecb6177" xlink:href="morf-20221231.xsd#morf_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_morf_OperatingLossCarryforwardsNotSubjectToExpiration_1ebf5291-1db9-482a-a2c9-44ff9ecb6177" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_cbe628fa-5207-4d42-aec4-790e77432ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_cbe628fa-5207-4d42-aec4-790e77432ed3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_5e23adaa-8002-47ce-aacc-7ab5f3f03051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_5e23adaa-8002-47ce-aacc-7ab5f3f03051" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4ec96e7e-d6c2-4d7c-b9c3-86934ac8a2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4ec96e7e-d6c2-4d7c-b9c3-86934ac8a2f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_aa7d31b8-9562-4e05-9a83-d646bcff83f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_aa7d31b8-9562-4e05-9a83-d646bcff83f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_21c2ebd0-3edc-437b-bb86-0970f050f400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_aa7d31b8-9562-4e05-9a83-d646bcff83f0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_21c2ebd0-3edc-437b-bb86-0970f050f400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_21c2ebd0-3edc-437b-bb86-0970f050f400_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_21c2ebd0-3edc-437b-bb86-0970f050f400" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_21c2ebd0-3edc-437b-bb86-0970f050f400_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8fd5d739-3e46-4d60-ab27-2cd966566cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_21c2ebd0-3edc-437b-bb86-0970f050f400" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8fd5d739-3e46-4d60-ab27-2cd966566cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_70664b85-c2f1-49ba-9337-6e0fa7d3e2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8fd5d739-3e46-4d60-ab27-2cd966566cec" xlink:to="loc_us-gaap_DomesticCountryMember_70664b85-c2f1-49ba-9337-6e0fa7d3e2d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_99bc4072-5751-428e-8c43-1a8945bc14ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8fd5d739-3e46-4d60-ab27-2cd966566cec" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_99bc4072-5751-428e-8c43-1a8945bc14ab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#OptionandLicenseAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails" xlink:type="extended" id="i3b190273b08a4ecc9187f03872023bd1_OptionandLicenseAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementTermOfArrangement_b2e40d10-3905-4a8b-9188-95bf0a4fb6d5" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementTermOfArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementTermOfArrangement_b2e40d10-3905-4a8b-9188-95bf0a4fb6d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementUpfrontFeesReceived_8f1c1108-2a73-4bb7-9171-9dc933d18adf" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementUpfrontFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementUpfrontFeesReceived_8f1c1108-2a73-4bb7-9171-9dc933d18adf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfResearchPrograms_53f6bb29-fd82-4e92-aa93-845e46ede575" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfResearchPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfResearchPrograms_53f6bb29-fd82-4e92-aa93-845e46ede575" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementOptionExerciseFeesReceivable_a3a3d568-745d-4326-b0a6-b8bbe70d0021" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementOptionExerciseFeesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementOptionExerciseFeesReceivable_a3a3d568-745d-4326-b0a6-b8bbe70d0021" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfOptions_911d81c5-20b1-4025-9773-d97f6dbce2d0" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfOptions_911d81c5-20b1-4025-9773-d97f6dbce2d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementProfitMarginPercentage_95cfdecf-6716-4477-9f9a-002b5c9a374d" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementProfitMarginPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementProfitMarginPercentage_95cfdecf-6716-4477-9f9a-002b5c9a374d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpFrontPaymentIncludedInTransactionPrice_e7e8f178-560b-4361-9f31-6200541e71ba" xlink:href="morf-20221231.xsd#morf_UpFrontPaymentIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_UpFrontPaymentIncludedInTransactionPrice_e7e8f178-560b-4361-9f31-6200541e71ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementOptionExerciseFeesPaid_1f8bbacb-f2f1-4143-806e-74c2deea51b7" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementOptionExerciseFeesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementOptionExerciseFeesPaid_1f8bbacb-f2f1-4143-806e-74c2deea51b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborationAgreementOptionExerciseRevenueReceived_d60272ad-152f-4d13-964b-270ddbe14b24" xlink:href="morf-20221231.xsd#morf_CollaborationAgreementOptionExerciseRevenueReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborationAgreementOptionExerciseRevenueReceived_d60272ad-152f-4d13-964b-270ddbe14b24" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7d4d609a-1571-41c4-bf0d-1a6f1a47cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7d4d609a-1571-41c4-bf0d-1a6f1a47cb3c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_634e3b6c-aee4-4281-9bb4-7be1f627f82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_634e3b6c-aee4-4281-9bb4-7be1f627f82f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfIntegrinTargets_cc423d9e-3e03-4e97-95b0-1f1ef5aa9a13" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfIntegrinTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfIntegrinTargets_cc423d9e-3e03-4e97-95b0-1f1ef5aa9a13" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram_2d2fc124-44fa-4f36-bc69-2221c0959f4c" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram_2d2fc124-44fa-4f36-bc69-2221c0959f4c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram_f1f4b091-fb6f-4d08-b2c2-bd2bd912238d" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram_f1f4b091-fb6f-4d08-b2c2-bd2bd912238d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementPaymentDuePeriod_67639d25-a31d-4275-98bb-fbf990206b2b" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementPaymentDuePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementPaymentDuePeriod_67639d25-a31d-4275-98bb-fbf990206b2b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued_5f8adf7d-e229-4a2b-b637-3aa60a004fd6" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued_5f8adf7d-e229-4a2b-b637-3aa60a004fd6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNotificationPeriod_31e6b74e-7bd2-4407-a687-a3143e8177a1" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNotificationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNotificationPeriod_31e6b74e-7bd2-4407-a687-a3143e8177a1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfOptionsToLicense_74d032e0-a991-41c4-90f4-eaacffff42ce" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfOptionsToLicense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfOptionsToLicense_74d032e0-a991-41c4-90f4-eaacffff42ce" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5fe7712e-178d-489b-89ef-620b6592dc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5fe7712e-178d-489b-89ef-620b6592dc8d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_8605c84a-a876-40f8-ae37-0d116dc90cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_8605c84a-a876-40f8-ae37-0d116dc90cdb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a2b959c1-d363-45b9-95e9-4df9e20c544e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a2b959c1-d363-45b9-95e9-4df9e20c544e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_09fd58a0-b223-436b-9c2b-ef31d2eabc72" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:to="loc_srt_CounterpartyNameAxis_09fd58a0-b223-436b-9c2b-ef31d2eabc72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09fd58a0-b223-436b-9c2b-ef31d2eabc72_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_09fd58a0-b223-436b-9c2b-ef31d2eabc72" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09fd58a0-b223-436b-9c2b-ef31d2eabc72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8c8ff76-c0bd-4087-a764-631a3e081be3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_09fd58a0-b223-436b-9c2b-ef31d2eabc72" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8c8ff76-c0bd-4087-a764-631a3e081be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember_e8433a59-5727-498c-a8dc-430c49d01b7c" xlink:href="morf-20221231.xsd#morf_AbbVieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8c8ff76-c0bd-4087-a764-631a3e081be3" xlink:to="loc_morf_AbbVieMember_e8433a59-5727-498c-a8dc-430c49d01b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember_ce937f64-8789-4101-84fa-589ea13a9d4a" xlink:href="morf-20221231.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8c8ff76-c0bd-4087-a764-631a3e081be3" xlink:to="loc_morf_JanssenPharmaceuticalsIncMember_ce937f64-8789-4101-84fa-589ea13a9d4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b56f6130-21f8-4b30-ac28-be6bc2cc6681" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:to="loc_srt_ProductOrServiceAxis_b56f6130-21f8-4b30-ac28-be6bc2cc6681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b56f6130-21f8-4b30-ac28-be6bc2cc6681_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b56f6130-21f8-4b30-ac28-be6bc2cc6681" xlink:to="loc_srt_ProductsAndServicesDomain_b56f6130-21f8-4b30-ac28-be6bc2cc6681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b56f6130-21f8-4b30-ac28-be6bc2cc6681" xlink:to="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d19943b1-b0b5-469d-86ea-f36cf275c27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:to="loc_us-gaap_LicenseMember_d19943b1-b0b5-469d-86ea-f36cf275c27d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember_fbe7f0ac-cddd-4216-84d6-9c7528b6ca26" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:to="loc_morf_UpfrontPaymentRevenueMember_fbe7f0ac-cddd-4216-84d6-9c7528b6ca26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueFirstTwoProgramsMember_aae747d2-32d1-4056-b247-5114e7ae1462" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueFirstTwoProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:to="loc_morf_UpfrontPaymentRevenueFirstTwoProgramsMember_aae747d2-32d1-4056-b247-5114e7ae1462" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueThirdProgramMember_fed3602d-4396-4ede-ae2c-e52d4ebc7982" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueThirdProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:to="loc_morf_UpfrontPaymentRevenueThirdProgramMember_fed3602d-4396-4ede-ae2c-e52d4ebc7982" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8b68a328-af39-4b39-b3d6-67e7618924e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8b68a328-af39-4b39-b3d6-67e7618924e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8b68a328-af39-4b39-b3d6-67e7618924e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8b68a328-af39-4b39-b3d6-67e7618924e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8b68a328-af39-4b39-b3d6-67e7618924e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7781b170-48de-4829-accf-920809f18b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8b68a328-af39-4b39-b3d6-67e7618924e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7781b170-48de-4829-accf-920809f18b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0b0a12f1-b96e-4a5a-8faa-6573b83be134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7781b170-48de-4829-accf-920809f18b12" xlink:to="loc_us-gaap_SubsequentEventMember_0b0a12f1-b96e-4a5a-8faa-6573b83be134" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" xlink:type="extended" id="ifa8a33887ffa4923864ffa49526cef50_OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c8180810-e5e2-47fe-83f3-68c150bb1aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_95dfd58c-4593-40cd-b14b-ebdfe11cafb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c8180810-e5e2-47fe-83f3-68c150bb1aa6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_95dfd58c-4593-40cd-b14b-ebdfe11cafb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a2546c17-a7f3-4d1d-a88d-50708effccfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c8180810-e5e2-47fe-83f3-68c150bb1aa6" xlink:to="loc_us-gaap_CostsAndExpenses_a2546c17-a7f3-4d1d-a88d-50708effccfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4c91843-ac57-4c0d-b7ab-d6478dd3df84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c8180810-e5e2-47fe-83f3-68c150bb1aa6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4c91843-ac57-4c0d-b7ab-d6478dd3df84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dd181442-5437-4115-944d-2427340b992d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4c91843-ac57-4c0d-b7ab-d6478dd3df84" xlink:to="loc_srt_CounterpartyNameAxis_dd181442-5437-4115-944d-2427340b992d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd181442-5437-4115-944d-2427340b992d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_dd181442-5437-4115-944d-2427340b992d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd181442-5437-4115-944d-2427340b992d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc1fbbf3-0836-4ce3-954d-0b1697fe875f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_dd181442-5437-4115-944d-2427340b992d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc1fbbf3-0836-4ce3-954d-0b1697fe875f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember_c88dd58c-6d4f-40d4-bfd8-0cca45d6ca88" xlink:href="morf-20221231.xsd#morf_AbbVieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc1fbbf3-0836-4ce3-954d-0b1697fe875f" xlink:to="loc_morf_AbbVieMember_c88dd58c-6d4f-40d4-bfd8-0cca45d6ca88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember_c7171c90-4225-45c6-a3f6-0d7a4f5ff17c" xlink:href="morf-20221231.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc1fbbf3-0836-4ce3-954d-0b1697fe875f" xlink:to="loc_morf_JanssenPharmaceuticalsIncMember_c7171c90-4225-45c6-a3f6-0d7a4f5ff17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_18cb3722-51fe-4c35-a023-7e9e463a661b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4c91843-ac57-4c0d-b7ab-d6478dd3df84" xlink:to="loc_srt_ProductOrServiceAxis_18cb3722-51fe-4c35-a023-7e9e463a661b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18cb3722-51fe-4c35-a023-7e9e463a661b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_18cb3722-51fe-4c35-a023-7e9e463a661b" xlink:to="loc_srt_ProductsAndServicesDomain_18cb3722-51fe-4c35-a023-7e9e463a661b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_18cb3722-51fe-4c35-a023-7e9e463a661b" xlink:to="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember_061086a9-3347-4883-807d-64e11ce80758" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:to="loc_morf_UpfrontPaymentRevenueMember_061086a9-3347-4883-807d-64e11ce80758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ReimbursementRevenueMember_33dac9ef-6394-44ec-88ae-07448214aa5d" xlink:href="morf-20221231.xsd#morf_ReimbursementRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:to="loc_morf_ReimbursementRevenueMember_33dac9ef-6394-44ec-88ae-07448214aa5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b282279e-7faf-4a5a-b58d-dfd0186e225f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:to="loc_us-gaap_LicenseMember_b282279e-7faf-4a5a-b58d-dfd0186e225f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#NetLossperShareCommonstockequivalentsharesDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails" xlink:type="extended" id="i3c6d204d453e4bb79491b89923182b0e_NetLossperShareCommonstockequivalentsharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43f87c89-dcec-473a-b675-8bc1f805076e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fdcdbece-ae2b-4f45-b6d7-6e97d443db8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43f87c89-dcec-473a-b675-8bc1f805076e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fdcdbece-ae2b-4f45-b6d7-6e97d443db8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_432e7df9-290c-475a-ad4c-8ebbf62f692b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43f87c89-dcec-473a-b675-8bc1f805076e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_432e7df9-290c-475a-ad4c-8ebbf62f692b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aac13bc6-c665-4b55-9a0a-0c7cb0a600b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_432e7df9-290c-475a-ad4c-8ebbf62f692b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aac13bc6-c665-4b55-9a0a-0c7cb0a600b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aac13bc6-c665-4b55-9a0a-0c7cb0a600b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aac13bc6-c665-4b55-9a0a-0c7cb0a600b9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aac13bc6-c665-4b55-9a0a-0c7cb0a600b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aac13bc6-c665-4b55-9a0a-0c7cb0a600b9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c0863a9d-3615-4432-b6c2-7de1972f9f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:to="loc_us-gaap_RestrictedStockMember_c0863a9d-3615-4432-b6c2-7de1972f9f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f1144368-bfa9-48d2-9f91-b4e762863f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f1144368-bfa9-48d2-9f91-b4e762863f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3cbc8a3d-4c99-44de-b428-a63c3025dbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3cbc8a3d-4c99-44de-b428-a63c3025dbf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember_2beeab82-c451-407d-8d86-c2e8c04d3a71" xlink:href="morf-20221231.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:to="loc_morf_EmployeeStockPurchasePlanMember_2beeab82-c451-407d-8d86-c2e8c04d3a71" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>morf-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3504fb1d-c703-4af8-962a-40bb538fa93a,g:d0f79058-117f-4d7c-9741-2cac766e63e2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5e4d82c-4115-4781-a32b-9afdb807ac44_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_38b3f10b-bc4b-4791-bf4a-4edc37088619_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60fb50e1-590d-4240-b3f1-77a0336a8dde_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_dc785b5a-04dd-4fdc-933f-77a2ab1aca11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciled cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a5e96d19-bb4c-417b-88a0-a5fcba4be495_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c358d0d7-9c52-4cdb-9a47-9c7c9adeae01_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfIntegrinTargets_47563f33-aee8-41b3-b324-1140140ed561_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfIntegrinTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of integrin targets</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfIntegrinTargets_label_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfIntegrinTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Integrin Targets</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfIntegrinTargets_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfIntegrinTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Integrin Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfIntegrinTargets" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfIntegrinTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementNumberOfIntegrinTargets" xlink:to="lab_morf_CollaborativeArrangementNumberOfIntegrinTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7ab879a7-6e79-4bc3-8c1c-fbd71f0521aa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementNotificationPeriod_c33724b7-e85f-40dd-8469-54358e1393c5_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notification Period</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNotificationPeriod_label_en-US" xlink:label="lab_morf_CollaborativeArrangementNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Notification Period</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNotificationPeriod_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Notification Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNotificationPeriod" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNotificationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementNotificationPeriod" xlink:to="lab_morf_CollaborativeArrangementNotificationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0048f979-b148-4f9d-88ef-a04383dbd3b2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementOptionExerciseFeesReceivable_ff319cc8-0568-4e09-9c0d-352a20bdd61a_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementOptionExerciseFeesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_morf_CollaborativeArrangementOptionExerciseFeesReceivable_label_en-US" xlink:label="lab_morf_CollaborativeArrangementOptionExerciseFeesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option Exercise Fees, Receivable</link:label>
    <link:label id="lab_morf_CollaborativeArrangementOptionExerciseFeesReceivable_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementOptionExerciseFeesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option Exercise Fees, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementOptionExerciseFeesReceivable" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementOptionExerciseFeesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementOptionExerciseFeesReceivable" xlink:to="lab_morf_CollaborativeArrangementOptionExerciseFeesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock_be6e745b-0d85-4c76-a5a1-fd80253f5483_terseLabel_en-US" xlink:label="lab_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of supplemental information</link:label>
    <link:label id="lab_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Supplemental Disclosures [Table Text Block]</link:label>
    <link:label id="lab_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Supplemental Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock" xlink:href="morf-20221231.xsd#morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock" xlink:to="lab_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_bf6fc93c-3313-48b7-8895-0be6fb538f5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1d69ac1a-66c6-4c83-9486-b770212b71ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_ae9a73aa-c78c-4a73-a5c7-fbc89930786c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_daae4b0a-e320-4684-b628-ac49e5dbf605_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid&#8209;in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_466458a3-85b0-4ea7-a592-e7ca128cd2c4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance or sale of equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35162e50-e51d-4c78-8af2-96b9610ef5db_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a41302f1-b027-4772-beb5-a181af3bdaf9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eee19970-d570-42a4-9b38-6dc953803671_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares upon stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3f174e92-9ce5-40f3-b0ce-3e0c16abb0d9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_02ba269f-c838-4fb2-9be4-e97a87481b58_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_dd5f6865-60d8-45cf-a818-eb2e1518bba7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementDisclosureAbstract_667d3f54-dac3-4e9f-a575-bab6df6c59c0_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option and License Agreements</link:label>
    <link:label id="lab_morf_CollaborativeArrangementDisclosureAbstract_label_en-US" xlink:label="lab_morf_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option and License Agreements</link:label>
    <link:label id="lab_morf_CollaborativeArrangementDisclosureAbstract_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract" xlink:to="lab_morf_CollaborativeArrangementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c3f4436a-ac5f-4cbc-8b03-b9b6646b2346_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_deecb9b1-0baf-41a7-8bee-2e4737c5c639_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59ab378a-67c8-4beb-9893-0447257f69ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_2affb35b-61ae-4810-91bf-6ce5b7b51cca_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_IncreaseDecreaseInDeferredRent_fcc49d10-cefb-437c-935e-6095ad4e5552_terseLabel_en-US" xlink:label="lab_morf_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_morf_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_morf_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_morf_IncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_morf_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in deferred income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseInDeferredRent" xlink:href="morf-20221231.xsd#morf_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_IncreaseDecreaseInDeferredRent" xlink:to="lab_morf_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6dd03627-56df-4ce1-9448-40b5661a3a3e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1886ff53-5b21-4894-b597-b17fb0b9362d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bc0dfc0c-9898-4bca-81ee-bf2c089cec79_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_801627db-7e21-4600-895e-3a1e927d2dc4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_651dc091-f94f-49ac-bbbe-b37e22af0e4d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9f5e5d4b-8662-448f-866f-e43b8733c14f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b31033f2-82c2-4b02-b2e6-2ace2c753f9d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti&#8209;dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_f7149d02-3ea4-48b5-b833-e3bb574866e4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_OpenMarketSaleAgreementMember_227ab88d-0637-45f0-b9bd-dd945d3d79fa_terseLabel_en-US" xlink:label="lab_morf_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale Agreement</link:label>
    <link:label id="lab_morf_OpenMarketSaleAgreementMember_label_en-US" xlink:label="lab_morf_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
    <link:label id="lab_morf_OpenMarketSaleAgreementMember_documentation_en-US" xlink:label="lab_morf_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Open Market Sale Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OpenMarketSaleAgreementMember" xlink:href="morf-20221231.xsd#morf_OpenMarketSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_OpenMarketSaleAgreementMember" xlink:to="lab_morf_OpenMarketSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock_f751afb1-c9e3-4555-bfed-a8750cfc2a3c_terseLabel_en-US" xlink:label="lab_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Contract and Development Costs And Accruals</link:label>
    <link:label id="lab_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Contract And Development Costs And Accruals Policy [Policy Text Block]</link:label>
    <link:label id="lab_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Contract And Development Costs And Accruals Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock" xlink:href="morf-20221231.xsd#morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock" xlink:to="lab_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_98a4b293-24a2-4410-a7e3-161120e28381_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_abc20f7f-d80d-4379-bf01-c86b8dc7920f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_90928e69-8442-4632-a6e0-cc7cf8f86dff_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_OfficeAndLaboratorySpaceMember_3900f376-061e-4015-8959-8e7c8d728f71_terseLabel_en-US" xlink:label="lab_morf_OfficeAndLaboratorySpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory Space</link:label>
    <link:label id="lab_morf_OfficeAndLaboratorySpaceMember_label_en-US" xlink:label="lab_morf_OfficeAndLaboratorySpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory Space [Member]</link:label>
    <link:label id="lab_morf_OfficeAndLaboratorySpaceMember_documentation_en-US" xlink:label="lab_morf_OfficeAndLaboratorySpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OfficeAndLaboratorySpaceMember" xlink:href="morf-20221231.xsd#morf_OfficeAndLaboratorySpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_OfficeAndLaboratorySpaceMember" xlink:to="lab_morf_OfficeAndLaboratorySpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_aec2390f-a15e-436d-9c3e-4c7f5f0b1e1b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_3155e27b-ad33-4783-9dfd-b79a68470a9f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6e8ed136-b835-4d13-9f78-5998c221ea98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ec407d91-af42-4a3f-b27a-6d58d4f7736c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a2db87c5-a9fd-4804-afdd-f20c548f9e57_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8c139537-bd19-48e5-9310-43e451504e12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_299201ac-acd8-40f4-9919-820e9bb7858e_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of restricted common stock</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_83e679cf-5fbd-4c90-b957-4e65d881af09_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c297b5ee-f835-4276-8840-d77c0ecd3022_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_92b5ee1e-e68c-4a7c-aa19-3a8cd56dbe9b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8f332367-b793-49b4-b917-fbf7238b5a5c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized equity based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_764be9f2-450a-4b71-bcc2-5eb6c445edbd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_fb5a1805-0b82-41d0-9171-17b0b33a5b3b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3ef33ebe-5bbb-49a1-94bb-b77e16b40a55_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bf57c228-2601-4fb0-b0fb-02d0f2d42545_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_f55fb316-4f0c-4cad-b854-09496dc66177_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_48287722-9a2c-47c9-bd4d-9c189ce04118_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_357c2757-256a-4548-b3ef-54b9b04ce143_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_TwoThousandNineteenStockIncentivePlanMember_884eeec2-e304-4b85-b0b9-a3742cfc83db_terseLabel_en-US" xlink:label="lab_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:label id="lab_morf_TwoThousandNineteenStockIncentivePlanMember_label_en-US" xlink:label="lab_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_morf_TwoThousandNineteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the 2019 stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:href="morf-20221231.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:to="lab_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fb1da8c9-fbd4-4901-96f3-09652b374ed4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1c8df72b-355e-4c1e-b1c5-08c7f41c194b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_be26fe0e-f0a1-4a18-9d48-bfc26df905d5_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of land (square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3262c51b-3dfc-4e9b-921e-43b5f0d028e4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_38d5934b-f74f-4d83-8a9a-1f4786273afd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_75e8502d-81a7-4ead-92a7-96974625c85b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94796aaf-b3e3-4f39-8236-19772821eb46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_63dc4ac3-60bd-4e79-bb95-e9dccb15a6c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of investments in marketable securities classified as available for sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_46bb2727-2d65-4ac9-a8b3-f345fb33029c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cae9400e-64e3-4ba6-a862-f8b0ef621838_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_UpFrontPaymentIncludedInTransactionPrice_eb5b6650-bb39-476d-9661-c5bd3a9abedf_terseLabel_en-US" xlink:label="lab_morf_UpFrontPaymentIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment included in transaction price</link:label>
    <link:label id="lab_morf_UpFrontPaymentIncludedInTransactionPrice_label_en-US" xlink:label="lab_morf_UpFrontPaymentIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Payment, Included In Transaction Price</link:label>
    <link:label id="lab_morf_UpFrontPaymentIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_morf_UpFrontPaymentIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Payment, Included In Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpFrontPaymentIncludedInTransactionPrice" xlink:href="morf-20221231.xsd#morf_UpFrontPaymentIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_UpFrontPaymentIncludedInTransactionPrice" xlink:to="lab_morf_UpFrontPaymentIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_ce7038b5-58db-45ba-9561-0fd2bbfc8639_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e4c5166c-b614-441d-b9ba-d7d691f87cad_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_debcdba0-49a4-4ddc-98d5-440791acb4c5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_757bd4ef-81c8-401a-a9f5-431b14edd97b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f47af415-022f-4bc7-9079-8825974ca148_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ffda1f2c-018e-475d-82b1-ba527f0dec9e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares, net of issuance/offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3afcb227-26e2-4817-9325-55731e56753e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccf06c17-f6f4-4889-9603-503c900dc156_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_240bf920-d4e6-4071-8e87-2096ae0a0f18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of costs incurred and revenue recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_498648e3-bfef-4b95-8b9c-262851e76869_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_60ab57ad-ce68-4705-9a0d-6766299ef098_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f839b19c-f539-44ef-833c-fbc1b187bd14_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_346089b0-e9b8-4bc6-b7e2-03a3158a3d39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_b39eb940-b565-4d1d-bf77-afe420744ed0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life (in Years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_0b9effde-9065-4a6f-8112-a42d80838d21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e120601-53a7-4d74-9373-ced9ae8f96ce_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of&#160;Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_067ff0c1-7547-4793-a7c7-67ee49cf0b02_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_43ea03d4-6b19-4e94-b93c-738ed109c09b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ab8f9b26-1fa0-42cb-be72-4ce1f0c0b7a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9bdaf03-7590-4107-bfa2-0fdde73983a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a8f022d2-cc0d-4fdd-9d9d-0cad2e94fa74_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_PercentageOfCommissionOnGrossSaleProceeds_6f26b241-b749-4995-8481-9cf56f0c6ffe_terseLabel_en-US" xlink:label="lab_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission (as a percent)</link:label>
    <link:label id="lab_morf_PercentageOfCommissionOnGrossSaleProceeds_label_en-US" xlink:label="lab_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Commission on Gross sale Proceeds</link:label>
    <link:label id="lab_morf_PercentageOfCommissionOnGrossSaleProceeds_documentation_en-US" xlink:label="lab_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission on gross sale proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:href="morf-20221231.xsd#morf_PercentageOfCommissionOnGrossSaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:to="lab_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7966b1ab-1340-4e38-8f1b-c514a1cc0242_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1d5b38d3-12cf-4338-8a4a-8770bae29707_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_c73db907-8347-4527-95d2-678ea2070a12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_43e8477a-f835-4b03-a615-c66329813994_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_56870229-b656-48a4-bd9e-773c92f2c812_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_55c9df58-f34f-4bf7-b91e-ff46d2b28373_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_437dedaf-8947-4399-ab80-a9ebb161d55d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_8fa7c46c-ec46-46dc-b451-4bbb8be9259c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_a4175a08-5807-4f5d-afca-94ca27aad0d5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_368d2325-aa1d-4800-81e0-55b6e83f5c4f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_4ba9c09e-7834-41c6-b484-ec47f4423ec4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_UpfrontPaymentRevenueThirdProgramMember_15f28bdc-87a5-45b3-8da1-2b1781d18a99_terseLabel_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueThirdProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue, Third Program</link:label>
    <link:label id="lab_morf_UpfrontPaymentRevenueThirdProgramMember_label_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueThirdProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue, Third Program [Member]</link:label>
    <link:label id="lab_morf_UpfrontPaymentRevenueThirdProgramMember_documentation_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueThirdProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue, Third Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueThirdProgramMember" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueThirdProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_UpfrontPaymentRevenueThirdProgramMember" xlink:to="lab_morf_UpfrontPaymentRevenueThirdProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_51c6612c-0108-4da0-a560-e72632d99f59_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6fb4f502-d293-4c08-bc28-3c46d8a176ce_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_45a4eeaf-7cc1-42eb-bb45-3cb69bd8780e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_e256ab8f-f3f6-45ef-94af-bdda8b4f89e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_878e5611-e3ae-4b59-b9c5-97de8350a152_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax examination, penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4480c21-ff0b-4077-89ab-8b6fa4fca984_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_36b23f07-5d54-496c-bae9-b3573738105d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ddcf4452-28c8-4b07-b272-b49bf042a266_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_39e31329-a580-4be8-9e4c-745928ddfce0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_73948a5a-bcd1-4aa1-8c84-5f2d3586b979_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_cc67c33a-331c-4869-9dd5-357dfd54a89e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_147064b0-ed68-4e10-9603-281ed1909882_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before (provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_bc012a8f-dbfd-44b5-a6a8-005bdd8d03f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_20b0220b-2370-455c-b580-94a26ccc30c0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ea6c657a-7f3a-4ccc-8285-76e9c97155ec_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bf1e053e-d147-4dca-a80a-027cd00b3cc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assumptions used in determining the fair value of the options granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3430f177-a067-49d0-bae6-32e26c055a38_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_183e8680-64bf-4788-b75e-6edefcd4cd4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementProfitMarginPercentage_2d742b8b-86c6-4097-a056-4c01d2eb1507_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementProfitMarginPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit margin percentage</link:label>
    <link:label id="lab_morf_CollaborativeArrangementProfitMarginPercentage_label_en-US" xlink:label="lab_morf_CollaborativeArrangementProfitMarginPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Margin Percentage</link:label>
    <link:label id="lab_morf_CollaborativeArrangementProfitMarginPercentage_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementProfitMarginPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Margin Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementProfitMarginPercentage" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementProfitMarginPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementProfitMarginPercentage" xlink:to="lab_morf_CollaborativeArrangementProfitMarginPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cc2036c-0b9e-41a9-8ecf-ea48007bbdd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_75786bab-a093-41e4-ba16-6d242387a53f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d9b722ae-0cca-4d21-a20c-cc1c5319f6fb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized equity based compensation expense expected period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_fd617695-d38f-4aa2-ae95-8033236714a2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at the end (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_ff040bee-79ba-4444-b89a-fb73e2fed1e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common shares under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f3240562-423d-47cb-8c43-90d1bde3503b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3703966a-fc95-4b10-b3c1-1e247617ebea_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares, net of issuance/offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_436200a6-20d1-44af-9e7c-72043203434e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of common shares sold in IPO, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_DeferredTaxAssetsFixedAndIntangibleAssets_e891caf5-8f2f-4999-910c-7a2005013bee_terseLabel_en-US" xlink:label="lab_morf_DeferredTaxAssetsFixedAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed and intangible assets</link:label>
    <link:label id="lab_morf_DeferredTaxAssetsFixedAndIntangibleAssets_label_en-US" xlink:label="lab_morf_DeferredTaxAssetsFixedAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Fixed And Intangible assets</link:label>
    <link:label id="lab_morf_DeferredTaxAssetsFixedAndIntangibleAssets_documentation_en-US" xlink:label="lab_morf_DeferredTaxAssetsFixedAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Fixed And Intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_DeferredTaxAssetsFixedAndIntangibleAssets" xlink:href="morf-20221231.xsd#morf_DeferredTaxAssetsFixedAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_DeferredTaxAssetsFixedAndIntangibleAssets" xlink:to="lab_morf_DeferredTaxAssetsFixedAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_10a18006-aae1-454f-b72f-b39ae7ff9d2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_AuditInformationAbstract_label_en-US" xlink:label="lab_morf_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_morf_AuditInformationAbstract_documentation_en-US" xlink:label="lab_morf_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AuditInformationAbstract" xlink:href="morf-20221231.xsd#morf_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_AuditInformationAbstract" xlink:to="lab_morf_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_df44b847-9b50-4c8c-ae4a-7ffe612874ac_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2feb3fb1-ce87-48f0-828b-9e1651630406_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4b2f0220-19e7-4a77-b083-6c381340337c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f48691e1-7870-439f-a780-176e97bbd31c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_ae0b50e8-d3e9-438b-897a-d8754275b0f0_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d013664f-76a0-4598-9fa9-8ea979e50296_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_SecondaryOfferingMember_2c7e5475-df56-487e-bd68-dad2245e83b0_terseLabel_en-US" xlink:label="lab_morf_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering</link:label>
    <link:label id="lab_morf_SecondaryOfferingMember_label_en-US" xlink:label="lab_morf_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering [Member]</link:label>
    <link:label id="lab_morf_SecondaryOfferingMember_documentation_en-US" xlink:label="lab_morf_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember" xlink:href="morf-20221231.xsd#morf_SecondaryOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_SecondaryOfferingMember" xlink:to="lab_morf_SecondaryOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_OperatingLossCarryforwardsNotSubjectToExpiration_3c96c491-88b4-4d1b-b618-e7558f2bee59_terseLabel_en-US" xlink:label="lab_morf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_morf_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_morf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:label id="lab_morf_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_morf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="morf-20221231.xsd#morf_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_morf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3ac92f53-6493-4cb9-bf52-4092197e2173_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_900d8538-d1c7-445b-973c-f20afceefaac_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_UpfrontPaymentRevenueFirstTwoProgramsMember_29cb7d20-e3d2-4d90-96bf-7f8372b98581_terseLabel_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueFirstTwoProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue, First Two Programs</link:label>
    <link:label id="lab_morf_UpfrontPaymentRevenueFirstTwoProgramsMember_label_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueFirstTwoProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue, First Two Programs [Member]</link:label>
    <link:label id="lab_morf_UpfrontPaymentRevenueFirstTwoProgramsMember_documentation_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueFirstTwoProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue, First Two Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueFirstTwoProgramsMember" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueFirstTwoProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_UpfrontPaymentRevenueFirstTwoProgramsMember" xlink:to="lab_morf_UpfrontPaymentRevenueFirstTwoProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9923aba6-af87-4b3d-91e8-655a8a5bc6ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e04361c9-dafd-4d50-88e3-1942c231319a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_5553195e-d8bc-443e-9bc4-30d09c4f721d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfOptionsToLicense_be054685-acb9-4d6b-a18c-ad2cb40d0e0b_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfOptionsToLicense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, license</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfOptionsToLicense_label_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfOptionsToLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Options To License</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfOptionsToLicense_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfOptionsToLicense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Options To License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfOptionsToLicense" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfOptionsToLicense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementNumberOfOptionsToLicense" xlink:to="lab_morf_CollaborativeArrangementNumberOfOptionsToLicense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c9bf266c-40ee-4c16-ae31-edeca4b3ba91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0d069993-b790-477b-9437-873210dfb8a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_507fc0fe-4d2a-4b52-ab8d-bca8d1e50056_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fe0ecc13-a957-4f03-9643-9db13eafc6a0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_05e91d56-4136-4acf-8ce4-e77f25c83ff1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ec17a549-60ea-4834-bbe9-0312d17a22c3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_e85d450e-adbe-4fa4-994f-c81f6a5789dd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_e126a3a1-b9d5-4825-8e41-3856f58790e9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram_63cabdc7-4c8b-4c21-9649-e740da2721ce_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fee for first two research program</link:label>
    <link:label id="lab_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram_label_en-US" xlink:label="lab_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Fees Received For First Two Research Program</link:label>
    <link:label id="lab_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Fees Received For First Two Research Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram" xlink:to="lab_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_1af38e17-1a12-46b6-9ffa-4ed9bb2eb95e_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a7d98c55-2adb-4b82-8e89-4ef6ee79ab72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_3fd450da-aa93-456e-9844-a7ef71b599ed_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_01aeed7c-63fa-4ca4-97f6-ff5ad5082d09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_14bad94d-264f-4640-b5cd-c364276ad06c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5973d242-fd51-47ff-965e-1a047dbaef20_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementOptionExerciseFeesPaid_a828b885-1189-408c-a3d7-c8ff0028e8ca_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementOptionExerciseFeesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fees received</link:label>
    <link:label id="lab_morf_CollaborativeArrangementOptionExerciseFeesPaid_label_en-US" xlink:label="lab_morf_CollaborativeArrangementOptionExerciseFeesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option Exercise Fees Paid</link:label>
    <link:label id="lab_morf_CollaborativeArrangementOptionExerciseFeesPaid_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementOptionExerciseFeesPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option Exercise Fees Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementOptionExerciseFeesPaid" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementOptionExerciseFeesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementOptionExerciseFeesPaid" xlink:to="lab_morf_CollaborativeArrangementOptionExerciseFeesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9873323d-d8ba-4c20-9c44-e54608b375aa_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ae15e9f6-6a05-4c58-8af2-f107ee51207d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0a6d6a89-ddfc-4ca2-932b-c13021292b36_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_VotingRights_4ee97ff8-1865-43e8-8be5-a6765008cf0e_terseLabel_en-US" xlink:label="lab_morf_VotingRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting rights per share number</link:label>
    <link:label id="lab_morf_VotingRights_label_en-US" xlink:label="lab_morf_VotingRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Rights</link:label>
    <link:label id="lab_morf_VotingRights_documentation_en-US" xlink:label="lab_morf_VotingRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Rights Per Share Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_VotingRights" xlink:href="morf-20221231.xsd#morf_VotingRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_VotingRights" xlink:to="lab_morf_VotingRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7bbeae95-1f52-4013-9ea3-a73f433e5b66_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f0490d77-1db6-4866-99bc-2e4144229896_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_68bd077c-41df-4bf6-8088-6fffbb321241_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f782fe7e-1734-4aab-a3fd-7c6a8db094e4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b2faa6dd-444b-486e-bb75-7b83444b37c7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a4672037-ddaa-4fa8-a09d-d7c3262162fd_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_39d6f147-b014-40d4-9f34-a7943588765b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_JanssenPharmaceuticalsIncMember_3f256e6a-7a3e-4e15-a6d5-911c1c6af1bd_terseLabel_en-US" xlink:label="lab_morf_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_morf_JanssenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_morf_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_morf_JanssenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_morf_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Janssen Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember" xlink:href="morf-20221231.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_JanssenPharmaceuticalsIncMember" xlink:to="lab_morf_JanssenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_968f03ee-6d39-4c91-8a7b-870dbb2887e1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_39205de8-8403-4311-9cba-26a0d984ca3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborationAgreementNumberOfAgreements_7691d063-525a-4442-b187-7526b364a57a_terseLabel_en-US" xlink:label="lab_morf_CollaborationAgreementNumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_morf_CollaborationAgreementNumberOfAgreements_label_en-US" xlink:label="lab_morf_CollaborationAgreementNumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Agreements</link:label>
    <link:label id="lab_morf_CollaborationAgreementNumberOfAgreements_documentation_en-US" xlink:label="lab_morf_CollaborationAgreementNumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborationAgreementNumberOfAgreements" xlink:href="morf-20221231.xsd#morf_CollaborationAgreementNumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborationAgreementNumberOfAgreements" xlink:to="lab_morf_CollaborationAgreementNumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d2ef9855-54a9-4bbc-bb31-a2e5a0c0961c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciled cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e6190ee8-d3f2-4666-8963-34eec2d3ce50_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_64af5193-f7d5-409d-a642-429439725894_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_98353970-1842-444d-bf1b-647773875337_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b353b6e4-a58b-4919-ad2d-0a057b20eb3c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_e734e81b-aafa-469f-98a3-c289caea529d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_345b32f2-3635-4a03-8588-e0764986f826_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bae12ecc-8d3b-4ffd-a71a-4c2c431db788_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0d7adce6-8055-42e5-a428-90d7de3c6a24_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c81b029-4b5a-4329-ad60-5a98d65d3b24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0d74103-8e45-4781-9f88-c905389d23f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_0652aab2-54a1-483b-bf8c-b9e2eedee64d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1b4262bb-8391-4a9d-b672-8c4409585d55_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_83fd0a90-ed11-4eb9-ba0e-2d93cefc6bc6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d3f41b1e-18eb-4946-bfc7-3c5e36bf7c41_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_33937434-4a6e-4c7c-87cc-30640822917d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized equity based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4791ef53-099a-4354-aa65-5c3647ca46eb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_644d35c7-0bae-45fc-9035-463e4bb5dbb1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of equity based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_87d50a59-bdf2-4bf8-9d6c-1af17e7c00f6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a402f15-c5de-47d4-9ff6-a9f0167eb991_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_7d5f4964-8440-4a03-9937-f22c82637dcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of restricted stock units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_967dbd3d-87de-4826-adcd-60afdc7465ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_d3ec015d-0837-4d15-b69c-1b5d3155f99c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_ddf4ff1b-c617-4337-a6d5-b41b0ff1d15f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_fed29ef3-d6b0-4c7e-ae98-30ba18da89c3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ab89cc73-9939-4442-9c53-f2d93b815764_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_a8e0916f-ead1-4f3a-91f2-54122098d06f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3ce49bf4-545c-40ab-8a00-0ef5f1ae630c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_913168c7-1365-4499-a9e2-8bb7dd734953_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9dd6b490-6091-4192-bdd1-b1ba36da31db_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f20408a2-2d34-44b0-bab0-a3155f767891_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b3693058-cbce-4bfe-8c24-d35d98b09600_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_d4ba9dbb-5807-465a-bac2-99ae50eb74f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs included in accounts payable</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_44e504cd-f1f7-4a0b-96a2-f6d1dc674ddd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9ba5bda2-a82a-404a-a234-0d4c68b30877_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_fdabdd20-06b9-4999-96c6-0686bca00b55_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_31b2bffa-40ed-4304-affa-7cc3d634ab4d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_afe790d6-b13f-4154-8e81-1e658d76dcaa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a72d837e-1bab-4749-920e-90a6bb8d550e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_601887aa-1779-4f69-8a3a-36621f559abd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price of placement shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_411ef38e-c24b-4fdf-bc6e-d621b1f76892_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at the end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_fa0d64f8-4466-4d0b-84ab-0cc3c81218e9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_9e7ab47f-f2dd-424c-a82c-87d2c12e572c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_df6a8e7d-f72f-4d70-827d-8afd09a8fdff_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_73f88dd2-885f-4fd3-8141-106be47b994d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1971bde9-9468-435f-8d04-005d8b09e12a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_61af5e88-663d-4f06-a1f1-9e68384f9b43_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1b6e723f-a4f5-4dfa-a497-3218b4cbbfe0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and experimental expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fbe91b9e-8092-4a06-881c-27bdb5d719b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18530836-3356-450f-8c41-2363c4a7e92d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c22c15fb-8da1-4bf3-bed5-6d288eaaabaa_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dc5eef3-e815-4a69-91dc-ec12c9c79b51_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_UpfrontPaymentRevenueMember_b3e990b1-48e4-4e0c-8bab-534a0358b537_terseLabel_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment revenue</link:label>
    <link:label id="lab_morf_UpfrontPaymentRevenueMember_label_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue [Member]</link:label>
    <link:label id="lab_morf_UpfrontPaymentRevenueMember_documentation_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_UpfrontPaymentRevenueMember" xlink:to="lab_morf_UpfrontPaymentRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_daf6bf4a-05e9-4db9-b1c5-1d7d424bd7cb_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cf606f1a-5abf-429e-b962-f1bb8a4ace38_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7524c645-b195-4ed6-bd00-f037c31ceb26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dbc2e5cd-66c0-46b0-b572-9652b7d12411_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7d7b16e4-fdca-4e0a-90b5-83c9199782a0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_fad9fa7f-19aa-481f-9fe4-7033a746a702_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction_b2cfa9d6-2ec5-4ec6-a67b-1fcb76d1a037_terseLabel_en-US" xlink:label="lab_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right to purchase common stock, purchase price (in dollars per share)</link:label>
    <link:label id="lab_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction_label_en-US" xlink:label="lab_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights Issued In Transaction</link:label>
    <link:label id="lab_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction_documentation_en-US" xlink:label="lab_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights Issued In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction" xlink:href="morf-20221231.xsd#morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction" xlink:to="lab_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_b607ff26-2611-41d6-9caa-9ad638927c91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of basic net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_ea296147-a7e3-4df7-aa18-bb726ae06b05_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c3724a19-5446-4f52-9a70-b879f6b7584b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f1e8fe4b-986b-4a74-b36a-82dfe90a6841_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_c760d5f3-68c3-41e0-955a-18fe032bb02c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_157057d3-95d0-4191-bbcf-930120399bb5_terseLabel_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of common shares available for purchase per employee per year</link:label>
    <link:label id="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_label_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Annual Value Of Shares Available For Purchase Per Employee</link:label>
    <link:label id="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_documentation_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual value of shares available for purchase per employee from employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:href="morf-20221231.xsd#morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:to="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ee9bc6d6-e108-4a61-b192-69e66f4358eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_57631ae6-9524-4aa5-9123-f6feb73352d4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_AtMarketOfferingProgramMember_7d1ec057-645d-4632-9a74-605321dcf3b6_terseLabel_en-US" xlink:label="lab_morf_AtMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM</link:label>
    <link:label id="lab_morf_AtMarketOfferingProgramMember_label_en-US" xlink:label="lab_morf_AtMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Offering Program [Member]</link:label>
    <link:label id="lab_morf_AtMarketOfferingProgramMember_documentation_en-US" xlink:label="lab_morf_AtMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents at-the-market offering program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtMarketOfferingProgramMember" xlink:href="morf-20221231.xsd#morf_AtMarketOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_AtMarketOfferingProgramMember" xlink:to="lab_morf_AtMarketOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_44d664c1-0d12-4a22-bd0a-15b134c7cbfd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_83727415-f5d2-4a6d-99ef-be580ef2b861_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3994e2e9-a2da-4b0b-865b-d96bd22f35a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves and accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b4b53ff1-7e71-4fc5-bfae-d2250158972c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ba2352c0-86e7-4c59-99fc-b100965a6b53_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40863a26-6951-4c15-a13a-2545f6276f77_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0857fe77-e029-4be3-ae13-dc15d19623b2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ae452c79-c416-4fae-be3e-32bfd1872424_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_23f0c8dc-d40b-484e-8ea5-facf4d5cb48e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bef6a472-5b52-4ab8-b949-732a80de2b10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0a215b14-747c-44bd-aeed-c0075e411bbe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_fc053f70-39f5-4bca-8fec-95742b09da02_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_be4c80ff-5b24-42c9-a6b5-2ebc4dbbf2b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CommonStockAvailableForIssuance_d2194e36-272b-4a26-8223-7fe00ddfd2b1_terseLabel_en-US" xlink:label="lab_morf_CommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of shares remaining available for sale</link:label>
    <link:label id="lab_morf_CommonStockAvailableForIssuance_label_en-US" xlink:label="lab_morf_CommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Available For Issuance</link:label>
    <link:label id="lab_morf_CommonStockAvailableForIssuance_documentation_en-US" xlink:label="lab_morf_CommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of common stock available for issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CommonStockAvailableForIssuance" xlink:href="morf-20221231.xsd#morf_CommonStockAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CommonStockAvailableForIssuance" xlink:to="lab_morf_CommonStockAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_435281a2-5c1b-4de6-a836-d83d8e1e2ae7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_51100e3d-f864-4dcc-a9ad-30d6118e622f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_87f07a55-179a-4f8c-9e8c-367202f8d490_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_83ae868d-398a-4446-8a17-1a675a53eebb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_df976b32-b56b-42e9-8dfc-1c535bbafb41_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued_18787ccb-f085-4725-8591-0bccb9d7b05d_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of discontinued research programs</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued_label_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Research Programs Discontinued</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Research Programs Discontinued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued" xlink:to="lab_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c1218be0-22f2-4871-a93f-b7aac4ab39cf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8f1b670e-191b-4d14-97f2-abf9c9f0d485_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid&#8209;in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b7fa6086-bd5a-4c7b-b7b3-4d29ea998852_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_49acb975-7454-47e4-beb2-4862f96febb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic market value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_92b8fdbd-d9ac-40fc-a736-cb45d277ba95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0415c84c-0efd-4f57-b158-77c76ab29c89_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_50973915-e270-4af0-8382-a7926c380cb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a8ef9e27-c227-44b1-80a9-6990395b9c88_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99b06366-ef30-44e8-8fdc-ce70aa507c73_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_a6e2b48d-574b-4a5c-ab89-e57416606c09_terseLabel_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_671310df-a306-4cdb-a6ee-5ba683462b87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_2260d2c8-810f-4c0d-8294-1b50a3b8d72f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_f0f5ee5a-0ffd-4173-8619-8140755df51e_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4ac29688-5e37-46b6-94c9-288795c138e5_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_421598e1-6b9d-4c85-8ab8-72463bd94145_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_099b00a8-ee81-4e1f-9f51-676f3dc4dd1e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, $0.0001 par value, 400,000,000 shares authorized, 38,584,678 shares issued and outstanding as of December&#160;31, 2022 and 37,085,397 shares issued and outstanding as of December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_faff9148-cf1f-4d89-ba20-4c05b8e51685_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b9e00626-803f-4ee7-8ea1-7aac77f50998_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4834a282-2bd2-4f2e-9252-386ea027836d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of common stock equivalent shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_86eb0955-95c9-46b6-94c5-7d33dc1cd0dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_73e82679-f9d7-4132-90ef-fb956d86cc18_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at the end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_1238159c-26e3-4423-ab92-9d13266fbfb0_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_70f06e2d-1eeb-4b02-93ff-d35f50e859c7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f3e7a47f-1ecf-4b88-b1a1-abb680a4c754_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea1305ee-f505-41e8-8fe8-8e4f2ce45339_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6dffe840-c6d0-45db-9b05-6d06c6fd3d29_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_725ed7b5-fa71-4edc-b020-4c5f6aea7227_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12424fad-de75-49c4-ab8d-5207f3517f7d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_bcfce385-1573-430d-a33a-726409d6013e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts from exercise of stock options included in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8a7003d7-c1c4-440a-82fc-41cbb939c6c1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_512239b9-3c72-4f8c-9133-b6ae1fb150a3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common shares upon stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2dd13bac-0f92-4e6a-b2c8-eaa3a1a6d9e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e54e7d59-b759-4403-b6ca-0530927e0c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f9a76d7b-9b6c-42f9-b4b9-72eeecaa0740_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_AtTheMarketOfferingMember_c4a797ef-2312-45fe-8983-44a503f05b22_terseLabel_en-US" xlink:label="lab_morf_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:label id="lab_morf_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_morf_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_morf_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_morf_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember" xlink:href="morf-20221231.xsd#morf_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_AtTheMarketOfferingMember" xlink:to="lab_morf_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7fe2f46b-616f-4a80-9ebe-fbd8fc80381d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d9a1192-59a3-4ab4-99de-e2b874911774_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9f31b8a6-8015-4be1-937e-3504969e5509_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e72c5d5-9259-43e6-92d3-38151e3fa6b1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfOptions_875735ca-c261-49d4-9806-e700f415ccde_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options available for exercise</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfOptions_label_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Options</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfOptions_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfOptions" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementNumberOfOptions" xlink:to="lab_morf_CollaborativeArrangementNumberOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c69a5287-5a94-4099-9fd0-64bb20535491_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_711e4d56-1143-4bd6-8e43-4ec8f71f7b79_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_786d1cdd-f16c-4c60-ba1a-095c85c9cfc2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_dd18a0c2-c569-42d4-9b6b-6024d81a236b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1c74bf20-06ab-42c0-9a32-e1f6eff9154a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_48eb7277-5c43-4ab4-816b-f7bb679ef05d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_647e7e9d-2a33-47fa-831a-a441c85c6894_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at the end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_134518f7-efc6-4e50-a1f6-90c091c0e28f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram_71e379db-2136-4d62-bd9d-5e92f3a824f4_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fee for third research program</link:label>
    <link:label id="lab_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram_label_en-US" xlink:label="lab_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Fee Received, Upon Commencement Of Third Research Program</link:label>
    <link:label id="lab_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Fee Received, Upon Commencement Of Third Research Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram" xlink:to="lab_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_b323130b-cfc0-404f-85cc-0ad171913099_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7572f1fe-1e91-4ab1-8782-4fc38dbdbe43_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effected at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_335017f8-ef0a-4422-a092-274d7f0e6d8b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding losses on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_ReimbursementRevenueMember_c9879004-f65e-4410-a1d7-e53b060283e5_terseLabel_en-US" xlink:label="lab_morf_ReimbursementRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement revenue</link:label>
    <link:label id="lab_morf_ReimbursementRevenueMember_label_en-US" xlink:label="lab_morf_ReimbursementRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Revenue [Member]</link:label>
    <link:label id="lab_morf_ReimbursementRevenueMember_documentation_en-US" xlink:label="lab_morf_ReimbursementRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ReimbursementRevenueMember" xlink:href="morf-20221231.xsd#morf_ReimbursementRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_ReimbursementRevenueMember" xlink:to="lab_morf_ReimbursementRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a1a2aa6a-1f50-4f09-b14e-71aaf2d84f64_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsUnderManagementCarryingAmount_b9c9ef4a-e7a8-4283-95b0-c588cc2d04d9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsUnderManagementCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under management</link:label>
    <link:label id="lab_us-gaap_AssetsUnderManagementCarryingAmount_label_en-US" xlink:label="lab_us-gaap_AssetsUnderManagementCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under Management, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsUnderManagementCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsUnderManagementCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsUnderManagementCarryingAmount" xlink:to="lab_us-gaap_AssetsUnderManagementCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5135059f-6971-4531-af30-5b2a298e5365_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9d881a1-0ad7-4f07-b98c-46360ee8263b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_8cde1f5c-1b77-4ca6-95cb-8ce8a90b1486_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_86c9108e-0751-4596-ac3b-be29d9f40aae_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_564eadda-7f24-488d-90a3-7013edec3183_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a2d69b2-187b-4e24-99bb-edf3e111af0e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction_8dbfcaa9-98f6-4be6-aa5f-4a3a5038f7ae_terseLabel_en-US" xlink:label="lab_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right to purchase common stock (in shares)</link:label>
    <link:label id="lab_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction_label_en-US" xlink:label="lab_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Or Rights Issued In Transaction</link:label>
    <link:label id="lab_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction_documentation_en-US" xlink:label="lab_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Or Rights Issued In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction" xlink:href="morf-20221231.xsd#morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction" xlink:to="lab_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bf3204d1-c13f-4e78-91b8-473d086978ba_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2c9c6779-9633-4fef-ae89-740de1565f71_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4e8a66ab-95bd-44e4-82c1-5647d15c2ed7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_73bb71ef-5e20-41c7-bd1a-ce4b9b005095_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bf62f999-3a0b-48be-8876-af32d9c1cff1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_312ed4f6-0849-4293-9857-c54909c4ad8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2382d67b-ac1e-47d0-b0e9-db5140d55589_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8c75b635-d073-40bd-9340-2826f934c615_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares upon stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1a82e6a5-78f7-44a5-86a0-233dbd220804_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash received from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fd9fb7ea-a0a2-43ff-b24d-8f42a908cce0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_94698c3f-1694-4846-9c29-3666927d494f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d63745bb-470f-44b8-972f-4251cf632980_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_668e092c-f09f-4fe8-adaf-3748b672dd0f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_cde9e2ba-96f1-4244-91ca-ccf4f9ca9aea_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_053f9fbb-b1ad-43cc-b7ba-31614f6461d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e9520700-b2fd-4ffa-8074-965f155f7a13_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c33cb4bc-d38a-49df-b03a-576f9d14a787_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets_ab804fe8-d926-4b66-9298-4f4e817d2749_negatedTerseLabel_en-US" xlink:label="lab_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets" xlink:href="morf-20221231.xsd#morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets" xlink:to="lab_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e5be5df6-b317-46c1-9b30-6d200ab03e54_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_e16f1514-d2ce-412d-bdf2-c61ea8f02d80_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_c15b70a6-4d4b-46f2-9f5c-98be527be1a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7eceee71-021e-4e0f-acfd-4b7216356797_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_77f688d1-c239-4349-933e-64adeb80e8ac_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_fef54586-a9db-4d20-961c-d6ccaea6ae1b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period ( in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_07a478e8-4e1e-453f-93ec-eea8e74cd907_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period ( in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_381197d2-03b4-4326-91f2-b48e8f361c03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_81cec3c8-1b2f-43aa-b20a-a1af3243c3c1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_a563f8ea-5318-45cd-aa90-21cef66813f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_7f72cf6a-9943-4277-8e91-bf579e1a5eee_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_059baae5-6df2-4e35-bf19-37f9988c7e45_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6110c996-07c4-4921-b5c9-c3145c470c16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_df0350b9-4d2b-49f4-b457-9ceddd8bffca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_95933bdd-0c37-4e7a-89f4-1bc9b393fc57_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c1c9565-1912-4ec0-822c-c6c4bc366111_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_26ce9d8f-1755-46c7-bb19-04934947555a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d8bcba0e-b739-4b6a-871d-cc540b241525_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ec186153-909e-4c61-809e-4bf25c9f354c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_8b741c83-7932-4b97-9370-8e9db01e3a37_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_fce569f7-d64d-449f-9440-0a114f3668fd_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_a0605038-f209-4bdf-80f7-1d571373463e_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_43556876-b98a-4fbe-b13e-7df547561b3f_terseLabel_en-US" xlink:label="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate to purchase common stock</link:label>
    <link:label id="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_label_en-US" xlink:label="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement, Percentage Of Discount On Purchase Of Common Stock</link:label>
    <link:label id="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_documentation_en-US" xlink:label="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of discount provided to employees to purchase common stock under the employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:href="morf-20221231.xsd#morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:to="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d11002cb-862f-4159-8703-2207ba002fc1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7ac7d848-17fa-4dce-a82a-045df5e6f3eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0dfa365d-4e63-467b-a254-7c91983cb957_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_64dc80ea-9a24-4191-a655-3512cc4194d3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium amortization and discount accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborationAgreementOptionExerciseRevenueReceived_d42712f2-b1ad-4a0a-a5eb-d3de1d996376_terseLabel_en-US" xlink:label="lab_morf_CollaborationAgreementOptionExerciseRevenueReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from option exercise</link:label>
    <link:label id="lab_morf_CollaborationAgreementOptionExerciseRevenueReceived_label_en-US" xlink:label="lab_morf_CollaborationAgreementOptionExerciseRevenueReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option Exercise Revenue Received</link:label>
    <link:label id="lab_morf_CollaborationAgreementOptionExerciseRevenueReceived_documentation_en-US" xlink:label="lab_morf_CollaborationAgreementOptionExerciseRevenueReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of revenue recognized from option exercise during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborationAgreementOptionExerciseRevenueReceived" xlink:href="morf-20221231.xsd#morf_CollaborationAgreementOptionExerciseRevenueReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborationAgreementOptionExerciseRevenueReceived" xlink:to="lab_morf_CollaborationAgreementOptionExerciseRevenueReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6cf802f0-ed4e-4d1f-b5e8-dc636cece4a4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementTermOfArrangement_8ff71bf2-6380-4115-8c82-1e1a632cf081_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementTermOfArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of arrangement</link:label>
    <link:label id="lab_morf_CollaborativeArrangementTermOfArrangement_label_en-US" xlink:label="lab_morf_CollaborativeArrangementTermOfArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term Of Arrangement</link:label>
    <link:label id="lab_morf_CollaborativeArrangementTermOfArrangement_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementTermOfArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term Of Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementTermOfArrangement" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementTermOfArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementTermOfArrangement" xlink:to="lab_morf_CollaborativeArrangementTermOfArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1cafe2bd-4b62-46a7-95c6-6b7c0085bd2f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_ddd35801-30a7-4af0-bcba-1f4834645a88_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_52efdfb5-1604-4515-a256-345e33e4b600_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6fe506f2-54ac-4b33-8000-e7337f95a905_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fcefb65c-46de-4cbe-95fb-8f5c10cbb5a5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83c83fa5-e14a-46a6-8fc3-e008a7fb1d7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_917f029c-25eb-4871-a45c-ebb9d051fbd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7e6b01ba-0a5b-4b72-9400-a7f78c365316_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from secondary offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c420f9b0-18ed-4645-a355-6e24c2acf9c8_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate proceeds received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_11942262-82b3-45f4-b3a0-4dbb23a28e84_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4fabb51f-a051-4b78-b43e-c9abdaee9770_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_eb00446b-077c-473a-a173-4f525b5f5ca9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_DeferredTaxAssetLeaseLiabilities_02a788a9-a24a-453e-9480-6f12ece15f1a_terseLabel_en-US" xlink:label="lab_morf_DeferredTaxAssetLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_morf_DeferredTaxAssetLeaseLiabilities_label_en-US" xlink:label="lab_morf_DeferredTaxAssetLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Lease Liabilities</link:label>
    <link:label id="lab_morf_DeferredTaxAssetLeaseLiabilities_documentation_en-US" xlink:label="lab_morf_DeferredTaxAssetLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_DeferredTaxAssetLeaseLiabilities" xlink:href="morf-20221231.xsd#morf_DeferredTaxAssetLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_DeferredTaxAssetLeaseLiabilities" xlink:to="lab_morf_DeferredTaxAssetLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_9a9a9192-99ca-4496-8bdf-f1a9305cb7ea_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_72ddb527-647c-484d-b485-5c2d4b01834e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f68d2e86-f957-442a-925d-0e5d4d71df7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common shares, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3d848fd7-37a1-4947-bcda-fa13b128e93b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_26404cb8-7846-4fd5-b9a4-fc016d9ed1c5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5f9bf4e9-2656-46c9-823a-ea4d67648028_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b6aa8d49-70d6-4c55-83bc-2ec6e452d030_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e4b10147-8e0a-4048-ab9a-3f714c43c140_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_60aec452-85e5-4893-aad6-8de8c523afeb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8a7e6aa9-6516-4b4e-86ee-c395ee9206d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7787c841-f4b3-41e4-b7ca-331e99fc5cff_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_7363eab3-7c8f-45e7-8f03-e8809c7f0ee8_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_AccruedResearchAndDevelopment_179688ee-300f-4211-87ab-d52aa99d82ef_terseLabel_en-US" xlink:label="lab_morf_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development activities</link:label>
    <link:label id="lab_morf_AccruedResearchAndDevelopment_label_en-US" xlink:label="lab_morf_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development</link:label>
    <link:label id="lab_morf_AccruedResearchAndDevelopment_documentation_en-US" xlink:label="lab_morf_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AccruedResearchAndDevelopment" xlink:href="morf-20221231.xsd#morf_AccruedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_AccruedResearchAndDevelopment" xlink:to="lab_morf_AccruedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_bc63bf53-01b6-4076-b9b3-d09adef66f21_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_2d0d7a0a-cdd5-4c42-a695-1b380d0518d5_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_e2e0fdfa-18e2-44c1-bb73-030bbf32afbc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted common stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_0619005b-c28b-4bca-b662-44994dd89f93_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_23396897-7c16-4823-9a99-74baaeef0eea_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_079f419f-4e4e-4007-b9d1-a4b3dc4a2c0d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a332dc29-150c-4bfb-ae3a-7251bf204c8c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_553cca1b-c5f4-4ee0-8e76-fb1bc85d2474_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_72a847fa-a7a7-4b1b-a698-7d587185b477_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_676d6c6a-2487-4e7a-bd72-de37b753a590_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0547c379-5a46-4911-9202-05e1a6841bf3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_9ee4a07b-08cc-49f2-b23a-34e1864162a5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_42d5be33-2082-43c4-886c-4474276442a5_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3f9213de-4348-4b38-8a9d-5c982dc77b38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_99a7b120-4566-4291-9c0e-32e5ca67608b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_dfc1a2f2-fc42-44ec-9847-b8e19b82fb81_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_d4e3f82d-62ca-46d9-a29f-222be3140127_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8edc3cf5-1e9d-4b7e-b283-eab8d513ee15_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_EmployeeStockPurchasePlanMember_8ecac3c6-9885-4aba-b755-c8a7c2754af3_terseLabel_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_morf_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_morf_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Employee Stock Purchase Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember" xlink:href="morf-20221231.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_EmployeeStockPurchasePlanMember" xlink:to="lab_morf_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_6c2e7db7-2216-49d9-8919-9353bf32acbb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d9903255-e076-4120-9f47-7e63944cbb3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk&#8209;free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_befa1290-f10f-4f2d-8ff3-22ea09dac4a9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2c8ebe0e-a062-484c-9c38-e41825a786e8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_f151e940-fc4e-4b0d-9866-5119447fc154_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of letter of credit (in years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_68de5a75-0e23-45d1-adb1-3078a897450e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_62b8176f-f749-4d7b-baac-e84621d3713f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementUpfrontFeesReceived_5b12db6e-8415-435d-bb34-d8e5758f3736_verboseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementUpfrontFeesReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees received</link:label>
    <link:label id="lab_morf_CollaborativeArrangementUpfrontFeesReceived_label_en-US" xlink:label="lab_morf_CollaborativeArrangementUpfrontFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Fees Received</link:label>
    <link:label id="lab_morf_CollaborativeArrangementUpfrontFeesReceived_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementUpfrontFeesReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of upfront payment fee received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementUpfrontFeesReceived" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementUpfrontFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementUpfrontFeesReceived" xlink:to="lab_morf_CollaborativeArrangementUpfrontFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_afdc6ee6-156c-4d54-a033-24148ffb1e9a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_3684cd46-4955-4ee0-a4e8-ecde358b9f32_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_af4db5de-850f-468e-b60a-1b88e6334c9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4ae70802-ffce-4be6-8588-b6ffaf11ca91_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b83e6490-776d-446e-a679-21559426adca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_14197d06-4614-4b35-be60-a5e6799eeab5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_018650be-014d-43f2-8be4-60299cf06b72_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ab8b676e-e6f9-48ff-a62b-3e5f4f26a9d1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7066e052-133d-4a6f-ba1f-bcadd0647f3b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ad2f8c36-e26a-4a66-ada8-a914c1fde555_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2e1dafef-505b-4502-971c-ea7be22199ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_9cf2fd12-0432-4d59-b117-7064765a6bfa_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_734a86d3-d640-47d0-a87d-bb38fd040841_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4636074c-0515-4e8c-af75-1c3592081eaf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_352d94b1-500e-482f-a717-db1a1cb4ba52_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_ComputerEquipmentAndSoftwareMember_2170d143-5f0c-445f-8162-6f9f068d297c_terseLabel_en-US" xlink:label="lab_morf_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_morf_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_morf_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_morf_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_morf_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ComputerEquipmentAndSoftwareMember" xlink:href="morf-20221231.xsd#morf_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_ComputerEquipmentAndSoftwareMember" xlink:to="lab_morf_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock_d3acab3d-0541-4fe8-83d1-e01bbb004199_terseLabel_en-US" xlink:label="lab_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on investments</link:label>
    <link:label id="lab_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income On Investments Policy [Policy Text Block]</link:label>
    <link:label id="lab_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income On Investments Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock" xlink:href="morf-20221231.xsd#morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock" xlink:to="lab_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2b363e6e-7a96-43e3-adad-8404deb5859f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a75da43d-e495-4e24-9fc8-7745e32ee246_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_6db7aaf5-2ba3-469a-9d84-aba1f8e7808f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ce31f9e0-0d60-4a98-97c8-9e688fdc4698_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of lease maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0dd2f4f3-45f4-4c8d-9887-c7c7e7303f5f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1da6c562-abae-479b-ba41-44631eadb4ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2f7d5e37-e30f-4451-a514-2629bde67bae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_abff1dfa-afd4-49ac-bd27-24d239006b30_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_7167803c-6f4d-4645-8407-9e00a1cd3feb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares under the Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_51a02518-be66-49f0-a1d4-733144fa6af5_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9dc82a98-df7a-4ac6-aca9-ed2b1c4cb91a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_fe1e4cf6-c331-40c2-9fd2-52640a5e94ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_FollowOnPublicOfferingMember_a438648b-d1ef-4438-92e2-d8f39d38c355_terseLabel_en-US" xlink:label="lab_morf_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering</link:label>
    <link:label id="lab_morf_FollowOnPublicOfferingMember_label_en-US" xlink:label="lab_morf_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Public Offering [Member]</link:label>
    <link:label id="lab_morf_FollowOnPublicOfferingMember_documentation_en-US" xlink:label="lab_morf_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_FollowOnPublicOfferingMember" xlink:href="morf-20221231.xsd#morf_FollowOnPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_FollowOnPublicOfferingMember" xlink:to="lab_morf_FollowOnPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_877176de-a218-4dd3-ad83-660af432e2a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding losses on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_d3baee70-6d70-41f9-831d-eb578b92302f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f9c9d918-b2db-4605-9d16-543a1954fbf1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06ba0246-8711-4e38-ac14-aaaf01cd9455_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9ae63c9b-6987-44f6-a22a-a5b63ede98f9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution total amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c0279183-e483-4921-b2d8-9d0ff94d943e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9d98c141-ade6-4e76-9cce-7acc8ad1e4f3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementPaymentDuePeriod_51948928-2c8e-49eb-bb15-ba81878d6b62_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementPaymentDuePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment due period</link:label>
    <link:label id="lab_morf_CollaborativeArrangementPaymentDuePeriod_label_en-US" xlink:label="lab_morf_CollaborativeArrangementPaymentDuePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment Due Period</link:label>
    <link:label id="lab_morf_CollaborativeArrangementPaymentDuePeriod_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementPaymentDuePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment Due Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementPaymentDuePeriod" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementPaymentDuePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementPaymentDuePeriod" xlink:to="lab_morf_CollaborativeArrangementPaymentDuePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_edd8c74b-7a29-45af-affc-d3c04668dce2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_ed9f4b2f-c9c8-40f1-8302-c245deef99e2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_309cb95d-6cf2-4ca5-8a81-63ab7ea14229_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e8d39b38-4bf8-4773-b8d2-0f1ba4f65974_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_AbbVieMember_41c19386-9587-4e65-8139-bb5740500755_terseLabel_en-US" xlink:label="lab_morf_AbbVieMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_morf_AbbVieMember_label_en-US" xlink:label="lab_morf_AbbVieMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_morf_AbbVieMember_documentation_en-US" xlink:label="lab_morf_AbbVieMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents AbbVie Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember" xlink:href="morf-20221231.xsd#morf_AbbVieMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_AbbVieMember" xlink:to="lab_morf_AbbVieMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_1a4ef133-0e94-47e4-b808-da9c992bc26b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_45c8cd1c-6218-43f4-8cb6-99706db512fd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity&#8209;based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a1d2fd73-6ab0-4f93-9343-d20161b989d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aae1d5f8-c84b-413f-89e8-8c863e11ab81_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_78027249-6036-4c9f-a722-b6233db9cdb2_terseLabel_en-US" xlink:label="lab_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored enterprise securities</link:label>
    <link:label id="lab_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_label_en-US" xlink:label="lab_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and U.S. Government-sponsored Enterprise Securities [Member]</link:label>
    <link:label id="lab_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_documentation_en-US" xlink:label="lab_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and U.S. Government-sponsored Enterprise Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember" xlink:href="morf-20221231.xsd#morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember" xlink:to="lab_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_169fc1bb-06f3-4c6d-bac5-156b033e72d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_59f4425b-35be-45c3-ba3a-c697aecee9de_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9a6fcc21-9e4b-47d6-8eaa-789d3c6dc50d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_afd07e02-ea30-4615-ad69-fdc99805f356_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfResearchPrograms_3e6219b3-b693-40f2-b99b-a8b287464c80_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfResearchPrograms_label_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Research Programs</link:label>
    <link:label id="lab_morf_CollaborativeArrangementNumberOfResearchPrograms_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementNumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Research Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfResearchPrograms" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfResearchPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementNumberOfResearchPrograms" xlink:to="lab_morf_CollaborativeArrangementNumberOfResearchPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_dc6ebc74-eaf3-460e-8544-29b8bfafd8d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_77374fd3-4374-4213-b28e-db4982544fbe_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e3763a8-7578-4ff9-b983-a66ebe7cb537_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Fair Value per Share at Issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17986fc3-2d59-4a61-8636-438a382f931d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7a4af718-1e5b-44b6-a26b-6691c2c62270_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6a0b0e73-60c5-451e-a3a1-f22ff7a22026_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a7118186-240f-4a8f-bd8d-15fd7c68c117_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1fa96e32-8fb2-4ccf-b689-7f0306bfd432_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_00401da5-3163-4024-a03f-58f0a3de7dbc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_0de7cfa3-263e-4e8d-b216-69384661c1bd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3151ce47-04c4-4bc1-908d-88efc38256fa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock_da337577-9d64-4024-8217-bdca010559ac_terseLabel_en-US" xlink:label="lab_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of information relating to stock</link:label>
    <link:label id="lab_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock_label_en-US" xlink:label="lab_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Payment Award Summarized Information Relating To Stock Options [Table Text Block]</link:label>
    <link:label id="lab_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock_documentation_en-US" xlink:label="lab_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Payment Award Summarized Information Relating To Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock" xlink:href="morf-20221231.xsd#morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock" xlink:to="lab_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_84fe20ec-ec3c-4e32-92ef-e28674a87d31_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_605876b9-b5fb-4518-bb10-e50c2c192d43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity&#8209;based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_54e01c45-f445-4b61-95cf-c377f513d34d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of options granted, per option (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_cd8d89ab-3dad-4e9f-98aa-0e8200ec50e5_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a63a21e-8497-4b89-8476-e281a1f9ebca_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_75d8ad2b-d5eb-48de-baf1-4312f91c26f0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_80751756-8b72-49eb-b7f1-72b4e95590bc_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_f6efed1e-90d6-41b3-9b8e-10f86bece0a5_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>morf-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3504fb1d-c703-4af8-962a-40bb538fa93a,g:d0f79058-117f-4d7c-9741-2cac766e63e2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://morphictx.com/role/CoverPage" xlink:type="simple" xlink:href="morf-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fdcabf06-2eff-4482-95d4-0d15e781ea6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_DocumentType_fdcabf06-2eff-4482-95d4-0d15e781ea6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_4d2b8ca5-f0b8-4db3-b376-3d21cdfd2256" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_DocumentAnnualReport_4d2b8ca5-f0b8-4db3-b376-3d21cdfd2256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c6e04be2-6821-43de-ac12-4b405e5ebfe3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_DocumentPeriodEndDate_c6e04be2-6821-43de-ac12-4b405e5ebfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0117ec2e-a0a7-474d-b9d5-1cb6c2563bb0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_CurrentFiscalYearEndDate_0117ec2e-a0a7-474d-b9d5-1cb6c2563bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_24dea992-37fc-4192-bca2-531abaf3c627" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_DocumentTransitionReport_24dea992-37fc-4192-bca2-531abaf3c627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2a7f4724-83e4-44c3-893b-58a82a636e5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityFileNumber_2a7f4724-83e4-44c3-893b-58a82a636e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6caa383c-0561-4d34-b0bc-d4d94dedcb96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityRegistrantName_6caa383c-0561-4d34-b0bc-d4d94dedcb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_76fb3aad-bce5-4e2d-9a7e-c4566d907117" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_76fb3aad-bce5-4e2d-9a7e-c4566d907117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fad36ef7-68a9-458e-a131-8028505e3836" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityTaxIdentificationNumber_fad36ef7-68a9-458e-a131-8028505e3836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9d00149a-4d88-46cd-8df9-fcedbfe5fded" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityAddressAddressLine1_9d00149a-4d88-46cd-8df9-fcedbfe5fded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f8bcd32d-8820-49f9-98ed-e184d66cd8e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityAddressAddressLine2_f8bcd32d-8820-49f9-98ed-e184d66cd8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_528369b5-0596-437a-be53-4b28b7b896df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityAddressCityOrTown_528369b5-0596-437a-be53-4b28b7b896df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_96054d72-9b3b-47ac-bdbb-19ba98664a27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityAddressStateOrProvince_96054d72-9b3b-47ac-bdbb-19ba98664a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_027fb454-6c8d-428a-a0ca-3b991b5d60dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityAddressPostalZipCode_027fb454-6c8d-428a-a0ca-3b991b5d60dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c6848e5e-405e-4b5a-9b14-11a26ddc36d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_CityAreaCode_c6848e5e-405e-4b5a-9b14-11a26ddc36d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2a3b6284-5fae-4dd9-bdfa-566d40ebf16a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_LocalPhoneNumber_2a3b6284-5fae-4dd9-bdfa-566d40ebf16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_19f52c5e-99c3-4ff6-b295-3311bfd5c41b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_Security12bTitle_19f52c5e-99c3-4ff6-b295-3311bfd5c41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_397f59ff-25e6-481a-bbb2-b671f78000ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_TradingSymbol_397f59ff-25e6-481a-bbb2-b671f78000ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_afc88456-2449-43c1-a962-e30fe9a83ba2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_SecurityExchangeName_afc88456-2449-43c1-a962-e30fe9a83ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_18f5c4b3-7b81-4047-9687-039e0a06a78a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_18f5c4b3-7b81-4047-9687-039e0a06a78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_385de0f3-dc66-4b59-89d8-65daa3ac14fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityVoluntaryFilers_385de0f3-dc66-4b59-89d8-65daa3ac14fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1a575a40-54f1-450b-84af-d4978250c3c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityCurrentReportingStatus_1a575a40-54f1-450b-84af-d4978250c3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4ad76343-ba30-4f54-b6a0-1887b4bae17f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityInteractiveDataCurrent_4ad76343-ba30-4f54-b6a0-1887b4bae17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_53926a1d-ce48-42a2-aec6-59de469c3b20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityFilerCategory_53926a1d-ce48-42a2-aec6-59de469c3b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f50b0f85-4abc-4197-8f26-2eda767cc49b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntitySmallBusiness_f50b0f85-4abc-4197-8f26-2eda767cc49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_146dec01-983f-40bc-abea-66eff2a2de4d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityEmergingGrowthCompany_146dec01-983f-40bc-abea-66eff2a2de4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_85f9b9fc-3720-4519-9bb7-9b571da3f13c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_IcfrAuditorAttestationFlag_85f9b9fc-3720-4519-9bb7-9b571da3f13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_dd794e6a-35c8-4e7c-b5ae-53c084e91912" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityShellCompany_dd794e6a-35c8-4e7c-b5ae-53c084e91912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f73f11cd-5415-49dc-aa87-7095777b7226" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityPublicFloat_f73f11cd-5415-49dc-aa87-7095777b7226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_eec2739a-e1f8-4822-9e1a-c2497eeb4bac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_eec2739a-e1f8-4822-9e1a-c2497eeb4bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0897aff4-ed39-493b-a2e7-fd30534359d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0897aff4-ed39-493b-a2e7-fd30534359d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1e352008-699b-492c-bc0a-6ded4e4b73b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_EntityCentralIndexKey_1e352008-699b-492c-bc0a-6ded4e4b73b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_db89f3f9-6e59-416e-bf29-969237c89384" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_DocumentFiscalYearFocus_db89f3f9-6e59-416e-bf29-969237c89384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4451a8d0-a9d5-41c7-8aef-deb6d2afe47f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4451a8d0-a9d5-41c7-8aef-deb6d2afe47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7f3ff8c1-89a4-4028-9995-673637abdff0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d8f507e1-417c-4949-924d-af1d1e0db2bf" xlink:to="loc_dei_AmendmentFlag_7f3ff8c1-89a4-4028-9995-673637abdff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/AuditInformation" xlink:type="simple" xlink:href="morf-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_morf_AuditInformationAbstract_2d308e61-507f-44d3-ae79-ba92dd4678f6" xlink:href="morf-20221231.xsd#morf_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_9dc6024b-6117-4631-839c-95e537d3bdba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_AuditInformationAbstract_2d308e61-507f-44d3-ae79-ba92dd4678f6" xlink:to="loc_dei_AuditorFirmId_9dc6024b-6117-4631-839c-95e537d3bdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_8b49e58a-3a70-4cb9-8ee6-d116b6b2ec97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_AuditInformationAbstract_2d308e61-507f-44d3-ae79-ba92dd4678f6" xlink:to="loc_dei_AuditorName_8b49e58a-3a70-4cb9-8ee6-d116b6b2ec97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_7d022b5f-0e41-44e8-913e-ac5b33c7c777" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_AuditInformationAbstract_2d308e61-507f-44d3-ae79-ba92dd4678f6" xlink:to="loc_dei_AuditorLocation_7d022b5f-0e41-44e8-913e-ac5b33c7c777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce06f7d-190b-4a4b-9840-26d44cc3b1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6da84f99-7d3b-4aa8-aaec-282c06af0ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce06f7d-190b-4a4b-9840-26d44cc3b1ad" xlink:to="loc_us-gaap_AssetsAbstract_6da84f99-7d3b-4aa8-aaec-282c06af0ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2c73e5ef-3431-4aae-91ca-03539d2dc7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da84f99-7d3b-4aa8-aaec-282c06af0ef2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2c73e5ef-3431-4aae-91ca-03539d2dc7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7fcf602-9a01-4990-821c-9677f5013d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c73e5ef-3431-4aae-91ca-03539d2dc7a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7fcf602-9a01-4990-821c-9677f5013d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_224ecc4c-424e-4c6d-b517-23218ce2954b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c73e5ef-3431-4aae-91ca-03539d2dc7a5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_224ecc4c-424e-4c6d-b517-23218ce2954b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_919f6811-3dca-4a14-b147-af2d52900209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c73e5ef-3431-4aae-91ca-03539d2dc7a5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_919f6811-3dca-4a14-b147-af2d52900209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_700290fe-04b3-497e-a522-6fd327dbf126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c73e5ef-3431-4aae-91ca-03539d2dc7a5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_700290fe-04b3-497e-a522-6fd327dbf126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9286ec38-59b7-4f65-82ba-4e790d394183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2c73e5ef-3431-4aae-91ca-03539d2dc7a5" xlink:to="loc_us-gaap_AssetsCurrent_9286ec38-59b7-4f65-82ba-4e790d394183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9eb10c3d-4370-419b-99a9-a85fe4db4a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da84f99-7d3b-4aa8-aaec-282c06af0ef2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9eb10c3d-4370-419b-99a9-a85fe4db4a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0aeb7e79-4e61-438b-bdcc-52a1673d80c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da84f99-7d3b-4aa8-aaec-282c06af0ef2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0aeb7e79-4e61-438b-bdcc-52a1673d80c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_6576143c-d346-42d3-a4df-5e9ad911e8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da84f99-7d3b-4aa8-aaec-282c06af0ef2" xlink:to="loc_us-gaap_RestrictedCash_6576143c-d346-42d3-a4df-5e9ad911e8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8b4aeabb-fcdc-4544-ac0a-5783c76aa977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da84f99-7d3b-4aa8-aaec-282c06af0ef2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8b4aeabb-fcdc-4544-ac0a-5783c76aa977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8ab3a91b-c90f-4695-9de3-924b4d4f0ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da84f99-7d3b-4aa8-aaec-282c06af0ef2" xlink:to="loc_us-gaap_Assets_8ab3a91b-c90f-4695-9de3-924b4d4f0ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c403587a-ab43-4c4a-912e-c1f38b2db118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce06f7d-190b-4a4b-9840-26d44cc3b1ad" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c403587a-ab43-4c4a-912e-c1f38b2db118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_20aef9b3-73a5-4c79-ace4-69ba89de4f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c403587a-ab43-4c4a-912e-c1f38b2db118" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_20aef9b3-73a5-4c79-ace4-69ba89de4f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4b865551-84c9-4ec7-9cc3-01f77ee6a99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20aef9b3-73a5-4c79-ace4-69ba89de4f06" xlink:to="loc_us-gaap_AccountsPayableCurrent_4b865551-84c9-4ec7-9cc3-01f77ee6a99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_daf75a61-c761-43e0-9ddc-53806ad7aa29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20aef9b3-73a5-4c79-ace4-69ba89de4f06" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_daf75a61-c761-43e0-9ddc-53806ad7aa29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a339f811-d283-4d45-9ae5-97858797d211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20aef9b3-73a5-4c79-ace4-69ba89de4f06" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a339f811-d283-4d45-9ae5-97858797d211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6dffdbe5-5472-42fa-887c-a85d32977473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20aef9b3-73a5-4c79-ace4-69ba89de4f06" xlink:to="loc_us-gaap_LiabilitiesCurrent_6dffdbe5-5472-42fa-887c-a85d32977473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_e635ca1b-7aca-4526-872c-2a35278146ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c403587a-ab43-4c4a-912e-c1f38b2db118" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_e635ca1b-7aca-4526-872c-2a35278146ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97253aef-03da-4909-8f85-5b06fcc8b422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e635ca1b-7aca-4526-872c-2a35278146ce" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97253aef-03da-4909-8f85-5b06fcc8b422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_50dbc89d-8aa6-4daf-aed5-dd434177b0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e635ca1b-7aca-4526-872c-2a35278146ce" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_50dbc89d-8aa6-4daf-aed5-dd434177b0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_40565819-b77a-45b7-a07d-19a97285db03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e635ca1b-7aca-4526-872c-2a35278146ce" xlink:to="loc_us-gaap_Liabilities_40565819-b77a-45b7-a07d-19a97285db03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bd086c75-1f1b-4afd-bac4-28da2711396e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c403587a-ab43-4c4a-912e-c1f38b2db118" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bd086c75-1f1b-4afd-bac4-28da2711396e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b7f6abb9-d32b-4388-8f20-3200b62ccf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c403587a-ab43-4c4a-912e-c1f38b2db118" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b7f6abb9-d32b-4388-8f20-3200b62ccf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f4bb497b-5d30-4195-9310-d6c1948dff77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b7f6abb9-d32b-4388-8f20-3200b62ccf3e" xlink:to="loc_us-gaap_PreferredStockValue_f4bb497b-5d30-4195-9310-d6c1948dff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_728d4c26-2063-4808-849e-582bec6326d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b7f6abb9-d32b-4388-8f20-3200b62ccf3e" xlink:to="loc_us-gaap_CommonStockValue_728d4c26-2063-4808-849e-582bec6326d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3bc07c63-ef24-4587-9efe-ae94fdfe4e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b7f6abb9-d32b-4388-8f20-3200b62ccf3e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3bc07c63-ef24-4587-9efe-ae94fdfe4e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_936eae1e-854d-42c4-b8f0-f2a11821808d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b7f6abb9-d32b-4388-8f20-3200b62ccf3e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_936eae1e-854d-42c4-b8f0-f2a11821808d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a818b4ec-241a-47a1-a544-c3dba4993ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b7f6abb9-d32b-4388-8f20-3200b62ccf3e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a818b4ec-241a-47a1-a544-c3dba4993ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7880ec9-4553-47f1-8348-68fb9a36ddff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b7f6abb9-d32b-4388-8f20-3200b62ccf3e" xlink:to="loc_us-gaap_StockholdersEquity_a7880ec9-4553-47f1-8348-68fb9a36ddff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_93df78f8-cf5b-4956-8391-284295c2d959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c403587a-ab43-4c4a-912e-c1f38b2db118" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_93df78f8-cf5b-4956-8391-284295c2d959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5a690e10-bad0-4efc-ba87-be6924732ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6150a58a-5b8c-45fb-8dce-3fab8aa350cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a690e10-bad0-4efc-ba87-be6924732ebb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6150a58a-5b8c-45fb-8dce-3fab8aa350cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_607a33b6-b8e5-4bab-97a6-1e45d9b81866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a690e10-bad0-4efc-ba87-be6924732ebb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_607a33b6-b8e5-4bab-97a6-1e45d9b81866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_37ce921d-36e9-4f74-8037-cfaf7f963bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a690e10-bad0-4efc-ba87-be6924732ebb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_37ce921d-36e9-4f74-8037-cfaf7f963bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4e3c765c-b87b-4d51-a7f8-ae087b8fa32b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a690e10-bad0-4efc-ba87-be6924732ebb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4e3c765c-b87b-4d51-a7f8-ae087b8fa32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_41cf6732-2bf4-45ed-adf0-992f5b4ada27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a690e10-bad0-4efc-ba87-be6924732ebb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_41cf6732-2bf4-45ed-adf0-992f5b4ada27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_22c9ce46-dc9a-4371-a303-d9b80ae5b2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a690e10-bad0-4efc-ba87-be6924732ebb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_22c9ce46-dc9a-4371-a303-d9b80ae5b2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4a1b3dbd-727c-4603-bd55-2db0d3c822ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a690e10-bad0-4efc-ba87-be6924732ebb" xlink:to="loc_us-gaap_CommonStockSharesIssued_4a1b3dbd-727c-4603-bd55-2db0d3c822ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d327c1ff-14ac-4a1c-8d30-7baafd8e8589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5a690e10-bad0-4efc-ba87-be6924732ebb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d327c1ff-14ac-4a1c-8d30-7baafd8e8589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c88be38-3937-4097-bd1a-05784be08fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c88be38-3937-4097-bd1a-05784be08fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_37a5495c-3931-4722-9dc3-f007eeba531f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_37a5495c-3931-4722-9dc3-f007eeba531f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e0af52a2-6015-407b-840f-d63ca1ae2f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_37a5495c-3931-4722-9dc3-f007eeba531f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e0af52a2-6015-407b-840f-d63ca1ae2f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a5d7d78f-3a9c-4dcf-a223-2099a5182b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_37a5495c-3931-4722-9dc3-f007eeba531f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a5d7d78f-3a9c-4dcf-a223-2099a5182b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_67f1678d-94c9-4f34-b721-ed76991bfae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_37a5495c-3931-4722-9dc3-f007eeba531f" xlink:to="loc_us-gaap_CostsAndExpenses_67f1678d-94c9-4f34-b721-ed76991bfae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1ae0a500-392d-4a58-bb42-13785061ef92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_OperatingIncomeLoss_1ae0a500-392d-4a58-bb42-13785061ef92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0259d51e-e8d4-4036-aad5-54f6f941417e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0259d51e-e8d4-4036-aad5-54f6f941417e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f4176446-a6e1-4c92-87c1-33ad35e5ec72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0259d51e-e8d4-4036-aad5-54f6f941417e" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f4176446-a6e1-4c92-87c1-33ad35e5ec72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_314adabf-e06f-4c33-95f4-fdbe8d56e9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0259d51e-e8d4-4036-aad5-54f6f941417e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_314adabf-e06f-4c33-95f4-fdbe8d56e9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6801c37c-51db-4b84-8cbf-05862b12dec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0259d51e-e8d4-4036-aad5-54f6f941417e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6801c37c-51db-4b84-8cbf-05862b12dec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16c2c760-fd70-46c8-8e4b-410f4ae538af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16c2c760-fd70-46c8-8e4b-410f4ae538af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_03311648-cd36-47cd-a401-5296e60cbc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_03311648-cd36-47cd-a401-5296e60cbc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc180001-8ea4-45cb-b4ce-703151fd2423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_NetIncomeLoss_cc180001-8ea4-45cb-b4ce-703151fd2423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1d6d9dfc-3ec0-4031-b1f9-f754d631ed1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_EarningsPerShareBasic_1d6d9dfc-3ec0-4031-b1f9-f754d631ed1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6134cc92-9b58-4967-98bb-daffb0294fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6134cc92-9b58-4967-98bb-daffb0294fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_96a91337-dc73-4914-9835-c2809e93fa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_96a91337-dc73-4914-9835-c2809e93fa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_05221c50-920e-42e0-a49c-a60f870a1a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_05221c50-920e-42e0-a49c-a60f870a1a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a3320ec7-38e4-45b1-a55a-43a57dcddb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07bc650f-871c-48be-946c-a7164ebfebf5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a3320ec7-38e4-45b1-a55a-43a57dcddb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_def74bfa-09c8-4cf0-8487-416c7397b9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a3320ec7-38e4-45b1-a55a-43a57dcddb29" xlink:to="loc_us-gaap_NetIncomeLoss_def74bfa-09c8-4cf0-8487-416c7397b9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_33d9f7c0-59d6-4c17-a786-5e24c7c62a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a3320ec7-38e4-45b1-a55a-43a57dcddb29" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_33d9f7c0-59d6-4c17-a786-5e24c7c62a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_4bd15f39-4cb7-4c7c-a111-78d86bfbe204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_33d9f7c0-59d6-4c17-a786-5e24c7c62a8d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_4bd15f39-4cb7-4c7c-a111-78d86bfbe204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8b8964c9-e533-4260-b1a9-78090a633ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_33d9f7c0-59d6-4c17-a786-5e24c7c62a8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8b8964c9-e533-4260-b1a9-78090a633ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8a749097-829c-4ba2-9108-f862fe61c346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a3320ec7-38e4-45b1-a55a-43a57dcddb29" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8a749097-829c-4ba2-9108-f862fe61c346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_53deb254-6c8b-4c56-b841-e329db0dd411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3a523b36-e880-4521-a879-90b33e9e2eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_53deb254-6c8b-4c56-b841-e329db0dd411" xlink:to="loc_us-gaap_StatementTable_3a523b36-e880-4521-a879-90b33e9e2eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8dec71f3-9163-499b-abd1-27b66cc36dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3a523b36-e880-4521-a879-90b33e9e2eb9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8dec71f3-9163-499b-abd1-27b66cc36dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8dec71f3-9163-499b-abd1-27b66cc36dbf" xlink:to="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_65749216-c6bf-4cad-bda4-04bdffe5c68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:to="loc_us-gaap_CommonStockMember_65749216-c6bf-4cad-bda4-04bdffe5c68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ae3f28ad-9e62-45fb-a052-84e43ea42d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ae3f28ad-9e62-45fb-a052-84e43ea42d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a7b8609a-2ae2-45cd-b980-84fb0e6fe166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:to="loc_us-gaap_RetainedEarningsMember_a7b8609a-2ae2-45cd-b980-84fb0e6fe166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f81799d5-fb1a-4c4e-901b-c262f560c1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4072a58a-649b-4bde-a4e6-594a8a0533f5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f81799d5-fb1a-4c4e-901b-c262f560c1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7f8e7c72-e805-4c1e-82d4-47235cf95819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3a523b36-e880-4521-a879-90b33e9e2eb9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7f8e7c72-e805-4c1e-82d4-47235cf95819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6483bc42-8f89-493d-ba54-44056efc6629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7f8e7c72-e805-4c1e-82d4-47235cf95819" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6483bc42-8f89-493d-ba54-44056efc6629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_8416f2ec-fa60-4da5-9b38-c63c10a42aa8" xlink:href="morf-20221231.xsd#morf_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6483bc42-8f89-493d-ba54-44056efc6629" xlink:to="loc_morf_AtTheMarketOfferingMember_8416f2ec-fa60-4da5-9b38-c63c10a42aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_1663e9a2-14cf-488f-a676-9437da26a2d5" xlink:href="morf-20221231.xsd#morf_SecondaryOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6483bc42-8f89-493d-ba54-44056efc6629" xlink:to="loc_morf_SecondaryOfferingMember_1663e9a2-14cf-488f-a676-9437da26a2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_664b10bb-3c9d-4ca3-935c-7b15ebd77a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3a523b36-e880-4521-a879-90b33e9e2eb9" xlink:to="loc_us-gaap_StatementLineItems_664b10bb-3c9d-4ca3-935c-7b15ebd77a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_664b10bb-3c9d-4ca3-935c-7b15ebd77a8d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_06be76a8-842b-42ae-95c0-33de8ddcc3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_SharesOutstanding_06be76a8-842b-42ae-95c0-33de8ddcc3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_479f3f48-950e-40e7-b265-5e036a8f35e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockholdersEquity_479f3f48-950e-40e7-b265-5e036a8f35e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_4e97f53f-7fdc-41cf-bb60-33b78f1f60f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_4e97f53f-7fdc-41cf-bb60-33b78f1f60f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_824f0bec-33ce-4565-92ea-947fedfab883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_824f0bec-33ce-4565-92ea-947fedfab883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b60f7bd5-ae14-450f-95ea-f6b0e371e849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b60f7bd5-ae14-450f-95ea-f6b0e371e849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1a21209e-3c76-4337-afac-a6638229b669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1a21209e-3c76-4337-afac-a6638229b669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_7ce8d45b-f14e-4443-990b-830fc1f73d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_7ce8d45b-f14e-4443-990b-830fc1f73d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_8aeaf679-e91d-4252-b658-644dcfc7a564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_8aeaf679-e91d-4252-b658-644dcfc7a564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5e66aa3-1cc2-4e40-8c96-00b18e947a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5e66aa3-1cc2-4e40-8c96-00b18e947a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d6886a20-b0a3-4ff2-b562-66cc60894cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d6886a20-b0a3-4ff2-b562-66cc60894cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f7ad7b95-c912-4024-91f4-1c5024dcf39d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f7ad7b95-c912-4024-91f4-1c5024dcf39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_379b670a-a503-4ef4-8012-cc726c17aac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_NetIncomeLoss_379b670a-a503-4ef4-8012-cc726c17aac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a207efd2-1fb7-4b09-b75a-606675e13888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_SharesOutstanding_a207efd2-1fb7-4b09-b75a-606675e13888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0f394d5b-4158-4276-bfe2-f8a29e45bfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acc5c95c-05eb-409d-8b95-771b5d034a4c" xlink:to="loc_us-gaap_StockholdersEquity_0f394d5b-4158-4276-bfe2-f8a29e45bfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_058878fb-401f-41c4-805c-ddaee32d4b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ca2efb81-2b59-43f8-b7b2-45ed5ef7b588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_058878fb-401f-41c4-805c-ddaee32d4b22" xlink:to="loc_us-gaap_StatementTable_ca2efb81-2b59-43f8-b7b2-45ed5ef7b588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d7cd93d5-2eac-42d8-9516-e1567a66197d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca2efb81-2b59-43f8-b7b2-45ed5ef7b588" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d7cd93d5-2eac-42d8-9516-e1567a66197d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6252776b-f3b0-474a-a080-d5e20c454033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d7cd93d5-2eac-42d8-9516-e1567a66197d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6252776b-f3b0-474a-a080-d5e20c454033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_54770528-1938-416d-a34e-9808573ed107" xlink:href="morf-20221231.xsd#morf_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6252776b-f3b0-474a-a080-d5e20c454033" xlink:to="loc_morf_AtTheMarketOfferingMember_54770528-1938-416d-a34e-9808573ed107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_4f42a152-5ac5-4809-82f6-f6a511c1e266" xlink:href="morf-20221231.xsd#morf_SecondaryOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6252776b-f3b0-474a-a080-d5e20c454033" xlink:to="loc_morf_SecondaryOfferingMember_4f42a152-5ac5-4809-82f6-f6a511c1e266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_21e7ff56-b3c1-446e-ad33-42ae85c4f073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca2efb81-2b59-43f8-b7b2-45ed5ef7b588" xlink:to="loc_us-gaap_StatementLineItems_21e7ff56-b3c1-446e-ad33-42ae85c4f073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_efe249f0-ef5f-43c1-822c-ee87446567d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21e7ff56-b3c1-446e-ad33-42ae85c4f073" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_efe249f0-ef5f-43c1-822c-ee87446567d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="morf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f0e6fe9f-662c-40cc-9656-b4f01f4b35ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f685c59a-7c1d-4dba-93f6-c435651ec745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0e6fe9f-662c-40cc-9656-b4f01f4b35ab" xlink:to="loc_us-gaap_StatementTable_f685c59a-7c1d-4dba-93f6-c435651ec745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86c9b4cc-43a8-4a49-bae6-8c9ac173d0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f685c59a-7c1d-4dba-93f6-c435651ec745" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86c9b4cc-43a8-4a49-bae6-8c9ac173d0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff369b45-0ce0-485b-b765-a0eedade4537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86c9b4cc-43a8-4a49-bae6-8c9ac173d0a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff369b45-0ce0-485b-b765-a0eedade4537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_d02adf08-47b9-4de3-a9bf-f90bfa57e747" xlink:href="morf-20221231.xsd#morf_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff369b45-0ce0-485b-b765-a0eedade4537" xlink:to="loc_morf_AtTheMarketOfferingMember_d02adf08-47b9-4de3-a9bf-f90bfa57e747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_af9eae88-1d83-4ec3-9d5a-89ddf74972ed" xlink:href="morf-20221231.xsd#morf_SecondaryOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff369b45-0ce0-485b-b765-a0eedade4537" xlink:to="loc_morf_SecondaryOfferingMember_af9eae88-1d83-4ec3-9d5a-89ddf74972ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f685c59a-7c1d-4dba-93f6-c435651ec745" xlink:to="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fef9137b-062c-49b8-8a56-c1c29b8377a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:to="loc_us-gaap_ProfitLoss_fef9137b-062c-49b8-8a56-c1c29b8377a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_fc1820b3-d6d9-422c-9121-64ca967d04e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_DepreciationAndAmortization_fc1820b3-d6d9-422c-9121-64ca967d04e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4625f81a-4644-4926-8f18-03a638198504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4625f81a-4644-4926-8f18-03a638198504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_78876594-4f07-47fa-9e0b-2ccfe670aef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_ShareBasedCompensation_78876594-4f07-47fa-9e0b-2ccfe670aef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_0eb60e2d-f7b9-4568-97bd-aa7b9a45e4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_0eb60e2d-f7b9-4568-97bd-aa7b9a45e4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_28b50e79-4584-461d-b568-228d70660153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b08b5a49-b8aa-430d-9fd2-6cf912edd922" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_28b50e79-4584-461d-b568-228d70660153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5b01d085-6f9e-4419-a6e5-a12b73a78986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5b01d085-6f9e-4419-a6e5-a12b73a78986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c00fc2cc-0dd2-439a-bea2-5c28e57f512e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c00fc2cc-0dd2-439a-bea2-5c28e57f512e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_afdc9250-82e9-450c-9222-de297263b80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_afdc9250-82e9-450c-9222-de297263b80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets_e3bc8e13-e6c6-442d-a7a3-77b54e944d26" xlink:href="morf-20221231.xsd#morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets_e3bc8e13-e6c6-442d-a7a3-77b54e944d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5fc36561-be1a-4685-81bc-23410c82384e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5fc36561-be1a-4685-81bc-23410c82384e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c793b955-914b-46a8-b6ac-65f0ff123a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c793b955-914b-46a8-b6ac-65f0ff123a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_4dddbde3-f6e8-41ca-92c5-9a2c956a25b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_4dddbde3-f6e8-41ca-92c5-9a2c956a25b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseInDeferredRent_42c7875d-9744-41c4-8280-f7df64ac1eae" xlink:href="morf-20221231.xsd#morf_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_morf_IncreaseDecreaseInDeferredRent_42c7875d-9744-41c4-8280-f7df64ac1eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c43181dc-0be2-44ed-8227-9e0e5a6a2191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e864871-3462-4a9d-830e-8c7a0161988c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c43181dc-0be2-44ed-8227-9e0e5a6a2191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58b06a29-df35-413d-8f94-9ae9aec1ab65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64a48081-e468-4aae-969d-0cc8c4941d92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58b06a29-df35-413d-8f94-9ae9aec1ab65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dedee062-a8c5-46cd-8b7e-7928f446fbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dedee062-a8c5-46cd-8b7e-7928f446fbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_41612a4f-f675-48c5-b1cd-95a2daa431c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_41612a4f-f675-48c5-b1cd-95a2daa431c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6059646d-256d-4fd9-a3ff-eb4fd2f4c1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6059646d-256d-4fd9-a3ff-eb4fd2f4c1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a3dfacf-3027-453c-892c-35c8fa292e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a3dfacf-3027-453c-892c-35c8fa292e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1b70faa-2653-4c4b-bd77-7606c19618f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_228415c0-01f4-46c0-8bf5-7f7d9be2d74f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1b70faa-2653-4c4b-bd77-7606c19618f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_5afc3379-a257-4840-990f-322ba801bc55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:to="loc_us-gaap_ProceedsFromStockPlans_5afc3379-a257-4840-990f-322ba801bc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b25e332e-da88-49c6-9983-7a01222bab76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b25e332e-da88-49c6-9983-7a01222bab76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_96291ef2-7a51-499c-b06e-1c01b1c0e04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_96291ef2-7a51-499c-b06e-1c01b1c0e04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d13db87-0e8c-4c84-ba35-dc16664534d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6926d6e1-697e-4978-a19b-59f911207ad7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d13db87-0e8c-4c84-ba35-dc16664534d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a9f25d0-4477-4b4c-883c-fc7d0013f7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a9f25d0-4477-4b4c-883c-fc7d0013f7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce0607b4-f289-4fcd-a13e-e3e5f1570e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce0607b4-f289-4fcd-a13e-e3e5f1570e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcc1f3ad-e291-4f22-8c43-36952b26158a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcc1f3ad-e291-4f22-8c43-36952b26158a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_54cc0dc0-0a5e-43f1-a27d-b8e84b2cb25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_54cc0dc0-0a5e-43f1-a27d-b8e84b2cb25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9e79c6ba-b792-4761-8c8c-91e733afeadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9e79c6ba-b792-4761-8c8c-91e733afeadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2a6ed651-62ac-476e-aaa9-0409e04eacdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2a6ed651-62ac-476e-aaa9-0409e04eacdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c1127085-170a-49f3-a99c-7ab090014eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cdf1eb1a-eb9d-41eb-9987-b79ad83793b1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c1127085-170a-49f3-a99c-7ab090014eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_03693470-8cc9-494a-b9a0-515226d5b6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5508b4cf-88c4-4aad-a09e-bb6deb785150" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_03693470-8cc9-494a-b9a0-515226d5b6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_ecd9a12b-21b8-47e7-98a3-e8901200bcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_03693470-8cc9-494a-b9a0-515226d5b6b9" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_ecd9a12b-21b8-47e7-98a3-e8901200bcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NatureoftheBusiness" xlink:type="simple" xlink:href="morf-20221231.xsd#NatureoftheBusiness"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NatureoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c9df06b5-613e-4816-a315-59d3258bbccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_563f30b8-a2ec-4bb1-8e9e-b9044702641b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c9df06b5-613e-4816-a315-59d3258bbccf" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_563f30b8-a2ec-4bb1-8e9e-b9044702641b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="morf-20221231.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_01aa101e-c277-4d69-a58b-ecb6dc468fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_57448e3b-28eb-4339-bf9f-bf8648304d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01aa101e-c277-4d69-a58b-ecb6dc468fb2" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_57448e3b-28eb-4339-bf9f-bf8648304d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="simple" xlink:href="morf-20221231.xsd#FairValueofFinancialAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_db74dcaf-7da9-495e-8f45-fefe63bc6a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d7f8504c-6027-4d8a-b4c7-4c6f9dfae787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_db74dcaf-7da9-495e-8f45-fefe63bc6a4b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d7f8504c-6027-4d8a-b4c7-4c6f9dfae787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/Marketablesecurities" xlink:type="simple" xlink:href="morf-20221231.xsd#Marketablesecurities"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/Marketablesecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a220b12-25cd-475a-8949-f7aac34f1378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ded20e0c-7f1c-4564-8d28-2e9d33a41dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a220b12-25cd-475a-8949-f7aac34f1378" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ded20e0c-7f1c-4564-8d28-2e9d33a41dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="morf-20221231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d34e8798-0216-43ea-89a5-de113c354aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_02653f64-6f0a-46fd-9cdc-de4e5889efda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d34e8798-0216-43ea-89a5-de113c354aee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_02653f64-6f0a-46fd-9cdc-de4e5889efda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/Leases" xlink:type="simple" xlink:href="morf-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fb6e0f0e-d508-4ce5-a0bc-809ca76c7aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ef7a07c4-f7f1-4560-afb3-65ceb8655eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fb6e0f0e-d508-4ce5-a0bc-809ca76c7aa8" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ef7a07c4-f7f1-4560-afb3-65ceb8655eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="morf-20221231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_63ad7f44-8ae2-455b-ab7f-1710309eda76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d41c3fa3-db5e-4132-9543-dc52201d1b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_63ad7f44-8ae2-455b-ab7f-1710309eda76" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d41c3fa3-db5e-4132-9543-dc52201d1b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="morf-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7e70d143-b7cd-40fa-b503-77dbff30c8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5a660064-cfb5-465b-b9a3-b0854febadf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7e70d143-b7cd-40fa-b503-77dbff30c8d0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5a660064-cfb5-465b-b9a3-b0854febadf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensation"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3883858-e6d5-430d-80e1-73e265050a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d0d5db8e-01f1-4b26-b1c6-e45418806a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3883858-e6d5-430d-80e1-73e265050a1d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d0d5db8e-01f1-4b26-b1c6-e45418806a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fb381edb-d58c-48aa-b255-97eae783f96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_71c76556-ba66-48b7-92b3-18f2fb18bc15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb381edb-d58c-48aa-b255-97eae783f96c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_71c76556-ba66-48b7-92b3-18f2fb18bc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="morf-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_161f4a26-7506-44b6-b4e9-7333e4100992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_74b540a7-03ff-45be-80d1-d909a65c39f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_161f4a26-7506-44b6-b4e9-7333e4100992" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_74b540a7-03ff-45be-80d1-d909a65c39f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreements" xlink:type="simple" xlink:href="morf-20221231.xsd#OptionandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract_46670cba-7525-4d62-9c60-e6a1a2ca32d8" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f0c83d82-ec8b-460b-a9f3-5a01433e4c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract_46670cba-7525-4d62-9c60-e6a1a2ca32d8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f0c83d82-ec8b-460b-a9f3-5a01433e4c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossperShare" xlink:type="simple" xlink:href="morf-20221231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5306634a-9518-4469-97b7-12fdf5867ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_73de4911-4fee-4178-92f2-9f7e5f3c3a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5306634a-9518-4469-97b7-12fdf5867ba7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_73de4911-4fee-4178-92f2-9f7e5f3c3a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="morf-20221231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d886e7d-677e-429d-be45-02a92725e68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7c58786f-8c96-4a00-b105-17a989d6b161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d886e7d-677e-429d-be45-02a92725e68b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7c58786f-8c96-4a00-b105-17a989d6b161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="morf-20221231.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1c24d441-94dc-4e94-8c4f-53a455fda398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1c24d441-94dc-4e94-8c4f-53a455fda398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7ba92ed4-bda3-473a-a232-b46d8c5b0308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7ba92ed4-bda3-473a-a232-b46d8c5b0308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3efafe76-c5d2-4aea-83c2-c70c1b9659b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_UseOfEstimates_3efafe76-c5d2-4aea-83c2-c70c1b9659b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_ab00d182-c316-4feb-80cd-54ee6ed33540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_ab00d182-c316-4feb-80cd-54ee6ed33540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_7c3552f6-22d4-483d-ad2e-8797c455e889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_7c3552f6-22d4-483d-ad2e-8797c455e889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_38b4d191-e58a-4072-91b5-c098e08ff9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_38b4d191-e58a-4072-91b5-c098e08ff9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock_39ece1ba-3fdb-4729-9250-b2357e7e5bf8" xlink:href="morf-20221231.xsd#morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock_39ece1ba-3fdb-4729-9250-b2357e7e5bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_54a6ed3d-730d-4cb2-bff8-16c2083f5a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_54a6ed3d-730d-4cb2-bff8-16c2083f5a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f9118871-4413-4fdf-8ac2-05e26d01bb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f9118871-4413-4fdf-8ac2-05e26d01bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b290bc12-d937-4855-a74d-25289fac516d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b290bc12-d937-4855-a74d-25289fac516d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0ebded19-724f-46b5-b374-a070dd387ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0ebded19-724f-46b5-b374-a070dd387ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_decca519-814f-4abe-85ef-f8ad4d6f0172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_decca519-814f-4abe-85ef-f8ad4d6f0172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_62505a2c-9062-4b95-8fd7-a3705014750b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_62505a2c-9062-4b95-8fd7-a3705014750b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f29f70f1-0128-4dda-a5c0-45a73d607de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f29f70f1-0128-4dda-a5c0-45a73d607de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock_bb56c83d-623f-4a53-8fa5-a262242824aa" xlink:href="morf-20221231.xsd#morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock_bb56c83d-623f-4a53-8fa5-a262242824aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_15df1690-d26a-407e-878a-3ada2f3de6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_15df1690-d26a-407e-878a-3ada2f3de6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_741bc8cd-50d5-4bd8-88b8-e964179fc21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_741bc8cd-50d5-4bd8-88b8-e964179fc21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_ddc7797d-8690-463a-a21e-1f1c5b853be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_ddc7797d-8690-463a-a21e-1f1c5b853be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_7f60cc45-92f6-42f4-851e-7070b27fd156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ee04055-efac-4771-8406-99fa07d6b0d7" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_7f60cc45-92f6-42f4-851e-7070b27fd156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="morf-20221231.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_816d08e7-189c-422f-8e3c-8fbf9dc3423d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_30efd6c5-07f5-44e6-8368-29ab0de31080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_816d08e7-189c-422f-8e3c-8fbf9dc3423d" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_30efd6c5-07f5-44e6-8368-29ab0de31080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_e8eaf7f9-ea8b-4040-b514-0bbefdcd54dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_816d08e7-189c-422f-8e3c-8fbf9dc3423d" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_e8eaf7f9-ea8b-4040-b514-0bbefdcd54dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ab653321-4939-4005-82ab-1c34acbabb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_816d08e7-189c-422f-8e3c-8fbf9dc3423d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ab653321-4939-4005-82ab-1c34acbabb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="morf-20221231.xsd#FairValueofFinancialAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_de130669-df32-443b-8b05-9be59bd481af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_19a3d0aa-fd99-4d62-a6f7-f98cd8d292a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_de130669-df32-443b-8b05-9be59bd481af" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_19a3d0aa-fd99-4d62-a6f7-f98cd8d292a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/MarketablesecuritiesTables" xlink:type="simple" xlink:href="morf-20221231.xsd#MarketablesecuritiesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/MarketablesecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd81f1ea-fe6f-44b5-98fd-bc0b3256c2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0d3f23c8-26e8-4c68-8c5e-47d2676461c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd81f1ea-fe6f-44b5-98fd-bc0b3256c2f0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0d3f23c8-26e8-4c68-8c5e-47d2676461c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="morf-20221231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_33cedd84-c0f4-4d01-9796-2068132f13e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_54131e4c-ab5e-45aa-8ba8-6693dd292b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_33cedd84-c0f4-4d01-9796-2068132f13e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_54131e4c-ab5e-45aa-8ba8-6693dd292b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/LeasesTables" xlink:type="simple" xlink:href="morf-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1812beae-3fae-42ea-afc7-e88178f1f53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock_67f63235-65cb-48ea-9345-6fe7be7b5783" xlink:href="morf-20221231.xsd#morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1812beae-3fae-42ea-afc7-e88178f1f53a" xlink:to="loc_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock_67f63235-65cb-48ea-9345-6fe7be7b5783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1f38bca9-c5d1-43ae-bb57-a9adc50ab761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1812beae-3fae-42ea-afc7-e88178f1f53a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1f38bca9-c5d1-43ae-bb57-a9adc50ab761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="morf-20221231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_824fd245-aa0e-4039-91fc-d7f300e28789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5499b7eb-8475-4b4b-92cd-a883876c921c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_824fd245-aa0e-4039-91fc-d7f300e28789" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5499b7eb-8475-4b4b-92cd-a883876c921c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7735386d-c8b6-4789-8916-1bcd169808b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_898de527-d2d9-484e-a9ae-769423650254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7735386d-c8b6-4789-8916-1bcd169808b2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_898de527-d2d9-484e-a9ae-769423650254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_ebd51f30-8ec5-4df0-9bc6-af0b2cf9a195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7735386d-c8b6-4789-8916-1bcd169808b2" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_ebd51f30-8ec5-4df0-9bc6-af0b2cf9a195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_cf52c695-df32-477e-8a06-954afa165cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7735386d-c8b6-4789-8916-1bcd169808b2" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_cf52c695-df32-477e-8a06-954afa165cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_940844a1-4e7e-4c92-b3ab-7ef0f0a9d90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7735386d-c8b6-4789-8916-1bcd169808b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_940844a1-4e7e-4c92-b3ab-7ef0f0a9d90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock_d7e1a94f-f722-4b62-97fb-960d62f0a368" xlink:href="morf-20221231.xsd#morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7735386d-c8b6-4789-8916-1bcd169808b2" xlink:to="loc_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock_d7e1a94f-f722-4b62-97fb-960d62f0a368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8c073ba-ac5c-4b90-8b51-54aecf7e147b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7735386d-c8b6-4789-8916-1bcd169808b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8c073ba-ac5c-4b90-8b51-54aecf7e147b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_76a50c44-e04b-451a-9b4d-6ed80c841be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4928085a-7cea-4039-a5e4-356f3e055593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76a50c44-e04b-451a-9b4d-6ed80c841be6" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4928085a-7cea-4039-a5e4-356f3e055593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f5498956-47a7-4a67-b887-b441be886f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76a50c44-e04b-451a-9b4d-6ed80c841be6" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f5498956-47a7-4a67-b887-b441be886f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3dfbdc3f-3bd7-4df5-95b8-b7af07c6dfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76a50c44-e04b-451a-9b4d-6ed80c841be6" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3dfbdc3f-3bd7-4df5-95b8-b7af07c6dfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_390b4d2e-9d6c-42ce-aac3-69e297787d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76a50c44-e04b-451a-9b4d-6ed80c841be6" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_390b4d2e-9d6c-42ce-aac3-69e297787d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreementsTables" xlink:type="simple" xlink:href="morf-20221231.xsd#OptionandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract_13f0029e-0a9e-490d-afdd-44eb69dc7ca3" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_22569779-4ae5-48cc-bb1c-145862ef5fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract_13f0029e-0a9e-490d-afdd-44eb69dc7ca3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_22569779-4ae5-48cc-bb1c-145862ef5fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="morf-20221231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0d3ffe11-ab5c-4ff9-b4f2-bb49f98fdd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_2dbf0864-f966-4be7-bbad-e5b804df68f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d3ffe11-ab5c-4ff9-b4f2-bb49f98fdd76" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_2dbf0864-f966-4be7-bbad-e5b804df68f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5bf70029-5f68-4da9-b286-99d7f98dcd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d3ffe11-ab5c-4ff9-b4f2-bb49f98fdd76" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5bf70029-5f68-4da9-b286-99d7f98dcd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NatureoftheBusinessDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#NatureoftheBusinessDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NatureoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1411b550-8eb6-4dd7-a925-337cbb43faee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_dfa6a9b7-a911-4f4a-92ce-0f3104003094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1411b550-8eb6-4dd7-a925-337cbb43faee" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_dfa6a9b7-a911-4f4a-92ce-0f3104003094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98725791-5f50-4e43-9468-6dc753cfa5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_dfa6a9b7-a911-4f4a-92ce-0f3104003094" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98725791-5f50-4e43-9468-6dc753cfa5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397e52a4-0b27-4185-964c-95b0e2eebe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98725791-5f50-4e43-9468-6dc753cfa5b7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397e52a4-0b27-4185-964c-95b0e2eebe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtMarketOfferingProgramMember_8b6be125-137d-4e02-ab84-7b334d2ff55a" xlink:href="morf-20221231.xsd#morf_AtMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397e52a4-0b27-4185-964c-95b0e2eebe6e" xlink:to="loc_morf_AtMarketOfferingProgramMember_8b6be125-137d-4e02-ab84-7b334d2ff55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_FollowOnPublicOfferingMember_99bc8619-9652-4694-8e1a-5ed32f6cf09c" xlink:href="morf-20221231.xsd#morf_FollowOnPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397e52a4-0b27-4185-964c-95b0e2eebe6e" xlink:to="loc_morf_FollowOnPublicOfferingMember_99bc8619-9652-4694-8e1a-5ed32f6cf09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_117ef25f-83da-439c-9e43-b83b691cb984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_dfa6a9b7-a911-4f4a-92ce-0f3104003094" xlink:to="loc_us-gaap_TypeOfArrangementAxis_117ef25f-83da-439c-9e43-b83b691cb984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6f45b05c-99d2-40be-91eb-34a7f8899e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_117ef25f-83da-439c-9e43-b83b691cb984" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6f45b05c-99d2-40be-91eb-34a7f8899e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OpenMarketSaleAgreementMember_7a425dfb-d2ca-4aa2-acce-17a208abd248" xlink:href="morf-20221231.xsd#morf_OpenMarketSaleAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6f45b05c-99d2-40be-91eb-34a7f8899e39" xlink:to="loc_morf_OpenMarketSaleAgreementMember_7a425dfb-d2ca-4aa2-acce-17a208abd248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_dfa6a9b7-a911-4f4a-92ce-0f3104003094" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_854b5640-8e28-4538-a082-f5000a10a62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_854b5640-8e28-4538-a082-f5000a10a62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_PercentageOfCommissionOnGrossSaleProceeds_11462649-0a8c-4c8d-910d-fe58dcf0d79f" xlink:href="morf-20221231.xsd#morf_PercentageOfCommissionOnGrossSaleProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_morf_PercentageOfCommissionOnGrossSaleProceeds_11462649-0a8c-4c8d-910d-fe58dcf0d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aaa1784e-d906-4c81-89a5-89c0aa16a5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aaa1784e-d906-4c81-89a5-89c0aa16a5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6c9fb952-1a23-4ff8-bea6-cfbdd0dc60ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6c9fb952-1a23-4ff8-bea6-cfbdd0dc60ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a4a70cfc-15fa-439b-b1ed-2acee792bbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_a4a70cfc-15fa-439b-b1ed-2acee792bbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CommonStockAvailableForIssuance_c3e0cf7e-1a3b-4e46-9eb2-be3c366fbfe5" xlink:href="morf-20221231.xsd#morf_CommonStockAvailableForIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_morf_CommonStockAvailableForIssuance_c3e0cf7e-1a3b-4e46-9eb2-be3c366fbfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_809ddd73-fad4-4b8d-b779-fdaa26e3a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_809ddd73-fad4-4b8d-b779-fdaa26e3a1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_252a69bd-8807-4f3d-a49e-3cce2549a66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_252a69bd-8807-4f3d-a49e-3cce2549a66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4fbaf040-a99e-4776-8a5a-6c236884acd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4fbaf040-a99e-4776-8a5a-6c236884acd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d2efd33b-6cbb-48ad-a464-d5a39b0da630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_0e76d07e-9fdb-4ac2-b517-7922c83757a7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d2efd33b-6cbb-48ad-a464-d5a39b0da630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0e443287-0eb5-4013-bf50-4c652e1de3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_aee20442-e145-42dd-a4b9-2b573cabe5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e443287-0eb5-4013-bf50-4c652e1de3ca" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_aee20442-e145-42dd-a4b9-2b573cabe5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_56edf1f2-8b68-47a5-b54a-96ff8af20198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e443287-0eb5-4013-bf50-4c652e1de3ca" xlink:to="loc_us-gaap_DebtInstrumentTerm_56edf1f2-8b68-47a5-b54a-96ff8af20198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_876c750c-17c7-46b1-85a7-de0a9165eee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e443287-0eb5-4013-bf50-4c652e1de3ca" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_876c750c-17c7-46b1-85a7-de0a9165eee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_cfe702fc-ecac-4a58-9e81-79eae61b4f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e443287-0eb5-4013-bf50-4c652e1de3ca" xlink:to="loc_us-gaap_RestrictedCash_cfe702fc-ecac-4a58-9e81-79eae61b4f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d143392b-dd52-4558-92de-677991cb3e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e443287-0eb5-4013-bf50-4c652e1de3ca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d143392b-dd52-4558-92de-677991cb3e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_27a419e4-2e34-4fde-addd-fb26e6cbb825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a419e4-2e34-4fde-addd-fb26e6cbb825" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1411bb7-c873-4003-a54a-8a11289d3d08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:to="loc_srt_RangeAxis_b1411bb7-c873-4003-a54a-8a11289d3d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26d3ee14-f907-40b9-aa5f-a8c07164cbdc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1411bb7-c873-4003-a54a-8a11289d3d08" xlink:to="loc_srt_RangeMember_26d3ee14-f907-40b9-aa5f-a8c07164cbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bace3ba2-766d-44aa-82a7-6dc800bb7419" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_26d3ee14-f907-40b9-aa5f-a8c07164cbdc" xlink:to="loc_srt_MinimumMember_bace3ba2-766d-44aa-82a7-6dc800bb7419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d1d4b82c-d12b-4031-9670-c3870bf26655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d1d4b82c-d12b-4031-9670-c3870bf26655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_93391815-7e38-4c35-9a10-279fce528366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d1d4b82c-d12b-4031-9670-c3870bf26655" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_93391815-7e38-4c35-9a10-279fce528366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bceb5e0a-1d7d-4656-a5a4-158de3971df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_93391815-7e38-4c35-9a10-279fce528366" xlink:to="loc_us-gaap_SubsequentEventMember_bceb5e0a-1d7d-4656-a5a4-158de3971df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bb106247-cdd7-4d49-aba4-23089adc4b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bb106247-cdd7-4d49-aba4-23089adc4b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef5cf639-c6b8-45c8-a749-cc449d9d67d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bb106247-cdd7-4d49-aba4-23089adc4b98" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef5cf639-c6b8-45c8-a749-cc449d9d67d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_91bcdaa6-2145-4181-8d00-a9888c19b750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef5cf639-c6b8-45c8-a749-cc449d9d67d7" xlink:to="loc_us-gaap_PrivatePlacementMember_91bcdaa6-2145-4181-8d00-a9888c19b750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_dae3c922-70f0-4a01-a4bd-b3991bbfd453" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsUnderManagementCarryingAmount_94e488a7-7607-4397-99bb-d8318b930d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsUnderManagementCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_AssetsUnderManagementCarryingAmount_94e488a7-7607-4397-99bb-d8318b930d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_dfa88ff7-4ac6-45c0-b15c-3f291ea038f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_dfa88ff7-4ac6-45c0-b15c-3f291ea038f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_209cdfe0-115a-417b-9b99-01abcbfab27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_209cdfe0-115a-417b-9b99-01abcbfab27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e47c8723-9c2e-4028-8737-fc3d7e513a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e47c8723-9c2e-4028-8737-fc3d7e513a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6c9f1264-8cb6-4ea2-9a46-567c192d681b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6c9f1264-8cb6-4ea2-9a46-567c192d681b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborationAgreementNumberOfAgreements_fca20fa8-8d01-45a7-8c5a-ba1036e57899" xlink:href="morf-20221231.xsd#morf_CollaborationAgreementNumberOfAgreements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_morf_CollaborationAgreementNumberOfAgreements_fca20fa8-8d01-45a7-8c5a-ba1036e57899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_da08d98c-8c48-4d34-8f1e-da1cd7660094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_da08d98c-8c48-4d34-8f1e-da1cd7660094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7dba6a4e-35f1-49f3-9002-9421239769ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7dba6a4e-35f1-49f3-9002-9421239769ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction_0212a06c-338b-4576-ac40-cf9862114448" xlink:href="morf-20221231.xsd#morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction_0212a06c-338b-4576-ac40-cf9862114448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction_6d3de7b2-45b0-4fd8-8a10-5f772ce92b18" xlink:href="morf-20221231.xsd#morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction_6d3de7b2-45b0-4fd8-8a10-5f772ce92b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3d071c37-b96e-4617-bc9e-00eb856373ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3d071c37-b96e-4617-bc9e-00eb856373ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_00a4ddef-a02c-4ac0-ad92-a30d4d21d82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_00a4ddef-a02c-4ac0-ad92-a30d4d21d82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_f4ec2b7c-e1a2-4629-a592-73219661b6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_25d37a26-2676-43a1-b543-23632cea12a9" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_f4ec2b7c-e1a2-4629-a592-73219661b6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_231f320f-6874-46ab-9df4-61d6949f4810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb3634a-786c-45ca-8b6f-1a39e2ba9e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_231f320f-6874-46ab-9df4-61d6949f4810" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb3634a-786c-45ca-8b6f-1a39e2ba9e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc0e30ca-229b-4d8d-ba41-5c71f08a70e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb3634a-786c-45ca-8b6f-1a39e2ba9e5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc0e30ca-229b-4d8d-ba41-5c71f08a70e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d36928b5-8b40-488b-812d-091bfad561ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc0e30ca-229b-4d8d-ba41-5c71f08a70e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d36928b5-8b40-488b-812d-091bfad561ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_3d502879-7e60-4a18-82d2-3cdce4232358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d36928b5-8b40-488b-812d-091bfad561ca" xlink:to="loc_us-gaap_EquipmentMember_3d502879-7e60-4a18-82d2-3cdce4232358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ComputerEquipmentAndSoftwareMember_8585eed1-2745-462a-ab48-900ad91c27bc" xlink:href="morf-20221231.xsd#morf_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d36928b5-8b40-488b-812d-091bfad561ca" xlink:to="loc_morf_ComputerEquipmentAndSoftwareMember_8585eed1-2745-462a-ab48-900ad91c27bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_25de5dbd-9477-4db3-b647-94330f8c61c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb3634a-786c-45ca-8b6f-1a39e2ba9e5f" xlink:to="loc_srt_RangeAxis_25de5dbd-9477-4db3-b647-94330f8c61c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4db221e2-3824-47cb-928f-849af51a8a9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_25de5dbd-9477-4db3-b647-94330f8c61c0" xlink:to="loc_srt_RangeMember_4db221e2-3824-47cb-928f-849af51a8a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_33c71743-e648-4a72-b856-e66fc3218e58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4db221e2-3824-47cb-928f-849af51a8a9f" xlink:to="loc_srt_MinimumMember_33c71743-e648-4a72-b856-e66fc3218e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b14cbd0-14c6-453f-a9b9-39b660aced32" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4db221e2-3824-47cb-928f-849af51a8a9f" xlink:to="loc_srt_MaximumMember_2b14cbd0-14c6-453f-a9b9-39b660aced32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f631e996-eca5-4459-967b-45a0b1fb5959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5fb3634a-786c-45ca-8b6f-1a39e2ba9e5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f631e996-eca5-4459-967b-45a0b1fb5959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_af97123a-e57d-4e1e-a930-cf1abedc5e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f631e996-eca5-4459-967b-45a0b1fb5959" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_af97123a-e57d-4e1e-a930-cf1abedc5e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#FairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_10cd6c32-0b1d-49c4-8f8a-5f82080532b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_10cd6c32-0b1d-49c4-8f8a-5f82080532b0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_852ab8db-bf25-4f32-9a98-ff8ea1fac7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_852ab8db-bf25-4f32-9a98-ff8ea1fac7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_95007fd2-9da9-4a92-b792-e715d523db43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_852ab8db-bf25-4f32-9a98-ff8ea1fac7c5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_95007fd2-9da9-4a92-b792-e715d523db43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cb80109d-9809-4092-b0cb-28e3feef9b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_95007fd2-9da9-4a92-b792-e715d523db43" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cb80109d-9809-4092-b0cb-28e3feef9b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_611cdc64-3d87-4c5f-b29b-8ee4ad96200b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_611cdc64-3d87-4c5f-b29b-8ee4ad96200b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_611cdc64-3d87-4c5f-b29b-8ee4ad96200b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_316f4bb2-b04a-4554-90b9-8cfd3c219c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_316f4bb2-b04a-4554-90b9-8cfd3c219c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_69144a2c-9969-471f-80fa-9daeed00cbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_69144a2c-9969-471f-80fa-9daeed00cbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7212aaba-a7e4-455f-8881-3618e181e25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69f53bba-3c9c-4800-8871-0465b32b6443" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7212aaba-a7e4-455f-8881-3618e181e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2c637c09-45af-46aa-9cf9-dee362582c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2c637c09-45af-46aa-9cf9-dee362582c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0c336543-22a9-4641-862f-5089664b8e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2c637c09-45af-46aa-9cf9-dee362582c7f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0c336543-22a9-4641-862f-5089664b8e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_afa1198d-acc4-41cf-a04d-6bdec034b27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0c336543-22a9-4641-862f-5089664b8e5d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_afa1198d-acc4-41cf-a04d-6bdec034b27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d6f3e621-c5aa-45c5-9d2f-3ead7ad7f783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d6f3e621-c5aa-45c5-9d2f-3ead7ad7f783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d6f3e621-c5aa-45c5-9d2f-3ead7ad7f783" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bf821f31-d056-4987-89d8-4611d3880a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bf821f31-d056-4987-89d8-4611d3880a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_b4da7dff-901f-468f-9066-3843e351a4a0" xlink:href="morf-20221231.xsd#morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:to="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_b4da7dff-901f-468f-9066-3843e351a4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bc5920f1-01a1-47eb-b6a8-3e551ffe2648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:to="loc_us-gaap_CommercialPaperMember_bc5920f1-01a1-47eb-b6a8-3e551ffe2648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7f6e873e-2513-45a3-8722-d97218dab4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a3806-221f-4d6e-8876-e0d28fd10220" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7f6e873e-2513-45a3-8722-d97218dab4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c9f6e3ed-dae3-4c4c-bc29-da797cc00af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b57ec3a4-a684-4bf4-85ae-0389cba7fe78" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c9f6e3ed-dae3-4c4c-bc29-da797cc00af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c9f6e3ed-dae3-4c4c-bc29-da797cc00af0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f9da26b0-808f-4154-ba47-9ba6ae8652c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f9da26b0-808f-4154-ba47-9ba6ae8652c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bf23758-4813-477c-9d02-1616c2342958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bf23758-4813-477c-9d02-1616c2342958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2d308c14-115b-49de-ac09-b86424115221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a83748af-4bdf-4f6a-8238-aba51c9f13be" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2d308c14-115b-49de-ac09-b86424115221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_d9e13b76-ac94-4f75-b005-4693c248eaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c9f6e3ed-dae3-4c4c-bc29-da797cc00af0" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_d9e13b76-ac94-4f75-b005-4693c248eaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#MarketablesecuritiesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0c2e8bec-22cd-4c5f-9ac3-660ffe66d40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ec645aca-fc7e-4f81-aa72-045e37515574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0c2e8bec-22cd-4c5f-9ac3-660ffe66d40d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ec645aca-fc7e-4f81-aa72-045e37515574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_57c2ba73-19c0-4e22-8206-7cf08ee139b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ec645aca-fc7e-4f81-aa72-045e37515574" xlink:to="loc_us-gaap_FinancialInstrumentAxis_57c2ba73-19c0-4e22-8206-7cf08ee139b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_57c2ba73-19c0-4e22-8206-7cf08ee139b7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_77085c53-3660-4755-a6d1-fb170bb88b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_77085c53-3660-4755-a6d1-fb170bb88b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_d779a5af-4a54-4f94-96f0-500b691320a4" xlink:href="morf-20221231.xsd#morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:to="loc_morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember_d779a5af-4a54-4f94-96f0-500b691320a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_989709bf-22b6-4f4a-aa55-39a864c5277d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:to="loc_us-gaap_CommercialPaperMember_989709bf-22b6-4f4a-aa55-39a864c5277d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5a21aced-5419-421c-adde-2c71b77b286a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9da158f9-6c94-4140-94f4-e34b57ac2ca4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5a21aced-5419-421c-adde-2c71b77b286a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6ee833ef-9ba4-4072-a66f-69cb4c8d4daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ec645aca-fc7e-4f81-aa72-045e37515574" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6ee833ef-9ba4-4072-a66f-69cb4c8d4daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6ee833ef-9ba4-4072-a66f-69cb4c8d4daa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_386ebd4d-3469-4fe4-be75-91d81e2cf643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_386ebd4d-3469-4fe4-be75-91d81e2cf643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c5eacd50-a56f-4d79-a701-1222bf96be1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c5eacd50-a56f-4d79-a701-1222bf96be1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_030eee29-3153-4cae-a047-180dfb308f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_030eee29-3153-4cae-a047-180dfb308f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_79afadf3-f168-4486-aa4a-2aaa71d9ab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_b4bce1c1-740b-48e0-ad6e-092213308f1b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_79afadf3-f168-4486-aa4a-2aaa71d9ab6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_2b62166a-a9e0-48ae-9a04-ac7c69094956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6ee833ef-9ba4-4072-a66f-69cb4c8d4daa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_2b62166a-a9e0-48ae-9a04-ac7c69094956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eda8b4af-3359-47b4-a81c-7b693f654cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_70f7d22a-014a-432b-90b6-b8b284d7b934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eda8b4af-3359-47b4-a81c-7b693f654cc9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_70f7d22a-014a-432b-90b6-b8b284d7b934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9eb96446-8b4d-4569-8212-83709f4a611d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_70f7d22a-014a-432b-90b6-b8b284d7b934" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9eb96446-8b4d-4569-8212-83709f4a611d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9eb96446-8b4d-4569-8212-83709f4a611d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_06d77263-f117-4f34-88f5-be3bfa7fdf68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:to="loc_us-gaap_EquipmentMember_06d77263-f117-4f34-88f5-be3bfa7fdf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ComputerEquipmentAndSoftwareMember_a764c3c3-44ee-4092-9426-21796d90cdcf" xlink:href="morf-20221231.xsd#morf_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:to="loc_morf_ComputerEquipmentAndSoftwareMember_a764c3c3-44ee-4092-9426-21796d90cdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d2074e70-bdee-4058-9e28-db554d9a4d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bbc2c4ec-4602-4f7b-a6ba-34783a2ffa28" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d2074e70-bdee-4058-9e28-db554d9a4d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_70f7d22a-014a-432b-90b6-b8b284d7b934" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2e3fddf9-f237-4dd0-957b-5ca7b4d11f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2e3fddf9-f237-4dd0-957b-5ca7b4d11f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f518fc9b-6705-452a-ad85-fbd328bd6b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f518fc9b-6705-452a-ad85-fbd328bd6b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4dacb52d-16c1-43b3-ac3d-561bef7d1074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4dacb52d-16c1-43b3-ac3d-561bef7d1074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7eb19c59-ddbb-470f-907b-02924e2f2de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85eabdbb-2142-49c6-9cbe-ebe668890d2f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7eb19c59-ddbb-470f-907b-02924e2f2de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_28ff3dd4-d4e6-4173-a5bb-ad6cb7fb6573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_86082cb0-e018-421e-9281-216c736ce776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_28ff3dd4-d4e6-4173-a5bb-ad6cb7fb6573" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_86082cb0-e018-421e-9281-216c736ce776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_f2dd5941-114b-4116-acaa-4e8e5fbe7682" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_86082cb0-e018-421e-9281-216c736ce776" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_f2dd5941-114b-4116-acaa-4e8e5fbe7682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4778a429-42d6-452a-9a61-79318d9399d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_f2dd5941-114b-4116-acaa-4e8e5fbe7682" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4778a429-42d6-452a-9a61-79318d9399d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OfficeAndLaboratorySpaceMember_44327145-2ad6-4b0d-a478-20de66446d49" xlink:href="morf-20221231.xsd#morf_OfficeAndLaboratorySpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4778a429-42d6-452a-9a61-79318d9399d2" xlink:to="loc_morf_OfficeAndLaboratorySpaceMember_44327145-2ad6-4b0d-a478-20de66446d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a666d11-3653-4946-b9eb-84be7588d655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_86082cb0-e018-421e-9281-216c736ce776" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a666d11-3653-4946-b9eb-84be7588d655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_e9cb51cb-554b-4b19-a221-1d29e2e2da29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a666d11-3653-4946-b9eb-84be7588d655" xlink:to="loc_us-gaap_AreaOfLand_e9cb51cb-554b-4b19-a221-1d29e2e2da29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_62f3457f-e966-4429-b08d-b6038cd34ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a666d11-3653-4946-b9eb-84be7588d655" xlink:to="loc_us-gaap_OperatingLeaseExpense_62f3457f-e966-4429-b08d-b6038cd34ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#LeasesSummaryofsupplementalinformationDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5084bf4a-b7c7-4fea-b8d3-1b481879472b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_86ce35bf-9c25-467e-a5b7-62b6d219901a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5084bf4a-b7c7-4fea-b8d3-1b481879472b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_86ce35bf-9c25-467e-a5b7-62b6d219901a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2bbba6f1-df18-41ec-9291-f46959ce231a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5084bf4a-b7c7-4fea-b8d3-1b481879472b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2bbba6f1-df18-41ec-9291-f46959ce231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_043ca2c4-73c3-4600-b12d-9c858524df04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5084bf4a-b7c7-4fea-b8d3-1b481879472b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_043ca2c4-73c3-4600-b12d-9c858524df04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_41d90889-6849-41fc-b222-713d51a4dec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5084bf4a-b7c7-4fea-b8d3-1b481879472b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_41d90889-6849-41fc-b222-713d51a4dec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bc370106-86f3-4e54-addc-eac493925552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5084bf4a-b7c7-4fea-b8d3-1b481879472b" xlink:to="loc_us-gaap_OperatingLeaseLiability_bc370106-86f3-4e54-addc-eac493925552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2ca45c73-ab29-47ee-a24c-f0f3b3d4f5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5084bf4a-b7c7-4fea-b8d3-1b481879472b" xlink:to="loc_us-gaap_OperatingLeasePayments_2ca45c73-ab29-47ee-a24c-f0f3b3d4f5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fc0d3a6-d642-48fe-bf18-68c8b8ede04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5084bf4a-b7c7-4fea-b8d3-1b481879472b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fc0d3a6-d642-48fe-bf18-68c8b8ede04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9418c09b-939d-41d8-8be2-a483657d6f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5084bf4a-b7c7-4fea-b8d3-1b481879472b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9418c09b-939d-41d8-8be2-a483657d6f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#LeasesMaturitiesofleasecommitmentsDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8d18e580-cdff-4313-8a50-24987af46883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_afdc4304-a016-4150-ab54-af479908588d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d18e580-cdff-4313-8a50-24987af46883" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_afdc4304-a016-4150-ab54-af479908588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_701685c2-d6d3-46a6-b062-5d58f46a4f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d18e580-cdff-4313-8a50-24987af46883" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_701685c2-d6d3-46a6-b062-5d58f46a4f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bbad5510-f4dd-48f2-973b-1b167dc7d253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d18e580-cdff-4313-8a50-24987af46883" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bbad5510-f4dd-48f2-973b-1b167dc7d253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9ffde2a-7e76-4177-807d-86c2c7bb0aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d18e580-cdff-4313-8a50-24987af46883" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9ffde2a-7e76-4177-807d-86c2c7bb0aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_59ccf6dd-b881-45b9-a073-ad0e315d39d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d18e580-cdff-4313-8a50-24987af46883" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_59ccf6dd-b881-45b9-a073-ad0e315d39d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6541b78e-8373-4c81-88d2-8e228b81b347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d18e580-cdff-4313-8a50-24987af46883" xlink:to="loc_us-gaap_OperatingLeaseLiability_6541b78e-8373-4c81-88d2-8e228b81b347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails_1" xlink:type="simple" xlink:href="morf-20221231.xsd#LeasesMaturitiesofleasecommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://morphictx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6017fee8-0a95-495d-866e-448ce9cf4802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_464eb3f1-70dd-40f6-96b8-dbb067f9e6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6017fee8-0a95-495d-866e-448ce9cf4802" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_464eb3f1-70dd-40f6-96b8-dbb067f9e6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AccruedResearchAndDevelopment_3a9508b8-d422-4323-a420-d3977777533a" xlink:href="morf-20221231.xsd#morf_AccruedResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6017fee8-0a95-495d-866e-448ce9cf4802" xlink:to="loc_morf_AccruedResearchAndDevelopment_3a9508b8-d422-4323-a420-d3977777533a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3ef424c6-afd1-4f17-a9c7-a957f1ae63f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6017fee8-0a95-495d-866e-448ce9cf4802" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3ef424c6-afd1-4f17-a9c7-a957f1ae63f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e1e58306-49f3-4f49-bf3d-b8b7ed2d36d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6017fee8-0a95-495d-866e-448ce9cf4802" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e1e58306-49f3-4f49-bf3d-b8b7ed2d36d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5f967761-a10d-4b0d-b7ef-be854fd0630f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6017fee8-0a95-495d-866e-448ce9cf4802" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5f967761-a10d-4b0d-b7ef-be854fd0630f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3a56f527-802d-492e-8380-af57aed0c862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_VotingRights_0f1f8b28-0022-44cb-b2f8-618663866a35" xlink:href="morf-20221231.xsd#morf_VotingRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3a56f527-802d-492e-8380-af57aed0c862" xlink:to="loc_morf_VotingRights_0f1f8b28-0022-44cb-b2f8-618663866a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6f2d6471-6c13-41a8-8abd-53f9e6f537be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3a56f527-802d-492e-8380-af57aed0c862" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6f2d6471-6c13-41a8-8abd-53f9e6f537be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_80cfca4b-d994-435c-b897-14cfd9cb4135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3a56f527-802d-492e-8380-af57aed0c862" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_80cfca4b-d994-435c-b897-14cfd9cb4135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_e07ae1bb-8c35-49fd-b78b-1e43149e6e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3a56f527-802d-492e-8380-af57aed0c862" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_e07ae1bb-8c35-49fd-b78b-1e43149e6e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensation2019equityincentiveplanDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68d9083c-4963-4baa-8d18-bf515ca10023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4d7fe7e-e70c-421d-a2c0-5ea20da7ddde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68d9083c-4963-4baa-8d18-bf515ca10023" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4d7fe7e-e70c-421d-a2c0-5ea20da7ddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_20597835-7d57-4372-a25b-10440a65ac20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4d7fe7e-e70c-421d-a2c0-5ea20da7ddde" xlink:to="loc_us-gaap_PlanNameAxis_20597835-7d57-4372-a25b-10440a65ac20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74b9a621-bf88-4b05-9cf5-bac1b50b48c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_20597835-7d57-4372-a25b-10440a65ac20" xlink:to="loc_us-gaap_PlanNameDomain_74b9a621-bf88-4b05-9cf5-bac1b50b48c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_1eef4d35-fe49-44c6-a8da-9419b880d2e6" xlink:href="morf-20221231.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_74b9a621-bf88-4b05-9cf5-bac1b50b48c2" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_1eef4d35-fe49-44c6-a8da-9419b880d2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b5f1cf-6940-4e1b-a63b-1967d1f220e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4d7fe7e-e70c-421d-a2c0-5ea20da7ddde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b5f1cf-6940-4e1b-a63b-1967d1f220e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_036444d1-b298-4663-ad23-f99b41ec4fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b5f1cf-6940-4e1b-a63b-1967d1f220e8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_036444d1-b298-4663-ad23-f99b41ec4fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af97f693-4a78-4c2f-beb6-4c1e27e0dfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b5f1cf-6940-4e1b-a63b-1967d1f220e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af97f693-4a78-4c2f-beb6-4c1e27e0dfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationEquitybasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d840c5c-d8a0-44b2-b010-790606232752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9faf57f4-675e-4fb8-8add-105cd0cd2f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d840c5c-d8a0-44b2-b010-790606232752" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9faf57f4-675e-4fb8-8add-105cd0cd2f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c99ba72-e273-428f-9cab-8d7d74747626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9faf57f4-675e-4fb8-8add-105cd0cd2f98" xlink:to="loc_us-gaap_AwardTypeAxis_7c99ba72-e273-428f-9cab-8d7d74747626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7c99ba72-e273-428f-9cab-8d7d74747626" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_19fad6ea-7780-49e9-aea8-99b752e2baf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_19fad6ea-7780-49e9-aea8-99b752e2baf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_855351b7-adca-4078-867e-f0b7f70db4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:to="loc_us-gaap_RestrictedStockMember_855351b7-adca-4078-867e-f0b7f70db4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_accdac8c-4faf-44a5-bd87-d625c79e5b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_accdac8c-4faf-44a5-bd87-d625c79e5b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d8122caa-afe4-4f5c-b3d6-7eb0b4ec9071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cf143bf-b009-4228-bcbd-fd16dcfa27f4" xlink:to="loc_us-gaap_EmployeeStockMember_d8122caa-afe4-4f5c-b3d6-7eb0b4ec9071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3eeb8ed3-b8a8-4435-930f-dce52b3dd115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9faf57f4-675e-4fb8-8add-105cd0cd2f98" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3eeb8ed3-b8a8-4435-930f-dce52b3dd115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_992b0e6f-5643-49d4-a25f-b025fe731fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3eeb8ed3-b8a8-4435-930f-dce52b3dd115" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_992b0e6f-5643-49d4-a25f-b025fe731fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_db36dce1-2999-40c6-882f-cca103bf470d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_992b0e6f-5643-49d4-a25f-b025fe731fa1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_db36dce1-2999-40c6-882f-cca103bf470d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d3697290-48be-4387-b347-5c417ada4a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_992b0e6f-5643-49d4-a25f-b025fe731fa1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d3697290-48be-4387-b347-5c417ada4a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00079faf-52f5-4cac-9bb3-6bc3a8327229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9faf57f4-675e-4fb8-8add-105cd0cd2f98" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00079faf-52f5-4cac-9bb3-6bc3a8327229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_49771fd2-b013-47b7-8d44-e17363a6c86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00079faf-52f5-4cac-9bb3-6bc3a8327229" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_49771fd2-b013-47b7-8d44-e17363a6c86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationRestrictedcommonstockactivityDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8d9100c-0705-495e-b651-8c5dc046e85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_382916f4-b456-49be-b11e-098e3eed5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8d9100c-0705-495e-b651-8c5dc046e85d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_382916f4-b456-49be-b11e-098e3eed5fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2696e5f3-57a6-4332-a9d3-9bbfa4b22371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_382916f4-b456-49be-b11e-098e3eed5fe2" xlink:to="loc_us-gaap_PlanNameAxis_2696e5f3-57a6-4332-a9d3-9bbfa4b22371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8b931d46-b02e-4afe-8263-fcfb4a1954a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2696e5f3-57a6-4332-a9d3-9bbfa4b22371" xlink:to="loc_us-gaap_PlanNameDomain_8b931d46-b02e-4afe-8263-fcfb4a1954a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_9f2f8fdd-e300-464a-94d2-42e1fce62386" xlink:href="morf-20221231.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8b931d46-b02e-4afe-8263-fcfb4a1954a0" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_9f2f8fdd-e300-464a-94d2-42e1fce62386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1493eae2-0951-4dfd-b188-c0d5375faade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_382916f4-b456-49be-b11e-098e3eed5fe2" xlink:to="loc_us-gaap_AwardTypeAxis_1493eae2-0951-4dfd-b188-c0d5375faade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb5af905-e27f-40c8-8337-998f8bac4015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1493eae2-0951-4dfd-b188-c0d5375faade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb5af905-e27f-40c8-8337-998f8bac4015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_09ceb54c-32b0-4fb2-af30-794a7db695a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb5af905-e27f-40c8-8337-998f8bac4015" xlink:to="loc_us-gaap_RestrictedStockMember_09ceb54c-32b0-4fb2-af30-794a7db695a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_382916f4-b456-49be-b11e-098e3eed5fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b1f8d73e-43f7-4bc9-a540-a5f8546bead3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b1f8d73e-43f7-4bc9-a540-a5f8546bead3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_71aa36b1-fbbf-423d-bda6-45e4449ef949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_71aa36b1-fbbf-423d-bda6-45e4449ef949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e18f149e-6484-4f13-bc6e-2fdef5676e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e18f149e-6484-4f13-bc6e-2fdef5676e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37ec0655-e141-4ff6-acfb-b2fcd406d7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37ec0655-e141-4ff6-acfb-b2fcd406d7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2294b9ec-9799-410d-aa2e-b6033614f371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f03d4ef4-a611-4c4a-9129-333387310abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2294b9ec-9799-410d-aa2e-b6033614f371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_491a9e4d-b874-4196-959c-d3add0a87743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_491a9e4d-b874-4196-959c-d3add0a87743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4141241c-1f1e-46a7-802f-bee31d1ee262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4141241c-1f1e-46a7-802f-bee31d1ee262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d4031fdd-03ef-4f0c-b3c5-f02b0e68ea73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d4031fdd-03ef-4f0c-b3c5-f02b0e68ea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_623b65e1-4f62-406b-92e7-1bc91baccfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_623b65e1-4f62-406b-92e7-1bc91baccfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9e26fb4-c3eb-44c8-b3f2-6bbbe0a37269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_11147080-1021-41f4-880b-d066cbb69014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9e26fb4-c3eb-44c8-b3f2-6bbbe0a37269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ddd628a3-f08a-4dc3-86d5-6ca173d32167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ddd628a3-f08a-4dc3-86d5-6ca173d32167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_73102d9c-d46e-49c3-a07c-4dd795aced8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1892a7a3-b981-491b-b71e-9ca7dffd4a6e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_73102d9c-d46e-49c3-a07c-4dd795aced8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationRestrictedstockunitsactivityDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6c4010c-23e5-4604-9c39-94fdf2b49ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993559b4-162d-49d3-953f-50c55afaca32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6c4010c-23e5-4604-9c39-94fdf2b49ce9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993559b4-162d-49d3-953f-50c55afaca32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_76053d25-adcd-4cf7-91eb-45fda93b462f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993559b4-162d-49d3-953f-50c55afaca32" xlink:to="loc_us-gaap_PlanNameAxis_76053d25-adcd-4cf7-91eb-45fda93b462f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_380aa657-29f6-42bd-926c-517b37a92c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_76053d25-adcd-4cf7-91eb-45fda93b462f" xlink:to="loc_us-gaap_PlanNameDomain_380aa657-29f6-42bd-926c-517b37a92c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_3c28f673-bf7b-40bd-9d69-455280ec2fde" xlink:href="morf-20221231.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_380aa657-29f6-42bd-926c-517b37a92c4b" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_3c28f673-bf7b-40bd-9d69-455280ec2fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_59cbdeb8-9dbc-4ab0-be29-4aedee8149b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993559b4-162d-49d3-953f-50c55afaca32" xlink:to="loc_us-gaap_AwardTypeAxis_59cbdeb8-9dbc-4ab0-be29-4aedee8149b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a05c8d3-2e9c-4f3f-bfff-1fab7fb729d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_59cbdeb8-9dbc-4ab0-be29-4aedee8149b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a05c8d3-2e9c-4f3f-bfff-1fab7fb729d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e36c9993-82bb-4480-8837-fa4a63dc628c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a05c8d3-2e9c-4f3f-bfff-1fab7fb729d6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e36c9993-82bb-4480-8837-fa4a63dc628c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993559b4-162d-49d3-953f-50c55afaca32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b0a4c4ad-0047-460d-a236-fa38ed7b2a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b0a4c4ad-0047-460d-a236-fa38ed7b2a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_38669dda-8a0c-4f35-b1a2-964233ee6296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_38669dda-8a0c-4f35-b1a2-964233ee6296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f7c279fa-fbb0-4061-ace2-68f5dcb9e11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f7c279fa-fbb0-4061-ace2-68f5dcb9e11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3cd42cc-483e-4cd0-8bce-26a9c454147d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3cd42cc-483e-4cd0-8bce-26a9c454147d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fbfdefd8-664b-420f-833a-ac6d3830418b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1290ed30-eedc-493e-8f73-c912993a8903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fbfdefd8-664b-420f-833a-ac6d3830418b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e5fd58ec-4257-4c15-9e62-2df14f297643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e5fd58ec-4257-4c15-9e62-2df14f297643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_28f0c9f3-8a42-49a3-8af8-660c8d96024d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_28f0c9f3-8a42-49a3-8af8-660c8d96024d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9219b3a6-3ebb-49a3-96fb-eb74fe9e637d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9219b3a6-3ebb-49a3-96fb-eb74fe9e637d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6c8c587b-87f1-49fa-bf9d-12aa09190904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6c8c587b-87f1-49fa-bf9d-12aa09190904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9843715-0fd7-448b-aadd-b9e7daedd77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0d8a8bed-3ed0-42f0-a6fb-0fd04f5f55b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9843715-0fd7-448b-aadd-b9e7daedd77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_84d23833-c3fc-4d1b-b5eb-b2e894fe5e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_84d23833-c3fc-4d1b-b5eb-b2e894fe5e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be42de8a-0277-4ab6-b2bd-dacd91a4af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be42de8a-0277-4ab6-b2bd-dacd91a4af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_44557a70-2f38-4456-ab6c-a59a6d349321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a48dff43-7f6e-4d12-870a-0c1cb3e376c0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_44557a70-2f38-4456-ab6c-a59a6d349321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationStockoptionawardsDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f251715-b814-4a4c-9212-1afff1b9880d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1894f85-defb-4c91-aebd-26b4318495af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f251715-b814-4a4c-9212-1afff1b9880d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1894f85-defb-4c91-aebd-26b4318495af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a243e8bc-9206-41ea-a08d-7871d4f6de52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1894f85-defb-4c91-aebd-26b4318495af" xlink:to="loc_us-gaap_AwardTypeAxis_a243e8bc-9206-41ea-a08d-7871d4f6de52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f92a7686-3e7b-428f-b78e-c158a137830c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a243e8bc-9206-41ea-a08d-7871d4f6de52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f92a7686-3e7b-428f-b78e-c158a137830c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bd5c8048-7a41-4911-95e2-1a17a76ac6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f92a7686-3e7b-428f-b78e-c158a137830c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bd5c8048-7a41-4911-95e2-1a17a76ac6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1894f85-defb-4c91-aebd-26b4318495af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e3838b74-5163-44b4-81f4-d5a6d4db65d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e3838b74-5163-44b4-81f4-d5a6d4db65d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60f6c7ef-d949-4048-88f8-fd1ec1f38217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60f6c7ef-d949-4048-88f8-fd1ec1f38217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_59cc14fb-7976-4c34-bed2-dd337851bacd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_59cc14fb-7976-4c34-bed2-dd337851bacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9309914d-d92f-4f22-8c2f-a085ae15f4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9309914d-d92f-4f22-8c2f-a085ae15f4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b670a2d7-a24e-4226-8c18-d816982ed450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63b75592-40e6-4a42-a2d8-88f092eaf1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b670a2d7-a24e-4226-8c18-d816982ed450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_680bf40b-0661-4185-9f9e-b2fae77031ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_680bf40b-0661-4185-9f9e-b2fae77031ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_350df418-58d7-4657-aa8f-0226544887fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_350df418-58d7-4657-aa8f-0226544887fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_98a7203f-8494-4892-b137-465dbe4097a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_98a7203f-8494-4892-b137-465dbe4097a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d45c55f3-3794-4848-bdfb-62c88938121b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d45c55f3-3794-4848-bdfb-62c88938121b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c05ab4ee-e555-4f96-ba00-5aa93483141a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c05ab4ee-e555-4f96-ba00-5aa93483141a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e1340d76-a259-4d99-a293-e3bf395e307a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9ae0bad0-2e9d-42e7-bfb1-a7451c9daeb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e1340d76-a259-4d99-a293-e3bf395e307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cae8d1ab-76e1-4bed-bf2d-e867183809f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cae8d1ab-76e1-4bed-bf2d-e867183809f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8809c2d9-8c99-4fe8-b733-8171cf30050c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8809c2d9-8c99-4fe8-b733-8171cf30050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0043ea7b-30ac-4106-9f30-53b1eda01ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0043ea7b-30ac-4106-9f30-53b1eda01ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6d6f0508-8c4e-490a-830d-8b40386005c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6d6f0508-8c4e-490a-830d-8b40386005c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_62868635-b893-4255-a45a-063f74b44608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_038d4e11-42d0-4bcb-a6c1-7d631190a9ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_62868635-b893-4255-a45a-063f74b44608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f8767495-dd0f-4d9b-bbea-7c475f94bae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f8767495-dd0f-4d9b-bbea-7c475f94bae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27afa4ef-703b-49e6-9c33-dca9294dda85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4edaad5-3149-4da2-bcde-a3a020f3498b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27afa4ef-703b-49e6-9c33-dca9294dda85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea561ffb-b91c-4498-8689-28ba16186304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a623e4af-c5a4-4b2d-b202-4e893939e27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea561ffb-b91c-4498-8689-28ba16186304" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a623e4af-c5a4-4b2d-b202-4e893939e27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_61c06f4d-049d-4c7e-ba34-c6612d52c51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea561ffb-b91c-4498-8689-28ba16186304" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_61c06f4d-049d-4c7e-ba34-c6612d52c51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_57efa899-8fb5-4b44-9ccf-c317b9bbd5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea561ffb-b91c-4498-8689-28ba16186304" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_57efa899-8fb5-4b44-9ccf-c317b9bbd5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1975a6af-677f-484b-ad7a-e8c4ec4d74d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea561ffb-b91c-4498-8689-28ba16186304" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1975a6af-677f-484b-ad7a-e8c4ec4d74d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5911a360-630c-4cac-b005-adbaa28d9ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1975a6af-677f-484b-ad7a-e8c4ec4d74d1" xlink:to="loc_us-gaap_AwardTypeAxis_5911a360-630c-4cac-b005-adbaa28d9ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_457f62a6-721b-4345-a180-c45c29aecf48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5911a360-630c-4cac-b005-adbaa28d9ed6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_457f62a6-721b-4345-a180-c45c29aecf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f22d4f18-cb31-4ba8-a0e2-bdd6312b24d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_457f62a6-721b-4345-a180-c45c29aecf48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f22d4f18-cb31-4ba8-a0e2-bdd6312b24d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_dd719a5b-d6dd-42dc-a935-646f07131711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1975a6af-677f-484b-ad7a-e8c4ec4d74d1" xlink:to="loc_us-gaap_PlanNameAxis_dd719a5b-d6dd-42dc-a935-646f07131711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9aa2418f-1e20-4639-b2f6-11f2f73e4230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_dd719a5b-d6dd-42dc-a935-646f07131711" xlink:to="loc_us-gaap_PlanNameDomain_9aa2418f-1e20-4639-b2f6-11f2f73e4230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_50e490d8-5f35-4ded-9df9-66a1fea63d4d" xlink:href="morf-20221231.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9aa2418f-1e20-4639-b2f6-11f2f73e4230" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_50e490d8-5f35-4ded-9df9-66a1fea63d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d34f2c-6153-4127-8d61-9690ab9a8c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1975a6af-677f-484b-ad7a-e8c4ec4d74d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d34f2c-6153-4127-8d61-9690ab9a8c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94d34f2c-6153-4127-8d61-9690ab9a8c05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4ed7d091-5423-4e64-9534-81757d7b05f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4ed7d091-5423-4e64-9534-81757d7b05f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b873b4e-93a4-4145-9b55-2b9ae686be7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b873b4e-93a4-4145-9b55-2b9ae686be7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3938a5cc-650c-438d-b717-cd69d6e3484a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3ef01fd1-ca99-4478-8975-f5c6b6c8df78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3938a5cc-650c-438d-b717-cd69d6e3484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EquityBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ed750e9-8e17-40e7-a6f7-026c8b345974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b1c2f5-ba09-4aef-9564-69d48a3b351a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ed750e9-8e17-40e7-a6f7-026c8b345974" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b1c2f5-ba09-4aef-9564-69d48a3b351a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1ff5bc4c-21a5-499c-b0f6-09713efc4319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b1c2f5-ba09-4aef-9564-69d48a3b351a" xlink:to="loc_us-gaap_PlanNameAxis_1ff5bc4c-21a5-499c-b0f6-09713efc4319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_65ca5168-ccdc-44d6-91ff-d6bfaee76bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1ff5bc4c-21a5-499c-b0f6-09713efc4319" xlink:to="loc_us-gaap_PlanNameDomain_65ca5168-ccdc-44d6-91ff-d6bfaee76bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember_eff2a2d6-c8b2-4a4e-bc07-a7eea444c1c2" xlink:href="morf-20221231.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_65ca5168-ccdc-44d6-91ff-d6bfaee76bcc" xlink:to="loc_morf_EmployeeStockPurchasePlanMember_eff2a2d6-c8b2-4a4e-bc07-a7eea444c1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d9c58db-ce74-4496-b625-aab43f09be37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b1c2f5-ba09-4aef-9564-69d48a3b351a" xlink:to="loc_srt_RangeAxis_1d9c58db-ce74-4496-b625-aab43f09be37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1cd2bbc-91b3-4be3-bd62-bf89ce7ba0ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1d9c58db-ce74-4496-b625-aab43f09be37" xlink:to="loc_srt_RangeMember_e1cd2bbc-91b3-4be3-bd62-bf89ce7ba0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ed93e22-65de-492b-8d7f-83ec5675a432" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1cd2bbc-91b3-4be3-bd62-bf89ce7ba0ed" xlink:to="loc_srt_MaximumMember_1ed93e22-65de-492b-8d7f-83ec5675a432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b1c2f5-ba09-4aef-9564-69d48a3b351a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f88512b0-174d-4007-93f6-c82cd9be2825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f88512b0-174d-4007-93f6-c82cd9be2825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94096fe1-bee3-492d-b42a-34170757bc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94096fe1-bee3-492d-b42a-34170757bc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_fd565d38-49f3-4b0b-8122-488fd8b3411d" xlink:href="morf-20221231.xsd#morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:to="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_fd565d38-49f3-4b0b-8122-488fd8b3411d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_7dd5cb03-3a7f-4e91-80dd-830b537d2628" xlink:href="morf-20221231.xsd#morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23028aac-5964-413d-98b4-a36eff2029e1" xlink:to="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_7dd5cb03-3a7f-4e91-80dd-830b537d2628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesComponentsoflossbeforeincometaxesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0701bfff-a8a5-4f2a-8c03-13b871252e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_49ee150f-efe1-4857-9844-d2d8d3efd5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0701bfff-a8a5-4f2a-8c03-13b871252e8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_49ee150f-efe1-4857-9844-d2d8d3efd5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3b231955-eb30-410f-8cf1-09288c0058c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0701bfff-a8a5-4f2a-8c03-13b871252e8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3b231955-eb30-410f-8cf1-09288c0058c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_c2987444-05f5-445a-b686-a3ad9a8bbdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0701bfff-a8a5-4f2a-8c03-13b871252e8b" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_c2987444-05f5-445a-b686-a3ad9a8bbdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesComponentsofincometaxDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a80f361a-aa53-4999-b217-9e35f4bc15ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_cbbdc3af-8181-4737-8b71-6274f3ca3b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a80f361a-aa53-4999-b217-9e35f4bc15ce" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_cbbdc3af-8181-4737-8b71-6274f3ca3b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f83b7a23-e1d4-4e8d-a290-9054d77d99c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_cbbdc3af-8181-4737-8b71-6274f3ca3b11" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f83b7a23-e1d4-4e8d-a290-9054d77d99c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b5816d00-b3ea-45db-b588-3be6ec2feca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_cbbdc3af-8181-4737-8b71-6274f3ca3b11" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b5816d00-b3ea-45db-b588-3be6ec2feca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9f3acf32-b0d0-43a2-a5e4-8ba5fd5798c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_cbbdc3af-8181-4737-8b71-6274f3ca3b11" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9f3acf32-b0d0-43a2-a5e4-8ba5fd5798c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_850aa7ff-04a0-4713-906f-6caa3c493c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_cbbdc3af-8181-4737-8b71-6274f3ca3b11" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_850aa7ff-04a0-4713-906f-6caa3c493c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_f04585f0-03fc-49d8-a14c-2fcdf01e4d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a80f361a-aa53-4999-b217-9e35f4bc15ce" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_f04585f0-03fc-49d8-a14c-2fcdf01e4d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7d854436-50e8-40d0-a7b3-d87d0178f32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_f04585f0-03fc-49d8-a14c-2fcdf01e4d1d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7d854436-50e8-40d0-a7b3-d87d0178f32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ffcfb2fd-b105-48b5-9d97-0caf82992bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_f04585f0-03fc-49d8-a14c-2fcdf01e4d1d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ffcfb2fd-b105-48b5-9d97-0caf82992bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_bc26540a-6c86-4259-a768-7b8b52515356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_f04585f0-03fc-49d8-a14c-2fcdf01e4d1d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_bc26540a-6c86-4259-a768-7b8b52515356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2197d6c2-c968-4c84-8f15-8ecd04431301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_f04585f0-03fc-49d8-a14c-2fcdf01e4d1d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2197d6c2-c968-4c84-8f15-8ecd04431301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_563eaa45-6f7c-4ae4-b05d-4be1d0296a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a80f361a-aa53-4999-b217-9e35f4bc15ce" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_563eaa45-6f7c-4ae4-b05d-4be1d0296a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesEffectiveincometaxrateDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3a791253-d6c9-44c2-bb4c-f77a945ff117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4d70bfc5-a666-404b-840b-a36af374302a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a791253-d6c9-44c2-bb4c-f77a945ff117" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4d70bfc5-a666-404b-840b-a36af374302a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4fd09bc0-81aa-47ae-8970-1f26e20c61f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a791253-d6c9-44c2-bb4c-f77a945ff117" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4fd09bc0-81aa-47ae-8970-1f26e20c61f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_b6befe58-e231-4227-b5c2-ef23c5548b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a791253-d6c9-44c2-bb4c-f77a945ff117" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_b6befe58-e231-4227-b5c2-ef23c5548b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_86b903cb-63cd-4905-96ec-34406a100e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a791253-d6c9-44c2-bb4c-f77a945ff117" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_86b903cb-63cd-4905-96ec-34406a100e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_07cb6938-db8b-480f-82da-5d2c23996b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a791253-d6c9-44c2-bb4c-f77a945ff117" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_07cb6938-db8b-480f-82da-5d2c23996b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_89e14a58-350d-476d-aca1-fa6b4290e978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a791253-d6c9-44c2-bb4c-f77a945ff117" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_89e14a58-350d-476d-aca1-fa6b4290e978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_62706688-a28b-42c6-9389-f551bb9439b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a791253-d6c9-44c2-bb4c-f77a945ff117" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_62706688-a28b-42c6-9389-f551bb9439b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesDeferredtaxassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_74ac7875-f776-4344-8fe1-ebe02843fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74ac7875-f776-4344-8fe1-ebe02843fad4" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_491131ea-68fa-4816-acda-5b612711c423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_491131ea-68fa-4816-acda-5b612711c423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1230d6af-4ecf-466f-9e7f-02a99776bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1230d6af-4ecf-466f-9e7f-02a99776bc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_19b5d436-6e2b-4bdf-988d-aa8796dd6873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_19b5d436-6e2b-4bdf-988d-aa8796dd6873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_a87cb73e-473b-4aee-8444-59b76a89f29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_a87cb73e-473b-4aee-8444-59b76a89f29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_DeferredTaxAssetsFixedAndIntangibleAssets_9125fbfc-7cec-4793-b6de-00f183cfdb73" xlink:href="morf-20221231.xsd#morf_DeferredTaxAssetsFixedAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:to="loc_morf_DeferredTaxAssetsFixedAndIntangibleAssets_9125fbfc-7cec-4793-b6de-00f183cfdb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_99bc8fb7-430c-4f79-a2ff-362dfe13a126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_99bc8fb7-430c-4f79-a2ff-362dfe13a126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_DeferredTaxAssetLeaseLiabilities_dd0d9847-0ff9-46ef-9bb8-58e39496e68d" xlink:href="morf-20221231.xsd#morf_DeferredTaxAssetLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:to="loc_morf_DeferredTaxAssetLeaseLiabilities_dd0d9847-0ff9-46ef-9bb8-58e39496e68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3ddbe7e2-7e5f-4e20-a7d5-e12506cf5006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3ddbe7e2-7e5f-4e20-a7d5-e12506cf5006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c4679f7f-b2a9-41c0-907e-23d544626d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_afbedc5b-462a-4a01-9894-704da95cd6b1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c4679f7f-b2a9-41c0-907e-23d544626d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e2fb2faf-d310-40bc-85ea-7ce49ca0d9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74ac7875-f776-4344-8fe1-ebe02843fad4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e2fb2faf-d310-40bc-85ea-7ce49ca0d9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_08786d9e-0587-4c4e-b79d-91096d7d5c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74ac7875-f776-4344-8fe1-ebe02843fad4" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_08786d9e-0587-4c4e-b79d-91096d7d5c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_cecc9ca6-c6eb-412d-ace4-ce856e0027cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74ac7875-f776-4344-8fe1-ebe02843fad4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_cecc9ca6-c6eb-412d-ace4-ce856e0027cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b371d5a1-dcd8-423d-ba9c-7349a3d8218a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74ac7875-f776-4344-8fe1-ebe02843fad4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b371d5a1-dcd8-423d-ba9c-7349a3d8218a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_bc30331f-196e-4534-8f55-b2de291f5e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74ac7875-f776-4344-8fe1-ebe02843fad4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_bc30331f-196e-4534-8f55-b2de291f5e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_59e55d01-4b8f-4f3b-ba8a-606f3f469871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74ac7875-f776-4344-8fe1-ebe02843fad4" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_59e55d01-4b8f-4f3b-ba8a-606f3f469871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f1a7b0b3-b578-4197-ad02-9492c27e5d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_aa7d31b8-9562-4e05-9a83-d646bcff83f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f1a7b0b3-b578-4197-ad02-9492c27e5d1a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_aa7d31b8-9562-4e05-9a83-d646bcff83f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_21c2ebd0-3edc-437b-bb86-0970f050f400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_aa7d31b8-9562-4e05-9a83-d646bcff83f0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_21c2ebd0-3edc-437b-bb86-0970f050f400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8fd5d739-3e46-4d60-ab27-2cd966566cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_21c2ebd0-3edc-437b-bb86-0970f050f400" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8fd5d739-3e46-4d60-ab27-2cd966566cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_70664b85-c2f1-49ba-9337-6e0fa7d3e2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8fd5d739-3e46-4d60-ab27-2cd966566cec" xlink:to="loc_us-gaap_DomesticCountryMember_70664b85-c2f1-49ba-9337-6e0fa7d3e2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_99bc4072-5751-428e-8c43-1a8945bc14ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8fd5d739-3e46-4d60-ab27-2cd966566cec" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_99bc4072-5751-428e-8c43-1a8945bc14ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_aa7d31b8-9562-4e05-9a83-d646bcff83f0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dc67387b-a3cf-4d82-8d2c-f17d3bdbf649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dc67387b-a3cf-4d82-8d2c-f17d3bdbf649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_33fb2a6d-2d70-45c0-b5f9-0ad65d27646f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_33fb2a6d-2d70-45c0-b5f9-0ad65d27646f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0ab38498-3d7c-487c-8ba4-24291aa97c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0ab38498-3d7c-487c-8ba4-24291aa97c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OperatingLossCarryforwardsNotSubjectToExpiration_1ebf5291-1db9-482a-a2c9-44ff9ecb6177" xlink:href="morf-20221231.xsd#morf_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_morf_OperatingLossCarryforwardsNotSubjectToExpiration_1ebf5291-1db9-482a-a2c9-44ff9ecb6177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_cbe628fa-5207-4d42-aec4-790e77432ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_cbe628fa-5207-4d42-aec4-790e77432ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_5e23adaa-8002-47ce-aacc-7ab5f3f03051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_5e23adaa-8002-47ce-aacc-7ab5f3f03051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4ec96e7e-d6c2-4d7c-b9c3-86934ac8a2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45b1d6b4-b60d-43ee-a35d-48188563c5f4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4ec96e7e-d6c2-4d7c-b9c3-86934ac8a2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#OptionandLicenseAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract_f5d34640-2389-4814-87f1-0eddb081ad4b" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract_f5d34640-2389-4814-87f1-0eddb081ad4b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_09fd58a0-b223-436b-9c2b-ef31d2eabc72" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:to="loc_srt_CounterpartyNameAxis_09fd58a0-b223-436b-9c2b-ef31d2eabc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8c8ff76-c0bd-4087-a764-631a3e081be3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_09fd58a0-b223-436b-9c2b-ef31d2eabc72" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8c8ff76-c0bd-4087-a764-631a3e081be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember_e8433a59-5727-498c-a8dc-430c49d01b7c" xlink:href="morf-20221231.xsd#morf_AbbVieMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8c8ff76-c0bd-4087-a764-631a3e081be3" xlink:to="loc_morf_AbbVieMember_e8433a59-5727-498c-a8dc-430c49d01b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember_ce937f64-8789-4101-84fa-589ea13a9d4a" xlink:href="morf-20221231.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8c8ff76-c0bd-4087-a764-631a3e081be3" xlink:to="loc_morf_JanssenPharmaceuticalsIncMember_ce937f64-8789-4101-84fa-589ea13a9d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b56f6130-21f8-4b30-ac28-be6bc2cc6681" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:to="loc_srt_ProductOrServiceAxis_b56f6130-21f8-4b30-ac28-be6bc2cc6681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b56f6130-21f8-4b30-ac28-be6bc2cc6681" xlink:to="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d19943b1-b0b5-469d-86ea-f36cf275c27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:to="loc_us-gaap_LicenseMember_d19943b1-b0b5-469d-86ea-f36cf275c27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember_fbe7f0ac-cddd-4216-84d6-9c7528b6ca26" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:to="loc_morf_UpfrontPaymentRevenueMember_fbe7f0ac-cddd-4216-84d6-9c7528b6ca26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueFirstTwoProgramsMember_aae747d2-32d1-4056-b247-5114e7ae1462" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueFirstTwoProgramsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:to="loc_morf_UpfrontPaymentRevenueFirstTwoProgramsMember_aae747d2-32d1-4056-b247-5114e7ae1462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueThirdProgramMember_fed3602d-4396-4ede-ae2c-e52d4ebc7982" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueThirdProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a1ef0f0-6927-46d2-94d3-febe8482167a" xlink:to="loc_morf_UpfrontPaymentRevenueThirdProgramMember_fed3602d-4396-4ede-ae2c-e52d4ebc7982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8b68a328-af39-4b39-b3d6-67e7618924e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8b68a328-af39-4b39-b3d6-67e7618924e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7781b170-48de-4829-accf-920809f18b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8b68a328-af39-4b39-b3d6-67e7618924e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7781b170-48de-4829-accf-920809f18b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0b0a12f1-b96e-4a5a-8faa-6573b83be134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7781b170-48de-4829-accf-920809f18b12" xlink:to="loc_us-gaap_SubsequentEventMember_0b0a12f1-b96e-4a5a-8faa-6573b83be134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bdd6d72-eb6f-4289-af2d-133f27ba371e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementTermOfArrangement_b2e40d10-3905-4a8b-9188-95bf0a4fb6d5" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementTermOfArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementTermOfArrangement_b2e40d10-3905-4a8b-9188-95bf0a4fb6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementUpfrontFeesReceived_8f1c1108-2a73-4bb7-9171-9dc933d18adf" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementUpfrontFeesReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementUpfrontFeesReceived_8f1c1108-2a73-4bb7-9171-9dc933d18adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfResearchPrograms_53f6bb29-fd82-4e92-aa93-845e46ede575" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfResearchPrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfResearchPrograms_53f6bb29-fd82-4e92-aa93-845e46ede575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementOptionExerciseFeesReceivable_a3a3d568-745d-4326-b0a6-b8bbe70d0021" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementOptionExerciseFeesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementOptionExerciseFeesReceivable_a3a3d568-745d-4326-b0a6-b8bbe70d0021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfOptions_911d81c5-20b1-4025-9773-d97f6dbce2d0" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfOptions_911d81c5-20b1-4025-9773-d97f6dbce2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementProfitMarginPercentage_95cfdecf-6716-4477-9f9a-002b5c9a374d" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementProfitMarginPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementProfitMarginPercentage_95cfdecf-6716-4477-9f9a-002b5c9a374d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpFrontPaymentIncludedInTransactionPrice_e7e8f178-560b-4361-9f31-6200541e71ba" xlink:href="morf-20221231.xsd#morf_UpFrontPaymentIncludedInTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_UpFrontPaymentIncludedInTransactionPrice_e7e8f178-560b-4361-9f31-6200541e71ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementOptionExerciseFeesPaid_1f8bbacb-f2f1-4143-806e-74c2deea51b7" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementOptionExerciseFeesPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementOptionExerciseFeesPaid_1f8bbacb-f2f1-4143-806e-74c2deea51b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborationAgreementOptionExerciseRevenueReceived_d60272ad-152f-4d13-964b-270ddbe14b24" xlink:href="morf-20221231.xsd#morf_CollaborationAgreementOptionExerciseRevenueReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborationAgreementOptionExerciseRevenueReceived_d60272ad-152f-4d13-964b-270ddbe14b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7d4d609a-1571-41c4-bf0d-1a6f1a47cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7d4d609a-1571-41c4-bf0d-1a6f1a47cb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_634e3b6c-aee4-4281-9bb4-7be1f627f82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_634e3b6c-aee4-4281-9bb4-7be1f627f82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfIntegrinTargets_cc423d9e-3e03-4e97-95b0-1f1ef5aa9a13" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfIntegrinTargets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfIntegrinTargets_cc423d9e-3e03-4e97-95b0-1f1ef5aa9a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram_2d2fc124-44fa-4f36-bc69-2221c0959f4c" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram_2d2fc124-44fa-4f36-bc69-2221c0959f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram_f1f4b091-fb6f-4d08-b2c2-bd2bd912238d" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram_f1f4b091-fb6f-4d08-b2c2-bd2bd912238d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementPaymentDuePeriod_67639d25-a31d-4275-98bb-fbf990206b2b" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementPaymentDuePeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementPaymentDuePeriod_67639d25-a31d-4275-98bb-fbf990206b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued_5f8adf7d-e229-4a2b-b637-3aa60a004fd6" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued_5f8adf7d-e229-4a2b-b637-3aa60a004fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNotificationPeriod_31e6b74e-7bd2-4407-a687-a3143e8177a1" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNotificationPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNotificationPeriod_31e6b74e-7bd2-4407-a687-a3143e8177a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementNumberOfOptionsToLicense_74d032e0-a991-41c4-90f4-eaacffff42ce" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementNumberOfOptionsToLicense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_morf_CollaborativeArrangementNumberOfOptionsToLicense_74d032e0-a991-41c4-90f4-eaacffff42ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5fe7712e-178d-489b-89ef-620b6592dc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5fe7712e-178d-489b-89ef-620b6592dc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_8605c84a-a876-40f8-ae37-0d116dc90cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_8605c84a-a876-40f8-ae37-0d116dc90cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a2b959c1-d363-45b9-95e9-4df9e20c544e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78778a5b-f9d6-4b23-8b2c-0f261851ad94" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a2b959c1-d363-45b9-95e9-4df9e20c544e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract_32836bbf-f895-4643-a5c0-ef09f134cea0" xlink:href="morf-20221231.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4c91843-ac57-4c0d-b7ab-d6478dd3df84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract_32836bbf-f895-4643-a5c0-ef09f134cea0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4c91843-ac57-4c0d-b7ab-d6478dd3df84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dd181442-5437-4115-944d-2427340b992d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4c91843-ac57-4c0d-b7ab-d6478dd3df84" xlink:to="loc_srt_CounterpartyNameAxis_dd181442-5437-4115-944d-2427340b992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc1fbbf3-0836-4ce3-954d-0b1697fe875f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_dd181442-5437-4115-944d-2427340b992d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc1fbbf3-0836-4ce3-954d-0b1697fe875f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember_c88dd58c-6d4f-40d4-bfd8-0cca45d6ca88" xlink:href="morf-20221231.xsd#morf_AbbVieMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc1fbbf3-0836-4ce3-954d-0b1697fe875f" xlink:to="loc_morf_AbbVieMember_c88dd58c-6d4f-40d4-bfd8-0cca45d6ca88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember_c7171c90-4225-45c6-a3f6-0d7a4f5ff17c" xlink:href="morf-20221231.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc1fbbf3-0836-4ce3-954d-0b1697fe875f" xlink:to="loc_morf_JanssenPharmaceuticalsIncMember_c7171c90-4225-45c6-a3f6-0d7a4f5ff17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_18cb3722-51fe-4c35-a023-7e9e463a661b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4c91843-ac57-4c0d-b7ab-d6478dd3df84" xlink:to="loc_srt_ProductOrServiceAxis_18cb3722-51fe-4c35-a023-7e9e463a661b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_18cb3722-51fe-4c35-a023-7e9e463a661b" xlink:to="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember_061086a9-3347-4883-807d-64e11ce80758" xlink:href="morf-20221231.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:to="loc_morf_UpfrontPaymentRevenueMember_061086a9-3347-4883-807d-64e11ce80758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ReimbursementRevenueMember_33dac9ef-6394-44ec-88ae-07448214aa5d" xlink:href="morf-20221231.xsd#morf_ReimbursementRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:to="loc_morf_ReimbursementRevenueMember_33dac9ef-6394-44ec-88ae-07448214aa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b282279e-7faf-4a5a-b58d-dfd0186e225f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3faddb1-76f6-4a40-87d7-17cef27f04d3" xlink:to="loc_us-gaap_LicenseMember_b282279e-7faf-4a5a-b58d-dfd0186e225f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c8180810-e5e2-47fe-83f3-68c150bb1aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4c91843-ac57-4c0d-b7ab-d6478dd3df84" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c8180810-e5e2-47fe-83f3-68c150bb1aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_95dfd58c-4593-40cd-b14b-ebdfe11cafb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c8180810-e5e2-47fe-83f3-68c150bb1aa6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_95dfd58c-4593-40cd-b14b-ebdfe11cafb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a2546c17-a7f3-4d1d-a88d-50708effccfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c8180810-e5e2-47fe-83f3-68c150bb1aa6" xlink:to="loc_us-gaap_CostsAndExpenses_a2546c17-a7f3-4d1d-a88d-50708effccfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#NetLossperShareBasicnetincomelosspershareDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8182f4bd-4760-480f-8023-0ffca2dc884d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6bbd312-627d-4ba3-82b2-92ffaf33afb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8182f4bd-4760-480f-8023-0ffca2dc884d" xlink:to="loc_us-gaap_NetIncomeLoss_e6bbd312-627d-4ba3-82b2-92ffaf33afb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9ff147f-d22a-4ea0-9209-dd959ed80a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8182f4bd-4760-480f-8023-0ffca2dc884d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9ff147f-d22a-4ea0-9209-dd959ed80a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_676bf2eb-708f-4d3e-a78f-b9ae75583796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8182f4bd-4760-480f-8023-0ffca2dc884d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_676bf2eb-708f-4d3e-a78f-b9ae75583796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4b82be04-aff9-473f-ad2f-150c165b2425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8182f4bd-4760-480f-8023-0ffca2dc884d" xlink:to="loc_us-gaap_EarningsPerShareBasic_4b82be04-aff9-473f-ad2f-150c165b2425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d1176d5c-13b7-4f78-99f7-383eeedd6c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8182f4bd-4760-480f-8023-0ffca2dc884d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d1176d5c-13b7-4f78-99f7-383eeedd6c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#NetLossperShareCommonstockequivalentsharesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6ebc30c1-e253-4b51-8798-8799bdb00236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_432e7df9-290c-475a-ad4c-8ebbf62f692b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6ebc30c1-e253-4b51-8798-8799bdb00236" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_432e7df9-290c-475a-ad4c-8ebbf62f692b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aac13bc6-c665-4b55-9a0a-0c7cb0a600b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_432e7df9-290c-475a-ad4c-8ebbf62f692b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aac13bc6-c665-4b55-9a0a-0c7cb0a600b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aac13bc6-c665-4b55-9a0a-0c7cb0a600b9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c0863a9d-3615-4432-b6c2-7de1972f9f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:to="loc_us-gaap_RestrictedStockMember_c0863a9d-3615-4432-b6c2-7de1972f9f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f1144368-bfa9-48d2-9f91-b4e762863f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f1144368-bfa9-48d2-9f91-b4e762863f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3cbc8a3d-4c99-44de-b428-a63c3025dbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3cbc8a3d-4c99-44de-b428-a63c3025dbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember_2beeab82-c451-407d-8d86-c2e8c04d3a71" xlink:href="morf-20221231.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_693b513e-1710-4ff0-a33f-70373a637d24" xlink:to="loc_morf_EmployeeStockPurchasePlanMember_2beeab82-c451-407d-8d86-c2e8c04d3a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43f87c89-dcec-473a-b675-8bc1f805076e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_432e7df9-290c-475a-ad4c-8ebbf62f692b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43f87c89-dcec-473a-b675-8bc1f805076e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fdcdbece-ae2b-4f45-b6d7-6e97d443db8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43f87c89-dcec-473a-b675-8bc1f805076e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fdcdbece-ae2b-4f45-b6d7-6e97d443db8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="morf-20221231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_df3f8540-3885-40c9-86eb-be07355f802f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_17e5eaec-7fb3-4a23-a389-5bad51801f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_df3f8540-3885-40c9-86eb-be07355f802f" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_17e5eaec-7fb3-4a23-a389-5bad51801f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>morf-20221231_g1.jpg
<TEXT>
begin 644 morf-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '$ ;0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPQO? %WH]CJG@*TGLK*QUB*=[&:*:W6%N1(TJ%0@*DLYP2"3G-1=N+;5G?\
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MXRL>G45#:7<5];I/"X>-QD&IJP-0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** (KJYCL[=YI6V1H,DUYKK>M2ZU=&1_EB7B.
M/^Z/\:T?%VO?VA<?98&_T:(\D?QM_@*YVMXQMJ92?0****T("N?\:^.-+\!Z
M.]_J4VWM% I_>3-_=4?S/05K:C?II]NTC$;^B+ZFOC;XH:AX@U#Q9<MXB/\
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MOTOZMFN68.I1DZM32ZM;YMW_ $^12O=-$]U:W]NR6VJV3B6TO&B60Q..0=K
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M]$8Q;ZGJ%%%%<QN%%%% !1110 4444 %%%% !1110 4444 %%%% !6!XTO\
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MH_\ K8K5KB/ =Z8[R>U)^61=Z_4?_6/Z5V]<TE9FT7=!1114E!1110 4444
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M6/"/AC4-7MO[&ANM&NK6);5;.)#LMS&&MHA.MPQ#J@7?DA=X)X_;2DW;2W_
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M9R5$HRL@JGJVK6FAZ?->WLRP6T0RS-^@ [D^E&K:M::'I\U[>S+!;1#+,WZ
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MR_9)59X(9$"+9!R'N"&SR)'57/ P17''1<OJSZU]&OZV_P OZZ_'GQ;\&P^
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M110 4444 %%%/AADN)%CBC:61N B*23^ H 917H'AGX%^+?$NQ_L']F6S?\
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MT6UTF/$$?SXPTC<L?QJ')(I1;.>T/P60RSZA]1 #_P"A'^E=<JK&H50%51@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>morf-20221231_g10.jpg
<TEXT>
begin 644 morf-20221231_g10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***YV/XO^$YOB-)X.3Q1X=;Q=##]I?0QJ4)
MU)(L!O,-ON\P+M(.[;C!!H Z*BJVLZU9^'=)N+_4+JVL;&SC::>XN)5BA@11
MDLS,0%4#DDG K$^&_P 8O"/QDTV:\\(>*O#?BJSMW$<L^CZE#?1Q,<X#-$S
M'@\'TH Z2BLWQ;XPTGP#X=NM8U[5--T72;%/,N;V_N4MK>W7^\\CD*H]R15;
MP!\2_#?Q7T!=6\+>(-$\2Z6SF,7FE7T5Y;EAU&^-F7(],T ;=%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU;^7Y?V/_:W>9_#MY^ /^(&/_JZ+_P QO_\ ?2@#]_J*_G!_X-6O@9_PR_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW8OM!]>#7Y+_ /!,KX9WOQ>_:EL]!L_$FL>%8[S3[DW=[I;".\>  %XHY/\
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M A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM7\0?M)_LI_!>'5]8T?PG\8?&E^OBH:9>26=QJECIVG27GV!IHRLBPS2^6)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X _P#! O\
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MM;_L1V/BSP-^S?X?U31?'30> ]/\.:GJ3Z;)<HMHHAN]Z*8;=45%7R@2/3
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MP_TWPIX-T'2O#'AG1HS%8:7IMLMM:V:%BY6.-0%4%F8X ZDUD>/_ -FOX?\
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MMG\1/&6I7_C+Q-:C_ESO-0N&F\EO21(O*1QR ZN 2 #7V!110 4444 %%%%
M!1110!E^-/!VG?$+PEJ.AZM ]SI>K6[VMU$DSPM)&PPP#H5=<CNI!'K7QW^U
MC^PI\,/AI??"M-$T+4K)?$GC[3]%U$?\)!J,GVBTEAN6DB^><[<F-#N7##'!
M&37VQ7@?[=?_ "$_@?\ ]E2TG_TGO*^7XKRW"5\'*K7I1E)<J3<4VDY+1-JZ
M/C.-LIP.)P$J^(HPG./*DY13:3G&Z3:ND[LZ[X+_ +'?P[_9\\4W&M>$M%O-
M-U*ZM6LI)9=8O;Q6B9T<KLGF=1\T:'(&>,9P3GA_VRO$5_\ %WQ9H/P/\.7-
MQ;WOC!?MWBB[@4YTO0D8B7+9&UIW A7KD%P1R#7N'CSQMIWPV\%:MX@U><6V
MEZ+:2WMU(?X8XU+-CU.!P.YP*\<_8:\%:IJ^B:]\5O%%O]G\4?%2X34EMV.Y
MM,TQ5VV5KGU6([VQC)?D9%&.PM%<F3X."A&I=S44HI07Q;6LYNT>]G)KX1YE
M@L.E3R# 4U3A4O*HH)12IKXOALDZCM!=;.4EK$]K\,^&K#P;X=L=)TNUAL=-
MTRW2UM;>)=L<$2*%50/0  5>HHKZ:,5%*,59(^PC&,8J,59+9!1115%!1110
M 4444 %%%% !1110 4444 %%%%  RAU*L,J>"#WK\L/VOOV/['1?BM\0+[P+
M-&/#GA-K-]42XRL=G=7LZHMK 54AP@D1CG&U<@DD#/Z4?&CXH67P6^%>N^*-
M0Q]GT:T:<)G!FDZ1QC_:=RJCW85\U?%#X87OPS_X)MZX^LJO_"3>)-0L=>UM
M]NUC=W.J6LC*?= 53J?N5^4^)V587-<,\-5C=T:=2LY=8I1:BD_[\E?LU3DM
M[-?LGA)G&+R;%QQ=&=HXBK2H*/23<XN<FNO)!VZ-.I%[73WOV&_^"==I^S!J
MC>)->O[76_%CQ-#";=#]ET]&X8QE@&9V7@L0N S+CDD_3U(GW!]*6OOLAR'
MY/@XX'+X<D%KW;;W;;U;?_ V1^;\1<1YAGF-EF&9U.>I+3LDELDEHDNWS>K;
M"BBBO8/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#I.G&VSES:ZZWY8^6ENFX4445V'"%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDU^T7_!4*TFOOV#OB%%!%)-(UM;$(BEF.+N G@>@!-?B5)IEU#<"%K>=9F(
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M.?BC4K$M_:LUL-/T[8VU_M-PRP1%?=6D#?\  37I0Z5X9\?_ /BYW[4/PO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC+L%@E_+*K+_ !5)67_E.%-_,****^B/EPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW:^Y^=^+W%V XBS]XW+5^[C",.9JSFTV^:SU6]E?6R5[;(HHHK]%/R\****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KY5_X*_P#QS^+W[/W[(FM>(/@KI<NK>,[:WD>VACL_M;%@8P/D
M[\%N.^*^JJ* /YH(?^"R_P#P5(:)?^*'U=N.I\%$9IW_  ^6_P""I'_0BZM_
MX11K^EVB@#^:+_A\M_P5(_Z$75O_  BC1_P^6_X*D?\ 0BZM_P"$4:_I=HH
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M-'_#Y;_@J1_T(NK?^$4:_I=HH _FB_X?+?\ !4C_ *$75O\ PBC1_P /EO\
M@J1_T(NK?^$4:_I=HH _FB_X?+?\%2/^A%U;_P (HT?\/EO^"I'_ $(NK?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M75BDT>ZX>29DNHKUHW1G9?W8*A3S0!]:?\%WOV[?C7\0/^"A'P;_ &*_V?\
MQI<?#77OB3;)J'B7Q39Y6\M+>9IPL44JD2P^5#;3SN8BKONA59$&\-P'[(/[
M2?[0G_!(K_@M=X-_9-^-'QJUGX^?#WXMZ3'>Z-K_ (@,IU*QFG%RL$BM-+/*
MNZZM)+<PM.Z;721=I&PY7[7L;:=_P>=_ J:X'D1W7AV!HF?Y1(#IFJ1C![Y<
M%?J,5#_P7E@D\9?\'+/["^B:6C7FJ:?>>'-4N($',5LOB*65I"3Q@1VTS$ Y
MPG3D9 /W2HKY _X*M_!O]LGXM_\ "!?\,D_%CX?_  O_ +/_ +0_X2O_ (2>
MSBN/[3W_ &7['Y._3KS'E[+K=CR\^:GW\?+\@?\ #&W_  62_P"CL?V?_P#P
M46W_ ,SU 'S_ /\ ! O_ )6FOVU/^YY_]2ZQK]_J_G1_X-AM&\9>'/\ @X=_
M:<T_XC:MI^O?$*P\/^*K?Q/J=@@2UU'5$\2Z:MW/$HCB CDG$C*!'& &'R+]
MT?T74 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7@7[7_\ R73X _\ 8WR_^D,]>^UX%^U__P ET^ /_8WR
M_P#I#/7A\1?[E_V_3_\ 3D#YSBK_ )%__;]+_P!.P(_VU&_X3;XG?!'P'& 9
M-<\8)KEP"?E:UTR)KB12/]IC&/T[U] U\^^'U_X67_P4G\0WC*K6?PQ\(6VF
M*K<[+S4)3.9!Z'R(@OT/N*^@J63_ +VMB<5_-/E7I32B_P#R=3^\60_OL1B\
M;TE4<%_AI)0:_P#!BJ?>%%%%>Z?2!1110 4444 %%%% !1110 4444 %%%%
M!1110!X_^W?XGG\/_LP>(K6S;&H^)!#H-FH."\EW*L) [_<9SQSQ6'^V+X;M
M_!O[-GA?1[4!;72M=T*SA & $CNH47CZ 5:_:;_XK/\ : ^#/A.-?,VZU/XE
MN01\L4=E VQC]9)0![U/^WI_R1C2_P#L:-'_ /2R.OSS//WT,TK](4XTUZJ+
MJ2^_VD4_\)^G</?N*F48?K4JRJOT<E3C]WLY-?XF>UCI10.E%?H9^8A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %([K&I9B%4<DGH*6OF'_@J]\>=8^!W[
M,&H-HO[NZUJ.2S\\#F %?O9[?6@#Z337[&0D+>VC%>"!,O'ZU9BF69=R,K+Z
MJ<U^&/[67[,MY^RG^Q%X-^*'A/QAXKN/%'C6&*[U*.YU.22-Y&<?ZI<\#GI7
MZ4Z!\=H_V.?V'O#6O:U]NU75+W3H;IX 3)/EXPQ;!YQ0*YZW^UO^T5:_LO?
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MX5E8KG][C[W3O4.@_M^:I\/?V*_&'P]N=4O)?&=OXN&B6D;3$W36Q;87'?\
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MSU/#_ B_\+!_;M\;:LV6M? N@V?A^#)RIFN2;J5E]POEJ3^%2_MZ?\D8TO\
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M>+8IR-OS LX7WYKH/CO\#?BI\+/'GAWQ[H_A6_\ 'VH?\(U%I4^G1?*UN^P
MY^AK]"J*=PL?/'_!/CX8>(O"_@"77O%&ES>']6UH8ETJ7[UK@YY^M?0]%%(8
M4444 %%%% 'R%^U'^QI^T1\6/B'-J7@7]H:Z\#:+(6QIRZ>)E53VS[54_9J_
MX),V?PO^#GB+3_&VO1>-O'GB".XC;Q(\!B>(2 XPG3@\U]D44 ? 7P&_X)F_
MM(? :_TG3]-_:6<^#M)D8II']CK@QDD[-Q&>]=KX#_X)01Z3\>;_ ,:>(O%"
MZ\-0LYX9;9H-H,L@($GX9SBOLBB@+'Y\?"G_ ();?M%_ W4H;'PI^TK)I?@^
M&_DNUTC^R%8!7;)3<1GVKL?VPO\ @EIXL^//C/P3XR\%_$R3P+X^\+1,+K68
MK7>U_(>K[1P*^UJ* L?#/QM_X):_$K]H3]FO3_"_BCXR3:AXUTO5(]1MO$;6
M>&BV<JH3ZT?!W_@D_P"-?#OQN\)^/?''Q6D\9:]X=N5GGF>T\LW:J,!?; K[
MFHH"Q\!_M(?\$/;+X\_M<6_Q%B\6?V9H[7)N[[1A 66[EW9#$]*]._:0_P""
M:/\ POGXZ^%_%T?B3^S+7PXEM']B$.[SEAQQGWQ7U=10%CXM^&?_  3+\??!
MW]N76/B=X=^*\FG^$?$ER)]4\-"TRMVH7 4O[=:^.X?V3/#?Q?\ ^"Z%O#I*
M+=:);V4U_>R*I\N.Y1BV#VS7[+5SNB_"7PSX;\2RZQI^A:79ZM,")+N*W59G
MSURW7F@5C>MH!;6T<:_=C4*/P&*D(R***!GRKXC_ .";LNO?MT:E\8_^$H,<
M>H:-_9/]F^3]S_;W5F?!_P#X)>3?"VZ^+,C>+#=_\+,@2%1Y./L.WO[U]>T4
M ?"?Q)_X(S?\)A\ )O#FG^,O[+\6K=QW%GKP@):U5.=NW\*RO@9_P1I\6>'/
MCM;_ ! ^(_Q6D\?:UY<5M<R2VAC,\$> L?Y#%?H#13N%CX$\8_\ !*KXT>%?
MC1XK\0_"/X]-\.]$\47:W+Z6FEK.(P.VX@UU_P :O^"9_C;]I;0?#>F>/OB@
M^O6.BW4%Y/$;3RUNWC()/'KBOLRBD%CY%\$_\$P)/@U^V7>?%#P'XK/AK2]9
M6&+5-&CA++>1Q@#;GH,XKZZHHH **** "BBB@ HHHH **** "BBB@ IL\Z6T
M+R2,L<<:EF9CA5 Y))]*=7 _M5_"*^_:!_9>^)'@/3-4;0]2\;>%M3T"TU)2
MP.GS75I+ DX*_,-C2!N.?EXH _(W_@IG^U+_ ,$G_P!M?XBW]AXV\=:?H_Q$
MM[@$?$#P/H>H1W<%R/NR-?6UJ\-X%PN'<3(!C:RD$BY%X>_;0_8<^$^FZQIL
M_@[_ (*/?LMZA:QW]E;7D,=UXDBL2I9)8699FN<J5 (-V3@XCB&37BWP0\$_
MM%?LA?L]6?P%UC_@EW\,?B1KFEVLNFOXO6RM+FQUYOF5+RYF\J022,JJ69KB
M-CA<"+Y47]7/^"'_ .Q7XL_X)\_\$R/AK\+?'-Q:R^*M&CO+S48;67SH;"2[
MO)KHVRN"58Q^=M9E^4N&*D@@D XK_@DY_P %?/V8?VTA-X#^%>GV_P *_'%F
MTTM[\/M1T6+1+^)XRPE:..(>3.1L9F$;&1%&9$3I7W-7G>K?LD_#/6OV@]'^
M+$_@?PZ/B5H4$MK:>)8K18=2$,L;QO%)*F&ECVR/A)-RJ6) !YKT2@ HHHH
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M'!JI;!.3A;[:2=_1.2M\PHHHKL.$**** "BBB@ HHHH **** "BBB@ HHHH
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MIC6\;N&:-&8="5Y% %/PQX>M_"?AZSTVU&+>RB$48/H*OT44 %%%% !1110
M4444 %%%% !3+B$7-O)&WW9%*GZ'BGT4 ?F_\(_#VM?"'_@J9\4-#O\ 2=2/
MA/QO90V4%U! QC4GJ=W0=:^E/A]_P3)\ _#?X?>-O#=A<:LUAX\O5OM0,DV6
M5UZ;#V%?1!M8S+YGEQ[_ .]M&?SJ2@#Y:\?_ /!)3X;_ !&\%^%]#OKK6EL_
M">KQZU9E)\,9D((#'N.*V_VA_P#@F/\ #C]ICXT^#_'/B*&\;5O!DOFVR1L!
M%<GCB4?Q#@'\*^BJ* /!?BW_ ,$_O _Q0_:$\._%#4'U*'6O"&GFRLH;>3;
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MH!VI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLQ_V;)L+A>M5SJR]+^SA?TY)M>4[[-!1117T9\N%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !116;XH\8:5X)TM[[6-0L],LXQEIKF41QJ/<GB@#2HKSY?VL/ABPR/'W
MA/'_ &$XO_BJ7_AJ_P"&?_0_>$__  9Q?_%4 >@45Y__ ,-7_#/_ *'[PG_X
M,XO_ (JC_AJ_X9_]#]X3_P#!G%_\50!Z!17G_P#PU?\ #/\ Z'[PG_X,XO\
MXJC_ (:O^&?_ $/WA/\ \&<7_P 50!Z!17G_ /PU?\,_^A^\)_\ @SB_^*H_
MX:O^&?\ T/WA/_P9Q?\ Q5 'H%%>?_\ #5_PS_Z'[PG_ .#.+_XJC_AJ_P"&
M?_0_>$__  9Q?_%4 >@45Y__ ,-7_#/_ *'[PG_X,XO_ (JC_AJ_X9_]#]X3
M_P#!G%_\50!Z!17G_P#PU?\ #/\ Z'[PG_X,XO\ XJC_ (:O^&?_ $/WA/\
M\&<7_P 50!Z!17G_ /PU?\,_^A^\)_\ @SB_^*H_X:O^&?\ T/WA/_P9Q?\
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M,XO_ (JC_AJ_X9_]#]X3_P#!G%_\50!Z!17G_P#PU?\ #/\ Z'[PG_X,XO\
MXJC_ (:O^&?_ $/WA/\ \&<7_P 50!Z!17G_ /PU?\,_^A^\)_\ @SB_^*H_
MX:O^&?\ T/WA/_P9Q?\ Q5 'H%%>?_\ #5_PS_Z'[PG_ .#.+_XJC_AJ_P"&
M?_0_>$__  9Q?_%4 >@45Y__ ,-7_#/_ *'[PG_X,XO_ (JC_AJ_X9_]#]X3
M_P#!G%_\50!Z!17G_P#PU?\ #/\ Z'[PG_X,XO\ XJC_ (:O^&?_ $/WA/\
M\&<7_P 50!Z!17G_ /PU?\,_^A^\)_\ @SB_^*H_X:O^&?\ T/WA/_P9Q?\
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M,XO_ (JC_AJ_X9_]#]X3_P#!G%_\50!Z!17G_P#PU?\ #/\ Z'[PG_X,XO\
MXJC_ (:O^&?_ $/WA/\ \&<7_P 50!Z!17G_ /PU?\,_^A^\)_\ @SB_^*H_
MX:O^&?\ T/WA/_P9Q?\ Q5 'H%%>?_\ #5_PS_Z'[PG_ .#.+_XJC_AJ_P"&
M?_0_>$__  9Q?_%4 >@45Y__ ,-7_#/_ *'[PG_X,XO_ (JC_AJ_X9_]#]X3
M_P#!G%_\50!Z!17G_P#PU?\ #/\ Z'[PG_X,XO\ XJC_ (:O^&?_ $/WA/\
M\&<7_P 50!Z!17G_ /PU?\,_^A^\)_\ @SB_^*H_X:O^&?\ T/WA/_P9Q?\
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M,XO_ (JC_AJ_X9_]#]X3_P#!G%_\50!Z!17G_P#PU?\ #/\ Z'[PG_X,XO\
MXJC_ (:O^&?_ $/WA/\ \&<7_P 50!Z!17G_ /PU?\,_^A^\)_\ @SB_^*H_
MX:O^&?\ T/WA/_P9Q?\ Q5 'H%%>?_\ #5_PS_Z'[PG_ .#.+_XJC_AJ_P"&
M?_0_>$__  9Q?_%4 >@45Y__ ,-7_#/_ *'[PG_X,XO_ (JC_AJ_X9_]#]X3
M_P#!G%_\50!Z!17!V'[4/PYU34(;6V\<>%KBZN7$<44>I1,\C'H ,\FN\H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\
M?^"!?_*TU^VI_P!SS_ZEUC7[_5^ /_! O_E::_;4_P"YY_\ 4NL:_?Z@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q[X
MWL?AOX1O=;U+[5]AT]0\OV:W>XEP6"C:B LW)'05\D_M$?M@>#?%?QV^#.I6
MO_"0BU\.ZW=W5YYVB744FQ[.2(;$9 TAW,HPH)&<U]G5\Y_M@_\ )T/[/G_8
M<OO_ $5%7QG&GUZ.$53#U(QCSTE9P<G=U8).ZG'176EM;;J^GM97EF49E"6"
MS.E4DU>HG"HH?PE[6*LZ<]Y0LW=:/:ZN>H?"']H_PW\;M2O+70QK0FL8Q++]
MMTJXLUVDX&#*BAC["NRUO6;?P[HUYJ%Y(L-I8PO<3R,<"-$4LQ/T )JU7@O_
M  42\37I^!EKX)T>7R]<^*6K6WA2U8'F&*=B;B0CKL$"2 D=-XKV\1BJ^!R^
M=?$R52<4W[L>5-_923E+5NRWW['SO$V:8;"8>MC<+3<8QC>,7)2;E:R5U&-^
M:5DM%O\ ,R/V'M7B\!_LI:I\3/$4=S'=>/M5O/%^H+!;O<31I<3;8455!=U$
M2QX ' 8XXY/!?M+?M@>#?%_Q;^#M]9_\) L'A_Q+)>W?GZ)=0OY9M98QL5D!
MD;<ZC:N3S7V!X8\.6?@[PUI^D:?"MO8:7;1V=M$O2.*-0B*/HH KY_\ VUO^
M2^? '_L:7_\ 08Z^5X@P6.P63TZ>'JQ2@Z2=X.3<G4A>5U.-KMW:MKKJKZ=W
M"/#F45,NIY-FE.<W"/,Y0J*%Y4H^UU3ISOS3@VW=:/8]0^$7[2?AGXVZM=66
MAC6A-9Q">3[;I-Q9KM) X:5%!.3T'-=]117W&#IXB%)1Q,U*7=1Y5]SE+\S7
M'5,-.JY82#A#M*2D_/51C^04445U'(%%%% &?XMTR^UKPS?6FEZFVBZA<0-'
M;7ZP)<-:.1Q((W^5L'G#<&OF?X[Z9\8O@Y)X+6/XU7E__P )9XHL_#K[O"NF
MQ_9EG64F4?(=Q7R_N\9SUKZHKPS]M_\ U_P<_P"RF:1_Z!<U\CQA@XRP,L3&
M<XSCRI<M2I!:R2=U"23WW:;/MN!\=*.80PLJ=.<)<S:G2IS>D&U9SA)I72T3
M2.P^$WPS\=>#/$<UUXG^)EUXRT^2V:*.RDT&TL!%*60B7?" QPH9=IX._/4"
MO0Z**^DP>#IX6G[*FY-?WI2F_P#P*;D_E<^5QV.J8NK[:JHI[>["$%_X#",8
M_.UWU*'BG3KW5_#6H6NFZBVD:A<6[QVU\L"SFTD*D+($?Y6VG!VMP<8-?-7Q
MPT7XQ?"$>$?+^-5Y??\ "3^)K+0&W>%=-C^SK<;\RCY#N*[/N\9SUKZDKQ3]
MM+[OPG_[*/H__M:OG>+L'&>!GB%.<91M;DJ5(;R6ZA**?JTV?3\$XZ4,PAA7
M"G*$FVU.E3F](NUG.$FMMDTCI_A1\,?'G@[Q+)=>)OB==>,=/:W:-;&30;.Q
M"2%E(DWP@,< ,-O0[L]A7HE%%?18/!T\+3]E3<FO[TI3?_@4W)_*]CYC'8ZI
MBZOMJJBGM[L(07_@,(QC\[7?4*\3_;L_Y)IX7_['+1O_ $J6O8/$&O6GA;0+
M[5+^9;>QTVWDNKF4@D11HI9F./1037Y6?M1?\%&O&7Q[\1B'3I(=#\,Z??17
MNGV:01O,9(7WQ32R,"2X.#M4A.V#C)^!\3.+LOR?+)8?%-N=9-1C%7>EKMW:
M22O_ ))ZGZ1X3\%9EGF;1Q.#25.@TYRD[+K9*R;;=GI:RZM:'W3^SP__  LO
M]IWXK>-MHDLM-GM_!^F2EMQ M5+W6.VUII%/'=3WKW:OB'_@E#^UW'XDM6^&
M>K6L,.HP_:-1L+U,[M0+R-+,LH_YZ NS C *KC *C=]O5ZG .:8;,<GAC,/+
MF<Y2E/NIRDY2B_\ #>R[Q2>QX_B3D^+RO/)X'%0Y5",(PZITXQ48R7^+EN^T
MFT]0HHHK[0^#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRJ_:<_9B'PA_X*4>"]8U?7KOQ9JFK0O<6MQ=#:^GINP8UP<8K]3=&.='M/\
MKBG_ *"* .*^+7[4WPY^ US!#XR\9^'_  U+<Y\I+^Z6$R?3-7/A'^T)X(^/
M6DS7W@SQ1H_B:SMV*R36%P)D0CJ"17Y]_P#!7C]COXB?%K]IWP+XO\._"&Q^
M+>A:$9&O=,N[GR8I@<?*W(X[]^0*S?V6_P!KK1M(_9:\?:/X7^$VC_!/Q=9O
M<V[:7IDWF#>%(+Y]0:8KZGWKK?[;OPC\->/5\+W_ ,1/"MIXB9Q&-/DO56X+
M'H-M;OQ1_:/\!_!/3+6]\6^+-$\/6MXGF02WUR(EE7U!/45^+O['>N>(OAYX
M7\,^./BA^S'X?\;6]SJDK2_$2^N_],"ACAMF?X>@^E>X:;_PCO\ P40_X*$^
M$M+\7:?#KG@&.QN%L])N,_9RFTE>/:@7,?J!\*OC9X2^.7A_^UO!_B'2_$6F
M[BGVFQG$L>1VR*ZBOS3_ ."7_A1O@!^WYXT^'/AF'[#X%M[.:[ALXR?*BD+]
MJ^S_ -KKXL?$OX3>"DO/AGX!A\?:LP;=9R77D!<=.?>D,[;P9\:?"?Q$U:]L
M-#\0:7JEYITIANH;:<.\#CJK#L172RRK!$SNP55&23V%?A?_ ,$R?VC/C[X)
M_:3\>W/A/X)VOB"^UKQ#*^N0->^7_9+LW[Q0<\[>:_;RX%YK?@K]];_9[ZZM
M09(0<^6Y7E<^QXH!.YYKXJ_X* ?!3P/XAGTG6/B=X/T[4K63RI;:?4$62-O0
MCUKT[1_%^E^(/#RZM8WUO=:9)%YZW,;[HRF,[L^F.:_$_P"*W[.7C+]E#XT?
M%'QUXY_95\/?%#PKJFK+=6^KZC>[39QE@-RKGO\ 0=!7V'\<OVXM/\1?LE>&
MO#?PRM;32?$'B0V^GSZ5#)L73;>4;7(8]0H/Z4Q<Q]D_#[]H_P !_%?Q#=Z3
MX;\6:)K6I6/_ !\6UI<B22'_ '@.E87C;]MWX1_#?Q2=#U[XB>%=)U82>4;2
MYOE27=G&,>M?E5^P7\)I/V)_VK?CYIUAJO\ :6JZ#IL-RE_Y@WR,_P Q YYP
M2>E;7P-_9$\"_M2?LP?&#X@>-M%M-:\96^MB:RU.X)\ZT[[5Y]:=@NS]AM+U
M2WUK3X;JTFCN+:X4/'(ARKJ>A!JQ7RG_ ,$;_&NN^-_V,[&;7II9KFSU"XM(
MGD.3Y2$!1^ KZLJ2@HHHH **** "BBB@ HHHH **** /*_B%^V_\(?A-K[:7
MXE^(GA71-10D-;W=\L<@(Z\&ND^%?[07@GXX6LDWA#Q1HWB*&,9=[&X$H4>^
M*^<?^"C7[.'[.W@+X5:]\2_B-\-_#NMWD*F%;JY1O,,LN0ISGU]J\>_X(Q?L
M52:!^R7K&IZ?J%YX4O/$U[=+;M -S0V[G*$9/8'BF+J?>/A;X^>"_&_C/4/#
MND>)M'U'7-+;9=V,%P'FMSZ,O:N5\=?MU_!WX8^()-)\0?$CPGH^I1DA[:ZO
MECD4CKD&OA7_ ()]? ZW^ G_  4?\=:3]LDUC5H[X+>ZM+_K;XD=6KVO_@IS
M^SE^SG\+OA!KOQ"\=?#7PWJVL7P:RM[N9&\TW$H(4@YZ[N>E 7/JOX7?';P=
M\;+%KKPCXDTGQ#;J,F2QG$J@?A765\-_\$)OV6XO@7^RE;ZO)"]K>:Y/,_D-
MG]W'ORO)YZ5]R4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!^ /_! O_E::_;4_[GG_
M -2ZQK]_J_ '_@@7_P K37[:G_<\_P#J76-?O]0 4444 %%%% !1110 4444
M %%%% !16;XPUV;PQX4U+4K?3KS6)[&VDGCL;0*;B\95)$<>X@;FQ@9(&37S
M[XM_X*%ZEX#_ +,_MCX*_%'3_P"V;^+2[+S8K0?:;J7/EQ+^^^\VTX^E>;F&
M<87!6^LR:_[=DU]Z32^9Y&:9[@LOM];DXWUORR:[:N*:7S/I2BO+_@S^T)K?
MQ4\5RZ;J/PQ\<^#;>.V:<7VL1VZV[L&4",>7(QW'<2.,84UZA73A<72Q-/VE
M*]O--?@TF=F"QU'%TO;4+VVU4HO[I)/\#G/BM\4]*^#/@JX\0:U]O_L^U=$?
M['9RW<V78*,1QJS'DC.!P.:\>N/^"GGPIM;^WM99_%T=U=AC!"_AB_628* 6
MVKY66P",XZ9KZ$KP/X^?\GY?L^_]>?B?_P!);6O'SVMCZ$8UL+4BDY4XVE!R
M?OU(P;NIQV4KVMTWUT\'B3$9GAH1KX.K",7.E"TJ;D[U*D8-W52.RE>UNF^N
MG?? []I3PS^T-_:G_".C6A_8_E?:/[0TFXL/]9OV[?.1=_\ JVSMSCC/45WU
M%%>UAHUHTU&O)2EU:7*G\KRMIYON?0X2%>%)1Q,E*?5J/*GKI9.4K::;OOY!
M7SW^U)_R=_\ L]_]?^K_ /I+%7T)7SW^U)_R=_\ L]_]?^K_ /I+%7@<7?\
M(O7_ %]H?^GZ9]1PS_ODO^O5?_TQ4/H2BBBOICY\*^<_VP?^3H?V?/\ L.7W
M_HJ*O5OVAOCYH?[,WPJO_&'B*/4)=+T]XDD2RB629C(X1<*S*.K9.2. ?I7P
MS\=?^"I/PW^*WQA^&'B33+/Q4FG^!-0N+W45GLHED=)$C1?+ E(8Y4Y!(KX'
MCO/LOPN%6%Q%:,:CG1ERMZ\JK0;?HDF_D5E/$V5X/-7@L57C"JZ->7*WKRJA
M5;?HE%OY,^E/VYKIOBUX@\"_!BQ:223QUJ:7^OI$<&'1+1A+.6/5/,<1HI[D
M,/:OH6WMX[2WCBBC6.*-0B(B[50#@ #L!7Q9_P $]/VJ_#/[5'[7OQ,U_9K'
M_"27]F$T:*Y@18=.T*VDB14#!R1++-,)'097*@ACTK[6KUN&L91S!5<UI24E
M4ERJW2$+J*^;<I^7-;H?%\(X[#YHJ^=4)J2JRY8VZ0IMJ*^;<IVZ<]GL%>)_
MM2_\EB^"?_8TR?\ I'-7ME>)_M2_\EB^"?\ V-,G_I'-6_%'^X?]OTO_ $[
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MP*P^51VQ7Z444[BL?E#\,/\ @CK\:K#X+7&EZW-X/M-;NYY9FCL9 MLF\D@
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M9:;9PQP6]G"D2I&H51M ']*T***!A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^ /_!
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M *1S5[97B?[4O_)8O@G_ -C3)_Z1S5[O%'^X?]OTO_3L#]TX1_Y&2_Z]UO\
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M^3D%GY 'J2 <W]F;X$7OPSL=2\1>*;J/5_B!XL=;C6K\<I'@?);0\?+#&,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*R225E&S_=OP_P"(;#Q7HUOJ6EWMKJ.GWB>9!<VTHEBF7U5E)!'TJY7Y[_\
M!&'XG:L?'7BCP>\DDNBMI_\ :R*Q)6WG62*([?3>LG/KY8]*_0BOUK@OB>.?
MY33S*,.1RNFM[-.SL^JZK[CX3CSA*?#>=5<JE/G4;.,MKQDKJZZ-;/TN9/CK
MQMIOPW\':EKVL7"VNEZ3;O<W,IYVHHSP.Y/0 <DD <FOS/\ CO\ \%0?$GQ.
M^)OA_5M)T/1].T[PCJ+:AI<-RLDTTS&-HSY[*Z@@AB=J!2,XW'&:^\/VW_AI
MJGQ>_97\8:!HJM+J=U;1S01+]Z<PS1S&,>[",J!W) K\;YX'MIFCD5HY(SM9
M6&"I]Z_'/'#BC-\!B*&!PDG3I2BIN27Q24MK_P!VT79=6K]#]S^C[PCDN8X;
M$YAC8JI6C)P46_AA*&]O[]Y1N^D7:VI^NG[$?[:NG?M<^$[H26L>D^)M'"?;
M[)7+1NK<":(GG82""#DJ< DY!/N5?GK_ ,$9/A;J_P#PGWB7QD\4D.B)IQTE
M';(%Q.\L4IV]CL6/GTWKZU^A5?J?AOG6/S7(*.,S%?O'=7M;F2;2E;S\M'NM
MS\?\5,AR[)^)*^!RM_NURNU[\K:3<;^3[ZJ]GL%>)_MF_P#'_P#!_P#[*/IG
M_HBZKU3Q_P".-/\ AIX(U;Q!JDC1Z?H]K)=W#*-S;44D@#NQZ =R17Y6_'[_
M (*,?$#XV^+M/O(;BTT+3=!U2/5M)LH+:.7[+<1!UCE:1U+2,%=@0<(<_<Z8
M\WQ*XRR[)L&L-BFW4J6:C%7=HR3;=VDEI9:ZO;9V]3PIX%S3/,<\7@U%4Z5U
M*4FTKRBTDK)MO6[TLEN]5?\ 6JBOES_@G;^W?>?M.Q7WAOQ-';Q^*M)MQ=)<
M0)LCU" %49ROW5=69<@8!#9 &#7U'7V>09]@\YP,,PP,KPEWT::T::Z-?\%7
M5F?"<2<.8[(LPGEN8QY:D+;:IIZII]4U_DTFFBGXB\0V?A+0+[5-2N([33]-
M@>YN9G^[%&BEF8_0 FOS*_:=_P""G.M?&3QAHAT71--T_0_">O6^NZ;]J#2W
M5Q/!O5#,58*$8.2449'3>>M?H)^U%\/]0^*G[//C#P_I+,-2U/39([95<*99
M -RID\#<1MYX^:OQ:U#3[C2;^:UNH9;>YMW,<L4BE7C8'!4@\@@\8-?B7CEQ
M-FN =#!81N%*HFW)+XI)_#?IRZ.RWOKL?O\ ]'OA/)LQCB<?C8JI6IM1C%OX
M8M/WK=>;57>UG;<_5[]A7]NRU_:VTR]T_4+&WT?Q7I,2S7%O"Y,-W$2%,L08
MEE"L0&4DXW+\QSQ]"5^8_P#P2=T=?#?Q=U;QIK&HV>A>&])TV6UDO+VY2VAG
MF<H1&"Y ;:H+''W<+G[PK[)U?]OOP/<W4MEX1M_$?Q$U2-MAM?#FERW2J3T+
M2L%C"^K!C@<X-?8^'_&WUG(:6)SRK&-5N25[*4TGHU%:M]/=6MKGPWB5P!]5
MXCK83A^C*5)*+=DW&FVM8N;TBMG[STO8] ^/WQ&E^$7P4\4>)K>-9KG1=-FN
M8$9"RM*%.S<!SMW$9QVS7XL^,?&6J?$#Q+>:QK5]<ZEJ=](9)[B=R[R'ZGL.
M !T  %?JGKG@7XM?M0:;>:?XDET_X7^#=1A-M<:7:&+4]7OXF&'5YR/*ARIX
MV!F'(/K7P]^T9_P3B\<_ [Q;I]O9QVNOZ/KVIQ:5I5W%<1PO+<3%O*BD1V!1
MB%.6Y0?WA7YUXS87-\VC1Q>#H5/JT+K6-FY-_%R7YTK62<HQ:[:Z_I_@3C,D
MR65?!8W$4EBJC3TE=**7P^TMR-IW;4)R3TUNM.M_X)&^+XO^&E/[+U"U74))
M-)G73)YMTC:8RL'<19.V,.I?<0,DXY&2#^FU?*W_  3O_8(OOV9YKWQ/XJFM
M9/$VI6XMH;6W?S(].B)#.&;HTC$*/EX4*<,=QQ]4U^H^%&2X_+.'X4,QCRS<
MI2L]TG:REYZ==4K+I8_(_&;/LNS;B6IB<LESTU&,>9?"Y*]W'RUMIHW=J][L
MKQ/]NS_DFGA?_L<M&_\ 2I:]LKQ/]NS_ ))IX7_['+1O_2I:^HXL_P"1/B/\
M+/C^#?\ D>87_&CVP=**!THKZ$^9"BBB@ HHHH **** "BBB@ HHHH ****
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M"I7[2'C.^\7^)_A;X+\(:I\-_!NJ?8+RZOG*W17/55R,\=Z=A<R/T\HKR_\
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M4U>UB'[N"<]0OM0,]PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _ '_@@7_RM-?MJ?\
M<\_^I=8U^_U?@#_P0+_Y6FOVU/\ N>?_ %+K&OW^H **** "BBB@ KPO5?'O
M[0$.J7*V?@'P--:+*P@D?6W5G3)VDC'!(QQ7NE>%:K^Q]XHU+5+FXC^.?Q4M
M8[B5I%@BFM/+A!)(5<PYP,X&>PKP<]H8JI&'U9U%O?V<J<>V_.G\K?,TIYY5
MRWWJ>!CBN;I)VY;=5^\AO?SVZ$/_  L']HG_ *)[X"_\'K_X4?\ "P?VB?\
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M6P%UIO\ P34^.FH6I=HQ-;7>JRQEE8JR[ET,C(8$$=B"*]P^=/V*KPS]M_\
MU_P<_P"RF:1_Z!<U^=7_ !$K?M-'6O[-_P"':?QV_M$0?:3:_:]5\X1;MOF;
M/[#W;=P(W8QGBL/XF_\ !=#X^?&&TT>Z\6?L#_'3X>V_@75;?Q1ITES9ZS>)
MKU] 3'!IFX:,@@:<S$"9MP4H!M8L*\'B>C4JY;4ITHN3?+HE=_$NB/I.$:].
MCFU*I6DHQ7-=MV7P26[\S]I**_('_B([_:F_Z1C_ +0'_?W5_P#Y1U5T?_@Y
M6_::\0V?VC3_ /@FG\=KZWWO%YMO=ZK*F]&*LN5T,C*L"".Q!%>\?-G[$5XI
M^VE]WX3_ /91]'_]K5^5G_$77\5!\=O^%6_\,)?$#_A9O_0H_P#"3W?]O?\
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MMH8@;L8R<4[6/^#E;]IKP[8-=:A_P33^.UC:JRHTUQ=ZK%&&9@J@LVA@9+$
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MV&E?\S)_;']H_;OMO_3K;^7L^R?[6[S/X=O(!^@%%%% !1110 4444 %%%%
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M (*H/\: /Z7:*_FB_P"&E_\ @K]_T ?B1_X*H/\ &C_AI?\ X*_?] 'XD?\
M@J@_QH _I=HK^:+_ (:7_P""OW_0!^)'_@J@_P :/^&E_P#@K]_T ?B1_P""
MJ#_&@#^EVBOYHO\ AI?_ (*_?] 'XD?^"J#_ !H_X:7_ ."OW_0!^)'_ (*H
M/\: /Z7:*_FB_P"&E_\ @K]_T ?B1_X*H/\ &C_AI?\ X*_?] 'XD?\ @J@_
MQH _I=HK^:+_ (:7_P""OW_0!^)'_@J@_P :/^&E_P#@K]_T ?B1_P""J#_&
M@#^EVBOYHO\ AI?_ (*_?] 'XD?^"J#_ !H_X:7_ ."OW_0!^)'_ (*H/\:
M/Z7:*_FB_P"&E_\ @K]_T ?B1_X*H/\ &C_AI?\ X*_?] 'XD?\ @J@_QH _
MI=HK^:+_ (:7_P""OW_0!^)'_@J@_P :/^&E_P#@K]_T ?B1_P""J#_&@#^E
MVBOYHO\ AI?_ (*_?] 'XD?^"J#_ !H_X:7_ ."OW_0!^)'_ (*H/\: /Z7:
M*_FB_P"&E_\ @K]_T ?B1_X*H/\ &C_AI?\ X*_?] 'XD?\ @J@_QH _I=HK
M^:+_ (:7_P""OW_0!^)'_@J@_P :/^&E_P#@K]_T ?B1_P""J#_&@#^EVBOY
MHO\ AI?_ (*_?] 'XD?^"J#_ !H_X:7_ ."OW_0!^)'_ (*H/\: /Z7:*_FB
M_P"&E_\ @K]_T ?B1_X*H/\ &C_AI?\ X*_?] 'XD?\ @J@_QH _I=HK^:+_
M (:7_P""OW_0!^)'_@J@_P :/^&E_P#@K]_T ?B1_P""J#_&@#^EVBOYHO\
MAI?_ (*_?] 'XD?^"J#_ !H_X:7_ ."OW_0!^)'_ (*H/\: /Z7:*_FB_P"&
ME_\ @K]_T ?B1_X*H/\ &C_AI?\ X*_?] 'XD?\ @J@_QH _I=HK^:+_ (:7
M_P""OW_0!^)'_@J@_P :/^&E_P#@K]_T ?B1_P""J#_&@#^EVBOYHO\ AI?_
M (*_?] 'XD?^"J#_ !H_X:7_ ."OW_0!^)'_ (*H/\: /Z7:*_FB_P"&E_\
M@K]_T ?B1_X*H/\ &C_AI?\ X*_?] 'XD?\ @J@_QH _I=HK^:+_ (:7_P""
MOW_0!^)'_@J@_P :/^&E_P#@K]_T ?B1_P""J#_&@#^EVBOYHO\ AI?_ (*_
M?] 'XD?^"J#_ !H_X:7_ ."OW_0!^)'_ (*H/\: /Z7:*_FB_P"&E_\ @K]_
MT ?B1_X*H/\ &C_AI?\ X*_?] 'XD?\ @J@_QH _I=HK^:+_ (:7_P""OW_0
M!^)'_@J@_P :/^&E_P#@K]_T ?B1_P""J#_&@#^EVBOYHO\ AI?_ (*_?] '
MXD?^"J#_ !H_X:7_ ."OW_0!^)'_ (*H/\: /Z7:*_FB_P"&E_\ @K]_T ?B
M1_X*H/\ &C_AI?\ X*_?] 'XD?\ @J@_QH _I=HK^:+_ (:7_P""OW_0!^)'
M_@J@_P :/^&E_P#@K]_T ?B1_P""J#_&@#^EVBOYHO\ AI?_ (*_?] 'XD?^
M"J#_ !H_X:7_ ."OW_0!^)'_ (*H/\: /Z7:*_FB_P"&E_\ @K]_T ?B1_X*
MH/\ &C_AI?\ X*_?] 'XD?\ @J@_QH _I=HK^:+_ (:7_P""OW_0!^)'_@J@
M_P :/^&E_P#@K]_T ?B1_P""J#_&@#^EVBOYHO\ AI?_ (*_?] 'XD?^"J#_
M !H_X:7_ ."OW_0!^)'_ (*H/\: /Z7:*_FB_P"&E_\ @K]_T ?B1_X*H/\
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M1110 51\3^*-,\$^';[6-:U&QTC2=,A:YO+V]N$M[>TB49:221R%15 )+,0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M -GX7O/$&T:CJ$MW<:A?7:K]V,SW$DCK&#@^6A5,_-MW<T ?0E%%% !1110
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MP!^QE^U*OB3]F/2]67XT:+KE_P#$'Q_K6N6LVKV]C+8W'VF0"*\PWE>;=7&
MC,SRG(;"@?TU5SOQ@^%.A_'?X2^*/ _B:U>^\-^,M(N]"U6V29X6N+2ZA>"9
M Z$,I:-V&Y2",Y!!H _%/_@S>^+/QL;X*ZAX,D^'NECX"K?:IJ,7C,7 ^V'6
M/]"7[$8_.SM\LL^[R@. -WK^YU>0_L2_L*_#7_@GC\&&^'_PIT6YT'PN^H3:
MH;6?4)[YO/E"*[>9,[/@B->,X&*]>H **** "BBB@ HHHH **** "BBB@#^?
MG_@Z]^$.E^"/^"KW[+/Q?^(5BU]\'[R'3= \1 V;W$0M[#6)+N\CD"AMWF6M
MZVV/!+".3 ;! RO^#A;QK\)_CS_P42_8O;]FK5? OB/XC2ZI%YMUX.FMKG9'
M]MT]])$CV^5&QA=NH;E$.<!2*_=W]IK]EOX?_MD_!W4_ /Q.\+:;XP\(ZOM-
MQ87@9<,OW9(Y$*R12+D[9(V5UR<$5X?^Q3_P1%_9C_X)\_$6;QA\+_AE9Z3X
MJDC:&+5K_4;O5+JSC8%66!KF600[@6!:,*S!B&)&!0!]6IPH^E+110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 5_/K^U]_P KI'PW_P"OC1O_ $SM7]!5?SZ_M??\KI'PW_Z^-&_],[4
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M]C[1X]>\30:B;76UG@T^;;8I;X1C]K94!,@7[G//3%?E]^VK<_\ !1#X[_\
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MH_\ !.M?^"B'_!/W7O@7H>NV'@&WU1].%I>+IOVFWL(K.YAF6-8%>/Y=L00
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>morf-20221231_g11.jpg
<TEXT>
begin 644 morf-20221231_g11.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )6!04# 2(  A$! Q$!_\0
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M<J'A!R(R0I(7-51BHN+P(T-$@M+_V@ , P$  A$#$0 _ -,
M
M
M
M
M
M
M
M                                                    R
M
M
M
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M51T@ /,[@
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M4NZ)BJ,X  <60
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M7/*EVTTQ3&4  .+D
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M-',C70R<JJNR<RQ*O5=NO4S5R;E-44U9SM8IY5-5,S&7L>MK9[O.P_IFR?\
MYP%^+A;Z:[6^IH:R%M125,3H9H9$W:]CD5'-7\RHJH9Y\2N14V(\9<-]K&2R
MTEKK;56S,@1%D<R-D+W(U%5$5=FKMNJ)OYR2-1_"#VVNQ^LHL)L5SBN=3$L4
M=;<^SC\7<Y%3G:QCW\SDZ*FZIU]_;9>%=%==-')CV.=-=-,U<KM<EP$M6VZ[
M9=;()5?1LM50B>\[LZJ%K7?Z'._TE^2J/ KH?=L)MUUS'(*66AKKM$VGHZ:=
M.61M/S<SGO:J;ISN1FR+UV;OMU0M<=%^J*JYR=EF)BCI  >9W@
M
M
M
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M[74M7=LU';887HOOHK6HITH,\J=F;&4  .+(
M
M
M
M
M
M
M
M                                              .-UBU4M.BFF609
MQ?(:JHM=EI_&)H:)C732;N1K6M1RHFZN<B=51.IGGPD<1F=Z_P#A )+YDL=P
ML%FKL=GFM6.RR/;!!1<K'0/Y5V1ZO1RR=HJ>5VBJW9O*B:6Y!CMKRJTU%KO5
MNI;K;)U:LM'61-EBDY7(YJ.8Y%141S479?>**6)C8_"_WMC&HUC<38B-:FR(
MGBT/0#[.*^]YAK[Q=8?P]8WE]QPG&X;4^]W^X6>98ZB9>616QKLJ*K41L:(W
M?EWF5SFNY&GQ\)VMN5Z'W'B#TRU#R"KS&/2^DFO=LN-:]SZB:B8Q\BL<]RJ[
MJU8'-:JKRK(YJ*J(W;]+5"^'PO\ >72-5C9L2:Z-SNG,GB\2;I_2U4_H4A[/
MK?/7<6W&M5T\?;4\.FU=%)(Q47E<M/0.V_T12?S<J[@<XZ@UINW#54<7C=6K
M^S)FW5:J.QP/?X@VB;6>*JQ(N=6\B2;JK%;R\C5W1555-4=)L[CU/TPQ+,(8
MO%V7ZTTMR['_ ,VLL37JS^A7*G]!G]BU1%#X%:=TDC(V^)5C-WN1$YG7R1&I
M_.JJB(GG54+!Z,XYJ+<?!\8);-,[S08QGL]@M\EMN5T8V2GA:LL<CU<BQ2HO
M-!SHGD.ZN3N[T"U(*&^H_P"$!^'' _ZE%_W6=]X,[7/.=?\ 0J^Y%G]\]'[Q
M2Y)/015/BD%-RP-I:61K.6%C&KLZ5Z[JF_E=^R(!;0                %7
M_9->&I?_ *25^0;G]V.8S?PDFD%?XEZ3M9[%8N3G\:]',$O-R[7?EY.3LGT_
M)ML_??GWW3;EV7?&;.4KC@H?[(GBG^41@G_\I\@^_G+Z8^$SBRG"+;=,PU;P
M3!\BG[7QJP^IU>[AXKRRO:S]WBKD8_F8C']$Z<^R]449F4M& 4DQCPC>G=+>
MZ:7(M=\2NEG;S=O26S3:^450_P E4;RS/J9FMV=RJN\;MT14Z;\R=W[)KPU?
M"2OR#<_NPS,I6@!P6C&NF#\0&+U>18#>_1ZSTM8Z@EJ?%)Z;EG:QDCF<LS&.
M79LK%W1-O*[^BG>F6  I_P"$#XP<RX5ZK3R+%*7')8\B]$4JY\BIJJ9D7BZ4
MRLY$@D:Y-^V<B]'?Q>[J8V,Q'*G)< &2'LMVK/\ *TO^2;Q]J/9;M6?Y6E_R
M3>/M3CSD/1Z/7_R8:W@R0]ENU9_E:7_)-X^U'LMVK/\ *TO^2;Q]J.<@]'K_
M .3#6\&2">%NU8_E:7_)-X^U.ITF\*-J?G.J^$8Q6QZ>2T5\OUOM=0VW6VZ,
MJ>RGJ8XGNC=++R(Y&O545VZ=.Y>Y7+B6)L5TQG\X:C  YO. %#<BXK^(F3,L
MK@QNW:8IC]OOMRM=$MU@N/C3HJ6LFIVNE[.7EYE[+=5;LB[]R=R=%V_;L4\N
MY5E#KKN4T1G7.4+Y S^]=-Q3?XAI#_J+K]J/73<4W^(:0_ZBZ_:GD]98/XL.
MCTJS[\- 09_>NFXIO\0TA_U%U^U'KIN*;_$-(?\ 477[4>LL'\6#TJS[\- 0
M9_IQ3<4OGH-(?]1=?M2;N$?7#4S5+(\WLVI-)BE/46:EMM71/Q:*J:QS*E]8
MQR2+.]RJJ+3)MLB=Z]5WZ=UK&8>_/)M5Q,NRB_;N3R:*LY62 !['> BKBBU-
MO^C^B%_RO%X+=4WZEFH8*6.[QR24JNGK(8%61(W-=LC957HO>B=_<M+UX[.(
MK;I:M,-__4[E]X-GA-&XS'4S5AK<UQ&W)N,#H?'Z2BJK!VIKBGHG)I*#-KU]
MG$7_ +EZ8?U.Y?>!Z^SB+_W+TP_J=R^\'O\ L[I7X%39?933?^%J:2@S:]?9
MQ%_[EZ8?U.Y?>!Z^SB+_ -R],/ZG<OO ^SNE?@5'V4TW_A:FDH,SKQQ^\1%G
MM-;7OM.F<C*6%\SV-HKCNJ-:KE1-ZA$WV3WR_P#HOF-=J%H_@V5W.*G@N-]L
M5!<ZF*E:YL+)9Z=DKVL1RN5&HYR[(JJNVVZKWFKQ6 Q. JBG$T31,[,VGQVC
M<7HVJ*,9;FB9Z8S]KL@ >%K0                      /(N686"SWBBM-?
M>[=0W2NV\5H:FKCCGJ-UV3LV*J.=UZ=$4#UP#PK1GF-7ZZ5%LMF16FXW*#?M
M:.DK8I9H]N_F8URJG]* >Z#^.<C&N<Y4:U$W55[D/$L6=8WDU954=FR"U7:K
MIMTG@H:V*:2+9=EYFM<JMZ].H'N
M
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MM+5.8UE,^L>Y9$G8U455J4VV5>Y>B;=;) [K6#P]B>5:HB)=E%BW;G.BG*0
M'L=Z!N.;W,^2?I"S?VM2E "__'-[F?)?TA9O[6I2@!=?[/\ <7N,/H?]E_5L
M3Q@ !;"[@  >+G'\"K_^CZCZ-QJ)PL^YFTB^*%I^IQ&7><?P*O\ ^CZCZ-QJ
M)PL^YFTB^*%I^IQ%':_]:L_A^;YS_:?UZQ^'YI. !5JE@
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MNK+#67226\S12S)*^EN<2M18XXTY>6%O3;?=5Z]R)J6
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MFNA.F^17K /';Q=L;MM?6U/HS<(^UGEI8WR/Y6U"-;NYRKLU$1-^B(7<
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M6JB;(J\J^=J^:Y0   "ANK_XWO0[XGU'T5X+Y%#=7_QO>AWQ/J/HKP7R
M        "*LDUSNV(X[=+[=M)\SI+5;*66MJZCQBS/[.&-BO>[E;<%<NS6JN
MR(JKMT08UKG=LMQVUWVTZ3YG5VJYTL5;25'C%F9VD,C$>QW*ZX(Y-VN1=E1%
M3?J@$J@  1_=.(?2JQW*LMUQU-P^@N%)*^"HI*J_4D<L,C55KF/8Z1%:Y%14
M5%3=%0D R<BP^PW_ %3UGJ+G9+=<JAN?7F-LM921RO1J3(J-17(J[;JJ[?G4
MV6C\'.-O<U$Y=#7XW&1@K/.S&:\V0YAPLY;>*F[7V]Z0WJZU'+VU=<*NUSSR
M<K4:WF>]5<NS6M1-UZ(B)YB!>&.;ALA]5CTTR:6,YL_NSK5Z+K;4WH%[+L5@
M[3_YC\+EY/)[]B*/4TP_\E+'\G0_W1ZFF'_DI8_DZ'^Z23[-7/?CP1S[26_<
MGQ7SQW7?0?$K/3VFQ:B:=V6U4_-V-#;[W0001\SE<[E8QZ-3=SG*NR=555\Y
MW^(9UC>?VV:XXOD-JR2WQ3+3R55HK8JJ)DB-:Y6*^-RHCD1S5VWWV<B^<S-]
M33#_ ,E;'\G0_P!TLCX,RDAHM+M2Z>GBC@IX<_N4<<434:QC4@I41J(G1$1.
MFR&ITCHFK 41755GFVVC]*TX^N:*:<LEO0 1]O0$7:W:$>K7Z"_[(>>8%Z&=
MM_ B]^AWC?:=G^_^0[GY.S\GNVYW^^5+];O>O7B>I+ZOFM/I=](?II\:].3_
M !OQKT0\6Y.;L^3L^3KMR<W-_&VZ :"@B[1#0CU%/1O_ &0\\SWT3['^&][]
M$?%.S[3]X\AO)S]IY7?OR,]XE$ 5+\(O_!713]:-E^CJBVA3WPFE\HL9TZTE
MO-RG\7MU!J3::JJFY'/[.*."K>]W*U%5=FHJ[(BK[QT7XF;-<4QG,Q/D[[$Q
M3<IF>V/-ZH(,]?!HG^6G[*KOL1Z^#1/\M/V57?8GS5.B-*Y[BO\ IJ^BX(QN
M#RWE/C'U3F1#K]_"C0?]:-@^DD/*]?!HG^6G[*KOL3C<VXBM/=6M1-#[/B60
M>BMQAU(L56^'Q*IAVB;,K%=S21M3\)[4VWWZ_P YO]7M&Z0L:3LUW;-=-,3.
M<S$Q$-7I/%X6O"7*:*Z9F8]F35(XW6C,JW3K1[/,LML5//<;#8:^Z4T54USH
M7RP4[Y6->C5:JM5S$W1%1=M]E3O.R(PXIO<QZO?%"\?4IB_56PJSB7$CQ5YC
MBEFO]'1:/14EUHH:Z&.H@NR2-9+&U[4<B2*B.V<F^RJF_G4_#/LZXIM1<$R/
M$[E%I#!;K];:FUU,M*RZMF9%/$Z)[F*YSD1R->NRJBIOMNB]QZN@WM'Z>_%V
MW_5HSNBC\7KCI*SB+EJCDY4S,;/O658T!@[EJFJ<\YB/:B_3[.N*;3K!,<Q.
MVQ:0U%NL-MIK732U3+JZ9\4$38F.>K7-17*UJ;JB(F^^R)W'TY;Q(\5>'XI>
MK_646CTM):J*:NFCIX+LLCF11N>Y&HLB(KMFKMNJ)OYT)'.&UW]I'43XNW#Z
MK(,'KCI*]B+=JODY3,1L^\O: P=NU55&><1/M7F3N!_&_@H?TN^.F%:@ ,L
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MMOZTKU]'3%M#ZRPVYHX1Y*0Q&]KXSY@ .]YP
M  "KWA-_<0ZE?^S?[2I29<GT TOS6]U5ZR+3C$K]>*GE[>X72Q4M342\K48W
MFD?&KG;-:UJ;KT1J)YCRO6JZ*_ _@?S8HOL@)0;^"A_2+O6JZ*_ _@?S8HOL
MCJ<'TJPK33Q[TGX?8<4\=Y/&O0.V04?;\G-R<_9-;S<O._;??;F7;O4#J
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MH!8,1E&2(@ ,@
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MUM_6E>OHZ8MH?66&W-'"/)2&(WM?&?, !WO.
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MFO!S$9[8]DQYPOF "\%:!5[CP[N'G]<&._\ Q!:$J]QX=W#S^N#'?_B +0@
M   !$MUX7,&OMKK+;<JO-;A;JN%]/4T=5GU^EAGB>U6OC>QU:J.:YJJBM5-E
M15126@!$MIX6\&L5KI+;;:K-;?;J2%E/34=+G]^BA@B8U&LC8QM:B-:UJ(B-
M1-D1$1"6@
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MTW</BA9_KMV(Y)&XK/=-W#XH6?Z[=B.2V-!=0H[_ #E5FF^OU]WE  #>M$
M#H]'_=#:2_IBM_L:Y&A!GOH_[H;27],5O]C7(T(*NT_UV>$+/T#U*GC( "-3
MLE(HVJ,Z#^TAIY\7K=]5C.Y.&T']I#3SXO6[ZK&=R?*VD>N7OQ3YKMPNXHX1
MY  -<]0 #E3MAB=C\/!S?P6UM_6E>OHZ8MH5+\'-_!;6W]:5Z^CIBVA]98;<
MT<(\E(8C>U\9\P '>\X
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M6.ZN3?9-U3O0
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M1M49T']I#3SXO6[ZK&=R<-H/[2&GGQ>MWU6,[D^5M(]<O?BGS7;A=Q1PCR
M:YZ@ '*G;#$['X>#F_@MK;^M*]?1TQ;0J7X.;^"VMOZTKU]'3%M#ZRPVYHX1
MY*0Q&]KXSY@ .]YP
M         !5_BRXUG</V36S!L6P6[Z@ZAW:@2XTMLH8GK#' Y\D;7NY&N>]>
M>-WD-;W)U<W=-ZVU>1>$0U3E;6T%FI,%M\C>9*>&.WTR)UZ(K:A\DZ+_ #_T
M@:9 S2H<J\(7I5-XW<[#1Y];F-YEIY8K?/YU541*9\<RK_I3NV]XLAPH<:JZ
M_P"2W+!\GP6\Z?:AVN@6XU5LN$+TAD@;(R)7L5[6O:O-(SR'-\_1SMEV"SH
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MV1QNB7XPJJ_5<_\ M>,G^I--4:3Z8_EGSA&M8)B<%.4^V%WP 7RJX
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M5<Y757VR  [76
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M>*3UI6F%LS#TL>FOQV\16GQ/Q_Q/DYX)Y>TY^RDWV[#;EY4_"WWZ;*$"ZO\
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MU!+4^B594\T#GLD<SEFF>U-W1,7=$W\GOZJ3&#)G(  P
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M8<=&AVL6;VW#\/S;T7R*Y=IXK1^A-=!VG9Q/E?Y<L#6)LR-Z]53?;9.NR$\
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M
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MK/=-W#XH6?Z[=B.21N*SW3=P^*%G^NW8CDMC074*._SE5FF^OU]WE  #>M$
M #H]'_=#:2_IBM_L:Y&A!GOH_P"Z&TE_3%;_ &-<C0@J[3_79X0L_0/4J>\
M!&TA
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M)^,Z_P"1_P#[:+0E7D_&=?\ (_\ ]M 6A
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M?=T  .IS
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M5)1PW^YYTN^*UK^J1#B/]SSJC\5KI]4E'#?[GG2[XK6OZI$!(@
M   5>3\9U_R/_P#;1*&MW#)IIQ%)9?5$QOTP^@_;>(_X?4TW8]MV?:?O,C.;
M?LH_PM]N7IMNN\7^QC\-/P:_MVY_>0+0@B[1#ADTTX=?1I-.\;]+WHQV/CW^
M'U-3VW8]IV?[](_EV[63\';?FZ[[)M*(
M                                       9W<2FI'$!KGQ6Y!I!HCD"
M8M08?;X*NOK$G2F;/*^..3=\J-<[_P">9&V-$V56O5=TZI&EU\)QJ39=%J;3
MQ+?)5Z_LN]5CU=5-HVR/A[-[6,D9$Q%9)4/>]T36M14YH7.5J\S4=)N%:[X%
MH9X07B*K<\R6GQRFN$%MBI9*B.1R2/;3Q*Y$Y&N[D5.\C;@_UMT$PSB4U[U&
MS')+?27*X9+62XU<*N"5Z+1SU-0]\L.T:\JO:L:*J[.Y5VZ(YVX71X$-)<WT
MAT(90ZBU;ZO+;M<I[S6K-5.J9V.F:SR9I7;\TB<GE*BJFZ]Z]Y8<Y'2_5K$M
M9<97(<+O<-_LR3OIEJX&/:WM&HBN;L]J+T1R>;SG7         <;F6M.GFG5
MSBMN69WC.+W&6%*B.CO-XIZ29\2N<U)$9(]JJU7,<G-MMNU4\RE/_ S>YBR?
MXX57U*A)<XE^ +3WBGSR@RS++SDU!<:.VQVN.*S55/%"L3)9I4<J202+S<TS
MNN^VR)T[U6(_ S>YBR?XX57U*A OD     B[U8,M^ [//Z[C_P#WH<==,LSF
MNUAQ?+(]%,U2W6NPW:US1.K[#VSI:JHMLL;FIZ)[*U&T4O,JJBHKF;(NZJE@
M@!%WJP9;\!V>?UW'_P#O0D>U5DMPM='55%#46R>>%DLE#5.C=-3N<U%6-ZQO
M>Q7-5=EY'.;NB[.5-E/J
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M[/Q_"K'<Z2]VFADC='!4)#,V5C*2EYO)8Y&[+.]55R*BHLGFU+
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M\-QJOTCRV:OLUEHK=424U;9G1.DA@9&Y6*MP15:JM7;=$7;S(!-X
M
M                "N^IW !HEJ_G%UR_*<8J:^_71['U51'=*J%'JUC6-V8R
M1&IY+&IT3S'+>Q:<.7Y&5GRU6?:EL0!P>B^B&(: 8<[%\(MTELLJU+ZOL):F
M2=>T>C4<O-(Y5_BITW.\          %#? S>YBR?XX57U*A+Y%#? S>YBR?X
MX57U*A OD
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M]4[Y  1A)0
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MD_QPJOJ5"/4?\(#\..!_U*+_ +K'@9O<Q9/\<*KZE0@7R
M
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MUSNA9>K_ %3OD !&$E
M                                              5?U9X?]-N)+B,K
M[1J2]]Z=8L:HY+/CGCLU)V:3SU7C%:U8WM=(KEBACZ*J-[%-T7F3;\.'K@CT
MKQS%[G-D6GM-?;M)=;C1,GS*%MRG2AIZR:FH4C[9JHR/Q6&!6<J)Y*MZJFQV
MO$SP;:><5=/:ES&.Y4=QM:/92W2SU#8:AD;E171KSL>QS55J?A-54W794W7>
MO_L,^BOY3YY\H47W,"RO#18++B>,Y58,68Z/$+7DM=2VB)'*Z.)B*Q:B*-55
M?(CJW5<:)YN3;S$NE&+7X'C1FTW.DKH<FSITM+,R9C7U]$K5<UR*B+M2=VZ%
MYP   @/4;@.T+U9S2YY;E>#^BN07)S7U=9Z+UT/:*UC6-7DCG:U-FM:G1$[B
M!^ +@8ETH?GEVU'PE+5?:JHJ+=:IG71M0CK7-'RO9R13/9U]]Z<Y?0 9=5'!
MYQ08S@M[X=K ZQ5NC]UNB529=/.QE1#3K*R18EC[5)$3FC:YS&Q.W<KD1_*Y
M32/3C!Z#33 <=Q*UJ]UNL=O@MT#I/PW,BC1B.=^==MU_.JG1  4-\#-[F+)_
MCA5?4J$OD4-\#-[F+)_CA5?4J$"^0
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MWR  C"2@
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MELU+3RPI$^6:)&JLD\:\W-"[IMMLJ=>]$B/P,WN8LG^.%5]2H0+Y
M
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MN629=8(\3ON4W2:]2V%CN9U QS(XHHY%V3>58X6.?T3RWNZ)W)*H
M H;X&;W,63_'"J^I4)?(H;X&;W,63_'"J^I4(%\@
M
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MHS#0C"\RON>T,-IR?+KA'4OML<C9'T\,7:<G:*U5:CG.ED=RHJ[-5NZHJJU
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M?74Z*_#!@?SGHOM2KW@9O<Q9/\<*KZE0@7R
M                                                          _R
M^-DT;XY&M>QR*US7)NBHO>BH?Z 'YTU/%2PMB@B9#$WN9&U&M3KOW(?H
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MLC1?]8-E^F4U.*QUAZYW0LO5_JG?( ",)*
M      ',:F:G8UH]@]SS#,+EZ$8[;>S\:K.PEG[/M)61,\B)KGKN^1B=$7;?
M=>FZG3E7_":>XCU)_GMG]I4H9CI/9->&KX25^0;G]V'LFO#5\)*_(-S^['Q
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M5]^/]BMN;!<_&UID\CF[:G27?;S^,=Z_RMP-.
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M63_'"J^I4)?(H;X&;W,63_'"J^I4(%\@
M
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M6]06JUZET+:R=R,C2X4=50QN<J[(G:3Q,9OO^<L,UR.1%1=T7N4#^@
M                            4-\#-[F+)_CA5?4J$OD4-\#-[F+)_CA5
M?4J$"^0
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MX'2\K8V/3O1Z11Q<R+U1=T\P%F0
M!3;C+]=YZIMK]0'^!WH/%XW_ .2/]O=O/S_[<_=/WOL.[R?>Z\QRW@9O<Q9/
M\<*KZE0E\BAO@9O<Q9/\<*KZE0@7R
M
M     (EXF.)C&.%C Z#+,LH+O<+=67*.UQQ6:&*69)7Q2RHY4DDC3EY87==]
M]U3IWJDM #+3!N)?&.*CPG^CV6XG07>WVZBL-9:Y(KS#%%,LK*6YRJY$CDD3
MEY9F]=]]T7IW*NI90W5_\;WH=\3ZCZ*\%\@*D^$E]K73/]8-K^BJB"B=?"2^
MUKIG^L&U_151!18FK.XN<4 UDWM'#Y@ )BASG+[[9&B_ZP;+],IJ<98WWVR-
M%_U@V7Z934XK'6'KG="R]7^J=\@ (PDH
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MQ9/\<*KZE0E\BAO@9O<Q9/\ '"J^I4(%\@
M
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M+6)Q'.6JLXRA.M#X>[AL-S=V,ISD !H6\
M
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MSU)Q&RY908M<,ILM!D]>Q)*2RU5PACK:ABJY$='"YR/>BJQZ;HB_@N]Y0.C
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MUS?7W6&"WSVO%LWR+FL\4T:QK4,BEJ'OE5.YR[SM:KD54YTE3?=%+S@
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MG4[5G7S6QE!+28UE=XCI+'-4,5DD\,+I>9^RIW<KH$7953F1[=]V*!>0
M                                    ^>X5?B%OJ:GD[3L8G2<N^V^R
M*NV_]!]  Q"XU=1-<]><#L>I&H%D])>G;[DE#8<><KXW22NBD>M0K'(CI/)C
M5O:/Y4\K]S;LYZFPVA?M*:??%ZW_ %:,IKX9[V@<,^,[/JE27*T+]I33[XO6
M_P"K1@=N     SPUC\&#P_:<XAE6H&49=G-);*".6X52QU]%U57;I&Q%I.KG
M/<C&IOU5R(>/X)SA:;;/1#7"N;64-/<DJ+?CELGE21S:19-GSRO1C>=RJSD:
MJ-:B\KW<OE-Y?:\+%F5SR>LTIT1LM0L,^772.:JY57ROW5D%,UR)^$U9)'NV
M]^)O]%]L/Q6VX-B=FQRSP)2VJTT<5#2PM_B11L1C4_GV1.H'K@  5AXVM;M5
M].H<1P_1O$W9#F&8-K8XK@V/M?0QL'8)VO(Y.SZ]ONCY7(QJLZHY%V+/ #)?
MP7MDO>-\=6JUIR:N2Y9'06>[4MSK&RND2>J9<Z1LTB/<B*[F>CEW5$5=]]C1
M3B;U_L_#9H_>LVNRQ2SP,["VT$C^5:ZL<B]E"GGZ[*YRINJ,:]WF*(<"'XSK
MB'_^\7]M4Y^W&[7ZHY-QB6B:MT8RW4W2_!U@FM]IM5OJFT5QJ'P,F?*^=E/*
MUVTKFQN;LJ*D"MZ<S]PA3@U7,:CPE6'U^?+-Z;;KXW=JY*C='IXU9IZF-%:O
MX&T<K$Y/XB)R[)ML;4&(GKB<U]D6]53U'+]Z</@[YI_1#_R1XMW^+=I^]_N_
M[S^#^;RC:ZR5TUTLU!65%*^AGJ*>.:2EDWYH7.:BJQ=T1=T5=NY.[N ^T  0
M_P 5FL61Z'Z/UN28EC+LMR)U3#14-K:R217R2NY4=R1HKW[=_*W95]]#,73Z
MVZHTWA(-,Z[6"I;+FMTF@N$M.UZ*E'"^&5(X.5J<K.5&_@MW1-^JJY5-FC,K
M73\;WIK_ .@HOH9P--0    '&:QZ4VG6W32_8-?JBMI+3>86P5$UO>QD[6H]
MKT5BO:YJ+NU.]J^<S XU.!'0_A9TMCNE#?,UN^87B?Q*Q6FHKZ1633=.>1[6
MTB.5C$5%5&JBJKF-W3FW37(S;O,Z\3GA6J*RUNU5B^F=,M0RE<Y58LL#6.<_
M;N1WC<T2+W[MA:B_F"R? 1PO/X8=$H;;<IY)LGODC;G=VJY%CIY7,:C8&(GF
M8U$15Z[NYEWVY42R(    9M<>6I^N>JM9JGI]A]A]+NF.(43JJ_Y(Y7L]$HF
MTS9W0)*K?.J\O91HJK_'<C%5"3/!">Y.D^,-9_U(2>>,7W*VKGQ8K_H'$ ^"
M3F?3<(5;-'$LTD=]KGMC;WO5(XE1/Z0/1\(EK[>K/9K3HGITYU3J/G2+ ]*9
MR=I16]=TD>J_Q.=&O;S?Q6-E=NBM12(_ G_P/U4_]?H?HYB)=)-3=:-/]5-0
MM4LPX:<[S7-LFC?#'<7T%;10VJF5NRQQ1K1R=$:C&\RN14;&B>=RKZ'@BM5L
MAQ;,;OA]OP&Y7ZQY%6Q.N&3TJR>+6;LX)G,27EB<WRU\E.9[/S;@:Y@  5&X
MS=6M;H<SL&DVB>/(Z[Y#0^,U>4.:Y6VN%9'QJO,J<D71N_:.YE[T8WFY5+<@
M#+KP-%'44&<:TTU7)VU5 R@CED1RNYWI+5(Y=UZKNJ+U4U%,QO!!^VGKU_Z:
MD^GJS3D   ! _%)P:87Q:^EE,QNE^MWI?\:\5] ZB"+G[?LN?G[6&3?;L6;;
M;=Z[[]-IX/&S3*:3!\.OV27!=J"ST$]PJ%WVVCBC=([K_,U0,>=:N!W *?B<
MQ/0S2>ZY'<\BJ42IR&YWJIIYZ:UTZM[3;EB@C7M$C3G\I41>TB:G5_DZ_:=X
M/;=,\$Q_$;/VRVNR4,-OIEJ'\\BQQL1B*Y=DW<J)NNR(FZ]R%$_!.8[69_6:
MJZY9(K:S)<BNSK>VJ<U=V-\FHG2/=55&.=+"W;N3L43S&AH   >=D5V6PX_=
M;FV'QAU'2RU*0[\O/R,5W+OLNV^VW<8D\:^=ZYZV8ECVH^I-H]*&$55?)1X]
MCCD?$Y%Y%<Z=6.3F?NUJ)VC]M]_(:C54W',[/#2^U)I]^G)?H' 7PTV]KO%_
MT72_1-,M?"<:^7K6Z^9%A.&N=/@.G:Q3Y'70.3L9Z^29L#&*[S]FYZM1N_5R
M3+LO(BI>77G*LYP[@UEK].+377C,'V6AI:*&V4DE541]JD4;Y8XV(KE<QCG.
M3ILBM15Z(9BY%E.9::\&-_TPN7#WEN*0W.M@KKQG5YCJ8F35#:ACF*]CZ1K6
MHJ-;&UO:=-]^JJNX:<^#S]QOIA_ZA+]8E+$E*_!:ZKY#EVAU!B=RP&YX[9<<
MHHTM^252R>+WKM)IU>L/-$UOD*B(O*]_?UV+J
M                     /AO5CMN26R:VW>WTMUMTW+VM)6P-FBDV<CDYF.1
M479R(J;IWHBGW #B/4,TV^#W%OD6F_N'27S%K-DUM2W7BT4-VMZ*BI25U,R:
M+=.Y>1R*G3^8], ?E1TD%!2PTU-#'34T+$CCAA8C6,:B;(UJ)T1$3S(?J
M    #Y+K::&_6^:@N5%3W&AG;RRTM5$V6*1/><UR*BI_.?6 /CLUEM^/VZ*W
MVNAIK;00IM%2T<+8HHTWWV:UJ(B=5\Q\M-B-BH[Y/>X++;X;S.WEEN,=+&VH
MD3WG2(G,J?SJ>L         /GN%MI+Q0U-#7TL-;15#%CFIZB-)(Y&*FRM<U
M4V5%3S*?G9[/08_;8+?:Z&FMM! G+%2T<+8HHTW5=FM:B(G557HGG/L 'DV;
M$+%C]965=KLMOMM56.YJF>CI8XGSK[[W-1%<O\Y_;]B=DRJ.".]V:WWAE._M
M(6U]*R=(W?RFH]%V7\Z'J@#^,:C&HUJ(UJ)LB)W(?T       \NNQ2RW6ZT5
MUK;105ETH=_%:VHIF/FI]^_LWJG,W^A4/TOF.VK)[>Z@O-LH[M0N5'.I:ZG9
M-$JIW*K7(J;GH #\*"AIK71Q4E'3Q4E+"U&100,1C&-3N1K4Z(GYD/@M6(6*
MQW*MN-NLMOM]PK%WJ:JEI8XY9UWWW>]J(KNOOJ>L         /+LF*V7')JZ
M:TV>@M<U=)VU7)14K(75$FZKSR*U$YG;JO5=UZJ?Y]*%B],'H]Z"V_T<Y.R]
M$_%8_&>3^3VNW-M^;<]8 ?#>K#;,DM\M!=[=276ADVYZ6M@;-$[;NW:Y%13]
MK?;Z6U4<-'14T-'20MY(H*>-&1L:G<C6IT1/YCZ
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M6E%IT0TTL6#6*HK:NTV:%T-/-<7L?.YJO<]>=6-:U5W<O<U/,=F
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MLJ>=53_/W+E@
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M'6@Y&X:N83:\ZI<+K,KM%-EU6U'06.2L8E7(BHKD5L6_,NZ-5>[N15.N
M
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M[H:'4ME35\F_[SR11[KMWISR1]_3SDQ\?7$!IEJGIAH5:<,R"VWJYI=:.O\
M%J%[724%.D2,6.9K?WE_,YB=F[9?(7IT+EY1H;;-#]$,XMNC^G5LO\UVG=75
M^+W:MGEANW:(UE0SFFD=RN=$B[-_!541-NI0NT:,Y/K1D6&8#B?"U7Z)8U0Y
M+3WG(+S=:BJF\89$KF[)45$<;G-:U\W*QCG]7IR\J*JJ%C]<XWU_A1M ::E5
M73TN/UE5.C47]SB6.N3F54[D56JW^?IYR\9573S3R^YCQ[ZC:E7FRU]ML&-6
M2EQFP5%=2OB97.>B2SS0JY$YFL=VK.9NZ+VB=>]$M4
M
M             $/\8ON5M7/BQ7_0.(&\$+[DV7XPUG_4A+*<1>&W34/0?4'%
M[)"RHO%XLE70TD4DB1M=+)$YK45R]$3=4ZJ9MZ4\,G'-HEBZX[A-=26&RK4/
MJEI(Z^W2)VCD1'.WD:Y>J-3S[= />\*JK)N*71*"TK&[(^RAV9%MVVRUVT&^
M_FYTEVW\_,=UQ;8]H9D/%C02Y6[.M6\WAI(XUTUQRG2J@IX^R18T56=DZ)NZ
MK.]JR.5>;=R(Q41?VX9O!\:A2:VT6K^O^41Y%?K=(E316U*E:QZU#?WI\TCD
M1K6Q+Y3(X^G,C%W1&JUWZ:K\*&OFGG%U>]:=%*BQ7AE^8K*BBO$C6+$CXV-D
MCD:[EYF<T;7M<QR.Z(BILB\P0;PUV1=//"AV*TVG"KAI9;;C3U:OQ>KN#:M[
M('6R:9$>YJKLUTD;).S5R\BHB;]$1)4T5_\ DH^$QS7 I7I38IJ) ^XT'.J,
M8U[NTJ(NOF:QZ5<#4_.T^S3O@XUXQ/C6P[6?+ZNTYC-5<]1?ZVWS,IV43Y:>
M:D[&-CU:Z1D4*Q*CD:FZ=-E5-W?Y\,IAM+28AIWJ%25ZV[(K=<Y+3$L+U9-+
M%)&Z5'-5.J=FZ%=E14V[9?S ?+P*T*\2/&IJ[KW5Q]O:;7,^WV.61J]\B=C$
MYOO.;2Q;.3_Z_P#.:2E<?![Z-KHQPLXC05$'B]WO$:WRX[MY7=K4(CF-<G\I
ML*0L7?SL7N[DL<
M
M
M                                              IQF?@U,<U/UHJL
MWS;/,DR:RON4UQ@Q>JE5::G223M'0->YSE;"J].5B-Z(B(J;%QP!_F)C8V-8
MQJ-8U-D:U-D1/>/]
M
M
M
F                                               '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>morf-20221231_g12.jpg
<TEXT>
begin 644 morf-20221231_g12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #V JP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\(^(
M'@G3_B9^T98:'KMQJ;:3:^%)+V*UL=4N;-/.-XJ%SY+KN.WCG- 'N]%>0?\
M#*?P^_YY>(/_  IM2_\ C]'_  RG\/O^>7B#_P *;4O_ (_0!Z_17D'_  RG
M\/O^>7B#_P *;4O_ (_1_P ,I_#[_GEX@_\ "FU+_P"/T >OT5Y!_P ,I_#[
M_GEX@_\ "FU+_P"/T?\ #*?P^_YY>(/_  IM2_\ C] 'K]%>0?\ #*?P^_YY
M>(/_  IM2_\ C]'_  RG\/O^>7B#_P *;4O_ (_0!Z_17D'_  RG\/O^>7B#
M_P *;4O_ (_1_P ,I_#[_GEX@_\ "FU+_P"/T >OT5Y!_P ,I_#[_GEX@_\
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M-4>?\</^?'X?_P#@9??_ !J@#U:BO*?/^.'_ #X_#_\ \#+[_P"-4>?\</\
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MVK0KJLK_ -IS1+/YEWVP'+Q?NSC.WD<"OHBBB@ HHHH **** "BBB@ HHHH
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MM??#FS72+RTNO&%FFH^7>SQ0_8+=YV@0R$G#.9%8; <\<9. 0#Z,KRGX3_\
M)5OC)_V&;+_TW6U9_P +_P!J/PS\1(]5GO8F\)6=K;V^H6UUK5S#'%=65Q)+
M'!.&W80LT+C8V&''K3_@?KFF^(_B-\8+_2=0M=4L9-:LPEU93K-$Q&G6X(#*
M2"0: /8Z**YKXD?$#2OA7X%UOQ;KAF&E:3;M<W MH_,E91P%1?XF)( '<D4
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M(VW+G&-I_O"OM/P+#-;^"/#T5S-%<7$>G6ZR302>9&[")065_P")2>0>XYH
MW***\ ^(FN>-_"O[1VEW.GWNIZ_X?F\*:I<P>%;2%(X7NX#!Y8,I^])(78#<
M0%&<#K0![_7@7[%__)-_%?\ V.WB#_TX2US7[-?Q ^+.J^ ?%DNJZ%>>(?$]
MOXNO(9(_$4_]F)#;E$<)!A),I&24 ].<FMW]A^2ZF^$_B*2^MX[2]?QEKS3V
M\4OFI&YOY=RA\#< >^!GTH ^A:IWFCV&I75E<W=E;W-Q92&6VEFB5F@<J5+(
M2/E.TD9'8FO ?VVO'GBKP/X+\!P^$O$,WAB_U_QII>A3ZC;P132);W#.K[5D
M4KG@'D=JN?\ #/7Q+[?M$>+O_!3IO_QB@#WZBO ?^&>OB7_T<1XM_P#!3IO_
M ,8H_P"&>OB7_P!'$>+?_!3IO_QB@#WZBO ?^&>OB7_T<1XM_P#!3IO_ ,8H
M_P"&>OB7_P!'$>+?_!3IO_QB@#WZBOD+XW>%OBC\#_!5MXL@^.?B/7&@UC3+
M5]/OM+L%AFCGO8875BD(8?+(>0:^O: "BBB@ KR'XF_M->%OAS#<1QI<Z]J]
MM>?8[C2;(!+B([2V\J^W*$+@,,AF( /->O5XG<?LQ6&O?$C7/$WB;Q!J'B*S
MOE;[)IMP6C.GLS*089E;<FS:0NS8<.VXMUH ]BT^\75M+MKM8IK=;F%91'.F
MR1 R@X9>S#/([&O$8OV-_!4</A2#[9JQM]!M8K&2'[0NW4;>*[^UPQ7'R\A)
M_G&W:>H.0:]SM;<6EK# K.ZQ($#2,68X&,DGDGW-2T >0>"?V6O W@^SUBSN
MK-O%-AJ"06RV7B!([N&VM8'DD@MXT*8VH\LA!;+<]>!57X"^&='\'_$#XO:5
MH.E66BZ9#K5HT=EI]ND$*%M/MRQ"*  2>3Q7M->4_"?_ )*M\9/^PS9?^FZV
MH ]6KSSX\?"4?&_X>R^$)]1;3=.O+VTEOV126FMXITE>%2""I?8%W#IG-=7X
MO\7Z-X!\,ZAXA\0ZC#I.BZ?$9KJ]N"1'"@.-S>W(KQG_ (;Y_9Z_Z*SX>_[_
M #?_ !- '4:1^RW\+M-::>Z\':;X@U.>X-U/JVOPC4+V:4XPSSS!F. % &<
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M/YOV@ZG.;@Q^3Y'V?S=V[R/) C\K.W;Q69^VYI=G9_LJ>-%@M88EA@LXX]J
M;%6[@  ] !Q7T!7A'[<G_)J_CK_KG:_^ED% 'NL?^K7Z"OG[]K3XV:Q\'X/#
M+Z7H6EWXN'N+D7^M6T\\*30H&BM8A"I9;B<L51CP-IZ]*^@8_P#5K]!2]>M
M%#P_J4^L:#IM_<V4NFW-U;13RV4WW[=F0,8V]U)(/TK0HHH ^7_VBO\ D[[]
MF+_K[US_ -(17U!7G?CKX+Z?X\^*/P\\;W.H75M>^#);R6UM80ICN#<0^4P?
M(SP.1BO1* "O.)OBAK$?QKA\%#PK>/I#V?V@ZX,^6&QGTQC/R]<Y[5Z/1652
M,I6Y96L_O\CHHU*=/F]I#FNFEJU9]'IV[;!1116ISA1110!%<S?9K>68H\@C
M0OLC7<S8&< =S[5XLO[3]EK'Q'T#POX<\/7^N)?;?M\^UX)M,)8JPF@=-R[,
M;F+;1@C;NKV;4+-=0L;FU>22))XVB,D+E'4,",JPZ'G@UY5\-?V9?"?P[MXS
M(USXAOX+U;VUU'5&#7%LZH$ 1U (! RW]\DDYS0!WOCSP/I7Q(\):AX;UN.2
M;2[Y56=(I#&Q"NKC##D<J*X?7?V7_A_XE\2:_K6HZ9<7$^M12I<VYNY!;K)*
MB1R7$<8.$F98HP9!S\@KUBB@#EO GPUT/X>>'4T;3())X//ENY;B_E-Q///*
MQ:2621N6=B>37RCX(\0ZOX9_X)RZE-X=\\>(+IM2T[3?LI*R"XN-3F@C*D#Y
M<&3.[MC/:OM>O _V&?\ DVGP[_U^ZI_Z<+B@#P2;]D?XL^)M6O=237G\*:)^
MX@LM%\0^*M3N;B-HXE6:<RVMPJGS7!;:2<8S\N2*Z_X9_!_QY\,_B);ZV^A6
MVJ)X>_MR5+JUU2%7U\ZA<0/&@+G<OE+&Y8RGJJX)S76_MI?!R_\ C5JOP:T8
M:-?:SX:C\6I+KZ6<SQ".R\B0,TC(RL%W%>AIW_#N+X!_]"C>?^#N^_\ CU '
MD_BK]F'QYKVH:];V^FZ9#'9W.L7T&HMJ$0&O"\U&VNX[9A]Y-J0LC&3Y=VW&
M1G'4)^S?J^J:3X6UZ\T6U@\26OQ,/BN+3VU",C1M.FNA)*@VMY;2!5!.W)^8
M@'K78?\ #N+X!_\ 0HWG_@[OO_CU<O\ %3_@G7\(+/X9>+9_#'@W4)?$D>DW
M3:8D.LWC.;H1,8@H,V"=^W@\4 ;'[+7P1\>_"GXDZ\^KDGP\ZZ@9+R:[CN%U
M":>_>X@EMU WPJL3E75S\SD$9QFOJFO-_P!FW1=6\-_L^_#G2M=MI[+6K+0+
M*WO;>Z_UL<RPJ'5N>H(.:](H X3X]?\ )"_B+_V+FH_^DLE,_9__ .2#_#C_
M +%O3O\ TFCKMM0T^VU;3[FQO8([JSN8FAG@F4,DD; AE8'J""01[TFG:?:Z
M1I]M8V-O':65K$L,%O"H5(XU "JH'0   #VH LT444 %%%% 'Q;^V-X5N]<\
M?6<_@_\ X16YN-.LI;O7;-M1TZQN[8L-J7EX9T9G@52..Q .#D5];^"2[>"]
M ,EW:W\G]GV^ZZL5"P3'RUR\8' 1NH [$5\F?%K]B[5_$GQ1U#Q;_P )5X+B
MT^ZUN36H;+Q'X?\ M+22-;1P^3/)YR>=$OEAUC/RAN<&OJ/Q)K]WX#^&%_K"
M6/\ ;M]I.E-<"STV/8+IXXL[8E&=H8C@#. >] '5T5X)^RK^TA?_ +0ECK4M
MWI5E NFB$'4-*>9[225S('A4RHK%D"*3QTD7H>*V_%'Q:\5Z1\>+'P-;>']/
M71[[P_?:G9ZI=WA#W%U 8@(RBC]W&#* 6.2>PXY /8*\"_8O_P"2;^*_^QV\
M0?\ IPEJ[\'OC]>>)/ASXL\6>+8[/^Q]!OI;>+7- MKB2TU*&-5\R6WC(:1U
M60O'N4$.8R5XKBOV$_B1HOB+PWXNT&U74H=37Q'J^L>5?:9<6H-K<7LCPR!I
M$53N5@=H.1GD"@#Z=O-/M=16);NVANA%()8Q-&'V..C#(X(]:J^(M2_LK2+B
M9;FTM;EE,=L]]($B:8@B-2<CJV.!S7Q/\2->^,?Q:^*7Q%T_X;ZEXJLQI_B"
MST;39K:YBM=&AA@MU;43+*4=A*S2;5PI((4@<&LCQA\#?C#_ ,(_;-XYTG5/
MB#;JNIV\&GIK*ZN\-Q/8-%:SX:&$(J2G[WS%-V[C% 'TEI-U\:-)@^'[^)]4
M\'VZ_:YHO$KJSH)E8D0+;EL9?'...1W[^R_VK9?;)K3[9;_:H8Q++!YJ[T0]
M&9<Y ]SQ7QM\=/ ?C'Q;X1\':5>^"]:\5/X=T&^T&[ C1UGU6?384M[Z++?-
M&DOF*9C@HQ)QWK%\-?!7QMHWQ&GF\0^"K_Q+<6C:K=:WJ$;1[-?T^;3K>&WL
M4F9QO82HW[ML!=F<_-R ?<MC?VVJ6L=U9W$-W;2#*30.'1AZAAP:L5X3^R#X
M3U7P?X'\2VU_HMUH=A=>(KR^TR&_@6UG:VDV,"ULA*0 -N0(O!"!L L:]VH
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MOVMO@L/'^E^&-/LUCU_^SV\/WD\\CG[*F?-$J*!\NWIGG-?6M>$?%S_DZ?X
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M42>X5<"1P "V/<U>HHJDK*P'->-/B/X;^'JZ>?$.JPZ8+^;[/;^;GYW_  '
M&1DG@9KI P8 @Y!Z&N+^)FB^!M731O\ A-DTUECNU-A_:$@3]\>@7)&<\9'3
MIFNT4 * !@=L5E%S<Y)M6TMW^?Z'74C25&G**ES.][[>7+^HM%%%;'(%%%%
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MP:W:N+S7+U[RZ<MI]N2&E;D@= .PH ]ET_PWI>DZIJ>I6=A!;7^J.DE[<QH
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M(4444 ?&/[=&BZEXD\9:1;P>'M9UVUL?#UY?0MX?L=.FEAO!(HB:Z:[R?LN
MVY5 &<Y/2O</#?Q66']G,^-]<\*ZA8+H^D-=3:3/:11R2^3%DM#&C,HC?&4P
M?ND5X%^TM8^ ?CYXTNK/Q/<:]ID_AM-9TRSATI8$\^:UM8;R6661LEXBC*H@
M?Y&8$L*^AM4L/%?C[]GW28_ ?B"S\+Z_J&D6DEMJ-]IJ311J\2D@P*0JY!Z#
M(7L"* ,;]G'X[2_%RY\0Z=?:#I6CZGI<=I=/)H.J1ZE9RPW",\8\Y%4"50IW
M(1QE2"0PKU[7]"L?%&AZAH^IP?:M.OX'MKF L5$D;J59<@@C()'!KS3X!_"7
MQ)\*X=8CUS6M N[:\:-[?3O#7A^/2;6!P#YDI568N[DC))X"C KUN@#E_AW\
M,_#GPI\/IH?A:P;3-)C(\NU^T2RI& H4*GF,VU0  %&![5Y5^QB2?ASXL)Y/
M_";^(/\ TX2U[[7@7[%__)-_%?\ V.WB#_TX2T >^T5YEXU^/7AW0]'\<)X>
MO+3Q;XL\+6$MY<^&M.N5>[RJY"E1DCG&< D>F<"O!;GXN?%?XZ?"W[;X6MI?
M^)9KIM-1OO 5PL;ZE;FUWQO927R* $G=$E##.$?:>HH ^N=;AU"XTJYCTNXA
MM-09<0S3QET4YZE<C/%>9>,H/B+HOA?4KV;QAHEFD,18S-9F+;]&).#VZ&NV
M^&L?B6'X>^'$\926\OBM;"$:H]KCRS<;!YA7''7/3CTXJO\ %>QN-2^'NM6U
MKI$>NW$D.$L)"0)#D>A!R.O![5RXBGS0E)-W2Z-_H!RGA&W^(NL>&=.O(O%^
MAW:30JPF6R,@;_@0(R?P%>E:1'>VNDVZZI<0W%ZB?OYX4\M&/<@$\"L3X7V4
M^G> -%M[G28]#N(X 'L(R2(CD^O<]3GUK;UW1X/$.BW^EW1D6VO('MY#$VU@
MK*0<'L<&E1@XP4KMNW5O]1QM=<ST/.?CUXPU_1OAS'JO@O6=&M+AKN-#>:A/
M&(60D@A68[2<X_ &NSL_%VGVDVBZ5JNK:?'X@O[99$M8Y@//8*-[1@G)7.<5
MX5XO^!7PC^$?PUM[?QA>:E-I:W0"32W4I9I6)(VQI\HX!R0O3/->A:%^S_\
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MP<XKU/2)=<D\.E]4@M(=9V/^ZM)"T6[G;@L/I6S113HNF[\[?J"T=SX(\;?
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MG$PN$V&7.-F<XW9XQUS7C/[<G_)J_CK_ *YVO_I9!0!K?M.>%_B;XF^&+_\
M"J/%,GAKQ/:N)O+CMX9&OH\8:%6E^6-L$LK?W@ < DU\N77[%WQU^.G@W3+C
MQ]\79[:YM+BYBLM(U[0[2[D@M) $$TIB;;]JVC*L"VS/#9S7Z!1_ZM?H*\&_
M:J^)/Q%^'MMX?/@;3YI(;G[2UQ>6^C2ZJQN$13;6ABC93&L[%E,QX3;[T ?-
M(;]H7PO\>-+^&$7QJU*[LH;VTLT,WA>%KNXL3;>9)?!]AC,2.OE,6?>6SWQG
M]#U!50"=Q Y/K5'P_=7U]H.F76IV:V&IS6L<EU:*^\02L@+QANX#9&>^*T*
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MUE>*O"VD^-O#NH:#KVGPZKHVH0M!=65RNZ.:,]58=P:\7_X:/\>?]&]>._\
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M=_\ 8[*:7=#;8254C*\MA"0-V.U)^PBLD?[,/AA9I!-,MUJ0>15VAV^WW&6
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M?&'B#1[87>JZ7I-U>6L!4L'ECB9E! ZC('% '7UX%^Q?_P DW\5_]CMX@_\
M3A+7/_"GX]>,?^$$UJZ31M4^,+6.M)86VHZ$+2&2:%[.&=W;+QQD1R2/%\O/
M !&037+? 7X@?$KX3^%=:TO4/@)XSNIK[Q#J>KHUO=:>56.YNGF13FX'S!6
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MC+IPQ'8BN)_:&_:(L_@SIRV5DD=[XFGA%R$F21[73K7S%C:]O3'EX[968 N
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M&VIZY;ZO_P )#X>\036=KK'@_4Y6AMH[:( +=V<RY:&[B?\ >*ZX#?=." U
M'F'P+^*GC#XE>/!HVN?VEXX\(>)Y=0M]2M=3TD?8(+8&0Q3P2! (P,"VFM)_
MWBR#(R.OUA\/OASHWPS\/VVD:/',T%O$+=+B\E,]P85+&.)I6^9DC#%4#$[5
M %0_#+X9Z7\*O#\^EZ7<7]\;J[EO[N^U2X,]S=7$F-\DCX&6("C@#I774 >4
M?'CXY6?PELK;3UM-4N];U6SO)K1M-L?M?V5(4!DN9(]P+I&71F1-SD9(4@&O
M"?V?]4UWX\:9J7@3XB6NJ^+_  IJ.CI?S:EJMJ$-E>;U -K>1*L<\,H/GP21
MXDCVE6P0*DU[]F?5K?XU:7I%M8:UK^F:G -8U#QQ/JLEM-IE^EU*?M$##.VX
M,,B0JB (R+\XP*^JO 7@?2OAOX/TOPSHD<D>F:=%Y4(F<NYY+%F8]26))]S0
M!;\.>';3POI<5E:!GVJOFW,V&GN7"A3+,^ 7D8*,N>2:U*** "BBB@ HHHH
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M_#_P_::1I:S/#;0I +B\E,US(B#:@DE;YGVKA06)(  KH*** "BBB@ HHHH
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>morf-20221231_g13.jpg
<TEXT>
begin 644 morf-20221231_g13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $D JP# 2(  A$! Q$!_\0
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M .!B?XT_95/Y7]QK_9>8?] \_P#P&7^1W%%</_PO#X?_ /0XZ-_X&)_C2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9 O-8)'!QK-UQ_Y$I?\ A7VF_P#/WK/_ (.;O_XY1:G_ #/[O^"%Y]OQ_P"
M=-17,_\ "OM-_P"?O6?_  <W?_QRF?\ ""Z09/+%_JQD_N?VU=9_+S:+4_YG
M]W_!#]YV_'_@'4T5S/\ PK[3?^?O6?\ P<W?_P <H_X5]IO_ #]ZS_X.;O\
M^.46I]W]W_!"\^WX_P# .FHKEAX%T@R&,7^K&0?P?VU=9_+S:/\ A!=(\[R?
MM^K>;MW>7_;5UNV],X\WI2_=?S?A_P $?[S^7\?^ =317,_\*^TW_G[UG_P<
MW?\ \<IDG@72(6027^K(9&VH&UJZ&X^@_>\FG:FMY/[O^"+]X]E^/_ .IHKF
M?^%?:;_S]ZS_ .#F[_\ CE'_  K[3?\ G[UG_P '-W_\<HM3[O[O^"%Y]OQ_
MX!TU%<S_ ,*^TW_G[UG_ ,'-W_\ '*/^%?:;_P _>L_^#F[_ /CE%J?=_=_P
M0O/M^/\ P#IJ*XC5-''A.^T:YT^^U']_?);30W5]+<1R(X;/$C-@@@$$8KMZ
M4HJ*33T8XR;NFM@KQ#]I;X3^+OB)=>!-7\&3Z;'K'AC5O[22/5"PBD^48'RC
MU'ZU[?12A)PES(SKT8XBFZ<]G_PYXCX);]H!O%6G?\)4O@Q?#_F?Z8=/,WG[
M,'[F>,YQUJS\-O@2VB:;\3]+\3?9M1TOQ=K5U>+#%G_CWE  #9'#=>G3&:]E
MHJW4?16,(X2"MS-RM?=WW5CPSXC?LX6]Q\!=.^'/@D0Z=:V%]9W,7VQR<K%<
M++(68#)8X//K6=\9/A3\1[KXT>'_ (@?#Z;0VN;#1Y-+E@UHN%^:0L6&WV(_
M*OH2BB-:4?/?\15,%2FK+3;;2W+M8\=^'MO\:K[5+VW\>_\ "*QZ++9R(AT?
MS3-YQX7[W&W&<_A5K]G+X1WGPI^"FG>#=?>UU"XC^T"X$(+1.LDC';R.1M//
MUKUBBE*HVFK6+IX6$)*;;DTFM7?>W^1\J2?LQ^.=)^%?CGX::)KEE%X4U/5H
MI-*:9V\ZVT^1]UU">.HZ+ZY/K7MNF_ 7X<Z;I]K:+X&\.3"WB6(23:3;N[;0
M!EB4R2<=:[ZBG*K.74BG@:%+97TMKK97;LOO/F*\_9=UZR\#_&7P;HM[I]KX
M;\43)>:':G<HLY6*M*A &%0E1C'K2>&]$_:>\.Z/I>E02^ FL[""*U3>LY8Q
MHH49(/7 KZ>HJO;2V:3,O[.I)IPE*-M-';2[?ZGS#XL^$?Q@T#XZ^)/'G@"Y
M\,M'KMC:VL\6K^82AC10=H7W7.<]#6QX*^ GC3Q-\2-)\>?%SQ%8ZQ?Z*&;2
M-$T>%H[.TD;K*V[EGX&/P],5]#44O;2M;Y%++Z2GS-MJ][7TO>][>H4445@>
MD%%%% !7P7_P49_Y';PC_P!@^7_T8*^]*^"_^"C/_([>$?\ L'R_^C!7KY5_
MO4?G^1^K^%__ "4]#_#/_P!)9\ATY<[2<<#K3:WM!\::EX>T'7-(M/L_V/68
MTBNO.MU=]J-N&QB,H<^E?<RO;0_M>K*I&-Z<;NZW=M+Z]'LKNW7;3<Q%ZUM7
M?@_6+"":2:S8&#;Y\2L&DAW?=WH.5SD=?6L[2[]])U.TOHE1Y+69)T6094E6
M# $=QQ7>^&?%FA:3XO;5[>2\\[49U22.[ V6J/*ID9I <R8 ..!COG%<M24H
M[(X,96KT=:4.;3[WV\M+ZZ_H^&?3[N&:.*2TN$ED^Y&T3!F^@QS4BZ?=_O/]
M$N,1'$G[EODXS\W'''K7J-Q\5--T_6]65)KS64O+RZE34+Y1(]DK[E7RAN^8
M<Y."N1C&#S4+?&"+SM)C7[8;2UU6*[N54",74*1)&590>2=K<,3P>2:X)3F_
MLGEK'8^5K8;I??\ X'RU]=CS^'1+V338M0CMVDM9;@VR&/YF:0+N(VCGISFK
M<'A?59+'[8+&?[.LIA8^6=RL!NY7&0,=^E=+X/\ %]MI_A.YT:07-K)<7$KC
M4+8 R6X95 *#()/&#@C@]:[6[^)VF75KI\"7VN0&QFMI?/RI>[$46PJ^",;L
M=\@#J#7!5E*]K'+B<?C:51PA1NKO77;IM?\ K6UCS;2=#N;V2WAM;=W-Q((H
MY&4A&8\ ;CQ5RWT6\FBO9(X2Z6;K'-M()#,Q55 [DD'@>AKO8?BU8C[-*MD;
M7RUCC:QAA78-K9,F\GJ0.@4'))SCBJ'@?QA:>'Y+S4)&99(M7M-02)2/,D1&
ME+ 9[C<OYUYE1L\Z>,QO).;HV:M97O>[UU].NW78Y$6-RLA0VTX<<E3$P('T
MQ6I:^%]5NX8I(+-YA)MPJ$%@"Q4,5Z@$@C)]#5FX\=7$FGZ:BEI[V%95GN+H
MES)N?<@SG/ S^?%:WA/X@:?X8M[IO*GN&O@%N;<JH5'^;]ZC]3P>$]>IKRJH
MJ]7&1I.5.G>5]N^ORMIJON.;NM+N["Y2WEA8RNHD3R_G#J>C*1U'N*:UO/"I
M:2WFC7=L+/&5&[^[DCK[<FMJQ\9VVCZIHS69N#!I5E+:PR[0LSLY=M^ <)\S
MG R3@"MG3OBBEI);&]6YNTAL+6V\II Q\Z,_/+ELC<03ACD^M>-52[F52MBX
MKW:7-\[7U?3II9^5[=#F8]*O&BED:!XO* .V92CODX&Q2,M^ XJ-HY89-DL;
MPO\ W95*'\CR:]#T'XL6&BZ7:6D5QJFH/;;V^VW1&[+.6 &22 ,CN><US$'C
M*!=6\/W\\,M_-80M'/).V7D):0A@3GE0XQGNHKQ,1&/<Y:=?%SE/GHV2O;7?
M1VWVO9;]_(S8[.Z,@C%I.7(W;6B9<CUQC)JY)I=[;V5K>-;NUO<*[1S;?E 5
MRC9'\.&!'-:]KXHM_LMS9MK.L/YJJ3JC8\Z+#9V*-V=I[_-U .,<5L77Q0BO
M+RU9;:9+"."\26RW QRO*6*,PZ'DJ3[YQ7@5HT[.\CGJ5\5S)0I76M]]K:;K
M=O3RZ[HY%;>>,KB"9I'&X-Y;<CU7CGZU<NM)N=(N1%?1-#)L27:W4JZAE_0C
MZ5U"_$*-;?6EM9KUKC4ED:.24@?8=Q4^7&<], C(QQCC/-9'B/6K;Q#,+LR7
M372QV\")*=RA$A56).<Y+#@>]?-XNG2C%N,KO_A_^ 84ZV(G4M.GRQ_'I]RW
M^Z_K2LXI-1NH;>$*TLKB-%R ,DX K6MO#NH213R"W8) [HY)'5/OX'?:.N.E
M16>O7$D]B]WY<D5K/')Y@B42;58'9D 9'%=##XKM9Y#/Y,JSP2W3V\2@;'68
MDC>>Q4L<]<CCBOF:E.C*_/+^OQ_X.QR8BIB(Z0@OS_RWT]-S C<)]SK_ 'CU
M_"O<?V54*^.-2+'YC9=._P!\5X?#A,+'\S_WO\*]P_954+XXU+G<WV+GT^^*
MY^'?^1WAO\7Z,^8XH_Y%&(_P_JCZHHHHK^I3^8 HHHH **** "BBB@ HHHH
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MQ<'B"<31:0\6DF[M[(7<EP/,,LT:.H\O;T!< G=[UZ'7J--;GF)WV.8\<_\
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M(W\@.Y_&LTKNQT4Z;J2Y4>9W/Q>L]?\ C]I7@6'2K^"ZTSS[J:]N$"1/^Y8
M)R=P.[.?8UZIX@URV\-:'?ZM>EQ:6,#W$WEKN;8JDG [G KG-2T>UTGQ!X/C
MAC!=;J?,S\R.3;R%BS=22>36_P")M#'B30[K3'F,$=R CNJACMW LN/< C\:
MZ:S@^3E5E;]6:XFIAZE1_58<J22U=[M)7EY7WMTV.9\5>(/!^H7.A1ZM+YCW
M5M-J%E-&TB%(50%WW(00"K 8[YQ5636_"VBR'4+GP]<:;-!;'[.TMJJM/&H;
M*Q@,<G#L<'!^8^]/;X.V,S/YU_<2)Y[- -HS;P$'$*'L QW ^RC&!5S7_A[<
M^++-;;6-76ZCCB9(Q':!!O8;2[#<=WRDC' Y)K+W=KG'J8]KJOA7[9)HL'AN
M_-]<N1/:>4#) (Q&X)8O\@'FHRA#QDX -;MQJ7A_P1J4-I%82I(L.^6>",NL
M$3OC?*Y.<%L\\G@DU1TGX/:1I=SIRE8;G3--^T_8[&6W4B(3-&V-V<DJ4.#U
MPV.U6]4^&\=Y-<BVU*XM[6\@%M=PS%KAI$WECM=V)4D$CN,'@47CW#4SY;_P
MQK5E>/'H-Q?6>DS21&2!4"D[SY@'SC*;@2P;@XZ&IPOA>Z\/6.J'1)+>/7)8
M4CC>(Q3[Y'8H3@Y0@LQR#QDTV;X:_:KN3[9K0<W$"VKQPVZPM- )/,=6P?F9
MN 6 '!;CYN-[Q5H]SJ,>C"RCC/V348+AU8[0(U)#8]P#TI77<-3('B#P]9I;
M^3HLTEU87<VG6EK%:J9@VS=)Y?/W2@R3D9 ]:R],\1>!;2Z6[@M!;V@E.-4D
M3%O%,B,QB#%OD*C>=H 4'/>M^;P-(MT;RTU(V]X-0DOXY'@#JN^,QLA7(R,'
M.<CG%<Y-\#X)/#MQH2:M)'I<TLMT8_(!?[1(C*[EMW*Y=FVX].::Y>XM>QTL
MFJ^$O$5RRR7%E=SW$?V9MYY*_?"G/0_Q#H3C(Z4_19?"VH6L^AZ?):7431F:
M6UW;S(C''F'=RX)_CYSC@\5G>)/AC;:\NI9N&C%X\,CQQH%)\N)HPN[MD-U[
M8J+P?X;UN'Q+'JFK+'#';Z6NGQ1JJ!B=X8G*D\#:!VZ\"EI;1CUN5O#%UX.U
M[2;^>WT:6**"U,LHO(\R2029._)9B=WE=SGY1T&*GU2X\,SV>@8T&ZU+^TXW
MO+6&VC^<H55WWY<<'<N5)()Z@U'X;^%)\-Z=-:V.J0QQSVRVLQCL@HE4%]S,
M _,AWXW>W2M"U\"W]D^B-#K,8.D6QM;?=9YRACC0[OGY.8\\8ZX]Z=U?<->Q
M?L=/\/\ B31_M$-HC6S322LN#&Z3#*/G&"K#!''IQ7.^&9_!_BRUCM8=&FT^
M)[9=0B^TIY+20X"^8&5B<8P#DC.><\UU'A[PW/H,,D)OQ<Q3!I)2T.UWG=B7
MDR&P!R %QP .35+P_P##^T\,>&+31K 6T2K&D-Y-]E :[0+A@V",%AGG)QFE
M==QV*5AK/AR::W6/2)K:QN[F*2WOGMPEO-,H58BISD'"J%R!T'M73V>M0WFK
MZAIRHZ3V?EEMPX=77(*^W4?45ACP1=O9V-A/J_GZ;8R))#$;8"0^608@[AN0
MI S@#..U6?#^BZA:^(M5O]0>.5I(;>WCFB&T2A%)9MF3M^9B,9/2D[!J,\<_
M\P#_ +"T'\FKIZYCQS_S /\ L+0?R:NGJI?!'YD1^.04445D:A1110 4444
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MU!+B2_A$7$]PVX0R=>BH^".Y13VK;'@G58?#]_H,-Y:#3+TR!Y'C8S(DI8S
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MLP)/  )P>.*VM'\>236?BB]U*T-K9:3>M!#)&0YGC"(P( )^8E\8XZBKUO\
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MXNUCQ)\+M<UVW273S+MCL8@A650K*CL<>K[\8_A />NON/&%@UEI36D,U_\
MVK$9+6*!<%D"ABQSC;@$?B15#P_XSTF;3HH=$T^YETVT6.*3R8P!;9 (0@G.
M5&"P[ CK2OY#^9C^(/$&K>'+[['%=V]AY$"36UJ8FE_M*1G8-$K,=V0 O"\_
M-GIBN(\">)M;L[S48;O4YM)LYILOJ5\IE6!E!VQ#><#=D\_[&!R:]57Q_:-#
M97+Z?>I97DT<-M=-&-KM)(L:D\Y7)8$<=.:?H_CRPU_Q)?:):VMTT]F7$\SQ
M 1*5;;C.>22#CZ4[Z;"MKN<'=?%+Q5I'E/=:29HH474;KR[=MTEHP,:)$/\
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M (Y73;AZT;AZT>T?9?<@]FN[^\YG[)XP_P"@EH__ (!R?_'*/LGC#_H):/\
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MYG_A6OA;_H!6?_?NC_A6OA;_ * 5G_W[KIJ*/;5/YG]X>SA_*CF?^%:^%O\
MH!6?_?NC_A6OA;_H!6?_ '[KIJ*/;5/YG]X>SA_*CF?^%:^%O^@%9_\ ?NC_
M (5KX6_Z 5G_ -^ZZ:BCVU3^9_>'LX?RHYG_ (5KX6_Z 5G_ -^Z/^%:^%O^
M@%9_]^ZZ:BCVU3^9_>'LX?RHYG_A6OA;_H!6?_?NC_A6OA;_ * 5G_W[KIJ*
M/;5/YG]X>SA_*CF?^%:^%O\ H!6?_?NC_A6OA;_H!6?_ '[KIJ*/;5/YG]X>
MSA_*CF?^%:^%O^@%9_\ ?NC_ (5KX6_Z 5G_ -^ZZ:BCVU3^9_>'LX?RHYG_
M (5KX6_Z 5G_ -^Z/^%:^%O^@%9_]^ZZ:BCVU3^9_>'LX?RHYG_A6OA;_H!6
M?_?NC_A6OA;_ * 5G_W[KIJ*/;5/YG]X>SA_*CF?^%:^%O\ H!6?_?NC_A6O
MA;_H!6?_ '[KIJ*/;5/YG]X>SA_*CF?^%:^%O^@%9_\ ?NC_ (5KX6_Z 5G_
M -^ZZ:BCVU3^9_>'LX?RHYG_ (5KX6_Z 5G_ -^Z/^%:^%O^@%9_]^ZZ:BCV
MU3^9_>'LX?RHYG_A6OA;_H!6?_?NC_A6OA;_ * 5G_W[KIJ*/;5/YG]X>SA_
M*CF?^%:^%O\ H!6?_?NC_A6OA;_H!6?_ '[KIJ*/;5/YG]X>SA_*CF?^%:^%
MO^@%9_\ ?NC_ (5KX6_Z 5G_ -^ZZ:BCVU3^9_>'LX?RHYG_ (5KX6_Z 5G_
M -^Z/^%:^%O^@%9_]^ZZ:BCVU3^9_>'LX?RHYG_A6OA;_H!6?_?NC_A6OA;_
M * 5G_W[KIJ*/;5/YG]X>SA_*CF?^%:^%O\ H!6?_?NC_A6OA;_H!6?_ '[K
MIJ*/;5/YG]X>SA_*CF?^%:^%O^@%9_\ ?NC_ (5KX6_Z 5G_ -^ZZ:BCVU3^
M9_>'LX?RHYG_ (5KX6_Z 5G_ -^Z9+\-_"Z\#0[($_\ 3/H/6NF>0)QU)Z =
M:KLVXY/)/^<4>VJ?S/[P]G#^5'-_\*Y\+_\ 0"L_8>7V[?G2?\*Y\+_] .S/
M_;/_ #_^H5T><]\TF?\ /^?\XI>VJ?S/[P]G#^5'.?\ "N?#'_0#L_\ OW1_
MPKGPQ_T [/\ []UT7^?\_P"?2EZ>W^?\_C1[:I_,_O#V</Y4<]_PKGPOWT.S
M'_;.E_X5OX8_Z 5G]/+_ $_QKHUS]#_7_P"M3EYV[>IX7V'<T>VJ?S/[P]G#
M^5'.#X;>%SD?V'9#^\WE]/84Y?AKX7D.?["LP@Z#R^M=(JB3Y1_JU_4TYF+L
M40XQU;TH]M4_F?WA[.'\J.:;X<^%MVU=!LF;_KGTI5^&7A<?>T.S8_\ 7/BN
MF50BX IU'MJG\S^\/9P_E1RR_#;POYCC^PK/''_+.DNOAKH'V>3[%8IIEU@F
M*ZLR8Y(V[,"#Z]CP>]=,G^MD_#^5/;[I^E/VU3^9_>+V4/Y48_@W59M<\)Z/
MJ%QCS[JTBFDP.-S*":TUW1?*$+#L0:Y_X9_\D\\-_P#8/@_] %=-4U$E.27<
M=-W@F^P5RWBC_D;O!O\ U]W'_I++74URWBC_ )&[P;_U]W'_ *2RU5+XGZ/\
MF*I\/S7YHR_%7Q@TWPMXP?PY)87ES?1Z9)JSO$$""%-^< L&<Y3!"*V,C/6H
M/!_QU\*^+/#VF:D;S^SY;P6B-:7".'AEN$+Q1D[0.0K<].*/'?PCL_'WBC3M
M4O\ 6KF*'309([.-8\1R%'7>KXW*&#?,N<-M7/2N9T_X ^&(A870\027.BZ=
M!;17MOOC\J>6TA>*.21Q]PJKMN4$#(&<8HM"WF/WKFUIO[1'A+5O&T>@6UT7
MAE@CDBU$HZPR223&)(URO(8J2'SM..#7<Z9XLTO6M#FUBPNA=:=$909T4A3Y
M;,KXR!D J1D<'%>)ZM^SVNK>%=9M]'\4/K\[:3#X?T];B2-$T^&.998V#QC<
M9(Q@@GDX7IG->H:QX=M/"/P@U+1;!/+L[#19K>(=\+"PR?<]3[FGR1FU&#LW
MH:44YS49;,\7NOVO+V:ZD;3]"M6LRQ\II9F+,O8G'%(O[66LM_S K'_OX]?$
MGP_^(,^C^$=.M%\-:K?+&I GMX\HW/;BNF7XK77_ $)NN'_ME_\ 6K\LS')N
M-L+CJ^'I3YXPE)*7-1C=)M)\KE=7WL]MC^BEPWDZBK4%]\O\SZZ7]JS6&_Y@
M=C_W\>I5_:GU=O\ F"67_?QZ^1E^+5TO_,EZ[_WZ_P#K5*OQ=NAS_P (3KQ_
M[9?_ %JY8Y;QQU_].4/_ )(S?#>4]*"^]_YGURO[46K'_F"V?_?QZD7]IS5F
M_P"8+9_]_'KY(7XP7?\ T)&O_P#?K_ZU31_&2['_ #(WB _]L?\ ZU;QRSC7
MK_Z71_\ DCG?#N6=*"^]_P"9];+^TMJK?\P:S_[^/4J_M(ZH?^8/9_\ ?QJ^
M2D^-%X/^9$\0_P#?G_ZU3+\:[P?\R%XB_P"_/_UJZ(Y7QGU_]+H__)&$N'<N
MZ45][_S/K1?VC-3;_F$6G_?;5*O[0VIM_P PFU_[[:ODQ?C=>_\ 0@>)/^_/
M_P!:IH_CE>C_ )I]XE/_ &P_^QK>.5\8=5_Y/1_^2,)</8#I17WO_,^L5_:
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MU=SKZHL1]KFY>7FAM9.]^:V^EM^I3R!^RY^17O:UUVWO<^P?^$TG_P"?>/\
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M_:_6K"E^/O?K7UK]D@_YXQ_]\"C[)!_SQC_[X%:KA!K_ )??^2_\$R?%2?\
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M7M)KS5K0WUC K@O<6X )D4=UPPY]ZWMH]*Q^JVZF7UA=C#61_P"\WYTX2/\
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MC^Q,S2W\<P?@,VR/E\X(;+'!SQ0!IV?PQELYK7RKR )$Z,S",[X]LK2?N\'
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MO;V4ZZ_9Z1-:W.L_;E,4ZO"ZK&7W;]Z$JH&W:W+DY KHA=+25C&6^QV/@/\
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M'P]\-K&NX_V?#GT'R"ND\DMRTC9_V3@5K6_B2]69T_@CZ(FKEO%'_(W>#?\
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MT/$O_0#TO_OJ3_&C^Q\7V7WH/[4PW?\  ^P:*^/O^&T/$O\ T ]+_P"^I/\
M&C_AM#Q+_P! /2_^^I/\:/['Q?9?>@_M3#=_P/L&BOCW_AM+Q+_T ],_[ZD_
MQH_X;2\2_P#0#TS_ +ZD_P :/['Q?9?>@_M3#=_P/L*BOCW_ (;2\2_] /3/
M^^I/\:/^&TO$O_0#TS_OJ3_&C^Q\7V7WH/[4PW?\#["HKX]_X;2\2_\ 0#TO
M_OJ3_&D_X;2\2_\ 0#TO_OJ3_&C^QL7V7WH/[4PW?\#[#HKX\_X;3\2_] /2
M_P#OJ3_&D_X;3\3?] /2_P Y/\:/['Q?9?>@_M3#=_P/L2BOCO\ X;3\3?\
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MZ*^./^&U_$W_ $ M+_[ZD_QH_P"&U_$W_0"TO_OJ3_&C^Q\7V7WH/[4PW?\
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M7]MSQ.K,W]@Z62>^9/\ &C^QL7_*OO0?VIAN_P"!]EB(L=TASZ+V%2U\8?\
M#<'B?_H Z5_WU)_C1_PW!XG_ .@#I7_?4G^-']C8O^5?>@_M3#=_P/LR238O
M RQX HCCV9).6/4U\8_\-O>)_,W?V#I9.,#F3C]:Z+PG^W&LEXD7B3P^L%LQ
MPUSI\A8I[E&ZCZ&IEE&,BK\M_FBHYEAI.W-^!]7U'))@[5&Y_3T]S7$Z/\7-
M,\2:9!J&DZ;K5]93C,=S#I[LA%7H_'D48XT'7R>Y_LY\FO-="HG9H[E5@U=,
MZF./;\Q.YSU:D>7:VU1N?T']:Y9O'ZR<#0?$"C^]_9KYI5\>0Q+A= U__P %
MKY-+V-3L/VD.YTXB_BD.XCGV%)YC2\1\#^^?Z5R__"=1R'+Z#K^/[G]FOC\?
M6E;X@*W":#KZC^]_9KT>QJ=@]I#N=/A(3D_,Y_$FD96D4E_E7'W0?YUS*^/(
M8^1H'B L>_\ 9SDFHKCQI=7T+QV/A_6'NV4B*.ZM3!$&[%W8X '>CV,^P>UA
MW+'PUD)^'OAM8US_ ,2^'YCT'R"ND^SJW+L6;USBLWPSI;:%X=TS2XW$OV.V
MC@,N."54#(_*M+[/&?O_ #MZL:FHU*<FNY5--029-1116984444 %%%% '(_
M%GQ<_@;X=ZYK,/%Q;P$0YZ>8Q"K^I%?G9<74EU/)//(TTTK%WD<Y9F)R23ZY
MK]!?CGX9N/%_PI\0Z;:H9+IH/.BC7J[1L'"_CMK\[O,_#ZU]KD2A[*;6]_PZ
M?J?*9PY>TBGM8L;J-U5_,I/-KZ8^?+.^C?5;S/>D\WWH&6=U=CX>^%NM^*/#
M3ZU8O9F(&81VLLX2>;RE#2%%/W@ <UPOF5Z+:_%J71_!'ASP]I5U<6<<;SMJ
M[+$NZ19)%XC?KC8"#TSG%<]9U4E[+>YM15-M^TV.9M?#5_=:/>:BL?EQVSQH
M89 5FDWD@;$QEAP<XK/DL[N%7,EI<1A,%B\3 +GIG(XKVRW_ &A-)_MZ^U&Y
M?4IO^)J]U9KY:_N[=+9X[9,;N"'?)'X\UF3?M "^T);+4+J_U%F\/_8;B.9%
M*7-ZTH9I'.>0%&T'MZ5S1K8B^M/MU_X!T.C0MI/^OO/)A97;1JXM+@HWW6\I
ML-GI@XYI&M+E)%C:VF5WY56B8%L=<#'->_Q?M%>&K6Z:X6[UZXAFOK>Z&G3P
M1B"RCCC;$,.&&0'V<^@KCV^*DMK\+Q<7=U'?^+;RZNH;*[,V^XL[67;YQ8?P
MEB,+WY)HCB*SWIV^?_ Z=0E0I+:?]??UZ'(>&? ESXFT>]U3^T]+TJQM95@>
M;4[D0JTC D*N1R<*:YZXM;BV4O)!*L6[:)3&P1O3!(P<UZ#X%^(VB>'_ (9Z
MCH4]Y>6.JW%X]R)(=.BNHY$\K8JDR'Y3DL<@9%=)>?M":5<2-#-;WFHZ5!-I
M?V73[B-1&L=NO[TXR<,S=.N:;K5XSDE"Z^[MY"5*BXJ\K,\N7PCJK>&Y=:-L
MZ6L=TMGY;(PE=V0N"JXY&!UK*:UNEN! ;:<3MR(C$V\_1<9KZ'T+XT>'K[4K
M4?\ "1ZU.-/;4-3>\U9(HY,M#LBBA&2"P+'"GTKGE^.F@-<I;R7VO,T>EM91
M^*6AC;45=I1(2$S@#'R#G.#6<<37;:=/\_\ +_@Z[&DL/1LFI_U]_P#P/,\G
MMO#M[=:/>Z@@4+:31P/;L2)F9\XVIC)Q@Y]*ETWPIJ>J6.K7<<#11:7 MQ<>
M<K*=K,%&!CDDD5ZY%^T-X>BU+[<EK?K=1W+SI.\:M).RV9AAED((&\NQ8\<>
M]9-]\=K+4_#+Z=<:AJXO+JPT^RN[Q$7S&\N1VG?.>20P SU QQ3]MB'_ ,N^
MW_!)]C07V^__  #R+RYO.\GR9/.SM\K8=^?3'7-:^G^$=5U+2=6OX;9]FF>7
MY\+(PE^<X7"XR:W?!_Q*M-#^(^JZYJ5SJ%['>QSP)JFU#>PE\!+@#[OF  <>
MYKH+/XV6V@W&NRV&O:]J-W>"Q2'4KZ-%G*12;I%.T\#;P.I/<UM4J5EI&/;\
M]>G]=C.%.D]92[_\ \MAM+JX#F*UGE"G#>7$S;3Z' X-)):W,4/G/;3)#_ST
M:)@OYXQ7O6B_M#>&;/6S>"XUS1[6'5;N]^RZ=!&8]0CF)*^>">&7I@9XK(D^
M/NF76FKI4OVRYTP:/#:)97$:^1]K2</O;DX&WC=U]JS6(KW_ (7X_P# -/84
M;?Q/Z^\\<DM;J&-7DM9XT;&&>)@#GI@X[TC6MS'<) \$L4SD!8Y$*L<G X-?
M3WC7XI>'_"^FV6H2Z]_PEC7&OPZFNDO/%-]DA6-@439P I8%=V.0.*\B^+GQ
M:L?&FJ:#)ILUW<1Z;(9C>7D"Q7&XN&V@AB2HQD9/7IBBCB:M9K]W9=_Z0JN'
MITT_?U[?TSF/&'@K5?!&L2Z;J$0>>)4+O;Y>-2P!"EL8W<CBL8V5V)C";2X$
MP&[R_);=CUQC.*]LU[]I+3]0U:PF0:E>6,6N/J$UM.JC=#Y*I'C)(W(P+ 'C
M(%07/[0&EV,-RMAJ&MZAJ*Z/>VEOKU_$BW;33.C1J<'A$VG!R>O2IA7Q/*N:
MGK_7D.5&AS/EGH>+RVUS I>6VFB0-M+21,H#>F2.OM6KJGA/4])T/1]7EA\R
MRU2%YX7A!;:JN4._ ^7D5Z!XV^.UIXNT'Q)IL\]_<17NGZ?':1S1KM2[B.;B
M4\\%O[W)/M5WPI\<M!T'P+X=T^:[UIKG2[&YMI]'BAC^PW[2LVWS&)S@!AV[
M5;K5^52]GK?;RM?MWT)5*CS-<^EM_G_EJ>._9;HP>>+:<P8SYOE-LQ]<8I?L
M=YYRP_9+CSF7<(_);<1Z@8SCWKV=OCUH+^%;^V6\UJVN+G2H+&+1Q;QM86DL
M;*3(AR"<[2>1W.<UH0_M&>&%\57^H/'J,4E_I\,$VJP0?O4F21F;RXF<[$8$
M @,.1T[5+Q%?7]U_6GE_5M"O84=/WAY'I?@;4M6T-]5C>WBM5,ZD3R;&W0HK
MNN/7## [U@S6MS;A#+:SQ!SA?,B9=Q]!D<FO8&^/6AW/]MO-;W,<MZ]_L\FW
M10PFABC1F ; 8E"6QZ]ZU;K]IC1[O7KN\OH+[5K2/6K6^TZVNHEQ;P) 8Y ,
MD[6WG<!SG'6DJ^)3UIW'[&A;^)8\'N(Y;639/%)!)C.V5"AQZX(K2T/PUJ?B
M'5M/T^UM)A+?3+##))&RQEF. 2V,8]ZZGXS_ !2T[Q[J&CM8-<7T-BK%KC4(
M%BEDW/N*'!)*C'<]SBO1H_VDO#D/FSKJ'B&0W%[87*Z;)#']GL$A<&2.$AAD
M$#C@9XJYUJZIQE&GJ_P_#YD1HT7-IST7XGC-GX+U6_O-=M88U-SHT;RW,3$A
MBJN$8J.^"0?I6EXJ^%/B'P;#J<FJ0Q1+I[V\<NU]Q9IE+(%]3@'-6O ?Q6L_
M#_Q@O/$^KK<W^DWTET+J/:'EEBDSM4@GG!V=^U=A=_M*:?J"^#[B]TR:ZN]/
MU.6\U1)%4K.GSB#:2>60/P".-HJ:E3$QFE&-U;^E^'XHJ%/#R@W*5G_7^?X,
M\8:VN8[A8&M9UG;[L31,'/T7&:U+/PIJ5]X?U35XXMMOIL\-O/$X(EWRDA %
MQD]*]BE_:0\/#QG97ACO[ZTCLKBV&J36J+>VSR$'*#<=P&,<GN<8I+3]I70+
M/5=>GDL[N\%XUG%!=?9TBGV1AP\Y.2!*N[*DYSM&34O$8FVE+M^?^0U1H7UJ
M?U8\?\)>%;SQEXC@T2TEMK2^F)5!?2>4I8?P\_Q'H!6OH?PHU_Q%IU[>6GV,
M+;S30)#+<JDMS)$"9%B4\L5 )K)\)^*M/\,_%#3M;FN;O4--M-0%RUQ)&/M$
MJ!L[BN?O'ZUUG@WQSX+T73?$=Y=7NL6WB749+A+6X@LUECM()"<[,N,.X."V
M.!TK>M.K'6"[=/O,J4*4OB??J<1:Z'=WNA7&JPF-X8;A+8PJ29F9@2"J#DCC
MFJL-C<S:A;V1B>&XGD6-%F4IRQ '4=,FO0/@W\7M'^'NFK!J"WC3+J\=^&MX
MPPV+#(G<CYLL./K61XN^*,'BR^\%7]Y-=W>HZ4H34+F=1OE"W!==IS\V$('.
M/2J]I5]HX\NG?Y?U]XO9T^12YM>Q'XY^&.M^ 9+9;UK6^2XFDMTDTZ7SP)HR
M-\9 Y##(XQWK+TOPAJNL:1K.H6]NQCTGROM$+*PE_>,57"8R>17KFM_M(:#K
MGBNWU1TU*R2-+ZT1[2"-7MEE(,=W&,X\\#Y6S^=,@_: \.--J\!U3Q%I[SV%
MG9IX@MH(S?W+1.S-)*-P )!"CJ<#K7)&OBN1<U/7_@_Y?\,=#HX?F=IZ?\#_
M #/#XK>ZN&D6*VGE:/AUCB9BOUP.*U_#O@_6/%%Q=0V=I*#;VTMT[2QLJ[8Q
ME@#C[W'2O7-._:,\.-K5]<M+KGAV-M7CU$3:7%$TFH1K&J&.XR1C)4MQW8_6
MJ>H?M)6C7V+&[U6VT\V.IQ&!5"@W$\KM"^-W8,,GMSBM'7Q#TC3M_7H0J-!:
MNI<\4FCGMXT>:"6%)!E#)&5#?3/6NPA^%>N37VK6@>S232VM5N6>;"K]H*B,
MYQT^89]*F^+_ ,3M,^(&D^&5@-S-JUA;F&\NI(_)CD&%"A8]S $8.6&,^E=Q
M:_M*:8U]J<=VMP=,,VF26*Q6<:RJ(&0R[V!!.=IVY)_"JG5Q'(I0AKU^]?I<
MF%.CS-2EI_P'^IY?HO@;6/$'BB/0;.#?=23R6Z3X;R&9,YP^,$?*:PIK6YA6
M5WMIECC<QO(8VVJP.""<8!KW/3OVCO#]FVA2RMJ;3Z?J=Q<+);P^5LMI#*3&
MR[]LC$NO. 1@\FL>/X_:-)X-:VN7U::].FS6$FBLB'3[J5V)^UR/][S.=QXS
MD#FIC7Q%]:>G_#_\ IT:%M)Z_P##'D<UO=6L8DFM9X8V. \D3*"?0$BMCPSX
M+UGQ9K5OI=G9RQW$ZNR-<1NB85"QYQZ U[7\2/CEX<TO4+JT2_O?%X=].D%A
M-Y;:=;B(([M$X))9L%2/<YHC_:<\/V#1F+6O%&ILVIRWS&^@C7R(G@=!"FUN
M55F7KZ9]JCZUB)0O&EJ_Z[%_5Z$9VE4V_KN>(^)O".J^$TL'OX"([RUCO(Y$
M!*JCYP&.,!N#Q3/#OA74_$^LVVF6T#0W-Q&\D1N5,:LJ*6)!(YX%>FR?M&6%
MQI#Z?>F_U*R&AVMJ+&YC4Q27L<XDD=N>C 8W=>>E:=Y^T;X:DU".8S:YJB37
M4UV/M\,?_$K5H'C$%OM/*989)QPHXS5>WQ*C;V>NI/L:#=^?0\(:.9;=9VAE
M6!CA9C&0A/H&QBM+1/#6HZYJMK81PM:O<G"37:M%%T)Y8C'(%>HW'Q]\/7'A
MJ.U$.H7$DMK:6?\ PCMVD8TNT:)U+3HP^;<=I/3^(YS7I?BOXN>&_"-C;7]Q
MXMN/$7VS6EOTT^&:*X>QA\B1?+0(<!06 &2#[5-3%5HZ>SU=[?U;_@=APPU*
M6O/HOZ[GRBT%PL+3>1,;=6V^<(R8\_[V,5IOX6U)?#-AKJ1>=9WMS+:Q+""\
MF^,*6RH'3##FNU\8?&#1_$G@6*PM-5U[29TL8K,^'X(HO[-=D/,I;[V6^\>,
MY[T_X8_&[2? _A?3+.4WT>HV?]J,LMO$"%>XA5(2"6[,N3Z>]=#JUN3F4-;[
M?+^NYBJ=+FY7+2VYYM#8WEQ>"U2TG-QD Q^4VY<D#)&,@<]:T/$WA75/"FO:
MCI%W TMUI[!;AK96D1<@'[P'H>]>KV?[1&B75O&+S4->TO5)M/T]+S7--AC:
MZGG@W>9&VX\H^1\WMR*W$_:F\+1W&O20P:E9M/?RWL+K:1O]M5HPH2<%N ""
M/XA@]*QEB,2I:4OZT\O4U5"@UK4/G8QW 4L8)@@02%C&V-IX#9QT]ZZCP[\-
MM9\36NB3VS6T0UF^:PLEGDVM(ZKEFQCA!TSZUT.M?&/1-2^$/_"'I/JD=XJB
MX%V(U",YD+&SQG(@4'*G)Y'2K'ACQ]I&BZ'\*=>GNE*^&;ZZM[^QA93<X=MZ
M2K&2-RG.,^U:3K5N6ZC9W:_!V^]F<:5+FUE=67YJ_P!R.;\1?"W6O#4-_<7$
MMC<6=I8KJ/VNUN!)%-"THBRC#J0YP1[5=G^"OB&UG2.>:Q@WW-K:"22?"^9<
M1>9$"<< CJ>QK>UK]HNUNKK5]8L?.M]7OM$BTZ.UDLXWM+>9)U<E%/R[&4%N
MG#$_6K?BCXO:'\4+MM+MIY-/N-2U72[DW=\J001+!;B.9F;=A1NR0.X_*L?:
MXI6YHV[_ (?\$V]GA];/^M?^ >.:I:W&CZE=6%W&8KJUE:&6-NJLI((_,55\
M^M?XK^*+7Q1\3/$VJV)!L[J_D>%AT9<X#?CC/XURGVKWKTX-R@G)69Y\THR:
M6QI_:/>D\_WK+-U[TGVH^M60:GVBC[1[UE&Z]Z3[5[T ?6'[$7Q#N+/Q5J7A
M.:5GLKR!KNWCZ[)4^]CZKU^@K[-$9DPTG3LG;\:^$OV&?#-QJWQ*OO$+(RV.
ME6C1F;'RF23@+]=N3^%?=NUI_O96/^[W/UK\_P Y45BWR]E?U/M<K<GAES=W
M;T%\PR<1].[]OPI/DM_5G;\2:4R%CLB XZMV%)M2W&YCECW/4UX9ZP>69.9>
MG]P=/Q]:/,:3B/A?[_\ A1Y;3<R<+_<_QH,A?Y8L8Z%NP^E !\EOZL[?B31Y
M;2\R\+_<'3\:/DM^2<L>_4FCRVFYD^5?[@_K0 >87^6(<=-W8?XT?9D/+C>W
M=FIS2"/"J-S=E6F^2[\M(RGT7I0!-1110 4444 %%%% !7S;\9/V2H_%&IW&
MM^$KF'3KV=C)/I]P"(9'/5D(^X3W'2OI*BNK#XFKA9\])V.>M0IXB/+45SX&
ME_93^)4<A7^R;9\?Q+>(0:9_PRO\2O\ H#P?^!:5]^45Z_\ ;F)[+\?\SS/[
M(H=W_7R/@/\ X97^)7_0'@_\"TI/^&5?B5_T!H/_  +2OOVBG_;F)[+\?\P_
MLBAW?]?(^ O^&5?B7_T![?\ \"TI/^&5?B7_ - >W_\  M*^_J*/[<Q/9?C_
M )A_9%#N_P"OD? /_#*OQ+_Z UO_ .!:4G_#*OQ+_P"@-;_^!:5]_P!%']N8
MGLOQ_P P_LBAW?\ 7R/@#_AE/XE_] >W_P# M*3_ (93^)?_ $!K?_P,2OT
MHH_MS$]E^/\ F']D4.[_ *^1^?\ _P ,I_$S_H#6_P#X&)2?\,I_$S_H#6__
M (%I7Z T4?VYB>R_'_,/[(H=W_7R/S]_X92^)G?1K?\ \"TH_P"&4OB9_P!
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M?VYB>R^Y_P"8?V10[O\ KY'YW_\ #)/Q1_Z MO\ ^!B4W_ADCXH_] 6W_P#
MQ*_1*BC^W,3V7X_YA_9%#N_Z^1^=G_#)'Q2_Z EO_P"!B4?\,C_%'_H"V_\
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MZ<YZJ>]']N8GLON?^8?V10[O^OD?G+_PQ_\ %;_H"6W_ (&I2?\ #'_Q6_Z
MEM_X&I7Z.QS*_'1O[IZT^C^W,3V7W/\ S#^R*'=_U\C\WO\ AC_XK?\ 0#MO
M_ U*:W['_P 5E4DZ';X'_3ZE?I'45Q_JBO=OE'XT?VYB>R^Y_P"8?V10[O\
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ME_=PJXY+=NWZ4K* T2_WOTHHH 0?=!]9-O\ ]?ZTI^5)FQG8V #T/N?4T44
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H2:1OWEQY;?<"[L>OUHHH GJ"U_>*9&Y9CCZ444 3T444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>morf-20221231_g14.jpg
<TEXT>
begin 644 morf-20221231_g14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $S JP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3/..] "T44@(/3F@
M!:**3</44 +1110 44BL&Z$'Z4M !129STYH) Z\4 +1110 4444 %%%% !1
M110 4444 %%)D49H 6BDS1G'7B@!:*** "BBB@ HHI&8+R2!]: %HHI,XH 6
MBBDR,X[T +1110 4444 %%%% !1110 4444 %%%% !1110 45Y%\?/C^WP3N
M/"UE:^%[SQ7JGB&YDMK6SLYUB;<B@]2#DG/2N=\._M%^/M9U_3["[^!GB33+
M6YG6*6]EO(F2!2<%R-HR!UZUJJ4W'FZ'#/&T(5'2;?,O)O?T5CW^BO*]#_:"
MT;6?CQKOPN:TEM-5TVTCNHKF20%+K(!=57'!4$=^>?2N[\9>*[#P+X4U;Q#J
MDGE:?IML]S,W^RHS@>YZ?C4N$DTFMS>->G.,I1EHKI^5MS9HKPK_ (:LTS_A
MFW_A;IT&Z%IC TKSE\S=YOEXWXQCOG%8$'[4WQ"NK:.>'X >)I8I$#HRWT6&
M4C((^3TK149OI^1S2S##QM[U[I/1-Z/;9'TI17A?Q6_:9N_AG>>"M*A\!ZGK
MGB/Q/ TT>CP7"1RP,JAF0G!#,.>GI7-S?ME:AX5O+)_'OPI\2>"]$N)E@.L7
M#+/#"S' W[5&!GW_  H5&HU=(4\PPU.3C*5K;Z.R]7:R/IBBH[>XCNK>*>%U
MEAD4.CJ<AE(R"/;%>.?"']J+PY\8OB3XN\'Z9;207&AN?)NI) R7T:OL=T&.
M &QZY!S6:A*2;2V.J=>G3E&$Y6<MO,]GHKSOXZ?&2S^!O@^U\07NG3:G%/J-
MOIXA@<(P,K$;LD=  3CO7H,4@FB20=& 8?C2Y7:Y:J0E-TT]5:_S'UY)\??%
M7C+X>6>G>+/#WDWNAZ:6_M?3)$YDC8C$@;&1MYSCUS@XKE_B-^U;?^$?BMJ/
M@3P_\.=7\::EI]K%=SR:?<*FU7&1\I4G ]:9X/\ VM=&\4>*(?!?CKP?K'P_
MU;5 8;:WUV+-O=Y&"@DP 2<XZ8YQFKEAZDHW/,KXRA44J,:G+*]KV>C];6WZ
M7UV$NOBCX9^.%KHDUAK\.@:A:R%I+'5!A6W#!*L.&(['^5>X1>(M(L[6%'UB
MS;"J@=KA/F/3U[U\V?#;X3>%['Q/XV^'/B"P#'07&J:1?1DI,=.GR0A8=?+<
M,O/M6MX3_9SMO$4S74K26&B&0M"&P9Y5!XY[#WKXVO.M@<=:E24ZE5+5-K2/
M5K9)7^\PPM;&RASN";>CUMJM'^1])YSR.12U%:VZ6=M%!'D1Q($7)R< 8'-2
MU]8MM3W@HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y!\
M4-8U#P[XPO\ 4],^6\M_#^869"ZAC=*O([\$UZ_3&ACDR616.,<@'CTKSL?A
M98RC[.$^5[I]CT,#BHX2M[2<.9;-=SQN^\?>)M':ZTV^U*WA6#4H[>;738DI
M#$\(D&8P<9W?+G.*Q/!_CR[\*Z''<37:_P!GWEYJS/=FW8+)."##@')7<<X'
M>O?S#&VX%%(;[W Y^M5-4GATS2[JY:!9$A1I?+  W$#('U)KQ*F4XB,_;?67
M[M[7N[*Z=OBU5E9]7?5]#V:>:8>4/8_5U[UKVLKNS5_AT=W==%;;J>4Q_$+7
M&O\ 3[?5=7M_#3BRM)E2YL&E-])(N9 ,$;0#\N!R*Q(Y-4T?Q/<W8!U:9=>O
MY((3"4^9;4$8(/?@<^E>S/K2FZFB>QDDEM[9+E53#,VXD;1[Y%%KKEK)%/)<
MQ+:R6]P()/XP)#C&& [[@,\5E/+75:Y\2VT[IN_1^;Y>G9;7=WJ:0S!4D^3#
MI)JS2MU]%S=>[WLK;'D!^*GB1=#U*6SU&WU>5;.&X-Q'8-$+*=Y50P,"?FX)
M]QBN\\(ZUK%]'XNTW6)X[R;3)C#'<Q0>4)%:(/\ =R>A.*Z-O$FBK&^;F$IY
MLD;*$)S(APPQCD@X^N1C.13O^$DTI%9A*=[,5,:PN9"0,\KMW=.^*Z</A949
MJ=3%\UEM?3[7>3[IW=WIIH['/B,3&K!PAA>6[WMK]GM%=FK*RUUU1XCX3L==
M^'GPXF\3V$=N9+VWMXEMX5<B-2YW7$H8X+@-VP.*V]&\<>*]>AT>W^VVPANK
M^>$WT<*R>= D.\Y53A6S\N0>]>CQ^-M(5KR-YDCAM\$,@+AHS&K[\*.!\V.>
MI%7]/U*"]OIK5+?RUAC22)F7;N5@<X4@%<$8YKCP^61I^SI8?%-122Y5U:=Y
M/1Z<UFOR?1]=?,I5.>KB,,G)MOF?1-62U6MM/U75>(Z?\0M9T+P[IMO;SP:.
MEOIT<]G:26;S'4I&9MT:MG*XP!Z\YZ4OQ!\9:MJ]Q=:??7<>F-'J-FD6B&U9
MI9$+1L9?-'H21Z<<U[]Y,?R?NU^3[ORCCZ4-#'(VYHU8],D UK+),3*BZ#Q+
MY;);.UK-=)>:LE9::IO4RCG.'C65;ZNKZO=7O=/K'RW=WKHTM!]%%%?7GR@4
M444 %%%% !1110 4444 >/?&:^O[?Q9H5[8K(_\ PC]M)J\T:*?WL?F(C)]=
MN_\ *N8\.>)->\)Z=K+RS&TN-5O+749;R>%I4LH;C<2VWOMPH]N]?0K1HQ)9
M%)(VG(ZCTH\F,YS&IR-IX'(]/I7RM?):E7%2Q4*[BW?2W]WE[KHEM;;2SU/I
MZ.<4Z>&CAIT5)+K_ -O<W9];]]];H^?V\>:OJ$POVN8M4FTV?4ELKY+5HU94
MM%96"9[D]\^U+XBUGQ/K5G;:;J.I1NXETK4$N(;+;M\YR"A&>=I&??VKWW[-
M%_SR3_OD?2E\B,]8U[#[H[=*Q>15YQE&>(;YM]]=+:^]KTW;>AJLZHQE&4,.
MER[;::WT]W3KM9:GC&D_$SQ5>^,[FQE6W18YYXGT^151XXD4[90<[B3@'&,$
M'BJUG\2/&=CHJW5S)!J,UYHXU",)9E?LK>:$8D Y<!3NQP>*]4OO%5CIMCJF
MHW,6R"TE-OO4!GF88RH'^]D?AFI+/Q!;7%_#"EJ4AF:2&"?C#F/.\8[#(./7
M!J5@JM^3Z[+FUMO]II+2_D[=+O2VA3QE*W-]3CRZ=NBN];>:OULM;GDMO\1_
M$EY?7%AIVO6VJ(;ZPM8=273RB8FW^82N><$#OVJT_P 2/$$<-K9ZAJMOHL27
M5Y;3ZY)8ETD:%P$4)G"E@<\GMQ7J0\0:+'M'GPH?)>Y"[""$C.&;&.,$_6E/
MB+1FWQM/&$RS$O&0A*_>P2,$CVYS3C@:L5KC=?5VM>]OCOMI>][=12QM*3_W
M/3T5]K7^"V^MK6OT/*O&'Q.\2Z7JUC;65Q:^0UE#/#=20!(]0D8X( 9LJ/89
M(K=^,>FW7B"Q\)6GV6W>YN-10/!<EF@#&)LABO) /<>U=A>>,-+AFM=[ JTF
MTM*A1HSM+ A2,G.,#'4U--XFLI'@\E6N0;I+9F*,OENV<8W#G'0XZ5K+"1JP
MK4JV)YE.VG:SOIJ_3\[NYFL5*G.C5I8;E<+Z][JVNB]?RLK'D6M>*/%/PXN-
M,\-6]S#LL[&(Q7-T@*WTI8@IN9LA5Z<9;O6A>:YKNJZM;7&H)'+':^(4MK>Q
M6,@QE8=^=X/S<G:#C%>S-&DA4LJL5.02,XI/)3KL7.=W3OZ_6M/[&JIM+$2Y
M+JT>B2V6^O\ P+N[U,_[7I-)N@N>SN^K;W>VG_!LK+0\2TGXJ>)9K>YFA:'6
MKLZ?/=3Z?%9O$VFS)C:C'/S]3QU.WBKOPOUB;7/B=J-U+K$>N?\ $FB!NH;5
MH$5O-)*8/4C/^->PK&J,Q554MR2!UI(X8XSE(U0]/E4"JI93B(U*4ZN(<E!W
ML[]K?S/?=WO;[-EH34S2A*G4A3H*+DK75N]_Y>FRM:_VKO4?1117TQ\X%%%%
M !1110 4444 %%%% !1110 4444 ?)_[:>N7?AGXE? _5;'2;C7+NUUBYDBT
MVTQYMPPC3Y%SWKNO!O[0WC+Q-XJTS2K[X+^*M#M+J812ZE=F/RK93_&_L*YG
M]L"WUO3O&WP@\4Z7X:U3Q+:Z#JL]S=P:3 99%4QJ!P!QG!Z^E;?AW]J[4?$'
MB#3],;X1>.+%;N=83=7%@5CB#'&]B>@'>N_EYJ4;1OOU\SYOVGL\954JCC=Q
MTM>^BZV9\[_%K1]5L/VEOB=\0] \R36? O\ 9FIBV3I/:LK+<(1_N?IFO6/V
MA_&=O\?D\$_#SPW>-)I?B"Q_X276+F$\Q:=&A>-3CH7< 8]5QWKK_ASX)U%?
MVGOC'?:II$PT+5=/L((KB>(^3<C8X=0>C<'!'O3_ ()_LM67P)LO'$]M?OK5
MYJZR0V)="&M;0!C';C).?F;G& <#BK=2*LWNDK?=^FYST\+6ESQBO<J2ES?*
M3_\ 2EH?/,O/_!,<]OWH_P#2JO9_#O[37CJVT'2X(_@1XPN(X[:)%F0Q[7 4
M ,/8]:\]?X9^*V_X)WMX;'A_4/\ A(%;>=,\AOM&!=9/R=>G/TKT#1?VM]5T
MK1;"S?X,^/G>VMXX69=.."54#CCVJIKF3LK^\^OH84).BX<\W#]W#[-[[^3V
M.8_:E\=)X)_:$^"'BF^TK4)UMH+J:33K.+S;G+QE=@4=2"W./0UD_&3]H9_V
MG/#]U\)/!G@O6HO$.L&(S/K4*VRVD"R*S2D,<GIUQ7H?Q-T+7O&7[17P&\4V
MF@:C#IL,5S->M+#@V6Z$G;*1PIYQSWK3_:V^&&KZE8:)\2/!5L\GCKP?.+J&
M.W0F2]ML_O8"!RW'('^\.]3&4$X)K6WXW9M6IUY+$2A+W&U=6U:Y8WL^]O(V
M?V@/&TGP)_9QF2UE,^LBQAT33MO#2W#H(E8>X +?@*\/\4?#J+]EWPO\&O'F
MGM&]UX=D73_$K0L"9X;LYE9O7;(S8]-P]*ZWXI>!=8_:>^+O@'1=?T+5M(\!
MV&C?VW?L=T.Z[E4!8!(.0Z=QU&#ZUM:[^P#\,M0T:^MH#KRW$D++$TVM7$B+
M)CY259B" <<&IA*%-)2>^_Y&E>E6Q4YSHPTBDHMNUFK.Z5N]E\B#]ORXBO/@
M5H<\$BRPR^(M.=)%.0RDN00?0BOI>Q_X\K?_ *YK_(5\.>.]#^(/B;]BW0-&
MU+POJMUXE\-^((+66VC@9IKB"W=U$RKC)4@J <=LUZEI_P"U]K3-:VQ^"GCI
M02D9?[$>.@S]VIE2DX*,=;-_H;T<93AB)5*MX\T8]'YWZ="MX$_Y/X^(O_8N
M6?\ ,5J?M]:%9ZA^SKJ^J2QHNH:-<VUY8W&/GBD\U5.T]LAB*X3Q9XD\2?"'
M]KCQ7XP3X?>(_$^DZKHMI;02:3:EP& !;+ $9&,$5)XUF^)'[84VE^%F\$:A
M\/OA]'=QW6K7^M$+<72HVX1QI@'K[=0"3VJU%\\*E]$D<TJL94*^%2;G)RLK
M/J]'?;SN>N:3X)U3Q;XL^'GCG>OD7/A=['6<OMD?S8XI(R!W(?=],U[)!"EO
M#'%&-J(H51["F65G#IUG!:6Z"*W@C6*-!T55& /R%3UYDHQ=3VEM;6OY7O;\
M3Z2C25)-+KJ_6R7Z!1115&X5!)?VT3%'N(D8=59P"*P/'5Q<&VT[3K:=[5M2
MNTMI)XCATCP2^T]B0,9[9I\/PZ\-PQJ@T>W8#NX+,?J2<FME&*BI2>YDY2O:
M*-K^T[/_ )^X/^_B_P"-']IV?_/W!_W\7_&LC_A7_AS_ * UI_W[H_X5_P"'
M/^@-:?\ ?NC]UW?W?\$/WG9?U\C7_M.S_P"?N#_OXO\ C1_:=G_S]P?]_%_Q
MK(_X5_X<_P"@-:?]^Z/^%?\ AS_H#6G_ '[H_==W]W_!#]YV7]?(U_[3L_\
MG[@_[^+_ (T?VG9_\_<'_?Q?\:R/^%?^'/\ H#6G_?NC_A7_ (<_Z UI_P!^
MZ/W7=_=_P0_>=E_7R-?^T[/_ )^X/^_B_P"-']IV?_/W!_W\7_&LC_A7_AS_
M * UI_W[H_X5_P"'/^@-:?\ ?NC]UW?W?\$/WG9?U\C7_M.S_P"?N#_OXO\
MC1_:=G_S]P?]_%_QK(_X5_X<_P"@-:?]^Z/^%?\ AS_H#6G_ '[H_==W]W_!
M#]YV7]?(U_[3L_\ G[@_[^+_ (T?VG9_\_<'_?Q?\:R/^%?^'/\ H#6G_?NC
M_A7_ (<_Z UI_P!^Z/W7=_=_P0_>=E_7R-R&XBN 3%*DH'78P.*DKAO%7A'3
M]!T>XUC18%TO4[%#/') 2JN%Y*.O1E(X-=G:7 N[6&<#:)$5P/3(S2E%)*47
MH.,G=QDB:BO/OC)XFO?#^A6T5C*T$MW(4:5?O!0,D#TSQ7A1U:_8DF_NB?\
MKN_^-=N'P4J\.>]CEK8M4I<MKGUM17R3_:U__P _]U_W_?\ QH_M:_\ ^?\
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M_P!_\:Q_U>P_2W]:]S;^W*_5O^M.Q]'1^ [:SFNIK2=HI+E%BF$L:R)(BQA
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M/T5PGQQU"YT[X,^,;VRGDM+N+2IY(IHFVNC!"00>QK\T(_BUX\8#_BL-:_\
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M9_Z]9/\ T&M'1O\ D#V/_7"/_P!!%?3?\NEZ_P"1\[_R\?H>9?M ?\@W2/\
MKL__ *"*\6R:]H_:"/\ Q+=(_P"NS_\ H->)[O>OH\#_  $>'C/XS),FC)J?
M2;/^T]3M;3?Y?G2!-_\ =SWK4M?"4]U]M E57AE6.,'I)DCYO8 $'\:[)2C'
M<Y5%RV,3)HR:U+72;74;AX+:XD\R(C<9% #KG#%?3'H:O3^%HK>2X5Y)%>%2
MS0-(@?[V 2W0 CGUI.I%:,?(WJ<[DT9-:-KH^87GN_.@@\U(4PO+,^<'T( !
MZ5)=Z*EC;LS,]Q)'(R3>2ZXC 8J,CKSBGS*]A<KM<RLFC)K3GT>/^W+;3H7D
MWR%%D$F"8V/)7CN!^M3:;H-MJWFBVNI (QO:21?EV\G;[MM&?0T<Z2N/D=[&
M-DT9-;<?A^V>UM+LW,BVUXXCA^4%E;+ EO88[>M5;/P]<7N_;-!&RW/V0+(Y
M!>3'0<4<\1<K,[)HR:T)- FCA\][BW6VZ&8N=N[)&WIG/![=JEM_#Y_M:\LK
MB12UM 9B87 #\*0 S8'1AR:.>(<K,K)HR:WKKPU#I\-S+//)(L.[B,!2V) @
M//US52\T>.WT^2YCG:08BE3(QF-\@9'J"II*<7L/D:,S)J:Q)^W6W_75?_0A
M57=[U/8M_IUMS_RU3_T(5H]B%N>_?'8;O@?XS'_4'G_]%FORZCMNG%?J3\<%
MW?!7Q@/^H3/_ .@&OS+CM^!7B8"IR0DO,_LCPHJ<F6XE?WU_Z2CZ^_8!C\O1
M?%__ %\0?^@M7UG7RK^P='Y>B^+/^OB#_P!!:OJJO,Q4N:M)GY%QW+FXCQ3\
MX_\ I$3Q+XF?\CE>?[D?_H KEJZ;XG'_ (K2\_W(_P#T 5RNZKC\*/YUQG^\
MU/5_F245/I5F-2OX[=I/*5LDR8SM &<U;A\/W$UK*^569)O*$9[CH6SZ U5S
MGC3G)7BC-HK5L_#DMY"'CFAE\P[8V23"@[@#NR,]ZCAT1I(I6\Z-_DW1>621
M(V[;CD>]*Y7L9Z:&=16C_P ([=*6W/"@0,79RP"X&3U'\J8NASF2-6E@C61E
M2-W8A7+#C''\Z=Q>RGV*-%7Y/#]TF%#122D;O*1B6QNVYZ8ZTR+1Y;B0I#-#
M,5!+^6Q.P#N>/Y9HN'LY[6*=%6UT><WC6Y:-&6/S2[$A=N,YZ9_#%2GP[>_*
M JESM^7)! /(/(QT]*+A[.;V1GT5JV?AR6\AWQ30RASL1DDP VY1\V1T^85!
M_8<[*ICEAF+J718V.6 ."1D=CZTKC]C.U[%&BM%O#MTI;<\**@8NS$@+MZ]O
MY50NK=[.;RW*DX#!EY!!&01^=,F5.4=9(;71_#W_ )&^P^K?RKF-U=)\.S_Q
M6%A]6_E2ELS;"?[Q3]5^9[M1117"?IP4444 %%%% !1535-5M-%L9+R^G6VM
MH\;I']S@ >I)X ')K"_X61HG_42_\%%W_P#&JTC3G)7BFR'.,=&SJ**Y?_A9
M&B?]1/\ \%%Y_P#&J/\ A9&B?]1/_P %%Y_\:JO8U/Y7]PO:P_F1U%%<O_PL
MC1/^HG_X*+S_ .-4?\+(T3_J)_\ @HO/_C5'L:G\K^X/:P_F1U%%<O\ \+(T
M3_J)_P#@HO/_ (U1_P +(T3_ *B?_@HO/_C5'L:G\K^X/:P_F1U%%<O_ ,+(
MT3_J)_\ @HO/_C5'_"R-$_ZB?_@HO/\ XU1[&I_*_N#VL/YD=117+_\ "R-$
M_P"HG_X*+S_XU1_PLC1/^HG_ ."B\_\ C5'L:G\K^X/:P_F1U%%<O_PLC1/^
MHG_X*+S_ .-4?\+(T3_J)_\ @HO/_C5'L:G\K^X/:P_F1U%%<O\ \+(T3_J)
M_P#@HO/_ (U1_P +(T3_ *B?_@HO/_C5'L:G\K^X/:P_F1U%%<O_ ,+(T3_J
M)_\ @HO/_C5'_"R-$_ZB?_@HO/\ XU1[&I_*_N#VL/YD=117+_\ "R-$_P"H
MG_X*+S_XU6SH^N6/B"T^TV%P+B(,4;Y2K*PZJRD J?8@&IE3G%7E%H:G&3LF
M7Z***S+"BBDS0!R_C+_D*>&/^PB/_0&J]XP\1-X7T5[\0><%D1&9B0D08X+N
M0"0H[D U1\9?\A3PQ_V$1_Z U;&N:2VL6B1)=S64D<@D66$CJ 1AE/#*03D'
MBMY?#"_]:F4?BE_70R%\?62K&);:Y:98DDN?LL1N(K8LH;#2)E>A!X[$'O5)
M?BYX=:UBN/-N!%)&9\M;L"L(8KYI!&0A(;![X-2V/PUM-&M?LFEZA>Z;92(B
M7$,#C]Z44*&#$91L  E<9  [5'<?"W3)FMS'-- 8[9;21@J,TD2DD#)!VGDC
M<N#@XJ/<*]XEN?BKX<M9+D/=.8K?S 9UB+1LT8.]5(ZL,$8]0:HWWQ?TBS6"
MX?SK>VVL\\=S;2K.%V*R%$VG(.X=<?C5A_A3I3272K++%:3F9_L\:J-KRDEV
MW8W'EB0"< G-/UCX6:3K=^MW/)<"58TC&Q\#"A0.W^R*/<#WBTOQ$TIL1K#?
M->&0Q_81:/\ : 0JL28\9"X9>>G(IG_"RM%/AW1]9C%W-:ZM.MM:1QVKM*\A
M#G:4QD8$;YSTQ53Q!X)NEUK^VM$D6+4I'/FN\A4E"BIM'!&WY02".H!!!JHG
MPSN[?PMX1TF'572;1;Y;R2['WWPDH.,YSEI1G/49HM$+R*6D^(/ &CZ]=W-C
MIGV35HXC)<LMDXDAW,5V-Q\KLPP%')R/6NE7XBZ2S>2L=Z;_ ,PQMIXM7^TK
MA0V3'C(7!4YZ<BJ\'POTN/\ M.1YKJ6[U'RWN;HR8<RHQ991@?*P)P,< *!3
MT^'D4=Y_:B:C<KKQ<NVHX7+94(5*8V[=JC QP1FLJ=&C17+2CRKR5M36I5JU
M7S5)-OS=Q\WQ,T*WN!%)-+&P$?G%HB!;EQD+)G[IP1D'ID5G7WQ<TRTU;3H!
M;W/V*Z$Y^VO ZHPC*C,?'S@EA^'-6S\,=.-^+DW%Q)YAC>Z$VUVN60!59G(R
M,@ -C&0 *@E^$]A=26RW.H7\]G9PS06MKY@"PK)@DY RQ4J-I/W<5K[AE[Q=
MU/XF:!I&N2Z1=3S)=PQM-+B!C''&JJQ9FQ@ !U_.HH_BGH4DD$*M<_:9Y8XH
M[?[.WF,7!(;'IP>?:@?#'3+FXOKG499M2N;ZVDM;J24A1(C^7QM P,"),8]S
MWJ"3X6VD]C+;3WT\JS21O(WEQJ2J'Y0N%&UN^\?-DDYH]P/>-KQS_P B=K/_
M %ZR?^@UHZ-_R!['_KA'_P"@BLWQPNWP;K '06D@_P#':TM&_P"0/8_]<(__
M $$57_+I>O\ D3_R\?H>7_M"G&FZ/_UV?_T&O$=U>U_M%-MTS1_^NS_^@UX;
MOKZ7 +_9X_,\'&?QF7;*^DT^ZCN(2!+&<J2,X-6QXCOECA438\F#[.A P0NX
M-U]<@<^U8^^C?7>X)[HY%)K9FQ_;]PK%HTAA=V#2-&F#(0<C/MGG P*;/KUU
M<PO%(RL'78S$?,5W;@,^@/2LG?1OI<D>P<S[FC9ZO+8AE78Z,5;RY1N&Y?NM
M]15@>)KH'=F$RE@SR[!N?!W#=Z\G/OWJA!JUU;1B.*8H@[;5/\Q4G]O7W_/P
M?^^%_P *3A=[%*7F.L=4:TU2&]+>9(DOF')Y)SS5E?$30Q116\<,20NS1-SN
M&>YYP3CCD=*J?V]??\_!_P"^%_PH_MZ^_P"?@_\ ?"_X4G"^Z#FMU+B^)[E-
MBJ(1%'@Q1;<K&P)(9??+'KZU6M]9FMEC"2+\EP+D%N3Y@&,TS^WK[_GX/_?"
M_P"%']O7W_/P?^^%_P *.3R0<WF7K/Q @MGMKQ?.MR=P5<$;MV[)'&>I[C&>
M],NO$3W&J7EYY<6+I/*>)ON[, 8XQ_='2JG]O7W_ #\'_OA?\*/[>OO^?@_]
M\+_A1[/6]A\VEKEV3Q5=3JZ3^3/&Z[3&PP,;@V.".X%1W&O-<V,T+XWR.G*X
M"K&H.U /8FJW]O7W_/P?^^%_PH_MZ^_Y^#_WPO\ A1[.W07-YE?S%]1^=3V,
MB_;K;D?ZU._^T*7^WK[_ )^#_P!\+_A4UCKE\U]; W!P94'W%_O#VJFG;82M
M<^@OC7S\&?%W_8)F_P#0#7YL1QK@?,OYU^EWQ?FDM_A+XIEB;9(NF3,K8!P=
MAK\^8_$NK\?Z:W_?M/\ XFOCZ=7V::/ZU\,ZE2& Q"@D_?76WV5Y,^E_V&%"
MZ/XJP<_Z1#_Z"U?4=?-W[&>I7>H:3XF-U,9BL\(7*J,?*WH!7TC6$I<SN?EO
M&DG+/L2Y;WC_ .DQ]#PWXH-_Q6MZ/]B/_P! %<KNKJOBG<.?&-W$6_=JD9"X
MZ?(*Y#=[UV1^%'\]8UKZS4]7^9:M[I[5V>,X9D9#QV8$']#5O_A(+S>'\WY@
MB1CY1T7I_GO65N]Z-WO56.6-2459,V(?$=U;HB0K%#&ARJHG'4'^8%5H]6GA
M@6)7VJH(!QR.0?Y@50W>]2P7DML28GV$]> ?YTK%>VD]V7)-<FD#C]VOF!M^
MU1\Q/4FG1Z]/&T1/ER>45:,2*"%*]"*K_P!K7?\ SW/_ 'R/\*/[6N_^>Y_[
MY'^%%BO:ZWYG_7S)SKER9C+YH$A39N4 <9S_ #I/[:D5B52%=V?,"KC?GKG_
M .MBH?[6N_\ GN?^^1_A1_:UW_SW/_?(_P *+![3^\_Z^8YM4D::20%5+IY>
M%  "XQ@5/'KTJR1LVTE2NYUP'8*, 9Y[>W/>JW]K7?\ SW/_ 'R/\*/[6N_^
M>Y_[Y'^%%@52VTG_ %\S1;Q*;>*.*S588U8L<J.22#TS["J,6KS0[-D@4HC1
MJ<= 3D_K3/[6N_\ GN?^^1_A1_:UW_SW/_?(_P *+#=;F^T_Z^9-)K<LGF?Z
MM/,#!]J_>+8R?TJO<7C73JTC E5"#'H!@4[^UKO_ )[G_OD?X4?VM=_\]S_W
MR/\ "@AS4MY/^OF0>8OK72?#EP?&6GX/=OY&L+^UKO\ Y[G_ +Y'^%=%\/=2
MN)O%]@CREE);(P/3Z4I;,Z,)R_6*=GU7Y^I[I1117"?IX444V218D+NRHBC)
M9C@"@!U%8;>+(+E_+TNWFU9S_P M+<8A'H3(?E(_W=Q'I3#I^LZKN^V7RZ=
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MR8=02,-@]:KVND6TUO(ZR2.)8_W+2*%VMO"Y.#TY%8S:Q>L03=2\=/FQCO\
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M?6?A'P)J&L2:9:VT=S=1P^>PBNI&55#E""0_7<",5J_\*K\+?] O_P F)?\
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M^@BOFCSO>OL<K5\+'Y_F?+Y@_P#:)?+\B_YWO1YWO5#SO>CSO>O5Y3SN8O\
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M2KEU\*$O?#>LV<L__$PO+F[GAG,LC)$LTSN %S\F58*Q3!Y/-;/_  KC2_\
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M^RP_\\8_^^14M%%V!%]EA_YXQ_\ ?(H^RP_\\8_^^14M%%V!%]EA_P">,?\
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M_P!!-)2C>SBOQ_S'R:73_+_(EM_L]U;QS0B.2*10Z,H&"",@T_R(_P#GFO\
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MU?RK\SGJ?\:7R5/+?,?4T 24444 %%%% !1110 4444 %%%% !1110 4444
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M4E !2TG^?\_YXI?\_P"?Z4 +BEZ>V../Y#WH]<\?T]OK3U4Y  ^;' [*/\:
M!0<@ #?C@=E%.Z?(G7^)O\]Z1?[B=/XFJ55"K@# H 15"C IU%% %>^O[?2[
M.6ZNYDM[:%=SRR'"J/4FN>'Q*T-@"DMRZ'D,MI*01ZCY:;XYC6XN_#=O*H>"
M34XV=#T8JK,N?Q /X5U=;VA&*<E>YE>4I-)VL<M_PLC1?[UW_P" <O\ \31_
MPLC1?[UW_P" <O\ \374T4N:G_*_O_X 6GW_  _X)RW_  LC1?[UW_X!R_\
MQ-'_  LC1?[UW_X!R_\ Q-=311S4_P"5_?\ \ +3[_A_P3EO^%D:+_>N_P#P
M#E_^)H_X61HO]Z[_ / .7_XFNIHHYJ?\K^__ ( 6GW_#_@G+?\+(T7^]=_\
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M_/[XD_\  [4/_BZ/,\(_\_OB3_P.U#_XNO4**/K'K]__   ]CZ?=_P $\O\
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M_P#@'+_\374T4<U/^5_?_P  +3[_ (?\$Y;_ (61HO\ >N__  #E_P#B:/\
MA9&B_P!Z[_\  .7_ .)KJ:*.:G_*_O\ ^ %I]_P_X)RW_"R-%_O7?_@'+_\
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M:??\/^"<M_PLC1?[UW_X!R__ !-'_"R-%_O7?_@'+_\ $UU-%'-3_E?W_P#
M"T^_X?\ !.6_X61HO]Z[_P# .7_XFC_A9&B_WKO_ , Y?_B:ZFBCFI_RO[_^
M %I]_P /^"<M_P +(T7^]=_^ <O_ ,31_P +(T7^]=_^ <O_ ,374T4<U/\
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MX_\ 0:Z94;[SG)]!T%+,<1-]*.:G_*_O_P" %I]_P_X)S/\ PLC1?[UW_P"
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ML7*,H.TE816W*".]+405X^% 9>P)P12^8_\ SS_6H(.:\9?\A3PQ_P!A$?\
MH#5G^,/#/@KQ-XHM?[>:*75M/MA?"V>[>,&!)-PDDC#!717&1N! (K0\9?\
M(4\,?]A$?^@-7&_'KX4ZU\0UT2X\.7L.G7\;R:=?RRL5WZ;< +<*, Y8!5*C
MUSR*Z?LPUMO^9AUEH+H'@7X6^+;6RETF&&]M-'<)$T-U,(GWL+H*WS8F7<PD
M ;< >E0>'O"_PU\3:]>:KX;GC&N6\,EW&SSS/!:-=JRF46[.(QO()( &<<]:
MXSQ1\ _%<WC#[?HOV:*TAUE+BQ2:^;[/#:"VAB*O!MY;Y&V[2".N>2*YZX_9
MA\6KX=OE2.U?6Y;>P6&XCU%E!FA\[?YV4/F1G>N5[CI@@4[+^8-?Y3Z0^&_@
M.Q^&?@?1_#.G?-;:? (_,VA3*Y)+N1V+,2<>]?F?K%]XFM/BA\15T/2K6_@.
MO3F1YYQ&5;)X )]*_4S38IH-.M8[DQM<)$JR&($(6 &<9YQFOB'QM\&-9\*_
M$#Q/)9:)J5S#JE^]]Y\,+S(^[N"H./I7SN?9Q3RW*,13J895Y57!*,E)PTES
M-RY91DM-M=]S].X'J4Z>*JJ<E'W5N[=3Q9=:^(7;PWIY_P"WQ?\ &IUUOXB\
M8\,Z=_X&K_\ %5Z@O@CQ'_T+VJ_^ ,O_ ,35B/P5XBX_XI_5/_ *7_XFOQN.
M?1_Z$N'_ / *_P#\N/U^6(H_\_%]Z/+%USXC_P#0L::?^WU?_BJF77?B5V\+
MZ;_X'+_\57JB^"_$/_0 U3_P"D_^)JPO@WQ!C_D ZI_X!R?_ !-=,<]C_P!"
M;#_^ U__ )<<\L11_G7WH\I77OB9V\*Z;_X'+_\ %5,NO_$_C'A33#_V_I_\
M57JT?@_7_P#H!:G_ . <G_Q-64\(Z]Q_Q(]2_P# .3_XFNF.>1_Z$]#_ ,!K
M?_+CFEB*/\Z^]'DR^(/BEV\)Z7_X'I_\54J^(OBIV\(Z7_X'I_\ %5ZVOA+7
M?^@)J7_@))_A4\?A/7!_S!=1_P# 23_"NF.>0_Z%%#_P&M_\N.>6)H_S1^__
M ()Y&OB+XK]O"&D_^#!/_BJG7Q)\6>W@[2?_  8I_P#%5ZXGA76Q_P P;4/_
M  %D_P *LQ^%]:X_XD^H?^ K_P"%=,<[A_T*:'_@-;_Y:<TL51[Q^_\ X)X^
MOB3XN=O!ND?^#%/_ (JI5\2_%[MX+TC_ ,&*?_%5[%'X9UD?\PB__P# 9_\
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M."IM2DVFU.[N^OO[]R:V8TIU)25&%FWOS=_\1\^?\)Q^T;_T3+P[_P"#J/\
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M_P#)G%]?I_\ 0/3_ /)O_DCYY_X3K]I'_HF'AO\ \'4?_P 72_\ "=?M)?\
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M_P#H&I_=+_Y(^>_^$\_:2SG_ (5?X;_#6X__ (N@>//VD_\ HE_AO_P=1?\
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MO?X5-VI_VI2_Z!*7W3_^3#^T*?\ T#4_NE_\D?.'_"P/VE_^B5^'/_!W'_\
M%T?\+ _:7_Z)7X<_\'<?_P 77T8TRAL#YCZ*,T>=_P!,W_*C^U*7_0)2^Z?_
M ,F']H4_^@:G]TO_ )(^#_ GBSXU6_[2'Q"O-.\":-=>*IK"T74=-DU-%AMX
MQ_JV5]V&)[C/%>R?\+ _:7_Z)7X<_P#!W'_\77KNA_#/0_#_ ,0M>\:6<-V-
M;UJ"*WNV>7,96/[NU>QKKO,D/2/_ +Z->AC<ZP]:I&4,+!VC%:J6ZBDUI/9=
M/([,5FM&K.+CAX.T8K52Z)+^;;MY'QK^SG\5_P!H/Q!X^U:PU;PW'JGAN/4I
MH[BYU%_)6Q(D(9(9\?O0O0##9 '(%?9]1+')C&50>BBC[.I^\68^I)KQ\RQU
M/'UO:TZ,::[1Z^;\_DCS,?BX8RK[2%*--=D<WXR_Y"GAC_L(C_T!JZFN6\9?
M\A3PQ_V$1_Z U=37GS^"/]=3R(_%+^N@4445B:A1110 4444 %%%% !1110
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M&[;C;Y\S2;/?&['X5,N5+3<I<U]3H*7_ #_G_P#51M[8YI0N?>LRQO6E]_\
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M!]KDL]/CMC=QWL8B6,6\T9C^;][YJF1%4C]V0N6&:^JZ*UC4<59$.";N>:_
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MR/J>WX4JKN7  8?D@_QK.3YG<M*RL-"YX'..PY_^L*7:&XZGT'S?_6IZKYG
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M+.>,GDFCRVFY?Y5_N#^M'-3_ )?Q_P" '+/^;\#F/^%B6N-J:-K_ *9_L>?
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M "1RIZBNA_X7-X>UKPWKTVK07T#2:A8"TL+&\,=RT,$6T2/)CYCD?-]>.E>
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M'4HHFG!\M4A:,H/KGMZ5R7B3XHV_B'X<V'AR6TFN;ZUG\R._NG5C F6)C0@
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MZ4 *9!'\D:[F_NCH/K2>06Y>1BW^R<"G?);IZ#]33?WS<C:@]",F@":BBB@
MHHHH **** /E;]JSX'W=U>2^-=!MFN-RC^TK6)<MP,"8#OQU^F?6OE7S >G-
M?JEUX/(KQ_X@?LM>"_'5U+>Q02Z%J$AR\VGD*K'U,9^4G\J^IP&;JE!4J^RV
M?^9\]C,L=23J4=WNCX-WTGF5]5R_L,P^8?*\6S;.V^U7/Z&F?\,,K_T-LG_@
M(/\ &O;_ +6P?\_X/_(\C^S<5_+^*/E;S*-]?5'_  PRO_0VR?\ @(/\:/\
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MXK^7\4?*GF4GF5]6?\,*+_T-TG_@(/\ &D_X837_ *&Z3_P$'^-/^UL'_/\
M@_\ (/[-Q7\OXH^5/,I/,KZL_P"&$U_Z&Z3_ ,!!_C2?\,)K_P!#=)_X"#_&
MC^UL'_/^#_R#^S<5_+^*/E/S*3S*^K?^&$5_Z&Z3_P !!_C1_P ,(K_T-TG_
M ("#_&E_:V#_ )_P?^0?V;BOY?Q1\I>92>97U;_PPBO_ $-TG_@(/\:/^&$%
M_P"AOD_\!!_C3_M;!_S_ (/_ "#^S<5_+^*/E'S*3S*^KO\ A@]?^AND_P#
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M O'.KJ5=7&02"">].7X@ZW$L*0WK00V\,EK;PI]V&"0DO$N>0ASR._>OH_\
MX8,3D_\ "8M_X"C'YYH/[!:X'_%8MSZV?\AFLYYAE]1WE+\&;4L+CJ/P1_\
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M<5_+^*/D+SJ3SO>OKN/_ ()]JP/_ !6<F0<$?8Q_C3O^'>Z_]#I)_P" 8_\
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M>ENF*PG!QR!^M%% $JJ%4 # %0V_S&1SRVXC/M110 7'+1+_  LW(]:FHHH
EBA^:25CR=V/PJ1SA&(ZXHHH 9;C$*'N0"?K4M%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>morf-20221231_g15.jpg
<TEXT>
begin 644 morf-20221231_g15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &: _H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***^-OB/^SWX-T_]HKX?>'H8-132O$$6H7&
MH0_VG/F1T3>I!WY4 D\#%,#[)HKQSPOXT?PG\6+GX5Z;80QZ#H?AJ/4+:XEE
MDDG)W[ C,Q.1COUKAM'_ &GO%_B+PQ\++G3/#^CR:OXTNM0M&AGFE2&W,#$*
M^X9.,#+#!)Q@4@/IRBOD^?\ :D^(NF^%=?UZ\\,>'_L7A36AHVLF*ZFW7+F5
M4)M@1\H 922Y.<].#7<>(OC5XVUKQEXOTGP!H6CWEGX1AC?4KC6)Y$:XF>,R
M>3"$'!"@_,W&:8'O%%?,^H?M1>*?%-UX M/ 'AK3[^[\7:3<7L<6JW#1BUEA
M8JZLR\%1M?W)Q6]^V+<7L7[,>N2W#"WO\6?G?97(57,\>X*>N,YQ[4@/>J*^
M$?",>E^$OC!\-9="\/\ B[X;V]U>&&^N_$MQ,;;459/EMU!9@68],X'->TZA
M^TAK5G\._BWXA72; W/@W6)-.M(2S[)T5T4-)SD'YST]* /H6BOGR]^.7C_6
M/BQ!X+\*^'=&N_\ B4V.KW-W?3R1B&*4CS> ?F(W#:/KFO+_ (W?&#QI\4?@
M7XTURQT?3;3P(NHC3[>X6YD74<17*+YY &W:6&W;D$9[XY /M.BOESQY^U7J
M?A/Q)K6C:+'X=6W\+V5N]VFN7KPW.HR-&':*U"C&X+W;/.!6_>?M >+/%7C?
M2_#_ (&T72)TU3PO%XBAN=8FD00AF(*,$!W=E &.3DG H ^A**\]^ OQ/G^,
M'PQTSQ+=V*:=>S/+#<6\3%D62.1D;:3S@XSSZUZ%0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#US5/#_@Z[UJWL=;?1;>47D<,,_E\27#R.,11*WRY.<F@#V2BOEGQC^T+?\
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M?WZ$ []IW_+QGBOHVB@#Y@\2?LZ^*UUNXT+1_P"SY_"&N+HO]HW\\Q2XM?L
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M=S 9"],^U?,VF_ ?Q_INJ?\ "4/J-C=:QK U*+5]-C01^5'=HQ4"?)\WRW2
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M31YYYRW]TT =_17+1?%'PC/K7]CQ^)--?5,R#[*MRI?*9WKC/4;6R.O!K*\
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M[75K.6TOK:&\M)EVR07$8>-QZ,IX(^M.L[.WTZUBMK6".VMH5"1PPH$1%'0
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M  N#X_?]"3_Y39/_ (NC_A<'Q^_Z$G_RFR?_ !=?6%%'U.I_S^E^ ?VOA_\
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MJM'$574A!079;!1116QR!1110 4444 %%%% !1110 444UF6-2S$*JC)8G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:5RQ6-;EPJC/0   #L*[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV%?8M?'G[/GCZ*ZN?!&G#X^QZFS)#%_PBS:1&K,0G_'MYI&[Y>F[/\-?8=,
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MO*Z75[<7[^<02))I#(X& .,L<#TK9HHH **** "BBB@ HHHH **** "BBB@
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M;44LI+>.XAM]E_<K!&6=L#YF&,]\>U=_9W"75K#-&5*2(KJ5.001D8-?*_\
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MW0/^$-TK7?$%Y;Z$VH27$<5NSM(S>5*Z,P &2 %!)Q@9Y-<:W@/Q4;-O!_\
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M9.E_,NT444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M23^SI#'Y,=OF2ZPJG=",_./FQGCD'TK:5MR@X(R,X- #J*** "BBB@ HHHH
M**** "BBB@ K@_B_XPN_"'A^.1/!VH^,M,NV>VU&VTL*\T4#(<OY9^^#T(!S
MS7>5Q7Q0M/'>H:;96O@2^TK2KN68B[O]4B:7R8MIYC0<,^<?>XH \*^!VA_"
MW7/%FD/IWC[7]4GT60OI/@_Q+=&(Z=)M*C;"ZAF*J2!R<5]55XKX1_9CL+'Q
MC8>,O%_B/5?&_BVR;?;WEXPA@@;G_5PI@ #)X)(KVJ@ HHHH **** "O$?VA
M/^2@?!3_ +&H?^D\E>W5XC^T)_R4#X*?]C4/_2>2F@/;J***0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445Q'Q5^+&D_"?0X[W4 ]U=W#B*TT^W(\ZX?(X4>@SR?I
MW(I[DRDHJ\MC0\4?$CP_X0UK1](U2_6#4-6E\FU@52S$] 2!T&<#)[FOD_\
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M/_T$5Y9^UY_R;CXV_P"O:+_T?'7J>A_\@33_ /KWC_\ 013 O4444@$I:**
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M[SDD9V MQ7N]<E\2/A=X?^*ND6^GZ_;RNMK.+FUN;69H)[>4# >.12"IP2*
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M+\30:_;^./"JZC#I2:,C'2I"GV=7W@$;OO9[U]+44 16JRK;1"=E><(!(RC
M+8Y('IFI:** "BBB@#Q[]KS_ )-Q\;?]>T7_ */CKU/0_P#D":?_ ->\?_H(
MKRS]KS_DW'QM_P!>T7_H^.O4]#_Y FG_ /7O'_Z"*?0"]1112 **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .'^&/P3\%?!O^W?\
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M*!\%/^QJ'_I/)30'MU%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*@@C=R*^P_&7PG\(_$*ZM+GQ'H-IJ\]J5,3W .1M)(4X(W+DD[3D'N*ZQ0%
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M>\?_ *"*?0"]1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(EEOMO[4NO*+7&3\A'F(-O3N/K7DOPL^(/[8&J:A?IXY^&'@O2K1(5-L]GJ
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M7'_4LP?_ !5<9\(%^-'Q8\"VOB-?BG9Z:)I[B'[.?#L$F/*E:/.[(Z[<].]
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M> K+XG^!]5\+ZC//;66HHL<DML0)% =7XR".JCM706=NMG:PVZ$E8D5 6ZD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>morf-20221231_g16.jpg
<TEXT>
begin 644 morf-20221231_g16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %0!.(# 2(  A$! Q$!_\0
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MMEO]=T6\OHKY(K5XVD2:*XCPLJE4.< 8/'-<Y\(_VU[[Q]XZ\)Z/XF^%^K^
M]"\<0R7'@_7;W4(+E=51(_,(EBC^:V=DPRJQ;.>M6HMRY5Z_?>VNVMG9;Z/L
M3LN9_P!?\!75WM9KN?45%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L#1?'F@>)/$FO:!IFIPWNKZ"T*:G;0Y)M6E4O&K'&-Q49P#D
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MZ]1S]VHXK:[7W/OYZZ>3/9Z***D HHHH **** "BBB@ HHHH **** "BBB@
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M6U2?2M*EM3,6\T3@1J\N\?<$Q^Z,H< U\RZ'KVLQ_ +X3^+M>O[O4?ASX/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"'3WP1_P">_BC_ ,&4?_QJC_AT]\$?^>_BC_P91_\ QJCZIP3_ -!>(_\
M!</_ )(+5_[OX_Y'T#_PT[\'?^BL^!__  H[/_XY5/6OVAO@IKVE76G7?Q8\
M%&VN8S'((_$]HC;3UP1+D5X5_P .GO@C_P ]_%'_ (,H_P#XU5;4O^"6'P'T
M>PGO;V^\2VUI I>2:34XPJJ.Y_=5%3!\#N#53%U^6VMZ<+6ZW]XTI_6E.+IV
MYKZ6YKWZ6T/HB']ICX-PQ)&GQ8\#[44*-WB6S)P/<RY-._X:=^#O_16? _\
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M\,?^BC>$O_!Y:_\ QRC_ (7Y\,?^BC>$O_!Y:_\ QRO(_P#AWG\(O^?;6/\
MP8'_ .)H_P"'>?PB_P"?;6/_  8'_P")H]IF7_/N'WO_ "#ZIP3_ -!>(_\
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M2.]8GP5^"7AWX$>$Y-#\/O?WKW-PU[?ZMK%T;J_U&Y8 -/<3$#>Y"@=
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M;YV[[V_.-NWC&.O>LJE]+7WZ6_&_3TU-:=M;VVZW_"W7UT+]%%%:F05^5_\
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M\9Z]KMCH.DV^N+*UHTL\F&+B)E?"H';*GC&<'&*YKP%_PUM_PF6D_P#":_\
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ME^!M(UG3+ZYNE@DE6&=[-1.VR-2S$MLSM4G/6O7O@Q^VA\&_VA/%4_AOX?\
MC'^W]:AM6O9+7^R[VVQ"K*K-NFA1>"ZC&<\]*CX^7D6KBI672\;OY;_(?P\R
M>R;5_1V^_:_F<#^U9^W?X>^!>I:=X4\+FT\5>.[O4+6UN;.,F:WTJ*25$:2Z
M*$;&(;"H2"2P/3K]55\;?MY?#GPQX!^ $LOAW0K'2)M7\<:1J&H36L062[N'
MOD9I)7ZNQ)/4\=!@5]DU$-:=WOS-?^2Q?Z_KY(E_&LMN5/\ &2_3^MVM%%%!
M04444 %%%% !1110 4444 %%%% !117.?$*T\4WOA#4(_!>H:;IGB;:K65QJ
M]L]Q:;@P)25$96VL 5RIR,Y&<8I-V5QI7=C\XOCEI/P'\1?MD?$IOCG\6-:T
M;5K2*SBT*#2[J:WAL[0P*SP,Z1,5DWDOMR 1(",G./IO]B'1/@?HZ^+_ /A3
M7CO5/&RR&U_M,ZE?RW7V?'F^5M,B+MW9?.,_=%>>^+/C!X[\+ZM>R_$K]C/_
M (2K4RRAM<\'16^M)>G &_:83*HQ@?/D@#MBNI^&/BCXT>,-2E@\%? 3PY\!
M] N)(_M>N>(7C>[FC&<A+&W2,EQD@>8^T;L\\BKHZ04%VMIHOG?[WUN35?,W
M)_CK]WZ=#Z^HI!G SR:^3/B%^W!-9?M(>#?AAX/\/2WUA<>)%T#Q#XAU*UD2
MVAF,3.;:V.Y=\P #%B"H!'!W9$KWIJ"W?^:7YM?>$GRP=1[+_*_Z'UI17S?\
M<OCU\1;;XQ:?\)O@]HWAG4?&1T5_$6H7GBV>=+*VM!*(DC58?G:1VS@YP.,]
M>.8F_;FNM2_9Q\)>,M%\,VK^/_$^OKX1M/#UW=G[-!JOFM&XDE49\I=A?@9(
M*CC.:(WDKQ6^B[O7ET_[>T]?D6URNS_X;3FU_P"W=?0^MZ*^7?AS^U9XET'_
M (6MX?\ C-I6AZ9XO^'>EIKEY-X5FE>QU"R>-I%>%9OWBD;=A#=R.E<_\*?V
MLOBC<>./AF/B9X5\+:/X-^*43R>&)]"O)Y+RQ?R?.CAO?,&QVD0C!C  /7T%
M*/,[+R]-;V7J[/3NK;D/W4V^E_P2;?HDT_1W/L*OBW3?^4MVJ?\ 9,5_]+(Z
M^TJ^+=-_Y2W:I_V3%?\ TLCJ1GVE1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 8>LZ#J&I>(=!U"U\07FF66GR2O=Z;!%$T6
MHAXRJK(S*64(QW#81D]<UN5SVN>$['6?%/AS6+C4-0MKK27G:VM;>^>&"X:2
M/8WG1*0)=JY(#9P>:Z&NFK)2A32=[+LE;5]?M=[O7ILD);L****YAA1110 4
M444 %%%% !7P!_P14_Y-9\4_]CG=?^D-C7U'^TU^TUX0_9:^'-QXI\4W&^9M
MT6G:3"P^T:A/C(C0=@."S'A1SZ _E#^P=\8/VG_ _P )=6T?X)?#?3/%OAJ3
M7)KNYU*^M'=DNS;VZO%O^T1J $6%L8S\YY/0 '[=45^9MW\0/^"C^OVLBV?@
M+1=(9HBHEA_LQ'4L.& GN6&X>A!'J#4R_"[_ (*,:YE;OXE:#IP8A"2;&/CU
M_<VA_P : /TLK\J_V!?^4IO[1O\ W,?_ *?+>NDD_8__ &YO%DGE:Y^T-8Z5
M9RMF633-9O(IEP."@AMH^"<9 <=^O0_(G[.O[*OB_P"-G[7'Q/\ AN_Q0OO#
MGB+1/[3?5?$\*37,NI/!J$4,I;]]&[>9(XER[')49YY !^ZVL>*M$\/*S:KK
M%AIBKU:\NDB Z?WB/4?G7CNN?M=?!/P[X@DOKSXW>%3:QVY@;2[75;>X42!L
MF3]V6;=CY<5\LZ%_P1(^&UO'&-9^('BJ_< ;VL8[:U!/&<!DDQW[GJ/3GTWP
M[_P20_9TT5HDO-&UK7W2,*PU'694,A&,N?(\ODX/3 Y. .,1**E:_3^OZ1I"
M3C>W5=OZ^\V=>_X*I_LVZ')-'%XWN=6DB+*5L-'NV!(SPK/&JGIP0<'(YQS7
MENO?\%J_A!8S3QZ5X1\8ZIY;,J2RP6MO')@D!A^_9@#P>5!YY Z5]'^'?V#?
MV?/"]O'#9_"7PW,D:A0=1MC?-QZM.7)/N37J7AWX6>"_!]O'!H/A#0=$@C&$
MBT[3(+=5'/ "* .I_.K,S\]HO^"N'CWQLK2> OV<M;UNS<D07:W5Q=>8 2,[
M8;7 Y!& YZ'FNO\ AW\<_C/\</[1O?BO\-#\.-.M#&-#@FL+FUGN-VX7&_SV
MRVTI%@A$X?\ BZU^@5>+_M'?\R]_V\?^TJ^4XI_Y$];_ +=_]*B?2\.?\C2C
M_P!O?^DL]HHHHKZL^:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KXG^.G_*4;]FK_L!ZU_Z1WE?;%?$_P =/^4HW[-7_8#UK_TC
MO* /MBO$OVVKR\L?V1_BW-8W)M+@>'+M?,"ACL:,JZ\_WD++GMG(YKVVO,OV
MG=!;Q1^SA\4M*CLI-1GNO#&I1PVL*,\DLOV:0QJBKR6W!< <DXKIPL)U*].%
M-VDVDGV=]&*6B=SX"_X)]?\ #5NN_#GX;ZAX>\1Z1)\)X;J2W^QZJELS"U2Y
MD2921'YY((?;\_4*,A>*_3W6TU"31K]=(EMX=5:!Q:27B,\*S;3L+JI!*[L9
M (.*\+_8%\(P^"/V0_AMIL-I-9%K!KN2.X#!R\TTDK,0W]XOD=L$8XKZ!KV\
MYQE:I7CAJ]*G&="\&X12YW%V<IO[<FUK)[F5.*M=-ZGY\7'A?_@H%Y\FSQAH
M03<<>7#I>W&>V;;./KS7W?X/77(_"ND+XFDLI?$(M8QJ$FG*RV[3[1YAC#$D
M+NSC-;%%:9QGTLXA"#PM&CRWUI4U!N_>V_D*G2]G=\S?J[GPO\=M-_;:TWQI
MXKU/P3XBTF;PC#(\^FV6G6=BTI@"Y5 D\3R-)@<@L<MG;@$ ?5'P!NO&5_\
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MFA*'=-?>FOU/BSXS>/-+_9B_;:/Q2\<"]L? ?B#P2NB)K%MI\]U'#?177F+
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M_LU? #PQ\/KO5(]9O=,6:2XO(8RD;233/,P0'G:ID*@G!(&<#.*]AH ****
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MT!\*_P#H;O&'_?\ M?\ XQ1_PZ ^%?\ T-WC#_O_ &O_ ,8H_LGA'_H:U/\
MP0__ ),/:8C^1?>?:O\ PF7A_P#Z#NF_^!<?^-36OBC1KZX2"VU:QN)WX6**
MY1F;OP <FOB3_AT!\*_^AN\8?]_[7_XQ7AWPY^!.B_LY_P#!37P)X,T"^O\
M4=.AA>Y6?4F1I2TEA<$@E%48_"N_"\+\/YE2Q+R[,9SJ4J4ZEG1Y4U!7M?GZ
MD2K58-<\-&TMS]7Z***_)CO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***^??BI^T%XB\#^/-4T2PLM+EM;7RMCW$4C.=T2.<D2 =6/:O$S;.
M,+DM!8C%MJ+?+HKZV;_1GKY9E>)S>LZ&%2YDKZNVETOU/H*BOE'_ (:N\6_]
M [1?^_$W_P =H_X:N\6_] [1?^_$W_QVOD_]?\D_FE_X"?3_ .I&;_RQ_P#
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M=0757&WB-;ET%OOSW*A>WO4,;&__ ."FDT>IL2MA\-UDT>.3[H,E]BX=/]K
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MO"JH?PDU_+Z]M[_B^^V@5OC:??T_+\/QUN?4M%%%2 4444 %%%% !7Q;IO\
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M1\Z!X9.Y(;J)6RBJAY6V!ZGK*<_P]?U*M;6&RMHK>WB2"WA01QQ1*%1% P%
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MH=Y#,22QV  <YKZTHIQ?*T][.Z\GO?[]==+A+WDUW5GYK;\M+[^9X?\ M#_
M?7?'^M>&?'?P^UVV\,_$WPKYHTVZOXFDLKVWE $MG=*OS>4^ =RY*D9 S7%7
M'Q?_ &JIIGT6W_9\\-VU]M*+XHF\;PR:6'VY#FV$8N"N>-O!SWQS7U+14K1<
MO3M_6OZ7UW8V[Z]?Z^7]6V/#OV6O@/XA^#6F^+M5\9>(;3Q#XS\8ZL=;U>33
M;8P6<$Q0+Y4 /S,@ QN;!/H*^?+7X1WM[_P49U3P]I\T3_#ZT>V^)&I6$:?+
M#J[0R6D0;L"[ SXP22N:^W?%WAT>+O"VK:(=2U'1QJ%K):_VAI%P;>\MMZE?
M,AD .R1<Y5L'! KB/@;^SYX<^ >F:K%I%]K6OZOJ\ZW.J>(?$M^;[4M0D5=J
M&:8@9"KP   .>,DDZ1E:HI[<JLOT7_;MD_5+U)DOW;COS/7[]7\TY+T;]#TZ
MN"^$OP9T3X-KXL71;J_NAXEUZZ\17GV^1'V7%QMWI'M1<1C:, Y/7+&N]HJ5
MHVUU5OE=/\TA[JW2]_GJOU9\V_M ?"7QWI7QB\-?&OX5Z=8^(O%&E:9-HFK>
M&+^]%DNKV#MYB+'.05CE23D%_E.>3Q@^3^-OA[^T;\8/B?\ ##XL:QX+T[PD
M?!NN0BV\"6>MP7MTUI,2E]<S71*0E@@CV(G.TMWXK[JHH@_9N+WY7=>6MW\G
MK>_=VL$_?33ZJS\U:WX+MV5[H^=/VV/A+XT^('@GPWXD^&-M#=?$KP;J\>JZ
M-#-*D2SAE,4T3.[HH4H^X@L,[ .]=G\-?A?%\&?V;;'P=&YFFTW1)5NIV.6F
MN7C9YY">Y:1G;\:]8JMJ=A'JNFW=E,66*YB>%V0@,%92#C/?FL:D7[&I3C]K
M7YVL:1:]I"<OL_E>_P"&MO5GY_?L<^)/CY\+?V5?A]'X,^'>E_%OP[J=D;FQ
MD?Q!%I%UI1>1R\4JRH5FC#Y961@V'VXXS7K.@_L;ZMXH_9Q^)OA/Q[K-K_PF
MOQ'U";7-4NM/1FM+"\8QF!(E)!=(C%'G."V#7O\ \'?A9I/P3^&?A_P-H=Q>
M7>DZ);?9;>;4'1YW7<6R[(JJ3DGHHKLJZJLE*<Y+KUZVNG^:3OOIN<]#GIPA
M?1QL_FEO^+TV\CY&N/%G[5NI>'+CP!)\(?"UK?RV)T\_$%?%:'3 3'M,ZV/E
M?:.Y(0]_:O?/@/\ ">S^!?P?\*> [&X:\@T.Q2V-TR[3-)RTDF,G&YV8XSQG
M%=[14<SU[NU_.U[>75[6*Y5=6V6WE>U_/HMPHHHJ2@HHHH **** "BBB@ HH
MHH **** "BBN2^*GQ4\,_!7P+J7C'QAJ#:7X>T[R_M-TL$DY3>ZQK\D:LQRS
M*.!WI-I*['&+D[):G@OQ@_9O^,'C?XC:SK?AG]I[4O 6B73H;?P]#H4=PEH!
M&JL!(;A2VY@6^Z/O8JO^QE-XQT'XD?%OP1XX^+EQ\4]7T"73S%*]JD4=O#+%
M(X8%7;#L<JR'[OEJ<G=Q\R?%CQ[_ ,$^OC7\0-6\:>*_$FK7FOZHR/<S0VVK
MPJQ2-8UPBQ #Y47I7U!^P;>_LX#0?%&G?L]N\T%O-!+K$]Q!>+,[N'$6Y[E0
M6 "O@+P.>.>=**:B].GKU77]?,FJTVO7T_#^OT/JJBBBH&%%%% !1110 5\6
MZ;_RENU3_LF*_P#I9'7VE7Q;IO\ RENU3_LF*_\ I9'0!]I4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\ ?!O_E,E\=O^Q,MO_1.C5]_U
M^/GC[]L?P]^SK_P4J^-?Q TZP_X3R#4-$M]!L(=)NT$4EV(-.#!I0&PJO:RH
M=JL=PQCKCO&\2?MR?MGR;=)L%^"7@>ZW#[0^[3Y&C)4<NP:Z=L9(:-41N>1Q
M0!][_&/]ISX7_ *S:;QUXSTS1)]A=+!I/-O)0/[D"9D;J.=N.1S7Q+XT_P""
ML/B?XH:S+X8_9U^%.J^*=59@@U+5+5Y@@+A1)]FA/RH1G#R2*!D%EX(KLO@W
M_P $@?AKX5NAK/Q*UK4_B;X@DD,\ZSR-:63R%BQ9E5C+(<]2\F&YRO.*^W/!
M_@;P[\/=%BTCPQH6G>'M+B&$L]-M4@B'_ 5 &?>@#\)_CYX'^.OCC]K/X9:)
M\:M;&C^/O%;:9#I]U;&)FTBVGOY(8<+ 54&.3S7"JV>1ELDX^Q[7_@BOIVK7
M)NO&'QGUWQ%=\*)HM-6)Q&!]W=+-,>N>>G/2N8_;Z_Y2F_LY?]RY_P"GRXK]
M5* /SXTW_@BG\'+=D:]\7>-KO;@E8[JTB5CG_KV)Q]#GWKO]-_X)*_LY6./.
M\.:MJ."3_I.M7 SQT_=LO2OLBB@#YI\._P#!-W]F_P +LS6OPOL+EVV%FU&\
MNKS)7.#B:5@,YY  ![]!7:6'['/P)TU0(O@]X)?&1_I&@VTW7_?0U[%10!\;
M_P#!2SP%X9\-?L,_$N72/#NDZ5*O]F;7L;&*%A_Q,K0<%5'8D?2M[_@EQ_R8
MG\,O^XG_ .G2[H_X*C_\F)_$W_N&?^G2TH_X)<?\F)_#+_N)_P#ITNZ /JJB
MBB@#P/\ ;0_99E_:Y^%VE^#XO%K^#6L=9BU;[>E@;PR!()XO*V"6/&?/W;MQ
M^YC'.1\'?\$G?V19=6\3:;\;AXQ>"+PUJ]]IA\.C3R5NB^GA/,\_SAMQ]K!Q
MY;?ZOKSQ^I_C'QC9>"=,BOKZ*>6&280!;=59MQ5FSR1QA37RK_P3M\)W?P+^
M'M]X"UZ2&[UC4]<N-3AGTUB]NL1M8%PS.$8-F!^ I'*\]<>UALVRJAEN*PV)
MQ'+BN:FJ4>:2?+/F51))V?-:%[^1T1R_%UHK$4Z;=-7N_3_(^R**AN[R#3[6
M:YNIH[:VA0R2S3.$1% R68G@ #N:^#OV@/\ @HAJ/B3Q&/AQ^SQI<GC#Q3>9
M@.O6\/G10L2!FW0C$F.297Q&N,_,,D=62</YAQ!6='!0TCK*3TA!=Y2>B7XO
MHF<-2K"DKR/=_P!L7]J#P]^SW\+/$"#Q%%I_CV^TRXB\/V<$:7%PMVT3""=H
MF!41I)M8LXVG:1AB0I^9[;PC\8?VD/A1X+C\&>.%\,>+=8M['4_$FN"=[,SV
MSPA[D)Y"9!:5XVV*$4XQE5KIO@=^P/I?A"^F^)O[0>KQ^,?&=Q-]J:RN9S<6
MT<G\/F$\W$F /EQL7& & !KU/0[?5/%/C+5D\,,UDMZTK,=PB\NW:0'!QT ^
M087Z=*^<XWQ&2Y#C,NHY+4EB,52J.4IK2+=M%"._*G]I[]+H^MX?PU;%8;%N
MM[E.4;7>RUUN_P!#POP_^P-\(/A5/]H\8ZGJ/Q3\5%O,EMWE-K9++G)+A&+L
M<]0SG/<#-?1'@'X(S:A:6\*:59>#_#*'?%IVEVJ6R^N5B48!.3\[9)SGFO4O
M!/PETGPCLN)0-1U(<^?*ORH?]A>WU/-=1]CU#_A(/M7V]?[+^S>7]A\D9\W=
MGS-^<].,5PYOF7$/%TU5XDQ,IPOI2B[07G)*R?\ VZO0FEB,%E:=/+(KFM_$
MDM7Y16MOG\QGA_PSIOA>R%KIMJEO'_$PY=SZLW4FM2BBNFG3A2@H4U9+9+8^
M>J5)U9.=1W;ZL*\7_:._YE[_ +>/_:5>T5XO^T=_S+W_ &\?^TJ^8XI_Y$];
M_MW_ -*B?0\.?\C2C_V]_P"DL]HHHHKZL^:"BBB@ HHHH **** "BBB@ HHH
MH **** "OB7]JKX*_L[?"GX>:78_$G0/$DG@S4O$UYK4U[IDEQ.EE?3IF2:<
MQG>L;<@  @$CCT^VJ\$_:Q^/6O?!O3_"6D^%O#NC>(_$7B[43I-G#KVJ)8VD
M;%,AFW?ZW)*CRU(8YXS42Z66KLO75:?>E^94?/I=^FCU^YO\CR?]F_\ 8[_9
M3O?$6B?$'X3W::Y?Z/<+=6UQ9Z]+<>1(!P)(F;*GG[K@'FOM.OASX+_\$^=<
ML?C9I/QB^('B#0=&\3V4HN4\/?#O2(].T[><EA-(1OF#$\Y )Q]ZON.MY?"E
M?Y;V^9C'XF[=M=K_ "\@HHKGOB!\0- ^%G@W5?%?BG45TGP_I</GWEXT;R"-
M,@9VHK,QR0,*"3GI63:BKLU2;=D=#17C7P3_ &POA%^T5KU_HWP\\6_\)!J5
MC;?:[B'^S;RVV1;@N[=-"@/+ 8!)YJ;PK^UU\'O&WQ0N_AWH?C[2]0\86SM$
MVGQ^8!)(H)9(I2HCE88.51F(P<C@U7*[I6U>I/,K-WVW\CU^OB?XZ?\ *4;]
MFK_L!ZU_Z1WE?;%?$_QT_P"4HW[-7_8#UK_TCO*0S[8KE/BQ!X=N_A=XNMO%
MU\FF>%;C2;JWU6\>7RA#:O$R2MN[$*QYKJZ\5_;4L;G4_P!DWXLVMG;RW=S)
MX=NPD,"%W;]V3P!R>*TIU)4IJI!V:=T_-"WT9L?LO?\ "&)\ /!$7P]UQO$?
MA"'3UCL=2D/[R8 D/O&!M</N#(0"I!! (KU*OE#_ ();:?=:;^Q#X 2[MIK5
MY'OYD6:,H6C>]F9' /564@@]"""*^KZJM6J8FK*O5=Y2;;?=O5O[P2459!11
M16(SQG]L3XJ:U\%/V;?&GC'PZ84UK3XK>.UDG3>L;37,4&_;T)42E@#QD#((
MXK7_ &9/B%JOQ6^ ?@?Q9KAA;5]4TY)KIH$V(S@E2P7MG;G'3)XJS^T1\'8/
MC]\&?$W@*XU&325U>*,)>QH',4D4R31DJ?O+OC7<,@D$@$'D:/P6^&</P;^%
M/ACP5;WLFHQZ+9K:_:Y%"F5ADLVT= 23@<X&.3UKZMULM_U>5!)?6_;-WMK[
M/D22OM;FOI\S"T_:W^S;\;G:T445\H;D<D<3M&9%5F5LQE@,AL$9'OC/X9JO
MK$]Y;:7=2Z?:I>WR1DPV\DGEK(W8%L<5XM^T-J-U9^,_ "P7,T*_:V?;&Y4;
MM\8SQWP2/H3ZU[/KBZBVD78TEK==2\L_9VN@3$'[;L<XKQ*.8+$U\5AHQ:=&
MRNM6^:/-HNZVUN>U5P#P]'"XF4DU5OH]E:5M7V?E8MPL[1(9%"2%0653N /<
M9[T^HX/,\F/SBIFVC?Y8.W=CG&>V:DKVEL>,]SF+_P"%_@W5;V:\O?"6A7EW
M,Q>6XN--A>21CU+,5R3[FH/^%/\ @/\ Z$GP[_X*;?\ ^(KKJ*8CD?\ A3_@
M/_H2?#O_ (*;?_XBC_A3_@/_ *$GP[_X*;?_ .(KKJ* .1_X4_X#_P"A)\._
M^"FW_P#B*_/#_@GOX?TN3]O+]J.R;3;-K.UU748X+<P(8XE&J2@*JXPH
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MM5>[ \8?\%*K2SU4++;>$O !U#2()%!"W%S=^5-,N?XMBA,CL:]6^.7[0/\
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MZ05XA^V/\%/$O[0WP-U#P+X8U/3M)NM1O;-KFXU0R>5]FCG6208C!+,=@PO
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M9<\??MA^(?BI#:?&'P#X?T3P.;65KB^AEACF20 >6(Q%-*78MP58*-NX[@0
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M%/\ HEGAW\K/_P"3*_2>B@#\V/\ A;7_  44_P"B6>'?RL__ ),H_P"%M?\
M!13_ *)9X=_*S_\ DROTGHH _-C_ (6U_P %%/\ HEGAW\K/_P"3*\Q\%_M&
M_M(3?MK^&/!_C[P]H^D^,;I&=M.MX(R?+%I*Z$,LS)RJY^]7ZZU^8OQ$_P"4
MUO@7_L'K_P"FRYKAQF#I8ZE[*JO-/K%])+S6Z9VX/&5<%5]I2?DUT:ZQ?D^I
M]>_\))\<?^@#:_\ ?,7_ ,<KRG]J;PS\=OB_\"/$_A&+PM%>R:C]EQ! T$;M
MY=U#+PQDP,;,_A7VG17'E&7XC)\QPV94L95G*C.$U&4DXMPDI)22BFXNUG9I
MVZH]?$9Q3Q%&='ZG2CS)JZB[JZM=:[KH?EW\(X?VV?@E\/-)\%^&OA[:)HFF
M>=]G6Z6TED_>3/*V6\\9^:1OPQ78?\+0_;V_Z$#3/^_%G_\ )%?HI17[1B..
M(XJM/$5\JPLIS;;;A.[;=VW^\ZL^2C0Y4HJ;LO3_ "/SK_X6A^WM_P!"!IG_
M 'XL_P#Y(KD_$W[7G[6/PO\ &W@[0_'FAZ/H1\17R6UK&UG"[3+YL:/M*2L
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MWK&,GDITKZPUO3?[8T6_L/,\G[5;R0>9MW;=RE<XR,XS7F.B? /^Q]:L+_\
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MNXKIS65:>88B6(ARU'.7,ELGS.Z7H]!4[<BML%%%%>46<O\ $WXE>'?@_P"
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M4/\ KWD_]!-7J@OK47ME<6Y;8)HVCW8SC(QFOS*:;BTCT*;49ION>+_LG?\
M(D:M_P!A$_\ HJ.O;Z\ _P"&1]/_ .ABN?\ P&7_ .*H_P"&1]/_ .ABN?\
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M'@#WKZ:KP\PRO'95-4L?0E2DU=*47%M=]2XRC)7B[^@4445Y904444 %%%%
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M7,,W]G8\SIY<C8WY[X^Y3H_P[]U?Y_+^EMN%7X[=G_6_]/='O=%%%( HHHH
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M$\$&O+M)^ _[3NJ:397P_:T\LW$"3>6?AOIAQN4'&=_OUI+6_E^HVK)/O?\
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M&1#]KM8+G"RPS1Y .2 2<'C%>"_M&6/[1O[/?P__ +>F_:HEU_6;VZBTW1=
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M7_AM_P )1/K?Q&\8^(OB1K8*HI\2:O)=SQQJQ**P3]XP&>=QVGT&2*]/\/\
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MLZ\' YXKJZZJU^2G=O;JK+XGMKJO/36ZZ7)6["BBBN4H**** "BBB@ HHHH
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MH*&/R8D3<S[5"[G.2<=R?6GUIS1Y=%J9O<\.\ ?M@> _B1^T-XP^#NDM??\
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M-"L9P531O#;/;33*2, RH3<.PZ9B,8(/*U[=H_[-NDJBG7=6OM6;D-#:L;*
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ML:]%I:N+A43V:YTVVM+K3K;IKXYX/_:T^'GBK9'/J,N@W3''E:I'L7_OXI*
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M&K'_  ?C[3^O2R-*FU.7^/\ #D/::***1 4444 %%%% !1110 4444 %%%%
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MS56HXM+DNO<YK*]_M<V]O=\S]%Z*^3O^'EGPN_Z%[X@?^$M<4?\ #RSX7?\
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MH>J>&]-F\%^-I'3POX[OTWWVEWA #:?-,WRJC#A&4*3GDM\Q'UA\;O\ A?\
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MBH1><=$TFZU$1G^,Q1,X'XE:^%_ ?BKXC?#!/V>OBMK'Q,\4^+1\5]6M=/\
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M_P"#%*/^&X?@#_T5SPI_X,4H ]QHKP[_ (;A^ /_ $5SPI_X,4H_X;A^ /\
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MZTE%P=F3?5KLVON=@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <?\8/AK8_&+X7>*?!.I2M;V6O:?-8O/&NYHMZD!P.Y4X;'M7SS\(_V7
MOBB?BCX"\2?%OQ-X5UC3OAOI]QIWAFW\.6EQ'+=>9&L7VJ[,IPL@C0#9'E<G
M.>.?K:BG'W).4=_^'7Y-_?Z!+WH\K_J]KKT=E?T]0KXMTW_E+=JG_9,5_P#2
MR.OLC5-4LM#TVZU'4KRWT_3[6)IKB[NI5BBAC499W=B J@ DDG Q63;-X6N(
MT\9VYT>6.:S$B^((_*(DM2 X87 ZQD8;.[;C!I=WV Z"BL/PAXZ\-_$+21JO
MA;Q!I7B72V8H+W1[V*[A+ X(WQL5R#VS6Y3U6X!1112 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBL3Q=XW\.?#_1WU;Q1K^E^&]*1@C7VKWD=K &
M)P 7D8+DGWH'N?(7C;_E+E\/_P#LFLO_ *57U?;%8&F_\(MXF^Q>+]/_ +(U
M7=;?Z+KUMY4V8#D_).N?D^9CP<<GUI/"'Q"\+?$&WNI_"WB71_$L-K*8+B31
M[^*[6&0=4<QL=K>QYIV=VNQ-]+G04444AA1110 4444 %%%% !1110 4444
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M#;?_ !%>Q44 >._\,<? G_HC_@G_ ,$-M_\ $4?\,<? G_HC_@G_ ,$-M_\
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M_P"(KV*B@#QW_ACCX$_]$?\ !/\ X(;;_P"(H_X8X^!/_1'_  3_ ."&V_\
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M7->_G[ONV\NQR5%S*?7FC9+L[-?G[U_.W0[CX_1Q_!O]J?X1_%=6%OH^N;_
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MZ>?.I-^C2MW5EYGT%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M]+<[<_\ R6R5]7%:;V.>5Y0J<NF^CWOR6C_Y-J[7M)K72Y^A-%%%8FH4444
M%%%% !1110 444AZ<<4 ?G)^T5>?%3X+?$S0M2G^-VKWWQ4\4^)EB\,>"[6?
MR/#;:.)5#I<Q/&$$BA]I<OO/&W)Y'K_QHF\5_';]JZ'X-Z?X[\2_#SPYH_A(
M>([V]\(W:VEY=7<EQY42&8J2(U )*C[V2#VQQ/QC^&/[3OQ@\'>)/@OXF\.Z
M!XCT+5]66XM?BA)J-M;K8V2W"R1QG3TC60S(J;0R\?-RQY:N_P#BK\*?B?\
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M5\2_^$P7P/JS> 3HW_"7K%NT]?$$<KV3R @E)/*97 (R P/!(."!BOF/P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHK\]5_X*C?$#7?$GB;3?!_[,/B7QM::%
MJ<^F3ZAHFHW%S'OC<K\WE6#A"0-VTGOWJ>97Y>N_]?>.SM<_0JBOG#]E']MS
MPU^U!=ZOH#:'J7@CQYHJ!]1\,ZP/WL:Y 9HVPI=58A3N5&&1E1D5]'UI*+C:
M_4E23NNP4445(PHHHH **\S_ &DOC1_PSU\$_$_Q!_L?^W_[$BCE_L[[5]F\
M[?*D>/,V/MQOS]T]*^-[?_@JG\0X_#]OXGU']E3QA9^#7B2[EU^.[N'MEM6P
M?.61K!8V7:<@EPIX^8=:E23;2Z?J5RNREW_3_AT?HI17$?!7XP>'OCU\,M#\
M<^%Y99-'U:$R1K.NV6)U8J\;C) 965E."1QP2,&NWK247"3C+=&<9*2N@HHI
M&8(I9B%4#))Z"I*%HKBOA7\8O"?QJT?4M6\&ZHNM:58:A+IKWL*D1231A2_E
MD_>4;@-PX.#C(YKG_P!J#XY?\,W?!#Q%\0_[$_X2+^R/(_XEOVO[+YOF3)%_
MK-C[<;\_=.<8]ZF4E!<TMM/QV*A%U)<D=[V^>QZK17(?!_X@?\+7^%7A'QG]
M@_LO^W]+M]2^P^=YWD>;&K[-^U=V,XSM&<=!77UK.$J<G"6ZT,XR4DI+9A11
M14%!1110 445X)X^_:H_X0?]J_X?_!7_ (1C[;_PEFGRWW]N?VAY?V78LYV>
M1Y1WY\CKO7[W3CEKWI*"W?Z)O\DQV?+*71:O\OU/>Z**QO&/C'1?A_X7U+Q'
MXBU&'2-$TV$SW=[<'"1(.Y_E@<DFI;45=[ DY.R-FBO*?&GQSFLOV>W^*/@7
MPIJ7Q!^T6%OJ.F:%8I)'=7\<K)MVJL<CJ=C[\;"< Y [=E\-_%%_XV^'_AWQ
M!JNA7/AC4M3L(;NYT6\W>=8R.@9H7W(AW*25.54\=!5\K3DFOA=GZZ_Y,71/
MH_TM_F=)1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZZ#_ &)_8'V#_P B^?YO_COE_C47A_\ 97_L']L#Q-\=/^$G\_\ MK14T?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% "5\)_\$L/]7\??^Q\NOZU]V5^;'A+]C#]L
M+X/>)/&LWPP^*?@3PUHOB+6KC5GMIE:X=B[L5+&73I-I"D A6QQWZTHRY:CN
MMXM?^31?Z,<ES07E)/\ "2_4W/'$?]C_ /!8[P*=&BCBDU+PLQU7R5 ,@\FZ
M&Y\#DXCAY/\ =7FN3^.GQ)N_%GQ/^*-OK7QY\;?VIHWG#PWX/^!KWLRV:*&
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M HHHH **** ./^+'PC\)_'#P3>>$?&VDC6_#UV\<DUF;B6#<T;AT.^)U<88
M\&G_  O^$_A#X+^$K;PSX)T&U\/:';G<MK:@G<Q !=W8EG<X&68DG')KK:*%
M[M[==P>MK] HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>morf-20221231_g17.jpg
<TEXT>
begin 644 morf-20221231_g17.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MI.EG5%78+W[)']I"^GF8W8]LU>H **** "BBB@ HHHH **** "BBB@ HHHH
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MH_X>;_\ !1[_ *-E\'?]^I?_ (N@#]::*_);_AYO_P %'O\ HV7P=_WZE_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'RA_P6[^/US^SA_P3-^)&O6-P]IJ
M5S9BQM)HW*O&\AVY4@@Y&>U?BI\ =*\._$#5?@S%^S5\7/CYXZ^/4NI6EQXB
MM[TS#0]"C!!G=]X^:/JHR2#7ZK?\' '@'QE\?/A_\(?ACX6\,ZQKUCXI\8VT
MFM7%G;-+'86T9#%I6 PJG&.:P?VGO@'K'[,W_!7S]G/QC\-_ EU;^'=4TQM
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M#2"9?W:X]&YKG;_XO^,/AS\;_BOKVCO87&FZ3';SW-IJ;2.51@,K$ <*WZ4
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ME?%?PN_X)F^)?A]_P6C\3_M(2:UILWA76O#LFEQV(4_:A-( #[;1BOM0<"@
MHHHH **** "BBB@ HHHH **** "BBB@ HHK@/VEOVI?A_P#L>_"ZZ\9_$CQ)
M8^&?#]IP99CNEG;^[%&/FD;V49H [^BO.?B%^UCX#^%?[/$7Q5UW5YK3P//:
MPWL5XML\DTL<H!CVQ#YBS CY<9K$_9M_;J\!_M8:U<V/A&S\=P26MNMVTNN>
M%[O28)(VZ%))E"N?84 >PT444 %%%% !1110 4444 %%%% ')?M ^*;[P+^S
MYX^UW2YOLVJ:)X=OK^RFP&\F:.%F1L'@X(!YK\'/^"5_PB_; _X*\?#/QAXZ
MT7]IR;PB-"UA;*YM[^%Y#/)*ADW)Y:X"]L5^\WQZ\)7WQ ^ ?CKP_ID:S:GK
MWA^]T^SC9MJR32PLJ D\#)(Y-?!?_!LY^PU\3OV%_P!EGXCZ'\3O#K^'-2UC
MQ-'<6<+3I(9HXHC&S_*3QNZ>HH \N_X<A?MM?]'D:;_X"3__ !-'_#D+]MK_
M */(TW_P$G_^)K]<UM9&' 4Y_P!H5XY??MX?##3_ (]V_P -9-:OF\3W,OV=
M)$T^5M.$V,^2;H#RA)_L$YH _.__ (<A?MM?]'D:;_X"3_\ Q-'_  Y"_;:_
MZ/(TW_P$G_\ B:_5?XA_$#1?A-X(U3Q)XDU"WTG0]%@:YO;N=MJ01J,DG_#O
M7B/C#_@JG\$? _@GPOXANO$6KW6F^,H?M.F?V?HT]W-Y&<?:)8T!:*$?WVPM
M 'PM_P .0OVVO^CR--_\!)__ (FC_AR%^VU_T>1IO_@)/_\ $U^@WQ5_X*&?
M"/X,3^&H]:\27$W_  ED4=Q8/IEC+?(D,A 269HP1#&20-SX'->S6US'>VT<
MT,BRPS('C=3E74\@@T ?DG_PY"_;:_Z/(TW_ ,!)_P#XFC_AR%^VU_T>1IO_
M ("3_P#Q-?K?10!^2'_#D+]MK_H\C3?_  $G_P#B:^<OVE+O]K#_ ()'?MT?
M _PYXF_:$D\>0_$*Y65EMH2L*0B=(GC=9%YSNZBOW\K\P/\ @N)_P3[^*G[8
MG[?G[-/B7P'X?_M70?!P==8O&G2-+(_:HY?FW')RJGI0!^H,@VE?=5/Y@&FT
MZ0Y*^R@?D *;0 4444 &:***  ]**#THH **** "J?B*)9_#NH(UQ]C5K64&
MX!QY'R'Y_P .OX5<JIXD"Q^%=4FDM9+ZW@M)7E@0?-,H0DH/<CB@#\1_!W_!
M5OXP? ;XC>,K'P/^T-IO[1]]H<DUK9^"Y_ NHS-$JR[0%N(5"Y7[N]B5-?H7
M^PO_ ,%)O''[3OQ0A\"^//@'XU^&.N0Z-'JMQJMW(LVESE@#LC8#AC_=)R.]
M?+_P1_:T_;0\4OJ7B+]GW]D?X-V/@O[=/I]E>M+!:ZG+'&^W%PPE1B_<@CK7
MZ<?"/7?%FN_"O0KCQQI]KHOBRXM$DU;3[67S(+2X(^=$;)R >^: -Z:>.VB:
M21UCC099F.%4>YK+_P"$_P! _P"@YI/_ (%)_C7"_MM M^R3X\57DCW:=C=&
MY1AEUZ$<C\*\'\ _LN^"[OPEI<DFDS2226L;,QNY,DE1GO51C<3=CZR_X6!H
M'_0<TG_P*3_&C_A/] _Z#FD_^!2?XU\PZ]^RYX'LM.:0:.RR*O'^ER?-^M<]
M%^SGX)T?0V\W39);J0ER?M<F%SVZUI&C)NQ<8\RN?7__  L#0/\ H.:3_P"!
M2?XTG_"P/#Y_YCFD?^!2?XU\DZ7^S/X'N]#M)9+!HY)),8:\D!?Z<U6\7?LT
MZ!;ZC:VVC^'[=H"W[Z66]EW ?]]5?U606U/L#_A8&@?]!S2?_ I/\:!X_P!
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MP- _Z#FD_P#@4G^-'_"?Z!C_ )#FD?\ @4G^-?*>E_LN^!=>TR1?[)N+6^B
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M_:$T<FOWWVQ66#9K=SMCR, CYZZ&7]C3PEX8TFPAN5UZ5UB'G/\ VU<Y)/\
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MWZ==? _P*EY8K)_;$=S>92*W_M:[S(WK]_I73]3F:2H-.US]"!>VY_Y>+?\
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M7/RD:W<G'_C]3##UYK63^]GJ8?A^I42E!+[C]&/MMO\ \_%O_P!_!1]LM_\
MGXM_^_@K\R=)^ 6B:#%=K*NN7K=5SK%T,?\ C]0> /@_I_B*>XCOM-UJS59F
MB@<:S=-O'K]^J_LV=OB1WSX9Q4(\\K6/T]^VV_\ S\6__?P4"]MS_P O%O\
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M?DU^RUX)O/C/\7/!WB'1]-^)4WQ@U;Q;>:QJFJW%W>KH=IH^]Q&BEF^SN"A
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M_P#@L#XA^,OQS\#6EOX1^#?B;QQ\(=2LTD)L[Z*SNKV[E8*B7%M)^\$:YSC
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MJ!;"]N;MYHVADVL25.W!/(Q0!_0G_9\W_//]11_9\W_//]17XK?\0Z?[7/\
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M2:YM<27P6*>4J2VU/NU4H\K.C"R]LKN&AB>([S1_$'C?0XKK2[X:D8GDMKB
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M\%6;Z^T_]A;Q@^FR:+;7S&!(+W59!';Z8YD&VZ)/>(_.!WVU\8?LV0_M,?\
M"P/!IU'_ (**?!7Q5HOG6YGT&WFMFNM0AXS H"AMY''7.:^TO^"J7[/4?[4_
M[#/C3P/)XJ\/^"DUJ)$.L:W+Y=C:88',C=LU^&/@W_@C;HG[#OQN^'/CZ^_:
M0^!_C"STWQ):&:RTG5@\RKYBY<Y; 4=23Z4 ?TJ#H/H/QHK/\*^+M)\<Z#;Z
MIH6JZ=K6EW" PWEC<+/;S =U=20?PK0H **** "BBB@ KX5_:B_Y3Y?LY?\
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M% !7,?'#PW>>-/@9XWT73XQ-J.LZ!>V-I&3M$DTD+(BYZ#+$<FNGHH _(?\
M8)_X)"?&GX-?\$6?CC\'_$VCV>F>/OB!<K/IFGF[CD7"= TBDJ"W;GBOL7_@
MAY^RYXU_8R_X)L>#_AY\0]+71?%FE7]_/<V:SI/Y22R[D^9"5.1Z&O?/VD_C
M#'\ /@/XH\92+%(V@V3SPQRGY)9>B*?8M@5\E_#G]OKX[:1J]OI?Q&TWX8VN
MH>)/!A\7Z+_85K>7;:<FY0([J)<O)PW_ "S% 'W73Y+=XD#,N W2OSC\#_\
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M  23_P"":L/_  2[_9PO/ Z^))/%%WJ6HR7\]UY7EQKN/RJHZ].N:^I***
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M,MP+&ULI!+/<*^&? SM /7/2NNHO:>\WT.J7MJ-.T?AN.T/X@W4IC6YAC^V
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M49QGTK]&(/\ 7Q_[P_G7YT_\$XO^4ZO[<?\ UWT[_P!$QT ?HI1110 4444
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MP(\GW$+(1EO89YH _'7]F7]K+_@H1\6/V(K?POX5^!NB:]X?UB*2R3Q0^O\
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M% &+\+?A_I7P9^'FC^%O#MO]@T70[9+6UA4YVJHQR>Y-?&/[4T[R_P#!?/\
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MB7Q1=?M)1ZG=2KK$%Q?>=->+-\DT6/W808XSS@5^M/\ P2W_ ."G7PE_:O\
MAQX5\ ^'OB.OC3XB:'H43ZLOV*>%G* !F+R* Q'<T >V?MQQ?:/V/_B%'T\W
M263/IEE%?*/[/.E6/A'P9HOA=F:5OLBDMCE@1ZU]8?MN?\FC>/O^P8?_ $-:
M^=_@_;0WFDZ'(L:_:?LJKO(Y VUZF75'%27H>A@:,9QE)]+'IWPHT?1_!\$]
MG8QL%E7#%GW;/]JK%Y8V]OJ:LRV\AA^>.209R.Y'O7/>"/#4F@WVJ3>8\\UX
M</$6_P!3GT'I6]-K4UKIHM;:WM;R[YCA$GW0W;<>N*VE%W*C4:;DD;2Z1#:0
MPS2+(&G(D12Y5L#H>.U,\::I<+)))HTT&GZY)L!:4866/N,CN?6LBUUJ\&HV
M?AW5[R74/$.WS'DAAQ! #TC#8Z"MG6O#XEU:&:Y\M9XTV,R'< />N=Q:=PA[
MR;:+'B*"\O;2UL]7%Q):R!7*QN<"3U!%3:1HRWELUC<:M)--&2;;"%2OHI)Z
MU#HWC"]L[QQ%:S?9X.=TR;HW/MGI63XL\2Q>&VGU*03;6D R@)PS?W1Z5,HJ
M6R-J="$]64M,\&>(-"6Z_M-5O))KEB)(P,+'V'X59\6^!5UGPS8HUY)8G[0L
MS2PG:7 /"D5N:IK=[-8V\L-PPWH-OO\ 455^U274$$EU,#\VTQ;!M^OUIRJN
M2LD=E2I5J8=15B/Q-KUO#=6\4WEPB0!(MS?-*1ZU>O\ PLHMK35+(_:KB$?.
MI?>(L^QZUDZ[X?M=>N+>2-HFGM3NCCD'S U3U"_NO!EI]J:6?.[/EQ+G/X54
M8-H/J\E!*H;FOW%OX@M%2146\4!0(OE'XBO/6_:'M? U]X@;28]4N6\(3I:W
MUN83B=CW7U'TKI?%=RWB1['4-+$4;28-U%+E'SV(Q6?+KZV6H30211![XA96
M,./,(_B)QS733IIQM-7*C3]HN1;'LN@ZQIOQK^'<=ULV_:U#A''SPMC[IKP?
M]HJ'[)\'O&VGWD?V>6'2;@X(/[T*.=N*]&^$5Q)X?\8-IHCN)HKF#[6]Q&,0
MIZ*?<UM?M-:'9ZK\#O%UU/;1R30Z-<>6^,%=R\UYLJO))Q>QXL_W%1Q1K?LT
MD-\ _!I7[ITV''TVBOD"3;8_M%?&:YCC)N)O%LD4C _>00I@5]@_LWC;\"_"
M('0:?$!^0KX<\=^,H/"?[1'QFDNF$<(\6-@@\DF)*K 1YJUCKR.BZN+45V;/
M6_"FE2Z@NZ-1YBKDY8#'UKIK.:'2I;=KY([I5&-D9R*\@DUHV<2W4-Q,KSQ8
M10W!R.#BNG^%.BZA?6V^XDDNH[?$TDC':%&>E>U*DXKF1]GB\OJP4JTMK:?\
M Z#^T_$FL^(KN:;2]+M=+SB!HI/WVSL2N?Z4/X/D^(6L/8:LK6_AV&'S%G@G
M:&Z\X?[I'%176KV9^(9UJ/S%N(X/LR@,?+"_[O3\:W+6_:_O&VR1_:)EWNI8
M LGL.M5*H^6Z1Y?U&I)<TI,[KX;:Z/"\$=C&/]%C3YI&.';C&2?6N>TK0/!>
M@3R1P:3))NNFNDGFG>6192>6!))'TKF_$'B(^'M.NKHQW%PT8^2*,_,3_A4W
MPWUE=>\-1ZGJ<EO8RQY+6H.]\]AQT_&N&IAGT9RXC+:;E:]V=#\6/"6M>,+W
M1[6UATV\T4#[1/)=H'=&'10#_.N5^)'AZ\O_ "])\N:S6W*N+B+E)%_NY[ 5
MJCQ->ZQ.^V22*%CM"^@K6T6ZCBTV.U9FDCA;'[PDY!.32YVH^S:)CE=6G[Z=
MS#LFT#Q'X=GT?4)H;YKE?+%H2<2[>N6%7)I'DTVWT\QQ06ML@BMDC&T1+VQ0
M?$6A^*K29-'T^&SGT^8I*WE8S[YI+FSO-2ND^Q[=T$196DXC=QT!]J(2DGRK
M8O#>\I3K+WMD<_I=GXHTZ>^T[45C-M%)YD<\9 :1>RG';VHU+4=0M]$FM;>\
M6Q^;<TSA6)'H,\"N9\->*M<^+5NS:A>+X?UC2+UH[B&U7=!<H.!RW/Y5V.N^
M'M%EMEO-:NH<1C:JERL<A]P.M=<JD8)=2\+%JA:I\2>_4S/AU#J%OHTK:M?+
M?L9"8I HX3\.*W-+FF7Q'#:6T2R6UX&,SXZ'M4]FVGV^BO' L,(>';$K-\I^
MF/:H/#$_V=YMC>7)!&SQN.0QQC%9RE>5DCJI1<Z;UN_,T/V*+-M/^+'QFA?[
MRZU;=/\ K@*X;]N-F'[7OA';RW_"-28!&<_O:[/]ABZDO/B7\899&W2/K%J6
M/_; 5QW[<7@1_B!^UGX6M1K%]HL<7AEWDFM$5Y&'G=/FZ5Y-*5J]WW/EO;.E
MC74?23_4SH_@MK7Q2\+?8[=TL;6\N0M[(5^8PX^Z,^M?1?PV\'V_@#PK9Z3:
M;A;V<0C4$\ "L3X;Z0OAKPM8Z>MQ/</:Q -+*/FD'J?>NG1F8EFD;9L(*],B
MNK$U'-VN<V(DZ]1RDM \*_$73/&.J7]GIEPL]SI[;9E((*GO^%<?\?/C2OAJ
MT32K>:..>8XD9#\P!_ASU&:I_ OP!X7\$W_B37O"^HS:E->SLUP))BZQ./O*
M<^GH*\T^,/B30Y_BWIUO)YPN_$(+0F1/W<;+T)/:KIX%*?O&V6TZ7M;SV.G\
M%(#J,4UU#(S,NY-S?*I[>YI?$EGJ!U@1Z@R3W4A(0Q@YV'D>W%,TKQ*RQ1VL
M@#3PG:6&.3[>U=)-9+H^ER:A=2?Z0\9\@DY)/I6LK<_*?3*O[#$I0U3V\CE;
M+6;C2[K5-/AOX;5=0LS;1.4^:"8]&8]Q[5FS^&-0\+Q6-CJERVH7RQJ7F1<"
M1CZ#I@UQMG\--WQ(;7KR^U+[1.A#6FXF'KG(']ZNQ\ 7<LOBF/5-2:^MH3<8
M$5VP<JJ_=88SP:[*L5&-T]3JDHT:CJ2=VS;-Q>>'&CMK=I-+U4_OI)"@:.5"
M/]6V>A]Q4>DW]W_;:Q^=(RY$CL"6/'6KGC>ROIO$%U>3LUP]U)YN^,@J5/0>
MU8WQ'UOQ%\+?@OJFJ:+;Z6WB!" L=\3A8V'WN*Y?91ENCAQ<J="C.N_>O;1]
M#HIOVC8?'^CS+X=\Z&/3IS;7'FQXW.."147PSU9V\;WU]=65JJM#Y3WN3YH!
M&,>_XUS'PPTYM.^%&AW3PPPWVKQ&XU'RAE'D_O#/K7H7PFT^.XLM0C6U8M<R
MI$SN/E4'G(K.K&-%76YY[]G'!*M56MU;T. O-#NM$\2W#%?)DC8N#T5U[9(_
ME5GPOH]UXE^)-G>7%Q/);%/+N+8(JPR#^]ZC'M7JB_!C3-&_M::\UBZNHKN-
MO*BD"[K4XQN7UY]:Y#P/9O\ "KPG'#J>J6VJ7*NX=V"I</'GY,#@9Q4QK/E:
MBMSHCG$*L'3H*S>EP\1:'IVA_MC?#6/38XXXQI=YNV]_F6JG_!3^VAO?@)HL
M-Q"L\,FOVX>-NC"J"SMJO[:OPZOEFNHX9]'N\6DX7,7S+A@5]:V/^"DT*W/P
M8\/QR?=;Q%;@Y./6O,U534^?JJ7M;3W.5T378]*%JB1R-:P1A2KG<7&.A)Y%
M7HO'L-I?^2WA^Q,141Y3@D>_K6;J\\6A2LD=OOAVKO=S][I3M(^SZQ?M(K)
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MI,HQO1AD9'8BOC7]J(8_X+S?LY?]B/J/_H]Z /N9OO-]310WWF^IHH ****
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MZUK6$=+4'R(8QSCGG=7TM0 4444 %%%% !1110 4444 %%%% !1110 4444
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M3:/3_P!J#XT73;GW>*&C=/;REY'O6>6R:KIKLSAR2HX8I6ZIH[+P!\+(?%$
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MU+S_ +#)J/RD1I'C>21_#GO]:=H8DU75[&2\T&^TS=*";:X='D9>Q.TD8I/
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M\0_$:WAL=-U"'2[A)/\ 39%VB)X^J_[K9XK;\+7MMINCM#>74EU<-@^<W9L
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MD7L,5P_Q&METJ6/4HVCD65=Q(Y!KD?#7B!==UOR;DM#YAVAF)*Y[5,L/*:O
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MXC75KHDOB+X46UOI;:C,L0OYEM5C-O$7/SR%^-@Y/I7Z1^)/@MX+\9^,]/\
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M8(K]17.7;'3/% 'SG^U1_P $O/AG^V'\2E\5>+KOQI#JBVZ6P72=>N+"':O
MRD; $^]?-'[9?_!$7X+_  Y_9@\6:YI]_P#$AKW3XH&B$_BR\EC.Z>-3E2^#
MP3UK](AU_P *^=OVG/ 7QN^./P[\4>#]/L/A[::/K#HEM=3S3_:$C259%+ <
M;CMP<>M 'F%G_P $$O@6^GVK'4/BCNDMXG/_ !6-[U**3_RT]Z]^_9)_8O\
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M=7 _M6>,-:^'O[,WCO7?#;7,?B'2=&GN=.:W@\^59U7*%4YW'/;O0!^%U_\
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MCR=5\OX-^.$*]OM%MC_T.J&H>-_B->A1_P *>\<+ZXN+;_XNOM7+?[5&YO\
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M,R=:J@OOE_F?8EU_P75^/UHJ[M:TY68<JUHO%0V?_!>+X\W,C*VO:6NTX/\
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M_!/X<Q_$S7OA_J\UY<Z9+=+;Q!&7 +,6!Y]J^UJDAADE)\M6;'7:.E 'XY?
MSXA_\% _@7^T7\3OB-9_LAZ/?WWQ.N$N+JSFUE%BLBN.$(DR<X[U^JO[/'B[
MQCX\^"V@:Q\0/#,'@WQE?6XDU3189O.CL)?[@?)S^=87[0O[;/PW_97U/3['
MQOKU]87VJ*SV]M9:7<ZC,4'5F2!&*K[L *['X6?%?P_\;? UCXF\+ZDNJZ+J
M*[H+@(T;''4,C ,I'H0#0!T%%%% !17+_&;XT^%_V>OAQJ'B[QIJ\.A^'=+
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M&44&B@!RQ,PR%:G&*1OX6->5_$;]G'6OB-XYGU2R^(WB+P[;W(4"QM8U:*/
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M[7GQ2^*,$_CCPOIOP7TSQSX%_P"$:>>&\O=0$$6JW38!M'SP@P2=WM0!X/\
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MX--H/..",@'![44 % .!110 H=@,9./2A79>A(^E)10 5\,?M0_\IYOV<O\
ML1]1_P#1[U]SU\*_M1.?^']_[.2_P_\ "":B?_([T ?=3?>;ZFO$_P#@H]\$
MO%G[2/["_P 2O O@:^;3?%GB32C;:=,'V9;<"R9[;U!7_@5>V-]YOJ:^5?\
M@I?^WAI/P3_8D^*6K_#KQ[X-D^(VA:<Z:?:?VG \\4VX+(/++9WJI8XQG(H
M_GK\/?\ !"SXF?#;5;N\_: O-/\ @3X/M=T:ZWKLJNEW-GB.)$+.^>3D#%?N
MQ_P0+_8M^&_['/[)VIGX<_$"U^),?C"\2]U/5K7Y8=Z#:B*O5<#U -?SC:+X
MQ^,7_!3OXNZ7X7\3_$:]UR]8RS6LGB762EG:9Y;:9&VIGT%?N_\ \&^?P:\/
M_P#!-3]GCQGH?C_XL?#N;4O$FHPWT<-OXA@DAM%5""!EN#ZXH _4"BJNC:U9
M^(])M]0T^ZM[ZQO$$L%Q!()(ID/1E8<$'U%6J "BBB@ HHHH **** "BBB@
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M9P\!_P#8&M?_ $6M?B]_P4[C:X_X*!_$R-2R[M8[''\"U^T'[+ Q^S?X"_[
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M@GX5?!#PGX-U#1=)\3?\(O8K:QWFH6B2R.QY=AG. S9.!7RE\>OACX9\#_\
M!>W]G./1?#^CZ0C>"-1F*VEJL0,GGN-W'?'&:_0:OA7]J+_E/E^SE_V(>H_^
ME#T ?=3?>;ZFO.?VN_V;-)_;#_9G\8_#'7+B:STOQA8FSEN(AN>$YW*P'?#
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MXP_X)"?\$E/!3:MJ6C^.OC%9VT6DW):^2X^PS8',Z@ELH/EY')%?'7_!-?\
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MW:>74981($P<>6 >,]Z^P:YOXE?"'PS\8M&_L_Q-HUCJ]NIRGGQAFB/JI[4
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M8UBW:+-E0>GS"ON7_@OG+Y/_  3JUMCT%_%7S>)DGB+KR/P+BQ./%&O\U/\
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M6_B[&>1]EH\/?LC_ !874C+=?#GQ8L:MD@VO+CT%.$8)[F-3B;!-<WMHW?\
M>7^9RIQ-HRRSMY;DX057C/[OELM7>7'[+/Q8O-*9G^&_BP7#R<)]D^X*BM?V
M4/BM!IT\DGPW\6274IVHHM?N+71[2"ZH\_\ M[!;^UC_ .!(X>&^V(RJM4O%
M5W)#X=NMR]4'\Q7?V'[)?Q86UDDE^&_BSSE.$06M9WB;]DGXPW.A3QK\-?%T
MDT@&"+7@<BJ]I!K=&&)SS!R@TJL=G]I'](W[*QS^S9X!_P"P):_^BUK\;_\
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M)GE6SPS,W8GVK'U#]G/XH022M#\._%LS,ZB(BU_U8'6L_:8>_P 2^\Z:W%N
ME;_:(?\ @4?\S/M9O[*OOE5RV/FS_P M![4ZQ$=QYETV^:/=@ =8O:NFU_\
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M=0FLQW\DL/W9/<B@#ZKDR&Y&UL D>AIM!.:* "BBB@ KX5^(6GV?B3_@K?\
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M_P"0Z?\ &D_X>G?MU?\ 1AEU_P"#T_XU^E_VB3_GH_\ WU1]HD_YZ/\ ]]4
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MR_\ !4G]K*&"21OV&_&BK&C.Q.IQX  )/\7M7FOPC_X+C?M6?M%>"&U[X?\
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M/_M&?$/]HKQ=\,M/_95CF\3>"[>*YU*T36V\V!9!E"W&.1Z&O2O^&^?VM/\
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M49']V/\ [X%%% !D?W8_^^!1D?W8_P#O@444 &1_=C_[X%&1_=C_ .^!110
M9_V8_P#O@4N<_P *?]\"DHH ,_[,?_? HS_LQ_\ ? HHH ,C^['_ -\"C(_N
MQ_\ ? HHH /^ J/H,48!ZJK?50:** #:O_/./_O@?X4;5_YYQ_\ ? _PHHH
M %'\$?\ WP*./[L?_? HHH ,C/W8_P#O@49']V/_ +X%%% !\O\ =C_[X%&1
M_=C_ .^!110 87^Y'_WP*./[L?\ WP*** #C^['_ -\"C(_NQ_\ ? HHH .#
M_#'_ -\"CC^['_WP*** #C^ZH^B@4?E^(HHH 7/^RG_? I,C^['_ -\"BB@
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M.7P[^'7Q$\6V6J7/QD^._P"SOXKTH6VIZO<P-JEI)JAY:XM6<[HE7D_*."*
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MM[Q]H6I:MXF\/6?Q8MW-]\,_B!H<*V\VIQ)S)'<PIP;4GY=S')ZXK]!?@_\
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M$@FU?5A:K:)<E?NK'"ORQHO910!ZY1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^QOX>\>?#?5I-+T?QEJT&ER^([FQ9O\ A'[>0X:Y>)@#Q[X'->%>'?V>K/\
M:<_:KC^%/Q&\>1_&WPVNDCQ!H?C/0V6RU?PS+@$Q_:8BQ ?/ SGVKRSP)X.N
M/CU^T;X/T?P?\7?&GQF\73:NR?$BVU"SDM?"D&F@D36YM& 13G&W;GI7ZB?
M_P#99^&W[,-E>6GPZ\%:#X/MM0?S+E=-M_+\]O4GK0!D?LQ?L:^!?V1]+OH?
M"=KJ5Q?:HP:^U?5[MK[4KW'023M\S =A7J=%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ****  '%<;XH_9R^'OC?QM;^)M8\$^&]3\0VI!BU&XLE:X0C
MI\WM[UV5% !T'   &  . **** "BBB@ HHHH **** &RP1W,;)-%%-&W!21
MZGZ@\410QVT2QPQ10QKT2- BC\!Q3J* "BBB@ HHHH *\W_:\_:BT#]BW]GW
M7/B1XIM]0N-%T&,/+%9Q>9-+D@ **S?VF/VY/AC^R#/I-OX\\21:7?Z],(+"
MSBA>XN)6)P&V("0H)')Q7YZ_M.?%#]I'X%?M,^)M)\=>(O#OCKX/_%J$1^&[
M'4[06VF7"N,K;&XY^SSC(V@CYB.HH ]TG_X*8"/X;K\7O"]_=>-OA7XRVVNJ
MRQV^ZZ^'3%=H>:W_ (TR06)K2_X)U_\ !,WP[^SS\5_^%R^"/B-:>+H?'UM+
M<:_,EFC0:G)(=R-;X/\ HZKG!4=:^=/^"5_[/'CCQKX^U9K;1-:^%>K>$[\Z
M7XHTO5[43:7XQT>0'9D9VM*J\"0=17ZA_"/X-^%_@+X*B\.>#]'M=!T.&1IH
M[2W&(T9CEB![F@#HH+.WM&=H+6UMVD.6,4*H6^I YJ2BB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** .9^,7P=\,_'_P"&NK>$/&&DVNM^'M:A
M,%U:SKD,#W'HPZ@]J^7_  )_P1+^&W@S5=/ANO&GQ4\1>#]'G6XL/"6J^(9+
MC1X&4Y0&$C#*IZ ]*^QJ* ([2TBT^TAM[>-(;>W01Q1H,+&H&  /0"I*** "
MBBB@ HHHH **** "O.OVG?V6O"?[7O@&+PUXR_M9M+@F%Q']@O&M95<?[0KT
M6B@#A?V>?V:?!/[*O@%/#7@718='TW>996'S374AZO*_5F/J:[JBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * <
M&BB@#X*_;I_96^('PW^-/C/XS:!\5M#\$^%=>TR"RUR\U+1/[2O-%MX^";/J
M59L]0*\Z_8+^!.E?M(_%KQ?H6F^+_'7QB_9WU+1TCU/4?%\CR)=:KP=]CO :
M/:>N!Q7Z;W%O'=PM'-%'-&PPR2(&5OJ#Q26=C;Z;;K#:V]O:PKTCAC6-1^
M% &?X&\&V/P[\&Z7H.FB7[!I%NMK;F9M\OEJ,*&;JQ [FM2BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N3^.^M>)/#GP7\47_@^R34O%%KITLFF6S#(EG"
MG:,=^>U=91G% 'Y"_LI^-OBMJ?Q!M?%7@?X8_&+QA\9&AD7Q3>_$'6#I?A?3
MI3RT<,7S HO('M77?L[?L\7G[>&JZY\1O#GAKPWX'\16>N2:#\0_!UQB^\,^
M)54D//"2 !)U(=:^W?VK_P!@_P /_M>ZQIMYK/C#XC>&?[.C:%H/#6M-I\-V
MC'+"55'S9Z<UZ+\&/@KX9_9\^'ECX6\(Z7#I.C:>N$C0?-(QZNY_B<]23U-
M'/\ [+7[(W@']C'X?S^%_AUH<>@Z+=7+WLELC;E65SEMOHH)X'I7I5%% !11
M10 4444 %%%%  >E%!Z44 -\RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*
M/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,
MH\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \
MRCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #
MS*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH
M/,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@
M \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS***
M #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HH
MH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RB
MB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*
M** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,
MHHH /,H\RBB@ \RCS*** #S*/,HHH /,H\RBB@ \RCS*** #S*/,HHH /,H\
2RBB@ \RCS***  OD4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>morf-20221231_g2.jpg
<TEXT>
begin 644 morf-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .PU$2
M  0    !   .PP       8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( :\$Y ,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /H+6_\
M@K'\<K+6;R&/Q19+'#.Z*/['M#@!B!_RSJK_ ,/;?CI_T-5C_P"">T_^-U\\
M^)?^1CU#_KYD_P#0C5&N[DCV/A?KF(_G?WL^E/\ A[;\=/\ H:K'_P $]I_\
M;H_X>V_'3_H:K'_P3VG_ ,;KYKHHY(]@^N8C^=_>SZ4_X>V_'3_H:K'_ ,$]
MI_\ &Z/^'MOQT_Z&JQ_\$]I_\;KYKHHY(]@^N8C^=_>SZ4_X>V_'3_H:K'_P
M3VG_ ,;H_P"'MOQT_P"AJL?_  3VG_QNOFNBCDCV#ZYB/YW][/I3_A[;\=/^
MAJL?_!/:?_&Z/^'MOQT_Z&JQ_P#!/:?_ !NOFNBCDCV#ZYB/YW][/I3_ (>V
M_'3_ *&JQ_\ !/:?_&Z/^'MOQT_Z&JQ_\$]I_P#&Z^:Z*.2/8/KF(_G?WL^E
M/^'MOQT_Z&JQ_P#!/:?_ !NC_A[;\=/^AJL?_!/:?_&Z^:Z*.2/8/KF(_G?W
ML^E/^'MOQT_Z&JQ_\$]I_P#&Z/\ A[;\=/\ H:K'_P $]I_\;KYKHHY(]@^N
M8C^=_>SZ4_X>V_'3_H:K'_P3VG_QNC_A[;\=/^AJL?\ P3VG_P ;KYKHHY(]
M@^N8C^=_>SZ4_P"'MOQT_P"AJL?_  3VG_QNC_A[;\=/^AJL?_!/:?\ QNOF
MNBCDCV#ZYB/YW][/I3_A[;\=/^AJL?\ P3VG_P ;H_X>V_'3_H:K'_P3VG_Q
MNOFNBCDCV#ZYB/YW][/I3_A[;\=/^AJL?_!/:?\ QNC_ (>V_'3_ *&JQ_\
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M3_XW1_P]M^.G_0U6/_@GM/\ XW7S711R1[!]<Q'\[^]GTI_P]M^.G_0U6/\
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M'1AP2#C()&#2NKV-/9SY/:6TVN=11113,PHHHH **** "BBB@ HHHH ****
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M5S_Q/^*.@_!KP7=>(O$NH+I>CV)037!B>7:78(H"HK,268#@&O)O^'FWP/\
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M**9F%%%% !1110 4444 ?0W[<_\ R3[X#_\ 9/;/_P!&25\\U]#?MS_\D^^
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MO[-'A^(NHD?Q/ RIGYF M;H$@>@R/S'K5\SLSSUA:7/15OB6N^I#^V+^VO\
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MW$[N,]A7L'[5W[;/A3]DVRM8]56YU36]00R6NF6A7S"@./,D8G")D$ \DD'
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MSO@J%!#.T3Y(!)?GGFB,VKW"M@Z,^545HVES)W^]=&:_B'_@M/H-GXD\G2_
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MA&J- !7S+^WU^QQXS_:V\3>%8M(UC0=.\.Z*KFYCNY95G,LCJ'=52-E;$:@
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M2U\\U]#?MT?\B!\!_P#LGEG_ .C):E[HZ*7\*?R_,^>:***HYPHHHH ****
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MC\^_&O\ P2:^)WCW2(=1UGXA:;K_ (H:41R'4KR[FABMPI)VSNC2,V[&%**
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MP6N-0O=HCEDNCL(F0<A-GEQ[1SP@SG)S[=10J:1-7,*U1)-VUOHK:GP%I?\
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MV3B_Y?Q7^9^>=%?H9_PX9_ZJM_Y;/_W71_PX9_ZJM_Y;/_W71[6/</[)Q?\
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MP_LG%_R_BO\ ,_/.BOT,_P"'#/\ U5;_ ,MG_P"ZZ/\ APS_ -56_P#+9_\
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MV3B_Y?Q7^9^>=%?H9_PX9_ZJM_Y;/_W71_PX9_ZJM_Y;/_W71[6/</[)Q?\
M+^*_S/SSHK]#/^'#/_55O_+9_P#NNC_APS_U5;_RV?\ [KH]K'N']DXO^7\5
M_F?GG17Z&?\ #AG_ *JM_P"6S_\ =='_  X9_P"JK?\ EL__ '71[6/</[)Q
M?\OXK_,_/.BOT,_X<,_]56_\MG_[KH_X<,_]56_\MG_[KH]K'N']DXO^7\5_
MF?//[)G_ ":E^T1_V!--_P#2PU\\U^J'PE_X))_\*N^%'Q$\,?\ "P/MW_"?
M65M9_:?[#\K[#Y,WF[MGV@^9GIC*XZY/2O._^'#/_55O_+9_^ZZE5(W9O4RS
M$N$$H[)]5W?F?GG17Z&?\.&?^JK?^6S_ /=='_#AG_JJW_EL_P#W75>UCW,/
M[)Q?\OXK_,_/.BOT,_X<,_\ 55O_ "V?_NNC_APS_P!56_\ +9_^ZZ/:Q[A_
M9.+_ )?Q7^9^>=%?H9_PX9_ZJM_Y;/\ ]UT?\.&?^JK?^6S_ /=='M8]P_LG
M%_R_BO\ ,_/.BOT,_P"'#/\ U5;_ ,MG_P"ZZ/\ APS_ -56_P#+9_\ NNCV
ML>X?V3B_Y?Q7^9^>=%?H9_PX9_ZJM_Y;/_W71_PX9_ZJM_Y;/_W71[6/</[)
MQ?\ +^*_S/SSHK]#/^'#/_55O_+9_P#NNC_APS_U5;_RV?\ [KH]K'N']DXO
M^7\5_F?GG17Z&?\ #AG_ *JM_P"6S_\ =='_  X9_P"JK?\ EL__ '71[6/<
M/[)Q?\OXK_,_/.BOT,_X<,_]56_\MG_[KH_X<,_]56_\MG_[KH]K'N']DXO^
M7\5_F?GG17Z&?\.&?^JK?^6S_P#=='_#AG_JJW_EL_\ W71[6/</[)Q?\OXK
M_,_/.BOT,_X<,_\ 55O_ "V?_NNC_APS_P!56_\ +9_^ZZ/:Q[A_9.+_ )?Q
M7^9^>=%?H9_PX9_ZJM_Y;/\ ]UT?\.&?^JK?^6S_ /=='M8]P_LG%_R_BO\
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M7^9^>=%?H9_PX9_ZJM_Y;/\ ]UT?\.&?^JK?^6S_ /=='M8]P_LG%_R_BO\
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M7T-^V=_R0G]G_P#[%!__ $H:OH;_ (<,_P#55O\ RV?_ +KKT3XS_P#!)/\
MX6]X$^'^B_\ "P/[/_X072#I7G?V'YWV[,A?S-OVA=G7&W+?6E[2-S>GEF)4
M)IQW2ZKNO,_*^BOT,_X<,_\ 55O_ "V?_NNC_APS_P!56_\ +9_^ZZ?M8]S#
M^R<7_+^*_P S\\Z*_0S_ (<,_P#55O\ RV?_ +KH_P"'#/\ U5;_ ,MG_P"Z
MZ/:Q[A_9.+_E_%?YGYYT5^AG_#AG_JJW_EL__=='_#AG_JJW_EL__=='M8]P
M_LG%_P OXK_,_/.BOT,_X<,_]56_\MG_ .ZZ/^'#/_55O_+9_P#NNCVL>X?V
M3B_Y?Q7^9^>=%?H9_P .&?\ JJW_ );/_P!UT?\ #AG_ *JM_P"6S_\ =='M
M8]P_LG%_R_BO\S\\Z*_0S_APS_U5;_RV?_NNC_APS_U5;_RV?_NNCVL>X?V3
MB_Y?Q7^9^>=%?H9_PX9_ZJM_Y;/_ -UT?\.&?^JK?^6S_P#=='M8]P_LG%_R
M_BO\S\\Z*_0S_APS_P!56_\ +9_^ZZ/^'#/_ %5;_P MG_[KH]K'N']DXO\
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M^)H_X6+K/_/Y_P"0D_\ B:Q** YY=S;_ .%BZS_S^?\ D)/_ (FC_A8NL_\
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M$K6DA,BC$@ W?-%(IRH(*'CH3[%1.FX/EDM0]I+N;?\ PL76?^?S_P A)_\
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M;_X6+K/_ #^?^0D_^)H_X6+K/_/Y_P"0D_\ B:Q** YY=S;_ .%BZS_S^?\
MD)/_ (FM7Q!XTU*QTW2Y(KG:UQ!OD/EJ=QS]/Y5Q];GBK_D$:+_UZ_UI%*4K
M/43_ (6+K/\ S^?^0D_^)H_X6+K/_/Y_Y"3_ .)K$HID\\NYM_\ "Q=9_P"?
MS_R$G_Q-'_"Q=9_Y_/\ R$G_ ,36)10'/+N;?_"Q=9_Y_/\ R$G_ ,31_P +
M%UG_ )_/_(2?_$UB5YO^S+^T(/VC?#'B#4ETDZ/_ &%X@O-"\LW7VCS_ +.5
M'FYV+MW;ONX.,=3346U<.>7<]C_X6+K/_/Y_Y"3_ .)H_P"%BZS_ ,_G_D)/
M_B:\D_:<_:/T+]E?X2WGBS7EN)H(76WMK6 ?O;RX?.R)2>!D*Q)/158\G /D
MO@'_ (*$ZH_QB\+^#_B#\,]5^'UQXV16T.Y?5(]02Y+'"*X1%,9)(&#D@L,@
M YJXT9RCS):![1]SZU_X6+K/_/Y_Y"3_ .)H_P"%BZS_ ,_G_D)/_B:Q**S#
MGEW-O_A8NL_\_G_D)/\ XFC_ (6+K/\ S^?^0D_^)K$HH#GEW-O_ (6+K/\
MS^?^0D_^)H_X6+K/_/Y_Y"3_ .)K$HH#GEW-O_A8NL_\_G_D)/\ XFC_ (6+
MK/\ S^?^0D_^)K$HH#GEW-O_ (6+K/\ S^?^0D_^)H_X6+K/_/Y_Y"3_ .)K
M$HH#GEW-O_A8NL_\_G_D)/\ XFC_ (6+K/\ S^?^0D_^)K$HH#GEW-O_ (6+
MK/\ S^?^0D_^)H_X6+K/_/Y_Y"3_ .)K$HH#GEW-O_A8NL_\_G_D)/\ XFC_
M (6+K/\ S^?^0D_^)K$HH#GEW-O_ (6+K/\ S^?^0D_^)H_X6+K/_/Y_Y"3_
M .)K$HH#GEW-O_A8NL_\_G_D)/\ XFC_ (6+K/\ S^?^0D_^)K$HH#GEW-O_
M (6+K/\ S^?^0D_^)H_X6+K/_/Y_Y"3_ .)K$HH#GEW-O_A8NL_\_G_D)/\
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MF[/G\O?MW;><9QS67^QI>:O\)O\ @HUXWT/XEV-O-\1O&UD;JWU/2[C=IK0
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M^$VT1-6U"UN/$18Z;<V\D*)>23B,"1YV=X?+6$C:JON(08;IQ/))NFWK=O\
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MYQO/V+=0^"?AGXK?$_6/&FK>/?B9>^%=1CL]2>S6R6T(M7V^3"C,%;*H!@@
M#  R:\=_X)N_$.U\+?%KX;>&[?P[\)[Y_$FA7,S:MX>\V;7M-*0^9(-2D8X#
M2.F-@&%)&..M5*<:J=2+V2_+SZ"6FA^B5%%%>>6%%%% !1110 4444 %%%%
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M-Y&1N&:ZO:4U%2V5Y>OR[$ZGTM?^*M+TK7=/TNZU*PMM3U82M8VDMPB3W@B
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MS,QX  [F@DMU3O?#FGZEK%CJ%Q86=QJ&FB06=S) K36OF +)Y;D93<  <$9
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ME;YI #P2$5@/1B#SC!^:_$^O>/OV6/B)\";[3/B=XU\<:E\2&@;6M"U>^-Y
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MC_8!T'4+36;/4K/PSI*W>KI8D2SPWDY,S6Q0'/GF27RU0X+$J.A%>UZ1\"/
M_A_6KK4M/\&^%+'4;U72XNK?2+>.:=7!#AW5 S!@2""><G-<;\0/V5;6YB\.
MP^!5\(^";+0]7&N7%@OAL2V>IW,:%8'E2":W.8F/F+\QRZ1DCY179/$0FN35
M*]R;-'S!_P %%?C7=?M ?\$Z=+\17NACP[>-XP-C/8"]%YY$EN;N%OWH1 V2
MA/"X^O6O/_VG]4^'?A6Y^'/CCX&>(/,^+FN:C";JWTG4);EKK?&1)Y\18^63
M+L3RL*'5W^4@9KV3QG^PE\3OBY^QI/X%O;[PMI^L?\)A<ZU EQ');QK"T]VQ
M9I(I+C=YGG(ZJ%4HIVL689KZA^'7[/?@[X=FROK'PEX5L=>A@1)]1L]*@BN)
M9 H#L90@<Y.3DG)S6GMZ=-6CKJ]%M;3<FS9C^+_VD'\,_M(>$_A_'X7UB>#Q
M&9TFUR8&WLK>1+2:Y6*'<N;EML)WE,)'O7+%LH/3Z\/^/D'BO4/V@/ASJVD^
M ?$FN:5X)O;R[N[JUO-,C6Z6XT^6W40K-=QN6624;MZH, D%N,^W1.9(E9E:
M-F )5L97V.,C\C7#42LFNQH.HHHK, HHHH **** "MO2_P#D1]4_ZZP_S-8E
M;>E_\B/JG_76'^9H*B8E?%/_  6/M&CM?A+J.H6\TWA73_$1.L,8R\"*3#M\
MP#U19@/7D=Z^UJI^(?#FG^+=&N--U:PL]3T^Z7;/:W<"S0S#(.&1@589 /([
M5K1J>SFID/5'YH_\% O&OPP^,_[8WPQ71=:T%] 7[%:>(=6LG0V<4+7 *))(
MN$RD0;J?E'!QM('VY\9/VD]8^&G@V[\9:9X7TW7_  #IUA;:E-JPUY89[RWE
M(+26D*Q2+*$C96_>2Q;R<+GACUR?L\_#^/PK)H2^!O!ZZ)+,MP^GC1K;[*\B
MYPYBV;"PR<'&1DUY;\<_#/BCQ5X\TOPJOP[UJ^^$OA^*WG-MH=SID2ZW-%M:
M*V>.>Z@,5K"54E I\QD X0?-T.I"?+'I'N_^&U%L>%_MH:[X5TO_ (*H?#J3
MQI=06/A/4/!,^GZE)=.\$8BNH]5M]KLN&C#&4*6R"N[)(QD5/V2[K0_AE_P4
M<UCPU\'M4N]3^%LNDO=ZQ!:7$FHV-O,L1(:-_F+D2"-58%F.]E!/0>X_%3]C
MK4OC3^V[X'^)FI6OA^;P?I/AUM,U31-5'GW4LC)>$*8@CP.%:YCS^\(RC$9P
M"?<O"'PW\._"O2KB'PQX:T?1(9/WCVVDV,-F)V ..%"J6Y(!8CKU%5+$14%%
M:Z6\M_S#EU.-_9Z_:/G^._B3QA83^%=6\*_\(O<VT4<>IMMN[F.>$3)))#M!
M@)4@[&9F (SM.5'J%>(? :V\56?[0_Q$UC5O ?B30M)\:3V,]I=7=YIDBVXM
MK)86658+N1P6=3MV*PP1DK7M]<E5)2]WR_(I!11168!1110 4444 %;?B_\
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M\':G;^&OL32;=T;RQW=JX64@9VB0?*21G /7*M"<5"SW;U??[OS)Y;:GR_\
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M;!1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOXC^.(?#FC^.M/N=7NI?(@B>WN((YW)P%262-8V)/  8Y/3-87_!4Z^FT_\
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M[]=_O)Y3XZ_X*N:,ND?L.^&XQI?BK0_.\:0NUKXCUEM6O(S]CO!DS?:;GY"
M"%60@<_*"36S\<?@G\<?VY/$'@G0_&7@70OA_H/AN_%[J.JQ:U#?F\8<,8(T
M8N@*@X1\\D$L,5])>./V6?#WQC^'L7AKXA7>L?$"QM]0&I0R:G+'9S12B-HU
M -C';J5"O)P02=YR3A<>E4_K7+%*.ZOKZ]O^"'*?//[5GP^MY=<\/:'X?UKQ
MQIWC'XA:RL,,UIXPU6&+3K6+]_>W*VXN1"%2%2BH% WS1X':OH2*,0Q*B[MJ
M@ ;F+'\2>3]37+K\(].;XRMXXFN+ZYU9=*_L>VAE=/LUE"9/,D,:A0P>1@FY
MF8Y"*!@#GJJYYRNDB@HHHK, HHHH **** "MO2_^1'U3_KK#_,UB5MZ7_P B
M/JG_ %UA_F:"HF)7S?\ \%&/V7/$_P"T%X<\(ZUX,-G<>)/ FI_VC;:?<N(H
M[\,8R5#L0JL#$APQ (W<@XS](45=.HX2YD2]3X+^/'P2^/\ \?\ XN^"_B9J
M'PWT&SD\!WEH;;PH?$-O--?!9?-EE,Y(A4%D0 9R 1PV#GVGXY77CN#QG\&/
M$%]X@OO#EOJFOZ9I^H^%K!P(4GEM[B2X6>Y5O])561450%3Y2V&)!'T77G/Q
MC_9W;XRZ_H]]<>-/%VC1Z#>Q:G86FG)I_DP74:NJS9FM9'8[9&!5G*<_=K?Z
MQS-)I)+^O,FQY?\ $2+5/BEXY^.+2>)O%.C_ /"N[&VAT%-)U:>QBM93IRWK
M3R1Q,JSLTDBJ5F#KM3  R:^>_BU\1O&6N_M\? /Q7X;T>Q\1^,M2^'%IJ*Z=
M/<+:0WKRPZ@\ZASA8SY;RE2> 0.#T/V'XR_9)TSQCK>LWW_"4>+]+;Q586^G
M^(XK&>VCC\01PH8PTVZ!C&[1DHS6YA)4X&,#&Z?V:/ Y^*/AWQI_84:^)/">
MG#2=)NUN9E%G:A)4$8C#^6P"S2#+*3\W7@8J%>$?/2WX6_%A9G@/P5_9W^)O
MQ*_;5NOC-X\T+2O ?]GZ:VGZ7I$=]'J4KLT31!I'B8*P =B3E2?E  Y(]"_9
M.3Q+HOQD^+FA^)?%NJ>+KC2;[3&2XN1Y,,1FLEE=8( 2L,>YN$4G@#)8Y8^Y
MW,33V\B+(\+.I42(!N0GN,@C(Z\@CV-><_#+]G-_AI\1]9\3?\)QXPUJ\\1-
M$^IP:A'IH@O&BA$,3$0VD;*40# 1E!(RP;FLY5N9.]EHDOD%CTFBBBN<H***
M* "BBB@ K;\7_P#'EH__ %Y+_,UB5M^+_P#CRT?_ *\E_F:"H[,Q*_/KX@:W
MXR\-_P#!83Q+?>!]#T_Q)J]KH<#RZ7=7@L_MMO\ 9;<.D<S?*DG*D%N/E/!Z
M5^@M<79_L]>#[#XUW7Q%AT=5\97UJ+*;4?M,QWQ!54+Y9?RQ\J*,A0>.M;T*
MJA>ZW5B'J?*_PN_8H^)_C./XW^,O%7V/P?XR^)FGS:;IMA;WJS"SC8JQ$DL1
M9=I"1QY4DXWD@9 KQWQ=^P3\6_$'[.6E^"['X)^#])U?0[G[1=>(8]5L9-3U
MWYF4*K[@8T"ON97?!\L8 /!_3ZBM8XV:=[+_ (;YBY3Y7U_]FKQI<_\ !1#X
M2^.8M)63PKX6\)?V7J5\+N$?9[CR+]-GEEQ(WS3Q<JI'S=>#BWX!_9K\36O_
M  4M^)WCK6-"@D\!^*/#,>EV]S-/!+'>OY6GH\30[B^T^1,#O0*0O?(S].T5
MG]8E^%OQN'*>3_$']C;P'X@^&/BC0_#WA3PIX3U#Q%I-QI@U'3='M[::(2+Q
MEHT#%-P4E<\[?H:^6[;]G3]H76?V2E^ \G@[P[I>DVLCJWB=]<B>.\MUG-RD
M2P+F16:3 WD ;>"HY8_?E%%/$2BK;]=>X^4^7?V3_'/CC]G/X;?#OP/X_P#A
M_;^%]/DO1X:@U.+6H;KS)VBEFBE:*(-M$SJ8^6&'()R' 'NGP6^*G_"Y/"UY
MK4-A]CTS^T[NSTZ;S_,_M&""5H1<XVJ4#NC[5.?E"MGYN+'Q>^%=A\9O TVA
MZA<:A8J\\%U!>V$BQW=C/#*DL4T+LK!75T4@X/<=ZO?#WP+I_P ,? NC^'=)
MC,.FZ'9Q65LIQNV1J%!8@ %CC)..22:FI.,ES6U V****Q&%%%% !6WX%_X_
M[S_KRE_E6)6WX%_X_P"\_P"O*7^5!4=S$KR?]MS]GNZ_:?\ V;M>\):?=1V>
MIW/E7-D\IQ$9HI%<(_<*V"N>V0><8/K%%5&3C)270D_/WXU?L^?M$?M)_LU^
M&_AWJ'@?0?#5KX'MXG^T'78)G\02V\1@A6-4)$.48DB1@"W.5X4?0&D:3XRU
M_P""/AK_ (2CX?\ CC3=4T6)]/3PYX4\86]DK*D42Q7$US'=6YV_NW"QI(P4
M2G<CE59?H*N5\??#:\\9:K9WVG^+_%7A6XM8I(&_LI[62*Y5RK?/%=031[E*
M\.JJX#,-V#BNAXARLK)??_F3RGP#^W!XEU;Q5^RM^SS?3:U'XDUS^U)87OIT
ME3SKB)UC*2[T20LCIY;LRJS,C$C)KUCXA?!'XR?MH?&WX;WGCCP/I/P[\-^
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MNRL SLS\S?PE:]TKSKP%^S!X9^'WCSQAX@M3J%U=>,]PNH;F56@M$>2265(
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M($1=S$L<*H&223CDFJCB(PCRP6J=]?1:ARW/FGQY\/=8^#WC-KG6-.^)^O\
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -OQ?\
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M]^ /AG]I7X<W'A?Q59R76FS2+.C1/Y<UM*N0LD;<[6 +#H00Q!!!(KQ34/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M^X_X^)/]XUG^(_$5CX1\/WVJZG=0V6G:; ]S<W$IPD,:*69B?0 $UH7'_'Q)
M_O&O+/VU/ .K?%#]E3QUH.AV[76K:AICK;0*<-.RD/L7_:8*0!W) JH).23
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M /CRT?\ Z\E_F:Q*V_%__'EH_P#UY+_,UB4%2W"BBB@D**** "BBB@ HHHH
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M %%%% &WXO\ ^/+1_P#KR7^9K$K;\7_\>6C_ /7DO\S6)05+<****"0HHHH
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M2_S-!4=F8E%%%!(4444 %%%% !1110 4444 %%%% !1110 5M^!?^/\ O/\
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M?5/^NL/\S6)6WI?_ "(^J?\ 76'^9H*B8E%%%!(4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 4444 ;?B_\ X\M'_P"O)?YFL2MOQ?\
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M_P +!U#_ *=?^_"_X4!:/<PZ*W/^%@ZA_P!.O_?A?\*/^%@ZA_TZ_P#?A?\
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MYAT5N?\ "P=0_P"G7_OPO^%'_"P=0_Z=?^_"_P"% 6CW,.BMS_A8.H?].O\
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MT2+4-1M=$\/>'(_#.DW7V(7_ -FU>;59/MUVS0LCR?V7M,4,T:8,X)('(S]
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M%O-/ ^JW.N/FY1UB5EATX)*B1S%RS21; .5GW)17P[X7_:#^*?[6?[2WP?\
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MCX#\,^ O$#?"JQC^#FOSSW/A[1[%KF.)M?TN5TMDN(I;6*22=E=Y)+>;<IF
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MMPKY#EU4.SQ Q'V+]H[XR_%CP1^T?X+^!OA75_C#XJDM_"-UXPUCQ+X;M?"
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MD@FADEWK/"61H(RLN&93],>/_%7_  @O@/6]<^S27G]CV$]]]G0[6G\J-GV
MX."=N,X/6@FQKU2\2>(K/PAX=U#5M1F^SZ?I=M)=W4NQG\J*-2[MA02<*"<
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M*>&=*^-&J?$*WTSR_&&M:1;:%>:A]HE/G65O+--#%Y9;RUVR7$QW*H8[\$D
M ><R_P#!.;X0K\/_  'X:LO#^LZ'I_PRM9;#PQ<:)XHU;2=2TFVE $L"WUK<
MQW31/M4LCRLK%$)!*J1O7'[6O@?X9_!7P;XJ^)GC;P/X!7Q5IUM<1RZWK%OI
M5M//) LKQPFXD&[&XG:&) Z^M>E:1J]IX@TFUO["ZM[ZQOH4N+:YMY!)#<1N
M RNC*2&5E(((.""#0+4\;MO^"=/P;TWX#:=\,]/\'?V/X-T77&\2:79Z7JU]
MI\^CZB9Y+C[3:7,$R7%LPDEDV^3(@579% 0[:M?$[]@SX9_%S5[/4M6L/%%O
MK%II"Z#)JFD>,=9T;4=2L5QMM[VYL[J*:]53DC[2\I#22$$&1RW8?#C]HGX?
M_&/Q+KFB^$?'7@WQ5K'A>7R-9L-'UJVOKG29-S)LN(XG9H6W(ZX< Y1AU!KR
M/]I?_@H;X/\ "_[)?QF\:?"GQQ\-_'WBKX5^'+S5IM/LM9@U2.SGBCD,:7<5
MM,)$5GC9<%D)VL 00< _>/3M/_99^'VC:S\/[[3_  OI^F2_"NWN;3PK'8E[
M6WT:&XA6"9$AC98F5HU"X=6VXR,')KSO]H7]C*7]H3]N3X'_ !&U2U\-R>&_
M@W!J]_"96D;5+C4[I(88%5=GEBWC59)22^[S4APN Q/?>-_VJOA]\$?!/AW5
MOB1X\\#^ 1XBMUDM7U_6[;2XKN3RT>18C<2+OV[QD D@$9ZUJ?$;]HSX>_!W
M2K6^\7>//!OA6QOK1[^VN-7UJVL8KBW1H4>9&E=0T:M<6ZEP2H,\0)RZY U+
M_P 7_A+X?^//PM\0>"_%FG_VMX9\46$NF:I9^?)!]IMY5*NGF1LKKE21E6!'
M8BN'^$G[#'PN^!OQ#C\4>&_#=Q:ZM9VTUCIOVK6+Z_M?#]K*X>2VTVVN)I(-
M.@8JH\FTCBC"HB!0J*HU?B/^V%\(_@[_ &-_PEWQ2^'/A7_A([87FD_VQXEL
MK'^U(#C$L'FR+YJ'<N&3(.1SS6K\6OVB/A_\ O[+_P"$[\=>#O!7]N2M!IW]
MO:U;:;]OD7;N2'SG7S&&Y<A<D;AZB@6IP7A?_@G/\'?!OC+2M8T_PM>1IH.K
M/KVDZ-)K^I3>'='U!VD<W=KI#W!T^WF$DTKJ\5NK(\C.I5B377WG[+O@2_\
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MXN\,>--$6=K4ZAH.J0:E:B50"T?FPLR[P&4E<Y&X>M=/0',PHHHH)"MOQ?\
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M/>(-6_X6_P#"_P#LKPG=1V6N7O\ PE5C]GT:XD9DCAN9/-VPR.R.JJY!)1@
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MO&__  DGB+2=8CUR33CI%W>:+XCU/0I-4LMQ;[+>?8;B$7< );$=QYB+YD@
M =L\[\7_ /@F/\$?CMJ7B.?Q+X/NKBW\86T-KKNF6?B#4].TG65AB$4#W-C;
M7$=K--$BQ^7,\1EC,,+(RM%&5U]$_P""B_[/GB9KI=-^.WP;U!K&VDO;D6WC
M739?L\$8R\K[9CM11R6. .YKT[4_'^@Z+KVBZ5>:UI-IJGB0RKI-G->1QW&J
M&*,RR"!"=TNR,%VV [5!)P.: ]Y&+X6^ ?A/P7\4M2\::9I/V;Q-K&D66@W=
MY]JF?SK*S:9K:+RV<H-C7$IW!0S;_F)P,</=?\$]OA)-\+O!/@^#PU?:7I/P
MWDFE\+W&EZ_J6G:KH1F61)OL^HV]PEXBR)*ZNHFPZD!@0 !TWB#QUX@T_P#:
M=\->'8=8^'L/AG4M O[VYTR[NY%\3W5S%-;K'-:0@['LT61Q,Q!97D@ (#'+
M?!G[7WPF^(_C;3_#/AWXH?#O7O$FK6BZA9:5IWB2SNKZ\MFC\U9XX8Y"[QF/
MYPZ@J5YSCF@-3G?$7_!/[X4^)?#?A/39-!U;3Y/!#7+:-JNE>)-4TO7+4W)=
MKK.IVUQ'>R_:'=I)O,F;SI#YDF]P&&Y8?LB?#W3;3P/#'H,C?\*YU6?7="FE
MU&ZEN(=0GBGBGNYI6E,EU-*MS<&22X:1G>5G8E_FKA?VZ_V^?"7[*WP:^(W]
MF^-/AXWQ8\,>$M1\0Z/X3U35X?MU\]O9S7*9LEE2XDB*Q,QV8.Q6(88)'5?"
MGXM^)O&?QHAT_4-6^' T&[\$:9KT6D6EU+_PDT%W/+,LL\L#,473V"*D3@;C
M)',"3MH#6UQGQB_86^&/Q]\:R:[XKT75=1FNC:&_L(O$6I6FCZT;642P&^TZ
M&X2SOMK!1_I,,FY$1&W(BJ(/V<OV:;[X7_'/XR?$;7KNQN/$7Q4UFU*0V+NU
MM8Z5I]O]EL(CO529V4RS2G& ]P44LL:LW4?#?]J7X8_&.[URW\(?$;P'XJN/
M#"[M9CT?7[2^?21EAFX$4C&$91Q\^/N-Z&N?D_;W^"]U\(/%GCO2?BE\/?$7
MA?P3 )]9OM(\2V-Y#8EL^5')(LOEQR2L-D:NR[V( YH#78]<HKYQ\&_MZZ#^
MT[\(/A?XV^$/CCX5'3?%6OZ1;:[:>)-9C^W6-O=V[3/I<:6LKJFM#=&%MY&(
MRLH.< UZAXX_:M^%WPQ^).G>#?$GQ)\ ^'O&&L&$6&A:GXAM+34KTS.8X?*M
MY)!(_F."J[5.YA@9/% K,[ZBN%^*G[4/PS^!5Q-#XW^(G@7P;-;PP7$J:YKU
MKI[113O*D+L)I%(61H)U0GAC#(!DHV)?B'^TG\.OA%\/],\6>+/'W@KPOX5U
MIXH].UG5M<MK+3[]I8VEB$4\CK'(7C1G4*QW*I89 )H$=K14.FZE;ZSIUO>6
M=Q#=6EU&LT$\+B2.9& *LK#AE((((X(-34 ;GAK_ )%S7/\ KBG_ *%6'6YX
M:_Y%S7/^N*?^A5AT%2V1RWQ1^"OAGXT?\([_ ,)-IO\ :7_")ZY;>(]*_P!(
MEA^RW]ON\F;]VR[]N]OD?*'/*GBO-/BO_P $V/@Q\;O$/BG4/$WA.[OE\<(!
MXBTZ+7]2M=(UV01"))[K3X;A+2:X150I.\1EC>*)U=7BC9<?_@I3^W38?L/?
M";P]<)X@\#:'XH\;>(].\/:1)XIO%CL;1)[N"&ZU":+SH9);>TAE,LFR1 HV
M[G0'=7+_ !0_;#\>?"G]GWXS^-;?QA\"_'T?@7X96WC'PZ?#_P!H$]]<-:7<
MYNKNU%U+LTZX\J(VQCG8NJS?O#@$ )/H>[:=^R[X"TOQI_PD$?AVWDU1O"L7
M@EVN)I;B&71XG>1+1X9':-UW2/EF4NP8@L1Q7+_"3_@G]\*?@CXWT7Q#H.@:
MJ=0\+VTUIX?CU3Q)J>KV?AF*91'(FFVMW<2P6 ,:B+_1HX\19C&$)4[GP+_:
MI\"_'&5-%TCQQX)UKQKI^GQ7>MZ%I6LV]Q?:2Y5!()K=9&EA"R.%^<#!(!YK
M2\%?M-?#?XD^+)-!\._$+P/K^N0V#ZI)IVFZ[:W5VEHDODO<&*-RXA64B,N1
MM#_*3GB@-3YV_9M_X))^#?"-GXGNOB-I-KKVK:YX_P!7\7M;:?KVI)HNHI-J
MTU]8-?Z>'BM+RXA5XANG@EVF)%5V6-"/3_C=_P $WO@W^T3XF\4:KXN\+ZA?
MR^.+2*S\1VMMXCU/3]/U]8HC%"]W9V]Q';W$T2;1'-)&TL9BB*.IBC*]M\&O
MVI_AC^T;<ZA#\/?B/X#\>3:2J/?)X=\06FJ-9JY8(9!!(Y0,5;!;&=IQT-8/
MB7]JOPGX[^&7Q,;X7_$CX2ZSXO\  NDWDDYO/$$-QIGAZ\2*;R6U;[/(9+>W
M66)O-)VL$BEQRIP!>5R_X@_9#\ ^(_B=X1\92:9JECXF\#V"Z5I=_IFO:AIL
MALA)'*+2Y%O.BWEOYD2-Y-R)8\[OE^9LU[W]BKX9:C\%?$GP[F\,[_!WB[5[
MG7=6T_\ M&['VN]N+W[=-+YHE\U-US\^U&51]T +\M69_P!J'P3\-?#?@:+X
M@_$3X:Z!XB\:6<!T]&UZ"UMM=N&6(/\ V>)Y \\9DE39MW$B2//+#/I5 M3S
M[6?V5?A[XDUOX@:AJ7A>QU.;XI6%KIGBI+QY+BWUBVMHY(H(WA=C&H5)I!\B
MJ3NR<D B+X%?LJ>"_P!G&XOI_#-OX@DN]0MX+*6ZUSQ-J>OW26\&\Q6\<U_<
M3R10H9'(BC94RY.,G-7?B?\ M/?#7X(O=KXT^(7@;PBU@EO)<C6M>M=/-LMP
M9A;E_-==HE-O.$)QO,$FW.QL3^+_ -HKX??#[PSINM:_XZ\&Z'HVLVCW^GW^
MH:U;6UK?6Z1B5IHI'<+)&L9#EU) 4ALX.: U/G^[_P""7'AWXH?M5_'+QQ\0
M+=K[2?B<=+M;!-#\2:IH]Y+8PZ9%:75G?FTD@\ZWDDC+"!WEC8')4$D5Z]\5
MOV*?AK\8[/PK#J>@W>EMX'M9+#0)_#6LWWANYTFUDC2)[6&;3IH)%MV2.-3"
M&\L^6GR_*N*?A/\ :/M[[XB^-M4U#QY\'YOA7I/AG2_$>F7=AK8;4;*UG2XD
MEO[]V?[.EC)'&CV\RD*RI,2Q !&J/VT?@Z1XG_XNQ\-/^*) /B+_ (J>R_XD
M ,GE W?[W_1_WA"?O-OS''7B@>IE>#OV!_A%\//!/AOPWH/@NST?0/!_BI_&
MNBZ?:75Q#;Z;JSM,QFC19  @-Q*!!_J5# *@"J!=\0?L5_#/Q3\+_B)X+O\
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M?&'Q \5:GXT\1O8.[6,5]>RAO(MMZJYAAA2&%690S^478 N0/9** YF%%%%
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M5K&ZUS5_[?U33;+Q)JEKH.J:B=A:[N-)CN%L)IG:.-W>2!F>1 [%G^:O9J*
MNSE?!?P5\,_#SX@^,O%6CZ9]CU[X@75M>Z_=?:)9/M\UM:QVD+;&8I'M@AC3
M$:J#MR06))ZJBB@04444 %%%% #[C_CXD_WC7C'_  45\,:EXW_X)]?';1=%
MTZ^U?6-7^'NOV5A865N]Q<WL\FFW"1PQ1H"SR.S!5502Q( !)KV>X_X^)/\
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MTWX>^)[*[U..TD:SM9Y;S2&BADF V)(ZQR%5)!81N0#M./F'X#?LR>(_ ?\
MP2^_8LTJU^'NMZ/XJ\*?$3PUJVM6,6A2V]_I(>YG2_N;F(('BS#*XEDD ^5R
M6/.:_3"B@7,?E[^T-X,UC1/V2/VR/A1K?P?^(7CGXB?$CQ'XE\0Z!)8^#;G5
M-/URVGA$VF727_EFT26R@BB187E6Y\RS5(8Y)7B5^X^-W[-_Q)^)?Q3^+%AX
M5T?7-.U+Q)^RYIOA;1]2DBDL[9M7^UZMFS%RP"1S@2Q[E+!D$JL< @U^A5%
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M>\N+.1]2DC64:9;^<TEO+.X4.S?K97AO@3_@G#\(/AQK^B7NE^']<-KX8O\
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M<Q'3I[N*X2;;+&BPR/*98738&VAJ'QO_ &2?$GQ+^%/P#T.QO=$AN_A7XO\
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M3Z9!IMOI]K]IL(;ZW*SWE[ LAD6;RPB9=7C<NJ1[)&^4_B3_ ,%#OB5\??\
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M^]\13.\6G66JI)'+8J,)=ZA 8D@%TZW$<L0E+F/RA( YKSOP/_P30\9_#O\
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M ,%(O!]S\&->\4W7AWQKIFM>&_%B>!;SP?<6MJVO?VY+)"EO8H([A[5VG%Q
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MK"DDYC"7$ES;RB)O.\J]AMY2@<[,HX6OX9_X*5^%?$E]X/OV\(>/M/\ A_\
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M'D=\\HCUWP>)(],OT#G:?(DEE>VE"D+) \LC(ZL"V?E4!QZGIU%%%!(4444
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M_D$:+_UZ_P!:"H[,PZ***"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA->NKW,L%I;I!&TK(JJ9"L8+%54$DX '%=5110(**** "BBB@ HHHH ****
M"BBB@ K<\5?\@C1?^O7^M8=;GBK_ )!&B_\ 7K_6@J.S,.BBB@D**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4$^)!P_V3_A'S'^\^V%>EF;K[$)]W[ORBXD_=EZ_4ZBE8.<\=_8P_P"%*?\
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M11102%%%% !1110 4444 %%%% !6WXO_ ./+1_\ KR7^9K$K;\7_ /'EH_\
MUY+_ #-!4=F8E%%%!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVKT2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#;\7_\>6C_ /7DO\S6)6WXO_X\M'_Z\E_F:Q*"I;A11102%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%;GBK_D$:+_UZ_UK#K<\5?\ ((T7_KU_K05'9F'11102%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>morf-20221231_g3.jpg
<TEXT>
begin 644 morf-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" -"!'X# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
M,XY/%&<]*&Y4BHR0O4G^5 $E 8-T.:B4[N<<>Q!I\><MG;^% #Z*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***:S%><9H =13-_H#2-,%4'!(]A0!)1358MU&*3S/F(_K0 ^BF+)N
M.,?K2ECNQMX]: '44W=GL?QI10 M%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !124F[C./RH =147G>BG_@7%
M.:0KSM+#VH <>AJ-BW!Y'XBN3\9_%KPIX M6GUW6+>QC4$D2. PQ[5\;?&;_
M (*U?#_P2;FS\*VDGB*[3*B<-B,'Z8Y_.@#[TW,RXSM8GC'-<IXM^+'A7P+;
MRSZWKUE8I"/G6250WY9K\@O%7[>'[0'[0&I?8_"%G)IT#G$9T^!P<'L6)(KM
M/AK_ ,$Z?B_\;&CUKXE^++VTAD(9K8O^\(/7GI^E 'TK\9O^"J7P\\#S-8>&
M;:?Q9><C_1FV@'\N:^/OB1_P4W^-7BIYUT?0X]'TUL[ T#F4#ZY_I7W[\'_^
M"=/PB^&-G&;C13XBO^"UQJ+[B#[;0*]J7X"?#^-=B^%-.$6W;L\KC^= 'XB^
M#_\ @HQ\9/ .N274NIKJ&]MS6U\I('/08(Q7W!^S]_P5O\,>*_L]AX\M#HMZ
MV UU$?W>?I_]>O<?BW_P3G^$7Q161UT;^P+B3+--IC!"S'O\P:OA'XZ_\$D?
M%?@]9K_P3>R:U:1Y*6LH'F^WS# _2@#]8/ _Q<\,?$K38;SP[K-I>K(>$\P;
ML?[N<UV'FJLA4R#?C[N:_G!@N?BW^SGX@9(Y=7T"[A;++\VPX^HK[(_9R_X*
MV:]H4EKI7Q$LX=2L^$-[#E94'J>30!^O8Z"EKS;X3_M!>"OC/HT5_P"&=8@O
M%906BWC>I(Z8KT5I@H'!^E $E%,60,V,$'W&*?0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW/\ R'O";BUF_P!YE0=?QK2\%^-_$FAR+I.H6-P-,QMES&4LD']TIW_*O;?
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M:_1M5PHXQ3E;.: /A*S_ ."/_P &T0>>VK2-WQ<D9JS_ ,.@_@C_ ,\]8_\
M PU]S44 ?#3_ /!(/X)>7A%U8-[W1K#U#_@CQ\+9586EYJ<![$W).*_0&B@#
M\T-6_P"",OAN:,_8O$=Q"_;S!N_K7DWC?_@CKXPT?>WA_78M37M&\>/ZU^Q%
M% 'X'ZM^PY^T%\*[AY+.RN84C.Y7L9FSQ[ 5L>#OVH/VE_@+*%NH=0O($.&C
MU*%I!@<<,>E?NH=R].OUK%\0^$M'\5Q_9M6TZWOXBN"EQ"K@_G0!^</PE_X*
MR:9KX31_BAX?6R#_ "O<KRI_X#@=Z^B]!U;X.?%X1ZIX7\46^G7F-R(K@ 'V
M&:Z#XB?L$_!OQ\'>Y\+6>G2L,&6U@53SWX%?,'CK_@D7;Z3=27_PW\3W&DWB
MG<JS.WY#&: /L3PM'XO\'3"W\Q=>T5CF*?=F0Y_I^->!?MG?L7^&/V@O#]QJ
MVB16^C^-8TX10%$Q'.#[U\MW7C#]K']D.Y,=V=3U[2H6_=M<EKB-P/0<\5LV
M'[>'A_XQ74=OXZDU'P)KX0)]OL"T(W<]A@]: .7_ &3_ -I[Q?\ L<_$4^ /
MB%%.F@R2>6/,)PAS@%<]J_7WPEXPTKQMH-MJ^CW4=[93@&.1&R,XZ5^.O[2'
MAIOB1X1%]!J$/C,6Z%HK[S ;H = 2>3]*I_L#?MJ:M\$?%T/@[Q-<RMX6NF"
M!9B08&SC@'I0!^VFX<<]:,YK+T'7++Q)IL&H6$\5U:3*"DL39%:B_='>@!:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "F-][.:?44S8!XSCF@#^?[_@H=XND
M\6?M):W)-(S?95\A!N)QAC_C5/\ 91_8S\6_M%>*K0"PGL_#ZD>=J$@(7'^S
M7H,/[/\ K'[17[;6OZ0UI-+ID.I/)=S@?(B@YQGW_K7[2_#GP#H_PU\*6.A:
M-9I:6UI&J_NT"[CCJ<4 >>? _P#9/\ ? O3;2VT31;;[;$G[V^:%?,<X[MU-
M>UPQJD8"@;>V!1Y>$*@D9IZC:,9S0 %03DC)I:** $P.N.:AN+6&X_UL:R#W
M&:GJ.3'0\GL,T <%XP^!?@?QU&4USPY8:@C'YO.@4GI[BOGGQ_\ \$N_A!XR
MAG:TT[^Q96R4^QH$"GMT(KZ^F/EJ2%(&,Y/->/?'3]J?P)\"M!N+C6=7A?4P
MA,.GPOF1VQQD=!^- 'YO_$C_ ()5^.?A;=76O^#-?CN8K<^9$OF&.08]S_C6
M3\-_VU/%GPCU^'P5\9M+AUW2T_=---(DSJIY'()[>]9?Q$_:C^/G[67B2YTK
MP38ZC9:+,_EI':952I[L3C]*]<^"/_!).^\3)'K'Q.UZ42N-YMXG9W!/8D_X
MT ;-]_P4*^#O@V\$?AFSU."R W&SL<!';N"-PKB?$'_!3'PT+B34/#7@?5=,
MU'O=+"BE_P#>(;.*^T?"/_!.3X*^&(8HG\-PZE(@SYUPOS&N\MOV._A'9Q[(
MO!]BJ^Z T ?EOXT_X*B>+_$%O';KX3LV2/D-=0 DGU^[7!:A_P %)_B1=,2E
MI8V;] 8Q@K_X[7[!7G[&OPAOAB?P;8N,8QL%<W>?\$^?@?>%B?!EFC-W5<4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1M\Z-CN/K0![-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24$
MXJG>:E'8V<UQ,RI'$I=BW910!X;^V)\?K+X _"/4=8>X6/4Y8VBM(B<E\CJ!
M[<?G7PC_ ,$\OV:]5^-'CNZ^,'CVWDNX&F,UKYS'#N3DL >WI7FO[37Q.UG]
MKS]K:T\':9.\^AV-VUO%;QYVX# .?T%?HK\<?'&C_L??LS)9:=$(;F"R2QM$
MA'SF3;M!P._% '-?M7_MK:5\,=6@\#^'+Z'^W[AQ%-(A#?9UQ\V!W..,>].^
M'7Q3\0+X=^U6ZQ>'O"R1B2?7M6;RY9WZL563J,YZ"OB'X._#W2O!.GM\9?C%
M<-JVMWN9M.T9COFEE<Y0E!\W2G>/9O&/Q<DC\2_$#76\,^#Q)_H7ARWD ED3
M^%3$OS =.2* /HOXJ?\ !30:/++X=^'-C-XOU8'RY=0,3>5$?7( %97PA^*_
MCO6M9A\2^,-4O_$6N$DVFB:6#]G3T#F,8_[Z->#>'8]%M-2MX;339_L><0Z7
MI-H\LLY[>9*H('XFOHGPM\#/C?\ $2U$>FPV?PT\-,!Y;*4^T[.^3DG)YH ]
M^D^)6I16@O?'7C+2O"EN_P S:.MW")=N.!NR2#[9JOHO[3_AVR#:9X/TK7O$
MEX[?),]K/) 3Z^;C;C\:Q/"_[+_PC^&MO'?>-_$UGX@U6+YYY-7U!&W-UX4M
M6AJO[<'P&^%2_P!GV-_$S(=J6NF6;R8^A53D4 >X?#_7/&/B2(76MZ;%H\1Y
M6(,"Q'YFNB\3^(K3PKH]YJE[,L-I;1-)))(VU5P,_K7R9I?_  4,@\57K0^%
M_A_K^IEFPDTEC/%&1ZY90*^9/VROVS_&/Q0CMOA39^&SH.IZE( YCNE=BK'
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MH_9%;!D'7[N: *R:A\>?V#=<A:SFO?$W@N1MWF(/M";!^>W@^U?H?\!/VEO
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MEC'9P1D?F.U &#\2_@/#^S/!:>)?!"B#3K-<R-*X!CQR9">X]O:N,^+OQ0\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0;NA)_I7T9:WR7EM'/"?,CD4,I'\0]: +5%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH _/31T\2?L$_%J:U<3:A\(-7EW1XSBQD)^]Z8Y(_&NT_;,T,>)?"_A;XQ>
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MJBBVL+>+F2V=AM\QA_=#<UUO@KX+:+=?!V\DO[N*?4M4B:\DU-N6A?&X$-U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/@^'3OB5X%N(](UGP_"OVI(N$N44[L,.A)R>?>@#8_:M^%.I6]U!\0?"MO\
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M1;L.T<=G'/\ :)#@#<N2H^E?%MQHL_[2W_!1[[1$WFZ1X5=E=OX2J?+C\\4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 9^I
MZ?!K6GW-E.%E@N(VC=6]QBOQ;_;$_9W\4_LI?':/XC^'K64>&YKM;J.6W&?+
M((W*<=!P/SK]LE4+T&*X7XQ?"W2?C#X'U/PUJT$<EO=1L@=Q]UB,9% '+_LO
M_'[1?C]\,=*UW3IXQ>M"JW-N6^9' YXKU^+;DD,2,]#ZU^.GPWM_&G_!//\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX)R?&J7PUK)GO_"4TG[M7SM>,L,$>^*_7?X6_$[0OB]X-L?$GAZ[6XT^[02
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M4YN%)SCCK0 M%96K>(;#0;=9[^\BMH^@:1P :CTGQ/INN#-AJ$%UM^\8W!H
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M]S<2!<_04 =?17 >&OCGX&\831QZ3XHT^[DD.%CCD&X_K7=1R>9&&5PP/0T
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M$@R'C;(Q6K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO._CW\3-/L-(UO7;*;=':VDAD*8W+A3L;KT+8KYW^!OQ":'XA?#KQI$/*7Q
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MTCQ%HFV..[L_E=AN'RL0>>M>J? G]A72_CIX#\+^-/&GBK4=8%W#YPLY"VW
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M?V?_ !/+X@U[XB_$ZWC3Q'KL+1-9J=PC1^2.GTKV7X4_LY?#_P"%4,5SX?\
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M8PI'#$L,2@*L:# 'X5:VCKCGI0 +TYI:3IP*6@ HHHH **** "BBB@ HHHH
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M=@: Q@?+(+=2"?QJ7]E3X<Z-9_"W1O$DEA%<:SKMNNH7=W(H9FDD7<V">W-
M&_\ LQ^'+KPO\#_"%A=1FWN8[&/?"WWE..AJ#]I#XN7?PG\(0MI$ N_$&JRB
MVT^W8\/)QG^=>L+"L*_ZM54#: O'>OC?]ISQFVG_ +5OPDTBYC9[&,O<HK<K
MO)9<_A@4 >9_&#]E?QU\2O"=MKWQ?\?QVVD6S?;I+=4&V$##;0<#)P*@\/\
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MK]%[<&.UB7[V%"_I4&FV<%CIEM;VL*1P1JHCC4  "GZA*(+663:SE$+ +[4
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M_%]TD4FI7.J/&9&4,R+$1& ,]/N#\Z^G_%-F=0\/:E:#YI)+60#'J5-?+7[
M?PNUGP#X7\:1:I$UN;[5;F6$2#L9&Q0!0O/AQ:_M<_&+6I?$<\LOA/PW,(8;
M+S"$F< 9RJGGDGKZ5].> ?AIX>^&>GKI_AW3K;3K<]4AC"]/4CK^->0_LQ^$
M]3\'?$KXE:?>V[);F[$L,Q'#[PK''YFOH\J,' P2/2@#\:/^"Q6MW5Q\8M%T
MMI&-I%:AT7/RABS9_0"OJ;_@DAX&M-'^ =UJYC1KV]U"13(!R$")@?SKS_\
MX*X_L\ZIXHT?3?B#I,0GAT]3'>*HY"D\']:]>_X)4:I;WG[,ZK%Q)#J$D;IW
M'R)S0!]HQX^8!<<_G4E1QMVR3QWHG<1PNQ!8 9P.M $E1L%.<C'O7%V?Q(L-
M9T?4;G39#=3V+$26_1Q^'X&L^\\?3:I\/_\ A)-'^?R6S<6^,GC[R?6@#8\>
M:M?:;I;W%E;IJ,,:DW%NV.4[UX[;^)F\#+#XHT'%]X+U"7_2[ G+6C.>H'89
M)&WMZ5;\3^/-4T^\T;QGIO\ IOAS5$2WOK,\^2YQ@8[?Q9K8T;PA'IOB7Q9X
M;@@#Z+?0F\AR,JLC\X'T)H I>)M!T^UEU#27;_B0^)(3+#&1G,P_>+CT^Z:U
M/V>M(NM+T5_-1B+@,7+?W@^ /^^<UIZ-X!FO/#/ARWO6+W>CR8#.<DX4H?T)
MK3\8>)M$^"O@/4=5U*_CLK2U1I<R$#>V"0HH Y7X0SVD?Q:^)5E$X5_M4#&)
M?X?W*_SZUVOQ>N6M?ACXFFC^]'82G/N$-?+/[ /C6Y^,7B[XF>/90T=MJ&I*
ML"DG&Q$"#_T&OKWQQH?_  DGA/5=+7AKJW:(?\"&* /./A[HD'B?]GV&SM'V
M&ZTQP?+X/F-&?ZFOCR3PZ=877]3N+O\ LSQ[X>C2TL$B?,GE;L,<>I4G\Z]
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MN$@@5-I'3 %;FT>E 'G_ ,"['4-+^%?ARPU)/)O;.U2"13_L#;_2O0:0*%Z
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'[^UNKJ2Y0'_ )9%CG ^G:NET_0(M)@MAEYIXXUB,K=7 &,L:X7QG^TM\.?
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M1P..N>U?@E^U'\(='^&?QRFT?X;:I-JDBR[DAM06DA?.<9'O0!^W/Q4_9_\
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MYF^Y;,<>>>G3KBOLU8PJB-4&U>.!C% $\:[4 I],C!5<'\*?0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>I"FOQ%_8PT6?PS^VUX?TV^7R9[74'1E;_>!% '[WZ9:):V%O"HQY4:H/;
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M](C2>6O.T#&<^G6@#9IDF-O-5(=:L9IY8$NHVEB&74-RH]ZDM]0MKZ,F&99
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M(S%<8_&J^GEQ8P"0DR;!N/X5+(WR[L4 (TC!NG&.*>TG3TKYJ^!OQ\U'Q_\
MM ?$/PK<C-AI,5J8/7+&4-_Z"*V]/^+VHZI^TYJ?@BW*'2].TZ&:8L<$,^>G
MY4 >^TQV(Z41ONC4GJ15?4KC[+8W$W]R)F'X F@"9I&WE1CCDTGF,VTC&WWZ
MXKYX_9/^-E]\6[CQ\+YL_P!EZC]GB/\ L ,/Z"K?P5^+^I?$#XV?$K1Y"O\
M9.AR000Y/.2BEL#ZYH ^@J9(2N"" .]*K J#ZBN*^,OCZ/X9_#G7O$3\O9VD
MCQKV+[3M_7% '9,[!NH(/3BA9&8\#[OWJ\J^#GQ>/C[X*V_C&[18IELGGF4'
MY=RJ3Q^5'[/_ ,3+GXK>%K_6IU,<?VYHH<=U&!_/- 'K-,DD*9^7( S3\U\X
M_%CXY:AX-_:9\!^#;=\V.M1J)%'J7(H ^BFD8+N'/&<4,SX/*CZUX/\ M&_%
M[5? _B+P1HFDA1<ZMJL229./W09=_P"AKW&*93'&K'+, 6SVXH G$C$X^[CK
MFG[OFZY!Z5&Z%MH/(QDUXC\/_CQ)XR^.OBCP4L8,.C0J69>NXDC^E 'N._DX
MYP<4;CU[5XS<?&:Y/[14?P^M(A)&M@UW*WH04'_LQKV/<%9L<[NU #O,^]Q@
M+2>82P&0"1G%174AMK.:4\^6C/S[#->#_LV?'^;XT^(_'.GRHJKH5ZUNCK[,
M10![]&Q?)[= *?N]:\?\"_%Z?QA\;?&/A6!0VGZ/!$5E_P"FA5-P_,FO7=PV
M^K>E  S/T SGI2))YF[!'RGFN,^,'CU/AC\/=8\3R)YRV,7F%?QQ65\,OB_:
M^/O@[8^-RJV\4]K)<-'G@;688S_P&@#TI69F.5P/6G$X!->5?L^_&N+XX>';
MO6;>U:WMH[AX$9OXMIP3^=>JL=JDXS0!#]H"J6+ C&<"G*[$[20&ZUX9\4/C
MM_PKWXU>!?!B1*]OKBS"5NX(VX_F:W?C?\7'^&D6C1VJI+>ZI.(8D8XX7&[_
M -"% 'K$;;L\YQW%.J&S;="K8P6 8_4BICT- #=YW8'2F^8QW @(>V>:\N\+
M_&RU\2_%_6O B0@76F1M([9_NL%/\Z9J?QLMK'X[:=\/EM_,GNM-FOF=6^Z5
M>-?_ &>@#U:-]ZY/6G-G!QUIL8VY'8<"B3_5F@!@D<-AL9/0?A0)'W@%0 >,
M5Y1\'_C9;_%#Q)XGTE(E$VBW<MN[9_NN5J]X7^+5MXF^+>M^#;2'Y-,L1<23
M9_C,@7'Y&@#TR-BVX'D@TYC@<<U'&QV<_2L3QYXNL_ OA34-<O\  M;.,ROD
MXP!0!N;F+#H,=1UHCD9LY3;^-<7\+OBCI/Q4\$6WBC3)!]AFW88GLI(/\JA^
M%?Q6TWXL:;=7^EJWV>"=X"S<$LIP: .Z+G<#G"^F.:02.Q^[CVS2?,!\PW<]
M^*\J^)7QLL_A[\0/"'AV:$,^O/(HDW?=*[, _P#?5 'K+-MX[GI3J\X^+GQ<
MM?A?86$LL?GW%])Y<$?JW'^(KT."430I(. P!H <2>>/I36<\#N:1R5;=DD#
MM7"V/Q9TO4/B/>^#DD_XFEM%YK)C@#([_C0!W@D.<8SZFGUQNK?$6PTGQ]H_
MA>1F^VZC&\D:@=EZY]*[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9D_O#*LFPG'J2*^2+#XE^$_AGH=A8>(=*NO'OBE;5#'"RA[:V&.%.XYR![4
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M2SPF\UG6+(:4FXY9PW[K/U[T >)?LE_'Z;0_@UJ?P]\->'KKQ+XEU2>Z26)
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M!D)C^'GV[5]S?LG_ !^N]?\ V?=5U3QE(_\ :'AN2YMKR9FW%O)=DSD]_EH
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M=L=YY8V)Z%B!Q7U!\ O'_C3]G&X\.ZG=ZH^N> ]<NC9E6?)MY!MP0#V^?]*
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MWD38RLJ\&@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=<^T(6@FTM2ZG'J3CUKU?]G?QA<_$/P%_P )#<Z==:8;JYD:.WN@ X7C&>:
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M$KQ3:>8;)H&TJVE?DOY889S^-<1X;\"_&']I:^\[6M'/P]T2X;-SY;EI=OH
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M>2:AI/\ PKW]I;0=;T>);'2EL)!/Y Q&RI&00Y[L0.1TR37JMK_P49^%.I>
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MQ8XSP3^=??'P3^&MG\*O MCH5HJEXD4SS#_EK)CDT =[2T44 %%%% !1110
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MVH ^"/V%_P#@HXOAFUT[X>_$ +%;PXM;6],84+V ; [5]S?$'X2GQG9R>(_
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M-5.0.?6GT4 ,\M<8QQG-+Y8W$^O%.HH C6WC7&%'U[TXQJW7^=.HH 8L:KG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH :QVBC/&<TK$*I)KG/'?C"W\#^%=2UN\^6WLX&E?+8^@
MH S_ !]\5M!^&6BMJOB"^CL[/<%5FZL3Z>OX4SP[\7/#GBBSMKC3]125)E#C
MS/E.#TKY+\#^'S\9O%EIX_\ B'=2:E;2"2;1='<_N($4C#,HZY!&,U]=6OAK
M1?%WA>R^U:9"EO<6Z2>5&-@7(' Q@T =+!?PW2!H;B.0$_PL#4VXJN=Q/UZU
MY9-\$UTZ0/X9UFZT$=,1MOW>WS9J+_BYWAT.J_9==@CYW2KB1@/3!Z_A0!ZR
M&=E!!4CVJ1>E>-:7^T596LSVWBK1[[PU*AP)KR,QQM]"0*](\-^-M%\66RS:
M3J,%^A&<Q.#0!O44SS .2"!2"8%]N#GZ4 244S<>?EY^M.!W#(H 6BBB@ K\
M/O\ @K)KUQ?_ +1TVFR[S#9V^^/<>,$\X_(5^X-?E'_P5R_9YU"XU:Q^)&F0
M/-9@-!?2*I.P\$9]N#0!W'_!&[PFUI\-]>UTCB\N1&6]=N[_ !K]($7:3Z=J
M_*'_ ()L_MM?#_X4_#=?!7BNYCT:Z%T\JW<SA(V5CD=?\:_2[P/\7?"7Q&A:
MX\-ZY::O!C[]K*' ^I!H [2BHO.'8$GT'-*TH52S @4 24V3.TXYI(Y!(,CI
MV-)-]S\1_.@#\T/^"S/C74]-\)^%=#M97BL+UB\RC@,58D9_(5^6OPY\#:A\
M2O%VEZ!ID,EQ=WDZQE44G:I(!;\!DU^Z7_!0#]FU?V@OA#>"TCW:UID;7%JX
M7.=O)7'O@_G7R/\ \$D_ _A/3_%7B7^W(8?^$PTUVBCAFQNCXP3@_C0!^A7[
M,?P;L?@A\)-'\/6L2I,L8DN& Y:0@9)_#%>L;0#G'-1P/N3L1ZKTI^[YL8H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.\,Z))X.^)/P@GL]*+$R201_) S<ED&WY>N: /NOP[\;-(U#Q5/X;N+Q([T
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MYW5SMU^TY^T=\+\KXP\ Q:K!#UGL05W#U^Z: /OCYSSN!'M3PHQTKXV\%_\
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M^.(;AX\1L3T .>IH ]NHJ%9_,B$BC*M@K[@U+0 M%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*\3VD$K#B.\?R"3W&&Q0![UFEJGIM];ZC"LUM<17$1'#0N'4^^15R@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "DP.N.:6B@!,>U&T=<<TM%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#R"*88RV#
MT(_6I** (PNTY"#/M5&YT&QO&8SV-M/NZ^9$&S]<UI44 >:^)?V=/ASXRD+:
MUX.TR\/KY97/_?)%>*^.O^";?PL\5M,^GVEUX:DD&/\ B5W#(JX] Q-?6E%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>morf-20221231_g4.jpg
<TEXT>
begin 644 morf-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )<!)P# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,<"@">BJ/VMI%#QR*Z!23CHWTJVD@= P/!% #Z*1:6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)V*M\V2"'7I71? [X4^(-/\ &FD7.K?#Z/P^NDC#:E/J;7!F/'*()6P..A%
MG8^O(I5DR%.<=>#4E5;'?AF==K'W[5:H)"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 1AN'3--\L?W13Z* &>6G]VJ]U;I,A0X7T/\ C5ND
M*@]12L!YQ=_ WP/JGB+^W[CP_9OJ,S>9)($X9^S'WZUWEK;I!'L15"H,*J\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF#J3TQBNS#%L$$$GI\U=U/$TJT>:G*YC*FX[EJBBBNDS"BBB@ HHHH ****
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M&;?4X8?L4S*&DMWZJ#7?<]CD5^A1G&2NF>"TUN2T4Q<[N:?5B"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** &M]VH7]QD =QQ5BHI>PQ0!YIJGQS\(Z%\2['P+>ZAM\
M1WB&2"V$3_,H!;KC'0'O7HBC<^=S8ZU\(?&7Y?\ @HUX&'8V1_\ 1;5]\1@;
M1]* 'U')CG/I4E4-1F,>3\P55#DC'3/3FC3J%KF/XNT2R\0Z/-!?_(BJ6\S.
M",>]?&'BK1=0^,7C+4- E\4K9Z3I4^Q99Y@JKD#Y0?6O<OB1\3-2US1+H:=H
M]S_9L<WEW$VX E1C.#GTKYE\:2> 8?%$\=A?S6,U\T<DUG-O=LG(+ KD \=<
MUW491IJYG)\V@FO?L^^"/AC;R:CXK\:?VJ\GW(;,LS?B *P_^$L\%^%_"\TV
MD:1"U]'*)+:_=1O7_>!_#M7MO@W]FOP'\1M%CEN[J>2>-_EF6]<EOP+5YC^T
M+\.?#_P.TBX@TS69]2O)F#K8&TAD^7TR5W?K7MX/&T:D?=DV>56IJF[(\N\9
M>-_$OQ4TPK'-!Y4K;?LR[85F]]IQG_Z]<WX7^$S0V9U'69/LTL;;%L8D9F/_
M 'R#Z5Z#X+TW6_&&@?9YK&VT72;6;8LJVZ&]9!UV[AP.G(]J]2U+5M(TWP_9
M6NG6%R-20>6EQJ$?EAEQR21U-=OUN,O=.64O8KGDB[^S[\06\&V=T\GAN1UD
ME6&TC9%WLV&))R?:O7M>\;:;\8/"=\R-'I.O:60##=@ [O13WKYWM_!TC:.=
M6BU^YM'LYFE2$.SXR>V,Y],^]>T?#OX=S26#:ZM[H]Q>S1K<,9'=BQ(S\RMP
M#SZ5X.,BG[R/4PF,IU5H>?\ @O0X_%&L:E>>*3-#J>F1E[-"2OS@@*R^O7]:
M]:\8+KL<_@.);6/5=4=?,>20@,%*L=I_2G:I\+]1^(DPN[FYTNUG1?EGTN5]
MY('"L#P!QV[XJ/X;ZQ:6^J:F;'2[[6]>TQ1!<3W%P6C3 '*@M@<>E>!4B>M&
M49&7\8M'\<?$)M,E\*N]D\+?9[^QDD"J ,@E>:\AAGE^$VJ:M9^*;'SGN+.5
MH9I%\S:X4G!//I7K&J?%G4+JU\87FBHMCJEL@/V&09+D8R5S^/2O#8/B%J O
MH=;\0P1ZC,7 :UG(D50<;LJ<CH37@8R+C97/?P\?:TK=C'\-^!_$'CSPWK?_
M  BETL>DSXFOH5'RY&&X/TQ7J'PWTVV^(?@^;PK+.EGK]HC?9KM#CE1P 1WR
M*]GT?X=?\(S\'=7;PK:H=0UB)KA$CPBKO7H!QT%?+7A_P;XS^'GAUO%ZAA>0
MW31218SL(.<X_&N>5&=XZDQJ)1<6CA]9\1^,_A_KUUHNHSW,MW]I"-)*"3LX
MQC->]_#&)6U73+W6UEM;GAXWN/KT-87QFM[:&R\*^+-;;[7XAUQU$2CY454(
M+''0\&IX]6OM<UC2[W4PT]E;LOF[3L&#CTQZ5Y6.HOZQ'0].BDZ#:E8^E=2^
M&?AWXB*=2M(H[/68_N74:X&>QXKR&^\0:UX+U5?#&O6K79:194FMHLQF+D=A
MUKVS2O"ZV.DQWWAC4I(Y& ;R9'+J1CD<YQ6WX>U[1]8TFSO]1BM([IV(9)%4
MNK#L/0>U>]+ U*U-.H[+R/EI57&;UN+\+UL_^$;1+&20(QW'=&5P?3I7>J=R
M@U4M884&($182,@1@ 581LJ,=,5[5"G&C244<<Y<TC,\5VTM[X>U&W@&^:6W
MD15SC)*D=?QKYU_85^#_ (B^#G@KQ%I_B&T^Q37>J2W,2[PV49F([GU%?26K
M7D5C8SSR\QQ(SL,=@,FN'^$7QFT#XRZ?>WGA]V>"RN&MY-V?O*2"/TKK&>BI
MTJ2HTZ5)02Q:***!!1110 4444 %%%% !1110 4444 %%%% !112"@"GJ#'R
M9-I(8#@>N.:\O^#?V%M-U)5/^FM>2/-#P&#$X!/X 5ZJZLS-@@G/ (KS_P 2
M?"'3M8U@ZA:7%YI%ZW+26<I0,?<9P:TC4M%H!?%GA'4KCQ%9ZYH\HBOHD\J6
M-P-LB_Y-<3XRUCQ;H]C/?WT^FM90QR&2T^4R%<#G&/:NT_X0?Q#&ICE\9W3V
MH7&UH8E./][;G]:\N^(WPMT*SAAMKC5+H:CJ]SY4ES-=N0L/ ? W8'!KII^^
MK2V,Y2C'<\LU&UT_X.VNI:]KWB>T;1+JV$EOID1#3S'YB.,>^*^9+HZI\;]7
MGCTKPO?M)<.3 JJ$B0'UR17O?CKX">%)=2MI+>ZN-5AL[B&&:\NIW=0I)^Z&
M.,<=N*[K_A;'A;P'&VG6FEF=8OEAFC3R@Q^J8]NM>Y2A*E'W&>-7QF'HOWD>
M%^'?V!?'US;Q3ZGJEKHMJQ!EB\X\+WSCBOH/PS\(O!_P8T^PGAU2UU%[@^5<
M9N<JI/?!/UK*U;Q'XO\ %WARXO+.R^Q63+P5NW<X/L6-<(W['/C.\UIM0N/$
MMM!87"!A'=7#!5;Z5S5'._-4;,8XRE47-2C<]PUJZM?#]U?C2+:'6-$$1DE^
MRLI\L9!!SGK56+6M1\1^'8=,N84M-(NQ]JM+J^Y41E2<9YYP>,US7A[]FW4K
M&QU"+3O%OG72C<;*WD/E3-Z%O3KQFO2=!UJZU;PC+X7O?#@>ZTRW2*Y1L!$0
M*%!0YY./2N"LZ-2.CU/8PU64M7&R/)?#_P -M(UB\U$W/F6^@6L:RB9%VO+(
M2"-IZXS^E>CPW6M>'?#]BFINS:;+<A+*+.7*%#LS_P "P:RK7P9/X<FM+_SQ
M>:4?FM4NI62&,@<*V",X]_2M"S\):C\<=:MM9U:YBMM.TB7RH!ILTL:EUR <
M9 (!KQL1=KEB>I2G&H[%3]H;16T'X:QZI?&^U:Z#),(T!(B((."!]*\\TO\
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MIUW8"."Y8\*K;7=3ZBO0H4\N%$Y^48Y.:[*:O$YVEN9/C#Y?"NK$'!^R2_\
MH!KY%_X)?J&^&?C!B.?[<G/YR.:^N?&3?\4QJJX)/V28X S_  &OD;_@F W_
M !;/Q: &&[6Y^H(Z2/6P'VDHP*DI@I] F%%%% @HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIS&U2TP2+NP#DT^MQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/(TGPV\6%F+'^VIOO'/\;T ?:*4^F)3Z "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$/2H)6*E,' SS^56*@F4Y! ^;^]Z4 ?,/C[]GG6/%'[6?AKXBV\T?]DZ9:&*
M13][<01_6OIV-CN]0!CBO%?%/[2FD>%?CMI'PVELKB34M1B,R3A!L'![Y]J]
MI0$#!X+'/% %FJE]"+B-X7RJ2+M+ U;J*7!R#R,4$MV/+M1^W_#V.Z=AYVE<
MDD#E0>^:\#\:*+'2='TJZ4>?'*Y8XP%4D$<>G->\_M!:U<:7X'N8X5+1S 1O
MCL#P:\5^,S0ZMX9\*^*+<;9KF-HY5_A.  /QK@JZ[GC9E44H6,G3;2?PS\7-
M)CU&4O;01+*DDAX )_\ K5ZC^T=8V%CH^F>+Q=-&;60*2C8#HV,CZ'%>1V4E
MW\8-3N8)_P#1;JSL_)7G!+C.*J?$GQ5=ZY^S3?V&H#_B9Z+<QI-&Q^8J,\_3
MBIISLK=#S\%5MIU/L#X?ZC::MX?LKFQ CMGCR(UX /&>*ZU:\A_9QN_MG@?>
M5*!)F0*>PXKUU6KN@TUH?244U'4?1115FXE&VEIK.%H CD4;?;&*\VUSX2Z8
MUWJ>JZ>A@U2:-Y$?&1YP3Y6^N0*]%N+F*&/S)'5(^[,0 *XS4OB;I]C>-#%;
MS7:1L \T&&52?7GI64G'8M:;'!V[:EINFA?$<MV3%CS9MY"N3[4[P3ILOBKQ
MQ'JTD'^@VB%8&V8 P,C]:ZWXEZ<^M>'8[N%F:.&1)WBZ[UR,_I72^'Y[=='M
MY;14CMV"Y51C'8UG*FDKFR=T8$=BNO>,+VUU+,D,$:200L?DY)R<=^E=Q9V,
M5F@$,:Q#'11BO/\ 1]0?Q%\2);JV4FPL[;R9I,8!<%C^/45Z2N=HK6$8J.AS
MN3O818^233E0+2\TM-0C%62"["BBBK$8GC'_ )%G5>^+.8X_X :^0_\ @F#E
MOAGXM+'!_MN;C_@;U]B>)+.34=$O;6-MC30O'N^JD?UKP[]D'X!ZE\ _"VN:
M;J5S#/-?:@]RODL6&UF8]P.>: /H%*?3%XI] !1110 4444 %%%% !1110 4
M444 %%%% "8IK1CCK3Z0T 074(N()$(X92N.QR*X/0B6\&WH@.'CDFC3(R!\
MQ!%=]-*L$;NYPJ L3["O/]!O(- \-W+S?.LUQ*T2CDMN8XQ^=1(SJ6E%Q9X/
MXFLX?A[X@T[5]/E98[Q6-RJ]R"0V?P%6_&ES::+XX\'^)].7%E=RK!(4'!8X
MZ_G7;KX,3Q-J M+I 4?SF(QG9N0@#ZYYKP'QOJ&H^#;J[\(ZGO98YH[RQ//&
MU\D#W(6N*46GH?,U:,^=/HCTSQ;ID/B+XWV[74X:VMX1F//KSQ7T#X#C;_A'
M(4<916*(,<;:\4^!AL_&_C+4]6N(]\T4*1[)E]N/QKZ-@MDMXDCB01HO\(K6
MG!'M8>'+&Y,BE5 )R:D!I IQS2@8KK/0%HHHH **** "BBB@ HHHH **** $
M(S3=N#3Z0T 02_=.#@G@&N-\>WEVT=KIMF=EQ=G9N_NCU-=E+C&#P"<5YG\8
MI;O2K%=6M2Z/$"'('('J,5RUTY(UP]HRNSR+]H#Q*W@?28]*A>--.LXHG^S,
M?^/@<Y%9'Q<6T\0^!GU"UB!CO8!<6[X^ZV,E/PS3?%WPRLOC%\$;C6I;NZOM
M:L;<[9-I!\T#GJ?NUS?[+>LQ?$KX3WUMJM[&^H:3&UM#:3'!W8(S@_2O*KTF
MY:'OT*D8^IZ7^S9?+XX^!JP2/YD]J'1/5,'C]!7&:W\"W^*D-Y<07GSV_+PL
M<C>#\I [&J7[#/B VNH>./"TI(:UG=RI/W I*D?K79>!_B5!X5\8:O;_ &6:
MX\Z4I'%$H)/S<'KZ5Y-2GRXRE.VQC6DW-ZFC\-]3^T1Z5::Y L.L>'\Q&0G#
M3*H*C^E>V>']-NM8U%=4OAY+*A$,:]D)R,_A7S]XAO#K'Q%@UBTL9+:)<QR0
M7 V,WOCG-?1?P_UK^U_#\,S+R&,6X_[)(Q^&*^@H<KJS=MSRZT&O>.FC7:Q^
ME/YIBMNIX->HT<HM%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BFL>E-=AM.>E*XADG<5Y/\;]>30]-LKE?);4$N!Y4;G@]>M7?C1\
M2+OP+X<,VF6OVO5)OECA3D_6ODS3;7QQ\4O&K7?C2>:RT6Q'GFVBD(Z]B/QJ
M92BMV<TZBVL>^Z+XZCUB[GE\5W-G9FYMF@M\$%5<L"#TZ\5V/PY\76EWILFE
MW%U$]S:[HF1G!#Q@X#?B,?G7C>O>%?"6HZ?:I>[-/TT?.LF_]XW!YXKPSQ7-
M'X'\=6]UX<U6XO-(D9!/O+$A=HXKEE/L>95Q<:#M?<^J8?&^F^'?$UW?:=:_
M9H$G^SRQ1GY9,G&0/QKT3P]X_74]:CTZ[T^6SD<%HF/1AU'Z5XSH_B3PAXZ?
M2;/PZ =3=X7G61<;=I!/\J]:D9+WXE:?9JW_ !YV6\@=B69?Y&KA)L[J%1U%
M=GI48VKBGU76;J!R!P*E7YNHQ73<[QU%1%@,LW %5FU.W5W1IHU9.3EA2<K#
M2;+]-9N,YJJMR9"&!7:1D#U]Z;<3!5R%)Q_"#UIW5KA9WL6O,_SFGUY%\2/B
MI?>%[[[+I=K]L,.'N6(SL4GI7IUK>+/ LJ,'65?,5A4J5RW!HT**BMV+0JQZ
MMS4M69A1110 4444 %%%% !1110 4444 )1FHY&P">H!QBJDFH(D@CD^5F'0
M$<4 7Z6J5M<Q7&&1]^/EJU0 ^HYLK@@X-/J&ZW8&W)8<]<"@#X)^,RC_ (>-
M^ R1S]A;_P! :OOI2-H/M7P)\9I5/_!1/P(Y')LR#M!/\#5][KOV@CYEQT-
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M?K5GX%ZP]QI>I:?*Y=+&XV(S=6/5OUS6@NFW_BC6&N;N)K&&.(I$ 0&PP_\
MKUA#X<W?@72YK[3M1:4VY>XD3)RPW$L/R)JI)QLXF<I.4>5GLD++)EN]2\5S
MOA'Q!#XBT>UO8L$21@_3VK>#5Z5.3E'4Y^6Q+13$I]:7)"BBBF 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-<Z?K&IP:C9M%IUS=-)#-@%1M48/Z8JCI/@O2/'WB#Q1?FW@6[AN0EM(B[2
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M<LN2>W6O5Q\/_#6M0P2V\*W%LPX:"\<)_P".OS75Z;I-IH]JEK:1"*-?[O\
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MI ,4 9,FAV4DQE:TA>4G.]T#'/XU)<:3;7&SS+>.3:,?,@.*TMM &,T 9/\
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M4 %%%% #*:RC=GO4M,;CF@=SSGXM3:U'8V,6E><(Y;M4N6@&6$6UB<<>H6N
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MV[O7H)\RT/(M9CJ*:K;J=3 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3(&BN)W&/-*Y^Z?RKL?@[\8AX7O+CPEXC6XCN;:X\N.XD'"AL 9KF_$UY=_
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M9!AF)!XZ5X_M\3&34]D>C['#R<90.,\3:IIEAX*U*[TXR17MU-'Y474!?FW
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M^6, #CG/%2#BO3L>^%+113 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+>)/VB],\,?&W1OAN]NQO=2@\T2>G!/]*]H1E8,,<K@?G0!9'04M(O04=Q0
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ME4QG]*ZZ?F<]1Q:T.XC/&">:?D4P<X/:EKJ//U'9%+3*<.E2 M%%%,84444
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M,-PJ;C&^1VS6_$^]0>V*[8V>J-T/I:**L84444 %%%% !1110 4444 %%%%
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MH6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IE/IE $<G7\#7SQ^VI>WNG_"7?9@R%KD
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M%%%%(04444 %%%% !1110 4444 %%%% "5#,P9@N.&&"WI4K?=JO,P^X6 W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKS5M 5KM/])A(1STS[UU\1;!)&*]:,M@I[$M%-W4ZM30**** "BBB@ HHHH
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MU%)^[2X<+O4],9ZUZ-9W<=Y&DL,B2Q-T9&R*WC)K1G-4C9Z%RBBBM3,****
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MEC:<BLFQT&PTZ]GN;:VC@ED&9)5')-:\>=@SR?:K6BL9RDI:CJ***" HHHH
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MQM)TSMYP/>M"RM$M(TCC3:B].:L".E'WJ97,]AU%%%!(4444 %%%% !1110
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M"HY&/SKVG5+EO%OB-M+@++;P#,[<C/H*ZEM)MVL7LWC1[4)L,;KE2/<=ZGE
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MA?X=CU*TU1=-A^WVUJ;**7;RD1P"!^0YJEJ'P1\):MHL6E7.E0R64!WQH?O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY(A)U&:DHH J6
M^FP6\TDR0QQS2_?9!C..E667/&!MIU% #=M(T88Y(!-/HH&,$?L*%CP>@I]%
M 7&[?88I-O< 9I]% ANT=P*-@]*=10 F*3:.].HI6 88P>R_E2+"!V7\JDHH
ML W;[#%+_*EHI@)2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 (13'B#XS^AQ4E% $?ED\$Y'UI]+10(****!A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>morf-20221231_g5.jpg
<TEXT>
begin 644 morf-20221231_g5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 02!'4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***3- "T4F:6@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4+[[#;:_ID]YV@CO(V?\@U?GW\6OB[JW@G]CGX<V,-S=6CZI"J331;A($X!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 -9=W?%,:'<!ZBI:*5NH$7EMZBI*6BF
M4444 %-"\Y/6G44 1-"68MQGH.M.5=K9XQ3Z* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD.: %HIO/K1
M^- AU%,S1F@JP^BF\T8/K0(=13<'UIU !1112N 44447 **:U)FF ^BF9HS0
M ^BFK2YI7 6BDIIS3$]!]%-7I3J!A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUCPDTVK-*=BS6."T1QGY@>G%<M^S!\9/%/CWPO91:AI5S*+;S!+J4F,2?.V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=1C\:<JY_A9OI7;VW@VRAY;<S5IV^DVEN %A5O<US2Q\8[(U5'N>>0Z?//\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%)36(C7)H 5F"\DU1N+HMD*<"FW-P9/E'2H?X14
M.1#D1J&5B>U+D>_YTZFLF.E9\S[F>G87_OJC_OJA7['K3VIZ]Q678:/;(K(\
M4?\ (*(ZFM@5A^*F_P")8?K6U!M5$1.*M<X.BD7I2U]1ND>:][A11G'.,^U:
M.F:'<:D^0I1*4Y1@KMCLWL4(XWDD"HFXFNDTCPF\S"6<;1Z5NZ7H%OIJ@XR^
M.3[UJ<]SQVKQ:^,OI%'13IKJ5[2RBLQMC05988'S=***\R4G+5LZ[6V$I:**
MG3L 4444#"BBB@ HHHH$%%%% !1110,****=AV"BBBBP@HHHH ****0!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1113T[!J'TJ"ZM4O
M(]DJ!JGHHBW%W0:/<Y'5O"(7=);_ %VUS,\$ENVV1=IKU12%)YSGM6?J6BV^
MI1D,F'[&O4HXSE:C):'-.FK71YO16IJV@W&FDY!>/U':LO*L0 3D>M>U"<9J
MZ9R./<7EO++'G<0!^5>/?&SX2:AXLU+2_$WAR[6R\1::V^-F7(D7NI^N!7L#
M$L23UI5ZX/3%.4>;H5%N)X'+X/T_QUX?;7/B9X>ATR^TAEF$J, 'P#UQU%>.
M:E\/M2_:K\2?;88X]#\)Z*IM[&81!FE(//U' KZY^(W@U?B#X-O]!D?RA<1&
M,-Z5X5XHC\2? WX KI4=S']L:?[+!/ NTQJ0><X]A7+./*]#>$KK4]%^&OB:
MP\ ^';/PQKOB+31J=OB%%3"_*HQC':O489H+A?-MY%EB89#+T/O7PC8_#>#X
M7Z)+?>-[-O$$6I6QFBUAE\V6)V&<ANHP:]M_9:\:W4?P?%_XFO72Q658;2>[
M.UGC_A.3ST H51[$RIWUN?0O6@_+4-O<17D*S0.)(6PR,IX(Q^M35TW]W0YU
MH[,TM%UR;1Y@RL3'W%>F:3JT6K6RRQD>A%>0U>T?6)='NE=2?*)^9:Y<1055
M<T=#IC6Y78]@7KFEK-TC5H=4MUEC(SW6KY^:O#::=I'I1DI#Z6HQ3UZ4%=1:
M***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44E(6Q[4 *
MW')Z5G7-QN;:IXI]U<%OE4XJMP*AR[$-]A?N\4E!YHK%W,=;A1113&,93N+4
MBR$\5)4;)TQQ5 /SQ6)XL4#3L"M<-VK(\7'_ (EN:VH_Q$R9_"<#@]N!3U7<
MP"J9">PJ2SM9;UO*1<Y[^E=MH?AV*Q57D4,XKW:N(C3C=/4XJ=/G?D9FA^%2
MVV:Z&Y3R%Z8KK+>!+>,(BA5IZC#>WI0WM7A5*TJSU.V,5$&9(U+.ZQ@=-QQF
MD5D=2R.' Y//'3_&OFK]IW7]6T_QGX8L[C4[[2O"LKE;J\M%Y!*DCGZUG_$3
MQY?_  7^"ESJ/A2_N_&BS3)Y=VTB%HE,@^4Y(/M]:PBD]V;.%CZG;"<$C<<?
MAQ0!CY203ZU\SV?[6]UH/P_T#4];\&ZJFI:I)]FAM_W9:5]A;(^;IQ7;K\?I
M-/T?PY/K'AN^T^YUBY^SQP2;"T?/!;!Z57(]UL2X2B[-'L/ X.,?WJ,CD9 S
M]TUY5XV_:%T;P'XFDT;4;252MB;[S1@J0 3MZYS\OZUA>!_VB-7\93W!?P#K
M%C9")Y;2ZF,16?"DC #$\D=Z7*[<W035G9GN/.<8 _&E;[PP!CZU\C?!W]JW
MQ+JLWBV37O".I?V=I7G3FZ!BVHJ G;C=G)Q7LVL_M :;I/PWTSQ6VFW#V^H2
MK#' NT2 L<9.3C%.,)2V0^5K<]2!+' Q]:7@]PH'>O"/'/[42^%_&D'A33?"
M^I:QJKV\=P1:[-H5R0.2P_NFJ7BC]J/4O"L@EU/P)JEK8Q,%FN))(0JGUQOS
M^E39WL#BU-)GOPO(?M'V<RQ^>1E8]WS8]<4MQ<PVI'FS11;Y/+3S&QSS_A7S
MK'XF.O?M,Z+/:W$RVDVDRR>2K84Y:/M6E^U=K#:+I/ABZ%U]FB_M:'S75RO&
MU^#5\MK)]31QYJO+'L>]G.<@@K3A]WD8KQ[3/VA+&]T?6[ZTTJ[N-/TI-S7@
M"B.7U"9.>*Y7P_\ M@)JVI:5]I\(ZIIVB:EL6#4KCR_*WL!\O#9Z^U/E;6AD
MXOFNMCZ,9=J@Y!!IO.=I(SUKQGXE?M"3^%-?DT+0/#-]XGU.-=\\=B8P(EQG
M)WL/;\ZKVO[46E3>$8-:GTB\@DAN$M;VV(7?:NS;?GYQU(Z9ZU%GO\QI-['N
M&T^HQ]:@N+J&T*&>>*$,=B*[8W-[5Y/<_M(>'H?B19^$O*D^T7-F+M+GCR\=
M=GKG'M7DWQA^,D?CK6M!ATN&[L;?3_$,5G).QPDW"'Y<'D?-BKY659GUOG<H
MX"MZ9S1TSOPF.?K7@_C#]I^+PWJUUI6D>'[O7WTZ,?;)K5XU$>%#'[[ YP:9
MX@_:ML(]!T:?0-#O/$>JZB#C3;-H_.3'7.Y@/UI<K(>C/=DNH9)Y84FCDEC&
MYD#<J#T_K4JKGN..M?(WP1^,EUJWQ(^(&MZU8WFE6]E9PL;&Z(W(VY\C@D5T
MMK^V#<2>(-&L)/ VKI:ZK(8[2XW0[) "!N^]TYHY6]@LSZ4Y[#B@*>Y%?/GB
M/]K:WT[5KZ/3/#MYJUAI\GE7=U;RPA8V[C#,#Q]*]J\)>*['QIX=L]9T]A):
M7(RCKS2<)+=$W2-FBBBH&%%%% !10WR^]+M/TH 2BCMGK29'KF@8M% YHX.<
M<GTQ0(**,$8R,&B@84444A!129Z\<4HZ9QBF/8**** "BDR%Y8[1ZT<?X4"W
M%HI/;^+^[FC<%X8X;^[UH\P\@[YQ2TF1QDX'KBE&#]/I2T>C8KC)(UFC*. P
M(QS7+:UX5R&FMACU%=9MW@[#N]>V*3 7A>G?-;4:TJ?P[$2I\YY5)"T+E'&U
MO>FM@?+W[UZ%J^@0Z@IV*$D/.:X:_P!/ET^X9)%X_O=J]^CBO:)(XY0<2JW0
MFL/QIX/L/'6AW>D:DO\ H\PRK;>%/J/2MW\,BC)VX!^N:[)13,^:S/%-%\%7
MGPQT/48/$VJVNL^#K>']W#.K2.JCH.5ZXKR2'P?K'[4CQV]@9O#/@.P?;!",
MQ";;PI&.>U?7.K:/::YI\ME?0K/;2C:R,!TKA_B5XMM_@S\/9;C2]&DN%A41
M06MFN<L2 O!K!T[FL9LXKPMJDGP"FEL_&'B**31YML&G(S%Y=_&!R/0&O<K"
M\CU&Q@NX&$D<JA@ ?49!_*OEWPS\%+SXA1W'C7XI7_D22)YEK8[@$ME/1B.S
M8_G6+\#_ (]67A?XA:_X>O\ 5KF;PQ'/ML;J:)V!P-N-P&,9S41DX/4J<5-:
M'V'2U7T^_M]4M(;FUF6>"1=ZR)]W'K5CC )/!KJ4CFE#4OZ/K$VCW"R1,=N>
M5ZBO3]'U6+5+=9$;![BO( 0<YZ?SK3T76Y='N R$M%W6N3$4(U%S+<[*-11W
M/7=HHJIINIQ:E:K-&>,<BK6\5X33B^5GHI\VJ'44@;-+0,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***8^-I.< 4 *6"L23@51O+Q?NJPZ]<URG
MC#Q24)MK8L6'5EKDC?W/&9Y.>>M=D,-*:N<DZ\8MH]-=E/.X?G2^8O\ >'YU
MYA]ON/\ GM)^=']H7'_/>3\ZMX!G/[9/8]/\Q?[P_.CS$_O+^=>8?VA<?\]Y
M/SH.H7&TGSWS[FI^H-:W%[4]0# ]#FEK(\.RF;38V9MS]\UKUYM2/)+E.I2Y
MHA1114#&%>>*S=8LGU"U\KWK5HIQDXNZ%)75C-TK1X=+B50N9".36C[>E+13
ME)R>HH1Y58****DL\C^-7CC_ (1YDLKWP5=>*--N%V_Z/&)-K8SWY%>&Z/\
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MK66FKH%Y+MC^SN3,!D $@-_2H/$W[57C"+2M0UW0= TR[TVQNC;!9[@J\C$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQC)X/NB52TU!;\7=GI_GATCP2< DGCIWKU+38_B;XU\-:S::_IMKH4LMLT<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&1ADM6C2+E>]+7S4IRJ3O(]%:*P4444F 4444@"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$+>T@4+'&O\ #5WC8QL7Z***QZEA1110(**** "BBB@ HHHH **** "BBB@
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M=D86AS'9^+/!.D_"/QKX<O? VK#?=7&R;3K>Y#HZ9'. >G)YKZKM6>:U@F=
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MIO UT8=6,79A7/BX\T=#>A:YZ51117@'K!1110 4444 %%%% !1110 4444
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M2TO%VW,<<NX\+(N0!ZC-,U:Z:QTVYN416>)"R^I/I7ROX+\,^-?C1_:6K?\
M"=WVC/'/)'':PW3A4&XCH#6$I*]C>,':Y]3Z?H>G:2/]%M+>W!?<[QQA6;ZU
M=P%?(Z$8->1?#GP#\0?#&O(^N>*CK6D!-FV0EF_6O7:Z-.70Y^5W=P7C KKO
M \&Z"64CH<5R/J:]!\,VPM]-0@8W\UY^-ERT['327,[FO_.BBBOGCM"BBB@
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M6((4YQ2T;1F0MTXQBO8E>UT<$;7LSR+Q#\;[SPTOB.XU30)+>RTLXAF4<2\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%%#U ****%HK##.:0 +T&?K2T4"$YSDT&EHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO4L?WABN^Z<>E>;Z%+Y6I1'..:]''KZUX&.7OH[:.PM%%%><;A1110 4444
M%%%% $=Q&9K>2-?O,I49]Q7X<?&KP7=? S]H2YEU&TEDMHM1^V!F7Y7&_?Q_
M*OW*(!&"<#N:\>_:!_9A\)_M ::B:W T=Y&N(;N(?,/3FFG8M2L>%M_P40^&
MJ?#QY?MDS:C]@:!;''RAMN,=:^#/@?X/U#XW_M&6CZ;;M%')J(O99$R0B!@1
MG]:^NX_^"4-DVI'?X@)LR?NKG<![U]4_ ']EOPC\ [-SI$ ;4I5"3WCJ-[ =
M!GKW-7S%<QZ]9PBTL(8,[TC5%7ZXZU/2M][(Z8Q25F9L****!!1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN2+@%6PWL?I3P\N:ZEL*NKM'L_W?^!5W?A&Y^T:<1_=.*X5<;0.O;FNG\%7
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M716AS1:,:;L[L]5<<D_Q+THJ&SG%W;POG)85-7RUK2:/4BTXW"BBBH ****
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MFU&+N.FN:1ZAHT'D:;;H>H6KR]*14VA0.@I:^8>KNSVPI:** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO(K"/KUP:]TV;> , ?Q>N:^9/'7P'M/@[IR>)_".H74=S:L)+BUFEW!U'/\
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M%4;N#TXKR,=/HCOP\>K)J***\X[@HHHH **** "BBB@ HHHH **** "BBB@
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M\'FNE-)7?]:'0W&I-?,\J^('Q^\=WU[XM?0O$^G:-)HLZQ6^EW%J9))<QHV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME$<:JHP ,5RW@?21#;M<NN'DYKKHVW+FO!Q-3GD>O1CRQN)13Z*XSHN%%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0^
MAJ.>%9HF1APPQ4A&:1E.*+VV%OHSR;Q%I?\ 9>I21_PL<K657HWC31_MEGYZ
MKF2/]:\Y_B8'@K7O8>HIQ/)JTW&5["=:AO+.+4+=K>=%DB<896&1BIJ7. >.
MO%=6YA?JCE?"/PUT7P3;W=K8Q9M)W\PP2LTB@^P.0!["NFCM8K>!(8XQ&,<(
MB@8%<A\3K/Q?>:2D7A"\BMKON\J@C^5?-?Q:T_Q[X.T=7UKQZQU6](M[>SL6
M82,Q!YPHX'%82DXRLCH2C*-VS[ N-0M862-IUC<\*&(R:GX8C! ([9_6ODGP
M/\$9/"WABR\5?$#QAJT=S$0Q26^E(YY V[N:^C_ GCK0O&6EJVC:A'=I" AR
M?WGMGO6O-?0QG%I71WOAW4CI]UL9OW;&O0!(&0.OS*>E>5(WRJQ^\3C%=KX3
MU@7,9MI."O0FO-Q5'3F2.FC-6LSHNG?-%-7I3J\/<ZPHHHH *0C<,&EHJA*X
MC?,N#2G[V>AZ<444F4Y,;M&0>F.13NY-%%(04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M= TZGEW[16H:I;_#J\LM&MY+B_OOW"F--VS/\5?/?B[X$_$;P[\.=%OI?$L6
MJQ:3Y=\FFV^FQK*&W;]NX)D\^]?:IZ9VAL?PGO2?>;&<]S@^W2G!\DKKH;>U
M:CY,^(=3\23)XDL]?\+6&NZ7XOO/LZW5O);2-!+RH8X/RCC/2M#QYJ$^D>+K
M?5M M]6T[QG<20K=K';R/;RC< V01MZ9K[+:W1I$<1KN7CCCCZ]:/)C,C.ZC
M=V)7/Z]:?/\ #Y?J971\2_%+QGXOUB\U32M=BU.UMWTP&V33;-@)93N!!95]
MA3]>\.ZEX9_9T\/^*8+.>WUK0RSK#<(P?G!Y]>G>OM?RXI)-[)N8#(9B3CZ9
MKE_B1X$M_B+X=;2+V21(I#EC'(RDX^AHC+E]T?/9'S?X+\(Z;?? 74=;\7Z7
M?7*^()#-=);HQE3<,'&WD=*[+]F'5M9FU/4-+66^G\,V[?Z')?0LK@>A9AD]
MNM>]Z1H\&AZ7:V$(VVUM$%5<Y#>N1^ J]'''#"$C"H,?<08%4I<RT)DN:2N?
M+G[0WB[Q):_$"#272_M_#LMK*6DL+=G=I,KCYD&0.3WKPA;'6-"^$FFI%#<V
M=_\ VR9XI+B F8K\V&V,,D<CM7Z,M&)%PZ_.!@-W'K7#?$[X3V'Q*M[3[1-)
M:W5H0T-Q"Y1@?J*F.DM#=S25D?,_PZ\67FG7WB2ZN;FXO_B'=6RNHDLO(5U1
M2%PFT#OZ<UR6C?VUXV\?>!]1N8-;EOH6\Z_6:W=(K>0H<@+C Y)X%?67@?X'
MV?A;Q"VNWNH7.L:HR;!-=2,Y0>@)YKTQ(TBSY<2*6.78<$_B*U<U^1E&HT[G
MQ-?>$=:?X>?$^+^S+QGNM962.+RB#*GVD'('?BNT^*/A>_FO/A,]OIDQAM;A
M'N?)A.8E$#?>P/7%?4X^5O5<8*MSSFD;N1R20>20*'4T0Y5'*^A\;^)KX>'?
MB>U]X*MM:M-;OKM?MD#6[M!,  N[##:O [5T&C:A>>!_VE+Z[U33;UTUN.$+
M);PL41O*5>2./O"OJ4V\1G\PKELYWG[PXZ9I6@CD?<XRP8,K8!(Q6?-=Q\@<
MK1DEU_S/#OVN]"O=>^%H>QMI;M[2[@N9(XEW/M1U9@!WX!KS*2XE\?>.OA'J
M5MHM\EK9":.?[1:L/+(7J<C S7V!M!#95<D_W01COFFB,!2-V/\ = %*G+DD
MY>9<JFL7V5CP']I'Q5X@T*\\/V-K#=0:'.SB>>R@\QU&!@#:"0>O2OG+PSX!
M\0:QX#\<S6NG:D5FU1KI!=1,KR)L4<#J>AK]"Y(UE3:ZJPZA2. ?6E\M55 !
MG;[D?3I3A+EO(7.?*WBWXEK\:OA#KOAO1?#E]9WJV#1F2YM'CVMMQA>/:N:;
MXJ:_9?";P_8:+IVI6L5K=1V]](UBQ<*0<E<C/;J*^S8X8X>8XU4^@X!^N.M-
M%M$L9C"*4))VE1BDY>[</:-JS/D3]F_2;Z3X@>.[WRM2^QW$<:PW%_%(K2$!
M^A89[US7AWQI/X5\%^,?"-WX6U'^T=4OYUM9([)\'+'!+8QBON/8%"H/]6HP
M!WI)8UF9&;EEYR1FJE4<M?)?F*G4<$T?"?P_^#WB>QFUS3)K29)Y= MX@[(P
M'F", H#CZU6^'?A'P_J_A[0/#7B"S\1PZE9-&DEN//$(9".00<8R*^]]HR2<
MDGG.<$4@AC$A?:N?78N<_6K=9\VW3]2)/F(=/A2"SMTC#E%B4#><XX'KTJQ0
MN1GG)-%92ES"B%%%%3MH&^PV3[N>W?Z5P_BK5OMUSY49_<IT%=!XDUA;"U:-
M3F5N!BN":1FY/4G)KV,'1TYI(Y*TNB$I=P5E=FV@=#V_&FL=BEG.%QG/6O!/
MVEO&WD7.A^%+76/[-GU6;RYG20HRH< $,O(ZG\J].K)1CH94HW>IQ_Q\L?%_
M@77-5\3>&-.;5X;^!HIC"%D> GH1GGUZ5C>%==D^(6B:%X-\/Z7?V:0W"37T
MTT+)D#J"QZUU_P#PI_QY\/4AU+PEXAGUZW9<R6%Y/YIE'L7)&?QKV+X4ZEJ.
MM>'([O5=%71-2(*31 (#^AQ65*GS:LNK4Y59'5:79_8--M+0?P#G)R:M-]X_
M6C)Z_P 5(*[-#G% W<5=TFP;4=02)!E0?FJESU'4<UW_ (&TG[/;FYD7YY.G
MM7)B*G)$UHQYIG3V=N+6U1%& HQ5E< <4T-G/I3EZ5X-^;4]?;06BBBD,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+_$^;2O _P"T5X<UG60?[)^PPP^>UL7RVYLYPOTKG_$7B+3O!/Q(_M/P/?\
MVVZU2] O-+N[<D+S]Y,CCJ:RC:\4O,UFM;GV>K;QN'0\CC%+572Y9)].MI94
M\N5T#,I]35JE)<LFC*'O*X4445)04444 %%%% !1110 4444 %%%% !1110
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MU#0].U;9]ML;>[V-N7SH@V#^(J)?#.D+=+<C2[,7"G(D\A=P_'%:=%2,0#:
M!TI:**-]Q+38****0!112'A2>N.U "T'"KG<,]PQ_K7.?$#QOI_P\\)ZAKNI
M2!+:UB:0Y.,X&<5^<LW[2_QA_:N^(%YH/PVO#IFGP;BNT#E0,]35)7*46S].
MED61CY;9'?(R!^(IP;/&0?<5^6GC#XI?M ?LBZQIEUXLU7^UK&[.3#PWRCKT
M^AK[[_9Y^.-A\>/A_::_:$"4C;-'C!5N]#0W%H]1HI <G%+4D!1110 4444
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M%PW4GZUYV*J>S5D;4:;<KLOQ*%PH'R@8%2TQ5*GVI]>)>^IZX4444Q!1110
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M ^A%)5#2]435(PR?>QRN:O ]<\8KPI1Y-#M4E+86BDZTM9WN4%%%%, HHHH
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M'8V<$"E*I?;^M1W>[/!M%_9OU'2]0\!WCZQ X\/1S"3$!&\N !_%[5[\H*J
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MB>E1I\JO(DHHHKC.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF.(^6GJ#UKKI4)3=S.511V-;7/%"Q@Q6_+],BN1FFDFD+2$EO4TT,>2>6/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHCOIT;;B!=O"@;:55([\4Y>E+7):^YTB<TM%%, HHHH **** "BBB@ HHHH
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MM(67/[M0">.]94(<J]$RZT[N-CYB\"W7CKXL?$37;"^\27-I8Z-<-MC5C^\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *:R[C3J*!;C=M&VG44#V"F[:=10 W;1MIU%
M #=M+2T4 %%%%*P!11118 HHHI@%-P?6G44 -P?6C::=10(;MHVFG44#>HBC
M%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>morf-20221231_g6.jpg
<TEXT>
begin 644 morf-20221231_g6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )]!)@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HI#2;J '44W=1NH =13=U&Z@!U%%% !12&DW
M4 .HINZE% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%(: &-2;J)G6-<GK6/X@\3:=X9L6O-2NH[*U0X:68A10,
MV@<T9Q7EE[^TQ\.=-SYOB>QVXSD2J?ZUCS?MB_"6+(;QA8@_W?,7_&@#VS=3
MJYWPKXTTGQMH]MJVC7<=YIUQ_JYT.0:Z*@04444 %%%% !1110 444AH ::5
M:,&FMN4@\8[T 17K+&JEB0N>HKY$_;"O-.T?XI?#G5O$UNS^&K.X<W#LI,:D
MJ<%O:OKR8><!Z"L#7_"%CXGL9++4;.&\MY!@B9=U2RXH^'QXK\&^+OVH[V[\
M%&">VB\*7$<EQ;*!&<A#V]*R;#P?]I_8C\2G2M.7[8\TDCLL):20"4DG/ZU]
MI^'?@;X1\)L\VFZ/!!<-$T#2 #)0C!'TK9T_P1I>DZ&-(@M$6QVLOE8XP>H_
M6L=6S56/S<^.WQ5\/^,/AG\&?#^B7T=YJ=B+5)PKX,,BQ[2C>^:[?X6>-?A]
MX'^'_P 2M+\?/:V>OW!D,$-ZH$LJ-"%5D!Y(W'M7V#;_ +/?@FQW-;>'K6,E
MO,)V@?-G.[ZU\]_$7]F?XD:UXAU>2RAT+4[2\)BM;Z[C)FMX2,;00V..>U6G
MR[D-'>_L%RV\WP'LVM#OM9+F8HS#& &.*\9^'WC[X<^#_P!I+XRR^,+BWMWG
MO%"2WVT*Z^1& JY]\U]7? KX3_\ "I?AW9>'IY_/EC!,TB_=W-DG'XFI-;^
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M7Q38R'.W_6KU_.N^T/Q-IOB:U-UI=[#>VZG:7A<$9H V0<TM1>8JX&>34@H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP\*>8Q)"Y;C]*^D/&G_(J:O_ ->K?R-?+G_!.MMO@_QF#QG77_F] 'V!&NU
MHZ#@4]::OW13EH =1110 4444 %%%% !2&EI&;:N: *\C;V( ;BODS]L3X,^
M(O&$EKJOART\^Z4H945L!MA)4?\ CQKZTE;;@@ ENU5V6-^ZC/7K6&(7-"PK
M7/RNN1J6G^(M/T;Q?$VBI",F#.TRGU!':L#4+2RN/&TA-M/>^&[F61;<A2V>
M1G^E?;OQ@^"WA[XO_&32;#7K%YM.@A+^9#.T3[\CC((R*TM1^%OAWP1XX\%:
M=IMC'#HEO%,B1R#?N<E.6)Z]*\&6 E47*F.*]DSYT^!^A0Z+X\MKCPS93V^G
M6L#F^N)$(R-OW1^-?8_P3LHSX#L+J-?](N<W$C9Y;)[^_-=6OA?3;.TGAM[2
M*".X1EF$$:KDFO-=&L_$WPE5M/MX!K/AZ/)61>)5[[>:WPV"6#5Y&\IJ6J/2
MO$7BZS\-6C7%U($@"\+CDGT'O7G4)U#XKZI;22:=)9Z1;R"59)AC?WSBN)\5
M^-],^(GQ \'$S7%K!!,R3VLG"A\'Y6&>:^C(U2QB8JX2&-?HNWV%=JE&L^8S
MTDR?RQ;QE(2 N!DMZ8QQ7PE^W#^U%-IFL:=X3\ _Z9XJM)XYKBZBZ6:A@/F;
MMD?SKZ?U'XU6M])/I^C6%SJ=QEH"R$*H)R.,D5\TZ]^Q\^AZ9XQ\5R2R_P!H
M:Y<1R3P!LND8=2PW9] :WE5459[#]F>AV7BS6/C3X7\.:'%+]J>2&-M2NE3*
M[QR<&OI33=-_LO3;6'+#[-"J#'L,5S'PG\+Z5X:\%Z?'IEM'91^2NYU W$[1
MDYKKH=0AO(_W,GFA0P+ Y!XK6E+F)Y;+4\]\7_$/5['59M/\/:0^J7" &20,
M-O/H:\_\5:]\0OB';S:#;Z ^B+(FV>]9AN_#%=S\);I;75?$?VF?YUGY+'H.
MU>C_ "O&^YE)DZ,":[)5/8.[01CSJS/RX\=23?#WQ'>:1.TT\EHQ!;!;<3W^
ME?7G[&>N/??#&Z:]D $-PQ*L> ,#KZ5X/^TCX#\4W7Q1N;S0+ZQ2?&Z8RJVT
MKDX& I&>M5/AOXO\6:+X5U/1K_\ XE<MW*?M%Y:P_*1CMM&?TJ*N=K$6HM'H
MO+X1H^T3(/V[OB;H6O?$#0]*AGCOH+$R))"O*JY*X_D:\WUC7M5AL;36[71O
ML-A&!;/,\80'TQ^5>D^!_@CX$OX/&>J^(9+BZUOS_.L))@XW,,_P]#VZUZ;\
M8/#=SXL_9(@N7@BMY+7;*T<<8C)P,#Y< 9KWUC(QHI0/)4'S:G@/AG3R]CJ-
MQ+*\<L4/VE88VVY/IG\:Z_\ 9O\ VNM8ELM<T^,[I;3):UN),L@5L$@GKUK!
M^%/P8^(OCC[%!<V$]EHTR*#>3*J@Q8^[P<YZ5%J'[!>OZ)^T5#IGAW7ULK"Y
MLVOIC)DL\2NBLI..>7%>+A9J55JKL=,I7I\Q]I?"WPG%\2O(\8:]<_VD\IWV
M\#G*Q_4>M>Y1PC P-@5-@]N>GTKE/AOX.M/ /A>QT>*5)5MTV[E7&2.,UU2W
M<?SH[KD'IGD45I\\GRF2M8N!OEP1^5)].E1>9[_K3@S8&.E<?O(>A)RM+NJ,
M.5^]2^8.:.=!H2TM1(_O4E62+1110 4444 %-;[IIU(WW: ,Z^MQ=PRQ.N8I
M1MD^F,&N0\!_#WPWX%COQX=LX+,3W!DG:V(R[$Y)..^371^+"8?#.J.K,KI;
MR."IQT!-?)7_  3Q\5ZKXPA\=2ZO?3W@BU:X6)9')VJ)F 'Y4 ?9<:[3T Y_
M.IUZ5$H/KGFI1TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@!/Y56DW
M+(KCH#C\ZLM5:8J I;.W/05)2.-G\9^&H_&D.AR7-O\ VZ\3-'& /,V@'-==
M')LC51T-?$NIVJ1_\%(/#JC>V[2)RREOESM?G%?;GV?S, 'I2&9'BS39=:T*
M[T^WF,,\JE1(/X:^8[_P[XQ^%M^9VCN+^-6R)H>3^(KZU:(F,@CG/!%,DM5;
MY61I0?[V"*YYT^<AI,^;%^/&K268MY(IGN".\9##]*Q9OB!XCU.X6TL[2\NG
MD/\ JVCVK^=?48T33FF\W[#;[^_[E<_RJ&]T=3*DD.U /X%0 ?G6?L7L3R,^
M?8OAGXY\11G:D>A;N2QPQ_.KME^RW--F34O$5XUT1]^-SC/TS7O4-P,E+E=J
MJ< Y-3F2#[RRJJ#KBME15M2>1GS+JGP/\4^"Q/+8:K)J<(&55V.ZD\ _'#4_
M!NH+I7B*":-9&VJ\XY_"OH.^\600%XXQO8=#7D'Q>\(GX@^'Y[P62QZA9Y>*
M15QG%<LZ<H?O"9<T=CU>]\46]SIJO:S"03H%R#T)&>:J?#[PS_9_FWT@P\K'
MKUZXKP[]G/6WU/4GTK4Y"Z[<IN/\:\'^1KZD@4*NU1@# _2MZ%3VFI<'=:DX
M7[OM3J1>E+786%)2TAH X_XJ3&#P/J;!MOR$9'T->2?LO6"27&L7S8>601)G
MT +YKU/XP,J^ =4+]-G]#7G'[*X!T74Y%_O(/_0JYVOWER&KL]\Q3D^[24J]
M*Z#39#J***!"49HXIID .*E7 7-!:F^:*7S!3:8%6\G%O:SS-P%0_P J^=_$
M-]YUY+.1N,CGG]*]I\?:J-/\.SMW;BOGVXNC,S'^#.17IX.%G<0_RUD. V*B
M,*22!%P"#]['-"R*L6_/)H9U7:ZGYC7M5&[:BN=9\*[R_D\7"$W,C6ZC[H/%
M>^+(#N^;E>#7F'PE\-?V;;OJ,OWY.F:/B9\>_#?PW@D6\O$N;Q,C[)'R<^]?
M/UJ;KU/=#F1Z%J.L6VG+YD\RQHJDEFX'YUX+\3/VJ=%T&UEM-%=;RZ!*^<@R
MJG\:\'\<?&SQU\=-0.G^'[6:+3"V/)B&U3GU8?TKT?X6_L?[KJWU;Q;<M+(N
M'&F1#"(?4G^+\:ZHX>%!<]1BO<X/0?"?C'XV:F;QUF\F1\M>3,=H4]A7U=\+
M?A#IGP_TM$CBCFOF ,ERRY=C_O=<5VNEZ+:Z1:Q6]I;K:0Q+M6&(!1^.*THX
M]JC(Q7-6QJJ+ECH@]FMV,CA,>XL=V[\,5*L(7&/QI6IZ]*\]16Z-  I-M.HJ
MQ";:*6B@!*BF]!UJ:HR-TE '(>.?!VB^--'.G^(+2&_TUV!>&<C:,=^:W/#>
MFVFD:9;6EC$L%K$@1(UY"@=*^=?^"@GB+5?"_P ![NZT>]DT^Z%PH$\3$'Z<
M5[-\$KR;4/AAX;NKAVEFFLHV>1CDL<=:SZFG0[NBBBM#,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN?8'@#Q1#XL\/V]ZDL<TC*!(B]FQ6UJFH6]G9RW%S(L42#YRQX(]*^-O@_\
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MJ:'?VL) FFMV12W3)&/ZU\]_L;? ?7_@?'XL&MM'LU"^FN(O+.?E:0LN?P-
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MIUCU& !$:4@"7Z5X7\1_@YJ?P\M9)]K:KX7F7/E(-\D>?8<XKP[2-!U/X?\
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M\_"/PE@ +_9T?\JROJ5,[^BBBM2 HHHH **** "BBB@ HHHH **** "BBB@
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M9W,]P#Y46=[2 @X*C/2B+ML7&FHNYO\ [.MU#Y.K6]M<K=60N9/)=6+ )N.
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M0_#>CQZC_P (Y#:I')-NF:V<'YB<G/OF@#M8P0S9]:F;[E5UQGC-3_\ +.@
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MEB*Y;W%>,?LN_!C5O@CHOB*QU*\AF%]?-<QJAY&2?\: /H%>E.IJGKQCFG4
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MN93HT-R;+R5.S 494GZO@?C7J%GX9^*>NZ.MUK,$:LMN5CM;>Y"#A3MR"#T
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M#O2LA'I.@_M>:OK_ (PBM-/T:'^RIKPVZ*S9N& )^?;Z?AW%?4L-UOMV=HS
M6!8AN.!WK\YM$^$L^B26-AIOA;Q,GCVWU?<^K2VSK8^5D_,),8(K]$]/AECT
MU$D_UJQX<D[MS'T]J /,M6\;Q>*/$UK91PD/#,T9(/\ =R,_I7JC2I:V4189
M(0'%>.^'88]&^)5\D\2M(264=\D\_P Z9^T!\1M1\+?V9I]A&8FU#Y&E8<*
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M\,:;K#0FV^VVR3B)FW$9SWI1T-9;'644S)IVZK,!:*3=1FE<!:***8!1110
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M#_AE9KR,KJ%VWG3;NH)YQ^M=^K,IPPSWSZ5X]168S'\7<>'=5/\ %]DE&?\
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M:ZA82K<6ETGF),K'^1YJM??#W0];O;>\O]-M;FXC;<DIC!93]<5[M/%)T^1
M<;X2^&FFZAXBU'Q9J%I%=7EYM*QW$881@9^[GZ_I7SI\9/B O@_X@^(+"".)
M8UF 'R ''S5]M7%O)##BW"H0A51COVK\E/V@/$VKZ9^T!KUIXA5H$F8F(,0
MW/8_C7IY1*]3WWH.IL=9XT\>CQ!9O$(XA+)RK>6#CVZ4SPQ^SC=S>$8?$<@2
M,:A<&")%^4EB&)(/;I3?A1X!U7XJZM'9Z9"K0L TDF!A,=J]T^,&N:M\./#G
MASPU/I[(=/G%T+A"-K*%92>OJXKV\8Z<9\D=3E2<EJ<-\!E\<? [Q9!;^9<7
MFA74NV:"ZE:0*I/4$Y(KW?XX?$#0--\7>']8M+M;^_TUPD]O$A8I&RGGIVR*
M\&/QPO+RS:UW1@R9C64 ' Z<'UKZ&_9N^&.CWG@<:[J5O_:.H7[2I--< ,2J
M,4 Y]<"O$QV']G:2T-J=^4H_$;4- UZ[\'^+X;2UN(FNHU+"(;@S-CYCC/>O
MI*SF1H4D5U"LHV@#@"OCSQIHFKW'B:Y\%^%=.:?34NXKIKA2,08=6*\GZ]*^
MN=+MI;?1K:*0*7CB0;O4@#->7B9+D1O'<\D_:Z^)FI_"+X(ZMXBT?:FHV\T
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M\=377BCQK-=C18)+VYB;=,NX<$]N37G8[,_J]10IZL^EP67?6H<]1V1[8OQ
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MJ!UX%>3?L^>)IIO%!MI.(IH5"_4$U\A/ 2I8WE3]VY]!A\5.M@W..CL?3-K
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)CWI:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M +;-4Q]V))]RKU(QCFI*A7''KGFI5Z4MP%HHHH **** "BBB@ HHHH ****
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MP%^GW:YWQI^R/X9U[2;&#2I9]"DMY1(+B.3<21Z\5]!M&2I&1GU(I%A,:E5
M'^U_]:B-*,>@61F^&]);0_#MC8&X:YDMX$B,Q_C*J!N_'%:6"RKSS[5(JD*
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M:(RYK.Y^:G[1_P $(?#?Q*DATE_LGG%3"I/!)-55\/>._A_#$NHZ#<WMO$@
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M*QMXK>UB6""-0J1H,!0.@%6U5)/G(YJ8=*Y->K$$0PM./(I%HDSL..M '/\
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M4+>Q@\Z:9%C"\R.V$'?GL*M3V[2*3G##G. ?YUY+XB\.#XK>(]0T2:>:#2;
MJ)TMY"AE8KGL>G->=&E&_,BI2.5^,7Q4TWQUI=SX6\/Q3:QJ<AVDV9!2/W+9
MKRSX9?LH:['K$,6LHJ6P?S9#NY.3NP<5]6^"?A3X>\ V:Q:1I\4#G[TI&7/X
MGFNK2P$<BN&;WKTH8MT8VAH8<JO=E/P_X?M?#VGPV5L@6.)<#:,5KA!TI%3M
MS^-/Q7G.;J2<I%[ $ I:6B@!*6BB@ HHHH 2HWSVJ6H9,X.* ,OQ1,UGX=U*
M2)MCI;R,&'J%)!_,5\L?L!_$K7OB5;>-)-<OI;S['J<\,1D/0"5A@5]1>,I/
M^*7U<D?*+63!R.?D(KXV_P""9W[NS^($;=3K%SQ_VV:@#[A50KD@Y&:F7I4>
M23TQZ5(O2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** &GO4#(&ZYZ'O
M4Y[U$<+C)Q4E'Q#J;R?\/'-"A\R0Q?V3.-N\XX5R*^VUC/E =![<5\1ZL"G_
M  4@T$GJVD3D#V*N*^V_,W0D9Y^E%[,3E8%D($A9N ,Y/2LR\\4Z9IZEKB_M
MX@!SO<"J7BO3;O4O#MW!8MMNI%(5@Y&/UKYGD_9J\:ZI>R2WNKLL+GIYC-^A
MXKFJRDGH0ZED>V^(?VAO"&CDQQZDMU./^6< +Y/IQ7D/B[X^:EXLO&TG1X)K
M=+CY>FYV^FW./QK;T+]D"S@9)+_5YIMQ^9554/YJ!7JO@?X*^&_ 9,EC:[KC
M_GO*Q=OU-<KISJ=3)IU.IXYX1_9]U/Q!I[0ZV?L-J_S_ 'R97)[MWK%F_9-U
MOP_J<QT.]5;60DC$K*<>AQ7UK':JC;C\S?WN]/\ +.6.<$]ZZ:>'21?)W/FS
MPS^S7JT\BG5M1C15/(4DN1Z9KVSP5\/M*\#Z>+7381UR[MR2?J:ZE4Y' SZX
MJ01X&.E"H\K*44AOEC;C'ZTY4&,4ZEKL6UBANT!?:H+FU6XB=#]UQ@U8ZT@4
M YI@>>V-C+X5UJ4E<6QY7TKN+"^6]0.O0U6UC24U.W*/D5A6_GZ'<",DF(#(
MK234@.N\SYL4[)K'M_$$$L@4YSZUI+<1R$!6#?0UDT!8J.238P]*<)%/.:CE
M8,0AX)Y%%@*&O:HNEZ3<7<C;5C&17SHOA2^^,'B9[B>1S8!N,\"O4/C'JQ73
M;:PC8AKAP& ]*Z+P+H,6BZ#90PJ$++EFQSTKK@_9JX'!:I^SIHUQIOE6DQCN
M8U^]S7CK7FJ?"3Q'%;WJR&S\SY6Q\KCKUK[$\D+&XSEFZFN.^(7@&P\<:+/9
MW:*#MQ'(!\RMVI4JKDK2 M:'XTL->T*+4K>5?LRQ_.Y/W"!DBOC[XW?'+4_C
M!XA?P3X:CEAMC+Y1G7@N<X(SZ&N(\>>./%GP3U/4_!:3[UNAL4EN%C)X(]^W
MXU[Q^RK\!8](M(?%6J!I[^Z4M&LG\.?XOK7=&C"BO:LSE&[-GX,?LHZ+X/L;
M34-5B6_U!E#-%*-P1J^A++3H+&!8XHDC'8(H  _"K$=N\<83<,#C=WI9(VC4
ME>=JFO,JUY5I;Z&KLHV/)?'NM2-XFC16S%"R[AVQFNYL+L7$B8/[DH"I[8[B
MO)=1OXIO$UW!<-AY,C!_2NN\'ZX'LA;R,-\&1N)ZBG43DERF9TNH:'#<1R,#
MM!YKPG6=&L7^(B)<6T-U%O"-YJ!AU]Z]*\7?$NRTFQ>))E:8\;5ZUY'9ZF^J
M>((I@V999PPS]:]6CSJG>X'L>H?L[^"=4;S)M'B7=R!"-O\ *LF;]DWX>W&2
MVD YZYKU^QR84/0LH/-23,(U8L<#'7)KRYXJO%Z-CY4]T?!?QL_8>MO#NJ/X
MQ\)R-']DR[PACE1[56\$Z_<:EX::ZOA(8K?Y7=UP>.*^TM=U**\CGM(5S"Z'
M<O!!^N:^?]:T>UC^TVOV:.*WG9ALC7 SZUWT<5.=E-$RBNA#\/?'R6MQ;W-G
M<J]ON VYKZ?T77(-4M8IQ(JAU'RYK\W/$FF7G@7Q!(()Y$@9MR*I.VO0/"_[
M1&M:#;P02(DD:?Q'DUWU,M]K'G@R8U>31GWC<*\R%D&X>GK7CG[0_P ,(_B5
MX*E@BP-0LP9XF[Y'.*YOX;_M9:1KNK0:-J:R6M_)P@V\-7N5L8=6CFFMY8SO
M("Y_4']:\)J>%JW9I%J1\F_LS_&R'PJK^&-<$@*2F)&?J).F/I7U1?0QZQ:O
M'( (Y(]R'KC\:^</V@_V<YI-2;Q7X7'DWT1\R:U7H0!DL!ZU=_9]^.4^LPP:
M!K#'S5;RXY),9W=-I_&NNM16*BJL=Q=;&KXZ\,(\)LKH<L?ED(_K7LOPYT_^
MS/">GVP;>V.6J#Q!H,/B&R"2(@E4'#^_I70>'].;3=(MX"<[!BN*4I<O*^AH
MMSP7]N;QMK'P_P#@M-K&B73V=\EPD:RQ]<&O7O@OJESKGPS\.ZA>,TEU<V4<
MDDC')9B.37@'_!1I2?V>9^=H%[&I8GBO>/@4!'\)?"2$_-_9\?N.E<D-RYH[
M^BBBM3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9(,K0!B>,9)(O#>I2QOL98F(;\#7SA^PAXFU?Q=X5\5SZS?27[PZLT46[^
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MM'KTKJ_#/BRQ\4:7#?V,H:&0[3ZY]#5QD!T=+4:M3ZU 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,9I-M.HH 9Y?O3MM+10 FV
MC%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #=HI=M+10 FV
MC;2T4 )MHVTM% ";::P ZG%!>H;B=(\,\GE@<GG Q0!-M"\D\494\ UY[JOQ
MZ^'^F7<EM=>+])@GA;9)%).H8'.*W/#'Q#\,>-5F?0=:M=9$!VR?8Y0^T^^*
M3 ZC:**KM<Q[@I;GT]*=]HC'R[P:2 FHJ(7"=-U(+J)E+;N!5 39I"P49)P*
MB^V1+U<4?:$W<,#F@"8L!U-&163K/B73M!M8Y]1NX[6-C@-(P )]*MR7T**S
MR. J*&+=L'I_*@"TKJV<$'%#5F:/KUCX@M?M%C=1W%NW\2&KZR#U  [4 2#C
MKQ1N'K43W"*O+8]S52[U:TTV"66YGCBAB&YG/ % &CD<4G#'U%4K'6+34K2"
M[MYEFMYAF.1#P:MB9/[U #QP:*C:9=N0W2F_:HUCWEJ )J0R*O!8"H&O(54$
MOUJKJ>KV.CVDM]>3Q6UK$NYYI&P%^M &EFC<!WK%T7Q1IGB2Q%[IM[%>V;<>
M;"V1GZTNI>)M+TC3Y+^\O88+6)MCR%A@'TH V=PXYI:S[:^@NK<2QS)) PWH
MZ]"*M+<1MT;- $O6D.!R3@4AD1>XIDUQ&D;,64 #)R>*+@2<>M+MK.L[Z&\M
M4NXG62%O]6R'(93T:KGVJ/\ O47 >P''K0%IGVA.NX8I/M,3,/FYH FVT;:1
M9 W3FG4 -*9I/+'UI]% $9A0]J1HE[IFI:* (EB&.5"^PIRQA3D4^B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQN(VJ&&2..V*\%C_ &3/$O@.;6-$M?AMX?\ %"ROOLM:O9BC(I)^\GEG<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %0W"[UV[MI/2IJCDB$FW)^Z<T ?-'[0WP1\;^./B5X9\
M8>"]4M;"[T,E@EX#M<["N,@'UKC;S]E_QWX]M_$FO^,-6L)/$NHQ0PV\,9;R
MH8D9"0"%SSLSC'6OL0V;,K*TK$%MPP,8H^Q@-N#G<?O<=?\ "DQW:/GKPI\
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MFG6JA+>VB6%..<* !^@H T88Q&*EIBQ[>^:?5$A1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2[N#495M(890(X1'(0-P_"J>E_#?6=+_ &EKV[N/%<]W?1>#Q>O-$X.XB6=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>morf-20221231_g7.jpg
<TEXT>
begin 644 morf-20221231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #? JP# 2(  A$! Q$!_\0
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M^G:\NL-?R/F67[,)4:(_*(\3DCN".N.*+1["YJUKJ?\ 5C>_X;V^*7_4!_\
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MDHHJ#K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M22?+7))]:331<91FVET,S_A$O$'_ $/&I?\ @%9__&:/^$2\0?\ 0\:E_P"
M5G_\9KK:*1KRHY+_ (1+Q!_T/&I?^ 5G_P#&:/\ A$O$'_0\:E_X!6?_ ,9K
MK:* Y4<E_P (EX@_Z'C4O_ *S_\ C-'_  B7B#_H>-2_\ K/_P",UUM% <J.
M2_X1+Q!_T/&I?^ 5G_\ &:/^$2\0?]#QJ7_@%9__ !FNMHH#E1R7_")>(/\
MH>-2_P# *S_^,T?\(EX@_P"AXU+_ , K/_XS76T4!RHY+_A$O$'_ $/&I?\
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M_ *S_P#C-=;10'*CDO\ A$O$'_0\:E_X!6?_ ,9H_P"$2\0?]#QJ7_@%9_\
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M*BLQ8^#M<+'@G9:Y_P#1U/\ ^%M$<#PCKP'TMO\ X]7Q3_PTIX^_Z"-G_P"
M,?\ A1_PTIX^_P"@C9_^ ,?^%'('UU'VM_PMMO\ H4M>_*V_^/T?\+;;_H4M
M>_*V_P#C]?%/_#2GC[_H(V?_ ( Q_P"%'_#2GC[_ *"-G_X Q_X4<@?74?:W
M_"VV_P"A2U[\K;_X_1_PMMO^A2U[\K;_ ./U\4_\-*>/O^@C9_\ @#'_ (4?
M\-*>/O\ H(V?_@#'_A1R!]=1]K?\+;;_ *%+7ORMO_C]'_"VV_Z%+7ORMO\
MX_7Q3_PTIX^_Z"-G_P" ,?\ A1_PTIX^_P"@C9_^ ,?^%'('UU'VM_PMMO\
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M(V?_ ( Q_P"%'_#2GC[_ *"-G_X Q_X4<@?74?;"_%AY&55\(Z\68X'%M_\
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MJCL5TO3TNK>2'Q4L!&JR7$#B;SM_[PR.1A@6Y7DC&-O%=WN.W;D[?3M068@
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M(H_X99\:?\]M(_\  IO_ (BBZ#V4^QX_17L'_#+/C3_GMI'_ (%-_P#$4?\
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MG&TD4?R88(@W _-@*&W>E\GF3H>R?V*.G]HZAG_KZ/\ A1_8O_40U'_P)/\
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ME#ZQ#L?97]B_]1#4?_ D_P"%']B_]1#4?_ D_P"%?&O_  O#Q[_T--]^2?\
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M\"3_ (4?V+_U$-1_\"3_ (5HT4!9&=_8O_40U'_P)/\ A1_8O_40U'_P)/\
MA6C10%D9W]B_]1#4?_ D_P"%']B_]1#4?_ D_P"%:-% 616LM%&^7_B8ZC_J
M7_Y>3Z?2J_\ 8O\ U$-1_P# D_X5LV/WYO\ KB_\JKT#LK&=_8O_ %$-1_\
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M4_\ 02U'_O\ C_XFC^Q3_P!!+4?^_P"/_B:T:*D+(SO[%/\ T$M1_P"_X_\
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M36;)[>%UCDD68$*S9VCWS@XQUP<=*5F/0L?V*?\ H):C_P!_Q_\ $T?V*?\
MH):C_P!_Q_\ $U6C\7Z8MQ/%<7=O:;;K[+$7N$;SVV(^0 21PZ\-@\@]"*TM
M0U"UTFU>YO;B.TMT(#22M@ DX ^I/&*+!H5O[%/_ $$M1_[_ (_^)H_L4_\
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MQR.*:/''AUK2:Z&N6'V:%TCDE\]=JLYP@S_M$$#U(XI68:%K^Q3_ -!+4?\
MO^/_ (FC^Q3_ -!+4?\ O^/_ (FI-/US3M6FGALKV&ZE@QYJ1/DIGU_SVJ[0
M%D9W]BG_ *"6H_\ ?\?_ !-']BG_ *"6H_\ ?\?_ !-:-%(+(SO[%/\ T$M1
M_P"_X_\ B:GL-%/VZW_XF6I??'2<>O\ NU:JUI/_ "%+/_KJO\Z!I*Y@-IL6
MXYUB\!S_ ,_2?X4?V;#_ -!F\_\  M/\*^$/$/\ R,6K?]?L_P#Z,:J%7RGG
M_6?[I]_?V;#_ -!F\_\  M/\*/[-A_Z#-Y_X%I_A7P#11RA]9_NGW]_9L/\
MT&;S_P "T_PH_LV'_H,WG_@6G^%? -%'*'UG^Z??W]FP_P#09O/_  +3_"C^
MS8?^@S>?^!:?X5\ T4<H?6?[I]_?V;#_ -!F\_\  M/\*/[-A_Z#-Y_X%I_A
M7P#11RA]9_NGW]_9L/\ T&;S_P "T_PH_LV'_H,WG_@6G^%? -%'*'UG^Z??
MW]FP_P#09O/_  +3_"C^S8?^@S>?^!:?X5\ T4<H?6?[I]_?V;#_ -!F\_\
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M<QVJQKY-I(9$5AN.68GEA@#'"BNL_MZW_P">%]_X!R?_ !-']O6__/"^_P#
M.3_XFCF8:&?X?\)MH6NZMJ"WI:"_._[##&8X5D+LS2D%F'F-N )4*#MR1DYK
MH:SO[>M_^>%]_P" <G_Q-']O6_\ SPOO_ .3_P")J=QZ&C16=_;UO_SPOO\
MP#D_^)H_MZW_ .>%]_X!R?\ Q- 71HU:TG_D*6?_ %U7^=8G]O6__/"^_P#
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M /84?9_#W_0OQ_\ @G_^PHY@^K?WCX-\Y/[Z_G1YR?WU_.OO+[/X>_Z%^/\
M\$__ -A1]G\/?]"_'_X)_P#["CF#ZM_>/@WSD_OK^='G)_?7\Z^\OL_A[_H7
MX_\ P3__ &%'V?P]_P!"_'_X)_\ ["CF#ZM_>/@WSD_OK^==#X%\$ZG\0M>B
MTO28P['YIIV_U<"=W8_R'4FOM'[/X>_Z%^/_ ,$__P!A5FSO-+TT.+/3);0/
M][[/IK1[L=,[5&:7,-8;75D7PW\ Z7\.]+M=-TU,DR*]Q<N/WD\G'S-_0=A7
M1W'_ !\2_P"^?YUG6NO6_P!JA_<7WWU_Y<Y?7_=I+C7K?SY?W%]]\_\ +G+Z
M_P"[4'>K)61>HK._MZW_ .>%]_X!R?\ Q-']O6__ #POO_ .3_XFF%T:-%9W
M]O6__/"^_P# .3_XFC^WK?\ YX7W_@')_P#$T!=&C16=_;UO_P \+[_P#D_^
M)H_MZW_YX7W_ (!R?_$T!=&C16=_;UO_ ,\+[_P#D_\ B:/[>M_^>%]_X!R?
M_$T!=&C16=_;UO\ \\+[_P  Y/\ XFC^WK?_ )X7W_@')_\ $T!=&S8_?F_Z
MXO\ RJO5:RUZW#R_N+[_ %+_ /+G+Z?[M5_[>M_^>%]_X!R?_$TAW5C1HK._
MMZW_ .>%]_X!R?\ Q-']O6__ #POO_ .3_XFF*Z-&BL[^WK?_GA??^ <G_Q-
M']O6_P#SPOO_  #D_P#B: NC1HK._MZW_P">%]_X!R?_ !-']O6__/"^_P#
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ML'VJ,1MN!(9<<BHE^+]G;V\[ZCIEQ8S+J-U800F>$F;[."9'W%PJX&."<DL
M,T^5A='?YHS7(6GQ0TJ^OH88+:^>WEFM[=;SR0(_,G@\^)-I;?DI_L\'@UG/
M\7-/>QT[58DN!ILT=U))"(4DF*Q(C$DK)^[*A\LC#=P00N.3E87/0,T9KB-8
M^,&@:+<7,4WVB0V[3;V0( T<3*KR)N8;QN;: N6)5L#BG_$KQX_A70=4_LV"
M>[U:/2I]2B:*-72&-,*)'#$9&YA\HR>#QQ1RL+G:9HS7$V'Q(MUOHK*[\R:X
MN=0DLHF2)88T*)$S*6=\.W[W(Q\S#.%^4T[2?BUHFN+=&S\V18H3<QLSQ*LL
M8E\HMN+XC^;'$FTX(.*7*PN=IFC-<9I_Q9T/4O[/:/SXXKRVFN_-EV*L:1.Z
M2#.[YRIC;(CW<8/0@U6@^,VA7&G_ &I(KK!D@0*3%MVS*S1LTF_8@(1@0S @
MX!&6&3E?8+G>9JSIHWZC:KG&95'ZU6!R ?49YJUI/_(4L_\ KJO\ZDI;GSEJ
M/[6+V.I7EK_PC"OY$\D.[[<1NVL5SC9[57_X:[?_ *%5?_ X_P#Q%>#^(?\
MD8M6_P"OV?\ ]&-6?6ED>1[>IW/HC_AKM_\ H55_\#C_ /$4?\-=O_T*J_\
M@<?_ (BOG>BBR#V]3N?1'_#7;_\ 0JK_ .!Q_P#B*/\ AKM_^A57_P #C_\
M$5\[T460>WJ=SZ(_X:[?_H55_P# X_\ Q%'_  UV_P#T*J_^!Q_^(KYWHHL@
M]O4[GT1_PUV__0JK_P"!Q_\ B*/^&NW_ .A57_P./_Q%?.]%%D'MZG<^B/\
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M<9I]W\.O#U];B"?3_,C"7" >:_ FE$TN#GJ9%5L]B.,5I_V_:?W;K_P$E_\
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M:+L/84SYL_X9+\0?]![2O^^)?_B:/^&2_$'_ $'M*_[XE_\ B:^D_P"V8/\
MGC>?^ 4W_P 31_;,'_/&\_\  *;_ .)HNP]A3/FS_ADOQ!_T'M*_[XE_^)H_
MX9+\0?\ 0>TK_OB7_P")KZ3_ +9@_P">-Y_X!3?_ !-']LP?\\;S_P  IO\
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M)H"Z-&BL[^W[3^[=?^ DO_Q-']OVG]VZ_P# 27_XF@+HT:*SO[?M/[MU_P"
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M:?9W+7"HR] I*1Q,<\;GYJM??$75;Z0Z]IUU:V9;3HERX:6V$?\ :[6[28W
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MXE?\E&\4?]A.X_\ 1AKFZV/#DWS,TO\ A)=9_P"@QJ/_ (&2?_%4?\)+K/\
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MFC-%% $MJ?\ 2H?]]?YTEP?](E_WS_.EM?\ CZA_WU_G27'_ !\2_P"^?YT
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MSH:*Y[_A0OC[_HL-[_X(K6C_ (4+X^_Z+#>_^"*UHNNX<L_Y?R_S.AHKGO\
MA0OC[_HL-[_X(K6C_A0OC[_HL-[_ ."*UHNNX<L_Y?R_S.AHKGO^%"^/O^BP
MWO\ X(K6C_A0OC[_ *+#>_\ @BM:+KN'+/\ E_+_ #.AJQI__'];_P#71?YU
MRW_"A?'W_18;W_P16M.C^!/C^*177XQ7H93D'^P;6BZ[ARS_ )?R_P R"\^&
M'A#4+R>ZNO#6FW%S-(TDLTD +.Q.22?4FH?^%2>"?^A4TK_P'%6_^%"^/O\
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M $6&]_\ !%:T?\*%\??]%AO?_!%:T77<:IR6T/R_S.AHKGO^%"^/O^BPWO\
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M:T77<.6?\OY?YG4V/WYO^N+_ ,JKU@1_ GX@1DE?C%>C(*G_ (D-KT/6F_\
M"A?'W_18;W_P16M+3N'+/^7\O\SH:*Y[_A0OC[_HL-[_ ."*UH_X4+X^_P"B
MPWO_ ((K6G==PY9_R_E_F=#17/?\*%\??]%AO?\ P16M'_"A?'W_ $6&]_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>morf-20221231_g8.jpg
<TEXT>
begin 644 morf-20221231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ':!#\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J&O:Y8^&-#U'6=3G^RZ;IUM)=W4Y5
MF\N*-2[MA02<*"< $\5?K@?V@/\ D@_Q(_[%K4O_ $EDH W_  'XZT/XG>#M
M)\5>&;[^T]!U:!;FSN_*>+S8ST;8ZJR_1@#57X??$_PS\5+#5+WPOJ?]J6VE
MZG<:/=OY$L7E7<#!98\2*I.TD?,,J>Q-?&G['O[6UKX)_9C^'.A/\)OBUK3V
M.E1PG4-%\'7%U9SX+?-%*IPZ^XK,_9Y_:#@^"/[&/QR^*;Z9.)+7QUK5S::5
MJ<;03?:)YX4AAF3[R$/*H=>HPWI0!^@]%?%7Q&NOVG?@?\);KXN:M\2]'\53
MZ1;QZIK/P_;PW!:V26^5,\4%VA,X:-2Q#.3G:3CH#H?';X_?$K4/C1^S[X9^
M%&KZ=I5G\1M(U"\?^VK)9HD5;>*=)V &\M%%YC+&KJ&8@,<= #[%JKJNI6^B
MZ7>:A=N8[6TA>>9E4L0BJ68X')X!X%?$MCXN_:2T?]HO4/@$WQ%T+Q!/?:#%
MXK@\?7V@PP7>F6'G-;RQI9Q8AED,P55WG 4ECNZ+VGP9^,'Q&TC7_CU\-O'?
MB"V\5>(_A_96^I:9XHBTV.S-];W-I),GF0)^[#1L@4X&#D]<9(!]$?#'XE:!
M\8/ >D>,?"]U)>Z!JT1FM+B2%X6=0S(24<!ARIZBNHKX"US]JKXJ:?\ L$_!
MOXDV&KV]YX\U_P 06-C>W%Q:0)'>H]S.C1,HCVQAQ$BED4$ DC!KN=>\8?'3
MX _%SX4/XV^(.D>//#?CO6U\/W^BVF@QV":5<21LT;VLJL9)$!4Y\TDD+TRW
MR@'V)17RCJ7C'XH_'+]H/XJ^!O"/Q$B^%>C^ 8+"%&@T:VU"\U"XNK<S>=*+
ME65(%^Z @!;!.X=*U_\ @G_XX\=_%#X#Q>+_ ![XU;QEJ.HW]U#$ZZ=;6D5N
MMO/) ?*:!$$B.8]X9E!&<4 >R>(OB]X7\*_$KPCX"U*^DA\3^*TNY-*M5MY'
M69;:/S)B9 NU,+S\Q&>@KLZ^<_B]\7O%?A7]LOX ^ ],U);?PMXIMM<DU>R-
MO&YN6M[,RPGS&4NFUUS\A&<G.:\T\*^-OCU\=/CU\;O!/ASXBZ;X&\,>$=9B
MAM]5.A07]]&)( 8[>*-PL93*2.\DF]OF"K@<@ ^S=4U2RT/2[S4M2O+?3].L
MX7N+F\NI5BA@B12SR.[$!550223@ $FDTG5K'7M*L]3TR\M]1TV]A2YM;RTE
M66&>)U#)(CJ2&5E((8'!!!%?"^I?$3XC_'3]A7X\V6O>)[?1?%W@&\\1>'-<
MU/3=.ADBUR&RM',L?EN"(1,L@4NF&4J2N,X&]\&_%OBK]F']AFS^*'BSQY+X
MXT.U\#Z3=Z+X=N-*MK)-.9K>-8+83Q+OE!:6&/=)DX7/4F@#[5HKXG\67'[4
M'PY^"UQ\9+_XFZ+K-YINF#7M3^'O_"-016"6RH)9H([M6,^](]QW%B"5/L:^
MM_AWXTM/B1\/_#/BVPC>*QU[2[75;>.3[RQSQ+*H/N XH Z&BOB;PSXV^/GQ
MT^.WQO\ !/AGXC:;X%\-^$=8BAMM5;0K>_O8Q) #';QQN ACW)([R2;W^8*N
M!R,KX-^-OVGOVD/A_P"(KFV\=^'O .H>#KZ]T%KO3M$COY/$&HVSD.TBS?+;
MPD>6O[M2Q8NWR@!: /K_ .*WQ9\*?!'P3>>+O&NK#1/#UF\<<]X;>6?8TCA$
M&R)68Y9@.!QG)XKKZ_./]JCXSW?[0G_!)B'Q_J$$-MJ6K&Q%W';J5C\^'4A!
M*4!)(4O$Q R< ]3UK]'* /-_@_\ M%_#GX]RZ]%X#\46_B";0K@6NHPI#+"\
M#G< 2LJ*64E6 =05.TX)P:W]'^)WAG7_ !]XB\%6&IBX\3^'X+:XU.Q\B1?L
M\=PK-"V\J$;<%/"L2.^,BOS$_9^M[C]G/X<_#S]H[28I#H2ZUJ?AGQ[;P]'T
MV74YE@O"HZO!*RC/)(*+P,U]<?!"\@U#]O3]H&ZM9DN+:?0?#4L4T;!E=&MY
M"&!'4$$&@#ZLHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N1^+V@WWBKX3>-=%TR'[1J6I:)>V=K"75-\LD#HB[F( RS 9)
M KKJ* /(OV1_ >N?"_\ 9K^'GA3Q+9?V=KVE:5';WEIYJ2^5("25WHS*W7JI
M(KPC0_V/?$GCK]E;XV_#+Q1!'X<U/Q5XQU76M(N)98YU"M<Q3VDK&,MM5FB
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MX+\3^$=1^'GQ,\.:'/+JOAS4'693$\+!9[>9>)8B2.<#[R]00: *GA'_ (*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO_DBC_AX9\.?^@+XH_\  6V_^2*.678/K%+^8^H**^7_ /AX9\.?^@+XH_\
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MO_DBCEEV#ZQ2_F/J"BOE_P#X>&?#G_H"^*/_  %MO_DBC_AX9\.?^@+XH_\
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MKV/I.BBBN\\,***XOXO_ !2TWX.^ [_Q)J2-<>3MBMK.,@275PYQ'$ON3W[
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M\<Z:M_(<):7Q>SE8^@695)/TKUI6#*&4Y!Y!%?DGJ6E66LV[07]I#>0MU69
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M (HGJWP1\#^!_B%>2Z3KDOB"WUB.VNKWS=/:$6_E0Q[]N&!;<0"/3I6?\/\
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M*&X)V16Z*&F=L'/RDA?J:+R%[.@KW1Y[_P ,):-_T-^H?^ <?^-'_#"6C?\
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M7J-13W<%JT*S31Q--((H@[ %W()"KZG /'L:/W;T]FOQ_P Q.G5ZUI?^2_\
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M5ZQ\F%%%% !1110 4444 %%%% $=Q_J)/]T_RK%K:N/]1)_NG^58M !1110
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M:;116!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;D?\
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M)?".ASZ_'KDFCV4FM1J%34&@4S* "!AL9Z$CZ&J?_"M_"GVJQN?^$;TOS[$
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MXCW;5DZY_>8YZ8^[^M:=%%( HHHH **** "BBB@#<C_U:_2G4V/_ %:_2G4
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MN+RVG:ZT[2;J9&M;&5L_,N%W-MR=H8\<=<5]64 %%%% !1110 4444 %%%%
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MA_K/EO\ ,_N(Z*D_X43\5?\ H>_"O_A/S_\ R11_PHGXJ_\ 0]^%?_"?G_\
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M1\!6S#&8EWK56_G9?<CQJ;]D'X5W4:+-X2LY-K!U+2S$AAT.=_6J=U^R#X)
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MOX<?1!1114&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI8S?#;Q:([ZUD)T:]QLG4Y_</Z&MVU_9=^$5G@Q?#CP\#_M68;^=5/B%\%_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVB:X!R(=2L7M';VWQLP'_?-<=K6N:QX&8#QIX9O- M\[?[4@(O+ ^YE3E/\
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MED_QXLUE(ATFX>//#/*JD_ABO3/DGJ]#U&DDC6:-XY%62-QM9&&58>A!ZBN
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M ,=@TP$K9!(&WU(!('4XJQ?>(M*TS4[#3;O4;6VU"_8K:6DDH$LY ).Q>IP
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MCIQ0!H45F)IE^NW.M3O@1@YMX1NVGYC]W^/H?3MBM2D,2BBB@ HHHH ****
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MWJ^-G7FIO_(_5:6&@Z4=7LNK+/\ PG7B./[VAZ=-_P!<]0=?YQ4?\+(UF/\
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M_,WX?^.$A\&^'X;BV8*EA N^-L](U'0UW6GZM::HNZVF#D=5/##\*\7\(?\
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ME\DS!/N[=_\ !C..^:_0UEV,R^AQ0!^6W[97_)RGC/\ W[?_ -)HJ^+/B?\
M$KQ1X=\;"PT_]Q:H$,4?E!OM&0,D\<\\8%?:?[97_)RGC/\ W[?_ -)HJ\3>
M&.1U=XT=U^ZS*"5^A[5[G*YTHJ+ML>7S*,VVKD<,LDVGQ22Q^5*\2L\?]UB
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M>+5]-_M'_!?X@_$CXT^)/$>A>"=:N-*OFA,$DMN(V.V%$.5)R.5->:_\,O\
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MU^)7[17A/P9:?#[PUXBU&STNZFFO])>R,!=V4".8%CAMHW+CJ-V?6OF'P?\
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M[26E7I)<0"=A^,FZN<^(GBG5[[Q#_P *\\#RQZ#)';)<ZSK4$2_\2Z!R1'%
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MHH **** -R/_ %:_2G4V/_5K]*=0 4444 %%%% !1110 4444 <GX\_Y<?\
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MHUCL%%%%8%A1110 4444 %%%% !1110!'<?ZB3_=/\JQ:VKC_42?[I_E6+0
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MI?+;^Z?RKE.T^=OVPO#*:EHN@ZA;SM:ZDDDUKYA&8S 4+L".N[*K@CU-=?\
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M^<_ACX@E^'K6GA>/1VL_B*?$.F^'=?GN=1FO[>^WPO</>QLS\,\2R-@JK*2
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M2?WV_,T>=)_?;\S2_L*A_,_P_P @_P!;,9_)'[G_ )GYG_\ "=V'_0/\0?\
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MT_RK%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#<C_P!6OTIU-C_U:_2G4 %%%% !1110 4444 %%%% ')^//^7'_
M +:?^RUR==9X\_Y<?^VG_LM<G793^%&,MPHHHK0D**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXWA&V^N!G&13U_E%IW*/B3Q5XGT?QQ?6>G6RWMJ\$+0V]Q;R;!B*5I'$P^4
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MF89))]?6G_\ " ^'5D$B:1;PR"ZDOO,AW1MY[XWOE2"2VT9'0X'%=5_9LO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>morf-20221231_g9.jpg
<TEXT>
begin 644 morf-20221231_g9.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (" P$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% %>>-6)W $' .:_,CXB76J>#?C5\1M6GUK4M+G;58
M6LH8(#(DB".($8[#@U^B'Q,U[6_#OA\7.@:?'J-]Y\2>7*^T;2X#'IZ$U\J_
M&CXV:YHOBZ:UU'PKX:O/*7,:W5ZL<A^0'YACL: /FS0?B%=>,_$T^OZC>7\.
MOPZ_;6]C 49=\/[K)QZ$EJ_53PQ/)<:#ILDP_>/""V>N:^8OV;UTCXL7TFH:
MOX2T&QO;*0&"2QE\TD@ \^AKZP6$1J B@!1@+Z4 2+G'-<]X^\&Z?\0/"]]H
M.J0B>RO8VBD4KD8(Q70BFLNYEXH _/CQI^R3XF^!\_VCPC\1[G0M,NI7\NTD
MP44\8 S6.?V7?'7Q*UJV\/>-?BM=7,5PP?[*-H+H?3%>U_M^R21^%_"["0+_
M *:02#C/W:X;1Y)F_:Q\%;V?R_L=O\N2%Y!H ^N/A%\*])^#_@73_#&C1^78
MVJ8Y_B;C)_2NW7'8TSS W<"G)WQ0 ZBBB@#-UK7K/P_8RWNH7$5G:Q_>DE8
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MZ]/6@"2BHQ,K,0.H.#3C(!QU- #J*2EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH X/XK?%"Q^%NCMJFH6-Y?Q*5_=V<>]L$XSCZ
MU^?&C^./!'B[XT>+M9\>>"-=UW3K^?S-/\ZQ/R((U! Y]0:_3B^T^"_79<Q+
M)'Z,*H_\(KH\8!^P0>@W(* /$?V8KSX<W7V\^!O"=WX;(EP_VFU,>1M'O7T/
M7@7[4GQ"U/X*_#^SU#PE96O]IW5[':(CKA2SLJ@'';)KB/!O[8&L:%';6WQ'
M\,7UA<3 ;;VUM\VX'KNSTH ^M*:QQCZUS7A'Q]H7CFS6[T35+?4HL980G)7Z
MUH>)+BZM-%N9[)$DN8XRT:2#JW84 >3_ +0GPWT3XQ#2-"O]7CL+NVG,L461
MESQQUJDO[.MAI/Q2TGQS)J#*=,A2+8WW<*#S7PK\4/BQ\=C^T=INI?\ ")6W
MVZUG'V2,!MCX/&>*]3\1_&S]J#Q5H]SI/_"$Z79QW*>29%W=#_P&@#[]T;Q!
M8>(K+[1I]U%>0@[6:,Y&:U%^7('05X%^QS\*==^%?PAM-,\1R+_:DDKS2(F=
MJEB#@9[5[Y$<J>,#I0 ^BBB@#YL_;2^&OQ)^+/P]?P]\/9[:TDN#BYEN)2NY
M>Z\5Y5^RA\"?C5\%85TC4;+1K;2?)SYUI,3(\@[MQ7W110!\D_$SX ^//CA\
M--;T3Q3/;V^HK>M=Z:89">  %!X]17(?!+]DCQU;_%#2O%GCZ>UQHMO'!9QV
MKYW!.F<U]RT4 8^JMINFVCWFH+ EO&-SRS@?+^E?$/C3Q#HWB']MCP,^BWMK
M<*DHR8,=,CCBOM7QQX3M/&_AN]T2^W?9;M=KE>PKX 3X(Z)\'_VT/!4&C;F1
MILG<>>2* /T:^\S=@#VH:%&_@&/I3DY8_-T[5)3NP/G[XM?L?^!?B]KG]KZC
M9K#>D[99%0?.:]'^&OPMT3X7^'8=(T6S6VBC !POWB.]=SCVHKOK9ABZU!8>
M51\BV1BJ,(SYTB&.,)(NT8!!)J:EHKSS8\A_:/\ A,WQ;^']U860C75X1YEG
M(3]V3H?T)KS3X0_LHW'AC]G?7?!.NO'<ZMK 9I[@')RT@DQ^8KZHI: /A+2?
MV;OB=9Q6WAG^S-'M]%MYE U)'/G"%3D9&/85[-X,^".N>'_C5J7B6=X)=,GL
M(;='#?.[)$JYQZ?+7T/24 ?&WC+]EOQ7KFJ?$F: P;-?FM)+<9/2-XB?_0#6
MKXD_9_\ &?A75/#'B?P9':3:Y86_EW,%Q(0DC%2N>G^<5]:T4 ?%WBC]GWXK
M_$OPG>-XCU&U?4KK4X+I;0.3%'&K)D#_ +Y-1^)/V6/%'A/Q=;^(_"FDZ;K%
MS<0 7=K?N5C$F-I(.#V K[5HH \ _9I^$?B7X=0ZO?>)I8EO[Z<RK:6Y_=1
M@# /?I4?QJ^#.M^//BAX4UNR%N=/TN>*6X\\YW*&R:^@Z2@"E'8Q(J;$C7 &
M-J@<U\W?%7X">)M-^)L?Q%^';6Z:Z\0ANK2X;;%*!S\Q':OI^B@#XZU#X+_%
M'X[>(M)D^)45AI>B6#E_(L92PD.01U'M7UWIEC'INGVUI"-L4,:QJ#Z 8JS2
MT %%%% !1110 4444 %%%% !1110 4444 5+Z0QQR, S;4+;5]:_-'QA^UE\
M6K/]KVWT.&PO%T%7:#[&4.UX]P^?^7YU^FK@;B#D@]A7-W7P]\/WGB:+Q!+I
MD#:K$AC6X*C=@XXZ>PH ^#OVU?VF_BAX \;^&],\-V5S!:O*LDL@4_O<C[GZ
MU]M_!OQ/J?C+X?Z-JFL63V.IW5NDDR-V) K;\0>!]#\526[ZMIT%]+;N'C,B
MCY3VK>ACC@4)&-H]!0!(N<<TM(.*6@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"*1@%<G VC/->9:O\ M(?#G1=>?1;[Q78V^H1R
M",PL^,,<<9_&NS\=-/'X/U][;/V@:?/Y>.N[RVQ^M?F-\#_A7\(?'.C^+)?'
MFJQV?C-KF8^;?$B1)!]TJ?3I0![S^V)^TG\/-0M=(T WDVKSV]]#?NFF_./D
M=6 /(_NUZ[\&_C%\//VBO#JZ1;0PWC6\8C?3[V,;PN.>.:^7/V.?AC\,? VL
M^,[CQMK.D:X[7WEV,NH?O1Y.Q>!N'J31\/\ QI\/O _[<#R>%]3T_2M!DTUC
M.8CY<)?+] !CIB@#[F^'OP>\/?#"2Y;0K2.PCN&W-'$@4#Z8KNVC63[WS ]J
MQO#?B[2?%EA]JT?4(=1A4[6DA.0#6TOWB,Y/6@#-N?#.EW6H17\ME"UW%]R8
MJ-P_&K#,(XTEDX '/ Q5MN%/&[VKB?B]X3O?&W@/4M(TW4Y-)N[A<1W4<A3;
M^(H ZZ&>.9 5;('N#4\8*Y^N:^+/A1X/^*OP%\:6]C?>+[?Q7X;N3\[37)DE
MCY'8_P"-?:%I()(5=6W!AG.: )J*** "BBB@ HHHH Y7XAV^NZAX2U"'PY)'
M!K#KB!K@[5!_#-?GMH.@?$/1OVT/!@\=7=I=3^=\IM7)4#(P,D#FOT)^('BJ
M/P+X3O\ 7'LI]06R7?\ 9X "[8YXR:_/G2?CC%\:OVSO!5PNA:AI 2?;LO8U
M0G!'/!- 'Z61\%O7-25 91#O9CA%ZUSL_P 3O#-K<-!+JT$<J\%3G/\ *@I1
M;V.E5V;&1@D4]3E0:\-^*G[2VB>"UTZ/3[N*]DGGVLRGA5[YS7=:/\9/">IZ
M?%<KJT"^8 2O)QG\*YXXBE*?LXRU['7/!8BG1C7E!J$MGW.YI#Q63HGBS2O$
M3.-.O([DIUVYK6/2N@XVFM&0_:%7:695#=F(%.\SWSW_  KX4_X*0>._&'@N
M3PJ?"VJW-C+)>QJR0L1O7:21P?:O7]4^-O\ QBK=>)8+HG6H-+2(@'YVF&U6
M ]\Y_*@1]$1W/FY*,#MZ],&FB_B\P+YJ_F,?SK\V_P!FW]HGQ9X7^!7BW6-8
MOY]3URXN7%C]H<N$9Y< <],*3^5>M^'?V5?&GBCP\GBO6/B)K4.KW4 O8+&U
MO9!;*67>%(R/7TH ^S&NT4J-R\^](MY$=W^D1GGU'^-?![?&[Q;<?!3QOX:U
M34I;/Q!X<ECB:\M'*R;&E7!W<'[K"L;PO\.=(U#X9KXBNOC;X@M=6:"2X\B;
M5)?+WKD[<;O84 ?H2UUA=VY0-O&3_6F)J$;8/F("?X2P']:_.GQ1\8?&NH?L
MK22W6LWEJ\>J0VL.L13,&EB,BJ6#=>A-=S\/?@KX=U:ST6[F^-?B&6\=DD:W
M.IRE78X^0KNP0>F* /N19O,; XXX..M0R7JJ#\Z ]ANZUEV,:>'?#\, NC<_
M98CB29\NW'4U\46EMXW_ &A+SQSXEM?%%YHL?AVZD@L;:QN'A64H,C?MZ]:
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M &?/B!\)?$'B"^\57S36,C,D:2.Q9FSU /:@#[J63./4]J?44,97EN20*EH
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MGA<WA'1?^%XPVPTRU$0T]I3'Y2[=VY!_6O:;6WALX4AB18HD&!&HP!7F$_\
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M #7Y4UXQ^U=JNK:7\#?$EUH8D6^CC^0QIN8=B0*]G=2RD X/K7D?[47C#4/
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M"5"P( '/2@#Z'2>.6,21NLB,,AE((/TKPS]M+[6W[._BI;'>T_D@?ND+L?H
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M2VG+(<8^:1_\:]!2FD?.)4NLF=%_PE6AK_S%+$?]O"?XTW_A+M#_ .@Q9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBC8LS9&.>*DH C+#=M[XS6%XM\30>&=&N+^?YDB&%3NS'H*U+Z\BT^SEFN)
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M.[NVOKA!AYG[UOB*,**B^;<F,C87I2TV/[O3'-.K#;0L**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *XSXM^ U^)'@F^T-[U[%+A"K
M2H!]WO\ I79UXC^U_P"--2\#_!S4KW2I&@O)!Y*S)G*;N,_K0!\Q6?\ P3Y\
M&^'3=+!\6)+$2.6,(N8UV-WX/2O7OV=_V:]$^%?CAM8T_P"()\23>45-L;A'
M[>@KXR\>? :\\.^&? /B;4_'.J2GQ)<1"ZD9UV(9)BA .,=,=:]:_9J\&K\&
M?VNT\.?\))-XCL[[3#=0MYRR!&(;AMO'84 ?H\N-HQTIDQQMY(/L*?']P4V3
M.Y<=??I0!^??[=/AVU\8?&[P1H_B[4%M?!]Q.J$.^Q,D\Y/;ZUWNF_L<? -]
M/MF^W:?*K)PPU''_ +/5_P#;B^$G@'Q7I=KKGCGQ--H]I: F&&%E#,1Z9&<U
M\@^']/\ @IJNH16,/CWQ-90X"+). L>3_M%,4 ?IW\'_  'X<^'?@VUT;PL\
M<FE0DE'CE\P<]LY-=W"NQ<5YG^S_ .!=-^'_ ,.;#2](UB77;+EX[Z:0.7'U
M'%>F0_<]>V?6@"2BBB@ HHHH **** .7^(%QKEKX5OY?#44=SK.S]Q%,=JDU
M^?.CZA\1;W]M'P9_PGVGVMDXE^06\@8=>.<GFOT.\;>*[/P/X;O=:U!7>UM%
MWMY:Y;\!7Y_M\;-"^,?[9O@J;1X;A52;!%PA3D$<]J:$S]',X(XZFC>-K 'I
MU)IA)4$YXSP*X#XD>-VTF&/2;!?-U>\XCC7G [YQ]16<I&D8\QB>,M<N?&&O
M#PII:EX5):ZN%;@ =%S[Y/Y5Z5X;T*U\/Z7!8VD82&(87CGZGWK#^'G@F/PA
MHL44I\[4)3NFN'Y=S[UUL8 !QZ\THFLY)JR)=H'08I:132UH<X5&WWB :DKF
M?'*ZTVF,=$,?VA>2)#CM2MS-(3.AW;LC'-"]AW]Z^>/A]XJ^(7B?7I[:9+5(
M;60B1@_4!L>M?0EOYGDQ^9CS,#=6M2#IRU$6****S*"BBB@ J-EW'FI*83G.
M.M)WZ#(I+6&9MTD2.WJR@T1VL,+[HXHT;U50#7!_$3XR:=\-V/V^POIXP,M)
M;P,ZCZX!J+P!\;-,^(5S$ECIVHP1R?=EN+9U7\R*U]C44?:-:$\[VN>DT445
MF,**** "D]:6BDP$V^M-VC/2E8D#C'XUY[K7QP\/:#J,MG=2M'(C;.AY/M3Y
M'/8#T(*/2EP*P_#/C"R\66+75B6*+UW#!K<5LU+]UV 6BBBJ **** "F2#(%
M/J.8X4?6IE:VNP]SQF\_Y.6M!V_LIO\ T)*]D_B->+75U&?VF+521N.DL5^8
M8^\G%>S[SYF,=O2N[&7ER*4;>ZC.G?5$RG*TZF1G*],4^N,L**** "HY,Y&*
MDJ.3MSB@:.5\>:5K&L:8L>DZA]AF4Y+=Z\>^$TWCCQ-XDU:.[UMWMM+O?)<?
M+\V,>U?1$B!T(/<8KQ[X$?/XB\?=@VJLV!VX'^%=V':>'GZ+\T8OXCV6'/E+
MN)8XY)I](O"BEKA-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $W<XKDOBGX8T?
MQ?X*U+3M<E2&PDA??*Y "?*><GTKI[FX2WC=Y'6*-!N=W. !7S!^US\4]!UK
MX/ZY9:)XJL4OE5E>&"X4NP ^88SZ9H \:^)?C'X&7WPNM/AIJ'C3S_[,8O;W
M\,\9>-PY8 <=C3OV%_"WPWT[XI7=[I'C&Y\4:^8BL;7DL;LD>#P, >]6?V7_
M  O^SKK?PMTN?6$T6]UCRREVUW,#)YF]NOS>XKZ/^%?A/X,Z/K_VGP-::+%K
M2QD?\2^7<^.>HW&@#VZ,YC! Q[4DC#H>A!R:<GW122?-QP0>H- 'PA^UM;:?
MK7[2O@?3_&4RCPDTJD),VV(G/1CT_.O2OB]\)_@9'\+]0FDLM$LHU@)AN89@
M&!QP1AN:UOVC_#/P]^+VNZ=X!\02F'7;@_Z)<6[ 21D\ BO+K;_@FU;W5Y';
M:KXXUS4-(A8,EJTJ;<>A^2@#T'_@GGJ5[J'[/]FMQ*]S%'=S1P3.<YC!&W!]
M,5]/19QSP<#BN9^'O@/2/ACX3LM T6'RK&V&Q%XSTZG'TKIXQA??% #Z***
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M375G'A,14K)N:/;_ #!_D4NX5X[Y/Q>M_EB;1'7U97_^+IV/C%_U <>RO_\
M%U\1]4_Z>1^\]*[/7_,7N<?6C</K7CTFL?%.PQ]HLM+G'_3&-R?_ $*H_P#A
M9/C&R_X^]!>3;U\B!\_A64L.XNUT_0I'LNX=/Z5"W^L?#<8Z5Y'_ ,+VOK5<
M7'A#6'/^Q __ ,336^/SLJ_\45KSYS]VW?C&/]GWJ'0G)-(&['3_ !D@2;X>
MZP"BEA Q#$=Q[U-\)(HE\#Z2T83!A0[E ZXKX<_;;_:ZUVUMH?#^E:;>Z*+B
M,&0W494E3]0*I?L)_M=7UQK!\-^*-0C&G]+>:0XQBONH\*YA/)/KZ^%:GE/&
M05;V;1^D^X4NZLO1_$-CKT(FL;J&YB/>,YK2.:_/VFNAZO,AV:6FK3JC48E&
M11NIGWJ+J]AB2,6X4CWKP[X[>&=,_M3PC(;",23ZM&DC#^,;EZU[BO6O)?CQ
M_P ?W@K_ +"\?\UKHP]U.S)D^78],TG2[72X?+M+9+:/^ZHZ\5HBHK?_ %8^
ME.SS6,O>E=C5[#]PHW"DH/OQ4IW 7<,XS2"96Y!R/:LCQ!XMTKPO;^?JM[#9
MQ_WI& KSW4OCQ9N_DZ%I=[K>_A+JTB+0@^Y K94Y2V$SUCSDYP<_3FO._C9\
M4].^'?@G5+Q[R&.^CA8Q1,X#$XXXKFFT;XC^,5$=_=V^DZ=*<JUN")U'Y_TK
M3L_@)H,UC+%K4ESKTCJ4,E\PR,^@P*[,.J5&K&I7UBGJC*:G*+4=S\CV_:D\
M;77Q*_X2A=5F,[2!5A7G"==OZ5^IOPK_ &D;#7_!&C7NIVMU;W4]NK2-)&5
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M$C(^3VKI_P!GGX9?"_X>_&#4M.\-:IJ,WB*V1TD@O95;<NWYB %':O-/V?\
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M&,YKHISI48.+ZF#C+F-Z-A)&K*<J1D4ZF0@K$H(P<=SFGUAZ&P4444 %%%%
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MI\)/^?\ OO\ P$/^- 'U%17R[_P\4^$G_/\ WW_@(?\ &C_AXI\)/^?^^_\
M 0_XT ?45%?+5Q_P4;^$%O"TDNIWD2(-S,]J0 ._.:;:_P#!1WX0WD8ECU&[
M>(]'CMBP/ZT ?4]%?+O_  \4^$G_ #_WW_@(?\:/^'BGPD_Y_P"^_P# 0_XT
M ?45%?+O_#Q3X2?\_P#??^ A_P :/^'BGPD_Y_[[_P !#_C0!]14AZ5\O?\
M#Q3X2?\ /_??^ A_QH_X>*?"/_G_ +[_ ,!#_C2ZH#Z>D'\Z\D^._P#Q^>"?
M^PQ'_-:\\;_@HE\)&C?%_?[E&1_HAY/IUKYY^,7_  4:\-ZUK>E1V^EW44&F
M:BDT<DR$>< %/'%=6'IJ534RGL?I#!RH^E25\=^!/^"DWP_UG3S+K$%]I4N?
MEC\@MD =>U=)_P /$OA'_P _]_\ ^ A_QK!Q49,N/PGU"M.KY='_  44^$?_
M #_W_P#X"'_&C_AXI\)/^?\ OO\ P$/^-0MAH^HJ*^7?^'BGPD_Y_P"^_P#
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M58Y\L$@$\>U>P?LI_'KQ->^/KGX=?$'28=.\2V\3,EW&?FF4 G.<"O-_A?\
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M[H9/2@"1OA#X2DDYT6V.><>6,#\*7_A3?A#_ * EK_WZ%=C'DD$C:Q'S"I:
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M6.EV\%S"24D5 ",^]=510 BC:H'6EHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZA,\-I
M.ZC<RH2H'TKY=_98^*WB'QU\7OBSHNK7S75CH^I+!:1RM]U3#$QQ[98U]27D
M?F0.H/WA@\XXKX#\4?L7_%?2_BKXK\2^"?%3Z+;:S<B:18I2I;Y%']* /3?
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M.HZ8VG6&E0F2U#@!F7S%4$_@:^P*^%/V*+>"S_:E^*\%O$L,2V>$55P HFC
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M],TOP_\ @3X'^%M]+=^%O#>GZ+/*NQWM(%1F7L"0*[^B@ HHHH **1F"C)(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8*PW#\*^4OV0_$%U+\?/BBEY?3/!:7=TYCFDRB()\9'I7#>%?#=M\!_VW)-
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M[!O[2NH?&'P5)H/B@K%XNTA=MPK\-)D;@V#_ +)%<A_P4^16\)^$5895M5M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027586192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MORPHIC HOLDING,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3878772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">35 Gatehouse Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">A2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">996-0955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MORF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 559,358,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,534,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div style="text-indent:17.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Portions of the registrant&#8217;s definitive proxy statement to be filed for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001679363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027472320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241026247760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59,272<span></span>
</td>
<td class="nump">$ 171,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">288,976<span></span>
</td>
<td class="nump">236,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">455<span></span>
</td>
<td class="nump">2,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">13,479<span></span>
</td>
<td class="nump">7,892<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">362,182<span></span>
</td>
<td class="nump">418,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,514<span></span>
</td>
<td class="nump">4,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">368,589<span></span>
</td>
<td class="nump">426,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,475<span></span>
</td>
<td class="nump">4,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">13,181<span></span>
</td>
<td class="nump">12,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">20,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,126<span></span>
</td>
<td class="nump">38,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">2,344<span></span>
</td>
<td class="nump">3,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,489<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,470<span></span>
</td>
<td class="nump">89,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred shares, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, $0.0001 par value, 400,000,000 shares authorized, 38,584,678 shares issued and outstanding as of December&#160;31, 2022 and 37,085,397 shares issued and outstanding as of December&#160;31, 2021</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid&#8209;in capital</a></td>
<td class="nump">649,549<span></span>
</td>
<td class="nump">575,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(297,095)<span></span>
</td>
<td class="num">(238,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3,339)<span></span>
</td>
<td class="num">(482)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">349,119<span></span>
</td>
<td class="nump">336,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 368,589<span></span>
</td>
<td class="nump">$ 426,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241025335264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">38,584,678<span></span>
</td>
<td class="nump">37,085,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">38,584,678<span></span>
</td>
<td class="nump">37,085,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027433952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 70,808<span></span>
</td>
<td class="nump">$ 19,794<span></span>
</td>
<td class="nump">$ 44,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">102,062<span></span>
</td>
<td class="nump">87,789<span></span>
</td>
<td class="nump">73,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">27,811<span></span>
</td>
<td class="nump">18,495<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">134,204<span></span>
</td>
<td class="nump">115,600<span></span>
</td>
<td class="nump">92,125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(63,396)<span></span>
</td>
<td class="num">(95,806)<span></span>
</td>
<td class="num">(47,180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">4,567<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(145)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">4,422<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before (provision for) benefit from income taxes</a></td>
<td class="num">(58,974)<span></span>
</td>
<td class="num">(95,542)<span></span>
</td>
<td class="num">(45,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="num">(67)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,041)<span></span>
</td>
<td class="num">$ (95,542)<span></span>
</td>
<td class="num">$ (44,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
<td class="num">$ (1.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
<td class="num">$ (1.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">38,112,498<span></span>
</td>
<td class="nump">35,797,969<span></span>
</td>
<td class="nump">30,594,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">38,112,498<span></span>
</td>
<td class="nump">35,797,969<span></span>
</td>
<td class="nump">30,594,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,041)<span></span>
</td>
<td class="num">$ (95,542)<span></span>
</td>
<td class="num">$ (44,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized holding losses on marketable securities, net of tax</a></td>
<td class="num">(2,857)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(2,857)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (61,898)<span></span>
</td>
<td class="num">$ (96,003)<span></span>
</td>
<td class="num">$ (45,064)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241023975584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-The-Market Offering</div></th>
<th class="th"><div>Secondary Offering</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th">
<div>Common Shares </div>
<div>At-The-Market Offering</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>Secondary Offering</div>
</th>
<th class="th"><div>Additional Paid&#8209;in Capital</div></th>
<th class="th">
<div>Additional Paid&#8209;in Capital </div>
<div>At-The-Market Offering</div>
</th>
<th class="th">
<div>Additional Paid&#8209;in Capital </div>
<div>Secondary Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period ( in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,110,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">$ 140,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (97,513)<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity&#8209;based compensation expense</a></td>
<td class="nump">11,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon stock option exercises</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common shares under the Employee Stock Purchase Plan</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of issuance/offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,157,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of issuance/offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding losses on marketable securities</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,037,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">145,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142,512)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity&#8209;based compensation expense</a></td>
<td class="nump">21,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">827,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon stock option exercises</a></td>
<td class="nump">9,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common shares under the Employee Stock Purchase Plan</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of issuance/offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,983<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of issuance/offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,708<span></span>
</td>
<td class="nump">$ 229,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,708<span></span>
</td>
<td class="nump">$ 229,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding losses on marketable securities</a></td>
<td class="num">(461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(95,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,085,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">336,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(238,054)<span></span>
</td>
<td class="num">(482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity&#8209;based compensation expense</a></td>
<td class="nump">29,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon stock option exercises</a></td>
<td class="nump">5,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common shares under the Employee Stock Purchase Plan</a></td>
<td class="nump">885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of issuance/offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of issuance/offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding losses on marketable securities</a></td>
<td class="num">(2,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(59,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,584,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 349,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 649,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (297,095)<span></span>
</td>
<td class="num">$ (3,339)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241025417296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_SecondaryOfferingMember', window );">Secondary Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_SecondaryOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_SecondaryOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241028054176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (59,041)<span></span>
</td>
<td class="num">$ (95,542)<span></span>
</td>
<td class="num">$ (44,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Premium amortization and discount accretion on marketable securities</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity&#8209;based compensation</a></td>
<td class="nump">29,048<span></span>
</td>
<td class="nump">21,184<span></span>
</td>
<td class="nump">11,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Loss on sale of marketable securities</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">5,007<span></span>
</td>
<td class="num">(3,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(5,529)<span></span>
</td>
<td class="num">(4,035)<span></span>
</td>
<td class="num">(767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(207)<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,553)<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">3,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(67,647)<span></span>
</td>
<td class="num">(14,821)<span></span>
</td>
<td class="num">(11,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,211)<span></span>
</td>
<td class="num">(1,097)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(100,977)<span></span>
</td>
<td class="num">(83,461)<span></span>
</td>
<td class="num">(45,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(238,274)<span></span>
</td>
<td class="num">(244,160)<span></span>
</td>
<td class="num">(145,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">175,042<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">7,146<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(365)<span></span>
</td>
<td class="num">(1,020)<span></span>
</td>
<td class="num">(544)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(56,451)<span></span>
</td>
<td class="num">(113,180)<span></span>
</td>
<td class="nump">8,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common shares under Employee Stock Purchase Plan</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common shares upon stock option exercises</a></td>
<td class="nump">5,171<span></span>
</td>
<td class="nump">9,536<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">45,266<span></span>
</td>
<td class="nump">266,313<span></span>
</td>
<td class="nump">38,297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(112,162)<span></span>
</td>
<td class="nump">69,672<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">171,994<span></span>
</td>
<td class="nump">102,322<span></span>
</td>
<td class="nump">101,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">59,832<span></span>
</td>
<td class="nump">171,994<span></span>
</td>
<td class="nump">102,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Amounts from exercise of stock options included in prepaid expenses and other current assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,434<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares, net</a></td>
<td class="nump">39,210<span></span>
</td>
<td class="nump">25,700<span></span>
</td>
<td class="nump">33,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_SecondaryOfferingMember', window );">Secondary Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 229,982<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_SecondaryOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_SecondaryOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241031395440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business</a></td>
<td class="text">Nature of the Business<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morphic Holding, Inc. (the &#8220;Company&#8221;) was formed under the laws of the State of Delaware in August 2014. The Company is a biopharmaceutical company applying proprietary insights into integrin medicine to discover and develop first-in-class oral small molecule integrin therapeutics. Integrins are a validated target class with multiple approved drugs for the treatment of serious chronic diseases. Despite significant biopharmaceutical industry investment, no oral small molecule integrin therapies have been approved by the U.S. Food and Drug Administration. The Company has created the Morphic integrin technology platform, or MInT Platform, by leveraging its unique understanding of integrin structure and biology, to develop a pipeline of novel product candidates designed to achieve potency, high selectivity, and the pharmaceutical properties required for oral administration.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&#160;The Company expects to continue to incur losses from operations for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months from the date these financial statements were issued.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, the Company entered into an Open Market Sale Agreement (&#8220;the Original Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $75.0 million, referred to as Placement Shares, through Jefferies as its sales agent. The Company paid Jefferies a commission equal to 3.0% of the gross sales proceeds of any Placement Shares sold through Jefferies under the Original Agreement, and also has provided Jefferies with customary indemnification and contribution rights. On August 11, 2021, the Company entered into an Amendment No. 1 to the Original Agreement with Jefferies, establishing a new at-the-market offering (&#8220;New ATM&#8221;) with an aggregate offering price of up to $150.0 million, also subject to a commission equal to 3.0% of gross sales proceeds from Placement Shares sold through Jefferies. Under the New ATM, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, referred to as Placement Shares, through Jefferies as its sales agent.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2022, the Company issued and sold 1,000,000 shares for net proceeds of $39.2 million after deducting offering commissions and offering expenses paid by the Company under the New ATM. As of December&#160;31, 2022, the Company had approximately $97.2 million of common stock remaining available for sale under the New ATM.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company completed an underwritten follow-on public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share. Gross proceeds from the secondary offering were approximately $245.0 million, before deducting underwriting discounts, commissions and other offering expenses of approximately $15.0 million, paid by the Company, resulting in net proceeds of approximately $230.0 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029739296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Morphic Holding, Inc. and its wholly-owned subsidiaries, Morphic Therapeutic, Inc., Morphic Therapeutic UK Ltd and Morphic Security Corporation. On March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, United Kingdom (the &#8220;U.K.&#8221;), to support Company functions outside of the United States. All intercompany balances have been eliminated in consolidation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed above, on March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, U.K., to support Company functions outside of the United States. The geographic location of all long-lived assets of the Company continues to be the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional reporting currency of Morphic Therapeutic UK Ltd is the United States Dollar. Foreign currency remeasurement is included in other income (expense) in the Company&#8217;s consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, and accounts receivable. The Company&#8217;s cash and cash equivalents are held at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and maintenance of liquidity. The Company&#8217;s investment policy allows funds to be held outside bank accounts, but to be invested only in readily marketable fixed income instruments with readily ascertainable market values, denominated and payable in United States Dollars including obligations of the U.S. government, U.S. government-sponsored enterprises, U.S. government agencies and highly rated corporate debt obligations, including commercial paper and corporate bonds, and money market funds registered according to Rule 2a-7 of the Investment Company Act of 1940. Investments in the money market fund shall be consistent with approved instruments and assets under management must be at least $1.0&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable generally represent amounts due from Janssen Pharmaceuticals, Inc. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign-hedging arrangements.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. At December&#160;31, 2022, cash and cash equivalents include bank demand deposits, money market funds that invest primarily in U.S. government securities, and U.S. Treasury securities. At December&#160;31, 2021, cash and cash equivalents include bank demand deposits and money market funds that invest primarily in U.S. government securities. Cash equivalents are stated at cost, which approximates fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash collateralizing a letter of credit in the amount of $560,000 issued to the landlord of the Company&#8217;s facility lease as of December 31, 2022 and 2021. The letter of credit and cash collateralizing it increased to $560,000 in August 2021 due to the operating lease extension discussed further in Note 6. The terms of the letter of credit extend beyond one year. The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:51.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,272&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,434&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests funds in U.S. government debt securities, U.S. government-sponsored enterprise debt securities and corporate debt securities with original maturities at the date of purchase greater than three months as marketable securities. The marketable securities are classified as available-for-sale and carried at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all securities with maturity dates beyond three months at the date of purchase as current assets. Changes in the fair value of marketable securities are recorded in other comprehensive income (loss) as net unrealized gains (losses) on marketable securities. The Company recognized net unrealized losses of $2.9 million, $0.5 million and $0.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other expense, net, which is limited to the difference between the fair value and the amortized cost of the marketable security. To date, the Company has not recorded any credit losses on its available-for-sale debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable related to the Company&#8217;s available-for-sale debt securities is presented within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODUwOQ_291e5ba1-214c-49bd-9743-84b648176853">prepaid expenses and other current assets</span> on the Company&#8217;s consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income on investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest income from investments in money market funds and available-for-sale debt securities, including amortization of premium or accretion of discount, on an accrual basis. For the years ended December 31, 2022, 2021 and 2020, the Company recognized $4.6 million, $0.3 million and $1.6 million in interest income, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net is included within other income, net on the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Expenditures for major renewals or betterments that extend the useful lives of property and equipment are capitalized; expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the related asset. Property and equipment are depreciated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:34.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the useful life or the remaining term of the lease</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its lease obligations in accordance with ASC 842, Leases, (&#8220;ASC 842&#8221;), which requires lessees to recognize a right-of-use (&#8220;ROU&#8221;) asset and lease liability for most lease arrangements. Effective January 1, 2021, the Company adopted ASC 842 using the modified retrospective transition method and utilizing the effective date as its date of initial application. As a result, the year ended December 31, 2020 is presented in accordance with the previous guidance in ASC 840, Leases, and there have been no reclassifications of prior comparable periods due to this adoption.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. The Company considers its renewal </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options and extensions within the arrangements and the Company includes these options when it is reasonably certain to extend the term of the lease.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. When a lease modification does not result in a separate contract, it is accounted for as a contract modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract modification requires the Company to reassess the classification of the lease to determine if it is an operating lease or a financing lease. The Company does not have any financing leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities may elect to not separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes an ROU asset and lease liability as of the transition date or contract modification date based on the present value of the future lease payments over the lease term. ASC 842 requires lessees to use the rate implicit in the lease unless it is not readily determinable and then it may use its incremental borrowing rate (&#8220;IBR&#8221;) to discount the future minimum lease payments. The Company's lease arrangement does not provide an implicit rate; therefore, the Company uses its IBR to discount the future minimum lease payments. The Company determines its IBR based on its credit rating, current economic information available as of the transition date or modification date, as well as the identified lease term. The Company&#8217;s ROU asset and related lease liability are not sensitive to changes in the Company&#8217;s IBR.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospectively, the Company will remeasure the lease liability at the present value using the same IBR that was in effect as of the transition date or contract modification date and adjust the ROU assets for straight-line rent expense.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on long-lived assets.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December&#160;31, 2022, investments include U.S. Treasury securities, U.S. government-sponsored enterprise securities, and corporate debt securities, including corporate bonds and commercial paper, which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the carrying amounts of the Company&#8217;s consolidated financial instruments, including prepaid expenses and other current assets, accounts receivable, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s Chief Executive Officer is its chief operating decision-maker and views operations and manages the Company&#8217;s business in one operating segment operating in the United States and the U.K.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date all revenue has been generated from the Company&#8217;s agreements with AbbVie, executed in October 2018 and terminated as of December 2022, and Janssen, executed in February 2019 and amended in December 2020. Please refer to Note 12 below for details of ASC 606 application to the Company&#8217;s agreements with AbbVie and Janssen.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808, Collaborative Arrangements, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not a customer relationship, in accordance with ASC 808. Through December 31, 2022, the Company had two agreements &#8211; with AbbVie and Janssen &#8211; that have been accounted for pursuant to ASC 606.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the contract(s) with the customer, (ii) identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii) measurement of the transaction price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations, (ii) each party&#8217;s rights regarding the goods or services to be transferred can be identified, (iii) the payment terms for the goods or services to be transferred can be identified, (iv) the arrangement has commercial substance and (v) collection of substantially all of the consideration to which the Company will be entitled in exchange for the goods or services that will be transferred to the customer is probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. Options to purchase additional goods or services are considered to be marketing offers and are to be accounted for as separate contracts when the customer elects such options, unless the Company determines the option provides a material right which would not be provided without entering into the contract. If, however, an option is determined to provide a material right that would not be provided without entering into a contract, a portion of the transaction price is allocated to such option.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also evaluates whether instances in which the timing of payments by customers do not match the timing of performance obligation satisfaction contain an element of financing and adjusts the transaction price for the effect of the financing component, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s transactions with customers may include development and regulatory milestone payments. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the customer&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net income (loss) in the period of adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price of the identified performance obligations. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#8217;s collaborations with AbbVie, until its termination, and Janssen, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred and consist of costs incurred in performing research and development activities, including compensation related expenses for research and development personnel, preclinical and clinical activities including cost of supply, overhead expenses including facilities expenses, materials and supplies, amounts paid to consultants and outside service providers, and depreciation of equipment. Upfront license payments related to acquired technologies which have not yet reached technological feasibility and have no alternative future use are also included in research and development expense.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Contract and Development Costs and Accruals</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research development service arrangements under which vendors perform various services on behalf of the Company. The Company records accrued expenses for estimated costs incurred under the arrangements. When evaluating the adequacy of the accrued expenses, the Company analyzes the progress of the studies, trials or other services performed, including invoices received and contracted costs. Judgments and estimates are made in determining the accrued expense balances at the end of each reporting period.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company issues stock options, restricted common stock, and restricted stock units to certain employees and non-employees, including directors. The Company accounts for restricted common stock and restricted stock unit expense based on the grant date fair value, which is generally the market price of the Company&#8217;s common stock on the date of grant, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company accounts for stock option compensation expense based on the grant date fair value of the respective award, determined using the Black-Scholes option-pricing model, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company classifies equity-based compensation expense in its </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">consolidated statements of operations and comprehensive loss in the same way the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 9 for additional information.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss and the change in accumulated other comprehensive loss for the period. For the years ended December 31, 2022, 2021 and 2020, comprehensive loss included $2.9 million, $0.5 million and $0.1 million, respectively, in unrealized holding losses, net on marketable securities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company recorded income taxes in accordance with FASB ASC Topic 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on temporary differences between the financial statement basis and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when it is more likely than not that some portion of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. At December 31, 2022 and 2021, the Company had not identified any significant uncertain tax positions.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements for potential recognition or disclosure in the consolidated financial statements. Subsequent events have been evaluated through the date these consolidated financial statements were issued for potential recognition or disclosure in the consolidated financial statements. </span></div>On February 13, 2023, the Company entered into a securities purchase agreement with existing investors pursuant to which the Company agreed to sell and issue, in a private placement, 848,655 shares of its common stock at a price of $35.35 per share and pre-funded warrants to purchase 1,980,198 shares of common stock at a purchase price of $35.3499 per pre-funded warrant, where each pre-funded warrant has an exercise price of $0.0001 (the &#8220;Pre-Funded Warrants&#8221;). The Company received aggregate net proceeds of approximately $100.0&#160;million before deducting costs and offering expenses payable by the Company. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. Per their terms, the outstanding Pre-Funded Warrants generally may not be exercised if the holder&#8217;s aggregate beneficial ownership would be more than 9.99% of the total issued and outstanding shares of the Company&#8217;s common stock following such exercise. The exercise price per share and number of shares of common stock issuable upon the exercise of the Pre-Funded Warrant shares are subject to adjustment in the event of any stock dividends and splits, recapitalization, reorganization or similar transaction, as described in the Pre-Funded Warrants.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029615344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text">Fair Value of Financial Assets and LiabilitiesThe tables below present information about the Company&#8217;s financial assets that are measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,942&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,843&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds and U.S. Treasury securities as of December&#160;31, 2022 and money market funds as of December&#160;31, 2021. The money market funds included in the tables above invest in U.S. government securities that are valued using quoted market prices. Accordingly, money market funds are categorized as Level 1 as of December&#160;31, 2022 and 2021. Marketable securities included in the tables above consist of U.S. Treasury securities, U.S. government- sponsored enterprise securities, commercial paper and corporate bonds, and these securities are categorized as Level 2 as of December&#160;31, 2022 and 2021. During the years ended December 31, 2022 and 2021, no assets were transferred between the fair value hierarchy categories. The Company had no liabilities measured at fair value on a recurring basis at December&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029579600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable securities</a></td>
<td class="text">Marketable securities<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s investments in marketable securities classified as available-for-sale (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:30.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,922)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,314)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:30.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive loss. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all available-for-sale securities as current assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that there was no material change in the credit risk of the above investments during the years ended December 31, 2022 and 2021. As such, an allowance for credit losses was not recognized. As of December 31, 2022, the Company does not intend to sell such securities and it is not more likely than not that the Company will be required to sell the securities before recovery of its amortized cost basis.</span></div>Accrued interest receivable on the Company&#8217;s available-for-sale debt securities totaled $1.4 million and $1.2 million as of December 31, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029631280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, property and equipment, net consists of the following (in thousands):</span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $1.0 million, $1.0 million and $1.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029517408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a lease arrangement for its corporate headquarters in Waltham, Massachusetts. In August 2021, the Company exercised its one-time extension right for its existing lease for 32,405 square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. Since the exercise of the one-time extension right for its existing lease did not qualify to be accounted for as a separate lease, the Company accounted for the exercise of the one-time extension right as a contract modification.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassessed the lease classification for the Company&#8217;s corporate headquarters as of the effective date of the modification using the modified terms and conditions and the facts and circumstances as of that date. This included using the remaining economic life of the underlying asset on that date, the discount rate for the lease on that date and a remeasurement and reallocation of the remaining consideration in the contract on that date. The Company concluded that the lease continues to be classified as an operating lease, reassessed the IBR as of the effective date of the modification, and remeasured the lease liability and ROU asset.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Supplemental balance sheet information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental operating lease balance sheet information is summarized as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_4277bab9-a4bc-4bb4-8619-266e108e3a33"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_450fd7b4-c958-4b0b-9afd-fcd530cac7f4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The short-term portion of operating lease liabilities is included within accrued expenses on the consolidated balance sheet.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other supplemental information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental operating lease information is summarized as follows (in thousands, except for years and discount rate):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturities of lease commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maturities of operating lease commitments as of December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the years ended December 31, 2022, 2021 and 2020 the Company recognized operating lease expense of $1.6&#160;million, $1.3&#160;million and $1.1&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029656368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021 accrued expenses consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241030522304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The common stock has the following characteristics:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Voting</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to one vote for each share of common stock held.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dividends</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of common stock are entitled to receive dividends, if and when declared by the Company&#8217;s board of directors. Cash dividends may not be declared or paid to holders of shares of common stock until all unpaid dividends on any preferred stock outstanding have been paid in accordance with their terms. As of December 31, 2022 and 2021, no preferred stock was outstanding. No dividends have been declared or paid by the Company to the holders of common stock since the issuance of the common stock.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Liquidation</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the common shares are entitled to receive distributions of cash, including in the event of a liquidation or dissolution of the Company, which preference is junior to the liquidation preference of any preferred stockholders. After any preferred stockholders have received their respective preferred distributions, any assets remaining for distribution shall be distributed to the holders of preferred or common shares determined on an as-converted basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029509104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Based Compensation</a></td>
<td class="text">Equity-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the Company&#8217;s initial public offering in July 2019, the Company adopted the 2019 Equity Incentive Plan (the &#8220;Original 2019 Plan&#8221;) in June 2019, which replaced the 2018 Stock Incentive Plan. The board of directors adopted the Amended and Restated 2019 Equity Incentive Plan (the &#8220;A&amp;R 2019 Plan&#8221; and, together with the Original 2019 Plan, the &#8220;2019 Plan&#8221;) on April 27, 2022, which was subsequently approved by the Company&#8217;s stockholders on June 8, 2022, to revise the total annual compensation that may be awarded to the Company&#8217;s non-employee directors thereunder. The A&amp;R 2019 Plan provides for the grant of stock options, restricted stock awards, stock bonus awards, cash awards, stock appreciation right, restricted stock units, and performance awards to directors, officers and employees of the Company, as well as consultants and advisors of the Company. As a result of the automatic increase provision of the 2019 Plan, the number of shares of common stock available for issuance under the A&amp;R 2019 Plan increased by 1.5&#160;million shares in January 2022. As of&#160;December&#160;31, 2022, there were a total of&#160;1.8 million shares available for future award grants under the 2019 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,828&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,894&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,418&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by expense category (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,518&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,866&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Common Stock</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted common stock activity during the year ended December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had no unrecognized equity-based compensation expense related to the restricted common stock. The total fair value of restricted common stock awards vested during the years ended December 31, 2022, 2021 and 2020 was approximately $0.1 million, $5.0 million, and $5.6 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the restricted stock units activity during the year ended December 31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.73&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had unrecognized equity-based compensation expense of $8.3 million related to the restricted stock units, which is expected to be recognized over a weighted average period of 3.1 years. The total fair value of restricted stock units vested during the years ended December 31, 2022 and 2021 was approximately $0.2 million and $2.1 million, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity during the year ended December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,781,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,553&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.94&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.19&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information related to the stock options granted, vested, and exercised during the years ended December 31, 2022, 2021 and 2020, in thousands, except for per option values:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted, per option</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.88&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.16&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.98&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash received from exercises of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic market value of stock options exercised</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average assumptions used in determining the fair value of the options granted during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk&#8209;free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.81%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.09%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.85%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term for employee and director stock options is the mid-point between the weighted average of vesting period and the contractual term. The Company determines the volatility for options granted based on the historical volatility of a representative group of publicly traded companies for which historical information is available in addition to the Company&#8217;s own historical volatility. The historical volatility is generally calculated based on a period of time commensurate with the expected term assumption. The risk-free interest rate is based on a zero-coupon U.S. Treasury instrument with terms consistent with the term of the stock options. The Company has not paid and does not anticipate paying cash dividends on shares of common stock; therefore, the expected dividend yield is assumed to be zero.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had unrecognized equity-based compensation expense of $50.0 million related to stock options issued to employees and non-employees, which is expected to be recognized over a weighted average period of 2.2 years.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective on June 26, 2019. The Company initially reserved 300,000 shares of common stock for sale under the ESPP. As a result of the automatic increase provision of the ESPP, the number of shares of common stock available for issuance under the ESPP increased by 0.4&#160;million shares on January 1, 2022. The ESPP is a qualified, compensatory plan under Section 423 of the Internal Revenue Code and offers substantially all employees opportunity to purchase up to $25,000 of common stock per year at 15% discount to the lower of the beginning of the offering period price or the end of the offering period price.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the course of the offering period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029695552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:6pt;margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income taxes for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,036)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,569)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,974)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,569)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax (benefit) expense for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax (benefit) provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#8217;s loss before income taxes as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effected at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities consist of the following at December 31, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,969</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,269</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and experimental expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,147</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,843</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,649</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,077</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,610</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,139</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,927</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,417)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,703)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(960)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(572)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As required by ASC 740, the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of collaboration revenue that has been recognized as taxable but remains deferred for book reporting as of year end and net operating loss carryfowards. The Company has determined that it is more likely than not that the Company will not realize the benefits of its federal and state deferred tax assets, and, as a result, a valuation allowance of $99.4 million and $82.7 million has been established at 2022 and 2021, respectively. The change in the valuation allowance was $16.7 million and $37.1 million for the years ended December 31, 2022 and 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in 2022, Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) amended Section 174 and now requires U.S.-based and non-U.S.-based research and experimental (&#8220;R&amp;E&#8221;) expenditures to be capitalized and amortized over a period of five or 15 years, respectively, for amounts paid in tax years starting after December 31, 2021. Prior to the TCJA amendment, Section 174 allowed taxpayers to immediately deduct R&amp;E expenditures in the year paid or incurred.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has applied this required change in accounting method beginning in 2022 and the computation may be adjusted pending future IRS guidance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred net operating losses (&#8220;NOLs&#8221;) from inception. At December 31, 2022, the Company has federal and state NOL carryforwards of approximately $180.3 million and $191.5 million, respectively, available to reduce future taxable income, that expire beginning in 2037, with $176.4 million of the federal NOLs having an unlimited carryover life. As of December 31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $12.6 million and $5.7 million, respectively,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to offset future income taxes, which will begin to expire beginning in December 2032. The Company&#8217;s NOL carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The company continues to review its historic ownership changes to determine if there are any IRC 382 limitations which may limit the annual utilization of the NOLs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes,&#8221; which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions. As of December 31, 2022 and 2021, the Company had no unrecognized tax benefits. The Company has not identified any uncertain positions with respect to the credit computations. The Company&#8217;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended December 31, 2022 and 2021, no estimated interest or penalties were recognized on uncertain tax positions. The Company does not expect any significant change in its uncertain tax positions in the next 12 months.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company files U.S. federal and state income tax returns and is generally subject to income tax examinations by these authorities for all tax years after December 31, 2018. Currently, no federal or state income tax returns are under examination by the respective income tax authorities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $0.1 million for the year ended December 31, 2022, income tax expense of $0.0 million for the year ended December 31, 2021 and a benefit from income taxes of $0.6 million for the year ended December 31, 2020. The benefit recorded in 2020 was attributed to a federal net operating loss carryback claim allowed under the CARES Act. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the collaboration revenue, the Company continues to maintain a valuation allowance against all deferred tax assets. The Company believes that it is more likely than not that the Company will not realize a future tax benefit of these attributes, as the Company&#8217;s research programs continue to require significant investment and future revenue is subject to uncertainties. Ultimate realization of any deferred tax asset is dependent on the Company&#8217;s ability to generate sufficient future taxable income in the appropriate tax jurisdiction before the expiration of carryforward periods, if any.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027464720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered, and intends to continue to enter, into separate indemnification agreements with directors, officers, and certain of key employees, in addition to the indemnification provided for in the restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, require the Company to indemnify directors, officers, and key employees for certain expenses, including attorneys&#8217; fees, judgments, penalties, fines, and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to the Company or any of its subsidiaries or any other company or enterprise to which these individuals provide services at the Company&#8217;s request. Subject to certain limitations, the indemnification agreements also require the Company to advance expenses incurred by directors, officers, and key employees for the defense of any action for which indemnification is required or permitted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has standard indemnification arrangements in its leases for laboratory and office space that require it to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under the Company&#8217;s lease.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2022, the Company had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any material legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029770880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementDisclosureAbstract', window );"><strong>Option and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Option and License Agreements</a></td>
<td class="text">Option and License Agreements<div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Agreement Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, the Company entered into a 5-year collaboration and option agreement with AbbVie Biotechnology Ltd (the &#8220;AbbVie Agreement&#8221;), a research-based global biopharmaceutical company that held Series A and Series B Convertible Preferred Shares of the Company at the time the AbbVie Agreement was executed (&#8220;AbbVie&#8221;). Pursuant to this agreement, AbbVie paid the Company an upfront, non-refundable amount of $100.0&#160;million. In exchange, the Company: (i) assumed the obligation to perform research and development activities to identify and develop compounds directed at multiple fibrosis indications (grouped into four research programs) through completion of Investigational New Drug (IND)-enabling studies, and (ii) granted AbbVie options to license the results of research and development in exchange for separate upfront option-exercise fees. In June 2022, AbbVie informed the Company that it had decided to exercise its right to terminate the AbbVie Agreement for convenience and the AbbVie Agreement terminated in December 2022. As a result, the Company does not expect to receive additional payments under the AbbVie Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the AbbVie Agreement termination, AbbVie held the right to exercise its license options for molecules with the selected pharmacological profiles by providing written notice to the Company and paying an option exercise fee of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.0&#160;million per option exercised (up to three in total). Effective upon the termination of the AbbVie Agreement, all rights and licenses granted thereunder immediately terminated and were returned to the Company.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Agreement Accounting Analysis</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the performance obligations in the agreement had included the research services for the four research programs. The Company has concluded that the unexercised license options were marketing offers as the options did not provide any discounts or other rights that would be considered a material right in the arrangement. All other performance obligations were determined to be immaterial in the context of the contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the standalone selling price of each research program based on internal and external costs to perform the research plus a reasonable profit margin of 10%. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services. The Company recognized revenue as research and development services were provided based on the costs incurred to date, as such costs have a direct relationship between the Company&#8217;s effort and the progress made towards satisfying its performance obligations to AbbVie. Changes to the estimated cost of internal and external development services were recognized in the period of change as a cumulative catch-up adjustment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the transaction price included only the non-refundable up-front payment of $100.0&#160;million and recorded this amount as deferred revenue as of December 31, 2018. The option exercise payments were not included in the transaction price, as the Company determined that the agreed upon fees represent fair value of such options. The milestone payments were fully constrained, as a result of the uncertainty regarding whether AbbVie would exercise any of the options and whether any of the associated milestones would be achieved. There were no changes to the transaction price prior to the AbbVie Agreement termination.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considered the existence of any significant financing component within the AbbVie Agreement given its upfront payment structure. Based upon this assessment, the Company concluded that the up-front payment was provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the AbbVie Agreement did not result in the existence of a significant financing component.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, AbbVie exercised its option to license and control further development and commercialization of Morphic&#8217;s &#945;v&#946;6&#8211;specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. In connection with the exercise of the option, AbbVie paid the Company $20.0&#160;million. Upon option exercise, the Company evaluated whether the change to the contract should be treated as the continuation of the current arrangement or as a separate agreement. As the additional performance obligations were deemed to be distinct and priced consistent with the standalone selling price of such obligations, the Company concluded that the license and any additional performance obligations should be accounted for as a separate contract. The potential performance obligations included in the arrangement were (1) the license to research, develop and commercialize &#945;v&#946;6&#8211;specific integrin inhibitors, and (2) options to purchase materials that were manufactured prior to option exercise (the &#8220;Material Options&#8221;). The Company concluded that the Material Options were not material rights as the price to purchase the materials approximated the standalone selling price. Based on this conclusion, the full transaction price of $20.0&#160;million was allocated to the license and recognized upon delivery in the third quarter of 2020. The Company does not expect to receive any additional payments for this program from AbbVie as the license terminated upon termination of the AbbVie Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon receipt of notification of the exercise of the right to terminate the AbbVie Agreement, the Company concluded that there was a contract modification to an existing contract under ASC 606 because the notification of termination of the AbbVie Agreement resulted in a reduction in scope of the Company&#8217;s responsibilities for the three remaining research programs thereunder. The terms of the AbbVie Agreement termination notification did not include any additional promised goods or services. As a result of the notification from AbbVie, the Company recognized revenue of $57.7&#160;million on a cumulative catch-up basis using an updated measure of progress towards satisfying the research and development services performance obligations thereunder. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company completed its performance obligations under the AbbVie Agreement. The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,500&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,197&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,056&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $60.5 million of deferred revenue, which was classified as either current or net of current portion in the accompanying consolidated balance sheets based on the period over which the revenue was expected to be recognized prior to the contract modification. This deferred revenue balance represented the aggregate amount of the transaction price allocated to the performance obligations that were partially unsatisfied as of December&#160;31, 2021. The Company has no further unsatisfied performance obligations for the AbbVie Agreement as of December&#160;31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Janssen Agreement Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company entered into a research collaboration and option agreement with Janssen Pharmaceuticals, Inc. (&#8220;Janssen Agreement&#8221;), a subsidiary of Johnson &amp; Johnson (&#8220;Janssen&#8221;), to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. The Janssen agreement focuses on three integrin targets, each target the subject of a research program, with a limited ability to substitute integrin targets for others, not explored by the Company, if research results are not favorable. Under the terms of the agreement, Janssen paid the Company an upfront fee of $10.0&#160;million for the first two research programs in 2019 and in December 2020 the Company reached an agreement with Janssen to commence work on the third research program and Janssen agreed to pay $5.0&#160;million for the third research program commencement fee. In addition, Janssen reimburses the Company for all internal and external costs and expenses incurred during the term of the agreement at agreed-upon contractual rates. The Company invoices Janssen on a quarterly basis and payments are due within 60 days. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, Janssen informed the Company that they had decided not to exercise its options on the first two integrin targets, thus also discontinuing those two research programs. The Company has focused efforts on the third integrin research program which includes the potential development of integrin antibody activators. In January 2023, Janssen informed the Company that it had decided to exercise its right to terminate the Janssen Agreement for convenience, subject to a 60 day notification period. The Janssen Agreement will terminate effective March 2023 or earlier if agreed to by the Company and Janssen. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Agreement Accounting Analysis</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that the performance obligations in the agreement include the research services for the three research programs and three options to license the outcomes of those research programs, which were determined to provide Janssen with material rights. All other performance obligations were determined to be immaterial in the context of the contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the standalone selling price of each research program based on internal and external costs to perform the research plus a reasonable profit margin. The total estimated cost of the research and development services reflect the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services. The Company estimated the standalone selling price of each material right by determining the discount provided to the estimated standalone selling price of comparable options and applying appropriate likelihood of exercise, which includes the appropriate probability of successfully completing the research efforts. Based on the standalone selling prices determined, the Company allocates the total transaction price among the programs and material rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue as research services are provided based on the costs incurred to date, as such costs have a direct relationship between the Company&#8217;s effort and the progress made towards satisfying its performance obligations to Janssen. Transaction price allocated to the material rights was deferred and will be recognized as revenue when Janssen exercises the options or the option period expires. Changes in estimates of total internal and external costs expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the transaction price included: the non-refundable up-front payment of $10.0&#160;million for the first two programs, $5.0&#160;million non-refundable up-front payment for the third program, and the estimated reimbursement payments at agreed upon contractual rates to be received from Janssen for the Company&#8217;s on-going research services. The option exercise payments were not included in the transaction price. Exercise of any of the options will be accounted for as a continuation of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the current contract if and when Janssen delivers the written exercise notice. The milestone payments were fully constrained, as a result of the uncertainty regarding whether Janssen would exercise any of the options and whether any of the associated milestones would be achieved.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considered the existence of any significant financing component within the Janssen Agreement given its upfront payment structure. Based upon this assessment, the Company concluded that the up-front payment was provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the Janssen Agreement does not result in the existence of a significant financing component.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contract Modification</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon notification of discontinuation of the two research programs and related options, the Company concluded that there was a contract modification to an existing contract under ASC 606 because the December 2021 notification resulted in a reduction in scope of the Company&#8217;s responsibilities under the Janssen Agreement. The December 2021 notification did not include any additional promised goods and services. Subsequent to the modification, there are two remaining performance obligations pursuant to the Janssen Agreement, research services for the remaining research program and a material right for Janssen&#8217;s remaining license option. The Company concluded that the remaining research services to be provided to satisfy the third research program were not distinct from its existing research services, and as a result treated the modification as part of the original contract (as opposed to a separate contract). Therefore, the Company updated the transaction price, which included the remaining deferred revenue and estimated variable consideration for research services and allocated the updated transaction price to the remaining performance obligations based on the estimated standalone selling prices at the date of the contract modification. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the research services, the effect that the contract modification had on the transaction price and the measure of progress towards satisfying the performance obligation of $1.9&#160;million has been recognized on a cumulative catch-up basis. The transaction price allocated to the remaining material right of $0.5&#160;million was deferred and will remain deferred until exercise or expiration. The accounting for any previously satisfied performance obligations as of the contract modification date are not affected by the modification. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes research and development costs incurred and revenue recognized in connection with the Company's performance under the Janssen Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,944&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,601&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue recognized</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,308&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,597&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,889&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Q4 2022, the Company recognized additional revenue of $3.0&#160;million on a cumulative catch-up basis as a result of changes to the estimated costs associated with the remaining effort required to complete the research services for the third research program. The amount of future expected cost estimates has decreased based on a change in expected effort and based on the timing of the research services.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had $0.5 million and $2.3 million, respectively, due from Janssen recorded in accounts receivable. As of December 31, 2022 and 2021, $0.5 million and $7.6 million, respectively, of deferred revenue was classified as either current or net of current portion in the accompanying consolidated balance sheets based on the period over which the revenue is expected to be recognized. At December 31, 2022 and 2021 the deferred revenue balance represents the portion of the upfront payments received allocated to the performance obligations that are partially or wholly unsatisfied as of December 31, 2022 and 2021. The Company expects to recognize revenue related to the remaining performance obligations through Q1 2023.</span></div>The Company's continuing obligation associated with the material right will terminate effective March 2023 or earlier if agreed to by the Company and Janssen.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029577600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per ShareBasic net loss per share is calculated by dividing net loss allocable to common stockholders by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents.<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net income per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents, including stock options and restricted common stock and stock units outstanding for the period as determined using the treasury stock method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are the same for periods with a net loss.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,041)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,999)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,112,498&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,797,969&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,594,897&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.55)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.67)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.47)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):</span></div><div style="margin-top:12pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,989&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,781,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,512,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,790,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,519,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the securities listed in the table above, as of December&#160;31, 2022 the Company had reserved 1,142,204 shares of common stock for sale under the ESPP, which, if issued, would be anti-dilutive if included in calculation of diluted net loss per share for the year ended December 31, 2022.</span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027498368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanIn 2016, the Company adopted a qualified retirement plan, the Morphic Therapeutic, Inc. 401(k) Plan to provide retirement income for eligible employees through employee contributions and employer matching contributions. Matching contributions totaled $0.6 million, $0.6 million and $0.5 million for the years ended December 31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241026266432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">The consolidated financial statements include the accounts of Morphic Holding, Inc. and its wholly-owned subsidiaries, Morphic Therapeutic, Inc., Morphic Therapeutic UK Ltd and Morphic Security Corporation. On March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, United Kingdom (the &#8220;U.K.&#8221;), to support Company functions outside of the United States. All intercompany balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text">These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed above, on March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, U.K., to support Company functions outside of the United States. The geographic location of all long-lived assets of the Company continues to be the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional reporting currency of Morphic Therapeutic UK Ltd is the United States Dollar. Foreign currency remeasurement is included in other income (expense) in the Company&#8217;s consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Concentration of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, and accounts receivable. The Company&#8217;s cash and cash equivalents are held at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and maintenance of liquidity. The Company&#8217;s investment policy allows funds to be held outside bank accounts, but to be invested only in readily marketable fixed income instruments with readily ascertainable market values, denominated and payable in United States Dollars including obligations of the U.S. government, U.S. government-sponsored enterprises, U.S. government agencies and highly rated corporate debt obligations, including commercial paper and corporate bonds, and money market funds registered according to Rule 2a-7 of the Investment Company Act of 1940. Investments in the money market fund shall be consistent with approved instruments and assets under management must be at least $1.0&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable generally represent amounts due from Janssen Pharmaceuticals, Inc. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign-hedging arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. At December&#160;31, 2022, cash and cash equivalents include bank demand deposits, money market funds that invest primarily in U.S. government securities, and U.S. Treasury securities. At December&#160;31, 2021, cash and cash equivalents include bank demand deposits and money market funds that invest primarily in U.S. government securities. Cash equivalents are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text">Marketable securitiesThe Company invests funds in U.S. government debt securities, U.S. government-sponsored enterprise debt securities and corporate debt securities with original maturities at the date of purchase greater than three months as marketable securities. The marketable securities are classified as available-for-sale and carried at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all securities with maturity dates beyond three months at the date of purchase as current assets. Changes in the fair value of marketable securities are recorded in other comprehensive income (loss) as net unrealized gains (losses) on marketable securities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock', window );">Interest income on investments</a></td>
<td class="text">Interest income on investmentsThe Company recognizes interest income from investments in money market funds and available-for-sale debt securities, including amortization of premium or accretion of discount, on an accrual basis.Interest income, net is included within other income, net on the consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Expenditures for major renewals or betterments that extend the useful lives of property and equipment are capitalized; expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the related asset. Property and equipment are depreciated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:34.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the useful life or the remaining term of the lease</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its lease obligations in accordance with ASC 842, Leases, (&#8220;ASC 842&#8221;), which requires lessees to recognize a right-of-use (&#8220;ROU&#8221;) asset and lease liability for most lease arrangements. Effective January 1, 2021, the Company adopted ASC 842 using the modified retrospective transition method and utilizing the effective date as its date of initial application. As a result, the year ended December 31, 2020 is presented in accordance with the previous guidance in ASC 840, Leases, and there have been no reclassifications of prior comparable periods due to this adoption.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. The Company considers its renewal </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options and extensions within the arrangements and the Company includes these options when it is reasonably certain to extend the term of the lease.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. When a lease modification does not result in a separate contract, it is accounted for as a contract modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract modification requires the Company to reassess the classification of the lease to determine if it is an operating lease or a financing lease. The Company does not have any financing leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities may elect to not separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes an ROU asset and lease liability as of the transition date or contract modification date based on the present value of the future lease payments over the lease term. ASC 842 requires lessees to use the rate implicit in the lease unless it is not readily determinable and then it may use its incremental borrowing rate (&#8220;IBR&#8221;) to discount the future minimum lease payments. The Company's lease arrangement does not provide an implicit rate; therefore, the Company uses its IBR to discount the future minimum lease payments. The Company determines its IBR based on its credit rating, current economic information available as of the transition date or modification date, as well as the identified lease term. The Company&#8217;s ROU asset and related lease liability are not sensitive to changes in the Company&#8217;s IBR.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospectively, the Company will remeasure the lease liability at the present value using the same IBR that was in effect as of the transition date or contract modification date and adjust the ROU assets for straight-line rent expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on long-lived assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December&#160;31, 2022, investments include U.S. Treasury securities, U.S. government-sponsored enterprise securities, and corporate debt securities, including corporate bonds and commercial paper, which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the carrying amounts of the Company&#8217;s consolidated financial instruments, including prepaid expenses and other current assets, accounts receivable, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s Chief Executive Officer is its chief operating decision-maker and views operations and manages the Company&#8217;s business in one operating segment operating in the United States and the U.K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date all revenue has been generated from the Company&#8217;s agreements with AbbVie, executed in October 2018 and terminated as of December 2022, and Janssen, executed in February 2019 and amended in December 2020. Please refer to Note 12 below for details of ASC 606 application to the Company&#8217;s agreements with AbbVie and Janssen.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808, Collaborative Arrangements, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not a customer relationship, in accordance with ASC 808. Through December 31, 2022, the Company had two agreements &#8211; with AbbVie and Janssen &#8211; that have been accounted for pursuant to ASC 606.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the contract(s) with the customer, (ii) identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii) measurement of the transaction price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations, (ii) each party&#8217;s rights regarding the goods or services to be transferred can be identified, (iii) the payment terms for the goods or services to be transferred can be identified, (iv) the arrangement has commercial substance and (v) collection of substantially all of the consideration to which the Company will be entitled in exchange for the goods or services that will be transferred to the customer is probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. Options to purchase additional goods or services are considered to be marketing offers and are to be accounted for as separate contracts when the customer elects such options, unless the Company determines the option provides a material right which would not be provided without entering into the contract. If, however, an option is determined to provide a material right that would not be provided without entering into a contract, a portion of the transaction price is allocated to such option.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also evaluates whether instances in which the timing of payments by customers do not match the timing of performance obligation satisfaction contain an element of financing and adjusts the transaction price for the effect of the financing component, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s transactions with customers may include development and regulatory milestone payments. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the customer&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net income (loss) in the period of adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price of the identified performance obligations. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#8217;s collaborations with AbbVie, until its termination, and Janssen, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.</span></div>The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred and consist of costs incurred in performing research and development activities, including compensation related expenses for research and development personnel, preclinical and clinical activities including cost of supply, overhead expenses including facilities expenses, materials and supplies, amounts paid to consultants and outside service providers, and depreciation of equipment. Upfront license payments related to acquired technologies which have not yet reached technological feasibility and have no alternative future use are also included in research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock', window );">Research Contract and Development Costs And Accruals</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Contract and Development Costs and Accruals</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research development service arrangements under which vendors perform various services on behalf of the Company. The Company records accrued expenses for estimated costs incurred under the arrangements. When evaluating the adequacy of the accrued expenses, the Company analyzes the progress of the studies, trials or other services performed, including invoices received and contracted costs. Judgments and estimates are made in determining the accrued expense balances at the end of each reporting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company issues stock options, restricted common stock, and restricted stock units to certain employees and non-employees, including directors. The Company accounts for restricted common stock and restricted stock unit expense based on the grant date fair value, which is generally the market price of the Company&#8217;s common stock on the date of grant, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company accounts for stock option compensation expense based on the grant date fair value of the respective award, determined using the Black-Scholes option-pricing model, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company classifies equity-based compensation expense in its </span></div>consolidated statements of operations and comprehensive loss in the same way the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified. The Company recognizes forfeitures as they occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive LossComprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss and the change in accumulated other comprehensive loss for the period.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company recorded income taxes in accordance with FASB ASC Topic 740, Income Taxes (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on temporary differences between the financial statement basis and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when it is more likely than not that some portion of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. At December 31, 2022 and 2021, the Company had not identified any significant uncertain tax positions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements for potential recognition or disclosure in the consolidated financial statements. Subsequent events have been evaluated through the date these consolidated financial statements were issued for potential recognition or disclosure in the consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Income On Investments Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Contract And Development Costs And Accruals Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241028046896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of reconciled cash, cash equivalents, and restricted cash</a></td>
<td class="text">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:51.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,272&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,434&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of reconciled cash, cash equivalents, and restricted cash</a></td>
<td class="text">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:51.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,272&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,434&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">Depreciation is calculated on a straight-line basis over the estimated useful lives of the related asset. Property and equipment are depreciated as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:34.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the useful life or the remaining term of the lease</span></td></tr></table><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, property and equipment, net consists of the following (in thousands):</span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029579600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of financial assets measured at fair value on recurring basis</a></td>
<td class="text">The tables below present information about the Company&#8217;s financial assets that are measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,942&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,843&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029641872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of investments in marketable securities classified as available for sale</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s investments in marketable securities classified as available-for-sale (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:30.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,922)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,314)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:30.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029536288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">Depreciation is calculated on a straight-line basis over the estimated useful lives of the related asset. Property and equipment are depreciated as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:34.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the useful life or the remaining term of the lease</span></td></tr></table><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, property and equipment, net consists of the following (in thousands):</span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029687488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock', window );">Summary of supplemental information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental operating lease balance sheet information is summarized as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_4277bab9-a4bc-4bb4-8619-266e108e3a33"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_450fd7b4-c958-4b0b-9afd-fcd530cac7f4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The short-term portion of operating lease liabilities is included within accrued expenses on the consolidated balance sheet.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other supplemental information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental operating lease information is summarized as follows (in thousands, except for years and discount rate):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of lease maturities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maturities of operating lease commitments as of December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Supplemental Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029517408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021 accrued expenses consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027665056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of equity based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,828&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,894&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,418&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by expense category (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,518&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,866&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of restricted common stock</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted common stock activity during the year ended December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of restricted stock units</a></td>
<td class="text">The following table summarizes the restricted stock units activity during the year ended December 31, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.73&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity during the year ended December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,781,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,553&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.94&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.19&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock', window );">Summary of information relating to stock</a></td>
<td class="text">The following table provides certain information related to the stock options granted, vested, and exercised during the years ended December 31, 2022, 2021 and 2020, in thousands, except for per option values:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted, per option</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.88&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.16&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.98&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash received from exercises of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic market value of stock options exercised</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of assumptions used in determining the fair value of the options granted</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average assumptions used in determining the fair value of the options granted during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk&#8209;free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.81%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.09%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.85%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Payment Award Summarized Information Relating To Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027434528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income taxes for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,036)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,569)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,974)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,569)</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax (benefit) expense for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax (benefit) provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#8217;s loss before income taxes as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effected at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities consist of the following at December 31, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,969</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,269</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and experimental expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,147</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,843</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,649</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,958</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,077</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,610</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,139</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,927</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,417)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,703)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(960)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(572)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241029793104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementDisclosureAbstract', window );"><strong>Option and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Summary of costs incurred and revenue recognized</a></td>
<td class="text">The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,500&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,197&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,056&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes research and development costs incurred and revenue recognized in connection with the Company's performance under the Janssen Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,944&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,601&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue recognized</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,308&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,597&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,889&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027552208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of basic net income (loss) per share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,041)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,542)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,999)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,112,498&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,797,969&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,594,897&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.55)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.67)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.47)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of common stock equivalent shares</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):</span></div><div style="margin-top:12pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,989&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,781,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,512,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,790,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,519,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027639584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtMarketOfferingProgramMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sales of common shares sold in IPO, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CommonStockAvailableForIssuance', window );">Amount of shares remaining available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtMarketOfferingProgramMember', window );">ATM | Open Market Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate offering price of placement shares</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_PercentageOfCommissionOnGrossSaleProceeds', window );">Commission (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_FollowOnPublicOfferingMember', window );">Secondary Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sales of common shares sold in IPO, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from secondary offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CommonStockAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock available for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CommonStockAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_PercentageOfCommissionOnGrossSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on gross sale proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_PercentageOfCommissionOnGrossSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_AtMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=morf_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=morf_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241026271600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 560<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of letter of credit (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59,272<span></span>
</td>
<td class="nump">171,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 59,832<span></span>
</td>
<td class="nump">$ 171,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,322<span></span>
</td>
<td class="nump">$ 101,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241024858368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 13, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList', window );">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prepaid expenses and other current assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segment | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborationAgreementNumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares) | shares</a></td>
<td class="nump">848,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction', window );">Right to purchase common stock (in shares) | shares</a></td>
<td class="nump">1,980,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction', window );">Right to purchase common stock, purchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.3499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate proceeds received</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Beneficial ownership</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsUnderManagementCarryingAmount', window );">Assets under management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Or Rights Issued In Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights Issued In Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborationAgreementNumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborationAgreementNumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsUnderManagementCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of assets an investment adviser manages on behalf of investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsUnderManagementCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241025322448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Property and Equipment Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=morf_ComputerEquipmentAndSoftwareMember', window );">Computers and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=morf_ComputerEquipmentAndSoftwareMember', window );">Computers and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=morf_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=morf_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241025010496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 288,976,000<span></span>
</td>
<td class="nump">$ 236,701,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">347,790,000<span></span>
</td>
<td class="nump">407,843,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">177,932,000<span></span>
</td>
<td class="nump">16,212,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">12,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">9,860,000<span></span>
</td>
<td class="nump">99,898,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">88,788,000<span></span>
</td>
<td class="nump">120,591,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">58,814,000<span></span>
</td>
<td class="nump">171,142,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">38,942,000<span></span>
</td>
<td class="nump">171,142,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1 | U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">38,942,000<span></span>
</td>
<td class="nump">171,142,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">308,848,000<span></span>
</td>
<td class="nump">236,701,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">177,932,000<span></span>
</td>
<td class="nump">16,212,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2 | U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">12,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">9,860,000<span></span>
</td>
<td class="nump">99,898,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">88,788,000<span></span>
</td>
<td class="nump">120,591,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">19,872,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3 | U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241024781504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 292,290<span></span>
</td>
<td class="nump">$ 237,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(3,314)<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Aggregate estimated fair value</a></td>
<td class="nump">288,976<span></span>
</td>
<td class="nump">236,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest receivable</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">179,854<span></span>
</td>
<td class="nump">16,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(1,922)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Aggregate estimated fair value</a></td>
<td class="nump">177,932<span></span>
</td>
<td class="nump">16,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember', window );">U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Aggregate estimated fair value</a></td>
<td class="nump">12,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">9,860<span></span>
</td>
<td class="nump">99,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Aggregate estimated fair value</a></td>
<td class="nump">9,860<span></span>
</td>
<td class="nump">99,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">90,076<span></span>
</td>
<td class="nump">121,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(1,288)<span></span>
</td>
<td class="num">(443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Aggregate estimated fair value</a></td>
<td class="nump">$ 88,788<span></span>
</td>
<td class="nump">$ 120,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL121698322-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267856-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241028888752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 7,301<span></span>
</td>
<td class="nump">$ 6,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(5,182)<span></span>
</td>
<td class="num">(4,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">6,094<span></span>
</td>
<td class="nump">5,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=morf_ComputerEquipmentAndSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 611<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=morf_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=morf_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241024928752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Accrued expenses | $</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=morf_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land (square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=morf_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=morf_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241024793936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of supplemental information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,514<span></span>
</td>
<td class="nump">$ 4,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses<span></span>
</td>
<td class="text">Accrued expenses<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 2,344<span></span>
</td>
<td class="nump">$ 3,838<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 1,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241028051088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of lease commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">4,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 3,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241030184512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 6,569<span></span>
</td>
<td class="nump">$ 6,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_AccruedResearchAndDevelopment', window );">Research and development activities</a></td>
<td class="nump">4,265<span></span>
</td>
<td class="nump">4,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1,494<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 13,181<span></span>
</td>
<td class="nump">$ 12,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241028927728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_VotingRights', window );">Voting rights per share number | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends paid (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_VotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voting Rights Per Share Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_VotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241025351456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity-Based Compensation - 2019 equity incentive plan (Details) - 2019 Equity Incentive Plan - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241023860640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Equity based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">$ 29,048<span></span>
</td>
<td class="nump">$ 21,184<span></span>
</td>
<td class="nump">$ 11,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">13,518<span></span>
</td>
<td class="nump">9,866<span></span>
</td>
<td class="nump">6,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">15,530<span></span>
</td>
<td class="nump">11,318<span></span>
</td>
<td class="nump">4,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">25,828<span></span>
</td>
<td class="nump">19,894<span></span>
</td>
<td class="nump">9,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">2,764<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027654848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Restricted common stock activity (Details) - Restricted common stock - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Fair Value per Share at Issuance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized equity based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of&#160;Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning (in shares)</a></td>
<td class="nump">2,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(2,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Fair Value per Share at Issuance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning (in dollars per share)</a></td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">4.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241024871408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Restricted stock units activity (Details) - Restricted stock units - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Fair Value per Share at Issuance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized equity based compensation expense</a></td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity based compensation expense expected period for recognition</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of&#160;Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning (in shares)</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">291,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(42,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end (in shares)</a></td>
<td class="nump">249,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Fair Value per Share at Issuance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning (in dollars per share)</a></td>
<td class="nump">$ 57.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">43.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">57.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">44.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end (in dollars per share)</a></td>
<td class="nump">$ 43.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241028966496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Stock option awards (Details) - Stock options<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning (in shares) | shares</a></td>
<td class="nump">4,781,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,498,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(459,839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares) | shares</a></td>
<td class="num">(557,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end (in shares) | shares</a></td>
<td class="nump">5,263,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at the end (in shares) | shares</a></td>
<td class="nump">2,990,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">39.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">11.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">33.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end (in dollars per share) | $ / shares</a></td>
<td class="nump">24.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at the end (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Expected term (in years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at the end (in years)</a></td>
<td class="text">6 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end | $</a></td>
<td class="nump">$ 38,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable at the end | $</a></td>
<td class="nump">32,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized equity based compensation expense | $</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity based compensation expense expected period for recognition</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241028055040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Information related to options granted, vested and exercised (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted, per option (in dollars per share)</a></td>
<td class="nump">$ 28.88<span></span>
</td>
<td class="nump">$ 26.16<span></span>
</td>
<td class="nump">$ 10.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Total cash received from exercises of stock options</a></td>
<td class="nump">$ 5,175<span></span>
</td>
<td class="nump">$ 9,536<span></span>
</td>
<td class="nump">$ 3,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic market value of stock options exercised</a></td>
<td class="nump">$ 8,507<span></span>
</td>
<td class="nump">$ 39,335<span></span>
</td>
<td class="nump">$ 7,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk&#8209;free interest rate</a></td>
<td class="nump">2.02%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.81%<span></span>
</td>
<td class="nump">87.09%<span></span>
</td>
<td class="nump">80.85%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241023807872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation- Employee Stock Purchase Plan (Details) - ESPP - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock', window );">Discount rate to purchase common stock</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=morf_EmployeeStockPurchasePlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee', window );">Amount of common shares available for purchase per employee per year</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual value of shares available for purchase per employee from employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of discount provided to employees to purchase common stock under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=morf_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=morf_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241028783296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of loss before income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (59,036)<span></span>
</td>
<td class="num">$ (95,542)<span></span>
</td>
<td class="num">$ (45,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">loss before income taxes</a></td>
<td class="num">$ (58,974)<span></span>
</td>
<td class="num">$ (95,542)<span></span>
</td>
<td class="num">$ (45,569)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241024804160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of income tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax (benefit) provision</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax (benefit) provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (benefit) provision</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (570)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241023811152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective income tax rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax effected at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">7.84%<span></span>
</td>
<td class="nump">9.31%<span></span>
</td>
<td class="nump">8.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Equity-based compensation</a></td>
<td class="num">(1.02%)<span></span>
</td>
<td class="nump">5.33%<span></span>
</td>
<td class="nump">0.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(3.87%)<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits</a></td>
<td class="nump">6.83%<span></span>
</td>
<td class="nump">3.34%<span></span>
</td>
<td class="nump">6.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(30.89%)<span></span>
</td>
<td class="num">(38.97%)<span></span>
</td>
<td class="num">(35.09%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.11%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027542560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 49,969<span></span>
</td>
<td class="nump">$ 44,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and experimental expenditures</a></td>
<td class="nump">22,147<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">17,101<span></span>
</td>
<td class="nump">10,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Equity-based compensation</a></td>
<td class="nump">5,649<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_DeferredTaxAssetsFixedAndIntangibleAssets', window );">Fixed and intangible assets</a></td>
<td class="nump">3,332<span></span>
</td>
<td class="nump">3,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Reserves and accruals</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_DeferredTaxAssetLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">18,610<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">101,139<span></span>
</td>
<td class="nump">84,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(99,417)<span></span>
</td>
<td class="num">(82,703)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Subtotal</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="nump">2,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(960)<span></span>
</td>
<td class="num">(1,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(472)<span></span>
</td>
<td class="num">(572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expense</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_DeferredTaxAssetLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_DeferredTaxAssetLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_DeferredTaxAssetsFixedAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Fixed And Intangible assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_DeferredTaxAssetsFixedAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241027612272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 99,417,000<span></span>
</td>
<td class="nump">$ 82,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax examination, penalties and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (570,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">99,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">180,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">176,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">191,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject to Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241023442448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option and License Agreements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>target </div>
<div>program</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>program </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>program </div>
<div>option</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>program </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,808<span></span>
</td>
<td class="nump">$ 19,794<span></span>
</td>
<td class="nump">$ 44,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_AbbVieMember', window );">AbbVie | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementTermOfArrangement', window );">Term of arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementUpfrontFeesReceived', window );">Upfront fees received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementNumberOfResearchPrograms', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementOptionExerciseFeesReceivable', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementNumberOfOptions', window );">Number of options available for exercise | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementProfitMarginPercentage', window );">Profit margin percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_UpFrontPaymentIncludedInTransactionPrice', window );">Up-front payment included in transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementOptionExerciseFeesPaid', window );">Option exercise fees received</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborationAgreementOptionExerciseRevenueReceived', window );">Revenue recognized from option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,500<span></span>
</td>
<td class="nump">$ 11,197<span></span>
</td>
<td class="nump">36,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementNotificationPeriod', window );">Notification Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,308<span></span>
</td>
<td class="nump">8,597<span></span>
</td>
<td class="nump">8,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | Upfront payment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementNumberOfResearchPrograms', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementNumberOfIntegrinTargets', window );">Number of integrin targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram', window );">Upfront fee for first two research program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram', window );">Upfront fee for third research program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementPaymentDuePeriod', window );">Payment due period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued', window );">Number of discontinued research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementNumberOfOptionsToLicense', window );">Number of options, license | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,149<span></span>
</td>
<td class="nump">$ 3,653<span></span>
</td>
<td class="nump">$ 2,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Performance obligation recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | Upfront Payment Revenue, First Two Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_morf_CollaborativeArrangementNumberOfResearchPrograms', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | Upfront Payment Revenue, Third Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborationAgreementOptionExerciseRevenueReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized from option exercise during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborationAgreementOptionExerciseRevenueReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Fee Received, Upon Commencement Of Third Research Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementNotificationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Notification Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementNotificationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementNumberOfIntegrinTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Integrin Targets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementNumberOfIntegrinTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementNumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementNumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementNumberOfOptionsToLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Options To License</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementNumberOfOptionsToLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementNumberOfResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Research Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementNumberOfResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Research Programs Discontinued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementOptionExerciseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Option Exercise Fees Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementOptionExerciseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementOptionExerciseFeesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Option Exercise Fees, Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementOptionExerciseFeesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementPaymentDuePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payment Due Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementPaymentDuePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementProfitMarginPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Profit Margin Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementProfitMarginPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementTermOfArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term Of Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementTermOfArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementUpfrontFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment fee received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementUpfrontFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Fees Received For First Two Research Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_UpFrontPaymentIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up Front Payment, Included In Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_UpFrontPaymentIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=morf_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=morf_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueFirstTwoProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueFirstTwoProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueThirdProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueThirdProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241023387616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option and License Agreements - Costs incurred and revenue recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 70,808<span></span>
</td>
<td class="nump">$ 19,794<span></span>
</td>
<td class="nump">$ 44,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs incurred</a></td>
<td class="nump">134,204<span></span>
</td>
<td class="nump">115,600<span></span>
</td>
<td class="nump">92,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_AbbVieMember', window );">AbbVie | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">60,500<span></span>
</td>
<td class="nump">11,197<span></span>
</td>
<td class="nump">36,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs incurred</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">5,376<span></span>
</td>
<td class="nump">13,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | Upfront payment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">7,149<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | Reimbursement revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
<td class="nump">6,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">10,308<span></span>
</td>
<td class="nump">8,597<span></span>
</td>
<td class="nump">8,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs incurred</a></td>
<td class="nump">$ 2,637<span></span>
</td>
<td class="nump">$ 4,426<span></span>
</td>
<td class="nump">$ 5,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=morf_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=morf_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=morf_ReimbursementRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=morf_ReimbursementRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241024731840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Basic net income (loss) per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,041)<span></span>
</td>
<td class="num">$ (95,542)<span></span>
</td>
<td class="num">$ (44,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">38,112,498<span></span>
</td>
<td class="nump">35,797,969<span></span>
</td>
<td class="nump">30,594,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">38,112,498<span></span>
</td>
<td class="nump">35,797,969<span></span>
</td>
<td class="nump">30,594,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
<td class="num">$ (1.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
<td class="num">$ (1.47)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241024888992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share- Common stock equivalent shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities (in shares)</a></td>
<td class="nump">5,512,643<span></span>
</td>
<td class="nump">4,790,736<span></span>
</td>
<td class="nump">4,519,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
<td class="nump">100,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities (in shares)</a></td>
<td class="nump">249,090<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">66,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities (in shares)</a></td>
<td class="nump">5,263,553<span></span>
</td>
<td class="nump">4,781,565<span></span>
</td>
<td class="nump">4,352,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=morf_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities (in shares)</a></td>
<td class="nump">1,142,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=morf_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=morf_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140241026330496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution total amount</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>morf-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:morf="http://morphictx.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="morf-20221231.xsd" xlink:type="simple"/>
    <context id="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i44dcf71d914947aeab1d6ca95df53425_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4baab3edb5cc4574a112258bbd3606bb_I20230221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e38059c1a8b4351a12208b4b17e67fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4bfdc1a144904aff961163efe0b71fed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6348a4fce16d4a8495c328951bd63827_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c14a9ad52b943b0a9f70a1adc012b62_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a0ec20e47be47eab177727935b230b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifa8445c41fd5491292904732bb0c4761_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76a6b759ffbb449e81cc565598a24220_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ceda5f5a33e4c9581ee108c783e1d6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03f523ed243944c1952b9f439ae6591a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70ca9447c43d4a3cb80fb8f78c3c39ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c5918a2e0b4490086688e38b5dbd9e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i875354d9000b443caa58d5fb686317b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8e9ea2357bcd4e0b80ea5f90c117c183_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9a2e7740aed41f39474ac66cdd34da5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc7a5cede0a3473c877c0673a0bcfa2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70cbfaa401bb4c92b9a9c2661d1df2b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5e9ea7d97544c62a5f4d876238911a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a2d410f10fd43e0a3d21d4b9a945a0a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5ee1b9fb78c472393ca0dd130c5b288_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib242abf1d8974e31acd46eb1e550e867_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04199a8b57a94afdb3894dd8f3611ef9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c83e86e5ecf4e049f03b221fd37ddc2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3021ee10eeff4228808670e25669c506_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib89e4e41db194455b68dae07e4088634_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i229d09b827bb41a89b5f692014a5d842_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib148686698e04b2b916642950ccd1817_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c7558e92e8d4ff7ac77d9a2a034d000_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i251a1f6f65c94d6ea46a8bf3f0bc6caf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i134fbbf1dfed4fa4814373cfe2ffcdb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica43711c0df64da7a4e706d076e6bdbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c50679b571740e19279ef7944cb3f16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71e5bf0a1e4948d0971fff4b2f4bdb14_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9ac40f3b64c04bb6b11779403daca223_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i73c2e36cd1474c26b0d1a8bf3509e772_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f1c028c600f492ea22a0fc290237655_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i64f737a67eb34edebd4b964b94d03e20_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6217b53477e450c9212104a64166f49_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1d715f0e90f4892a783060db407d98d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbc0fc6fd3cc4a6085dbb3864bce300a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadaa15dc21b14e3db8588f66b4714a49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb7bba96f6fe49c1909da2aba38db320_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic313ab40bcfb4f66816203628eb7f0eb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6416f8f824ff4d4d8207b91e5c244618_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e2edc7e86b640748d022ccc69c79483_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i5c75f7519ee24eed9649f1ec0217b28e_D20210811-20210811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-11</startDate>
            <endDate>2021-08-11</endDate>
        </period>
    </context>
    <context id="if2d9d037833b403cbf8e599aeddd0edf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id5715e43038646d4a427f7c14f57c05d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8aa7e1aba8a4110a761f965a1b311a5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i37b2d1f438d44a009cda649034cdd00a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c29f3379b1841039eb81933bd0e600a_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i6e771d535ddd42f284b6e48b0a3ff9f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d3ccdb187fa404d929dd2ec91a44bcd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">morf:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a4ae752e5f34d0d89ac694b9812ea06_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">morf:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib9cb810990e746309b39962a67440438_D20230213-20230213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-13</startDate>
            <endDate>2023-02-13</endDate>
        </period>
    </context>
    <context id="ic242dad1f07949378faf34c59d7f5f88_I20230213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-13</instant>
        </period>
    </context>
    <context id="i604092d4d0e140bb95115f6f5f1a846d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d512dd5bdfe419cb8800b44352cd997_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2254b383dd1434c8eb41be8f1291d19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i702273bf69ee47298902b18d256ef436_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fcc2263734a44549091a97cc1630de9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8d95317815642b1abbb1b41f9d0fcbe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i51d81cccb60449a6a2bf1592ec8cf208_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i06caa44988a1401d9cadf3a6919cc075_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84093c3db3c34ee9975edca937505f59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28d8a3c8f6ba4c55be3e856fa074e12c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i451016625f664d87b0f1149b4b460ca4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18e50ae5e2db43a2ba46810dc63df33e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if75f48a62b5e4f50be21277ae7a6a555_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f6464b00ff1424290015908d925bcff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0afb206a6a142988b4b7c1c5c112488_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63cd7797863b4c878b6bd0037f63a034_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2cef8c55113245b18d699b291da71849_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75b5f1a419654cec9538eeec4eb6d001_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i11d5f8b0c8cf4bf1904278026e089ab9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i291a0cdf99ae4372848ba10ce4515329_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc86524fc8604efaabb07582c77cd814_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i162590f81a47412f95d12b41a46788fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i420d5fbd11644553ac2f20de753fb3be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie895696982894ca393ad2b4731ed0312_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d32d3ada9f945c991fb1e2c468a3056_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibee7cc6c73784af3a95d08dabf38f780_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f63d08cf43c445aab401c01568c17c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06e9b237f63147898db008b76d81cc93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65bd95f6cce84501bc85ceb141f2ad69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b24e4bd1eca47dd863579e21bc04e0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8f9f8031a004ca58585fa9bc615ac4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie618c17501df442fb50f6f5a9d0af3e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i461c0f15b1c64560b66aee8c7c5e1946_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i396cbab97ede453fa4531ea88932d4ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97846bbf5a2a45279b8fabd054295701_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2d05e295ffa4672bb1aa0fa78c22da2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fb707bd819f4336b205ce25f8057e47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i608c2d9be0664c69a0ac30c84a5bca4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05301005239d4ade9956b8262164a5aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d650c04838d45e090cfc3ae81926a54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55b4f455938e42d8a96daae58b3fa4c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ac46ba0e0664b0e977e59505ee5d97c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f3d728458a5471e9ed4c1a92d4f66c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf582a62191e406a9ec5e7e9b0698e8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f2e7300f7184ac58092340abcc0b069_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">morf:USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5a3f4082fa1417b962818adcf991f1c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b30679359684bb791882ad58c6a044e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2813f455dff462a99153011829d659e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97f1c205a6d14e4ba2e8721db48b2841_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb71b13217964931b29e2541f7607577_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8a7102b9d5346c292e630c2c88780d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i196fe36e4f60419799bbe38a05fd598e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">morf:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i765d898d413c42ecadfd22771b559151_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">morf:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e316a0be4b34afa97bceaaf82979c6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i773e6d896fab4cba847b5f4fa4a9f8b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic70e9fc24c404da2964ca9969e1b1582_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">morf:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i0839d27335e24a70944c9e307b2f4ffd_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i836995cd69774ea6a3b54d9201496a27_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ed3baf9425c4deb80dc4f747f071420_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i77e987ed93cc4e8d9dfb645f146cde1f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i174e9b0c5f7c46c78a563fe182cdb790_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd74a7f3cc934ea7bcea941a7ceb4135_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14cc5a3c0a534d1798020230d15314ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45c1bfca603942ca815065d9e1dc6770_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib31c5cf61778485d991ddab611e9d542_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37a599d132d6483baa46f6bf673c0e6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88474183cda941d09a44d4d825426649_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c8315abe4964879986d1a88cf096b3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76ce846988a44545a5367eba9a038043_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i318589b3af594468b4d7a4f435e6ebbe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib69dad785ae2431ebdb2f50942f10325_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48f714ec6be446a99691b35600899a4c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9687b7a51c845ac993e26a0f4880580_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ief146b6ab46a43909d51d8b1c46787e1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34fe4eecb36748f5af8018f88fcb0c6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2140ecc30f7b44bab979e57fe3c6d43f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d4cafd342524466bff01db8b6fb6b1f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i101397ce8aac488895ed850a9c62f94a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i902baae07eda49b091ea19d753ae4bae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d6a05d3b283469d804ddf8e891690b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e4a0451e3944bb8b1e7d8a518951a90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic584c82f7fa941aaa1d9a7ca334e75f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44c3053062ab47179828227426197a95_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa9f54446643489fac9a8dbe66be6f9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8748f4e6ee9480c88e24d869168b315_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26b5fdb614974175853f2513fb83dcec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f297cc869c04c60a6c213e1fb23bdf5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7ad5b858858b4142b730f313c6ba0354_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ff85e46b56d4930968dac9e3affabd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9a49673c39d457ca1650953807a3049_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia4c949b67a814dcbae7f09a0249d0ed7_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="id499edf539a74aff9a76526f02dd5aa9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e430e2b2d7d4b9bb5788a847d6c2d7e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i98ff867a6d934dccaf584133870acc01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i673a9cb8566f43ce9616ebf94921885b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd87bb47b7414650a95a2d45e1fd7c80_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia34a0708e91b4ea5b31cedcf12f3227d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia1c53362d437417b8664cb0139c5b714_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2dfc56e30ef4261a5bd22e73cfeb905_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i2ba08c24b4f646afab272849bef04fb2_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i3e82d416fe9845cd845831adb23f5e51_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d620038457943e389fea375d17a3511_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i605039ce4c3546db8544ca5afe90071c_D20200825-20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-25</startDate>
            <endDate>2020-08-25</endDate>
        </period>
    </context>
    <context id="iebbb4e4977534118b7062dc97e877188_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d9a0e35c7f042cf912b4e21edd47242_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76974348b5dd49dd867e3970e5e16d4c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08cc4df0448c42e6b1396ea92fa4ae8c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9645879e89545f6ae321d39d2ff49ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="ia278688cc742407d889eeaac1398e425_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i0af313c7bd8a4b4388148bb57bf130a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i995f63fe81fb4b9abb9716382e1dc8f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i10cf228deb344a0bbe41e4dd68f6091d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c05f87e169c45feb95ae818058af3ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueFirstTwoProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie9e8a3b2b5f94dc1967ae1463aa4c8ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueFirstTwoProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5d1093edead46de860e94adc1452272_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueThirdProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2b07511e4f7642a9bfe31d2963ab5b4d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia95f81bdfee4430b81915be0cd95860b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id6eb38babcc241e89553761903a11d61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5084eff2ed1d4f48a7da4984d71799cf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i035b3de5190f487586bd1ed38307c379_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7af92416deea43878ba0ead3d0ecb13f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3511c82559894a9f98fb91e24620713a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5743f7e935fc434da814d8855536f21b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f5251e4aa084f7983207e980fdcdba4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia02854bc64fd499c8dbac9ce00351643_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iccd44d1dfb9c487f883da622bc30602d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0a6c624908e845829a9ec116c04519ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ce5d6357e054eb89f9f7070956ddd0f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i53395b8e2227477fb7c23b0353062b98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a1b74d6b2bb4a4f98e936d596b79284_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i436cc872d64b4d7b9aaa708f0706aa2a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia296bbbf833f49b2a6ab65ef01ab6bd8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iadfe8416bc324e919e5e25cbad2d3372_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i289b44ada87a4da1befaa2bbadc04a61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01c3a69a38b5461d93693d703c6eda55_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i22a2adf60f5a46a4a34b1aa1bf2511b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia515039667cc4b22b0294f91e2b2a44a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>morf:segment</measure>
    </unit>
    <unit id="agreement">
        <measure>morf:agreement</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="vote">
        <measure>morf:vote</measure>
    </unit>
    <unit id="program">
        <measure>morf:program</measure>
    </unit>
    <unit id="option">
        <measure>morf:option</measure>
    </unit>
    <unit id="target">
        <measure>morf:target</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM180L2ZyYWc6OWEwMTkyZmQ4MjM0NDgyYThkNWJjZDVlMzFlNmFjZTYvdGFibGU6ZDNlMjQ3OTAxNzkyNDQzYzhjY2QzYzIxODE4ZDVmNjcvdGFibGVyYW5nZTpkM2UyNDc5MDE3OTI0NDNjOGNjZDNjMjE4MThkNWY2N18yLTEtMS0xLTY3NDc0_ce6a431c-60d3-45dd-87c9-b227c4a97b88">0001679363</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM180L2ZyYWc6OWEwMTkyZmQ4MjM0NDgyYThkNWJjZDVlMzFlNmFjZTYvdGFibGU6ZDNlMjQ3OTAxNzkyNDQzYzhjY2QzYzIxODE4ZDVmNjcvdGFibGVyYW5nZTpkM2UyNDc5MDE3OTI0NDNjOGNjZDNjMjE4MThkNWY2N180LTEtMS0xLTY3NDc0_832ce996-a6ed-47c2-8740-9c639f0e13c1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM180L2ZyYWc6OWEwMTkyZmQ4MjM0NDgyYThkNWJjZDVlMzFlNmFjZTYvdGFibGU6ZDNlMjQ3OTAxNzkyNDQzYzhjY2QzYzIxODE4ZDVmNjcvdGFibGVyYW5nZTpkM2UyNDc5MDE3OTI0NDNjOGNjZDNjMjE4MThkNWY2N181LTEtMS0xLTY3NDc0_85efe7b8-ca40-45ba-847d-3b9e1210dcf8">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM180L2ZyYWc6OWEwMTkyZmQ4MjM0NDgyYThkNWJjZDVlMzFlNmFjZTYvdGFibGU6ZDNlMjQ3OTAxNzkyNDQzYzhjY2QzYzIxODE4ZDVmNjcvdGFibGVyYW5nZTpkM2UyNDc5MDE3OTI0NDNjOGNjZDNjMjE4MThkNWY2N182LTEtMS0xLTY3NDc0_e6d14b42-d0bc-4bb0-b57b-c7ee723cc710">false</dei:AmendmentFlag>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODUwOQ_291e5ba1-214c-49bd-9743-84b648176853">http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_4277bab9-a4bc-4bb4-8619-266e108e3a33">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_450fd7b4-c958-4b0b-9afd-fcd530cac7f4">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjMw_8695308b-2501-4e81-a604-f0db07691787">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6MWUxNTQ4Zjg1OWJiNDc2NmEwN2VmNjZmOTdiNWFjODQvdGFibGVyYW5nZToxZTE1NDhmODU5YmI0NzY2YTA3ZWY2NmY5N2I1YWM4NF8xLTAtMS0xLTY3NDc0_fb717dd0-4d50-432e-9bb2-cf5d49cfddd9">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zODQ4MjkwNzAwNDg4_773d21fe-8963-4109-9192-4001aabb3683">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zODQ4MjkwNzAwNDg4_c272fba2-a22b-4989-ab89-4f97750ea16c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6Yjk4NzYxMDA3ZGYwNGIwM2JlNzA4MmRmMTdiNjcyNDIvdGFibGVyYW5nZTpiOTg3NjEwMDdkZjA0YjAzYmU3MDgyZGYxN2I2NzI0Ml8wLTAtMS0xLTY3NDc0_ca40bd2c-cec1-4f16-b511-1eb1ec7583d7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM1_fc33e89f-f502-429f-bed6-9cc56361b459">001-38940</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjMy_1f97b690-1b3f-4ac3-ba2e-0825693c93e9">MORPHIC HOLDING,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8wLTAtMS0xLTY3NDc0L3RleHRyZWdpb246MjBmMTdiNTQ5NjZiNDI2ZjhlNTM2NjgzOWE2OGQ2YjFfNQ_54dd6e1a-5b1e-4fcb-9663-1c47bda5884f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8wLTEtMS0xLTY3NDc0L3RleHRyZWdpb246YmQwYWUzZTM0NmUyNDc5Nzg5ODdmNjk4Mzk2ZTE1NjdfNQ_5b863ced-4650-4d84-bf8e-842f22ad8f19">47-3878772</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTAtMS0xLTY3NDc0L3RleHRyZWdpb246ZTc4OWE0MzE0ZjYyNGNlNjkzYTNlZDdlYjM3OWE4ZDVfNw_47eb8979-f1a7-4e8c-9976-5b2ff1875ead">35 Gatehouse Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTAtMS0xLTY3NDc0L3RleHRyZWdpb246ZTc4OWE0MzE0ZjYyNGNlNjkzYTNlZDdlYjM3OWE4ZDVfMTE_271e64f9-7789-4711-bd08-187a81d59670">A2</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTAtMS0xLTY3NDc0L3RleHRyZWdpb246ZTc4OWE0MzE0ZjYyNGNlNjkzYTNlZDdlYjM3OWE4ZDVfMTQ_0872bd01-1590-4825-a117-07c0731e2d4a">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTAtMS0xLTY3NDc0L3RleHRyZWdpb246ZTc4OWE0MzE0ZjYyNGNlNjkzYTNlZDdlYjM3OWE4ZDVfMTg_5ea312b0-5c0e-4aac-8ea4-12aef09c9a08">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6OGUwOTQ0MWIxNTU1NDMxYjgwNjNlOGRiMjhlODBiN2IvdGFibGVyYW5nZTo4ZTA5NDQxYjE1NTU0MzFiODA2M2U4ZGIyOGU4MGI3Yl8xLTEtMS0xLTY3NDc0L3RleHRyZWdpb246OTQ4ZTNmMWY3MTFhNDJjMWJmNzhlNjJiOWZkYTQwNWNfNw_8695be7a-e570-40b4-8ac5-f94f17563ec3">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM2_034aacd7-839b-4dff-a2a4-ffaecce2260b">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjQx_c3f0fed6-aaa4-4ac2-900c-678cd13dbd9a">996-0955</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6MzQ5NTE2NDM3ZjljNDgxNGEzY2MwMWU3ZGQ5Y2U5MzMvdGFibGVyYW5nZTozNDk1MTY0MzdmOWM0ODE0YTNjYzAxZTdkZDljZTkzM18xLTAtMS0xLTY3NDc0_724cee08-3544-4580-8759-37bd0c7ef59c">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6MzQ5NTE2NDM3ZjljNDgxNGEzY2MwMWU3ZGQ5Y2U5MzMvdGFibGVyYW5nZTozNDk1MTY0MzdmOWM0ODE0YTNjYzAxZTdkZDljZTkzM18xLTEtMS0xLTY3NDc0_8db3c336-98f7-413d-8c49-eb3c12b6a825">MORF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6MzQ5NTE2NDM3ZjljNDgxNGEzY2MwMWU3ZGQ5Y2U5MzMvdGFibGVyYW5nZTozNDk1MTY0MzdmOWM0ODE0YTNjYzAxZTdkZDljZTkzM18xLTItMS0xLTY3NDc0_7531ecc1-4b1c-40f3-8eb4-f687748aac49">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM3_714d9f77-0313-4e2c-aeb1-75944eb56d37">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM5_e1ed53ea-a1af-4c5c-b8da-71772e831f0e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjQy_32d96485-16c6-42c9-a5ea-8e65cd5c0fe6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjQw_b8d89020-9ff4-4182-8472-e56e4ee4a9b2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6YmIwZDc3MTljOWU4NGFmY2ExYTU4ZDAzZjFlNzRlYmUvdGFibGVyYW5nZTpiYjBkNzcxOWM5ZTg0YWZjYTFhNThkMDNmMWU3NGViZV8xLTAtMS0xLTY3NTIxL3RleHRyZWdpb246MzNmNWQxZTM5NzI5NDg2ZmIyZjZkMmJmOTkyODVjZjVfMjE5OTAyMzI1NTYwNQ_765afb11-0408-4f23-8cff-8d70d3e0f858">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6YmIwZDc3MTljOWU4NGFmY2ExYTU4ZDAzZjFlNzRlYmUvdGFibGVyYW5nZTpiYjBkNzcxOWM5ZTg0YWZjYTFhNThkMDNmMWU3NGViZV8xLTEtMS0xLTY3NDc0L3RleHRyZWdpb246NjBmMDVmNmFmMzIxNGMzNmI2Zjc4OWJjZjQ5NjJhNzRfMzg0ODI5MDY5NzI0OQ_476b6239-b51d-4f27-b1c8-58883168f9ea">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGFibGU6YmIwZDc3MTljOWU4NGFmY2ExYTU4ZDAzZjFlNzRlYmUvdGFibGVyYW5nZTpiYjBkNzcxOWM5ZTg0YWZjYTFhNThkMDNmMWU3NGViZV8yLTEtMS0xLTY3NDc0L3RleHRyZWdpb246NGZhZDA5NzVkNWM1NDI0OTk3YzIyMjA4MDJlNDYyNmNfMjg_383def54-ab5d-4970-b297-49321616bb2a">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF84MjQ2MzM3MjEyNzY5_11b0713a-1bc2-4d08-abe1-cebaf09a0986">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjM0_d2702fe4-637e-454b-b667-91d1dfe1ebaf">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i44dcf71d914947aeab1d6ca95df53425_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8yNzcw_39f651f9-d32f-4e2e-8298-b3dd4b808f67"
      unitRef="usd">559358817</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4baab3edb5cc4574a112258bbd3606bb_I20230221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8yODU0_9224666e-750d-4c6b-872a-30a0de7c9813"
      unitRef="shares">39534138</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xL2ZyYWc6YjQ2NjI2YWFjZmE0NGUwMDk2YjQ5NDAzYzllMDNmNTgvdGV4dHJlZ2lvbjpiNDY2MjZhYWNmYTQ0ZTAwOTZiNDk0MDNjOWUwM2Y1OF8zMjMx_dd49a2f5-0bc3-4aa4-85c8-d56d50479ff7">&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:17.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183My9mcmFnOjk2ZWJjZTZmMTc2MzRlNDVhZTA0YzllMGExOTVkZGVjL3RhYmxlOjE3OTUwMzBjMzc1YTRiMjQ4NmE1MGQzYWNjZjViNzRiL3RhYmxlcmFuZ2U6MTc5NTAzMGMzNzVhNGIyNDg2YTUwZDNhY2NmNWI3NGJfMi0wLTEtMS02NzQ3NC90ZXh0cmVnaW9uOjI1NDI4M2UwODA5ZTQ2YThhODlhYWIyOGM2NzhjNzVmXzcx_d766cbae-af1d-4110-b216-0b105ecbbde3">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183Ni9mcmFnOjBkNzBjZTdhYmIwOTRhOWFhZWQyOTc1NTkyMjczZDJiL3RleHRyZWdpb246MGQ3MGNlN2FiYjA5NGE5YWFlZDI5NzU1OTIyNzNkMmJfMzg2OQ_22646969-e870-4123-bb5b-c37776a2a9dd">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183Ni9mcmFnOjBkNzBjZTdhYmIwOTRhOWFhZWQyOTc1NTkyMjczZDJiL3RleHRyZWdpb246MGQ3MGNlN2FiYjA5NGE5YWFlZDI5NzU1OTIyNzNkMmJfMzg3MA_fd8b8376-fe71-4ac4-be02-027b915340b1">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNC0xLTEtMS02NzQ3NA_8d226283-6294-4295-b8cc-883dc1aa5632"
      unitRef="usd">59272000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNC0zLTEtMS02NzQ3NA_3c6825fc-d2a3-4939-b3a9-0102ed2dd383"
      unitRef="usd">171434000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNS0xLTEtMS02NzQ3NA_486417b6-701d-41a9-8dec-a21ae6f5fab3"
      unitRef="usd">288976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNS0zLTEtMS02NzQ3NA_1b26fc9b-3a5d-41bf-b530-8bde840fddc8"
      unitRef="usd">236701000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNi0xLTEtMS02NzQ3NA_2799196b-9300-4b9f-907a-f4749382cf21"
      unitRef="usd">455000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNi0zLTEtMS02NzQ3NA_4b215eb9-60cf-4acc-aa95-98f80f9d80e8"
      unitRef="usd">2307000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNy0xLTEtMS02NzQ3NA_39a5e659-da44-4391-8ea8-549038afec38"
      unitRef="usd">13479000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfNy0zLTEtMS02NzQ3NA_f4b6659b-bd5e-487c-a804-2b26525c9618"
      unitRef="usd">7892000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfOC0xLTEtMS02NzQ3NA_be92317b-8aea-4693-b9ac-0312524ae3be"
      unitRef="usd">362182000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfOC0zLTEtMS02NzQ3NA_66255cf5-c188-4fa8-91e9-1c2339c94c02"
      unitRef="usd">418334000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfOS0xLTEtMS02NzQ3NA_07c3bdef-2f94-4677-8150-d56c9b7ae2de"
      unitRef="usd">3514000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfOS0zLTEtMS02NzQ3NA_4948de17-f33d-4312-95ed-1ea6f622ae5a"
      unitRef="usd">4806000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTEtMS0xLTEtNjc0NzQ_8d393b48-d588-4c1e-bb81-f6da25fc7870"
      unitRef="usd">2119000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTEtMy0xLTEtNjc0NzQ_b46b1b6c-aff7-4265-93cf-344a0317ffa8"
      unitRef="usd">2583000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCash
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTItMS0xLTEtNjc0NzQ_3c87d602-47e9-4459-93d5-6dc4df9f0e37"
      unitRef="usd">560000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTItMy0xLTEtNjc0NzQ_055e322e-fa9e-4f9c-8950-95f4ab0ed127"
      unitRef="usd">560000</us-gaap:RestrictedCash>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTMtMS0xLTEtNjc0NzQ_bb8cf4a9-f10d-4039-90b7-d4d427eebadc"
      unitRef="usd">214000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTMtMy0xLTEtNjc0NzQ_45a45b4e-4a86-43ae-a22b-f36f7510a2c4"
      unitRef="usd">7000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTQtMS0xLTEtNjc0NzQ_b525b5df-6c85-469d-93fe-524203ff1c70"
      unitRef="usd">368589000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTQtMy0xLTEtNjc0NzQ_2aeb6b26-3f08-4b16-8c3b-0f67236b993a"
      unitRef="usd">426290000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTgtMS0xLTEtNjc0NzQ_43363c13-e278-4676-8e34-599dd9906efc"
      unitRef="usd">3475000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTgtMy0xLTEtNjc0NzQ_9322e5c8-0e86-473c-b58a-cebc7b484ab2"
      unitRef="usd">4798000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTktMS0xLTEtNjc0NzQ_0291cdd4-4f6b-4f36-9223-91c1da56341a"
      unitRef="usd">13181000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMTktMy0xLTEtNjc0NzQ_6e0d5863-8f2d-4353-a860-66943036d235"
      unitRef="usd">12838000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjAtMS0xLTEtNjc0NzQ_7b774f4f-4c2b-413b-a0a4-1cce96ebeeb4"
      unitRef="usd">470000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjAtMy0xLTEtNjc0NzQ_44a49125-3676-4b43-b028-803cd5b50a33"
      unitRef="usd">20628000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjItMS0xLTEtNjc0NzQ_86245366-d396-4f7e-89a9-362ff98bc2c9"
      unitRef="usd">17126000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjItMy0xLTEtNjc0NzQ_d1aab1b7-e960-4989-ac45-7eee2ce5a2fe"
      unitRef="usd">38264000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjQtMS0xLTEtNjc0NzQ_9a778d72-43f0-4556-84a7-04c2ee95e748"
      unitRef="usd">2344000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjQtMy0xLTEtNjc0NzQ_d528441e-5b66-4ad8-a4a2-d8ff7ca88a1d"
      unitRef="usd">3838000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjUtMS0xLTEtNjc0NzQ_db48c8e9-823f-470c-904e-584929650917"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjUtMy0xLTEtNjc0NzQ_094af5e0-e072-4223-92ea-79552a1fec0b"
      unitRef="usd">47489000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjctMS0xLTEtNjc0NzQ_e9b4800b-19c9-420a-84cd-f6399d88b24d"
      unitRef="usd">19470000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjctMy0xLTEtNjc0NzQ_cc0d5339-f9bf-408b-9823-ff026000ca78"
      unitRef="usd">89591000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjktMS0xLTEtNjc0NzQ_9301f7ff-b8fb-45f8-a3ba-8dbbac69fdaa"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMjktMy0xLTEtNjc0NzQ_7f5e347b-c1f8-4c06-8238-f3640d30dc4b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl8yMg_ac712806-4792-4744-b1cf-68abe45e4edb"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl8yMg_b3429064-13c1-4d3e-aa43-8577387838c3"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl8zNg_09d0571f-32aa-4c1e-bb0b-3c8c0cfe7b3f"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl8zNg_2686ef59-8d1b-4c47-841e-897cc6254a00"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl81OA_200c4f37-8a81-4da9-89a6-199c381734cc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl81OA_393feeab-e3f1-4de2-8304-79ae9b1b7890"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl81OA_aef066fe-5a44-43cb-a45a-187af5e2862e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjplYmFjMzI4NzFlMzQ0YjI1YjUwNDczNWM2NmU1NGViNl81OA_cb3ac5a8-963b-4a15-a49d-dd684bff9bed"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMS0xLTEtNjc0NzQ_33ed1b18-057e-48a9-8d0d-da645a6c8c65"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzItMy0xLTEtNjc0NzQ_4132006e-f041-4f92-bee6-27b1c98a92e6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8xOQ_1242b7c3-4d98-49c1-b06d-048d63bd7814"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8xOQ_851bbed0-3ecf-4187-8295-ad9899d28abd"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8zMw_7d24002a-513c-42ee-8715-3e661e004b2c"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8zMw_c4ad2668-2029-418d-9107-9a90a837cd0c"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF81NQ_da49aa8a-1965-4eb5-b4ad-04e9fef61bbc"
      unitRef="shares">38584678</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF81NQ_f2261ac9-0510-4e86-ad0d-fbb3acf3ace5"
      unitRef="shares">38584678</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8xMDE_4f681ece-5070-4bf1-99e7-50c2a32d8086"
      unitRef="shares">37085397</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpkMGY1OTNmODhlY2M0NTgyYjcyMzA5YTJhYjBkM2YyNF8xMDE_5f608d03-bfae-4539-b3b4-9b1cfbf25274"
      unitRef="shares">37085397</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMS0xLTEtNjc0NzQ_fdc9c284-ec2d-4dc7-bb97-9e510afce4d2"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzMtMy0xLTEtNjc0NzQ_243cdf31-e6de-42a2-8fc6-682002977d90"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzQtMS0xLTEtNjc0NzQ_dcd931f6-3bd8-4560-846f-a07b618e36ef"
      unitRef="usd">649549000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzQtMy0xLTEtNjc0NzQ_d7483917-a0a1-48d2-8f75-5232c3a446b1"
      unitRef="usd">575231000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzUtMS0xLTEtNjc0NzQ_dd6f306a-9719-4c1b-8b27-392bc5b074e2"
      unitRef="usd">-297095000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzUtMy0xLTEtNjc0NzQ_00c94aab-b8d3-4209-bb6e-ba75860e230e"
      unitRef="usd">-238054000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzYtMS0xLTEtNjc0NzQ_88663390-518a-4db6-85db-eec3fd7f12b6"
      unitRef="usd">-3339000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzYtMy0xLTEtNjc0NzQ_df55a1bc-47cc-4473-baaf-c11b8689ba62"
      unitRef="usd">-482000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzctMS0xLTEtNjc0NzQ_bd9a3647-cf2f-4ffa-a53b-074528e055c7"
      unitRef="usd">349119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzctMy0xLTEtNjc0NzQ_af313be0-1c41-499c-9595-637e9b966ced"
      unitRef="usd">336699000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzgtMS0xLTEtNjc0NzQ_cc87060f-97d9-4a8f-b8be-34e24a8725f5"
      unitRef="usd">368589000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM183OS9mcmFnOmUxYzhlOTc5MzQ1OTRjNTc4M2E2OTUzNDM0MzBmMzgxL3RhYmxlOjNkMjVmNzk1ZDVmYjRhNGFiMDZmYjFjYWM4NjlhZDhhL3RhYmxlcmFuZ2U6M2QyNWY3OTVkNWZiNGE0YWIwNmZiMWNhYzg2OWFkOGFfMzgtMy0xLTEtNjc0NzQ_4b0980eb-6895-4a8d-87a9-a006334ae774"
      unitRef="usd">426290000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMi01LTEtMS02NzQ3NA_9f56309d-f949-4192-89fe-9af7958d4b82"
      unitRef="usd">70808000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMi03LTEtMS02NzQ3NA_8d351d2f-4c88-4b36-a93e-452b7d358384"
      unitRef="usd">19794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMi05LTEtMS02NzQ3NA_f9abe18f-f5be-4db4-a476-902c5d27be64"
      unitRef="usd">44945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNC01LTEtMS02NzQ3NA_78cc1b24-435f-499d-8985-324ef9c08463"
      unitRef="usd">102062000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNC03LTEtMS02NzQ3NA_59ce9c08-a48e-4e69-86ed-780fef9d33ea"
      unitRef="usd">87789000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNC05LTEtMS02NzQ3NA_e6987f22-b7b9-4601-9c67-39bfb016451d"
      unitRef="usd">73630000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNS01LTEtMS02NzQ3NA_37a959ee-b456-4f5a-af43-060c4acd6d65"
      unitRef="usd">32142000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNS03LTEtMS02NzQ3NA_296d4127-6315-46f7-818e-e8a1a72dae03"
      unitRef="usd">27811000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNS05LTEtMS02NzQ3NA_5289e9a0-cfa1-47c6-bfec-b29a5abd5954"
      unitRef="usd">18495000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNi01LTEtMS02NzQ3NA_eb12cec8-ca34-4f7a-ba12-c3b518cdae67"
      unitRef="usd">134204000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNi03LTEtMS02NzQ3NA_e878d80f-a6b6-433f-869e-e28bb97ebe88"
      unitRef="usd">115600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNi05LTEtMS02NzQ3NA_19eca252-2099-409a-911d-92023016b2e0"
      unitRef="usd">92125000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNy01LTEtMS02NzQ3NA_aaee53e3-1e44-4cf9-b2b9-6bd6e87abac0"
      unitRef="usd">-63396000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNy03LTEtMS02NzQ3NA_dbf18caa-4a4d-4a37-a602-32f84ca70977"
      unitRef="usd">-95806000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfNy05LTEtMS02NzQ3NA_40e0aba1-7e69-4c71-8201-a575c1560336"
      unitRef="usd">-47180000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfOS01LTEtMS02NzQ3NA_4a6a0000-c980-4a3c-a733-d0f531e35878"
      unitRef="usd">4567000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfOS03LTEtMS02NzQ3NA_869b60f7-3369-487e-bf0d-c9a6bf625631"
      unitRef="usd">272000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfOS05LTEtMS02NzQ3NA_a28168d4-0324-42b1-9319-8a059ed8fb1e"
      unitRef="usd">1630000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTAtNS0xLTEtNjc0NzQ_37b77f8a-632b-49ca-9553-df2efdd10cb2"
      unitRef="usd">-145000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTAtNy0xLTEtNjc0NzQ_91cfdc6d-46d6-4e22-81db-0e7ccc5f1d6c"
      unitRef="usd">-8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTAtOS0xLTEtNjc0NzQ_8def3d87-7085-4214-8e40-745505c9acad"
      unitRef="usd">-19000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTEtNS0xLTEtNjc0NzQ_8ef89b17-b507-4cc7-8be0-71981ae739d5"
      unitRef="usd">4422000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTEtNy0xLTEtNjc0NzQ_7df90600-1da5-4ed5-945d-013a24c29713"
      unitRef="usd">264000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTEtOS0xLTEtNjc0NzQ_34b00d94-ecef-459a-b828-1354d0c38ac3"
      unitRef="usd">1611000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTItNS0xLTEtNjc0NzQ_7d919a79-77fb-4be0-a7e9-12413bae7d67"
      unitRef="usd">-58974000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTItNy0xLTEtNjc0NzQ_9ceb770e-0faf-4484-8cfb-bab02c62ca72"
      unitRef="usd">-95542000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTItOS0xLTEtNjc0NzQ_130996d4-dde0-4294-9109-6ab10173451f"
      unitRef="usd">-45569000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTMtNS0xLTEtNjc0NzQ_216af7b6-1528-48d8-b5ed-363606be8b11"
      unitRef="usd">67000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTMtNy0xLTEtNjc0NzQ_dc59de40-cbf2-4301-bb74-73806b5bc046"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTMtOS0xLTEtNjc0NzQ_85da4a11-835d-458d-8b57-db57afea30ef"
      unitRef="usd">-570000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTQtNS0xLTEtNjc0NzQ_24d5252a-cb23-455f-a737-795060391e32"
      unitRef="usd">-59041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTQtNy0xLTEtNjc0NzQ_c0112ab3-dbc5-4802-a516-2bf18aaf74f9"
      unitRef="usd">-95542000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTQtOS0xLTEtNjc0NzQ_eda87952-8418-4060-af1c-70f89a9fe608"
      unitRef="usd">-44999000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtNS0xLTEtNjc0NzQ_8c120276-2bc6-4b34-872c-85daef93b6e2"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtNS0xLTEtNjc0NzQ_8e3c3f6a-4b36-4cfc-86d5-c3ccc5acf0fa"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtNy0xLTEtNjc0NzQ_4820e5a1-ef95-49a7-accc-25a78483c9b0"
      unitRef="usdPerShare">-2.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtNy0xLTEtNjc0NzQ_ebf8398d-ddd5-4420-855d-fa4e70772f67"
      unitRef="usdPerShare">-2.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtOS0xLTEtNjc0NzQ_4d7f2820-df04-4b89-a27a-291b833519b6"
      unitRef="usdPerShare">-1.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTUtOS0xLTEtNjc0NzQ_adc5ad40-3a70-454e-a2ff-0b90701d020f"
      unitRef="usdPerShare">-1.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtNS0xLTEtNjc0NzQ_2e10b9a2-f35b-46a3-806c-7c070981994c"
      unitRef="shares">38112498</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtNS0xLTEtNjc0NzQ_df112c88-b6b6-4937-8614-2f52efa78acb"
      unitRef="shares">38112498</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtNy0xLTEtNjc0NzQ_18bda248-9708-4384-a6ac-988bf55597de"
      unitRef="shares">35797969</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtNy0xLTEtNjc0NzQ_21df57bb-4c26-4d15-8ce2-507b57e876a1"
      unitRef="shares">35797969</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtOS0xLTEtNjc0NzQ_3a8b38c3-ee84-4a67-810b-a33df352ac0c"
      unitRef="shares">30594897</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMTgtOS0xLTEtNjc0NzQ_e5a6d91a-86cc-4203-af57-9eba6082677c"
      unitRef="shares">30594897</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjItNS0xLTEtNjc0NzQ_fb67651a-858c-429a-a3f3-293f20b0873a"
      unitRef="usd">-59041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjItNy0xLTEtNjc0NzQ_54c7bb68-07e0-470b-8a04-6bb5f8a07fb0"
      unitRef="usd">-95542000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjItOS0xLTEtNjc0NzQ_866b5f69-fcd9-46be-800b-80ec15a13292"
      unitRef="usd">-44999000</us-gaap:NetIncomeLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjQtNS0xLTEtNjc0NzQ_37e1975a-69e5-4845-8543-e04a108737ae"
      unitRef="usd">-2857000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjQtNy0xLTEtNjc0NzQ_5ac3d248-3d84-4f04-be71-b86518ef18c7"
      unitRef="usd">-461000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjQtOS0xLTEtNjc0NzQ_d206e762-f9b0-40d0-87df-fc80a9c69394"
      unitRef="usd">-65000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjUtNS0xLTEtNjc0NzQ_7d439a6a-61a1-45af-abb3-98b32a009d74"
      unitRef="usd">-2857000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjUtNy0xLTEtNjc0NzQ_559f622d-cc87-4b26-8c59-3c67535369d0"
      unitRef="usd">-461000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjUtOS0xLTEtNjc0NzQ_cea2f643-6e34-4112-9764-2acf51843c0f"
      unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjYtNS0xLTEtNjc0NzQ_7b5f8104-5d56-40d1-965a-95fa87c2f651"
      unitRef="usd">-61898000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjYtNy0xLTEtNjc0NzQ_e9ffc1e8-aefa-4975-982b-b9340b9277c2"
      unitRef="usd">-96003000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184Mi9mcmFnOjFlZmMyMGZlNjI5MTQ3MmU5YmE4ZTdmYmIyZDI0ZTMxL3RhYmxlOjYwNDAzNzZhODUyOTRjNThhZWJlNTY3YWY1ODc0Mzc0L3RhYmxlcmFuZ2U6NjA0MDM3NmE4NTI5NGM1OGFlYmU1NjdhZjU4NzQzNzRfMjYtOS0xLTEtNjc0NzQ_8c1bd1e3-e244-4a50-93fa-f2e825ae6bc5"
      unitRef="usd">-45064000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i4bfdc1a144904aff961163efe0b71fed_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0yLTEtMS02NzcyMw_c58a28c3-8443-42cc-9676-149cc26159cc"
      unitRef="shares">30110251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4bfdc1a144904aff961163efe0b71fed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi00LTEtMS02NzcyNw_ed866a63-c71e-4452-b4c5-3b12dcbfc798"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6348a4fce16d4a8495c328951bd63827_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi02LTEtMS02NzcyNw_a945b2bb-1c62-4317-870d-8658c9ea3c54"
      unitRef="usd">238384000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c14a9ad52b943b0a9f70a1adc012b62_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi04LTEtMS02NzczMQ_1c8a2fa7-40ff-4f13-b3ac-f4f2273a8303"
      unitRef="usd">-97513000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a0ec20e47be47eab177727935b230b5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0xMC0xLTEtNjc3MzE_089807ff-1fe5-4094-b6c6-110e64c53983"
      unitRef="usd">44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa8445c41fd5491292904732bb0c4761_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0xMi0xLTEtNjc3MzE_43a14105-3021-48d7-beef-c03fcc7fe4e0"
      unitRef="usd">140918000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i76a6b759ffbb449e81cc565598a24220_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMy02LTEtMS02NzcyNw_17893d80-fe23-4eb1-8e19-7c830e87e227"
      unitRef="usd">11053000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMy0xMi0xLTEtNjc3MzE_d71575e8-1cd5-4084-a968-b8f1d2230423"
      unitRef="usd">11053000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i9ceda5f5a33e4c9581ee108c783e1d6f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNC0yLTEtMS02NzcyMw_e9cc6d2e-ac62-4efc-9dff-13649ff19d5a"
      unitRef="shares">252890</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9ceda5f5a33e4c9581ee108c783e1d6f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS0yLTEtMS02NzcyMw_6ef945d7-9a66-4ad9-8698-0e41ab9563b2"
      unitRef="shares">431554</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i76a6b759ffbb449e81cc565598a24220_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS02LTEtMS02NzcyNw_54ed4db5-472e-4f81-9a65-9302d51a1e6f"
      unitRef="usd">3532000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS0xMi0xLTEtNjc3MzE_94fdd8e9-0006-4c03-9dd0-2e793bd04174"
      unitRef="usd">3532000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="i9ceda5f5a33e4c9581ee108c783e1d6f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi0yLTEtMS02NzcyMw_0ec7a217-362f-4774-9fbe-df76b89b361c"
      unitRef="shares">85298</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i76a6b759ffbb449e81cc565598a24220_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi02LTEtMS02NzcyNw_dc1a38cd-b103-47d1-b5df-9e2d13699b58"
      unitRef="usd">1112000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi0xMi0xLTEtNjc3MzE_6401bf24-8571-4a08-bf99-d05219456b8f"
      unitRef="usd">1112000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i03f523ed243944c1952b9f439ae6591a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0wLTEtMS03MDMxMS90ZXh0cmVnaW9uOjhmYTJhODEwYjVlZTRiNzk4ZWU3YzZiY2IzZDI1YzU5XzM4NDgyOTA2OTczMTk_c09daf62-8df6-4c1e-894d-131b1c9b5586"
      unitRef="usd">1500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i70ca9447c43d4a3cb80fb8f78c3c39ee_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0yLTEtMS02NzcyMw_29df9d51-b763-44a9-8db8-6c0fc8edd9fb"
      unitRef="shares">1157693</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2c5918a2e0b4490086688e38b5dbd9e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy02LTEtMS02NzcyNw_ef98c11e-5fb5-4db2-aa9c-de7f668bdc23"
      unitRef="usd">33646000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i03f523ed243944c1952b9f439ae6591a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0xMi0xLTEtNjc3MzE_ad695ac1-6226-4c38-9287-78103a6d0e63"
      unitRef="usd">33646000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i875354d9000b443caa58d5fb686317b6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOC0xMC0xLTEtNjc3MzE_5a5905a0-d1ba-4bd1-8721-a5d828265a78"
      unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOC0xMi0xLTEtNjc3MzE_aa608424-b665-41a3-8cbc-65aa103cbdef"
      unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8e9ea2357bcd4e0b80ea5f90c117c183_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOS04LTEtMS02NzczMQ_69fe9a00-a9fd-45b4-a237-26c40c603539"
      unitRef="usd">-44999000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOS0xMi0xLTEtNjc3MzE_af0618c9-c36a-42c2-a1c1-2adead0132f9"
      unitRef="usd">-44999000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id9a2e7740aed41f39474ac66cdd34da5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0yLTEtMS02NzQ3NA_84bc669e-7182-419a-901f-55f7c316cdbc"
      unitRef="shares">32037686</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id9a2e7740aed41f39474ac66cdd34da5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi00LTEtMS02NzQ3NA_d9a8fda4-a1ea-4659-bf4b-64dcc6d2c48f"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc7a5cede0a3473c877c0673a0bcfa2a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi02LTEtMS02NzQ3NA_56aaf0df-21f1-4b4d-a8a8-99d1fcb1d6cb"
      unitRef="usd">287727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70cbfaa401bb4c92b9a9c2661d1df2b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi04LTEtMS02NzQ3NA_30ceb722-cf3f-4f9b-8589-554e2640716c"
      unitRef="usd">-142512000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5e9ea7d97544c62a5f4d876238911a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0xMC0xLTEtNjc0NzQ_cfe16f3e-a739-482c-bb2e-eff7257f80ea"
      unitRef="usd">-21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMi0xMi0xLTEtNjc0NzQ_e0a7f4a2-d870-47ea-97eb-c4fd0ee84a97"
      unitRef="usd">145197000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i8a2d410f10fd43e0a3d21d4b9a945a0a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMy02LTEtMS02NzQ3NA_3f6c6c8a-b5f2-479e-b5a4-1cb503c73643"
      unitRef="usd">21184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMy0xMi0xLTEtNjc0NzQ_5cde5cae-f01d-4335-baa9-7633b5266088"
      unitRef="usd">21184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if5ee1b9fb78c472393ca0dd130c5b288_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNC0yLTEtMS02NzQ3NA_74ea9f40-2a60-41e5-a1bd-80cf2da479fa"
      unitRef="shares">127335</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if5ee1b9fb78c472393ca0dd130c5b288_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS0yLTEtMS02NzQ3NA_33fa3da5-9c8e-48d2-a6ed-58ba7f84da31"
      unitRef="shares">827830</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8a2d410f10fd43e0a3d21d4b9a945a0a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS02LTEtMS02NzQ3NA_ebeee3fc-1746-4628-b64c-3c8e1e019612"
      unitRef="usd">9536000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNS0xMi0xLTEtNjc0NzQ_53dabf53-04ac-4cfb-87f7-3aec864cea6f"
      unitRef="usd">9536000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="if5ee1b9fb78c472393ca0dd130c5b288_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi0yLTEtMS02NzQ3NA_3787c6d4-45ac-4ce2-bbda-cd36afc49e5a"
      unitRef="shares">35563</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i8a2d410f10fd43e0a3d21d4b9a945a0a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi02LTEtMS02NzQ3NA_d4d64efc-dc08-4be3-967a-d6dd2ae50c3d"
      unitRef="usd">1095000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNi0xMi0xLTEtNjc0NzQ_c4c6c55e-a806-4348-a821-77920406deef"
      unitRef="usd">1095000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ib242abf1d8974e31acd46eb1e550e867_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0wLTEtMS02NzQ3NC90ZXh0cmVnaW9uOjMyNDVkYzFhZTVjNjRlOWM5MzQzODIyZGMwYTExYWFkXzg3_17dad606-14d0-4697-8e99-e45946ac161e"
      unitRef="usd">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i04199a8b57a94afdb3894dd8f3611ef9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0yLTEtMS02NzQ3NA_d1f474bf-4059-4736-8eeb-0ee33bd236a8"
      unitRef="shares">556983</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0c83e86e5ecf4e049f03b221fd37ddc2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy02LTEtMS02NzQ3NA_0d434330-d55c-4a3e-a37b-1ae7ba43f1f4"
      unitRef="usd">25708000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib242abf1d8974e31acd46eb1e550e867_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfNy0xMi0xLTEtNjc0NzQ_4e61c495-e5ef-41d3-8bc2-38bbb751e900"
      unitRef="usd">25708000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i3021ee10eeff4228808670e25669c506_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtMC0xLTEtNzUxNjkvdGV4dHJlZ2lvbjozZWFjODdiMWU2ZTA0NzBkODFkYmRkMjI5ZWI1NTFlMV8yNzQ4Nzc5MDY5NTQ5_0d8e50a6-cbbe-4a7d-8eaf-e1d33012fc29"
      unitRef="usd">15000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib89e4e41db194455b68dae07e4088634_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtMi0xLTEtNzUxOTA_88fc00c4-09ae-40bd-bad2-c43b0e89d770"
      unitRef="shares">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib89e4e41db194455b68dae07e4088634_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtNC0xLTEtNzUxOTA_3a28c3d2-9452-4ff7-99f1-87db8e0972f0"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i229d09b827bb41a89b5f692014a5d842_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtNi0xLTEtNzUxOTA_fe053c29-b629-48ba-aca5-a29924ea0a2a"
      unitRef="usd">229981000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3021ee10eeff4228808670e25669c506_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTYtMTItMS0xLTc1MTkw_4ab3b220-ebbc-435f-b884-866195c74d36"
      unitRef="usd">229982000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib148686698e04b2b916642950ccd1817_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOC0xMC0xLTEtNjc0NzQ_c5bf771c-800a-4ac0-be75-52989a79d540"
      unitRef="usd">-461000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOC0xMi0xLTEtNjc0NzQ_206f1273-438d-47d6-8e27-c90369890eb9"
      unitRef="usd">-461000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i0c7558e92e8d4ff7ac77d9a2a034d000_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOS04LTEtMS02NzQ3NA_0261aab1-6bd0-4d42-8d95-f7017767a95e"
      unitRef="usd">-95542000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfOS0xMi0xLTEtNjc0NzQ_c437d198-a568-4b70-b231-b3eeb3cda6bc"
      unitRef="usd">-95542000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i251a1f6f65c94d6ea46a8bf3f0bc6caf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtMi0xLTEtNjc0NzQ_1a6e5286-2bb6-4998-b040-ee21c6e1afe0"
      unitRef="shares">37085397</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i251a1f6f65c94d6ea46a8bf3f0bc6caf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtNC0xLTEtNjc0NzQ_a34fb09a-0d31-41de-b1ab-8beb10999ade"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i134fbbf1dfed4fa4814373cfe2ffcdb2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtNi0xLTEtNjc0NzQ_0b0e6133-0516-4fd0-87f1-d8b2d92ec7a0"
      unitRef="usd">575231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica43711c0df64da7a4e706d076e6bdbc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtOC0xLTEtNjc0NzQ_8e07d2be-3445-4393-9005-301437c3f821"
      unitRef="usd">-238054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c50679b571740e19279ef7944cb3f16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtMTAtMS0xLTY3NDc0_76bfd3dd-b79b-4b19-892d-296d559e6dca"
      unitRef="usd">-482000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTAtMTItMS0xLTY3NDc0_5126120d-66e1-47be-9562-5919a4f8d9ff"
      unitRef="usd">336699000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i71e5bf0a1e4948d0971fff4b2f4bdb14_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTEtNi0xLTEtNjc0NzQ_abc46a98-2158-4e73-b94f-32cc519122c3"
      unitRef="usd">29048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTEtMTItMS0xLTY3NDc0_94a7ef94-f214-4359-90a2-287510764d54"
      unitRef="usd">29048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i9ac40f3b64c04bb6b11779403daca223_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTItMi0xLTEtNjc0NzQ_5c663391-87eb-4089-806e-33f118a1bf1a"
      unitRef="shares">9171</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9ac40f3b64c04bb6b11779403daca223_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTMtMi0xLTEtNjc0NzQ_ad57d752-84e5-45e4-bc50-8d76484c32b6"
      unitRef="shares">459839</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i71e5bf0a1e4948d0971fff4b2f4bdb14_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTMtNi0xLTEtNjc0NzQ_51f9f668-fd26-42e7-8694-c39677d17d0c"
      unitRef="usd">5175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTMtMTItMS0xLTY3NDc0_b8838c54-edd2-44b4-b7d5-4a024dccfc8b"
      unitRef="usd">5175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="i9ac40f3b64c04bb6b11779403daca223_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTQtMi0xLTEtNjc0NzQ_d13919ad-8a7e-4c14-b806-cf57c9557d94"
      unitRef="shares">30271</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i71e5bf0a1e4948d0971fff4b2f4bdb14_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTQtNi0xLTEtNjc0NzQ_67d9764a-ddfa-4a13-9dc2-aef3c7044458"
      unitRef="usd">885000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTQtMTItMS0xLTY3NDc0_9e2b2114-97a9-49f7-b44a-e9f3a1409de5"
      unitRef="usd">885000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTUtMC0xLTEtNjc0NzQvdGV4dHJlZ2lvbjpjNWY4YzYxMTUzNjE0OGQwOTFmZTM0Mjc1NjhhOTM4N184Nw_3c96caa5-2c4b-4e24-9bde-01ed3d91484a"
      unitRef="usd">1300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i73c2e36cd1474c26b0d1a8bf3509e772_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTUtMi0xLTEtNjc0NzQ_79b3456f-992f-4357-991f-a3e9ddd53b5c"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4f1c028c600f492ea22a0fc290237655_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTUtNi0xLTEtNjc0NzQ_bb73ccae-1d1b-490f-8d07-3499279acf0f"
      unitRef="usd">39210000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTUtMTItMS0xLTY3NDc0_1ebe206c-9fd2-4bda-a8ff-b091c17739de"
      unitRef="usd">39210000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i64f737a67eb34edebd4b964b94d03e20_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTctMTAtMS0xLTY3NDc0_8b373330-8638-4bdf-a9e6-fa132cd55e6f"
      unitRef="usd">-2857000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTctMTItMS0xLTY3NDc0_6a3e9446-d361-40cf-9116-de85b490791c"
      unitRef="usd">-2857000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="if6217b53477e450c9212104a64166f49_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTgtOC0xLTEtNjc0NzQ_1742f430-05d1-4f8b-9f41-67124f810e0c"
      unitRef="usd">-59041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTgtMTItMS0xLTY3NDc0_03b76e15-0446-466e-9aba-0ed580054bda"
      unitRef="usd">-59041000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ie1d715f0e90f4892a783060db407d98d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktMi0xLTEtNjc0NzQ_d6a9de1b-17b4-4689-9916-dc83686b4317"
      unitRef="shares">38584678</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie1d715f0e90f4892a783060db407d98d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktNC0xLTEtNjc0NzQ_e65aefc2-b232-496c-afc5-4bfa6d86ce07"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbc0fc6fd3cc4a6085dbb3864bce300a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktNi0xLTEtNjc0NzQ_d9b1448e-4369-40f9-8af5-467604a35425"
      unitRef="usd">649549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iadaa15dc21b14e3db8588f66b4714a49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktOC0xLTEtNjc0NzQ_0be88f6f-2dff-438c-86f1-49f280462994"
      unitRef="usd">-297095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb7bba96f6fe49c1909da2aba38db320_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktMTAtMS0xLTY3NDc0_3329f5e5-89d4-411b-a1a5-ef78c03e292b"
      unitRef="usd">-3339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184NS9mcmFnOjJiYjkwOGFiMzZkYzRkZDlhY2EzMGM3YjA5YTU5OGViL3RhYmxlOjliMjc5MjU2N2Y3ZjQ5ZjI4OGU1ZmQ0NWNjZGM5YzRhL3RhYmxlcmFuZ2U6OWIyNzkyNTY3ZjdmNDlmMjg4ZTVmZDQ1Y2NkYzljNGFfMTktMTItMS0xLTY3NDc0_c62cec13-b422-4785-9968-dbda6af1db55"
      unitRef="usd">349119000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMy0xLTEtMS02NzQ3NA_5b8576b1-3031-4464-9ed6-cfca771a5ddf"
      unitRef="usd">-59041000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMy0zLTEtMS02NzQ3NA_830f8740-3441-4805-87f1-eae092711042"
      unitRef="usd">-95542000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMy01LTEtMS02NzQ3NA_1e3e17c8-194c-4362-94fa-0858289d74df"
      unitRef="usd">-44999000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNS0xLTEtMS02NzQ3NA_0e208fe5-4765-48d2-8459-d16fed3502f9"
      unitRef="usd">1005000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNS0zLTEtMS02NzQ3NA_6c90ba51-1dea-4195-9619-56c679b48502"
      unitRef="usd">1030000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNS01LTEtMS02NzQ3NA_1d793fb0-9e3f-4559-a80c-46b369cbcaa9"
      unitRef="usd">1126000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNi0xLTEtMS02NzQ3NA_82fab613-40f8-4ab9-9ee0-1eebd6823ba9"
      unitRef="usd">-800000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNi0zLTEtMS02NzQ3NA_327b0e35-e97c-4a33-b740-c77ec80f3782"
      unitRef="usd">-1215000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNi01LTEtMS02NzQ3NA_be2364a4-d1d0-4a0a-b52c-571b3a66e5c7"
      unitRef="usd">-450000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNy0xLTEtMS02NzQ3NA_7ca8b885-c980-4765-add8-2778a7588b91"
      unitRef="usd">29048000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNy0zLTEtMS02NzQ3NA_dcc45184-67a5-4a27-90ca-fc5f6d252635"
      unitRef="usd">21184000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNy01LTEtMS02NzQ3NA_57d3a19e-3ea4-4a32-9716-2bfd4332fa7b"
      unitRef="usd">11053000</us-gaap:ShareBasedCompensation>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC0xLTEtMS03MDU4Nw_a1131f93-3f5b-4771-8670-68f6150c956d"
      unitRef="usd">-154000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC0zLTEtMS03MDYwNA_bff8c9e0-0e00-46ab-a1bd-d2fab1e09f3e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC01LTEtMS03MDYxMg_813a599e-88d4-45f2-a5f9-b80756ffbc42"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC0xLTEtMS02NzQ3NA_5e198048-57b9-49cc-8d85-367cb03f2ee7"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC0zLTEtMS02NzQ3NA_032ca2cf-0624-4977-ba9f-c1b109879e23"
      unitRef="usd">-4000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfOC01LTEtMS02NzQ3NA_c8ba3c52-b5f3-468d-92a4-4d30d56d5c13"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTItMS0xLTEtNjc0NzQ_f2b06517-84e8-42b3-bb64-b2b3c84beb99"
      unitRef="usd">-1852000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTItMy0xLTEtNjc0NzQ_da0e665b-96b1-41fe-909f-ebca6c1eff49"
      unitRef="usd">-5007000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTItNS0xLTEtNjc0NzQ_1da5f8d9-82c6-4eb3-8be6-cd9bb5cb5ae5"
      unitRef="usd">3847000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTMtMS0xLTEtNjc0NzQ_abbaf1eb-7e49-4760-b712-e2e2b9d24364"
      unitRef="usd">5529000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTMtMy0xLTEtNjc0NzQ_eff1db6b-6404-424a-b4d7-1523ea2fa5b5"
      unitRef="usd">4035000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTMtNS0xLTEtNjc0NzQ_3626803b-2a00-48ff-9371-ddd561befd1f"
      unitRef="usd">767000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTQtMS0xLTEtNjc0NzQ_51e7bea8-5294-4358-a137-603e740aa995"
      unitRef="usd">207000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTQtMy0xLTEtNjc0NzQ_f0bfec8d-fd23-48d6-98c0-a0d2578eb514"
      unitRef="usd">-59000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTQtNS0xLTEtNjc0NzQ_f6c6d308-236a-4212-8054-8a91eb155cd8"
      unitRef="usd">-75000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <morf:IncreaseDecreaseOperatingLeaseRightOfUseAssets
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTUtMS0xLTEtNjc0NzQ_74cd1f4d-3979-4f38-99f5-828edd0af494"
      unitRef="usd">-1292000</morf:IncreaseDecreaseOperatingLeaseRightOfUseAssets>
    <morf:IncreaseDecreaseOperatingLeaseRightOfUseAssets
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTUtMy0xLTEtNjc0NzQ_e43d9912-9a76-46b6-abd2-ffe59c2e8019"
      unitRef="usd">-1098000</morf:IncreaseDecreaseOperatingLeaseRightOfUseAssets>
    <morf:IncreaseDecreaseOperatingLeaseRightOfUseAssets
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTUtNS0xLTEtNjc0NzQ_86c9b29b-39a9-47db-8352-aa16e588fe37"
      unitRef="usd">0</morf:IncreaseDecreaseOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTYtMS0xLTEtNjc0NzQ_a7f01116-5ec7-48ff-9a29-8b6adf5b10d5"
      unitRef="usd">-1553000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTYtMy0xLTEtNjc0NzQ_2f4daf7f-c8c4-433f-b1fa-44e98cc71498"
      unitRef="usd">970000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTYtNS0xLTEtNjc0NzQ_5d7a4b8b-ed33-4060-9f14-99f7f03acd7f"
      unitRef="usd">-1071000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTctMS0xLTEtNjc0NzQ_c53279af-abe3-4077-a4ea-72a2980a263f"
      unitRef="usd">60000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTctMy0xLTEtNjc0NzQ_c372fe8e-a400-4507-9d59-b4221329dc03"
      unitRef="usd">1467000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTctNS0xLTEtNjc0NzQ_0a3734aa-f4b9-41b6-8e38-40bd921ee4c9"
      unitRef="usd">3521000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTgtMS0xLTEtNjc0NzQ_a6c8aeaf-8669-4e03-bf7f-c0c2e1feb7a6"
      unitRef="usd">-67647000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTgtMy0xLTEtNjc0NzQ_a66ac5bf-05b8-4220-a443-c50e1dbad266"
      unitRef="usd">-14821000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTgtNS0xLTEtNjc0NzQ_a0b8fef1-6af3-4f95-bef1-2987a68637be"
      unitRef="usd">-11466000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <morf:IncreaseDecreaseInDeferredRent
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTktMS0xLTEtNjc0NzQ_b0f4419d-c075-404d-94ef-ef1e7867a4ab"
      unitRef="usd">0</morf:IncreaseDecreaseInDeferredRent>
    <morf:IncreaseDecreaseInDeferredRent
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTktMy0xLTEtNjc0NzQ_2f414be3-8815-4498-815c-6edf840ef742"
      unitRef="usd">0</morf:IncreaseDecreaseInDeferredRent>
    <morf:IncreaseDecreaseInDeferredRent
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMTktNS0xLTEtNjc0NzQ_d0f121de-c1e6-4727-a43a-4793cf0d98b1"
      unitRef="usd">-65000</morf:IncreaseDecreaseInDeferredRent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjAtMS0xLTEtNjc0NzQ_ee3f0cd9-35c2-4660-bd48-a46e58669171"
      unitRef="usd">-1211000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjAtMy0xLTEtNjc0NzQ_a2595d3e-4b46-46a9-95f4-8bdc80178861"
      unitRef="usd">-1097000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjAtNS0xLTEtNjc0NzQ_83d3b9b9-23f7-49a7-827d-86f228e00f19"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjMtMS0xLTEtNjc0NzQ_782f66f7-20c8-44cf-b413-5ae0f738ca3a"
      unitRef="usd">-100977000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjMtMy0xLTEtNjc0NzQ_ac51a6d0-51ba-4e98-a1cc-d7bc91054062"
      unitRef="usd">-83461000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjMtNS0xLTEtNjc0NzQ_8822f9e2-8095-4cae-b243-cb2c12ce9e3e"
      unitRef="usd">-45990000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjUtMS0xLTEtNjc0NzQ_aa93e1fc-b17d-4bd9-a769-583347aa92dd"
      unitRef="usd">238274000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjUtMy0xLTEtNjc0NzQ_9ec08918-21fe-458c-8b5b-94212703c090"
      unitRef="usd">244160000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjUtNS0xLTEtNjc0NzQ_29eec71d-75d1-4a39-b089-f2a95b1cd07e"
      unitRef="usd">145275000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtMS0xLTEtNjc0NzQ_6a4795f4-d270-45ad-b388-0a504e120a53"
      unitRef="usd">175042000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtMy0xLTEtNjc0NzQ_fdf8b720-35e7-4abf-9225-58bbfa2e5cf3"
      unitRef="usd">132000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtNS0xLTEtNjc0NzQ_cc60d60c-731c-41ca-8b66-8624a2b447a4"
      unitRef="usd">154000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtMS0xLTEtNzA2NjQ_909bd59c-82f3-47f7-a9e4-e29a8ae5be80"
      unitRef="usd">7146000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtMy0xLTEtNzA2Nzg_ebc708a6-484a-4f84-8b11-9214de5a5469"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjYtNS0xLTEtNzA2ODI_434590aa-38bf-4837-9910-fa9ed7f63afe"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjctMS0xLTEtNjc0NzQ_b0e7f3aa-3b70-4bce-8a44-702443e46250"
      unitRef="usd">365000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjctMy0xLTEtNjc0NzQ_ebcf1ef9-012e-4a36-a8b5-1db56f08dbcc"
      unitRef="usd">1020000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjctNS0xLTEtNjc0NzQ_f5c9cc2d-3678-4bd0-904f-5ae922e9ab01"
      unitRef="usd">544000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjgtMS0xLTEtNjc0NzQ_139f4165-9028-4cbf-8392-b6363da0cd74"
      unitRef="usd">-56451000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjgtMy0xLTEtNjc0NzQ_e2e18f00-158b-43f2-95da-7b0a5dbcde7d"
      unitRef="usd">-113180000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMjgtNS0xLTEtNjc0NzQ_aed1795a-473b-40c6-ac1c-e141eb14fa73"
      unitRef="usd">8181000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzItMS0xLTEtNjc0NzQ_d5c6bd67-a295-4661-bd22-a2079a2bf961"
      unitRef="usd">885000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzItMy0xLTEtNjc0NzQ_8841dcc7-6955-4f72-ad38-71a6dd5a46ef"
      unitRef="usd">1095000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzItNS0xLTEtNjc0NzQ_52429770-52bc-45eb-933a-ef855c64c90c"
      unitRef="usd">1112000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzMtMS0xLTEtNjc0NzQ_6b1c383f-3a22-4c09-b199-7c68eb974b73"
      unitRef="usd">39210000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib242abf1d8974e31acd46eb1e550e867_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzMtMy0xLTEtNjc0NzQ_c6794c42-471e-4ae2-b880-ec078b41d46e"
      unitRef="usd">25700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i03f523ed243944c1952b9f439ae6591a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzMtNS0xLTEtNjc0NzQ_a02fb1c4-b24f-4b77-a9f6-34895994784c"
      unitRef="usd">33653000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic313ab40bcfb4f66816203628eb7f0eb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzQtMS0xLTEtNjc0NzQ_3391e22b-cc7d-4d68-939c-bc164a37298f"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3021ee10eeff4228808670e25669c506_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzQtMy0xLTEtNjc0NzQ_1485e62a-5e89-4d9f-8e0d-1e6ac468612a"
      unitRef="usd">229982000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6416f8f824ff4d4d8207b91e5c244618_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzQtNS0xLTEtNjc0NzQ_f3ee1789-050f-4665-b247-1dc4adf9fa93"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzUtMS0xLTEtNjc0NzQ_9059854f-3ddf-4553-adb9-b0245aec9633"
      unitRef="usd">5171000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzUtMy0xLTEtNjc0NzQ_3b1d033b-6519-4a00-ac0b-b6a6f68f4f3c"
      unitRef="usd">9536000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzUtNS0xLTEtNjc0NzQ_dbaeb6d6-2083-4d8f-93c7-748936d95873"
      unitRef="usd">3532000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzYtMS0xLTEtNjc0NzQ_67a41cae-e0c4-4552-adfa-bf8ad87cab48"
      unitRef="usd">45266000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzYtMy0xLTEtNjc0NzQ_9f87f00b-d022-4488-ad44-2a8912177ae7"
      unitRef="usd">266313000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzYtNS0xLTEtNjc0NzQ_f91bd88a-df7c-4b74-a1ed-38cb1e734006"
      unitRef="usd">38297000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzctMS0xLTEtNjc0NzQ_a4c197bc-9d8d-4563-873c-63b9248779f2"
      unitRef="usd">-112162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzctMy0xLTEtNjc0NzQ_ad9a0585-7fc9-44f5-acee-ec27303aa698"
      unitRef="usd">69672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzctNS0xLTEtNjc0NzQ_19c4642d-b7bf-45e1-ad07-087f9493da5d"
      unitRef="usd">488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzgtMS0xLTEtNjc0NzQ_79a08e75-1fcc-42cc-b0f7-b79c2ec77ca1"
      unitRef="usd">171994000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzgtMy0xLTEtNjc0NzQ_6572ea1e-9f22-4972-8c9d-20d05d74e68b"
      unitRef="usd">102322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifa8445c41fd5491292904732bb0c4761_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzgtNS0xLTEtNjc0NzQ_585054ca-5bc2-42b7-a8da-79faf255d28f"
      unitRef="usd">101834000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzktMS0xLTEtNjc0NzQ_3c90530c-e43e-4e02-91a6-6b5205d8e1e0"
      unitRef="usd">59832000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzktMy0xLTEtNjc0NzQ_fdd53fe6-0a4b-46a5-8305-438fce83433e"
      unitRef="usd">171994000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfMzktNS0xLTEtNjc0NzQ_6158d58c-33ca-4e21-b130-25f24c0f2502"
      unitRef="usd">102322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDItMS0xLTEtNjc0NzQ_520bce4c-2581-4796-bf43-8e3da4fe77d1"
      unitRef="usd">176000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDItMy0xLTEtNjc0NzQ_27a8b4ce-2341-4592-b23a-f9f93fd771b3"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDItNS0xLTEtNjc0NzQ_a72096ab-109b-4d4c-af65-b4dedb17b24e"
      unitRef="usd">11000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDQtMS0xLTEtNjc0NzQ_008c092c-5e5a-4e66-a52c-ab83f3440c97"
      unitRef="usd">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDQtMy0xLTEtNjc0NzQ_af9f7e80-6c73-42f3-9dbb-820c407d0c81"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDMtNS0xLTEtNzA1Mzk_e8fc0c2e-d42e-4e4a-a858-7042808bda43"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDYtMS0xLTEtNjc0NzQ_5b921b27-44f0-463c-a03f-3d2de811d5ab"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDYtMy0xLTEtNjc0NzQ_0284ee1e-09cc-4b8e-a3ff-d1fc9c29dc3c"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDYtNS0xLTEtNjc0NzQ_1bc4dfae-cd4f-43ba-b588-8a26c5bf17f5"
      unitRef="usd">7000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDctMS0xLTEtNjc0NzQ_c5a963bb-2cea-42ba-994b-26896290bb87"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDctMy0xLTEtNjc0NzQ_6ec9ec53-428b-4a96-8053-fc846057af9a"
      unitRef="usd">4434000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNDctNS0xLTEtNjc0NzQ_df0ad64f-7b07-44ae-8656-a46cfcd170ef"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNTEtMS0xLTEtNjc0NzQ_86839409-12fc-491c-861d-b2add84a013b"
      unitRef="usd">50000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNTEtMy0xLTEtNjc0NzQ_79627aac-5b68-4678-b61c-7d3f6bf754ba"
      unitRef="usd">170000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM184OC9mcmFnOjJiNWI5YjFhNjlkNDRhMzA5MmY3ZjNhYjU5NDgxNGZmL3RhYmxlOmZmNDc5ZDJiMzA4ODRhN2ZiMzVjNGFjNmNiZjg3M2E2L3RhYmxlcmFuZ2U6ZmY0NzlkMmIzMDg4NGE3ZmIzNWM0YWM2Y2JmODczYTZfNTEtNS0xLTEtNjc0NzQ_b3949d5c-057d-42eb-b419-2c2b05709614"
      unitRef="usd">480000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzk5Nw_b10cc8db-11e9-4897-a23b-47af69bce445">Nature of the Business&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Morphic Holding, Inc. (the &#x201c;Company&#x201d;) was formed under the laws of the State of Delaware in August 2014. The Company is a biopharmaceutical company applying proprietary insights into integrin medicine to discover and develop first-in-class oral small molecule integrin therapeutics. Integrins are a validated target class with multiple approved drugs for the treatment of serious chronic diseases. Despite significant biopharmaceutical industry investment, no oral small molecule integrin therapies have been approved by the U.S. Food and Drug Administration. The Company has created the Morphic integrin technology platform, or MInT Platform, by leveraging its unique understanding of integrin structure and biology, to develop a pipeline of novel product candidates designed to achieve potency, high selectivity, and the pharmaceutical properties required for oral administration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&#160;The Company expects to continue to incur losses from operations for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months from the date these financial statements were issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2020, the Company entered into an Open Market Sale Agreement (&#x201c;the Original Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $75.0 million, referred to as Placement Shares, through Jefferies as its sales agent. The Company paid Jefferies a commission equal to 3.0% of the gross sales proceeds of any Placement Shares sold through Jefferies under the Original Agreement, and also has provided Jefferies with customary indemnification and contribution rights. On August 11, 2021, the Company entered into an Amendment No. 1 to the Original Agreement with Jefferies, establishing a new at-the-market offering (&#x201c;New ATM&#x201d;) with an aggregate offering price of up to $150.0 million, also subject to a commission equal to 3.0% of gross sales proceeds from Placement Shares sold through Jefferies. Under the New ATM, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, referred to as Placement Shares, through Jefferies as its sales agent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the year ended December 31, 2022, the Company issued and sold 1,000,000 shares for net proceeds of $39.2 million after deducting offering commissions and offering expenses paid by the Company under the New ATM. As of December&#160;31, 2022, the Company had approximately $97.2 million of common stock remaining available for sale under the New ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company completed an underwritten follow-on public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share. Gross proceeds from the secondary offering were approximately $245.0 million, before deducting underwriting discounts, commissions and other offering expenses of approximately $15.0 million, paid by the Company, resulting in net proceeds of approximately $230.0 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i0e2edc7e86b640748d022ccc69c79483_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMjQ4Mw_1fad27ea-cae4-4a48-8a1b-556fc30eefcf"
      unitRef="usd">75000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <morf:PercentageOfCommissionOnGrossSaleProceeds
      contextRef="i0e2edc7e86b640748d022ccc69c79483_D20200701-20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMjYwNw_726e772d-f288-43f9-a625-759987c37b5b"
      unitRef="number">0.030</morf:PercentageOfCommissionOnGrossSaleProceeds>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i5c75f7519ee24eed9649f1ec0217b28e_D20210811-20210811"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzAxMw_b1d896ee-28e2-4f1a-b2fc-de88ec06583c"
      unitRef="usd">150000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <morf:PercentageOfCommissionOnGrossSaleProceeds
      contextRef="i5c75f7519ee24eed9649f1ec0217b28e_D20210811-20210811"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzA1NQ_67ca1d74-1031-4b96-a0ee-f476f8cd6122"
      unitRef="number">0.030</morf:PercentageOfCommissionOnGrossSaleProceeds>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if2d9d037833b403cbf8e599aeddd0edf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzI5ODUzNDg4ODExMA_00291d13-ab6d-43dc-a910-94029cac6999"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzI5ODUzNDg4ODExMA_ba9141c5-613f-4bc1-ac41-b9cc8e58b505"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="if2d9d037833b403cbf8e599aeddd0edf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzI5ODUzNDg4ODEyNg_adc71cbb-6a99-4cec-a5de-a8cad15783e3"
      unitRef="usd">39200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <morf:CommonStockAvailableForIssuance
      contextRef="id5715e43038646d4a427f7c14f57c05d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzU0NA_e0245143-bff9-426b-9047-54a16fe00903"
      unitRef="usd">97200000</morf:CommonStockAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzY4OQ_1e0d860b-cf0a-431d-a33d-f2fef11e57a8"
      unitRef="shares">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="if8aa7e1aba8a4110a761f965a1b311a5_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzc0Nw_da01164a-f801-49fd-b302-fefa4c5b83b8"
      unitRef="usdPerShare">70.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzgyMw_9f3c3c06-4d86-4cb1-b950-931e39d36d7d"
      unitRef="usd">245000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzkyNQ_6f4650d8-c256-4d00-9e8e-f295805b653d"
      unitRef="usd">15000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i440d991bc30b4cdab580a32b5dfbb99e_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185NC9mcmFnOjYwODQ4Y2U5NTM5YTQzOTU5NzhiNjE5MjBiOTYxMzExL3RleHRyZWdpb246NjA4NDhjZTk1MzlhNDM5NTk3OGI2MTkyMGI5NjEzMTFfMzk5Mw_a05aae18-69b8-4597-9dc8-0b8b4d2549ef"
      unitRef="usd">230000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjE_c461549b-3523-4f2c-abce-f507ef70263f">Basis of Presentation and Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Morphic Holding, Inc. and its wholly-owned subsidiaries, Morphic Therapeutic, Inc., Morphic Therapeutic UK Ltd and Morphic Security Corporation. On March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, United Kingdom (the &#x201c;U.K.&#x201d;), to support Company functions outside of the United States. All intercompany balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As disclosed above, on March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, U.K., to support Company functions outside of the United States. The geographic location of all long-lived assets of the Company continues to be the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional reporting currency of Morphic Therapeutic UK Ltd is the United States Dollar. Foreign currency remeasurement is included in other income (expense) in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, and accounts receivable. The Company&#x2019;s cash and cash equivalents are held at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and maintenance of liquidity. The Company&#x2019;s investment policy allows funds to be held outside bank accounts, but to be invested only in readily marketable fixed income instruments with readily ascertainable market values, denominated and payable in United States Dollars including obligations of the U.S. government, U.S. government-sponsored enterprises, U.S. government agencies and highly rated corporate debt obligations, including commercial paper and corporate bonds, and money market funds registered according to Rule 2a-7 of the Investment Company Act of 1940. Investments in the money market fund shall be consistent with approved instruments and assets under management must be at least $1.0&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable generally represent amounts due from Janssen Pharmaceuticals, Inc. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign-hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. At December&#160;31, 2022, cash and cash equivalents include bank demand deposits, money market funds that invest primarily in U.S. government securities, and U.S. Treasury securities. At December&#160;31, 2021, cash and cash equivalents include bank demand deposits and money market funds that invest primarily in U.S. government securities. Cash equivalents are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of cash collateralizing a letter of credit in the amount of $560,000 issued to the landlord of the Company&#x2019;s facility lease as of December 31, 2022 and 2021. The letter of credit and cash collateralizing it increased to $560,000 in August 2021 due to the operating lease extension discussed further in Note 6. The terms of the letter of credit extend beyond one year. The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests funds in U.S. government debt securities, U.S. government-sponsored enterprise debt securities and corporate debt securities with original maturities at the date of purchase greater than three months as marketable securities. The marketable securities are classified as available-for-sale and carried at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all securities with maturity dates beyond three months at the date of purchase as current assets. Changes in the fair value of marketable securities are recorded in other comprehensive income (loss) as net unrealized gains (losses) on marketable securities. The Company recognized net unrealized losses of $2.9 million, $0.5 million and $0.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other expense, net, which is limited to the difference between the fair value and the amortized cost of the marketable security. To date, the Company has not recorded any credit losses on its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable related to the Company&#x2019;s available-for-sale debt securities is presented within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODUwOQ_291e5ba1-214c-49bd-9743-84b648176853"&gt;prepaid expenses and other current assets&lt;/span&gt; on the Company&#x2019;s consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest income on investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest income from investments in money market funds and available-for-sale debt securities, including amortization of premium or accretion of discount, on an accrual basis. For the years ended December 31, 2022, 2021 and 2020, the Company recognized $4.6 million, $0.3 million and $1.6 million in interest income, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income, net is included within other income, net on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Expenditures for major renewals or betterments that extend the useful lives of property and equipment are capitalized; expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the related asset. Property and equipment are depreciated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life (in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of the useful life or the remaining term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures its lease obligations in accordance with ASC 842, Leases, (&#x201c;ASC 842&#x201d;), which requires lessees to recognize a right-of-use (&#x201c;ROU&#x201d;) asset and lease liability for most lease arrangements. Effective January 1, 2021, the Company adopted ASC 842 using the modified retrospective transition method and utilizing the effective date as its date of initial application. As a result, the year ended December 31, 2020 is presented in accordance with the previous guidance in ASC 840, Leases, and there have been no reclassifications of prior comparable periods due to this adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. The Company considers its renewal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;options and extensions within the arrangements and the Company includes these options when it is reasonably certain to extend the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. When a lease modification does not result in a separate contract, it is accounted for as a contract modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract modification requires the Company to reassess the classification of the lease to determine if it is an operating lease or a financing lease. The Company does not have any financing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Entities may elect to not separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes an ROU asset and lease liability as of the transition date or contract modification date based on the present value of the future lease payments over the lease term. ASC 842 requires lessees to use the rate implicit in the lease unless it is not readily determinable and then it may use its incremental borrowing rate (&#x201c;IBR&#x201d;) to discount the future minimum lease payments. The Company's lease arrangement does not provide an implicit rate; therefore, the Company uses its IBR to discount the future minimum lease payments. The Company determines its IBR based on its credit rating, current economic information available as of the transition date or modification date, as well as the identified lease term. The Company&#x2019;s ROU asset and related lease liability are not sensitive to changes in the Company&#x2019;s IBR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prospectively, the Company will remeasure the lease liability at the present value using the same IBR that was in effect as of the transition date or contract modification date and adjust the ROU assets for straight-line rent expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist primarily of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 820, Fair Value Measurement (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At December&#160;31, 2022, investments include U.S. Treasury securities, U.S. government-sponsored enterprise securities, and corporate debt securities, including corporate bonds and commercial paper, which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the carrying amounts of the Company&#x2019;s consolidated financial instruments, including prepaid expenses and other current assets, accounts receivable, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#x2019;s Chief Executive Officer is its chief operating decision-maker and views operations and manages the Company&#x2019;s business in one operating segment operating in the United States and the U.K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date all revenue has been generated from the Company&#x2019;s agreements with AbbVie, executed in October 2018 and terminated as of December 2022, and Janssen, executed in February 2019 and amended in December 2020. Please refer to Note 12 below for details of ASC 606 application to the Company&#x2019;s agreements with AbbVie and Janssen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808, Collaborative Arrangements, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not a customer relationship, in accordance with ASC 808. Through December 31, 2022, the Company had two agreements &#x2013; with AbbVie and Janssen &#x2013; that have been accounted for pursuant to ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the contract(s) with the customer, (ii) identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii) measurement of the transaction price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations, (ii) each party&#x2019;s rights regarding the goods or services to be transferred can be identified, (iii) the payment terms for the goods or services to be transferred can be identified, (iv) the arrangement has commercial substance and (v) collection of substantially all of the consideration to which the Company will be entitled in exchange for the goods or services that will be transferred to the customer is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. Options to purchase additional goods or services are considered to be marketing offers and are to be accounted for as separate contracts when the customer elects such options, unless the Company determines the option provides a material right which would not be provided without entering into the contract. If, however, an option is determined to provide a material right that would not be provided without entering into a contract, a portion of the transaction price is allocated to such option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also evaluates whether instances in which the timing of payments by customers do not match the timing of performance obligation satisfaction contain an element of financing and adjusts the transaction price for the effect of the financing component, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s transactions with customers may include development and regulatory milestone payments. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the customer&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net income (loss) in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price of the identified performance obligations. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#x2019;s collaborations with AbbVie, until its termination, and Janssen, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are expensed as incurred and consist of costs incurred in performing research and development activities, including compensation related expenses for research and development personnel, preclinical and clinical activities including cost of supply, overhead expenses including facilities expenses, materials and supplies, amounts paid to consultants and outside service providers, and depreciation of equipment. Upfront license payments related to acquired technologies which have not yet reached technological feasibility and have no alternative future use are also included in research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Contract and Development Costs and Accruals&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research development service arrangements under which vendors perform various services on behalf of the Company. The Company records accrued expenses for estimated costs incurred under the arrangements. When evaluating the adequacy of the accrued expenses, the Company analyzes the progress of the studies, trials or other services performed, including invoices received and contracted costs. Judgments and estimates are made in determining the accrued expense balances at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company issues stock options, restricted common stock, and restricted stock units to certain employees and non-employees, including directors. The Company accounts for restricted common stock and restricted stock unit expense based on the grant date fair value, which is generally the market price of the Company&#x2019;s common stock on the date of grant, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company accounts for stock option compensation expense based on the grant date fair value of the respective award, determined using the Black-Scholes option-pricing model, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company classifies equity-based compensation expense in its &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;consolidated statements of operations and comprehensive loss in the same way the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please refer to Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss and the change in accumulated other comprehensive loss for the period. For the years ended December 31, 2022, 2021 and 2020, comprehensive loss included $2.9 million, $0.5 million and $0.1 million, respectively, in unrealized holding losses, net on marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company recorded income taxes in accordance with FASB ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on temporary differences between the financial statement basis and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when it is more likely than not that some portion of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. At December 31, 2022 and 2021, the Company had not identified any significant uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements for potential recognition or disclosure in the consolidated financial statements. Subsequent events have been evaluated through the date these consolidated financial statements were issued for potential recognition or disclosure in the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;On February 13, 2023, the Company entered into a securities purchase agreement with existing investors pursuant to which the Company agreed to sell and issue, in a private placement, 848,655 shares of its common stock at a price of $35.35 per share and pre-funded warrants to purchase 1,980,198 shares of common stock at a purchase price of $35.3499 per pre-funded warrant, where each pre-funded warrant has an exercise price of $0.0001 (the &#x201c;Pre-Funded Warrants&#x201d;). The Company received aggregate net proceeds of approximately $100.0&#160;million before deducting costs and offering expenses payable by the Company. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. Per their terms, the outstanding Pre-Funded Warrants generally may not be exercised if the holder&#x2019;s aggregate beneficial ownership would be more than 9.99% of the total issued and outstanding shares of the Company&#x2019;s common stock following such exercise. The exercise price per share and number of shares of common stock issuable upon the exercise of the Pre-Funded Warrant shares are subject to adjustment in the event of any stock dividends and splits, recapitalization, reorganization or similar transaction, as described in the Pre-Funded Warrants.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzI_3edfa120-3b27-400d-b539-18b40f2b3305">The consolidated financial statements include the accounts of Morphic Holding, Inc. and its wholly-owned subsidiaries, Morphic Therapeutic, Inc., Morphic Therapeutic UK Ltd and Morphic Security Corporation. On March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, United Kingdom (the &#x201c;U.K.&#x201d;), to support Company functions outside of the United States. All intercompany balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzM_6b4f76ee-e767-4632-af3c-dab7d2e23a5a">These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjU_6519ec43-878c-46c0-a242-8ee32669613c">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As disclosed above, on March 2, 2022, the Company incorporated Morphic Therapeutic UK Ltd in London, U.K., to support Company functions outside of the United States. The geographic location of all long-lived assets of the Company continues to be the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional reporting currency of Morphic Therapeutic UK Ltd is the United States Dollar. Foreign currency remeasurement is included in other income (expense) in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjY_b7c76003-2c33-4106-81ed-0711730df6db">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, and accounts receivable. The Company&#x2019;s cash and cash equivalents are held at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and maintenance of liquidity. The Company&#x2019;s investment policy allows funds to be held outside bank accounts, but to be invested only in readily marketable fixed income instruments with readily ascertainable market values, denominated and payable in United States Dollars including obligations of the U.S. government, U.S. government-sponsored enterprises, U.S. government agencies and highly rated corporate debt obligations, including commercial paper and corporate bonds, and money market funds registered according to Rule 2a-7 of the Investment Company Act of 1940. Investments in the money market fund shall be consistent with approved instruments and assets under management must be at least $1.0&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable generally represent amounts due from Janssen Pharmaceuticals, Inc. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign-hedging arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:AssetsUnderManagementCarryingAmount
      contextRef="i37b2d1f438d44a009cda649034cdd00a_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzI2MQ_9d083f51-d45f-4924-ae7e-d4ee14058213"
      unitRef="usd">1000000000</us-gaap:AssetsUnderManagementCarryingAmount>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjc_e35f84d5-6c0f-446a-9724-cbafa3d7f9e2">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. At December&#160;31, 2022, cash and cash equivalents include bank demand deposits, money market funds that invest primarily in U.S. government securities, and U.S. Treasury securities. At December&#160;31, 2021, cash and cash equivalents include bank demand deposits and money market funds that invest primarily in U.S. government securities. Cash equivalents are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNDI0Mg_0b99d401-3537-4a8d-b9e7-53882577e375"
      unitRef="usd">560000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNDI0Mg_73445cde-9cc0-4528-bb33-68b901de3665"
      unitRef="usd">560000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i1c29f3379b1841039eb81933bd0e600a_I20210831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNDM3NA_a3b56460-8a41-49ee-b2e6-dcdffce93091"
      unitRef="usd">560000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNDUwNg_79ce7cf0-1fdb-4ef1-a809-33a8572ac1ee">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTc_6a0e1e7f-e7c2-4ade-96d8-9b1ac870a068">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTc_b90d25ee-94ff-479c-9ec3-43ce5e932fcc">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMi0xLTEtMS02NzQ3NA_c2486978-a86d-41e1-9b62-3b04f2e220d1"
      unitRef="usd">59272000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMi0zLTEtMS02NzQ3NA_34db2127-0a7b-4444-809d-bdb2aecb88c6"
      unitRef="usd">171434000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMi01LTEtMS03MTM4OQ_edd3ab12-3566-4641-a782-4117ae5eb28c"
      unitRef="usd">102047000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMy0xLTEtMS02NzQ3NA_21a81e45-0e8a-4361-80d5-99f36e36cf6c"
      unitRef="usd">560000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMy0zLTEtMS02NzQ3NA_22d07640-46c6-4f46-927d-8789af8b6503"
      unitRef="usd">560000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfMy01LTEtMS03MTM4OQ_0e53e2e5-30b9-4e8c-ae4b-1825e19f1b7b"
      unitRef="usd">275000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfNC0xLTEtMS02NzQ3NA_5765234a-0b17-48a1-81e9-bd6617fd2d9d"
      unitRef="usd">59832000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfNC0zLTEtMS02NzQ3NA_c52c19f6-a567-4c7e-b2f5-e1d2ccb46166"
      unitRef="usd">171994000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic21ffb6c01f24ddd8b4a59545a35a49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOmZhMGRhOWZlNDRkNDRmNzZhM2FjOTI1NTBmODhhNjRiL3RhYmxlcmFuZ2U6ZmEwZGE5ZmU0NGQ0NGY3NmEzYWM5MjU1MGY4OGE2NGJfNC01LTEtMS03MTM4OQ_ecff4cf2-b354-41d7-9ec2-49ee8a3d82a8"
      unitRef="usd">102322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTQ_236fb0b1-ae9f-4d19-b82f-400fe9880d79">Marketable securitiesThe Company invests funds in U.S. government debt securities, U.S. government-sponsored enterprise debt securities and corporate debt securities with original maturities at the date of purchase greater than three months as marketable securities. The marketable securities are classified as available-for-sale and carried at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all securities with maturity dates beyond three months at the date of purchase as current assets. Changes in the fair value of marketable securities are recorded in other comprehensive income (loss) as net unrealized gains (losses) on marketable securities.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODU0NA_c7903147-53bb-454a-9b99-cd2c179c4d53"
      unitRef="usd">-2900000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODU1MA_a1e2d31c-ad7a-42e1-8134-a13613608cc1"
      unitRef="usd">-500000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDczODU1NQ_2f9482a9-0411-480f-ad16-70e50c9ef280"
      unitRef="usd">-100000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <morf:InterestIncomeOnInvestmentsPolicyPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTI_24a9d5fd-86f2-4990-937f-961aa1861352">Interest income on investmentsThe Company recognizes interest income from investments in money market funds and available-for-sale debt securities, including amortization of premium or accretion of discount, on an accrual basis.Interest income, net is included within other income, net on the consolidated statements of operations and comprehensive loss.</morf:InterestIncomeOnInvestmentsPolicyPolicyTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNzY5OQ_1e9b5065-2f74-4d77-a763-b4a77b67906e"
      unitRef="usd">4600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNzcwMw_7029d3f9-48cb-46df-b1a6-4b4341e50a9f"
      unitRef="usd">300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfNzcxMA_f2384bcd-1994-4788-bca6-b5f247b3a71c"
      unitRef="usd">1600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzA_70ad240f-944e-4315-9df6-21adbb6a1be9">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Expenditures for major renewals or betterments that extend the useful lives of property and equipment are capitalized; expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the related asset. Property and equipment are depreciated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life (in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of the useful life or the remaining term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTY_63f6d970-c122-4db1-99cc-f74dc00d3833">Depreciation is calculated on a straight-line basis over the estimated useful lives of the related asset. Property and equipment are depreciated as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life (in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of the useful life or the remaining term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022 and 2021, property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6e771d535ddd42f284b6e48b0a3ff9f8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOjBkNzYzMmM1NjBmNjQxN2M5ZTc0YjZkYzA5YjQ3MjU3L3RhYmxlcmFuZ2U6MGQ3NjMyYzU2MGY2NDE3YzllNzRiNmRjMDliNDcyNTdfMS0yLTEtMS02NzQ3NA_ac5acd44-1cb6-4675-b4a0-b8347f362d41">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0d3ccdb187fa404d929dd2ec91a44bcd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOjBkNzYzMmM1NjBmNjQxN2M5ZTc0YjZkYzA5YjQ3MjU3L3RhYmxlcmFuZ2U6MGQ3NjMyYzU2MGY2NDE3YzllNzRiNmRjMDliNDcyNTdfMi0yLTEtMS02NzQ3NC90ZXh0cmVnaW9uOjg4NTg3NmM4M2I4YTRjY2NiY2U3NGEyMTBjMzczNjY1XzQ_4d5611c9-5eed-4694-9176-aaa896288664">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4a4ae752e5f34d0d89ac694b9812ea06_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RhYmxlOjBkNzYzMmM1NjBmNjQxN2M5ZTc0YjZkYzA5YjQ3MjU3L3RhYmxlcmFuZ2U6MGQ3NjMyYzU2MGY2NDE3YzllNzRiNmRjMDliNDcyNTdfMi0yLTEtMS02NzQ3NC90ZXh0cmVnaW9uOjg4NTg3NmM4M2I4YTRjY2NiY2U3NGEyMTBjMzczNjY1Xzc_65fedfd0-073e-4b4b-afc5-4e2a1efb2e3a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjM_5a842b36-0b09-46a2-88d8-8460b9bca08a">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures its lease obligations in accordance with ASC 842, Leases, (&#x201c;ASC 842&#x201d;), which requires lessees to recognize a right-of-use (&#x201c;ROU&#x201d;) asset and lease liability for most lease arrangements. Effective January 1, 2021, the Company adopted ASC 842 using the modified retrospective transition method and utilizing the effective date as its date of initial application. As a result, the year ended December 31, 2020 is presented in accordance with the previous guidance in ASC 840, Leases, and there have been no reclassifications of prior comparable periods due to this adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. The Company considers its renewal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;options and extensions within the arrangements and the Company includes these options when it is reasonably certain to extend the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. When a lease modification does not result in a separate contract, it is accounted for as a contract modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract modification requires the Company to reassess the classification of the lease to determine if it is an operating lease or a financing lease. The Company does not have any financing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Entities may elect to not separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes an ROU asset and lease liability as of the transition date or contract modification date based on the present value of the future lease payments over the lease term. ASC 842 requires lessees to use the rate implicit in the lease unless it is not readily determinable and then it may use its incremental borrowing rate (&#x201c;IBR&#x201d;) to discount the future minimum lease payments. The Company's lease arrangement does not provide an implicit rate; therefore, the Company uses its IBR to discount the future minimum lease payments. The Company determines its IBR based on its credit rating, current economic information available as of the transition date or modification date, as well as the identified lease term. The Company&#x2019;s ROU asset and related lease liability are not sensitive to changes in the Company&#x2019;s IBR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prospectively, the Company will remeasure the lease liability at the present value using the same IBR that was in effect as of the transition date or contract modification date and adjust the ROU assets for straight-line rent expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTg_1873fdb5-3370-4335-9d21-41da47831740">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist primarily of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on long-lived assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTM_f00cfd4e-6628-4642-ace4-8e2c2d1d476e">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 820, Fair Value Measurement (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At December&#160;31, 2022, investments include U.S. Treasury securities, U.S. government-sponsored enterprise securities, and corporate debt securities, including corporate bonds and commercial paper, which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the carrying amounts of the Company&#x2019;s consolidated financial instruments, including prepaid expenses and other current assets, accounts receivable, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzU_12eaad6f-a84c-4c5a-a233-033f42617471">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#x2019;s Chief Executive Officer is its chief operating decision-maker and views operations and manages the Company&#x2019;s business in one operating segment operating in the United States and the U.K.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMTU5MTU_f93b705f-b12e-4d69-b239-3544d4dd9d5d"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjQ_decc2aef-1338-4434-83d6-1bccf3163c34">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date all revenue has been generated from the Company&#x2019;s agreements with AbbVie, executed in October 2018 and terminated as of December 2022, and Janssen, executed in February 2019 and amended in December 2020. Please refer to Note 12 below for details of ASC 606 application to the Company&#x2019;s agreements with AbbVie and Janssen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808, Collaborative Arrangements, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not a customer relationship, in accordance with ASC 808. Through December 31, 2022, the Company had two agreements &#x2013; with AbbVie and Janssen &#x2013; that have been accounted for pursuant to ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the contract(s) with the customer, (ii) identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii) measurement of the transaction price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations, (ii) each party&#x2019;s rights regarding the goods or services to be transferred can be identified, (iii) the payment terms for the goods or services to be transferred can be identified, (iv) the arrangement has commercial substance and (v) collection of substantially all of the consideration to which the Company will be entitled in exchange for the goods or services that will be transferred to the customer is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. Options to purchase additional goods or services are considered to be marketing offers and are to be accounted for as separate contracts when the customer elects such options, unless the Company determines the option provides a material right which would not be provided without entering into the contract. If, however, an option is determined to provide a material right that would not be provided without entering into a contract, a portion of the transaction price is allocated to such option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also evaluates whether instances in which the timing of payments by customers do not match the timing of performance obligation satisfaction contain an element of financing and adjusts the transaction price for the effect of the financing component, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s transactions with customers may include development and regulatory milestone payments. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the customer&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net income (loss) in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price of the identified performance obligations. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#x2019;s collaborations with AbbVie, until its termination, and Janssen, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.&lt;/span&gt;&lt;/div&gt;The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional</us-gaap:RevenueRecognitionPolicyTextBlock>
    <morf:CollaborationAgreementNumberOfAgreements
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMTY4NjM_38459861-4a95-4724-8981-b089d5f60a44"
      unitRef="agreement">2</morf:CollaborationAgreementNumberOfAgreements>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzQ_e657a4a8-4256-47f1-82ad-9af720863734">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are expensed as incurred and consist of costs incurred in performing research and development activities, including compensation related expenses for research and development personnel, preclinical and clinical activities including cost of supply, overhead expenses including facilities expenses, materials and supplies, amounts paid to consultants and outside service providers, and depreciation of equipment. Upfront license payments related to acquired technologies which have not yet reached technological feasibility and have no alternative future use are also included in research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <morf:ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzY_312a4d85-9c4e-4059-a61e-eb4f0af66f18">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Contract and Development Costs and Accruals&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research development service arrangements under which vendors perform various services on behalf of the Company. The Company records accrued expenses for estimated costs incurred under the arrangements. When evaluating the adequacy of the accrued expenses, the Company analyzes the progress of the studies, trials or other services performed, including invoices received and contracted costs. Judgments and estimates are made in determining the accrued expense balances at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;</morf:ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjg_7562c43f-ae3e-4dc0-a7ef-86579f55bfc0">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company issues stock options, restricted common stock, and restricted stock units to certain employees and non-employees, including directors. The Company accounts for restricted common stock and restricted stock unit expense based on the grant date fair value, which is generally the market price of the Company&#x2019;s common stock on the date of grant, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company accounts for stock option compensation expense based on the grant date fair value of the respective award, determined using the Black-Scholes option-pricing model, which is recognized over the requisite service period of the award, which is generally the vesting period, on a straight-line basis. The Company classifies equity-based compensation expense in its &lt;/span&gt;&lt;/div&gt;consolidated statements of operations and comprehensive loss in the same way the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified. The Company recognizes forfeitures as they occur.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMTk_bd9c4a24-4a24-49da-9bbe-7dc6ee73979f">Comprehensive LossComprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss and the change in accumulated other comprehensive loss for the period.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMjY1OTM_386f2f02-3bbf-45fa-be81-374912fc7171"
      unitRef="usd">-2900000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMjY2MDA_941cec29-4b1e-4ed3-a8ff-51a835c0f108"
      unitRef="usd">-500000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMjc0ODc3OTExMDIzMA_fb19a50c-c31c-4077-a82d-bb18c517604c"
      unitRef="usd">-100000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMzE_0c743abb-5a6e-4bf4-9838-c8af4f613e6b">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company recorded income taxes in accordance with FASB ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on temporary differences between the financial statement basis and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when it is more likely than not that some portion of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. At December 31, 2022 and 2021, the Company had not identified any significant uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzMwMjA_7dbb7092-a339-48e4-8907-cc8d7fb5e21b">Subsequent EventsThe Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements for potential recognition or disclosure in the consolidated financial statements. Subsequent events have been evaluated through the date these consolidated financial statements were issued for potential recognition or disclosure in the consolidated financial statements.</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE1Mw_4db126ea-e534-4106-9185-b45e60af5e6f"
      unitRef="shares">848655</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic242dad1f07949378faf34c59d7f5f88_I20230213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE2Mg_a9e4736c-1231-4a5f-9611-bb0614adb379"
      unitRef="usdPerShare">35.35</us-gaap:SaleOfStockPricePerShare>
    <morf:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction
      contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE3MA_a191a429-a3ed-472d-8178-49e0203e69e2"
      unitRef="shares">1980198</morf:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction>
    <morf:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction
      contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE4MQ_50cdca5b-9abe-43be-a956-0d33ccef0e5d"
      unitRef="usdPerShare">35.3499</morf:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic242dad1f07949378faf34c59d7f5f88_I20230213"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDE5MQ_b3ff756b-a1f9-4c58-9b6c-e6a03244472c"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDIwMA_202187b3-ba3b-41d3-a307-78552fddacf7"
      unitRef="usd">100000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="ib9cb810990e746309b39962a67440438_D20230213-20230213"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM185Ny9mcmFnOjg5MjhmMDA4ODEzMDQwYmE5MTVjYWI4ZmNiNWFjYzQ0L3RleHRyZWdpb246ODkyOGYwMDg4MTMwNDBiYTkxNWNhYjhmY2I1YWNjNDRfMzg0ODI5MDc1NDIxNg_a2f82795-2cde-4360-b31b-ee6d48436679"
      unitRef="number">0.0999</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90ZXh0cmVnaW9uOmYyNjdkMGI4MzkyYjQ3NTQ4MTE0NjUzZWNhNWE3NTY2XzExNzI_8ca8b171-5bf7-4972-bbe3-4faf961a7b56">Fair Value of Financial Assets and LiabilitiesThe tables below present information about the Company&#x2019;s financial assets that are measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of money market funds and U.S. Treasury securities as of December&#160;31, 2022 and money market funds as of December&#160;31, 2021. The money market funds included in the tables above invest in U.S. government securities that are valued using quoted market prices. Accordingly, money market funds are categorized as Level 1 as of December&#160;31, 2022 and 2021. Marketable securities included in the tables above consist of U.S. Treasury securities, U.S. government- sponsored enterprise securities, commercial paper and corporate bonds, and these securities are categorized as Level 2 as of December&#160;31, 2022 and 2021. During the years ended December 31, 2022 and 2021, no assets were transferred between the fair value hierarchy categories. The Company had no liabilities measured at fair value on a recurring basis at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90ZXh0cmVnaW9uOmYyNjdkMGI4MzkyYjQ3NTQ4MTE0NjUzZWNhNWE3NTY2XzExNzM_2941ca11-343a-4438-af13-1883ef6c4102">The tables below present information about the Company&#x2019;s financial assets that are measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i604092d4d0e140bb95115f6f5f1a846d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzQtMS0xLTEtNjc0NzQ_dcf9eeaf-4ea7-4b85-b39e-f1fa8fee885e"
      unitRef="usd">58814000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2d512dd5bdfe419cb8800b44352cd997_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzQtMy0xLTEtNjc0NzQ_7411cd35-9c82-430f-b3a5-b72154c0dea6"
      unitRef="usd">38942000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic2254b383dd1434c8eb41be8f1291d19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzQtNS0xLTEtNjc0NzQ_68a67950-af7c-4b5c-bac7-ba40f88e9560"
      unitRef="usd">19872000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i702273bf69ee47298902b18d256ef436_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzQtNy0xLTEtNjc0NzQ_d9dd43a5-e0c8-46df-9c5d-1a3be552cccc"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1fcc2263734a44549091a97cc1630de9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzYtMS0xLTEtNjc0NzQ_b004a39e-a0e1-4709-babd-617df228b09c"
      unitRef="usd">177932000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8d95317815642b1abbb1b41f9d0fcbe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzYtMy0xLTEtNjc0NzQ_ad84c569-0f37-4ad5-b768-89a8f3849454"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51d81cccb60449a6a2bf1592ec8cf208_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzYtNS0xLTEtNjc0NzQ_cddc7af4-d5a1-48d8-8981-60ae5cf72b62"
      unitRef="usd">177932000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06caa44988a1401d9cadf3a6919cc075_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzYtNy0xLTEtNjc0NzQ_a3686ad7-fad8-494e-9024-ab4880fe1095"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84093c3db3c34ee9975edca937505f59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzctMS0xLTEtNjc0NzQ_4d47438f-9c8b-42b6-a094-c811a7c59603"
      unitRef="usd">12396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i28d8a3c8f6ba4c55be3e856fa074e12c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzctMy0xLTEtNjc0NzQ_de4053f2-d4d9-4743-bdda-1e4ccf492237"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i451016625f664d87b0f1149b4b460ca4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzctNS0xLTEtNjc0NzQ_3c6d7a37-16eb-4ef0-b1ea-2e9f9cfb0953"
      unitRef="usd">12396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18e50ae5e2db43a2ba46810dc63df33e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzctNy0xLTEtNjc0NzQ_2348c55c-6ed0-45ea-a403-353939c1cc5e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if75f48a62b5e4f50be21277ae7a6a555_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzgtMS0xLTEtNjc0NzQ_c059c03c-3e83-48a1-a4b8-4be119b6856e"
      unitRef="usd">9860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f6464b00ff1424290015908d925bcff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzgtMy0xLTEtNjc0NzQ_396308ed-55ff-4dcd-bd0f-3732f1ee92be"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0afb206a6a142988b4b7c1c5c112488_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzgtNS0xLTEtNjc0NzQ_2f733238-19a8-4962-8a6b-55e782280a7b"
      unitRef="usd">9860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63cd7797863b4c878b6bd0037f63a034_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzgtNy0xLTEtNjc0NzQ_91609bcb-9132-4d1e-b482-68689bbb2337"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2cef8c55113245b18d699b291da71849_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzktMS0xLTEtNjc0NzQ_904e6e22-456f-49e6-8d0f-08ff03acc181"
      unitRef="usd">88788000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75b5f1a419654cec9538eeec4eb6d001_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzktMy0xLTEtNjc0NzQ_affbfd9e-d2cd-446e-9154-b2f43bd769d8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11d5f8b0c8cf4bf1904278026e089ab9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzktNS0xLTEtNjc0NzQ_e1bf8781-e369-4246-933d-c2847f6c8ad8"
      unitRef="usd">88788000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i291a0cdf99ae4372848ba10ce4515329_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzktNy0xLTEtNjc0NzQ_2a3f3b6d-d237-4ae6-8b16-82ecf4cfd9da"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc86524fc8604efaabb07582c77cd814_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzEyLTEtMS0xLTY3NDc0_5a345cd7-2bb5-4f26-ba2c-2349d991bd31"
      unitRef="usd">347790000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i162590f81a47412f95d12b41a46788fe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzEyLTMtMS0xLTY3NDc0_52a4e083-9c0d-49ae-82f3-75cdc66c4d50"
      unitRef="usd">38942000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i420d5fbd11644553ac2f20de753fb3be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzEyLTUtMS0xLTY3NDc0_6cddbcb6-28aa-4610-9106-9d2048c0916f"
      unitRef="usd">308848000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie895696982894ca393ad2b4731ed0312_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTpmM2MxYWVmOGQ3OWM0Yjg4YWEyMWFkM2IzM2U3NjcxMS90YWJsZXJhbmdlOmYzYzFhZWY4ZDc5YzRiODhhYTIxYWQzYjMzZTc2NzExXzEyLTctMS0xLTY3NDc0_d01570b2-6f37-405c-a2fa-e88ed429fb6a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d32d3ada9f945c991fb1e2c468a3056_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzQtMS0xLTEtNjc0NzQ_9fd04a49-97a7-494a-b08e-7b12120f30f4"
      unitRef="usd">171142000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibee7cc6c73784af3a95d08dabf38f780_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzQtMy0xLTEtNjc0NzQ_f78321be-d154-4617-9ce3-c0e1ccc7e4a4"
      unitRef="usd">171142000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8f63d08cf43c445aab401c01568c17c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzQtNS0xLTEtNjc0NzQ_1bdcc2e4-bd70-4cdb-b350-eae22989c311"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i06e9b237f63147898db008b76d81cc93_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzQtNy0xLTEtNjc0NzQ_7d9bb5fd-3324-4cf2-9643-120ecac1485e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65bd95f6cce84501bc85ceb141f2ad69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctMS0xLTEtNzAyMzQ_f4b75f36-12f4-4b80-af9d-8f7597c41463"
      unitRef="usd">16212000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b24e4bd1eca47dd863579e21bc04e0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctMy0xLTEtNzAyMzQ_601b9c31-5750-465a-9fcc-304cc9717d25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8f9f8031a004ca58585fa9bc615ac4d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctNS0xLTEtNzAyMzQ_7fcd9095-5627-4cb1-8e4f-dba9e95a53ae"
      unitRef="usd">16212000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie618c17501df442fb50f6f5a9d0af3e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctNy0xLTEtNzAyMzQ_c249f1d2-ed46-419d-ae89-0330a85ec8b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i461c0f15b1c64560b66aee8c7c5e1946_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtMS0xLTEtNzAyNDY_1bfce5d8-00c2-4aae-af80-959781bc85bd"
      unitRef="usd">99898000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i396cbab97ede453fa4531ea88932d4ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtMy0xLTEtNzAyNDY_7fd62d1d-9163-4e71-ac41-c84ab7b4b1af"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97846bbf5a2a45279b8fabd054295701_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtNS0xLTEtNzAyNDY_c7e0dfd8-b089-4cc2-ab6c-21504bda8463"
      unitRef="usd">99898000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2d05e295ffa4672bb1aa0fa78c22da2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtNy0xLTEtNzAyNDY_d7a7b849-cdfc-4eb6-8407-831a258639f4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3fb707bd819f4336b205ce25f8057e47_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctMS0xLTEtNjc0NzQ_f56ad89e-2e25-4ad2-962e-18e2afab30bd"
      unitRef="usd">120591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i608c2d9be0664c69a0ac30c84a5bca4d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctMy0xLTEtNjc0NzQ_68f63eff-4785-4451-9f94-30069c95e5fb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05301005239d4ade9956b8262164a5aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctNS0xLTEtNjc0NzQ_4f96ba7f-c029-4b19-833c-239ab271f95b"
      unitRef="usd">120591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d650c04838d45e090cfc3ae81926a54_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzctNy0xLTEtNjc0NzQ_769a822a-c117-4b24-9f2d-c11df18221a1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i55b4f455938e42d8a96daae58b3fa4c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtMS0xLTEtNjc0NzQ_4a23379a-91e7-4abb-8fdc-62af670a3e23"
      unitRef="usd">407843000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ac46ba0e0664b0e977e59505ee5d97c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtMy0xLTEtNjc0NzQ_d67d2919-1b27-40ac-a7d2-d1d584f395e1"
      unitRef="usd">171142000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3f3d728458a5471e9ed4c1a92d4f66c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtNS0xLTEtNjc0NzQ_c7699af3-69f8-4876-8246-ac6f7bcb5344"
      unitRef="usd">236701000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf582a62191e406a9ec5e7e9b0698e8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90YWJsZTo5YjVkNjRmZmI4N2U0ODYzOGI1ZDRiZDk4NWFiMGIwNC90YWJsZXJhbmdlOjliNWQ2NGZmYjg3ZTQ4NjM4YjVkNGJkOTg1YWIwYjA0XzgtNy0xLTEtNjc0NzQ_9478462d-8611-4530-90db-5030a9ed99b1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ifc86524fc8604efaabb07582c77cd814_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90ZXh0cmVnaW9uOmYyNjdkMGI4MzkyYjQ3NTQ4MTE0NjUzZWNhNWE3NTY2XzgxMw_4db3c805-c8f3-468d-a710-4a0e4bc70043"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i55b4f455938e42d8a96daae58b3fa4c0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDMvZnJhZzpmMjY3ZDBiODM5MmI0NzU0ODExNDY1M2VjYTVhNzU2Ni90ZXh0cmVnaW9uOmYyNjdkMGI4MzkyYjQ3NTQ4MTE0NjUzZWNhNWE3NTY2XzgxMw_cbcc4f65-4b93-416c-9e3f-840f76c66b7e"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90ZXh0cmVnaW9uOmY5MjU2NTljZDgwNzRmMzFiY2IyZDNiZmQ2NzViNGE0XzExMzc_d9f03f07-5831-49f0-af3e-ffd2781d1d48">Marketable securities&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s investments in marketable securities classified as available-for-sale (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;within 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;within 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;within 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive loss. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all available-for-sale securities as current assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that there was no material change in the credit risk of the above investments during the years ended December 31, 2022 and 2021. As such, an allowance for credit losses was not recognized. As of December 31, 2022, the Company does not intend to sell such securities and it is not more likely than not that the Company will be required to sell the securities before recovery of its amortized cost basis.&lt;/span&gt;&lt;/div&gt;Accrued interest receivable on the Company&#x2019;s available-for-sale debt securities totaled $1.4 million and $1.2 million as of December 31, 2022 and 2021, respectively.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90ZXh0cmVnaW9uOmY5MjU2NTljZDgwNzRmMzFiY2IyZDNiZmQ2NzViNGE0XzExMzg_10366ec8-9b74-4af0-b7fc-52c948582713">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s investments in marketable securities classified as available-for-sale (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;within 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;within 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;within 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzMtMy0xLTEtNjc0NzQ_654ba5e5-9ab0-435a-ad07-b7dc2f5ad187"
      unitRef="usd">179854000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzMtNS0xLTEtNjc0NzQ_3192764b-cfce-48df-b6be-962192072996"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzMtNy0xLTEtNjc0NzQ_f654555d-e556-4ea1-9949-d5649cc1446b"
      unitRef="usd">1922000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibe8ee5ed3abc4d759eb0cb5e403307db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzMtOS0xLTEtNjc0NzQ_4efdd6d0-d3cf-4f8b-ab32-2553fd61d6e5"
      unitRef="usd">177932000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f2e7300f7184ac58092340abcc0b069_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtMy0xLTEtNzAyNzY_c45a5d6a-c5f0-485b-ab24-cebfb5ca2700"
      unitRef="usd">12500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8f2e7300f7184ac58092340abcc0b069_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtNS0xLTEtNzAyNzY_ded97b41-11b4-4e41-a9e1-9a810fec5c9b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8f2e7300f7184ac58092340abcc0b069_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtNy0xLTEtNzAyNzY_f723781f-6f9b-4392-a580-99e49c20e73b"
      unitRef="usd">104000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8f2e7300f7184ac58092340abcc0b069_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtOS0xLTEtNzAyNzY_bb71c166-ceeb-4eca-b2ed-59d5c8e4063a"
      unitRef="usd">12396000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic5a3f4082fa1417b962818adcf991f1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtMy0xLTEtNjc0NzQ_2019a766-2254-4175-913f-bf4ffe54437d"
      unitRef="usd">9860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic5a3f4082fa1417b962818adcf991f1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtNS0xLTEtNjc0NzQ_54806ec8-dd00-4afe-8816-9f13a3aa0885"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic5a3f4082fa1417b962818adcf991f1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtNy0xLTEtNjc0NzQ_555a1f41-1ff0-40ac-b549-b77019f647c9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic5a3f4082fa1417b962818adcf991f1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzQtOS0xLTEtNjc0NzQ_d70a4bcc-d572-46e7-959a-3979caa91e79"
      unitRef="usd">9860000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0b30679359684bb791882ad58c6a044e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzYtMy0xLTEtNjc0NzQ_7a7e0aaa-43fd-4860-88e3-52bcaa58fb2a"
      unitRef="usd">90076000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0b30679359684bb791882ad58c6a044e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzYtNS0xLTEtNjc0NzQ_bb00be5d-096a-45b0-8c98-61caa5744b03"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0b30679359684bb791882ad58c6a044e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzYtNy0xLTEtNjc0NzQ_eaa9743a-0f6d-4b7b-b3f9-e7695c8cf4bc"
      unitRef="usd">1288000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0b30679359684bb791882ad58c6a044e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzYtOS0xLTEtNjc0NzQ_537ad60e-317f-4214-91db-c205ed26768b"
      unitRef="usd">88788000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzktMy0xLTEtNjc0NzQ_1aca9669-9e98-451d-be6e-e6020dae042a"
      unitRef="usd">292290000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzktNS0xLTEtNjc0NzQ_33184684-cbf5-4017-b31d-8927f0bd1a03"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzktNy0xLTEtNjc0NzQ_73add59f-c421-4a8e-be7c-e9bc313066e1"
      unitRef="usd">3314000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTplMzMyNzFjNmU0Zjg0YWU2YjBmZWY2NTc2MDVkYTU3Zi90YWJsZXJhbmdlOmUzMzI3MWM2ZTRmODRhZTZiMGZlZjY1NzYwNWRhNTdmXzktOS0xLTEtNjc0NzQ_0902f10c-f1b7-49df-8a66-dbdd1796faf9"
      unitRef="usd">288976000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie2813f455dff462a99153011829d659e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtMy0xLTEtNjc5MDc_2c246cf6-f5e1-4e5e-837d-397369f58a65"
      unitRef="usd">16224000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie2813f455dff462a99153011829d659e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtNS0xLTEtNjc5MDc_23e08f17-4b52-4114-a148-7a3f3481d0fd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie2813f455dff462a99153011829d659e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtNy0xLTEtNjc5MDc_c392901a-0717-4761-8175-b57932599b9c"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie2813f455dff462a99153011829d659e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtOS0xLTEtNjc5MDc_295e0524-faee-4375-ba2f-e4e250e78fad"
      unitRef="usd">16212000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i97f1c205a6d14e4ba2e8721db48b2841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtMy0xLTEtNjc0NzQ_fc2e2b1c-d818-41f5-a66f-0587f5252751"
      unitRef="usd">99900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i97f1c205a6d14e4ba2e8721db48b2841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtNS0xLTEtNjc0NzQ_47eec613-0e0d-44f8-a33e-0cd2b1446a1d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i97f1c205a6d14e4ba2e8721db48b2841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtNy0xLTEtNjc0NzQ_7558cfe3-002a-4c56-83a9-4ed143edc5fb"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i97f1c205a6d14e4ba2e8721db48b2841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzMtOS0xLTEtNjc0NzQ_1b884d33-1ddc-4cc9-a1da-c2086156f6b8"
      unitRef="usd">99898000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzQtMy0xLTEtNjc0NzQ_249dffaa-5285-476f-892a-1aca93f828bf"
      unitRef="usd">121034000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzQtNS0xLTEtNjc0NzQ_4bc1c7e5-efbb-4cf3-9d68-6f947b6bfe6e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzQtNy0xLTEtNjc0NzQ_10f6edd7-7bba-4e01-b5ce-f77ec9612535"
      unitRef="usd">443000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i52bfdeb8b59f402cbbc9ea497f8b3f79_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzQtOS0xLTEtNjc0NzQ_9ea4dd1c-9918-41fd-a323-9f2c6092eebe"
      unitRef="usd">120591000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzctMy0xLTEtNjc5MDc_2cf2c52b-a3d1-4049-8260-8579c2c34a3c"
      unitRef="usd">237158000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzctNS0xLTEtNjc5MDc_cd0f9aff-4557-43f0-aac9-6c2fd2124df4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzctNy0xLTEtNjc5MDc_d625ba59-fc41-4444-a68e-d74660725221"
      unitRef="usd">457000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90YWJsZTpkN2U3MjkxNGNjNWY0N2IwOTA1MjJmOTJmOTYyNzIxZi90YWJsZXJhbmdlOmQ3ZTcyOTE0Y2M1ZjQ3YjA5MDUyMmY5MmY5NjI3MjFmXzctOS0xLTEtNjc5MDc_373e7de7-13f1-4e75-be5e-450e106bb340"
      unitRef="usd">236701000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90ZXh0cmVnaW9uOmY5MjU2NTljZDgwNzRmMzFiY2IyZDNiZmQ2NzViNGE0XzExMDU_e40a2e61-d61c-4033-8150-b9931de9f4d6"
      unitRef="usd">1400000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMDYvZnJhZzpmOTI1NjU5Y2Q4MDc0ZjMxYmNiMmQzYmZkNjc1YjRhNC90ZXh0cmVnaW9uOmY5MjU2NTljZDgwNzRmMzFiY2IyZDNiZmQ2NzViNGE0XzExMTI_8757e51d-5f78-43af-92dc-98bb5549f64b"
      unitRef="usd">1200000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90ZXh0cmVnaW9uOmM4YzhmYmRmNTYyNDQyMDk5NWMxN2JlMzFkZDQzYjNkXzIyMQ_bb4cf2cb-db54-43d4-9a47-11319ca58bf1">Property and Equipment, Net&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022 and 2021, property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was $1.0 million, $1.0 million and $1.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibb71b13217964931b29e2541f7607577_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzItMS0xLTEtNjc0NzQ_f59e30dd-d94f-41d1-bb53-2a720973d3d2"
      unitRef="usd">6094000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia8a7102b9d5346c292e630c2c88780d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzItMy0xLTEtNjc0NzQ_7f370f9e-cc4b-4da1-b3c5-e0f198225ffb"
      unitRef="usd">5608000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i196fe36e4f60419799bbe38a05fd598e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzMtMS0xLTEtNjc0NzQ_175ce0e5-c1e0-463a-9734-96e83b9ef609"
      unitRef="usd">596000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i765d898d413c42ecadfd22771b559151_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzMtMy0xLTEtNjc0NzQ_d7153d17-657f-4f13-a789-82ad6e1d4c76"
      unitRef="usd">546000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1e316a0be4b34afa97bceaaf82979c6e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzQtMS0xLTEtNjc0NzQ_609bcd68-29c3-449a-a5a7-94499f9b068d"
      unitRef="usd">611000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i773e6d896fab4cba847b5f4fa4a9f8b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzQtMy0xLTEtNjc0NzQ_2fd06390-8722-4a50-9744-70dc4786852a"
      unitRef="usd">606000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzYtMS0xLTEtNjc0NzQ_a06e0eb7-4a00-401f-b08b-ae350d694a0e"
      unitRef="usd">7301000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzYtMy0xLTEtNjc0NzQ_ba07b9b7-089e-4808-98e7-1d31522e4428"
      unitRef="usd">6760000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzctMS0xLTEtNjc0NzQ_e6c6312d-c45e-4a81-9825-d243bbdeb21d"
      unitRef="usd">5182000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzctMy0xLTEtNjc0NzQ_f22afe3b-27a5-4df8-af69-68fad59ce59e"
      unitRef="usd">4177000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzgtMS0xLTEtNjc0NzQ_389a21ee-d7ec-43f7-a8ca-160a248a659e"
      unitRef="usd">2119000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90YWJsZTplZjM1NzFlMjNjOGM0NTZlYTU1MTM4MGZlYTRkNDQ3ZC90YWJsZXJhbmdlOmVmMzU3MWUyM2M4YzQ1NmVhNTUxMzgwZmVhNGQ0NDdkXzgtMy0xLTEtNjc0NzQ_69c369e1-314a-463e-a535-2b86186dd9ec"
      unitRef="usd">2583000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90ZXh0cmVnaW9uOmM4YzhmYmRmNTYyNDQyMDk5NWMxN2JlMzFkZDQzYjNkXzE4Mw_84bd16a7-f151-49a2-b0b9-ff55e1495d73"
      unitRef="usd">1000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90ZXh0cmVnaW9uOmM4YzhmYmRmNTYyNDQyMDk5NWMxN2JlMzFkZDQzYjNkXzE4Nw_2e49e696-eb44-4d30-a444-305effdebb6c"
      unitRef="usd">1000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTIvZnJhZzpjOGM4ZmJkZjU2MjQ0MjA5OTVjMTdiZTMxZGQ0M2IzZC90ZXh0cmVnaW9uOmM4YzhmYmRmNTYyNDQyMDk5NWMxN2JlMzFkZDQzYjNkXzE5NA_5873bb0d-e044-4743-8ae8-e32897412270"
      unitRef="usd">1100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE5MDA_f8a5b498-1709-4aef-be25-e01a8d01ed17">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a lease arrangement for its corporate headquarters in Waltham, Massachusetts. In August 2021, the Company exercised its one-time extension right for its existing lease for 32,405 square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. Since the exercise of the one-time extension right for its existing lease did not qualify to be accounted for as a separate lease, the Company accounted for the exercise of the one-time extension right as a contract modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassessed the lease classification for the Company&#x2019;s corporate headquarters as of the effective date of the modification using the modified terms and conditions and the facts and circumstances as of that date. This included using the remaining economic life of the underlying asset on that date, the discount rate for the lease on that date and a remeasurement and reallocation of the remaining consideration in the contract on that date. The Company concluded that the lease continues to be classified as an operating lease, reassessed the IBR as of the effective date of the modification, and remeasured the lease liability and ROU asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Supplemental balance sheet information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental operating lease balance sheet information is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_4277bab9-a4bc-4bb4-8619-266e108e3a33"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_450fd7b4-c958-4b0b-9afd-fcd530cac7f4"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The short-term portion of operating lease liabilities is included within accrued expenses on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other supplemental information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other supplemental operating lease information is summarized as follows (in thousands, except for years and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Maturities of lease commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Maturities of operating lease commitments as of December&#160;31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Totals&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the years ended December 31, 2022, 2021 and 2020 the Company recognized operating lease expense of $1.6&#160;million, $1.3&#160;million and $1.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="ic70e9fc24c404da2964ca9969e1b1582_I20210831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzIxNA_b8aeef85-a918-4986-9907-7cdb94f487a9"
      unitRef="sqft">32405</us-gaap:AreaOfLand>
    <morf:LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE5MDE_27e197cd-2a94-4206-b927-8e549a58a81a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental operating lease balance sheet information is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_4277bab9-a4bc-4bb4-8619-266e108e3a33"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMC0xLTEtNjc0NzQ_450fd7b4-c958-4b0b-9afd-fcd530cac7f4"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The short-term portion of operating lease liabilities is included within accrued expenses on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other supplemental information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other supplemental operating lease information is summarized as follows (in thousands, except for years and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</morf:LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzEtMi0xLTEtNjc0NzQ_62cf27bf-5787-4cf4-9af8-c97ef098bdc7"
      unitRef="usd">3514000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzMtMi0xLTEtNjc0NzQ_2ec4b880-e796-443e-aaf7-77298e307eed"
      unitRef="usd">1494000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzQtMi0xLTEtNjc0NzQ_8dc95eb5-38fe-41de-add7-6ad59b52520d"
      unitRef="usd">2344000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpmMzIyZmE0ZTc2MDQ0NzY5YWFiYWFkNGY0YTczYzM3Ni90YWJsZXJhbmdlOmYzMjJmYTRlNzYwNDQ3NjlhYWJhYWQ0ZjRhNzNjMzc2XzUtMi0xLTEtNjc0NzQ_c28e9d7f-d6ff-4ae7-b04c-458c5af3060f"
      unitRef="usd">3838000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTplZTIyYzgwY2JhNjA0MzY1ODc5MmZkZDI3M2NiYjBkMi90YWJsZXJhbmdlOmVlMjJjODBjYmE2MDQzNjU4NzkyZmRkMjczY2JiMGQyXzEtMi0xLTEtNjc0NzQ_9bff4786-eea0-4280-b96f-14171e66970d"
      unitRef="usd">1507000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTplZTIyYzgwY2JhNjA0MzY1ODc5MmZkZDI3M2NiYjBkMi90YWJsZXJhbmdlOmVlMjJjODBjYmE2MDQzNjU4NzkyZmRkMjczY2JiMGQyXzMtMi0xLTEtNjc0NzQ_338dbf81-495f-4fef-8364-4d88d27b2d1a">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTplZTIyYzgwY2JhNjA0MzY1ODc5MmZkZDI3M2NiYjBkMi90YWJsZXJhbmdlOmVlMjJjODBjYmE2MDQzNjU4NzkyZmRkMjczY2JiMGQyXzQtMi0xLTEtNjc0NzQ_e74ba7ca-f1ed-44cb-bbc3-8c16545757ab"
      unitRef="number">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE5MDI_95c820ca-1da1-424e-beba-8a5c735eeea6">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Maturities of operating lease commitments as of December&#160;31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Totals&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzItMi0xLTEtNjc0NzQ_4d7efcc8-1e18-440d-b307-bd7b433e7a25"
      unitRef="usd">1700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzMtMi0xLTEtNjc0NzQ_23ceca63-c74f-48f6-b38e-a96a997c725d"
      unitRef="usd">1732000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzQtMi0xLTEtNjc0NzQ_ca5d6a0c-8e64-495b-97f3-e17be7c0f7cc"
      unitRef="usd">728000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzYtMi0xLTEtNjc0NzQ_ff606e9c-f38c-4338-9690-fe3785bd2a5b"
      unitRef="usd">4160000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzctMi0xLTEtNjc0NzQ_ad9b4b77-8b46-40ff-9f99-c01ce30720cd"
      unitRef="usd">322000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90YWJsZTpkOWE5MTYyOGJjNTU0MzliYjY0MmM0NTNmMDFhNjkzNi90YWJsZXJhbmdlOmQ5YTkxNjI4YmM1NTQzOWJiNjQyYzQ1M2YwMWE2OTM2XzgtMi0xLTEtNjc0NzQ_da9e9b31-c1b6-4a5d-b653-a05c466f042c"
      unitRef="usd">3838000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE4NzM_9360133d-fd56-4b30-bd89-6af5eb3660a7"
      unitRef="usd">1600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE4Nzc_5be3c4ac-0a58-42ad-9e92-f79b8d90a0ea"
      unitRef="usd">1300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTUvZnJhZzowM2FhYmIyYWExNjg0NjM2OGZlM2Q5ZDhjOWRmZjA1My90ZXh0cmVnaW9uOjAzYWFiYjJhYTE2ODQ2MzY4ZmUzZDlkOGM5ZGZmMDUzXzE4ODQ_27d7a0fa-36d0-4902-8dc9-be563486a546"
      unitRef="usd">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90ZXh0cmVnaW9uOjUwNDA2NmY1OTYzMjQ4NzY5MjUwMjkwMmUzNDBiNDJiXzk4_a9ba284e-1439-4a28-a3c8-e7802d503034">Accrued Expenses&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021 accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90ZXh0cmVnaW9uOjUwNDA2NmY1OTYzMjQ4NzY5MjUwMjkwMmUzNDBiNDJiXzk5_ead585d2-6ad0-431f-8531-c63fd96fc4ff">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021 accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzMtMS0xLTEtNjc0NzQ_84cea0f6-70e5-453a-884b-d27a27057fae"
      unitRef="usd">6569000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzMtMy0xLTEtNjc0NzQ_c5ac51a5-ce0f-4d85-acef-342eb0a29b33"
      unitRef="usd">6396000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <morf:AccruedResearchAndDevelopment
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzQtMS0xLTEtNjc0NzQ_f05bf0da-0be0-4079-a1cd-838515fc20a9"
      unitRef="usd">4265000</morf:AccruedResearchAndDevelopment>
    <morf:AccruedResearchAndDevelopment
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzQtMy0xLTEtNjc0NzQ_314aa269-6a5a-4af1-821c-346b17277c1a"
      unitRef="usd">4268000</morf:AccruedResearchAndDevelopment>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzUtMS0xLTEtNjc0NzQ_6a399bb4-5f71-475b-b561-dd3e8cf0bd97"
      unitRef="usd">1494000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzUtMy0xLTEtNjc0NzQ_cf432930-0c22-4aee-b254-6eef6bd94991"
      unitRef="usd">1211000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzYtMS0xLTEtNjc0NzQ_51d5e3fb-c23f-4662-9b68-65497e2daec8"
      unitRef="usd">853000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzYtMy0xLTEtNjc0NzQ_de0cb0d4-6f9b-4fbd-ab12-350c9f48daa1"
      unitRef="usd">963000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzctMS0xLTEtNjc0NzQ_029d2607-0f82-4aaa-90d3-613ca40ae3d8"
      unitRef="usd">13181000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMTgvZnJhZzo1MDQwNjZmNTk2MzI0ODc2OTI1MDI5MDJlMzQwYjQyYi90YWJsZTo4M2U2YmJhOWYxMmM0Y2YwYWI2NjQ4NmE3NWI2ZDdjYS90YWJsZXJhbmdlOjgzZTZiYmE5ZjEyYzRjZjBhYjY2NDg2YTc1YjZkN2NhXzctMy0xLTEtNjc0NzQ_d3a21e53-41b3-4297-a4f0-d551bf6d078e"
      unitRef="usd">12838000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzExNjk_bc473e6c-4d87-47fd-9ea8-8ba235a44f09">Stockholders&#x2019; Equity&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The common stock has the following characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Voting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of common stock are entitled to one vote for each share of common stock held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of shares of common stock are entitled to receive dividends, if and when declared by the Company&#x2019;s board of directors. Cash dividends may not be declared or paid to holders of shares of common stock until all unpaid dividends on any preferred stock outstanding have been paid in accordance with their terms. As of December 31, 2022 and 2021, no preferred stock was outstanding. No dividends have been declared or paid by the Company to the holders of common stock since the issuance of the common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the common shares are entitled to receive distributions of cash, including in the event of a liquidation or dissolution of the Company, which preference is junior to the liquidation preference of any preferred stockholders. After any preferred stockholders have received their respective preferred distributions, any assets remaining for distribution shall be distributed to the holders of preferred or common shares determined on an as-converted basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <morf:VotingRights
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzE0NQ_0097286d-1906-45d3-bd93-67cd9231b324"
      unitRef="vote">1</morf:VotingRights>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzUzMA_50613f1d-bd62-4fd3-a6b9-14a8dc07da40"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzUzMA_5328139c-8055-43a4-9431-318d9bad1efa"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzU2Ng_018a0a23-a42b-493a-9183-7a799f2ae55a"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzU2Ng_52b25a35-f0c0-4f70-aed4-5cbfee34c7b2"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzU2Ng_e7769b23-51bd-4b4e-adf4-111eb55ce294"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjEvZnJhZzo1ODE4YjA5NDgwM2Y0NDcxYTk3NDdiOWMzMmEzNDVmNi90ZXh0cmVnaW9uOjU4MThiMDk0ODAzZjQ0NzFhOTc0N2I5YzMyYTM0NWY2XzU2Ng_f8438998-57e2-48cd-af9c-3d6b270c4fde"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2ODE_042e2e82-7626-441f-94ce-6ee377c46f38">Equity-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In connection with the Company&#x2019;s initial public offering in July 2019, the Company adopted the 2019 Equity Incentive Plan (the &#x201c;Original 2019 Plan&#x201d;) in June 2019, which replaced the 2018 Stock Incentive Plan. The board of directors adopted the Amended and Restated 2019 Equity Incentive Plan (the &#x201c;A&amp;amp;R 2019 Plan&#x201d; and, together with the Original 2019 Plan, the &#x201c;2019 Plan&#x201d;) on April 27, 2022, which was subsequently approved by the Company&#x2019;s stockholders on June 8, 2022, to revise the total annual compensation that may be awarded to the Company&#x2019;s non-employee directors thereunder. The A&amp;amp;R 2019 Plan provides for the grant of stock options, restricted stock awards, stock bonus awards, cash awards, stock appreciation right, restricted stock units, and performance awards to directors, officers and employees of the Company, as well as consultants and advisors of the Company. As a result of the automatic increase provision of the 2019 Plan, the number of shares of common stock available for issuance under the A&amp;amp;R 2019 Plan increased by 1.5&#160;million shares in January 2022. As of&#160;December&#160;31, 2022, there were a total of&#160;1.8 million shares available for future award grants under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by expense category (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Restricted Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the restricted common stock activity during the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Fair&lt;br/&gt;Value per Share&lt;br/&gt;at Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had no unrecognized equity-based compensation expense related to the restricted common stock. The total fair value of restricted common stock awards vested during the years ended December 31, 2022, 2021 and 2020 was approximately $0.1 million, $5.0 million, and $5.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The following table summarizes the restricted stock units activity during the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Fair&lt;br/&gt;Value per Share&lt;br/&gt;at Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had unrecognized equity-based compensation expense of $8.3 million related to the restricted stock units, which is expected to be recognized over a weighted average period of 3.1 years. The total fair value of restricted stock units vested during the years ended December 31, 2022 and 2021 was approximately $0.2 million and $2.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity during the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,781,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(459,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides certain information related to the stock options granted, vested, and exercised during the years ended December 31, 2022, 2021 and 2020, in thousands, except for per option values:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of options granted, per option&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash received from exercises of stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic market value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average assumptions used in determining the fair value of the options granted during the years ended December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk&#x2011;free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.81%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.09%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.85%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term for employee and director stock options is the mid-point between the weighted average of vesting period and the contractual term. The Company determines the volatility for options granted based on the historical volatility of a representative group of publicly traded companies for which historical information is available in addition to the Company&#x2019;s own historical volatility. The historical volatility is generally calculated based on a period of time commensurate with the expected term assumption. The risk-free interest rate is based on a zero-coupon U.S. Treasury instrument with terms consistent with the term of the stock options. The Company has not paid and does not anticipate paying cash dividends on shares of common stock; therefore, the expected dividend yield is assumed to be zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had unrecognized equity-based compensation expense of $50.0 million related to stock options issued to employees and non-employees, which is expected to be recognized over a weighted average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), which became effective on June 26, 2019. The Company initially reserved 300,000 shares of common stock for sale under the ESPP. As a result of the automatic increase provision of the ESPP, the number of shares of common stock available for issuance under the ESPP increased by 0.4&#160;million shares on January 1, 2022. The ESPP is a qualified, compensatory plan under Section 423 of the Internal Revenue Code and offers substantially all employees opportunity to purchase up to $25,000 of common stock per year at 15% discount to the lower of the beginning of the offering period price or the end of the offering period price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the course of the offering period.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0839d27335e24a70944c9e307b2f4ffd_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzY2Nw_b112753e-b6e2-4771-b922-26724ccc308b"
      unitRef="shares">1500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i836995cd69774ea6a3b54d9201496a27_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzcyNg_7f20873d-2e58-4b30-bf41-989808079064"
      unitRef="shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2Nzc_1e01b72a-e4d3-45f0-8aab-e8898540cb1e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of equity-based compensation expense in the consolidated statements of operations and comprehensive loss, by expense category (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzItNS0xLTEtNjc0NzQ_e0742164-d02f-4cb5-830b-8649c42e1d8c"
      unitRef="usd">25828000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ed3baf9425c4deb80dc4f747f071420_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzItNy0xLTEtNjc0NzQ_810f5be9-eee0-4da5-923a-de786dc0e551"
      unitRef="usd">19894000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i77e987ed93cc4e8d9dfb645f146cde1f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzItOS0xLTEtNjc0NzQ_1c237725-1414-4937-bd00-1e795019b057"
      unitRef="usd">9418000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i174e9b0c5f7c46c78a563fe182cdb790_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzMtNS0xLTEtNjc0NzQ_d956f2fd-835f-4f6e-a1e4-35b8c0e5e06d"
      unitRef="usd">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd74a7f3cc934ea7bcea941a7ceb4135_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzMtNy0xLTEtNjc0NzQ_0e21c237-f8a8-4f39-9f38-eaed67a4ee60"
      unitRef="usd">283000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14cc5a3c0a534d1798020230d15314ca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzMtOS0xLTEtNjc0NzQ_6d563a0b-352d-4a6c-8aa9-b13c3d796a94"
      unitRef="usd">955000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45c1bfca603942ca815065d9e1dc6770_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzQtNS0xLTEtNjc0NzQ_e0e069b9-11a5-4353-bfe9-3db8c1a89620"
      unitRef="usd">2764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib31c5cf61778485d991ddab611e9d542_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzQtNy0xLTEtNjc0NzQ_850e1051-b239-4402-b5f1-16b2327b1986"
      unitRef="usd">403000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i37a599d132d6483baa46f6bf673c0e6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzQtOS0xLTEtNjc0NzQ_fe83688f-369a-4454-b517-45db35fcc433"
      unitRef="usd">187000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88474183cda941d09a44d4d825426649_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzUtNS0xLTEtNjc0NzQ_80a9a1b7-be3c-4cd2-8c5f-7cc3e091a3cb"
      unitRef="usd">450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c8315abe4964879986d1a88cf096b3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzUtNy0xLTEtNjc0NzQ_54941bef-957b-4da7-8d81-4439ab030174"
      unitRef="usd">604000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76ce846988a44545a5367eba9a038043_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzUtOS0xLTEtNjc0NzQ_6d5c7d8a-d26d-4221-914e-0f65c17d6cc3"
      unitRef="usd">493000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzYtNS0xLTEtNjc0NzQ_e1f0e8e8-1f93-424d-b275-eaa8ce54cbe1"
      unitRef="usd">29048000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzYtNy0xLTEtNjc0NzQ_340e0113-0e93-4148-a76e-a27f36bf28ef"
      unitRef="usd">21184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTowOWRjZTcwOGNlYWU0ODljOGQyN2YzNGQ3MGRhMzQ2Zi90YWJsZXJhbmdlOjA5ZGNlNzA4Y2VhZTQ4OWM4ZDI3ZjM0ZDcwZGEzNDZmXzYtOS0xLTEtNjc0NzQ_a9f35fa6-fa4b-46b9-99d1-11bcf2090a77"
      unitRef="usd">11053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i318589b3af594468b4d7a4f435e6ebbe_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzItNS0xLTEtNjc0NzQ_3d1a4538-8db5-4a06-8f38-73be335137c7"
      unitRef="usd">13518000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib69dad785ae2431ebdb2f50942f10325_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzItNy0xLTEtNjc0NzQ_aab8049b-b6f9-4856-8389-0bd4ca73ca48"
      unitRef="usd">9866000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48f714ec6be446a99691b35600899a4c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzItOS0xLTEtNjc0NzQ_6cbddeb0-3f9d-4078-881f-2d599941918f"
      unitRef="usd">6114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if9687b7a51c845ac993e26a0f4880580_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzMtNS0xLTEtNjc0NzQ_f6beb895-c9e7-446d-b292-cd98f43b5a3b"
      unitRef="usd">15530000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief146b6ab46a43909d51d8b1c46787e1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzMtNy0xLTEtNjc0NzQ_495e6084-a884-40cb-b253-e55d544d26da"
      unitRef="usd">11318000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34fe4eecb36748f5af8018f88fcb0c6f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzMtOS0xLTEtNjc0NzQ_e3f7423a-bdaf-46d2-a8fe-04cb8aa5e57e"
      unitRef="usd">4939000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzQtNS0xLTEtNjc0NzQ_28f15521-fbbf-4952-b858-3b0a82c78ab4"
      unitRef="usd">29048000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzQtNy0xLTEtNjc0NzQ_e03d7e5e-c190-4130-ac04-d2164f1e8859"
      unitRef="usd">21184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphNDVhOWMzM2E3ZTQ0MDY5OGY1YmI3ZDgyNmNjNWUzMC90YWJsZXJhbmdlOmE0NWE5YzMzYTdlNDQwNjk4ZjViYjdkODI2Y2M1ZTMwXzQtOS0xLTEtNjc0NzQ_b7452af0-6d97-4288-a87b-647dcac6d5d5"
      unitRef="usd">11053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2Nzg_2a3f50e5-a8c9-4e19-87e5-4aad9ac1e5ab">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the restricted common stock activity during the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Fair&lt;br/&gt;Value per Share&lt;br/&gt;at Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2140ecc30f7b44bab979e57fe3c6d43f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzEtMS0xLTEtNjc0NzQ_8bf01171-986d-42c7-a69d-0ed1e559458b"
      unitRef="shares">2171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2140ecc30f7b44bab979e57fe3c6d43f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzEtMy0xLTEtNjc0NzQ_90389787-6c3b-499d-a036-5f2538ed4ae1"
      unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzItMS0xLTEtNjc0NzQ_88c9bd04-a012-4f5d-81f0-73a30cc3189e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzItMy0xLTEtNjc0NzQ_e106550a-aa08-42b7-94aa-5855a05ce8b1"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzMtMS0xLTEtNjc0NzQ_90a4386d-40d9-442c-8e07-e3abc03d87b2"
      unitRef="shares">2171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzMtMy0xLTEtNjc0NzQ_0785d32f-5b17-4b35-888e-9d082c2ab9ee"
      unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzQtMS0xLTEtNjc0NzQ_4f24f0d5-3314-4f51-b53b-ca36c906f95b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie0ca337f31ed413a9a2e9f4a27d9a6f9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzQtMy0xLTEtNjc0NzQ_45cb7c04-d88f-449d-a082-dab7b0935f6e"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5d4cafd342524466bff01db8b6fb6b1f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzUtMS0xLTEtNjc0NzQ_cfe793f1-e4cc-4a06-81a1-a4fae4ee6aed"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5d4cafd342524466bff01db8b6fb6b1f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpjZmQxM2E2MjdlZGY0ZTM3YWVjMWM5NDBmNTE5NTE5OC90YWJsZXJhbmdlOmNmZDEzYTYyN2VkZjRlMzdhZWMxYzk0MGY1MTk1MTk4XzUtMy0xLTEtNjc0NzQ_c23a5196-46bb-4399-a2a4-d51521adecc6"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i101397ce8aac488895ed850a9c62f94a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzEwNDQ1MzYwNDcwNjA4_4f5f0a19-f3a3-4126-82f7-aadf7c6925a9"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i101397ce8aac488895ed850a9c62f94a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzE1OTU_793c7c0f-a559-479a-8600-b9b2babe3669"
      unitRef="usd">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i902baae07eda49b091ea19d753ae4bae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzE1OTk_8656d00a-af11-4e41-bcf5-40af806c47a0"
      unitRef="usd">5000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i6d6a05d3b283469d804ddf8e891690b7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzE2MDc_962ee974-2513-42a8-a80e-5e0315992b00"
      unitRef="usd">5600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2NzQ_d0980cd6-00f9-41c9-af67-3ac081f2c000">The following table summarizes the restricted stock units activity during the year ended December 31, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Fair&lt;br/&gt;Value per Share&lt;br/&gt;at Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5e4a0451e3944bb8b1e7d8a518951a90_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzEtMS0xLTEtNjc0NzQ_656f289e-9113-490d-b89a-1d8bd8c2edfc"
      unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5e4a0451e3944bb8b1e7d8a518951a90_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzEtMy0xLTEtNjc0NzQ_b7a82df0-aa6b-4e41-bd47-4e17a617ed00"
      unitRef="usdPerShare">57.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzItMS0xLTEtNjc0NzQ_7fbe7fcc-6da2-4105-b763-ef29665c6c51"
      unitRef="shares">291970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzItMy0xLTEtNjc0NzQ_e1da7873-724e-4de8-8f48-6d68ae21f98d"
      unitRef="usdPerShare">43.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzMtMS0xLTEtNjc0NzQ_15e13a8e-c679-4024-b84f-0a28aaa08ad4"
      unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzMtMy0xLTEtNjc0NzQ_a73afb14-e0f9-4e1c-90b8-629926a95788"
      unitRef="usdPerShare">57.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzQtMS0xLTEtNjc0NzQ_0c19af7d-8488-48fe-a488-c5986f2bbec7"
      unitRef="shares">42880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i4c493892db224a7497fa47e163d3f8f4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzQtMy0xLTEtNjc0NzQ_f96b698d-f23c-4514-aad9-411ad6235c94"
      unitRef="usdPerShare">44.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic584c82f7fa941aaa1d9a7ca334e75f8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzUtMS0xLTEtNjc0NzQ_e55d3f05-671d-43e2-9911-4c05e4540a0c"
      unitRef="shares">249090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic584c82f7fa941aaa1d9a7ca334e75f8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZToxMjExYTQ5NmUyM2Y0YTBmYTIxOTllOWUzNmJiYTZmNC90YWJsZXJhbmdlOjEyMTFhNDk2ZTIzZjRhMGZhMjE5OWU5ZTM2YmJhNmY0XzUtMy0xLTEtNjc0NzQ_e7675d99-138e-4b2d-ba6e-26bf6afe5995"
      unitRef="usdPerShare">43.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i44c3053062ab47179828227426197a95_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzI3NDg3NzkwNzU5NjY_660c4ee4-fb3c-4797-9ecc-bfcaebe80496"
      unitRef="usd">8300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i45c1bfca603942ca815065d9e1dc6770_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzI3NDg3NzkwNzYxMzA_34059424-6c15-4a65-8ac7-317e7b00ae52">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i44c3053062ab47179828227426197a95_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzIwMzY_4dafbe39-def4-49fe-aae9-292af9de6ac7"
      unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="iaa9f54446643489fac9a8dbe66be6f9d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzI3NDg3NzkwNzYxNjA_7f16a8db-60a2-493e-9907-b0d4473cff0b"
      unitRef="usd">2100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2NzU_cb83fdff-7740-4388-b3a5-c4aa70e49bad">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity during the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,781,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(459,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic8748f4e6ee9480c88e24d869168b315_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzItMS0xLTEtNjc0NzQ_49d23301-cc47-4c2d-801d-3f6a66b546f6"
      unitRef="shares">4781565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic8748f4e6ee9480c88e24d869168b315_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzItMy0xLTEtNjc0NzQ_af278f4f-36fa-48a3-8a1f-fe98ca9a51f8"
      unitRef="usdPerShare">20.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzMtMS0xLTEtNjc0NzQ_07a8eda1-1bbb-4863-986d-c426dd186a62"
      unitRef="shares">1498918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzMtMy0xLTEtNjc0NzQ_d4478333-81c1-479d-a24b-6bd107f6d507"
      unitRef="usdPerShare">39.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzQtMS0xLTEtNjc0NzQ_742a067e-48c7-4763-a86c-a58245ed0eb6"
      unitRef="shares">459839</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzQtMy0xLTEtNjc0NzQ_9adadbeb-c3dc-4ec9-8a8e-dd8d11d108dd"
      unitRef="usdPerShare">11.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzUtMS0xLTEtNjc0NzQ_f21c2a96-53b6-4937-bb1e-118748df9fdc"
      unitRef="shares">557091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzUtMy0xLTEtNjc0NzQ_f1233ae0-74bc-4a8b-8f51-2c3c2d40b131"
      unitRef="usdPerShare">33.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzYtMS0xLTEtNjc0NzQ_9240e5ed-4c03-459e-adc4-2205f6d6f139"
      unitRef="shares">5263553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzYtMy0xLTEtNjc0NzQ_df3d2572-e971-4742-951c-a454d7b44c48"
      unitRef="usdPerShare">24.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzYtNS0xLTEtNjc0NzQ_06b858ee-4646-4150-8bb9-324136ff3647">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzYtNy0xLTEtNjc0NzQ_d2e8e8a8-fbae-417e-b208-5e1379d43cc8"
      unitRef="usd">38525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzctMS0xLTEtNjc0NzQ_8e49b9be-0735-4cfe-b991-37b1a09dac56"
      unitRef="shares">2990254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzctMy0xLTEtNjc0NzQ_873fd673-2d8b-40c5-b99c-9f59c3528f2a"
      unitRef="usdPerShare">19.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzctNS0xLTEtNjc0NzQ_fecc4b0a-8655-4227-9713-97f24d74811b">P6Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTpiOGYxN2E2OTZlYmI0MzM1YjkwZWZiZjVlZmM2Njk0Ny90YWJsZXJhbmdlOmI4ZjE3YTY5NmViYjQzMzViOTBlZmJmNWVmYzY2OTQ3XzctNy0xLTEtNjc0NzQ_3b39e4a5-5056-4645-ae11-8d4bb6999ffa"
      unitRef="usd">32522000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <morf:ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2Nzk_e0fe9038-407b-490f-8356-caec9a008e81">The following table provides certain information related to the stock options granted, vested, and exercised during the years ended December 31, 2022, 2021 and 2020, in thousands, except for per option values:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of options granted, per option&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash received from exercises of stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic market value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</morf:ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzItMS0xLTEtNjc0NzQ_f7d4e942-ff71-41c8-8553-0b324c0fb1df"
      unitRef="usdPerShare">28.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzItMy0xLTEtNjc0NzQ_7ee04590-7351-41e6-8669-f20138ed6288"
      unitRef="usdPerShare">26.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzItNS0xLTEtNjc0NzQ_29e1676c-972e-4fc2-b935-9196bf552cb4"
      unitRef="usdPerShare">10.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzMtMS0xLTEtNjc0NzQ_02dd57d2-261a-4ad0-8198-6e26bc2f52f7"
      unitRef="usd">5175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzMtMy0xLTEtNjc0NzQ_114c853b-1b5f-43ed-b5c7-f8ed429c1c37"
      unitRef="usd">9536000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzMtNS0xLTEtNjc0NzQ_cb5e53a6-a6d6-4b4e-9aeb-b41b8ab3ec82"
      unitRef="usd">3532000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzQtMS0xLTEtNjc0NzQ_8a5f5288-147c-4edb-aa63-896b2e461d6f"
      unitRef="usd">8507000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzQtMy0xLTEtNjc0NzQ_fae12beb-8008-486a-9da1-a8fad903d11f"
      unitRef="usd">39335000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTo3MGFmMGM2MTNiMTA0ODgyOWMyNTU4YjdjY2VjOTQ0OC90YWJsZXJhbmdlOjcwYWYwYzYxM2IxMDQ4ODI5YzI1NThiN2NjZWM5NDQ4XzQtNS0xLTEtNjc0NzQ_89e5908a-a1e7-4881-a75a-ebd88ace48e2"
      unitRef="usd">7752000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQ2NzY_d2caeca3-4b6f-4097-8861-5c57b7f1a848">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average assumptions used in determining the fair value of the options granted during the years ended December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk&#x2011;free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.81%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.09%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.85%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7f297cc869c04c60a6c213e1fb23bdf5_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzItMS0xLTEtNjc0NzQ_3a83606f-224a-43c9-ac48-6c9babad392b"
      unitRef="number">0.0202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7ad5b858858b4142b730f313c6ba0354_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzItMy0xLTEtNjc0NzQ_fc15b31c-5e1f-49fd-89a7-c1acf05009af"
      unitRef="number">0.0120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7ff85e46b56d4930968dac9e3affabd5_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzItNS0xLTEtNjc0NzQ_9a7b15c8-8780-4da7-b68c-644c9ac7c351"
      unitRef="number">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7f297cc869c04c60a6c213e1fb23bdf5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzQtMS0xLTEtNjc0NzQ_5aa613f0-0f7a-45a2-9c7c-c11d059ae979">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7ad5b858858b4142b730f313c6ba0354_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzQtMy0xLTEtNjc0NzQ_8cb5134d-090c-4bca-986f-87cd6ca08e11">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7ff85e46b56d4930968dac9e3affabd5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzQtNS0xLTEtNjc0NzQ_aea0aca1-0127-4b3a-a9a7-929e4f36409d">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7f297cc869c04c60a6c213e1fb23bdf5_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzUtMS0xLTEtNjc0NzQ_1a4b9138-9bb5-4fd2-b1f9-eefb3883b774"
      unitRef="number">0.8681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7ad5b858858b4142b730f313c6ba0354_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzUtMy0xLTEtNjc0NzQ_720a6d7f-3718-48c1-b0ef-14c46161cc80"
      unitRef="number">0.8709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7ff85e46b56d4930968dac9e3affabd5_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90YWJsZTphZjNmYmI1NDE4Y2Y0MzA5ODZlMTUzYjZlOWYyYTk0MC90YWJsZXJhbmdlOmFmM2ZiYjU0MThjZjQzMDk4NmUxNTNiNmU5ZjJhOTQwXzUtNS0xLTEtNjc0NzQ_bcfb828d-8b53-4cfc-a17d-c52015e22109"
      unitRef="number">0.8085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i26b5fdb614974175853f2513fb83dcec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzM1ODQ_7bb88c06-dc5c-4e25-9a2b-f2d4ab837a9c"
      unitRef="usd">50000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4e80a31d51494c71a479f3ce7ed90191_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzM3MjA_a17939fb-4686-4845-8dcf-59e9610f32ae">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib9a49673c39d457ca1650953807a3049_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzM4Nzg_f3991708-e42e-4920-8f34-b39e9c1199bf"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia4c949b67a814dcbae7f09a0249d0ed7_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQwNzg_88e7b948-0704-481b-bc2b-9cbf23f4052d"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <morf:EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee
      contextRef="id499edf539a74aff9a76526f02dd5aa9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQyNjc_89016654-3315-453e-afd9-3badc61d4ae1"
      unitRef="usd">25000</morf:EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee>
    <morf:ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock
      contextRef="i6e430e2b2d7d4b9bb5788a847d6c2d7e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMjQvZnJhZzphZmU4MjE3ZjA5ZWI0YTg4OWJjZDIwYTQ1MzQ5ZGUwMi90ZXh0cmVnaW9uOmFmZTgyMTdmMDllYjRhODg5YmNkMjBhNDUzNDlkZTAyXzQyOTg_5896e6d5-e855-4836-86a3-d3474abcca96"
      unitRef="number">0.15</morf:ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzUwNTQ_64f2cdfb-c0f8-40d2-9e0a-63cad88cb929">Income Taxes&lt;div style="margin-bottom:6pt;margin-top:18pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss before income taxes for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,036)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,542)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,569)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,974)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,542)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,569)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax (benefit) expense for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#x2019;s loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax effected at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities consist of the following at December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,969&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,269&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and experimental expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,101&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,843&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,649&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,077&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,610&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,139&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,927&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,417)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,703)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(960)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(572)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As required by ASC 740, the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of collaboration revenue that has been recognized as taxable but remains deferred for book reporting as of year end and net operating loss carryfowards. The Company has determined that it is more likely than not that the Company will not realize the benefits of its federal and state deferred tax assets, and, as a result, a valuation allowance of $99.4 million and $82.7 million has been established at 2022 and 2021, respectively. The change in the valuation allowance was $16.7 million and $37.1 million for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in 2022, Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) amended Section 174 and now requires U.S.-based and non-U.S.-based research and experimental (&#x201c;R&amp;amp;E&#x201d;) expenditures to be capitalized and amortized over a period of five or 15 years, respectively, for amounts paid in tax years starting after December 31, 2021. Prior to the TCJA amendment, Section 174 allowed taxpayers to immediately deduct R&amp;amp;E expenditures in the year paid or incurred.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has applied this required change in accounting method beginning in 2022 and the computation may be adjusted pending future IRS guidance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has incurred net operating losses (&#x201c;NOLs&#x201d;) from inception. At December 31, 2022, the Company has federal and state NOL carryforwards of approximately $180.3 million and $191.5 million, respectively, available to reduce future taxable income, that expire beginning in 2037, with $176.4 million of the federal NOLs having an unlimited carryover life. As of December 31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $12.6 million and $5.7 million, respectively,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;to offset future income taxes, which will begin to expire beginning in December 2032. The Company&#x2019;s NOL carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The company continues to review its historic ownership changes to determine if there are any IRC 382 limitations which may limit the annual utilization of the NOLs. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company follows the provisions of ASC 740-10, &#x201c;Accounting for Uncertainty in Income Taxes,&#x201d; which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions. As of December 31, 2022 and 2021, the Company had no unrecognized tax benefits. The Company has not identified any uncertain positions with respect to the credit computations. The Company&#x2019;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the years ended December 31, 2022 and 2021, no estimated interest or penalties were recognized on uncertain tax positions. The Company does not expect any significant change in its uncertain tax positions in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company files U.S. federal and state income tax returns and is generally subject to income tax examinations by these authorities for all tax years after December 31, 2018. Currently, no federal or state income tax returns are under examination by the respective income tax authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provision for Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded income tax expense of $0.1 million for the year ended December 31, 2022, income tax expense of $0.0 million for the year ended December 31, 2021 and a benefit from income taxes of $0.6 million for the year ended December 31, 2020. The benefit recorded in 2020 was attributed to a federal net operating loss carryback claim allowed under the CARES Act. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Despite the collaboration revenue, the Company continues to maintain a valuation allowance against all deferred tax assets. The Company believes that it is more likely than not that the Company will not realize a future tax benefit of these attributes, as the Company&#x2019;s research programs continue to require significant investment and future revenue is subject to uncertainties. Ultimate realization of any deferred tax asset is dependent on the Company&#x2019;s ability to generate sufficient future taxable income in the appropriate tax jurisdiction before the expiration of carryforward periods, if any.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzYwNDczMTM5Njg3NzQ_5be0bf16-93a0-49a8-bdb4-57dced253174">&lt;div style="margin-bottom:6pt;margin-top:18pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss before income taxes for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,036)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,542)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,569)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,974)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,542)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,569)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzItMS0xLTEtNzYwOTQ_1423fe86-e478-434e-b2e4-79a0423a6371"
      unitRef="usd">-59036000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzItMy0xLTEtNzYwOTc_376d8ca0-b2a0-41b1-a1b6-de5c4bb2750e"
      unitRef="usd">-95542000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzItNS0xLTEtNzYwOTk_fb5185a4-bd63-4b6b-840b-d3daa2fd23d2"
      unitRef="usd">-45569000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzMtMS0xLTEtNzYwOTQ_2be19248-746c-4f4e-a949-9862fac7ecad"
      unitRef="usd">62000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzMtMy0xLTEtNzYwOTc_5ff68582-8d30-4d7b-b2be-f7a3824b2615"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzMtNS0xLTEtNzYwOTk_aaca796c-f1a9-4620-9045-64b19405e2db"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzQtMS0xLTEtNzYwOTQ_d80aa237-cce1-46dd-88a8-d55e8da2a91d"
      unitRef="usd">-58974000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzQtMy0xLTEtNzYwOTc_310b7773-e753-4657-9447-6a97c0d552db"
      unitRef="usd">-95542000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTozZjU1MDQyOWUxMzY0YmVlOTAxYWNmMTMyZTNkODY0NC90YWJsZXJhbmdlOjNmNTUwNDI5ZTEzNjRiZWU5MDFhY2YxMzJlM2Q4NjQ0XzQtNS0xLTEtNzYwOTk_b7bd1d3c-8b83-46da-b306-16ed555d07c2"
      unitRef="usd">-45569000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzUwNTU_26549a8f-3abc-4c69-b682-37131fa6fcb2">&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax (benefit) expense for the years ended December 31, 2022, 2021 and 2020 (in thousands) were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzMtMS0xLTEtNjc0NzQ_5cf50b3a-b165-4e30-9848-129ce44cd741"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzMtMy0xLTEtNjc0NzQ_1eca8ea6-6708-4df6-9172-e9ca60073dc4"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzMtNS0xLTEtNjc0NzQ_ef8a79aa-f84d-40b2-8b45-d4c2cc48c737"
      unitRef="usd">-511000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtMS0xLTEtNzQyMTE_aa12ebe2-bc67-45a9-8c41-735d97bc82cf"
      unitRef="usd">55000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtMy0xLTEtNzQyMTE_bec6f15f-22af-44bf-a615-614293934cc5"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtNS0xLTEtNzQyMTE_dcb16f58-2ac4-4b82-899d-65c77de9abd1"
      unitRef="usd">-59000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtMS0xLTEtNjc0NzQ_94b2f15c-ed03-4e49-af67-64eb3d6e7399"
      unitRef="usd">12000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtMy0xLTEtNjc0NzQ_e7e08f28-eb82-4d48-996e-2000707a4b96"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzQtNS0xLTEtNjc0NzQ_46251ec8-54f4-4f6d-b220-24773b3ea8ba"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzUtMS0xLTEtNjc0NzQ_db1cc014-5a0d-46f8-8dd5-fe7309bc90ed"
      unitRef="usd">67000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzUtMy0xLTEtNjc0NzQ_d905f150-ccf2-4a5a-a7a2-304457f83929"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzUtNS0xLTEtNjc0NzQ_9653b116-e3b5-41de-a063-414a491b4036"
      unitRef="usd">-570000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzctMS0xLTEtNjc0NzQ_9ecee8a1-bdf8-4b3a-a1fd-7db648af6c14"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzctMy0xLTEtNjc0NzQ_fd835f1c-d903-42a4-b28f-1a42717c7c41"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzctNS0xLTEtNjc0NzQ_cd9827fa-743e-4146-82a4-7266144779a4"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktMS0xLTEtNzQyMTg_3eec168a-8c5b-42d0-afd2-4027a1fcaf97"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktMy0xLTEtNzQyMTg_50d95f18-4997-4736-a296-1998300c4cbe"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktNS0xLTEtNzQyMTg_27f37c9a-197c-4ad3-8809-d435d032103f"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzgtMS0xLTEtNjc0NzQ_79bb802a-90e1-42f4-aad0-465c58dfd7c5"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzgtMy0xLTEtNjc0NzQ_189f26ff-2882-47dd-9330-d40a5726df8e"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzgtNS0xLTEtNjc0NzQ_43ef0903-fe00-4520-8dc2-d5d3b621cf7f"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktMS0xLTEtNjc0NzQ_7a03051e-d8cd-4f25-b3df-f946aa340527"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktMy0xLTEtNjc0NzQ_9a28c106-fd16-4820-a156-5d9e809890bf"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzktNS0xLTEtNjc0NzQ_5950a6d7-9616-472f-bb12-bd7ea85d0cf3"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzEwLTEtMS0xLTY3NDc0_73777845-cf54-4f1a-87c6-598c4506a28e"
      unitRef="usd">67000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzEwLTMtMS0xLTY3NDc0_9e345a5f-1051-4847-9475-f1d8c9f5ea6d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTphZDUzMDJjZTdmZjg0MmI2YjgwMWJkN2VlYjQ2ODRiZi90YWJsZXJhbmdlOmFkNTMwMmNlN2ZmODQyYjZiODAxYmQ3ZWViNDY4NGJmXzEwLTUtMS0xLTY3NDc0_d17cd875-9af3-4c20-89d6-c4c2dd43779b"
      unitRef="usd">-570000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzUwNTY_6af83491-a212-4ce0-a5ad-984a28c12ba3">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#x2019;s loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax effected at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzItMS0xLTEtNjc0NzQ_bbed6925-f51a-4a26-9347-a0d35773cfc5"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzItMy0xLTEtNjc0NzQ_eed37909-8017-44ea-95b4-9b2800632b30"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzItNS0xLTEtNjc0NzQ_3e30df3b-ea72-4896-9deb-621de90a9250"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzMtMS0xLTEtNjc0NzQ_c3489d28-8e0e-48fc-9b25-f68fddf90dc3"
      unitRef="number">0.0784</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzMtMy0xLTEtNjc0NzQ_5f7ad433-fd55-4939-81b6-f7f949941db6"
      unitRef="number">0.0931</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzMtNS0xLTEtNjc0NzQ_ce2524c9-b9f7-479d-b2ba-16db611ad92d"
      unitRef="number">0.0838</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzQtMS0xLTEtNjc0NzQ_a53cb37d-b7e5-41d3-863e-148c9fb9a6b9"
      unitRef="number">-0.0102</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzQtMy0xLTEtNjc0NzQ_19acd531-5825-4958-ba87-d0f6756c99be"
      unitRef="number">0.0533</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzQtNS0xLTEtNjc0NzQ_29634af5-d68f-4a76-be63-1a4afa53252d"
      unitRef="number">0.0076</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzUtMS0xLTEtNjc0NzQ_015c6a14-5882-4acd-a839-037eaf732e6d"
      unitRef="number">-0.0387</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzUtMy0xLTEtNjc0NzQ_1497ea27-2b8f-4ee1-bbd7-8b4e3696a0f9"
      unitRef="number">-0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzUtNS0xLTEtNjc0NzQ_fdb62068-3ebc-45de-9c3c-5f7ae267f59b"
      unitRef="number">-0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzYtMS0xLTEtNjc0NzQ_6ed0388f-1871-4f1c-85c9-a697adc30e1b"
      unitRef="number">0.0683</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzYtMy0xLTEtNjc0NzQ_9952c3d2-acc5-449b-8567-4d5da852a260"
      unitRef="number">0.0334</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzYtNS0xLTEtNjc0NzQ_402796fd-6d80-40e8-925f-ef0699ca4206"
      unitRef="number">0.0621</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzctMS0xLTEtNjc0NzQ_50899f35-92ef-4d3a-b6e0-bc4dec3ec411"
      unitRef="number">-0.3089</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzctMy0xLTEtNjc0NzQ_9b3eea6e-fc6c-41b2-a7a1-8d9b9fabddd5"
      unitRef="number">-0.3897</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzctNS0xLTEtNjc0NzQ_5876021d-a72b-427a-97b1-68c4d1c2a3c3"
      unitRef="number">-0.3509</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzgtMS0xLTEtNjc0NzQ_216f72d0-3cd1-4f90-9f8a-07119cd3fb9e"
      unitRef="number">-0.0011</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzgtMy0xLTEtNjc0NzQ_a96b4a97-c814-4eaf-bd74-ea4a486b3633"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZToxMzM3ODdmM2Q2ODA0ZWRmYTZmNDcyYzM5MDZiMDU0NS90YWJsZXJhbmdlOjEzMzc4N2YzZDY4MDRlZGZhNmY0NzJjMzkwNmIwNTQ1XzgtNS0xLTEtNjc0NzQ_a5d76cf9-38bc-48d6-9b88-5b6c944353a8"
      unitRef="number">0.0125</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzUwNTc_68d23801-806e-4836-b0cd-afe490cc3c03">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities consist of the following at December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,969&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,269&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and experimental expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,101&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,843&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,649&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,958&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,077&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,610&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,139&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,927&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,417)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,703)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(960)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(572)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzMtMS0xLTEtNjc0NzQ_cd1203ea-fba3-491c-ada9-25218bc91dbc"
      unitRef="usd">49969000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzMtMy0xLTEtNjc0NzQ_df710122-eb70-4d92-9b1c-51af8ba68fdb"
      unitRef="usd">44269000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzQtMS0xLTEtNzQ4MzQ_e430e602-07f8-4a42-a4e3-1c4a79f2bff9"
      unitRef="usd">22147000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzQtMy0xLTEtNzQ4MzQ_4f031394-50eb-4f79-8fed-959971ad60ed"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzUtMS0xLTEtNzQ4NDk_0892586f-78b8-4fa9-a9f2-d83fef282c51"
      unitRef="usd">17101000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzUtMy0xLTEtNzQ4NDk_674b308e-cf20-4b87-89e1-fb1c660bc614"
      unitRef="usd">10843000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzQtMS0xLTEtNjc0NzQ_cd244029-2dfc-4901-a072-681d00632f3e"
      unitRef="usd">5649000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzQtMy0xLTEtNjc0NzQ_ca8a50e0-b1e2-4c74-a362-d1165384a9a3"
      unitRef="usd">4958000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <morf:DeferredTaxAssetsFixedAndIntangibleAssets
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzUtMS0xLTEtNjc0NzQ_82312c31-49f3-4dc7-82b5-c2ecff8e06d4"
      unitRef="usd">3332000</morf:DeferredTaxAssetsFixedAndIntangibleAssets>
    <morf:DeferredTaxAssetsFixedAndIntangibleAssets
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzUtMy0xLTEtNjc0NzQ_a0041ece-951a-4d15-a449-07955d4e58b9"
      unitRef="usd">3077000</morf:DeferredTaxAssetsFixedAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzYtMS0xLTEtNjc0NzQ_322cb65c-5b90-4421-adbe-af2915bcd7a2"
      unitRef="usd">1764000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzYtMy0xLTEtNjc0NzQ_5ad324fb-40c4-4109-b469-c8aa380357bd"
      unitRef="usd">1790000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <morf:DeferredTaxAssetLeaseLiabilities
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzctMS0xLTEtNjc0NzQ_b71d6204-c926-4464-96bf-c03afcaecd34"
      unitRef="usd">1049000</morf:DeferredTaxAssetLeaseLiabilities>
    <morf:DeferredTaxAssetLeaseLiabilities
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzctMy0xLTEtNjc0NzQ_fd60171a-0834-438e-a923-f1f9dd1a0151"
      unitRef="usd">1380000</morf:DeferredTaxAssetLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzktMS0xLTEtNjc0NzQ_4d7bad39-14e1-44da-b059-50011a8bd536"
      unitRef="usd">128000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzktMy0xLTEtNjc0NzQ_afbcee56-8f0d-45ac-8a3e-5d381813f69a"
      unitRef="usd">18610000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEwLTEtMS0xLTY3NDc0_af002c8d-84c9-4f5f-b51d-3138b1f50fcd"
      unitRef="usd">101139000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEwLTMtMS0xLTY3NDc0_e6b698ff-6ca2-4a8e-9388-4485af498dc0"
      unitRef="usd">84927000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzExLTEtMS0xLTY3NDc0_6e547c4e-c294-49dd-b3cc-6da5ded7af52"
      unitRef="usd">99417000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzExLTMtMS0xLTY3NDc0_88fe1b55-ed15-42a6-bc12-328a4beb9a49"
      unitRef="usd">82703000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEyLTEtMS0xLTY3NDc0_0e74a217-52c9-4241-b073-9d85d32ea098"
      unitRef="usd">1722000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEyLTMtMS0xLTY3NDc0_ad2db470-59fd-4e0c-9bde-41d46e3d86ed"
      unitRef="usd">2224000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE0LTEtMS0xLTc0OTA3_53065da0-64f8-4b8e-abaa-3796f1ec2c59"
      unitRef="usd">960000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE0LTMtMS0xLTc0OTA3_3afe4317-0361-4f62-92e3-0fe41351118f"
      unitRef="usd">1313000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEzLTEtMS0xLTY3NDc0_0a557a45-5fe0-4580-8e3d-c90d72510f81"
      unitRef="usd">472000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzEzLTMtMS0xLTY3NDc0_8374bdb2-77e4-4134-bfb4-317095c1caa5"
      unitRef="usd">572000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE1LTEtMS0xLTY3NDc0_55cea0cb-9faa-4ba0-9dcd-62e20d021de7"
      unitRef="usd">290000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE1LTMtMS0xLTY3NDc0_75cc11ad-eb10-48d7-9b0a-a35226c7c510"
      unitRef="usd">339000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE2LTEtMS0xLTY3NDc0_f85c5638-2efb-4f7e-ba4a-488ecea556ea"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i2e38059c1a8b4351a12208b4b17e67fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90YWJsZTo5YzNiMDU3ZDdhMDQ0NTIyYjg2ODk4YzE5NTY0MTAxYy90YWJsZXJhbmdlOjljM2IwNTdkN2EwNDQ1MjJiODY4OThjMTk1NjQxMDFjXzE2LTMtMS0xLTY3NDc0_48977828-17ee-40f0-9ab9-13e406aa9e3a"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i98ff867a6d934dccaf584133870acc01_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzg0Ng_613d6adb-4693-493f-aa2e-383bd75fe37b"
      unitRef="usd">99400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i673a9cb8566f43ce9616ebf94921885b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzg1Mw_1089a070-b09a-41ac-884d-c4d475cfdeeb"
      unitRef="usd">82700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="idd87bb47b7414650a95a2d45e1fd7c80_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzk1MQ_aac47385-5f3a-4e4f-a021-bd7c83b7f963"
      unitRef="usd">16700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ia34a0708e91b4ea5b31cedcf12f3227d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzk1OA_b3c0cac7-1df1-413c-b3e4-6692de32a65e"
      unitRef="usd">37100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i98ff867a6d934dccaf584133870acc01_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzExNzE_5c9577ff-4620-49fe-b22f-313023aced67"
      unitRef="usd">180300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia1c53362d437417b8664cb0139c5b714_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzIxOTkwMjMyNzEzMTc_c4d3249e-f89b-4423-8559-a328e6e129d7"
      unitRef="usd">191500000</us-gaap:OperatingLossCarryforwards>
    <morf:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i98ff867a6d934dccaf584133870acc01_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzEyNzU_99812e8c-380d-469b-a4eb-9cd033bfe3fc"
      unitRef="usd">176400000</morf:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i98ff867a6d934dccaf584133870acc01_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzE0NjU_bec92a04-04f1-4d2f-adc2-ac2b7d832374"
      unitRef="usd">12600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia1c53362d437417b8664cb0139c5b714_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzE0NzI_c6a22634-81af-4c02-acfa-bae49a4cb2ef"
      unitRef="usd">5700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzMzOTY_300fcf09-4a61-41ed-be71-6e6c4b132975"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzMzOTY_470d3c44-8a68-43c3-9c9e-1b30c49f1184"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzM5NDA_7537337d-9ec9-45a4-b595-841b741803b3"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzQwMTI_14d1310e-4bf0-4422-9390-778da3a38a6a"
      unitRef="usd">0.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzAvZnJhZzphMzY1NjRmODI1ZjI0YjA1ODU3NDc3MjY4YzIzMTEyZC90ZXh0cmVnaW9uOmEzNjU2NGY4MjVmMjRiMDU4NTc0NzcyNjhjMjMxMTJkXzQwNzg_1758c22a-40a3-4d10-82b3-aed0b98c2049"
      unitRef="usd">-600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzMvZnJhZzphYjU0NmM1MGI4N2M0NTViODViOGE2MGIwMDI4NjY5YS90ZXh0cmVnaW9uOmFiNTQ2YzUwYjg3YzQ1NWI4NWI4YTYwYjAwMjg2NjlhXzE4Mjg_01d196aa-134c-43be-881d-fc07adb98822">Commitments and Contingencies&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered, and intends to continue to enter, into separate indemnification agreements with directors, officers, and certain of key employees, in addition to the indemnification provided for in the restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, require the Company to indemnify directors, officers, and key employees for certain expenses, including attorneys&#x2019; fees, judgments, penalties, fines, and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to the Company or any of its subsidiaries or any other company or enterprise to which these individuals provide services at the Company&#x2019;s request. Subject to certain limitations, the indemnification agreements also require the Company to advance expenses incurred by directors, officers, and key employees for the defense of any action for which indemnification is required or permitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has standard indemnification arrangements in its leases for laboratory and office space that require it to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under the Company&#x2019;s lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December&#160;31, 2022, the Company had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE5MzEw_bd855219-410c-4e34-b244-e401573961b2">Option and License Agreements&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Agreement Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2018, the Company entered into a 5-year collaboration and option agreement with AbbVie Biotechnology Ltd (the &#x201c;AbbVie Agreement&#x201d;), a research-based global biopharmaceutical company that held Series A and Series B Convertible Preferred Shares of the Company at the time the AbbVie Agreement was executed (&#x201c;AbbVie&#x201d;). Pursuant to this agreement, AbbVie paid the Company an upfront, non-refundable amount of $100.0&#160;million. In exchange, the Company: (i) assumed the obligation to perform research and development activities to identify and develop compounds directed at multiple fibrosis indications (grouped into four research programs) through completion of Investigational New Drug (IND)-enabling studies, and (ii) granted AbbVie options to license the results of research and development in exchange for separate upfront option-exercise fees. In June 2022, AbbVie informed the Company that it had decided to exercise its right to terminate the AbbVie Agreement for convenience and the AbbVie Agreement terminated in December 2022. As a result, the Company does not expect to receive additional payments under the AbbVie Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the AbbVie Agreement termination, AbbVie held the right to exercise its license options for molecules with the selected pharmacological profiles by providing written notice to the Company and paying an option exercise fee of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$20.0&#160;million per option exercised (up to three in total). Effective upon the termination of the AbbVie Agreement, all rights and licenses granted thereunder immediately terminated and were returned to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Agreement Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the performance obligations in the agreement had included the research services for the four research programs. The Company has concluded that the unexercised license options were marketing offers as the options did not provide any discounts or other rights that would be considered a material right in the arrangement. All other performance obligations were determined to be immaterial in the context of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the standalone selling price of each research program based on internal and external costs to perform the research plus a reasonable profit margin of 10%. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#x2019;s best estimate of the length of time required to perform the services. The Company recognized revenue as research and development services were provided based on the costs incurred to date, as such costs have a direct relationship between the Company&#x2019;s effort and the progress made towards satisfying its performance obligations to AbbVie. Changes to the estimated cost of internal and external development services were recognized in the period of change as a cumulative catch-up adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the transaction price included only the non-refundable up-front payment of $100.0&#160;million and recorded this amount as deferred revenue as of December 31, 2018. The option exercise payments were not included in the transaction price, as the Company determined that the agreed upon fees represent fair value of such options. The milestone payments were fully constrained, as a result of the uncertainty regarding whether AbbVie would exercise any of the options and whether any of the associated milestones would be achieved. There were no changes to the transaction price prior to the AbbVie Agreement termination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also considered the existence of any significant financing component within the AbbVie Agreement given its upfront payment structure. Based upon this assessment, the Company concluded that the up-front payment was provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the AbbVie Agreement did not result in the existence of a significant financing component.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 25, 2020, AbbVie exercised its option to license and control further development and commercialization of Morphic&#x2019;s &#x3b1;v&#x3b2;6&#x2013;specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. In connection with the exercise of the option, AbbVie paid the Company $20.0&#160;million. Upon option exercise, the Company evaluated whether the change to the contract should be treated as the continuation of the current arrangement or as a separate agreement. As the additional performance obligations were deemed to be distinct and priced consistent with the standalone selling price of such obligations, the Company concluded that the license and any additional performance obligations should be accounted for as a separate contract. The potential performance obligations included in the arrangement were (1) the license to research, develop and commercialize &#x3b1;v&#x3b2;6&#x2013;specific integrin inhibitors, and (2) options to purchase materials that were manufactured prior to option exercise (the &#x201c;Material Options&#x201d;). The Company concluded that the Material Options were not material rights as the price to purchase the materials approximated the standalone selling price. Based on this conclusion, the full transaction price of $20.0&#160;million was allocated to the license and recognized upon delivery in the third quarter of 2020. The Company does not expect to receive any additional payments for this program from AbbVie as the license terminated upon termination of the AbbVie Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon receipt of notification of the exercise of the right to terminate the AbbVie Agreement, the Company concluded that there was a contract modification to an existing contract under ASC 606 because the notification of termination of the AbbVie Agreement resulted in a reduction in scope of the Company&#x2019;s responsibilities for the three remaining research programs thereunder. The terms of the AbbVie Agreement termination notification did not include any additional promised goods or services. As a result of the notification from AbbVie, the Company recognized revenue of $57.7&#160;million on a cumulative catch-up basis using an updated measure of progress towards satisfying the research and development services performance obligations thereunder. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, the Company completed its performance obligations under the AbbVie Agreement. The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had $60.5 million of deferred revenue, which was classified as either current or net of current portion in the accompanying consolidated balance sheets based on the period over which the revenue was expected to be recognized prior to the contract modification. This deferred revenue balance represented the aggregate amount of the transaction price allocated to the performance obligations that were partially unsatisfied as of December&#160;31, 2021. The Company has no further unsatisfied performance obligations for the AbbVie Agreement as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Janssen Agreement Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2019, the Company entered into a research collaboration and option agreement with Janssen Pharmaceuticals, Inc. (&#x201c;Janssen Agreement&#x201d;), a subsidiary of Johnson &amp;amp; Johnson (&#x201c;Janssen&#x201d;), to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. The Janssen agreement focuses on three integrin targets, each target the subject of a research program, with a limited ability to substitute integrin targets for others, not explored by the Company, if research results are not favorable. Under the terms of the agreement, Janssen paid the Company an upfront fee of $10.0&#160;million for the first two research programs in 2019 and in December 2020 the Company reached an agreement with Janssen to commence work on the third research program and Janssen agreed to pay $5.0&#160;million for the third research program commencement fee. In addition, Janssen reimburses the Company for all internal and external costs and expenses incurred during the term of the agreement at agreed-upon contractual rates. The Company invoices Janssen on a quarterly basis and payments are due within 60 days. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2021, Janssen informed the Company that they had decided not to exercise its options on the first two integrin targets, thus also discontinuing those two research programs. The Company has focused efforts on the third integrin research program which includes the potential development of integrin antibody activators. In January 2023, Janssen informed the Company that it had decided to exercise its right to terminate the Janssen Agreement for convenience, subject to a 60 day notification period. The Janssen Agreement will terminate effective March 2023 or earlier if agreed to by the Company and Janssen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Agreement Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has concluded that the performance obligations in the agreement include the research services for the three research programs and three options to license the outcomes of those research programs, which were determined to provide Janssen with material rights. All other performance obligations were determined to be immaterial in the context of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the standalone selling price of each research program based on internal and external costs to perform the research plus a reasonable profit margin. The total estimated cost of the research and development services reflect the nature of the services to be performed and the Company&#x2019;s best estimate of the length of time required to perform the services. The Company estimated the standalone selling price of each material right by determining the discount provided to the estimated standalone selling price of comparable options and applying appropriate likelihood of exercise, which includes the appropriate probability of successfully completing the research efforts. Based on the standalone selling prices determined, the Company allocates the total transaction price among the programs and material rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue as research services are provided based on the costs incurred to date, as such costs have a direct relationship between the Company&#x2019;s effort and the progress made towards satisfying its performance obligations to Janssen. Transaction price allocated to the material rights was deferred and will be recognized as revenue when Janssen exercises the options or the option period expires. Changes in estimates of total internal and external costs expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the transaction price included: the non-refundable up-front payment of $10.0&#160;million for the first two programs, $5.0&#160;million non-refundable up-front payment for the third program, and the estimated reimbursement payments at agreed upon contractual rates to be received from Janssen for the Company&#x2019;s on-going research services. The option exercise payments were not included in the transaction price. Exercise of any of the options will be accounted for as a continuation of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the current contract if and when Janssen delivers the written exercise notice. The milestone payments were fully constrained, as a result of the uncertainty regarding whether Janssen would exercise any of the options and whether any of the associated milestones would be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also considered the existence of any significant financing component within the Janssen Agreement given its upfront payment structure. Based upon this assessment, the Company concluded that the up-front payment was provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the Janssen Agreement does not result in the existence of a significant financing component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Contract Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon notification of discontinuation of the two research programs and related options, the Company concluded that there was a contract modification to an existing contract under ASC 606 because the December 2021 notification resulted in a reduction in scope of the Company&#x2019;s responsibilities under the Janssen Agreement. The December 2021 notification did not include any additional promised goods and services. Subsequent to the modification, there are two remaining performance obligations pursuant to the Janssen Agreement, research services for the remaining research program and a material right for Janssen&#x2019;s remaining license option. The Company concluded that the remaining research services to be provided to satisfy the third research program were not distinct from its existing research services, and as a result treated the modification as part of the original contract (as opposed to a separate contract). Therefore, the Company updated the transaction price, which included the remaining deferred revenue and estimated variable consideration for research services and allocated the updated transaction price to the remaining performance obligations based on the estimated standalone selling prices at the date of the contract modification. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the research services, the effect that the contract modification had on the transaction price and the measure of progress towards satisfying the performance obligation of $1.9&#160;million has been recognized on a cumulative catch-up basis. The transaction price allocated to the remaining material right of $0.5&#160;million was deferred and will remain deferred until exercise or expiration. The accounting for any previously satisfied performance obligations as of the contract modification date are not affected by the modification. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes research and development costs incurred and revenue recognized in connection with the Company's performance under the Janssen Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Q4 2022, the Company recognized additional revenue of $3.0&#160;million on a cumulative catch-up basis as a result of changes to the estimated costs associated with the remaining effort required to complete the research services for the third research program. The amount of future expected cost estimates has decreased based on a change in expected effort and based on the timing of the research services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the Company had $0.5 million and $2.3 million, respectively, due from Janssen recorded in accounts receivable. As of December 31, 2022 and 2021, $0.5 million and $7.6 million, respectively, of deferred revenue was classified as either current or net of current portion in the accompanying consolidated balance sheets based on the period over which the revenue is expected to be recognized. At December 31, 2022 and 2021 the deferred revenue balance represents the portion of the upfront payments received allocated to the performance obligations that are partially or wholly unsatisfied as of December 31, 2022 and 2021. The Company expects to recognize revenue related to the remaining performance obligations through Q1 2023.&lt;/span&gt;&lt;/div&gt;The Company's continuing obligation associated with the material right will terminate effective March 2023 or earlier if agreed to by the Company and Janssen.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <morf:CollaborativeArrangementTermOfArrangement
      contextRef="ia2dfc56e30ef4261a5bd22e73cfeb905_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE5MzEx_8cafce82-12fb-4288-8d46-68021cff56a2">P5Y</morf:CollaborativeArrangementTermOfArrangement>
    <morf:CollaborativeArrangementUpfrontFeesReceived
      contextRef="ia2dfc56e30ef4261a5bd22e73cfeb905_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzQ1Mg_e5abd893-5750-47cf-b6c7-17cb39a50560"
      unitRef="usd">100000000</morf:CollaborativeArrangementUpfrontFeesReceived>
    <morf:CollaborativeArrangementNumberOfResearchPrograms
      contextRef="i2ba08c24b4f646afab272849bef04fb2_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzY0Ng_68e38c09-b564-41d6-be2f-972b84096bdd"
      unitRef="program">4</morf:CollaborativeArrangementNumberOfResearchPrograms>
    <morf:CollaborativeArrangementOptionExerciseFeesReceivable
      contextRef="i2ba08c24b4f646afab272849bef04fb2_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzExMDg_9c06c734-aca1-4fe7-82d2-8929ab69a89f"
      unitRef="usd">20000000</morf:CollaborativeArrangementOptionExerciseFeesReceivable>
    <morf:CollaborativeArrangementNumberOfOptions
      contextRef="i2ba08c24b4f646afab272849bef04fb2_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzM4NDgyOTA3MzEyNjU_758f06ba-e5fa-423c-b9f0-02633ccf9c52"
      unitRef="option">3</morf:CollaborativeArrangementNumberOfOptions>
    <morf:CollaborativeArrangementNumberOfResearchPrograms
      contextRef="i2ba08c24b4f646afab272849bef04fb2_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzMxNDA_1573b020-4d56-4a2d-8f3b-f6515b7ef547"
      unitRef="program">4</morf:CollaborativeArrangementNumberOfResearchPrograms>
    <morf:CollaborativeArrangementProfitMarginPercentage
      contextRef="i3e82d416fe9845cd845831adb23f5e51_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzM2NDE_6dd73b0c-261e-4664-a453-d4550383ea1a"
      unitRef="number">0.10</morf:CollaborativeArrangementProfitMarginPercentage>
    <morf:UpFrontPaymentIncludedInTransactionPrice
      contextRef="i0d620038457943e389fea375d17a3511_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzQ1Njg_e11287d1-5dd7-4571-8aed-8559e3507fe5"
      unitRef="usd">100000000</morf:UpFrontPaymentIncludedInTransactionPrice>
    <morf:CollaborativeArrangementOptionExerciseFeesPaid
      contextRef="i605039ce4c3546db8544ca5afe90071c_D20200825-20200825"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzU5Mjc_082cdbec-8b8a-4643-9ede-5bad31fdb0cb"
      unitRef="usd">20000000</morf:CollaborativeArrangementOptionExerciseFeesPaid>
    <morf:CollaborationAgreementOptionExerciseRevenueReceived
      contextRef="iebbb4e4977534118b7062dc97e877188_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzY4NjM_968c6ee5-cc8e-4cf5-8e08-1ee03aa8d6d4"
      unitRef="usd">20000000</morf:CollaborationAgreementOptionExerciseRevenueReceived>
    <morf:CollaborativeArrangementNumberOfResearchPrograms
      contextRef="i3e82d416fe9845cd845831adb23f5e51_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzM4NDgyOTA3MzEyNzU_5a4fca68-dcb2-49f1-aa88-3e5c26fa2497"
      unitRef="program">3</morf:CollaborativeArrangementNumberOfResearchPrograms>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7d9a0e35c7f042cf912b4e21edd47242_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzgyNDYzMzcyMzgxMDQ_dd244783-8224-431a-9452-96cf2c206154"
      unitRef="usd">57700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE5MzEz_7c86c2bb-600d-41f9-b60b-3ead77051363">The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes research and development costs incurred and revenue recognized in connection with the Company's performance under the Janssen Agreement during the years ended December 31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d9a0e35c7f042cf912b4e21edd47242_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzItNS0xLTEtNjc0NzQ_ae977fef-184f-4b11-8671-cc77a661118c"
      unitRef="usd">60500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76974348b5dd49dd867e3970e5e16d4c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzItNy0xLTEtNjc0NzQ_2ddb77b5-a127-4524-a027-3e39b0f0331d"
      unitRef="usd">11197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08cc4df0448c42e6b1396ea92fa4ae8c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzItOS0xLTEtNjc0NzQ_115a04e8-bef4-4c14-96fa-ab473f29a785"
      unitRef="usd">36056000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i7d9a0e35c7f042cf912b4e21edd47242_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzMtNS0xLTEtNjc0NzQ_d6babbe7-3039-4298-81e7-0d7a48410cef"
      unitRef="usd">631000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i76974348b5dd49dd867e3970e5e16d4c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzMtNy0xLTEtNjc0NzQ_638478e4-41ff-4230-af92-8a403710214d"
      unitRef="usd">5376000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i08cc4df0448c42e6b1396ea92fa4ae8c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTo3ZDA0ODIyMWUyZjc0ZTBjOWMzOTdlMTY4MzllNGZiYS90YWJsZXJhbmdlOjdkMDQ4MjIxZTJmNzRlMGM5YzM5N2UxNjgzOWU0ZmJhXzMtOS0xLTEtNjc0NzQ_5f084308-c7e8-4e9b-9526-3d075ab1da67"
      unitRef="usd">13474000</us-gaap:CostsAndExpenses>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ic9645879e89545f6ae321d39d2ff49ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzIxOTkwMjMyOTIwMTU_09c3f913-f178-4cd4-9cdc-ee56abf9d4a1"
      unitRef="usd">60500000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <morf:CollaborativeArrangementNumberOfIntegrinTargets
      contextRef="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEwNTcx_e7d3f15b-c427-42fc-8683-4ef357f3a867"
      unitRef="target">3</morf:CollaborativeArrangementNumberOfIntegrinTargets>
    <morf:CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram
      contextRef="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEwODUw_1e2b07e3-21f9-4fec-8e50-9ceac09715f1"
      unitRef="usd">10000000</morf:CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram>
    <morf:CollaborativeArrangementNumberOfResearchPrograms
      contextRef="ia278688cc742407d889eeaac1398e425_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEwODY3_9a568229-a7f7-4631-9db8-d31b44594450"
      unitRef="program">2</morf:CollaborativeArrangementNumberOfResearchPrograms>
    <morf:CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram
      contextRef="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzExMDM2_7bad93f9-f554-4193-aceb-bac6c239b55b"
      unitRef="usd">5000000</morf:CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram>
    <morf:CollaborativeArrangementPaymentDuePeriod
      contextRef="i686536135c5e42e2b4cf2e7ce1d0cc07_D20190201-20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzExMzMx_b077c860-795d-449b-9612-543e11f8504b">P60D</morf:CollaborativeArrangementPaymentDuePeriod>
    <morf:CollaborativeArrangementNumberOfResearchProgramsDiscontinued
      contextRef="i0af313c7bd8a4b4388148bb57bf130a0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEyNjA4_7cd17903-3b35-4e5e-a5be-555435643caa"
      unitRef="program">2</morf:CollaborativeArrangementNumberOfResearchProgramsDiscontinued>
    <morf:CollaborativeArrangementNotificationPeriod
      contextRef="i995f63fe81fb4b9abb9716382e1dc8f7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzgyNDYzMzcyNDQ3ODA_ae9b85d2-5a44-4e54-9e2a-e2787c1152ee">P60D</morf:CollaborativeArrangementNotificationPeriod>
    <morf:CollaborativeArrangementNumberOfResearchPrograms
      contextRef="i10cf228deb344a0bbe41e4dd68f6091d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEyOTI4_5e3c32bf-5fcd-4636-96a1-c6432313b5b2"
      unitRef="program">3</morf:CollaborativeArrangementNumberOfResearchPrograms>
    <morf:CollaborativeArrangementNumberOfOptionsToLicense
      contextRef="i10cf228deb344a0bbe41e4dd68f6091d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzEyOTUz_aaa76a42-46db-408a-8ac9-b942790183cf"
      unitRef="option">3</morf:CollaborativeArrangementNumberOfOptionsToLicense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c05f87e169c45feb95ae818058af3ef_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE0NzUz_d8bf68b6-3f1f-47de-9720-5f64bc5cfbc1"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <morf:CollaborativeArrangementNumberOfResearchPrograms
      contextRef="ie9e8a3b2b5f94dc1967ae1463aa4c8ed_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzM4NDgyOTA3MzEyOTI_5c44e22d-017a-4f15-805a-a8d78a0015e7"
      unitRef="program">2</morf:CollaborativeArrangementNumberOfResearchPrograms>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5d1093edead46de860e94adc1452272_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE0Nzg0_ec4f00d2-3033-4b69-a190-28aa5cfabf10"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <morf:CollaborativeArrangementNumberOfResearchProgramsDiscontinued
      contextRef="i10cf228deb344a0bbe41e4dd68f6091d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE1OTgw_8daa9e6f-a105-4831-bfb6-73b742472c1f"
      unitRef="program">2</morf:CollaborativeArrangementNumberOfResearchProgramsDiscontinued>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="i2b07511e4f7642a9bfe31d2963ab5b4d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE3MzY0_664ea947-40ef-4774-b591-475392cb111e"
      unitRef="usd">1900000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i10cf228deb344a0bbe41e4dd68f6091d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE3NDg2_6758bf6a-0fc7-484b-b0dd-e03ad671c705"
      unitRef="usd">500000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia95f81bdfee4430b81915be0cd95860b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzItNS0xLTEtNjc0NzQ_a1ea2a62-9e51-4bc7-a383-e645e27313d0"
      unitRef="usd">3159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6eb38babcc241e89553761903a11d61_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzItNy0xLTEtNjc0NzQ_8a3fbde2-b567-4cdf-8a01-09023170daab"
      unitRef="usd">4944000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5084eff2ed1d4f48a7da4984d71799cf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzItOS0xLTEtNjc0NzQ_cfa419cd-ec64-487b-a610-a32f4b434f02"
      unitRef="usd">6601000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b07511e4f7642a9bfe31d2963ab5b4d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzMtNS0xLTEtNjc0NzQ_1b324df5-22ad-445a-b9b8-5bb7d5f577c3"
      unitRef="usd">7149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i035b3de5190f487586bd1ed38307c379_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzMtNy0xLTEtNjc0NzQ_52a95617-3df2-4bd1-9a39-a71926f06a3c"
      unitRef="usd">3653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7af92416deea43878ba0ead3d0ecb13f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzMtOS0xLTEtNjc0NzQ_4c2d495e-39b1-4353-8e9b-b2260f0a7526"
      unitRef="usd">2288000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3511c82559894a9f98fb91e24620713a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzQtNS0xLTEtNjc0NzQ_31748199-1609-455c-9a05-5340fc07987a"
      unitRef="usd">10308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5743f7e935fc434da814d8855536f21b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzQtNy0xLTEtNjc0NzQ_42b7f052-6859-4689-ba5f-1e519238e25d"
      unitRef="usd">8597000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f5251e4aa084f7983207e980fdcdba4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzQtOS0xLTEtNjc0NzQ_c77f6688-6da5-495a-a07b-2b2985d53dfb"
      unitRef="usd">8889000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i3511c82559894a9f98fb91e24620713a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzUtNS0xLTEtNjc0NzQ_bc1620bd-62be-4d7d-9539-ee87c1728c2b"
      unitRef="usd">2637000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5743f7e935fc434da814d8855536f21b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzUtNy0xLTEtNjc0NzQ_9ad7f66e-dd9f-48dc-832b-cc321d6e1721"
      unitRef="usd">4426000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6f5251e4aa084f7983207e980fdcdba4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90YWJsZTphMDQ0MjdiZTBkZDk0ZTEwODkwZjM1YTBiM2FkZjlmOS90YWJsZXJhbmdlOmEwNDQyN2JlMGRkOTRlMTA4OTBmMzVhMGIzYWRmOWY5XzUtOS0xLTEtNjc0NzQ_049e8297-aa9f-4996-8903-4c41d314a07b"
      unitRef="usd">5865000</us-gaap:CostsAndExpenses>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia02854bc64fd499c8dbac9ce00351643_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzgyNDYzMzcyNDgzMDU_a7e61a4f-e997-425c-a0bd-f3d387f3dda3"
      unitRef="usd">3000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="iccd44d1dfb9c487f883da622bc30602d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE3OTI0_ef08e55c-109b-499c-9ea4-23a6ed539390"
      unitRef="usd">500000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i0a6c624908e845829a9ec116c04519ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE3OTMx_275a8d32-074f-4f04-859e-981fde75c118"
      unitRef="usd">2300000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iccd44d1dfb9c487f883da622bc30602d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE4MTU5_01b53adb-5016-45b0-84a6-91d658cbece2"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0a6c624908e845829a9ec116c04519ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xMzYvZnJhZzo1NTMzODAzOWVmZmU0OWRlYjExOGU3ODkxM2IwOGQxNS90ZXh0cmVnaW9uOjU1MzM4MDM5ZWZmZTQ5ZGViMTE4ZTc4OTEzYjA4ZDE1XzE4MTY2_e7bff0a1-f944-4003-addf-87505c35ebd6"
      unitRef="usd">7600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90ZXh0cmVnaW9uOjgwNDM3NTUwODlhNjQ2MGQ5MDdmNTdkODYwNDZjZjYwXzE1ODg_a787569b-b6ab-4c7f-b131-54eaef880a6f">Net Loss per ShareBasic net loss per share is calculated by dividing net loss allocable to common stockholders by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents.&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods with net income, diluted net income per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents, including stock options and restricted common stock and stock units outstanding for the period as determined using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are the same for periods with a net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,112,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,797,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,594,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,781,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,512,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,790,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,519,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the securities listed in the table above, as of December&#160;31, 2022 the Company had reserved 1,142,204 shares of common stock for sale under the ESPP, which, if issued, would be anti-dilutive if included in calculation of diluted net loss per share for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90ZXh0cmVnaW9uOjgwNDM3NTUwODlhNjQ2MGQ5MDdmNTdkODYwNDZjZjYwXzE1ODk_315585a9-471f-41a9-a531-d4cd9cd9c3b9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,112,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,797,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,594,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzMtNS0xLTEtNjc0NzQ_0a5b64a9-885f-41e5-b258-a862e472151a"
      unitRef="usd">-59041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzMtNy0xLTEtNjc0NzQ_f0010e89-74d7-405f-97b4-b322d58c11f9"
      unitRef="usd">-95542000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzMtOS0xLTEtNjc0NzQ_ddb92cc5-9262-4b20-b6c1-2669237c1a3a"
      unitRef="usd">-44999000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtNS0xLTEtNjc0NzQ_498d2895-ecf6-4f52-be83-0846fa66d26c"
      unitRef="shares">38112498</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtNS0xLTEtNjc0NzQ_e3668934-a4f9-4e69-b183-45cf367ba9ef"
      unitRef="shares">38112498</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtNy0xLTEtNjc0NzQ_1232b63c-b918-4d23-af44-6e06a69b9529"
      unitRef="shares">35797969</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtNy0xLTEtNjc0NzQ_8cfc87f4-86c2-4e38-8900-bddf9868548c"
      unitRef="shares">35797969</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtOS0xLTEtNjc0NzQ_2be1a754-c211-42a5-9fea-412be202b0eb"
      unitRef="shares">30594897</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzQtOS0xLTEtNjc0NzQ_557c2e6f-e754-479c-bc0c-8ebc29f1348e"
      unitRef="shares">30594897</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtNS0xLTEtNjc0NzQ_3ccf7788-681f-46a7-bf77-cad7c4f2a9a4"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtNS0xLTEtNjc0NzQ_47616873-dd98-46a8-8be7-3c305a3747b9"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtNy0xLTEtNjc0NzQ_2b861220-70ba-4f16-885c-933334cc0a41"
      unitRef="usdPerShare">-2.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtNy0xLTEtNjc0NzQ_98a28844-ab61-4b56-bc57-f100b21c5a80"
      unitRef="usdPerShare">-2.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtOS0xLTEtNjc0NzQ_09566b39-e1e8-41d4-a54d-cb113d42afcf"
      unitRef="usdPerShare">-1.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTo5NzE0N2E2OTlkNTU0NjNlOTUzNmU3NzFmOGYzMmM2Zi90YWJsZXJhbmdlOjk3MTQ3YTY5OWQ1NTQ2M2U5NTM2ZTc3MWY4ZjMyYzZmXzUtOS0xLTEtNjc0NzQ_0d1edf40-d2aa-4333-a92b-77fef7f150f3"
      unitRef="usdPerShare">-1.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90ZXh0cmVnaW9uOjgwNDM3NTUwODlhNjQ2MGQ5MDdmNTdkODYwNDZjZjYwXzE1OTA_1c96e2d3-b99f-4bae-9129-63cb6e45170a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,781,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,512,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,790,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,519,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5ce5d6357e054eb89f9f7070956ddd0f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzItNS0xLTEtNjc0NzQ_c4fefd7f-b015-451f-84df-448f77e8b119"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i53395b8e2227477fb7c23b0353062b98_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzItNy0xLTEtNjc0NzQ_ebd0bbf9-468d-47b4-942d-c1952f6b70af"
      unitRef="shares">2171</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2a1b74d6b2bb4a4f98e936d596b79284_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzItOS0xLTEtNjc0NzQ_e79fa5a9-ccdb-4cf7-b1e6-6fd30be38f5b"
      unitRef="shares">100989</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i436cc872d64b4d7b9aaa708f0706aa2a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzMtNS0xLTEtNjc0NzQ_fcef77f7-1dde-4746-8444-ee0fdc1c8b51"
      unitRef="shares">249090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia296bbbf833f49b2a6ab65ef01ab6bd8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzMtNy0xLTEtNjc0NzQ_781b8d36-28b0-43f5-8971-70feff067edc"
      unitRef="shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iadfe8416bc324e919e5e25cbad2d3372_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzMtOS0xLTEtNjc0NzQ_6c0a9e3d-e823-4238-acd6-d0da14644ebb"
      unitRef="shares">66216</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i289b44ada87a4da1befaa2bbadc04a61_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzQtNS0xLTEtNjc0NzQ_26dfec0c-d090-4baa-830c-e7ce0d266cf6"
      unitRef="shares">5263553</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i01c3a69a38b5461d93693d703c6eda55_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzQtNy0xLTEtNjc0NzQ_ecafc3c8-d6df-4aa3-ab41-444d1efe4d56"
      unitRef="shares">4781565</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i22a2adf60f5a46a4a34b1aa1bf2511b1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzQtOS0xLTEtNjc0NzQ_559f305a-aa7c-4b83-9388-dfbdfae0322c"
      unitRef="shares">4352095</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzUtNS0xLTEtNjc0NzQ_e631c65d-9179-45e3-adeb-4b3d3be95216"
      unitRef="shares">5512643</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzUtNy0xLTEtNjc0NzQ_695cd8a6-e691-4eef-8cbd-2d31429f1fe3"
      unitRef="shares">4790736</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90YWJsZTpjM2RkNDk0MGY1ODE0ZWYwOTM2NTI3Y2VlMDk3NGJjOS90YWJsZXJhbmdlOmMzZGQ0OTQwZjU4MTRlZjA5MzY1MjdjZWUwOTc0YmM5XzUtOS0xLTEtNjc0NzQ_8cea717d-032e-47e3-a468-e9238c0e4ec6"
      unitRef="shares">4519300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia515039667cc4b22b0294f91e2b2a44a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDIvZnJhZzo4MDQzNzU1MDg5YTY0NjBkOTA3ZjU3ZDg2MDQ2Y2Y2MC90ZXh0cmVnaW9uOjgwNDM3NTUwODlhNjQ2MGQ5MDdmNTdkODYwNDZjZjYwXzE0Mjc_7a784a52-62fb-4ceb-b60a-af720ca18b71"
      unitRef="shares">1142204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDgvZnJhZzpmYTZhNjViZTM4ZmE0NDc5ODUzN2YwMTAyN2ZiNWY5NC90ZXh0cmVnaW9uOmZhNmE2NWJlMzhmYTQ0Nzk4NTM3ZjAxMDI3ZmI1Zjk0XzM5Ng_6e47ee4a-ac19-471d-a9c3-144fd268c43d">Employee Benefit PlanIn 2016, the Company adopted a qualified retirement plan, the Morphic Therapeutic, Inc. 401(k) Plan to provide retirement income for eligible employees through employee contributions and employer matching contributions. Matching contributions totaled $0.6 million, $0.6 million and $0.5 million for the years ended December 31, 2022, 2021 and 2020, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDgvZnJhZzpmYTZhNjViZTM4ZmE0NDc5ODUzN2YwMTAyN2ZiNWY5NC90ZXh0cmVnaW9uOmZhNmE2NWJlMzhmYTQ0Nzk4NTM3ZjAxMDI3ZmI1Zjk0XzM1OA_8ba63d99-1d57-4d7d-a044-6d4337046b3e"
      unitRef="usd">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i2df75b528b7a4719999b82b29b6f7d0f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDgvZnJhZzpmYTZhNjViZTM4ZmE0NDc5ODUzN2YwMTAyN2ZiNWY5NC90ZXh0cmVnaW9uOmZhNmE2NWJlMzhmYTQ0Nzk4NTM3ZjAxMDI3ZmI1Zjk0XzM2Mg_2f40da6e-9f49-4b9d-8968-9adb9e4d8b0b"
      unitRef="usd">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i6c1115fec2c44ae8a4f16ad4c5ff1f22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTU3ZGRiZWUxYTQ3MjNiOGIyYmZhNzVhNTlhYTIzL3NlYzo2ZjE1N2RkYmVlMWE0NzIzYjhiMmJmYTc1YTU5YWEyM18xNDgvZnJhZzpmYTZhNjViZTM4ZmE0NDc5ODUzN2YwMTAyN2ZiNWY5NC90ZXh0cmVnaW9uOmZhNmE2NWJlMzhmYTQ0Nzk4NTM3ZjAxMDI3ZmI1Zjk0XzM2OQ_5caf56d9-d9ac-4767-bd20-62c774cf411a"
      unitRef="usd">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MFLM3;;-H)R@K5Z [B:;<W; P_164#3#[>RGQ.+$'=!T[^0M02P,$%     @
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MZ&V@0P,0Q'Z4]&";4E&<(#OLJ(4=.6%?,4GR)R",C+5QB&#</Z"FF ]C/'1
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MTO>)K#CHE@ZZAYS 077>?26JZ;?]5L?S7ZBO"?2@WVYVO7KQ#OS[?PF/D']
MT1?\>YBHBZQW86\T *;[^HS$@C )*)YK*&QX^OJ+O*'))XJG64\PXTIW&-DP
MUDT@%B9 OY]SKIXGILTHV\K@#U!+ P04    " #(25=6\G /F@L&   '&P
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MLTC'15Z*0R6-\A:L#:WK0&DNE.9!:3Z4%D!I(8K6#&QMVA"Q:=/7WN[.:%M
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M(Q&=BT@K2N"2:9)LJZ_A2U+'>;L[(%]L"%#U98:4"_5^-DJ"<H4,TTPM%F$
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M1>R@DCP::E':OP)XB5)9^UGVACG\2T!D+F?U.0MD8M&QK\\%!30H(\BW/%/
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M-CF^MYAM]3A_@ML =;3=3;E_:6(!0+EI-5L1JUT\GV.O\)QV%#L0TM+8D,3
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MDT*GNHI^CTA&*UJ@[ECV!ZYJ+Q(?1NXH3+.1GN<H\67">4@Y@BULP @DM 1
M^$PB'G]T<E>>;8]Y/:PWC@5Y4 'RI1^:Z58G75S+%3<T)W0#%%8$.[-/HY8
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M;QF++\#S30O;E0^X0/@-VQ?_!U!+ P04    " #(25=60%03E7X$  ",#
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MLG] A<=.&>LJ]CP?8<"Q"BNXE&6'"5%-%QB!T>C:2+ NGS+.<&FUCPF)2>3
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M9;+DYUJ8"FOZ#87C#@0\TB_IV+C',APKE0V%$R2:O8]03I;!\IIZG=/KZ=Z
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M3B%0UQ8^L1?/D[^C5+\97LM+:=D/?2Z>@$]/KF<S>#&?3^;/;N#%<C697:^
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MIO,[9W09J%1;/VDE8?>2 S5RDBUPML  875"_9VRQA(X49[[G8K5A+MF'?M
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MI3&:V2"B]H3TH]',S!.C,K@#'.D2'KQ2J(FMQ"V]6LD.%PE\<9C*X5H?XBC
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MH2)S5$;?0:%B8U>("!18:XWT1@65.O=I,9"L'RB&HZ3(!MXN>1,,%NHL;E(
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MR6[UF&61W92F=VHP$E7?D->!KIC[Y(4F-#/](P/W(A1,C3^F<-3H-$*$=!M
M_,J#F)/(P/L<%*3M_1$=(R%)4GBA=.%$F1M_<;,YWO ".M4 E)9\V0&<:LBY
M9U_'N+]GLJ<C[75,VAI=)3;I?_0M-89/%."R3%VO25!447Y-63-2HTX!3/^V
M(^;KHK$YNM,4>@^**+5>"!XS7^RM>BH;4A>DO$E^C>G6<KY@'3-=K/3)^6"=
M1>V3?7)N0L<VKZL55V;'S,YI\S ]O#*R:YQ=I579R?%)$W^FQVL!&QW9P580
M=RR'NS"IH]3%R+7:8L<'#'<OP3:0=O:$A3DPX461\I'6@4UR4</V)_X"QD[;
MSI#_"D(JTH8)R$VF2=[;M8;>B]+R62478Y?][3M%Q3L<3/[MD7$M[6(V(;NT
M5^85;YI]D9;S*' ;^<?C@Q[Y0Q&Y+2?B1.>T='3B*#!LVG.SR/6 1E]*)[5O
M]*=3/V'6T-P6;]\7W51<6&I+BBQH?YU-6KUGW>1PCO-J_@SFC6+.>QV\B*R+
M_*MG*=[YG+-5<C*-79D->6G8R10RN!P/H4%#KX=\*=9;/I.,P8=1F.",UM!Q
MRQ9ROPK2+Q)4 <=NH@0XQO=T3P">H3/DW;BO+N K?&5KNN&P2)(!.\ KYJ0;
M.G2$[HUS,/GXE13(Y$B:B_SSV;@7!-'+SZ!E2:^^VX!,8 C&V<4I@"\(8%H/
M(W,[[L'A?G";%80X]8"UF&Y,F^B;[/%8%Q+@&:XYO@L'.:_F#U9^D!-R'\()
MN2S?_>I97#A*G7?N'!Y&HU0+Y[;WWAF:K%>/6CEJ)[Y>K_^F09@5$8P+9.^J
MOD.?8'5Y]81Q(_: &1NXV;L-[#+@.])-G\[T2JT-M3/ 5-^RPMASFP \C">Y
M7!;O.77J#Q7_)]A>;&!<XX49Q/Y@(T :^& V>*Z/+Q_';0E.O]QOQS',J4+>
M: .*WF6"+/7(<S\.Q2!Q#3>I2$VU 9Q12&!"-B\\.P_A!A?4_$JWZ1R'P=A!
M#$L4F%\^60#8\:#K"+Q%:L&P/]^=?[VCT\RLP&$<>T,"'SF+V'L0K2G]<I1Q
MQH349&G<6PFJ$E)6;&I/J,^:B#"Z398)+DR-Y'-M[#-86D@)#1U?OC!$F>1X
MU6*R1>CR"6X#%.-VEW.)T]0/@'+7Q6Q%K';U=(J]_'/:4>A<24NJ8Q(#=V,,
MCV=AY.,B,B)1A<]I >D4L&'OG#.PC-*ND23XGCRP;8>],%@/ $_0Q3,4QD;Q
MKL04UA&&8DZ6 [9?Y)PR1)P3=!U3BO.Z(=KFRC@:^9.5.<?FY8AD!+T(\+=)
MT_E<N-LI<T*4O21FBP4SRN_QRQ&#V0JL0:1#4O**?;-I* M*X1;+_>I@ORO.
M]+E/,:1U:L>[9_8\- DX<BQ@X.3(:;H48[G@(PPC%SU6/C-SH3@EN?OXF!F
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MF.8:9 $/"C76AG6YJG-XXIN:%SQCM8'K+)-M;7B]@0<I>,91P]DS6PO4YXO
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M;AA$5AG"<1."/I_#X/_-X<!E[-L4=OFC'?K4_8+&B9N<9HBL:2E.XI\I'+#
M]</H:!E%H<VM[_:3X&<*AT,WZ,>OB4?]8:MO.'"'?@#GOD/>21^AN/*V6U+]
MR:8R74LYK!X:\JSK0\?C73<G]7-165679.KWAGT'5-<ANXF1==N5%M)0CVN'
M*_JI0&4/T/Y22K.?6 >'WY3I5U!+ P04    " #(25=6P$J"!D0#  !7!P
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MU4*K'6AG36ANX$/UWD2.2U>4:ZMIEY.?77U "LG 3S=L+= <+6)+H&XK+CJ
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M%D6)J5WR"P&5U)K [0KXDJL"S&HF"' -8UEA*=%PY/#E7*.J/CZ!/P17+>,
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M-:6ZX\O/V/D3:KR,E](\8=FN#=,!9(U4O.J$R8*JJ-LW>^KBL"60.'L$O$[
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M I*0947*YL7LF<B8_RD8XA-=9IDG%E_FL\FPD\XF9T22C2+)?EHDA^2L*A\
MO_?BD4NJ_3[;4PHYBWU:WB=D P:M<9VWM5?-45E?XT0">%:&>ZU6X-[1C>KI
M[ 4 MR_TA&W%* CMUM136".V3DJR=Z+9:-5X!B6792]'U1XZT?ZO7UZOSF.
MIP&@J"7WK+#DO?%S(+0;.YH,A[=3O:R.HO/6BE]]!+I?O,K/]X$!-\"[3E(<
M*M[/R_X.:3)%Z;B]B/#VS3R.XG<0LV@6012&K)@7Q]:#6=\**FV<TL 4(<Q8
M&(:0YRR.<KCW!JIS]3*0L3A/6)8ED++9/&)9GM$JR6)RS.@THYG(4W]:A&R6
MY+3*HH(E!'A*T=.CZZE!O?67L*$<J-?#337NCO?\]7"]/9L/'PF?N=X*HBAQ
M0Z[AY8P$K(>+=WBPJO.7W5I9NCK]LJ9O%=3.@,XW2MG#@PLP?OVL?@!02P,$
M%     @ R$E75ML% D-[!0  F"8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&ULO9IM3^LV%,>_BM5=32"QYJ%/P$HE((G&-"[596POIKUPD],V(HE[
M;:?<*^W#STY"TI1@Z'08+VCB^/Q.XG]\?'+DZ1/CCV(-(,FW-,G$16\MY>;<
MLD2XAI2*/MM IJXL&4^I5*=\98D-!QH51FEBN;8]ME(:9[W9M&B;\]F4Y3*)
M,YAS(O(TI?S[%23LZ:+G])X;OL2KM=0-UFRZH2NX!_FPF7-U9M64*$XA$S'+
M"(?E1>_2.0]<6QL4/?Z(X4GL'!/]* O&'O7)3731L_4=00*AU BJ?K9P#4FB
M2>H^OE;07NU3&^X>/].#XN'5PRRH@&N6_!E'<GW1.^V1")8T3^07]O0+5 \T
MTKR0):+X3Y[*OA/5.<R%9&EEK.X@C;/REWZK!F+'P!F^8N!6!NZ^P>@5@T%E
M,'BOAV%E,-PW&+]B,*H,1N_U,*X,QL78EX-5C+1')9U-.7LB7/=6-'U0R%58
MJP&.,_UFW4NNKL;*3LX^4YES(&Q)Y!K(52[4=2'(D0>2QHDX)C^1AWN/''TZ
M)I^(1<2:<A DSLA#%DMQHAK5\6V<).HU$5-+JEO28"NLW%^7[MU7W#ODEF5R
M+8B?11!UV/MOV+L&@*7&HAX0]WE KEPC\3)?]8GCG!#7=IVN!S*;WU+>)X/7
MS3VS^:]Y4IO;7<-A-O<@K,W=#O/@_3?O&L9R4+]<@X(W>(5WGR]$',4J8A'&
MB?\UC^5W<@MRS2)RDVU!2 #RUV_*BMQ(2,7?';=\5;H8=KO0@?=<;&@(%ST5
M607P+?1F/_[@C.V?N\3#A'F8,!\3%B#!6J(/:]&')OKLGB9%/%&A*WP\(5F>
M+H 7#57L$"*'B!RIN%&V''>I;O1QJ.J8, \3YI>P<0'32<!VYMC%W]3:[@J*
MY+0EZ*@6=&04]/+WVRZ%C$:'*H0)\S!A/B8L0(*U9!S7,HX_/AB/,47'A'F8
M,!\3%B#!6J)/:M$G;P9CH8-OR-*4/4=<(E@2Z<3M9GZG(K3Z?E$]V'()/,Y6
MJJN0XJWX;'1[Z(N "?,P8?[DG?$9R6E+X]-:XU.CQG/.0H!(D"5G:;&\TBP$
M/<E%M11#,=F[9#22#Y41$^9APOP2=K8CX^"L[^YIB.2QI>%9K>&9>8U-69[)
MG2R)@RX+Z.E(M^I#C"Z4DLM*TBXAC?A#A<2$>9@P_^R%D&>3%T(B>6P)Z=C-
M![7]5KI$_B%W&U#?Q90_JN!:9,27*PZ00B:[U#,C#Y4/E>:ATGQ46H!%:TN]
M4SMQ/CZEJGQ@:8])\U!I/BHMP**UM7<;[5WS-%^I";VB$IK$:</CL%AO-XGR
MJ^=Z%<T[92_QH]W48K275ER;[^%@-5^ZG(S:'GU4CP$6K:U14WYRC(6.V;5*
M>E4^I"O81U002C; 0R5+9T9;L71(J8?'[MN#?4E02TCO<^JC.@VP:&U5FOJ0
M\T:!"$*613IHWE4SIU,.U H0*LU#I?FHM "+UA:WJ14YH_]A242M+:'2/%2:
MCTH+L&AM[9L"DV,L97Q<L<'L]^#W8?SBHWXPZOBH]U#=^JBT (O6EKHI*SGF
MNM(\7R1QN)_Z:!DCEB24"[W4EI)V*XI:/T*E>:@T'Y465+16"M>\MFTQF_J1
M\]\*2'L3N9B\G6*B5I$JVNXCNL/1_M1$+0^AT@(L6EO-II+DF$M)=ZW0VJD7
M:K&HHK5JI"_D0BT"H=("+%I[MT%3+G+-Y:+/:D'<M":@J/-C9LB/S=A#1:QH
MK4DWV%\/45WZJ+0 BU:J:.ULJ$F!KXJM3T+-J#R3Y5:2NK7>7G59;"K::[]V
MSKURDU2#*?=LW5*^BC-!$E@JI-V?J+'GY3:H\D2R3;%M9\&D9&EQN 8: =<=
MU/4E8_+Y1#NH-Z/-_@502P,$%     @ R$E75@6OE(2# P  P X  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&ULK5=;;]HP%/XK5C9-K=0U5P+M(!(M
MH$W:)-2NV\.T!S<Y$*N)S6P#[;^?[:09ES0+4E[ =L[WG>/O'-^&6\:?1 H@
MT7.>43&R4BE7U[8MXA1R+"[9"JCZLF \QU)U^=(6*PXX,: \LSW'">T<$VI%
M0S,VY]&0K65&*,PY$NL\Q_SE!C*V'5FN]3IP1Y:IU -V-%SA)=R#?%C-N>K9
M%4M"<J"",(HX+$;6V+V>#;2],?A!8"MVVDC/Y)&Q)]WYDHPL1P<$&<12,V#U
MMX%;R#)-I,+X4W):E4L-W&V_LL_,W-5<'K& 6Y;])(E,1]; 0@DL\#J3=VS[
M&<KY]#1?S#)A?M&VM'4L%*^%9'D)5A'DA!;_^+G480?@AF\ O!+@'0*"-P!^
M"?#; H(2$+0%]$I KRT@+ &AT;X0RR@]P1)'0\ZVB&MKQ:8;)ET&K00F5!?6
MO>3J*U$X&=U@001B"S3G((!*7.2;)NB>+"E9D!A3B<9QS-94$KI$<Y:1F(!
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M>BV89JJ>F,"U@?J^8$R^=K2#ZM$:_0502P,$%     @ R$E75L'E8ST,!@
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M\N^;-"U^/JF^5>3P+3++_P%02P,$%     @ R$E75K:Y#:S.!   I1H  !D
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MLN!\3'K=E+FF@ZIRI66ID J5:^;T9P!M)]#WM5+XVK'5JOO7I/\ 4$L#!!0
M   ( ,A)5U:5H[].P0(  )P'   9    >&PO=V]R:W-H965T<R]S:&5E=#0T
M+GAM;*V576^;,!2&_XK%JJF5MA(@D*1+D-IDTW8Q+>K'=C'MPH&38-5@9CL?
M_?<[-A2EB1OU8C>)#>=]_;P8CL=;(1]5 :#)KN25FGB%UO65[ZNL@)*J2U%#
MA7>60I94XU2N?%5+H+D5E=P/>[W$+RFKO'1LK\UE.A9KS5D%<TG4NBRI?+H!
M+K83+_">+]RR5:'-!3\=UW0%=Z ?ZKG$F=^YY*R$2C%1$0G+B7<=7$T'IMX6
M_&2P57MC8I(LA'@TDV_YQ.L9(."0:>- \6\#4^#<&"'&W];3ZY8TPOWQL_L7
MFQVS+*B"J>"_6*Z+B3?T2 Y+NN;Z5FR_0ILG-GZ9X,K^DFU3&X<>R=9*B[(5
M(T')JN:?[MKGL"<(^J\(PE80OE40M8+(!FW(;*P9U30=2[$ETE2CFQG89V/5
MF(959A?OM,2[#'4ZO<XRN8:<?-[A>Z% D?,9:,JXNB ?R</=C)R?79 SPBIR
M7XBUHE6NQK[&A8W<S]I%;II%PE<6F4%V2:+@ PE[8>B03]\N#U[*?8S;90Z[
MS*'UBU[QF],GNN"8%=,0^P H5^3W]4)IB:_5'U? QK'O=C2?VI6J:083#[\E
M!7(#7OK^79#T/KGB_B>S%^&C+GQTRMV$EX)SFUT"IQHW']K-=P5OW&+K9EK"
M)DWB9#3V-_N!'$71*.F*7H#V.]#^2=!;C$YE5EC2'#;8<&IL'[KY\IEF;M[&
M--E#Z8=)?,#K+!JZ>>..-S[).UU+:?!J(6V#$DN"O592S:H5X8"MAG!&%XPS
M_>0"CX^8@OZH?P#N* J#P V>=.#)2? ?N@!Y\AU(CE8=QM$!V7'-*(G<8(,.
M;' 2[%YHRET\@Z/7+8B"87! Y*@*A]'A+OM[O=.<6]^I7+%*X8XM4=>['*"!
M;,Z"9J)%;=OI0FALSG98X/$)TA3@_:40^GEB.G1W(*?_ %!+ P04    " #(
M25=6/9^P),@"   6"   &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6RM
M5M]/VS 0_E>L;-I 0N07;2>61J*%:7M JD!C#],>W.3:6#AVL)T6I/WQ.SMI
MUK(V;&@OC<^Y^^[[+O9=D[54][H ,.2QY$*/O<*8ZMSW=59 2?6IK$#@FX54
M)35HJJ6O*P4T=T$E]Z,@&/HE9<)+$[<W4VDB:\.9@)DBNBY+JIXFP.5Z[(7>
M9N.&+0MC-_PTJ>@2;L%\K68*+;]#R5D)0C,IB(+%V+L(SZ<CZ^\<[ABL]=::
M6"5S*>^M\24?>X$E!!PR8Q$H/E8P!<XM$-)X:#&]+J4-W%YOT#\Y[:AE3C5,
M)?_&<E.,O0\>R6%!:VYNY/HSM'H&%B^37+M?LFY\!^B<U=K(L@U&!B43S9,^
MMG78"HA'!P*B-B!Z'A ="(C;@-@);9@Y69?4T#11<DV4]48TNW"U<=&HA@G[
M%6^-PK<,XTQZ:V1V7TB>@]+OR=5#S<P3.;H$0QG7QXEO,(?U]+,6;]+@10?P
MPHA<2V$*3:Y$#ODN@(_D.H;1AN$DZD6\A.R4Q.$)B8(H(BMI@+PE/M$%5:#;
MQQZ>T[]'#5\"W.$==Y6-78;X0(:VEM\OYMHH/*T_]A6S@3C;#V%O\+FN: 9C
M#Z^H!K4"+WWW)AP&'_<I_D]@.VK/.K5G?>CIG31,+(FRMT:3"E132"+J<H[&
M3_?A]E6@@1TZ6-MR5FF8^*MM6;V)7REKT,D:],J:85,!I2!OS\7)YIA@0]2&
MBMR*/F*BW3Y&H0=/Y&3PA]3@F=0^CQW^PX[_L)?_5)8E-DMM;_D)R=F*Y2!R
MC8TNX]3*LMQSR='8^FI[[WV3:-##OL]CA_VH8S]Z%?N*LG]A/GJ1>9]'P]S?
M:K$EJ*6;/)IDLA:FZ67=;C?<+EQ/?[8_P:'7S*C?,,W$O*9JR80F'!8(&9R.
MD(]JIE!C&%FY1CZ7!L>"6Q8XN$%9!WR_D'C'6L,FZ/X*I+\ 4$L#!!0    (
M ,A)5U8;.;2B80(  &D&   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;*U5;6O;,!#^*X<'HX4U?DG:=9UC6-*-== 16K9]5IQS+"I+KB0G[;_?279,
MRIS0PKY8;_<\>IX[^YQNE7XP):*%ITI(,PU*:^NK,#1YB14S(U6CI)-"Z8I9
M6NIU:&J-;.5!E0B3*+H(*\9ED*5^;Z&S5#56<(D+#::I*J:?9RC4=AK$P6[C
MCJ]+ZS;"+*W9&N_1_JH7FE9AS[+B%4K#E02-Q33X$E_-)R[>!_SFN#5[<W!.
MEDH]N,7-:AI$3A *S*UC8#1L<(Y"."*2\=AQ!OV5#K@_W[%_\][)RY(9G"OQ
MAZ]L.0TN UAAP1IA[]3V.W9^SAU?KH3Q3]AVL5$ >6.LJCHP*:BX;$?VU.5A
M#Q!/#@"2#I"\%C#N &-OM%7F;5TSR[)4JRUH%TUL;N)SX]'DADM7Q7NKZ903
MSF9?'QMNG\]FE(D5S%5%;X=A/L%GD$3Q)T ? %SF*%W&H19,PLDU6L:%.=V%
MM3QPTX<M7-@9F))I-+N!2[CE0A"]24-+\IV(,.^DSEJIR0&IUYB/8!Q_H N3
M9  ^/P[_P>0A>$A)ZS.7])E+/-_X:.;@W\P-.6NI)L-4[DN],C7+<1K0IVA0
M;S#(WK^++Z+/0S[_$]D+U^/>]?@8>W;?%I)MJ/IL*1"HD4#1V$8C<&,:1B\
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M :X[J.]SQN3N10]079G/_@-02P,$%     @ R$E75L5Y32AE!   C1,  !D
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M&-IB6"S1;5]"MXESL2 QC!S5!P3P%3CC/__ ?>^O-OX' GL7C6X5C:X-??Q
M.<1L1M/_5$3 %*[9P@F*FX4++WK<&HH"/S+XNL&MQF$G\)I_*FNK)E^K1WOR
M[55\>P?D:ZYF ZK*2%F"5(]')8">UQ8/^_H!>@7"!<(HU[L,]5%"7MNVZ<2*
MLV>4^E64^E8O+V8S#C,B0?42U8+4!R9&*[U#V@CWMPK Z_@;*=^>XW?JLGCG
MXZ#R<6#UT?=PA(I6BZ[5-J7ZVX5N,]*:%2O6[V[8 X&]HQU6M$-K^_IGF3^I
M+L6F!:+I5JUM/CPDXP.!O6,<58PC:Z+_74HA"4U2.M-M6<X!/<$LI50_.%$?
MN^(3>-H6A *YWZB[@6I(&\5I77Y/<MBKQ8)GI?>#$ZH[S"=,2I0F%3_"T6"3
MC'VU?=DTI ^VLGE4FF4',GB+S%E+8NQK[<O%K[GX5BY*TTXAW86.OTVGZX?A
M%A_K>OORJ84/MBJ)MHT$]'-RP7;A=2,OVB)W#!F#:QV#N\>7=?A TJ2,R#&$
M#JZ5#K9+C4_[9L*R3&L1'1Y3 .WY+U8)&_GO#3J#8#/]Q] KN!8LV*Y8FEUT
M1UX%( X:Q+I!)PHWB5D7WI=8K7*P7>8T&NJ.O ;;O%H3=@P5@VL9@ZV:8:.Y
M[D@M;$E9MS/H;5([AES!M5[!ORU8WOKLCCRCK2VG*C/<HGE0X>(V#CQRX#-S
M#B34SZ(EE<791_6T.FNZ,"<L;CV].*BZ(5SU&8$RF"I33R7(0;PX^REN)%N8
MXY,G)B7+S7 .) &N)ZCW4\;DVXU>H#J!&_\/4$L#!!0    ( ,A)5U9;F AJ
ME 0  & 1   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;+6877.C-A2&
M_XJ&[G22F<0@83"DMF><CWY<;)O9--V+3B]D.+8U >25Y#C>V1]?"3"X:] F
MWFDN8B&DH^<<2>>5&&^Y>)(K (5>\JR0$V>EU/K*=66R@IS* 5]#H=\LN,BI
MTH]BZ<JU )J6G?+,)9X7NCEEA3,=EW7W8CKF&Y6Q NX%DIL\IV)W#1G?3ASL
M["L^L.5*F0IW.E[3)3R >ES?"_WD-E92ED,A&2^0@,7$F>&K:^*;#F6+OQAL
MY4$9&5?FG#^9A]_2B>,9(L@@4<8$U3_/< -99BQICD^U4:<9TW0\+.^M_UPZ
MKYV94PDW//O(4K6:.)&#4EC03:8^\.VO4#L4&'L)SV3Y'VWKMIZ#DHU4/*\[
M:X*<%=4O?:D#<=!AV->!U!U(R5T-5%+>4D6G8\&W2)C6VIHIE*Z6O34<*\RL
M/"BAWS+=3TWO/FV8VEU>:\=2=,-S/=N2EO&Z1 ^*)T^(KZOP;:E()3J[!459
M)L^_>B_1.^0BN:(")&(%>BR8DA>Z4I?_7/&-I$4JQZ[2R&9@-ZGQKBL\TH.'
M"7K/"[62Z*Y((?VO 5?[VCA,]@Y?$ZO%6T@&R,<7B'B$H,>'6W3V[OP0OOJQ
MC.0WH?7+D?R>D7[?Y',0B"_00X?)BK6R,.RV8';DE5S3!":.WG(2Q#,XTQ]_
MP*'WDX5OV/ -;=:G?VR45'I:6+%$5"&U C2')2L*4W&FYZV*Q#GZTAF3RH%J
MB+ <PF2 Y^EP%.$@#,;N<P=;T+ %5K9?!"V47I&OQ0B.,/ PCF(<=6.$#49H
MQ;A[ 9$P^0:0\ CD<AC$D1]W@XP:D)$51&>@!3 3$2X0O*R9> /3Z)@I"$9>
MC+N9HH8I>NOZ@>+U5-$154!"/PC\;JJXH8KM5'4Z@FKJZ#R#4^CB(SH2QQX)
MAMUTV&OSK6?-"A]+G="S-WL&H74/[=<8NA<L@<X4Z?T/60(?* 3^OCR1\BRC
M0J*USG9E1$UHVXS:Z5(U9'087V_@]<P])BTK>77>. 6KLH[] RX_'HQZL%HE
MP-9$_E4>.07,/P;#>$#"'K)6 [!=!'H3RRF0PX[H^8.H#[(5 VQ7 TNF.04S
M.,8DPT'<M[5;L<!VM7A%ZCD%-SS:*C@>X!Y!P:VBX)$U$96'DLOY\<%O)O0F
M6H(^>BLTWZ'#=O=T5U;/S&'P M4.7Z!9FC)3I!FZ93+)N-R8H]3?L[E40A^\
M_^ETS"IYIZ:U5KVP7;[N7M;Z9J"=4B#R<G)VH*?FO!/5;FI4=44CE%>'U1"E
M=&<[0^)6SO!WZYF%VVX[K+DQWH/CX%ODI%4Z8M6EOEVKUWL7:FTL.,P=44!Z
MSI&D52_R#?6RQZ^/!A_IOT\"0GIH6GTB=GUZ+ 0D?%FPSWKA07GW0M762@ZW
MH$[$N@R]=.0H5H&G_WKH6IDB=IEZ(QWL=Y#.9HRG:*$EI#9@VG62VP%(O2!)
MLQY)[WIT#RZ].8AE>;67FG13J.K^V]0VGP]FU:6Y;5Y]>WA/A3[/2)3!0G?U
M!B,=65%=YZL'Q=?E%7K.E;Z0E\45T!2$::#?+SA7^P<S0/-19?HO4$L#!!0
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MOCU2/L/R13*8(J35Z6'EX&5'5#Y(MM ]PH1)[#CT,,$N$K@RP/=3QN3;@_I
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M!"F:%XH>B: *R%T"BA9,_KQP%:ZKT6[:KO'4K!%<6<,/R"=>J5R2YRJ#[)+
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M/W_2WR@-M[:@6B^!W8M9@;>RPAE9.WJ)22*.Q$E__@F&WJ^V$/\G9Z\"]ON
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M1J"?[SA7+P-SCNC/C>E_4$L#!!0    ( ,A)5U;E+(?$<@0  $\8   9
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M=48.2/ <K5/QB6Y_P:5# Z47TY3KOV!;]!T$#HC77-"L-)8SR$A>_*)=">+
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M#R4Q5IQ>%S>"KO1Y[HP*03-]N<0HP4QUD,_GE(K]C1J@^A]"^!]02P,$%
M  @ R$E75G,#G*=S"P  ])   !D   !X;"]W;W)K<VAE971S+W-H965T-3@N
M>&ULQ=U;;Z-(&@;@OX*\H]6,U-/FY%,VB90$J(-FNJ,^[%ZL]H+891NU;3R
MD^[5_/@M,#8N0\JP>D>9B^G$H9["SO=AX 7G^B5.OJ5+(3+C^WJU26]ZRRS;
M7O7[Z70IUF'Z/MZ*C?S)/$[682:_31;]=)N(<%8,6J_ZMFD.^^LPVO1NKXO'
M'I/;ZWB7K:*->$R,=+=>A\F/>[&*7VYZ5N_PP*=HL<SR!_JWU]MP(3Z+[.OV
M,9'?]8_*+%J+31K%&R,1\YO>G77%W7$^H%CBGY%X24^^-O*G\A3'W_)OV.RF
M9^9K)%9BFN5$*/]Y%@]BM<HEN1Y_E&CO.&<^\/3K@QX43UX^F:<P%0_QZE_1
M+%O>],8]8R;FX6Z5?8I?J"B?T"#WIO$J+?YOO)3+FCUCNDNS>%T.EFNPCC;[
M?\/OY0MQ,L"V7QE@EP/LLP'.Z)4!3CG :3O +0>X;0<,R@&#ML]A6 X8MIUA
M5 X8G0]X[64=EP/&;5=I4@Z8M!U@F8??G%E4T/Y77M2+%V;A[742OQA)OKST
M\B^*HBO&RS*)-GE_?,X2^=-(CLMN/V[W9;J9&;]%4UGWPKA;)$+(%LA2XU?C
M0Y@D85["QL^>R,)HE?YB_&1$&^/+,MZE<EAZW<_D>N1:?UK.^;"?TWYE3LOX
M/=YDR]3P-S,Q:QCOZ\<[E\:3"_/;&J O7\#CJV@?7L5[6RO>[1;O#7OPSK!-
MVS2^?O:,GW_ZI>F%T3.!>)+,.&>LR8$QLC!9R WE-HD72;AN4#V]^G&:O3<<
MJU#'1[7DC+@H@*9?@E[UQ/2@VG9[-="KG\56JN;%%Y+\)2M'VZO6N=K L?:<
M[KGRUDSUZ]74M'/<,CB%Z[SBRG><5?@4E]U_)S<#FT6Q62@V%J???\R6(C&R
M9;@QU$'__DV:!LO$.OU/PQ.[WZ^ V[P"^9[!5;H-I^*F)]_Z4Y$\B][MW_]F
M#<U_-+46$O.0F(_$ B1&D!A%8@R)<1"FM)%[;"-7IY^V4;%'^2PV.]'4#%JF
M:S,@,0^)^4@L0&)DCPT*+#^L>+X=F6-S?-U_/JWR^E+69#1QU:58?2G7G;@#
M=2D.6GVE+@?'NAQHZ_+NZ4D>;#05HG9<UT)$8AX2\Y%8@,0($J-(C"$Q#L*4
MZA\>JW_XUCLW0V0;(3$/B?E(+$!B!(E1),:0& =A2AN-CFTTTKZ)>&(NDD3,
M=/LU6J%K'R Q#XGY2"Q 8@2)T3TV/-FQ&9H#TSS;_4%.R4&84N#C8X&/6^PE
M&7\>3HXU%;A6Z%K@2,Q#8CX2"Y 806(4B3$DQD&8T@>38Q],WGI_:8)L(R3F
M(3$?B05(C" QBL08$N,@3&DCRZSB%E/[AO)%)&LCGAMAU3)-S:!7NG8#5/,N
M/,.!\4.$25,LY$/7(X!J!*I1J,:@&D=I:@><!(Z6MCZ^;N=)+-\HYD*D\KAA
M*N2;0U.(=Z]W.O< 4O-*33D-:.;_J3O"/G36 *H1J$:A&H-J'*6I%6]7%6]K
M*_[#;OTD]XGD5C_7PV2Z/(2&J3RR>#T_O->[G3L J7FE=GHDZ)X7?WT11UTD
M@*X3N3PAA4[(H!I':6J95GFOI<W!#I>"B.\BF4:IR#?0C44)36VAFE=JIYME
MNVFK#$UDH1J!:A2J,:C&49I:[E4N:^F#V6JKO+\>)#7"YS"2!ZPK6?IQ4O7!
MGZ]?,'*OGZ-S,T!CVU+3; U]Z(0!5"-0C4(U!M4X2E,;H0J"+7T2_)C$\R@S
MUF&RB#;&5E:]/"@-%\T;?V@X#-4\J.:76GZP=&P?\[UUOO\"#7Y;S4FA<S*H
MQE&:6LI5JFMITRYY;/GK_N!R&_XHSD9&F^EJ-Q.S_(K5+ DW:;B_+'N;1-/F
M H?&ME#-@VH^5 N@&H%J%*HQJ,9+37,B06V%*IFU]-%LP][\A=,MHS;[S@_Z
M:3N7-#2#A6H!5"-0C4(U!M4X2E,+OTIL+7UD^VE_*4)>Z_%B$_U7;OSE>\+A
MJN]C0S2V #3*A6H>5/.A6E!J%S8=!#HIA6H,JG&4IK9 %=9:VA"KH04:JQV:
MN$(U#ZKY4"V :J343GMG,!J=]PZ%3LJ@&D=IZJU75:1JZP/'UE?8ZYVN!0_5
M/*CF0[4 JI%2NW )&2T74W:,+6LR.KO2K$%S)#<\N](>]134$JTR3UN?>7)Y
MY)F*QC.(^I&=BQ*:<D(U'ZH%4(U -0K5&%3C*$WMA"H+M?<AUAM>2&9#4U.H
MYD$U'ZH%4(U -0K5&%3C*$WMJ"JVM?6Q[8<XB^;1=+_W\RB2*&[<V]<KG;L"
M&MM"-1^J!5"-0#5ZH3*&IC$+?S1=B<>@Z\%1FMH!59)KZY/<<N]*?Y6^WNA<
M_]"D%JKY4"V :@2J4:C&H!I':6I/5*&N/7CS_2QH%@S5/*CF0[4 JA&H1J$:
M@VH<I:D=567+MCY;;G.OHY[HW!+0]!BJ^78]MZR=PPF@4Y)2&^JFI WK93NU
M^Q.A*\91FEJ85=)KZY/>]N<_H;?B0C4/JOE0+8!JQ*[?0FN93NUS1AH6&P_J
MIS\;EAJ/)^=G/_^*1-:N$EE;G\BVVG)"HU>HYD$UWZZ'I0U;3N@-LFVFI T+
MC8;U+2<T)T5I:F%6.:FMSTFK \?#34F'Z\9TE0J-3:&:!]5\J!9 -0+5*%1C
M4(VC-/5# *MTU3'?^D#2@>:R4,V#:CY4"Z :@6H4JC&HQE&:VE%5&.SHP^#_
M^W9 O=NY3ZS:KJ.MOME[T G]A@G/;P>$3D@N3TBA$S*HQE&:6J954NOH[UIM
M=Q&9'NE<D]"P%:KYI7:Z?^S4KG$,H',2J$:A&H-J'*6IQ7[R6<?ZJ*S-(:J>
MZ%SJV,\KQGY@<?TVVOHA*G1*TF9*"IV2036.TM0"KC)01Y^!5CL5T283BR2_
MWZGXW/A\GV+_56--0U/14M.\X7K0"7VH%D U M4H5&-0C:,TM?2KJ-/1W[]Z
M\H$RQ8W;\RA),R-[B6O[UXT= $TQ2ZUV.]=Y%T#C2:@60#4"U2A48U"-HS2U
M"ZIXTKETZZO:!=DR2F;M.@ :6CJ-P6"M :!A)%0+H!J!:A2J,:C&49K: %4,
MZNACT,?RU/U,'K-N7[T,4H]T+G;]*KU^ 9X'70\?J@50C4 U"M485.,H36V
M*F9U]#%K=0@PB]*I?"^(Y(%L_2W@TDE&:! +U3RHYI>:Y@1H )V07)Z07EZ$
M0=>)HS2U9JL$UM$GL+4/87IGK,H_0Z?[V"6]VKE(H1DL5/-+37O2'!JL7IZ0
M0B=D4(VC-/5O/55IJ0NZ%U7O=*U@J.9!-1^J!5"-N/6;3$>6>W;Y%&U8RAD.
MSKJ"-2QEV^.SR[HX:OW5^JRR1U>?/3Z*I/B;NINI,.*G5;0X%*HNX]&;G6L5
M>HLJ5/.A6@#5B-OPD<.3VBERZ)P,JG&4IM9^%6BZ^D"S?K77X9"QC#K?&4%Q
MZO#+2VP\ECO+C?T S3RAF@?5?*@60#4"U2A48U"-HS2U;ZILU'WS/P3K0J-5
MJ.9!-1^J!5"-0#4*U1A4XRA-[:B3/PG;-JSM>')&[W;N$Z3F037?K4?)YR=G
MH!.2RQ-2Z(0,JG&4IE9TE<&Z^@RV_7$O-&Z%:AY4\Z%: -6(VRJFIM!)&53C
M*$TM^"IN=?5Q:XN#B2]% ONHV9I#@U>HYD$U'ZH%4(U -0K5&%3C*$UMF2J@
M=4=O?AP!37>AF@?5?*@60#4"U2A48U"-HS2UHZK$U]4GONWWNJ"A+E3SH)H/
MU0*H1MS&VW!K.UW0SS6&:ARE[>N]GRZ%R+PP"V^OUR)9B >Q6J7&--YMLGR2
MDT=E<<_SSSV^NK-[_=KC#]:59S4\[EM70=/CQ+IBQ>/]:MK;ZVVX$+\7?P0E
M-59B+E?!?#^2OZPD6BR/WV3Q]J9G]8RG.,OB=?'E4H0SD>0+R)_/XS@[?)-/
M\!(GWXJG>?L_4$L#!!0    ( ,A)5U8;VU/Q4 0  &,7   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4Y+GAM;,58;6_;-A#^*X16#"VP1:+>+&>V@<1:L0XM
M&B3+]F'8!UHZ6T(ET2-INQWZXTN]6._6$I1 OD0B???H[J'N\N@6)\H^\0A
MH,]IDO&E%@FQO]9U'D20$GY%]Y#)7[:4I43()=OI?,^ A(53FNBF8;AZ2N),
M6RV*O3NV6M"#2.(,[ACBAS0E[,LM)/2TU+!VWKB/=Y'(-_358D]V\ #B<7_'
MY$JO4<(XA8S'-$,,MDOM!E_[>)X[%!9_QG#BK7N4I[*A]%.^>!<N-2./"!((
M1 Y!Y.4(:TB2'$G&\6\%JM7/S!W;]V?TMT7R,ID-X;"FR5]Q***EYFDHA"TY
M).*>GGZ#*B$GQPMHPHN_Z%39&AH*#ES0M'*6$:1Q5E[)YXJ(E@-V+SB8E8/9
M=[ O.%B5@_54![MRL MFRE0*'GPBR&K!Z FQW%JBY3<%F86W3#_.\G-_$$S^
M&DL_L?JX+^G/0O0^#N1Y KK9,0!YM(*CG]&:<GF-L^# &(2%'8,C9 >0UX#N
MLO@_N?W:!T'BA+^1'H\//GK]Z@UZ);W0'Q$]<.G$%[J0T>;/U(,JLMLR,O-"
M9-A$'V@F(HY^S4((NP"Z3+/.U3SG>FM.(OH07"$+_X1,PS1' EH_W1V/N/M/
M=S<FLK'JD[,*/.L"GGS3$[*AC.2%@VX8(]FN.+;BD-KKCR("AD1$,M1U^ON]
MQ$3O!*3\G[$#*@.PQP/(.](UWY, EIIL.1S8$;35CS]@U_AEC%R58+XBL [Q
M=DV\/86^NA^\_V/<E1A.@9$WW^-J9GB&M]"/;5*&5G@^F]M=*W]H9=MSVZFM
M.FDX=1K.9!K=RAY+H?1WV\%9MFGTHEN/F&''-8Q>$D.SN8G-"TFX=1+N9!(W
MFXW\5X"^GIO76!J3",]]BU6"^8K .LS-:N9F+]T^9BJ)5PGF*P+K$._5Q'L*
MVH<WJ!;7</HUM1Y:82P;2*_RAE:6!'/'*V]>IS'_SO8Q'Z9@X5X"0QO'FKF]
M^(=&L@_-[/'XL=$H'V,R@]])QCEDLGD\[K=,2@VT)U^*-[Y2.*.:91+SN2^U
M4C1?%5J7SY:2Q"_=4:H(5+&O$LU7A=9EWVS8-Q6TE0JD74LS;,][53EB9;F.
MU2O+$2O3]+P+9=G(6CPIWEIE>0]QNCDP#O];E$J%JE(T7Q5:E\U&JV+[Q8MR
M4BX_FWV5:+XJM"[[C<3&TQK[B44YE,86=@9%.;22'P']3X41*]<U\(6B;&0V
MGM;935%.".UIC&>_"$JEMBJT+G^-V,8OKK:Q4KFM%,U7A=9EOU'<6(7DQB-J
MVK &G^PC9IXST-QC5IXWOU"'C>C&WZNZ*X#VL,!TK5D_B:&5;9M]X3UBY7AN
M_Y-=;TT?4V"[8HK+44 /F2B'<_5N/2F^*>:CO?W;?()<3#4;F'+\_(&P79QQ
ME,!60AI7,QD2*R>ZY4+0?3'CW% A:%K<1D!"8+F!_'U+J3@O\@?4<_75-U!+
M P04    " #(25=6BVX;^3T#  !["@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970V,"YX;6RM5MMNXS80_15"710)D%@72[*4V@;B>(L6V"V"3=-]*/K 2&.+
M6(ET2=K>_OT.*5FKN+3K GFQ>3GG<,[PHIGNA?RB*@!-OC8U5S.OTGISY_NJ
MJ*"A:B0VP'%F)61#-7;EVE<;";2TI*;VHR!(_88R[LVG=NQ1SJ=BJVO&X5$2
MM6T:*O]90"WV,R_T#@.?V+K29L"?3S=T#4^@GS>/$GM^KU*R!KAB@A,)JYEW
M']XM,X.W@#\8[-6@38R3%R&^F,ZOY<P+3$!00Z&- L6_'3Q 71LA#./O3M/K
MES3$8?N@_K/UCEY>J(('47]FI:YF7N:1$E9T6^M/8O\+='X2HU>(6ME?LN^P
M@4>*K=*BZ<@80<-X^T^_=GD8$,+T!"'J"-$Q(3Y!&'>$\:6$N"/$-C.M%9N'
M)=5T/I5B3Z1!HYIIV&1:-MIGW&S[DY8XRY"GY[_AR?H@E"(;D.2IHA+(+5E0
MQ0K"<8KQ0C1 KFJ$7%N,LIBK)6C*:AR[)<]/2W+U[IJ\(WX[JY!&GCG3Z@8'
ML?U[);:*\E)-?8TQFY7]HHMOT<87G8@OC,A'P76ER'M>0OE:P$>SO>/HX'@1
MG55<0C$BX_"&1$$4.0)ZN)P>.NC+R^G!&3?C?O_&5F]\0N\]E9SQM2*/_?[]
M>?^BM,0+]9<KW:U<[)8SC\R=VM "9AZ^(@KD#KSYCS^$:?"3*U5O*;9\([%7
M:8S[-,;GU.TU,&?<E;&6F5BF>45W\]LD#V+<_-TP%PY8GB1Q]!JV=,#B.,_S
M'O8J_J2//SD;_V?[OD%)Z XD/M<$KVV#SVIW'_&]5QHO()Z4&_-,XNV^8H?9
M:Y?I=KET$.8X"\,HSK,CVPY@,LDG>9H?&7< @R2/LWSBMI[VUM,WLUZR>FN@
M_V$^O=2\ ^@V[P">-3_IS4\N.K??G^;A_I:BKJD<3#K=MBMDPQ,9CI+DR*H#
M%8W2R9%/IU9\PF36F\S^M\GA3EYF,[O(I@/EL.G4^I=-?_!9;D"N;7FC\'QN
MN6Z_5_UH7T'=V\+A:'R!E55;"'V7:<NRCU2N&5>DAA5*!J,)WC+9ECIM1XN-
M_?B_"(VEA&U66!V"- "<7PFA#QVS0%]OSK\!4$L#!!0    ( ,A)5U8>$JF)
M\@,  +H5   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;,U8;6^;.A3^
M*Q:3IDW:BLU;0I=$:DNG3=JNHD;WW@_3/KC$2:P"9K9)>O_]M0TA(:&HU3RI
M7Q(PYSSV>8X?.#Z3'>,/8D.(!(]Y5HBILY&RO'1=D6Y(CL4%*TFAGJP8S[%4
MMWSMBI(3O#1.>>9Z$$9NCFGAS"9F;,YG$U;)C!9DSH&H\ASS_ZY)QG93!SG[
M@3NZWD@]X,XF)5Z3!9%_EW.N[MP694ES4@C*"L#):NI<H<L$1=K!6/Q#R4X<
M70,=RCUC#_KFZW+J0+TBDI%4:@BL_K;DAF291E+K^-6 .NV<VO'X>H_^V02O
M@KG'@MRP[%^ZE)NI,W; DJQPE<D[MOM"FH!"C9>R3)A?L&MLH0/22DB6-\YJ
M!3DMZG_\V!!QY* "[7?P&@?OU"%XPL%O'/SG.@2-0V"8J4,Q/"18XMF$LQW@
MVEJAZ0M#IO%6X=-"YWTAN7I*E9^<_:6VUC<F!"@)!XL-YN0CN&%YKE*BYDX?
M /E5T2W.2"&!T(\%>)<0B6DFWH./S=#$E6HI&M!-FVFOZVF])Z9%'OC."KD1
MX+98DF47P%4QM(%X^T"NO4'$A*07P$<?@ <]KV=!-\]W1SWNR?/=X4 T?IL6
MW^#Y3^!=%9(N:59I48 %22M.)57<WSZF6:4( RO.<IVHLI+8"(BMP"WF!2W6
M LSWN00_OBE@\%627/SLRU*]BJ!_%?J=<RE*G)*IHUXJ@O M<69OWZ (?NIC
MV"988@FLPW[0LA\,H1OVW[X9>S#^U"9!')+PCA;-QG_?QVF-'1EL_=K=SL(0
M>5'@3]SM,5WG=L$HAB,_ZMHE/78ABGT(6[M.D&$;9#@8Y!T1DM-4JLV4'@F^
M+Z)!H)?N$IM@B26P#H%12V#T*C0:V63?)EAB":S#_JAE?_0'-3HZTQ0\4>>Y
MA8=&Z$2:YT8(PG@<]RMSW(8V?JXRZV]P55#9^Y$=Q'GIUK )EE@"Z_ 7M_S%
MKT*8L4WV;8(EEL Z["-X*"GA'Y1F ]Y17A##^%2@/78C"$^LDAZK*/)0U*]0
M=%0VH\$8%T:8K-3;I[_^'?1_Z>ZPBI;80NMRYQVX\UZ%/IMEV$J!3;3$%EHW
M!8?C!1JLGW]7HOYYB>M%?AB>EK@]AL%HC,(H/)5ICZ$?JN6%3PCU4,JCX5K^
M=C&?]\8PZ/;BS6$3+;&%UJ7L<#! X>O0I]5SA56TQ!9:-P6'HP4:K)U_5Y_1
M>5V* L^#P:D^K1X';*'5G+E'3:V<\+5I#@IU5JT*6;>%VM&V 7EEVFXGX]>Z
M,6F:90>8NJOY'?,U+03(R$I!PHN12CJO&X7UC62E:9W=,RE9;BXW!"\)UP;J
M^8HQN;_1$[3MVMG_4$L#!!0    ( ,A)5U8*&G8>;P(  (D&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;*U5R6[;,!#]%8(-B@1HK<5+VU06$%LI
MVD, (T':0]$#+8TM(A2IDF,[^?N2E*PZ@1SXD(O$&<Y[LU!\2G9*/Y@2 ,EC
M):29TA*QO@P"DY=0,3-0-4B[LU*Z8FA-O0Y,K8$5'E2)( [#25 Q+FF:>-]"
MIXG:H. 2%IJ8354Q_30#H793&M&]XY:O2W2.($UJMH8[P/MZH:T5="P%KT :
MKB31L)K2J^@R&[EX'_"3P\X<K(GK9*G4@S-^%%,:NH) 0(Z.@=G7%N8@A".R
M9?QM.6F7T@$/UWOV;[YWV\N2&9@K\8L76$[I9TH*6+&-P%NU^PYM/V/'ERMA
M_)/LFMCQA))\8U!5+=A64''9O-EC.X<#0'0,$+> ^"5@= 0P; '#4P&C%N!'
M'32M^#ED#%F::+4CVD5;-K?PP_1HVSZ7[MCO4-M=;G&87E>U4$\ 9 825AS)
M0C!)SC- QH6Y(!_)_5U&SL\NR!GADMQP(>QQF21 F]Q1!'F;:-8DBH\DBF)R
MHR26AES+ HKG!(&MNBL]WI<^BU]ES" ?D&'T@<1A'/<4-#\='O7 L]/AX2O=
M#+N#&'J^X1&^6T"NP5XHW!^%(;^OE@:UO1I_^N;=\(WZ^9Q<7)J:Y3"E5@\,
MZ"W0]/V[:!)^[9O56Y)E;T3V;(ZC;HZCU]C3N?W(-%]NO*J@0B8(J]1&8M\(
M&ZHOGLH)Y#8-!Y,DV!Y.YH28K"]FW,4T?00'E[0"O?9B9TCN:FL^^L[;Z>F5
MEY$7_IG5V486_],T(GW#])I+0P2L+&4X^#2F1#?"UQBH:B\%2X566/RRM/\*
MT"[ [J^4PKWA$G1_G_0?4$L#!!0    ( ,A)5U;>K+UG20,  ,P4   -
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M_E/69VN7?QP_///6U-TAGPU_,IJ] 5!+ 0(4 Q0    ( ,A)5U8'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ R$E75OHF #/N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ R$E75IE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #(
M25=6'Q]$^1$(  #X,   &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ R$E75N,F><P[ @  O04  !@
M         ("!5!   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( ,A)5U;.0HDJ P8  'P9   8              " @<42  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #(25=6$QBN,_\"  !B"@
M&               @('^&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ R$E75O)P#YH+!@  !QL  !@              ("!,QP  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,A)5U8T<8YR20P
M /28   8              " @70B  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " #(25=6X T. K\"  #F"   &               @('S
M+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ R$E75I7J
MBVTG"0  NC   !@              ("!Z#$  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( ,A)5U8 FMB&@ @  $@5   8
M  " @44[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #(
M25=6IYNI,L0C  #/=@  &0              @('[0P  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,A)5U9 5!.5?@0  (P,   9
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M970Q-2YX;6Q02P$"% ,4    " #(25=6IYG3@KT#   U"0  &0
M    @(%O?0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M ,A)5U;/;2R^-0L  )H@   9              " @6.!  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ R$E75L01I09!"P  I1X  !D
M             ("!SXP  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " #(25=69+%RUN\$   %#   &0              @(%'F   >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,A)5U;@%+(S4!(
M ,="   9              " @6V=  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ R$E75I.QRS$#!0  G0P  !D              ("!
M]*\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #(25=6
MF029)K,"   6!@  &0              @($NM0  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,A)5U8G $#522(  --U   9
M      " @1BX  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ R$E75AJ8 B@!!   GPL  !D              ("!F-H  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #(25=6O"L:A;@#   W"0
M&0              @('0W@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( ,A)5U:;KXU0D ,  +((   9              " @;_B  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ R$E75L!*@@9$
M P  5P<  !D              ("!AN8  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " #(25=6$T="Y)T#   T"0  &0
M@($!Z@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,A)
M5U;6+,.<LP(  .<%   9              " @=7M  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ R$E75H;8$O(]!@  *!,  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( ,A)5U8%KY2$@P,  , .   9
M  " @3 * 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
MR$E75L'E8ST,!@  GB(  !D              ("!Z@T! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " #(25=6:D<7G,D"  "W"0  &0
M            @($M% $ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( ,A)5U:TYM7UN@<  %%&   9              " @2T7 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ R$E75K:Y#:S.!
MI1H  !D              ("!'A\! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " #(25=68M,EP^T#  !U%   &0              @($C
M) $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,A)5U8U
M+34Q$@,  % ,   9              " @4<H 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ R$E75@.PX'NK P  ^@L  !D
M     ("!D"L! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,A)5U9'=A0-; 0  #H;   9              "
M@;\Z 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ R$E7
M5B)/C!E"!   /A<  !D              ("!8C\! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " #(25=6Q7E-*&4$  "-$P  &0
M        @(';0P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( ,A)5U9;F AJE 0  & 1   9              " @7=( 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ R$E75FX;+1@Y!   HPX
M !D              ("!0DT! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " #(25=6#QZ.KCH#  #V#   &0              @(&R40$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ,A)5U:+M2Y!
MR (  "L(   9              " @2-5 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ R$E75@=EDL!7 P  FPT  !D
M ("!(E@! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #(
M25=6"6TB,((#   8#   &0              @(&P6P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,A)5U;WVGO1"@0  $,.   9
M          " @6E? 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#
M%     @ R$E75N4LA\1R!   3Q@  !D              ("!JF,! 'AL+W=O
M<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #(25=6<P.<IW,+  #T
MD   &0              @(%3: $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;%!+ 0(4 Q0    ( ,A)5U8;VU/Q4 0  &,7   9              " @?US
M 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ R$E75HMN
M&_D] P  >PH  !D              ("!A'@! 'AL+W=O<FMS:&5E=',O<VAE
M970V,"YX;6Q02P$"% ,4    " #(25=6'A*IB?(#  "Z%0  &0
M    @('X>P$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M ,A)5U8*&G8>;P(  (D&   9              " @2&  0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ R$E75MZLO6=) P  S!0   T
M             ( !QX(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #(25=6
MEXJ[',     3 @  "P              @ $[A@$ 7W)E;',O+G)E;'-02P$"
M% ,4    " #(25=6'HC '0X%   D*0  #P              @ $DAP$ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ R$E75G=+<84& @  \20  !H
M         ( !7XP! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ R$E75O\GIW7C 0  ;"0  !,              ( !G8X! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     $8 1@ A$P  L9 !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>207</ContextCount>
  <ElementCount>334</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NatureoftheBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/Marketablesecurities</Role>
      <ShortName>Marketable securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Option and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/OptionandLicenseAgreements</Role>
      <ShortName>Option and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Marketable securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/MarketablesecuritiesTables</Role>
      <ShortName>Marketable securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/Marketablesecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/AccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/EquityBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Option and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/OptionandLicenseAgreementsTables</Role>
      <ShortName>Option and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/OptionandLicenseAgreements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/NetLossperShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Nature of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NatureoftheBusinessDetails</Role>
      <ShortName>Nature of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/NatureoftheBusiness</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Basis of Presentation and Significant Accounting Policies - Property and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Property and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Marketable securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/MarketablesecuritiesDetails</Role>
      <ShortName>Marketable securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/MarketablesecuritiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Leases - Summary of supplemental information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails</Role>
      <ShortName>Leases - Summary of supplemental information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Leases - Maturities of lease commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails</Role>
      <ShortName>Leases - Maturities of lease commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/AccruedExpensesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/StockholdersEquity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Equity-Based Compensation - 2019 equity incentive plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails</Role>
      <ShortName>Equity-Based Compensation - 2019 equity incentive plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Equity-Based Compensation - Equity based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Equity based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Equity-Based Compensation - Restricted common stock activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails</Role>
      <ShortName>Equity-Based Compensation - Restricted common stock activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Equity-Based Compensation - Restricted stock units activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails</Role>
      <ShortName>Equity-Based Compensation - Restricted stock units activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Equity-Based Compensation - Stock option awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails</Role>
      <ShortName>Equity-Based Compensation - Stock option awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Equity-Based Compensation - Information related to options granted, vested and exercised (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails</Role>
      <ShortName>Equity-Based Compensation - Information related to options granted, vested and exercised (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Equity-Based Compensation- Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Equity-Based Compensation- Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Income Taxes - Components of loss before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails</Role>
      <ShortName>Income Taxes - Components of loss before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Income Taxes - Components of income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails</Role>
      <ShortName>Income Taxes - Components of income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Income Taxes - Effective income tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails</Role>
      <ShortName>Income Taxes - Effective income tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Option and License Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails</Role>
      <ShortName>Option and License Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Option and License Agreements - Costs incurred and revenue recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails</Role>
      <ShortName>Option and License Agreements - Costs incurred and revenue recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Net Loss per Share - Basic net income (loss) per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails</Role>
      <ShortName>Net Loss per Share - Basic net income (loss) per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Net Loss per Share- Common stock equivalent shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails</Role>
      <ShortName>Net Loss per Share- Common stock equivalent shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="morf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="morf-20221231.htm">morf-20221231.htm</File>
    <File>morf-20221231.xsd</File>
    <File>morf-20221231_cal.xml</File>
    <File>morf-20221231_def.xml</File>
    <File>morf-20221231_lab.xml</File>
    <File>morf-20221231_pre.xml</File>
    <File>morf-20221231x10kex211.htm</File>
    <File>morf-20221231x10kex231.htm</File>
    <File>morf-20221231x10kex311.htm</File>
    <File>morf-20221231x10kex312.htm</File>
    <File>morf-20221231x10kex321.htm</File>
    <File>morf-20221231x10kex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>morf-20221231_g1.jpg</File>
    <File>morf-20221231_g10.jpg</File>
    <File>morf-20221231_g11.jpg</File>
    <File>morf-20221231_g12.jpg</File>
    <File>morf-20221231_g13.jpg</File>
    <File>morf-20221231_g14.jpg</File>
    <File>morf-20221231_g15.jpg</File>
    <File>morf-20221231_g16.jpg</File>
    <File>morf-20221231_g17.jpg</File>
    <File>morf-20221231_g2.jpg</File>
    <File>morf-20221231_g3.jpg</File>
    <File>morf-20221231_g4.jpg</File>
    <File>morf-20221231_g5.jpg</File>
    <File>morf-20221231_g6.jpg</File>
    <File>morf-20221231_g7.jpg</File>
    <File>morf-20221231_g8.jpg</File>
    <File>morf-20221231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="772">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "morf-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 772,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 207,
   "dts": {
    "calculationLink": {
     "local": [
      "morf-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "morf-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "morf-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "morf-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "morf-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "morf-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 487,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 7
   },
   "keyCustom": 34,
   "keyStandard": 300,
   "memberCustom": 16,
   "memberStandard": 28,
   "nsprefix": "morf",
   "nsuri": "http://morphictx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://morphictx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Marketable securities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://morphictx.com/role/Marketablesecurities",
     "shortName": "Marketable securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://morphictx.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://morphictx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://morphictx.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://morphictx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Equity-Based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://morphictx.com/role/EquityBasedCompensation",
     "shortName": "Equity-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://morphictx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://morphictx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://morphictx.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Option and License Agreements",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://morphictx.com/role/OptionandLicenseAgreements",
     "shortName": "Option and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://morphictx.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://morphictx.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Marketable securities (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://morphictx.com/role/MarketablesecuritiesTables",
     "shortName": "Marketable securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://morphictx.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "morf:LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://morphictx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "morf:LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://morphictx.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Equity-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://morphictx.com/role/EquityBasedCompensationTables",
     "shortName": "Equity-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://morphictx.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Option and License Agreements (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://morphictx.com/role/OptionandLicenseAgreementsTables",
     "shortName": "Option and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://morphictx.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Nature of the Business (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://morphictx.com/role/NatureoftheBusinessDetails",
     "shortName": "Nature of the Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "if2d9d037833b403cbf8e599aeddd0edf_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i6e771d535ddd42f284b6e48b0a3ff9f8_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Basis of Presentation and Significant Accounting Policies - Property and Equipment Net (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Property and Equipment Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i6e771d535ddd42f284b6e48b0a3ff9f8_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "ifc86524fc8604efaabb07582c77cd814_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Marketable securities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://morphictx.com/role/MarketablesecuritiesDetails",
     "shortName": "Marketable securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://morphictx.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://morphictx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Leases - Summary of supplemental information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails",
     "shortName": "Leases - Summary of supplemental information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "morf:LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Leases - Maturities of lease commitments (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails",
     "shortName": "Leases - Maturities of lease commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://morphictx.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "morf:VotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://morphictx.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "morf:VotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i0839d27335e24a70944c9e307b2f4ffd_I20220131",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Equity-Based Compensation - 2019 equity incentive plan (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
     "shortName": "Equity-Based Compensation - 2019 equity incentive plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i0839d27335e24a70944c9e307b2f4ffd_I20220131",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Equity-Based Compensation - Equity based compensation expense (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
     "shortName": "Equity-Based Compensation - Equity based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i101397ce8aac488895ed850a9c62f94a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Equity-Based Compensation - Restricted common stock activity (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
     "shortName": "Equity-Based Compensation - Restricted common stock activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i101397ce8aac488895ed850a9c62f94a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i44c3053062ab47179828227426197a95_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Equity-Based Compensation - Restricted stock units activity (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
     "shortName": "Equity-Based Compensation - Restricted stock units activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i44c3053062ab47179828227426197a95_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "ic8748f4e6ee9480c88e24d869168b315_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Equity-Based Compensation - Stock option awards (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails",
     "shortName": "Equity-Based Compensation - Stock option awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "ic8748f4e6ee9480c88e24d869168b315_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Equity-Based Compensation - Information related to options granted, vested and exercised (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails",
     "shortName": "Equity-Based Compensation - Information related to options granted, vested and exercised (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "ib9a49673c39d457ca1650953807a3049_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Equity-Based Compensation- Employee Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Equity-Based Compensation- Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "ib9a49673c39d457ca1650953807a3049_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Income Taxes - Components of loss before income taxes (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails",
     "shortName": "Income Taxes - Components of loss before income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Income Taxes - Components of income tax (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails",
     "shortName": "Income Taxes - Components of income tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Income Taxes - Effective income tax rate (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails",
     "shortName": "Income Taxes - Effective income tax rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails",
     "shortName": "Income Taxes - Deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4d7a4e8f9a4b4b73a7a9fabe1cefa5d7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://morphictx.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Option and License Agreements - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails",
     "shortName": "Option and License Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "ic9645879e89545f6ae321d39d2ff49ff_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Option and License Agreements - Costs incurred and revenue recognized (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
     "shortName": "Option and License Agreements - Costs incurred and revenue recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i7d9a0e35c7f042cf912b4e21edd47242_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4bfdc1a144904aff961163efe0b71fed_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i4bfdc1a144904aff961163efe0b71fed_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Net Loss per Share - Basic net income (loss) per share (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails",
     "shortName": "Net Loss per Share - Basic net income (loss) per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Net Loss per Share- Common stock equivalent shares (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails",
     "shortName": "Net Loss per Share- Common stock equivalent shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Employee Benefit Plan (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://morphictx.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i72986ada1b4041fe8cc9f13d24082278_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Nature of the Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://morphictx.com/role/NatureoftheBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20221231.htm",
      "contextRef": "i5e56220d8e2d4da490cb30ea87e6180f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 48,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "morf_AbbVieMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents AbbVie Inc.",
        "label": "AbbVie [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development",
        "terseLabel": "Research and development activities"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_AtMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents at-the-market offering program.",
        "label": "At Market Offering Program [Member]",
        "terseLabel": "ATM"
       }
      }
     },
     "localname": "AtMarketOfferingProgramMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Offering",
        "label": "At-The-Market Offering [Member]",
        "terseLabel": "At-The-Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://morphictx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "morf_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Warrants Or Rights Issued In Transaction",
        "label": "Class Of Warrant Or Right, Number Of Warrants Or Rights Issued In Transaction",
        "terseLabel": "Right to purchase common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssuedInTransaction",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "morf_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights Issued In Transaction",
        "label": "Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights Issued In Transaction",
        "terseLabel": "Right to purchase common stock, purchase price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRightsIssuedInTransaction",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "morf_CollaborationAgreementNumberOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Agreements",
        "label": "Collaboration Agreement, Number Of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfAgreements",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "morf_CollaborationAgreementOptionExerciseRevenueReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue recognized from option exercise during the reporting period.",
        "label": "Collaboration Agreement, Option Exercise Revenue Received",
        "terseLabel": "Revenue recognized from option exercise"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseRevenueReceived",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Fee Received, Upon Commencement Of Third Research Program",
        "label": "Collaborative Arrangement, Additional Fee Received, Upon Commencement Of Third Research Program",
        "terseLabel": "Upfront fee for third research program"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalFeeReceivedUponCommencementOfThirdResearchProgram",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_CollaborativeArrangementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Option and License Agreements",
        "terseLabel": "Option and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "nsuri": "http://morphictx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "morf_CollaborativeArrangementNotificationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Notification Period",
        "label": "Collaborative Arrangement, Notification Period",
        "terseLabel": "Notification Period"
       }
      }
     },
     "localname": "CollaborativeArrangementNotificationPeriod",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "morf_CollaborativeArrangementNumberOfIntegrinTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Integrin Targets",
        "label": "Collaborative Arrangement, Number Of Integrin Targets",
        "terseLabel": "Number of integrin targets"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfIntegrinTargets",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "morf_CollaborativeArrangementNumberOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Options",
        "label": "Collaborative Arrangement, Number Of Options",
        "terseLabel": "Number of options available for exercise"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfOptions",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "morf_CollaborativeArrangementNumberOfOptionsToLicense": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Options To License",
        "label": "Collaborative Arrangement, Number Of Options To License",
        "terseLabel": "Number of options, license"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfOptionsToLicense",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "morf_CollaborativeArrangementNumberOfResearchPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Research Programs",
        "label": "Collaborative Arrangement, Number Of Research Programs",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfResearchPrograms",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "morf_CollaborativeArrangementNumberOfResearchProgramsDiscontinued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Research Programs Discontinued",
        "label": "Collaborative Arrangement, Number Of Research Programs Discontinued",
        "terseLabel": "Number of discontinued research programs"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfResearchProgramsDiscontinued",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "morf_CollaborativeArrangementOptionExerciseFeesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Option Exercise Fees Paid",
        "label": "Collaborative Arrangement, Option Exercise Fees Paid",
        "terseLabel": "Option exercise fees received"
       }
      }
     },
     "localname": "CollaborativeArrangementOptionExerciseFeesPaid",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_CollaborativeArrangementOptionExerciseFeesReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Option Exercise Fees, Receivable",
        "label": "Collaborative Arrangement, Option Exercise Fees, Receivable",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "CollaborativeArrangementOptionExerciseFeesReceivable",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_CollaborativeArrangementPaymentDuePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Payment Due Period",
        "label": "Collaborative Arrangement, Payment Due Period",
        "terseLabel": "Payment due period"
       }
      }
     },
     "localname": "CollaborativeArrangementPaymentDuePeriod",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "morf_CollaborativeArrangementProfitMarginPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Profit Margin Percentage",
        "label": "Collaborative Arrangement, Profit Margin Percentage",
        "terseLabel": "Profit margin percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementProfitMarginPercentage",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "morf_CollaborativeArrangementTermOfArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term Of Arrangement",
        "label": "Collaborative Arrangement, Term Of Arrangement",
        "terseLabel": "Term of arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTermOfArrangement",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "morf_CollaborativeArrangementUpfrontFeesReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payment fee received.",
        "label": "Collaborative Arrangement, Upfront Fees Received",
        "verboseLabel": "Upfront fees received"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontFeesReceived",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Upfront Fees Received For First Two Research Program",
        "label": "Collaborative Arrangement, Upfront Fees Received For First Two Research Program",
        "terseLabel": "Upfront fee for first two research program"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontFeesReceivedForFirstTwoResearchProgram",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_CommonStockAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock available for issuance.",
        "label": "Common Stock Available For Issuance",
        "terseLabel": "Amount of shares remaining available for sale"
       }
      }
     },
     "localname": "CommonStockAvailableForIssuance",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computers and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_DeferredTaxAssetLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Lease Liabilities",
        "label": "Deferred Tax Asset, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetLeaseLiabilities",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_DeferredTaxAssetsFixedAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Fixed And Intangible assets",
        "label": "Deferred Tax Assets Fixed And Intangible assets",
        "terseLabel": "Fixed and intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsFixedAndIntangibleAssets",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual value of shares available for purchase per employee from employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan Annual Value Of Shares Available For Purchase Per Employee",
        "terseLabel": "Amount of common shares available for purchase per employee per year"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-On Public Offering",
        "label": "Follow-On Public Offering [Member]",
        "terseLabel": "Secondary Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income.",
        "label": "Increase (Decrease) in Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_IncreaseDecreaseOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Operating Lease Right-Of-Use Assets",
        "label": "Increase (Decrease) Operating Lease Right-Of-Use Assets",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAssets",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_InterestIncomeOnInvestmentsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income On Investments Policy",
        "label": "Interest Income On Investments Policy [Policy Text Block]",
        "terseLabel": "Interest income on investments"
       }
      }
     },
     "localname": "InterestIncomeOnInvestmentsPolicyPolicyTextBlock",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "morf_JanssenPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Janssen Pharmaceuticals Inc.",
        "label": "Janssen Pharmaceuticals Inc [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Leases, Supplemental Disclosures",
        "label": "Lessee, Operating Leases, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Summary of supplemental information"
       }
      }
     },
     "localname": "LesseeOperatingLeasesSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "morf_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory Space",
        "label": "Office and Laboratory Space [Member]",
        "terseLabel": "Office and Laboratory Space"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_OpenMarketSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Open Market Sale Agreement.",
        "label": "Open Market Sale Agreement [Member]",
        "terseLabel": "Open Market Sale Agreement"
       }
      }
     },
     "localname": "OpenMarketSaleAgreementMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Not Subject to Expiration",
        "label": "Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_PercentageOfCommissionOnGrossSaleProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on gross sale proceeds.",
        "label": "Percentage of Commission on Gross sale Proceeds",
        "terseLabel": "Commission (as a percent)"
       }
      }
     },
     "localname": "PercentageOfCommissionOnGrossSaleProceeds",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "morf_ReimbursementRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Revenue",
        "label": "Reimbursement Revenue [Member]",
        "terseLabel": "Reimbursement revenue"
       }
      }
     },
     "localname": "ReimbursementRevenueMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Contract And Development Costs And Accruals Policy",
        "label": "Research Contract And Development Costs And Accruals Policy [Policy Text Block]",
        "terseLabel": "Research Contract and Development Costs And Accruals"
       }
      }
     },
     "localname": "ResearchContractAndDevelopmentCostsAndAccrualsPolicyPolicyTextBlock",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "morf_ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share Based Payment Award Summarized Information Relating To Stock Options",
        "label": "Schedule Of Share Based Payment Award Summarized Information Relating To Stock Options [Table Text Block]",
        "terseLabel": "Summary of information relating to stock"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardSummarizedInformationRelatingToStockOptionsTableTextBlock",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "morf_SecondaryOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary Offering",
        "label": "Secondary Offering [Member]",
        "terseLabel": "Secondary Offering"
       }
      }
     },
     "localname": "SecondaryOfferingMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of discount provided to employees to purchase common stock under the employee stock purchase plan.",
        "label": "Share Based Compensation Arrangement, Percentage Of Discount On Purchase Of Common Stock",
        "terseLabel": "Discount rate to purchase common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "morf_TwoThousandNineteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2019 stock incentive plan.",
        "label": "Two Thousand Nineteen Stock Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenStockIncentivePlanMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Treasury and U.S. Government-sponsored Enterprise Securities",
        "label": "U.S. Treasury and U.S. Government-sponsored Enterprise Securities [Member]",
        "terseLabel": "U.S. government-sponsored enterprise securities"
       }
      }
     },
     "localname": "USTreasuryAndUSGovernmentSponsoredEnterpriseSecuritiesMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_UpFrontPaymentIncludedInTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up Front Payment, Included In Transaction Price",
        "label": "Up Front Payment, Included In Transaction Price",
        "terseLabel": "Up-front payment included in transaction price"
       }
      }
     },
     "localname": "UpFrontPaymentIncludedInTransactionPrice",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_UpfrontPaymentRevenueFirstTwoProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment Revenue, First Two Programs",
        "label": "Upfront Payment Revenue, First Two Programs [Member]",
        "terseLabel": "Upfront Payment Revenue, First Two Programs"
       }
      }
     },
     "localname": "UpfrontPaymentRevenueFirstTwoProgramsMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_UpfrontPaymentRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment Revenue",
        "label": "Upfront Payment Revenue [Member]",
        "terseLabel": "Upfront payment revenue"
       }
      }
     },
     "localname": "UpfrontPaymentRevenueMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_UpfrontPaymentRevenueThirdProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment Revenue, Third Program",
        "label": "Upfront Payment Revenue, Third Program [Member]",
        "terseLabel": "Upfront Payment Revenue, Third Program"
       }
      }
     },
     "localname": "UpfrontPaymentRevenueThirdProgramMember",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_VotingRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voting Rights Per Share Number",
        "label": "Voting Rights",
        "terseLabel": "Voting rights per share number"
       }
      }
     },
     "localname": "VotingRights",
     "nsuri": "http://morphictx.com/20221231",
     "presentation": [
      "http://morphictx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r267",
      "r272",
      "r538",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r311",
      "r491",
      "r507",
      "r534",
      "r535",
      "r552",
      "r558",
      "r566",
      "r604",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r311",
      "r491",
      "r507",
      "r534",
      "r535",
      "r552",
      "r558",
      "r566",
      "r604",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "auth_ref": [
      "r520",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]",
        "terseLabel": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]",
        "terseLabel": "Real Estate [Domain]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r218",
      "r492",
      "r554",
      "r565",
      "r599",
      "r600",
      "r605",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r218",
      "r492",
      "r554",
      "r565",
      "r599",
      "r600",
      "r605",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r294",
      "r311",
      "r341",
      "r342",
      "r343",
      "r467",
      "r491",
      "r507",
      "r534",
      "r535",
      "r552",
      "r558",
      "r566",
      "r598",
      "r604",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r294",
      "r311",
      "r341",
      "r342",
      "r343",
      "r467",
      "r491",
      "r507",
      "r534",
      "r535",
      "r552",
      "r558",
      "r566",
      "r598",
      "r604",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r267",
      "r272",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://morphictx.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r108",
      "r120"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r564"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Premium amortization and discount accretion on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://morphictx.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r67",
      "r135"
     ],
     "calculation": {
      "http://morphictx.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r138",
      "r502",
      "r515",
      "r519"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r20",
      "r99",
      "r459",
      "r510",
      "r511",
      "r579",
      "r580",
      "r581",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r564"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid\u2011in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r586",
      "r587",
      "r588",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid\u2011in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Equity\u2011based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Amounts from exercise of stock options included in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total equity-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti\u2011dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Area of land (square feet)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r106",
      "r114",
      "r137",
      "r158",
      "r203",
      "r212",
      "r216",
      "r231",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r392",
      "r396",
      "r419",
      "r564",
      "r602",
      "r603",
      "r650"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r131",
      "r139",
      "r158",
      "r231",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r392",
      "r396",
      "r419",
      "r564",
      "r602",
      "r603",
      "r650"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsUnderManagementCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of assets an investment adviser manages on behalf of investors.",
        "label": "Assets under Management, Carrying Amount",
        "terseLabel": "Assets under management"
       }
      }
     },
     "localname": "AssetsUnderManagementCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://morphictx.com/role/MarketablesecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://morphictx.com/role/MarketablesecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r226",
      "r244"
     ],
     "calculation": {
      "http://morphictx.com/role/MarketablesecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r60",
      "r225",
      "r244",
      "r496"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Accounting"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r133",
      "r537"
     ],
     "calculation": {
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails",
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r43",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r37",
      "r42",
      "r48"
     ],
     "calculation": {
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r37",
      "r102"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Option and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r109",
      "r119"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r252",
      "r253",
      "r521",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r586",
      "r587",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r564"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares, $0.0001 par value, 400,000,000 shares authorized, 38,584,678 shares issued and outstanding as of December\u00a031, 2022 and 37,085,397 shares issued and outstanding as of December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r144",
      "r146",
      "r152",
      "r498",
      "r504"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r287",
      "r289",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r287",
      "r288",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.",
        "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
        "terseLabel": "Performance obligation recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r287",
      "r288",
      "r292"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r287",
      "r288",
      "r292"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r555",
      "r557",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Costs incurred",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r585",
      "r640",
      "r642"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r585",
      "r640"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r367",
      "r377",
      "r585"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax (benefit) provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r585",
      "r640",
      "r642"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term of letter of credit (in years)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Issuance costs included in accounts payable"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r227",
      "r244",
      "r245",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r597"
     ],
     "calculation": {
      "http://morphictx.com/role/MarketablesecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Aggregate estimated fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r591"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "negatedTerseLabel": "Loss on sale of marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of investments in marketable securities classified as available for sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "verboseLabel": "Unrealized holding losses on marketable securities, net of tax"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r585",
      "r641",
      "r642"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r585",
      "r641"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r40",
      "r97",
      "r368",
      "r376",
      "r377",
      "r585"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax (benefit) provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r585",
      "r641",
      "r642"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r95",
      "r639"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r95",
      "r639"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and experimental expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r95",
      "r639"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r93",
      "r95",
      "r639"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r95",
      "r639"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r95",
      "r639"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Reserves and accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails",
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r95",
      "r639"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedTerseLabel": "Prepaid expense"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r95",
      "r639"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contribution total amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r40",
      "r65"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r40",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r315",
      "r346",
      "r347",
      "r349",
      "r354",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r153",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r181",
      "r183",
      "r185",
      "r186",
      "r187",
      "r191",
      "r409",
      "r410",
      "r499",
      "r505",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r153",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r183",
      "r185",
      "r186",
      "r187",
      "r191",
      "r409",
      "r410",
      "r499",
      "r505",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r160",
      "r358",
      "r379"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax effected at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r636",
      "r643"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r636",
      "r643"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r635",
      "r636"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r636",
      "r643"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r636",
      "r643"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesEffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://morphictx.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Equity Based Compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized equity based compensation expense expected period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized equity based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized equity based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails",
      "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r74",
      "r127",
      "r148",
      "r149",
      "r150",
      "r164",
      "r165",
      "r166",
      "r169",
      "r177",
      "r179",
      "r193",
      "r235",
      "r286",
      "r350",
      "r351",
      "r352",
      "r372",
      "r373",
      "r408",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r459",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r412",
      "r413",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r268",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r413",
      "r464",
      "r465",
      "r466",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r268",
      "r296",
      "r301",
      "r413",
      "r464",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r268",
      "r296",
      "r301",
      "r413",
      "r465",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r268",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r413",
      "r466",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r268",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r464",
      "r465",
      "r466",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r247",
      "r248",
      "r249",
      "r269",
      "r283",
      "r398",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r549",
      "r593",
      "r594",
      "r595",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Liabilities measured at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r28",
      "r150"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r159",
      "r378"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r23",
      "r103",
      "r110",
      "r122",
      "r203",
      "r211",
      "r215",
      "r217",
      "r500",
      "r548"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before (provision for) benefit from income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r159",
      "r378"
     ],
     "calculation": {
      "http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r359",
      "r360",
      "r366",
      "r374",
      "r380",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r637"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax examination, penalties and interest expense"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r161",
      "r178",
      "r179",
      "r202",
      "r357",
      "r375",
      "r381",
      "r506"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "(Provision for) benefit from income taxes",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Total income tax (benefit) provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://morphictx.com/role/IncomeTaxesComponentsofincometaxDetails",
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r355",
      "r356",
      "r360",
      "r361",
      "r365",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r582",
      "r648"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r30",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r104",
      "r113",
      "r123",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/Marketablesecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Summary of lease maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r158",
      "r231",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r393",
      "r396",
      "r397",
      "r419",
      "r547",
      "r602",
      "r650",
      "r651"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r107",
      "r117",
      "r564",
      "r584",
      "r596",
      "r646"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r132",
      "r158",
      "r231",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r393",
      "r396",
      "r397",
      "r419",
      "r564",
      "r602",
      "r650",
      "r651"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r37",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r41",
      "r111",
      "r121",
      "r130",
      "r142",
      "r145",
      "r150",
      "r158",
      "r168",
      "r172",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r184",
      "r203",
      "r211",
      "r215",
      "r217",
      "r231",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r410",
      "r419",
      "r548",
      "r602"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r50",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r180",
      "r191",
      "r223",
      "r224",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r350",
      "r351",
      "r352",
      "r370",
      "r371",
      "r372",
      "r373",
      "r385",
      "r386",
      "r387",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r493",
      "r494",
      "r495",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Non-cash activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of restricted common stock"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.",
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r203",
      "r211",
      "r215",
      "r217",
      "r548"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r647"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesMaturitiesofleasecommitmentsDetails",
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://morphictx.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesDetails",
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r445",
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r451",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r450",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/LeasesSummaryofsupplementalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r74",
      "r143",
      "r146",
      "r151",
      "r428",
      "r433",
      "r434",
      "r497",
      "r503",
      "r579",
      "r580"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding losses on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r294",
      "r295",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred shares, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://morphictx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r564"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred shares, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December\u00a031, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r578"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common shares, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Aggregate offering price of placement shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from issuance or sale of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r33",
      "r59",
      "r154"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r86"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common shares upon stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common shares under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r130",
      "r142",
      "r145",
      "r155",
      "r158",
      "r168",
      "r178",
      "r179",
      "r203",
      "r211",
      "r215",
      "r217",
      "r231",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r391",
      "r394",
      "r395",
      "r410",
      "r419",
      "r500",
      "r548",
      "r561",
      "r562",
      "r581",
      "r602"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r66",
      "r134"
     ],
     "calculation": {
      "http://morphictx.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r68",
      "r118",
      "r501",
      "r564"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://morphictx.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesTables",
      "http://morphictx.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life (in Years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r89",
      "r124",
      "r658"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r577",
      "r583",
      "r659",
      "r661"
     ],
     "calculation": {
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesCashandCashEquivalentsandRestrictedCashDetails",
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted common stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r75",
      "r116",
      "r514",
      "r519",
      "r564"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r127",
      "r164",
      "r165",
      "r166",
      "r169",
      "r177",
      "r179",
      "r235",
      "r350",
      "r351",
      "r352",
      "r372",
      "r373",
      "r408",
      "r510",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r198",
      "r199",
      "r210",
      "r213",
      "r214",
      "r218",
      "r219",
      "r220",
      "r290",
      "r291",
      "r492"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r449",
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from secondary offering",
        "verboseLabel": "Aggregate proceeds received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Beneficial ownership"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NetLossperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of common stock equivalent shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciled cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Summary of costs incurred and revenue recognized"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "auth_ref": [
      "r51",
      "r53",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Schedule of basic net income (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r84",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of equity based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of financial assets measured at fair value on recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of restricted stock units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPropertyandEquipmentNetDetails",
      "http://morphictx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r48",
      "r105",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciled cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r78",
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of assumptions used in determining the fair value of the options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]",
        "terseLabel": "Schedule of Subsidiary or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity\u2011based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at the end (in shares)",
        "periodStartLabel": "Outstanding at the beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "verboseLabel": "Number of\u00a0Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Fair Value per Share at Issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk\u2011free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Equity Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants (in shares)",
        "verboseLabel": "Number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable at the end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic market value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average fair value of options granted, per option (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at the end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end (in shares)",
        "periodStartLabel": "Outstanding at the beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r319",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable at the end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Public offering price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period ( in shares)",
        "periodStartLabel": "Balance at beginning of period ( in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r74",
      "r127",
      "r148",
      "r149",
      "r150",
      "r164",
      "r165",
      "r166",
      "r169",
      "r177",
      "r179",
      "r193",
      "r235",
      "r286",
      "r350",
      "r351",
      "r352",
      "r372",
      "r373",
      "r408",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r459",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r193",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r1",
      "r2",
      "r74",
      "r75",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common stock under the Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sales of common shares sold in IPO, net of offering costs (in shares)",
        "verboseLabel": "Issuance of common shares, net of issuance/offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r1",
      "r2",
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r74",
      "r75",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Issuance of common shares upon stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r1",
      "r2",
      "r74",
      "r75",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common shares under the Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r74",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares, net of issuance/offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r74",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Total cash received from exercises of stock options",
        "verboseLabel": "Issuance of common shares upon stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/EquityBasedCompensationInformationrelatedtooptionsgrantedvestedandexercisedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r58",
      "r564",
      "r584",
      "r596",
      "r646"
     ],
     "calculation": {
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r157",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r286",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r435",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r435",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r435",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "terseLabel": "Subsidiary or Equity Method Investee [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r269",
      "r283",
      "r398",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r593",
      "r594",
      "r595",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r545",
      "r555",
      "r557",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities",
        "verboseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r194",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r182",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r181",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://morphictx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://morphictx.com/role/NetLossperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL121698322-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r568": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r569": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r571": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r572": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r573": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r574": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r575": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r576": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001679363-23-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001679363-23-000011-xbrl.zip
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MT?<]U%_X)87O16%\F\(\Q #"VG &Z,JX-0W%I&]0JP,F&'D708XW]Y^0OFM
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M1QCQ!A \DIII*E4TH#<=UUY&'I4:7S.W9*"99*";%^]=\L3/P&K$D$YW7Z*
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M\!V.BK;?ZIR4Q6D=29P7R9(T") M$8UESAK%I.611<.,!JBW*)(U/5(]X/E
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M N5. DPE+FI,@&D(#MXS248)]F8[1O2LF&0ZVV6$EFF[J.7 %=I[)62@6J+
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MS4->]"4'3755#U%NJ0\<M [PCP3+93T.GBJ*I*-2S[\.>DY :#J)-$S48+_
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M%)V30;^ZY' [;IBRFW</>^]#N0ML$GX?WEW!\[NJC%+-K0HD)=J7,EKI"+4
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MY-_N/" :&"TT>90&["M[G1AL-0-S5 49^B :,,V@C<%=KJ44!'!PDN!6=C*
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M6%"OW,-+0(;L7>YPC!&.KL5==0]%"I30@WLHTG:,92N@2/?7Z!>[1E%[I30
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MN@\8;,=8MCQ@\"E'^6#S43[H.\H'AT>?=Y2/'SW8<)0_:SZ?U<]W2YRTP);
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MUWUE?\RS07/PIZ=TB,$B ?B6I]-#,R&:,3B9:J?T5E\YFE :>2J<5/(9V0W
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M2+?0B\C\4P1"9L8C+";YPB TD\6MFE[K5^VPT_?VU\3ML\)T-6LU]8E7A.J
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M3S*$^"C;5(R@0'%KE777B:E0^*#*'C#KS5+J>\*X"JN3J*/@/"U";E7G5"'
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M#5@;Z6.<#N"N(+8#;51]9]_H3A"2VE'R:N8V#2UBBRQ7]Q./D/9U@%DG*'C
MIFC[6+S?$3[20'0*,G2ET.JLO.R(7DAX@N")SD *>=K2UGI!B=8+;!U/ [OQ
MPJ%5.,_(2C@GM5C.&]1K5742MK3RC4'JAH8L1;A2C.=C8O[Y9=4=GUY==D2S
MZ1-F%^1V#;&?UW,DGPIA8,^'^3RZE;/3R/?F#Z=O%-01AH]=]W)4B:Q"T/7*
M=X* @,J2:*EZ[@B"F(@<)I9\OE0.U79L3PI <+S\7I25<52QY4RS"I0C39!F
M* MMAZ[6EGT66'< 6W?E\MN,40 $HK VM12B4>$)#/5 CZY"QEJ^Q9$51EM?
M_;JA?>G$O4BE/(L'I9(F44<Y'B0+5N/N%RKPY-U7F1A?K7:5AX^I0Q7].W>O
MOM>IX,B2_^4Z L$=2J&3<;XRM.%A)XY;S@G4>N7.5DNH4N$(@S'#7X=K55LI
M1>#$Y#/04BC0U3?S;#].-5=>:_T4AZCM=$IX&9ZC/VOB!04&&",OF!B:*W";
M M5<2\%/T45^X?1K2[.IF,B56:\:25"KB'#<2/NOH:")^4>"2R[JM1<FWD-%
MP^'JMG2Q+G X5]8P3!PQ+DD?B*G]]IE<B!DIZ0E'TOGKVD] K5"Z@@I\U ?&
MPZ!2=]-8;^;"+CI&0<F<L6"Z_B82.6H= YF8K[79;+]+S.?B[;.@+"HT6$II
M+1-)B&])N/DP?9?I]@?WZ?;M&,L]2T)?;4C7+2<CC"-IB#NQCF@G/J%WJBQP
MD".]+O3U>CFS0CZ7C-FX$64E_Y:KZY+V)ETR,.D-?IWL#]2:=!2106 J" 1P
MLQRS*]EZMBA=9%L.@F_4B=)I>=_0$GOUPL5URPM:(P%TVF^L)C!U<3P48XAY
M@W9.=3F1_LFL.LEY0M*12Y/*6NO0^=HDY56#XVC ]$OP>U%&*JCXR%@:Z6(<
MD)75Q $B9X]S.P'&_;H$[[)<FI?,=J0PIV<]QE@[I)*&+%0^M#+ #  $6Y$A
M6J56H\(MXIJ%_M&3TUL?0^WNP$FG.EBHPG68QO4MWDXJ@YAF] VI^:HWKXO&
MP9+ $- 'DE@R8W%>N*7S407: OGEH2L*JY2P4:CL@,482_\Q]F\<FT?7_77W
MKXL4!-.274&"N0K:7@2RZ$X,W=MG&?+CRW/]#9EH2.YW?61.Y ^T?R5MN#-C
M$4'S-7,9'Z:4D^0%N1"K(=M(43USN.VZ:8[%Q&)W;6.(R28TEA\^(" CX^-L
MHU)+H>;&OM=&!&U/>B*#@3A$=27Q $ZL\T2TNT:I4#=:=\A!5V8KAWW6:6BW
ML[_KF4?47D1:7S92X$IB0>CS_>",19X[E[M&*RH3*:=B..#$&TR[PQXYG6A.
M"\UR">]'MOA\'? +J/## 5J00N94,(V\ OM[Q9H$OQ_G4T0]Q%K68G!'MXB@
MH28Y?,"+7H+; ARU)-)2/R1!FUEN6V^]"Z6!N72LR2;,2L:+<&4T)>H4\U,1
MG%V90+-U**.DW^\<\"H+<+UT"84P!.7>+S%!T0%WTC,+RV<WQ./U$DM2IZ]H
MD=IG076SVZR*5/XL&^*&!4D(7S&ZQV'TB?N&7 1%83Z"-EYSGDW=ZIPI+L?0
M, -IWBI,%6CSH]K3Y=\0<Y@JPR3>Q#$X#L=;BT,AV[AS&W;"@3V)Q,>BK\O9
M!9+1(,DXPIK3D:.;4SL4]04;1G%20I^MW_8=!"3'X@VM5@; 1>:B_-%[?1+[
MI&&=0! G3IE/UD54!WXV/HGLXL="MTHKD<^=%IBFJS3N)>C'Y=S#P%(B#=4;
M&LZBP+ %U.N5!K/_'WMOVMPVEF6+_A5&WWHWJB(@M8?,K,IVO!NA]-"9?<ME
MA^WJC/<1)$$*91!@ X1DUJ]_9Z\]G'T D))SD&45.RHZ98G$<(9]]K#V6F$4
M]1%D&/F?.E2NF"*!?9*%Q4$$AY5,M\.;I1KH'H/A"F&4S*):.E5D#.K/XKOT
M%']XFCUY!'DH+/A794?C]_\%)TZ4W37CE>S[\,M_)S@\Y^HD]^9+@O1F .!3
MC.\?LZZENY@Q[DP1,_E<W\>G*CB+!G)7%B^+K&+C9U; XJJ0GFE?BX3_BC7-
MK?DD7\8)1ZRHA%6?:E/!E!F#Z^Q-NR7()F$99B\*@GV*^P2:^F*SW1F?8U?8
MP']]9D,S<)2F_^Y1V"9[56%1)K:M%ES^QLY:=,@]';1?AHIQ)%=V&3FA\#'J
MM8XT-70$=(0>L*N*WT_9.&:-C?Z/-/%6!2>)Q(VTO0"("O-XOB&O>U#C")?"
M\V3FXL$2=7RJA5!["]YZOH ?E:B)9=II3AM\W3APEZ3*PG!A#T,GAUAZ$'N$
M6:M*#HM>TS8?+4!+NLME<+8FN!S^@T1H$!S@DODU*8E0"GMW&8,B(1E-#8Q:
M[6C9G['1&3V-*,+O_=,,GH*8@,I/>$VH7/VR!R#&TO16BS E<UE2(C".FUN.
MEJ;&EB'=<&5L_N 1$!H[AZ-W/(?NU^POU\[!9] M6:>RVUFYTC/G8G#"+KZ,
M\R5D <D[#&A9'61*PA'*+K@03<:.R42@86C+C8"89_%03DJ<35+RA!>/V[&B
M34MA;!+\5>'=.9%,@V%ELSA'7ZT!<VGF%9,FI>L9H(1T3V'XTETFO$1(UZ-W
ME9().ZM3=DS:@BB9#BOC">#$N7*>"7'9WJ7&8?*>//.Q<XBH"0'/MH[='L54
ME7D"T^0^@LXNPB0QM,XRCSI@QX>@;%1F7<HOL:@.F>K(TQB;CG5$M>9!.A.Z
M?@<7EP; T>MREJS<B4Y9!;).(@7MV(5/+_/UG9H_L*/+8Q8]O'BVX CTS@CK
MH7@1PMBDB!8'SN:1@SFLWO[G\[?#YH/D-GIQH,&98VD_4RG.R+F4:Q.Z3R4Z
M5\_-O#'D*X;/._%]7:$0.GA*)5]#K3F%4AC\ QMN\9^OWU+FHA/VH_ WQ8;I
MX4#N=0XU;_+:/5=8XOI:@LT.!GTMVJ(I!$LMG0-<48ZD_ K)^B\,PD%SI;FS
MSD9O[,:G[%L9>U9=3SE*+J^9/X^^ 0CT(&0W?XL#YZZ0OU+2ZM#?W)X/]A N
M#\]-$?FSQN>.@&KW5B5,8IQX3EKPVHS /E)!UFR?Y!;)U,B!.C!^E+C-1-:D
M5BF-Y"D=H<ER2>Q@24QL7JRM8V$TR!&Y3G@]6;K#1(%E-/:I_ZE&=<EO0U8?
M* 6VH_$^/*C71,\"MTP\"J8HE4R)0O:8 \K[#3A^EBC:#E>"= ;\DYNFE$EL
M%.1C[W%[@G(22!PW'T*PX.U&WA93=P)%6QYKL.)).SCVSIWVNE)R+J,/#L(P
M9I*F,A(V3/:[EZ_?9XSFJ;;!/X?)-0,B2>>TM!"6,38DFT'#VTGVGRX(EU53
M%YO"3 P1&S(S*G5EZ6^)G)*=$J[\+,BKIM1_T;%:A0#.C'(WG@TP;'W'T(:7
M'R[>__V<_^.?@$]?)=G5\@JUN&'0D9:35A5!_**E,0('W+0Q:'/+TLJ9^YEU
M"C@=<$!(0N\V ,'3*(K>X:"GKXP(0:O32_+01GF3 W\##XKSRNFL*!B6"8[#
M7"H?5))S?QU.X 9,W$,1AH-&* 7V^V13F)FK(FQH'(90X,/[VNV<H1AZCA*K
M&B?V\&DZ#21H8RW;_!JB0<.SU[7Q:%#2J?L&D6[HKD@4- ^KB@,YJ711C!4I
MV[5D:?O[A(-(<!#?GG 0]^-9[A,.XOZPT#^/?1N0%1*K%V%-L5U!\&LNE9LT
M5<32HO:"(&]OA[7OC0*Z(G7YM342X*SH>CK+ZCV_876!^U+H[ _?I_\0FD,T
MXYWV&S^9)HQ,5EX<F<'W8K^+"P)BC&85WTA20]%'%XY/@A/ [\NM\R4<9VLT
M"25CIL<;O4ZOY61T<V- EB;.K1IT:*17ERY]W@[]Z[O9LBG&GWL@[94YL8^%
MZ/!CFF,/ W2Q6!05Y,:7UH'YM05J+I'BBYJR'104D+0I*FO$LMQI#8S3/%3"
MBDE01@%(KF^2-N1VY=;& 1Y= ]+.J9/$"#I>/[*P#Q$.T0\CGY6#IN D;HJ=
MN,6$J"^6D>K ;G\^^[OAY]VZD/*1=(I)$<H,!-SSE$A/BKK#9#&OKB(Z]?%;
M4IT>QR/HU? /PU]L:LUUD/,%XX=#GI]1%.@B*-M>-;UM#/)0]XQ5E7(U]9#:
M0< C=V#C2%E ZSAH+;$*CAO ! \;!DL@3&FU1"MAT_=*)P3*G/6:ZAS TK<D
M-"FX=B!+U-X9*O<51</>7/+<(7?>%0M+MFI2PQE]G[\L.\M#T(#23@N>+#?A
MXUI41XVDLBM_@3HRT*>/(N<A_7;6+<(YV8N@WR!E815V58,;J7JD-Z,Y<4VZ
ML6@X^]'I B6I!?3D2>L.E9I<ZE?2CGXT<%0P3IV*[-1@6PGRJ=OIL Z*][YG
M*,DQ'EACHWC$53;*V/8S!M8OW478M%#S%K2# -3D(@G.W'#^D?E>ZV$[;OKY
M*B$:SL"Y*<[=2>=:.*VM)TUZ:$8V]ZC'8Z8^Q*4U]P]ZQ06'SMHYGAE)?Z"\
MJMT#%"9S/0S("3T$.M\*FD,(MUF3I0J'TK8I57H,9U_>A44UKT@6_2/1BP"P
MQZ+%-K5R:Y:_J7U?1WI!\?5$SV(I$J TK)0 .0@J<\BS6SU7N%B$K=WBLJ;:
M,_%&N_RC0.P:M(OTM;0[T$7Q2-39$,%O)!>T&+ONT:2P0;-$?T5[%" 9Z>'R
MAW5W3N?,Y")3WC$846JK6<-YP'0.#@K3;I$*)2<IG%Y<DAQ)('"<9D=$0J^[
MV@OK%<OW3N)PAD,8>:G<=4<M<WP,"'R9M)Z788362DF?\<FD0,_I5*(9*S8T
M<[5:!;Y.B1&5,B-,#-.C%[4 0:U;,K; )$P-M7 ;:'-E,F0R2EC^_&EZ4[\-
M=&^J8#5]/29A[?O"AT[I')\&5WN=E'),D5229EACYG\"NE'>&_);N$M47*+E
M US.FTU=$O?FNP*J!)%DY,V["V*:8  +HXUJZIM>*D6 YKO9('+V?" D>VS'
MG,_>DI"ZM$;*_>P0[&+&?.G5LO*)*=]K&R(=#;071XN(2</@UYF32M=UCD%,
MWKF51P^5]%UU?CGPA?8^+R!*[D?6Y]X8%B!^)MGNLB+-8JKR6'^SL)-%" C>
MU&$37?-X9VV@W+1!WDA48V'"E$[<GF,[1T#UR2M%8&+T49 2SW=Z8CS^BX*>
M1H,H7 ;AXX!]B#]+QP1]L0 0VKZ.D(F;J]GM\DC,=N;!3>J+TZ#H1!5T#J53
MI/8F_"V\O?1=YZD2YVIL7Z:LWPV3Z@CD_!4W1;%+EX0;VK@2W=CRRI4Y!.!I
MKS/X5>HYCID%I_P<H.S%']'PVY$?>(9".DNZ%-6>A. X?U!T*)G]B/V[91A]
M@L^F][@,%CZW$DH().@)5TIQ@S)@WUY1(_3Y[/WHL3MX4LV*,&3>GT+P1HT_
ME3HX!0O/Z,(?^654MAN&JY92;*25'T>)Q!N*$&W+==.2WSHXRUQYXQ##!#M&
M'NO,^/-OX$.ESLBX+T-/5[I*]/*22$-?[I>>X;_B (?HZM'SFUW_6QW>LPL@
MIX6Z"G4=KI]%T*L7@+%Y$YRO.P03\H^4)&P(?G/\8 \A3?D#%7)4//2#( 1=
M3'POW_&VF4GO(BR9\<VE'SU?%!_:BG =9F)\[_>Q;"6Y5Q2;_)(,)>,UMR2K
M2Z<I(<YLORH62-)W2>:!!>;V2;;2EW;+#58]&]8TW#5N5K(R$^@M@N8[$1UG
M$V.T/[E^OGQB<^X?2X&O]R&[.3E>R]\BS_GK=^I4<?!WN,Z_9&G]NU-I_7X\
MRWTNK=\KS\!U"=V6%_8>>0'QA/+=3DBC^.08"D$'&Z*L.V/JA$>[\N11KE#V
M"!8]%A+ETGN_*JXU<-=6MJ@.'3F6J:O0/Z\_.S1?*$="[%H<]>L%WSE!VF(<
MND,#P6.&UZ&S=BEZW<->=6Y/U2)IP]<B-)R,E(AOLPQEM4^H=@]-@95](%&X
M1\QN>IIA4'"(=Y=48^$!"A&(IB*4--< 9.+A(9MB:2\IN.!0#V$--RFZTA;C
M;$FU.T5RC$@9<@5CKRG/+OED72WN<TG/-UWRT+L'#[90'EGNC:3F\3,BN'0Z
MVS',DI297RGLP>3&"9C%WWCEHQ=1>7WB'C37GJ=.-X]'T4-88G<Y[$Y!GS-"
M.$.+6&TG_H8')',J[ KL'*(N+0L7IOQ:O+68@>CQE*TH9/IL,/>P\SCC =R[
MV>(;_B$N/FG;M[='?.HZ))P4W,'72[9^-DL^$<M=[D(37PO;%M300.E@M#VH
M]UA?YR[_-%O0NI2$H\):$[D.Q-C4_UFJ*JT64Z<Z<1]$_/N"S9(0P!O5S@?4
M2'Z*->][^:Y'3T#?$#S,$PG!KDHA1)44GX?"T9=)6V2,H1G/S-W39M4C3#HM
M9SO4P+D?SF%%PLS3F"@G8S8BAO4[AH9,4N]11<7S3W:>@CU'$Y%A+H;/B-0T
M5?^7A6DDI_R#7I?%M5I;:W@3OK36]Z$QZ875UK7YAW^6(T$7X2R-Z;Y@BY,5
M.;Y(5^AWI5R\#$.Y9\#C)%@=^[W?<C=MH_S(=OQK(6-,KX#;G,^>#Y1@^DX$
MX.T@]]+&<8K#_4@@-"IITS"2<HL8,"N$4$9E0K?^0=B7M\'DYCMRFS[?F-P?
MF87H3<?W>:<GQ\M@&\)AJ27*M^]>7F3<)-ZT">8S+ C\6CB8 =V7-KB$"OK6
M-..\F?-R@]5OZ%U ?RL"FE3%%=!)]M#!$8Z6Q?A<E4YMV71&LI$RZ$;ZANE+
MI0##([UZ+GEDX0?5VCWM_W5>7D$S@)+8U/';HD"#SJ($H45C=S[[&2V*LO/9
MA6)L#<U$]&'H"&=5A."J18_#XY[=6ZBOY-P(:MA"PYB@Y[Z^LA<-_0^49QPJ
M6M)[/[\LJV7PO&PA__#V^446847D!A&= _'K$G3ZTQFZT%1%1#N&]XD'J:'@
MEG*_Z-6OFUK^X3N>!?)$_2]JPF,]$I)\Q8XLL?V.:7WBC3RWC$=@37%/#(]A
MQQHCO4LN42O11%SW;M%O<E6N+Y0MV?S14N[F#_(8/'QDM_FZ)7A>;?E?=&C%
M':9EHS'>$)@=>6ZAK,A2%9*9WC &PUI--QINE6(!Y"8LM!41*)\3)CM&,)'Y
MFM8#^])(Y2_A)&B\X:.>3.B\*B,3LE'!D/A-1;6TL*(>QEE'53^3%'KGRIM?
MW8'WAI%5"B35TF'&1/D24C(3C*L5&HE*4CKU==[SV2LT][)K%G<$G&@G3L8'
MX4!O)W)\<@.@2/9H0<K[[K%5;J@QA,HH:NYAC(GKK^LW19O*CS6KU1D:8+P0
M63@F>F*,.I,"Q%@$L0CCHN1I2(:4ICOCJ[3N3XY)_+(0GCXR=$@Z*AS7%*K1
ME:GGOE5S_<$OFF-#WFKQ-A4-%2M\? 7M]?GZ#K0+Y>^\XDY3M7W&T66N N=O
MPD0IZB@)ZR) :-2L).E"]5H0[GA8X:#4;SWLY/6C&*?@!?O+[3J:%6S /<TW
MM:(J@:F0=@PD?2S;HG[7M@J'?P(0<\UBN?"6+( V#!$*'492;76B2Y!YZBQ(
M,QF21,![I XH]5JGTV4J@7A)X_%T357F+T,90S >A JD'XEQ0J*YB)![,;B+
MZ ZH?;)H-*P1/!EX*KK#H3Y_VKKKV)WW_0[)Y46M<<U, ^<D6QD]Z>1;Q@>,
M/*<@:6VI]G5>UTT?IGNI1""8K)@WSA1P$EWO"[!PZ>>[V2&F"!=SC.@^:$S/
MJ4VK0;1:I2QY[<2,L)"@,/.'A5E8^$)QA;+60NDT5?*B3\DB4>)53IIR9_.A
M9WLW*6Z(M6UHFG&_M0 -R=,:R)&1YQFETP@HUPWYYJ<:L55J %1@-:0GK O[
M2-LU,UR 5/"*4!)HMB<RBW4-8&G2R1UE))B"=T$HAF/1Q[]D??G/I_KR_7B6
M?]WZ\M'8@/R''_/=XO+LY_P34<&'*/LAQ#QO6G1I_] T'V=_96#55Q?L!(^E
M*XJ/"3[<)244K:0\8!:%CQV&X!SLTA.>DV:<\+@&"Q$2=G3H7J6T1;7CJE5?
MZN]HP$IZYY=08,5EU?/"U3O</-+^#?%[/BV'=#^RU\H4,$R;7*@'"4_JK5+H
MX=4^N*8RRGUJ3]-+SV;/!/OAQ#(_F+$(MEHTR$F?VB^G,"1H[ D^1_B!VH!*
M:22,17:MR7NU=O+ )*')7+#>F<_G<SITD;\X*#AYP0B!&C_$#%@J-&&S8;X$
MO.;+W#$#C$KBD1V+_AR<PJ)>$Y,3:DDL9 #/5BXB@V,( TM!4OFWMI4Y+YO"
M383RUW#[R2Y.%[ 8]LF=)KW<7<YG;W:7"L/0[)%GZYF^5<8C-=@9E'7UNT,@
MU@Q9X$:"6-K)('=IY2&/K&<Q/5$"*'R*G-EV1AGR,J5^U*7F0F8NX%!33LZL
M?+Q8P2_9JOX&,I1/'CW3119'KL-?'C^;&$'1]G/P^XCYY\7+N5?B(#6ULTB)
MW%E.4#>ML5'X:?K:VF/I^$N7R) Y@:FJ#+CPBJD"PV]K#@WW0SLW2H3H-IPP
M9XG=>2^@V4BW&!^* QM]%-K/I-'G-L)2C;G/(D,'$:W9-&_$1"QZ?6YMR-?H
MHR%8HBL]$\F[Z0_1]>2#H/Q"NHU_P6V<'E&C^A5C95D)C>7"^#Z>^1D4#\JK
MJ=N72$P%!V#)#6I"&#E'>9/"R-@9Y!2&.4<RF&1C;BTJR1'*QL^M9?TJ# *'
MS# R,OB<$P-3=!>5('%USLQY8!0BQ3^2R<A;DK;N=W_"BJG"K/?YN/"*UZ1^
MF"*$CLNS9G5&B8PP,&;ZW&K,=7323_-%3 XSOG)\L,NPP@I:=Z,AEA;5BR&T
MQ(^U:]>@GC/*IH^OP]Z$OAC,5X%\@6X&T!S*.@*S8\((9WASKQ1M#Z&SS2\H
M],+#[69[;/B"BK,"9DD?E]L%L+9 $TJ;D"H)L[=YFT-K9O;3?Z</:4,\6%J7
M*#\(U_&Q"SB3,KG=F=R^X(; ,C9GWWQ%9>34;2O5L48IRO'$=F:S))!8+@';
M>PC@A\-7I&VT8VD2:1S,G1W")&'S5/EUUY>L)J/,G?*LMWTW!0)6YN,<NY&4
MDK[YUM#ZO XCM_RQ8<S[<$CEZI@(R"PV2@Y09C:BD?M""0+"C9X^$E;,S%FY
MU$7.PBSO=I4UV6$[\8MP+\0L1+2L[&J,LNZ=J;=\I@0#J_PJQ+X4O<KXIJOS
MZTNE#XTW3Q!MC6-&J;;*'PU%W=1G=M+$VNQA%U_/\$G#90?E@R@.OHP#<B]?
MYSC^A>+0OPU+(S@UH*3"794[\%T0J=OSE]:-W\4P.K?#&A0Q$AQMFI)<>0N>
MV%;J.O,,-+5#V0HC=RZ 4T$HDPY$N"1#O$ASQ:*U!-8ZS)G#V:1<^\Z@SG0G
M;(=19@!OKB$!F$/4SLC#Q,C19+Z4WY^ZS  M%EQZ&*CDR7C!2S;ZB.%4P0L]
M&XW1:^#(C79<)I]6^#)MZ2,W$F' W64?S&JXO'\K40")W$UCLSL&4)_/GBN^
M(Y(9:E)#T<TXHY>1)GA,[">@252.H)D6+IHI'A#QH12E\6T(,C"D6R#BI-KG
MP2/CED=;J%HO#%_!<M>@-,%B=L'[C,YCB)$3&A?!7?S)B5 VIKH3U[@V"F(A
M7=,L$<NB,:[%6">*-"6,UQ_2E1R1Z3QMG-'2A1NWI,D3 $W&I(O+B(>?F,-[
M:;\^%ZO!.^1#T6YF+Q7!="]?[!9\\2F/=G-=%ZUT3@H D+,AXH,+U91@"1@8
MF\-PRA[1$UQ&A5<6NM9QRLO?"5?EP%_LS"\$3YT3P7JU\HC%R'LFZ2F&-?\1
M2%MB/)D7NVNR_=1YFC@A]5+H,[6@_R<.=B.^2&5<#EPQ_782*?_)!F"3?X)D
M:+AD/$3XW7$QL2[2:T/^3&1$<X(U%E*YB+!DKI$M$<NX33RF\Y#;-3OFH[%A
MCFCE..!JPEEL:_;X&WYBP7U3-HM.&[F*/+Q*UC ,1Q<$'GD#F1]),+C][V<"
MXYLYCYK76M+"G+-235MN)A;2Q>$_FJA7YZ^/MY_OX\&I4@+H\JHA5<03N&KZ
M%A,E&"-DR _>S$BYQS"C\8/1(4 8OZ5_$IXJ1A)Q=S==ZN\U<M3O=\ PB9&A
M9_[0YLN"W)'9&Z('+X:]T]P*-S#OPDF)>J^>$O)X$:F:3SXQJ]E+#JCLA 6-
MT!G3(Q(SMA',[FH@[G:\G9*45^09/!6E?5'Z+Z>B]/UXEG_=HO3GEG/AQ?X8
MI2O^FE]_?>A5!T%C$K<+@[$IVBVIXVT3.+QK!@.+(]EC=N[WVX)5PG::<%\5
M2WR TDA>4B;*VQE^3M%ATA4]FP>OVA3#71.K"BH9\CQ].(6A<HZ/[)OS5#I.
M:!D:GCA0SCZ6BX]SHI%DL#?A"E=Y%2O1^FO7,.:T2W"] 8CVJRP_Z51=T)C\
M7QV3]_SR-.>7Y;RD2<_18JKQ7)B3CM&<0,(Q/W9954P0"7E"%$"W^1[_[4B?
MN-R)O@JG$YBS>-/3Q.NBI'E<%*)U%/Y*56XZ9C-R$T,8QDCDJI ?H'\D%\U;
M"N@!YY/\F7REX"^@9Y8%DZ0EP\UG\$\V"#^+]JH$"U>YF0?'E&F+48]\#39O
MPF;R3Y2K-PI4&4:*'LHZ1\HN5;KAWC5X1V^EF?%MV^R*B/>[(%3@$C=\3E^Z
M()!>6&2;1$Z1C1!_@K[U4M'5LW<D^T0X1OXG^E46Q-.)A)(6]2ZH>T6ON1-X
M-;D\:0)8EX7L@C!_XHM!")UAKM+O'VF-F>><A(9HRQ,L,EPA]OD9"R!?LDD4
MD792>;\JFPIJ]KNH;\600ZZ/\=\E_BIMF\8<&9S;;5M(VV7L;\+RD)XS#8$&
M5B2%<PI!&KFVE]P'O32A(#1BZ?H2'"U5/JGPN*?K!/>E37<-%7_DBO1/XBG;
M71H3$=,AY+.ZW\QYA<8FE-B]Y4T.()?421;>8=XPQA+KB?CDK%V(2O@>6X_J
M0?AD5RP,K\Q+.+FL4.IEFNSP]T]N"A('L&+7883#5.\S&2@UV)).(4A_D>YW
MSY_!&]\+,<7Q%8AJ(J#HLHC:9Q&^&%ZIUL05->K#&6>JI;TVMMG;8 7&=_GJ
MS/<KV:.+,+=,W1E&;@-01'*2T5DU9!)<)=]]A8\_YX_#<*CA9XC!<,MC$47C
M+^JA"N%=Y'T7@3;R1^Z2<<_%75WY7BF6_5.M*;BK61\B?"K>B5O$)NY"7=KQ
M!K%N;L8HN?4V&&^Q'TZ&%&^/=F\&U<!D"P/;]-/9,>%9*/2<P(S$HR+\Y;H@
MGL/NEM?F&@'S8)JEB;>Y1N%SYS?)2E(O<JWW/6S?>^'S)W@X<P-'#VY@_R9=
M'89_I^* :D",-G$7O2QLLW#LK(LE=$!7TDLHV".Q"87RI J;X@*!.9^^720M
M!LR-T[Y]%T]!-TRT\8O=]*C'^>'9RG?:-Y@^)!?,X3J02+$AU\*Y$[S*9D,6
MWO"+!.I?[ 9( ?<YEI>EZJ!.JLVW.2:372%JM">\7K]])]NP#%&BY^?( DP)
MJEY0ZZ+S!8X[@UAYX@78,6PU'CV(*:=&\U@(Y1Y84%<@/-3,?VR>/&Z&1#:\
MX[017@]+T%SSIO7^=RI<=-/;P%X>L'Z2TU'7@9Q#.?ID@<:%M4R\PW+I]A#'
M0SKY9+0 W-2]QZ^5R6T8BU.Y?O9@&[_"0^F-=X?C3&UY;8O!=M9EU>8]#UH^
M)P"1[UCFZ:&^F1UY5=LB+%TX,7)9G:@;HA2X7!!,=R<.Z@!I[)''26RBNR]=
MNHN2'L'V.Z[7Z!7EC.J$=8H, /T[9AC9PUE5?:$@F.2JC3BZ>2RTIA'(,#QA
M#(@'NX%1H:0#PMJBHU:!;3/U#VQ>%M*TG$87/Y%&*+J+WI+:@VQ;$:FBEA[]
MU047$Q]___UW.)1__.GMQ<4MI^50\%A\@FLJ0=UN!^8A7C?\IT)$:C8XJ)>%
M+J$DH%/J8=E^<'/G,*_A54D+!/N,K20!C^@:?<5$(P5E?UFZ3;R7W BFR>:6
M'=(">VGIXM_2"M\C\\\)\=:9.6WA&L>=P\?D%O]:PD([<Y9%58)]/5S!+>*!
MH*KVDV=BL>*"^?IR$\G)*,OJ8#3L*80^%(O+.CSDFAW^EV$XPXQQ*[(1.<GW
M9/D^>?3H>UF^'UX^_]&V4-D"+Z9RVJJUQWD+IU:3NM:OL,-,J8&4E&)307C
M_PI!)NWZ)]]FX<Z/GV9T96J!$+H@S<6I.Y#F$0C81Z&D$"M 6)<?V+ML59%3
M6B28(JQCZS;0JHDV5B9N*;]Q3,!U7;,H(Z^P$"K$?DX]"]-V[> 'M2'XS;@+
MME4N*"$NBMR%Y!N*&BM,G+S00.%:!W9#K86(3;4SM0<$OMTHKX+,%/S!$-2M
M^X13J+S*%_![%SWKSV"*@XWK7#?TYSV<4W0 C-##()F]4=K0E:MQ$+O[#LTF
M,GQ0S2,8-\ZHRN-^[L.=RTJVZN'2G:=)H!C/5"YW<E#-"S+85&)J0D_K<-E,
MK1*$_4U'FD&*1^+(41;H6GVW@LQZTP;;V5G>EU D.B(X$0E(HT^\<"0%^29?
ML^M7UO\PZO\P<';(-7W+C1$B(Y$X@S E,7U+."9[&JO%DT09CU/3[=P[BM(.
M*M:(%M((G)]EX-5OR.+S6^.N'+KX92D/$J=Z/*$'6;SD^N%+HDX(HD#V#[@;
M"O- V]5Q=E]#ETUJQI0B@5N]TP8<;AZ1DCGZ-;0*2LTH=!ZS!<98WA>QG%=A
MUB\+3A2;4(UE/.F'YP7W(J^\=_>_\\WV673\WEL$2MP_Q#% B47(UB\!!Z%-
MTY)-QWXQ19=!YG"5=*\H,WRC^5C'29/,LK/Z<L1CH<-.K>3"U$[&&8K+?4<.
M)&TO^YG6:@F6=X*F48 B021='U=P'43\=]$LI\Z;3'%N+'Z +G_J",/G\K#?
MPS#NAA_$7\\VY?(:4$,85EIZM$$NFVY+5;;TH&&0V,:D$M'(=%E4T@BDK^6.
MX7*S ?\/Q;6T=H('1VG2A)]5(6E(%A!^I"3*W,??\$(7#EP/.D3C6UW302+*
M$1\ FA%I/E"0E9(1\EQV,V8X4S# 1AI/F"+PNI@3]>#DY9VNAC5Z2?N,7P6,
M&Z$.,&S[ T'0^>R$*O"H@N]/J(+[\2SW"55P/\.9- ,THTR!\>8,CPV7?D79
M'&=&I/7;(E(=$;;=0 IEM7RE.I3KKLN5_,Z.'R[-B.>9QB+^6.&JO*;>.VV8
ME3>T:L)5SOHG]GQGRO@:2U0IXMD(FKR/_#$\$@Y#?F!J0 X/1J)/.\J[-O[>
M4>B0(6T";CA$=Q=IHYW(&A]"3;\+DP%MJ6933%W?T<S%A[6\]T OUX<W_FG2
M5!G=_A_A\)+F/^3/(R@PD^0#C^YX\?#'UTU/=?$#Z>;!>PQ* LGRLQ#8$]!8
M=ELT(KVJU9)&ZWEZ(_ 9-73M?P2/MULJ_,3+\LAH.H*@,1ZERRNYFNIL^W0-
M-,">#VAR7)4B'.SD*U/VC-TQ1K."^ PE)G;_[>71QM!(:V6DOW&+7JH?H)#"
MF1V/ZJ^N[>DE&(HDB$+LC@&(49\OILM E.V2$Y)%EPR1ZX2Z 4!C56*O5(00
M3.2ZG4&,P1IEWIQ(UZKIV::A,3<M5" 4(^,R$%G;35637;QD,^GW+"8YBZ'T
MD!_VJO#?D[@UHQ "_RZ[==/R$"(#%+9"(R5/+BC1IJDVP@\*O%2O?%5DOW;^
MS;.PH[AR4 17K)3L+.65.><9R9Z,OQU]G]+&H+SNG$\NMQ9SNCJ;YEVP.=Q$
MIB6V(2 &.4CL#G>I"62,']@#!50*%=8<(J._"&W<*;=G3* -AU0^V.^4B9!L
MB8-@&%_"I&6CFI9PT8EI(K*Z(?6XGK4&K:! T]:?(^KF@CS_3%?JM#F%L.AA
MU;=4,1#%+Y8IIX;"J(.9UUJ[9,X()+["/^):IP>F GDQV#1\G(>UE2SO<*F\
MBLX$,[@3\:, 66@(HR[R#BPC7@K UJ$1FXJ=R$!!2'@,/M(7VJ85_DGR&ISP
M)S)CP._O9:/)9T)%H:_AD**LU/LU8D7'P'W&*1D*0,_(R'<W+S)A)2!3(SGZ
M*5#'T"2@UB*9476YPGER1@9ISQ4VE;'D0DHK2U,@;)KEY'Q=3*&I&<E8PLZD
M=S)V>IDN\5)449Q9ZO;=KMAP0N 0TC1V9?HZW*I9]&ZK%W*0IC0U<>]1]4MS
MQ528RO]!E7)R?#A4U]9V]F?0P?$I)R\,I>378%I_\NCQHUC/)Q'H@?;S=9YJ
M%<W;)E]*ZWW7Q8(LM0QRW2^3W@Z1&:$#37"WZ[:YWEW&(>;A(II#' Q%?2DJ
MIN24D3&1%/*@SIN1(XJD+Y);80#!S^C/94-+N!O%.D=\5IT1/IZYE((+YY_$
MF"&=*]@[^[;,(KAA^4NN8*K5%4*M[F6A(# QOR1,''<%<FJ=.',\G+2+.- P
MK6%[7[K5+LX"TK^[@M^DT!ZE='&$1\L7TOR/17I@-4YD@[Y,&C8),=@5\,M9
M^UL3*)$4&^ _-5O7%)^:GW"F*(-$NLY#M%G/WA.+!+"3WU-=[<ECWA(_E%CI
M*6]_K,?EP4==%F>*' 93&84://%FR\A^\%]D1Z'&3WA7\33#K+>4# TQ(DWX
M\Z:&B(78&6PECW_"$<O=AXBS%:8>C:?IN >S(GZ C@K>VH-U?V*,%3# RB J
M=/6Z*G[;I?#D5DMA-OM][G[+A4@*]6'$+OHUY7[#BGAB]K"LJFE, HL0__CC
M>YJWNE@W3"N"RDA153$"'\3W/*/SDNK.Y4+"Q>>OWSN X !%3NWEN]D/^!Y^
M?$%W%V\4?8J7X67.F$&VI+H"K?]U59QU3=_*<I(;)1T63!  -W$'W/MN]F=I
M_?_CX\?RDW"6\=/^R9HX04?$)HL>GCZE@X#];'@$&YJEC,>.N?M%6GI*4(8O
M3DLS]@D.+]/Y&9*T_IQPOX5ST)'6?_)=9E3KB_#6M)5!GV2@Z451QODZG_T0
MC%!=<ZXEEN ?/7F:EH/<K+Q9[!HR)[1R)C[T@NU+6&:J7]TU'/"%13HB=&X-
M!\VNBAJ"L(X.KPA=6JPK2 X3T#J>ATY4>DJU #RN]%!;:J&4D^-]$>Z*\D'X
MK*SNF,O1"N).39 RHBN1WKHOE^P5$%'QELTU$T&;B(,>ULKJ*]TWK\=#0#3"
M0Q9A'<EQ&*X9P\,A^&1M1$>!6;;0W]NI<P(2]*Y<JOBNK]''+I.QGX$J.#,K
MX 3B1!=(P^-8$2"#>W+#NOG6V74=5"R6L%U,AUT%C]"D00N8@UE>YD^=50!H
M=CQ"'+T9K=;7!_5Y'5QS&MK,<$W,*0;S5$PA_=6+2-$QYF=(*.ZP%H>]:%IY
M<0?Z!.H+L&_\%(6RV3][W2R)?>^?UF4C"**GR,6^?AU.G:%C:-?'"K($.Z^^
M UUVO(3]*X6C((<'GUY.R#'%G3 PN 1?!3%E"<2NI-B).[:9.R1-W<1!WU/!
M4DJD<@=.MHK1XL>6,NV9^E8H%<-B#1+-()7T;Q+YR0SPP0#A3:D2Y*X/QAUT
M9O$%CR+<-SM'O;JH<I+M_/FRK/C<#C/"YREW'W8JWQK55Q+;'G&9L#7JHTL(
MRF@(YC"?F =Q&UT!A5\J"E 1U9:\(E44KNLIB#KF'D$'F=QZSQZDYN32+P@,
M@?E"+2-#+YV6D7-#1R<7LSJ/] 7YM_WZTM8IPKVA 'D_>_H(.+N_\%[_$)9P
ML-J[V<_A2*C(Z+P*UOUCV-8A @@N7I/-_@LJ(;/7B[\&CT$V?;X+7[X.7@0Y
M@?GL';*/825]:/?1!CS^,Z(2BN"P.,DXY]>RD_/K:9?3>'1SRY1 <.BZ:3\F
MFIRB@<C<0!RYZY^2-*2 J=(Z7_031="/V0'!#/)X*'W(^1=R.UII?EPW?"3Y
M;"<]F]<%.9^Q'MP!G!(GIIDHA=^#.P6*CZR<A-5,S@"%4$7=-NQNC\0C.X$+
M\P<YOVT2)6Q/Q#:SPQUN L9IM9XR=)+;?3:[;*X+'#X#80Q!/"4:CC)7MQAO
MA_WM6PBWZN2VNG0H^T#+XP3C<#OXZ:,3C.-^/,M]@G'<(\6"'WN2*7B> ]9V
M+PL6Q_D6@_%O]D5Q6_:*^T3JA6CY1;% EN]__Z_'WSUZ]O1QIID=*DPL9X\?
M/8%PYAG*^86^[?GLC67D]7?9[)NGTAP:#OOS%^=,=OKVDGY\!4^JY!83UN^Y
M+A2B(&?NLJ#<C*^-2I7">/9[:A!:YQHMG,_^1LWDU,,1_F(/(GH)UBA+OGM.
M?,[H(9%&9<=W%)OZ@Y_>KN7\@_:AU%)P0I(O&QQ>,#^W@G$)7NAEN17=\^09
M2D(F/Q 6NQ<02H70)M"]/]52Y;Z7+W=TT?]<&!4_PU8I^B5W2;%=*@DERIG!
M:605,S2RPJFG!@S&*&C3>X@X0Y#$&63.(W&7)N2>*VI3#(NY()S:IVQ6JY/#
MC/O!D=M=UL3EL:<B$3EU:(:@CH]P)VD,PW=[_I*V3V54?B.O2)L7%O9 P3E#
M!H3_%>E,D<TS8@/9&1%. N?Z3=^Z,C5!CS<8F'1[<=,NCU_Q25O;%1H7;$=#
MZ&:\G'5"2T=),"=*4:D9>!MF0A!4XPW-!-I+[NYN(*&U%#7M.FIBA%BPBZ)9
MG+(E7SI$812$S8M@G,J&R=V&DBJHPB\57XSRG/565ELEC<YTK#%7L$DH,85%
MS8'S?HO'&BP1+E;J&N$A;HM%VY<[SH-<ELSNXO2Y,WN(C&5'ZBY>+%]>412
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M(=*<TW).ANM;CL4FVF,DD-"?BCZQOM3>!J^-2D(,+ O_JZ!8O^G"_$VQ6>^
M87CG-)UH.'\P[!%1^UIU\)<+,PP6XN_ZOI\)!$[JQD2)T1+@9D!&E&3?7&7'
M5)%*)EA%N*1(5&'_%YA 7AM$U4O1\()DGV)4S?+Q[B]GJKW+P?]-2*GN77)K
MGB\^AMD,Y]R9/,<*__?LKIYJ]>7.D'_[/SUQ, \8PF@J^W:"'F (-H#FMA#I
M$ IK[6(SS'E$T/ F29DSB.X&!P G(AB3;/N'_A&QO;%[R\@ QA0A"'@5*>1V
M<EE/X2CL12="-2Y;.,:>2&L]KO;QZ*251CQ/8GO<" Q'UN6 %_F6SU6[;L.,
M:M):Q9@.9[TZ3Q<3F3N5%4O:Y_U5:<1['CU?L4FFBV60&]66<3 ;3Y\FAVJ:
M&1?$<XUCF@C@JE(33A-/SRVPSI60.Z:FU)=TQ?)B;%4DK^]&*"UFJTZO,UY2
M+@4F2:Q.":)0P(?ZC0''%\4R/ '#X#U@2-)@,9=91J[L3L]==RL/U;4Y;BJ[
M'3H'*051@E$#N8H2S=/A(K4L3/-SK@"AX,\NY*PJ/I7=Z WT#7G,DS1ODLAP
M4S ZYH83<S-N7\C=?SO<_H/T5.Y5XOWK]T9H@<N:#A% NRZ@KK:%^$&C9$]L
M+8Q$BQ;=VS:LY**>O3V??2BW95L7=9F!$S.31%)9K$9L 6TBZLU63G2Y-8@9
M$//Y=F2:3,?1QUNG[(AW'/TV!JP6[+_V1^.+/-E.FZ%1_=F$6@C$VR*,".;-
MEM.<QY\R1EGI,U)\)H]H;3"4)I/8$J+@H]*]5T>]6X,A:N;^W$(X2I>/.ZD5
M+2;E:1+,MX3,)I.U(<$*HF(TI3-;6O26_98G $ U76 \<L;KK9U4.=HI])O'
MEB7328PV.*^BN-^E.5#:L!=ML/UY9=X: GPF/NF8\5[?@%H46"11>DFHM9#2
MY7;+.F>T_2'@S8#FJ>BL&T].O]<_U1]F;R6IGUG/'LT0)\R7[A[<S3?&!.$(
M)E&#'_1Q#U!>#K;4,0;SWIR8P;AG3#;%ZSN"<GENQS,ZDQXX.--*QL@Z++?F
M6[S'!I6)G##K0]>,?Q/<3CY;PLJ*I"AYU^6+RY[$'K /2] ]B?8E-><(:T4G
MKI_RG1[J!U"O&!_-%SEXHI2CE.T.D9R5NUZ\R^>^1$:04R+/+-)-(\L(8+-2
M! *[PIPL06:GQ^=E*2)\<C;+CHE'=+S!!(K<@\@GBWGD1-L%4-I3'BP9!8)&
M"+DORW,P]P0;/M:NF!R1S,O/6KGPJ',N?K<>IW"\V6S1V.%TE1Y'[5?6G73<
MG>$;C@;.L\A% S1PUKT)C">O\WQ*D$&2@GB)L]#%9]Q=G:7!4I:J$D9!I^G0
M5P''0VQQ#$ F7A@Z9GC1W=Z_@>E7Y3M?5>27L#8H(OHP?]\=KE/66 OT$@NG
MF:B3L_YKG76W*R1 XL(Z[8E,C]9,1]'M FUE*VO#?TG'&TT1=3=2U@"SE.H\
M)0&X'8SSO@VN@]^^!QK&'\ !](O'W-?KTQ*]@/N4^?J 9S.>*YAGVY<,=T87
M_P!#.D:XFML'_BWHTHD[(L>/>YRC0&>NL:3/%98,N!^N"T./3CE1)HWD^,/]
MYTR)JI0^XO0NL9*= E5%37[B?FDU9PJU]\'ZI[HBC!0?7N,K<0Y^;T=A7XO6
M+<T"<?UY(;VZ#S-->GGTN$J%[*Z:".PVHLMMUW2\4 )?1PJ$HKU<=*WXO&!Z
MUPDUHRFMGD$W(JMJ+315MR195B$!/M:P)M4*X6'8MD2IO+-#H]3X[Q_A7.OH
M3WR2\WEU2'+PT,! WH$8N)3[7K< 'VL\]6XA\9_Q1C)K'0?..W(3=KI2]7QB
M0=CE"&/3%KQ#.3]9Z6UGVP:2ZWEU9&?HM;FQQMCX1CTX$S <G]>3!7D$ILN$
MOYJ9@W! 1D!Q=>Q@L48=@K'!X89>!J;?&^U+2? I\R&O6%9#3 63ER74Z"Z5
MV=J!SOELYD@KWXWO/1JTSW8 3@ 6!V!Y>@*PW(MGN4]"3O?8TXH&8J&>J._*
MK,>U;#*=4;N4\&UD!ZD?<VSSCN2/*/%&=QIA*6_MF66'_.=(U#+RC3U4%:PK
M<*I9HX0.2?J]9(@H9?Z)3_)+T4D?GP\9$>AF%/*3:=;#G;5ID[.5CU"6(15A
M%Y>F@[)1S_::PM@]Z^6Q=B:1->F=S6=YN+&6G=T4G)?D3"50=9I8:-7+$JFT
M+=C.,1^"B:/96W5M0M?XJPF4[Y/=^)E(#JYCGG#4>WN$@Z%0&*TC:$FZ$493
MR[NYK"EJKDV/*-7AF<ST2/RB?BJGFZV;,"+2SV=O1S=EN%A:\V@-TBNMY<Y]
MGZI_J"L.AYW;P^+3Q(Y !T^3^[F>6E;R3%5()6^>ABN,8?=T_?$.DCQW(R/Y
M=3''DM%5MA_+D7I="%[$ZI73@4!105X-37UG%2=:7!26%35(,+A^N>!]XB6"
MI1QB;"Y4SA(])!=_>R7PON,FAZ[O2'1)-+3(="_;_%H\;O7=SV?O$.%5,C0@
M'PJ/QD^*^81J5[\C9KQLO :,.R].BTK:+R-T;.\$7+G>4FYS":Q&B!$M,LAL
M#K1HB:V7'RZ,-844K7CSP@62ONC@R_[>=."%X-!8G=IBV^]BKM-ON[I8PRV'
M;D_..A\\5?Y3BZ;;"97)JAB0,=("6BO,+HP+4M;\?ILQA16*)VJTH^H')\#]
M0>!1=IX/)@3BQ8Z85W)6-(*Z['  &*+"VKN9E46QB7L10D]*\:.LT4!-6*R7
M 9]P3B@SH-871":(Z 0'95VKYZ[#1B5AW+C6XM$D'HB<3ZP0](?'C\X?48=P
MA8PT!Z]9U/%5Y)$<>91^+DCY)3QF-WU>QOM!AIP./L=H8FMJ0./A@O[C>1X&
M.=@K"6!+^I+D*37^UOJ<.ZCM]7.2>NQ\.D!? 3FV5WU+)GT#U? )1>=C[TTJ
M;$2&R?RKV,_AQXJ!H5"]&A#UQ:-KV L\[6-0=H#R&UW#'Z?-(_7(';-LVNL)
MKQ1*G4N1^YD^D!RGPE?@M'P%'J=#E1^0-\U B!M&B$VJ3[ (^HTSC^&;VB]>
MU&M65PM[MK-JJD(L@!G;%IYESX<F=5/#ORBC.7#9H2B>R%%%##,>@F,YXN[3
M< X,^0HG7;5YOW3C67',)<.YUT:KWWIJ0^@;9W.^E^RK4EHHT0D$];BTK$C$
MX"A]K 2(3W6(<-A6Y5J>)8ICKA#Q#'*VY/[%&B7K'\!<[EHZPHSD"+N?Z':Y
MZN080GD0H15OU:,N^%_4Z#F1])PW2RQ(_Q"I\QB7H$+I.ZIXE]UE^BTG&L@S
MAF><$YP#FCX.$,NO)GJ=T4CY]Z#VD7R7VTM6>R74! 5OL,F<-_TG!.^-OC*\
M?F^>N)AKC,6ML[/TF/-B37Z<<P\XB4!W-A=!(I._UT E0ZI(G.]X?&%I]Z@E
M"X^'C@;+6HECF69XH](,.V #LLK9T%RXJZ+=L?Q8,+6G7AZ08(\*DB*%/]^7
MCKNVA<:<%0J$;U4GUQ!3>9ND8HI/.Y&/G)INWB)+Q>AP8(5UDLT^EHN/A-8G
MGZ^H5F=+JA(D.&=:1M"JA @?,.(?W%L/;B5$1<$Q6&CE3?1P!Q)Z4J7)I*^H
MUJC2#PN7[=@WIF%CI6*12EF$D0AA!,'(*!7-C^@B* &]3(UL5-[SIX;TE%#\
M(: O=EOU#!$L5[)3YIYVO7",Q&/HND,+Q/#&'S=A545_0$,ZJKB,@PI/:$Z+
M5E 3$\DY(1)73*.^8S#C4EX<6/@X'C'I6 /=N(!WO0P+>J?*1IQ.#WLN3(GB
MM4426- 4.]=-EEQ;P6H$_<]%HS.\!?4;<]0#QXT7 2]8T$#:P>.@XA:2(P!D
M/#;6<%]_K(F$ 4KG'!DM)<=!GCA[@LR3J[E""-1P;)1@5Y*T@&."%,4P7$^;
MX@@<#E\7E\E]O<K;;(P^*ZZU?@O!@D)JCSZ@-^#=SY@C,KOBSO:Q=JDE\ @[
M9W9 "A^ED2KL\"N!FH9W9S@^%A:RH)G2,2V^% Q]F#8FFNW8'IZ$QV$5A.->
M=*7UJ5"<HZX9& /@!'' +O,-Q5MX,/R[[-9-R\8@PP8OP^:0!-<EXDC*B6HL
M!GO6ZYDLQY>/EC7<A6#Y*"T::YL&$PC'8J8MI<HS8=&T",-Y4)DZ4K"1[CP(
M+L5F3O.JC\JKTGTSYC+BT+Z&8+!@[?@?)? > +(2>3,R"F%-B'G7U@T!>Y:J
MD1<-4I@"LE0/,WCY62'%NM(3IR_R:TA?B"0KZKWM_$;9-NP3GC.1KOC\W9M4
MF5/]9J;0-,]9_<!@,9E/4S=IFR9SSE4W+'B9+>E=P<_<SXOV+-_M^+S754N^
MGL?.A]W1]EMO Z!0'>)W>@/R,\38>L6O!)@<4THQD:MFE67TP&%"E??%P/>4
MKACXF7 I+2[_C-;/ \9FTC ]O)(!,^;I\6F9,#_*=# $4[5C*)%VDGN6949>
M&C8YCJP[;9)<3@*Z/[Y!<(WPD397NUIX(%^ZCJ6CKB'@$.B?$]&'$R;"82*^
M.6$B[L6SG# 1MUJOT:9<F\G***<OG@DD>:E-@.'P^8:B1$Z:-_6* XWT]/!.
MSF2]'SF=+2E4Y(#ZRC$U/( X6**D?#@:->"QXTKK$\MFAE 1.L*+'@IAZ"0%
M]%2LKK0?V>-J!=TY6X:3G'ZIJ*]@R1\"-USN.WJ:S&E&\AGNF@T@#)]3$@1'
M*94QUWW>+B7"Q#.CCB)VV:4'<DX!Q9,_$U]00;F:GZ$3V,C]S;_IFM6."*!(
MO@S]OSB*6*E<>#.L&*&.RDHJHK<X/#AR;,23R'2I1*$66D5"LZ<'W>20(MIO
M^AU7Q98TF(9>/?(LZ>$E#E^L8(0?1)X8GE_9+L_(N]\GF6LX=C'"8J2I.%"'
MUP)W&0,]6GW^,:MQM_,\/<$W?-8)GM\L\4BE[=E<TN@YILS#C=.;H763P6FX
MZBNJR$FZ@",S]@SAGM(.QIMW$O]V@ZNNBQWGAVS ++\@\*!NUG></&VJHN8
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M[%2A%CT^3_A:L,;DO,Y[:C8RK^"Z@4;5AK*%J,FH<YO6F^Q":MH5Z&>(;Y?
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MXS[],ZO!'GT9U!#HC6(3(3T4-6H1)/=7O,KC)^??I2_R[?F??\EK/(&8!D>
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M]"1]!W+D=Q%42ZG;5W;TO54V7IK3OQ72 /4\W])1_5!="T N8O\]I%NHO6,
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M.=F8*9V*!,HPVA4**P/TO/Q8L)J3)++8EI8+84>\*FI >6"Y-2NRJL)=YW;
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MJMD5B>U1YF:!6;H3ID=NX_K*XYV<ZF:BT)@=;\AQIPSC.4-4G5-&SSA=V3;
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MS5\5V@K"(?$DN4KN##EESV9+SR\TM'3.4L01<6I48R Y(!?/?4 M0V*]T3\
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M7AX^MIFMI%.F_U6FL6O9=_ YB(J1Q^  $Z]VLD##"S 2\;SN,QTRKR%N'!N
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M+Y$HA -<T%Q-N7D';[BMD"E-.O)96$!0CH[$D7R=E+,M%5..R='F6#6%#L^
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M"M]ZN]5Y]Q#:BTU3UGM>GN"@YJ<$H7DG$M6NN+:O2B@?@=2U]UU%5-N)<7L
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M)083@MEN$9:,K"A^A4>7H85[UGA*B75]))M-]5@@X^K:)WQ/,"/I)1'7*3U
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MT,W[2X^E,NZ=C0M02&)GW>^K=3E@"W#4<$Y]+)%,(LSKZU?MV]5WX4]P(H1
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MPL5UJK_A2.ZEYOZ?N@']MH4TB\8#W/80M46X+Z.C;ZVJN8WH-3DF4GQI8Q4
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MN2<5T+/'T43!L %)82%6%Z'HV!EF &G8JU#"X2FD@B73E<3?A[C*[+=J\U*
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MCD[Q4GLWZ#UKQ#H"V];.7'"I5/*3DB0A^.@5D7#>8ED],U1 YN3VBE@-Z8V
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M$Y9 :DLE\<C.^&AT>_I9O8.Z_::*(I]8K*=PC.!));]J. .->?)NIR%4I+V
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MJ?:V_/E$2HWZ'@=";]#=I3,0'A[V@?63B^O[C#Q?;CPL?WY"@-KA&OE?)7O
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M3O"H(FGD&?4S^%YAXQ%JCIS/%M97#+UHML0H#1SXG[^D$AJ\DD"!!Y[3'YJ
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MQM""*^,IIS!U&K"JG_^92O/(A/NRH%>CN__A^WGC'4_'=<W$^T+TYBEY<V0
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MTLNRHAMH]K/##&KK!9[8AN? VJJ@O2VMR'&"R+NL#\(H]*DGV$*/!A3=6;S
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MH -*\ E#D!>-_E#+)+T=81UX*.VP\FI05C#.R'G&8&)SL73'%A2-9 K",6S
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MSCH082& L,I8YID[N*R)EJ\GABX1R8X:)Q++'<)EH;@2]D_3 K5!]D)ZKNA
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MXN$1KXC<:.C5!#,JT9Y_,F$-ECXE)"/T UEIG0%.OCA2AEAGDH4T% -7<T)
M6&)FP\/<A%,$QI$M@G_$@(^XYBB ]3MWY<&26BMIH:MH;&QH?2*)\+C(EP5'
M+VVP7S_2[DI8,4"LQK"@Q[I-@ _1PA:DY5YW;%JPD (*IR[-E5(]<YZC<C-!
M7,K&_=S=QFF4>,-A?Z?;)+3P6>H@E!3Q$I.1'@J#]N"?N%JN5410X<AU,STX
MOUW#OI?HLL[H]T=_B$37T[U$U]>-:[A#B:Z@+A5$I$:_C^1\IX+=YU$F3:JW
MNQWBWJB>VD/V!Q?N1@56FU_W*5&?6>W]F/(C:6X%C$.;::_DM.-)-\_$+F%3
MO[JI[^X[[<"$A K^3:OWG#H=$L;I?U?TE(A:EKT'@3=4)<$R";+#72?$H8#T
M,!1DJ9R1Y_<QI,:4 \%SDV-[3-!R:AT[04/)I-:LB/I9%IAM%8/ =9BCC"]\
M+-D+"I&4IH,AW!U""/:^:%B34)7RR5^\BO/4Y8GO>M&!#_5X7LQQCTIG1I"M
M0MI*S>QHJSQZB297'35+4TBZ34'POII"\E>/3Y[)TMOMC?JJVZ+= T.O[T-.
M1IY#GNK/V#?K\BX:[.S/ZT#NGE-(P34!2!V) /CFG:(EA)S5E!_$%+&#+ZT(
M!UI\-%W66.Y2P!A58?01^IWI\HDV;!+6'_8')D&EZQDK 7%N?D8*-NOJYT;A
M3#I31,.:WM:W<H-IHI28[]X.S95#J@E$<X>'4A-D.[P,Q+7]XB1NUFL8YY2]
M-F/?I _;]H[[H0OMXW;H;"?YCI]JED<AV=3F;AME;9,L#G-%K-6]]L1>FW>'
M_D [:FS?XMA-TH5M6^QUD#]X&RMG^HZHW5_?D#[<ZKD.1;FA[9S[0B/&&)-]
M(#&VJ?M7RS8XG4ZQVXHY?#2AU*@(#M=%^D]ED*=,>M3M64M&+L4ER2V_34S/
MD?9:MY-0S(P0'F-PJ)H6]H$PMPTU8XL7#=/HM,4(K1KQ(4X5-DI;1ARKBO65
MYECFC.#2O?=, HO-\=->A[XQ^-J<SX/CG%C^CN&G(?&)1.TN[XY%K>ICUQ $
M7'?[L\[=0P=]]XXW:O?OV+#?U^S/AHMC*5$ZB%G[8>4OO:2G5H-HA61N8X_T
M0+?XMJ^TI5D>VA4=NVS:#5+I&*<^]9EX&Y+,7+?+F"C/WS08<X\^/27H1UIA
M;8J<9_PM\^ZM>(V8..AS!>+.3JX1B+O#C,I+01L\@-/LG74+7P2W<+<=GW?K
MG%F/ Q%B6A-$$@*EIAR&H( 5B[B5:QQCOGL>;^A>]_PAZPJ% 5\]8(0C-I$?
MMIR%9TN62#C(W:SYX10_H91H1G(-/QP<?W]G,T6%D<?/[H@@!)/#T=@</T+&
MYS_]EU;C?3"F"\=.=)WF*7> J> R'Y(, CQ@856LYL$OV;+*5:Y?61ZG_&P_
MQ5]HBGFSD\ PPU+#;N,JGS)(6J%JU2FFS;T1<AXAY$-[D!;3'&+*]I/[Q2<W
M0EL;6D3&=QB<M^%STX"CK-9W0NRG[HN97CVB_3G,!V(WJ4XTNZG=AM)NJ'@[
M)'!Y]Z:6N,4K1UXZH;..]G($X6'<QWZ*O_CNE-%G^H@!R-1LORUW9\X*Y6V1
MXM.,^7"PV<"Y86:O[1SF]?Y2@^7(XL!C;O?3^\6WY+*%B>/V0DEC(NI,H*:J
M\U@<> P]S!W/;1O!^WN;>3]U7W;JS/:C5KY,@-)X4@:N= \CM/T.ZZ?FJT1T
M'>])9W;C678&G+4W2Y]AEB#JXIH)VZ> ,T[SO)QTDBI16BMDZ;@P+1&U53W
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MGYXEWQ_M9_;AS>SI2?+H^*8.Z7YV[\GL?GOZ:)?V[#UT5^YAFH6IPI@;X/,
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M/&<82=9L=+:_X@CUV\<W*&OL\P[W9%91./[XY-G.91[VT[O?M/M9O8^;]FL
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MD_OD79*#5FG>NYFNSBM+_ I>[389T%YO&-<E>7OF>_)TU_246Z/=0')TUU-
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M;(G<(B7GN8/)]G3?N&=SXQ9I!N*VK4/+;3EON+S%,;W<+ZW*6%4!TIH-2YQ
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M_N&W8+EK3)'B I!G=^]B,4(U>,_=)",1RS0.S?GMW()6LU=;;?OV3N9XHA<
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M7GI5^F9XXG\Q'5A869L45522)R:5[M;0UK#0"!-E8!N5AE9J)QPE?@J&/)V
M(=&&%]?518!Z7:4WG9;#$5+288/Z]!J19SI&5>Y(N,/O62P:[30VQ#U)0RP"
M*#^G>36\.=&G._$(5RBOR9.7P'F&J$1&-, 3(7+QC'WQM# @9?$*G*)(;^0;
M@8[X9&AN5(*!?556K7&M1EYL[7^ML+ZJC,I97X9V1!%6K5V7XDFXU<%JC[E
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MXX<M,FN4LZ*EVH:BY^W2\ZS2D3J1!^0<D2AQ&7$"'Y2.P'"(%5F>:[EQZ)E
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MVTH#)Z:^$?H^Z&2N'AB*"R@NL&EK3'&!)^$"LY:98S #!+Y)?$ST=6+?) $
MC%#7=V/3]0S;]@[>.+X.*E[[N< ^=#_B(P6UC)/'+M83KNH.4VML9HV]RJ(]
MPP9MK!A+^M"U =O%6D*5E?-40>$2@83Z(9W#G>&@RD/HL-T8)[\3"LG%?!*M
M0SV*^$7B,##0+(D)]6V;@&WIVB:SW< /0"'17<]O46:.(NRVAWM7(VQ%N^O0
M[ES/)@_ 8Z0^ :,!C E@PB1*#4#<D'I1ZEFN!U!Z8_DJ^_T94^[&([5*)&^9
MK&=]!-0*3"]('&+86.IO128);3,D 37<D"5!&IF@X9J;J!YL:;)LF^V>AE-
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MX.BXCH>Q/^Q^BLT!E>>/./10KK&<:SRI\JLK7+SH.^2YB+@>6UKA5;?8;D]
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M^8LA?]:F$B8!K<."]EHA[JA$V@N#F)=*,,&D"?BV-M63Q/T3@/[=F6,%^G<
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MP"-V&D<KDL&@^BE/]$TR$Z[1\6#'FBAU67\K09:E:6UOYKHN2Y.BL1@C:U)
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M.;.*L619L (9KR/B.E!D90Q(:&=5TCQ8D.BZ!K-*,]PB+U/!>@D4/!(I/61
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MD1BJ3$S*<.X=2T0NA>\*I2WF[LQ_FL.*;]GNEL?OE70IL!"0 TDA[HA!VM"
MJ)%!"!-E\!9L]"L.*A8^*WRV\GRVB*,Q,HV%\<1JQUGV.E**X:$C*DJ50K&2
MVT)QVY<I3A J"<4!21D)X@H4.",D1<(08WG2P:2TMLZ8[$ACBIE<,M ORF""
MT)R4A,W/S@YCON.CX]@?VH8PXI?\.)8$]9+G5:14I-3ZBC.*1.$2MB1RPW7
M1A'8-+BC\"<X,BFI2,^2\>CWU9F-\&$\'#65C?<'&S!S>02V]\IVPW9_TQYW
M1[;7Y+#\DLES\P)W3KHH'N>'P]<1>';8'<4WL?[4]7%RPNUU](.#?G/%HB,M
M3T=Z,1=)L,YS:8U&E B->%0,.<,38M1[00QHNIZMK5/3P?S6I=$+.10*+U(J
M4EI%*2VPT8H(-B;-I>1IX,%R@[UC.%JMHB1ZFO5>-MI'OM'..2,,MRHFPU&B
MA.?B< 89;"FB6@F"E>1!\!;NM$^H-MQ?<3C*!>$&J:KA8=WU(S#Z)TG>#YU4
M_X@8\\JL>6,]QXDYR3WFSDE'B%*&8Q:LMY2R[Y#FH@T=7I_+M_G8QF=;3ZIJ
MO!S4*79'X[KT>E@F'V[/I=L++R5C)M>&CPYQK W26$;$6")$6^(2L6OKID/4
MK4M*+[$"1T'^#4(K4XUVY?SG98&4!5(62%D@98&4!5(6R*HLD)969'U"D?+K
MVW2.C_/C;&%5@^-IU#S6OCO\08.ZN"#;:E!?]#2^F,HX% MZ>1;TSIP%;8-0
M00F*-(\"<1$Y<EY@I(.27'//J)-KZUR8CF;SV4TEWM!JL)>HT"I(Z2'3+[[5
M\.<6;%SB.S=CX]E$"D&225)JE *5B-.HD):&(\^,5"H0%;!?6Q<=HD3AXM5"
M>>'B(J4BI=7/HR@[YL/:+[,9$4YKIKW@*(9 $><.#!@5P)2QF/+@??+:M6_+
M?$()$=]P[/1#K*O18:Q>'!WW!B<Q5@V"JE?CVA_:8:Q>]6R_)$T\*A_/F:@G
M7/FY'^OA8?<X"[HX>I9'E'_,.7H"8?G 6D#:JHBX)\"3&DODDU#>"*&"X6OK
M#'=HR958-< _>)RB2&F%_3S?8N2BG2Y$NK/^' FLJB2W*(24N\$1ADSP%-F8
MF%>8<R[TVKK6MU9-"Y8+XQ8I%2FMHI3:ZLTI^^+RC)&Y<RR1.DK !C'*&L1-
M4LAQV">C2<P2CDV(HFT;XY*2<6[LJPG=3V?7GEX"Y<\_EPTWM,J3,SJ$&S\X
MK.P(C0XC.K+UQSB"CZ68,=6I^LVSJGMV 3\8CH;YE7\LHA13HZ4-ECB..4E1
M>V\288%RK"E5^GO@%[/@?V5/FO-P>^F<!O+H-O/@SB$N"\1O /$_1S.-D#^%
M7__BX;=_]][1WB?WX?C#[M]O^=O3MU_@LZ>['U[@O5__^+RW__+HW?X.AC&2
MW0^'AWO[.WPWW_/G]\P;Z:T5B'KN$(\4J,*%B#")@05#N.9V;9T\8W,$4<'"
M[\&#<XH ')7@REUY#Q7S-#+I ^&*>RH=#J0IH"^PB4K1)7L/X1:;M\JYJN6"
M=\9N5<8Q+F1"QM"4CYDJ>$02LBR:$()@3GA 7P<68O[3HL!*@7B)<C\2*2V@
M&O%$/*;:2XP3-S1:2BU.GAI,F9)"+-4N6I"#BXUT,PZ>]1TZ!WNKMQ&10$ #
M,C@A';!"C)M<"M?ZA'/=0=.AI!#PBD&[$'"14I'2_8?5;NE!*-ODPV^3<ZY$
M$EVD6'ID4DX <\$BJU-"#AOBB5+,Y#9AK=LGGU &V)_].L(H3F.H<N'J7!VG
M-Q@.X?H UXFOT+I>K(;1 XA&W5(HIX2ZBI2*E(J4BI2*E%9;2HMT_)$\*::L
M5-$Q'D-T@3LCX0\/F(&.=P/U_)K6/WNCPUCGFI9U/(S]8?=3W.[[P5'\JIG\
M-E%,?K7=_N^@F^SUWYPK(QMU=PAO753PFRIO^_9+4>V7I]K[^>Y"VC'%&,-(
M2Z:S:I^0-5'"0B6,^B!$E&EMG7:TF&^DOG!_H4()+:2$)23\%$I8:4J8L?9E
M#D%R+E%@DB".?4*&$'@:M7"P/!08_:VBA"=4P@<@T!CVI2I/\307*14I%2D5
M*2U#"4R2$N4$XTI%+K W(%^"N96<2)FX^7$E$':LB=:7%;RBN2U/<SN8ZWY-
M%*>)@RV'10#%+6F'3.($244H/",X-J5M<N>"^?.G-]?<"HX+VQ8IM=/D+FQ[
M9VP[9R=CYI2,1""<C64N943&.HMP#$)C+'*<O%UTNZ2 >#L,Y*L+3O]B>\WQ
M%SNJMJ*/1R[6%2.=*N/HH4/>T[Z_D^EYSD"(83#.4?D\*[=N6=ZZVM^+G7*(
M)"@B$HX&)ZX-M4HS+'%P'*M@]*1Y]XT.-S17WQN/AB/;SU-6SC$LCP8_SA<]
MD=:$2!P"^X$#"VJ3SS%(%+QF4DO'&5%KZTQWA.8=J>9;9JU<;?BEP?B!0R /
M2U=MVSC^\6#+8 'QMXG%Y]7:'Z/P:U(^<QI;K(>3[NY%65V0I7=G7 -1"AN3
MI\A11A$WTB.;O$#<)2N#ECYB8&E>R+F0<R'G1TG.WGF<O$R!><^MQ%H$YYB6
MW/G(,+:W(>?B9E@B<\_JU\81SG5$G$F#.$X&:9N N:62F%LF.!5KZY*;CN#S
MW2,*?Q?^;@%/%?Z^>EX6<1K;8"T1P5,"A!!9<%IHG218V(IPR\WU!'Z-K[@P
M^=TR^6QX#KN8!980#2E7?- >:9E(+LU$->:2&M,T%E<=;.:+,BV<6568M#!I
M8=(K_11..6>-!"Q&;CPQV 1+K;-,!\<H+DS:,B:=RUIGC)HDHD#:!(XX(0Y9
M8@6*26F?#S(8ZM;668==T5"M$&DATD*DRW I\* LCSH9RQUWBEEE3;(N$A^3
M%4$5ET);Z',F<\%+ZJ,G##E.*>)*"V2,U"BX8*5-)#@A@#ZYZ1!2? I+RKOX
MJ3F!?U8L\4+ET2-;'W3[S0 (O4R:/@+<ZF43 <'?FVR:)WO_,%;6^\$1_/9)
MKBC0'XS@ZK:&E_M5%T9V4-M>=6SKIO+HZ# .<]G1?C-_=A1#E;I]V_==^-!P
M!"\TE4"?72X:>6$>IC_.Z3,%8OCY>##LYO7VO(X].^I^BC]_[H;1X1E-7?CB
M5+#XZU>L@T&,1]=_I2US_!+QF2*:%_[.XVT(#JQ$H4)P,1++%65..^J25<(*
M8RUE[[5>._O28?VUHNU!1*Z.]B.R"6[QN>U]MB?#M9\NKSY8>C,S/SMIUTY-
M2G<V-1,4 .,/:MN(M.EDE#\%8[*M&4MU6.>M\'^^+R(%@&I*< !4-O,N"ECX
MUT]V?0X.D]E>_Y>K?UJ_:FU<SQPP,],J'V>X:)@-)JEGCX?Q^=F#GT-W>-RS
M)\^[_>96FR_]/+W8%$QY'<QP6C,+D[>G2\289UJPO$JF2673'YXNH&?- IIA
MZ>DW]3.#KW\;/R/_>XD\KT]::T5NVMPRNEJWVME[_>JW[<WJM[W?M[9W?^U4
MV[N;SQI!;^[MOMG[?7MK8__%5O5F'_[9>;&[_Z;:>UEM;KSYK7KY^][?;ZKF
MH__<[@/7#L8PD#"\;,Q<VF?N=RG #3[#$XDNNA:D>":DO-%:6&B)/1.*_M!5
MO_V>8#=;MVT8*]/\3L9Z,VG=$+G7IE02<1.43_;O-IE0;Z.MJQ>P1X1+.:CS
M4+W%W%SP UROOWXK<;=]TW;3%-T;W.\3FS92INU'I@TO@LBE]YY8[CUG6=S@
MKC?M\+!*O<'G897JP5$U.(Y9IP7C+AOWGYK*"\]O<[A\6<OLAP\7/=4QKO;9
MCKGENUCY@UM7<&G?K2[LGVZ%B_F&-]>.PW*OZD'JCE;GI-S>YE=_\^[?V^+M
MAY>'NQ]Z'W>W7A_NG&Z(G:/L#]X]?/OA3[&[=?!E]]=W1^?^YJ-W1[M;7KS;
M^G<7/LOWX#N[]!T\_BO[B3_L'NUVWWTX8#OT!9WU-[\[>@OCZGW<.=H^W=DZ
MX+N_OF#OX/'NWSOX[=\[]"W]]]'>EC]]N_\N[9Q,DAYVWF"Z>_H'V]UX+YP&
MB\$1Q# CB'/)D8DAM\7U5BEB10AI">?DEEA0YIX";H65VG5SB[ 2#4D))ZAV
MRG)%#/SG-'74.)E4F+(2.6,E4ECIH5GI=(:5-,-)*XX1XQQ826.!M$H$11NQ
MH8H0S.G:NA$=P6EAI<)**\%*TA-"1(J>>LYMU)8G(FW@7J1$$IVT"L-GK(0+
M*STT*Y$95B*11:*\1L1PGU/^*3(\682UT%2;H'C6E3COP'[3#E9Z9&Z3JS&X
M$3Z,AZ,F?EV-!E4= 76^VXM-U\ULD.97\V.?_2OC80Q5M[]\YTI;G!.MOL;C
MZ/KP_879Y ]LQ6-8C-TF+%W9?JCLT0"&=]J\<.U26[6:MS=$Z4-VN;XHB(U^
MV+@@AK)A+FO#W'TSYUS D6*=HD!<2?A+!XHT%P8%(E,,3&":S*2-9IOZ7#_U
M(M;+!_02[/$"Z(< ]*Q=+KW!S@J"2(@6<6($,I(8)*27RCBN =(-H-FM6TT5
M0+<8T$LP90N@'P+0<R9M4(8EAY&)+"$N8'.V&H-Q*QV3QCMO;;-#$RI;!.C'
M45/^AE;$JSH>=<='EXR'QIH(W:&'FQSE// Z-B\OW$]NU:I]MM+8N,8KMW$F
MEHMLMI>VIF(; L]-93O<[G^*4Q=&8;1%&*T[9W-HFJR3A.5J'!IQZPQP6\2(
MQ.B"U)2YS&@:MZD7YE.OX=M*BV/)J"Y*S-(@/VN5,*H<CDR@:!2H+I8QY'+P
MT"L5/5 X4[JQ2BBYM9NA@+[%H+^[ %O9RN\#U[/&B8N426XY"B1@P#6V""C=
M(Z&(8U;**'RNBRC:M)4_J0#'Y#QX;H& S<_.YLA:/I$:^\,2XKCG$$=36/N7
M+(+-"Q(H:L?2Z&D^=5)YJYW6 GFC\23$ 8M6(ZJ4MDIH[0S)):,ZF,\7UB[>
MT,<#YJ6'-PJ8[QS,LS9$\)X+&#Z2R@K0-:A"P,D6)5 >9:""2B8 S*0#GRE@
M?L1@7GIHHX#YSL$\:S@(%9@E)B(6P7K@EE%D%)&(NA0X8S19Y=;6">E@P5H$
MYB<5ULC9JCE>,;23LALE;M&6N,56=*,+K;X_V6XOB^7EH'X#LGH][0Y^UA:\
M<-4"7'56=1:XBNUL_<EW/[^WA#"2#$,L"0=6A")(2X61U$F2W.Q3R !<)6ZM
M=137Y?V5CWIP"V)1#%]41E+W2PSH--:#@NW%L'WZ%=MO/V<'9DK:FX@1CA@C
M+FVNA.H""CE&22(VB<7S%J(%WX\7WW>0+U7P??_X)A?P_67GX+TFS H#=H;6
MN=*Q2!19D0QR&BLA4W(^'U-L'[Z?5)#BS-#(Q=0&8&UD8R/^=]P]SC&Z$J*X
MOQ#%&1OM]3-'[:57=3Z#-3IYU;/]T8LSB12N6JZ=<>X3B<1HS#42RAG$C?=(
M!RT0D\H[S!*-42V-JXJ'L\7 OKO<J)LBO"#Y1ZR*\U-5C'I+?4)84M ZC%+(
M69.0)XY@HY6)E%W5+K)@^/%@>.D&1=F<'\*0.(.TU\XR+RAR(K'<ISL@0W/H
M(C <A S"$];&S?D[AL19_6(8;/PV%ZSR)Q][D87&BMH\M/V#.%,X83B,HV%S
M%J77M:[;*T442A&%I5?W\),4VUS7(W8_92]7,=H?("JXW?=UM,.X%2?_;O?/
M)//Z7# EJ6%IU8?.NP)];5&9J,-2$(4TCQIQZAAR3G+DX)'7W$5GFK.:6LS7
M1"NZ_^/!^-W9[P7C]X[QDYF&XA9'*85#)M=DY21%9##8]M%Y"S8?J 0<,"XZ
M&*N"\57#^#T7"RS8?EAL[\[LWR18D70P2%,O$8^P?VL7)?+!.">\$S;FQGX=
MS>>QO<K5 UMO9YR563BVW5#%+SE'-T[,VL'H,-:5']=US'46&GOWJ>4DWG,Y
M^.^QUE1.6S%%D$IX,1'71C_L95EM-"(J/+8\'MN9LT.L<S:1Z)"*W.1S3Q@Y
M12B*-%)G N5,\JRC"'J;*J@EG:G-0%]ZPF(!>@N /F.,P$(FP4F'),<<<<HM
M<CPH1 1ET=)D806LK?,.9O-U%0K0'P?0[\$.N1G0"Y87PO*L\<$DE1HSAZC-
MJ<@Z)628(BB$("1Q,062UM:5O(WI43(4?\ST:-;Y;:R+)^(3N0?KHA'%[J _
M-?D*^?P ^?PQ9S$($I4#.2$P"4"18$(C2YA"$K.H.+;6F'RX^@J?YBKW<GGL
MT&UIR*) >"D0GK$%$G:@!.J 4J LEW*7R&B/D<6!"J6C$R0;_?,6?XE*/!X8
MWUV!M0+CNX'QK!F0I)>!88THDQ9,>D*1QH(C;0V)C@CA@P8SH$WM&)Y4%&+O
M/+FNEV%0-?.#!@F-X<G3C#\\:/;3T:!.<^1T+J3?\[/7>:Q[Z<]A+#[)91/8
MGW.FA.(^D,0#8D89Q!/3R)@DD*8ZAH!MXH8WM5[-K9.@BF.RQ5!?OD51H/[0
M4)\-/W 6C $-Q5@E<T<*B:P+%*44A?$T:DPFW:/,K<LK%JBW&.I+"T'<&N'E
MP-,/@WO6$-'2F\S6L(_;G$00'-),4&0MD5%HG2);WG'D$ICX,6OD_.S%L3UY
MB@<O[CDXL7!6]JN)6(H:LCRF>CN?[J02A@U((A&]FD9.+35(.]B$DG $!Y'5
M$'%%+<D2OF@ON-N5[30'Z8+:Q5 [8SS0!"2<5$)>^QQR9 DYDBSB/!KMO2+<
MZ+5UHTJ?RI4#[CVG+Y5=N0WXGK4?1  J=MJA&%CN]28Q,HGP[ R$_9I9'U1J
MG .*M&-7?E)AC-PO:1R_'J8H,8N'3&J:2N/WKS4:"OTL1#]^SBCP@E%E;$+6
MQ4P_2B'+HT6*@FF@L:62 ?W(-G6F*H[)U30+YJ!;U(HEXGK&;/!,T11U!#3G
M-&F!%3)!&.0X4"^C)GC,LEK!KTB4+M!^/-"^G^/7!=IW".U9BP%;IABW%B6>
M"Z 2)Y&.3,/F[8*A)$;N33Y^+>B\Q5#B#?=B-IP= :KJ^"GVQR7>T))XPYE<
M7D_$4GAJ>3QU,!]OD%[;"*:%EA)X*F*&7./(Q)Y&DB(HFQ),"]61;:D34?R6
M;3Q?7=#="G2?S*);6B]<0EBX7,2-8C U.$->X$B"LX%*0#?A'7V%&E+0_3C0
M?9]1B8+N.T3WK(UAL=,I)H*DS76<DQ'(Y:?4:-BUM63*Q:;Q))>R'>A^4F&)
M"_;%#[9^>1K>CZ7%)*[,N+S(2:6D_)*XZ..<'>%PXIP86+I8"<0Q#\CPF!#P
M451:@EYI71LS+(LSL[5QB@+G>X3S?$(3X3G8J#4!.'.C$3SP2,:0-,<QJ7;V
MFBMP7@'SX4; +@!>","SM@$0+:$D1.1)E(@KFE,&F(5'AOF$@]&.K*W+EI12
M>U)QA]E3UQ>ZF9001#M"$)>/:9T%34^*.V-IE/5A8\Z$B)$E[(-!3'B*N,R5
M7@/7P%OYC):4ABC2'+8FQ5?Y6$%^KZ6;"LCO >2S$0DJC @L(NYX/F9M#3(B
M<:1=\!H3I;4DDV/6)=RX2B!O5[;3C:!=W 4_C.JY\]4L,&><090EA;BQ"FFJ
M M(2Y*DC!F/$E(Z2+?WD,H,RQ+3=^MJ-H\K;X6$U'L8PTV$2EN.G'[?#IM/B
M!G6(-1H-CI_C/*9J..AU0Y5O;269O1TV&HAM$Z3VJAY\ZH88?CGY$\1W@>@W
MSF57]+?E,?U\.PZE:9*@BX/\O$:<^X0<)PP)&W%23'O++.AO&'>,6D)U[YN"
M:87\Q4^9'^[.O"O\\$#\,&O?>4&L#!@)XBS*Q]^1)=ZCH)PW! N.)5U;UZS#
MY6V\.(4>'B,]W%VF6J&'AZ&'.4-14YI,S'6 C4#<VX@<S0FICGI"?321@5W"
M1<>8^=.LK:.')86MVF(PJ2L!G'%3I=[@\[!*]> (3*9/<3AC+SV_UF"ZP6S<
M1$H_U-7^IBZYISK&I1K^K#WK^)J6F^/:']K<:W.0JB-;?XRC7#BE&D8_KF]M
M]3_VK7GIA2->V9.CV!\-]P<;_K_C;AUWSD7RYEPB93->WF8\7]W:6L,B21XY
MH@+B+AADE31(:,:X@G=I"&OKE.D.5;P=B2(EOZN--GE!]D,C>\8*-]%C;8A&
ME*2(N- >:2<<,KD'A\+,8X,!V9QWR!558PJR'P>REQYH+<B^=V3/&M#4Q.@5
M"4B)0!"WS" '4$>)6B,<\0&K?.8++&AZ15^=E4_N7 $SHQ[ U(6IL0PXF,)B
MN5;'T\@46;[1,17.2Y#-&^"AC7[8F4CH9"\5,KM;,ILO=BU!X6RROP(H):"F
MV( <TQIA*S"/@"<K<OTK)3J8W[K!3LD):S'2EV^$%*0_*-)G&WJ&!**E&#$1
M%:@M+B%#J4!".Y<LC<*GC'1&.[ F"](?,=*7;Y04I#\DTF<-%.\E#A)[I!CQ
MB!-O<^\*B;2DW%+'.1 \(%WPEB']B05#+EDI0UCQ)2K20OMD+VU\LMU>ELC+
M09U?^4IC6]&-"I7=B7ERND%W/_SQWF#C@C >:9KKZZBDD#61HTB-U38*%S5>
M6U<=PN?+ZY0C\ \$<X)7SC99#.7EV,KMK9(,\-.#]]%YA;65B&MN$4\ZGT,C
M!$P3PD,45G"YO&,K!>+MA?B=&R4%XO=MC@#$][:VWW/&A<'6(J9= IPSA8PA
M&%:<B4$ER6R*;83X$PN:3'.SLA%R7.<36:.3RO9#%?\[[AX?_6C]O!7VJ+0K
M-^O55":O>K8_VNB'%V=B*?RT$#_-M_9Q.*K$,C^Y' )Q/B+8?3A2F'+.(I=4
M@(W!;E6HI_A#VXS>N\^_^@9ZB_M@B=">B7F =9%(3 :!OAASJH9$5CN!2'!"
M)JR#\[XI=4%ODX)5P-UF<-]]"E;9FI>%W]E(1A+>>$\#8E+IG!Z-D<$\Y:/.
MAM)HK,-D;5WPVZ1&MS6 L3IE'/XYK>/P?]EP: [W5>[DRD-*I:C#BA1UV#X3
M7CF5>1=,-]\$B#"3.)$"^(T"TWF7D&:&(B>99,%B'Q0'II,=+LJA[4(/#US3
MH=##7=/#K"%#(]$)8T2$=HBS1)$1P2+EL!5@Q82H0NXSPCJP'11^> +\\) 6
M4&&%AV&%N>Y#,1!E1"XISH 5L)?(>N)1))Q$1WBRBJVM:^"$974X+>4<[J"<
M0^KV;=^7<@ZK/\92S/*)IW%VA\,Q8+F)HOK!T1%LS,-#6\/OP?W&NGIQ=-P;
MG,18O1D-_,?J/.B:78<ER_.!LCRS*+( AD4A640A.=V>\V($X:4+4B%+<VTI
M*0ER@5)XBI6QU"632XMK/1]*+9E<CP>M=YNM>0&MQ;98(I1/9LO$<1*\5T@:
M 5!."E <F$8JUY8,(G<$29,N 07,CQG,=YN76<!\)V">=10(RJE1"B-!G4=<
M1(<,8Q;%I 5LV=R#0I7!#%S<(C _L03,2X:$':'18423XV!@322X:O^@4_6;
M9U_M##\8CDK]BNOI2U&C@:XL<1QSDJ+VWB3" N584ZKTK2R'[:D4]M)F8^LU
M=%:8;'E,-E_\7CKBF68),0MV!??8( <:)E)>ZNB,XBZ[/)GI@(+9HJ.M):]K
MV<!VL*59ETC0(/3(B/4!5%)'HA X:JEN96048-\]L&?L#2^5X9X#IA7)J9J1
M(J<U1M%CI1W8(B#=M74J.JI59]8+L)<-;,R2H"S"#LT,YYX8T%E-@B<V2F&(
MO97!48!]Y\">"U)BFF#3YKG*?$*P/^<CW$DBQK41QG"E.=@>C'6D8"T"]E..
M8@PC(#+8^N1.#(^GX3?QC# +1H?SR?$DI2:28B8I:*DJX>CNVO H!UA_D,'^
MF+,Y&#,D4NJ0][E(=Y :&68\<IY(;EDV,5,;#[ 69^BR0<W DHB1X'ROG%+0
M3\'2P)$**8T76!:CH^7(GC$Z"-<B2FJ1B-H LDU".N* 2)36<ZDEH1:,#FHZ
M1K?),UJ0O?0P!R<RZ:1!1TT\\* I5@YH7WC*N23ZKJV.LEW_,*CG#HTQH&@%
M>,8"IYR$(++IH1 )GMN03+*&M7&[?LKACF_D31WGQTVVU."X07'\$FO?'9:R
MW0^:,+77"&/X8BJ,4!25Y7':?)\@@X71@B?$0@!.$X(A&UQN/$"YL-$;R8#3
M1(>H6V=Z%^=HBW%]]ZE5!==WBNL9 X0Y$C!C#DE!P "Q&"/KL4-.6IFD3CPQ
MO[9N.H+=NKYEP76+<7WW658%UW>)ZUD;)#@;G0P2I*49 G,R(<.\0HIKPV0P
M0C=I"H#K-C75>*+U*RY6K;CJ+%:I6M$.&^2:8Z<OST16CIW>!;E=T3,(=$^2
M^X9'['DV1G)J>++()6V#5MXZKIL.XE0NJRIW.9#^F)AAZ59,888'8H;9IJ=)
MJX3!?@DX9V=RK8$9.$?4:D,H4<I&M;8.M-!AY-;)'H4:'B$UW%>MBD(-=TP-
M<U$90US0VB+@?I_3P#BR) ;$M'<D*@8K1X)%I#O4J!5AAD=6K.)Z*^F? ((Z
MVF'\OZK;GSR"!XWQU)F84+E(^"? 1W\T;(J&UW$XJKM^!$95?O\VD9K'1H;M
MJ/N7.3'_>?%5<*_/99;?V.B'RR]<^.0KN/4!D.AD*6Q-%P<\[XVS.%Y\\8>V
M?Q!?VU%\D8#+2Y7C)5+K? %SF[.DE?/(!!W 'I,,:<4\DLP9RK52)M%<'(QV
MB)QW-RU<*;4M"M<2O<N/C6,>TA8KS++"S#)CS]E@+!9:()6\ 7LN"61!MT*@
MGBN&F;72Z+5U:3I2+<N/7=CE,;'+TLVY^V:70B +$<BLU4>,YY+3@)S*O9]$
M),@&K!#6*AEN6+ BK*USK5>$/984(6N+R7=]?<*;V76=RL6#;K^?XV6Y;U2#
MKW(HZ'IE*S*-A?'$:L>9(): ]08/'0&#3J7P?OL>=*RB,BV/\>8+N2O0F'14
M I'D/>(4_G(X*2! XVGT2GE+P!A3I&/,?-N*<J3@\8#=4Y*2DQZ#HL-#"(!S
M*XS@PC)AN7$-V.]:Y2E@7RK89^PC*12-ED1D4HYW&461]B: +ANP"(I'J1V
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M4"0QF\=HV^PQZLW3MT<9%*<:SE"1%R;H38.1HIRBPCE&LTQFA)FNWMR<1(Z
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M(:(G WIUQ,E.?VN*\?:+?0IWC-?[*U]F$H=_S^,^U/+<)CCL^"ZPVT#H26"
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MP[#!0.LQ3MM@H,8VS=<P]#*.&>V.2&]0@/TIEC^7$<HOEB2QK]*>+F;IT8W
M$<CR=F%MHKQ4?+V[&G-HQQCN-[GSJN[F?SU]/IR=3V9J]-K_.1D?_QFVWCZ+
MK]!G??8.CH](D3-OM4",Y1@%GQ,:-B@!A.?@:1>,Y!S_(%F<)54 ,P UH$@.
M@V=-+(SO[2/&=8WBNDI6BU&]&6BA8=A:T)T;NRAV!ZN7!UFJW>#$C<H,!J@/
MD+AS-ZL<"#!*@NZO! WX7H L4;J2448LI;$&D0,ZO1W 'HXMB ZW!+VHX8G4
M6=1]I00JEP5J'H2^!H4(8=%Z$8"+\3+(H\ETMKS9FA#G.#9"1@\W^:432%2
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M#4&S4V]8FUDC^CF:!SY=S[=7,&0,+<6V4R@Q?6@QTC^!#@=D$%F _CIXLYB
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MEGHA#TY2O01?3(431,GDGTXNU*C;/+4J=SH%YE5E>;S3C=#2@]D;"_K!EYA
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ME*)Q'D)<)! S%]#=ETFIH0M9Y:3@?:' %LNF#RLA 8FYRQP-8DED'D;49:@
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M-=J8X*L+Q+4,!TLR@Z1C'@K-?9Z9+-.Y>_)T/%FQ858^&(R6!S X2V/@+(R
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MOXJ"<_87NQ$46_>+9X,(9K#],G$DQAX\'O$/45<0Z,)*PA@^_9O5+8&0N"-
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MC1]>2-[#HL]8,Q.H8DQ$RJW"AG-O<G\\1Q-/H^@S/.FN9A83_NEO]CC;^V4
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MF7EJU[N('?V[8(R]B@_/Q\9[5W.G!>B+?-F.?D3 >]*!P<%-RF[U]H(U.E,
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M\?K4^DID%D9DCO:T%#+@G/*5"$$\<H*<3P)QG,F=I>?*XI5UL39+VG\I,AF
M'B(V,DB+16".:L:E"1KS$)*.VA!IL%.%V,S2"55BLQ!B0^N;?L](&J-1'%%!
M8,>E-K,(X8A$Q(P(8ZC#A=C,=DF[%!O8#(]CKK.'G6IMIG[^39!?%(P3M6^@
M"H/7?\%;;?#:,]-Q_.D/8CAIQ^UT$S%',4L5+\<%+\>7O8"-QCY(A'%N1D@\
M>+Q)*L2LQYHDZD$DIIEEI.*4)V92U(EK#AAK>336Q(AE4I9-\W@\C".CM%8S
MM \>0Y$Q32UUMT:(0B&NY=RY\TU?@8&#$_%(!@ZAY+.06AC^+ P<XGD&>[_;
M5@P<%0-'Q< QAV/A*W!>$7#,]]PW<HNY()$9SIW3CD05M!5$&T&LP14!QVL<
M7_3@^H]Y3*+1^796ITVXYE=XQM;/[9UV>_L[&&&=WUO-G=U.8_KXXA">O_,)
M#+4CN@MCWP4#KOYY]P#N)^ ZL;L#=^O\?M#H-/%U!!S@9R>J342&9(_)X("<
M-A;E[FA!>QI#\BOK:A5DN"+@F!N*+!P,S[.M]%L_%'X4@B[HH7"%G@]#S[-I
MUFJK:4@862O=*$P9N,IDE<I*HF(HXDUJ3<V9M/K9T/.]E6M4K!YWVXS<<\.T
MH<%1RJWB1B7+5222!99TXHM4K'$;JT=E.SX%_6:I/51R427OD0R6(DZP0$Y)
MAF*B1DKAI1<D]YHBJT95W97?#$;<;!H]$2@6F=JC@HJ'0<4,A4>P2BN&%.41
M\1 URN%Q0 ZI;:0D&1U6UCE;,XO4J;DB\'@')?H/)/!8)F/H_1%XO!3"S1)X
M$!$)LSHB+Y5!'%..G.8)84NUS<1%-O"; FD5@<?"HL.;MH+>)X''"V+$E!5D
M%;/)$8YBD3D1B4<&.[""J#%46B.4UO,-%U4AH8K!HS*$[J+PJ&RAI^#<+(\'
M]L38I +27&O$=8K(YK]Y8;1,U+GH%7A[=%7KIQA#54BH,H9>B\&C0HB'(<24
M)92,=-+H@!)E'G$!-E'NZH8X(39(RH0WX"UQOJ;$VXL'+;3U\[B$K(JFXWF.
MWKS0W.>BP60-)]9:$HQ5F12)1R627G2:CLJR>@INSG)U1"%@W\0"244"XBQ2
M9$RND/)81"XXMMBOK%-N5K&9<\)6Q=6Q6$!2<77, 2FKM*PW@9+3IXU**A&,
M083IB+BC 3DK(Z+2)6E3%,:(XK11/]FZ?"Y&CMG^]C?5(XUP.1?I+4B#XX<1
M9SR0ZP#N_)"B7LX]PX)A2:WCBBBCJ:94<2J)4=:(^]('O"+5QKNMZ=UBC<U]
MUC@_.FV<?Q.-P^:>E-CS&#G*G>TSDX!")GJ/7/(VNJ@Q-W)E7:_-AL_'];VW
M<&5,>#FKM=.#EC^HM0:%W/G1!2[__D)6>Z#--5L['<%YS8YJ?8Z+"&,6U-N*
M5[GP) ];8F8X]583@26 5B3!2Z7P/8I7GTTFRQCIIUY_]%'^';EBV ,T^ _A
MI)\K*]^U7#9_UL\W]AC' E:1(^E);E O!=+6*\2(BLIA;*.@*^OLDN%B7&Q:
M,JG<BYEET@E_("/+F(N%/)&+95Y@6C$DO(;4GM;/FWL\V.0B,^"1)XZXR:%Y
M&PVBAMID0I0VA^;QVFP+@0L$?2BOAK4F"9[Y\SCCVB3KC=7!12GA'WAF1<>R
MR%)S!>L:AQM[*A&9UP])G+-^#8O(&*R0PX%SQ7Q*.+=LOI7-YT$<&Z]BX,Z-
M=J/DVA@)VM57?2EJB^L-@V)@8P6H^"W&_!;?]KS3+(64D%(<(\ZT1HY9@3RW
M5N'(C;-AFJ_B9K&5"^.6W8-38^27%6R5ZI?!R.;H%4+R&&:-*<5^!>H+A=5C
MJ"^X6-/TYJ\?S2:!UR1[W&WOHKY@ST)](1Y'__$*@Z5PVZ49;)Y94Y&*W(-4
MI"#(J#A%KN$4*?[^\6?L^]8@UOX $R)6,S0[0U]CQ[:Z\![%?_T&-\KFZ EX
MVCNQWWG',W;A]!03<^'YU K7YR$\- ^8H(G#0G+]4>$#9GDIG[<4HO'/5K<,
M*,WDXE73,YJ>X4'O!&X1IJ;H/60(;9\,!T-X]>P#/ ,]T]O/Z=&*Z\2CC-%P
MC;T&)Y\'+0V1VC$BGI^":>3U3RSD^\G=.89Q-'\VZ$>ZO;/;;G:V</V\3IJ'
M1Z>[WW=;NX=_M6'TM'%XA!MGTYTBMCB,DS5WFJ+1^:O5//QR7C__J[6]\RM<
M\WNG\?VO3O.\"??]PJXKE^<F4,8P0=YGBA!/ ]*8!,22M%(ZP662*^M\56FR
M*N0BG4Q7.3A5#LZ]<G >A6SSR\&9Q;6I7)NQNU1X2Q6@/130ILO9$E6PW DQ
MF2SBVC*D+4DH1:.]-5:0I%?6*5[#BU3.-N^ZUV6_QWLK[ZL8G^Y1VQ<UMHP$
M0;CA7A'+E4G,1Q6#P<20%ZSMNY:PY7._-QA4UNK\P'V6SP KJV.P!!&7^YII
MR9#1$C2!4QD"T6"STI5ULLJ-7C5DD5A;JEJ^YZKE>QHJ/-S.&SP(%"I;;YYP
M,&7KY=P.S1A8>,23G'D9D*7<(>D"P2K)(+!:66?YP/4-0\&RW^.]$5J-,:#B
MM'II<R\GCN2F!C%L%MDB)427![F3F4<7*U19<_.#[UE&!L6IQ5)%,.2\ O@&
M:\YJZ9$5FG(1 XXNQQZ%6=7,5/Q4RZ/I;\&,&V- 9<D]"Q1,67+&!AM<=,BS
MX!&/WB"=>>M"T($0L.9T".#8D34ZVR6OBMHMRCW>6]3N@L&IUNOGFJQ6_]V%
M\%[?J'MB#&^"86>C&S[F12SN\*[HVE\*^&>Y(Q(EGEHCD6!.YL(-A9PC$1&2
MC^U",BGXE74AU"HVL\4;%2W7P@+#,MB 3X6&RB2<)S),LW'!^C(;,5+<@4EH
MM4,Z"5AZSSP-'#L"R[_.V)I^LDFXP."P[/>H<@_GQ43V/KG&J'0B!2=A2U"<
M**$%2[F/>G(:/,7HGY]KK,I+?'[T;\[8A89R'$4,F42,(2Y,1#9XCF#_%TD&
MF0@S8!>N4LE6A5B61F95&\BJ#>1S6M"/0\LJUW%90'+Z_#NQ0(6B*!J5S[\Y
M1480CRP7/"C'N><YUY&O&?Z^ ').EN;"8L+UY$V/<9_GQ&9RI^)?5#Q.%#OF
M6D?ZUAB<7AH3&M,I<M)IH6-$7'*).!$8:><,8I03)E-BDJN5=;4F\33MTSW*
MZJKJBG=;73$72P.Q9S0UKO(DW<\]8Q7*W ]EIBT/&G745J/D+$ -41$YBC7*
M_<:4"9QY#Y8'TZN"+E+-V)P.*!<:H$:*48NEJ5UPV\PS*C6:DGL3<$]_586L
M7BID]?%2 JJ0U;PQT<^$K'1FX3(N(JR80-PGP$1C"&+*$8M-L%Y(\,96C<&K
M5#S9(YNG'K[R:<?K8<W"H??]S<NYSLV2XN_"1\(F(+B*A,T3>Z?L4:U8"E(Q
M1(-VB&,O,O9Z9)(PG@FJ$[4KZ\2LD=E$XO>+NP^YQ[S>=RF09E'C:S?#R4WQ
MM3?'D/[22#,=7TO1>^ZP15H*L/(H5<@HPN"/1'E07!/B5M;EFI%SB:]5EE-E
M.2UA1&\^&'<UHD>JD-Y<@6W*A&*.F<BM0 (+F4\/!+*1$*0#=TX:8U("$XK1
M54%G>?B7T(:ZTMEH4C>?C^SZ*O?T]/8PR]:=7UV^&C7W,U'!=WK]="T/_"06
M_#FF  ];W5+I0<J^YBXYL.P[O<EBS8H>_OQH+^(4#68:7!\%_H_!"6D&:NQM
M],9BK*,F)=ZWNB=@-&8,Y8F0P+CPD7 N$]=&VRAL,%))[I.>II._CJK]N-_[
MT0H@<QY4#0S06NMRN::[&DWRM@]J^R7CS>JH;<QJT<$CC@MO[]U%IJ1V'/>2
MP:NU21K,5;BACX /,*;< 6E,&E]TLAE\N-% NU#/J\W.)A1TI"B<KJE<I'3<
M&Q3]B#X4K]SZ$7\94ZL7BC1QX0CK\.4EU@UZ[9/AS9?,T(Z^$AY\0D1-3='$
MGP?]2^[5_8A</]HC9!,,]X-MG]JSP<J_KT(<X-O4+$Y/P(VOF=*SO>9M73/^
M8Q=F++6#?L;A_VG)1(0*P<68_5'*G';4):N$%<9:RO84*&ZAJKU4R[YA+GW]
MS[_ME+!?S/9Z0;Q\W3)/J4.)LU@JSJS#/CG&H^1:D)18($)B+IQT*P_OG7+M
M<^[$JI?NX@!2NH9+27UH&P?!UK1ZAC8.;$V0^_'W/^P[IGDU6'J_VSZ5E9R(
MY>1M;^:6*Q]GMNCG9VR_*PMQL:?MUD/XA[WO.YNVF]F\JVF[9=KPNR.&'\?)
MT;@3ZM5>EC/NR*6;\&QE!_<-IW9:(;3CPH=3YUYU\:KO_8BSYD<%0Y[QT/E6
M!L*WV]F=U3]_ZM0_UVE]I]&J[VS@[<W]L^WO];/&SC?>/ R'3?K7X?;.%[P]
MT]G=GS:_-T^;N7$NW?I9W_S"MS>W1/-\BS1V#EH-VCC<_5X7#?C\.@[]I */
MAE.44B[#(%XC+01#V#'*/4Z.A 3HJ]?TDQE)GZT,XT+GEKI.K4+,Y4!,&I(2
M3E#ME.6*&/B?T]11XR0HTP@QR1@QGY^<OT+,9T;,J;,F%2/FPF"DF,B(&272
M4AJ48)=D.@9)=2Y<DVMD7G1?%6(NH&U>5?;>&S&E)X2(%#WUG-NH+<\=KP/W
M(B62*"T0$X\1$U>(N>2(.9UV1$TD4DF/C*(1\>0I<H8)9(B1+@E!O>,KZP2O
MF<6U,=]?+<Y.;VC;-6\'![5^]+'U(X9:ZO<Z%P>=15W.E8/1IY 6O374O^X5
MEQ?9YQLUN";QZGIZZP)_G\!NO=SY5"^%V-?T*J$A"!4HHI)8Q&W 2!.CD8Q4
M.D^3H$EE!ANBGEPAN7C\915JO5'4>J+G7J'6HJ'6E&=."/=:,(>($PEQ%@-R
MPBN4P"OGU'CB&:"6617L#;(N5JCU1E'KB=YSA5H+AEK3WK%W8$TS*Y&502+N
M>$3&1H<<)TY;QZ+7=&6= 6K-*W7]53S@)3Q^+SW@UKB0H]:Q_:,XO#Q_OYH4
M'&]JC53Q"+U19)Z_%SR?BNW+OB^%!+\_;J&7 O/9ME#:"G".M4:$J]P+)CAD
MK61(&^EHY)($F5;6]:K :H&HA2K"M KH7M9QKH!NV8!NNL.!C83FIE<:8YV[
M&5MD<G-CJY,-!K- 2,KM2U<96R02M0KI*J1[66>[0KHE0[II_UR;* S6%ED2
M%2"=!I!3PJ+H@M;61P[F_\JZ6E7BR?[YO-DBQQ7BL^6@%V5QSU D?2'Z=]5)
M3\2:LAR7FC$8G'2JXNA1<71S+]!<!FT9XF!K(8Z-0EI+@H07RJE$K.8SQ<X+
M5XU_7?7U8%PE/R@*I4^G2QWLI2#43G)5=:L+0#N,_4Y!%51<=+4<(G\R51+Q
MV%+L#S,5I@\J ZW*.9>L0G*I!EN5<U;EG%4YY^),6U7.695SWLL/_=H:'/V_
M_]$4FU]2/\9\LA3[<3"L]>TP/J6#Q2UB\2C)6,R2G.Z(!_R*GZ(2-<I[+8W'
MW$MLI:>$19(<92XD<<<9#)^;OWZ1+C[AP>0%_P0KO35:Z*^PSA?^.*)+ZM*,
MR-X.=@\;G68'G.C-C[Q)F[A^OB&V-W?;,&9XYFY[^WOSK+ESA.O3#CFX076Z
MVVH>?L/UG8/#W4SVMGG$&YUO/QO@W,._Q>[A[P?@S)]>5[+(K&82@S=$*;>(
M,V^0]5PCZ8VSS@9FJ .$6<.S_O@_GJ-/3*6I]]-4&T1N[P/_=YQPZA3#B1'F
MI;.8"7['(4*EJ4N@J=.'!)X(QXC/K542XB8%I(U5R!/K$Q88&YM6ULD:Q4NE
MJ8MB:CW3AIJTB%PZ(0,W#!NI@_4F,IN2=4'<$0&OU'3QU70ZP@TJZ8C(E?]*
M8\0#:*B3VB/)N3?6*\\$65G':WPV;?8?#S'BQP$ON,$=M:?+_,OW4!OV\>=Q
M] 4]9NQW:O]L=<OHZK_F01.^5+;/M6<GC_))YD1$?1UJCE?K+7/JOQ!XSF9\
M"6LE80DCG!1X(\)29  RP<8A 0MCHU$F<^K/M*PL5>8YB/7?J=8]QK^HM&Y)
MM&ZZ9XYW@C >$#;8(^Z\14;+!!:,#]);K",AE=:]R%[W"'>ATKKET+II1\%&
MBZVW!,$Z*M Z9I'-_KRA)O+<G1F;<%^M>P\!_PLS^4<O4ZNW6\.S>80UE@HU
MWD(<?[R.?UTL8Q5X>#B>?)NQG8GESA"FD7%.()X"18XD@T#:'=.:.:7XRKJ6
M:YHL7H#P36OC(L?J*VV<DS9.$]M10-V@$F**Y)1^3Y##,2'"/9=$$D!G#-JH
MUO!L'\KET\8J)%]IXR)IX[2M[7QRFNJ M!,L=^3VR!(%8B]@A44$$P@;T$:\
MIF?K:ZZ)RE^D@M_4ONO%%8'0469PO!),GN4UKQW80<W%>)G_"Y\5SF#MY+C7
M+?LSM3K'[59JP6>=.#SHA56XPMN302R^SG)NNV>UT(.A=WM#N.6/G(*<4LNW
M0+IK!ZW!L-?/\##5!6H?Q#YG$+>&@XMQ#7LPDG[K1WGO*\-?JWW+?6[@B]:@
M9H^/^SWK#U9G?U=T=8HPYMY9C$7:<6CUX>M>?ZJJO%6F1X/M@(Y[+1BIB\/3
M/!>32=.U<=(T3%YN294'?%Q4BQ2WSC_-@#)JK3H:Z,[DO(PGMGS:I;M2C'-Z
M/<JY'\W\Q,Q-7 8#L3![Q_TX@.DMVDK5,FX?YV^.3UR[Y=MG-1A13M/TQ2A:
M\/#\M-.#EC^X:4'RK/ZPK7:18-WJUC+J%U^,^G2-7BAG61'U"RS9:??Z$9;O
M?_W@X2'[L0LSVH8QPG?^I.P%=O'>=CR[.>L<U"&_ 8#DX"0G<M5.6\.#:U;\
M,J&]?':_-3A"LWE@^>D3#SJ/_1YL=86@?UO[$R[M1PL/@E%V!\/^2<;FT1/A
M(8.\S@-XJ<M/X4ECO9II9'95"+*:9=TXMJU2;BZT!98=].0XC^[8GF7I*F@!
M 35:(7;#( ]UD'>,@A(P3T;^(#_IE_S0?H0%C%-:,+ZX=M:*[5 L;)Z@LN6:
MB\6+KSTR#?_U*ATVBAD8YQV7Y3^7-0;#*[,-\-4%G>_M=W.OP%K\[PD('RK7
MWD]LS,6<=0>%=O_O\S=%%=/FPL<13/T9^S]:/EYO/31ZW;(97F$H#(HJM<GO
M?^L-AHW>L!EA<.-7GBP NC 8Y)+:"X\O]*F3[4VPOIW3VF.)@A>9.8 *9"QU
M*-' +:R8LL:OK N\-ILK [M#NSW5M'!Z%\EL/_GS\9XS*#0<[H(N/ED=06]K
M,(%<A2Y.2&D/=AJ I9F=YQ(0G[D-^;-)8UE>^:G7'WV4?_?F(LA/D%(8_\8>
MF*"&F>00EUJ"C\@%TL$G)$PTDN#$J(TY]Y)>'P%^+*"/ZJJ>"=&+.WYH@8RT
M_)T8?UN3Q;%LU@IDJ_UQTO>PJ<;:'VW;O>>;RT79R;:ZL&D1<W73L@$0)986
M9?ZV=ML;U_Z9S3"*?_GXYQ]_%'\EO_QK##+9.@?#"5QW )IL'0)\_7[2A=O*
MU>+65VV35M;'PA[+%F4_<Q'?N!.6ELC49NB,Y48JYID)7"AOB138"*:QL@QS
MDS=# *"IS7"K\6ENSG.C<.U'Q;"#C1/P4HHFP?>KWEY6[O$G  YOG._O)68,
M45BCR#-WN*$8Z<0XR@V_C2?$&)=Y)C!>!768W1FOMTH+/V, \UH[&7EKL9:%
M=*T&]EOV6P8G[>'88K8GH)>PR!Z$T&?C>]0Y>)"%;O2;?'&I*64 IV 'N_[1
ME^Y+'D3>F&W73P_DXE'@=)P]4-(M]X8;)Y75A ?O;%0)&XLI-P''H JSKXC=
MWF[VS4O0Q^\+.VO!K7\_>7]_9N"7TRSO6D?E#-<(*\QA@R4..0]FH/$N498X
M%C04N9@W< V,3<&Q] &JVNZ)!7]QY(64N%H*61;V_Y[8,G"R>NET].#GQQG!
M2ZG\,Y9RQRD;"WR1@-L%M_EK_!&[)QFH0QG'Z &B]P>UP8D;#+/?6( V_#%A
M>?:.CWO]89;BLVQ@'H\WC9/C_)\/<7$"-R:&))BQBMN4X%]24)D*_FIKS1VG
MAA/P7G1VO[ MLZ:.][*\E6UT80[;1>CS.KF^^&GLCV]1H?H-4G[6./1[&JQ]
M*05'C!&!N& 1V10,8LX&+PEX/)& &2FN!_5I2,UM#[-Y6;/#F['RVLBZC)SA
M2!T-*G"73R&5UE9S%:2'S^(#Y>=.R 0!R:<1X#!MI\W6P/=.NL/M[EA\MM-O
MQ6L5XK?\$?2G",GVSOZ>T$9&&02*6H"0:)8;+5F& N.@[,Y[:^3*.KDF_%T+
MH[D=AP7;O=-R4\[_X2)8UP6'Q)@T(D/61,ST&!P6^+3<CF,WW/J[^[HT"V/8
M_W9=:"G;(N-) Z-C#,F#&;MD4.L4\<<<?!^,J35^;5M_A/[T![TV7-*!K:"=
M9S[O)R?#> -51[O7.\K'>1/6U''[I Q 7VP)%PN9MQ9X^$0DP@YNB)+]& T8
M+NP/X@V+-[5LLPPY$PLYFCY.UU0FY#CN#8K@P(<BW *^RR4/QS^NDJ^,EAY?
M7F+=H->&.;GQDIESRU>2DD^(Z*DIFO@S#[C ))F(4"&X&',LAS*G'74I\R,)
M8RUE>X3AE?%5!_U+@H7]B!Q8N$> ^_"2'VS[U)X-5OY]58% 5Z;F?GK:;IR<
ME)YM<FZ+ /S'+LQ8:@?]O,?]S]UKI%;6"ZZEK"J_Y>VQ.QS\Y]]V?0;9RME>
M_X_K_WO].N&XGG>(9$J T?D\RCEZY2?%R%LPW.[P \J?/+NDSU 1%)).\%II
M.L_^^<P$65M= +"X8W]F4Z#=RZBZ,'17YQL7>W[]O$D:AU\[VYM;9/<0]OS#
M#;*]^8TU-CT\L\F;<)_ZSL>SW=^F]_R/YXW#;[3QN0DVPU^=^N'75GWS&V_L
MY!-N#X;@P6']L/ZSOO/[T=_GWTX;.U_V)$_4A^20QTDCC@-%)F*+)/,V:.V=
MH::TX0"I8]C(]C7XM19L.(U9,)QJYH(6*3.V<<Z2D'R:'JN<]AK,>QS,G(1?
MD>JI3:%<DKL?=W5X(BALP!$WWA#.'#$,'#I+J;)2RB3Q[?G5<^5A*]_\U^(X
M[E+XX%^#8<MO='/P&S2CNUC$:R\NB<U3N!_<IRX:A_NLJ/%Q$;M$)#+,8L2-
MU<@%QQ' JH^!"D;4C)3=VQ)<&'B\F;LMVUF];MX6\A8!2)7S,;(0Y3A5UJ5A
MUJ7"B'PHTUI1/#@\Z)W &,/@7S6PT^.=[&OC(X%[3EM%Q[9D#&=+-=B*CJVB
M8ZOHV!9GVBHZMO^?O3=OBN-8]H:_R@3WN?>U(RA.[5UE/R\1LI =<GC LM'Q
M0?\0M<*@888[BR3TZ9^LZN[9AT4L&J!]CB28I;NZ*O.7>^;FM&,K6Y^S#2_3
M2GEU#S;-^VEV?Y^<.;V_3CG%[5M9?X^]^.%Q)P -X8'AI]6^@3] U?YUT#]_
M75J4L),'%Z'T] P7S+@PK VY)](._AOMNJH=_-</9^])>^_=Y0&L#;Z/TST/
M#E]].?IG'];=OOQPN/_Q8.\([R^U@]\_WS]\#S;>6_'A,-F%^?E$>^_7TR-Z
M!-?ZO=NF[_C^V3L\UWT.[,*#PW?'A%,6@Y(H\$(ASGA :;(/*K3!\):1K"!;
MNT)OXQ53)K^M0<H=AU$T4-5 U;W,\&F@:L.AZG(6JMPQ*Z17SF  J.2V(I8@
M0ZR$_16.6TL+@</6KA;;@B^WRFR@JH&J[P15]S"$IX&JS8:J_3FMZN-QM((H
M83BR7N99)Q8ICBWRS!M#HZ?,TZU=#E EEXN/?[R;Z7K%5-R--UVKB,U]]=VK
MP60!63</3K[GE-9O )'JF!J8N!5,M)>,+VH#T90K5'#I$(]@?!G-=>K]1:-Q
M17 F-2!:UF8VJ>'7<V2R>Y\0>A<FFQ74L?,E>)2*21OFNRWS+9@3H'U))11%
MRK/4)KBP8%C8@&)AF*+<4DG$UFXNO:8_-QSXU"=7-ASXW3EP44LVQIE"@^2+
MQ&C$)<5(8RZ0Y)9HC@5H./:&''B? 1XJ-EQ+SO6_WQCAJ5(_P!!H^?XX)9)D
M$WS&/">-G^*.V_0,?1B/$1EZ-1H-.G:<,Y4.^W^:0;AI=5T#P#<!X'=+]H=7
M.&5,%PB(GP  >X]2O1#R0@3E#36:@/TAU+8NE@OTOJ=']7KV;/RM][%1SQ#)
M'B-PU"#9@R/98FR(8%L4!4.A2.WEI"B0YKQ TNC"8<"SK$IN8&RH0;(&R38X
MKM0@V4,CV:)1; OKB6<.*:L2DGF#0-.6B,@ ,"8\+MRM0D=7=\I\K%*=UY.2
MB[ILY]!\>5.6N/X2>B%V1B^\3"<5C+T_IE*D>IR(F+$.<2=UFEU&4P]C1J*1
MT5GZ[:4Y-Z\QV8S2G%1],RW):?U@2TKY<:[.^V%*=)HRFR=7N?*D%MN4V31E
M-DV9S>9L6U-FLSEE-AMBRZY^Z-?C03*"?KJ+S^"&8]/O8X#$(TQWW^!EKK[^
MRTJI"SZU?K]QN'#%LSYG)],5Z10;[BKZGCF#%0A6M+5DRC_SC(F+TP][[[^V
M]WX_^W#HSS^<G>#V^5MZ=';RN?W/[Q_WZ;^[1V?OZ,$>K+VS-$7EX_YA^W/[
M?+^[3S_ /=]='IU]Z!SLO?IR=/Z.??CGWYW]O2.^_]OOYW,)@_5T7A<%3G,*
M+9$"\< PTHHK1*AV@7/G"TX>-V>IP9$7A"/WGA;9X,@CX<C";#02G%'!2"13
M+VKNHT2:%!0%[8S$N&#>\09'&AQY>J&K:Q&E08Y;(<?B'+<0E2FT,2@J[A''
MEB)EN4!P=M0YKES!BJU=098GG-ZQK.DI=^3X>V1&X;Y&)3_';.^',E#RQK_J
M^3_ZK@&#NX+!;/[@NTM8P[$QA 8;*+).%H@+HY%RG*""":\+ZQ1U$<!@N:7U
M)HU7?8[\]%"*^G7\U*CK]\-GE_-\9H-+78\CHM1$Q+F-R$@BD"2<:J89=^Z^
M2Y5>.K-ME#;;B+%[9:_]!3'FG24R"H6H<1QQFVH"M?9("E<4/FAC?>Z!U%3J
M-Y7Z&Z#43MI:-SAP3^IL9=MJ;BF(68>"QPSQP#4R$11;R8-E7H:":;VU2YIR
M_.>BSJ[GI$:1O5]%MO8>%0&K2!4*2<ARSQ726@8X-8P+#(=KTPRDIN;^F=3<
M-VSVR IMQ69<4D&"4TCP" IME!Y9T#00Y47!+ ,5Q)JFL'Y-87W+E52[D'(^
M&>MU3XE?-Z@??T[8\E#*\)IBD@9";@4A[Y=T86^)<YAP) SVB,NHD/)>H A:
M,-;6:1Q2:ZIBX[Q-+Y?%'DI+7LMBC?2^']9;4)*]Q@+,4(R<BZ D&V&0*0Q%
M#',NBJA8&AJVL=[>9\9_&^4';H3=_7#<HKZLI6"6$(D"LP)QX@,R.#5N)1PT
M%6(Y9F"6BF)Y>/.#>( W1$=>7?^P%V( 8O3?5@!1/?!]5=(\I+7_+-?XHM)N
MUI0^//O8Y?<TRVIXJ/:^T1T?4I*YY1!& +I5AB#KT\#95"I@2/2H\%9R92*H
M*/>=V/O2,P6^IX76<-OC<MN"I1:]8F"J.00F&VB+-#7\IRHB8C@M2.$*=^_E
M. VW?;]P1L-MC\IMBU::\UK1(AI4<!:2;2:12BQ74"D)YT6AS4UEVXM*U?GV
M[/,7$O=\,"5X+F^O@8N'A(N/"\GI)\<L!$>D,D@Y84$X>XQ,]!1Q3 O0B9V)
MNFAR#9Z=*MSPW&/RW.4\SPGL-2C$8'EJ72!>,(D,U1+!^2J&L>/.AH;GGIU"
MW/#<(_+<_H*< Y68%4X;8++"(6X\0TIAC3QGPF,&(,KB=TCVV7BU^"X9["_$
M@GXX[W"Y]PU4/"14G"QYAPMMK<+4((W3O <:.3(&]&(NA1/*1U\T=63/4"5N
MN.UQN&VQR8K2D<H8$54IV;WP'FG&, AF;$1!I8_JOI7AAMN^OS+<<-NC<-M2
MSCL+$:<P3 P8))J@&"GO*/+",RLI<;%X,#7X"N_P$\EY]Q7QWFO2^W*2RG/(
M"-P$_;D!ET?R)=>*L\$,"Q*05\XC'JE EOF(HN;2&,:QH!OL2WZY#/A@*G7#
M@(_D6*[SF@Q5CF")HB<2<072W1 AD? Z**R5QO:FTKUAP.>@93<,^$A>YKKS
ML!;82%\@+1,#%C0B:PE%UA>@SPB/762/ZV7>$*UZ=99\J56OG%VT5J>^865-
M,\'YX;?IB;1<_9ZF2%.+=!] ^^9S MG2W#A*Z\''!2N*0G&!7!2I>)\8I H'
MJHY6C@LL01,*CU9Y>V_,UDPQ?4%33+^GA=8HA@^-5^UYO-*!<6%$1 0+ J89
M3Z.7"X$B\<KI* *HC8\;YFA JP&MIUKIW:A5]P53[^=ARI/">06XI$UDB+L4
M'])>(@<_>L]!Z=+VQC7>5P]5SB^67[&#?TTA+K_^6!.7WT0@SU'G4YA0U%]F
M%/X*<$?7Z79,>K1FY/+AT;$T43&N"3*PHT 8 2,CC$^#E;+3D5K#;C5R^3N.
M3P[UH<^Z'@9P[BW?@;=2@"\.^N=Y9K(Y!\0?Y8G+XQ&\82];YN*B>PFPG=^/
M9943/(89C4?]P65YH5$_OYL&>IO>91;KQ<_#5K<_'+9L "5K]M[P=&8(FE>W
MV_\\;(8L/X.YQ4]JL<V0Y6;(<C-D>7.VK1FRW Q9OEE2$J@MI2X#V&1&"SK(
M/9BTU\TT7FO@;Y[=NM9L[8T3HM]O'( O&APW,3->U>/8_JZ/<>[#$]L6T2=J
M@I3&;1^^WV8'>_Z\39,1^PI_^.<ON,>'<_C.Y='7MFCO?4CF"-[_>\&X/7OS
MM?W5\7UZ]/4#&+'MO;^Z'WZ#YSD_@O7^?M;^^O'S_OE;,%?>D?]\?;N4GF1M
M\%)3@:(@!H'9(I%FO$ &>R:*@KF8\OHIJ$O+UNW__!>1^.=OC$7>A(W(TW#_
M_/>#)EPWR'0M,MTQ$M @TT8@TV+#_^!9H;%&"I,"<1X,TL)RI"U5&$M&0?@T
MR-0@TT8CTQV]_0TR;0(R+2:TL<"PC\RB8 J*N-*@,_E@D:3$!XT-J%,-,MT*
MF9Y7]]LK>BF5GNW[&N_]+"'S>YB9J[M0A&&#E;?#RO:2?>D8X*.G"JF  V!E
M=$F! W-3JNA]U-@[MK5;["A^5ZB\HI+N%ECX('G^#5M_'QNM8>M[8^L%XTS$
M K18QE#T0B"N&9AIQ$H4BZBYUIQX*[=V]0XC#5L_:[;^'@9.P];WQ=9+?5(#
M%90[C:R.J0F;3M/?K$%$ C\38KRF?FM7[3"U06S]$J):;_YWW!E=(FN&P>>\
MF] ;9EZX2T#K"8+3^DS+![(EUN1:W@BF3LT@_)).[/7,@;WYXL)P"%^HTC/_
M#(,4.6ZPZW;8M3R"V0@&AUL 8A4A3^)A2$D6$.$IE]QJ(VT:P;R#EX<P_WA;
M?\QC:B/WZ(U]@@S_!(R,ALT?E,T76V-IX[Q@! E%D^4A%$A%52 X75D(Z>#$
MP]:NV&'LGGRO#:]O)J]_%\NCX?6'Y/5%<X1JR;B) GFI(N*FD,@&R=*0%!-!
MWH.Q N8(WBGD!O'Z2XAE[/=[R <_AKU.2?BA+#AZ:7&-IV2,P(E-#ZPJ$&L
MZG8 M3SJ&A/AI$FCKG.?3M!,D%%,(\R*8&+!:$@%K*G^XPXV1^,!W6R^OKO1
MT?#U]^;K12.#:V!@6B!JD^(1 D'6^@(IRP.36AH<=5(\\')XH^'KY\+7=S<P
M&K[^SGR]:%!$;R7%4B$6K$-<^("T8PZE<&:@LH@B57)O#E^_A-!&E:S8&H1A
M, -WVC(]#VST*73[%^<AE1D/@N^,OLVX>"G.D.^1- 4OOBZ/YJ_JZ!J NAU
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M2$"OB88U9O'&B=D;<U C:.^1O1:]V=$"M0J)5,0><6$<4H8%)#Q31!$6I3;
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M[X_^'MLS>-3#_INTZBPU7C!!O0%">G^LM2(T*(>82GW9)%"2X<$B[3QFS,;
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M9NO@4U+#P^<-27Q^VVL=@,Y=9K,3-:\L5$9N:<&:UE508*B/3L@ [!\YE<3
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MFT(^<RFK&20K1;1<XGF*&(R2TC._N#A.10M)WX0EI;O-30.KY<-XIE/A()P
M0N:0PVG(.F=EI9;:ZV03JOJ$694XV^S5EV;>-L-AWW4R5DZ6.9PJPZ"3I<I0
MGQ\$EEQMZFQCRM6P<''3R,V3UFYS!<6,P5 69W:&HU#-;5OL(E5U>80#G';V
M2U&GBC27-NH$)$O5<>IB'D6!9L8N:2,[K5^R^*Z<0(F54H;XL'3V+-0/+UE:
MB^"<TFOF:I" KL&8LN-A*L$95KKTL,J['DW,_(OQ($T$3,\\C8M-GG8G.T\R
MY::T[_D\]]4FX+K'7>?7FMA\%?=4.SI_&M>=Q;J@Z&/3V$&O]6I\ EI$BXJR
MJGX2X)Q:QGG@X$6=5%+;R;D"+5F._2X S"#S^UQN27[__#Q=9:[FN=T?7)QV
MW$15^Y__TES\_"G](W^6^67R<]58U&6%ZF202E5ZIQW;2<5 $UH8 9&,:E&?
M,U%&\ VPO\N*EFD-&%!)_\( S3J@G^XYV&B#RVGJR@]O__SUQ[*L;1K9GLEG
MR1%^>-1>-=MF$KV=P. <!*[/_+I5VPH,1H=V@3LFN/16"<Z=$08L0HP+XJJV
M%8H*5/]P+U&8/V'1C7*R6CEY+]IG[ABVVGD;'%)6&; 3.4,Z^("$-9Z1Z,&$
MM#>)O^RTWB<D7= K%O)M)Q-7:Y&:+:?2,*B[QU;NFYG.NIDQJKFGU2<F(<W:
MZ5/61\RZF')58=(+)GDO$T=L3A3)8GPF]^-J+U0XGWB@@"/A_J[J3YO$MB^%
M64+,T4PVQ!5>FU+;F:TUND;BS.)4%J'7KWRZ@=7<I$HTS6_*Q%V6=:Z+?GJ&
MSA57750+9W<\[]4/Y,>Y%>=4F]*PWI[DX2W":;@];E8Y4_3'V1PID*= 3L,P
M\4#6;LK2_=D;1Y/%H9]J6HN:\&RZ;[MV-5;!NFFJ[#4A@<4O3M7J>=?HQ 5;
M4L;L$Z17IT\Q,YKB:I]@K=?46DVYN&%&\EPH-DX-[I84SUM:E\%:RP/712$8
M)T39 DOJG2Z"*@JB5(7G1=6&"&N&;X;G_=Y$-9E'\[]*JZ9)UKTFQ9'OG[6/
MM51.AB"0<RH@[J) *F"%2 B8&:.\]/Q&0?7<=JC;[;N9>L4Y+)KQ^&1-VH<N
M',_@<F(UGG8&OO6_8S-(C12!RJ:]CFZ2F[> =+4=6*I,G>'$WYW+92M%I>*H
M"?Y, ["EKG]]L'=SVWYG-3<+VKQ%%UE73/EST]+1N%*9NV$>YG5R:%".SS53
M,7W>]].;YZ+$TG@H#83J0V58/(T7D%B"1')F7"'<TMJO/YW*5"E%D"E'497I
M37 2KG\Q>>85/9(NDIS.)=R=;P^V?ELXHPFV/D:BR-?WQ\+PZ%+#;.\L30/N
M" +(4X@%X:B,AH+86ILH,@BI0U@BWN6.6M,,CRI$ K0Z7$NELY0\1^6UQ5UI
M4DL@!U"6#=63?M_GJ.LTAO%JV<\U=^D9&)SGY!4!CUM*_,)K@P,3KHB84Q<U
MH: !4!*\YP7E]-;-2E]7X/ /Z,NOP6;O@S+X1]U?82KMJV4W\GXU^9]<[N\=
M?6U_=9?MKR=?VGOOCKVGG!>*(5!5.>( 3 @T:XJT=)$ZBB41(/M%L6*>TKSL
M3_[FE9$::Y*?83RLA[A=^-(16@YIJ7Q998!J16SJ9@'$M=&K&1Z\1?+W2KG=
MM(U?E3!.FX3QS5C+IB2,7YL OMA=3F+-.4E^/<:CL@;$A RB<-(+3H1>6>O^
MG3N*C@<U-%W=X'E>.\X57Y5+>1U@75%*=&7!^3WTGOC;G8)NW T'<9VNF?HJ
M[H.2OZXX?>HF&&8">^&]*KX>%TY)1ZU%$J>9J"1J!.1N0;<TOBBP($RR17XP
M)D0<@R7.!\ZB5(8KK0QP!#-.%W*Q5T52+<L9;9DF,V,/Q^? *$#15V2I+&2@
ME-9YJ>O-YV4L.O\K@O[_YHEX/>&V_#R[K!T]-=,".S<Q_B$[!?IC8%4__/&G
MJ_MN7-F69R507;_1"TTY5 P H80 -'%/"\6M"51YZHPAEA.X3[7[M5P?P):@
MS"T7P_!3_<//OC.\Z)K+GSJ]#"WY2S_/QV&3[,O5_*"H5H(^(W_Y]E0L[N!2
M-(X&\,?7=Z[>WLEO_6ODE]\3>D<4=.W;>(?,O@<K3UO]_V\!L5:?JY\!SB-L
MS"=O_/B$[$BB;_KXMWB/*?Y-WWQ6BZ7/B[#^E9EKL.XK51NKGW"+9*QYE!43
ML71_>O$EK>#G)=M@$4A*#+EOU4E=UUDK ]514I?>+,'_!,I?TAD^["<KZ9.$
M(-X!<=("D[+C6^F$?WY2)),T@QO0QTV>]P;'^YRVC33;]BW;AA\<C;X#PJ7A
M'JDQ3<^C:B>="R'&JTXG-69\G+.YWN[.A_/7DGWR)(]JJA2M/96;\A-N/85S
M^S^+QW1OCS_[V#EFN5'/_8CQ$K;HS:EXY==!_WQ5Z.3-ERH]\%5.8PW^T'RY
M6="$/5%GSM$_OP\_'/;9A[U7^&#O[67[G_>7'\X<_G#XR]G!/VF"KN^V#X]X
M^VNWN__;A\Y1_9W__'YJSWWWX,Q_;.^]X^VSMU\^'/Y^OO_UKV[[M[8X2E/C
MZ/LO^V<GL([W^,/Y[Z?_^?IVM/\W_O+'X9O1_ED:%O7NV 1=%#%$1!2/B%M"
MD)(%0<X5A9&2$*+<UJ[$VP*O2[-X*#8"_&C=DIVNT@6N$S6+^D0#A@T8SH.A
MU 5G7%D!Z*>]!SX)3!<XB$"DY^ZZJ88-&&X<&%[.@R'UWA:%%<@0FFJ<*$<&
MPT\,SMGBB!DC/LV2VB9Z7=RY <,&#%\"&&+E'/>@%7+E. W2$J9E,)I&DR9Z
MNNM&>#9@N&E@>+"@&1(B#.9!(1LB1]P1CK2,!AG+"Q:I-H426[M,;F.Q/#7T
M*8'AYIGBM_::Q/S?D_*:O)X+]#X[C\F*$WENLF_5(SX;^7;OGH],[Z]ZOAI,
M/6SDTZWD4WO)<^&E-=8&T,XQTXA3K9 B\"OVA>$JC6$)<6M7,G)7X;0:7!]4
M&U^XY8VU\09UGCCJW+>+81EU&I7Y'B%IP7\@F>*%"JDA?XRINR=&)FJ*E.&8
M%01.C/NM7;'-BCMKS TH-:#T5$W]!I0>$I06[7@1L>(,*^0*,.9YT!9I025B
M'A?"6.*-++9V"=OF!=]X5-H\(S#;ZO_*V;*KRG<V><+&J[G>6G,#:<GR0-K;
MU-DY+;E0A0Y*"RZB-(%1XIGV-$:N8\S%I<OJRXW*ZY(#<+0?1J_+;ADON&SN
M[9>#PX^?VV?MRX/#MY_AV8ZQ=@Q,588B*8#7G>=(.^]0"$(:&[7GAJ1H[HY8
M+AJ=5,S%I2YLV]6P[E0U[;IF..S$3MG*)'1R!Y2Z<TF:XQQR56?]RD5_4)<U
MYT8;KAH<5U569P=?.:G>='/&_O TA-%POBUEW7\1 &,Z0'U2%U!.A;NH.G7F
M[B8SI0)SS<A6%GRG.MC.BM9S]8HFS=ZJIA7FY"3U8AO-SH9;W0AMJ>G ^H+
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MMNKASM/994NC0*^Z2TY(&92=9V?FY9F+BV[.4LE#2^#3Z?F[G8^AVSGME\-
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M-?ZYQC\W)UP8V(I.42&TTMSHJ%6TF@3*)4V-"$QC+CXMX?)NR5QDI."*:(U
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MTFVC9%G&*X6YCC0(?O( H&JN0>T:-<"E-FW-JQEVS? JJN':S*.6);VKXP>
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M-69>/>5+;QW/K1A.I0*.K%/K4<UQ#>99-56K4,VN+I9C:@Z&031FC&32)YV
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M<V3M76USV[@1_GZ_ G5GVMS,*;9D)X[=.#>*+%_<.I9JR<GU4P8B00D-1>H
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MRXYLGGA_&[[5G.]9GE!*EF+48!P3JW(B[AF(4F1,@CG/0T<I]XM(>FHG-^'
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M6W%* VB3VKW]V2USN_<81:/D[MDGGJ&HUR=<E^4?&$D!L8]J=5RHWOP>64!
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M?N87.#XFQ/-OF/WXBG_]>3H\^7J,9^]]F6!9B_YLR!64J7#^1_VV7[;&](6
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MCA!WEIFT&S+UJ)_#SV@*WDGC@F"F&%ZM>L5"+==K<W)&I0*F>8KCX64T]<F
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M=7ZPF%2L"BS9VK[3),_ $=R4M XY9.ORDV]MUC-9NJB@!Y*LMD Y*U0B8LH
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M]FK9V(&-12IGR/KS0M5VQHF%S"435M2.QEJ&YH''3;$]-O+THI,^.B2MD\)
MDK'BD]"U_F]D.F1DD'@@I\%JJ>E-,M9VM8L].G8TD7H/^=CGUNBEO?HFF#D@
MC6]>@RR05U.<89'S&FP-*DGM$9H?<&T([2D;.GUHKX?]JH7 %C'E:!PF!9J!
M]3206#3S!I!QY4.*X JZUAM:,_"[2C0Z('KN1>^'DK1T/OI??RS'6K_U]61^
MB2O]F =IO9$0?8Z,C *:CD75PMC!LU)H3HH"R:76UZTW@+6OHZ4]\64=:QOI
MK<\%]2: RP/732#VE-6T ;S]9#4U5^TZZC36RYXH% SGKF0"F"$P#4&RZ.@/
M=,)D(U6.NG7P86_4N2.KZ1"8TT4=.V+,]'PM7IY;I.BYX"&SX,F)T;QBY"DR
MZ5$5Q!(B[VU#NP77'IV$5@K=@#!;::.',.>E27/^\C^&.*&'?/GQ%K_A\7S>
M6"%23E8SE;TC$],4%FM>H$?4D(.5G+<N8+D9LF<[J+'V>HAGW3@/KN-=SKA-
MP.[0*%H+=._F43.-;[)L-577KG:^]:!#,2I&8"J%Q+3GG'GO!./:FJADM'HG
M5M..N;6Y_70@U.J@I3XI]6;T]70VG4M G"7N"%MTC'6OUL"T,9J%6F7.IY)5
MDB*DT+IZTBUP#L-T:J3(=9394@M]VDZ7H,FS#NE!: VR=DBW9-8Y49CG!:H9
MB9@Y67BQMRCH=3A/C2#WT<*.5A!UUNN^]HX!&C(XU)6[!,U[P905'H47*$WS
MTYKU<)X:0>ZCA1XLXYO3&1:YP<DJ5T\9M:GGF1:(M:D$LA!166F\3*[U=>SU
M:)ZVE]5(2ST<#7_ Z6PR3#/,-V.\^=VS_-4-L/?D:&V#>S]^5RL.C/>LP!YV
MN:W&P)-2=MXN0=;XFM6">2L+,]P':W7T:%JW4CP\\MWAF!TB][KHK0?._3X>
MX8_?8?)/G+T^'>4S5%! B. S@Y1HE1>IM@C2F=F8,7&EHW2M6XK=C&3W]M3N
MM#ENKHH^?+.SM)LW(Y++Z?Q2ZKRZKRT*K10L&:@N8S+D#-!(%4)V]%]QOGGD
MYV8H3]NF:J&?Z[2Y=QOR,UCSZGL%)U4L'W'R;9AHR$?E!K33>G%Z>O.OSNY3
M;S"6G@RLEN/84Z"[!4'&!Z;='G;"IF,J7H'RW-(^(,B<R!:KFVT9\BQ]R8)H
MUOH>T>$S]:ZP^:$3M8M2>R#H'Q\_3>:[RH^+#/NSRNC%$R0E6.;&,AV\8SYD
M7[N'BJR\YV!;Q\#6H]F]R;8_+8][45'KFBT7L$A ?WS\V_@;3D9US!^_CD?3
M,9DIKT8SG'R=#*=X';C.X'(I+/ J#^OK*VN9\EJA,@(TK"QE:ZJY;(/B"7)J
MMYKK8;UZ.3XYJ;V.X?@]D%E]WL3!!,F+8%R 8-IA9-&"I]7<&%$*2JM;G^?<
M".0),JJ=8OJ(X(\G7\<3F.&OXRJ>%2J[8M$[A4R:>I',@&+>2<ER<%+X#%%O
M5G"H$VMN ?2DV=-*46OC^.UJ.2S"*=7)GEZZHWCON@VW?=VV-1HVAKI2CT&Y
M6(R(&3!DK72*(EI>7/'6D^$<U>"V+VY5$GG]C="WY[=K+*)7"DN].:R9YDXR
ML+8P&Q*QPF?:K5H;J9T ]G=3^3Q2]&G\@C0_&_XWYI?CZ6P> CJ_<QEU3"B2
M8$[SR+3'VHR=9B8/Q$"EN"^B=6KHEI#WT.6A-\9M?L>YO39["-NNPK]Z,?LZ
M[H'R%B-)A"E=,SP*:A;1D:LM<CV]3\4VS^3KBG$/%Z5W28(["-A4@SLHU+""
M-Z73D]-C,AORWR;CZ?2/$?DUQW4 ?R-%_(J%?)E/\'V0#$+*AN1D;+5,7&#@
MN&!"2AE+L!%%ZVR-)L"?N=FOKONH#G'/0;REGRX&P15'1!F8$J;>&0:LQW..
M"<]SB56,O+55TP3X,V'[U74/24HKH%>&].I[.C[-]9PQI<DIYC<U,(33V< %
M*)"+8D58S[3VE@%H8!( G,@!HFV]I-X/Z=.BY ZTV<.Y[NVH5\"^*/3WB^/C
M\9\P2O4S+R>8A[,ZJ08R6BFL!08!:XULFDN!)A.K-T=MX$$'TSKQOQ7VQ^SV
M[$6_/5BCMX]CD7:!R6H#"5A)#LE@]H*F$@F+:X/*&6&,TSNEX$Y+IQP*I[KK
MXF"*GJPYL#8NR0A.,1$241^E9%YRRUPJW",*%6+K]JP'EAK57.,;)CUUD?RA
MIY!L,I;GI*<U!&Q"D#YS2>ZCW4-G;,@@C"^!V7GE-:$Y"[IHADI'XR#)!*WW
MT\-GZCV3G@Z&J%V4NMND)^>X-XD<<65K%R1G#)DD6; 2A>,Q>A^;7^QZM$E/
MG;2\>=)3%Q4=5-)3=N1GSV^"@*E%)$DHP1;.#.?1!J$D7UW*GI.>6G!JMYK;
M6=)3\,'Q$(D@Y!83*$UN,=!D4 &\U<E(YUI?SGJ,24_;K%+;*Z;/I*>K#M,2
MG $I:O<39K0(3$N1&.2,3"8GHG-1^N99O;<">M+L::6H'20]G?6J@TMMZM[A
M;(N\ISN^<=O4IRZ 5[*?G/("+6 NAH2?:=X&I8(5,<6 '.W@CN_NJ5WN1>#,
M&X288V12:,ET2):%%)%A1&N]#SS+UE;JW:AZ:Q,\/SX;2%0E9YIIM?H_TSG3
M3#,N,I/ 19V%*,VKZ]^.Z(#:A-Z/&1LW!NZN@#Z2CR[.4W_#KQ.D];A*FUX?
MXUSLH[P\5)N_OW8P@V*$+RE$9EVMX&YJL]/L#?D/64D?LXV^=42A%?9'1[F]
M*+4'"WTM,-H5!CI#BD9F)FP23*NH&"1%&SOM*%A<%KSYD=!M>!X=B9H)OP=C
M?!-6#QQ&$9()+%<):,?KG1I:6;D,4J,L,F/KZRN;X'IT1&FNC![R<3;N#DW
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M&^I68A^WD-D.#OK?C.@E?H+O.'T'D]J>[!MN<9A_V]=M>V"_,=250_GLB^7
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MD]<\X $>SMV'AT<!  %NM+/".0'_!_\;(/8G=]P[P)Z:C2DZ5:UB&)$0V])
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MY33!9Z4#4% Y)+4S]41 C3;>9EG-QVKH@LS# )_3>\T^J*0>?BKOVC[*Q5N
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M%V))]\6-4_5 PK9E+(5^P(XJM_XJ\4F=M*;MT:M(WD<*_L)E9D/'"G,#N;<
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MP^/MKQ<EC6:(JA)PZ:\;PY/ABNPE-%2O<8)_[5KF(*T$?\R)M&IR-3(HJ/=
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M+Q\%I7*%8HN'#5/9J<20?)%WML:TMM4Q?@36IUNTX.IJ6LW6#!WS9B*'RZ/
MR+@7%*CR0VPS;9K;@ZU.^R,BX;D(EY\A6T8 1;;6_)*:M> 0?A1UQ-B/U1D.
ML<X64N,RO2E+-JBKF,455P$O]BG::<=:Q$X?6W]/_8:(6"9*%\9S_>WJG,P,
M403$W(<F[Y*@"'4I#F3E0"L":;< :4A"D%_ I_Q%X1G!RG+@NO.&#('-[-ZT
M9$J\K8^S)R%A7X(Y,+;(/4]B0*7"2#A?:24KL4ESPE\V@74FO$4_.$&VCO 2
M3Q?C>"V[:R8Z)2(5@J+[)FQ,JN?-+\+,HY)"='!XN$;TI,[3SD@#L2EWG!,>
MM?'GU*)6E$U(IK'O^5NMUT\20C44O(QL.^V,'M8@)?M!T0^),UK3>1I(S!Z:
ME(^BA*1IC,;/?TQ-Z-EEL\]$P*>.".=-#UA1#P2R_F1\GN;%?UU8 ^)ND-V5
M8 L*_/W>PCO.*L.LV7M8H_\E:[-X::@)^LMYJF=@^[,(EPY5#GSR]Z!?GQ+H
M4\92-*+KEV\!;"VJ5]7@Q/=[FO%%VJI%QEM+MP#UV#<7:E1+1BL+Y<8.U>_8
M*QOM$N6IHN7F6T,8]B'9^+CB0\9**&"GZH%0&VTB:&XZ<7 ^/:]@264K(C5D
MW;B/K;5WV^'W=IK'[@Z-ME99W#$;&%Q0>;UCH.+HX]1EQD"H2+\GHR2O+4_'
MS9-05+HRLWGII =ZEAT3ER'&5E\UY7-YV@(^*KM+RO3-C(L84&.ULJ.5*<^'
M3J>WS1;VK6R7GSF/39/(GK(ED$Z>Q(C!BF6!:,^)KFH*N_GS5-OGM$*T 8],
MZ_Q2LXI:=.J37!N*:&?#\5RO?:-EG5$C7X^D&=:Y*J_;'!-?UX;M+Z70A75O
M<!IO=9.CW'I$3L2OW'1E*I<N6V#\24FO)U1/(Q.K&-T3<>]SJ+G/E5XW^1T5
M+:7=4&N:69RVF;^$# $?8NK8D+FG+3Q.*:TUEE-W@YX+Q9!,ZH^<6:HW9Z@V
MUS16?>]P<WXZ0!TQ9?A.#M/E:2$@V#ZM:WER*ITVP1]B&YS.&. 9D*%TXRZ+
MS:I;"<7R1?2P4/V=RIXO?Y-J$P4-U.R ;4_,AJ.@S$"@OP9ZK1@C+BOD')I.
M6S/Q>/)@<_3]G6VO+L-+C'9,XGNS<.E*0/B!MB-SF"EFPE)31]-E)M6Y_A80
MB]G5B\Q_Y[ZWL[Z/O8;8CNDNH_EUKFW2'=.VC"&$]>>8>HCNQC(Q$I*Q"B29
MM6/4K >3L'$QF2VIN E91U".*W?]C%/9N&AM;2VMD)N,3BJ4%P U<(!O ?6^
M6%,H<5W.J:* <\$>M::"&]-_M?/S+[SW'K\%[*>HA+UC63VX!7R.5C\%1CG/
M9'B/GRXB[CUV_<ZI>2:=<7*@3^/YMEIB[H^JMU6BXMPC!\.?YP"KE$L.C2EI
MWNM7W@OM5XDMR)-.6<)X\R@XTJLSBD<[?/EJ[;4Z=Q$]T%\JFU*2K6TR<@-7
M&6:%WKQ^[6V[RG'.A3*-+G8_,(-6D+Z:[AT"XRSBW4\#)A&9O;5,B$+%"9B$
MMF;@^--/2FOR52$1G6(L;!'REP<?GTR7\KLW,1_2G)S;)4=J2O$A=7TT.BWD
MNAQI!B_K^=NP <4W7D+QFWI[=W*$]KADN<R;3V5B MND&_\)$8D<<9&+>PL0
M$P#@]A2T/DKI0LD<;JE:R\C:8@/K"3\Q"@FTY_>5,NZM+IFH\'AX#CD"?99^
M#BSIO=;15/AH<S>A@']ACI6R=!I#GBL9GMPN\A3.[C[$-?F+JZ!M+EM2>5YT
M?@5;[VC71Y_@6;,:P). \@HO;F2RL6YP//E[,U0/3%'/^WTFT]RHW[_^0CM7
M2LY4)J:EW682K.E6/&GB=0L0ME]:EK-PNJ 38GOX>$"%%4 (-W->5X^B/=\?
MW1D-*+@*R'+1!1&L9O30;$,X42'9ZPW9[(LY+_,$%C+;.=86K]/!E WYJZS,
M#@XCWP?%XTKTUKY>6*X4W0+X!^>GI:U+P'5T*5]'&&X!B<J>'#?'+\CA!I6:
M9L4?LDIH+.%[.K\,W73BG4<TLL*YDL.+Q_Y:LQN^D\<+)'6?Y^^,@KX65YVN
MOY,+TRVYR_C8TWMUX=S61$-&;[9.P5.9? Y:GR!O+T /,,;C9W^4G4//K<?@
M%U$_4W>66AX%J'F]W([MA?TH*D.J=T:L$)<OJ->?J''\_(D9B]Z\?PL8]0T0
M2CGF6:7K4CV47>!;5WE6 /?$6E_!CJ]C_+,*=^M_59=9TBRE#<@T!G$C,#&9
MYT6ZZ\(3%2"YR!_KN73N?4^^#C4F17/"%1-5K%W"&#D'I 16.?'84F):99_>
MK4I>97LCLSI?#S<[Y^"$K1@O2_ZY-@4J_-HH^L[NEW>N&7FM,CN[X^A/XPQO
M"<$^'\W]50*M+BX5KJE5>##&]OW'(@XBZK+'7_^)E+\<DJR)/QJCDH/V-/9V
M;S G5_BS4^/E)=A[Y$=9?!W\9Y4H\96%\BPLL=9VZ=CWIXDTNZVF,U;];-,<
MU+ E]*"]DF-_1TKX%F" C3;W2I'D]5O;J@,7&C5'>-B28EIVQA:7.EGN:WY[
MQO ]9#4!W\6E]2$8K^<6@ O#..::F[59!GBM<QX<; <93O)7\!5Z0LY!%? +
MX@QWIX7^S^HBB/D !#JUG<O#R^'C1NW7NN!$78'T3YUE/8]9 9C>O/E&?9VR
M*8S:>I&JZBV !OQW9T;]/*9\=EBZKS1;ESM+A5E7L*!6**[04F96_YD8*1',
MUN9HN^8,DKKO>_E.M@FZS)5?ZU$QY3P^LV";9\J<<IEBD,[ (D&1'7M?3Y'^
M<?3O&"-KWY8>4UPFB<H;)353OFV5%)5L\('H <RT5(S0O;;6^:S<(LBI]7KC
M0?"0CX*_^^IN7]<IR+!#WR#E3:'>/WOHR>-^SOL#<(L_X!E9YCI_XSV\H9H1
M.<%H)<Q]I:W?7K!WZ,M\<V_U-6S!^A#>V_*,+DDK%K72W$]63F;M]ZVCG)X1
M9_MQ/SYYX !QYB0#;]SP:&4H3O'R'Z0Z=A7W"=O>Y#Z.F=1?FG]60M:4/><@
MNOW"]%4\AT3K>S+9K.8%]M*]L81[9]'+,2B,WC8\S>*+@;^)0*R1.E07"SZ6
M9CK71>7%-*KXK#/QT^S--'-//%_[DHDBV$JBB70S$1IH<AQ\4_2<]&%-LC$^
M[%=E&2O>CL.E4N=*I6)9#D9GTM'?$'Y#M788FXV 6E<C$Z)CG^66@A/A!(]B
M?A:[!A*]Z%;>H,-GO"J7P(\M*O7\BV_U'JM[=O^D30UJ"C6M.2J]!?P2AHO1
MW;ACTT<R=YL96K"C8ZL?7%$QO,W9=RXE?*J4M=7KCU3?@<JEE2GB#'AC>:7O
M;#*N9S/F):= K?/CW_/8_P,BLXK%0ZV:\69J'BXS^EJ#*[Y*SZ%49K'KJD'@
MS*7:U1^S(*H8A)FUL?:A+>LV><P*,Q^&%Z7Z#ND8VNE,A)&P.TV<VFA J27_
MX@<.<B:N19:Q6>*$/8E(BR0C]?5J#3#&4L8$UP/#GHT^EY8I +OPGITU_R)/
M>A1/43DP*K!(8^!\^?DQBX)/SS>070RY=VIG2DVHQQ% K=C[&<-\6Q4XT]GK
MP4D)1D\0S\%U@'% ;,6?DJ*_ "[;L0H*,:-&FUOZ6:_QXO9T3.LG/3OT<Y1]
M0JW&I:O51DC2SMD*^#1>FH2\K%&W/8%Z)IKS5M71R$IY&(D<F\=<IJ0_J;N6
M3>^7[/6$,"/B2EJH1^K7Z4.1I7#T+>"JB++>LNQK#3%G5O'W_]$L.$S*7G(X
MIODBJWF1XT0-$8&)?7&F%.P3U@)=^#!<,7:AQ];JG"$4$20!LG#=OW2)5 [S
M 3DVAOS/];8X&B(5<01#OLE^ "33<>(Y$7O? K[4U!-^$>$'FAFCG0V0,2$B
MI&8+UXQ,)8Q[T^Q5QN+?]VL$0JJ_O:MY(%](L!)'Y\T1L_!&;4$5VHHYRLO>
M][AFBVLQ1V"!?=D%Z?=Y;>QR%:,5Q+D[[M4=T7M+]G3[&E;5LYCT)09N*IH]
M.[L@C(1!/^"P9, 'V([?-^!1.AWWG=&S05DO9YA-!9*DG5PG Z>?WRU7,Y;F
M?]\V[2\_+N>WT5X$H@CQ*0RKSN@B_8'6<)GG\TOD?%8#<J[9O%2^UT'=^BUE
M@)A4C/P:8H5D+V[6O&MS\,[^Z"GL]_L%81^O!G(SEL'ULG8;2B+G.;-RMN^F
M]/._X/\B^><QC8[UG9<\$Y:_GQSS1%?1,#4K1EOO=($DAL)AVD@Q@T'0].W?
MSKS X1Z<U!,,X;IZ?$Q/#R&+ 4*L7'8@U-OSCYOF9,'A6$P7_YC/Q?Y'M%!/
M'%I)2^.;U02;> K51<RUY4WF[L0COYE16J_O>[1_%Q=ZV0-UR:*;B$2,3<:>
M0PAVK\A^99NAO5Y-'EFFK]\"NM*Y:^P/2K*_4-=Q/@ME2E'0O)XBOL_Q:?7*
M*["43_8)1F;T3)UBIV7VJFHS2_633?\.4EE)?!DO7^;57WQ<O =;C2GBDL=:
MOPR7S;>W H99Q5LG?G"N[AQ/1"<=FYF7W'B\:&1:9QMS2N<)BC L2^SV?+$#
M25C>8_1,6/_%>^!\\/$L0%2K>-2D._YUEX%@7#$1VPLM&:)[C34&$VQC9PPE
M5E+A+$S7_3[W"O0J4919=6PPR^>*YNH,[$:45;< JOH9D2C^CGJ!L5,#W@,-
MW$ F\:FGP>]4W_,!.#CR"F B,Y4_9H3]BCA(KJ<NWT;4R9/IQ"[B$M*,VTN2
M[-&>+ U)ZTD&U%<,>4D1O-805.'X^RC.F\:V0[29$K64E+'F3+\+>6+./TBY
MF^2RI*CO]FR_NR>J=R!#ES5?.)>Q-F_(8JPHN/] 3=7X:/O&7=SY6TK/U[.1
MKZCJB@"'E,*>\AZU\I^/)TIIGS>J@FEQ^5.*@W,>O"G_=2-PHN +ZG$F7/36
M[P[>BA@PGNW\'>GX7%:O9P=2#![FV4#%N<+XK&T@F3_&@Z4%$[A.%(TN^=EO
MG//O-*/;[XFY-G9PF<W1N$V,T0I6KR8:4'3 A!FX!<0X8P"P1)Y9J VOVS6H
MA\[(391UDM> ^ZHWU.46T.,U4_9C^MR@]MPWX!: 5$]8]^>?=JU/ 0-]_&LP
M?!ZW *:J Z5V*(4T^Q]O52P%E C1+.A34MIH4;*[;C/(&<AD13QV62%[5]N;
MHKZM %(.(??1%6:HI"\**V&.V:$&52V-$YLI3(:\6?4/350H%]FT*'O+\4D#
MWPFZ*.<WRZ"WS$-62$2@% N[YT912ZFMO#-:CM5_^T_8[(6'IBPC:STM>G6E
MHZL&,13H@G40)1K>B25'B>:M02G,[6GUO."ZR&^QCJ/OK+6=N:7C:&+?&G]9
M.F$MF)?"AJE[ 1$MJ["-&_76K:8I?D3-7N-4@\F%(QEBWZBI>*Z5#.>*A7P'
M/%G4@Y@Z1<14[9Y/4,6S.?0@HL&2O_K#;,(YBZ/^JY]BDKGU:/OXOK4#;>;\
M!O[&OP4$^S27%+1E[7JE1$U05U4&'[);,SRA4!7H&64\Q#Y6.9Y3PEX#QQL[
M>I9Y)S DJTO&9E,6*5OM_;C'Q@M=6RJB$$U&KM4*2FK<EWT;7XSV"JIKA,:&
M3"XO.K!4:,/UD3!S<HQ'(>9%[1A&%VZ=JEW1 %X1))>D.?D-_F:9VF]OQ+\<
MPKE@Z./8RG@5TFQ]D^8."J;%RL9!R?VE)_VIUB=L?;B-'<3(I?50N8@%4R4
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M\TQ&K\?W5UG/K"68OD@ -;PQ/!DP,317B6J^O6]"\7'CA +H5[UBW].WV[<
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M[Z(ILJ'B:U8XS^]6[O/8G*%B4Q\!BY<,MC+4NHR'TO?RA>=F T[XR$=Q8K;
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MS$=L6;8/FUP!+$T=BV9"=L[M6G(G<QJV6S<3]MM\@=;#>=S6Z_CM4 702_
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MWD9;:?%U<FMFS*;D]2,U[9-GV0U=@1HBD<97 #VS<Z/Z?DEW?D<V&QURFFX
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MK\N?WO]1^?N/0D\\DO'U[3/::IV;+R;HMVD="#?XZ(<0:DG07RJ:*@#.$DO
MK]/"_X2M]_^/__=Q-?U? %!+ P04    " #(25=6?>?(NH;\  #!1 $ %0
M &UO<F8M,C R,C$R,S%?9S$P+FIP9^R\!UP3[Y<W.D@5$*0C+2J]"]);5 0$
M1 0$E!:5#@("T@.A22\" H("*DVD1*0I+=(%I#<!*0E2! ()8 B0\L;=O>^^
M>_?_OO?NWOWL?^]G?P\Y,Q,R,SGGS'/.^7Z?S#/D[^1EX*R1OJ$^0$5%!3RC
M_ %D)&"C%^SN @ F)H 4   , "TU%4!+V:*BB!$U]3^L_PA@=O8?M_\LS-@
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M[*("J*G^K_8W[6*CV'6*<@UHZ/_8174JZ,\.;#2T%Q3HV*^:T3_PY;BH&,7
M>2WC36W':>'+YABNAWYCC-PB2DA1[!_3_L&R_W>&1?^[+/N?AOVS77, ,Z5C
MGF*C9@/  )'P-DD"^$O^DK_D+_E+_I*W2>N.> 12O5W8</DGUB#>MF>T"Y<[
MVEMZ>C)3AF[_3/ON);EQ%O2G#KI(#2FIQKKJ>_@@PT^(2;GJJD>/5MS+/WW*
M?AA'8Y;Y[=L52^I,PR]5IG%D@+=5&)MEDK_?*22%64JJ0O\PD#G6*3USX*LP
M3*UT\XL0*_UXI(:1M&I/^Z5Q*#5ROMK184II@<>PUE1Q#4=:E:U&SYR,"#][
MK]W/9?L%Q$Y0Q4*NV-MV+IX?TS(NK7O1LY8=SK7Z^<&D3VJ>G_;E*_Q/S/0
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MKJ6YE969KM0@V]&=];$#VW K%<Q:GEK+)R909FUBK,Q@SKR8_MX5-2:' C)
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MYSQJH\:\R$" F^G[O!\_81_!9^H>:0NT2!>"Y,KY;A7?3HHV,PK@B\[.-%Y
M7-Y+SX@S3NIV"6G3NN5N;IDMLBZNKJ[*Z#[4BV[:M<V6V]O7EE\N[S+VB8&=
MAFHCP^RKN9,=!>LT#G*N*.Z2@5-^0Y1%S=LDZ8T/^- GDOI/1=UZ1'*=LC-/
MTG-['GH\E#9EN[=HX6URZ+6 >,DH\;;QTM][H.:_FOR'S'YX4V32]+DU&F4<
M[/2I8>'GP%>FGD\/&@N+A6/2&I3_GR>J<$1!BE)Y\2]7$"R$N[#%OI7T-!OG
MM S)AQT'+4QA@\'WPH!A46\-C%]8N.>),\'")P;RD0RD*F_XS8S^&O&\7RQ:
MN F]"@!^IGD7,>HK33981#*,*;[#-'J)LM]3C?XWP8?7&EY$I>XEV]8)1\C=
M)2EC6N^='->6CF=:P%#/)R]00NM$=S]"A0RXP_G +K&6!B3)(8MXDM%[$OWT
M'3.]\+'C*__;:39)$8M%>_I*B!,^)1A1)JVMYF\$ZS[A'AFX^,@4+WH$,NF
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MI1@I,?]P]SZB[:!$2]WM\9Y]\92_SJCM._E8X=HN\$%.+T?ZOY9Z\]K)@O)
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M%0>_C8SB*A2+Y#*]9W?";!836+<P-/WB>29AI";B9O:=%=/?8V;E\?;)Q&H
MQ3WKC%SO)*2^S?O!W8$8YH(X^:%B>]T &Q<6?$*Z+M+XHH[/B1T)&[$V!>'Z
M+5! <^,K.&92FD 6&#2R#><T3._^=NZZZL\G5\ZD(MP "-.!\:& /CDU0Q/_
MZ%?8B4MOK3EN^+'1X4ZL4608IH@PA2)4AC5C)!&-A-NXBK[UN?6DG,:HHO'\
M^V-FZ>D)+OOJ[UVYWZ:>4+LA_=3(U9N*$76=W[HSZ5=.2+82>=GV6[< *KL
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M;#% @@J5._=NWNMP3N.6*+-&"55X-*#;L;3TUTOW\R#5K@/6B: S/@IR(#;
M)VAF!&_PEA2;SW)BK+M-(_E,/X/;ZA9:DCX&N]^F1V_3-TJ#59 =!8I4IYQ_
M3M)ME@$M/F'E1TWE&FP%73OE;;_1+76T89.2LG!A0.;26^ESPB=<F3.9CW_9
M_C!7?KS9P ,)[+FMM)T!84LA&TUD.*5P1X9-$[)B@ZT,#::/T-\;CDS"'GE)
MY=! %XZYG#</3.P[F 27<I5Y+O:S!U +9HM+,$/Y;_(NVW7 Y"!<J3^T/BK
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M-E?<0]0F<&CF;R".S'&>8KY2+*O-&^O '^J[>51J,:C1:>7DE6VS JI,3-2
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MJ3HB+C%*<MLF@8YJ)A&;P("Z;ZLHGYU;#*">LH-OB;Z0OGJV35>M:/QG**;
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M?VKMTL2B_S]7R=RTX0J+L32!2F8#!Q6ZO!NF-T_I<<5C,X_DQRWO\E:"K$E
MG6S/@K]K%;+ES[!LS0+ET/L"K+!GOXZW<XWMD"W\0(:5YHB0B%QCKB['\,^M
M-NP+$)8M\F=W*9(Z237[5V?0?JSD-G8+#_2O_JCS#SG_D/,/.?^0\P\Y_T?(
MF>!V0^A!:-I1^BCS!5TL0==F[^U5_[H]M<&1#S#UNW3NND0MWA. $]=B_G/?
M4/_7KQZZ3Y#":9.7Y>"0 9T>*9FLLW6[CWW/0OE\V5-2FR'KBKC;(.-;"'?N
MA$B;;(/O_XG0A1_OK\I).M0;6KPPN_X\5[TN54ZGRC?I?LX3;Z5K,LIE-@IK
MF,_LP*DH,,4L9JG*$VE=.:23-/6>\F/I@.:IG=<6:FT$1#XAWCIW\D!5^HMH
M>D\SN&JYT5CM"ET[5K.*L-?K=LB\T^?A2^50S8>,"D%)D>-.JLEKAPG&5%RU
M;M&%O?2U0O]>E,[@[U*_8PZ;T+IE'TQE)@K3=[<,B9XJKWB7Y?@[;[&X$^-_
MFLNX6O1M\\;K![?%<D(#2NV,)Z?$FL"Q2%%=+<M@4$..A^?%A+!?"^FW(<JJ
M91?3.J33PD$^#09?^*034CGSF"OL.3X&LVK*EH[SP9L^(Z^Q+C[^X*CZJ-5,
M>1_28%%CL0(GUT3.,[6/,82./ZERG+3>SVK0-PF9EGVFS\G30QO[UD^_8/9&
M]EDT:.%'=\)G6-=XH,Z?W!XT4P'/ _7:.O=F_'NVY@6107;4<"FV/%#_0$]8
M'&3R$ _DM8"<RX[CW][]8SF%0+=U=TP.ZC,1F@WJPQO,9V<_DL <"+1_&/%D
M>-F+3)V4F^-#(+9X"2S.,;VS_X'AF>"EUZ$NU/.TQV-3"GNF<=%<P;FI>LZI
MJ7U I5<,E6'34KS)MO^4=55&/O;[[M-DIVW[)=<TQT\ESG=#2"=>'-<(8%E$
MG"MSG)^F$$-EP6]FP#07MIY'-0&+!ORQ'0V>9K+'YO<9WZ=(/])!)R)$!HP@
M9>X6X?GSJ?%EUZT2M$BF'7<$4C*(S\\X[<); BS6=O91NF\+)J9:+BQ.^SJ6
ML1_/=)[?6GIW-/M H.KC"T:_WHTEWHNQD?EQ&E-9S+?)V]!-3>@.'FC1/YT'
M,I_&&":?_*ZD(D +Z$O.+[ X3,FI+!8NQD8:-AB-;'CHIT^=<*W#)+P3[+8K
M27]Q@W0EQ2J?%/1C:2$0>C\?.,I2!028L"&,KMCN6:);X#C[KXFP+"<<;L_C
M:.\[*U\4'G> 6,1\6],H$VG!"Z(V(]??OE/JM="N]8.=-MHC+VAQM<D^Y?2Q
M5$L-SS4+%4@K7JJ<T1,;7!5EM_]+__H1N8EIW0R*[R4998.]7>VARBSB-V05
M<3& ODRF33:']JX%L'2)[ #O?"B*5K]IQ'(]^,47-?V2UFFZ^6<K: 4B,8."
MK YF(]E@/K-"?4#.)GW:1)S\1G=)%BF^<:3I/DK]BJUU_HQ\/JG.;-9(^+4W
MO3;YR/7B'WNS3H4DYZ??WE?IKY/CY%99!%BSU 'IJ>#XZ4'<B;QQ_ZV8UDHW
M"]7L@O&??J]2.T9URO*F3<]L-PIM/+-F< 3SH7'J[K EHEWPB@ZUX?T+Y[$T
MLV_>E2).>IB:-L<,"UKWT3.&6AFC=S2:(8$\T#H/) !9_. /WMK9'?D&YDLC
M< E3,YP7W2H\T-E:C'P2Y)>C\Y]Z''V42)PT#Z22#6%N<%-5QF;?)VZ=^OT$
M9\_L8Q$$^5V:-\L#L=S^:<> ?W4%'YE(^.7\SS)2U\84^3(2_\A(5R']D2$Q
M?5DL<8)_>TP6G="2J[B*[^$T?/"8H]SQ_7:RI7>I'1[TPY!"D.2JLO6&\/M@
MWS;.,7:A0S[,.YV4A'TX7_](5<"^-Z/\>;/RLW,'"?=&GASU.6W;J8:%:S,@
ME[' 7/!'MAT>^V2IW9TQ@7H+0_Y(N6G_P=TS//C@#$2SKRK_V52$'-NL[8IT
M7O;Y&!>KS"I)-O&@<SHB[;=%626Q:VO[5_SQTO2!%MLBI=L2=U<0?5=Z+3;;
MLZU-GC]<724 JC6+&Z4P%#6&@/+!?L'^A!N*+(@VOW/ Y;I,@+7$&('./C=.
M/9%4>D^P4M>0/_U@X?143>QIY9CS^2$?'<\:@ 1 #M@M@1UW4Y04NO9#+8,"
M:XY:#N&RK4Q+,](L/!<1 10!>6?*ZY%IQ[=O7SAX2R[[?1C/J:BO#ZS7:DH\
M@BDS4?U?,?GV:.7E:H9.VG$'VS2;ZU=*)F62 3<>B/NE9N6M"&$'VX>.:4FB
MV1'/$=<:W*@7T[\1GI&NJ[CIYSW^V3NEG8R7 @H.?0/"H/VZF96I[UZ[?5==
M>0-3#QESID(7C1E4*O0K#T1R9R9&D\%-&LB$_6ZQ=3T?/:S"?T6E5+_>UF,,
ME** 0\NTHU&LT]P?8 D<M,C?VWHH&.MY[M:C$\&??UBH"7#2SZF;T:2D@'/T
M!:Z0?C@9HP1(M_WD]BD=9_@41,&7BV'J[FK[/Q\Y+;[<MOL,IH@'FLI#RSPP
M3)H4@:4[<#X9.=)O++CW6G.J'W]PDZ6^3GUNX97[^L]<S&#$,!A;G<Y2@AO%
MM;BUY405C?:<>&IZ^^S=LST1?< 9EAW@3!6(9FL47?CH[E\SH5VCOU\N\/NW
M8QXBOW8N7=)8<;;BE(0&HPATFTA%L ?#=#EEN6K<CDQTP>WT^9*\3W)O5'%.
M)2<#Y\Z 4 L7>2#??/;5(?BI\+)1ZT,IXW5LDKE"QI5(5N^UVJU2.HLK)/@.
M?IY3MFPB-CH;D2_7^B8_"Q5V0.G*P/R)Y&G\(TP+QWM*H 6LQ ,U7@JU$01\
M*8<QY*B <_3!UI;<(]7@.6G,WC,B$-+!>FTA;B]:08L'NJE1W\D.*?6<GQ2]
M6%.7^]9](_OU]7@A[L"?!?GS&JL"5#1MF;+\+ +<"!$ !%J(V= $7$!^^T>H
M!TGOIEU^D,"\QEIE(Y.HA]C71\:]*CM&K4KP3<6O/=L;I#9_W[SX=0U-@[%A
MR7F)%PGPTAO*2PN$7(RW4@WYO&=3^9H/FF4,#XQC1@.^URE)GB<W+E<.Y+E>
MLT+CYIN5$S<Q7.'KQ3A"1<-TK#,'[ H]9C^[78@^"1PA_MG+$5RYL1A##[,"
M0BF&M%U4N\_]B]E6WE7O\8-:P%4-=.& \V^^JVG'L+TY_)@2%,]6H6HG;,VT
MO!'SP&*/)_$15F#N69GGQI6)G",,)N:3GY<DKJ[WP?J@[I&K+P-?,05M/D1>
M/74C$3BVS"1S*MXS5(<8W.]RJIE'[WI;15-V=K7G@N4;#)V'H<+K& GX6<#*
M-Y1BK04_2M'HL"%I'<CZP5*)U(\ (0B,C4:$%.,W)F9=6\*/B3B(OW (C];Z
MZI[P(O1 1'86!=VVO)LM1F='8)+8I@6P,.M7["]+P87BEVC)4Q+0;'05=+&%
M(/"G) MBSR V)6*Y-?M#Z?8Q=X_Q%,RUG(X5HH!,$7*J"J_6!S=DG8,;!2=2
M* M3*Q-NK[22K57/?)TP]XJPE^KY:;.'.\3=":1.17E[T*\0"@"2HGB81WN^
M1\GWW'9%#4.F,>?S ^U1M4:W,NR[D7&7]KSYD_XU>\>.'ZM0\\K8+.<#TT6@
MG5[S9[OJM/DZ\-=8%SP8*//1UWM^GM$D>1'6?#]YNJ&>*WB4XF]TBG49;DE_
MDXST[2L8"@XBZ4*.WIW)UCSFO>:6>"3_S^3P;>UL5\Y;N 1=Q=J]1Q:69T8?
M+]Z[HV;C+ZDS&[H7R (T>_H,=7V]%?,$YT_^4YG?K?"53D14W_=>3-%?."I7
M2)?^?K*=L,.GM@8PSF/[#"EG[%?<Q_V_N'OOH*:^KV\T-E 0$*5(C0("BH!(
MDQK+%Q 0(B!$:5$1D2X@$B D"@)2HR"@($2DB0B1KI2$CH#T)C4%!>D)0CB0
M=N/S/#/OO;_[NS//S//.O#/W#V8X)\D^>Z^]]EJ?SSI[K^5_1M=UM7X2SQ58
M9 #@=O5O!9\#Q\9Q#?;D+/@3_;%&3X&"HF>/MC6=N@//Z0;RK"S0"N6W=K_@
MGA.J0IZPA9<?U_G'-=QZ_R!DN\#AH+K:/X$63H5[EC/'@52:O#D (_6L!CDV
M)/=#/U_K44$?6H%(,HU8#4SA,O:0N+$4\(M2LN7  3WKDY&"#C%)W72*S:_>
MYCEYD:?8.DE,_.:,?&O%TCBLANKYHG/!/'#]^2"D 5IPFWD.V"$1DE0>S1ZC
MZ6 H>^ZSG>>[29:_=',[PP "?1BH#Z4YM: . :=(+ OE>9I<@KJPLT*S=9;P
MQ2L>AN-OT,UX,/\J7@ Q3%F(.5F7O/(;=2+\RD/X_-=)C7H)^NHU]>+=#&=\
M+*VH!76*%KT=N\D!'?$,R9S-9+N,OK*+R9QIE B7;&85XD\BYLBUK9TCAOO(
M!YF>93PG?631"L+)QEY,+]9KM"=T\E@KEFJC'C=[8H#-Z^B%UQH-/A4!_T>W
M'F;E]UI@<T$K<F%M)A!]!*^/@)"-"XIN 1EMF=9QP27F/R=,0BXDE<$9'X7L
M'%T/C&K#A1%"5O5C9TTQGUP=2V8<5=89"OF![[:;U^%9$*H]<<*]2BB9*,AT
MPR'BM]NZ(CZM5'[^*F5G'1#5>"Y\0'-S8VC-@/%@/L8DY33/KV"]PRK10"W#
MEFD \.N;S$$D'LA*IESD*V4-M3@9Z8\16B0<P-&9PH_MP?>L;U(:." ZCI5A
M+,1THC9R0'$H183Z/S0C?*S7N/7V!R<OTWRZ_.=W@E%DS&HXM77.M(BN?@A8
M;D6=J.\S+%%I3ZO<%"VA:=)CJ9#FK!XGM"A09$)E;C\[>)3^\Y^AE(<:V#!F
MS]\*G\@30(@_PQSI (SF+CYF'P,""L_W%Y@(KLMI2?#ZA=]O,&/SW2+/>--K
MJ:R%#LP1+WZ>;'*_Z-2BONE;Q0-^JYG0=.=]+]OMX_"Q:_???'1:UM&8<>R5
M:6_HEE"XDO8P[(A7^T-"Y55[0(;<F/B)<#=!RNDA(ZHQQ/[4 1'[",<A2Y;.
M@SMO2G^^M/A4,BI4"@HRE@,8),(AQ-IPRRXVKBH<?(28FT*$9I)4V[KUTUP+
MZT8"Y'A<[6,N;>&Z<9-!]+O@@VA2@2S_F';$?UH>_FG':1<!7%'ARG&NY<&-
MS!Q?,*OB@,I.<T#OXD$4O"IJA"B(VN?<+)38X,%=N *60=C3ZFOIQY2&M8/(
MX-5#) S&\=KX[&&:*8;B;?!816%,?.^]R_J1)J@(KNMRA;@1GF/%")[$O0"A
ME7#0!Z7ZVU'X)>Y13SU6\?33SN[I9(/MGWR]K'0.R+M4ZBHKO2$B#X"3=3!4
M:/N8?Y#?I.L;W=>ZT2?P$9<*598BEDO94X2#3.VYT;_SW ;EFT3$O375VE&W
M]^.7C?+U8]JP\IB\5.BUZD::?X(65,AQ5NG-_MIQN5-I$9>,3%!J[,ZPA>=X
M602\U?@"D,O0 - =8]OZ^:7J;9;+A,VFW&2I^^C8=[NP+YX$:C)W /] 2+G&
M1X>8+D6M90@> ZGHRB$_37I@EKFKT0=QC=VGU)(YCV=X/02:X=3,/CG$-"E<
M.TW/DF@K__GX6]E[@M;?;'=L$?\GX-J%)&-IX#[X,R VV^?]Q6=.J3O^,JN$
M"Q0FERF=;81GLWR6_3&H/;&=DY4\,QZGQE^(R^AMYVO64#TZL(>8_XSB?+0@
M1SS#"N:S3\<L27FV-@CJEPBVP2S/ENR_MM9L;VIN%(WB0O?F\^@'_1C\(58^
M,SR(#(E\C#^!'VNXHK+\0GL]@Y6R0FRX'M0WZTW?(+EZH_A86X2)];+22RE'
M@GY]=849=\;O,<CQIN  9=YFZ#X@)D+I)I!-8AG85J=VIT]&7!*[.C6 <=Q<
M!;?OPI\;&M95)VTUCKU1< V;[F#DG4Y<ZR_4PW$98#RQ,B.1X"Z4!!9!!L]A
M)V"M1!%#E8]>/<'^)4NZ]59OW9],E^1P0)<&8#_0T@0_54@;O (6TZ!+[1X;
M-J?QQ@G@L<9IA[/$K6I?^08>W^(36KSFW#D!$2(\X(#V,&$T@=E4,D'L0>98
M@1L'!!8;RY S/\D!(033HN?\IT+(X%:T2+:0*Q!'=E%R.!IJ.C2_8^LRT:&Q
M#$^#?X:W>$+NHB=KY^:S[WSD@#R]Z@2S!+KA.U'(1 Y(8U_.0_-%)_@^]#WH
M7O8(MI*W0^BYK,Z@KS9.PFGYKK>J-0FK/XP?71C+CEQAQ0QM649X0V.6AAZL
MJ9:)& :>[*[+>299#N<NGV8IIG<90*1KEF>Y9MXJ\]GB3[B:<R7UU\D]9B25
MI>Z4R']7STX%B&;X,T\"5KB:# K\>8[HH+:(@G;CS$;G"7D<3QTT&ETE'HFZ
MX-BE^\S0)@\1?[S#9<5O?ZX97F4!S(52*V2& 8*?[-!(4Z?HMJ(%ET->%$?[
ME=DTM)[]RA>$A7O1U@%Y\15[Q:>,4\N2.=@/K@C;/VWCM99^ P*] O5O<R6,
MGE)>UV$1@-/<0B33?\[H2FN=65Q5A)GST)3[3*+XGOE:X\3&DC3:^.HX-82,
M>:XPA+Q$DV\),RZ0.+E:ADO7$TG^RH,7_9N3$2E8"QSZ6_F*-I9*[]).<C0@
MU=95$9;]XV0<&W%LOB"&'JH/S8\_XDTXTA!,'6\-JRE'2G;/KMWSUYJV.&@K
M&+:V4+ G:(D0391ID*%5M)<UR%.LE-ITEL[?*W]K\0XE.@9K15,O^T_XJ3]%
M5Z3A<0KJWJ%E4,T= >Q,)T&E:Z$@HNM_9;'X/W;.XA;^W/A]:F>TMJH%T;IA
M3*F\)@6QXKLW*Z'#7L%,EL(SW\%S54+[SWH"FI0;EO&$ ZJ$U!CS,6V&.: :
M?\K02L./4MY)OX+^C*-LQKK.,*8@]&M,0'2ST_)Y;_9,*CS,2OW-S_MOUOC5
M:\=^SD7X]RC6>U$RX9J+%BH][,/L@4QB.U2TIW )<A@91)I"K&8&1'PR\ZM9
M:WYUL#-#7J8S0#[QCE58]"-RP*-R+5:!RE2O-J#U9B*RTZ9]B#ZB[EMMF\#(
M3V4*!E%JVXU42/V198:72B,(#./10?#*X\"9WHS;><(=GSI3-)\VS3>$<:%<
M*+5PC#T[=HOI(C/ZPVV_.CEA*^7V.[%)O(,3*'&NT/NW!16"P6Z@X)7KK%
MRP&9^WIW]GN[_3;5_EPMEYIV8?)Z((IUM;F^N--=97)&=QS*&Z<AD2,IC(LJ
M.=C>]TKUC)_UUAE3@9D;R=VPZCK_LNSMIO5)NU9(E2Z]B"F?YPC^P89-0JJT
MLA*$MK+HJW]>AG! )3ZK?1?Z;5RV1&#5,4D/AFUPITX'>P86;324%F6M10@>
M%26;FQT[=7K+R[!XN2#U56EA%IY]"6[$M0$;W)]7$EGH)0YHUU(TXM"_N8F0
M=N& Y+8X(/@#].*NQ\C#?L9/PO(HFJ5Q??<HE\$7&B-5%B!3O&SK6#J2 _K\
M:YL=']_H1(\!=G+9WXE\..8=BO+6H4>-1A3SH]VG4NZ?OV#24JF\-*$G_P25
M1NWOA -GH*WH>.)QU'%$ZK5*FJTG>_^(FGJP:$[WJ9=#_R2)]^RU/?[+^I(<
MGC?YSPJ!/_JFL\F#CKQLB<!:W)E2'N)[<\++6]!C[@C#45*Y_1Q?65+HWT]R
M[6M_OW+:T5R$3F4NXE4144T$GK..Y@JTL<*,W=U_'MX95#UNJ><V:M@I_#[G
MYSDZ+M=W=:ZJ-EDY[^;?/15RJS?V/0&M'$#>XM*)3=9'IB;C!FJ<<$R;E=G)
M5,B@W]%Z4';;)-9ZH#0_3G0?KX+EV>%#,CRP,P?=AO!C.*>8\E=!!V#:!:=.
MV3I_G#G)_P&7%8C-T*X#B[=<6#%^4+)P0S'_8T^ZSB*?[]^/LNN")E9$*>AJ
M=6:Z>B2:KM7% >4'P?X>/!\A;-S$<XW-CV$E]LM>)YH9(_:_$CRSW)ZA?]XC
M+,_XLS2OT[N5W^.?[;S '6-5HN>XOID#8KV*T.2 _G'YCV8F"#0.B(IF=QN_
MX8#>JY4L $5LDS0CKH\I:-OU$^* 7E9#S#F@Q:-&%=Q)?6=\[[\57GM+Z=\1
MM>> :M&;7[!VS>@-O3P.R!_-;:6/VTJ>\4V5=HBO>CT5RWTNA@.J+IE<_I<;
M"U]*V";!Z%4BZS38JIFX<>$_&SAO5!:OK+27.Z+43@[(5^BY^"1OZT&D^KM:
MICWV2)GITP)EWU*AUQK:S9TG[R8$B<D<<IQ'>T'WWF2JL[)18"XY=4G75X_;
ME+J :+Z=<5 7')28.IWJ@.+MYH"J_%>%/S&O!<TCG%H6U6.12IT]CZ9BI]1A
M(YKJZ9\NG"E*C!_\E]T+!+WOZ*GS3#\?MH1)"Q:0VTKA@*3+AI</\* *TG ?
MYF^AKN&5>ZUQ+&3*D#J[L:6K+#58>#6J0$3P%>QWYZ_<_UWE^&XP+]W=+8P+
M]I<U[,I3_KJ8"N-ZUB0"*8N[\##)$'=P'$$JV/^HRV+%)//2J-5:NJK[]&#9
M$ \'=*67:^%7N,AR?Q8-%LD61YH-,'T#"IR[*"K+RZOJ*QM^US=2W(@[?^"Y
M?W,=05=Z&6#4&'@/3QRY@PI98420(\[?)X9KO_+_8'@O-?M'EU<CPY0+!8SP
MD!](GVH:K#5"G>LT[^++TU48_B*FE6:>\I%\39^,[67*X04B=E\^H:XSSW&=
MIS[3ZS.@&E"P'(0P'G:JS[F5:2"Q=TIQXRJ(;Y6M@F[60T$0BO HXQ. 4S!9
MC 9MG;HEAW>QA6^&W%^N'7'3WH6:B/.#^9A[64_99Q#A]*81XU- Q?(EE1(@
M,)S_]:K"8K#<VQ>0^E0G\%X.Z(Z /]FL13U>TC^I3.LK%[.*W#0_6A6X]\A1
MZYLYV=ZK9WII(=%GD4'DDAEYV]C^SR-RY_IE QJA-IE7RG>.<:4ES$HSGF#8
M(J_23'YN$"<!(5CJM6%)CS_"\K<#?BV\VPV#K9@\A.^%W,?PL'O#7%C8J*KG
MFUD1MOY5SM%W.V"+*="Q^LG]:1@NXB95S\H\9B57XXZ82:?H1!U_<29QX:S*
M=[8:JA=UBBN9:'8/X6 P>#_1,R#IZ!0TO#Q(V=:P\5//%AW7@%=D:@WBSR'D
M.*!6_(E*)Y:\'52-PG/AJ+IC/Z!)U6R%@ Q56 ED%T//.K]5]O7 )FFWQG/E
M?W 8]%V(!"*#WCS #/8/*.2 [B[2'/,_#*$V7X_P-#%5EH1D 7UU,!<LF6=2
MEH8,VI2'IO!=QWZ'.[2+Q"#!(7]%0+5:>%XXDD7!==BG>$<]=(,+7Y6WM7[(
M6Q#QE$H@>S!/^S\;0TD-J>.J%8?O:#0'?/A^/_/*5+AL]0^;B^ ,=!5F)9KA
MA_1@%:DR?7UU6P!?I)&\TV_:F\]6Y3YL*CJLL6<.%D7P!HLB90=)GZGKS=GH
M]B/=QN.RM7M['QP1_" %E*R>41;%/(?<QOR N@)[*/UBR&M :2%@8$ES>&?5
M%O";KWQB"EGT>$ _0B62*\HS" <.J),H@E)"L$EGICHI4E/'RYFWRYMQ S@Q
MA&UG!QO\96A+&<DP*)B2\_ C;Y6A245-ZGSL?E?9KT,-2@6=!3]FG;5'RDO$
MB/+!?@_X9=)$;"ZV_,6Q0JQ*[%PWPA$"V"R2Q4<K=),>40Q#<*_1]]<!)>Y#
M(7'$:L5RFCK]64:+XJ[!U0QS*SZKEM.I((^!P[#?P2)[J.LKRURI$FF][=RO
M"RA1.N/4M*'\3-.1L06+Y,F=_)2ADSD\J 4_W@*$TJH9!\0S-3GS( S"/$.4
M1.26R8VZY:P-WQKE=S([J'<_\9&@ 6QI561-19XDX\06V #\*8U2T(@K';*0
MVK'2Z_X-U:-\>CYN.#M,Z7UT\UD"*2ES>\6,-M4V>Y9+1G#:!QWIT)77*=1O
M:B?\DBZL*WW%#4J>=M:S68!433&O06-3P-'>N9"X$)D\APM/$@.P'00=O#B[
ME5 ;TN(_*=5&/%8UA8NN0"1TZ,K-V24[)38O1LO$3+*\WS_]T4Z5&!=ZJD4$
MKAYX#T2ME- '_=GY4$R6/T,/UT\ E&-7<(S;[&&BV"<T63R#W$N(8FH&TV?D
M5\^O?@FUWO/'Z MN<$E9H+^?F(RM@*Z:,:ZRVWU)+&]7ZGS4G*5!@IMG4+[+
M<3<-^;WDUR$G[C9.T;, 89H*A7<EM #!W[(]B1CS^R0WK%V24(Q(45=6B':J
M/Y:Y>SX>M--/?_0WV?=O-!_Z3@(\*F2EQT,USXD(]6FR/'U?R:!^O -;C69*
M>1<NX??>X!(&=5$!!ZO+I_,K1[<NC[DZH +%"TGZL*7&OV+O0;MA)WK1[N@G
MF;I1&;;X42GHM2ZCD4+8V8O?NE:$++;.*.>?^[B+FX14%C(4^ZM6C+FJ65]?
MX]4NLF<GE'&-_0U>0^P@3-Z?ZDBO1*K']+>F:$F>EWC8,5V#1D :77L8=J@?
M8$G"O?6GQ,-S(Z5(]6(N+Q%KE,WZZ#2I_N;PX\Y]8<E?MW&U);$T[,HB&?Q<
M5KN2QE-:4#I??+>;:K'R,#KLB+Z=* 8+>= (I3>-GAST,SXVQ=1+GJ48C9=\
M8E8HFDEY]T'<^@&%HN>&*M3ZCG&LB/9!-=0)1$5X5EHX?])8N>'' ,!/>_>
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M,]!@,B?US3TE>/1FYW[W\U=G-M^I152:($.YTSG.(C#AC'^ *!@5VBZC=&V
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M2TSE#R?+')Z-L CO/H('$3CMT8DYS+7)$ &V-@+=O ]:/Y0_DOFG)0/L)WQ
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MS_TXH,6KFX !VTP$O;K.4C2K'C01W53ZGOCE2_+0H5-I0Q?R;-?6'G_<TZ5
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M)'VMF' 52%8H4U!]C_&C ,?BN_,,&"B.AN:X($WP'65!W</(K8@':[=^B9R
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M+@D<0QS"Z?)@#Y,(U['KFE-2/-@[.1X,/'H2[F=WN9^(36Z3X1:C);W1>HR
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M:7/'0U=V%IP0#H[>5@(A#V0YJCV/H+I8Q\J#1:\!;))=*,X<._FD6T+SG#6
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MEGT[8E5V4"%+SS-8[:Q5D J58!X-;3-MS<$&^:R)1.N:*5C6^.=9%'89+CC
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M4:/PQHW-JA@[:N&$X8Y2!DI 8EV$<T>8C-.[ ,+BF@ME<[ AU&HMF'CPCQ.
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M4(5).['4Y]Q=M.K\G?AH?+L%SBDM_16S]EMH2#UXG[WG43> CN.7U8Z$Q0F
M4[@JZZ$I;] N6V6K@7(#'2'WZ:L7?S+C>4&+(@Z8]8.CS,V-\27R?$%J$]UL
M2;'M%D']JZ9<Q0K[%QSFZ\\Z:2;JW, M'7O&S(_3N!V[:"@4ZIOQ><"7;$OX
M<55DG0H>Y)$V7]4?+/!"95,-7#$#BKC8R[ZU^AD".0/<_8M>@+$C9#%E[ )P
MSS%YZ0*N).GPYGBU:+?_YU^;G%X_"#],T@(95M3#Y5\Z'^,'[5;?H ]+(=MO
M>H<@ ==<3./GJGZVW>/T],,>\H=6![?L9M9S1;U)WA7/K\X7H71VQ?_,2:-'
M[QME,^5Y?(#?[>WLF7<8MT$)C41%ZE.!PL0E5W<W.! (E!,6<NS K*Y)6'U,
M:US7!>\[4B2&E)X;[5:,T96&+F33NY1:*\7823AQ+TX:/7+DJ@XO82&H:[&#
MXWXSE2J=V7#H:SQ+,A,.QYAG)V&S<[")S<_33>I&'(Z?TN_%,8RH%W@E!WXX
M&V#Y:"?V@>;,AUT%;_\V5[]Z5=]O"IYKGGE)5268SN2W_GGKE1;1A_DY:J5>
ML@BK#%ZGSFMSTZ)^T6,,7GD2@2P$MGWLL>FOM387XS<7B/OE68ALH]KX-$K7
MVSMKCD;^EM:VI>'B2L>"32VD@+VJ8^V6[@-6G]*]^^!IF+*/@*DY7U#Z&].A
M4N6*J+]=1II1RKFO^=:PKJ'6TK'LVV(;3NLO=1*=CR:WOP:>+X&&S>A7'D_D
M5X5##1PWP0:B3:%U.A-*HE#..1Z;P3@]QX(,-WNR7\NPL:)$-Z>=NG.8(T_P
MD/_%!@<J!MVYO=XQL!U3A=AS+>] CO)13L/*8JK,HQPI%@==V3J)](LN.(Y0
M;&(V+E9"^<71?9KA-5KZQK*GXP)W6D32.<KFT!,[EY>:YU02#):5I/NQ.($<
M.\O%\:EI;8JEVG)HJ>]._OH%U2&6%=W&<FWG!3P55 ^O=^Y8,6Q@'IW8?W1<
MM;#]J*^@#KQ[_/X$0" =17MZ2-UL<GG!.^->LZ:LO<?,E8[N]V=$CTX8=Q40
MCD9@>E)QZ)TM[8ID0?C#\UO?7$2/-4X )P"7I70K'T6C-[M/9S>-N"=O<CH]
MW/W8M,*&+(S':?*E<Y9+4O3FLLHS345RYK"=YH,@N),U@MTQ)ZPU$E*B M^I
MM./4#8R:8]@_( QPM?/D&FN9E9]W<]_"[U*R[6J]'%MZZ?H[6"9+.SNW_=8)
MIPO8T588L%<RHKTP8I8T5LM/$2Q^.E)FN7F^0]?@"JC45&=[/_WZJPZ5F("F
MO.G8:"Q^T@GANI@ZT5NF_.Y"QL#.;[28RPK/]A8V@X_\*8NAY+<1##UM=QHW
M_-J_]([' 5G11@[\S-[%1&US@R?[#>46&OV]JO!<2 E\V22TU.C6U05]!<70
M*<,,7N0'_5)'MXR4+Z?[H>_YB>3ACIB ]T6!=L\^ *H/W?P2UTV[6)R64,]>
MLIHNGIK)+UPI^"AARU[G!H#V*_DE@%O,Y9"N^C@J9Q_,'OJCHSSY<=5MPP ,
M8X)/PZKP"6!?*7-V&"5X66G:@7?WL^U^BBH7X0C5,;97Y7:$V5K@"9Z.?4EK
MF/6/D9U1A]FPUZCF.'S$3=[AE:M?G'1/3W%)2?-LGZUUZOL"L)TQKK"2-8[)
MRZ%DKFHNKJ\Y7[_"^T&Q[UY>@7<\P@=?2JFQGYK<5(KH;NS_M+B_[><J.XS&
MKHA[$>3*!OUC,=H3$F7X0[LDT1/ Y^(CU)=+Z3\J\UA3)<=^I/6:X6)>$X3*
M90:@T,MQ! =>M3U^.^/4YBF[&U4'QIL;'U9"N,\)ET%_IDCI2U0T3[;61V:@
MM6*9X@5TM43 ZKKE.9':&K(&1:73ZL*;0W'V44&.+0C$YS)D^^U4?GZ6!P/M
MVQD$05L=06%"17*!KL<&5C!E]?!FA:;MR&=GC:C.?M<P9-=20!+UCEZS<(D6
M](P$[E9EGDU%Y[JPJ[@D;V8<T^]*/!=YF!(.<6\5.;*+6@_\:W3G#'1=(R.:
MP_CX@OB3$CG3:]V["X *L]2$C/*+7FBE*_-E=/7%,W#GBKXJ'&\V^9&ZWIZ9
MO;V#X8\]:*?K8BY3#)OA[#">BA] 6,),U2/RY%9>.Q?] /5A0X_B(M\MXM J
M>K*Q'4#^1[PF885+5W(IA%CJB,8($'_3?4/7V_?[DG<:TK81M^#TE3JDXX"+
M]*K3;C;,&9XS[(5'^$S;>7JVD&3E!\GGT;;;!E?]7DWX*,I#/^S@'$#-,AG+
M(0,9]B')>_OW=D)$*V2'B")O#LW5U_>3WP%YLH94JTAV=HE +8LL!_G#.#_N
MGO5?*C ]@BIL9?Z^4HT2^EAW)OTVU+_UTL+=\=@N FN9TKM]_37"DSX?L9$H
M[Q. 8)BK9 $U_?G 'T&S%&R37N7EHVC]1O2N([M$)/!0<%\QU,QCQ^\=J;#&
MP#W&J+532U)SWRA%LT=_(D+6Y[D3I)2*(+@*_*.'7F![OV"2.@Y&AT%V%.KM
M2PT#3 :#QKPQK[WWDB*=I+@W71TI(%WW>738C,**<4#,X>VQ]'M"2C\O7>/V
ME(\Q=%U05!RL<\^H-,3*DMD7_!\)OM9&B"";MX6)GF[&886;,-@&=\A?Q[K*
M8.#1?6'L!,":U5BT,/I)QC>I_J>J[GALSX;VM)):43R+8A/9S'<YMS1VM!>P
M0J,- D<Z,A*#+Y:/[06A2E]X3@WL]O)\9O66UV[7T^P0N\V^.;!6X"OL5-+2
M[2Y44B'UZ@2PK; %0IT KHB.)/J:*J_S+*>!#_X(B]8'E.7TIHV/;2F8@D)
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M4%F@4A=MF)/,2Q#>&ZRR^W ZN\^DZMV13?EQ?_5.D\N33ZFFATZ^7&NG/)1
MN_XW$^!N4>1+^"*IXJ4.@JUSHGK-!G:H>06SUN/V&_T$OW(C9X18&PK?B,:5
MJMSH*Z<6#GM2_(OGE*P1J/*N.B,-Z 2+E>?[QEH_KN:%U[)@NVA/F"ID_]/U
M'  -#_5><!>.J[F0ZM(SK/1Z3$/D5\X7;/4S]3N2(#C>O'^.T? /B\&HP$N
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M1N//.^+[)8MAW;J[O95;+U@FO[ /[?Z8JX:W'E,^D*>NC"MM("PGMM&^\L"
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M_^X/;#6\XY@2OA@)5JF^ 4?,EY\ !M?BSW\Y ?B< !:4G,,7&)ZEW27_.G,
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M<C'1XA+3C=V)'#>P*ARM)B<<M#S;.U^'(#)?>A.TR"'R8Y4]L2BKN.ANE;%
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M\G*_=42HU2\V*A5RNVACZ YCRW(UU&''HJRM"A6=KLM]_!IIRS:5<@B@-R.
MW&-HJ]EA)7P)<\E:#BV5V,4:3@O/2:-!/LE-F(_,$^LYQ.L-X[OP,CN5#<&J
MO8&7KIS_'S^_8%RT"AK_J9&*)$R*OP&8_'3V7T]+KMX;%UDAKRQ.7K@'>&)X
M_^_O+10<]^NQP.!21BI_EZ>R>O'U,K=WN((>8"O2A'NW><#KL_1_&UP]_MO;
MWSF"_U$S8 1951Y/O>Q[B6?=WCY(/]"RUAS-/XD^X)FKQ1SZ]^A^IBTK!/7M
MU@LGI29UE1_KW !N!$D7[]\^!91'VG5ZG1S>M  '\$BT#2K7I*_@UX)SL6?C
M878FG$)S5R;R\?W7^@^$3 T[SF:T\'::YOL;8E0;F.S!PO7$N!M2CG< ]_]%
M  10%#77XLS)E5!9G5!$!C3O9H"1Y_ BJ$BZK<5<:[!V7<HI)T4(YI*;E##"
M[#0RLHQSOOVH3#?ZR7UE[34KI)]8(-0H81<T/6.?2!DWVG*Q%(VR]HO$AZ42
M<VP10&+^XI0+&DS@)!(VTT'K/*_UU)_&T[]V]+3P@3<2*"@&MW856KJQ.,8V
MZ*B^JO86#H?[>H;T22%ADBI6(3A>^DRL8J?2UDS+)%W_$G,D+79'9Q9JK6!6
MN(ID&0Z(? T1]$_EX4[K1"79J:HN$.O;@[,I\_1%$]^T#]UPA[>V9=%/"QWM
M#8M\?*[&K@>@./AX4?NB2R+[E19[=,+LAI?X$JJB[-'W.-["MVCBV/OB=N2+
MKW4BAID(M:?$\L4KHA'<LH(P=Q?^'(MJ8$ZYJNZ,$JQ#;:5^\K>H^X$>46U%
M$%E)\?-I-H9HC(N.*G$&C*/H]O#.T,Q+4Z90\.H62SI?MVB8],+^N%[U9TM4
MZQ)6!54[5TM=&M91,VL-E5*'P.1BBHR]*G)BS)H@<C-XWAE0S[4#VV26>M&F
M94R;CC9(#"-O0G(&VA[=?!$3MJ.D+$5KKN\]G_V?&!#Q:#SZJ=K\0VJ?+I]!
MVT)X+-9JR[%\_?;:Q92,X9*E0[U1VV!Q9E%P2/D14XZ!OJ!*&KWL[LF9>@I8
MEE@&9BVE>?2M)1Q>G-VU^>F;>13^:L\HIT>:\OV.VO/-Y!;+2:.@WP;U&#L)
M]&NE;;CSDAB[2"M<M3MUFPGH^>71P8LFM5 73G>WSVM'PST!N.DA7_+M+' W
M.CU-+^'$XCTXO%0 NVTTYA9':=;[EY0 ]E#8Y[.Q[4"DOYJW54:33L*(*-4.
M7!'P$H.[:)2P1BNIH*S,V"8$)'E/SY<OJ'WX8II/1)P""*P<#\I_?EM7U2"T
MTX6EKO*N>;4P*B&IS3/  ME.A&0 OJ8,$W=OW3XGA?W+.=3S+Z4C)1\HV?H&
MLM0>,%]#O$]70:PF&ULZ"19;H,AJ903U]X,9)J7ZS/DBOOD#QC..O9I=MS&1
M$?<^J$ST6KEOBZ4XC3.))8UX6WU"3203QL&4'4/^ BT_/C,8Q+X2O]ISE.4C
MK7.(EK(0!B9A28'*TOH!!CY>=SN0"W@H(GC;2\3G99.I3]RYYLVJ(O&>!+.5
M2ATQ@46BFS=8+,/,UV3OZZQF2Y6D7UYTBU=VL>Q<*O(=^LX?1_37Z.:Z'/P4
MP#,:&J!'. !]#/BE\.$U:Q=+Z>/G0R<XPJOPP4_:RR[YP44\UCVPO^G;(#HG
MZNZ=*UEU&M\$_-AP%94TYHKG.G[."$K6T95J/%R.^1Z%%O%(](D4-M@6*:&J
M.*V*MW7WU8ZT_=/!\(F\P06OY/7\C,$;Q7,I>EDOWOWY.>I7EYGSCI]<KW,D
MC382$\?T?NS92UN9]K=QL4C-1410LW=OI5O6(CM:9Z;U^=C*O?RV7W6T#<Q%
M>+=O=39W2+Z2W6YR'ISF.FK-66JB*.C6WZN?@=UVT V4N[0NLOZ;0/>Z\M7B
M"]Y52<N>"2?AI .NE$N?;U=6:ST4&?K'D%ICW3=,I/"==SEU.W28\4'8S]%?
M9MVEF>PI_4Q;51VZ84V_[I]01O;]: 6VZBY37XF=BM+9QG:TR<"Y1-[.[S1J
MW@.H]/Z1]"&U['763P6?#(E=@,>MIP<WGP*.RUBR_E7#_G=B$9MTC!![](5V
M[F/V@0#";="@^+YO!Q3NT&*,$Q:H9,,'KSAMJU4N["N^!A=623Q<?DE5S(R*
MNN%4JVR?]!-*T1C?D;(([=*!\7H""^3D)?&Q,HM[GOMBJU:_($P>!++126J5
M\U:0=).>]HI1YUB[D!7UAQ?88+%?IG6W;8=VB/O[F+_O:Y,:#&OO4JCP??;-
MX0?;=\VEODN>YJ+W1\;:6( M6OM"Z<>&WG9>1@IV1JN;)Y=REQ4GXB3:90K"
M%87U13E'4,8>10[S<#"4(FCGXZIE*AN7D]3J4@V>@3):!#AD%_PLS(RU/Y_G
MVSM7:RF6 //E:QTI)Y'M>;4%"F>7ID,PNE,;MR_U^3";6]C8O15/N-Y7>%I2
M1C00#6(L;L4L[:[@&_AR[-P F*B9@X/<2@T6*NN ,;"BA'08U_.]K5>#FK!O
MWBW#8HKNZCT6"WQ5F.;661!O?3I'Y/#)1?9B5NRF2X_U>2LV @,&]O$AMCD7
M%*3P&+G&9G68E>5&)%"5R):5R74KNF'5?F]R$X,$K?,MN*85I:TD(^@/R?*S
M8K$9=#YA96D@D =8">. =5HYEI!M%%(SA)!STT;]%.ZMF0)-&?8?OH"2>3$\
M.AD9%QM5"45N3TKXI/@+L.BH8&OEX+2+Y*5VI^*I1K^-0*ZQ\W^JC0?@_C+)
MS;(!^$'M+]49M8E2IIS'7I;CP?+7*&W;QSX7%8ZFC9WKZJTQ\8"SV!X 0%[I
M]JZ*L\0\;FS))2;KG/]_%X8!EY4''7\3/3[;7[@*^-'MYW]=1A];:'O8YA\9
M&'Z6A3]6$G^LK3?1CUETK4TWDLQ):&Y@<L1*)W=:P6GH&0R0!C,BP$XN,P-^
MUQ>1J0_CKC(WE'.5H7,!#^%V'0=R"(P6G2&[H@H=KKPB!7 (J?B80&%L",D6
M>IXWA[D&QRF)@3_5+0Z5!A6= G[RUM'IZR00<+5M%>9^G_7.F;E]8BKVV: /
M<*1CHUMB\*!*[2%Z!W<E;TE^<Z0M)(4^;6L89+S:3L#I/@< 6!5^;B;[XJ.J
MMK'%!;0AIQ<^4)B]43COL\9^IL6LA.H3,J-&Q.+AJ-37(N=8BWOC*:HXA5K[
M<A-"0BLAC#B]\94..Q(N(817$;-]!+HNO[;T*/,XCF2("'G+)*5N&I0F! =&
MW<O8:2R<U0U2#U9T,B1VP,?E^+^LXY4H?46X#BC2##W@N ,WI,["0.9M,L6V
M0]O>>EZ5(Z0JFNRT#5#@$:/H4%^R]OZG%3^D/J:@=')@SQ^+FT^ $>A&:CGZ
M;+ 5+R*8C/@N=&QL,/V+^P6WKAU?Z*\92.7*JH>;@TAWM;#R$;1+[PH*8^ .
M-"JRADAB#GFM$,-'JSD*/H7ZY38]@/6(PKGJZ-:>\GGXK5W-A6N:H/GY^1M#
MF.896J&PM+TZ<"F5R+]<>:(H6"/@3(GV:,"-2BIZX=K\2T<*W7H'>TL,M.8R
M+X>=,# ;(\6VMSN7Z;)>=YNGS^I]O/B<>]>A\8/VIVWM9\@VMPJ%6^4P2R1(
M3W181_IGO&4+C]7V3*+J"G0XU6>^*DV/ZOE9[Q-\"93)_"6"%KQ>.X?Y<A"=
M7</5W/$ W'=^XNRGO!P(YUG_K: N;3R]6]MP(J[/JW/()3?*4;3=-LFA];L+
M[0ZJ]S;4!OR? #+ CR^$U /4#S-\U"=H?0NQ43S'7?*6ZV:#VQJA;">SZ?I[
M9.^#W)S7IP!49U* ,>W8X([@H_^F'V>*A2?E3P$QIX!#IS(A*[U&GU. P"E@
MIYOSM_\51&#M$7%.^E1-*?1"&2^]799VBH4NO-DQWO:2ZZB7<*@[&3X%I%E>
M4=V2[C\%"&^Y-!R?VY(B-06X()O>+Z4/H5;[DI("=S>11E$/'FAV;1P_?N^B
M&S;2RRB4-3'(P!JW-EN:LOM5\O'D'G=8A<U*ML>U^'/96PLG=.MJXCU[OFP#
MG4_@R(BK#8N\7Y'TH_C^DH=B!T51MDQ!O&7]&?$H)IMA$I'EY9J6[RSY6G1C
MY2&K&JD&GEI=.H,\#$(&]1U@Q%]\<D(FF,JH:+O>X'NE.X1KT(WO2D"KMTG7
M>\>J9V,@*]A:PX[.#+>HI>]:^JGJ=<JTMI"8O2+,J/=NUVNTP->IW02N[,PA
MX .QK1)#@X]\8$6=Z:@;)I&V[*.JNF&A2X"]*>KP=*6Z9R"+] I;14P",H0$
M,E\5V&&R'^B]![!<69/V?TL-CN*P-LB2B/ES0_W?)_A M]F.[DQSTPO?3^_-
M%.;_E/%KWQ#BWB!?U.0P6KJ_E0$9 _D%#XOK&NG)'E(.!6V7,(C@?;6"=C/K
M&B["+9)O#;3*)L*'SG:K.3DTI48L@J8#OY?O$%C*!@1]9PW]@Y6WX?,K-[VL
M_I%@UNU@]0,QQTK+&E2OI13:2D3ILF6FL-LT:F_G:#B?F3$L(3N?+6@9XU_@
MP1J^+SSHZNA>,'$B9B6][7/ R35N.'X;ZK"C0%,YRC&<$9,8/5_")-Z>YLZ4
M= Y:LWJGI/R/E0^%<R;6(7I;33WZWBXOC]IT?6PYV[VNV&V-0VTRLK/*,[6Z
MNW>HFII*4@HTNTZC::U0\1%B1/E8NECW^<3J)'%Z:Z51^_%F*AW)E"V<ZGFJ
M&L@$ !90_[KL&KK_E,1Q4S=JN$1'J<^X<B@B1>^KH1X/][Y(-KQ<=L<-HSM@
M>BL2000*@P:S-PK//O,5W2Z^EQ.U&[^8VSVMA]"88X(M$27,N8AG\V;+/?!:
M[L)ZKV*_E?7C@%#UO?EN-_UF >R$AT&#I@RA28G?!&'OW<O/#R32$CSK$]A]
MIN:<R*%WRNUVS!1J,\:UO6G&JHSY1:=IU_=M/''>*"LZ0]^P\Q='ZXORTT6\
M\IY"FI]'*T:FFT602]!2)A&1;C2CU+P=WM.O63KU&FH[J58KY]+#QD:(4M&\
MW#BA(D]=/SLNT+WD?I'X:N-(:UQ'K+$.;Z"Q/TY8K\Q6+U 7]/Q,UX>Q=:+\
MAPC.S0# ]=!/XWD5D9NAW#S3*8E:] 8*_@-<Y1*LTTT@.\!+*RR\*H>WI#*@
M>10CWDP7F2GQ#,PU2_@8I)27J'@&>WDA%LCMF[M^PX!;,QNEX#R10)E%Y:GZ
M![-P^,-1&&3UHYF<H9E*M@XCAKY_?'31B(*S@W(\UK[<N5/,O;X<FEP!=%%2
M1%&AJ_Y6D4R*Y2#F;FMU<=T[1SFN(V4'V<SS4>$=EDAB['QH1<:J1B3\(>YB
M(F2DEW];M\/@'O,H 5.36B#=R'I+%BGN[7BA+TV;MT;<TAJ5FS)^155R0^R)
M9$_Y#8YH6(RU:!BA6JY%=0Y7+6>-$)DH?*4AC(]3$8!%1ZG]O8/)E4"HG2N<
M>1"@\JBL[X?ZEL#&]Y<1'_VP$,XZ)N+5A1B^/8U!&H$,W<QV^W!;/--I.;OG
MW=?\U*D=$AKJ5F[JY$:/AW,[&/49:?[HN:^+GR-C5B+5\^=[]#D4WNPK_<>4
M K\^P#$*7K#7F.YK6F8P'#Z)CK1BBH-@^D)\*:^!&M; CQA$<Q&>#/6BX77=
M*AB$##N9!W_MP&/17(L]-)O/7#PWN 53O:Y;=\W]/W F@MT8P['^"!SMK\[Z
M%G#W'BJM[M#.J7[Q7-M6*\(S4>Y/, /B>[&8WDW=#B9BF@$"%X *$\HCFT1E
M#DJF4;S'V(I?[RINH)ZH^B!Z5W$ANL&E@"[$*W>8X5T]02M>B/F!_S^TB<-/
M^>;@4?0I8%@UBSPBY5S IFF_K=IX?/^ ==@W>B]01\YV&!U8L"HEG1K4JOQI
M#&F5BJQN.&E4OJ)\KKX"&>QWION5>,_5FS)]H=9J<;KK]=JCD>B'2B>W#0V'
MT4H%CH=;T=/#M+@U]%@JY?!N;]@_U^M_1C>97_)S/7^@!!A/<3_.AIRQZ;\1
M6'>QZN!+NDBJ8G$41"Z ,*AP"LBP<\.SVQO7PKT78O(&/WD6REIRYO=]J6B!
M%R]5TVWI=)T<U^C04G^3EIOL;*9"*J.[J@,T#D@6*H'4WN^=&N)2QY*5\3<K
M?A*J/3&3-__#8S=<HE;8E)?&3M\7BNJ42W6,80W^@_( \\?/#^(':]7:O;0#
MA5K'8P>T\1; ;PES9:C^?J6-SV4NK<6(1ARIM!*.#)M%<JF_O"+4L17ZY*8*
M@>9.:D,.BJR"26!#HJ-MOHMB<A[ZJ%=8.)Y 3"W&[B;R3GG7&Y>(V3?"?_ZT
MZC&VU*(PGT@YIT1>Y@ZC(+L0$JI>?C6S%O_E5,[S)+OH9CC3.T%(T_3)![6-
M)@;9\@H=$QFQCE\H* -5NV@$"=;NA7(K7S;:%-'[4Q5&$Q4>!"C;Q05L_"K:
M)@$!LS1&#?-1'A31C=:?E$B9YJD#-7^,Z.B0KEHM;TY7H-LH_[5D P#\5$W_
M56SO:I<R9?(4L)O59"G5/E-MXAE 5;K>8<!T><\DHU07#EE=YQ%$,6KC3$&V
M/TB_S& 32 2"DJGB"X7/?V'#D,Z9K_%E!%LVG0)6GZC3C+4]:#UTHV?]YL(9
MG-I"5PQSO/M74/K&<D7N_AS? S$_WIF5B-($6<.%?UU^_D'J9NOOWH:R^;(8
M"R0_J\I^K8XNVS9:43/J:0\C,+*PV1NU;##Y[.QL(A (S%)!WCJGU0Q<<"ZJ
MZE 2PF4=DL6@R9U8N:!9+R,P%<@O;)E:7Q/J.7YMX(INI<NM-"?9Q+&[C2L,
M)07$ JEP@4]KMUS3^KI3:46KG9N& ZI2L>!N"W4+&G;/I\LT@)<[1UR.R!!2
M*YB$1\AL#^S(CXL]$=(2B!5TC1-VOH:.5%,BX/I=:^:BC+Y>BO[,>L[,Y6.M
MZ.X#<6VO%F0T;NSN8VR )\18G5:47^".8MOPVE>H[/3*!B4Y9)NBQ!X$]EK=
M>= ]("IM!I9:.@J^6#(R+X%.N2G@[6$D*"UK+!6;E-IB&U,MN@J#\V=GM\ST
MO__CA&Y=M<V<Y/9QP4TGVB5^MVNB+7I\]C-5?S=KM$Z-G@T(@6)<TM96=PB&
MM[\SJ/USR5NZ"=2UCH>NE3KEM;&WB-V$5HD:$S.TVL#>, ^JT:N5:;PU3UK8
ME,M03?5J:4S G)/']<U/_MJFIKDIF"LL[EET]RXW<A2)JNDO)\KA%#5M%4$E
MBK>-E3?H67#I/[RN/'>LO!OA/RZT0^M3'KA2/$<,NY>QL)R"9% 0R<-+R=$B
MO]W6&R4RAVS>XC.^AF^&JYW$^+"/JYQ$]YT"?+'0?KT0EOUZO>,)C1]+>\1V
MZ,>&VZK'XK/V#]FVH/$FC>;.=/*-E.V4 R6-RN.$0NTY(YEAA4:YF1G$Z@@N
M-3A]'Q\D]>EX^>\]$D6@OSOUTZ@"MX8:^-VT'35&\J9)RM6ID4\;!6*E5'[%
M7W[@U6 ;^Q][\P+Q]+14R2Z98NE&@DRTV.NZ37MRA6&+H;F#JTZLTVT>V$(2
MBQ$"%!<8 W>7P@NUE/*R:JV-(.HU-ABDI0$SD(]J/+W<477^YY<QE28D#Z@Q
MD89FLJ$W[[#[_B\JQ7^EBZN%(P"GQ.)9+HMZD4:@R^J@>LDVC(T)S%(GF0S(
M.4BI(OQ$$=YZDFW^G&F0(#7C )KI3EX)P ,KD7WC]2\O.AO6(KP3VX#]=<7O
M$_,U!\NP8-Z:7@A\K[ /5?/';_Q/9D[_';I<^=T.&2T?B(VS];I.+&O#S)'4
M26^:M&%/CK%C12/E"J.F-;P^8=:(_];=O;&^VJ#!#J'VL?!1P49/2,^N@F7K
M/8YM5\UD89!9+,@B0[<UR@BZ8H7+_VAGYA;NP-%>5&^S8\ZT\\P5)7P8'B?$
M%$%A:CD9="/DBM<RLZJXSL\J*\5MS3\B($+G^'=@>;JOF<R@?NF("]N[+UXI
M9L/;G8ET/;"J=\MU+SV0C4MZ66L-H1AJ&0.W6Y'XH:G;:31S:+%P\=Z:*S*6
MFJ'6<465$X?69!\BD%$6D4Q>7!BAD,YQ]?<_#O'CHFS(\Y%'-EL?5@+MMK!=
MVB;#OQF-RBG)B2[;3KKL9_GS5LO"\UNK_2R'L_F^G97YUEUS.W3U8F+DY(<K
M<=T\2L9R<(_$U,;9PIGT_D&-D1/GC-V[R^'A5/%1/?1"?N+_%_G<OX?!_];K
M_@==;&A 7^N #EBR-L'OU4Y<&]#&FB!]MS$X8UF->=L$0I-K34NUG/%W<\Y_
M"H \EVK?O/D[87Z!&H#KBS+HUWJCHC14!336Y-^5I,0TXZ9WXPK9%F=JG3A_
MB+/IQV;&F(FX;]'8+):.UG24H +[-<DQ:R6=(5'#]G"0V4Y.# 8Y=UY^T!.4
MK3BW,P0^!=S$#^>D%%'')FRJBW42,X*,EX^2E/3]*T1K%=N4% V*D.%6_5Z-
M6XP.IAPC&+)I*H$^BNV"HLL&^D;("=W4[$1JHFJL2(X7/VWICS6#K&7?<;8^
M'(_,&I^%2@5,E,9J$D3H\3)=UCL-YD=O!>8'[;'9%&:'NL1;XL-+R\B6C71.
MND6I<JO$3?DAI#C1>U"K!6AY62=_V>IK3RNA<0LVC6S9CT[%X54_;Q=$CH"T
M-D:RVZ*<5P#A;Z:NUHWPY[RJJS0;5-%*)^;8,:+Q'&S!YYS[:G/U/R::VB6%
M4$1%V4;)&];(ZY@JHH(Y\"T-?#^OSLA4("+(L=1'=08!]#D[O37_Y;5?#M<)
M:/D@Q]HIMV)D9.$I9V:93VV_9/O7$6*G-[ZY 16CWT-*^SJR$KBCHK/EKL]/
M3Q?Y@GKP0@L]YN:]O?*2RSM\0RW*7VYSHQ)6W_VL]J:7\,L^02;Z%/"QPIW2
M_/0(\M7GUNJWN4_D Q?_[,;2>7*,_#"J6E+P%>?>JL)^C$T"!]]Y!<-F#%P8
M@V6I^_.(T$_;M]=^.7KP+;C_NUQ6-?WI ZY_<^MWU(,(>HLW"$JMV>&Q=;]F
M*L)0<+)+?J&)28AD6.'18Z'U7KO7(*SK_OF[3(OQS_)?)(F^"\5)9AH3>:]-
MS=DMIE+DQ%>\LH75BGUY':_R^L^7UW;W/*/#I2]TV.'DVO!C0AIVV-JPG:H,
M=0%S!5[ZC+MXYW?1IK$9^M\UCI!@^6J<XS%?X(LD3L333*^\_JR-#/21(0P1
M-07PA)DF?>X5\@QT V-<7%.P&RI^P?F#:Z<UNF3A(=R_J>:)UKV2-KJ6MMZU
MRB64G;LPB*U##7BW7>^3U3?1[YZ!,I#XX9Z(0V%A<OQ6=TFOMDR4&@VORK0@
MUC:'I:Z\:+K!JV[YX>W$F8]O^IH4S?R0U6(%W*@ALATS[0U9E1D<M1V@:Q5>
MRGFWV)A(0#X7*0X1"./9"7>"7JGG*DZD![2"$G]MFA]KD;G>89LIU3BU,"B^
MY"CE2HB&0:$,+5-B@#@BZ8<'E)_)LNDJL<1M<\NSXEOWH8*6>-5([]HTRC)7
M8S;,-=*K\F85T7NCXA&C&Y7BEF*X()MA>]->@!-HODQ)F;V.J";QR.C$<->G
M0\I/?LTY\_JOO14J/G_.%%Z,^XN;D1X@6#=0Y7CPD7;,H<_">;=H!33QB\NM
MG:C;]P%/G\U" G>:>X('KB3-Q_=/BKK7,;@E#CY2CZ52THSE/P\J9-E__RFC
MU3< M6O/_FV+QV)-S[B]-1PN+@!:YH[='4VW:21,E4YF*("%'>*Z8),<9)/1
M00V*259T-E&N1*?'+\[]<RCEIZUBWH85E)V9OTY@M:;/AQZI@%;.D0(M;FQ+
M(<'@(8,8&=WPXJ5I:_@4"4MT1=<\77,K2(/U#25)1DVK>])R&-K>I?VRW*_5
MIJ'>+IU-)1TP1! [S-"'8>@S6G_X'Z,A]T6+KW!>$A>.G#:^;!H5_3?:%*V_
M/"RF=6["!L29?8\."PA;8,*YA5/CW"7%XVT&O_GVI.ITQE;QILI[EY5*.8"W
MM[3H* M<6+4!!ADR"P"<.=N//%LF88S2SC!/^':"F^(2!F_[9$0,J@R!3 ;
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M'PM-6,[H3=[O)3V/L2AV@75K4*9C*.%S,\6ZA51A(SU:C>6"V1Z8612$ZSW
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M%"C+*W8LG164#3I\^Y>\>%]B]==-[]O1YX\=LT4&@K?^ FLY9KKG7BF=TYS
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M%B:W,$:$ @#7O=V57!?']3/^1-Z:=<XMB- IP):#^*";6$;D2#6[-Q2ZH?E
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M1J+QA $V5BG6/NG>!U7$(:Y."7^)RBHO-65'(H8DX$7SV6U?<)=Q2R\XW7\
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M7/RQECH,1HUF7.LHYOW=;B^ET)TBS/)"P+-)04<L![OZI,13*&_'UN0@;L%
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MB^N\QJ$*OL=;W4^KJE(C,AF<P@&T"C'O/KW'>LS4!#T.;!T$!54J=%B&V8/
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M5 .%!, 3&HX)FE^Q]C3E,K4)?!$Q%G6';O6HGVW8ZX,TMJ9@V]PZ#-=!]^0
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M5(POHI8V/1B_Z7<KIED^H5#QS8C04$N"7\,:$0!AFW71B]@G'4=+8"L"0$,
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M=U;;\]9'$M095"!^I78V]EAIFP$PV)':N5&!\?0^2%"%7D=\3 R W\Y!QM:
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ME!XK94Q[P4K9@R)"T(@ZZEU]4^2T>BB+Z&3=[7L%G)_*QR&6=[E#N-^#^?I
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MJME8XTB9$?HY?*CMRAY?"6 M\L\%X,V9E=<2AEJ\RL:)^6#>B3G17+JBM+#
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MO>X2S ;ND"_870!,D"JZA?VDBH"@C'\IB\5W) :A#-QF\THJWKJ/7MJBA""
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M<D+L39-,@K9;KG6MU@-C@QWW0WHZLE\J:$61&AUF?->+4@55;(C1^P>VQ:^
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MJ:N?J >OP3>87+*42"ON2>O&ZE'J#HC6I5)!&5)L;=4IK'5/SO.\+DT2 )*
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M%,)U%KL 8K"$EFIOMPQ&O9VHR U7<=L8$.)RYH\86Z==T9^XS]L,!,*4<!>
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M1]"<(S<%,BDBZ%U=EMG_AZG_"_C/%O\+4$L#!!0    ( ,A)5U92C_8&A+H
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M3X^8AJ,%R?'8+M.JLM!$FD<Y&-J+8,B6W6@+\C&P&XIX44^^MP=&HU(P=["
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MR VZ5AF3]\2#;^/;NBO=>S O\_X3BUN2>MVR%+HY>[O*!7X<-Q"]91/7ZEA
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MR! '<)+3Z_>G/;:%O8^EW/ZPRSRKPB$JK*<EF_!LR8?Q\!VJVE)AD'>&R4+
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MUO_H^L;ME=0U@O*_@RS*G8%+ED7AD#7/L%O*M#4<N1)W26TI#WSCKZG.GU.
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M,FQR,^2YSWD\-G108$YS<(]324-T'VP\%CC,G.-L'./1BR@8>M:>;QKTQ]=
MTZ;DA7?1#J-K3NYY@!&H(]S -+AY7GE<GQZI.#LS/:U9='D%BO[,(<STED/!
MZ.Z# Z8ON21+)*O51DA,5+XQ*DJO99Q5VE@%M+^:]K#J%87JAYE$^(:E<.)H
M8IF]: _P!( %E%6Q]15!2ZW^1ZDPI8TME>)_&<>K#_D$? 3D-7CF;A_87C>2
MJ7/#@+I/"6"[RDL0HE>:U[O('_<<_L/.]$(2T@9-;2R1V,-*043,MG?I YEZ
M9MZLASECRUH+@"U#T%]/@1W &\ZLAP8OEO<)5"?D@+ %\]WR[?K0:.VFY,P_
MHM4GHN^^/EGVB/4>M.Z QE9(^*>@[=?LRZ-YB.1;AB_/8/#$^@J;\U!OZ9YD
M2A=/XZ*/=M6%OB5LB2/0 MKXW%NF;J_O<3)0XZPNHG32UQMC%,BO_(, &.H3
M&[(TSWO116?\IIDU41U>D>2QH,X1NM996)A Z<'VA)DTT'UUM'%!S"[7<$2M
M(:,P4L0P,Y ,"RCQK&<+/-NWMQ-PJF9X&+O +I1"\WM.I-Z*4$M%0HI%DB*:
M-:G+:+LICD"LX.#D%?P1/,N])'%J9#Y <BY\N21F?3,B8,"Z7,VW;B]!7H<E
M]QW&B(J@;.FLVR Q4_10@66Z@_2L4])@-"\P:Q N40R33.ZM>_YTQX+C[3ZN
MW-A#9$N4 -BFIC'90*WWM:O*&.? -E7,3A=)JOJU,D=D)X0<]?-7C4>RD6 $
M(E\HZ=<GD639[OV1TC^J D&!#L.>&*O.W!UI2%.1W:R#YZ4?7 9&[J6I4O_G
M@,.7KUS$7*7A\#Y_U/U*D:29S#J\L&$I I;">P'T1M.S<^KNA6)M IAY$BTE
MPSGCQL@O?:T<=_N%5P,;SXKEU=I]YL/#!<\:KL\IG*+Z;0]>[CK'?15D,8P5
M_OO9>WDQ/(!SO%I=G"0N+ZJ]G"G1&=?DY9LDLH8@K:=+S+A=+L,M3V;7=(K+
M[91A9DD(]4N%J"/>Q2T)'W#$/C^[0\.WP>,7''#];LZOPJ\%R67#5N.WXXSW
M?Z(LH*JKN_Z\TKG)>BJP#[&&3P.5+LPUOQ:2:4@^[E/(6:B[<5NN*7#(L1N;
MM7?=*7FH5E*XO?YBHZCEV_!&1DD-?V*TRT4M0T\U$OZ9JW&>>L=ZP*5DZCP2
M[TOY[VRU%A)7T2I6<O'-\:D"G?QRZO$"R]$*N\OFJ]FK6:N:9B1K:KX79'\2
M*5\620A-U0*G63[DUU>82Y!J:\4[[]*:\B.WRD8)O1I_%+NYSQ@ZD1-7HUR^
MHDKI/+):._ TI%LYSTKH4Z,*_-$]PYD%93ZE\CZ_^')K*X:W>96!GH++W:*S
MXNE%QKOZY>U7N2DFYLJQXK7?RN<I$%[<[/AEY'4]/L>%\4I)RCS=4KD3AZ#9
MXT6S4A_!:N10ESML;]II@2_U1\(>.)K_?N& %4*:^P<WS%Q^9R@$N7'+IY7'
MXQ]F$D<<<E::E"@]*I3@1>^X$NAFHBY@?&''*W9J_6ZB^SKT5=&JYK6[?S(G
M7-S5KH<3'*X+V!DXS3\\($-3F<L;<?[Y[<5L\RA\4F(7O'N !8B6P)&A.1T%
M*N4[\0*1O>;2/XA./O$J:+Y(3'CB+)NV^[$EO-ZL'M&)'#J95V6.N"@HRV[*
MK=BS9G%^XY8%L3]>GX"5_E)EO=JDL'$0&WAUYXG+L.[51-P^7W^!7Y^0X)/&
M SO#S$_NPZ:40"IS%J,NIVB^96%W*G/$XF365._!Z7"XA&?*U(BIV7P'2PB%
MW.#]KFYVFP&+2(RRPH328GO9@H,$Q;W<V*&=COT=B;!$VYCOW3FH]/76[02'
M5+/G.];/+W0C+)DH_"8OE82KW+9U7[@(;FW:F?G]P#,Q#*[=HC['133[4LA
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M1\7S@0'X1+9;V,08'IL=>ZT$'\OD"ZL?9Z^J,R#X^&JD 0/A.2LV*;%JI96
M:\_-TL#A:E$ZHPB-_D?AQ&(NY18+?JWO!7WTL8 (I@XXAJ6Z=F)O3>+)[[ %
MAI(\HT_?L_'B<"[< @%]@Q^5R5/S^S2R00B$">A,#99SJD0)2W%33DA7,]GU
M/Q^]D3<HDH91^+WU-5/846.1>$IOEI<W5YS'JD(P^'7H:>^##Z6+?J91:EB
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M-^F+KX'1DO%18^[9?0I]@M81+W@%9[VT&>#OCZ?!W?7$)>2M5WG1M">_TMW
M3N%O[=H0,<'/9"N>]4HI9,-4?Z*,F>(>+I6I_E*EZ_^ DV&-8VHE=P @]]-W
M;=\830B8X3.!+D*%SM;+<UVD3:W EO.'4P?7%E.9F]*2W>FV0-<K^>EQXGP3
MLRU5I:A!TEIF_X6%JI0L^L2+ E"N&<ZG&*YOA2MV#T4>55#%C]VM@I6@&;@:
M$9R#"<073Q+\/M-X.KYCO/P!(BTWQ)]/P%?+%PK9![D7%:7;OO9YDS\UN-9
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MF<>P,>/PWXPILZBC#S!UUI6K!S_6X<K8ZE?U!!Z2Q5DN&<'V?AC?'V2TE.J
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ME'J9@*L@#&K'T.9U23XJ*(3JZ%HM]30F$.H#QFJ)42OPFT.$=D/E\O*8C"G
MY(K63![WO59T)-N]K+ =**CT:V%A1YY24X%5K610:6"T3DFR[+L+L9T\GBHR
M'6<X8FI,P]R>ZO6O6-EB2OKG(J=TJ)?V68@)X=GR0@*I[ZM;V:+D_<&*U!HV
MD,;7_.JC(8<,%[Y><*'Q&<WPZSS$X*_NF]!FD8\WYRYGB/\P](UY9T7YN)6
M__Y*U&*+8@0-?\-0'B#SY'ZD2AJCZFW 5X;/<KL56,1=C1^;4HG0?)RG7N]:
M$M>;K0FPIYUH*95>Y?RRB?O\)*L$*^:"EZ56R*AZG%D(C47'TK+.N^S%@I[;
MUO?98W38@^=*(A901?-H<D+".I%] F9K1^1#5?;/]2@7O6RA;I;$6F\[G5OK
MX)#)T'\;&3:7@@4-D[JOC?D0']$\D5#(L(3+IH2H@-\BAZHG*BAVUJPJ0"16
MCDHRQN$G'?WH,@==,%XH1YFQ=@=5?S]BDR=:JWS[X\]BUDRF)>DO-/ZL*@["
M.OYH(1#MKM85XL7$X+6G&#M'2?*]30ME<?)VP5%+!]ZM!VJTNQ9WYZH*)[9N
M=KLIYJ:G%AL;=)S^=#U>):TN2F7%]<V+;?U!YBZ7% ;\]639#<JR5-:^WFP,
M2O2.)Q^^*.ZSS+X!@,@X\P*ZDNA@]6R*1@*7/,<D"2I19WN>SHXV$KGN_EPI
M,SKZ*M->X?0T+&#-YPYI(90@ ^<W)?V3\,461J95 HP.=KJL\^YL<C>6(P?+
MO"UJ-Q*;4;&'IVMK/RPCAQ<OF8PM@YST&98VJO)M]J$3[SZ_1CFXS,R<6_#O
MZ3$0C3UBA[\Z!CRK] %. \]YA=>8"^<J^,.'GD;8/AF]%G3*_OU[L9R;IDXZ
M2)-]_H,X+1S?E(*^W@9AQ@"ER-8[:!SEC #?PNRYQU]$ZSNP%]=$%N,SPXNE
M7@SV/F24=#"-H5/J1$OX\,&G]@-W5H7!<[T#$T2Y8.L[T=Q,U@DBD,UJ8=_E
M'ZO'@*=RI!,&5.M+Z29C00&AO,#5ES:?Z*+C5"QV9D"H&&!\[0X'D#.B?P?B
M3=6,.3OA!=?;\&_P8ZW8U/YH(SE<4X2*D@ I5*J-SKLOS+"1Y#"(BK,JNNA<
M][GF2_\*JF0=LE?BT;?_1>;[8C/M9Y=FP]Z3I_J'VLMQNE.PU?&G6B;KX#Y6
MLVI4A.$7)0KCQ:(6R]8'0F_._GPOUJ3"FXOX.CJN"'EB5!8N1AU,&I]65\6>
MT8L=I.LMGR^*&_E.UJ1/)2/9-N%%-:60C$@U6ZS2!UY<3&"+C;O5,!C2-2%G
MNJJ3*(=O&7WE[Q&]?>G^ HS.YR6KCX)#+?.:3;<)V(;8?4']RG#8=Y^V,-D;
MBHTMMOOD.O9[ZQ*5L;QG%1/<M$<LH1X"W4N%'Y<M[,R?<"$1]U:S]KI%DG-V
MDD2PBKG 8$&\4LY2.3*WO'2D<<;@O=@=>+%D<3,3GRS@C7'5I\$<2LZW$P$@
M4:Z!*+04^EKV583N2GXM76R!A?N(ZR*B9</U2$25-!62R:M)?FJJFK8'65MS
M^\8Y82&#J8G[*3VY2\"20F2NK:=4+/%Z<5FQ^3V+^F?4F@-?6BCF'#]2"U:/
MJ;_RF%51]J40$__&CYRX_M77V5(:IX]%!DE,GM<Z13Q?$S)ZQ"' 2I ?:T3O
M;8"K5W41'XM"A+V>FA]\8]-E;EWKN*$L%#GBE8=5*9H6NO) W9W:%.+B4&$R
M<;AP.98)TFNMK]+]Y?IL:-L@4%:/7PIWR:V\*GRWL BJB'$NJ"]0]KY5?>=J
M^.V1A8((/ZN87<8VW+.?G2&EX_HJ?;O4WF6G2[I\J@L4P34*#5@6GG)CUYB[
M8>:!XY-A+#N3K_V8^N4%?HZ&LFL,F-X<\6_8*]]F%&NF*-<UU@VYRBZ5RT4Q
M\2$QI/N-X8N,E]CY=_#7-5<R%[2>"\^4!.7]R"N5$Q<OHHBB-)H>29FFHVZ>
MJC:5,Z@P8A'P_P"?\CH&A(L.1C:ZW7E)ZQL(:@O!UMAAEPE*#92F+YEY)Y\6
MF8[E?0[UOI>&2G91--NA4A"@7%MK]^A"7*D[6%EUO!9H8#135ADU_>.12^K[
MBZ^H/J>OSD=HN?FQ;HR-\*;E:#M92>UKU0IAA5#.3S3CN?'-G,ZO&UVJ M_B
MU27G4$)=TL%>[R-Y\LCVV=Z_D>:T8NK4G"NKD4/@0H",INW>4#:/)^V/W,N_
M!MRD?%XS[X&?+Y?K81Z%C [.'FX> P8+E9HLZ>A")4]5F2*+3Y?9HA<IVD])
MN+AW?G<]&'28C9E9#7JQ"THZQ["5TY.R#M( 3-MLW*@H,A4I+QQR6R\RM7G.
M]03DS2O>ZDBVTV[84W/)&0KA31Z\T$K.O45YUZ<BZST$0 YFSZO8)JS;6S)X
M>>IB-N_%W32N;NDVI7XY^SS724_%3KS#6T_F6X<#QW:=!3>ZQWW9E-O4MC!3
M3"*.S,![R^B#@?Z^K-FEMWWW*><2L:SCC(XL'5NMNP(.'F6V,[0++<\] :;\
M+HJ?!I !-2P3P-H0@\HK%[.B3%9'X?&R+I.:R53V!=@4:C"TD#?+TSYVRW18
MV3'Q#*\J__F(R:!SX@L.!5%:F?Q;\ZG$4D"QVB4*9JMN.ZZP^9=;I$EO2*^9
MHT-]K#E/?X&<>O0!NB1YY,Z'!*EP]+LG-1.=/Y?M]K;7^D]%@6UFU+:N?HOS
MTPQ,7B(_W+1(V!+TU5$(=#4CJ6/GJ-:T;G]@;^.CS?/$1WH4,K2985%4MVTI
MDDHWG-*RDB2$QF,:DS[!780>&FM&Q3Z]4X.ZZND<W3?3'[ !Z6](,&_!H,H3
MQN3,6UY]9*ODZ?LBPZ^^H,K4DI^'/+]4)\-3_L4KS72_HKPH/J/Y7,S#AE?)
M5)./2S_1\T,LO^U[7CXLZ*]]JRS4/N9G=AE+^R1L5MV \T)[Z[R,8A^9/.;\
MCUM:_EFU*[JK90[@ )MG$_G?&Z.3Z=IZ$9*3TA^OI1P\K<###OL-U<-7=JJ5
M*R-DUMYI<*M5DI'V3\?^;,,8[?5(T7U5_=MLD_6J1D0.'$37$[3G(T^W3Z5O
M+MS*&LT[:</8[B,1#:3SD2HJG":DT/I2M0AD;H%=>J1@PS*,!= I</_'7AS7
M0G#>/]XSK4J8ES=_[-5KQY(5CAGEZQ5FT;=G$E +9U7YIC[]G.8]G9DN>.KH
M&,"9NT&8_-C=;8;$\[5.WAXD30A?7+N/ 6?QL!VRP6/ AMD.(5R[;N_+FOL#
M0X'_>AY6!P,2 .[' /P5!8XFQ*/_\9K=>;0B(;<42%4S8' (V9TK81[9B[L8
M?^H9\T$\*3:-@PZU27[E8]:26_$A#P8E9JU?VC!N<6/*/8,2[EIUN?5I?^_D
M G9>^W@,H/DX97E(;I>RWY<R;1&XIRAR8#@1(;*J*0W[>G@8<D!%9!5OP.R<
MZ@6MYX*:X#C'2?IC0-<E\#$ G7D,8 $5;?K&3;P]TJ>9W%!$IZ-)G4) ^Z8(
M@4P"<[2DLTEZ24 'Z1"PT]FALYEQ!+PR[+L *KLY?@R@6#X4F*'#.:Z?^*/3
MQ,^<>,.6U) \WU80WX[&VQ*;&_<L7]#] 848<D!!9)4C0:'H!<G^0O)?EG_'
M@4E'W_Y/X!,<&7^9_LIBQ<?29C^5V%?OB:=#+B#AQX _ XL0#TF1?QE+DXPQ
M_T*]<DY@^ACP._A_:/AMK_6'_=^1'Y&'X(Z(K$I_0PZA^[^0?TM'*Y*"=_V'
MLO^R_#ON+[9(. 9;*O\?OOXR_$7]/V"S"$RO_QGX/ZA_F_\/U)0AN'TB*_AO
MI.$@(G_ _E^EKTM'*Y#B]_P7Y>#_@_(O.4@X#%OZ-\;M0/]U:$ML^AL4VA#<
M-I%5Y\19SS'@Q%OTR>'DK\-_TE)T'1E!*F<I7NN7M]^\]/V?O&@(3&-P$)U_
M\%(FK_5_\$(?@ELFLAJ2HI/_!D,BQO(2K(OZ?RZ)QG3T+5+\_A,UE?ZU) ;^
M$-=_X& )N0'K.*"5KB7;,:#>P2N1^.J%)6&7#T?:,&@*IJ"'9':PDP6J2EJ?
MQ4==,/O'U42JH3[#9N#&R 3O,2#U<MPQP%>=* '[P]CD#V,"/'0%O?&;F 5D
M!"FQ7[P(_27SP?\ ^P<Q+P2F83@(_.^9J1#*\-IMK],60]<__I-VZR2KZ;P7
M#]5YQ-BB=SAB2&=QO)1G,&R!*MM]%_8KZ<Y-OI-MH?T8\-LT<"^;%?/3UU?9
MYRTIRY0I'=(V!$LDG9I(27'PD)+B^'B .4DBC/CPUXNKC^#((HW+OQ9W#\D;
MB<(3;W$G2JO=41 \W,(32V%64T<B-2=93([Y^EW!.*7,GUPU=.X%6<O*+?C&
MR:+YL[H*HR(I"!,2*3[@WB,J\#!AK!4^K_K'%OB[?O4/QS\]BB!$DW9_[8>3
M7SD>[<J+S%JR T<M&WY,2OEG10Z[\H*2!/Q&+?@>PU>TA%1])/ZH$LD%<"3>
MZ1CP>D_@L9^!B\X^U]2GD,FOH1=VY1-P6!@$29]:M\!R_Y 9=)+ RX9CP [9
MGXI:<?P;L\-<<$JEFKWQSID;GFK' #=OAZ5Q&#^NF^3BD@C?W9YA3(V)SB:"
MI!OH2>EO_2Y]^']*7VS 2,4W#S7(BKH=#W"RZE;VL2,1CIF"'0(6?\E*RW+4
MM6'IQ^30+6,^M/4O#1?!OJ-W_LS **AH_&IG^AZCD,]CDN6W7Y:6OP2)EZ8*
M/@8L4&3!)O5@X<"A(<SL7VM%3%U*A$+0BSQH>CA*VVA7<A..E]H/QK>?Q)'Y
M.J<-,EFHX3MRSH\+OA(LK_C%5+3>;''K\HTUW2IX6FZL;E@(1HAHFS-G9"?G
MZD?5O\L6]6A5MY*@H-#N? O4V"[>D&#-$A"=O6PXH!_6[$J;O/+NX0+>F\$J
MG,J2KY+8X9.P;7XN>#BC\N%;0\TE*SCTA_:\@DGD[,CH R?8'8)#+!28_XF&
MJN$<J):0<)!ER:%$CW6C@1T#3B.CP4-]*R [VGGM:\0;M%.R>PS)5N &'[KU
ME$4S#)Y/M\7ED!8#7X,]18. )@:X5P5UMK<.X>NPI[6_3M?OU]QP:MHZ/^8W
M>2-C,O4L9\U\NV!)K@+3+58SMAR<@B])DZ\L;WK%9E;_C@@[/' WL-KFVO6U
M LV+E"OF0S_))N!6BM]6'X\5;0S<]2,U+U:D?JT!#8S? 7(61J\LC55?AII-
ME?B(9Y7[8\?%P>$-&*OR" IA&9X'Y^'?2]&=S*3V0^Y%46Y.'X*W.D9+\M1'
M209=X]@_;_;L KKL8T:DQ'D6.MS<=(:279A'Q#?P$S,-YVT:^^+T6^6W)'HU
M&B=499\^<5%7K$1V64;X,5=LPNI2+BR6YUA7V<HO9%@4=G]YCHD8P:]M@^@*
M? OOI:UD#^SC;_DAOC^CM>BYL?JD:4GZ(4PLNAV9K>A3@@[?-?VQG[GMN\#\
MS-U#D0-G6H#+J-<I,*K]&,3\SJ.X@]Z[)HOFJC+("^!J)O+1(M1AT]X<^(V#
M;6,OQMWY&1M4SGZE2'CQLOJ5H,E"*7(ZS7G&3N-^]9=":Q!E?<B15L33P7K#
M?1.%N?2B ^=1>=O'[QD3M&9>%XG&LK%-E<R45/N;M=HY,VE>%KD$J%S\%"$P
M*G0,L-7B.WIQI%OIJP'%)=3V)QPX'%6[E7NM1K-67)WD]I,?L)XL!:"[8MON
M5V'ZC&M >ZQ!<\HW7%_T!-BQS;]G@%"ALEQ5RJ\=]JX.$LFZ%KK*HXGH[5;_
MF%&50B'A<]+CT!M?AA??1MBQ],QR&XV,V'C./DQ_9,K^7+3])=ZRU#"@P"D!
MZ[2['/04C:IB<=M0X2R.D!F]4!_ 3+;GNB  AX9$C>!%KESQU)W$E6\M+;$*
ME$@=A<H9>QPT!F[$<E%/1ME&7"N92$+#-FZYG[V?69ZRN[^[X,+!O,'3&5SZ
M<ES_2 ?<DP^Q,>* :,_<+> BOUNHRG?.(;FBK*)<;^L.?V.U[8>F;ZR]I\+8
M!E-Q5Z:D@K&D??5%A+_"[&Q$GK/7_C4UMX7"C$CY@I#,%C_]J&9.:T-U[Z.[
M=H;T$N*F$_:W'ERR@]GTKG'ILC0[86IE6NO%W983G,J\.M3O+J^MSO!HA(;4
MY'<*6YY9*L!6NF<X+CJP]PP?.(;Q>%H+GRN496)WN%'@%/OS-@1Q"76-ZQ(4
MI-SDL.!+/:T:B"P3T"5UNQQE,KVC]_LFM@W4,J*%:%O2WUF_^5I4EZ(Q'S>=
M_6KP!I1GKZ:=(W9 %Y>5%E[&Z/%!34WSYWF?MY]^#C@W#$(0.MO' !'<K14[
M00567@3AY)HE^4Z^\HW5U0'XRQS.^^71JA2C1=>>/NN0RA9S?INB$:>UD8WX
M;+0TZ/RU6SGK*^H*ATMQ4OXW%4I9[DB+RBNK--B%,A$43\'AN*K+=N8Z2VET
M\7#\X]B[9UC;BJR:.7:C?3='VO0WVA8'60(*183S)8X$JAN4MUG;(D<\.[RY
M;U(HW&YF()1?)8UPZ,D-]3V)*Z/KQP# EH@P5*YURWJ[!/5]R'.^E]W5Y!#V
MSMT<K-Z/Q);[)CR+FZ]KJ;/\A'U>T5HP2877*.TB<BU5S66YYE@TOV3;X,TM
MHUGAV:#_25<]!Z#BF*NB!H7'CM T50L%U"+MI3W?-%[M0V8H?\K4<XK4[OTZ
M^G5)Q]7T0:ZQ'=,>?G>1X"'N?TO'&(S!4[0]+JVJH'U2EGP?03/;T%YZR$9+
MPQV+$E6:5RAMI</OV,:+S(<9UMIB2J4#''=+O(0EVSD&V W6]E>JW"[&[YZ9
MXT8FG\7&95-ZY0<K*B[&F=@OZA&*YS59Y*6";9Q9#H .ZO7K3MJ4$]+N>_D#
MUVJ/ ?XG'WF3V&. X'66U^5=P*8Y5H91 U[=10%>\13)\3+K:@,HT3%NNE-%
MFC.G(^[Q-_-1O+74\1J<B@O$BV0/V],O3V[$2C9A:+.KP)T,D];^5H]TI9Z3
MQY[VM'HO@[R&J]RT;VY*R'[+FR@YWO#",<#*VYN\T;FB I(:P)W3I*)C$9\>
MP5OP%.-I,WEX-R\0H06"64SVRL*9O 0>;J@4"2?FW./PBJ&N15M("I*=,V4:
M;YDJ"H\9BJ^#")_ZZK2%CQV'FUG)(!T',79"H/O]^;QW<BV,&@L5TR1+ES+<
M%#4RO5JY7&X*DDUS/K@"*J6,LZ+Y/F3/,I&64PA_:0=%6C:$>O1J+G3G?L->
MLOO6NMR3S;@IGY>0C!E\/ZL2*#Z;'!C:!G$ECXL=L7TOU=-S[SO%"^L(='_>
M9R\=_1XW!:!A+%"L[8'_O#_V=/GG2B4,Q>R,8:K7Z'09(K042&]7T@ES9EQ+
M033;L747]E4'S4WI=Y[&U+8J]GO6I;"5LE-]1;/WSE4/),R#BRK+4U1#F(CU
M?CTED&VF3S\IV:L?5O4?/*A-1HU^'UR=O/N07[[==1%"A,WF3F-LJFYZ3XVX
M4HK/'6B5 ,V>Q*UX)KO4[X'ALG'/X:V0AA>OPZ8G:I/0"K8B6-,CFYJ!@D)A
MMQS!)]V--9#'=H*.F2V!G)]6^2+'YB73Z%:9L?Z;#XFIFTNBZC!$_:F1_ M^
MN[SJS(EMP9]65$Z14]"J:O>+7+2T'(>9>,,,NI"/574F.%2S<*QZ_:72_58O
MO0H>=&3J\#:-GQ.HFAX\?U-NX/P 2@I[OKRD@0WKT_+1$W@GLA7Y" HW8>_<
M&VV'NK*AD+"25I3R>=Z Z]WQE%^?W(]M1K[HKR)D2[RL?;&V=4B]:M*C8#]P
MI%U>%>P,);]M]?Y\=!DJZ:OK)_?,O"G]@:3F%5M37*P\QY0LQ'I87N\.KWCY
M@^O.RV\$P$H; X@I=E.=WE4(+_VDYI=Z[LCB)N,(,J$PJXFJE+!C $/I.L<2
MBYR19...%']CH>29RS>LQXY"V.@UPCP5.@2Z,PB9-;)TB;>6.*Z^'[,8,BM,
MY!8E)'^[^MPZ@I[)^H+,SV<AE0.%N4VZB#P\B.[CQ0SE=H3"E2FO]I0WNZ9'
M[1X#3'UC"]TU*%'1JR%Y[YYDH,]2+9I8\./TIX"4];FMGY48P(C:&I=5W\8$
M&\'7OMID[28;P$8'$!W^4<VF8B%*^E!K)^[NDD+:;.P-\3(UOD_L24>&CSV/
M-.P.W^ 4I_8U$Y;6=?IF:_KIE?5*$!V<(^JS[T& "*F0A!A1T03=\'Y,%L[O
M>HY^_7>:[P:PP0/B^<V \LH([",'XP&/HR()33;"%>8",.B</:E'[I?TFAJ%
M9G?2U&S*7#/?BKIPNDE'8^\&S(Z.CHYYV()I?;V J[BBG"5S( =5WGF5ZKHT
M^U<KMN1YILQ20I8;M8*A13)8KOJ;UX#S'?<]MQ#?R$ Z65E.C>KBS'DY%2UP
MPQ-(EO!DR@&-;IJO/<Q 'E9GP5BS&1?TLUN(I[P4'1]SQY?O0U;@QC9>-941
MF8:_/HA71EA,F/B&"=7TWG[?YI(K]".2W-KHPU;C;=YB'[ZI E ]B$%BU<DA
ML59)J[3O=)N9.M/1O1Q6N9#Y=6"!>S+-9N>;'7/I!L\XPZI&5+ [LS#]P!2U
M9*R<&C>?G-@T[<^?Y3+L B]Z\]@?5;L=_<B]^P'--YG;8++@Z5G%V)1W-AP;
M@!4*XU?_^/$UYV=:M>F$/)KP'R/^M9'!V(IDY?#+-C?:+E#I]O+64OR<;%P%
M8M<2OMA3>_4*(]EQ#E[U-*'G@\?@B8(RAP.JH>CKWZ;:UD];3FAY>N8L:ERZ
M7YFD<G!W[(HY B1UX76' G]MEJ7M=!L"%K>['SK<.Z,W-U@$C/!C6O8CBQJ&
MF@P<"/-&C7/W9FU_31"3;KH]<[-EFGU9!+P1D)=OQ]*1!G5J4N#[?G1/,)^'
M,,UHQBOFS;B<,+EZ-74Y60#5SRXIP!TN4G!QE3/<8MB&L]F3J4-^0]&@<U[S
M[=ZKC6FMO*_N.A?MUA7\DQ*\WHR<:2>TW5MIY\YX#GA_-P)!4>"B@A:(=-4?
M)-(=P.K9:2. 'T=>P+X> \3KIU!5%7:7!>QF;7'N$;Q/,&:T I;U:+H!>5UG
M=YJDS-314;#;JJ!C7KEH+&!ZW;FGUE6;D"$O,]*_VP8N]/*0ZI_NNS=BIBN1
M\,Z!)2UBFMN*!^P\#A_(70*6QF18/FE:?UC>VQZ!N/CZP77I2]]7J:<]']7S
MH60*V'V4>B16"2\NY'295,7)Z]G.H\(Y;'G\N9F5N&V4?,4'JL_X,2Y'6]H/
MO%[IT1(J,)A-=N0GI.:$S;,K/D[12)PB]?"KXE.4T=B85V/M>4:F\5#A3'AK
MQ!W_<Y<5?I QR3X..S1T=B"MLG#?W&8/%)6FN%V44;Z!<_YG3FNQ]4=W9$<\
M9E+J/KL[LX7<#ZCUVSTTB]?/^-&7A<!3'29;IN-8C3:I0KBZ''].NG-OF6;B
MH%<_BG]2O*GZW>&<@VF\@>%+NUB9L:8MIE'[+S*<GQZQ["O([45L$!)M];Z/
M).H@ECRO4//4*!JTV9W/;&K#.(:!D3*G'FTY<(#@(Q+)- X.<?W9M;<<!^AM
M\X/<CG+-@X_,X/LU'9X<XN]E<\-]E'<1"#P(3Y[$<KGG!6D6Y5"5K.W/?Z)>
M\"Q 2H:.6S,UY;9: ?P\3L1X\VD9-&MXN(V]86DEW)DU_?']HGF.5X-E>#7<
M++9=Y'Y5*?AH\DJ@[ZT[CZ5C1]PK@KBJ[_V,,O[R .Z:P$5 R(,>=<>7(1GL
M'4<^H7Y 4\-]@I*I[IR#.#TTCD-F^WY6+ OZ(,)B@EDN@AFF,8\\E")6)W--
M0<\LH2^!J3"O@M:%K&HB[IWZG#%/%G&3]6VC>#V:L0^ODS]J%]LE(2U]L2:2
M-48TC__&DSM<R:=?.*:4VO@WO3_T7<3TY0<$.M@+.EGI,\05=7!'CB:'44J[
MSV?93?AUHUFB[T=8255^YA[4-X>CZH%XC?Y4KX;+1SHW8IGYV*Y/2UI,TF=
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MFQO[V1\#7&0Q%WV$!FHD:0B-#>72ESUB!7((A0,_U1FZ2M,%,V@S9;]Q]'O
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M@%DX^R>EH+_Y3U+9OL;V3(C0W9IQ4CL_T!QPF$$.LSSCYTEJQ;CP>B3@/"?
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MHE'@"?' 1JU1V)?5;=(DW[QDN/ ])T!\LE*Q]':UOO-1^[\*X$(J "?^(:D
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M6=;\;EX!TXNT.Y":DQ/P'JP].\-7)[N2&\D5\'\*RW^I>G&^KV=$28BO.Y&
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MZX(5%8(^E8%W!*)][VE//1Z"K%#8G\C?08ENQ7?H9G;7H^<FK^%:;2W5#)3
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M:BK-/4("LE!0;QF](/=S917)?[=CJY\A 3+F*,Z/I:Y _<$,^-]MU6+*IP"
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M#0\7-G<OD "_CF/H6]\]F;V+)@V"E/9?J,SA=+<S#B_8WQ*37Q+5$"=3#M?
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M-A'4L 88ANL1BAK'?HA*( GJ1.# R11ZQFJ%"D/4AQ8K2DW%3%UOJ>HIBE#
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M$9!>>5EVN"1*+K^XIT]Q[BSM62K>+L X-$W5\X7E=T\D/&T"C$(Z@L03Y&U
MBRO<S"&74NZ:H/ZG>429Y[9".%LS=DR^6)762;_G3,*7T$TBG,.=? )>:C W
M2ON_\RZ9*&MJ!W]^5B[BOPZ^LW00>029X68M-B2"_D8.WJ0*!(!^G2XBZ.QU
MO&WIR?GY%Y)OW*K$>846C:TB%KUZOM8_W367D/WJ/(QDZ)7B9ES.',2SD\>*
M5T4204]B9D;4)B<ZG1X[G[T;*>5$H;%4/%'T;S2)H/>Q@"NF9B80SG'C!KKD
M&ST_X?_K!QR6?1WFS>4W'E0/"3A^0PUO]T].3DQVL(Y_#?\HS;-NA+EK;AV'
M&A?X_4ZF-F=$=.--:!4WDYT\$;2H8-<S6?P;7'YI<T!6A@B"BL!7;]=#=S<V
MA">ZFKP1'V19LRW6R@?-(^3G4CSG=+K9K=M^4YA=%=U'1G8OJ5(X01Y"'3Z9
M&!EE'*"6?;.L/>=-_5[9>>UY[7\YB#I$\<D/$ Z7+,9XEUR9_/W8_&S\TD^W
M?T:5PNN.M'^RM/4DSS=ZP?A?O'))3W)O>*KQ6@),\SS*9&2I)JIWR)'-^%9Y
M)*UY]V#^V88SL67.L0BU7>B?H7](_W2SA(0P*16D%Z]?6O#A&+I24)T\LM35
M(Q9M(:8L\6WX/+OLHD?[8ZSV6KUXR8_@KI@=TY!1VZ68 Y6O;JOTY'>#S@5X
MPWZO).Y"_DFS;[WX%PK&/L2!;0U[2%9:HG76F/G%X(2 DI4< ]MG%K!9E%H/
M5C($72:CNJ > F.R+W&F3OSJW\4&&8GJ?^H<P!]XHGPR&P<&U.>SDQ?)=M=#
MP3UC) (B'R5?\@<*Y0G(##[?7Y?-4JLOO:^@[Y]32SW\/+2[/IH P6L(H#9J
MX<=7"X1)_S54!4R_V20[O-8PZ]=:_(\IJ12)Z*;DZ-2GZG=706=+DM/I>6W#
M I<XXE>F$+20Q3A<&*$1L \Z3.4:5,G7YSL6%23H^*)LU!%9*_@ZB/>;M<[3
MCD:#>[U#OPCD]6[SJ!A<.FM?V!-G9V>#L:(:)/OQR;L[85?>?!I1Y)3T$\[Z
M*K,O'W<:#9@*_;SP,9J>\'9DC\[7$.-*N"ZG;N3'W90P:(=]W,4Y-?<@4IS%
M\55DG9/,V#B31GBBXU>8@_A4Q6!;@%P+;O;6EB;_!@[*@&5@&'IBIW1<]Q6E
M69^]@G\6J.?*..I^W;5DR;#:0-TB<4\>AOOU"Q<-)/.Q>_ ]HR+_L98(RV=9
MS62O8A@Y[4R[SI>7"$\_%[E'D>F. ,M"_%XL7!2W)*N+&-8._/* KR"/-E<N
MBA$IM$O]#3FPELG#?@05R=6ECD(.5$&J#Y5?SPB4V(<L&6<%D5<D7K>YOA0]
MKG+9Y^GB"]EP?4^\JCU;JI#%O%UAF(V,*+B+XAS9&,[',J=(M%L^*.K.,5/1
M(Q=9/^4CP%&6BJ<@H3=CFGRLZV)FYMX;54=*-#L(J7#$_#H*$EU;4YGA*_$:
MU=N]&2@9XJ#@[*;V6_1UIVS2'MI,^;/?%;9G>V(N-X]/-2!(R 9*-V^P5BE>
MVJ$L7335(.[+QQ?V(G-FWA_A0E.CA8CP5VBW(\$95<ZJG8/3G/9D]+NW#];)
M[Z_$AOZ6;5ZU!:1,C[[[D%4GN:"W&/_PLC\7TWL=M:OMP=;<VY]NHOMNN?:S
M?4JPN/G6GK%?E5W@.X>J3==.R^_+E9 G6BQ+D?:?2 0 X1!\[!NQ(QZH^=<F
ML!#!PF<:0UVT]M:<)<9YUE8?<YE+ALXEI1QE/YS_4+AO56LZ&<7>+12?]_EJ
MKH+$RN3-RZ_I6H^"^P>6P0^5;_-:YG'$K)W"S:D&M6Z8E!63<\7,\WL.3G><
M%#WA^'+0KN7_$O5!]H%#KG$G"Y@GYO[:C='3GV\.75399GG:SKOX ]!X ;0Z
M @4<5!5;]PDH9/34!*[H)YDS>^V/!QS:M^UJY!]-K':+#C'H1B'%)J'731_N
M:'@(=L)$W9MO4=$$3^E(4: RG=G^(C2XJ'CJGX480^SC6%\CY_E->^2-4J&"
MYI9Z%1-P]XK<SGO'5V4249@WN]CK:FRD%9&)OVN;5^T'Y<EMZ2<2(@3+SKUI
MC4LK494Y2\_QE$>NY_%@../(FUS=ZY'IF;,BDZ,K0V+:BE[*Z$9%VB=G_J>7
M2C>MU> P9\6SZJ@YMOH]4)6<\VY*2M/7=D=E*++J((,;Z;M_*(]04_ ^)$ )
M>2#(*1SJS2NS3P1!5G;2 JAW!T,A?8#YR0(UF2Q0=+<%4!?!^_8S)[+S;LC)
M6[R;>'-TIDT9]DQKLGUFY_1& &=!9^W=]"F50=7,\8Y-%^-4':TU$S=='>?Q
MD(Q#$?C<]0'(*HTE4)BO$6CA3=QI\/[;[430F2$\OTEHD=<AO8 /(P03LHK8
MNU ,)%8WH*2!_.L8ND)%EMTMEN)-*R+H7T?S .E+ZQ& I6(4@2P;9U!&Z]I7
MZ=)>#-1$%U)"B*#[86 \A18FG4 C=YWPY@8$1X68,QG6[I.?ZV)KT\+?]N8^
M/2L Q[!"FJ)PC_:TCL\9 96]-#S07EM9]B3X?Y<IW>*!3;%1KL&?,\,5NI?5
M,@@*1=J*Z@[K;3&FYQ4/C."D538=N;89(L(_FO^Q2D81;!W\U\J>T/A0CZ?_
M^:WTS>] Z4]:?1.M,Z#XB\8O'DQ:T;/#<R( (:WA6=0KU7Y]#OJ?@^6[J$D+
M@8[H!&G-W]"//_O'^IS;4?^<25V1_I_TBSSTQKZ(VXGU<"LS92[R_#"36 KE
M>>C7W^U=W'@/A#67<YFY3@1%A[4J$U(6B* !=9.ALJ24<I'D/?5<\&2M(A&D
M4(<@D&<30=>5_WYHSI4I,[$VIJODA&W9JF)</*OH)1^U@*0OBDJ?,FM(T%X?
M55D3'\R@IDU1C5'65_#@DK9:X1XL5"."K/TAR]PWZH?PD ZT_#00_.DV@6I.
M'()+=/-&A%CV]ETQR3ZI^ DY,%G"0[#<9B.WAG18I6?T:JH)O4%V*S+=;Z>Z
MA^Z1,=\W8%;FV$V$XP4GN^ING.B5#J$?2</B*YS-M(J3)QXR[O3=/W/NK?_A
M@U /PCH>WFU V 6F7-U"UBKZ.0C6M0<)OGBKSX/M],TTUGJB-'&TT HNB0KA
MQ%Z05OI*5Y[LMEC@X,)BZAQSR=O;L,3$UZ2>T/6]MF;P>6!9X'A&*TMK[7C%
M>YJJ]O,EM99I^2M;H\C0^IO0U>.1UJ#D]/K45X4&6VO=(0S6S^\K"C13O/5@
M>=.P;7'#[M,S5T^EE-M,V>D:LST6)W*(HY0M_:3G.R$_/>W6./-\O&0\S"$=
MO1CA8'=H\#&MB<V7N3!WLN5$FWKS7<AKRXH]M#G]07LH?-6\ C#2?=)#?E^^
MSN^/)K_PR)FU<RY*J4B(-\"V2EC;!$A-M6_E/&/VNT.E(DZ>B;W4(@V)8!_D
M#-9*,4UW.*=6$A<I>LO%[-WNM;.6X-9)NHV!3,U <;4XL;1R$R+HRZ)!OBZ-
M]DB^=I7<9,41J^7+&>YG09BE*K9#H)1L&8*7U@)UI$(/DD".!,S!6 )%@]R_
M5*C0-MHVAJY6DTTH%&M]'FO_(S"D3K.- U'5(-7SU!;.(+Q_*5FQ\)7O!K.G
MU;"%>J=$QVURV4=Y%!14FEJ/GY>A#ND7"#8LJ!EX\!$K\B A!+)J7 ;(";0L
M\R_YD33KQX^I/7(];3G#'[H-FDQQ()D.'3Z?"Y"ZMYR-84/FV%\L5/43$&EG
M^R;P>L8DCO]JXY-QV11[#Q/2<[F'ITY G'@@]BG=YQZR'=_>F3F$1W7$SVX>
M&F![+D2J9#Q9_4E^@?WF$![HU58226Y57'N)5!I' *4Q$!+XI@NLJJP&,APX
MDC_\\SM1MR%'RRC X7ER^3JB.J((7DC ?W?8 =>T)[EL3.C9_WM/\ZY_4Z(]
MS]84#YSC20LE_R]_E> _7]H=TWHL9PZ_#@8PLY-O'%) 7=<T+,?DO%E>']!^
MK89325-O16&!+N%>*@@!5(4;?KRBBN 5/#"Y+2B-E!@.4\\#1X">D4<ZA #G
M]AU:*KD:9WS@/;(&LI5-&4&0L,*]KM<679H[8[CO/>MVD!%\_J[4.KPMH5.W
MR[=]N/_<I_^1R?_UBZ[+4XN@)$P''UN$'_/:YQ;I-@T*^/-A]2XK]!Q\R/SE
MO7DW@'GM(YQO GSY%*)G+1P*&7L(U<.2QV9U"[I?VK#WB(./=/^V8I/J0VIZ
MCZC[/6PV##GPM!G*C-)0>A+ZI+ Z0#M@,Q6D=^Q6Y-,Z2[7/ZGKBS<Q?0ULV
MFL+(+1F/%HAF&*&_\(",X;Z2M^C=/$,H18H?M>;W2 *#1D%%;(D 1*!0;.9E
M$.,B6<#X!EK7=M*EZ(2YG' ;$Y@YFN!@^TI4O-GKRED>&O7O15J'1KE\U$[.
MC\<$\?14B]5#>S4U7Q5M3*%<$M&ODQ=!WBSEV[D]KL<)3:</GXR*R\'T8GK1
M*X%O?@RANVT>WQ] =O<<_GC0N084E(2KZQ4F\HF<P]^"=6-ZQO3J;+O4W040
MHOD@A;@KX2Q6#@SB%MO.]K_0FWO3EPP2-"M+/=]+"T0^+P_("64TOJ,*<J?L
M)J>2MS1.X<!"WG*%\I\J[J$5O\7=5N+Y46N=<4;K\9L:EKWYM $"RY0)S@,Z
ML 5+#QK248A6?%YP8]+EV<\MCIV6<M$WL9%E!EK!TN69A?+I/EY9]V>M*LH>
M%9=9S?.VU,9,1=ZA>#6\YM>.M(2V2 .I&R_,BAV>KZB(;+N;H_[5H<%K"[MM
M1F4\Z7EO97FET/HE&POF2O./NLR(&+O#@:-ZLXM,ZB)9^LQ+1PU45!2:_-#6
M%%!8JP5G?QGOEL3$KXL&\WV.!JMW=!DL"<TYS[;-RJ(:C4NGA=4?^#CDSHZ7
M-7@)+_C%%'RF_*5$X13!KN#:03&:6%9!X=]N[F<YQVFJ?A$MUGGN;LFDZ>>/
M@;J[K.D,C&U^6*U^K6#9!XYC\0:O'3C1/[JDO?B7&9;.!'STP3C9QY3A^%DC
M&E0B4PXB,6J$5]=@$6F*^D8-?M]<WC&>*UI FQ)!EWTI(,W)5]R<O5C1,7P_
M5"QOP^Y$(5Q?+)N=3NU0,#;0)A>FG_?9-"K%I@3;90NV)A=VJ*Y\>7QC5'@9
M%HZ._G)V\>F;SGVZ8G<_\NRY7*2@M3&Z2)#)*-,B,OR+CMR'VU7J0">_@?AU
M)6/M.+/@JCG4S,RBIFUN,4CYQ4YTW!L=U[<S7]KXLX9KD\%-AOS"L0[GZV)Y
M=]I^]9]KHWW-]C:Q0N2[S/A46 -JAVMU=G\#O%,XT8HQ$Z9X[^86K7:O+(K/
M.^J3P0@?@J5. 4Q)R9-6(O!_;9^WQ&X:53%0C+R\]F'4VO:3E>QL;<2RK=2*
M;.PA*C6#&[6 V"#0@A KLT _AL^%) #5I_R>SI,SZJH$>-_1? (0<!!K]R^%
M6J3\6HA:E%O=[P,/36YHZ4N!J+^R4/V$M 6<I[@)DEQX,ZXHD]V1# ]!]7DK
M$N;="%RY^@I%H(;4<_J4=WB'M>_3;2/1>S52CD7+ZCZVAJY=MYIR]KFJYK#\
M#Y]2JKNL>ETNC_FHG'-D5R\5X2B$EX3Q!;_5T)1PDV/(*Q&"7Z6>,S>'V2KQ
M=EHL&W[*&'Q=W$7:-@9>YT&ZO$X$8<7^?B@^/*">B-A!H0@@$S\BB!K'+4C:
M\$61L#]+.$-*G -_/QS35609)H+B2/=:S@YMX^"-4C"<,9/P81%P@@I*X(KZ
MVU%U(L]R-AY)6OEQ P%O)ES\'[E1%H<LP>%X4.D) 8S1-"7<4 H[W4#AR1*(
MH)#TOQT5985*Y9*>EP5JXO/9LZ3+IBZSF!]BT&USX P+"J\!_MN1NYAVC]81
ME'3#1E">" K&7X__LUT0$>0-\ =: E*V[;^?L,]-BWP)_TD@@G!G[ [QD-])
M%7B!"/J3,3B.0IA49/[MR%R#UE678'@(% "7M%"D.PQ+J#DK6]1,#>E2.!R7
M"/G;T;IM^O]KH;>R-]E^O[^6EK(F/+@NSI,@46SV@$=WQ".+F6V\U?L\G7;2
M[6W:L3X"*(F3TV9L&H!JAP@2;8+LGLQKX:F&(;AJV;X+0*NQ'0+!R#P!-+$Q
MS%,H7[Q!PI;]U['?+$9+>%<6J#<@]1S *?1#(B@LO1L3A2?@@**)K(R:(%2G
M$/J/ =26:X?P1EG4W_\?];?I]BEYCMN1)..0B\K^W^,G?8,-!<!U((_PP%_O
MPO_]_ZO_SAWR25I4@3=)>63_!?^9D5KG"S[L2I3XYC2V& [.F"E7NEQ4YM24
M:_7VH_6!0P%#\0%KU?Q#DY#_1I-&N_\P0['_WXW^'^U&_Q^#/CUV7BFTY["(
M8/%NTV4'OIVXGN&2!SII?_/$<2'H7CO%Y-BZ[=^UT0UO:AN H[Q(\/MS9WMK
MX8PFA ^W@'FE($W5S]O'P$-$T A^=6HF>Q=P-JW>_P"#["_U6!)N"(6=GJ":
M>DF78?[ZC">+Q?-G3<U4X>%]1%!><E6=:M\& 1[WG[R?_PO(!EP(@+3_/Y"F
MU,;2*Q).?Q-!%5*>1%"[]Y@F Q'D,PL9P_/^U%02K=RC^+XO]F_H+M//"X5%
M!]7T/3N0\H?B/0IE"#<DPB+R#I]ZP(J[^@@RYM)+]8K<9-L27MDE'S#2*3]Y
M_D_R=_0O0.O<0$10]E\*LEY%S-22C6VZ+ #=8]$7[?K=),2#?IUNY^M^_S[X
MSSYP_V++H[C,.<_>\7W;0JMMUJ92V!&-^9-5T<<Q,[RFPDQ2:_%/;)<S1X7_
M$,B=!F*8IOU_]T34BCRGK^:(+/6"UB6[M)^C5ZCU7H<ZF.Q)1?5V7'2DQ$3B
MT2^.5.>38C\]3_@<6YHQOO;)\!V.^R"1/H7&9_:J[=C5ET],3LL?E4]H+]@/
MO?SJM9'T8M46*XGFE4 @[73LZL'U59B%SAR!L?"PZD63[-YGS#_N//2;Z[#@
M\TM"VM/W,9L=AO(G8(1;!"7GF=83I._9[4W*1-NS$I037!KI/K>OTWXW.WZW
M!I7 S1[$8Z^L1)1-LE+HO)WI4J^Q%V5Q)G_:->;,'N-7B;PDT;VVB(,7C+W/
M9,XXTD?[%1V8EWG74<-Y?]YE[%'5;2ZMTI^$#\E7I]7?@4Z0M2L3+-D)>&&<
M7B=VMYVBZ#MD^R?@EKXN"]UE1%!7U2G@"S'RR1BEI_53\H<$Y7$QP_8P[$+;
M[!X]^' )WI0%C4P1;\<'!I\>F8PXMYD16@A+!!O86^P&NGD;ONCGH^C[$<$B
M:P-?%@ H#V]@2]JXB_* CZ-A$4[4FUI;T&4;'(2E?LH?(#Y*:_@S'YO>1D%X
M_HZ +WR,8/0UF]V]#CY<LU=LNT=_P'DHO"OJRQD!=83X$$'LZVK\RW2XUOFV
MC5SJD[TR$;P95IL(^OR1"$*IFQ0)-4**A:O@7[[.F3T_<3Z9/0(_UH9*9+<B
M:"OP+<JGQR9Q_ORXI/UATL<!9X,KIR%^7?CNV<OS8Q-1,T10Q[%$Z-%7,QPZ
MS].F1ZC,W$6&_T7T<V..#T]K6,XT;)NDSP>'*#U K1"J"MWDV9MSE-*SQ1DM
M>B=D3 X\1L<,T6[J<P4F8XF0J".P@C84$A5"X(#L$"#;$\-A6-&6%P0H$;3#
M  148R=$EW S'C#OD2G#764L(-<L#Y(<&F)Q&[(#./#'T4QH"-LMH& '?-"_
MU61>EO]$! _I1NS#K]4/P\$[<H.A1[OJN!&/@I?>\<G6A8JN?ED_,J<N@GLN
MOD)31.(@<?: 5?D0X'!LHVF?;+J:61GO3V%EF\)T0RW_W&F/1[7OZ%B9H5%'
M;).*GCFX-TAXWS;A'M\C[$'E- R";=0]K0LB&/N#EY4/V-B/$A8(RB7:%M+U
MLJ-$T H0IECH'K: Z;,Q*;$2N04;-&O'OAP7A3BUXER<I,E,=7MY#1*S-:^Y
M>'/$3?K%5,:KACAV(MOQ4<YIM:%@-OOK2I$5;Z*'1<H;.]AO#N<O.%@!-C=&
MN,<+=WA",,3!OR .Y/PW2)B,\B#YV,1&(2L;P)2T^]CX(O@2Z2,==)(6$D<
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MT@V'[9Y9O'(? I/D/X#:>UQ+@C&'!*,'GAM2"CN]+DP%_[T.A*WZ=R>RJ%W
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MOO[T'L#')X /\SE $&<@=X,7D-_BO'WV#K/?C W5>_MS'U/"_PNQIH"Q<1M
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M.-.N.:*C?<+1_C4W79'6P#K0R22[79A\M2)!(J$:.;[EL%0=JI)"?YEIYJY
M)</*TE/EPY(WL>9+GLKA*!LBB,I7$VM0@VQ%PC/,M9Z?.'RQ,K4D6];_C5TN
MHJL+M#M_XW3>&O[#>RML09"_A2ES!F'I-&0^\>!\:XN_*36OC<Y 4,=<:#AZ
M_0Q;686%X6]88#4\4)YK@XV[ DLY?<7.QK- +T>$W/VYT;N31H;[N>T_,T+W
MU;YPI+PS7*?55E3I56^#T,F*_V9<"C-'20BR9D^JBSW6:U\N,#Y'I7GX(!)U
M)\>!(.3Y<L.@>&B^*GFQMJJJ-.B9 W?,8(,HW]'GB3NBD5Z-[6JMN$8,$BBU
MKNX+7YG9. XUFEQ#2A^)2*=-A5Q]=I$;9\[NO/4VUQ/Z>SK[O1CJC"W6ODO\
M,,A_R(7)'2J"75*^PB[D>HC@&,U]F-#=NU,UCA.>EPA;V"Z/X%*/. B4_;55
MF/'FH'(JDJZ!D\&%^5NKV_X*A**6U77NTUC1MJ^R_7P^6A,S9?;R3EO>$C;@
M?=!-OJ(1?88&MOW5D6L_O.F9)Y_D3<1_HXK-FIXUNW'CH%AVD%:G_66N98 4
M-UEJOKC%L;V]CY3%CDI:V60(DPWE9UD7+3KV>S7@" +5B/!"<<G(E9'%*,>P
M<W=DI$05AMK;9-K"M;+N>.4-^?IB'.ICOZV+6DPU.Q2H<KR>W%RBRI*2S181
MFFHCPV>42Q5)SJ$V5^9F@U.X,'T?'/:)H'(->]9AE4&1>6RFA^T'J<6V&)6P
M<,Q+Y ?XBU.@5E4:V,S&6I=>3%=W9?FA&8W@S:X^4;'JHA9ZXI2:M'B]U<UE
MJ'[9,#DJU3;GU4KH\BCOTR^.MZS/6RM=9O%>='KY<D6<<DG6#ONP&4$]\0 )
M_7H^LE?]X'7(%]_/X_J]]]<O(5F=8R>JJW>AH;.7]L"A$V-!Z#(YM7L9@RLQ
M\QIRYA[335@1L5=5O4,?IZ5S\B*0VZ\>(QTNN?JZ8,+IUU["'%F^(G_(#HS_
M[&\Y&;UC<;]&7[TZY[ES;.@T9KOERJ761"+H@Y@#'\Y\=E6DG3PU-**<EU7]
M_'3XW0:I-B=/\243Y0:OTD*RI@GQA+"YJ@%9&;=#P]%#&@KZ!(MG3KMW'"FM
MKF;C KA3B]+GM!JGV>>40V7O'UM4>'F*\Z1:/O-QX8RYF:5@Q;W-VKT2NVVB
MJM#;_6G)3TLK+93_^@/&M[F6_9>Q%G 8=J714.<ABTFQUW+0Q=$SYU)LQK-L
M+7\NW/Q"]X95B<J^/M$6/>=E[1[)<?[+U)P>549*4RVU^NE7_-TLW%<M["MY
M=IWO&Q[2,5UULMG&JG=-@WHEVOGIH:XFBHJSGT.@WZ:F\+Z8B,RZS1_J.4$E
M2<UB[!I)/U-O?>PL%?+]'E!.^(Q\4%8=>CS*_('#^.F7&RJ+%N$95C0XPW?K
M"#)WF0[\ T=?+QC+1$;_E+UVF%ZX63/3;Z\\9O[:RS*7R?7/UC4K)C*6YNO"
MY.JZ[9E28\;8M&\^13<V,++*:'/2UO6'^:F7:BO:&/?A\MM-)-]J( ]:!TK5
MX[ZD?VQK=::U,>PD([M0X+7Q+G1%J%[>\W9?\QC35'7;M,AUVR#8K=[E*GU;
M;261;OU/'Z485X#R(ISMS "!QZ[:X%WN>L@S#N_WDIU,'6FJ Y+\;6>D^%9[
M@UE#D)*UIW%X8>'W91JTN)2M45MA1UB,IZ/^^;3'5_E4DB^H#.BKME&H3?#=
M. Q?7/*CML <MO10M!!NUPZ\>I$T:\JO>K)A=UM5W]12['$#!>4L+W\2TWI^
MMRS=[TG$%:"KUQD31] 9;QB:E/*>3W*YG5%\'^%R+W++,/\:17>[^%IWXP..
MWP8NJG*4$<?1TV:9R05CUQQWYI6BRP$?%G&BT#5C1;0CSK^DOW%P4(U".-\K
MM8IX[CN_Q#C/'2FOS[&R==AF7Y[XNS..15C+E4#W>X;Q-&X/0;E1[5_HD*\V
M9 *WI;_6PLJQ.V:E^ 9-"4KU?I&IY^6^3%M5S5J  /OR3<B5Y[.O1]M5"#7Q
M+@ZN7!@HDM1(1JT'S7VA[NJQ]<R?KPC&@^%T<7L)L19J \HL$A(N9J)BH9L!
MKUA;7OFX'2)%WOU^_ZXI6W/(USY;^9M06L5$8-)5ZN^H^+QKK-]Z6WX&6_=U
M^^7[0''*DN&OT$)"VYNWAWM+CP>,KZ.OJC.$MUY[2A-'LRGK1.7W\NB97V=M
M9!8LC,#XSIC0XQ-6N"$]H>HBL"A1;';G_%,OYV)K*;)G*QQ499F_4:QV];+%
MU;6#"_61_*9?!)9.W)/BNSF5^-;) C1'SX&=S32039YEXC7??V!E=3V5-O0T
M#+8URD-8:_?=/[;]>!<7WA'Z2S;<\E[19",;#=N5H6VT8M]$_5BN^3IS^0(,
M(:I:,LM<C-/KBA.4Y'6%ZJ9FDNY)$4$C2C._EC\)^6V(M.UG'I+.8;//]VFB
MDH5F2#\-M73_<N;:)B]NPH\:!>UP59JN/9T]K(<2JE+)%[*1L%T"[9+%K\Z]
M[:/7>+M&>=TW[<AI\+R=OH=3NN<>"S<19!% 8RBUO=$'#MG6U(ZN9*/ ?F\
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MJ)RD7%?K/:"13U3%[\BH<;L2QD'SK=F[80NLJJ9#4[FN%)ZXW(4CP4K,;3P
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M;\CQZ(_EXJKZ,F]U.E]\NC&K\E!M5'516&;$"H$T.H_.X!RH EPU;$UWRCC
M"A*[CL),Z)\#SDA\+OQY>N)D9]^@,%MP%0;B+]PD/N@A]=N=XR59,[Y5&4YJ
MIU0]L)3@V5;!]WZB/G.DZ'3UIT7E0\X\3A_4KH#7NJ;1QY\'AX'G  ?@==OY
MSM%"QSV:HF9VD5M\>U=DM[KM1C*Q">:"#[GTM6NX7 #M'5D]T@3\UY[8[0*[
MD5F@5\AH$5K>4.Y:FD)#P6JC[9^FS(AX!]Y71">(E1]SM9&.&HH?&?0Y'9-.
M84K$R9H?A\60 >62N8R2998WCF7K52QPZ,KY<P!#;D6+DEI#_ZF42N[!<_Q
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M(MQH&1@CAU;F;*XV?IUTK)TAF9$Q;J@W7I:VE01A=MEDR8+1?^->Z_59$Z?
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M+2YEHZDBJ0^Z%,UMQ$DKF6B0ER\P=VE2BU- W*[8/RS69BTTL-G<]#6<9LP
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ME$W"!LQ].</*<A9QSW%;KOO9-J"W]XB!,5F=O8,/@4A713W3I@>+->PX=R9
M 9G1N"O4ZQQP7Z%LZ>3G\[W-@/KW!8R#2_(NS3MW4E,@-3MR9YO+*U+77]TZ
MC?VZA/OU2[(T_:FCL2PWKJ,AUR]QY1=(0_ELUT7XTQX3ZVO6S^'L@+\^A(N0
ML9(9_\GAA7JA/H>4>1?8!J=N$G=#PP>R4_=CJY%ZK=U+*]T!^>XS.YQHW+V
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M4HB72_$O1^"8)KMS@+0;''L-U ;;L ?NXLA/ T]$*$]1X9(:%W]F.*[ 4<M
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M/]*@J;<RMEM3_TUYWANB_5^2#-8G-^J!AOTH&?AH6LQJ6E7<[):!GT-S\^N
M3"SH'S[V%)R3^PG,)&1U?4NW LA$%FAXRY-BIU#::8@6[%Y%>?D9GURL09<%
M[]?G !D&$US'8F#=610-UBE^UHT"<A%V%(F1G*;P]5W9R@1YD&2>Q'GA1B5M
M7?^BABBNIZ@DE4CR&"ECV,'INDU,,%OWDDTW><'>L@#\>H\XS/4U7R_8ZZ++
M;$B:@>E^@ITW <Q&=_(9.3_2!@[2@:]TMC[J#.6MK4*0IXWZ!'YXRAEQQ*J:
M'%=*%EZ/Q5$7=-F;&VU-!9?JJ8P, ++"ES.^_M%>>\F<\GNAX-G^AKI_"@''
M \9K@Q:UB[=H0$H$W!#5EX<&%)SH$50^@1T^7BI?$) <DVQ(TX#Q8D,%U<8N
M+<D8&B35-XYD]C4\8*/<(XOWQ8>E22L_/3@YG(14"F]I?V(37)]C>3V;2!,^
MV@!?_N!2W\4B.$8))K;HX&A0.?GJYJ[2<?5\U8Z,#(\2Z:$>+9TLWLRI7I[X
MT:5^!UO1ZU,,\\..JV!/Z?+'/#@B+2+YM1X,4V[//%SX,[2;7BPFK%&)H,KL
M;EME=K5 T6?QA8UFM<TR43U\8.&4I?M:5-MNX.2AA&S>5;O95!JL7"_8TN/3
M0^O0#$?0PB^J]9$&U=-4X"H$^DG([>Q00RK&MS2ZT=EW4<9\2WWK4PL19)Z:
MB:5:QGZA\5%R1%)JO@K <1##@FIJKG:-#_^^WT,GBO0,K_HG_8*2%4PE'6<%
M0):I>"K?85'M\46-$WH4$-"17KS2C_"[+&?DP0&"R)WU:E45)$=)#%MG[%\H
M53N,[1(PR_R9=R_V.O_*1K9K?.@^Z5SO)=&2HHVE3A-D  QH6H64+69Q>GO[
MS-;R?"'9#R-SEFRW/Q%OE@X=W@K)'<8P"!D_SQ(&6BTAYEJYVC$4&#68BC?S
M&"_3U;]5<X]CCZUJDNB Z> _]_3DTXP#C.J2[E(6.&5:I13X]PW2@B?P&J1'
MGB111YR<8518SOW)K<3DLRQZU3HZ_G*WMTQ>4QA^*^]R<GX5JP <QF'E[+ON
MQF#!H9<^1(MCG!CZ7ED>J@Y<?;1;9<77EMWN7C#:7D!-%LV/7_R(]]I23-S&
MO8DX 8);:Z;KG/05&:8# S2;7L=D/:M)/>),,LM4ITRH9,4<)DF:JR]R5/%Y
M/,AV#<03%NRSQ-.)_3>_&)C;]\WK,C<N-+KGXTS5.GTA00.0:F<MVS>2TR#G
M&W=(%!I@DQ#4"D2!XBM;[V%2(\/A.^TVN=[XNM8^0LGL$\549!)SM(Q[,?=?
M]I 0N4(+B:J89S7O%C4X?]!$T \%C%U8DG^L7T^1D9'95VF(J2T%5=_E/JN)
M/,CJ;4_'%OK0GCX?<7)TG-2ZKXPA+[+;7.5[Q\.ILCP*Y=F)=Y@EWOCIS60%
M 9$Z@WYG1QY$JD"U)+YP_G%A5;41W6X4AEH.Z$_,\O6:JBWY0C('GTWF=(,6
MFHE*E%3;2^XH-; \E \9TQV>7HAM$2NP%.@:+C33;!#A:H$=3L3:6A[\*[/.
M&.XN@:Q3E<"YBT3)L;"ZM_2L=H3+_F.&H6JC#?7!_@6-\*-4WSD!R0Q'D9\I
M,HZBB@GVOOUIH\FGM!V="L(B_R#O G[T<91#,L-AE*MK64:8V]P/P%^<9 F^
MCV$W$P1CG;IT_ ^)_9NY8<S.D4Q,?U9CG 2KF'A'0?NYFE&_G\S;>TE'MYP.
MQ3)5;OZ[N\BL"VRM\4"D(WY3/N.4P1-H,"_#4:'CJAH'&*_'!.AX85.SF^89
M\EZZX635Z.3)">R?%ZXH&\G.Q;Y[E;.QOD"+D =181,6C7;B0"/;XVR2B,Z.
M<ED>' F(1(%J7'RAV6.!RM^I*DT S'&P_6[]**QF>B$&OIS,WE2?;C=TT37X
M<3&/U%WLG2YS\:/-W7'-J:_A8N[R8@56]WH6C#YVK='6?])P3]QZ6I":6"VC
MI]&5@Z_M%!$1T5'X-9R(YS\QOO%0&8BQQUL@7O,L^"R^W$-O_D%]74/"QS]5
M->FI,7\2C30$D&3:7C:484X"8=W&UZ).0-::7\>Z,1:]C-\M+6OY2#/Q_E2]
M8!G3<'.$IH4K+,==W?3DUFZ>0V-QFXPC\;8C#^BU9.OS)#JUWHVB2*P-L**)
M&+3L+M=:YTQGW>1!1>,E>P'OG2_HUGT;I$1QDT2R[3_!9?XV>9;,*ZQ YF[J
M 8A'GK3^YZJ5OH/0N(*4D/#O%Z!:^NY#C7D!>0W289X_73Q<KPB^=1G[?"-R
M.746$C,U^*:_0.DQR1JK$J1:=_/\EA=^E.53X@(4JZZKJ=<5=3;G55<YE]8\
M(R=&5FHBBF/$EUX_;;924YLIG]J;.N)Z4?-T_7'W V:*UW&%/,,.S_)X%C/,
MMUIIQH6#I>Y.7*/F@'*!Y-VRA7V?OP?&$?,M^L]SBJIP/T<#5L1E5.5^)' )
M15D>.U6*H0'1'Y&.:, 3</'=33H:\"X?Q6@(R[TCK<^]/+)!<><O&OK7IK4Y
M'!-;R\\5G:VH%5?:3O/\>[_8_]&//;V^^';XF/S[FN!<33#?P<7Q3K ][588
M?"H74TAVP+5H0+LW&H"@">O6A(BC 7G5TZB[832@YWF+"LW!5MN9,S.^H+.F
MN-TT:A\-X/C7;W3^-Y&6>Q#?NL!U$_W>G953]]!=1^>QUY11YK]13O@P%-%1
M5$5C=U!4N??&E,1*^J=.0HI5D,T52QV-OD7V0Q4:/:R_9K;,/OD*P1U1LFNH
M)=%B4G]B43M[9/"4I,#=F#F:80#X"W/L0);8#A;76X-!I#NL HB[BIK5.^P+
MI@$Z!3GP77^*#^.@B"U468T[O:^]ABU.8A[(Z;R@&^^&@406..77UAC]&C]E
MB[>#C<=SU8U+-7 ,'U]V;HI&CR #20UC&7\+?!08V6NP)V+9_=W9GS%XL<S>
M7,P]2XLZYTFP?YD--FHL#46,G%]C8TY\:FFZ?,]&=^J"@K\P.^^GIP\TN_CE
M1.:%"P].I^&%X^<VPCT4X0?S1#^9\Z"Z+%(#GD\A*?ZYHXGA8]XM;Y2.7-BH
M0T?$,)()_BBJ-M%@>!3^:VI9FZ[4;=K,Q9OB671@-[:2@P/S96\(UE_,1:BA
MX,_0F"/?V;FS@]&U?5WJH_H?PD^_/I#JJ(KN2H"F$T38J$^J &CT_]E,X@(#
M+L+;6N;*YYY/'AZ>:95^-IYB*'-(6=NU[LWRD=?,>)BJ@[T1"=4W_!,ZH1C8
M1(I/*G297OW$QUY@/F4E-/M5\O9//U^2:,FHB6\L9@I../,\E9EG:, "FS4"
MC$IU29O8#4/(3REESHV(+,TO\?<[G=H:]Q_%C %(R%3Y--<O"C)7NHW-,R:^
M!KF?W:]['O7(89$_O=0I.9M73@G<$Y%#B!T.?/.UQ; '#:"5UPK"J,'FGOHT
MOCQDO+;6)]I"D^<C8*BL"#M^I^%[%E5R@D+#B3;Q_6#Y>G^I:PA]4TA%00YS
M8TO*6>M!>KO#:4(SI,Z0+M02[G5JRZQ'T#QIK5%XZ_!K;M42#:"42*2:6BIL
MT"H5 ,X>9HM[NYG>]O-(?A[]$*YH8UY8#K%%Z$"]6!-\/^.'4:CAG9]WJWUK
MF,=KK>[KP9__:>\A$6K,QH,'Q=4CJ-6W 3VY40N,M&ZO862+QK#Q8WF/;L&.
MO,1:WCO6\0>]R]CWMWCZJ=(R\K:TR6R'U&NJ31Y43VR=N:/;&'[\.A;_5N'?
MHJJ5\>ICE[+][U5;?X(A N,B@FD:DV2DX3KX\IW\RZ+YT0*+SJ^N] M)GU^*
M6HI9<:;91]9.IG:5NKF]2 %:WNU!GR.WPUZN:YMT53F)_-F7??WG3XN-\^_R
MERP_TF0N*<.M54U_!.**C-.$7Q#QC:"((>:Y:\:?2]  %_/%W>#"[,E>KI2K
M;^P>";+1&OKJH->X[B3X2I7/OF#'=;8A9B.+D#6Z\-ZQ8A)95!ZQKNNK^15^
MU\\CTGWXY*&_6O_GNH9 Z.$]-( +9[7X+O$)&J"Q4>E>27F7!]KX J%! ZI*
MPG;E/TZP+JG0&&#7%Y:H%.Q>FM0<45@\G=:HM3O4T^BX)D*\O+&#R+X@S#)$
M SHX4!*'#<:3UA;#'O*N_*)YB>LOWP^I$H*BO$#PKZ%L9" 8Q508G-E$P-ZJ
M[L#<NOA;9!K^8QO+A*S=H:F;(\RDWYC-W[Y=7XP&A*O=NC8C'1%AW2MT+V>X
M)E@W9WN3N6^><@--J43&%4A5T  B/MCE'1&C+@HG;@7>'W%&CE?8Y62N7?&Q
M <]<W_6^XH8C[IUHF.S81R]-K84A@2!NC[@<D\?:+_,D@.G.E9V,YD5YK!^*
MK%8T&;[61VUYMJH;<:Z?5/+ *WO:[^]EYH8GWN4DB!_3/1'8L0@3UK(GZMPJ
MLTMC5Y7+OPK7$U[A79VKU&+49NIGCU'#,S.UHPB.M :3=[+P=9<[ENQ,[U'M
MF?/[A+U2"@H\L9@_2DP?-,+TZ(Z>]SFS'Z_"^1H1)$()_E*LG,B(PIUN#0_*
M3KJ8H#"RN+E#1^9+;"<.$T>"[Z5M8M/ ECDPW%5?MK@+PXSF7#K]J9J+P%;.
MKN:0?<*G#;)[(&%?>_GL=1F)/C2@BZ 48H"0C%H;U=$Z)E-AS0K"U7*46UBQ
M8'B4T%<FK#3BM!AQU)TD9FB&#+WIQ.RV%E#^SK<2)5BSM&TL>&XLL,"@IK:Z
M)>/DM*7/(M0RFY;CT0-B1.1:6_,J&X7%XJ+*RV)G_.E#MH7,NL*1V6GMED@<
M+7(ZI!YYQ@..K=W.LG$*R M$8OGV.P_Q4A:B$":U7V6UG<SCO&G[A[SN3_CC
M_$N,&PT_ES>2+=VL,$ >34' )76'O[:^V?+/MK]LLI(]_Z+5#/FPJ4F@?RK%
M0;#%(3\3 ].-:>LLF>=J239?L5ZT&6;VIL!]3_A4*82&D&.]C;P<X!D<TWM,
MN2-I?AY=Z@7;M[+5_K4ZC0;4,O)!:P:9Z]=>#+H7%J0HDBW%_5GW5\1O3 Q8
M<RA=3Q0=VMKM+?^5$AC7I\&_GOGKT4F9%&?;<TSC^HFE/(5P0.+0^@%2+B\P
M4N_GC#E8N?MYYH6"DD>9>X+A$]$G&]@QN #;H?=*!!+&<ZNZ4>7@C7<"9UT:
M0ES)VRU!+,M[E"0'9K&<U0DW5.I?B*[[$_S8\"&D4W[-A _;9]*&=9.DCUG>
MJ$_5ZM^.R*#DMWYJ6ZPU0%L4I&)[#]MCW-GAH[\^M01R?-;^8R(G7/5F>]B.
M+-2!GPDGJM)DIH6Z<&^9M@%^V*7N.X#7]+7LK>1#.R>4QW?!$)>T2OCPDUDT
M /:07G]D97'4?:[9GL,KQB.]X:;=UW$V7#H:6;7V(G'-IFK7!AXC^/,N =P>
M=''8[G(CM""U[7@]!FG]N7AKMM:82PIY]>M6#I9+&ABF\WONU&+%A9Y^KIX^
M.)Q0J#"1XQ[!R+T'MR.>>6H$TI56:$"4$.P8J=Y>)[7'JKO8CI$GU:&8;?SR
MQCH@"*6KO=CF%K*T(BDVJN(%5U.4#'8SEC*O2/0J+IA\$E*T7"O%^KR:@3,Q
M"_GQYQCA:D2"'H%$_JT!HA)*I ([9-.>$G*K+9$@55ZT-HL4GZK->_$,+)*@
MW#_R(M#^*G@V<;NWU6"N&_A@)K-KTEU\A7+1J91LRYZ7,VUH1"?HY78]8<>5
M&FWAMUMB^'(>:9G>\'?G6-+WTPXW>+?)6<UZ&I0Z\UQ]9FUN1U=9.<[I[5@0
MD:!O6C[-!@UU*6O$?5.'QU;\HSURN-Y7MHD=JI$3A\R.F8#3^+!XQN*W&UE/
MIX=:#R^:*W3FTOVEI'9QA9?=B-@CMSDS:,B42P@JL5OQ=5FL]E>P_"HI]V3E
MS);5"I=;KD.ZAHF:5:MQ$@Z3]2\V6._CL^RKZ2,E\FP(-]ZL&TQ5YK<TM4+U
MIH\6^-Z^3E^1C=[13P(:$*[:)EM0( DT&N#R*.KGGVMC#^UKTT<^YYB8X1!P
MJW+%LXQXO\X$G"P9KFW'^_Z6UPAY:9M/2MQ-;O>A&Y0]1\_+3S$ NR])4?)Q
M]?U\!RY945'ZNA MTL0$D59(?@&>BWF%2#$=Q9M,K<APD)RD9L)?B" )CWKL
M<QJR<$X,C0HFG4VOW#VFV5JT%,[JX);Q$!1/E,S!G#57SZ<A$I."_'Y::DFV
M9(7?U<HLR<4W_G#T["D=B!%Y'80XX?2?)=KV-(U#:Y5@4=.^NQ>!;WB-[[8S
M_Q">$[[7^"'MX,]QTR&XU0\@&D7,]2IX] #)?DFPB!*'4&/$P%OP1N:N0VI+
M<=+MXDCRX0N1G_=+;:796UW0@-70B ")VHO+X/KT(+?+E"<!Q2OBHI4+A51C
MHK+1+R>2"'3Z"AN17#"+1%9M 3#WF]':W /PC[&.=U)7&005=VB Y/H@1B=]
MG 4^#NSJ&N^Y_M5:%"\8"].(JL\GCE7I72_0'_2$UQ]615%!(B+I%@<91OU
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MK>P??YPYI(M37^$Q=].K&CS_/B3GMF .OF3%^)*DPJ?_^XVL%>"EW>9AD6B
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M'EB8S<+DZ_M'9!T7,^<KGJQ)Q7JT2($+%.+9_QMQ[P'5U->FBT=10*KT3E1
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MRRK</0L$C]2(UAU9C9<K7;-TD,73V/WDZ3 +<-#8IRHA:U4H&*^T7T[;4RG
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M7LT,@&@HNLXUL2\ST<5W2IV\X-6<1A3$,>8*S?EQJ7:MXCR0LNFD=3BNS7Y
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MC\$JT.:<#_.?SE\F$S$Z0]YLW2K&PR^+Q!A0H7T\QE?]UO1G>3F6>FWO+_6
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MJ !>V[/0+5*W/: B%4P6D)^I^SL&-8<XZU'@]^+J+'I3[1KLO0Y^Y#OP]&'
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MV"*+/H\R5Z__Q)C>'YGWESJ\0B@L,E% I[.=1=C3ZN!FYRC(BZ'QE;[5AF1
M3)JRL"7RN^WQ?CH"N(DR49([]Y>:PU0&XXJ'E@ZTRSQK]';=U\5Q\U4EK[*%
M%5Z-4&&4I/:SVJ)&5=U%.@F-\AH7W]49!K\(6Y:PBXZ^4<,D'H!CE'S/]NW
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M<+4OSGP"3)O(PT(X8.(>!5='H>=JK-SQ:C&;RE\?_W+KCYTH\P-Z<^#H?<P
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MT\#*S(/+]1&Q %/ZQ<V$6:8)EPET8,$E4E,K$<&URJ/J%WK??/1BAJ67DR7
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M&OZ/<BG^__'_RH ???LO4$L#!!0    ( ,A)5U9"YU..I4H! *)C 0 5
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MB2M;X/B>^ Z=XI=0F9?$_P/MOR'[KP%[]?\)V;\!^Y^X,,!I1@:Z\1BY 3!
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M8QOYJ>9RZ91>BI?= P7ARBYU/J$?FD#\XL6:VG)Y'3]#U$AAU@I&]KL82]9
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MQW'F$NG3Z)#I."/ISR/^L1I%SZ6#&/9#V79\?)J-O=Q/9*2XJVJT?4E</7S
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MBS%JMJS0Q@6ZJMG=:#V 9:!R$PF@6#$5(AHOPR'<W65W\%K8-.>3NP"'BG#
M>\D<"Z->\JY6G6W:<\4NOXCEK(S8 #-^:-:&(:4X8,MIOB)5M4_/Y9.[5AE,
M&2ZV>3[#)B'NUR_%#P6AWM]WDRQ-M[JN^=D[CE,<ZHW+CP7+>0L)EB,H;-K.
MUS6OR?V5//S&C\ 0PX1:09CQXU*]N3ZKQG'^-I</DR\328)(!KP(K.'GXGEG
MZX% &E CL*53!A6@\G=EXT9^+,Y/V:I]98G:#I!%$V^O5D\X.)^5^<"H])C
M)U5OMTX#/'=.$GWF#S>E\ IW< 8)Q6YV%__^&K)WJUOCE10:"04B6<ZGV*.,
M+K6,MP42>G!(@RB )#CT^#HK1BT8\-_J=%'O.Y6:B*]%KLG.P#**4$7)?]H4
MW-7A^GT^_2ED16)D$<R:&#R/%?S;B:Y6[1-$?K)5;.$;%2U/6K!\%]9:(4YX
M1]SRPYFU'Y^^)A9) ]BLX\DFI=WY;M<4<L\;;0OR*TB\%DW^7/I48_^<J_@
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ME'=DSFJBU$+83KLL"( 6C>M[VF-/MO):V)9WRTB]J.;0$'F96C')*OE=%4(
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M];'J[?)>(;-E>LI=L99K67V4XO S1/3"TX0Y'S[HN34"B%M;Z$MWF3NAL:#
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M]7W<O^GVZ%;M'U6;BTJ&:[OG/T:!@OH/%[>XWLR> G'#!+Y GV]D8:.CR$_
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M7'+&4H-\_"XAOKAA7FTUCOA<U$B?-:<L2_A-GX&N.:9"A&%"Q*@\LCAQAN0
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M!7:5K@[TP0[<@F@#G!0Z4;HM_0(I+(QQ'J$V]EP'1-)L'=N>:*>7")@\*9S
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M%?'S]4,[YZU?>,Y@_ ZQVC-H0SJO82DW7K4Y36!NDE+F8U=$_4:P#UAKL\Z
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M=G5%Q;DW87-<U7ZTUF\$RGL-\^DI[MMAL(W4W:B_5]FFIJ(V6$.ST4%:#LI
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MB_)MWDRZ)5V,5%P;VE!T5[EXP\ZHX;W)V3^:]6>-[F:_@9B,+V4TH2-PXGM
M($U[1.=5@3^[ 3&W@#"%YKFC;L]SE(6I;FS57C]UOET(K_X9$C/3/SV^X@SK
MKCE=QP3$07<8M8M^&Q(0\(X; T(,9 W C7_T^?K7?F:-O_\E)W =^-PZ'?D+
M=VH+R4?C(0U$^4P]\]CCX37YT8@)G=>S^_G^=FCGU7ZUB-UKA$8-FD;,/+ %
M+.PO9;<T?!\R[#+,^/U>HL7>F!<C??7JO+1>)5L3L@TK[HN>%">[$<.B$?I'
M*\5&MZ=O^)(-IB1B3FSK+QUE2,XZ$#@ \=&*,XJ=6"?4ZQU&'P2@<XEXN/4@
MQJ9A6,A-1?5L9#9,9EBGET_J9<''?+DC;[Z<(#2$_E<K)=C?V3-;<!!5E&80
M/2LJ%VO185%V]NDIU8WD*?;RP@J!WW\%6C$!Z]KB1E19VJ43.6#R[2\7.X].
M!Q]88Z;MVE_!E03:XIL5/L5IG;Y<&_N64X?/R%UY@U"!B> \9WPF_*:1A+N@
M^?4FP$D >U606C\\5BDIWKT?K4%MUD\<VV[8VKY$1C60DU8<Y<Q(N<'%1DJ)
M 0U?5DZ7<"<D&TK>Y5P^V-4M<JEWV"%;$AO:I\O;405VAILV3Z)^%?Z%_"-K
MTK1_O@%E.OQX<'?*3OQQR^RD1L3%3?OJ_*8NG10:5:4DV=(K6B_R">R+<Q\J
M(:%Q!]<KOS@RXG"L."]H) N*V$)/(WU1S>;JU 8P^0T]Q4-IPZ4.,[P7+E.?
MR-E34DXO;,<87V\YH2A1?95CJ'%O'&&)Y[EOV% YHF.0D_-I\/*=5O-HG0L2
MM.90Q7;D)61_!33]/ 8FJ>H!TZA9,+MI^$ES0M]1B?O$O/B U@+;-/L..8<)
M./*$HIKU&QP8.(\6G;*]GK.08IIZL9##FQ'S<([T^8OE'3,)V-&[%U_>W;<P
MLV^PL*I"K[F65:MRA;7J\UISV/3?'RVR:<]SJH3-[F-F@S9XHQ!J)RYE^@>;
M_BX4] X2EV#KE*W)8P):O/'80Q%U+(V'Y5$BT,%/67.M@)!,EXD#B?N/&4\?
ML[)+O<RIRPERS4.UQC/XF(!?R_-P&F<%*P8..#Q:'?9V*PC<6,D$\*^(536_
M[;0L;_BLLJ4RBY=Y'C G]64L 7D;U:RG)[*".\H$S.6 !.IYLQ_-.+C52H4'
MN1YM7[FOEO^C0LNK,$N'_!?6=N4]"?5/X?8T37NLDM((I#R1.IR0]*F[USTL
M?^9]4G"?*4D<OQ'35L+/<YE!($R*> @MZ);=:W];/O_1OS6CNWZ-(:K="MD5
M&D5MY6,I$10=0W'UEF5!3\KM4P6B'9?&$'6(9/)OA*%=>'?!XS+?+[)<)BM2
M,,8S,G!C1I/Q5@B[3T=U8'513^A0\# 6MC5I :VCVCW,&?7E53')?< "EO!/
M86_!&GM@VF6_4.P?Y4(F &>.(@ENJP2SIF^-R-NN&NF@73V"N$$PM0P]7'TQ
M5F'W]N'TQ<X^KOD4.N0M)9XG)%I-D6"YY_SA[3M9[E$/\R3MVMM7!CTF"([E
M*8(7@AR5"E>IRDXIB^4!BNY;!8=G64XA*8P)^*.=RQK,1ZAY(]IY!R 3\'4S
ME145LA @"F')!)Q\36$]G+Y?)&B+CF8"1+(8DFQ$-"-T2P2%HT(8ER 0>GP+
M:%>C@#75K)//(SHKVU#GJ -5*/QE(A- Y_#!T;AC:,]8\6%/*VL.)(=11!40
M"1V!Q?\"'F?=W8,41F=%A$S _&E4ZU<]099,S,SS4ID %JEWR#.Z\,!#L1&6
MK^9E N)YW=XS#/8SW%F2YHQG @Y/KF IPD#*R%BC_""ZE)\;9MM!\,,_C5@4
M3<4")%(H\?_TL Z2Q.6YNQ^H6JSKF2&XYOK^.F0"S(>_A6Q:!9G$YBC+AC2?
M^60I0E/$<K?00,D6;?5UE[ZL6N1<2_1Y=?^>==7!8:S"Z.-Q'768\L#HH7PF
M]KQVR_^(EHK+N(B,2N'W];SS??=O?2\?6JRJVJ[6;;-02QN4_A)[1O(A&2UP
MI?]BC?+1]^W5F3B5B,,)[&!ZHTT"P3N@/U10Q0E=5)UDNJ?W-K/1G D(+27!
MZ>R5$"I)DPF0S&*(U;5C=T\.HK;:<+27C6 ZJ@N4 J%P[3(!JX9P6AD3T!13
ME(_FI\B2,(\H\82B!K7[E<-S;Q7E:JPJHPU@+<8C?]G\=CP9&&!=/?Y[\54N
M4+.UV$H0(UY56-W9[:+EBRBM:WUJL50>H+WY_^\ZDH!=C/5,=\]R=]RNQ^$!
M>61'@:9I)S]#JTFE*07&;!REWK2C"50-JL]HWJ@C94333+1M_T@)#R\\7&R(
MM?:N^XE3,C_3_(KW.,^KJN5P[/,@/1/?#(H^DM_=]I:[LY1HQ:COT=%',()&
MC8\0=6<ZWV%V[\1S.$NS<N.-"LH4GQ!GG ;GXS>#9<DJDJ#)IGM!1:-Z6@A#
M2M:<5J4OQ9L8S!"*>U2<N\<$X,]7#3+:'I0VAX\<I);C_'+[ T9*SHKN)3"L
MXF-6 AO)BJ]^V!E/+?MDK,&T(4-;ZU32\&WZUT8@^OTN53%*ZG!V%:9M.0CG
MU!3S73>K?BC3:7&24\>)[\4UZW^LNN9%6,IMI!+CYZU?ZY@35W'XZ#*8]Y7@
M_-^M!0;YL3[$\"-+QO,&2J7=_LIQ:BGS-#6JP9HMBB;0&#@TE/'^\!%L[H9'
M22UJ(^23C<$>/%FF,&$R/F)LT$VE?J8>[<$RWN>Y'^;NUIDU)FYMWZ4BE*AO
MRRN!@L_2%827#<:4-#R?^) U,Q[7FC#Z7GS&G4@UF3BWX'R7\^=/-/>/&(+J
M>@\Q"8\+1@HCI)F D *IC#QNTWV6]4@<-Z*JOR_8R= %?W9Z&1L]^WFY!#%
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ME-.Z/.N@#C\3=?G8R\R*2UWLQ[FT5FRN9);V6< F)'D$YR%'6*JC^@Y2:=6
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M.E3N;DZ>3UJ6"6HV0+JC6GOTY%"_N%L@% Y?)J!+_9]W:"R@BD6DMC9!-YF
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M(ZDM779<'5:V"G'9T?E<LK'X_. .1.:'J(3C-XY>ACP%1, TXR)PQQB"?YB
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M/C0&A;+ZS ,/^94@1SN1#(!N$6Q0)*P%03#=^/S22JR*R-KRT3]?+T\X)_3
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M!5\KZ-4N"9&H'UM+K]9\8<L/<34X5!XL+H$;_]K?IDH@11"K+% & -;& '2
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MS,WV8 K?GE:'W8BWB^HF$&.S3&:O)R8NY5T%V;M[I.JHUX\XX/G2RFPFIXZ
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MPU/W2I'HG,$N*]H8M>@@""D/GQ'E)=H5Q\PAHA'<>QRH<^3Q1G7,Y(^A3;%
M.7EWN;,M7NSY((6^18=PS<O*:\ R5 M'PCLPX#60V^V<X#ZFU""DP/9ZBV'(
M*VMH!)@TI >\!1ISTXB"#WK*6$TUW%\1;-<#J=F9IBN3,#TO%F=1?XHD;QHP
M_0JXUX[ZY7"4<HX:1$0T8B?\6Q3<$.RP%T26EM2J"V6N0@EO-B^8I,C,/!#E
M^/D@FOAA?5,"\,O"I$GDR#F, 7#"", >D>6)= 2?I?X<\AS,JC9Q:UPW\&ZD
MT=UPARK>4LX+S].^R05XVD8?,"5%U5P5]<9X4SIK(V0*S.2F$TYS#(!+2.KF
MK&>:9B(#4#!+[OB24.\32QQJ4*\JZE%[.#EC3;<PWAYD>O(3%K!U:/8W=! #
MD#9PR&) ^ZE]F>S9K (_7DW[AA8S7MBP4WXIEM@]Q*8)ENDZ/\"4^]HN=V/Q
M_>+BEWR5F2ZH%-R4MOT&7(9]!^/-G^[P+;!LD:A"L9R/,I9!R42]>YML[IWU
MU^*WB4X:K'=;ELZ4NXI\3YX\K;2!0PC8&SUP42H/ _".>\&XC1O( +B'U-%Y
M'?* F]NEAXCG%)E3\OMI_5_JU"@%\=_VBSE(?PC%5;CW:+:+POJ8T78D$6B
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M$HKVFXH05PV'GVS)M X9\'57P:G=R/BQDB(I?N*U?4=&RR0#$!68,3PN\&L
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M=*"]POV8._EI03U?S<H%CKK@7Y2QI;WQQR4$9)A2_ZF_-*1QY)F6@RKN/XE
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M*[% !?)CBA&B69YR*P RAZ2*(UR9UR2R[1OC^ZM>4K3_2GG*=^[T46E)VY[
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M*7$>!BRQ>3C60NGQ2D-/;-V(B^\@EO;2/^TQ.6*5DWS>=+!*#<%!^./TQ'U
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MUFNZ7RV44O3J+C#)X_<:2(A>SXA9XVP)- A;$QG1ZE^M2C/UDKIGX_8A1Q7
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M]B,O"PLWG&KB"9%EU9\YCJ"=<WL8.E&VU)% ">%^)#@_?O+6D\H&TR &&Q-
M8LG+I9F3G6 84#MI-U(!P>O$LU\65C3F8F;9O!%.,ZC1G4HTN%L66@B\]ZB!
M?":Q8)DB\'2XP,&UR/FH5F5YJK?N^OT7_.R.CQ;83DD 9D05-PU6"URF%^'.
M!E$#4-'P-A![3]YH<L*]QPH1PV]?2HQVP1:)TEGT,GF,XF(3+ZX5B)=J&V]7
M[U'^'GBBZ>VK9<]L"CFLYR<3$& =-^@Q$ RYYJ:1ZMX_0I\HH2G0WS?%;SH%
M3A+BW1@QNQHN%@-0Y0+=K\[C867)+_F?!A6/)?%]JCSQ^/G[8]=OB^2^-2W>
MJJ1LD2+:4.<6DQA2Y,Q&FRQ_>1UR7(9K%E5/<^)2@U;]??/ZI<@?P;527#$R
MTPD?O+;]UL@SL>;?X16X:#=OJ<+K/L&ZI=Y!05]U.5GK:N).^HA^N%O_(NY.
MFSWJJJ2F,^&:E6\L:J5G<Z=.2O-I\Z-.*<R<'[R. $IU/C WH+9,29NW)?B;
M=;0SA!K("NIZV?CEX4VKCH&-NT!_6LO7=0T7%.H#0Q[V=Y<1> P!&: K3F6(
M:I+%P[([@_*I<>U#EP?[-R?EKWNFH79B]+[TSG> 'P9A5A=F5I!1D"/0(\3N
M7\$8T]^N;F6O/=4'^+; Y-7A)/T'N&=X<N.AM_X.F?Z3AO7!ZT+F7."I= .M
M[*AK;/^ Z_]];K9*^IW<I7'*NT*GU-:S$TZ\U?UXJSL>C#(=2[:?I8S.)W<H
MBED6[NWNK 1_VA03$-=P,U]!JM#%C(.2YCS";G+S^O"& ,]%+EXO]G01J8+3
MW->V9R0WQ4<:\98,\RASN=T6^!FJ>S/H:)\W_)1T'=6ZMU=E>Z,"M]#>-W.M
M6_P1_5W&F&JO5X]WXARD OO6!QD.K\2]H=\D"MI5#%=-*%K75S_G,;AV]U>;
MG^0UG8EW(5K:QT>*1K3LN-E=_=L+JAYX[N[.#]%&ANGXC<'/4"F]$Q<,K3Q>
M_L^EQL\G+W_[-J2@MF)I&.+4W]JMII!_X[Q0_!C?_G"LO7^2JPSA3E."^2:\
MPN2R&ZRO/L$!&K<3ZQ(DZ64V'+2VM;GN>B]MO"-IMPX/3T9:T\_E/F[_F-Y>
M='0N^C6+4";ZBJ9S7V.)M.LW_"<C8')LO4?[33RWM'.U7-+Z@GPN_2$IOW'&
MU>''OM][!1KN@F-?!R@KM^46NJW*,[C=9RT3E):L\J=VJ9B<9G" 1/\E'R8]
MP<;"A$@+T2@ZBX^[]'KN/KK$4][5Z07H^9B8[4FY=:"RYF+@R JB!7C*BGIL
MFO)VNN<>I)&LN9[FF+2YO!_'OGL]9T,)?"G^$:#3)C[8N09Z_?7K5B-48)R^
MRO.)*U6UI=T.X[M:SD_F*\W\;D5)S1C$ ;^A$ Q)NL$PW3 7&D1FB2A19#W^
MT<G*HB3IRU41LP"O]OJ3*GM>R\_F$&C&+_BQ'2;@#>-$;5_#O9DU@XY=+TMT
M\\0R(.RMSC';ERD$%GY53_F^,U[+,W*_4)QOXB0X/VOEF;H,/$YUIM%Z/)L@
M'5GI#LI2*L_]ZC1"&@:FF8"VTQL\4"VRVSL/%W:35(NRI U^-5)\@(-?F<X$
M7EBU[!BEY""9;DJ[ W%4!@E12TO\CR@LSL:9JRGZAGBV F^\GXW%D!&?OW7<
MQBJM<HX9413)X-6MF5)(J]E"FZ5>NP?!+!BY*G>[4_#FZW9=]G@=7;X9)Z/.
M3M&HK17;T5NCUYXM!V2'/9OH0E2F>4Y<W<(GPI7=,AVR(EH'"@2JBG[/>YK$
MH$CUDQ0Z9Y$C2N(@'\2^ A=NXN^>SF!I'X]XZVXVK]JS$S7[H"@@ZC9;]<#(
MG-V<J:J0:2^6!3Z%1)Z%"4(?DIB 2#0G0F XSR[?(G*N/$32^,]7EIOGQ7KK
MS55>%4ZEOYB*6SUCGF1]PZC5VH.<]]1J\(^$^&K5;G;MT\E,RT?*DN+QL2/!
MX%^TJ*A-R'AWZSCJ'=:>\#ZU-S)8*:5H;(FKTSW [7:\^)2;T>A49F!<3NK6
M7V+ <C@*U@GB:1S<*/,1[)1Q?_?'LJO_YVC=!_9*KD> H[4YGXR3#-1G,CS;
MLPO<,!Z?4$MY32]_U=:JH_;@*=MSAZITY'^ITM_V#*;*!'R4: 52.&N8@-^N
MYHD1,\@]+N@=)N %#7' ,WB$!/_W3]"03#CI_B$,4P;R,P&C([*,C^,CBW;_
MSJRYY;YVGA;H?XQB3Y[ AM(-<ZCQ3(!A:KO&';M^Z=+94*WUQ2-RCR)\;=Q&
M9[T@NJ;"Q(UW5@#JVR+Q/"+BF+][:VK4_8OF/1 =3-UG+=9+QWZ&KIWX/*,R
MNS^"21CN=B36;ID]*7R TVDRA:6F#!IY' :AJAMC,Y0X4O*:XE0A76_ZRN#%
MZNHZ%[4TRR=_--6YW@BRN,@)%4L=+?%W>^W)(DO3A8V+'#E(5N00-2 _;4)_
M7;Z5[JIN4J=8I-/)IS+9(_:QC/7G=S'R /=J$]\A,I[*$)$6;:E30GY9>ISD
MN.I=;US]]C37K[L7V5C%$MYV*FJW0SCH5\A<@HY0T^E@WE82_J:_Z+ WU6U8
M7/3XUX^/^K7S? Q1"=H*/LY]:<T3XVPNF<,#DQ@X%59F5MAI>S"#P]ICQW.:
MD6BEZ%)GV(6!G0P0A_BT=(&E_:EL>_LGW[_&/3_")_P395OF]P-[!BI)6I^<
M)S1G\OUNN'FB.U(B6FN 6/7\&?O)EP)O6L_,UUW;\KKV^5I-+4[V71@OJ5 -
MG3VQ,SS7DJ(I65\90TTAV]REFMKD-Q53TAKOF=29<\CJ#!"WW!5/Q[.>NQ_Z
M-OVHWDWCQZSVACT>DW('!=O@"-")0?H](I;#/Z%EER+MAB7%6;2XBF>]=OA\
M[]2;-K4?,@LO=^W5/)5=Q8[-,P%5/NG[P+4PVBU_K/$'/%5K;,?RFEZGT'6>
MW1$>*N:,UX\$E\L)[;>%=8J Z.K:'/]W,]K-W1QW)R?A'%1!(T0K0VK(]L-U
M,XOKS8*:B74GG%+L[5X!DN9Z 3T!?;J;D+4'N$X)5.\DI5%@QT]:*-Y<BU$Z
MV;VQ&S0YCZ%?.&^,'H!Q47F?#(HC]"LPY.%W'AZ*?Z(%;D=[\J>,9A1=.*K;
M>Y)3<3&UXQ!N\'NG50:3O;XK^\*, OIDWU]?9X^,,^U^S@I%3 ,6^AL0E-%#
M.\J0@IXF<:PAQ@ZA\+(5^'?IT,23()=%S>G8E,"2CRHL+!^ZO/I&:I:PE9P_
M>G@?8YH&&.?]!=KW)UH__,'[N_6JBK[\G9AT\8Y(=KXD3;4 HW;HLB7C#":C
MS3=1!]<<VF!\ P6'7B/$A0[#5E4F/R)9H8)+G:W.5Z;RA+;E=E[^_"#'\VNK
MVM7OTV\W('[TBYH)TYPAB9_DJL-LV;[]%%U=:@O K(T6 U>]R"^?WBU:/ _X
M\N)(!S=G,V$\9ZHI@81J5MI%\JJ?=O5RS3$3Z],EZMT4>_7MHIWDO.V-BS$V
MJOFYN<LR7:E[5Q112+B\I 2.U8^"F/\#I-]L]8?<*:>>HT'UIC<XOJ="PD%B
M_LZN5@NZ&,OJI2*SKF.][\^<;7#?>@'0P8DW85 ?8>=6#&$#<'1^ 1G2LJ%^
M**H27SJG,X F-ZL.P4VE7M.RB^=WGMBC16[MK(LNI22_U<,(_10\I@I[]A#@
M[5"'2@_"E]RP%6@$[T%V^PP+R*(\0!3JD&41)]E._S2CH0#W4RAE N+')TTT
MNXF%5U<PC'@4$Y!@Q?"[ 7:%O&T2.\033 #_Y I(I6Z@2<B1(5S7%-%<=]^:
M7_'TXO3'H?4RT-;=7)G+5JS\$F^D^I@ :]R> C8429$>@R]F62JO<3,!XH=@
M2);15JK'!.CFECE0KA_>0(^J>]AW(ID1=:'02:"<"6"960.C]$0?I!DE4YF
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M/Y_C)+VS[5NYTY@\,8]+;&V/*I5]*4Y,TT47QVYC'4;FNV&<!WE?J(FT^RM
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MELF+L3*N.>7Q1P?^W'$7-TS)Y7-@TQD_J1F<:&5'SJ$X46UH]Y[C[Y!/_Z"
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M9\?SDV+F*]$?>FX()M'EZYJ26^SO71VO>7^F9=@(J@YL0PJR6TX!RAQ2IF4
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M!AVS-R%QY"E"P,S'*]]V>NJG1SU1"=;\[J(2J2'%*W,G@X1]A:Y9:I,"FU'
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MA@RBXFCYL4O\QP#H+'SF>YUKU@O64()RLOB-7UE)?7M'O.JO8[/Q3M") 7O
M@LIM!Y10S;K0E(H61;AE+_PLP^M$7=5;WN;37^WF"_>%G>*Y>.+ITFL*>!5&
M+9DEOH'(!**_9&I3_+#M6,F9OI" (O<&CXX_TU'O+SJ%GRB]<*-.W7#>)2/G
M8U%GH?['@'LIQ.\+OMCY3-IZRH*^<::%ECJX7E%]RW^(&:\R"#F/A %4CE#I
M^PR\@L_I>O=VSQP?=6YB#0V5IPW9ZX]-1WZ0;!/,^A*G+WMQON,RGW<(C.!#
M2QMCJ2(5@8,D1'C+Z1%?L C2O+GN<\J&?D,B8;%_#'(!'1C#L_;N7=#\+7(S
MCB;#3$/>I&LP#HVBI #"BM[H&O%>8YI83;V3;\J8T]U;V8;#\.>3!YZW2HYW
M<P;[3GR8VI_(-6TJ;T?"3%\I<),TLILF&G%!]@F57XOL^-= C5-/=U#U3$.J
MTLHF$^./!GCL>EDSJ0KT_A#3#&ETS<=/^+7%/1BSH9PU5\RL05T,C"<5K.TK
M"(21N:-8\H#,[$<M^U(;V!N(]/1A3T_$X?;FT:FPH4='U T^X[Z6U4;UA<0S
MA!K)^054WK86I:K/0$D!TF+PZM2"O?@?JPR_WA#SSPKN1ZY>2@0LSERSNT3<
MDN19;KF$% (&P9W: Y(,.2HMU<^CR+HL@\,:+:=Z@GRRGCX*^E%ZYXY)N!C/
M)Z%$,UD+Z"28IC^*X@;FNM''FZP+7>\'XKN4Q>J'&&>?CJ7I11?]M!1&?(CR
M-+[(7:2I9.)XG5YF5HS"+3;L[%A6#7\=JG+8D#.%-8RA,N-V@_=2\+.YQ,VG
M;) 0&[0RQ''ZM[.P"2WBK FT))8-<B8>8ZA3,*N-Y-A;)J2OOK;\)^Q"\TKE
M;H*B/)][B.C&0!Y_J-O:?8-MPL/C7_T9Z,9/$KL@!RC,OMC,RM+6$Y9;[O>U
M;(NLY]YM/#5X=#$R.]/+7NX+>C^,H0(HSB(.NU?;VKG;B,2Z%=CU.G__T91P
MJ["35R&QGEL,1.?I%[@?^W# 36.9: 1;9YHL0!X.+TQK(ELD4+"7E/QZ-)6?
M=ICYAB6&U!IRJ:L TN>./5]F@SSWG8LW#HGBK1?[UEAX_L."]\.861<$+?KO
MK0(V:,*@-5B],Y9_#AR#.B,;G->,C_(%B\'.CL;^]$[A(N3_\(C8>E%H>D!%
MPPY<P ;!S2;CS9A%$(GKI#T_-Z1NF5MJY>\T2.71)S?=?%^$*WV0>!]V74PJ
MWIT*%47UL$%24#>55?ZC#%\J[E5\^YK@'^U)98:$FV\J84Y?S&K-Y(*@X/4>
M@7FG] /A,A::ICE)@UMR"[WKRWO+8RL+_3DG]>1*@V#8*PB'C-',;P.>+5[T
MYT@4%1J)4@$L=,Q+&88<UYYA<#-L71=!:NSV\!\?JO-2[3T0?B^FZ["LY(O)
M\G::!C5TH]N,HWZ%D5+@;F.L9*"%5>^@ZEMX[ULST>7G%1Q%N("SRQ1]5OR4
M:V.IZL]2%^(E7M2<?!87B^('MLSJXNE7W0)07-22:3/2\H]'1^YK_+5G>N+1
MFL-S3;%G)%8ONG(11\&1L;$LA4 R&]3^=@XL/,5KY(L^.*E;GN#\NLC[)2L@
MX'RI]0M-)5-CYVJCVT+A->X..$_JSEJH4LVF@DFYU:@WZXA/L-]PB0Z<=7B7
MTKW*,:0[,(XZ:[,F1_D4P]S0E#BC(A>#DYNV:V"7*18^)BB]0?"2PSA'9EYC
M@Y). U';E6S0T(0"?A5&O\JXSTSQ4SD.W&:#;"F9.$H5>7/I?D7:](54:Z&>
MA7!KX<C$RG#]KP?3-31;OVRCIV3^?C'N)JJ_18'"'WFAAJ[L:$&')D"*9+H]
M6^P[O-46;_F#%20?FVG\&8Q&#7T,"C&@<&R81/KCM((H[Y2?:XQR D,)Z40=
M)G/'(KGILJSN@B^L<WC*6%ZA6:Y-(\&N1]+\E7OZ?5]]F)KNQ#=U+B][E:XM
M*IAFQ,QMX?XM A-E.,[%:G?;?%L67TPBPS_/5S]Y^E*L;#9.-6Y?E-$^JU.%
M>W$FP:*=Z E\UXP6<(FN!>BW/_AQ>J1%RL%M7+P&IRY4>J54X(P&[HS@P\0"
MB;80<B."L$1SXBC.@3<8KIT-?N*RB#_J"!4T6GMB)#]9-N6T$G_=\83/SATF
M[<*2<:':+AI-,-UM/UOT+!(?L:0D$XSD* (,>D^]&9&Q&A0?W^0U%T\(H0U1
MP:W'^+MMEMH1^P&HD7&?PU:[8%Y=0:$=]/VWHN?77=\'%4/NA0EO\I$B&%<Y
M-A\V64VK'&5Q!^(Z&W =Z,-V@+?9\5_!=0TK%XJ>5>8T=E[]<N "LDC_H<MI
MKQ>&?[^AL;M:,/<62MC'TD *4]6BL@#"^A>WAKI8\EMKV6%5PZXO8C/@&?TO
M9Y@_C"X5*&XYH\/05; W9:A+</Q)UF4XP2P:<MH]#4U[("(NW)3@%FQ?9%\F
M"7$9.*>OOPAZT3?N#X]0IWD9&[CYP$HQZHKT/8])Q>"5^_TFZU@)VVR[)@ZH
M>K S*PLD8C4;%(Y21DVA>?TP;W>AX@S[V5@4F?4;>M350;K%UEYZ\(E&K"=)
M(.EY8Q=?$$&SW\L<W7I=QX,:3S)8=9D5V]D098,<D7JPX]==BMU91T8\E1T;
M8>?FN+U+32)X8GIJ+I"Z05;V)+-)E;F-57HV$/D%?4@G:'8")06W2K)K]R+;
MVE:6N#YY),SZ]OB[]^67[V#@BY)'D^S17> )3SH9NYJ4CSP_PKG=AHUHWZF_
M=LXW69$U91L30RI@ST._]U<*)PQ>>_+ @SZA.9YVZ=Y[T8:/4@V_QM49X,4?
M#38/F@W\]W:6G3$JRYZ$C^J,$W-D];<Z!RA8DA0Q0L>L%/#^3>\8J]LU7]9Z
M78?U$GO98R2N=O#].SX^O7L =8 A#*<AY5CA*UBF:,A=QG-F'-Z52-#^TG*D
MDHJ+:0%W%P(N#\+(RE#]Z$T)HVP]A:W>*SF- R^R+!QC#RTMY>O&DZU6N\D8
M,=04F!=UT1JV+!#HTD:P&U.OPPG=5I$-L'UQU%7FO,%&ZH96)K_4E5QE\<HD
MM"=B?GD2):=C_F!)>GMH;VN:Q3T J^'N,&+<HXYW$]3?0+2 KF[Z.<E GU;T
M@;1-^"]#+FUW,ZFZOH4V?I7O>\9S"IJ0@ +&-6K\&I2C5W#4]<8YM"A\H"30
MS/R#X.]O"QYL4.V96V^?J;^TVAV,UTGD.W+^=5(<*H*2NAI +9CM[H1%64&/
MZ<!GI] '&=>:$UFLK0[QT,ZNL@+M#P_?"%ZN['EU&O05V,#)+,+"P!6PZ"9N
MNAS#"I#' I$&K@SC4"](<LGRHG6,5X-^H4MLHH[:X_L6UI'?@^8R(3!:4.?Z
M;!E+=I05LA(:RI?IM#;[1QX]7X:VL36S-SW+@)8R^-F@L >_I64Y 2R^R4FM
ML@A WQY96T>HIKH,&:?[7;2^?-#U-.C=<:'6%7.D/C.GY?0R_@#4"0,*-.X(
M$ ^(@\A9+U,= JLHO(UO YL^<U4YVVTDI-FEZ)!LWQG*_!"EP8!!,F+B50>4
MJ\FJ./#DRJ6)R66;@XM)RN0I9AIW%,Y>N\OV>YL O:;;5&L,&P]]W,L&@9$'
M ,U/!5&SE.Z.@8B4,8\\(.R;D-\SW/'<QR,EKYUCTU1/O>-[(,BO$%)\6[#L
M/N*A9NM42?1BPYZ;W[BC@EO7ZS,UB>9T0BR&&!*Z]!?2/;V;2#'#"R UJ:88
MJGD75) ABEVY](O BIU[NS,B>_2W80KA?E;V%ZO3!F('9%_]K_E=W9K?42\$
M;+S,%["3?+E?^(_W0WT.\[:W[]7;O7?>^:#0=6=BQJ;W???<*ME2!:<=>V#@
MYUY>^5OC3\+?A3;%#^X&?VOY:-^\Y,/]EGS6O_/;:_ASBY2OY+&9G2Q6/<;U
M6&85$X<*[\ZS97:B?V?:!"[\=\].[\=UVW\3[HE>_6,O-YEU3K%7_K30Z(+(
M"<<$]-]%3WCRR>)U3^:2Y_*9?_\S[)Y\U__?O;W3Y^YI7O+VEGV]5>[ZZ?':
M/^>E_Y;Z<?K8/]Z_:^N,:OBN_\E?^^/WX7VR6]O^,WA?J?$L_;;Z1?-/G]"G
MRL4I?HQO/_$PS@F_<_6S^:'W-V<?E>/\N[5.JR9^W_Y+JA^N=VUYH?-F;>ZS
MJ>N52R(8C1;V*,CORLDM>V7QY5=:][VIVG]B=OVZ^V^:TK750?=YOWS9]#</
M-$6)<E SE3%;?N<ZG;<UEJM\5_BJ;FTIV[3UR$7-]#Z#]F(&1I7&R0?LO7[4
M/](_/+]M/D\=2\9^P7]"KZM:9OT1O^"\-.O9KV3;A\9)'E+"6^OW>7%<M["4
MF?7[Z!2CJ8D3*A2NS\CXS[!9_M![_A\'*A;[?\AM7;=I_3.5KA1#MSN)DX3N
M1<FQ:RWX^M7TW=.*%PFSBZ=,VE46MF72_MW:M]UKO[Y>;#=;_<S+I]]+5:UC
M[4+S(I?,WZWR=O&^?]^F?Z^:>_3JUFL['TJN?2J?MG?/QI3$RZ<G/C[XIW/]
M)/MT_ZZH<M"06FWT ?D/4U_\8_[1O^AD9<[\#Q/]9;<4GKNT6V7F!($'>0<?
M]I^^++%^\^NS^Q3KSMGS_M/*<@[X:-ZJJ__^Q]U2D4G17C\DI.^I!?V0OZ>V
MF+E[H9_QXL[N)Y-[MFS.//;MXHO+OG=C3NL>>Y@9-$U:4OS$4\GE(K/]S*-6
M9EP.*@^WR_GAOK[B_C=@ZFA=^^'Q,3NCRS;IJ6*3NC-7O S[\'=BGL0[=W>/
M9-VM#:^L%AY?&_HAO4?][V)3^V9[_O=!GJD?=DX/^.AB+&-T,J-FAG/5.UOW
MOR;KU^;^T4W]L/K ]VO_F#[TSCZ;+^V=O_B6Q[2D=WX'ER8X)/]]=K9R_9O+
M'XJC/M1WV.0_GB_Z,BQ*OF-/:%6:5&C/:JU(YTFWO=>?BIW9F<3)SO#]P'?[
M+1L^]69]:&H*>^)U\O.G3]M/[5Y^=EGGT:Q:[K,;+B_M/'*YJ77MFTM/?3T/
M3_*?FEOZ_JZVILJZ\]6+NK0?^9]W0KK0EJ_X6#WO'^6/<M(6-9$/<\6/"MP\
M_3S:?6WFA;MKA)*E+WBLW;KQ3G$LB\'Q7"YGGFR1P!4AO2*L 18,C!>"7RP^
M88-R.>X 83[[1\</V7/^*?C@^[RE)G=);_[AZ_DRDR-G=R;<N;BCQ/I1:6$;
MPX=,8%OWG_ /YP?[6];N,7XPE^WZX5NR.^]LV[9@[AD'UKLWII5;2*:IS"G*
M7KNH]=V]N^7L:]=?H.XR%/+P_YL 4$L#!!0    ( ,A)5U:9'_7C4&$! "5S
M 0 5    ;6]R9BTR,#(R,3(S,5]G,3<N:G!GQ+H'5)/?MB\:1*H449JT*%T0
M$*6WV  !$4$ITJ+2:Z2WD&"A2(N"@H(0Z2!-J5(C75!$0 B$$@B])R AD/;R
MW^7N<\_9=[Q[WKAOW$4F?%F9W\KL\S=#Z!/T.<!)4R,3(P 3$Q/@)>,'0)\'
MV!N&>[D# .;F  4  , .8&%F K PKI@89,K,_+>_?Q' \N3?K__Z9<D'./[W
M_7-CEJ?^=?T7'X I[@, \!E!GP)<!QQC8OKK\8_%S,+\UV(]?IR9A8V5C>TO
M8N<XP<'.SLG.QL;)S<EY@HNQV#AX>+FY>/ZZ_NN0OV[_ZR[&@XN=C9WKO[WH
M7P%\[$R&+/+,3)* 8WQ,S'Q,]&X D"$I"]/?%N ?B^D8\W$65H9(G"<8#/4G
M&>(S,Q]C",MRG*$B4S3C=<!Q/I93YU2OLIZV?,@F&<!_Z<FK/':I:Y\[!*R&
M\=*7'P4^Y> 4%!(^(R(C*R=_7D%-74-32UOG^@U#(^.;)J9W[UG;V-K=MW=Q
M=7/W\/3R#@H."0T+CXA\]CPV+C[A16):^NLW&9EOWV7E%Q06%9>4EGVLJ:VK
M;VC\TM3<V=7=T]OWK7]@9/3WV#AZ8A(SCUM87%I>65U;)^SN_=DG'I .C_[2
MBPG S/3/]6_UXF/H=8SA@^-L?^G%="SL+P:^XRSG5%E/7;5D>QAP6O+2$W;^
M:Z_R/G=P2%VVP@L\"ASF%)16FY<A_*7:WS3[WU/LZ?\GS?Z'8O_2"P/@8@3F
M,3YF/@ (0![8HW%VS4^!2>=]X;4@RKG<LW[>9H8MM-EI@[Z!.(#R)6/]H,2C
M+\DB^5"5PH8:=:G"-8][UA,JL'X@YMI1Q-L9A._8.D ^/_'_/.49+22^G-)R
MG(>SLAW].AY\M[5ALH4$JY/VI:KVE?4 -!+E/QS[OT(D.=J)5W0 2P AC'+J
MP(04Y38'X5PSD"8((92SY'\6VTUUYS7X<A:>^M']8.58ZT5XASD=,%?08XV:
M?P<5C[O3=6"UR_Z-!KI^!5BI9KO82-'#TCCUZ0"C[W,[Y'T5.D#(^+]N_3=Y
MY60<_#4?+.A?QK0'D=@(UW$K+U#>8#ZO=GF'<,HIOO3; <5FG+>&WVMF]&U'
M97R#C1&$_NLYMR&D\RL4_B>9;$0// RT\1I%<0+ :K,4=QUH$A"&!23H@ (W
M?!CU*),.2"KX-WL?>,?_CW 769#.5U/X8<;6P%J59XVJ7ZF_V^ [S0"J9SY*
MAV'<ERB\+3@)V+"R94(X/6_<,W2,!.^@2>(OZ!8CS'DJN9[M&)]]%-ULNUH$
MX+<T_&^0U0F/AQ30P00=( )(34S?K(E4H1)!O8B:_E74?W\WF2NKI" \WH(@
M?>I[,79RG6]JX)?I^.Z+XX$J7"7B[/J&MJ1G<[T$U)-]\W-I,Z@Z)8S,:5,;
M_>Z +WG<R4<G?;KH@$<6$WPH5WVP?6NV;2-:=LQH=7FO\)1]QO+-I[4"JG'D
MPI2)=7- -(>A"?&^OA"-#%PPGG3] R9OPE, QO^-3>U?O1%4'J\Z@,3K.Y&6
M5UCX__\AH#R\PY\&<J3]!.)O85^([*=T8;QM-1[UCGA.E_?NBC=9L6N?V0(G
M(@'!U3R4*V,PKAZR.M21=+A0C;!:M\F4D&QLN\S->RWYI$?8K('G46G_6?1Z
M(T6,:0YX!@HEP?'Q\XC8ULL5/N,&YPDI=5EC/3FU9N*Q=:ZJ7G9<"N]=LCJH
M)>U,&\!:38K 'C&(@.B"'W-R((7=&Q6]0M"??5+RNC[E6$IEH)3HE86R#\S$
MS-^MQOA&VHDA/,^N7Y"58*X2?C%#Y$V:A=S$MC(_UQ>$[N5<4FF[?GB7+1WP
M]"6\PT4/A"_OPC24>>"_SZFYV!-N$854CF&]V:A.3:Y2C\5_C\%)6HI7"73
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M4X\P06:DJTNO>>GG"NA@)C)X%7?>Z/>*/ZIZY1=XPKM1+2>G;J/LX :<K4Z
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M"=P/.)5-O(V/[XF6(I;6_JK#"AE>^#3AW'=YR%_J9>]U 6%M*3U&>1'J0Z2
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MMKA&RO42LB,=,#Q[G0&OJU&]"%*\!;&)#BAHC:?1 6!X"@#VFP[P&*0#].@
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M>>(R]_#IW[P/'>1P+!DEZK\?-[X+X'QD VGFO<6Y+$=ZR%V2+$6P[CY*,[\
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M BIFO(*3"Y?#E=%R +PTJP:F=C,@[6X@]Y@T7@J;KC(!>B<<\+>WT*)M-84
MM,F\#+&D.TZB7<SQB8U8KW6)@#%NO=3^<\N&KT![G0;SO!?S2:8PJQJDE?4K
M?2$]Y+FH@+,<?N(#\,:6,E/@<&:Y]Z:J]SSL$D5C7K'P'A(3 L3?"?";P.V<
MX-;4!)>7;]Y/6'G%=)%)L,D68=<4M$T%TLX18SXMU8)6ZQ7R.QQ%UQ[^KN:3
MY)U:!7^LLI0X_N2)FL)TXFZ3,%_@^IY4+8W"6>W:=C8VG <F0JY;VN1X\EFT
MU,#%P+/$IT7LWS8P\&6$TQD^YF4A,H4V"J"BE/D=_&[I%4M,%@2G_3B77!].
M=V-FB+XR<,8U((<,I 3SZ<EIV0SFFZK!<ZB*JT;*-XAV$7@ONX3&/[F53]YJ
M( />45T0W3D^U).6T%. JMGAW/QQA5S*RU#^SB9'JG#ISA,ZJ-]W3PV6>W_]
MV#DETVR%1KH*X/>']Q#T+4KID<ZLAFVL 5C@=#%;HBSY**5<K#Z$+^/)78X_
M6QH-[KA_B&,IC.1"N>3=?I_W)-93@$'FLU70*,3 ;#5[8AHWL;.=C&<.&)JM
MXJU&YK&YY>CG+\96U#Z7_=HF'7';\4_LK1JCYK\^FR](^87O?VL)1DES!M8(
M-IOI!R<J+PC4[)=$6#@1G60#><:W[XTIJE;U^=X)O?Z42;/-^@<R'=)&L##C
M*(6C,Z0G^T+?T^%J9LR\__'OKHS@Y?^T0QZ9&#1F8S;[P]+3N7)>[Y6:;JY#
MKZ_SA!QG1;PNAR#VGS>H[#B_,7FY2 GG;6XUB-S4_(I'=ZV<\M2JJ;(H2=22
MRW'_P06LV=-'']*D$!Y^;WJ$00).'G>43'5>$.W#I._5GHP:UL=!$ODUFUN[
M)@-9[#L:+UK8M\G>Q\299%:(]HL*.;YGNJ+FXI0RNS$AN]/VOLV/L?$4H&\8
M.'YO[+J6YT.@["AK2]7Z?H%PJ78W3X*P86&HOI$ 2;8!QCA>;^#[_@M LTJN
M_P$OVN\4T-HCAI31$2 7AVD,Y!V$E6_X3;RLPU,M_ @XS6G!C+&MZ"?T?8P&
M8Q);]1R.Y/Q$^-9@$O,*,/C-VVFFXNYGPB'+3:XP H.:%@LKZ>DK_D,-@L@@
MB!R*)LH<A'%IQ;RI@?WS,K%J8OGFE\D#L/Y>:5*'MQA!HVQ,NNP65)!Q[/42
MGU)8AWTO"IF8)<VL=MV?P&KT<*%/@/*E2V;T98IKQ7A/%-"AAK7K]U_YSE02
M"C_C#9(]1JI^=MUMG:3FU_.1PT,W,NGKH04X#;+ONQ&7:_\ &ZX\P8;OP3X;
M,_L@.AGSP[8$PY>9T WMUM<+LC/=0>"*B5#[(MHUDN<8>;A;6EZF*Y'28M';
M[_N[N%N(K8PP>,#"K8^D2G^= ] XC;?29;D#9,,/S^M6 BN,.R')"X($&&OW
MK4@FW+,K;XTG@>4^6*)$ZVT/3OC30)5&;M)<Y ]BYN8-4HI._HU619/)VSM:
M7X1_W5A&6J,$LM<(8\9V@R!B?H+XC[H<_67AQ:4/71.UD"=9(WE5D,7HU3?6
M-O;\]9]T':;:JU[-O$ IFJ@QMOR9)]0B@N7%LP*@C00M\9RJ]A'-+@?]C(1-
M[?CP98TIPL[1K]=(,60!C>['R2A)L)P@4I,_LE=G(?'X8W;\ 5:!N>;D&S!H
MD1)<HA12@H3A)]_MLOH(.;C4XT]6N=\8FS5\IX1X_J1U5$<SE=^_"O_5M+5'
M@[A-'*.VN9QCC[-M<6LFY[LWY,>U<Y9J-9+V.>/,1^(54"'3?XGU-R8[@</6
M>BGJC[T6.(0F:C9%GA(M/RK&MN1V"Z[GUVHMIR_%V@HE7HC3&*EINNX31O%_
M65LK.6,N;;T8+K5[\X1%KBW UG.;4:-PS0TTV<NK8Q;4L#OI.DHJY4RV'TZK
MCJQ,34!Y>0!9%>\A?5H/--#H4-WZX:?4YSL6/[S5>6[1T=83*+'X]=Y3@(36
MSG(YR*U4G'_I+GAKY1=+D:*N?\E+JDW<?9--AK\B(+7::#%9!2.[N,<@OOJ[
MBS?C==)_4F6_1!L;93:F]RD(#BEJX*?V E0<8"E+\#('K?8ZOZ5@\Q2->-VJ
MT3[79Q#G3R(VD= ;$LZOX&I9E*(1F^$]BO/*Z/(#$5^3P49'<>=M&9%<*N_L
MT'-3LY<"WCSGR-G,<?!B*R)NY]NZA+^-^Y%%9KCTZG;%IIJU[+#6LH:BS:58
M_P==,"<9,8U75<."Z*IZ$%^J^PN\2>Q?J>92^S9+88RR&*C<B2T"?VRMV>"P
M=0=M,63^8]YMYL1P<KV1=]BV$M3OM,:M+EN4),(=.G,-C1&._62AT]I1Q%I(
M$FHRD,*/R0<W1HDX87H#.U6LOM[' Z^)N.NDV)*X91.'11,Q'R,'HT/1>G;3
M 8WAI.9?K;P\92)R/8')Y)^*DL I'#1JJ?N",ZEZ4;)3TK3'."%.OE!M('5B
MNV_H.%P4JT<I(Z6P47N1((]30.GY:A@V*CD0TW@#VXMHE1$\QS&X#2D_#A'/
MK:<DD4),N3QB2LP2@>1F8QZJJ\^-D]N!$X&L:,X.<@2W)8=W'.2Y<6QH^NCR
MJJ7N [.&.?>EAO*\*$\^+>#80,Q\)9JDTSIG7>51AJZO8?"_ TYNBZF56@>K
MT62) 4T?%$7L<Z==6,FN_XS=;#Y?ILRURH!',9BLKKLJM4VWT^G</\SE+<#5
M>MA9F>9"4_\1&>6O+9/AGBUUM[J[/N86-Z0H0F)[08HN1-CGFXL>R/M#OVO>
M+MRF&/.1=A>T*4[#TL6^.=&^T7=M@ _I*>YC=H4T!B)],.TF@J#KWWH4.?T-
M4UYN?EE0O.PQM<=]]:](O_)#2KQJ)@&7#A-*$Z>I,*C8Z,UV]@[%3Y=F7'Q
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M27_GSB-^0B^/^+EO^BTWO!U*=S7OYWT:*$S9NBOV[P@0/X.?&O>+T#LK>=B
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MFZ"S1J:>?6MJ1:IDG:GF78HY M1_7H0J>D1E3<N%1_S/-N;_UOY3X>/ZESB
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MN9_RX/PX2B+LN9?Z/N^X&T.-FEL:!%V;9H9<9K["U^[N[H:?\GVTOQ3*\A'
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MUN&-7<D[P<2VN\-PQ?R)MSUH![)E=!BWC]-QD&Q#5=>+NE%Z"4=KV<D,@7G
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M*6: %3IUKHJG'_K"*NS]^7&R)-IA06YFSZT'>'J/B_M?:W7DF4"+Q9H"(N$
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M>\5)DS%RB7H;QA/'1/FL+.T,_:&' ^\^QPG6Y;#YQY82T5%X01Q9.GQH@%P
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M]-@- &4N?9 RX.KF(13;.V*O*%?AY'71F%>KHEOG# "R/"WLD@G/ $':)M[
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M*0892UY-;JKM=)*6GV>7=D)#E;]RYUM%]M]):GV1O"CG6#,Z1AC%__/W+X.
M#+P[(5LANLGPA_/.C7N_[[O97W_>D57^2;&\\L_W9J9;2[$0:'Q@Q(O1S,1A
M"Z$:7;X04#M!->/B3W.V,<FYLIW:EFRJ61C,FIPZS@A411YE,/6? 8+YS-HH
MZ@A"N%1G#%S)MWQ'P^OAY8R:=UEW@FC OD81OW9.S"H^.YX!##_G;8_5)R,V
MR+ZJV^U2IR-4R%CUQY%P7RH'FY7>D$KZD#)U?HCL@Y++T61?Z;4>\5*[6"SV
M;V=.=L%_->#"'*YC?J^KE-3)]O2?5>AZ''*1'AHNS/:4+I$R%PFL,.O8^T^9
M6@'"ORE*%3%5MWQ4OA&&7QR1HBHH/TFG8K3T9DM+P_#->(8 K9=I\>HF @C2
MKO-\963GEQT[P<7RF,8D2LQH^D1&S?J?K^?CLR-\\RQ=0(QE(RWD0=L)5O;!
M*=Y5C>XCV0$77!FXW\'N*NE'<]V>S1BHLKS3V3TYE^"Q-&XR!'+8,MH$5]9V
M/OIB'P?A)?S\S@0=#ASPX(E6SCGL7K<(U;<)@"X\(@U*"_(IA[PN3<G8.[\3
M75$ [F+U['-;3O]3"GIY!HCA"*[ SG?&7E0\ VAN/'(CBH:8/[K$WL(;4.6-
M)TK8W[ZMDI4G>://J*J<F70)FM9O;:WK>^L5FB:P&",\E%!@:ZN7XR??D97?
MT >=2EWZ[!>-Q)8VF9?4G0%2GR!LH5.12ZV9[TE*.'LM;=(I5LS%R\;<($IZ
M_0P@]?= @]2!8G /SZ%648J3S<II$J:VR42*)'AZ/CZR3NS!^\UE?H>$TZ(S
M@/\I6G^A?"IFR;<\:C'Q8!$9G8- "!7)!S+&)VL1\4Z$VA];"F;>(?(X.^?,
M*6_74351\I3[()\!B\,^0M$T'CX'7GN#3QEN&WPSQ'O%(DZ_;#-A7O]GR #7
M0K!?60+( 1[3(P!:M"(T<J^$IL"8(=UG  Y.(^G9$"7<BZ[21,9R2;7SBEJ7
M=NV-HW[J>P>_FCT#!$+3>K_JYXA7U::L+)XWBZ7LI?29!7H2Q4GF32-I\$5D
MS/GVGK;0I%WZ:#3^*:'T0J9J8H@"[F6J46;A=_2NA$^PCF3AP1F@]J<5T?P,
ML*"SN-@R&?L#\:C3S$MC<;JT;YSN@'U^$M(#Y>"8T!6F,GU(Z0G+^5(GJH;I
M$MJ]LPUX2'(XGR2="Q<1"UZBS;D\LUPOO/OYOHT4\\,QVH=Q1#$^RD#6W[R+
M\+]Y%P^J>F98_FDHV)G"79U8'[)Y1 S-=]3&?#\?ISL Z8,,*#MT11+5"0*#
M^YRU#8CAG9QT$:Y7DUKU=!O@.##6&/9>0!X-]8!&I;>D+AA<=35-3<V_)8*H
MG>4K[*81#8[>_],KZN^T8@TRU.#[H70KS]]O.Z3/.=0CU_D8/>!8>^'4T>J\
MWTFR-JE:'<$4Y2L/8\5,UV8*K\OH!3#/TXVRC[0354A/$E7\4JFTH[?\%GTK
M+M\/9ED&=8+%7 5K(;%E3485]DH<7UJ'@D[%RZIOZRI7@@-/.>PS[(JU,<9%
MO$?C'$UB"S&/<F030[/&4-QO]GWM=PSG"1FZ,1IW!WR# SV%LL^YU($'$8+D
M+(B(:FRMP'G<PSZA8*^: I<)/F05N/,6@OU5"S^AZJ4(U2EKGEC-M23F^]*+
M'N:W''HN0 IL34LMQ<9S0):XB"P1CK@\ZT"6K_RHRXR>Q6ZK<U4/*HIU.B37
M!G^[CI2!'.>CT%X]LO/,(5;BX74#V2NF-D/;Q3A%O0'F=A@'8VGR0+GE@8NC
M[E!6TUC+J],?W!%F6O#*MO%8Z,XJQ8DUU![/\ 6S^6JM=44;\V-NB&]PWB&\
M$G79X+$9U>VTBX8\35^T-(BT%74C57# _9+/  [S4?AN.QB5=I9JTV$,3Q"Y
M!PUNEHS"DS]D^L;-QXNC/\#!5)E=PSEW&J;EFRRK! _GM^WF:[OU%I0&Z9(_
M4X2:YIL);DLU<16-#D4SMU.I!JO#;42BO!W**Q30&^8ZAF9&?">ORQUG19YV
MIG;E99O>AD9!T]:+516\U#=XU)H5B>.(14;YP;4EE<AI&>T4Q=#ZPW/^I8'0
MET,Q1G2>V/5.;JX32-]Q2W+5XCQ5F9^DQP@A+X<\0]/N)CD?Z_L\QP4$#!TG
M6C?[*GJ+'U]2=F<KUMHC]I&&&D$+\+\!!!$8J\[U$V<67^)FI0F><YYPR6"
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MS?UAPYJ<=1Q[,09NF+UUMR+4M*IY62FTBK0-UXP07"LAVDOVW]\$SFXI2C(
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M&C_'@_9=6#FF9A+L@%_S7*>>R(Z31[]2MV' +]>&=\$81I]Q_$^,CJ?A*)M
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M7GNOM>]]]CW/^>/L<_: +\PGS#GF>,?XQO>][QQC$J>(2X KNIHZF@ R,C)
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MY3T$+VC3I9P(:%$I) *X\PA\LZA10F0Q$,<\ T75GY7%*@A,J=9%$_Q/*[?
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M1 @8JXP\8E]7#JF#"Y!N7DL$= \&D!-:RJ%;UA.3.+9%@G,&O@.*'GC7/%S
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M=0UE=PL?$7SIL:HA_CMH*7,0A5A1Q\RVS.#">%&"LWPK"FW1SSX J"5_?0B
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MG;B)=FHRP%7F K3"(/&Z B.O8:#'[7"QR\*7KO%_<J'EQ\7]LD(0""DGBQ9
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M&$STSV4E7&'J\STUW\@M'#\Q,YXM/0PAZ@7D=!2[[8%Y8&X*8_$!8A.*G\D
M[^RK >)U3&<!?-YV2K"S% 'ZN .KD;WR.)THDB@8Z#P:X8'AE1B4E8A5Z#.7
MO2:7=D;PF^]ND:>%IV#&-.$*=D>'X'K\%'HTH%5]+*D4PCFRL\V]')C?V)"!
MWU]*TQ-V"7 P,G-\SJ'-H<YCOO36Y\7DT]-^SVH+7M2\)0/8;'YBW3-@4[U(
M'@-_1_XO"H-5H!G7>/XO9>%AZK1\YMUD0&7!YF(9S!V+[+Z91TA=A)QUPY/D
MQ]Y75F'WOU>>]6ZEM[Z[P/F:[QUK\GD:E>5$U1<+!5VM0#1R:W)Q0XH3M?EQ
MEF!EU-[@FKJ2L8(!3T\D/Q1.>C,;J_HP$6!ZP13@!+7#G\4AN\2(&L#P$'FP
M %]T#T_J^/M"=7E=3WL!W[0S@%T7[K"7^:8@Q;&;&M0T?(\R[]=N-5'B$"/J
M=3L8%1^TTUM!N+P34=%BX%4_M9*R6)UK,R=&O15%#QYCX_-.SM-0_2S:&H"L
M<UY]H<81,M7.1!*$F50.[1N=<FOJ3FL#VIQ"+V9\#6S&)"\[6;>\O]4LSA)_
MGRKZ%@4)B--^VA+"^U.D H,".WEDID0JAXFF9P[S^K+\A:;M5)*O4_.^>8U?
M>.1WJM420A!5;,2Q]PKP-A'>XL#6A/!W!$-[U:A4Z73^-#RMT+=4FPP3+RH'
MI:2D!I>FUCP%#JG4Y8W=3<."X0F2^/"OL@"CX>U:"7H/(S.VVH3<>KJ4.;KG
M;@RZAJL_+G!.,7W74!ZTJT"2)&#*0W[ Z1*T4:S4D[J-H#WW2MO9E@HAW9=K
MTXY:#+H)9_2F0A]4R[%8)(<\KY UUA-IRE'_$"<.^/-Y;'\_@ON(,#T2+O_^
M-F@18W20H.'OSY]0FF(@[-5U+CU9YU%QW!D]82R ;^D[S2OS%X_A6&-@&$D8
M]R!#"HFH::RE._!>,JS4JV&[=<>1M7'Q>:G>5L8.B0GV!(OJ(P-.ZV!DZ-9U
MS(;RWBSH(ZH-((W?T5&3IE;A\Q?*+AMZFR<_\GPLP#,"$WTTWF2+=,R?JJFX
M'C5^.DI.J#(@N!@P\U6??319;VEL_?"8=,[Q6 /<7HW8; XLA7HZUXXK2/ST
M:Y"NBP)K7&J6CV/FK>M5%WW_Z)EYA'M3?2+(&3(EM^"<^!9WLS?[1CI&/DDT
MQB_!Y7BK\E,B]DR:,&@]Y4D5QZ_=LY+F@FY&3*L"X .B@M,>T%\FJF84QPNF
M-JKD:4D;<)GH/'VLKUYJXR#K^/33UZ]<RJ=C>PUL/\2MBOV1B1(0?3(@"?B
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M[GWIW:,^T9>^@T[0?RT/,54:Y.?_SN>".%8FJF!W8H7&_<@ *H)LGT74?96
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M^IR[7HUHA#6R&M5%($J(1+2=P0;]3/Y:SUR0P#.]67%IE<EA\N/'_HY>;8-
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MW22D]'*R$\S-L!7$2P>*0SH"^=.>VX[9K+)ZPC<UGJ<*;KJX .*WKANO<V"
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M$#7AY2PDK%W2S(U2R*UD25#@*$_;G2]\.+,'? ZJ$XUI?XS@GAK,(5X;>T>
MP+U](1Z8Z023RWNPO!1FO$&;2Q\4?X9!W06PEV2[;Y=-R5R!F]0X6C2B%T[5
M+QKN 5,D,8^NO#7#P=0N*TE@).XFO[R<C7&@@16(-]**TO@>L5H37G?*GLS-
M3[PE-0DF'$5Z$+A(H!W0QA>[98O4/VVM^&;H^+*U_>[%5>865%=VS$RHE"_<
MOGQ-#ZPPI7F0T/0MLI\Z.8<*\8XFFZHBYTIU!_\H,U],E<ZE5#_[1@L!.J$&
M!;_5?@7I;F0ZO&ZBQR[*5N(D+(3M<1M'XQ!$Q3B_PWVXYQ'7%L\3\./^IZ+G
ME$0.XY84E9!OD_J/-A8"^OA!FEC1KO;H=OK27R">N0YT=V-#0[#KIF5PYE5A
MX\\H>6_#03D#<824HS"G1X]W^$:3SN;Q@@QS3Z&._0*<SB*_A%<KJ.Y(H<4!
MQ[LC&7H/<G]&4:.<'K/S:9Z!X#ZM2P9$0-!JE84V;M[6;VFQ3PL@Z(I*^;<!
MVKM] >YH9T'7QR]AN4F9U!/BWS,?2!Y S.>WB?W+=04#OZT6E9 &XFQC@7'@
MO.O?ZKT@L4FDMM6^B4#8*[2\X.AVJI@[AVN[0-7HY247-T!X#:/&CN![":9%
M(=^.,'/@;/'1RHI)MZ#,^O'JZ7[)N["MK],!$G=MZ!E#J3UNO4-:$,HHSFL9
M9Q1/.DN\AEW)*H)ZJFIV-FV-UY<J# YV1&GZ>KGZ1<8_V?68_<AUSD),E";C
M*+P#2=/"A5TT2=[K:F/%MH4'7I40/GJ:>KHTD?F>I0+-ZES-4?=%FISR([_=
MAM+)K]  2C+'2AJ9F&>:Z#SJ22A+2U++S1C\J8B;5Y&;[EZCD6R>$_0$[,6>
M^QI_7A:-*IB(=J\D?"1-9L!C<PAPC%L+R!F]4<&DL#OG9F^K!_'(LWH>M:FW
M%!$9^R7V.D#;R,B[G"?ISOBFA;$6Q^M_?Q6?S4,&)/E:DP'E5\B ]V84" <F
M:0WZDAH*2)$6?AQ22;AZ(F>%P:ATNVL[_8P.Q]<IJ?28#RD/6)V*+\9I:7O=
M=$K*?O/H1I(M+\5K:1$BL?6+S EMG%.$FP^^K]3&@83,1N5;/]#S<@M0,?AP
M *ZH7X9(?;S_4AT%S+=L0[AB&&7!_+?&IXZ^+=\Q.-U]2S?O_JCL1T&$HW4K
M<G,'2P888K?&$9 %.UJ-W'G9UL'X(*FJZ1G9S")HIX<#\RV-GJ?&/6)BLQ[P
M[L'>Y?931%TL(J9%;;6K"1\.SU_C_.D$EOBYG#C,6.!XS>SFO>)K9BHLN6$Z
M"MCVK<L8T"EW)/;!+!/D@KNE&Q84HW))JJ 97)66SC)C92T.O"&KF+-MK?SH
MJL9GOHEVTO?V:I&:.8FJ:/1XBFO>3UO)(?-.@4OZ[(RO+&UBFA(U?)*6E60_
M'21%JALZVSYW>H"#;PJ!7K1[2O'VI9O-L;<1X 4_A73>:K<DY"<;?!S@D4D>
MNO"&RDE(*JF^X%06]RW&+\<%ZTRKB:2>J<04["+I'/TBD($H.B;C#XFH7(,\
M"V:L&7;G?#H2<?>"W8KT-$E+_&&FD_-'NJ-F//0D1UI-!6PK4]V +2]"FV-;
MEUN;-(N4N7S[5)NLM7=OTVY;Y!3M#L@QH.LR"S=5)+#'760 O;Q5C(H<NE54
MIU[PBX?\6S$/FDVJ3YT1-GWO)-57"RMD"-1@3 D0,<^FX.'X*>32=[]V'MN'
MM@]G9F?7JDKI(?:,S9(EIT<3N;,5IVLM'H7=^<5JDNMN:ZL?4/@DJ*+;B.\'
M41;+68N1TB,V,S)] :]]\WZ50,^B^NTJK8\6U'PS$GML777R$J:!T8]9LN,E
M&EJ1 >S6'#;)I1-BO7,*RC2G$0."7N>K'YW[A9IZMN T7P/O!",H =9#,=JQ
MR,:J[?TER\,M?P^^%T*?U)PG6XH3%C(!VG3"YL\<'9G>.#+6MK@QMC9)&FN'
MGXO+ 5#]!/2X<HMU#CPC::Z'V!$!A 3L:A<0>Q<9,\>!H\DP@<[MXE<XAEW4
MFS(/G$T];.XE;"VW!5(O=YUZD!U, ;Q4B\#3!'.\;?5'-9'O$]U3^$J5@S23
MV0\VDMN]8@[B?;YR?6?VJ9/I'945]L\21!>Z%D$$/1":%=M'%+9U?7M2=)).
M.TT)[<^^3;>K'0YZS?/!G<N8S0GFF--8\R@BZ!VA,5O*SJCY8V74MX>U]&XJ
MQSZ[8G:ME[8DNQ=T^\:;Q!TN&BLWES23 ;:WEBN7VK$6\RP6[J JQ3Q[2+"K
M=W#^QE,@N#[1V<TCH#0^VR$\=:8E/C3I<T4F&> &WHE2XR/ L:M]2%KB;?-%
MD??>3BE:N>ZR,]9W0U!5&I(T]:_F'#[0=$8S=8&IDWXA>B$_!GJ1-4J;1>5N
MU8RB6KC5>*(1&7!6($<@S\=20G?T];NZ/?N' 8%F:^<8G'UX:5Q:)] ZF[-H
M8%23"\(?&$$4A6# $LH.C6-2\@TF&+>TJ^6DIY]6O6F6=GT''TC<RF1KW9Q'
M>1 C72970Q1/JF&F]CBUXXXV1H)=(90,>(@=3*WMBW6N&[/_6#_BG &Z>CM!
MT%YHJ_\<G2@-P\+BSSL$6GS%2:B*VZ(,(D1US ]R:HI0!>)1K1U/*$>RP5V0
M]-;BQ9]1D(; U>5%P,*C_<\532IG/\Q!(9^.%+,*;?EOD3I[Z<%O<\97'B28
M+I$!H5=%<:42VN>N>9':@4.,UN,4>/OZW1_.3O[CH/XSOJ#$Z=\UY[M#9,!&
M/_Q-Z9US::L=;9PX2'0;.[S#LNWR.I"M0G[VTAP9H$VKU3K^T&SFO?Z30!_0
ME]S>9+$EIVC#W*(%,N!?PQ":,&\LHA/.GCW;HH=&,$,CRT"C_$:&49M=I)W7
ME-AINM-VAB!Z?US*GQ=)2[!<O/<QPFK:1C_WTYY5-]6]F&798BHA0&@8N'G#
M>-FMH%A_6VZ9'<,5[Q>K0NO/LYX!UBMW2Y=U^R)]_T98#,^M[_$D+,UA5>-A
MX)K=Z_EJLQ=8S3[0Q_I804)HJ<4/Z$!7P(W(\<2">\ESNW*25P-#'ERL0S7I
M/A=R7* ^")J8 OVK",44_N,MZ>Q>/I&5</,$@6/O(E'C;%N9"A1F6W]^M-JY
MQ&71^:%?17PC2EN9FN_$O6@T4JPVI 3RVOT;".]P4D*TP>:0SL[F0NN[YX X
MT?A]W9 ?3]K,$,$15+GL,S,?)?CLC5-MJH;M.4S[!X.#T8-VQ_"N<26270I^
M [JMZ#E;'135ZR47O]\36+\5_&[#5N@D"Z:'MJ,GV!E/0& :N3-N:?W."EDM
MBEH?Q*,T58;LK_=M=[$FIOX@7FH9E6[C7W,K^AF4'KTCY3$\I:^_YK'TZOR]
MYFJ(9%'-HM#*MQNAUOO63HW#U1ZAPY1H_.W>O^'8OQIFJW'M2ZP?*#I7L5]Z
M8P9G3@R3MSO:)]5P\+^)MCM#L.II$R!04-9I=T)Z(>Q.RXC?BV<G%_@Y#QXZ
M6_E$2E4N?R8#Q%-X='.2DOEO)!?LB*^V_+4&61D7OO?#NW<K^.ZMDLZ65$#9
MC*87,2*UD&<%:XI*"%_:B,UM/G5/H<:6+S$L"RG+H1'WO,J?G0)O@297%R$O
MU&[\Y F($<961/LA&-8-O(ID"5'@M[]V\Y(OOE;K32*B@$3\ M\NM+R5Q !5
M,V)=.^J"&G49E*R)5?Z8YY=FKIG\L"3>)S+[^8SAJ:3XB1=0\X6RE0)<Q:<C
M4C2V> 0M.<57KZ1VJ3WRU[*!Y75!L2>+G#YRUA)W!T2.(UX\CKA*]6VH]L[+
MXIF6IL/@SEK$2Y!3%O,"$N%G%S<EVK-E931B.6&3;CP2?Q2?YBO*)M3/-$Q3
MKMS)LGJ28KM#2?=&"<L8% .I)ZBNJ,2M[3(N,C^]5#$+_?IB9&Y3TXLG[H4V
M;19;0_U?RV]I4\<3W^O8'PN2 1TJ'J3S0&Y@3!,H%&9S4EO*KZD_[R)#ZHU^
MZKO:J7CMRZJGSL!$J"T9L)@B&JXF8 !^1W#9,Z,_6UL_XH>LFG[]J@@0JO*Q
MM[ MM!H%&'\=?UMXAK/9?V2)]3:02DT<WKE#D$.W<P6''\N0V'@O[(3TKQ[.
MN\[(U8>,S2)L<M9L_ -U-DW?@4EG3K(HL1W)!O4UP>*+T,UTI<Y<2IPI.GY?
M6EH,(/)(&0C2#5]A7BX>>T6^[LJ3\\9:_U3EYC\.YG]O6_)_E=V46RV">FX"
MPT#G_"GV[JXG7&?)^':VGP\>XI"SK+']]=825LY 9/8EOP('CHW"+PTU.2A\
M(0_14^;;H7;6+OI&S<H%^YJ&!@^30>YX;R,1*T=M)X#]K<I?UN%V&B&4K(6G
MQ>#X=L@W2Z5XF*ES[MI15+7PUGE+F(D.<W)RS>.GS<U.FZ([?D)Q4_D"7@BY
M7X<O7O]"<!-&] @!:/ 6Q'I4RJ]5U"!^T-??"RT4&^03K"<(N"[\7%:78]6.
M#N1I%PD2@#T\B43;79A<MVP^XU3[+'#+UB-'U#4SMAW 'HD"9*=B0%BK@;4R
MBCIQ*B\]'M[H,1NZ\PYWZ855?0=^ICCDG7DVZ;OMM:%]2D00F^\$TR=P&1/
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MT30^DXDR;^[=]EE9[A55CL^AE@&Q.,\\3TT@ZD5LN9,GPO3'>?O7%8,5@_(
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MTNRRE@W1@E^(K^[?WB]T2!+N!C\DM/;\8E-+Z43\IU1Z!K"R);*IO,<F(V<
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MV7[5RZ##>:+D(QJL;']>W$".?,Y6V,MB45QCZ)%/>LK.";YJ$6!9PB](KB#
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MR;9Y3=]L;_.TN#*8M9(PVIK>E3-7UZ/$61,)5XZ1!,M_T'-D0W:VR@1<;EN
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MK'':S04=U$A"F"\PK?'YSYGX]2W_.CZAP02KDZ5@=A-V]M[G^[L+6#7B0=A
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MI4_T(1&=BYA#E [,6)E620)#VKN3;^VBBSQ\-%O?8:+=E#RS=/#U#G*$*^U
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M*?M[YVWBF)(#,B <(9.\%SO9MLU3^S)7LD*,VV=FJ%(\T?6'<DG\:[;,!AV
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M_5[&T=2W!5Y]<MX)^G,'_\O=0_N?Z?#?:23'_^+TM)@,. /H:[^%Y#_5(OZ
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M""S=B0DL^U^,O6=8$V_T]QD51:2C@( 0I(HT18I"3$2EB0BH])*?(B5@B(!
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M)]#S!';K"T])WO?[XE+SBC5WW;* *KKW"@I037W*NK"@*:377G:2+>"S-1A
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M0<L]:\^Y\AY5ST\_JH%\1LT4#4O_7#Z -R714-%S6H -1^Z;[66M8^P8=QR
M[*PG@HES$CJYX%O5+?4-YN;"!O+V9)0$ =-AJQ=?E!SU'7'HP]M3I;,O['[
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M[JL26K%K4HXM?=&(T-[3\HFMJ;[WW?0=,C^US\[=XH-I91\5OFY('UVL6*$
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M>RW'(%60(AG4FIO]*GF/BY&TC/$ICTGCW$%Q/.'*TQ1[9:?:MHK??S4.^:-
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MK:"]4S6)5%Q<GH=-0;5:"E]-SAU#-Q=-MP"!NN-\#4U*OB["/^PU>!%&,?<
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MODZE"'3UQTYH@+]8U0,E)T'Q:Y$@ :(?6 PEPOJ*3)K(R]?*5P*NO@;D/R;
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M96M0D=WYR/@? '[.48)TCV]%QE5OYMO,M_97&[*?S\F=OBESI0PHT9'\>/N
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M":[ETT'>1V 24V[!$[2F:]'QJ2N1D=J20[W'SB3\N)&'.**D00T"HEF,N*L
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M.P&A5!\%R,3W[1A'J\X-(]/(_"S/N5.D!F_M1TX1\W49+?RYU^XI7P84>K.
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MG0H= $Q,+22DP=M6S7NF-N_ID5F[@^[\96_OF_Q$UITF1S]W^QIC*47'D$0
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M[Q/!L"K8JS^ITDD9O&Z64;3^/<*)[WJ16NC;;+*<R>,X:^VMT\N!\_+_E<Z
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MB,>D9)LG90B]'QN4U[J29>-(? W F7S!"SQLM;D07[D_F<B6%KN2$H9TU7P
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MC*"_?[)QR9#BHWN@QW:<!>E+G(@K;3CVM22-[S_\J__#H?QO^R*A).)BZ1N
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M>:9J;R99UB?D(]];RE#ZUT?IQWL8?W>,6RA3.).G#$"I,;%(Q/>>RW2KHEH
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M?]-O]'_@8?N/ [TW_7\!4$L#!!0    ( ,A)5U;*BVW)=ED!  *% 0 4
M;6]R9BTR,#(R,3(S,5]G,RYJ<&?LNV=44]^[+;PA()U(%Q"B@J @(M)K4$1
M1!"EEZ@H'0(B/23T7D2EB$)01$1*Z$T@($U%.M)+( K2$VH@(;GYG7';ASON
M>^Y]/YQ[QOBO[/DE>^VU][/64^9<.Z%-T'# R5LWC6X"# P,P'/Z!Z!- WH
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MXM<Y.UB+XEHS[DVR@]48D.JL&)L@[-31M>,RY;J/7EN7PCM-G.1?^Y@62)V
M:I Z%F@ 72/>S##!)#2SP$54>>WU59YJC[OL8?SI?&##AGP585F;XIQ1HSEY
M$]:;\I#.J()$@*->7=+WA=Q@<VB]7.[T6PZ[][RF/[ZH.2?J,XL]&9!@43_
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M<TSYQ.T'0.-1U.$@RVJT:[I=#R]7^L:4-C_W+T<:X#BRFXWH7?OF=1_<(O'
M"C^?0@^=SQ"!5HGYWB(2Q$"PHG&J];[H1^&#N\?N4#"%[;@4Y<ID7.8"&RM]
M]J8<.@P_?0:RN3P7#K6HA:?- 4,[^QB!E<KG/E;]3.,*_N0'B O5CZJ"JB8J
MJ/BH8P]<"5T"H^+]#1$;+MU#WY]1ZC8ZJ?Y*:(+^FXJK>5=C3,G)KJ!U4P'D
M,)J=8@(2A?"X[CA<.7Q!%(@*==&RBEU#"S:#/MW>/_J8YO%^LEJ .CBH+%95
MWV!6<#C>AU2B9RTHB09<KWWA)6H99>DOS!-1DW,XW86N4NV&1S\U\O/+7Q6,
M5$R7^V@'S0#".A;AT1 NG3,&$D%^/3(C5V8*.BL2T@8%G09:$'UXS,163ZOH
MZ,=1)=%KB)1,LO/+IQ8!1S&@74RNOYA?=^9P<-.,;7(D%->:DN@R[Q]BV@&=
MJN[4X6FJ/[D64I[%>^4N<_3Z<^Z0YZS4^PR6,![$75+@LZ'9.7<AP4H:T"MF
M7=>Q4;/4) J9 M94AKH6T6P]OU,YFTR/I P:03E':?JD[\'$IUV2K</-4.+E
M4?FMY$']_0\'W'A?Y4)P.RP&<K*\P!#?3*AK2>;2-(_)&5:< !WXSA<"0>-Q
MCPF!"4J=#80QS''6TP[JM<9M9^DYW^^4DD$E,?#=AB&[WL::T<LC:56K 5_Q
MVPW29\CXQ+1.:.7&QZ1/2K:M.8\KTJN:NM_.>7T.0:ZC8CREUP_P6QPK!-6X
MR^5:=Q=^1NTKO?%D;^F]80J_;<8\P+$R;O:Q]TW+O8YQ]<6+.V$/:$"$#$"1
M?:<A8K\JZC_/\=5SA@9\"_WJ+>=, X(S6&#=-<U">!2OZ]/++S]9SW IBC[Y
M^>32<]2S(M2/EOHV) ^AKI;/I+!'/A+S6/.%EUQ*<Z#T:$R/\!X_P[(E4IPH
MA2["4,[.7:TE7DVG 6>@?'I+MWLGX(]0&?H?UT2LFP0=E0CE903JGAW4G; >
MK;NQJCNEX(@MI<AFF8R:DZT&Y?Q]9G1JG7C+?KIK\-(?*<UVO0;+O2I7F+W;
MY^.>8R<_X%)Z>;GG .DYR)+3(QW_>.2N4NX]8U),09M:17."R3?3ZW>"RU7M
MC]&M8(J]T9W" OL@*WN)X]L=@L3&M8B1Q#V2#@=)9N=G8YT^P;NBK!%M_-8N
M$SJG:=AG3C2&_9VRKAU3=N#KGKIMNMWNK_7(IX"4='J'-,C2[T/MP_)0F5;[
M0G%POEF=S&S74S\&X-)U_9$MU0O0#?]RNX8AJI0KO&C^[)1\6<1CU'X:R,MC
M G&'\#'#W?L93%2OJ.H3^,.<X^'S'NJ/9/KTK)9[PZ><<'-%^U],4):U0UO\
M/%IFN"[5<99T78CE7_$+P\TFSO6V3RB!=</R7*(N$-M)6(;N[BG, )KDCHG0
M87[]FS"?BJJ\+%#]V^W'D.T/U+1%-TIFI)H>;A44U9'UI=3]/YARB?-ZU[.M
M>H3%N\-U=CA%U93@,%L*;HR>3ZH<N6ON[4.Y[6<;R&7/H64^4ST4P8B/BSU?
MO:.H.2?U 60IO:^INOIAG)@',:H+0K!.2PB)_3VLM*'SX_+<XP?H/XY&BZ:D
M"P8]</$2??@BQYK9LKACGKT_#0@(AP;48N(=10F;^&(/RX!K-XTRS60[D9+(
M>32KCF@/=(IR,\NO6\=ZHV(ZK<B6$C!$%4<.0B#EC*?\-^QO31NUI._3V:O0
M6.MKDBF='(8351KA7,O)_A=J/J*P[LEZ.'*$K@A*$(JKM-WX,SH8)'$]]H>R
MI(&_9G!A7/D,RO:PP)J(WF CFZTZ^KZQ_E*?O7&RS5$M>%_@*(50365#$U +
MB]T'(C(>6:XG#D9/&D93U3%%6K*X,*%VC9"IO[9>Y1G>T,BQ,P5'_^SKM&%)
MD@%?%C]E61"7"J3R4O7",B_%P4D"82N$I'T^D@4A=HSAX4)OV/6-FR:_MN.>
M0XH%=F_Q6N75K (%+@^YDADU0UUQ*6J&0[J 16Y9*F"_UV6L#]PL%0C^MK%C
MWBAL?_1+SLG<1.9'Z&N&)RE^E5;G6TK^H))@I^E\F2,>(;N 7M>68(98-W<P
MP\RRI<*UT_"0'AK C9"LW(9[O_!R]-&OC43GW5Q7H*\(>*JR&8+[XMR8H P7
M6F7IBS--IFY.VFUN0M>375)_;1M0SE!EQK4L5#"AOOX84NR]-W:]?2/8XTII
M'>O=WX]:,TC*9!$'1R=;8L9,15\@^7M9P2-QF)L==DU7% 9&>.$Q\8&.-]$!
M2Z&E8=C[[=L;[:OI1V]]\V2'M/R)16VP:OF8B: TN[O/!++?G?V84?DVSR/F
MF"[,7=.XD=THCN%YO8KZ.+-<=INIZ\!O8@-579E42)18M$K&NL)%[=USWF;E
MM.QUHIOJK_>?&P 8="%VU$$4P0(M3!I>W3$B:$@E%:K\MBM%[D7@M9Y1UOYP
M0,"46Z3C4J45^.>@%XLN'8;3K^_GD*WV=>B1X&""-]$9[YSG&9V:,/Q!7"'?
M68)LL!]?)[D0HK["6'>#2A%R[Z=6!F]^,9U<M @\D$X$*,])>G27RR >I)Q-
M7.[,<EL@!P,/Q%0K(7=D__9Q4%G'<;V/0??&,=YV("E!A:BU;H]=+RMVM2YU
M._5\<'0I/;32:,")(9:\J9J4>2%)9_HW'?E45AHPH.U$ T!<87WZ ()>%0F&
MT$A'1Q[_!W,'-ROVP"2)GJ^3%C&%2T4,ZR;?U3"#(A= .WJ6=".NDKQ=!R::
M#7PY]G=.;*TYFN!1) E,LE+8QL)Q@)Q)Z$TB_FA\79^?@00I07:@:X2^?HE[
MT?]CB3]YTZKR=75/A4 E;FLJ:C^+Q''![I,_Q[>3"P6C[]Q.L)Q66($UQ3W=
M7=LKA9TD&1L0[5'.OVK60DF)N,).&1R=G1]V$+*H[-\_>BPHH1+%(79G:(#L
M#$8&A5,36_O;PF))4B<&&7P.@G4)'ODOJ9Z3#6?8%RZ/6I1>YR/ >]KGEK^.
MA3PKO?*D-N+^SGP$[$K0&I5-"/YAU@A%F.\\$#%9S/U1K8G4$\X'5VK)09(H
M8E?J=X0<AZR7+AXXZZ%72.,1R,GY2E0LU%4>/.,^)6EY!$UQNL.C>U?A-(X\
MWAOH>(7.?!YKOA2;'-W;D!$\GK;/;$AIVSU-M%.!U,?%414<#.#X8F4(H\<"
M8UAK6XU$H'8LV!;X0P/H3'PJM(L&5 YTWL.!X^_>R>%\$>ST4YK5+]Q*NV3O
MX*OCE>%FK_QI]R/MT<"Z>^%.Z:(2:BNP5&Q-7.R;18-H_5V1:!U%P;^VLEM7
M1/-9=(U^'\N@U[G([N[S3 @'<%2SB9]LD.U*)'/V\P>>^/ 0,Y:-CPL]VJ[]
M'O+7QB\U&WUL_V1M*O#KPP]V8[['EN^/A^;"!?_#7Y#^?R![/E2]:/2>"@->
M;2D<BMXB70A,^D!TV3A?]ETI>?X)[.R)1=]8*/X^#7@"F1CHPM98)98!%7D#
M':L&N9\,6>U1U8Y1X'4:4(H<@M6-83\H?QA>>;YJ>GX&AXC/7Q8^H-:2C0G+
M;1K0#AB[]5];Y1Q;.]N;)>0:C@9\<1<0O-Q& R:A;1#&W6EC+S[].K*G$7EZ
M*0;1H[8Y:Q)JK_#Y)F-$?1VSN./)3Y+.>06NW7ZZ#&9W#+\7TMG^;>Z&I7<-
MM;'X8T^/,P?"Q:OJ"H/;H9R#+,QX< 22A3CZ1'F V]J=M6=I)]\\)#3Q<)F>
M7PG&V&CQJ[$!-2/8RB>>K\@B3.RAS\ZUMF8?NAN:GU!\V1=TT&,ZA6Y#,]:(
M)J6X6,7L78GN*/IZF#Y]^O$S2 J A%,,Z>%K05I>\/HUAL7U(36SRP9>\Q[&
MJI_0'B"-F7:@IN]UH5GW2 @!XAOC.(?AD0,3I6')_L_!IR-#0\=@G:93:?CE
MC2>+QKFR[2H:*9E)BH=N8A\M;N6MWX'>VAN(A!*,-+?X)$-Z.C="[LJF+,U)
MN_B8/C(E#9[H.Z#PR^*VHN!,2.'J45P5R+>ZLLW &Y?RM0%]$M5^&Z%T67)4
M2QD79G5[-'3VTH5"&C!WMCJ1;/ 52KAC&MEZ*O8"NL-GU?S,0*X/5J%\>WI?
MDV3@(OZM&?*H9#-\D.4/-@6*^Y0G3V1N#EA;T%0Q/.3R!R31L"_V@N]H +,T
M*?U99V%ARIO=$PJ16-(&LMT1V8UEA<=*$[R2DIU$F?T"T013=,1!3 +A28YB
MH$47@+PVAVK70U[MY3!@2?#V.KEK7>@)+O2M1]=)=QW?^CMC@L^]][/_&EF/
M2$]V/[$$D_E(\V>$48]=@9/T2?:D\)OY+?PE;M8PD-Y\I@[-\]06"V\A;#[9
M:W(**M:9KMEG'*36;ABA-T0*?\8T;6:D(+? )*F!=AV_A4\#'YEM_^%-SRA\
M]69V7P.V4G_2AV$3ZYIYS:94]O(;TVBEV]&K;=ZZ W-%E%!F#[00==T6OBY*
M,#7U(I)D?BK[-\'7JPD=1K+[<#9KJ3ET$PN=-^R\ 4?5'M_1/3-4RS9! T[6
M(5 R:S602>RB54(\M9<04/RTIVCS>M1A.FPH]0T!^[7I>DSMH.>YN]/K?U&%
MWGKOK6UQUUS@P&[J><@W,Q:<:C0*EXL2U3*ZY*$:?5EI%'7HX?,7H"1@0@CR
M%)[Y[I!7Z<:8M8!,G^7E! ZAGC^P2EE61Q:.E3OL0D6W ))5&XQ@E!:C(Y8J
M-#H5YO@7/,=V]1[TNL=?&"/U.X2="MG0,(U^1CKO^.*0%2QV9%6E]/ 51C=,
M[9T3^Y<0<KJN@-*QS/!794.Y]PGW8B8*(JP"4AO>W;^ ,Q\$!<AK<8<,XQB2
M?8W_ZUXG'6<9&B3.5?EO<4UZU*UP=:+.>.:^=4E^0+9LD5"9,3O!$D<1*B!9
MJHAX1:M,IQJE7L&F"2R@Q5LO(TRJ?\%ND."XQCV;RMH]]6:LE(XVV\ *S$!%
M5W)G]W,@WY3-]6U#2_[5]<\&V_P,AT;X@8E >IB8++J,(GP_72N,-_TF];R*
M6Z$-E+A*!:/:E5O/4]C'H+6[7O".@YS4IRE^2[ZI!I1JY?WQ9!T)CR.Y\6DE
M_:I?N\^1KDQM]DCVB8'E^Q1MLF60^=+..O6,D+CPE_Z^^K\^/1/E-R^ 6*Z1
M*HGWVNHN>N$AS,:EKQZ('QAL=]XJ*'F0H05VWT6S4)X2T,F58JTE8BTXS<?5
M32?4>5IT/$$DD74E[$FWN7.U0B)A,T)UZU<_JK 0NWQ@_"B7>7;*[:2PKL_6
ML CREUX+UK^S"=V*NN)O..,'(U_ 3;>X_<P_L@"08DQ_B]Y^/"F-+!A$? :-
M%QQWE"#PU4THQ\<>I/A1+ [ '9"D.1%2[<*:EU-'4[)5Q>V(9/>.IRZC9BQ>
M^@K6RTQ(B4*=</8+[_\-?"#U'B7S(5VV\;)3XJ]JS)B-2]3@?+Q=IU=&.!5A
M.H@'QS%(0<H#FP^C2FJE<+3<?J]KQN/9M08_F'YVN^=PL#55(GF0!6_: R=)
MRW=N14Z].D)W)"65^9E*/^UA^F!80DJ'\5&NUQ/ERDM7%K6OXDU&W\'GM#L?
MJT.WG-#]V(^3<L/VWL(@4JA5.N7Q<0820O$9^1W5*:(E%7#:OC/"'GF?X? 7
MG8OU'=<6$:C5D(YYP56[FL-O@EE6X*\!W:8+L#++>F-_[_.I%J[SK_PUH[@[
M12A6Q\4HW!O'*R39SW0RS"AYU)V8THB((O\E#MPZ@E/9*LF.J]0K'NBX5LU&
M8P>#.]?$L%,)O%"O(IWL?/"0ZP%*2'H*?5>_>U =\!>3L?T/WZCZWT'F8L$.
MV^FT+.%BUWRP!IW4PJZ3G(H]K(Z\WB?-FN/Z?'UT9R9!+2'<X_-O_X3)W/H?
M[P]+SE5%@EG&$Q/="E(<)B/#%1N.S VGJW/SBW'UMZTZ(/4'&^\@'<=<%"Y<
M,75ZL<^H=>"-7N/"MS.+X9>ID_/U97%?I^W26$GBUTI(30O-,2HTH'G[#8OT
M2!EBCZQ";:/*'^=K7:,!;./=LN0"#Y\YU(2S7]/MMZFYS"'CZ^?)K%WO5NKF
MH*0D_IRLA,MMK\^.L@4D054,M=>V6E2.NN%7.2X^.L=7TQW.?&=B,5Q]GH$B
M31CH,#G'!>V8DBN+OI+RV?S*:1K0UC1N7U(=U;_IUR.@K">9'AQA?'GK]B!H
M?,NO7F?6;7<@XTX08_H3(S6NE[J\YN8C=DOYS#/:[J(EG^3>N>3IIUY1O^PC
MFTRJ)CIUS+-J2?MA/ [2[6S:2B?2"=81;\&V%+?C0BSN/15*ZEGD:%'L$*K^
M>R2(/WUWFM/H7)XB7:ECQ%6.BY#"06R2(MBD&M+Y-*IU:2-\N-F@$TVX#X[*
MX6J+=IB%G?1MFGB";,ZA?"9 UM.(+_'/>GUR[GSX^J<^K-ILOC9BZR7L%@E.
M9<4OEND9V]2&A5WRSG;YD<2ID\L%(%\B)(Z+J:<I#ZI3O?@Z+3\&^R89V5]*
MRONU%ADT\5A-HKX%*8RX02]?810W$ENQ3O'"?.V<[=?I]UG&SU^K;5[/V8=/
MTDF\_B(J-J06'46]O+)3M<DCNA:1<$[\8SC4]G:BPDMK\3.DB 4:P%[A8'4_
M]B=Z:_F(/>DK]*026,RU[J@UI=AVSL;^IO!C(X9N SWK.1T"=PI^0WVCW*3J
M"V=P-B=* \B13YD[\68SZ,6W8^NT%5NZ;N'3D@M@B'.H>AYZ2Q:/%J9V'=6V
MS%2[/M?[_$XR.I/X'G+GE*5\' UP@4%6 HV6$*I5KZ]U[XU+@=;2-,)U=FJ)
M.EF('W4'E3_L/HZDV]J-CS57+\B'PSI"9+X7_R6N6!E"?QT7+X&(ESS:L1[R
MI NJ,4CFZ5DW#;E.C:)X/&SO;MWO>UNZ$*?OH4PV.^>MB;/]0T>COJMU]U E
M7V+OS%\*'\=E)6&]!E+1I^";HG=&M\QG$Q["G5AF8;<C;)"G205D [<OFS4K
ME.L_3.=<D_QVSX5#\S$*8:X[0JDAXXNH*+K2*Z(!PCJB?6)IB>M9UD%JKMYG
MMN>)9]C)*!R4PH]?&.AB/5,S7NY$Z/_H<^JVKSBRAF$_<V%-]X&'A %1*G?1
MY(K#BFK%7/NY3:.S#^Z/YU*NB4N.+(9&$WE=QSI]+Y],IP%AG&8LI<W?3YV?
M.2,V@;.4JL1CP'\5#K..6@JK0FH*CJS:80(($WQ2R3LOH2XY6^KWZNV_=3P_
MYF^7.C=KC"^@.K&\09GJ90B%17E> ZS"K(>JHEV,SL<K/XJ(_ Q'?]Z3DNX0
MN>*;1\I?K(X2SM_&4?T#C*YO'%: M36M!N:K#:*HTJXBB)=!B_MSP]_-+HF8
ME"IXZ6J<_O0;71;:THERB^N5K[3WK5F( 1X%E72KY$&>V%SFG9U^ATBWET]N
ME?3PLZ$S:=9U6X=)W]JNW6@)&O EL7)Q*S:$^D$JL\/!Z+U9P-2LG<3CH\?E
M'G1=QA=DT*W#,WKY_*B2B8%A[MML3$ULZ+>!,95+)8?L0"V^]YMDGM$>W5'7
M0AP.^Y7%V/_DG3]@AQU9#>A(DF(6M5G,7LR6ER+/N/[T>>YXO7)N&N-C=/<E
M:?S]"JPF, 7!4D(#G%?O2F$]9"$YKK_*S4).A4\?69GZ+D*B4&+UMJ0TT[2.
M$#*B<L9NLR9;M43&BX4^3>T4+5+X6'U"( [%Y^@Z%2]:.%@K*"D(^5I8=24L
M)>P=P6\_VE3 IMUIL02UKATH*O;XE(TVJ[8Z)DG+GZSJX2C:G+HXBDEN5F'9
M+%^?]OH-&K^R\$8,Z3E>0+DXMEDS*3%",14F0F-C!<4LA(0L38XGV7'$GKE\
M<'6K)$*1<-"5QCGK>C2'YG[GX2=LTL\PG=Z.Z4X3=H>=Q.+RYL6DXPP;&FE
M]%/C%,+T%S[^H:AOPOAPE.WQ>X*ZQ=""R@'$J_(!DY_BD_@#C-0Q!NNLS;>?
M2/(+<_+S1D^K$+],SC!WG)#X&$:X /+;=SXNH*B2]8+$IRV'-Q>I@Q80]YK9
MG9L3RU''LI.6%D]FP *438HFZ1T>-K&,9QK\.BX(]U!]Z>]R5O-)LG@#9C8M
M?%[X65HJ%+R+Y7434C Z/70Q3UFK-/HI-@8(\>(?]?H!KM7X[QSD?X:L<D.N
M^,7W!BE-D0SW-J)@V2C"7>QDUCU2(,8.84L*!DT,<( "ZCCJW4YOGO$?4#Y*
MLA$_.WQ)2\])Y_6G:0-_CZ=OQ"_>O_HVM7F0I0]6@=JP<2+N+/1EE!TORB=X
M.O',ZDD\G$CF7&S]O,-_L)5(,3[^T,RS")^PVG\A?H%0D3?=,>[WFN^'=.]C
MN=QH5%[&T3NR$G+0UF"#C;#9ZU"1 WKF!*NUNSFOH:*95@:$*O]?_2;X/P#G
MF1:+Y]SO3DSV^2K*&/!F/9I]9<822YU 0TI; 8K$J']<@_6>NI-KV3GI\]L:
M$1L]RS!6&M"NA75NL<(;I&ZV7@G:GS-N$'%2QKSMX?[]NX*EOC 8LZ%,U+0Y
MQD ]/$Q9W%XV'XFE3-MUP<4#<%>X4==@[[&G$;X%U)[YZJLV;D.LW@^JC$5O
M1".63+Y<:]OJ OQ@M:B-LD*$PJ]\ C1._AUUOL&7?_@LU[Y_3U_$##XY=*15
M#'&/R$@*W+!<$XIKOI2>(#U>Z[S])_>HTN+EI_X0=E(<;JMC5K9=(Q3QA-3E
M,U57'_JZ9D,X]; PH]_L%43U5F":,S&MZ[L$4;Z3R[]9$4>4/A**D_O-:,-'
MNM^)O2*F?BY<)XE43!>K2B):5:3 A;[D.?E?$=M_1CE-_MP(>PH(9!#B%K&I
M>V7.$%Y2QWTL4;#!2"5'*A,\.3*HGNQ$/5+&S8FEZ=>,EBW4C+B0Q7VYLSY,
M:57UAP:_^'0&*=6:0*AO&TBA 3QR-T(\55!<6DIMP9Z%.B/5K7>,OB^%:Q^9
M)MB^LHP\Z'&\.MQ\T9L&*+JN!;)F>:N)5AGJ3'X^DM^ +DR?F7*)VBT+[<Q*
MG9<<\-!ZSK>VA/>&BG02L.M80MI"67/@G"I1&1VO;-T:_/O7'I-7WWB,G*T(
M9J.=(+I@3B^N$_.=/^/<;5<RX5(Z,?=_F[$T(*#C6DZ+AC%C]1^["CJ#K:,8
M.Y'.3?)\I,21KTW:2\6A5SO<O/B,)%^H_++GI-9N.V?1YX@SJLNJ#!Q#A:P=
MO7;^:G(^F7C3H-Q&%_,:ZHF9AG9#^27J2/=<%JKS5T->A:NGKC@D5K99LD\Z
M'H>Y@CI0KJ9)<UK'=:UJI@OS7-JSF['29.VRMS*(0N%VYS:ZN^7#JNHI?'[M
M4-;=$C&[SH"$,E)ZAJ.>#ZB'9W<JZ%@6M2]P_#QM_1BWYM%BJ>F1XO[WTO M
M?L7+P>1?>VW)B-GJ&3/F,%63VF%/\['^4QM>^%/W4ZY_HC#;@OZ<4B]\S!4>
M<K>&F^46L*3E5.9NJW11.1-]_(X;G M!H-Z.1U!NDS@(<?LY5:%>>D8U56.$
M:S),0J)8NC2>Y[69LY](?ZC1_NR$56#((0WHON=Z8(O>MTIX\*8C3^+E\4V,
MA^@E[U#O!RJIOBNZD#=842HSQ>SXA9:%EXM7^=K+H!-&W_BLOY&=;N/EZHL$
M]DP[H)-6YJ1JW*QF)U*$-% B&AH_6I&Z,=TK^4SBK=5PDTJ9QV*?%+X-=O)=
M3?,75\J'AH?9Y5;Y,K/?3^-$#E5ZS,=1.#0-$$??:;+9U#D5],*AXEM^D^T7
ML;;'/BQW=<7*EM<+R==(=Q3I59<&= DK2R>_/-7T1+-%,?W.B)8IV9ZB@[<9
MKJ$!O+9ZW[<1A9=8!A/)<?J_\L>50N6NC[DN1RZ=?Z$N<:9$%C#XZ[$$G][9
M?UU#8B:4;T]-F?D?FZO$SBFA7OMU;W64 8A@LA$]4=S5LE>2Q;*M-!D.:NG]
M%'H)0E\2/P5ZV2_[!S*YM>]![-EXB'?;/!/K\<7^M3>\_-0&\D-*3\L#A#!)
M<Y$&3$4M?A ,N-L7IOQK\ 65V--[^O&?V;0[0EJA5FLN411(&)F3]*RL);>N
M<2'XN=82BT6C)0!.]\O\+@9HNX+@.*$8I"A%G##C*#:F)>^6#YLR2-C"Y(LZ
MP^]*^"!?E\*3=#2'+_MO55.4AH7,QI[82ZY CD[VD&%^2KTEUEBWT "B:CR\
M;'>+VV['[8/<#P.E5(TLIDTFPA7?X08OU<5"=#NVQ@X:5VC*IJ!9D' ;PZVS
M<QBE79GJ"BH>0;*3 KM$]L8I<BV*QB;N-WC:_3@Y3K,J/#>^P'[':,W1@2A$
M99LES'=FJ7(5:;H--_Y8%2QW,-O_9A]#T?TL?I7TO90TTC76!/]J\YA8]B%A
M/ZT:=N-Z\>Y,F\NIE9R=%(EN*!]5;'J@Y)J?;W PA^#H,]'\NP7[^I["++ O
M.4!I3EP/>D+5/J9TJ86H&OG;:^X1N$:J_7 #1[;ZBVHSG;)K0]=D1>!''4-Y
M@H2$0L(FA9,C1F,W^H)0[:@I#R-2=;[QZ;'T&9L+/.XA)J.HUH34X/L/WXK[
MI5V#Z5#'(%7<&-S$%O(<Y<R8.!?OBE_PQY7MA?S-2>!W6E$A$%9)5-S'D,0(
MBC]MEH>[?H8YC3@9B>HL,&!>-?O34\:KV/XC0RW%!7B=[:Y=PM4&RE7994@X
MMN+.%_*=($<4STJ>?$0Y8D>LJZ6#N@=6_Y$7,EY/@E%9.TJ-SK5B\*><DL4?
MI6BD_0C7(G>B"%:8A/$?O873MA.G?R,WK,$#RLOU$(*Y:>K1T@=YB7%0PPJ_
MR@_=@S;;8VZ2'PU@^DBRP^U%>EDX_RI_F>4,3\>R'TEW8*O!7[? 4Q]4\KB&
M7]]_H#D=.9\+(.U($E3V,F)<!]D@7JEN3.+4;UM6TL$9]B.7!0.* *;-48;#
M:Y$L/8C)7I>1"$@;>7%5=CVA%830R;WU?4'L8K="6G59<%8G9L)X =)IZ*B9
MQC7MEOI--_,[TV,1('*.+C,V^!Y)C^R)27D4QV[MBD;'XI R>E8O*/>/X_>T
M+\]N:LF=%MG/N;HT9L,X$T$#'!(X45N?#]'X+ J?RZ)J^_0*Y1H!8]'45)&<
MM2VWW/FI8- E9V<^!DLP@R71@.JEXN,,O*QFF?FP$)NDZFKO9<557UV(*4FO
M0^<2P5NHP_9/]\M@X<Y6R*^WGQNIJS]H0*C.3X^A9@F\5.VO3-.3?^<)2:N\
M5XR_/I3UT#C:5E$X*(&RH[S!D:@:K2O6JV7P]QZ;)YP:D\M'UG\[05/"1.E"
M,<[68E?4.=0K],9S[X3"A]+BW>$:4-#W0I67)X>?I+I:>XN><B* (AQ8>!6^
M4EJX/7HO[<'9*.I$EWU$?5EA31Q/C]^K:!K0U),VUB)6&WHS5EAPD_?EZ9O3
MW>#!Y1R 0J?XD;G(GA)\&2="EU#W]DZE._NL/N_V-_5^S9Q#*)5MFFQI3V$C
MI4!B]UZ_UM(LOEU1=2LH)J+;=[H,.0^;ZOILT^OAQVO,],UBJ.):'U(<U6X
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MA#%]OY%T$T21QC<R1.E&[DPY'TM\Y+&[NO-3Y1M\-/!IY%D3:VT)-:!S["O
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MWB[8)VZGNG534/C,:WR_!3:Z>5_F%40NLSKO5M&L*NQG]:D<78W'\?PI;WP
MS\61LTA9*<" #!H."ZXKQ"8?DX05T=Y#<R\70:'W^/V#DN#+^LN_9S\NBL*
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M7" AV\B\9;5 O+F6A"C7.I[$I*E.0C=)[<@.9$SX^)K-]6G/G"=0!9]^EOR
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M0E<26M@3X*49G'SCUR!_S/=VM=#ANW]]K(BAV.'I38O<^Y2J=FQ\&U!N7;W
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M#DB<.8'A::L\O#M_=U)^$=R65'3"O.BF*AET NQE"DK*^00-=!R?[YZ[2/^
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M^6U+UMK#ER+.X!L53]\<B,5@B=85E$(;6KY@N?N%UM%S[7>$D=+(W&^@I5)
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MMG*T6_F.C/G=])Q24J$+2S@C7>4IS0E#1@M.]6./4XS\ _PCH?PP$^08BLM
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M(JI6,R*1PI,'((^,1!G^B3,C\C\8/"0MOJ<C[[J54Z*/0QSFF&G0QZ@$K"8
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MZZFX;J59.?-$!P='>TW_ZR>T(YO^H?:56$,?X:LW:<-I#+4:)_<YI9]-1]+
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M?Y_!%>L,+^PU([I9_(Q0C#C*BX&->6Q%1F,/WW#9!Q7%W'W.ZL$[3%[=K?L
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M_GR;AD/_'HB?.*?= %(_A+Z,>IRV<-/I7+G??4LV2F*%<'BB*'+O%NIZ+='
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MO0I99H3L:5@&M'')L&4ID6V^D7)HT6][JD_/0YSO'^R!W#ET[EU%CV6_V:A
MGUN^<WU2#;'S_&(GGG62V#6MFWN)< 98\WJ8V8O5Z74BVK&ASI,M:]"[M@^=
M\Z*+SG-3L2!,ZV7T":3,+T<'M<"P#E!A7:)4+,1N!6KL48RZL'<U*^2_AKIZ
M F/F%C;F6&?X:@&M,RPX"0HO=D^SMUU6T2RTL?CB+2REY*0M'U AV241TX5U
M8UIX_P"BV[*2JQUD3XK[79&N"Y*9'N'J0 ZW&TBP"Z"PP%E5R8=&!I4JFV[^
M9Z,^Y?A57J!-,/#]^R!A9!EE']1BO[(/&J>0EUWC'C2(DKW&G2(%7CSF!BB$
MO@8$E@LYI:&7+L]L.Q/^WO/E8,'38Q%YD^DM_68S[#*#DV24$9TG@W&N:\J)
MH15GK7_#!5L6<EWM%ON:,-?=66*;J@"G"P8.&$LC2V*E/%NOIST?ZE5_*Y7>
M \(--?C4J;ZL60I(J(YGV92;J =L1,I??9SR=A]DMA/'C />A%'ZN?_ CJNH
M7GKR:QX16!-U)BOA2IE?AUL$[VM_&OP?EASPIL"V_3U@TZ8 ?_#+ZP%E_6[.
M?-)O5'NP ^O4<(5.OL",&*95$RT";)Q>PP>4A>O=J]<CVQ\Y:A1^4ZF]!@(H
MP!*@IP(U1]O[I2P_J%^]%_)3<E-D>RT!/[9$_A3*-]7ST?,,:MS9$56C/[:8
M=VV[HL?X=;N<'_,9'XC5!ZO"TE[.S<H.<\[!I_YY>VYB"=1YMXF=O0]Z!CN!
M*8"CC$?.U* EV0;6Q ST.V47&[P&K=A;/1'$(@P19],)<HR7.7@(DF1QF_HQ
M8M5W2W]E@2B*TOM%G#T  ,BG&GZ:C#["4/6UMT*\]D3J0"J)&)!T[5[,_>YB
M)T?(GAWKT)"!-DOAUZKJ)VJZ5=V+7H]+.@] #$-IFY:9)#)OMRK7&#*]O0XA
M?^KF^X> C+U31F=P<'1O54:$_.KC]A%J*;Y==:R*F<7@724R I#F]S*-!^4;
MKXZ*/D,FUSU^*\'. =XQ#LVT0?BVB*>ZI@.;KEK*>\D(^5T&KQA"WCAR 5O[
M(+Y@9AZ0Y?/>W1]A<)YTR;FZZKKAMXB>M(=,B K"@J*:2.1F.>"!0@#;ONOZ
M@7*,6I]NGERG]5ILS8L_B:KY>Q<6A_(HL9U&9ADBGT&-*3<1!24:C7QM\'SM
MG^MO,'9XI[WS0&?@MRVE7+N5NR/M;XJ0OX.PVO)OWSHS6>[<--SX"H=//N_L
M:#E4B7'V5X"^ZS+\TO3?\\>_A8&?C8Y )"^ITX.[3EX0P!=.?B$CN__M.([8
ME&N9EAB"AL_N@^)E)$=I)V<Z'67@=;8S9Y-9YP-W&J+[PF8Z+<GF=^GX5:U"
M<^BY35N2<NR_.2FV[>@5F.-?+@J\$MZ]5 V+ML.USP@B0U<Z" J_%!M,GQH*
M^%Y?;O=5+.9I](G#0 PNHGO1(EF6OUA257\2GKMT7$H^&YW2]!?_-F!*D0)K
M3Q9J-Z$?OK+D#Y_X-$HN5$D0NFGKI[/4";.@JW9,(!)JDH-V6$8^O]4UM*P)
MI$=2D:G;<8K9(/8]=B[1L_\89U!"TK)P,CSG;O3\U^&%'>>;3.E.%.; S)_^
M4JF>$4:>]#)4JTS.- W:, 23FV8L4H9;[!2C#)210AX:>P6H6HGR(M],(?74
MX8+ BCCF^Y$*F <X98C<<Y3334_!"8^>J(6A)LQ3L8YA UP,R0>,&9I"(6#<
MP21ERH@/!HBE(/B3[T=D.KR^.-:J;VRVS%(_>/11!K[=RVRZNRO4JZ+Q?=N*
MI*/'R]C[TO;BBR*;L7@ZC)+5(6I.\[?+E%: L$7Y38_QO7TL(L777+2D13Q2
MT\^O^K)<H7E0TSR=]\UY@3_$\SK6OC_#W;FWUN?Z.[S E+H7JRRC=U,?UG !
M,1E[I2W?Y+XL'*#_993E?RV98,!Y_?7$K94XM3&/@?@Y0]OQRIGS6W@[=O)6
M"4&:90U@Y\QUS)&>))+@S6E-F+P]ZT?D4F[!!CZ=(X_((IXT4$<2*?>+8C5[
M2[Q_?QE2F>\:GC^5I?/W.R5"/WN&$MRI@J *[X/$48IT]NR0-PWZFO2G"ROO
M'"4>A93GVX9$0>A67G)=,LHR@HSF%WGB#'7I>!?RV:"_DV"1G>T26Y8W@Y/#
M+BY;T;HL=^2-\LBK0S(17)VA;FV8F 9XI^!=.WIW8NU2WOG:X>RU+HX!O\EK
MSJ7\C8/9MWZPK5YR34XS'*@E/?BV-"#!RJ$3NVABLW$T#X:<77-=EO6O"A=1
M9G;XYTL;)VNV^E>G&.B5:^R,P&3CCG2-(:2K8N2"JT)AUSTISOV=>:D\90))
M$YQ /I=6N9)WKN'54OI5<+J$SC\[^F#I$NX_F"/ )A76CI- %G21W2*>5M4Q
M3J3XN\G=%#]__TR*Y2.5<.D]'<ZT# 1HQ&O%!OZQ;Y\^9_WTN,/QDS;206_9
MB,WB!W1<5[B]=5WS*,LH!.,K%65YH=!/$M:^.YH/J,XY%'=B^)'?W5L&.&>0
MCA":N'Q2QC[H@5'MT<4,WLU\\$C_RZ%N<!M.U 3<R\[R;_21,[@KH[1IS[P+
M;,W!HO9!(-3=0L_4GH\KNPO% :1=E_=O%#;(E]]AMT-X-_#O6 Y[)E<C]X0Q
M7BN1:UMZ$US%-R!'"E-'74/T_?P0F]MM!G(,Q5;]JY, K-W/TU&)%-F0ME,P
MZ368(,FUBE1DY(.+#GB9."%A.5[6RO@S?8[N7>[UH==7OM>W6CIQ[:';VVT\
MT4 (Y4\O[@8+5N#G7@+K8N)I<NWO_IXERA+GS@.X"E/-[B38\&-WV]^1_@L7
M(_QTG6#)8;QMX:X3LPZX2/0YP)KY9(YMMZ6\Y:7_4_K8*^X,WM.+HT,1^G(<
M/FR@FQ,5'Z.^?'(GR,I32:$C#G 2*,0M/IKIP">0MVDG2I%&=P"OV97D!^UM
MEL0],ZLOGXC!LLZ;VPA5YC1#I)AVA%%@/GBCROP#$-JZ99_18O TLK%79M$#
M+^3@1(6\%%X*5=XV$*+/5V/^U!Y7NU,W$D,]8/T)M-@!8"8X(HTZ2-,']#;7
M$\!]-D+UZ5%&Z5)T]2C948)Q+H>J(C%Z?\B[H.ES0Y*I=,<M'=YB,Y8G'1[;
M5YP0$"Y'D;)V\ BMIO%[.ICZ)L6J1!G0M_ U,.?SZQP!UD-&5MMV(V(&O-3+
MG+CJ^BWEG"+WAC#7;Z*(9A]_VSZ(;O6-94&QC_?2Z!.=-D\HRLILN<@S@T;D
MC, 0N7*F[.)+''G IVVWMK$@/ 5AG';^:MS4V<N^Z9S.D -MJO P@++?-SE0
M]YJO>-E<&UP(,_&Z$ZSRX_L8?\KL+*[MJQXNB2@&O88X7C.43R<DY8=<57EU
MFA?T&'P =EDL+G9C$S]CPMKK@D(XM]W]_C&?KFZG8>Z:\#,:,?FNH/#AF8D:
MM"Y+#0@$=UD$,7DR F R2R2<5U2P0[)\(L\_3D (DP;W1_<<>'?%UG_=B^[_
M@KK('41YI+=Y#J+G39WHAD.ZCC['#K13T(81ANK0,<QJX"45<FKZ94"M0&IG
MK^D%6<'\X-\DM_89,AVE!7RE6DJ/ W(/ZP<T2P9X'D:,:5U0Z9')V"0U4G$T
ML P")TS\[$Q**2VYW7#C4\EIJ4^?/C[TX^7/GDBGV'3AA'>NK#Q72'XI335_
MG?N.UQ!T.&#)$'( F%7]--PLG"P93L@((J._0, ?I@73G$9"1]WVC&^FH209
M1B8\1PJV=J70-3L^LQB!BB_O$=/:],FT/XZ:].E+9)X[4I7YLB<V\NZ>/B"
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M*TFL^=)\;)AX@V-;S^0L(=?G2WX0DV*@;,WFKHO\XF$U%:ZP5.H3AVRJ,B[
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M!.[DR@X<9NY-2YY[GXMF26CL9C82N'>]O*(.$EI&:>G;\5E5(9L_5)U5HKE
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MJ_OYN7;A5RK)ZME(9;?YSJ!;+=GC9JZDDU1[>U:>R:G]// [90R/"Y1;2S-
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M4<#6Y=^52&.@_>^EO==SJTQ)"L_JV3[??%J2#-^I(&2\U;I"41BI%@^GVN3
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M\H+T'M>.SLB>0>U_FP3U3>G>_"_+K("9?7/ A@R"[O>^J722NWY?X>TI:%?
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MIQ\>?\#KNL[U7,YUKG.%-% T]NWU]\IO=LSC99AGKT?UN[]'T ,HA"N-Q+*
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M?QMA5,Z%WH!J<3]'CAL%/,=TUDWH5#/.KJX4 T2)T*(3EPW=K@MUT9/FXJ8
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M*!EKF&%=C!7E+<!!]ON<ZR?(%8W6Q=!6Z9&>_3M_6'0G&$:$U:KW3N+=^QG
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M8D[@[O?CK^4LW8(M;C+3CJ%"<UY,VXQP<(19TS-\,NRX"LL%30^.'7X:1.>
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MK5$NG70I/YMH=%40DC]_+4YA6FUN?L(>VK,B@=IPMHG=" !K(&7;UZTB6>[
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MH3W7OU-U)]N^[%FP1YL$S<3,S_L2 ]3;\6/WL.R>(;&:7%Y8F*]KC"]7C )
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M4=]' +ML'-\.K1H678N;Z !]43L-NA81K=CK3RSUIB@?$1G[8G#]5OG&L,:
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M/OS@:'VEJ3?"^Y=\;SZ6=[W-\F20-H(AC;M/AS<@"WR(,[GX=.L$#EUNKD?
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M?B4Q]\;*TX65196J?M%2T>R0=YT)!*PQ@U;9QI?>-H2-,JW@87YA'%P73;!
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MI,CW ^MO)O#8!E5",#L]J_7E3'8/%*C F#5*C'-FF:BP?0_5?7Q/G_!>YQW
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M0>F,MU$2]N<7CZUC6L+['$&9VS4VQ,H+_MD4UTXM31A-J(@FB7$)E7&=^8<
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ME 'I+Y'V[U[B?"ZV]/K(@F2VC[0?)72CSP;Q< 8U ?@XDW_#)J5O^>.R,:4
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M]O]_I<G$2QN $H=%Q^PHL+YP_R ;DQ+X4Y"J"1#3M!K"O14AM/LE$BN+^&H
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MWG=%-=FV70;Q!04!D5ZC E)#[P2"(%VJ2&\"TD*1'EH0D2)5D"95>@U("<T
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MUD_2N0TW!E,EG!2/CLB_^U/&_ZVW0_X+_X7_PO^_(+Z9_F]02P,$%     @
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MM.C;(#55W];N81+T?+<V LEN."91<KUS\,-,QT4]H4H>N"0>7;3I8C^@SSW
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MK^OTF'Q DZ4R;MR7;RH;*XN>[[R@#(<I)ABE*H+Q7 :-9Y)D]WCQ5XVM.B6
MW:)5IHPD<X;S4%?AB+ZML2\>"0?@\R5NHCDLT0KH$A&:/9?UC?GZI"*>\?EK
M_RT"L2#C@P[&.?TF_;*%&6R"VA^ Y;&T.N4VX50@)?" :G=9A"SW>3[IUHOA
MMEXXV("WBBV6O/VRT5 $)><F5SX;?*8">;1[D+OPLI)E,<;[>-<GKR&$68;@
M%\J$NS:'(6D"J];%;?;ZR^K1@VTC*C#=0!JKQ<MI'0EZ&U?UGM]]]*KK#G)*
M)KS->R.R^;UC<F0]__8T,MP^)T,E(?MB],YIA5GW$A.-<7$(D:4#$8>6R939
M>-F<CLCID)?%R7'*F;R-ZH; ?&@NBGYVR*#P>14'-(J)\K.R$"O_'#MP7CGE
MK9?CTE2X'"?9?C?P@7(WF7L>OOLJQ>)G/U?#J2'0BUK]WZV+ N/PP<\!W[P_
MW#S. 7-\'_W/=9KWKIG'+=!_Y- >!"DT<Y(!/$>\V7+B=6"!?_[_^.RRX&=#
M$_CWN$]XNKD&Z_=!'X(??NLC[^$XF"5@HVFP)$=RI^>\3MNYC_?4,\:L &@K
M:@IQ0 VZ<+QW)1FOK.Q>=_E<F8HZM4I!ZQAE)!75)'8I?3-\(5 ;)>#G86W6
M\.FKS=EC[Y5BUG/=(7_R.CAQ5P2U'>D@!M>D.(0*;3$B<@T\[CQM0X]$^EI<
MLF^/V]9\-K9<I%"&J:T\=>VV^1U=EV^6?QUV"[!CQ6(^SU%^"PSKTJF,-4);
M]'I?;-)ZG]QUQNHBLO;PO?SP4<]6IVJL#M>X7LR!VN1WL7"4-2N0XA:@']2[
MKL'LJL(10J:A_C3O)>&?10AP.S-)_&$EO$F5GQ-(:IV3_(_E8J=6?H23H*SH
MM:\P_B4.>0N@:R%9NGJ/P?]J65M;V_AKPM%W_MM^XI/: 2>0Y$;C)01_SA"D
M>JDV7L99-@W4_?:*[3'ETZ )F)L1;^0)PP^-'BKOTSUVH)NN6/C1=5:[U.-.
M--%1!WZ?:%D4,UC(.32V%F)$TX\=NI3$9G6;W$-#36B3:=4>;_]2L.<O:_/-
M)D0R7Y":OD-=+JU\/-N5]1U<7A2_W*C(@WSR4;6G/EJ.D 3L:%X)HJ.#\U])
MV4[ :($#R9ZX^WT0%I&#X/-)SZSJ84@9*+TG82%)6<)0[7%'__-]70(%M??P
ML?==9_T](GF7V?>0DV?=4L#1"OM7OJ6KRZ$MK]!+R0VJ^2M##(CA#I;A'$N=
MN(0B,2&__>9[(,F$U2WH_)!G-Y^A_LZ3SJ)&6J438L[O]D;$'*#^%23XFO$P
MJ8I:?IKJ4S2LV\B7&ITTG>.P-OYI::@YD8BZ63$OOYCUZ[*O%%Q<#B$AA& )
MRS;<T8'7E-(UN"\$$3R9 ,0J;C2J**_<5")N 2&B+7&2X9]6KW6.-J)IE<@3
MG+<3$JYV%U!VR*K:Q_,Y[211)971P?,"HE>-TN>!=O'>E]K]I7K$B=PMU%=Z
MF*'>KR@!/R&UJ@DWL9FUN)Q4_0WMN[AGT5($I\L1!B:5Q5A]3BB*"&[(%>S7
M/!"(3^\=#1P51,EI?R:X!9"+H^8^7/WVWK\%[&INC');N:XI2\VV]O"")+>2
ME%6D';L7,[,VPQ312FW,F:*>$,T),VPZTI00*)AVDP[\J<Q9K0"H^6[>.ED)
MT83[*N5C3=6$O&%7-+[LMP#.%XE<4J*KQ[> .=G5X9]^IWJ^V@64Q%!J+K)'
MFY4C_/7S.N:[_F:;BY2GKICUT\95VHA%ENDI-V",Z :F0MHKP&,@H3[&@WQG
MZ3&6![+ESX3IONZ8+V^I)DYQ>%NRD/1PF+C<)ZKB)^$QT-E>U*CSV;D^%:^P
M>+0"3-_R'OBQ,!5'M(0-]_/SU,,_0Z@^ [L=A/E3*S][^ ?[-"5OO>FR2Z3.
M2+02=Y)SP+JVF8AA0Y"E4J2@7F78V$V[ UJ6L*E$EJ0,1X2U'O+3TTHL5&EE
M/.#)S8%%R<;^"R[9M=V#V<+N5O076).IE;$)7%LTH^&\%-8QM&$&<>+1A=X"
M0F\!9.*&&,..&TX,7NJGPMDM]!!U*'N/,EE'[9+DU,EC>B5MYB]BZ/N]9.0*
M4KQW)$0V2@1$S/-8M=)E-XP-5QTCKI0P+WNN^1]*$._!690$'NI[0/M[U6GQ
M6VTO3.X)CI90+*_W4$H>8S(65B+7O,'D'L@)$<F3'SNNC[GNH$4US6)]P 8O
M'5[CVXQL:@P0&,GWZ;Y<E%-Z@\S7])AR8*W8)$80$Z53/ZKDW@\?H2_-DO K
MG3(/9]&,)QRKU3!2"^?'JS03EW5C_47/L="!F$QACA:9$+F>]^JQ?3A =4#Q
M]IFR&<\^ "69*V!6%2\ZUN/B); ]:[ IU0'BE\)!V?F:^OQ1;MI=QCDT4[4T
M?2?QRT5\NT?$PTT'O09= 5#***@Q:;NHK4!!G!?=Q,XGCY#[*ZMJ,J\YMI=I
M08(CO09D<RI'_>1EI9<CS,A(^'##\$\(5@CQ'(2_NIY4D&0%!%C6?R<\8^3:
MLY+PT64Z$Q EK3^6CT%DD$-(96,^U*9KP;XQQZ;BIS;"R4>S9 ]C>7K+?44P
M#Q$?1$/S"V#EE;^P"8Y%[8XOFBM,AV(&U?=F;@%6+"T]8U=*E@TO2DU-#;M=
M2J)>V^"MLP;R[*:-DW](+OKMY"E4I=B^$57?*TXDQZ]83N4D_<C?B &Z06N(
MDQ@'MQFR]^-_9NWI3XQA_4$Q;GD>V&=F'%,@JALQ/\1,^NJ;DV[:\<&CW8@2
M_4=92Y"[EDU&VI28M\?6'UHBEW(2G++I3KN=,KZ,_1NIOYJ6R:GO\1T88(13
M'=(/%0?O0%C3/&MEC4RC8"LE=JCES K@._73>,7AO'HF5]PN@]4IR(_][CKA
MAWK'0S^-<42TU"#9A>0J^@QO\];V.\!LI<S_W263:?9&=?+?W[DBV1SXX;EH
M;.%\\V DE4L"^ N2V@598DCB_OKGN77^_Q.;Y?&Q@*'.Q,\IZ'PI=<\6Z[>N
MMHO/Y1KOB?M&YEQ/I3!A'=S?=!G8T2%E*7.RJ@Y(4"PTKD4)R6BP>N#/Y>N'
M#;+DI_XXN1&ZN6Z=-AOX],MK-:0I]$RGTKBS"J2C*%7_TES'KS64/]W+MVNB
MW#/@(?.;)]J#0!2-)-=U8("YBL*J8@ 9MN)>A'82W[T62>OV?>"^_/FO@ BF
MK(Z8QI!-W$(J,FAZ?;KGGZ'F2?\O*LEB(?^LZ_V5]-;Y\U02^,_/=Z.7H8W%
MG;G;E+K5/^0(*!T[('!6C*%*_;0_'?;+[[$:(S7KK3+1F/R'SH7%Y\\NW_J/
MIL%[8Z)B\I2+E JPSN[$5<]?I4L;=SE(+NA6^\I<A_JR$G=$&79E/L0H+]O2
MF/N;5[U*SUDHQ+_+:.J-G5=&*TZV<-T".L1*302^!%A_W\A4I?+M(C4MEB+U
M)5]UQ+\9/,LD0@>$V^VMA(Z&Y\6KCP]V)BRX=]N;NW,( !FE MK%;P&V]CK+
MW6@L;A?\P(]^AMV"*5,6PDS<1G,MH/,;[9KIM8NZT$6P[JFM+LI^N,YKXCJ-
MA0[8N#(-O2SN@"0BI5+)+UT=&CE_:@V\#%0K+A)9*Y,$LQ5;?I(C^Q"H(4?^
MY@^@?/IG;6*_I/*S.Y,J/%THA$F&T&V4G-(GB%^:C)FJ9J1*\S Z),68%'LY
MDB^\CV?Q?*2;"31XWV Q1NM*RT"<[S-C]RY^/:Y;DSYR-6DY!H%,.\R*-L6?
M1W E'V[!5?) 06\>^%"MX9A E([HLXG.&3;'&]=I2[^S"U>O;1UG/;@9JCD=
MM_VL1@:Z0;W.XC+^@2:6[?9J@:T<T'<B4%*]F=R7*H6A^?5X?I*SI^? GO%%
MY^ A/V+D04BN"K:<N,N&BRE%K3ID:%+W8;W9N6(?-40"DQ+=)'<I(\L2]U.F
M0>BK[O--S3H3YMXSPT I T3UPFY#W$%:0+<:44%ACC5:C7\DX/YK7I;UXUWC
MCNNQMI&2LS,(.U93G#YGVT ^RJI8MMB6(MCV_>##2T2S450A';)F9S>T:#W1
MKDTG.JRX)LZ[K/R0H24I0\XH/KZ:S#"B?F_:,V[9,-Q,A&'*LFFWO>6I8+5?
MIN7U[!9P%/E1]^D: W"S5,LMWVSFZV3L!3M^.>=GZW];[##UK'B*M"Y*+R%0
M=&R-!56<CB#4<&MD3?$<E*><@2<9OS_3XJ]0XIY,@V-T?LTE;;\5!O-%6I5_
MYGDUB]HVV:")>>4PP@M3M3)G&>5!*<N1S[C^LX:N7/Z5T2?Z^X&FP3QL<H N
M@,<L\N*#;7[ZY\AJMXKE3E&:V<X-Q:RF3TOUN],?<B[3)H(3ZG_F;#_(GP>0
M45.9PZS'N72;.7TG"U\F-,7(6?]%VF'YLY<U_X_'$;>5H$1?DO_K+;+9J2GD
M7EX%7TFV3$)QWS 2WDRUHM5"L*D5:@C'^\,U-%V#)HI4G_0N,*8\>K> =O$6
M[B73A^PFUI^YQ/OSE[08%N![.!HSYA>50UR@DY/%OI(-_L@R7^0ERTV?J,+>
MKAGG6L@!;/[[:=.PJ)NX[EBV?4=F73^9VPH)OJT!%_M?)DHI]I^[[S_;WJ@S
M'$^:_.+MXF*#JEK"F:GJ'\[=[!O?A"A_BC>/\#3]\J'-I477KTS9=^N'J8(J
M+KL,WBT;Q@>?!<_5B3P'S<:%O70V50[K8N>@$_@\P;YL@[;5@0"='R=32^K(
M"#\]@:2V"-NX8H,1W*$W#.W.U^&KN_'#RU9BXJA<9]F3&]@)'O)8H.-*':M0
MX/L>5GN4Y\-Q:;EX;\V,FUH"F./<P,)96+S*2'M#@N58)0Y"3#<)AQ>"<E@T
M'#D;DY)E,S-4_-A7#,]/N/&WSCQM=1!ZY#_\Z:]WUTTI0#[M68].BB#BLA!C
M[+)Q4.L8?S>#&1X]+U^O0./*0<P2WX2XA2-K))3ZF/C!HGRI/1,+N9>$GW#W
M)VJV?7NV(SL_/;'-XFTY!4=QW==E<:)-=C@Z6C^"-77?^:G:0TD$K?5/&3ZL
MT?Q%AP,J%\WT?+TYD;\/>;WN)-U^8)!&E#?GD%UEM<YZ5Y?K>19,5QZZ(_Q[
M\"1?B@>_7++48"%_/"_\",]HHTPWQ,&8^*/!OX4UFN>0F0C0Y42J..G/"4#M
MPXU<_#A^UM49BGDFRW; $W<-(FS3$N,K!_TX((1J<XJ;Y5QZJ:@;M?(7^##R
M_?DDO</:R?]0:%3FI/80AXK?.]1S$WD7FW?O>%P^+\Y,H5M"'0HNWP:&F.A*
M[,),C3X2\6C,S/6:$3R/= 9GA$[WVIY[3V7H&QU_8M#^].=#;9/_U6WTKQ @
MMPC#]^?U:A36 :QSGQ@/<(SM%?B5Q2WH+!3+BR;=\HM)8GCKU]\I:?2J0F&%
M%=OEA8NO'WZ;6=.Q\..W+)'?.EJO7V]Y@6X-:J%;,@$M?Z@A=&H[3WB7W4J?
MJ!L)JKKLEH(Q_[(1E8R\4/N:&X"]:CPW[G7))E;SOB@T&MT35S([-98?<_P\
M\JSW3F'EA/UQ.FBEZHOPYRB/DNR>>[*%+DC-+F^NS#23)*#EC_*F3[@,A9':
M<Z^]3^BWRM/6Y=F/7N<O" 8M3\>#C5])UHJ-W-F5D1.,;GM-35TQX@2AK&R*
M[]@1B47:G+<D[1JH'-H**KT4E'T$CPK/[]OW_O#R:,ND+^<[]&3;2-D,4A[R
M+S[.C5/^7L2!'36=W5!',2H>Z008HMCP((2)J-';;M &5.?Z]E80.OE]V_.>
M6C2Y/B&46Q./7'DTQ;7Y"_+SIXH\&Z:D_[<,Q7F"E&<KS'R'@64"VBPSK];4
M$$U;FO!-(_U>6+F-\?N:FL/!MJ]1#T605.0KC)0G(V'+3Y@>,H;;E\'F*6\!
M"O7Z]P]G/&SK)R?5HZ"27S2;5H^N7@04%>H.+^-*60_8F^HYX@'G0IH:ANKF
M"2?5DNIP(]<0+=_Z+-N>HBY[KSB Q6^'%ZHH$EA_#;$C@L["A(NV1';N2/%\
MN>-):GP6"HTKG ^?\3]I%=V\8L^[+EDMB//7%O>!NP#HS,"'/-KG*2_%V'H&
MU'>');9=T]@@-*(L;G^QO/[_%,/_)TER'CUD9\M^A/)1,99?A%LO1@9' X?W
MGUDSLW7>4Q/8<<QHTGV!0+$.6-1%.BV#S/*]O[];:-D5 <KL;+[R8A[_Z*WY
MPT.$7[?1I_0'\./6:]$_X4?H7U" 83$&KU$*9^>+D(^"'?'JD'.21/F$P:("
MKV^^FN1)B+5K1T]B_@!'YG!=CP)_B0N'E&*KX2[;NHDLD5_)Q?4<^@6#KMF,
M6JJ1.YF&YNM_H8+>$<&1X$C$3.?9HW3NV?'!M<4C"/@CG<C,X8F@8 W1T)\<
M#K^+.^"6%%G\^\/>)R)F9AQ)<PJLXA/A"TRO_-6=;#C"L5$(0I..)=H HNMD
M8QTE)#%]5_83!O_/O,"9'V5E7LKZ1H?+<QRGD<U8,W>N!*$P!Y/I;6VS28!.
ME!+SXS=BT<(H[:M[Z,U5QBYNHEE;DIEMOAW7WI:C 4E]R[-'^ *N/:VD5\^\
M$!R$#WL-7F%@#6'*YZ1N]T8TXH:%R>GA;=QAK8^33H@? =7R1X0>S?DV,6(?
M2(W_"EG_.<7MJ4EZR7<EAO%(=_9:I8CNU:I),-=-/L=CH0\Z&&]N;+LP*<T#
M?1X>T6]4'IAI.WIAM%YWH<T=NDRT=T.#]:?G&K9JNN\RH3(U/]TPMP->UQ')
M.\_H_JS?[,=^6H-R=XHKZF?)W><H0OLG,@IQ"0_?LS HK X-T8KAF]SFOWPQ
M@<I]>WQ>LO& V1.7):J5@V$6\@Q[<OG6QO2.?.Q%4AX<5R/C(XD\7RTK'7R@
MOUBIQMLY&"@+=XV+Z\MGPJ??'1#_A$$JHX=:0ZS @O6U\/4/X4B'+';)YF^0
M-^E=!MJ1SB^&\^WM+.=D!MB(^_#)RL[>(,;R,_G>K"%;ZXK\%QV8U2UB7+G[
M**2/8AQLEJT#^]>5>/F0'LNO+?R;)G=4\S+(,B>;O5V/R];@Q[.1<8;+\VI.
M0HRO%(F?NE4PK4"Z+K/"T_Q+W5WM?BE9^;RHF;DQ"NF1ROA@QDK)O>M2YBTO
MTLVJ3FS65T)34U^XA6E<,C&<,_<MY<^V.JG 7^7N[L0\:)(Y4R*'BAI?U3CW
M;P B*>E."JE^Z]XT1,\9'1^LCC@D9G5'WP+>#84937 Q\W06&0SP9C0R?6<(
M$&UR>'9T,_(J6U&718HOX7@C/F)=Y?RK=K_A>H^UZ?=8G+[=;DNA;]#OYGJ,
MFE E\LIU_DZG:Z#RD'$]$8'9B[.KNHN-;SZCFN8#2H<_%43XLSJ(;7.)O_'W
M5Z0M2<B,V\2:YPQ*FCI #;#!*BU-UD];:Y(_/N!YE?L\=L^$F8B0X;I4$-E%
MHYW^RM668K21CBQ>_>7D7$A^<U&F#3)Z'@IY^N!\(XMCW7'TP1E$',G0I!4V
MU.TE-]+S(@61QT!>;6@O/Z[,Y[XAOY+15DM]"PB$:ZR8TB@A)&CL9;5@QLRO
M*H247_=,"8^8VOI6/>"0(&J<3EF>%U@7K>W)BT"TAC6Q?OQE:F#[Y-V!ZZ/
MV ]6T\WD,!2[@USN\KQ?=LTRYSK@%B#Z@IJ9Z:WO$-0];V0@<ZI[R5<?O1X3
M%1:RWA+N_NRQ4XNC>+R$7VE1 QS:*!;#8B_ST$N4S>O-HA:C%]'R3P]PKGN%
MS2GMO6X4K-CU,)R946B\HO?ET/UXW@*^*VL70L[W$Y_'Y,B&_K*3_ZLTP-\B
MZHOSY5--<:_[4%H:*I*ZPT$5%F:#[@_YS(KXWYK-E?PP1S2:4FS[N]?5106
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MZJ%7?><D,N2+_'0IB8WF /'OVA, "0W$)L1VGBPI0]F9?Q!>!KR[N%GN=%X
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M6[2BOR372X$G;"EN <3N_6YU2\IK-:XDO7 Q%7N-K:O([?T87&SA:A>&LJL
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M/UMYZ[?4\D7DRJ726W5+5=PP.HO0)*/C6F!B=Z]N9Y";[_.S!LX!M\;;GC<
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M+#W3F9.[M0O*%NN>C<CBU>40N*69#MYF&N*A$8[,6OO![8:%0[O1XIJ(8X@
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M[L2MJ_D0Q^)YT#' TZ3I(HSGKH35SB<PM.E[L^C"*#W5VN">S V@[Z-(X%@
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M)H7-<%A80V,<'3?5E[ANO37:+A^0SJ6S3YY^(T+*G27)\;-<Y(AJV.M?2=$
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M+=DKG2/6;OZYA[S\[1>%184X=_VO**ZL7^E&KG5?F/T0&LN42$-F_Y6Z^M:
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M7I2F1F[C2-2_^D9?_YMRY6V9L+QLZG0.1::7/<J*]O3J7*WU-!>O^J$*!3<
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M[CVCFORC-=$H(BI-D5Z5(DU$>@<%Z=)["R)*+])#5Q"1+EUZ";TD4D+O54!
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M_O>[QY!Z-W)HUM'=\^0\I/MPX6'N;1C[0OPCB88Y#SBXK_Z?:O +:CTUD'X
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M:+Y>/E U[^ADDIT/>TG5.!7/H(?'D2!]88LUK8-KR2)#H?6BF)?1 3RS#)+
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M\D-?A)G/B$Q0,H]"G+T5:'A)H:FX,L:V%7 T$# 9DFU21\9L!/$8KFM/G%@
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M -KG8[IH98*@^)#8#< OC$!O,@(_Y4DR:JJO9/PJ17982N-P%.=3P+BF*;L
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MN>\DZBC98WYJ/\!)?[B'7?HL-#4<J=RT'402N%^R8 .]Z ?3=DV^5O^92$8
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MEN=J55VYA)<*N:D_\[9MK3!66W B/-[%ULJ', 8/G$?'2ICND7X(J0OLL(5
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M74MR;X!D!2)>A=TXJHQ5_/NM\(+ 8TS GMS\R?L)M;8#5%"V=WE.\.;0Y.$
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MI. A8R2<EU?#C)UO0ITZE(B#\9KIS6VRU^AC^PES7*]<?3IUX<JJ[B1VQS(
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M<E*9=4/-HZXETPF@?.<9ZYM);Y7GC$92"A%W #*7H[R&&=%90](&^K;#,(F
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MN@GSPX3!+<G^LUO><>@GMB?:96 V@[KT#PW-DRX@GWG^G>$I=]3K1\+@T19
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M.C"_>;3?UNQ'W*X3J/;4"&ZZR)"GV6['L%8DAJ'H,XMAL\CNK 9[',X@7T_
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MFWCYN$*HU]6X8&^F*F$BD%)MONDE#//':P#S*M5#7*"/A=CPAJS*Z]56[HC
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M.Z_ZNG(-Z*\4U*A-U.]H/MKR0=^.?+;X <'5$*PO9BM84MK,45/Q5ZDZ?OY
MJ3_4-?!#PUAFK,1PA<*HSQ+#+)@J5Z_92H]J;8,L9BJUW\)>*<@ZEI!S^_F
M]1H9!WJ$)$<8*8>FKMXN>D!66=^<]+B)]2880H4J9"O3!"GBFH1/5P\J[7;[
MO2=#LWT&75LHWU)N6QU&.C:11FM9W#ML1-G8EUHH"8:2,6?YK_4XF!ZN_/9D
M^5N.<*[!/!D[T(!6E?WWD&"O >&^RM;>##)^.X/)@\!9NF^(//$;"VAGI 7!
M\JP#_SFP,=YN,O\9AVG8^5YAN1\%NCT02NU::1"4/RZ?O\Y->ZH7T@=DJ:RL
MD\F@S,!99?H*VE-J7]PX8>-.@^>9B58OO*CE^/V3+!=^>DRQ9_>?>M?']2.C
M/%:/Z]F'O@5\V[C/);)CMB9)+-KBL)_]MBWA,L*X<B)8\$DCX./<LBA#J)0J
MO<QLO%S:=J[.5Y>2FE!IW>^?]/;<UPTK&8=(N-'G+7I?@))UX?#D.-2Y_,T9
M]?!%[7Y8.?[P[.]$!\O2TE^,#!"#0=F(\(1]]BQ;(3'5\2I%[U!,D$0(8=AE
MP$)%2T>Q2W%Y\$SJC42LQ1+W; 5,H[0WN-2Z^$]%KXA4!C&3$(MK7 O9!Y:,
MK%4:[#-GB%).(UG3#"D'M)5]<F;^L5WREG&3?6#]M@\=&W"DX(NC+E-/(=/*
MN09T:Q9Y7:HN_F"C\6<+*:WT^Q?2W\Z]LKQWC(V'6+BHA-?%L&+C'-:]U0S5
MZELO-8DLW%PJ9%[85-^K'"X3'\EQS^* Q/W7*];RFE=9=?OL;^H[9NRF7[DZ
M3K^I^[5/P;C/D:1:'I/SM;E3O0X'W-?+([0@02GNTJ\G#SX,ZO7] O?=_\+9
M?2MFJ8EPA3TDF#1TJ*J]GQ*_61?TQ4ELPA<1U\%,2.T'\[;A-5,+,A-9G>^Y
M.(!,<OJQ*2K7@!M2/"G0_8RQ#D)_*7 /44I4T173-+@_-\[A;ZHYX-;WX[W^
M?JN!8'6EFX'D[FO2C#^<AK"_"E%>4 6!ITG(30O,G&;EAL.G<3X_A//_*GDB
ME2OI3@T:>VED:;4LGF6;K'F2=3#<J1(\;2-! *TZ1N*^KI5&U4O<WV99';.\
M_?I]NM&P/ >L4SC+ORI0C\:DC6!7"9VB93Y"]YYS29*F&AH3*.C<?808W08.
M_"7<CC7"\\_.HT*<Z>D((&0#F*G-/*+0WQG]6M25.OQUBD_&L25B =%CZ1#D
MSF+>4AWAXRF7SR%L^YQNRJ=5A6$;?",8_V!D%;FOC-VWTZI!T7WWS+=Z<2Z%
MT?FH&'M '*9_';.OQ@CU!-8 $UZT!%$1=\M,7O$I_OX-'3PO>9%HC%83MU@@
M'!NC*F2#6O-9/B<4DN=R4-MAIH1 0ULJGRRY:VR0L8?Q'?3_P>)U7<;2)AM8
MZI#5L$O2RNL$<8, L?,*QC/W8S![+ 2WB31HU-+26TS'][\0-- VA,$E!2KX
M9C*%+1\EBN S3W'F5!0-2KJQBPDU*"MP'\D(E@W\T*_TD?IQP?_=[+^+='>7
M3C%D ,IEW.:V3SPB?E16&'B;%RPTEJ8_$;%Q?VS8?OOV,=N(1U3WF9 8VIE,
M;2 K?2=V>,NK>XQ.J]C:_E8<M4?O]E.?^[ OB;]=>#4\6VZ>+IP4BQP7["NS
M),>]J[H(4.P:KQ*")>OT-+_.-V=*:WSBDT!_/[EGA\D<1 DW\DHV);:WW^:R
MX54H85$<9^D#8AEFR*351OSX[-B;$-^O 2O93?^[_SX0<L:6>0UX[OHO9$!G
M%!O\DN<[)_;M_6!:V.3E+1>6)4X<(I;%J#9]3'.6W][\4;)4<2+P29[6[,@Y
MM-08M)W@@J+\WZ;"<F\XCG-@4W "% >-76V,B6A6[8PD KGR(9#L*>FW]KZ'
MX%%HB88OA8N#, 6":6.9!G%+J&I;NI</=/>/XFUTNJDB!TDV7,,A*+J52[>2
M:$%(6X-\=S^A93LA:!W8-PM71(5$A?H<7IB.1W:P;3\(B=ALQ(NW\T^TNI\S
MKQJ9?#M5><,E3,BGZ+V2!^':8W+W0^K2_1.W^EZI5Q\.WD*G+1!*28QZ%@MO
MIATT&L,_:RZY4+ED*@AZ!,*9CLTJ>M[8%Q0VZPOM?)^&GJ^.$WF%.^APCCGN
M[J\I,YR-71Q4D3[F7%2X_>48WDQ]%NFA0OV?-9:#.M'\? ?CV)CM4T]Z[54#
M^ATNU1J&;)VY"Q&(Q\>2KB=F^%-B>2Z7F@$] 6RM9_2'-!;Q6M3HXZL\)V>K
MHT"_*E$/N1*VGIT=]7"9I8K,?FX:=R)]<6:PT8Y&?<=OPVW37K]#NXM_Z-@=
M3$-S\9^2>.REG?_E1*)7J$JX:J+K&3TK(;</SA>IB:>(DE5E[_&;3:[ R1QN
MZ3X<-XPQ4 D$1>\"F2M66F9/#N\$?#5T70)?-O.(O@KSTUEQ>#8:>'2FGV7Y
M)\MW+SM%]<#@)H&^A\2NB8^,&MFAO?OE:>W[O+#N!2NZU$M-: @VX3N$)5)%
MPC,X8+V<4]/YTY*9U]!6/=0>?AL?&2\;"_5T]_0LRB1\%57+\J:8;=?9/7/!
M6R,B3DYF\E(UIZ8,3G<Z("L?+D!\-PZ$EI2\^[[U[%8W!E^"8"_1Z<_(M J?
M]CYBEOS'*/);Q:4<]A3?M^2P6<^7G*LMAYZ$X&J[F$ELT1(PV[-XC7O?S6X;
M(U_9\;0)]G_U6^)L2Y/9UUPVBE70,NXJ-D&E8UB'VE,5]02[6K8P*<'/35JI
M,^\/+ORB#=2,S;=86%#9]Q+U3T;6R(9'(5GWP?XN>.XW;3./IBI.RB2JX'C=
M]Y:D6UX+&:>=%%#C/K  GK_AXR]+C&O*0CVF*.Z&2"ZB/>"H-"J([0CEJ>GC
M)W?6P=1BTBDO;6FC9O&:ES;.P'@T6 R;ZH1ME>0.<T._1CDU'GM4.5R<??R^
MDIM79;IV9HE/KRPI8N%VL![3;<#Y?2*@)T-H.MB[5X#4F.U]#JD_4OOI5D?!
MM=O638$F]OO255D.*)S!Y\Y[AVJ<+HU'NTK&0[<W1H;%>6S2++TX2#Q5,'"D
M";J--[B2D/CFJ"XS0MW!SN.IN90FC5W65F)/HZ^[^%:W?,9RI&_V@S7+B7IR
M%[>E"7'#ZB&V_3%7^CLPEAFB W_2#%]3+6XF,]JVML777T%Q_^00_*6@02(M
MR[$,U['6 [_=@%[_5,\I &W\HZXX%*'B/6@@\FDT"-C[S?W _;!-^<-V2*%5
M3\U"-/SM.X>!*8,FF<XZTTHG;.?G!Q$I8?=<F0?&9D6]K2-FUG9<Z6]B$)]/
MVQFGWR0_"O@PIVFV0G&[Z4I#83I.SZX U1O$"5DQB"IT%Q=HQ16C%L \/F<F
M@C\0>1\6ZIIK8LQ^32H=F)XR]</,6NH:">Y5!C[U,>;#]\3">.WB"V<;X!S5
M-A3;.1#&@8=/59\B=;:-3&M$_ZY?K>X#)50A0VKB\-]J%(3F,LN=!P<9B  6
M;5YLYA'"SH0KRS@F# 724THMK3#373)56<,N=^?2PH3J[SK+L1L03YRV+M#?
MX#.YMV':>$VT7O.$H)E3]9>7N!3*M)</RX@O@>'!@G6!],/Q>7Z5,RYE/@TZ
M\6F)P_$^9R&$2&P[[ 5&_1NLW_W749X];'EKMF,8UQFCHE%$$._M!7-/V,?@
M;=FKQ%EHFHZ0N=Z0O]_%WF4>]B6$8 R=+<VF;[THY(H1*>F0\ITRHBSG_4UB
M)M"=]YR=LP1^*1= ^ WHAN8QA&'J2+PP[1I"0 '?](LIZT4.=4_6(;LLZOV2
M/J_:&R,<H&A"Z!*0"18R?;+;W3)M4,U8X2;%=L[(?GHEDF* <;%[F5;I2/B^
MAN5$T7-'BK)ZFD!GBGCQ%$S)B%<"G0;T,*T8]MB@1,(IRN))H;];&E?]X8/X
MJXY$)['3OAYE,UX7/KZWMPT#X2;'R[%MVA+((*&Z=O9>%M _F(>%F(6669][
M+G;=GLS2N&/DF0XR'(X*J:V\BHS8G&F3\.(\C?_%>-MT>]SUW]H9!'(-(!C_
MN^__UQ3KCKH[LQY"!7^P._NOI!0;PF SC+$7%_\LU7#^MDM\22DQO>/'Y)[8
MR0BE6*4=0_>#?1,R#I,9'>$^C:]V0"%7MU+7]-,ROL'7"113Y6V?$A;E@NR]
MP-[M>_%B*/A$BA,0"AK_WZ)+@R 7/(W! XW8'?D6C2_3F0YLB^:%"\3XP,/8
M-I<2@K)V\XPLS0]L#/\%N4_;OQM@6]QKB3;W\EV22D?40HB+TL(<\N' 0^LY
M-VZKF(.29M_DM(,].QCPZD<I6EQ<YH]G;Z.?4GSCF.T+H%^[O!ZAMW!9N+UG
MW*[=/U'Q)>LU0*#Y95U3WE5>[7V&J.)?CP:Z0Y]999S2&O=@P,4W(C;'F%D'
MY "2VQKZVJK4J$*O-7>E7?7.IFGQU>8<#$6N:]8)TQIWC19RU&XM2^UQL-&2
M HM^1\JLG)7]S^;7_ZA["7^P!!CMJM@C%6''NE:4Q8N<644:\M@A;WTJU:XJ
M$1)5>NY?,)".$HBI79<WA&U6.+ S^>R'Q_.][4WI*W]BQ4%M/[O22*WFF99)
MIAPL3'1E@IX6=ZF6/VS6W0LR>?6B['7]FS76'_#A&MNT)\-0(TF++W^^G^=1
M"]U1WW0 ;0E22Y7.YM(VT^U=VJC*?9027HGR]@K3^D*A0_$;9-8E?).8_1$Y
M8G@1E*$W]'E/:ZF\5?7'T>5:QLVU1\AT<J!:W3:OJ5%IF@J#D3 VT&B?ZPOC
MVUTUSFG?:@Y0@^%R18B78)2<VN<8\;I6\WW[FO1YIX9DE<[:%7>R::;V3]NO
M,-)9/D\Y4&HTDW[(NU/[#1IWHTTF=7[BDX ,&KEA'V)IQNLM7?RVE<3[/<5\
M&B<"0;IU=+U'A<XG>4ZR/Z$>O> (_M9:RZBTQO#O9%*_%&_=.WR5V--B,[]I
M_H'0,RK\^QKP^"+[_?WDD]?6^N3_^6=SD#B<%NG#>/FL=N;!GT.Q_.84CF_?
MDSA+?S$]!U+^'2E&EM*JS;NQQ44\8ES[O:BM@*ST5=92H1_.$W[21C]<1)]X
MH.);Y7(-:/2+QK+6"^K17PIK73Z($W@*\R* T+M'Z+Z,)2!V+8=;8?WOL1,*
M=WIV=!QWQVOITT46ND]$>63Y]@[.?)"G.9WE:-F/<K7#./+,&U_2E'#>DMVV
M\ULG\HLT:)9+9LJC?OR.JYRI9\T!E)IWBU7E!$$[ 6>$:4S+W?BY?H-HD+%5
M9I#54[R$?,2RM[PFHC#U^%07NK;W8X5[H,J"--8A.W8-V'^1ZFDK?PT MRZ$
M1%X#[H+X3_F5$]3>"9>4EQ*N ;T^ 65;UK<YQ4BV5@DQ.U'Z+P?J"1)KY2I/
M6C07)J@&2?6!UA*K!I&K4EKL+8(FVO[W3C8;8#3X89=3YY-LCUE=2-N%_? 3
M;P6$UX4.;#&"S4BX,#QLQAD(O8 1_?"1GT<X+7I,PN%'BUIQ)-GM$!J2DLLR
M(T/!FTNF'=RCU(_7 )T#%4LLIW1_BTRZ1=JO#VE^APOIG,<9%_2KRZ&G]//C
M;\+Z+(RUO0HCE\S6D_>"A;\X:(W>KZIWF@36T5YE)_9D.R#>&27>C;==:/KJ
M2)-,R,!USJ&[F/&0KQC$/&I!D_I1:FXFQ^GY:,!Y[/^&=PG6&-6.<$BQM@N?
M0KINKJ*Y%9U7W#_T]#*5BC(PG,0469THGVJ9^=FHR7T_-7&V9F,K5T4[+K@H
M\5U32PRENJ=9).P?2/8G[/F$FSH+ZI$IN- 7UOX3#+-"B_,EJ"I=C4C?+# K
MM"Y4G8LSL99?,4B4O;C=?^+W[UUJNLO!'>21)D^3I'F$P-)8MO0VCO# ZJ?1
MM_$X;H92PJ=5-C'W&Q 1SS^]C875A^!Y'#TVCHM^HG\]6;&]^=4@_=859%W/
M8M>& %F=W_,L,% V\)02H)0;XO*F5[M U'<P$*VFV@)6")X?SLR=&A+/!TOC
MY]9!=*"P\J@^I1GFR/*,F02NF/P7)^9BJQG,]$>BL>-,N,Y]?MRP&-E 8H5+
MC:9CU@:6PU>%9#/;T3_39FW'%>OENT7Y^NYWPQP-F%<Y> ?(V.8K\[OR3/?[
M9[]6_;70  7BS]H85.8;+/Y>\F29W@B#8($Z3 +/WK?$.;5?6>&0H;"R72.E
M=51IP 2#X2.*L9F7BEN7DLERT7? G9'UP28KXQ$M'F'82W87M_RT2?B[OU1
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M!%=>2G:==5 VQ#7-K_=*;)8"*X.>;_FK9.#IY[^:UZ!4:)G:&,."76&1QG]
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MSTYY64_<K@8F.ILTLY_@U9QV&!BZI0C6*;.KMY0T#TK3WKZ#W_M>(#;_9$Z
M4>DP3W:8QQGOQ2MB]BY:!T0&ZI)BN2@N\;PZ^W[,EY+V/'N$!.Z(M77:B+P6
MJ7UEVZ.IW_6[FZ3U=?ZR%AW<]0OEP0@!HR%4=_&L>*\F;173*,;KN;L(D2P3
MXSB.:=D-6K?4C,:5V+25B\YGHJ?C;Z@PQD'O:D5^2!0MX/WU>5VLRZ9L?)L_
MP;@RLL]"7IH)'O?$IMH0>/\<X(@Y;>>*@!0XU$6]O?+M8X#ROHIY;L:<(%V(
M!7;^5",LRO'EY)+S_.;&.W*H#M=$LOO;OHYV"/#IIS@K%J+7$JAVR8!;'/LW
MTH6#4&SB'N\TZ2^(?#+JSTWV._#3U[Q6.%TF97IS_^8)MA\+KCP*0\\9$^IX
M$QL:X@2O; _':"T^0@&!$=DAR%W'U?@_H&P6.[_!TB-P<CV]?.92[JGQ]A&S
M/ZPQ#=L/ I[EPON\LR%V$/3NU>.4H?M=JYT-W!V9/)5,P*65P0C0,$_27_F2
MQD7>MUT!(U7-MC=<4?%T<ER_\F;B*4_)!TLH0,>]FEJ]R.Z^V]51*T$L;Z"7
M$?_RKHNJBB'=#L[J%NS@RJS/.)#+33L'7%?U$^MRPW(%$_JDWY677?2F)AYV
MM65.[:D38T(%.8T*_0HL.L*%OWATKUULW&12-O4Q\.QW?.Q@I=O5V\1 @9;^
M/>*H]A$ZAK%K6H&/'6N6PG9V#E Y&(73)Q8]OQWE,XQ[:=Y><]]'72()??(Z
M52.O;,US9FHZ)=R-'HG*L=='EJO54(HV#"YMSK.1O^=K]KO8'F5SXUFWQ'WC
MGD<5ZA<=QD5WT1YKZIP^L4_Z\MV.FQ^*:6>-2&X[!U3F!R%UX,MF"_?>XU==
MULV5,UMBZ1QGJ,-9#[N "ZZQ;7#O<T 8^)T4DVJX;W;RB!1.)1NA_TJA1JG?
M&UCK^U>XEE#E<U"R+V2_S,1Y% K.S)58_<G;D)8,R10QS*$ !@)TCR. G$[0
MJQACWIB:EGDCAL//=&^+U@-=TXPU3A_Z#Z5  _VYYB!.TA:.9L$5&DP8N[O2
M5Y1H\GU017N0>QL0O9+8*.1+.)RT>9@_XVR%R!X3J+9PXY![;; TT?1,52VO
M-#9[VC0K6#NA[X(/(SVYB7KU'$",T:".D2;RW\_#9MB#_BPO5^GYY^^BJG]>
M,JZAB?%O<++P@Q0&W/OYJ_:-\0K/?KY"'T37(P]3?RAG]R> ^(R%Q=%*E,RI
MEI'L<'=NN%;S*E?"2$/J8DE:74#K.8#1;%9SV( IROYO&^TU48,P?\4A59H?
MC84X\[#%D2!:V^\*3%UYEYP1=D;HB<H9\QD%-G.+)X+A7U_#U$25DX>F9C2G
MS<34'\A'_/<OW/^K,OU_5[0>Y#TIU@RP1K%M04H5[)T#) <I12N#9.%">2HK
MZ9- \D3>.6 HI;&$))3)5Y9K,:63:/JJ=&E;;,"?AG+M-UDXQ]''+WJV.MP/
MB94<9;RF']#Y40WN7FE7(J%%3XBZJ ,ZN M@M]*1+YOJ-S#ANUV= A$Z4;3,
M3LRVU3QJZ7B2VTLGA=>F.'@A!(;L J<G#^+?I/FC.ZV0_"1P!"=(B'2AMFHV
MM^2-Y2^\@)S!(8P44E)BNCFMV>"Z"IV$ZD3//7TW 'XL-B]?[$J)W"UHMIE1
M.P>8?3[[ 92@#F=>DQND73=JY"*^8>U-ZAV^=^O=I0@;X#.G;N0EN/?233,#
M]@'GE0;8D6O1QS4>PLQ$8\195B.M)5*KIG*B,C(IR'C46@6PJ*ND$L"#37%*
M6""W60SY\RVL5TUK%KDZE&^O=/(F9V@UB@7F6&X%>V8$@WDH+T:<!8>CS""$
MI&"7MB[9N]<_K 5JJ34I-Q$C[I4B7=[Y+:TO:^=_Z7?[)?U-$> ?4DK66[(,
M#:7>-D>HM*<>0.YKK9ER!T6Y(4"8(*L.<'0CD"(RQJEYF5OL^.O[ZFAOYW%\
M@&W?S*]M<VYWR9?IY/'<6>03TC_WDJMY5QD/EG:_VJGUP6D0:;C(:[>T$S+S
M]*6=(%NE9U+U(ZT4?'K#Z5LLI& 6T=9.E3\'?$YN,[/.#?ZV>_CTBH.6E6AH
M) :*6^!$1.J,.B/O31Q-&!QF5BQ3YI36"59M$ZKYL@WXGN0EOX%4G)XEL%/!
M>J3K)3<,I?K[1ME&+:5HT^5SYM7*IN!Y8*Q^]>[D]:8_5^CZ%U)".^;I@-=
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ML2!R0T<VFV:ZT9R<B$*4ZYEX^#I]C\[(OQ\@1?NQ"^WG@F?@EN)TP(E]YO>
M)F[DMX OFCGQ*8Y4>B^9YZ 3!A,G:3[%=:V;?""8C6T(5# \?_$KE^EY#T6$
M:(4F#KX803/I3CN48KZF?WQQG_L<, Y]0]8Z_#Q\("(0> :)FKTG[6I.%1UJ
M[/+FW3<B!:]PBUZA!_VEPC_A6 )]I*(J#S!E!F4+>*%'0YFY_OWZDJ@=4;7!
MHG8</BPO7LL0WT2[#KRA*G^HP%H\L2OY-^_Y'LUFRK'3,[(ZB6Z16@-7X[J%
MABF#6)=Z/)X/O8:C'A&K8^50GWW*$;Y0HY2YY789>=>($[Z)$S6S3K&O'PH6
M>?+O?")89@P/S;P:!(ET. Y^VP=/$RIKVKD.LOVR6$__+(,"IGFCK3>A54;Y
M>+'OXDB)O)LMQZ"A18*!SR88)@9E)KLLY?8OIUA</"1\=NV)SKF^C\H$7;:7
M/SR49^'O%/J@0#@36R)G*X6P,)YEQ'19*B/[^6+!P?!S $\EI_+*GH5^*-*-
MI2Y_I RI3@1!=,^<=][ZADEG:0QXHF[Q-YP#M$?&-&[^G?$W&VX<Z7W,^ ,H
MLX):BU"%?U\BF>F3U+P^1V5Y-#'*SO *M,ISF G\,C/_\4PE8TUN;F;.^[/8
MV=($)G1IH%@6S K)Z?;7^\((W0F(LZJ5:-Q*Q*GW&>_K:Z7H*;1V8H[B5<W&
MSB++WKN/Y.)Y)I!>3"R]N%+QU+)UZ)/$Q"@IN/N* 5F$3<!_L"*^N,49K_@R
MXG#G8TY :Q8Q1(E./S9N'\7V#TKBRMM.E2VUM;E=^+MP$%]HLUKVDE3PC6LS
M[P5:@+JVZ2Q/LB)$HUK_]W/@_Z^*B^%,,=-<[P=8D[-VG23H=W%L6=I9DO4A
MWA<QPH<:9#2.)3*#ER0Q7R\KH^=4J'IE^(Z%:$+,6LKA#K>F>>O)SP% M<NR
MTTHF6=CW'-#!B8>%"IS:/O47'[MPJ'$Y3D?TZN)(BL%KYJRBI[EQR0CG)I_B
M<6]SI^L5*YWNIKT38RSI)1ZU&*E3/6_/>IN*L1(OZ8S@CVO'QD.;"2%41C<5
MXUYHY5&[,+$I!B,%2J#[_@N]S+%T@])A]I";. WQT\G[\ZXL0N=:=GETK\]^
M\?W=HQ0AA<:<49L^V&P7=AXC<QA"U-4Y2\01U) -GBV!'=<V^;?73[#5%E;J
M]-HC-=<Z%63XOK$O1ZH=M0_>$"O]ZZ&F_/[SFS\U:_SI>AZRB76LFU@=5_PY
MX%+_AR*^G[*BI;%89YFN1IW2Y*Z%JQZ#?+(*,?Y]A9U@N/P%4:=>^" C.;8-
MS!X:?O#53T\3;3&=HP5ZL6?5OP2.X.*,?B.1M] AHE[U1/.6^E\GP6(T?Y>4
MW1(4Z/!,+<<G.(H8/!TK*!SK'E*224>1386,YTR@4Q>J'.-+YS:;:8;H=YZD
M5I5NW:'NGFVDB#\8&'DP&C$BN_V@M'3X"^=M['=$Q:)P*-(0U5@!=R9M, T8
MAHSXN<:@-U+=!Y3R88NDB)DI+U:\N__ B7Y65%W(SX(_Z5FFS=#\N?^V[Y6#
M0^ $H4XF4=-]$8D5-H:PY5D=/HSQ$.R6J*:FGW:.R5-'PX= 0L!!0?2]KA^F
MMQJY1\S5B83H3S5.WR46M:.ZR+T%W$T\1DD,HGN#:.U?CS]ZXQ/T(B:ZWSHV
MW5\>/8PP,WM]5^+&LXM<ER3NO+YW06F.H+F-IAT!2@T=K*&-4T@22PYW/T3D
M7_JV^"QKN1DM&GA!^((^Q!O<KO(7S1)F=7TD8CO.CM/*[MVS!V<:'LI''1"Z
M1[!JKJCW^%763B^9TPM6?HO<$/>NA>M"I."S;-._0P^)9AW"S&Z/Z%R&_EED
M-4T#.0A_!EZB)I5OL+G4I1U_R"*.U%)WT!\FP(S"Y&A!G^J([953\$),B_\S
MQ<7K^W*UI(2EIV!66<0V!#]CY4!8G>ZKCHJ9<XH>]I=SXN2")46^R^XIVNPM
M%_P$PAV_YW15Q*LYZ7K]O@FLS&\?O.(_,,_DI *1O K7^^;9YMS.L?*!13_Q
MN&UQ!LB*="3E^,#3"U*?U7W]O<>\=.5]_'S? )CKC)5<="JS":U\Y5D-DHAG
MDK1/.+)F^8Z-N;%?$C 5<*@Q"J+5*X#.]O%N%[K6<AC=FKGYOH#RL71#,>Q%
MT.ILAN;<(!W9Y1Q 2QCG-C-5U?&^8=2M[K_E-M^PD4P0E@]?BGX\V +BJQ)[
MEU-J^>ET9RR!T.\G<?K<?ZB/& "!@#I9P,\P4=X: :$"I4XXEA JTT2C&O))
MS+1O+</L[*TUUYY7&Z^P11^C-JC4G(;QPL_Y?8(QL4L&H1BMO/F 5LM\!S?'
M%%>@;=S/QYY!YP"L7#UN,)(3)$&:]91)+:%=KS=<[AQ!T(%+_!:(.TOSF<1S
M0&M2G4:E'L^SS!00R/T,#[WI/\O'4CVNZIT[CS"EG__'P_J[!K3;:@&,QGT!
M=D,=MH/<0_MV897B/J&M!M-%ZL2!V( WN(97B57P:Y;2Q(T/E[V7U^16SP'L
MC<)6R*?DG[ "!%0'Q)]I\'2]#62ADU$\RW.( E37C"Y74P?K*A)>C!D:)#/2
M>4MMJ]7(;5NQC',9,)!]-;ZT6,/%?@2N*R*^LM: ?ZPVS&IRQ1<<FZYUOM^D
M\E"[ZO)CY6QP+&%8W,9!T\J$S&E-/6&MQ,]F$1SB VR;$S=?ER_KXF)D^N%N
MUG@S@MM2?OJ*I6"8ILQMJJ0RKD+5E<1B0%2+\&X;J/F*$T-T6LX,T9-61"/G
M5H<6<%H*I 0K#+IZM)))]&'U]-<,J^U><$])0&@FXQ:%,\_[A_?)UQ_B6&G>
M/P9(XX](6_)/'$Q^4X^D2N6H"1GH_*!>(/C%#W&(RD,RE<9R(J#:$];JC,95
M/>"D6?99F8B4N.<1R<_3;]@+'#]<O*!_^AFM7:.4$Z?P$VJVYE/_6_I [$ZA
MR9Q9=V_@HJP5^7;$[N G<,5\,E'M("Y_%MTRYISBQ1(5^,?\!)M'CEA<KY,@
M=%N./**-:=JY)-3H=A9!E=L\!]SZ2;+9'!%?F#J)&GI\P\:Q./B5_\-G=&.N
MO]\T=ZF.]8W\^,QNP1J40-F KS]D^!]6[5V4>[@@(WJHA,MW+)'4;\ZG_4VI
M'_L:PW^TM!9ZEU1I)23/R@L7N!?O<B%P+R'*V(7Q8^>5S2CC3N6N,#F:?\Y-
M.[1O@'XJ.S&R^K59\-@+0%:DB&TMQQ[=EG*4O&\_OO3N"YWZ)/86SB"$@VNZ
M*3G55C4PL!I]9BW%\M<K);H5IWC!S>]C\0X-^4B?-)""]4%NWK'B?;8K)B(C
M9CF)AU$O=:Q>KFL2=GE437>,M5S*#*US"7DKW4I;GHE[D[)N&/F[1:++W?2D
M"@W+GNKQ\E7U)&H=?8\1-99Z95RA&95PMU)*I;H[:+7GK]@J2Q20K6E)@:26
M$9JKC8+=F%VTZT_XPHGZ*4S\=0[@;K(7.^U[F8>0%/!WYGZ3!**VL9>=@BD\
M=6B.^3ND&]Q2"VL1<^> 3X,DH'\VJ3AWYV_4S.HP#[2=Y?,+I%H5>DS=N;P!
MMR$M4S:3V2TO5G"6@80*AQX493(Y#K3E)+7'<'NR'*"\2=6?8133I=,2^:7'
M5T>_@^O.'@&CD>:D^K9&9;*"N\TOL]BJCFN[$RO2GI\VCXU37T050G2Y6+G\
M!^=!!ZL/@@(G!WR-.7'='!!'FB%2VIX5]ZDD=4P+9TS1/J@R.7A8_]+UE+P#
M?8@('$\YF8>*N4E><#PJ,(PBN#L5.CJ8FI5J#5QH+MK5.T3T+5:?-H@&0LV[
M;G=WT41DP!X+5;^I 8CB_5^7BVL5/MGLELU_]1$N:*@G<ONM$G]B=OBKI(=]
M&96,W]%AU]<D@G/1$R4N@B(\05X3Y5(NMV,XSD9^[Y?*O!B[5'\+5JWI_I0C
ME:^B^J,H=T&DA^(S):$*BEJAW'8R0^V?ADU]^'PV5O9;R21YYW"-R%I#I*;B
M4MW4IP<*A0;JKPB#O[&OUH5VE1BW9URL(J++O;7+?FEO,<A$&<^"KZO2O2-=
M;SD)"?=0S:F!%-V^->WGU$VY="KY-Y/YO;.+W5Q H?B3DK:HZ)HN74)+W:L5
M?TO]Z9K:\<!\OUC5LWBXYBCRD;NC9;;,PU/\EV5**>!,;(XJB'PP@G1UCN\F
MO/-*R^F+W8Z7@<I3!X_HJ!PKVR,\.=4//@^^N7,.H/^+5,AV E?2M;NP=Y60
M S?:-(>W^::QD$]57Q[-U!^GI$TG*E.WXKH>3=E[R"]<H$!=%+;E&$S?;!2_
M*C4NZ_1/P^K8$/$0HMBC8L2@83#[S8M1^#?O25%4]FX=$H,Y^<*BZ?M4JW(2
M4[MRT$SST0M\=]CRKVHKK8N8/2LR,9,;Q+/Y /HW<YJKH:&[RE2\QQXK>'%.
MA2:SM?%QDDY0U'&:8?]Q+FRPNK*^SZE/SZ$DS[@Z/<"S6W%FAET^.V=Z8T)F
M:JZS_)'T5[ASJ-P>*'(I("S2>XEV6*KW+ZO&U7B%[D6;#^ X5('-\<]GBR[-
M@Q,-!WW<C^RC:HNW_1W]A_^EWQWB0GOAG1'H5H;K2_J$%L%Q0^)1#!78QK:A
MS-1/P&@#:JM?7!_SE-MO(B0L?4WI['H6P[*?*?=,^6! 4ZR-PG+Z!)&'/_P8
MJ3.^$X<1=BYK48O42O\<13.1SYWXLO-EO2I%D^-FJ*^C<.@6\AU>);/<H8YW
M#,)_43A1O^.$!#6G<),?-S'O_[P[90KW?B8[:J.B5K3*<98CM\-"<4XU::B-
M80D]K,+2=0<K?6FE 0=HF1WH94[7$Y*GK<(+R)[G@#;/D^7W,#D1X^7F3ATP
M\8Z5/*=H]F=LH<=]UI]#)\\)N/'BE6I_+5[?TXB5%"<4TQQ/H2\HZ"SE>'2I
MJ7V0=9*LUZ$<&[QM2Y+EMX\NEGFKPT4Y#>=95.B+_8G*4V4HL$2TM9S )LH<
M85)"#T=:V_+9=UH=>V3*==Y'L7"1 [3)<=9_/+N\Z%=NU:UB%EJH*N/^/.08
M->Z7!C(&7P@Z,@L3#9WG@&:2OM[,G]<N&NQ_G,!79TQ;!X;30_DMD%.EDV,A
M$_>1W:2F&7>#&A*XA7S [59:=<0@0%B&K6*D%I/#LN)'>N55$+0/_L6A\809
MMHU7<TT#,XQ6>K'YM";ZRZ=)3SFB4(53 -$%=^DPT=GJZ&E5YDH2Z/%E[H\4
M&6BF*^BY>&O:5T[UQJ^S[Z>.0H(+NR1J0*^[S; UXS1/@CR)&&POE95,>CO1
MR[5D6!9=_,$)54DN T?<A:EH7-Y>C@+>LV.G+)(-@ >-VB4LCHK=NWRI.4Z_
MJV-+MDU-L]'<DX4G$8>&Y-B\"K87CRH]57$8]580W81LO6?&QOPC=X]:E5#'
M&1CX>7" K_.Z\%./[D/4AA5KSP3=)2ZX52&?$'^^2KW::^3#43MP>_99;FD(
MPWA=583)@&%1\UN'GX9,C-^=I\X!F\95Y!=@<CXA_'3\0,[A<<KP["K!Y@L9
M3_1IPWL%K1 /LS\,FU=&WF; \M<M7"3;LEQ!N$"&":E_0GI9Z6LW.[PY"0FD
MER9D-6(,WG(HW:;)-)']FP^V@'(/*XF!_,.K1^,H"QVXMWU\_848[5+: _FD
MKC<:-XQ"'OT_>Q3L?RV(2YW#V(1EKP;@-:)3J515*0!V[4_\PV:6UG\($$)A
M+28#6QO%*B>VN'I]2PRW;_,5)9T#N$[<7]2&M,[[UF<>/+\CO&X!;6.)R "2
M"W,7+!&>'C4QT^[.IR]OWCX''!1>^/OA'%!$=SH[4M;\PSHN^<,B[B/7V^95
M3#W.JQ,FU8R-<Y"XDV#RW4L#L"\0](]%M#/%[%;QN0BUM: M>&RXE<@8^H9Y
MY'+$S9*OYX"^NU?R3XPE?-+*QH(EWAN2X43QC?G[L9WS=S,)V. 4/3VO6ZR!
MS&#1H\(F=VZ5[AMOF;K6HXR\/K^-/>6;D&Z6SAMITG6)%3Y5"(8+,QHF<=R.
MS7TJ#'PW$ D3]#8(EY-B16J28%VAQ:;O/?2$GZLUJW8S2X/-#DJ CX*TRM"5
MGQY_>TD7VW" BO. <D"U4"8:3BITWJ,!:IK4 -U3R>&(J2X!MS]%F=W&''QN
M14)_',;68'R<I_KV/C$_?ZZ[MWG?S8MFFE3^&/[[S^<HU"C[LD]HD*KP8@B)
MN2%7;KPQT<F.\2?L78LT&R6-V<=X]!S A@Y@6D]AG)@72.T>W;Y1)#_RP<!?
M[ O99ND< )CZ.[)>9WC0F._D-K.R9\[=]28(RT.%S[Q@*F'*_=F"9#G[\2Y6
M:PHGWW J6!+I+1BK"'6#^*GDS'<5FK7!782_P_BW7UJ4-BRF U\,S3>;M/"H
M7(D^_%0=,[;P6?(<0 S-8>.)])Z^.?@KRCI"TKCB4N%<D?,S!T=90WK XLL.
M3T#E<XW[_Y<S_>B3T9G<![^@'^Y9:G_1D-V3M[GB=6J-"="/V<-?VJI64) V
M)R-K7X7(!"[#J8GK\_>KDU\0J45VC@_<#O\(@,B** 7R2WP#@QYQ5MERF33E
MR+'5(^[V^[%Y;$K=3PY\/V_SW_V P$;VH>WX55XYVV\>*3:UH>N6T0?C>0GT
MW;L=+FPQI0\O8LSQ7@2Z;+)=JW+LH1#*1;Z6AW&"V,GPX,WV)7]+,O[P!SD5
M?UK(^1R;'^=]6>Q]8=0)O"0[-.UHB&5\, S(B[R;;9_\NZM8\,@:/->:XWJ"
M#4$JD-%+"P!RX<'5G<CI#8X2V7B16^%'(EU[J! D[R)+^+QH!<1*3>!9W:@
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MFU71F5R)>ZCF- JB6_A[#N!K%'3D$VF(G^A5S].QL<GNN+TW,95^U:LK(#%
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M3B\P4IZ#(Y% FX(_UU3Q3-4I(VA.B&-WS-JG@!:M;P%M:K,!V%GX=L"%5^>
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MFW'B2,+:KE3C?!+CPQO=1TS+]1PDJ1K-$LOD3LV3H(8D*V,R*?:YJHLF_6(
M_A(P93?I>%*7*R3<;^8Z]*RUP).-YS!1Z+FX&37E(AS86>[V2SV0K;%9E34*
MR[QV:PB>DJ,8 QY$VA*^?<O=?=(D>VP?XL;',-X,9R ;8J!2D :. ]HG#:./
M:%?7L]<-39EW%*7F^5;9V9GO)E)V]*\J@V_J$9UA%5:5/^;Z\.Q*YPM5ZD'X
M[0>#N[;"X:T6>SI;[_W#_5?SI*F.JP51(JYA+\TRT'GH2X =XN 2P.86_,&$
M>7Q_[,ZPF!FU6JI="+&U2Y1(L332^KWOPJ;Q(W-2QZHON8-B)J/ZT-IWF2O1
M189V#-&%?SN%Y_+3-M?JS[U%ZL7-W>P(MH^N(@/]H5JT@F]J?PPI1E#X@%3#
M%?8,XLT6[@14Z?4J/)UVRO8/?F^X&_4LY4W@[6N&O;\=^1@-GD^=WL?<J*-^
MPDC_Y!H;>4->>G(F^I[*J^&]J%9EL(KUSV-1X-=<UO,OA[N4TVNGO4LM:7J?
M36TJ*XM!CG;_,N-0JTO $H>-?F"Q-*9N.PV,8.=[Z7C0&RH34#!C;X64[*G5
M[*"KE(,+DG9QPEZQ('K/;QG.C]D;(ED ?S5/S.$.J58F\14FG_S >7@0:[L[
M.(55>)V'5IS+&710T3UVU?M%2#Q>A25L1&$W<7!#4M=_S85_>F7/[AFQLQIL
M0 +AZ$RZC/7S@UQ%?L\OT'YT>A7(AJ7(E<!B4.DDQ3,UM[1U%H7GU:E_YI[F
M*S=U)?K8G29T]TU._1DI])O.VC(I'*#UW)<Y*,@,8DO//A5>6HC&$V#1;PXF
M]2-Y*+U^SZH%.J>K;A#E?M;ZTEG,?3BW\.^%9%3(-Q0U5P:.+5T(DHU^H>A)
M[@:,X%II,SVQOM>;P_[SK)@J)9TBJXT&_;_6MGW\FC-14>,HQTM 9(IF7=AH
MX+6T+\VJWE)VVP0V(.E%&-/ ?%@G^URB3_QJ_(X;WZAJ?KS0T/]Q:V7V[(T
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M-Z+(EKQ>"))5O+%<M7?_AOP-\.\B]A<E-72MN8%$BBZ?S4S)NI)=G$D]/IL
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MD59<P[HV9'%?6)W25!6\"=OV.2@^SU3I;SHUA_H81];>$S6@NNA&0C6.@IA
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M4^B0(?VW6$(YYKF;[ZR>'Z]-0XR'V(8\4\;>3"!/'TJ4Y(A+$*<A&Q*!L;O
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M8^8]IY> /ONX<("2FPMK0L!OJ+IC^1^9Z:>IEX#REPQ<Y\*@WH7;*#G7<*H
M4()9&']]J'+5<HN^Q'=J)[VO?K\);C8_T;.1T@[L0E*C='V_S'@E3MZ4]D1O
MS0FG$(X_> 6D -9;HH1D"_Q<ZQ3>< 9F4!=!!4HOIN9!]ESS,QOS0K84QHW(
M1VJ%LU:O:'A';>= NC8#=)JK<[>AFK^VH:_%8Z8/':<R[WA_?-1]'3W/=X#G
M;?//MCW/17@VROKV!CAZM^*RI3(<?J=4096)"3C9MDK(@M4OT>2O'/CN<?VC
MY13_G*8!:F[Y:NMN>VXE4X+XD3W)!?R@B*T)4T5T">4"?'YYHZG_XNAZ<>&7
MYSFZJVM#OPHCG[YL?W3MX5%I[KQ,TLBD1!-0$!YS"7"!3\-[K(Y[MT&=Q\$X
M$DR_]=UR\H6U@9CV+/,)S4$G*"/$:_L>,<26H.?*01V=+2>3%&9PGV;9[N[=
M/71\OKSE]O&@!U?NF]@5C;F]1 ^\S&H8\_EWY"T\D,L.8OU\:G$R(,$P4.TZ
MWW+ =C*H"+J*!W&3S4E&</A[I#Z.4_3MJ#WBJ^5\:(9ZI]P3--PC#XW7OP1$
MAI-!DUL'<R8]V8DMT#T=O_LB<0"=.F2DSM7OT,K3%GL>5PSJD0%]:+G Y-^4
M$8M'OHP^N;D(C$@.JSC"Y"[0YN@B8P_4!TM0@$=>/-Y@R78R>Y1@2[=3D.VJ
MKJB3^Z7/QT;CN/<?.R@P=-LRX+[--Y<,% ^'7I-:?R7>QCER7[EE<6*BU+=N
M^P0Q+(-X/?%_M7?>04U^W;Z/@$9$B*CT$A6P4$5Z#<)/$.D=08CT$B @ @%"
M(B!%6D0$%*4(4J0*)!"Z=.G2$@A-"$4ZH49*./[>.W?N_>O,G7O.>^?<>]\_
M/K/G>6;/[)D]ZUE[K6>O_=W\&Y!U=IY>!9X7:SX6:5=NU*8>U5\&VO6+[%20
MVU7%AM'NJYN7G\ N]9QM3(#7AWNQ_#JNF%,^,A>F3=A*UU<FM94C\KN>UWFF
M71ZG*[O\\:[$[KF4=/KDG-W&AZ-/YN.2OP%\X@*R91];/*NBE[N8?D0'F].3
MVX^AAA^I(WIHK /TT-;9=R6BYBLK;CD+,PS)@!"(55_L?A8U+?/\L4.!S9.Q
MS"MN5MW+B??:MQV8=G9/ >XO5+LIP#AIS,65VI",7/^O4RNI(F[G17HDY>GW
M2M_O5Z?T>[=NQ/GLEL7YE;$A=IJ#HEK)<[%32FW&*X>Y-:(_?+G+N282"158
M@Y@9[L8;"&@;[?;P\?U\MR!4K$BH)R]4>@)]X:S#AD1EZJ3-P<&='Z;NW5SG
M[</E2?4TOZ7,<\J!(>3-EZK\%!4*V+VI4OL6'Y#^C4CKWB;)H?.*NZH 05DN
MIU,B8I?#];,HRJ59046E@&LOSB>AH"U5U4'B&<B]=V1/1.7F:*D,3[2G1TOZ
MIN\U,Y.Q$-C+DTR4B.VQ&=4EG]IX..A!H&++-Y0#/;MIR>2F*L%P"\I2*S/=
MW*1[K0PA5[!:\5&6Y%0HPV>ZX.,Q%25#8#TUIU41W@YG#$DR&.V5W8Y[$.C<
M/,[K^S%\.&:G[#RJQX(=)3J(VV1%U.ZT[2S?J[32\GYGV4_0/2&/I<TUV=M8
M]3S M).<>M%;&!UX@39D7_J=:96Y+U:BBM._K'A-AHFIH<=-65PJ97M"1=,M
MU'E<5S@K#ME1RI)\H? 4P#AEPI+\U[]W <G_ICQZ79]BVE0C]HR6^;9@];:7
MVK8@Y],@^QJ#\U2#5MHE7&UL:TI5U> 3@T7=ZP+O%;KD-PE5]9ZG@!N-GVY1
M1$7)$S&_B_;/$N!^ XS41IW5]^)Q02.ARN3ZPK!).E?Z5<'N4JG#Q8_8[[1?
M<QE8P,KM[!?7/FQ*\)T"<@,EV@>BB8U<(]@^H#8&5?1%=FQL5S>IJ\SZO?;D
M?2X!>I6B;E4Q!#O9%/^5<O9#*#KWBY\NNMBLAW6O&*:=NQ&ZY=(AIKIRT'F8
M]V&N*#!CRTO$]T:*1H=Z63ZDO^!8BJI%Y@,:AYM7;QVWZL4_)F@,>X'DRPKJ
MG<B;3$C=V ?IV 6YV"]B)21IC=YXHEO7?ED6CCGXKZW24-X L8OF/5Z2YP5$
M/S^GJZ]I-XU=G%SXZ"0VD(9VT0'+:8S\R5J(Z_&+77X7HU@> H]%?L'#9=U
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M8*Z73-G^](J+$1 QH"3UQRN6,W^X5X$MON_92L^9L_94]N>2S]&DWRG@@FZ
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M9^0KER,YZM$<1UP61:*M!&K@FV^E#7=PR:NL*/I*XDPQ6^):FFZPW@^D/BA
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M9XV:8KGS1(=4ABO>LB'->]EL#G]%W +@!U1@"(KYVG#GS;\G\_M_-3<'=1X
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MAV7H_A_@<LH_MY+U7_R+?_'_%_2GX_\&4$L#!!0    ( ,A)5U8BU'2W"5@
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MC D1&&]>"C%AZ,U"X>!MO9KPQ?$WS?SET.)&I3/Y)4]V<GU)XOK-KX6/)W%
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MO&A=I+E B_NQ.[R^Z2W??<@R)AQ&_/JA,-NJ$F9@]Y4X$)S]T8BT( Z,UCS
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MUC7<9FC^F0=8C]S7HUGXGW](45REW@*&)VV"-L%(8]6"T2(4\+.^*LU.UU!
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M'>;\^RK?C/:%(SYTU@Z (-MB*N'>R" T%-]710'3Z@-\11!/N,@?,Q52,Q;
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M?3_<I7/ "C9TYKH%;[5R=!3?%+/HC.Q__U57&B>=U/+B'IO"G"'7-[, 9V5
M0!4MZL):Y!2S#4SV84M+,#5O6?J\7LG.Y&'O%1"_IP0\WL;^C!,YC!VH-PQS
M4?5F$-<*NWTM1=!#0^EZ$&M2L6*D$C?[;E](/PO!'+',<OS;H.'[@S2E++KP
MSYG6M51W54[""!I5FE_?(*!_].& ;8VN:PUZ935,^]-2!HR[.V;1"/L)<C#
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MT>Y(5S4<$ A+)V/@?DR=EZ%2J$0Z?OT,B;[4@'70ZO@S'' %@2G- Q] ?6C
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MJ"SV+@)Z5Y^?T.#++'6V3;";(-;;Z".&'T*9M/? /RL-^S5_J4C4: =/Y9,
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M2U_/.FW+C+&Q_,V?J$JEK31O#&C1(.8O=*DA4R9,F4*_:.1MR.WKT6SRQ.$
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M84]:F(1FR%>&K-WLO=*!B8E+;&Y!TQ>VOBD&AS-=R%ZEUE1VX(M-C+4=S=2
M[BY\T5=F/H]19M*C9C=3''5?]2O1U*U"0,MGVN'07%7FOOY=W]9B]:!.!TK<
MU3%^WPJZ/5DZ$CXBP</\LL]6)7YVF0F=V5+3<DI-!D#]/<'5!RA_!!GPV$ /
MU.H[1GD&N;G>O;;2=BZ;XKN85]T,CF(W7N\](5JR"S6Q@>/DQDFLN"S0(<>#
M(##^9 1)!MA:ZR$"":X,^":S1W5D0&EBA2KA*S)?WZ"OOL/_5T G2@>,NT8T
M61;$(#XSNE7M'G:=UHCQ[!OH2\9ASX!^4V5WD[9SVTYR?&:9+&'/A;L(;;%P
MC7("Z)DWXRCIML?N0"H9\%&1#&@?_38:<-N9C2"5O77@J(_(,BX95MTF U:F
M"9 ^^71C,D"80F5BR8 ]'IBI'0>OG_>T$)1B/?!N+E)0%>>0^[:"/]\,&5!Q
M";1?6AW>W<JP"=\8L^S472C@V2<#^&^-X"!F3D +M=#OUPOOP^?KMEE86(^R
M2,TFST@)H\./(VW*P2X@HUP2/\*(#.A;8L/HAI:RN1](L68>--9Y&) !9\XQ
MC-0+\BN/'DC+I4MV3K<*;YL]R0?=HK??8BY*2ZGP8=$)YM/9#=<=XLT*__CN
MKRS6\UU@J)_BG3B]X;>EKT![D^W7=4]7K4A5$3PM:'HRH+?!WD,A"*6?_(AP
MB=&BB;FP0+PX^=./@^_;"_#5=X*[(<Q_-';-*XA!:^;[1S* 0TE/?1=N!"7)
M$QS\Y$L%,'$G9RPCE(7?X'..A?=8?H2J(+]_1]SS3O63P;J!U_T,\@;) #"K
M-9A(O7Y]UQEJ?5J3P4[1HL_#15 ?LD!?,]D]_#1I%?1R8C2)= Z]XMJ-:B,#
MKG"2 5\]/H).D\J%]S6B*@<_7R(#1'_'4^#6>B@^QV>9HDG"*1AZ$LIMF6#[
MEU)BED 4G'S%U^NU%M!"#X*5L!_4PLZI3LL]S+9!GNKOX[E]<I@"=DC^\"Y"
MQ^9ZTP:%/G.3 4LZK"AE+)M-WVBE+\6I6&3H[A9A5V5V""2["3+@<& L#H\T
M5+;9Q!#RY2,@3$LDR+)-ZA^H:1Q'=/[\4G^-KKY$F>=#=OW"QO.QW^RM?5<"
M@NI3^++B/32W>=8K8>VIAXZD/!Z'77CKQ'[QGATC6B?OKMEONU]D0',8,,==
MKST1*Z!_M^-J))]*YC-_0)Z^J<;[I/9^N^$\30T7S6%J)GT]>R8#O_8IA,\F
MZ4@%).,.<$V!M\$N.SQ-=CK@ETJN[[\58$8&H#4_FNCN>CX"8G<42FRWG LT
M (2+$C/ZIJ<F6Z[IF-6: &6(T@?()WTXP1>7!_XXZH;]!<(NY0,QKRJ E$<3
M.VNN-I=AO<RKDL=?+$Z:GPSW+ZN]B.NU0MUR-XC^Y/.LTE=U7+@.\H7ORNKT
M03RB;Y\'Y[MX S+N!=.$D9K%)_[6<"@T\[2&@[T.7XPE PPL\Y1UQ7TZ_-%+
M?Q1,T5)-*F';6_8-Z I%UE\M@Z5.DT8H"HY<0UQA(=GV"R)FQT$=_$C>K(-_
M6W8/^0Y*A E)%/7*?3P%+5Q<PZ0+0)H*(4<2/KU:V):?M;N_(VF.0W)7#J8L
ML_5U/:F+'E=HW](6#^+]^(-Z)N@QO."GG"\KR./@R($R'Q$9=Y^))!)%\[_2
MW*O#%JY3]94-;T&);MY\FS[T#60 Z.@Z1>D]2-! O;K0?/AO-L\4\=JO(M'W
MK&ZV+KI0-8N*'18XL.@ >X1M^ALIMK#D"MZ-7"^G."7LY7D?)=H29:DVE"\"
M=SKNKADXZT?\0'I<7Q@^MWVIXTN+N.OGI3=IG2W5]6FB:6ZW#YE=-&0Z LXU
M"O)@^?'59("D<"LHI/GFB *OE\8VW=V;PC;CFU-"I1=3E*UEKBB)2(,TB$!X
M8#,;&=#]9!=.#"X!';PW1DL<F+CE\&HFS^ R;N?1&M[/5^9VRLBDH,9BOZ__
M].+N&?8N?!AH%M13YF"_2'P"VX8M/Z_\G[SY>V89=EV!;9U#&A>S6_,LO&?B
M6'7(G2TB7=G)).#9F^K,"P$G,S0ZZ0X]E9 I1+O/ZU W:0.U4:NQ$H7;U0B!
MF/X;UGD[/5]^OO>@Q&A_?64'UO+P<C&W44\%NUUXVTY8,\MHP%W<<R]CK;KA
M1FU(P6Q'$>3MW>X;&9*,4![GAW=<8T4:INL@C $]"OQ=;19*2F;/A07G1[]A
ME</J#*.FQQ-B;>79XYTL'\H9(\<,?>UXW(1?5=ND;7MPYMI5ZC]G#6;2?T3]
M7Q2VF+_32:E ?!7>(/]?X$<;Q [R20;884<0)C:PSXZ7PHZR!!8:O*SB$7&D
MROO4V(K M/<.GX>;K^ T6SRR3SG;9.2#X#>#NJD@Z"<O2>[;X&M<SY&ZKZ3U
M?[N2 7[(9,LYML2?"R*CZ+FJZ*Z8\+@5NW+HE!5_90LC>'OS!LFPSRL.(QS4
M:,UVKP*C?9<,\"14^CXQH1D>.P],=W<S3#-VL&EQ1T\E;B@:U>&\%S33!9-B
MLC9TD!ZBD/)BB#?+V%7YHK!1@J&K(QQ(3UFJ26V6]PQGJEU_O"F-A[ W9H>Q
M3+Z7#<>WUD$^H^DJ=<,MV?UYS&H$F$X2D5_2*Z8U%#;+0(96$*HA)#TGC4;]
M]&#=09T3)/QGMXIN"CMLU6N<N7]-BK4KF*#M.0]CKN\N->E:,;6G;; 9%W0-
M%(T>D)$YDA@Q[A[/X1-[E[&R^=S<4,#VQD36-L4XF</&_AF^_5^5PG<_3T?T
M'P%ER8"WZ@S![B5T=Z18(1^%=@[I5"1I7A;'-29Z;)&ZN=3:3O/E'0+0'1QW
M?0<9)]>:1:LFA 3=BHQ96&"OPYD1R;VBJK?/>$6QV5>_>_Y:8A-F^_%MVZ^(
M:[=Z)!GFKHKL^V"[)/1PGNH.P#)VH?8I+ EZ]'(/M[:W>,O8N#IBEN-%JXZL
M[L$!J<DWPR(+-PUF-K=C]5/@:Q[:_#Y*_]U9./A'8VU,WIO8VQHG;POUEO)/
M:GBDY2;+<0F>GD4F:T6%K<@:2Y[:RBO!8%&V2X;.TO44)K[(=@NV@[5,EX1:
MNW 7]5H[<$Z3 5T-<GQ:H.U;?HA@ 1_#2*FK,ZJVCNSM76YQ GSL R*)TMW2
MBRF6(\">-_F&1A1D"]HGU2A RK#C$W$8AP**,X9@V U'5K /7ZI-.ZQMEW(_
M:*?Z6'<V:XFW>^;A#;C*KO_*YZH=9O,.[V(Y(U.)DDACR=W''[>DH S)DD>W
MOWR0\2N*]D6Z"D'S9M0OQTZ:_MK-C+[GQ?1U[-"0ZYU\L(E:K.3[S_GFVR\*
MS]A$OL2GG3G1YRN+]7B<%Y+&VKB=!#^A( .Q/O>=6^:KL"O"B3O/;+YWV$CT
MIS?#N(0YK#Y5KKG5BO*_IGY^I?$,$L[#T Z_:B>C98S>C3';&-7^UN;NU2K=
MW)TWJRNG__/]Q]O4WC<_7DM/GC?^L9%!-U*U)658F3@A:U/0;E5?5Q7UU.[*
M(34V+B-M?-5-7G)ZPO>YVX9:R>O!=-I'@5R_6F9JVP+$Q]6XFD9L0TONR^KT
M6A(A\'8L=C'==-!@W WE3(D+;]96C,J&K2=*LSY=LN/@25QNX_OT J!L'GFV
MK?1AG 56*NP>DFMW.W !).^XR5D?:E1?7Q56RIVBRKC3\T+MR[T+4>_;YV,L
MZ_%"Z=P1)@JP-Q/:D2CQ"S;2?TS'*N!9W!L?Q_;JD=X\DV[N_';ZHU4MSF%Z
M!7 KU($-':]0\G1BA4!:H-/8-RP+[W9TZQBW?7$=DXBQ8MP5G9=\+Y9!_0["
M+)R9VF5)/_H;F;5[(!DSM[YO*:;";LC)*-1_8H%N<OTE#<!:9AH*5Z;2Z3JC
M!!SADE^,MZX4?[V]9,,9[7!#77DVN[!$ZBG]_2,"<,Y+ S=J_N4-OF.IK*48
M]:;:R-';_<JSFB2]AFF>&"_ 9VLCSL!$JAQ'X2@)7W]3?WK@-8F!)/?BCCS%
M!<V<4+='9N+("\5,*OUUADPQ'YY':R!_F#^?GE65<T4IB;M^*"^.*;H(6+W!
M^ L_)OK&Y^VTS]I.GJE\T*)CT:/<.Q]C/G6"-%#372<ZX,(Q,]W]@YUQ,XL#
M.9_!A>O9PE/%PGY/ISWB?J\;Z^/"1I@SUD>F8FPN)DQJBM7TL?Q^MECJ4(<3
M<1 '7C[0C$@2M5B_@(_<$PT6VO\UDLA9=M+%/#[X?7)6L+[?QE$4E=9:_KCX
MKG17SX43KX,BW@A6OKN?E&_09@,8%/5EPO7+C21R'NO!Y'+\0;V$:"@&08C7
MI24#)DU'R0!5;O]],)6?% 5_AF' IY=,(:M+\&:'J=Z BSXP8#NL(V\-3PDZ
MEBU8S#_=6W3.$[C.10:XD0%\'25%T,.KD'I(PHNA?_P7FC"'#'%D-M8(#J&O
M$^?/Q17V*D8H&D*[,^:>138\X&]L\(YL"5SLQ4_ .@>OVI-88&H3;ND&>J$Z
MT=L3LMV..36^O-9VK0V:C.=-+E%5OEU#1CL,<^]&ARH@..KN06WO5;$&:RM^
M,Q#]<.'&V]>9G*OV, (_A-:_L'.%Q-@D/%@&,.T^LNV[+6)=$_U G7,H!94B
M97ISKWEINK/!W6&AGU^Y*OS6G-G,3&-%HNP3%0E:P+;6Q[A)UO*($D(J6GN-
M8ZN(!WQB%PW9@4V423B?\,VQ4HBX#H4%9PL6E1:C'_=56WCV2ON+]4U.]FA&
MH9HMB9*'.S![7Z&RW^PE>9MSDSW=Z0T!.D1/]Z.U?KM-Q[J6#LF$G_V&$^4-
M,.U.F]FJEVO0.1N8N2/1KL$=+;RSEO&JC2"Z&$"2/4#A5J:K>+/F7Y5OR*8Z
MK*%<[\T4)W>"/#-\5G9\W7(,)SQ+CT>/G+111EI;78/1/BMY-:;#61&!\2P6
M>YU@S7W)RX3R+71#!E'RX*\95>UO^<O>C'-:CB--K<!.-PY*^'BII.EL^FXZ
M@GKGZEK_3-2)Z.EV=)S+MY'*XKJ6>I2[*5 [V[#2)2]Y<+S18:^O_+//=N*H
M&CGJ&B:Y;2*21MJ1P[_V7-/I+/OMOP7J11.GI-ZB#D]1B,N^$U%,E_L,D9*E
M*Z.>CE!9(ZW7H,8N>9%C?_R(Z$:JF0.E]^:98DKO2X/RDH?':Z;Q^BXW)R?D
M!MAT]XYK=O],QI(BM2VHC[U0S9ZSOQ3)9'NZ'(+2<CU X2?2F<POE]?O)+[#
MOTXN*]O3K/'824)H-_FN3&>T/=]G<[ [E5*8[;WGL74B-F@QZU]O%$5I,&[A
M\'[;7];IC]0'1$[[7)$@3U2)F%/#,I$HUC=%G/+8F3U<J\$.5MD/*__LMYVH
MD9P8+:O7;DC46@0V#,J[IL_-\OX1NYGN5)-8<)RL!X&(W^Z4K]\W?:9WWG+6
ML_?F'T.H.^'N)**E E)]/ >K^(5J]ATIDS=UG*%,7H["H/T#$O*46?Y!\"<O
M!_H14@$-]1Y=32+&YI,-,"UTE5B5;><66N'A6DT>PG2,HM6OO:6.CM#<[?94
M3X': 0C%"FQV? _R;)[O*QS!EG=(FZG56_C#69S-7.6;;Z]>T#E?:JJ<69!'
M&>G4$7\_7(,V_!':T_])%LJ[JY.*#+@=@SI&GW)[=_A(=5YELN-*.[-R59=P
MMI'! M?T;76O\D%E2GQOR_6?;X&[G%W+*=.R'!P\.#A^U6/,.+$+N]#7'28>
M-@':$>C170[?(D@LRO-WQ)3]J.TK%-U5D_S5C#LX9E:5B*KGS?H@AS@*PCF
MH'(<*2'1F7(FWQXB1G*HDJP4O!@*?V4[R;M8FF!T&5&XAK9JUJ9\?N8QZTC'
M"<G57_YM9T&T^"^WKC@LWZ]TF0=&9HCLMCLLKR$[Y!3S>&Q-PDR^^%YD@G4V
M1O:$IPN_J8$N^:-I%],%E%J[3\M1XY!D!(5H] *+_C=D_6Y."#>%83B[H:0^
M474IPNP(52W^(T/O-.21T9,[T;)4*=L.@PJ\JSZ)90N#(4G7)2O,46O3V+KZ
M6)&8<P&:I4<'-V\'2)1(W-08F?S=KO'=;M\ K9.TL1Z]UWHDJ-$YMSU3H>C"
MVLLFFL#]_.75"[_F#R0D,964OX.'\\AXOQ>[*U%5NK0;87;Y0B5YO2Y.&]_7
M)G(O5=A7\&O?2((,:%F'*@\X#/KYSY^F&X$9)*&8= >-78WIN39BBMM$?<K<
M\HQCZB;I'7_"0.=@CZIBR@23#;^"34JID%NJ97^#V4I)X\%&W68S%T6'..-G
MXV^%@Y&PW$N<H"1Z#"GA3K2 ZV#?PX/2R:COX2<1[1!Z.5T78OG='V.'2H*A
M(5G1Z^L/*G2&=.M?S%\+,5P.T>%?0RZG;A@8,0:9P_'EPG2F)2::T_S<-7-D
MP)-/6>'\:3O_DL[]?U!DA$/(@#U].7XRP-I!EW@KX;C?CVX73=+@"89L"MI1
M7'1L\PG\VU]QC/K_,H[]%<LXBR#=1KM(8I [ _&FHT70XKM!+23P?W_H;K#*
M/4;(Q1GL&A\54:*KT^KA[,N-WCRA\OUUTQGD9;>&*.FZGOS9JH2XY><_?TG/
MVTC@*SB_VP_T796@CA#YJ2<3:^>*JI)(>*FBJK?ZLXC_<A##.:!]#$R ($@&
M!'WQX\;58?/]I(:CB^@.V[<<\]:3]/BFP1IU)P9T=:X?*W_</.KWUP7?)U"D
M$N3HQX-3Q?[P4Q\!&M4V5J>75F[=6W_I8';3#"2*\92<2<^$WG+O\#?Y+PGE
M_RWA_(U *9DVE(WZB=@XWP^_U.:^XCC_ \QS":;[=64-S&L\!JI>(73#CD[)
M@$K^Y76*$U'@Q$7R=:;GF]M)#<V9:@S-/$;%($_\^9J851\>K'SR4P6&5[(Y
M*@)4K:N?=^U*KX,&2]XBXPCG&SV@SRMY1 JB]>0O_@+],B[6>W5,>[)_%%G%
MZMPA')+22I>[:KDF"C,4"=.#H#7QR"'W>5@55P\>V;KA3@98$!OW&(Z?,*2T
MUNO$CVZ2 9QC/=\7H[,6";W[8F^R"BWMCUB="?YS*)2O-E\!(0P> O)W%#1Q
M"F^#=EFRQ5I?Q7W4VM<]P[K%!,O5=BPZK^Q^)Z;N<MYM(IUDRLS7'M&I&5/>
MK!C%ORVJ07WU(H&7ZA.NRD6B&H:)NUS^!-SNXR,2%;YM<*<GS9UFI*%<9]&<
MIE/XA ;WW),,^)2D0P8,AS2=B0]ZS[!LVCL/[5L)Q;[>(ZH,*S/'#/TOYVTL
MLLBVY7IJULK*$[K]]JWS(='";:=J_?J6W#MXG$!P-?]]GF,K]QT+,($7%HXX
MD,<9DP$73_Z\*MZ0/[^.A,I)R@F\<O_XT_!( J7K_WFU (1Y0C D S)W6A$X
MW4$RH)L)TAJ&*R(#E-#!D%T8C((=^9TWIXE)<^_(@.(3YWU0;71X'(E)MP.,
MY_ACBI\(9  A1O5?QH/^U0BXH6!&&-SFS/I.!@1?PQJ30A$4=(H!@<@ +GTR
M@)9G 4YD"& F UH#("2U[%-)A.UQ*'XPD0P0._WOS8Z7U ^?\L>0*I81?:0%
M&3Y=G#Z(&;+JNPLG7:/$Y#UEX&Y6 !\9,'2, 1-X5LB I7!0A<,1V OR?_XU
M)G-<."6L05LSVWB5S:(S[8#XZ</2/B7%-):]Q=<H6*5+>NW?4X427_="DHD=
MT_R<+?CVYMN[B6&% Y_CT,_;7.]V'2O)G+_M^W*BR3O*9!+_M5O]7CW%2ZE9
M_P_N#Z51_A>O]Y]DV&XZMP@;S-?&X2J)(#V*4YY4D./-"@?\8XG^]X1:594+
M*4OW6'>OV/2O"GX8%@*M!)YI<Y1L"*AF-+\8Z=2C=I>WK]QM+?BI/XXJSH+:
M#WGZ".W5\!S[,D4K@%7F.'1SCJT(+-L*A;!J_[C:JB\:]%ZM4[ZNY'Z'AM%+
M#?/"E7H<L$M&M5V7H:/D39RV8-PO+*,+E1*?3)IH^0-JM>/#$CQ%,8&P:5$O
MABW6Y@RW68W?^ 7O!<>'Q2;),.X^K>WW_JZ#53[46@FI:OD-?Z+W4[&8<<12
MD9<#J44FE!1975I?QVY&TJ@)06Q>RX>L]MIOX,<5@BR>3+[LN<_7OQ<D$WG,
M?#*+$48YM!ZAJVF]:)W#+!7&Y238^WS,68QSAZ;["\+2V5^BKK@Z!3PY9[5T
M;>AW<T7<$1SGZ?@.6YT9P!75D_;\80L-L,^X$Z_;1@9,E2./NL<:WU5/%Z(4
M;9SAJ,D34?^O]E!7J62>I,BM,_I!*VQA>/V>TQNG/N ^Z(@']?.@!XH=W-Z0
M4(B=[EE<!;AL1/QT8TIX)^=*:[F)S'V;=5V-0UHC!U>U 3'CB%I]9:8(6LM&
M>FWNU[A0==+<D+N@V* D^FU-+'K <,9FYKL3%:?T8/ZW2RZSBN*"XJX=7'S/
MQ</G"[=.IQ[^[*3W%U&R-.NRKQ%VH44]>,ICQZ2B9&-'E^8: S5'#I*N$Q.$
MY4"[B'824U(GB\&,P[7B;N^R"*6RV7BJ!EP-W<P[3?_-,9^:S6S? C_6H<;K
M&<*UT3O:]:<&EN>L?SM-Q0]L;EGD.;,G!8:C$EEPD2<YDWA6]>S@!74NM3FC
M*=8&@$59&J^\SAEICGC\+@@8T%NC()+:<A[(,C.5%SH?/6'T?)+M0^!@<M1,
MF<!Y46G!08F=-PWZQJ5#-$M\7+%5Z3W:AX\I?H[Z_V5@6D:C7$DO!T_]R8!I
MYKU#_[!34R^AE8X4IT#!F%G/UT=!/S+D.ISY;P/!\2^:0;4UB0.O0[PR;G[!
M9,=H_"#PO]GTPD$7RF5X2__<@4J[XZ<H[FD:[VR;^S'M07OLZ9E)WY3LKQLD
MFM5RD]6DE,APXZU8:JC\L-C@@CJA:,1>UM>K>&LQZ,($KXW>Y_ '3/1!W[_U
MR;SW8M[GZ=36\\I>7 FIG(Q>=6.7]%=Q/K*T659A:![JPL*]L:'A;QMEL\%@
MRQG!IN T0?F^3:]G^K$*5?LT;3&></42KU&#L,PQ.777HZ^8@!^F^:ASD.-?
M@XN6KV3*@^][KQ']H'#,#%/1BT7)RFB$!SIL^IF# VV%:-N-5P\%KKPDVFOP
M+T$G>Y ICAF9%\.W!^;6[\UWR6FL0\[R1S7CC,]G]+O/$U4@%^R!7JH.I[TW
M=;\GMF^V'&KGS374\RT^5'UE*Z-7@!7>/QV@HBP+IN#F,IJ01MO+'!Q8K=*K
M<Q+O)Z:_< 5R5V2H+<8[)ZNW#)YOP"\HW//C' [@04UU>W'TFHS.:.?93\QH
M.]R^$\B>_/X,'T1C<XN KN@X"C&"6>VSB@0+1JNQA]CG_1IQ01>D"SM<7S0P
M'"8#8,G<JC;7\Q8NSJ';\,^FV_-1+Y.?*SLR'GBG1I(!Y0W0*C?+B[OZV)*E
M$0L6Z),JB)#%IR(+];'."TN\OV94>:0/X0[E%4&=<VQF;VRJJB//1?/&\]W%
M V2,2S[U$K,,^;8F<7TK80H%^I@?X7MFS1'=GJ\CGA-HL KEBA-R9ASQ462
M4 :P\O+BY*"D*^YV:0CR2'?7KX<^?WJ@G#B0731 ,92?>H70GJ;"N5G!H7-
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M@"J>Z%?Z,/24#QU>1N TW" "ZL0\Q^7XJT[HSA&4(MYI<4/'^:J=2!)=/JI
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ME5XRZU=MVZL^%XD\\MZF/_=+(8K"70-3#C5."R68[>T="@@GT-9>ZO""QQ9
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MG+H><+L)*T_LKD1D=*D$3U]H[FGA6(['S#2+LMS^<%XLR)\?1&(DRJ/<)L@
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M_1N4:^86RK6RC/*^V'U;]-46*I(NF*-!4]LU%3]C?\93Q9\_3)\GC5!6Y-H
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MM3CVMM.5:HI;IA^FOU'(4C7V79<UB!'2X&Y$1F!L;W>SKSPTN:667]^XV:U
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M/\/N=#[:D-1&M\('QI/S!OST:]CC**AO0JOV)O42 5R,]1WNX=4Y")(;3XB
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M9,2X'I7>G=[@PO[[!'0GI7TE9%5LNM4S]B/SB!,;\D,-._O,7:+WVJS0$0W
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M#G>.)0%]](>XE0CV!W-*R"VUC6/[/NPHN2XVS]*=^TR[3$*2MH47KN%X<Z%
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MD%57+< &8J7T&ZKHSL 64T*:_TV&\96-Y(ZADY74\&& LJO+D>#MVC?WD](
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M3;X/J 7 ";>#Z\EWR)U+G80RN>#,Z\G?/B\UUM9&$!G,\Q%#V@B)( G<S^-
M0F'1^-%0#>Z=LLQP19I6P]N<\#_3*!K:.8+04(?KC'87D )/[;P(IL.).HL]
M'3&N6)DNJF8/;LB8>9]^5()\/>NACYL^?Z:-KA#K\L#!N[R/Q8B\PWYH%IR&
MOPFXCB\F.>22ZJ1:R#+SM7@U^I*OMW$K,@ @?6ID)7YNXM14EX*1[4XQ8XEW
MS8M=%B]<Y8P@;LT8^Q9'0UOA!]Q115,_:H>3XE7+-MPJ!O#N(8\]:>2'^+@$
M21:LB7!]79E7,AT25*2Z1+EUNCLRHL&3412/'VWV)0WC0,<DG6EBO,W[+[C6
M]^?7=B0>5LXT[9-"I1?@TWG/L;SFOHU7CM]I0KN]FEV3._!F=W#-^R_?$4@\
MKRTH+1ME;C';%Z#D0*)'$1C=9Q T$BA3_$^WVDK;;=&&.=HQ\")[DLV$-SRO
MGR>4J"TLV#H3Q897"SL>Q#S''ATR^W#!^Y<[XZE>V2JJ('X/ 7T[E"@7(;,O
M3?D:M>UF5]0*OK1]1@Q%*Z*]$+VT,]H=B3U%0R]+0+/5:D9QZA4 V*>'\E!T
M\H!FS5-W*LEEGX6Q&D!OB'5QP5/*]B(#]7BETA-ZAX+<A/?A7Q6J9G:T2D%O
M/+)@3M1J^\J@$?,O;DQ2HIK;I-#JG"L$4H$"*Z%OTMKOLLX5O;2D;=I60"QX
MG.J3CT?2 /;V=&T4Z$..$4D7<K Y*U:<(A;X -."E1H*4,C?+UYB%-(0R8)Z
M'B$*6L"5YK[!&C5C(BS*K2,W;%\,/F#-IA:G"XIQ/RIR9ND180 ,W?._\&PS
M14<M9:@"^(?5A@>N%@ZS6#GL]W'U\:9Z,0!F@[W]AB8R5!D !O\2$ZZI<?6\
MZ3#&!6!=2I^(T8)Z9Z-T!<^$=MID0,1*KSGY7$O8L3_A&U032[)PW(QP:K+L
M-DO^XLKW7N;#RG=#-;DK8/PS/Z]DSW@'!K_HFZ_K^P@3QZLA?TL/"*U>YTT7
MTOJ]Z*;WT-T:_IMX^%_.:2@MPJM/GF@![X?]6Y^OQTPF_3\6(# 34O6OCRY8
M8JR;[HZ-G^=FF+/\/4XMG>::S; 98_>G05F0UK!U8-^,5^E;/F2JFLA M7Q&
M,X197%*\G6)A><(DLH7]Q5*9 >/B%P/XVJ?RHD-I]/QU$->T%02%'O#PO_VU
M;9HMK42\#_V\_WR#\VG)Z"?V-V>,-^RN1;%YJ;H"DX@%P()]?*G)-?+>%(*Y
M@?_5H'<;E!Q0YQ46N";C;U_QJ%@#TR'<G;;Z]%[>)$D!]&AA'H76;,82KN@'
MK^-TP86,@8O..?[.?XO@9,%.2A%MO^OK$J."F'!YK4;8['-IUWZCTVOL@3B^
M V7E]'Z=FC:?5KDO\X@M6Z#HA34_; 1.KV2[!(Q,!;Y7XESZ"*=0]7-PF7F:
M8)K$0OS')7%%?@95?#%XA4)XC\6AF+*K2M1C)1C;ZWTB0^TK9B,NT=OE1OD)
MN'U10W3\C9B!9!+UQ<N']).(=/=P!UU43<)78Y*Q1+TH9Q7A-=>9&>.&X2M[
M? E@L##[(UW>#^&]H?^5FVCHRIAQ"L28=L<W?8^28-7@)@AW@9W%:NNW]Y8*
MJN9&3[EA&Y159P#A'VT4%[/S5(=9H>^H"TO*GZ ^R&PFOIY[Z!'3V.-U,E\?
MUE%A.*$-J=!<"^IEDQ?)(K\$<&;3?F[CV !7#_0&%^F59-'!WS 9">K5\YS.
MXA;=LW2%#VW;Q3>P.*MN1YCK%+1JY;3GXTX?Z^R VQ7HX#RPZEWZ$!CGR+V5
MT<]Q(17'Z3%A\58E$&*SOA6UG%N^%'D "D#F/Y4""K:/*'5GWGDI8>?8.<KH
M-E.NTZ4V#FPWBF&^;O*][D?1U*W50-U,_1CD]N3TG!PF)"M62=8OUUKJ(_6/
M'0_V)+FS2/QY'8X]'\I.J%%B=2T84.J_TTOXIC'0SWO>APH$:Z#[7Z]QLR7G
MQB8K-VX8_MNH)"D[ <1I. 'QB_L4_^2-Y-3D3Q003[_7C@+V^L>REVHL!]^3
MV=R6^>Z>B#NP-AEY'0@RP0V<D^$>H<F[E2E[9"4T'>]\*CW1IS/5S7%C/NC
M"V_0TJS+9#*/.-<,*%-Y3VS>8EA>5&FO\,[/5E8?_B=A^'\%40@:>'T#)CN\
M,E+K+[<GPL\BS!/:UU".I,:+8_:"#_6V*Q0U@YQ9M11.;5>-)D&U4\,J'++!
M%S=QUNT^)LQL,HG4Y0?]J\U"5&M;EG^)E<&_BX&$7K/F'(IH11:X;WTEF%]M
MX>N:5L4:?6;[7V+QKZZI7^14_"T)R;.#>F^>/GB;P1*2&YO4/[H;Z?6XHE:%
M\RZT:\/L>7K)"5_^'V7'-$()6,B;ZYS.A:MFFO:)APZ^F-O?P&;L5?IMQ#V<
M\"7@-I(%/J6*C$,\M6&/W)]_C]QGP\82/IB?4@QJR@Z,H=*L!J:.0LYSDU.1
MGD:EO][_-SR.0W& ;: /ZI@E""]=T3::N2/ W+ )L]M<.#>[E2RR0JA6KTEX
M+O(GJN27S2$?%V2GK/CQ;VU619\2P/E2VXW)-A;\(YP85K;GK"YE84>VYQVL
MU7WMD?2J1:>W$#J4*ZL" "6XEJI[V;FZ+SGL*3U?E./?MQE/D*=>>4]W/Z9J
MH?C:[FG8N_.\XZ>XYY@A]6KK6S@M7R]J-=\+Q]37?OIPSU"^R Y" MS>V;Q+
MP37:%>I>:-:K9.!_C-QN]^$3LE45DD?O)N(FC1:0TR87C"D]CE#MQ0JGS2'U
MAE5+7C=Q^_VA+17@XSP7?7BA\-K03/6#-JS ]M:2/[7"!&2FI"*#CL7$0T8U
M@)QM)UI]O_0LV+S\VI_M_>;3S[U@-L!IWD+6=A)F!+V8',1?L;#E,V8U#=V3
M^@[TEO\^:SE-B(/1<=AW>,-/QK+PQBXX$[1Z&%X33;E'@]+C\)CF]ND <*SA
MA8>-@SWYHEZQ 7HP\*!#,)&#^P8;31976E'OVZ_=ND1X3>FF4@8;SQS=IVS_
M,LQ0C%]LH'(?E<]Y396?2>;^UYSGYU>H1MY(B$[(=U:@V5^H8;Z58D4WEHTY
M*(6(9C7,;=Z''*P]&(%Q;R#K?-Z;]!GF5]]HLQ8)8O?H^+YGG0,"8UN+ J$"
M<,2L^8 /8^JN[XZMA(;*6F">].E! 10V<E7DI^<H&D9K".JZQEFN*7 7+/U[
M^2ZB'@ L.9LH@F/YJ$1(;NB>\J;6OZ-UTG&!<^'*;J5M_:/?/Q;5MTP@M-V9
MG%\G*Z9=*R86B=/)^&QC;363&-*J63+O#Z]FV.J8#6?$$)?_>!N@,-&)GS%7
MXLH0MZ+&I+0KB,Q'U(8F_U(T_]XK,CAE(2.WVKHJ]]B=AX88(ZY?.2#\4'R$
M[]! U>$E@X$J@-%L:<&L=W?7.S@=?5@FK?ZT6B$TR\.YI6NU1&5KS+X5X.=5
MOZ.ZH+@70>_+0_U2LH)GS?&\N3K*J,7_7!?'NU@?7E/!;CZ>^_Y$/ZL_FOSE
M._IUX541]HL;0P&%%\.Q:!,L9]^QV0\!H!R-:3JZP(*0#U[(1(7UZD6@P!%O
MO#824 */&YYS$(<K%A]ETS9XSAI2F_6RESE>^_JK.<_]=[ )LZ+:NY-*VW;8
ME7OXP-MY]CI&E*_!W/09]^!;7Y8!SQ_7]6_T[SH0C5WEPF"@V13(%.GH^F;$
M[\NZ(&/?L,X!>8&H TN-@88Y Z#&2&G(R>D/&3? <3I(1%625%^S?4!">RS"
M,OV%2=F[ ,B/-E[H*R;O^E2?L(HLH[$)B8YL]F%_+G481%[G@67:<)[0OD'$
MT+SOEE8=(>=%R&ZN]:% Q'0:BV)*Y/&C)6H)$%D>)'YFP!J+&*AX] 0+*\-R
MSUM.608TF3BR24<'S328H.9NXHQ?E#F\\YK=U.3LC@_S_7F?E[?([."KL?TS
MHU50BL)/#,[A8;X0Y$>L'HAGA%S H 9X/ WO3;L$W !%PE?OVEX"@FY<2/\H
MZ@#29B$I9<]'9''CX3 *WV<\VHX_;_>"'(%XR&_#5/7!.]KE7X;AG<8Y"'S/
M/75"BP!N%+XH^OL2L"YN=PF 3^(AS!<,DQ_\-VY= N;[+@%+)?.80CSO)4#%
M]Q*PA[X$1-,8;4MS@%&?HF-QVC7@,ZKG\/FC2P";&M8[;!]M^FWK$@"^NI3X
M2P"%:R?XD#SVX@*,&[V#DUVDSKX$V*JY><2*7P)PI1:C9C4R7S?\*^9_U2.@
M*L.> 3*K6^>Z(P_HF$[M#7V!9OO :>22:FRD]!XCWSTF3==48Y5WE:3FN"$,
MG;)KEYC]8@6(W;\H8.Y%?)OU0%D/TCXK>$X2@X@I:JY- (K^V,AN(@T;E)/?
MLG)V2H)5<QGO9ND$=RS8I8P5K^T=@]:MF\2UGWQ(CKBQC*X%M7J@_UND_L3D
MUG37O0.)/BJ'5SXN02K] IA*#SWL?)CT#D@;YZ4M7WZKKK;#?07C?E(=4UNP
M5"%^-$3KA'H++=P=,26A__WM)NV6=0J2'L^+'5U0#_2*I9R>ZBAQD+2HJ;(H
M=]F5!;EWZ9-O!A2,L87DF\A(J$LWQR8\5DP*JRIIZ8E^JT<>TT*!W\7I88N.
MTT:N#-BS9"ZJ$1=G.JI[U8_XMUV484XGB$ P/4S6M[X7^ J[%GI/*N.VS;W7
M]6K6:5F& <4D&QTCC?#P3&J0 @;?9#/F(C6R<'$\%0C7AQ1&!ZM==^Z:N/+%
M)SVF,"J\_!C>P)W$0MV>7OZQ85]0*N T93%L&U[F"&;QRGB([DXM19UJ5L6(
M\U.ZZ:+.C71JF63<S%G-GH40[[D<863#X L%J4-1V0EK*CB_,B<,\=-^9UM>
M6ZX&A *6? >+I=.+?J<M\*&V6&1)SEE@._8+?$%N  #+SP_L98F36QM)+V=Y
MQ1%Y  ZRIA.[$/9EFK<<.Q2.)L.FV3[_DZ,.-.;E:1621C5DDU]Q#='*)8"K
M3<(,>@MS9S[<Q9F_S6;.LK6UB>EU(N=]Y:T^Y$M7E(<Y(9<72SV(>/F&M +]
M..Y;DIV^Y'?EK74XIT.J2_/B^=3>3D[+8[+',09Q+#Z(&*1-8; Z5KTG3'#X
MD7/9C^WB!LO/.RI S8M1:Q8^G  FQ0PKW>(H/5M#A>D3F!69,AFZ!%3K[7!B
MS9>.2_+U2AXM'N3.DB8E#Z(]U_,O 72[<OBR D(>B,^7>:FH@V",2+T$& R7
M[Z;.H<\%H=A%-1\W7T0RC'K6D0V^P[CPTSK$+&2E-W3K>EO]=W[IV0.7]J5
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MN!\[5@&O3W\QC;+E^=)<G]S1T, [(L]),=O[%57TJPS)B>\EZ7?$5-B\5-(
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M[H8'FO11T>,DK@1E&W4-E%AP2:;=MLG $N();GQ-[//+(AE<O =Q:1;2AA2
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M5:+\-GB!<MU]&JX,0$-N-2QEM\A3-"6C1.WIE6Q.#'="K*^Y9_%/R-L0CZS
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MTH\ 2=E<Q<6H- 1A#GD"M$0_8 "8N"@#?XQ]XDHGC:36I=T=HEW-M,/#\ZL
M1>5.GEV<C'VSBK.XNA144'G!Y%E8[\-#IA8-DV  D =;5!;0O [0S PBQP#\
M=9"\OY<2$**K"VMD +BX*88, &AWAG(<T97P#U+^.>;6/\P9]/=RLH[< _>
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MGOZEF59<7 _J7FQL6HUN"7P-Z9[\P#3,$HBJHTNX@06Q8?[6UOXSERM/E5+
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MQ;4)W_:>V;<Z<4L'Z/_7BE0<[9O]]GJJJJ!,F.Z!+GP,<A8M1*DR4^>+++?
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MYQJ@U]>; ;CR).LGVI%6<<A7 10(.4"] ND\UI!2)M6^ I6,198'UJI N)Z
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M,]@_NUF%W3'RO7@Z8/Z3=G/I( -@+P^$+LV9OJCA\.@Z\][2^AN\JS?+;CH
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M(68BEEAD$8<X#&.(TRR$%$4,$JH$RX*4<HQGU?J5G\D%_.US)UTMPD7C_^"
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M"I.$)]JLS1 D.$L@2]- TS]+0\IG>]5JSGX6CF)8?2IV%7J\IK7GWZ4 5*\
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M2JR"MPX]?&JL8V0#1KA>P?([L-DQ2E\P!B8-:QS<"YH?4-A7K?+M1X];AOR
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M*-1@JUY'"];77YAK^6[QM*K*]Z8(:-@6,&$J3GD493!*@A!BQ0+( L5@$(E
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M?:=^T.AI.]OB'TK7V?G]R)&Q9YM3O_DN"YZ7LLX$_*0W0&I9F!MG""=!1E@
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M2OU?J$TA#AF.0VT@,98Q2:*8<!=RL!QW:F319"/P;;G!7(OLF(1JB[H==0R
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M7PXW'+R_4/U/+@&M )/W^<)$P1F#]NET7Q%;<)G&EB420QJ;9N(D))"*2,"
M!G'*HD RQ%MPWRS$>-!V@XT"K-2VJ#](+4WZBT :VC6])=R_=.[HVTK;<6S5
M)/972W!'"Z]5SH\CXLO^WA]@7//ZJ()[UO/Q*_NM5%_H]U>%%'GUBA;%LUH6
MI@G,[:-9%&<RU<9OI@F54M,@+"$*DHPBR*.,<"II'!&G$I,GQIJ:(6SR&GDM
MJ][N;X2] ;06UXT*3F%LQPF>D!N8' QHC9C@U0YHMZ=!<R8$"S@\,<.ID4:E
M" N57W*%S2U3:U'X=EDHF5<K_5K^39I$*BENO\J"WLNZ[]1K6LEU-<L9PC%#
MD=ZMHP1IDYH&"&9QED$9I DF6:*RR*E$QC34FAH5MK*W#0XOS0":!L97[X0X
MU LQM/DW6I_$+8!N0 <1:#%JNB@"@])6A>(_0BO%/O,^^4:+3DK]#VG#V&<B
MQVO2V$LZ-UM R'SV9E'5<NAEB-8]D_2#Z:M58;9_,T9E&$G.8280@U@I 6D:
MUOTK.$:A8&F6V:S.YP::VGK9R JVA#5$14$KKMUR>1;=TPN83\P&7E+ZPF5-
MZK98'*#94O(_WR^__JP?T3"L_LN&6,\^>!2JLU6O(Q_KZWMN#6@=TV;<%%WT
M0\UAY;NR7$GQSM34TT17G_G. I%2P:4I3A5K SXRE9UQE$%3^$Y(Q!,:.15Y
M<1E\:K1A9#>^QMI??M,6?JY_4&L \EJ%"YJ,NTR,I7D\$-Q#&[$MTI\;I#<!
M?XWPH)$>-%5(._D]&I<]4/-E KH,/:ZAU@.4/7.JSS,NC<.Z*Y9Z*UP]W^E7
MS)05-:;9D[')FE!US+.0!9&)NS(AM2@RIRA) &-*,I'$VC)R9#C+@:?&;IVT
M-Z"6MP[R64M\:=; F3FP)+,!D!V8R"X#]8(X*3N$O ='G1GV2A%1=F <#X.R
MO-]7HYYU@8%7]"FOZ/R6Z5VD)L69U$87#HT/56)MC*59"(G*,LA)$*.,B @I
MJP H]Z&G1E:;9,7ENNX&K6M UY_8O"W*D,OR+Y=V]3DZ&W:D-0S& ]/6D3X_
MFQHGK>C@]TYXOZ6,'1$;K/G/T8&OW 7H'"#GVP&=?4+?$LBLVBK3_I7F<T.1
M;Y>%,?UN.2]J,T]3A"RK6Z7_O)W/E]],,(>^ICD+>[\LRUF0Q!&E+#(A\2'$
M&6*0J8Q#1F0DI9 RP4X'V[X$FQH1MI+KK[,1O>VS[=[.S-O,V='B->9C8-*L
M>VAL=+H!:ZV@6A;0Z'4#NOGJ5+L!U"@'UMH!?6UW1&\4]%FIV2_DWJHX>Q)K
MY K/?L'<K_[L^?G]^/S7Y4(^-WTXWJX6HFPK_H0,1TG$&,P0T>Q,B8 L22.8
M<8P#$F>QB&,7=CX\S-2XMI82/-9B F7D=*/8(V#:$>;E$ U,?PTZC82@%O%\
MK2EG#CN-@B=&.C+(J/QR6M&7;''FZG[?OM[U<FUJE6^U<(WC[B4-;0C*T-4L
M0TH$E 10BE"S@F0$,AI(& F"N%0\8=PIV,=5@*GQ12<_,-,+RM:G_7AY>S3G
MF;&CF"'Q'M[/M@5U=WQ@89'YHZ:^Z'DB+>?A1Z6SON"\)+K>S^E'@9^DZ3$F
M15?!N"MXB!0.62AAF$F3>($3O3GE*40\EBAA*N5NO7L.#S,U.M-&Y^IQ-:<F
MRNNU5#G/'8.LCZ!I1TZ78S0P!74"@G65<?_FSVD0/#')D4%&Y8O3BKYDA3-7
M]VSO\/@T7SY+32C%UYS+PY%@'Y9-"2!1!WV5=3[=]N]?+<OJP[+Z+UE]DGQY
MO\C_VS3T6?*_MU%@,X0(2G'=/R>1$/.4PRSE'*(@P4$6121,G?Q<HT@]-6;Z
M;5&LY6PS%TU'!%,(8CL"5C8]DQS[(8SR&MAQX.0F=V!*/1BCO(F]O %K7;O0
MY4:'&V"4U+^MP+/>C&[T])_G,NJ4^.H?,8K,X_:C&',:]OI;C#IXSQ9OR\?'
MY:)^8&MVX92$4L4(!H28N)<80TJ3&,8<)3CE%"?2J1_&W@A36R4: =L0,L>^
M:WOHV1'V19@,3*X='$:X 4S5HZK[ZG"V]_QQNY<=4V^O,]G1"R^-:[.B'7,J
MP.N_F6H^';'<U=GRAG*VREDE& L4ZVULP*@V16/%(0E,UEZ")&8L%HPY[6H'
MDW1JQ/)Y]?A85W]5OHW/X2;;CK\F,877-C+;5JNB+7M6ATML&Y,C53X;: :\
MAP#ZEO-*,8,#P7T\R'"H 4?.']^-Z][VSM9Y;;,L%7% 8P*9,$7<F,H@$0F'
M(55A*E,>!"IQ:]LXE*@N'#52Y\>7&2>TD[F.&C'Y)W4(2?\,E,%FG>(@4F$,
M>2RT;9'6S?=4 BE109BDDA'B9EM,8,Y',2T.S;-:F;11<-]T,)[>9%O:%A.8
MPA%-BYZY^'NI3[<[KT*M\02RZBWGY-IY\N?$_&-DOEN"[2V7W7:\2S>T:Q?9
MINQLO6_^;9%7Y:W)@M5[J]K6WNQCM#6A,$DPS# .F@(SA* 4JBCB692@5'#5
M;]/:0YK)K1Z;C>G_S]V[-KF-:UFB?X41,]'7%9$X%R!! NC^E.5'7\]U.1VV
MJT],U <%GIF:HY2R):6/\_SZ"_ A46^  IGTC9D^Y<P4B;T7Q,4-8.^U6^+8
M9?EJ\NS<Z+H:[3)3H2O.GO'OF_I;^N7;4XJM*_6^6^E,TG@ST$KR"F2CKQ:[
MV/)**\(K8#N]ZKOFIIWKS1:/^CO_^64QF\J7[0/*"J*$RA2P2S0;HUOV!%Q)
M!0K(C9($%SD/.HH^-=#86+*R,[&&AAX+G(32C^MB -0SC6VQN4DJ*Y._ZO_V
M0E*7((E7Z75\F*'KNLXZ>Z2*Z_SGNR:Y_=#S9UUO)[F8</_KK#(M(<H5@-2&
M5EC9=;PHF 1(Y"I#>6X8"^I/<G'$L5%$;7#2LC@T]>T2QGZ4$16YGKFC :U7
MPO &)%IRW*7Q!LZ3\W3_,&7.]\)NI+*I+W5%2&UUT]6GZ5Q_7.O'U40I@XU3
M@Y<%LK2266XI.]@+C 2T?[ \$[1V\QAS;,2RK:AV-N]H\JZ2OYS926EWH/"&
M#_I^A!,9TYXIYWHX@PDH *!(%.0SXJ D% #!/@V%7-JQ@G%3;K.M#*BH;F*T
M2IDV&5"%@"[W5@.N&049%!Q1Q2F365 5X\FAQD8[?UQ?@W0&5S]FB8-6SX32
M JI=1S3$4N@R/K'*'4\/-&S)XT6'#\H>+U_1M3D07^NM/!47E@HD*;>66=5U
ME\D\ \95-@J*<E*$283MW'YLY+"QKJ/HURYVGMN^G1'I>Q_7&XP./5..^1RM
M7\K.S0?NE7+,L<,^*4<_U3&]N5)&_:#M)7Q6WOIVKC[9.9A]YS_K#*[?]5R;
MZ7HCX,2IA@P5!FBN$, FXX AXR1G4)I"1A4L@M8?78P8V\-?^Q"HFM4)?C]F
MZ!O4GOFC-C^I[;])2@_*5,+2AQNWM]JD&"9O:D=^ZT58ZQHH8V5M=S%AV,3N
M*T ZR/V^YEYCZ_OR7^4QU<=YE6SHT?I%:LR$P99.<PDPY )0#B& VN0&<5UD
M4 Z4Z!?;M_%E!E8.C+S]2^@WR#-T'(N](WKK#-<$IO[BV>]=A=+_GSK!=)S_
MUTYRB^[7KY$5U]=T#M<2IJN!W2*%VU(NMPY1-D$Y0QDJJ"0 944.,&8,<*93
M0(4@2I$,LSQH3_3H*"-=]-0*PH%KG^,X^KV[KD:GY_=(9=]-T^FEEU7)60PB
M<>GQ,0;EM;-N[G/,^0]?>R+K%( _U0K9+Y^M^77#(J94(3"#H(!.U1&Q% BE
M$!!(\*Q0W'6$ZG8>>V+$L?' ]OAP5JI?-S+B+S?)7*]=*F=M>/*T6(8G@5R>
M@= SV0BX#G<BZXR]23YM,=T:W,=Q[ 5LHA_&GAKOE8YB+[A_^B#VTH5=A<&-
MMO=1W_G/BMR.MKY=?=4K;>_],#$IQ)#R%*3*B2-A 8'@]G]XF6]&"D+#"L8"
MQQ\;,S5VE1N'2O_0LT750N1(!^S @]S0F?'CJ![Q[IFQ&LO+C=DF #K1-]O^
MI?$@IDYW)^BBR7&'C3ZPZG8G: [%M;O=)HSZ5LOUY*M;%-[^G*XF(BM8!G,*
MI)#:U3UK0&6*@<IRQ:B K(!>O5MV[CHVFG);W-/5>BKY+/G#ODB>E_79J3/6
M\QQY%[;S;-,9C %.C3O@X$T51_T^1P#V@M;#;W_:/OB[]QKD<3YJ?O.0'O]C
M]W8D'^NJ^%(>X6,5SJAWSTL;Z[CHAJ\>[I9?N WG^:S^N=UF46'!F1("Y!02
MX&I@;!PB4\ 8USG4@F 3E/IQM45C>^0;9Q+IO$FF<SE[5M6.,)?2Z:.LDB?^
MTJTAR75SYQNI##@CO<<N8IUL9J3T)FG<22I_DMH!^QPEM4N;7_723#,:OA'[
MC5QGS^"-1J+ =ZS#2)P;=^/F<J'YL)BICX]/R\6/\@792$)C;,D52P4,,L15
M=0O "KL8-(5"2A8$*Q54BGAFK+'QZ<;49-JR-8PZST'K1XJ1 .N9[K98M<WL
M0<S0 XY(['1NI$%YQ\/E?4;QN22.#G]+BKY6HI\PP7.A+$=PFG* (>: IQD&
M4&%94)%!2L@UFOR'0XZ-.=KZ_"J&/O\1E/W8(RYV/9/(H6[_FR.=#DXGT5PM
MXG\:G9X$_8\,^*KB_J<!N"3T?^;*CH?B]9+EZZ:+XF>]KL_A)D9QH50* 2P$
M Y@Q9J,26=@?:2$DAU"$=3T[-]@(R:5:RW7M+WD66<_3\DAX]7UHWD"UM?-B
ME\?-$7O$<W4/M&(=KY\;:MA3=@^G#P[;?:[IV$*M2O]9?5_<RO]^GB[UL8JE
M289$*HQQ48M6 &<0 ^Y^)%)FJL@P%UA-YOK>T9P?LWB-Z_7(L.J1:8_>WY/S
MQ=[HP<:0JUA]TKS@]R.?>) .U!&MMC=9+Y+:XN1H-6/$#F@A$,5J>^8UYK"]
MSD)@.&AP%G3QE=6-54:B2V-<S-V@Y8D+-YHPJ H@4&8 1CD&5%,$D"YRJDBA
M).>=BAV/C3:V,*?.>MX:&71TY0>P']]$@ZUGG@E&K'N=Y#DD8I=-'AWK=:HH
MS[E]LJCR[$7=:&.3>-PZT71!DXV4[%JLWE[D)%4T(QH@P07 !-LU4@HU8) 7
M0E"5YU"'L(?/H&,CD;+*X8<S.EG,$^Z63)6YKB_$-#"&\4+=CU)B8]DSLVR+
M15R630-A_,W=$%@BT8S7D(.R30@(^Z03=.WUO:B;0ZL[\V5IUVMK_65FOT!N
MT$D!$:6$<X (80";@@'*,PZRHDB1R7/&1="YD=^P8^.?V_O[9;E>L\LHH\NG
MYFDYE:46[5-C=*T9W[WQ])EI\%Q110>W[R753I/IS3&[1;4V.ME8W4];Z<LH
M]=!,^LR@K]9"^C(0YQI'>UP]</%U70#V_J=>RNG*+?;VJK_JO^@O[CF>8(2T
MR:@&,L4VR#+* "$+#91E.8$,*2A+!^FF$6;WV'BRMC[16_,3OD[6#SK1\U<N
MI@[\1GBN*<<WSSU3=H1"Z$VI<\O[(U7.#0))"<$(RIN[S=EK%R\'6OUKE"9W
MFXIHA<<=A^_<:/9IJ1^L>=,?NE*LKB39]@6/#8>JP(8"C(L"8 4%H)@+ *7,
M)$4IHIH%]I_U&GAL;Z$=N\O#P.#>M'Z ^[TC^H"Q9Y+?1;"R>1B-QE"PXO6^
M]1MVZ):X06 <Z90;=GW'(%W?.V;\JLL:WOG]\8>%:<(%)L9I/"J 4RQ=8IET
MO3%2B5*=DS1(\MYKU+%14VVT?:3,8OG(PRN>_;#V#%YC(]AWZ%F#MS%X&$H*
M@BE6M.<UYK"Q6@@,!Y%6T,5=V_#8)UBOUA71U5IPGQ?S15.(_5FO)\H4G&JB
M@"&IL3$2@8"F]D?*C8*,4[OR#U*H]!ET;"34V.Q*B\H7^UP'YK5Z0>U'0K$!
M[)F#-MC5?7S>U!;_5HHO;(RV/YW!M$,3'W^0HC7T\1ARX.8^_B <-OH)N#:,
M?I2>3MXM9"E ]6&ZDGSVOS5??K"_64U(9BA5*@64YL9M*V: (HP @H70F C&
ML-?IR9DQQD8NC9E)96?B#$U*2_THYAR<YQDE$D@]$T@'?+SIP@.!(^RPTO)O
M]XL?_[>]NB(&^X\M'YR[YR"/OX=3S=/N\]%NL87+7^6KAR_+Q8^ITNKWES]7
M3E=NH_%2]Q6<ZM5&KPPQ@H32##!<4( S2P!400P@S)53)] H#<KZ"C=A;-3@
MS$_,;/'/^KQO0[X)W]@>*!7785[\PI)^T>Z98ZSQ20EV8[[;D'_C/+ AWV_)
M5D%JZT4O0G3=08P4Q'0P8-"0ICM ^P'.%7>Z,N7UTZ;_58&XR36EH"@R9:,=
M6 ".# ),%S2CV#"!@Y0N#X<8&Z.U>EE\ZMI9[ B0GMLW5\'3]UY-&#+=4U@/
MG(^=M_KI=5J G7;P9(;JX2<C*<M]G)?)'JN-?M/M7+W;2J9-D"@T23,#.#8Y
MP,IP^R]&0)8B*K 4PF@O)::N!HR-%M[RI^F:SZ;_LB_<95MG3MN%YW+J3+:1
MO_MAKJ;KY^"DL> )\B.4/F'O>U5U3&+.2:A7]F\TY<I9:+G0H\:<)WA]B<Q=
M&OYU5>8\P;DH,^=[G[&U_M@TJ?_\7*:;&Z$9$DP#"EGJY%D*0"F2("5"B5P1
MQ$0^>2I5S"W=+]>> =10]H<PP;X7/6:C/:]7:_O ERO,*@M-Z/OIW!6ZE[EH
M5<+N:+IY['\I$,TS2+,"9%E> )Q# ZC$"*19D4G,B6:IJK\4[^>>=:PC_DHT
M/@SZA6C2$D?^5?!<$8QQ<OM>: S6F&6#@?UGB<((4A*[3MQK)R4&V_UKI"5V
MG8[A.J*<,J#CMGCK!&WG:&TBTU2BW A %4=.G#<#0JL<%"JE5'/.A:MY7MAU
MD.?N]ZF1@M9^F_'ZXZ/O;HQD4?)'Y_/UT[AZ[E['0*OO3>J6C0>GZ1'WH"]!
M$6NK^>0XP^XH7W+W8./XX@57UC;__K+YY_\SM0/91=K+)[=$*TOWD9*Y=AWC
M-46Y7?@4###[.Z E2B63Q*Y[@KH2^ T[M@VC;6%NLC&VW*KX?/M?G?02/-'W
M8Y/XF/9,+=? V;W8V0N=V.7.YP=]G8)G+R!.ECS[71U&2H^+I9G\^61MGJ_K
M<.FKO>7<%5B7ZRN1:<:@L)$*U1A@#26@3FXASS"'64Y%GGEI75X::&S$4YOJ
M],3+%=&R,M:/;"ZB>IY>8F+5,Z$T,#4+Q]K.R]()87BI.G>EC/8'P6UGQ,'Q
MNYZ$?;&H:-=]NN12E&:HY-.+UP_"H+Y>-)SI_?F.!6>54E\5#1ZTU9XH;@IA
M, <PUPQ@)1@02.8 *:)PBH4B4H0L[<X/-\[U7=.U;LU_)F]$TV+>:31/5\$U
M'1?P]@O2XJ'8,Y<VG2_K)9\[L*MM3=[4UD9<_OG!$JN*[/Q@P]:.>3E^4#'F
M=U5'*> ??#ISQ;(?%LMO?*9=OX2M!%]+>?@_EXO5ZL_Y4E=GZ*Z"\W=M%DMG
MT42: A8&<9!S80!.F0:"%2DP2 C*L?W2931,VS.*75Y/V*#:GZ6UR?/&W,0)
MR9>M..WO0U,.XLR='Y4--Q\#]I#9.G"3;!P$UEC@7+2_:RFD5S.W=:P6-!:E
M;XXQ(VH:Q\0ZEOAQ%)N&54F.">.!G'+4F\?H=?S5B1W<F3]7NDS#F) \Q;+
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M YH:"3"20K",R4*B$)(\/=38V+ V+YEM+0Z4!#@#JQ]=Q0&K9UXZ)C77BPC
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M=L$M6F9FT. #)VMV >8P?[/37;IV0_[VR&>SWY]7-OQ9K2:$F()2UQ,BS1C
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M7TRH,00)&T(7&84 (Y0#*FD*D$:\R%)I(/4J7@\;=FQ4Y@QT(03?FM@M5KN
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M0AIBVF*W_(EC5,=WN%WIW9GR=-TIOTZ5KL9NTM'OYM^M&RLNRVPTH@L!D>
M\MR^<P5) <,0 KO,(E1F19X%MEL.&7UL[\C/NE0;DEJK556?L=+V:ZSX\B59
M&*-=K!7X<@R:#(E3:)B  %&M@,M' #S+<U#H%,N42\,D#3M#[VTZACE6O[V_
M7Y8UOMMI60;5*W6;!\^@HB]L^PX">-4SH;2\TB'?V+XI!W.5S"WS([ZFNZ 6
MZ[4:-/:PK\$NL!R\MCK=I+/,0%EM6^M>OG6*S//U!"&&T[1( 4U%!G#N>C1G
M' *LA$@SGE)-@TJ0C@\SMA?'IB'14V5F<+G_,2@]3R"N!JAGNME@4UMH&:>R
M,6HA_AD,XA7:'QMDZ$+Z,XX>*90_]^FN4OZ/3TO]8&-BRR@?YW+QJ&W8=&>^
M\Y^;S&-LN! Y,H##'+F@D@*!,PTDXT)QK1DA,$R6_N*88V.$'9.3V6*U^O=0
MN?K+./LQ1&3T>J:+7> J<Y,WGRR OY7=[5WD8BV_26[7Z^54/%=**^N%I9=E
MJ9W40Q9X (+1]/$OCSBP9+XW!(<J^OZ7=FY':6_J[O>\?EBX1E:W/Z>KB180
M8EP(  F1 )., XZ(C4I,GN8B-[GD+*P<^M@P8V.>^I&Q9B8;.^U382T-KG$^
MBJH?Z5R/5<\\TP6F+KTDSZ 0KWODL4&&[A=YQM$C'2+/?;I#4?$[;;1K">/N
MZ8[0=D0EIWHU@2DGE'(&>.I2"G(;C3!,(2@,2NWJ".4&<>]:XDNCC8T2/G43
M@O5#]CP?1,>K9UIH3*V(P1E[4\G#)L$%>W[P!10'QX1QH)K@Z^ ,*P7VA>=L
M!?#%FPQ7^.OKSTZ]K_=%X8UW;Y_5U,+_R<V"^ZXR;O\?8BE@3'+7?*P U/4M
MLDS*,IA+0;07I1ZY]]@(M#8O:>SS[[>[#]IYMKP2BKYW<GQ1"&JS>\+?3EUV
M]^\U6)/=$TZT>^R>^DCX@_A^OK8ATX?I3"_?\K6^7RQ?)B152N0I 05V:QV*
M%1"8YB"7J<("(IIAK_YA)^X_M@>R,C$I;4P:(_V?RF,(7GXRK\2EYZ<S#)*@
M1_2,XYT>TV/W&^Q1/>-,^W$]][&.[?_J(\P/UIR/J]4SMZ;NM@,R!56II@4P
M+"?VC9IRP-)< :ASA15!RI"@%A871QS;8_UEY_!]6IOLMOR:%C\NZV)UD\QU
M8/W'9?#]]C6B0MHS(^RB^;&%IE?OJ_!&@;[8Q&H7>'&\89L&^KI_T#K0^\)N
MQ+.7;/3YV=5WWYDR@VEU][Q>K?E<U6G$<I*Y)CI&$9 1C@!FF  A%0>&HTR@
ME&J6B; DE*#QQY>$LLE@Y'4&XPX7)8NM S>)<"Z4:;757P-S:<-FRH^Q>D._
M9_8Z2!RM+"\S5RKD[]K(E^;'X[).J$7BM;"Q!^6X3K#L\UVWFW0\KJX.O3]H
MEPLS^\Y_UKV<?]=S;:;K25I@B*6@@%!< &Q4#@3C&!@)4:&85D@&:4=<&&]L
M 5=M9^#1] 5,_7@I(E(],U%M:5*;6NYEUL8F;VIS3Q-]^&FS'S"Q3IHOC#;L
M*;.?ZP<GS)Z7=<QTFY5SIM7QK/!ZK$ENF#!8,Y 6N6620C) TXP#S;$J2($I
M3(.TQ?R&'1NA5,T>==4_3)0%)+)=:*(KLP,3Y/QFP(]WXN/:,_U<Z!9VTW!1
MQ'RZ((ABY=?Y#3ILOET0$ ?Y=V%7=V.GS]83OGJHM+NKTM /T[E=0MI_?USK
MQZT0O2@XIPHS0*"R!"7S'-!,2)!J66B<IPIF@0I]WF./;U%G30?.]L0E0_\H
MC\8"$_3\@??CI5[ [)F::IN3C=%E)>#&[*2TNY>4O&"T(K&4_[B#$E4P'/M<
M%7Z#SNG#C].JQX =XNUB[@;3=AB]FF@L$$28 *HA!W9=1@&WBS&0&8*PQ)E$
M.#1M^-188PN;6J:6CY!L&YN\^;Q8ZP2AP-VD<UA[KM'B(-CW^FP/O!T[HV8!
M7P(C7O;OR9&&SOJ]Y/*1;-^+EX0?>=>R12_O?\H'%_A^ME^'20&YEC9P 337
M.<"498!S&]I0I:G,[=K+^'5\/S7 V$BBL3%IC$R<E?ZGWD=!O'SL?2TT?2^/
MPE ).O@^YWJGD^^C-QSLZ/N<.^VS[[.?>QUEF=:V\%D]$,J)MNL<!HH<V46.
MP!K00FL@,Y9KS5)8*#RI&NI]6_/EVB^2&,CZD*=JWX?^'K"6\0E?E[T)A;Z?
MSN?N%V-0D/'];A!"B:08 8-=;2K2& @B;7R9(<V8D;DTIOYNO)][-KD>[3>C
M\6#0[X6>CT-3R/<;X1<%CW".!]QRO%8G:.>4]I=1 PJ<LY'H_OA:_4LI_ 1.
M16PMG]#AN_;/DFXSN.[V0;(BT]R^I.S[R@"<:P*H@1G0E$(FB8%:!YTE[=Q]
M;,N:VKC0+EAMO/QXO#,*/;-M;5</'5".>ARM1U7[W@,WHCKBUF&WJ6,?ZE!;
M>"OE\EFKKWJE[84/MW/U3O_0L\53V=P1$590:E<8&83V44T1 I1P 52>VF4(
M4S357OWL+@\UMN>VL;+<<U-;.UM'*@&%<N=1/O^ Q\6NYZ>]MC/9P&<M35JF
M1L,LH+(P&G9#M1KER^6+6W?\<**Y"5^YK,!R8<IG98[SZD'K=:*<<IC]RT+,
MIO<;:4HGFFOQ7S\L%\_W#_:_O/ZD^Q[7 CZ)62R3Y8DO^-^2/UW NU[83YB9
MEM7:1]990D].5MV&RK5%K:K;Y(VRQOYSNGZP2Z3%7"<O]O9.CK7^E?OX?+%\
MY+-D\51*-UD/Y8NTYDQ-,EO8>&7YV]\B54MZ3?G94LGS=QBN3M++DYTB2;\K
MNE9YU!689>9V*>H\$;+(A,DS )$H (:D (+9Z$Y!QI4V16%2%';R?F24\9VQ
M;XS<E&W\3_@W""&R3]FR>G1O$@1O[*_<_S4)U;P2!?B7MJO(^:+YK2L&<3G8
M]E%<M#<>RD?_G9;E:_[?_@<JX']DZ"9Q7]?RPT?_A$*+1P[GU"_DO'*>>GX5
M;2>HU@*LI>H_EEC'+ PYB4*T4I##$08N_CCIXF&YQ^F/=EP\ZK4+^.[,6WO7
MZ;JU8KU]= I@DU1!13CD0"J5 RQQ"GC!<H!$1J&35J<J*,OYTH!C"U4K>\LZ
MLM+@P+7F)7@]EY\10>M[15J96I:*E<;N[N)5]D9<IGHB$VOE>FFX81>SGLX?
MK&]]K^O&*38X6B^G<EW35+W1HE,-C3+<*12G &.)@!#$!C89%,)D*3<BJ#//
MT5'&QAY;(S>E7V<+)P/P]&..JU'JF2Y: )4&]K"3=1:"2+QP?(Q!R>"LF_L,
M</[#<9H4;ON%;7K4?%\<M@[;Y+K" C$(<P%D2IV>O.1 %(6C"L:P4I09E@55
M05QGS]BHY ^^_(>N)"N[-@F_=H;\*&= W'LF)Z\^A]M&76Y;9[?KX4W"C8L>
M73K_/\O=);<Y5,=%3IBTEP3G2!/04\/$4&M>M7]B1^@NM5/L>MO.ZB%/>KE^
M^6*_W&O75.2_GZ?E?M6GZ5R7&=J3-,M801D!1+K<)YIF@''& ,&"<ZW=J:&7
M()?_D&.CU\;BFZ2TN>I+U%B=_.7LKFH2 J50/<#WW0^*"6GOVT-7H]E%0\03
MH'@B(I<&'%I%Q!. (S(BOE=VHZ#_U'-77VMO?:L>I_.IX[7U](>N"]GJ)0TD
MS&#$#, ::X A)$ PY5KYB4Q)S%,)50@+>8TZ-B*JC2X?&;YC=K<*6#_H_3@H
M.J ]TU ;RUV+-U7X\=>;02!%HB*_,0=EHR 8]@DI[.*NVU0_]/Q9.^DD5VOB
M JV_3]</;Y]7Z\6C7K[_*6?/Y9[8:J7M_W>ZJ!.>9:F2*0,HA]*N48T 7&<<
MD#1'PJ002QJXB15LP]CXZJU+V!6+N@G4LG(H=(,K?";R/).2(P&D:Q2$M8:
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M[26EPPN3:-69Y\8:N%K3P^W#ZDV?B\)76F\7/_1RVZ@Z5;G066;QHRG F<2
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M'W69U[="6>WE#.;_6"ZX6JW5Q'=7S'&[FJ_5?[6]7I_%YEXJRW"&LPQF*1>
M1A #Q+DN<,4Q2-.02A0KXJ56@^R&$G1J9+W7)WBJ%"K'GHBRH_@S7?V/V)1Y
MO.N=<G:&WV ;;F8T3F$;!WZ5W+^[NSDN1E.'WQ]TOM [!^1R!70C;#TN:K?7
MM=9!J^7Y35.&>\O_>UN5L=\$5.I&,TIA?U;KT%OBR>(=3,Q1K>6AP3ZVM =?
MS^VU\_<=D>U7VXO4R#+C<4Z%R$*0<O4'@I( '$,.1)YD."=1'$;28;J$V>I&
ME#+^=(D6:>@7@QW[&^)NQN4>81R'F?<"'U!S"]$6_?HC6#N</-&EX:*CDI\=
M$,=49GFU8YH*>Q)\JZ=4G(X_/:HPDX013G3$->(Y0&F8 ,)A"A(44T@2)'-I
M-874?.FIV:R-Y#H=A=9C@X73I&8+^,TX:AA0!^:I-I[GQC /6<IG#YBOQ!'S
MA<=-%K$&Y"1!Q/X.;N3U*-:;U9PI0^0=73_=%N5?NDGB#W7<*#;K\[^M_5)A
MFM,P0BG &80 B1@#RB "E%(90L8)LAL4V$>8J1&<%K+,IRA_:(GK6 '0:Z/,
MB&\L^ >FPA[(6U.?#\@\D6$O44:E1Q^@'1.FEWLZM]J?%VI=G0D]S[?:8:ZS
M]>H\OI6.5ZV$_BU=O;8_U*3F4)'&C.0@)3@#",D4T"BB@"9Y&@LN")9&K6#]
MB#,Y&FU)&)2-_ /:G1,RQ!Z9\>=XR _,H+4BP0'X6I5=7O(J.-#F\).^DW;\
MX.IOQD ?8<:>1N !N#-S"WS<U7'$O2+OS:MEVLGA11-ZT"K!!DDL.:^SKW'J
MAS<?=XKZ6<5.AJ>?_U3O83JM<YANHC(OOM^N5CJ9K6P9/&-AE!&(8R"0^@.1
M"&I7#P:$AU(2I$Y$L7#P/AL+,%$']./\^],&+"78KD5 RV$GSO-XKNR \:O:
M(Z!O,+GG8-A@+7?0%GR0P3UF6/F?YG-EW;<:\6,&1\?<'\,;./JE=7G?;W2M
M7]7/VK-:Y>3N%_CM=?^1>@#9[9]TQ2ONO"L4=VZK<:HZ(OCUB1;W+V5SWW^H
MPY;@=T45WYL13C"#" +*10J0R%) &--]RAG#E$.!9-R0GJ%?>R31'>AR8*:L
MY M^F3?EF9>#2F^[Z8:^]"EMY$B>>*T/*!4*VDJWV3G(7X/VYVK-@U+UFZ V
M"UO:!U5SUHW2/Z@!N GJ[XKZJE0@>/3HC[QMON(!8XD];C1AY,TXB46,O;[3
M[+N%^EDWCY[_$"W1:G'>;T5-6PDD"),(@XAAH0QTD8,\APG(*88XPSS-4Z,<
M0ZM5I^94:^B&;T7PTDT=/:#N?D,,!N#0T86VR&U.O]FQN!+[&B/W@-5J-)Y_
M>$<;D.<#9MMQ>79P71F:9WBS,4?GV>EW-$#/\F+7[I'J6'3'U1WG<L[*+]GG
M;1G#%)QCEJ%<'2LB E!"):!2,L!C%J(TQ9P)(^:^NM+4V+KNC:A/_8?B!I6\
MMETD+P'<S==>81O:K>J*F$,WR2MH].@H>>G.(W>5O*+@:6?):Q?TG9QVNZE"
M"F4:S/)!69[%1K$#D2B/)&"$88!""0&.PPBP""5<"$F(L!IMWKV<%46,,.1<
M9_4VJ?_U$,V-'KKD.A/M+,1F)WY_P U,$H>3S=K"!IME4(F[JZ?P6CUA!I'W
M,65G%WNC261=BE\>-M9YU<A.THK4[F7YO^NZ8>;_$WP6AX3E).$@93("B-$$
M8'6X!&E,\TQ0B*+(*I_#NX13LV\J^0*Z$_ -O)\7=W-@-Z>//9J^/[/24J<F
MUWN]5W0"/LMK>_#6SLF+\OUS>"&OP>O-W7AUH=[!_[)WS5K]T/RNGB-U(&C!
M?Q.%D//->B8PCTD>*WLTE^J/+(M!CGD$E'6:4R33A&3(,K7/492I<7[E&@9Y
MR1:L);-S6H#MWECG"0R(^)B) Y4:-^7/N_^H5;DY)'B=0]VH,T@Z@2.D_O,+
M; 5YJX0#1\ Z,A!<[^@0H[G-\W_,15V1@""#),8I((G.>A:ILI)A3$">)QD*
MDS#,+#KKM.\\-::K9+,(!!S 9!!#<55^8-*IQ')IA7, @$6TPQ6(D2(:C^)%
MW:X,YM?8J(/MY:GU=J&+<[IWAB<.+A@O!'%.SH,PP]D/^!L[4=+=9[%YMUV5
M/BU(D9 PCD$H"%(6FD#*0@LQX)0P0J*<1:E5KWB#-:=&4/Y'4!R#;&9J>89N
M\##P^7$4=3/3JN?*KO]E()>KX)T">;X)M"-+&5J51L,.K;@ WX"C*XY7?/,!
M%A<@,!EC<>E2-S;:=^19?UW><O5-T!42BP<ZYW?%._HRW]#%^:-OU0B^RIAY
M%.K@M)YO1-U+NHJY/@JV_%Z4=YRAA&'&(0-IV40KE@A@EBL[BV1ARO,$1I+;
M,-I(<D^-%:L#ZK_]*XY"\K?38VK3J\".+,?Z#I@1[@1W=FB;].'NW<UY1V4[
MP:32K-61NF3OY7H3M-3RQ]PC[X,G]A]+ZE'?("-OQ?%;:.SE^_:[^2"E8)M=
M@["O].<CW0B]4L'FBWDIV5$+%@JY>@%E,4AI'@(D20Q(C&+ HQ"F,">8<+OH
M6 ]AIO;.:?=PV6D3M 8C:H6"0XU<>^4X;)UA*&RD#1DZZN6P%R,UV7''U7O;
M'0=1WJ@1CSMHEUOS]+BGHT>#KI^..EB<]+TX_$7KD]5KH+%IFAD;ZM^+K6[F
M^.$G*X<R:!4JQ6:4"L@3B0'#* <(QA)@(K Z3^ T%A#2'$.;G*IQQ9]:CI8Z
M21Y.FZF-RWD1,*7J3?EG(%KM:G3\9;7#H_Q_2^?,N-\70S_/9+\%0[N,RET^
M;DIT$^R5#:J/Z'T_^N7A%14*YR?F[+ (&C"J5U4%AT=_TYMLHR_7U;C"C^L%
M>Y.-.7&HO8T4#F');U^^ZMMO5Z]*I&]??E_^$*M"G\&^O*C#U%*'1 ME_;^L
MYNM6%]$Z/)7A,,HB1$ :QBE C$A LR@">1K%,<\)X[EY.5D?2:9VEOGVER]_
M";[O- #K1H5 ['2P;DC??[\,XJEC[<+ ;YMR QI-RE=*^9O?SVW)7J%6DV.7
MT&VOO;$(]8ZU1R.%AGOOE:<HL@]8.Z/.O188+TKM X>#J+:7&[I&P9^?Q8K-
MM1OQ1:SJ9PVF1#*8YR!,9:S>6RD'.64)@$F:AW$LLHB'=G'O,ZM,[9VT%S)X
MT5+:1KK/ 6D:V^X)S^#1[!TRI8#7N=\A/MT!@;>(]+DU1HY!=ZAY&G7N^K!K
M >T[H6/9B[N"BY__*5YG"9$(14D.XB07 "4L5L]Z3 %+248%$X)P85<X>[3"
MU)[SNORSEC(HQ0R4G+:%LL= =C_K7N 9^#FW1L:A(/:"]CT*88_O.'(![ 6%
M3@M?+WW0,6%$W9//%UOM8-[;!)_5[E9=K&>$II*Q" (BM'LVXRG @E*08<)C
M]49G26B7Z7%EP:D]YFUY#X:S:)$=NZQ?!=TPM<(CE$/G1/1#T3[;P1 :7VD*
MUY8;-[_ 4/F3Q #3ZUQKZW^(*N^@BF3=Z<.(^LV,2AYF(HR H'$(4 H30'E*
M@.1,?:_"1,9):D,QEQ::&K4T<M7%]+9E]!?0-.,.'Q@-S!E[$>N(N X[5%+Z
MK)+OQL%;??R%94:NC.]6]K0F_LKG/?90:^HJ'\5:J#L^/:R6WU?T>3V+11I!
MDJOC1$IBW7,C CDA.: XCW"&4L2PD1/!:?6I4<:^QGE52QJ\U*)ZZ )V<0\,
M'-I#(CNX7^)B%[ :[WL9-/('#R/@[:'[F@_<W[X+FPO^?MJQ7<//J2W;Q9N^
M?7NV:_H:M6F[>A,WR_$CG:_^01=;\=OKWTL'=[G8QY7XWZTHV.OMS[EZ9%@J
M<I8A941J7W,:"H 3A$!$<IQ+96)B;C7TT&#-J;T<6G(&.T&#/[2HE@=4$\#-
M[$S/, [\)G!"T-KFM,#$D_EILN*HEJ@%!,=&J<VESM,*2_:Z+?A[\4,LEB]Z
MA;ID_6&YF+/769;%&9)<,8WZ&Z (*OLTP@+P'!$<*>*1N9&[VV+-J='-[HVL
M0\DMH9L^#Y9]X4Q0-^,<SU@.S#G78+P)*I&#/^J_!TG\ML#,WR3!JRN./3#0
M%((S<P&-+YW:F(W/R_*4+_A_"3T_1_#;'V)%OXO?U:TW[^E&[ CW45E]'Y<K
M?=<9%'&6QA2#+,DP0%(2=2K',:"I,L-$QO(DSD;I/S>,?E/CVD;VH!8^T$('
MI=2ZMWI5;1C037"W7F]U+?A4YGFX?;O,>'YB4D_HG3+>=) =4C?!R7>T1"O0
M<+6_KD.,H9OH-^&M>_H-I-T_1T? 8;=VO/$E_<3L6WQ[5:_U)<7*FK09S A.
M)8M!Q!,"$$TAP*E.8H\QC7$D20RMT@>\23:U-WR[%+2BY;R3OM=[_LY/^;LN
M$K5T^_C;=L,7^%MLYM"OWI-]['X-KSO?PU?WL4>%KR?,O9?[]I7KC6I_/<%Y
MN1#8UP*N&=[G7?YZ$/-BJ=UP^QK^C"(J,X@!%$D.$,KUL/DT!VE*((M8&D69
M9=ZW\=I3H_7J)5[Z=C[-F78'!+??5^+*]-3>.V#&OP/A^E;AVF OM^+-(;QD
M#H!Y2SHW7WGD5'1K2$X3U.UO89^V_DY/ZEX)^F[)Q2RE81X*W2 F9 E "12
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MT+-*Z%J7]OR8<\%_>_VV%ORN^#@O:,'FQ?=;W:RXK!S?O35CF$ F4 9"Q!!
M.8. A(HL,!:2Q3A*4DEM>,)>A*D12-EM52Z6?ZX#O=6!;$0/Z$[VO]HQBL.^
MF%'-L&@/S$&Z'W()=B.^3K?X16L0S(M?@YT2P5Z+08P==Q ]T9B# */RFSM
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M,F])&SQ7Q=Y<5[E)74[T0\MNV=? $'ZS@]$ H [\HMU)'+21;15G[:7VV.[
M#B9?+0\,5QVW[8$=%">M#RPO]UEJ/$O#!&=I3D">R%RG3&*0YS $(@E9Q"")
M.(K[5_Q.C8&N3&CU46;;J]IU0N1R=>+I9_60E%.&?*=I=4,S:!7F%(HA+WJ
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MKC:DA:Y6\P:2VZB%R/W++\1UP<4"\]N-5K8RM^9L1085U[_90N-'L]E9./F
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M.E$,%!,TYXFCN-V;X>^MC&Q?7+20: _GT=V:%L'1EE+[M,G$02F#$/*ZEVA
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MZ69>6-X?DZ0D=SQ3)!V1!*8PU])96]\;40?:"_P9#L8MQ/76)/NY0LX&JNH
M@[O?KT^TBXSH]Y"+U+2[)'%6O"*#C/2_Q$,TK5^$=Z=NW)#TF5\I!E+:_G"<
MTSX;$HZ;;)_[!2F$4[P.!:W5P^23TE<N%@V6K+ZG/9BM*L\#RP>H[*0TY>V0
M=0.ME-2!5;SH8_%I?I3^ZVRZ."_FJX'W58[%A'A'9'26!%<;YYA46Z!:!.N%
M*TJ9$DOKHMN=".NRVJ 9.K:T'&FGJBZ>(DA\"3$O7Y-\:W+$T2S_'E:5G1_'
MY5X6%;DP(JA"\9*M;9R(S\B)3Z^#R"&06]*\C_J3B>RRB& P9 ZJPAZLY"T&
MC\OMM+,KWFIZVL0P[8TR&82F/U3)'H(L!3#2UZ*HQ-, -5A/HK'+;)?G0FA3
M!?8 T-MGPXT$,]J/5SEF/LA< OE#DE&PIK1,X+Q(('5RA?QG@;RY]=R9NBZ#
MFV<[T-LHK8M3?7=13A*/EI400!@M0245(69KP1IF$O>&N_),Y=#W4#?N&]PS
M W(@I?4;;;^>SL(L;;FV\,)D@QR,)_=9>>L@<!]!^^(Y%ZQ.(GH>6#Y Y;B'
M^/-$VZV4U,,Q?=T-J8U7JJ4GH862I+3D8@A-UMTI5H>SDK$7(@;'>$RZ]7WC
M_91T&4\WT_]#/N%^RN@,4A==2(_+B_GIZ7PSUV82A48I!4(.SI&,DB&&G(3Z
M%B J4]&V?OE]E*@NP^/G -KA*NH,<_?/2/=&>(Y%$ >:$T,^060&@2?:0/0'
MLN97U8\2U67 ^VS&[2 5=8"YW>4W,9G+')T%ABZ1;^H4Q" UY,2-,10\J=RZ
M1=?NU'49X0Z%PH&4UD% 4=FJ_Z\A^K=P@NOB%9+8-%$$7?^"PO>;/[CVFYNA
MIG=?VM/)69TU^.I[^A)FG_$#>=>O2D%2@@N^")T9*&7K]$%%\;^3"4JRF3$N
M:W#7&-+/R^&XVZ)Q(-,Q.'[VK3-)R RS44$1SH,JB?3")0)*U(5KRY"WCI4.
M(GC<"Z2>@/TDU1TX^9+X7JPZ0&M)B1=)(D9RMHAE(8"D+D$:KT44AFL7?CJT
M#I8 WA5:GZ*Z3@;^UKHPXN+JOG:6+UVMM3@OG;J4"\?( V#T&11]70-."]'Z
MD)VLR>^MTRQW)F[<K/#6=YJ#J*2+(>7G6:?KBM@\79V1HMYLZA+S;V>K=_/5
M?^#J?9CFB58IL5R?)(+&.J*)0Q V0W3H5!2IWGXT-X*[T3;RA><PX+AC!@?0
M4P<W C>:O!QE8HW4%DXJ*V]FYTS_+2P68;:JMV[UR@.M3R:&*C8!RAI.)MW5
MQH!HI0P%0V[=?>3)1(Y\,_HLB!Q6<QU LZ:0W!@)=K'A7I[59OCG4CY>O"<O
M=1I.SK^_UG]_(H+!;#0'(^KL5%MGDX7@@2DZ>9C"D'+KPON#B1[Y@O59H/N\
MFNT RK<JP(_C*I!C1/OTXB+B]7RQM4*$<V%K#Q=N60#E2YT!XA/8$)EGC"O,
MK:.? \@=^6;V6>#[7-KL +@?S[Y^/5E[\N'D8C;;FUF9+TXW.KT0)Z. 3BK+
MZ$!)GMA2=,CXP("\>B%,UM'$UE>K.Y(V;I5CXT!H"'5T@+)-0\%/X3LNJ_OR
M#E<33-G7+E4@>*SCC]""=T$".L\XT1!3;)TX=)>*L2>2#:#LNX6*ATB^R[FK
M[VK6/,[+Z@O^=K:D?;=<WJ1WMTFK]WW,X;-5'R6NT335X\7G,#MOB?UB/EO.
M3Z;YHL7[^VND'Y?S S*<7-JJ:Z>DSX69J,'4*V;EN($@N0;MLQ3:Q9A2ZPR$
M)H0?:I .(J+V'S^9+TG-GTB9OYW4W!1M9)&,]E,02/YJC!1Z837ZGBG:NL(H
MWGI^;6L>QC6&SX_GVZ9R5$QT:6A_"\OI<EZN,Q]F^>/T\VQ:IJEFWV^:$)$7
M_)ZDE6KBQAZ&>)]E#C?4!S/7R)#?7>;JX.<A<,81DJA/UMEX" 1BP$2N9%+&
ME=A\5-!6:@XUN6MY']^0]]$C\KZVE:Q2#B7Y+(X".26EAUA\H3]J#P?)5-:M
M7V(.H7?D"31M$'7;/CZ; KNTA:_#=/'OX>2,7+M+\[_I]D=6XWISL#T,X,Z?
M?;C5VX^-1J;N<O&KT_(*FCE:E5,H8'.H48Y&<$5I*(0 (V,R0;7VH!ZBYU!S
M=]]G7VV';$N=0I/ K"O5LJ.03B7Z*IE"+DQ ZUI'OP\2-*[!:H:+VR:KG1*Z
MM$E71>/+JY+Z/>S/O9]SN*UYG+Q&=N7:\*?Z\G!>$[KZ<6W^R67A7Q""12Y
MZ)1!V?549>6AV!"25(5+V[KD?'?J#K]FNURI=D);KW6EA#NKSO(+7-2K[4^+
M4),F-^? ?9$,J4@P9 ELX:E.AU'@LG @D.(J&13/S0OUA^)E[-D!@R#U[JU?
M!T#HTF1>%(^':W7C]2)X#ZNY[:,.-YP[$=G(=FZMIK\Z@*5"9[T#)K@AUQTK
M$(.&C)S+)+4*V#HQZ5&B&M1FW;_ ?:!GM7J[$-1-J4]ZIF3P*2<2@$+MG,?2
M_('V*?2-:]':XN>> JUA]-2E<5H_)>_EP9W_R\--SWTD-+(TFX^^A$6)!EEA
M"%DS1SYWG5K#8@+'? K6)#KF6OL4-RDXU(:\13HF;TT"N!9=(!W4S"9%!W;A
M]:AD$$J48'3"Z(S6B*USDQZF:%P[<8#V;QN%AH+OT@R<-UH_'Z*SESVX_1&'
M&X8'B6KEBVQF&52'=+U<.+E68"D#Q>N*_,U0^^AJ'2%$6X!;SB3SF$/[^OSM
MY#089'U]>L/%"C>ZZ]_K?RN>9 D2<JS)QUP*\%K1MTE3M, SCZZU+[8GJ2-[
M)8V0=,]$ZL'UUJ5-6E?'?YF?D-J6F_AQ'[-TSZ<<;ID>(ZV1<=I\]"6*+%J6
M.:DPVAJ>LQ(@:E9'_.18BF3)-2^?OTG!P9E_=\3V;K[">]^Q@S&,D5^=2JS-
M4FG#1$]8CLQI53"&7%H7D^Y,W+AFY@!,W,G\&T0=7=J2#7MWI\SO85"V?=3A
M5F4G(AN9EBLMKQO>7"[V 4]JJ\%U!OUZZ'RLY%PT1+P:N2R=DTX[0)/U9N2R
M8\C!2J2(F&D6>/,JB(,H/KAP9-?5?[N^^K73F&6=Z<2MW?\H0HC"U+ZZ!E!I
MQ9UC)C3ONW,@R>.:N6?$YYU*DF=4=9?&\EH"[SX&\OH_/]PH;B6FV4/>^>=?
MJ?W:C8%T''.$K&OKFSI=/HHZ>LQB?:F5Q9L!AJ)O(Z=91OQ])[SER1JM":IT
MU!.KT8(744)M%UHB=S$U[][Q$#UC/YFUP<36S/A#-="EV:A]\Z:;%\ P(S.Y
M3LO"V;XIF@]]W.%F96=B&YF9:^L=W5KO'I!QPXL*='!8S>HPUTBH4.CI^)(2
M%6?,^]99F$\B\. .!;LL=FUKJ*@5"Q98[?2N=$0ZS3.'[)D/1B?IFS>B?AJ%
MXYJKX;!UIV/!<'KKTJ1M>C.NTQ33>KK\YP5NDN_WL6@/?-KA!FU74@^T9^L9
MB"_F)_2C>7T+^89'M1W 9[SY0GJ)-F6,92D&0IO0-?M7@$^&D5\>>! I2)'=
M8W)[XIJ'&Z?'5KI">&')R>P$8')U&BV+$&K]K0Z,J[J?DFG>065W\L8Q2T-"
MY*Y!&D9775JC=[AZ.U\NO^)B'7[N8X)N?T2#XL.'B&IU#QX6,SIH:@?&]2)7
M\S0E,T:J %YS1V>9\>2'D^/,1<E%.V-C:)W3O(V60ZW.[<^]=HK*C,KSVNH,
MZT..=108%-HDQ:(N,LE@6GL_6XD9^>Z[!0YNFY V@N_28+PBDS#_@?@;SK!,
M5S6C::\;[WL^IL%M]V/$M8N\+J_PUGT%5]/%MJ.(9><,V@S&UI;*PF>(J#0P
M$;RP0J-QK0M"GD#>P1F(M,YFE>/5%UR\G]/'7BYWKH;[_?BDG76F@$N>0H;
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M*!/% ;'XG*02LO4KSW"5!1_3%\QG)WA<'DN1NI:%P+!DDS0P6^CX5VC 2>-
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M<1$Q(,@2:@<L.L-"21;0.6Y=X47+]B5"+<8QKM.;[AT)^/'L*^FMPC2<7!\
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M!8 ;E6+>Z95^%Y",6>1R@+)NJWL/R8VL\-^GL^GIV44A<@P)90R$=6-J4\)
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MY^W*T;DY#VYB8A'2:@?*58?'V@0^,P'<<).$5,(W[X>T*VWC!N[# F\0_?2
MNVU2FX@LF4M<U:& $93/"*&^S$9GE%#T0_+EG^OD'3<('QA9332P/Y3FJW#2
M]MGPFC]R'UO9(\EC/6S#D[=<K(;(6.T9Y642RF%HWBAP1](Z240<W;$;0I-=
MULI?#2=>7K/G>]?%/_1QA]? [TQLHWKWJS&>ZS/NO%_"ZMKSR*7]8TF@BYA
MB)0W&?X^) G&L%+0F*Q8Z_2GW:D;=LCSY@8 DU&:T XE6:2=X#B$V@J)*8WD
M#7"M;>M1>3N0-6XD,!!^GC8O^>GJZ< IV_82KVT2,5@)W"<&"H4@-X,9L*DP
MAV2+?6P]X/Z0!)S!D-5<Y3NFUCQ%_AW J.D5/H737+OBP:S/>JX8>%44H%11
MVY!$"JTMW-]_:LV3 #5D:LU3M-L!LA_(U;"6.9VT!&EJ_V*K-023.93(+8O1
MN=B\0N#_$ZDU3T+([JDU3U'7J%.5#D_+R-;ZL$YK#[I&2R1&;PH#S5@TGDO!
M;EO0_S^YIC4BGU>+'5C*^_,VO/.6^4C@$M$0$RJ0<T1;3_K_W=ZW-;>5Y&B^
M[W]!;-XO+QOA=KDZO.&V';:K)^:)D1>DS1V)])"4JSR_?I$4)4NR+KSDX4G*
M5=6MDBGYG 3P 0D@D4!PAMQO86WK>.VY%]<<8A\/%U(72-O4:=SVSC?$Z"!X
M[0D+6G$/2O $(6<$D2R/UD;AFE>\/KJ@9U1<<QCR6@FM P3^:%;[\&G-CP2I
M07128JDG@L0V1K%A,*: \2FJY++*H34B=UK@N#OUT"'V<++J (@/DW2=1?\T
M?T&^R&KZ/YA?SI>K=?+^.AT654S($P>K6 3EL(X:-0C,DRLH)7.%MVZ+=."2
M>QGKU1Q,6Q\#MY=LAT"^8Q5^HG,BG<%(' 2I:AN+@@HB6@V>Y]IF(!73O%_2
MKFL<N3SFF !Z KQ-I=G! ?03]*5T<7YQ1KY._N=BOES^,:,@\*P2_$_RHOZ!
MA0*_3^&O2=(84M;$5VUJK;+U$"SCP 7YX<6;B+QU JG)PD>NOND7UP/(O7_3
M_"#1;^A//XAFDB&B\""YKE4" >O-= O<L5QB93MK[00W6?C(!4$G"/;]Y;X[
MV/TEV&?XN2ZD"=P?CT=>_97.+G*MB4EI<8'Y=<W?X7(UL3Z4D(N$PHT#I9RA
M$$4%$($B%9Y]B*:U,=]OI>/F(\8$]!$DVX&Y?IS*.\2]*/3?%V=G\S_#+-7?
M>4D+GJZJ"D]$-((;$R!XK#,<27,]J2[4?M;&,Z^\;MT7LM7:>YE^.'20.(JL
MNZRONQJX$V[,VGF+JP-*[)YXXN%5=KLLN5&AW8-CB:[M*^;@H@H%I-2U.V0D
M##B>P$;C93%:I72TR62MRNJV'BUF6;%9B ",U[ZK4L3:=]5 =%$X\M.CEZTK
M3[9=6Z?3LO;"S<,9VH;RZ6 GWF8FN\?HC5*F#DK.H+3QX,@&@9.6^:)"[?MQ
M+'W[L:Q>DJPM\;#MA+8]A=,SWFX,YHXQB:0P@3),U$+Z2-Y&[0.KK)-!E!)$
MZTM=6RRK4^NV+Q2VA=J><ND :M<D7+4R--E:86J,Q&T=@:/ N:(AHHPEV)*+
M:0VK.TOH%$+[BGC>CM]C]XEZ.3__>D'/^N$TS/+'>5G]29R]:EMIC4HR28JN
M$2]GSG@E# ANO<F>I9S*4_[ZEN\:-S0<"B=#,+H#,_,&PQ*_S,_RZ_.OB_FW
MRZ;F5^5Q@EF%ED',:U*T X_"08Y:J^R#RJQU>N*1Y8R;)A[:_+220P>0VF+P
MK],88HZ1M$*).O'2@$\1 2,:XYQG6;1.Y3::SGV$E-88+OE^HND9;.LCDXE
M67(N'NI%?E Y,_":]%*G0 %TYKPTO_C^^(HZ=:+VE/^V\-I=&!U Z\;YVV](
MBTC3M9SH^S-<"VR6-\<HZ\\?)'Y2-'<E^0C&U@O5FG0W9*>AQ"R%B]E$USKI
MU6KMG?IR;> ZBH //8']-+SI?(NKB<HA12TR<),X[3)10D@R@S8\(FU G#6_
M!/W8>CIU_@8VF[L*HH.ZK6T4:6(Q<I^TAUPYILBC(1>&-@(FO% HBLC8.I>Q
MS;K&/;<?&&3-!=/E(>4ZC%J^#8L%/><;'G X^<"3#C^4W&:)C0XC+U]U?8(D
M7"DR9P59H0'%+9D237(.V:1H2S3:MB[HO;V"PY,5RR7B^IF_X3(MIE\K[R_#
M(F>8$RDR0,9=O=^"X(7CI"HF66D26ML^6?'@<L9U\P^0^\]YB38L']&?7RY6
MDW^1D?L</N.;>9@M:]^E</9JN5K?E?I!%#WG1_2]/I,@@Y>U5QPX5V0/.:_M
MD>K@#'2H2T1KG-@&5+2$&X"B/_T T_ZK&QMCC8 Q/ZJ4>L7AVW".5T3=2"DJ
M:UU0HE[8R^8RLO#!<+!><I>]]#X/"L#[ES4.\HZ%D&T V4!<8Q\:O2MEFK!V
MI@NQ7AN=+[Y__!K2U3F&4E)8KC2(4$F)+$-0UA%N,CF;2IFL_%,^U!;OZ1!*
M+60['X;1'63%[K?[-V*48(S)O ZDK=7H7AF('B,X5:\;.9>-UD?QPSK)Z[?>
M)X>00P>P>K' \*Z\";,\08II-4\1M*[&FB)2"&14@&?A4:#(0;0ND/SQ]AZ=
MJCV%>C?;N1^'.\#&.S+%)(+9YS5C7OWU%6=+G!A1I-*V 'I#=K-:YLA<AFB8
M="E+A=AZ8,:]"^G1O+1!S.%\[SA']/'B_#PLOL_+\N+KU[/U>7N@)Y7YXGR3
M(SLP=;3M"UIEE/8B:)A$DV:N#DX)$&VJM5-(W[DL@4?EN+->6=&ZYT';1--M
MY'^8?OZR>E?^6%YV<Z9M.Z'4L8!/HC9(MECS*1:,B"8+[CWCK2]:/KJ@L?>L
MO67_N,$YA.W=[5I7W;>_O[Q85*Y.1(PQF,(AE^K[<4SD^WD.11FO?4(R)L."
MZ.Z*QM['!D+108SO'D8?:\!:3?V-KE+OY\MI%=NK:MN74PHTWDR7JPE3,@61
M%-AU=:)A#"(7F;3)::>%RH6U/M%MM?9Q3W^/!LV!A-DOB-_.9VFCE8IGSYSS
M8)SRI)4E011"@.4RURFG&=-6B<[#T?EC4>.>!P\/NSW9WR^>)C%)RS@SX$PA
MM4"M:I.[!!B2\M(+K?614#3N.,3AL;,3JSNH2[E-QOOP?5U@/:G]%'6J!Z*Q
M9G8MDD\I5(+"BHPRJZ*;5Z+<OY*M\&).#B][,;H[ _,?6$,1S"^^T:>?\0/6
M X&K'W["Q3F?Z))8EL% -K4TQQ6$6/U+XY*+#C,RU7JVY:YKW IB]N0@UE@X
MO8.OCFR:7\Q6'\A7?(^+5'=OK[A+S$<@PYMI]\X.7$0!03EIM,VF-._4M^L:
MMP*?.W7P'2J<CO.E_PJK31.4>3FKG]#/SZ=7(X$.S)5N\_!6>=*="1DF1^HR
M=Z@=@Y1+ 26Y!!<T Z&\LZ$HX]PI%.,]X!Y>[?N_7>!;XM^G/_'L&_YK/EM]
M64Y"R4G)VOJ&\5J.5MOTQ>H^%F4]12'U5&*0$^+=U]I59G47Q-Q_6CRPL#K8
M.K>E\S\Q+#[].9]0"&.<3H(\@USS*.0C1&8$Z*P=<32H(EO[_SLNL:NT[#$@
MN(]H3@UY!"6<Q!BRUIQ!43E7KU2 MS*2%\*-S<EFH=OO #LNLJO,Z]'0M[-X
M3@A_D^Q+R2@"6+3K:G +CMD,SB21;(PLA+%@UU7"]1AHVTD8'631'J7KCUG>
MA#^87_V5Z%=?G-<_3;1/J1A2HN@<!Z6C)V^BIH(R0\EUIKCHJ)OL0POM*F<[
M&/R:B*D#@_=08MIHQ:-U6!M'U7;(1 OYJ (<"N&BXU&JUH-5#SD#.%9.]Q \
MM6#U::<V)G<:$S1.;DSX,=,;=XFY3G#\[[V8N&F"NZD//"09],"3#F?--DML
MU0 V?%^/=:]7:^M;P]D/'32,VX+H@ 6O07E=-WJ#M>-U0I^*<JSU\>0CRSFX
M0QV)=/X="2;K%@I79H&0=U5JHXS"* L'RZH+S8H!;V)M7$21G"T>36A=HOOD
MHD9NP-(('3]UKVLJB[&O)FW4]0/)AA;QA9CU&W[#L_EEMPU)[&&N+ET)41L@
MD8NB! -R4&S]1TL9GK(T3[]FY,XGC7'2F*W]NG]7<)=8E%#)0"B9G-G"+02?
MZA=M"P]H9#F2%[B+W1FN@\E =J>A%#K U$9![K&>R,EWEHQ"=%^K78KR$(NL
MH5*TF$66)K>&TX.+&;E-R4!(:L/[/D!4P^GEAE%7?+J7-%V\L=9P")SER[N?
M1%.!B$ZKDIF1K/E\LNV7-VX^9$"@#2*?9NFYE@'NQ]4\_5=M*TKPK@V%5M\/
M",\>?MCA$=J6"VT4I%V^X1I.LHZ)TZ+F7@6)V8N:T7",=BUM V:6G&D=E]U>
MP4'>\K_G=0->WY993ECAI38"!<:J%Z=2A"B* \-)023]/TB]E7-\\ZGCQDP'
M".N6^[LWGSK85-Y?O7>M)Q^_$..6[RY6RU68U8%:$U-$-LIR,(G3'LF# Q=B
M!BUK9%>TM+%U^>$32QHW?FJ F2%8WP&27L[/S^>S-2V_3;]-,YG3Y7M<K.GZ
M#=,9_2=/'$LE!14A^SJ&7NI$WI:WP%4JN4[-XG>MR,%PVF9=X\90#3'57 B=
M ^ME6'YY'Z9Y@HQXPV,$EV1UW$IUJ%P$CDIR1?J"JO4EM&W6-6Y(=21@[26$
M+H]M+AGVC["L\RO/:TY__3S!N,?UCZ:S6GH[_89?S\(A-_GW>]'AWG # AMY
MRK6B^6R^O%C@NW)S*9M$<QT?NERC*];%7I4V_ C47+U7)A.AS-#F&$. >A!)
M ;SF.E%4Q43K8I/#5MQN$M[Z'3^)\,5B$6:?+\<[_./[C]_9K./%GV&1+YL#
M994IQK4(:%FJS8$R!)$8: R"Y6!SSJU=NF:+'S=@.")F'QZT=TSQ=[#[UZ[%
MM7':NMV>8-I;1WN+S=J2YU('K@I-&PQ3B@6C0Q*MS_UNOK^7V7I'A<#=J&5?
M>72$I4WC/:NB#T9P4D#G:A).@T]U$E=(/&H6E6M^-?SV"D8^,MY;D@] 8@^V
MCGT@_.G/^:<O\XLEA=QOIS-<(5[ZN*^OW*!*VZ:?(D<L*A.+"M:K[.O3)Y<#
M>,5]=(YE@>8IOV_7E_:!D'T$.S\"ESLP*4^:XH<L\9OK3FK!15UXJF/#%0-%
M 10$4^O!O;&9%R%8\ZOBAZ^ZEYE68VZ%1Y9]!VB_D05X&;Y.5^'L,FU9*S\6
MWS#_/E_\?K$B__CU<GE11]5/F#1*J4PV0WBR&<;4LE\AH7@?:XLD5>Z.AVR9
ME]END2.[=4=&T<.)G0%$V@%F]^;OVXNZ(6U,S/+%MS ]JR:#&/)/^KNK22C>
M%N,ID@N6^)!$/;Z-AK[C*"RR7&+K%,10M(QLS<?5@"X LK>B?,-%G!\[(7KY
M\3K+D6Y\C)=ET.WSHMN];[#TZ![D]I$EU=DIEG2"[ *IA8H"(N,,K&>&&2&%
M;=ZVJI<LZ57A\D?:Q:8)'U#RL_4CZ;MWY0.F^>?9]']H4;B8SB]7>NDD^E*/
M2(H"8S6"*K&>Q.9,P;%.F:4LBF_NH0]!R$EG3W?!\L/9T[%@T8$C=!GUT"^O
M$SXVD;L6K #:BFB'$JZVOPT17+;9*OK7B-9CK6XMH)=<ZFB N%L]N+=T.H#6
M_E'X#[)G^4ZZ2:7"E8SD-#%6AZ,(!S'%#"5SDU,)@CA];/]Z#SK&!?H!L-K5
M31Y:QAW@_-I8U'#YW7HBPE7:DG0_&PQ@K:/=R:.'@,$!\9OV)10Q- ?K@XOI
M/)\Q.$X>N,)VF- Z0-\')%>( I9-Q>"&"*>UU#Q:"#D%4(Q"35=;V!<6;;$L
M1X6M;Y#<NY#.<PC'1MWAPNH/<7_,IJOEAX]_;(@)*>607")/)Q3RR(.&F)V%
M;(1.UJ..S6\=/[J@<:LX>T?@ <+K (FWC/B&A.RX$'7:8BBHB(Y:QRJS 8N1
MD2(ESRP?<L_= 76#E7AVA[I#!=4!UE[/TOP<KX<FO-F$?FL/6B+6QKX2HB-'
M02FIP4M6("?4@HC*G+<N8']D.;V<PO821+>27+\@W&BH]R(R- 6T477Z6E:U
M7*<J+'U%*WD)K4W?HPL:-^1H)O;MX+2'##H U/W=&3:=:ZX,=91DX)&#\)X,
M/TL&G!,%4JU.I0U!D8O:WJ-[:EE=@FL?$/SLH#652 <@^R?.<!'.ZMWG?#Z=
M36ONOA9XW2%*&F^%IY#;13+QDMS.VM$+=%+<AAQ48*W'^&VUL'&WT^& UEXJ
M'4"MC<_QHX2 ,6:K[P%:% TJA00^1@DF)AF<%%8TGP[<F(21X]_NO,$Q$=*!
M@FPHH_#_7L*OQNXJ;RTO>7V:2H;%1@LN*P7(K30RF.1,\U8A6ZULY.8 8X+G
M[ME@>TF>TO7+'XFLM"Y67-;40DBT@QW6=N20UPU6:[0[L7V4&D67/6<L ;-L
MW3D'(1K-P26=$U,&G6X=.O12:G1H#;ITPG-#>UQ4NC:C(N\K<H[ O$,*7S/Y
M=ZWSZ']?R-P5L\-=R-Q%_!VX%;>OC1EO4!<)V@9:NY0"@L^R;FTEJ"B$;)Z"
M?XX7,G>"P*,7,G>01T=8VL2X+GK)LZKS6 0Y^Z$@.&$DE%2B"MQKU;RM;T^U
M.OM+\O$+F;NP]90N9/HBBBL4#*)D#)11]98@N;]*("\)C9#N>5_(W$FP^U[(
MW(7+'9B4VP5O7'F) 0594MK75:X=:;ASD%C6TNH20O->%[M7N9[ -<E#-JC]
M)=(!G 8Y7X]1A^+)Y41A2TWJ.W!26O#>%1=#4JSY(?)SKVS="5;'J&S=1<8=
MX/S^<C7F$T:M$D@16<V^DA-29+USH8+-T7@=6E]\V;^V\+0J6G?"QU:UA;L(
MJP/$-;CUR9T7P08)T=?!4IY'B)9V)9^(X%*R"J9Y)ZOC=$XXPBG-F"[!D65_
MRFB_3!._GI'&7ZRE\F[U!1>?OH3992G[\NU\]HWL >8/\[.SW^>+^I<FA<FL
MD(03#"?NI.JT<^%!TC_.2LY"\[:]QZ6P\QVA,7Y;J<_P8&IXC[UK9;N\^S^)
MO+AL92V7*!943!Z"5HR^%*>5B1AR-ST@=B7N1%7L"!@_OCKN ;>]-?'K^OCZ
MXRHL5IUKX[K-QO+U[/+ ?6)Y"-)$#B5&<JE%'>62:_)4HU+*8_&J=07/L6CK
M_'+5KZ"+!X#M6?N?_U[+[YHOR%VIO;[!*%?O>G#R<))!$"5CT<8:=.EDE/ V
M;9W?+_L5E/  L.VNA/Y2"6?X>3WZLF\U)+D5G-YDCK28F-$:D*LZ(Z\8"*FL
MQ]&DK)C)-K6^&'Q$\CJ_=O<K*.-AD'OF^GC7=1?"J^@Q@;?U(D<=^Q:"J 5'
M3$K#56E?*=-7I#C8/+^_=?% N!T8*;Z:G8PN_@?6(6V87WS#1?B,:Y?^-S(F
MOX?IXM_A[ )O"IISKBQS##@3)&A.(G>.1<C,F!2C\8P?O?_0<5EPHE'GR219
M!X/CLPXXMV??A"0>/*HZTM=2?,"] :]]@BQ#SBPX:]4)IF>?I/O99VZ'4YP.
MC<!.*/[ELKY;L(]B$:%X E[(]"L3U@/P:B]FE#QS1-%\"&\WQ)_H#OY+68(A
M\?RL'8';R<"G&9<5D[Q6,C.)!51AM0U1TE#8^FJ]PV!/QQO8D?AGG[M^!H9@
M2#P_\[J,32KR@G#]--^,D-%HK E*(T Q$\$+M,!CH@@QI%32Z1Q1[4+YL\^9
M/P,C,!B2G[4KL$,T53PY2"4J2!)C'3#GR&H6 2;&B"Q(*\SI5(DTS@F<<H[^
M&>C^0"CN)+^_54>5:Q:L.;;\-%^%LYL_KU?ZW\Y7_XFK'_U6?CSI\B_=9>LD
MYVR$"Y(\(Q= Y23!F:S!I,"MS%)PT_HD?#1B3]31;Y.S/PV(];(3QZ?E%'>V
M82\^?UZL#^A?SU:+Z6PY36N#=<WT23TB%;FF+Y5!DB]Q*C";B&?9>AT29M>Z
M4<QXU)ZHQ]WP!*U_D)UF*ZQU7ZB+VM/]&)VP'G[;$1IA;4EJ'WVPT-2KFRR!
MD*A!&:9(5Z0'KTHN(A(4L75X\5SZ8'DOM?;DTW(C<FUQ*L%K64"SI'4H(07Y
M=Q^L>PW]$3$[7!^L7<3?@0MUJUN/-4S++'2=ZT)K3\6"YS4PTR4'+Z,RHG43
MS>?8!VLG"#S6!VL7>72$I4UO .E8"$9;$+X84")F\,(DT-Q&:8,72;7NC]U3
M9X_])?EX'ZQ=V'I*?;!D$JX82SYZL<085NG*QA.+M' ,4[T-\90'>-)]L'82
M[+Y]L';A<@<FY79['.U3S!@=+3E2%!0B@XB"%A\P(SJN?&S=R.59]L$Z9(/:
M7R(=P&E_QCW2 \<%II,C'@KT=1 9,3*64H"7$&V)5I""'?LHYL3[8.T$JV/T
MP=I%QAW@_/&A>2A-\F0#P(E83UT< ^>DA1)4,#(G(YI?;CU\XN%I]<7:"2\[
M33S<17@=(+%!\C8HETM1$FRI6=#,!3C+ K#$4Y0HK4FM^^D>ONKGTA_K$%?A
MR+(_9;3O=XF/"\\P2P:(F:R,EPBND&^?ZE4^+X/S['1*09]E?ZR=\#MN?ZQ=
MP/3,ZS!_:EC$0KTAFX$Q96MF.4,0TM">*QUF&\4IE5S_ROVQ=L+X>/VQ=H#;
M+W=3:B*=,3[G .1CKUUK#9$' =XH(26B$?[HX?;?_;&>BRX> +9G[7_>:5E4
M;!)U$%SM&\9JR3:'D%" <47G%#UR?CJ=67_A_EA]*N$!8'OF_7A^;E:49,I*
M)!*>JQTU4V;@8D(0)OBDM.+*#E*(>!SR3K3R\#DIXV&0>^;Z>-=U+['V[,L.
MC%$1E&"ESD,(9*],EDXRQ5WKFH>^(L53OGO3ORX> K=.[L_T<._HIJ!9=L%%
MS""1[)@2A4$P)0(KF:FBB];Q.5ZD>T[]L3I/L@X&QV<=<.YPBQ!UR=HAF6FA
M+?DC7(.GR!Q$+EP5X:WYNS]6/WK;@^)T: 1V0O$OE_5]FGW"%99\D>""$N2P
MA?I=J9X12RY[PX0ZG3CX[_Y8S\X2#(GG9^T([-I/R ONHPR&Q%\+I"KC?!4_
M1JL*DDF5)Y00^[L_UK,S!$/B^9G79>S652BYI)V-% N6>N>[!(C%9^ B!.:Y
M9YZ=3N/KO_MC/2\C,!B2G[4KL%-G(:>DI1B*Y&QKF72$$'*&Z-'F@#E;>SH'
MU'_WQWI.NC\0BCO)[X_7O,BI+*23$I(LM4=*;?*BL8[M0>?)5=)H6I^]_=T?
M:XR<_6E K(.=>#!&7<8N9&8W']7?XY.(2F1T)$1A;;VU9X@Q,4,.*7L>5"@F
MG(H"WDOAB7K6G6O=X6#J0-76[(A/"R?N["X\V25,*:UML Q$D8Z<!&V N)4@
M:!],ELI+,<A,ME&H/5$'M^%A=?\@.Z56=.LKMO,U$\+:9+7O/_?@*P9K.K<=
M47UTFN-%:%Y#G.BX(CNO$GAB*?!02N'1.\=:I^N?2Z>YS*O3Z31DI*!6)<\A
M(&V1PD0EN5->A];MNO[N-+<K9H?K-+>+^#OPD&YW^ A"272Q,HX94!P#!.8R
M6&=Y5L5DU*V[).[>RN<$>LWM!()'6_GL(I$.X+0_XQYIVU%JFV#CZEE;[8XE
M7(%H'4+BV@4NK9/LZ#-53KR5STZP.D8KGUUDW '.K\/NZM-=>NN;3C QZ^28
M<F"#6C>UYN UUEV(DZ=N0C*A]478!Q?3>2WBX#AY*%=RD- Z0%^#@!<5YA"R
M!LF5IX W"(@I(P09F&"%0L=^KL2\V:E]SPET^CO$/3BR[$\9[9LLRKN+U7(5
M9GDZ^WSS&-+(:+7V=;05FAHN" @B.W"N,"\P%)ZZN6+R*"6=6_G&>&RE#NW
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M8J\+UZ',&,@$X*Q%L R@$UHN20IQ1\@BE*5<83*'@WDP-<">N2:ZC!29! (
MH@*TN.F,TR>D9D8BJ1:F0*GF4V$L=."64'SH]08MRVM@,X4R6]H^%;RU#@YO
MXXW@/'_VJE$_.3,YHO*^ %.$BB(!MRYL0T(U=P"!@(N)Y!A(P@&5$RG,#,F1
M+(;TB"D2[YDPH50F SY,G%I)CY14JY S>&S($0"#<4":C_[@+IS19,I)%W+2
M*)- X3KD]A$_=JRN1<8[?RNP=TP\0E$^P<2U!EP/)-1E[XFBC8DBF CM? AG
MH,"Z_A5]4_/E 4&4'@Y$ZT'M!/W0YP:V!Q M5]$^#Z4R%MN09F9_%JQZ$PZP
MR&?R=51E&@1 <IH+XU(>4/'$R<%6>94LUQ.NYI(ZG.6%=(65<IZ,<5! X@1=
MC)*"N2,$DTV,8()J@08(7^Y="4A04F:P!+ME:5R]=@E2&0X*64C(R)12 'B8
M28IY'<QR2JQ*.7#XQF"]GX&K"4="2+W S]E7I-J#PO'D<'"<I]I-&.^=K[;0
MO'^FVQO4L!#F@B%6J5$)Q91.#> <FTH$,-6L !/ 6]")D,(NL;COFA:7EL.=
M@Y1?%1ND:TVIJQQWN4%IIE. M''-2!@JS9P"KCV=\@1Z# G(AA&>XI)!$FB]
M/7IA:8D4DK?#+WD"  X/!\!%(A[,J<Q<ML+P\BB"!E',(3!F1Z/WPNR3=_WM
M[J[/0148(6<:WUM.5&8?GWN?RD#OJ3DVSM'G]SID4K3D;O5Q[P/0QR,-)G@"
M8&.' [8B6_I@;H,"-]QYQ^9&=O:O7Y CL9"K,,PTAGZM:NZ0&BMCX3F>4X(L
M$X*@WS(HNB#ZZ!&6"# ,V>L!=:XX[).X.RO 8P1W#N3U.O9:S:BY;S$P[SG,
M<^8*@O-'GJR71(I;+O.#@P?TY:]V4? $-E[M@\/W7]MXN1-$5BR-\BHW8:I<
MA^<J32' OJ#9V.I:[U6CT+E:I<U]?7</0&0<"VLYWRX!]ZP3!1T$CC,!^CDA
M1P!BR+L&\SK\Q?ZY6'G\MTR ^FZ594GHSA6._]M??;.RWI70DD&+* !IN*7%
MS7$H.$ C+]#W^YP%I[=8<7V+YFJN:R[=Z69Q!O2%@/-[$G^BL".A40:<AM_G
MLT?1F?>DP (0@]:Q[.N^@:)OLA@  FYRUN1U9.=QV5.JZ8>W ^I"Z8XTI V,
M.G>9#H#C#J-SA)5]Y1/)7,DYQ_*7T&E^IJ[SY,CC5*HEA]'%3/F,2#?P"WC[
M6WJ#_0J?6T+GUFV:\N$)P(_K"KA:TM3P3G%Q!ID[E739$8ESF&,ZRX5-E+4J
M[N![^CFF?^@7\O>B#E!^.'^%?WH:G-1.\"V^U?"?%1/G+_@#]X*_:MGV6+L1
MM.JGCP[7@OJC8W\FMM4.FJ\>9UT76W4J>[7!,2:ER>M2LU0PY,#I--([4M]\
M>X]8>N@;[Y9_?H6Y;RCZ@%I7E\A;/M$9OKMI-,ON<X][Z.3N^!-+:VCG%WIG
M@^?[=^3S9RU8F>YWYROJ#6_^?2[*URDN8Y>AB#N.(X6]WY,'=[_8_Q#T@V_D
MN^_).;V9X!$9W/$PPS,#<K764_?SCA0_@CJZ]L=(4 2VB(^W_5AU^7OOSSUV
M?&>UQO/@4ZU4^6_5.OXX><ZW/MY:@=C5C=J*A4X QYG=9OG,]U[YK__ZS'T'
M=_$'4$L#!!0    ( ,A)5U;*2%E)20@  "DH   :    ;6]R9BTR,#(R,3(S
M,7@Q,&ME>#,Q,BYH=&WM6FUOVS@2_GZ_@NOBV@3PFVRG29PT@.LX5V/;I'!<
M=/?3@1(IBP@M:DG*CN_7[PPI^25.MNYUN^L&6Z".))+#>7DX\Y#2^4^7-_WQ
MKQ\')+%323Y^>OM^V">56J/QN=UO-"['E^3=^,-[TJDW S+6-#7""I52V6@,
MKBNDDEB;=1N-^7Q>G[?K2D\:XU$#174:4BG#Z\RRRL4Y/H%?3MG%O\Y_JM7(
MI8KR*4\MB32GEC.2&Y%.R&?&S1VIU8I>?94MM)@DEK2:K3;YK/2=F%'?;H65
M_**4<][P]^<--\EYJ-CBXIR)&1'L345$K4X8GK+.ZRABG>;1*0TZK\.3((Q/
MV7$<!/2_ 2C9@.Y^C+$+R=]4IB*M)1SG[W9:]>.CS)[-!;-)-V@V_UUQ72_.
M8Y5:F$_#>'_IQ6P)L_S>UJ@4D[3K3*KXH65SI*32W1=-]^\,6VHQG0JYZ+X:
MBRDWY)K/R4A-:?JJ:B ,-<.UB'U'(_['02=0S]W.O<K'($>*E)<F!"U4>G"?
MB%!8T@[JK4V-UPVG>@*V6Y7!*!"[IGL$SN;Z;U*^/QB-AU?#?F\\O+D&L(YN
M/_6NQV1\0T:?W@](T*:UH'- #\G-B 1'K+RY>M+0?3%L_&Y ;@?]3Z/A>#BX
M)8-?^N]ZU_\9D%Y_#.J3X+3=J>Z]$;U;TKN\^3@>7&Z$!NQRX6HW6VB+,[4W
M>MN['MS6;GYY/_BUM++5;.X,R>]N8N=1$X=5\H'JB-Q&"9^ B+1*(JZMB!?$
M)M2^?'%T<K;SJLHH8Y#T:I+'(/^D7&<B91#%;@V?_$UF!O72B+]^]@=N:=:/
MT U#DM 9)YK/!)]#N;"),*27ICF59,0SI2U1*;E2>DJ"9NUGHF+R0>DL$1%Y
MIR3*JY)A&M4A0J?/(4*MO8O06VH@+A"$Z8+<I6HN.9OPJ@^4]A%B"E1(%11]
MF(&*E-!T0?+4ZIR#!4 #'". T%$RA3LM(+@QC>"1)FH*1<LJWV^K0\HC;@S5
M"^PRI7<<YEV3:> 9 V5@2NGH!,R!'2*A@3Y MQ2&@R:,:S('S"3$Y/BS&C_G
MFA="T("I,!)X!E*6N; )&&@R'CD%46X&JBD&9LY@&"/A8MT-SP6"[1\'@IS$
M(H4@(UY60:T"_J [-.NU=I'&D$4HLERXCF3.0"8 9RV"50"=T')!,H@[0A:A
M+.4*DP4<S(.I ?;,T><J]L@E=  @*D"+F\XX?2)J$A)+-3<E2C6?"&.!>UM"
M\:'7&[2LKH'-E,IL:?M<\-;9.[R--X+S\L5)*S@^,P6B"EZ *4+%L8!;%[8A
MH9H[@$# 12@Y!I)P0&4HA4FP.W:;0GK$%(GW3)A(*I/#.$R<6DF/E$RKB#-X
M;,@! (-Q0)J/_N ^2F@ZX:0'.6F42^CAN/'1 3]T0QTYQCM_*Y UIAZA*)]@
MXEH#K@<2ZK+S1/'&1#%,A'8^A#/TP+K^#;RI_7J/($KW!Z)!O7F,?KCD!C8&
M$"U7T;X,I2H6VXCF9O<A6/5"#K H9O)U5.4:!$!RF@GC4A[TXJF3@U1YE2S7
M$Z[FDCJ<%85TA95JD8RQ44#B!%V,DH*YPP.3AT8P0;5  X0O]ZX$I"@I-UB"
MW;(TKEZ[!*D,!X4L)&0<E%$ >)1+BGD=S')*K$HYC/#$8)W/P%7(L2.D7AC/
MV3>DVKW"<;@_."Y2[2:,=\Y76VC>/=/M#&I8"#/!$*O4J)1B2J<&<(ZD$@%,
M-2O!!/ 6-!12V 46]\>FQ:7E<.<@Y5?%1M<U4NHJQWUA4);K#"!M'!F)(J69
M4\#1TPE/@6-(0#:T\ R7#'8!ZNW1"TM+9)"\GPM^H_W!;YF'!S,J<Y>L,+H\
MCH$?BAG$Q3S"\UZ97=*NOWV<]#FDPD!(F<93RU#E]NFY=RD,=-F;(V^.O[S5
M(6')R-WBX]X'H(\#FIO@&:"-[0_:RFSIH[F-"MQP%XS-M3S*7[\B1V(A5U&4
M:XS]6M5\1.I4&0O/\8029)D(!/V60]$%T0=/#(D!Q)"]'O0N%(=]$G=G!7B,
MX,Z!O%Z'7JN$FB7%P+SG0,^9*PC.'T6R7A I[K@L#@X>]*]^LXOJSV#C=;1W
M^/[_-E[N!)&52Z.Z2DZ8*]?AN<I3"+"O(!M;K'6I&@7F:I4VR_KN'H#(Z518
MR_EV#5@.#14P"&QG O1S0@X Q)!X#29V^(O\N5QY_+=<@/INE>5IY,X5#O_9
M7WVWNMZ30,F (@I &FYI<7,<"0[0*"KT<I\SY_0.2ZZG:*[H.G+I3C?+,Z"O
M!)S?D_@3A4<2&F4PTO!E/GL2G04GA2$ ,:".55_X#51]DT\!(. F9TU11QX]
M+EL6]6> M/W; ?6@=,<:T@9&G;M,!\!QA]$%PJJ^\HETIN2,8_E+Z:0X4]=%
M<N333*H%A]9YHGQ&I!OX!;S]*=Q@Y\(' ;9NTU0TAP _KFO@:DDSP[OEQ1ED
M[DS215>DSF%NT%DA+%36JFD7W]#/,/T#7RC>B#I ^>;BY?WI:?VX>8SO[ZV&
M_ZR<N'BU7W>O]AN6;;<=M>J=X/3)YF8]>++MC\1VCNKMDZ>'KHMM.)6]VN 8
MD]'T3:5=*0<4P.FVLGL2;+ZW1RP]](UWRU^_PMS7$Y> 6E>7R!4/=8[O;EKM
MJOO08PF=PAU_8&D3[?Q*[VR,^?$=^?)%!U:F^WWP<GK#CW^><XH5B@O8Y2;B
M#N)(:>F/Y+N'+_,_U"_KW\EK/Y);^HG@,;E:9O6;-1[MVVX\80'26;3]X[6+
M@X_^( T<MN6ZPVW_-%P%>Z1 %D+;4&V0(RG_R5W7GXW/^-8W:*MUZ8I@<S6$
MAK T<[L]Y N?K16__B,Z]SG?Q>]02P,$%     @ R$E75D,__OBZ!   01$
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M>KGX,#Y/()D_&<G/XGG0AP_NPIVXL)A-K/=!U/7;,%[ >#J_2&;3%Q5.$\3
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M;NBC.XM/FUD?G?8G%1+B?M[(QRI_<<U1/ZM+%WW],_X34$L! A0#%     @
MR$E75O2""HU8"P0 ,O(B !$              ( !     &UO<F8M,C R,C$R
M,S$N:'1M4$L! A0#%     @ R$E75BIIE<W!#P  S:D  !$
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M2P$"% ,4    " #(25=6?>?(NH;\  #!1 $ %0              @ %Z^@0
M;6]R9BTR,#(R,3(S,5]G,3 N:G!G4$L! A0#%     @ R$E75@6MJ,>JNP
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M              "  9B6#0!M;W)F+3(P,C(Q,C,Q7V<S+FIP9U!+ 0(4 Q0
M   ( ,A)5U:!OQ+@FND  +$% 0 4              "  4#P#@!M;W)F+3(P
M,C(Q,C,Q7V<T+FIP9U!+ 0(4 Q0    ( ,A)5U93(O>-J <! %4Y 0 4
M          "  0S:#P!M;W)F+3(P,C(Q,C,Q7V<U+FIP9U!+ 0(4 Q0    (
M ,A)5U85MBE.:V0! !A\ 0 4              "  >;A$ !M;W)F+3(P,C(Q
M,C,Q7V<V+FIP9U!+ 0(4 Q0    ( ,A)5U8BU'2W"5@  $=W   4
M      "  8-&$@!M;W)F+3(P,C(Q,C,Q7V<W+FIP9U!+ 0(4 Q0    ( ,A)
M5U;+OZ5;E.L  )(, 0 4              "  ;Z>$@!M;W)F+3(P,C(Q,C,Q
M7V<X+FIP9U!+ 0(4 Q0    ( ,A)5U9T)/.EQG@  $J+   4
M  "  82*$P!M;W)F+3(P,C(Q,C,Q7V<Y+FIP9U!+ 0(4 Q0    ( ,A)5U9O
M0P9>Y^,  "R1"0 5              "  7P#% !M;W)F+3(P,C(Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " #(25=6GL((C[N-  ""D 8 %0
M@ &6YQ0 ;6]R9BTR,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ R$E75N0%
MS#L/ P  @0X  !H              ( !A'45 &UO<F8M,C R,C$R,S%X,3!K
M97@R,3$N:'1M4$L! A0#%     @ R$E75N)QB>RB P  I0T  !H
M     ( !RW@5 &UO<F8M,C R,C$R,S%X,3!K97@R,S$N:'1M4$L! A0#%
M  @ R$E75@:?TDM/"   8B<  !H              ( !I7P5 &UO<F8M,C R
M,C$R,S%X,3!K97@S,3$N:'1M4$L! A0#%     @ R$E75LI(64E)"   *2@
M !H              ( !+(45 &UO<F8M,C R,C$R,S%X,3!K97@S,3(N:'1M
M4$L! A0#%     @ R$E75D,__OBZ!   01$  !H              ( !K8T5
M &UO<F8M,C R,C$R,S%X,3!K97@S,C$N:'1M4$L! A0#%     @ R$E75DKV
MN9>[!   61(  !H              ( !GY(5 &UO<F8M,C R,C$R,S%X,3!K
?97@S,C(N:'1M4$L%!@     = !T I <  )*7%0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
